PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33907580-0	2021	LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S-1.	Oxaliplatin	101-112	lactamase beta	Homo sapiens	0-5
33982772-0	2021	LY-294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF-1alpha pathway.	Oxaliplatin	59-70	AKT serine/threonine kinase 1	Homo sapiens	92-95
33982772-0	2021	LY-294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF-1alpha pathway.	Oxaliplatin	59-70	hypoxia inducible factor 1 subunit alpha	Homo sapiens	96-106
33982772-3	2021	Abnormal activation of the PI3K/AKT pathway plays an important role in the acquired resistance of oxaliplatin.	Oxaliplatin	98-109	AKT serine/threonine kinase 1	Homo sapiens	32-35
33982772-4	2021	The present study investigated the effects of the PI3K inhibitor LY-294002 and AKT inhibitor MK2206 on the chemosensitivity of oxaliplatin-resistant liver cancer cells and the molecular mechanism involved.	Oxaliplatin	127-138	AKT serine/threonine kinase 1	Homo sapiens	79-82
33968197-0	2021	miR-188-5p promotes oxaliplatin resistance by targeting RASA1 in colon cancer cells.	Oxaliplatin	20-31	RAS p21 protein activator 1	Homo sapiens	56-61
33968197-3	2021	The aim of the present study was to explore the molecular role of miR-188 in oxaliplatin (OXA) resistance.	Oxaliplatin	77-88	microRNA 188	Homo sapiens	66-73
33968197-3	2021	The aim of the present study was to explore the molecular role of miR-188 in oxaliplatin (OXA) resistance.	Oxaliplatin	90-93	microRNA 188	Homo sapiens	66-73
33982772-12	2021	It was concluded that LY-294002 enhanced the chemosensitivity of liver cancer cells to oxaliplatin by inhibiting the PI3K/AKT signaling pathway, which may be related to the inhibition of HIF-1alpha expression.	Oxaliplatin	87-98	AKT serine/threonine kinase 1	Homo sapiens	122-125
33982772-12	2021	It was concluded that LY-294002 enhanced the chemosensitivity of liver cancer cells to oxaliplatin by inhibiting the PI3K/AKT signaling pathway, which may be related to the inhibition of HIF-1alpha expression.	Oxaliplatin	87-98	hypoxia inducible factor 1 subunit alpha	Homo sapiens	187-197
33542444-3	2021	Here, we investigated whether single nucleotide polymorphisms (SNPs) in two enterocyte subtype-related genes, MS4A12 and CDX2, could predict the efficacy of oxaliplatin in first-line treatment for patients with metastatic CRC (mCRC).	Oxaliplatin	157-168	membrane spanning 4-domains A12	Homo sapiens	110-116
33542444-3	2021	Here, we investigated whether single nucleotide polymorphisms (SNPs) in two enterocyte subtype-related genes, MS4A12 and CDX2, could predict the efficacy of oxaliplatin in first-line treatment for patients with metastatic CRC (mCRC).	Oxaliplatin	157-168	caudal type homeobox 2	Homo sapiens	121-125
33542444-10	2021	Thus, MS4A12 and CDX2 SNPs may have utility as predictive biomarkers of response to oxaliplatin-based treatment in mCRC patients.	Oxaliplatin	84-95	membrane spanning 4-domains A12	Homo sapiens	6-12
33542444-10	2021	Thus, MS4A12 and CDX2 SNPs may have utility as predictive biomarkers of response to oxaliplatin-based treatment in mCRC patients.	Oxaliplatin	84-95	caudal type homeobox 2	Homo sapiens	17-21
33907580-0	2021	LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S-1.	Oxaliplatin	101-112	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	10-13
33907580-1	2021	The present study investigated and evaluated the correlation between the expression of LACTB and LC3 and the clinical outcomes of patients with advanced gastric cancer treated with oxaliplatin plus S-1 neoadjuvant chemotherapy (NACT).	Oxaliplatin	181-192	lactamase beta	Homo sapiens	87-92
33907580-1	2021	The present study investigated and evaluated the correlation between the expression of LACTB and LC3 and the clinical outcomes of patients with advanced gastric cancer treated with oxaliplatin plus S-1 neoadjuvant chemotherapy (NACT).	Oxaliplatin	181-192	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	97-100
34052504-0	2021	The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK.	Oxaliplatin	57-68	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	25-29
34060205-6	2021	Additionally, sEV-delivered LSD1 suppresses oxaliplatin response of recipient cells in vitro and in vivo, whereas LSD1-depleted sEVs do not.	Oxaliplatin	44-55	lysine demethylase 1A	Homo sapiens	28-32
34060205-7	2021	Taken together, we demonstrate that LSD1-loaded sEVs can promote stemness and chemoresistance to oxaliplatin.	Oxaliplatin	97-108	lysine demethylase 1A	Homo sapiens	36-40
34060205-8	2021	These findings suggest that the LSD1 content of sEV could serve as a biomarker to predict oxaliplatin response in gastric cancer patients.	Oxaliplatin	90-101	lysine demethylase 1A	Homo sapiens	32-36
34052504-0	2021	The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK.	Oxaliplatin	57-68	AKT serine/threonine kinase 1	Homo sapiens	110-113
34052504-4	2021	In this work we determined the effect of SHP2 expression on colon cancer cell proliferation and resistance to oxaliplatin (L-OHP), a commonly used drug in the clinic.	Oxaliplatin	110-121	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	41-45
34052504-4	2021	In this work we determined the effect of SHP2 expression on colon cancer cell proliferation and resistance to oxaliplatin (L-OHP), a commonly used drug in the clinic.	Oxaliplatin	123-128	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	41-45
34052504-7	2021	We selected oxaliplatin-resistant SW480(SW480/L-OHP) and HCT116(HCT116/L-OHP) cells and found that the SHP2 protein level was raised in these drug-resistant cells.	Oxaliplatin	12-23	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	103-107
34052504-8	2021	The upregulated SHP2 contributed to oxaliplatin resistance of the cells, as knockdown of SHP2 decreased the IC50 of oxaliplatin and abated proliferation and survival of SW480/L-OHP and HCT116/L-OHP cells in the presence of oxaliplatin.	Oxaliplatin	36-47	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	16-20
34052504-8	2021	The upregulated SHP2 contributed to oxaliplatin resistance of the cells, as knockdown of SHP2 decreased the IC50 of oxaliplatin and abated proliferation and survival of SW480/L-OHP and HCT116/L-OHP cells in the presence of oxaliplatin.	Oxaliplatin	36-47	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	89-93
34052504-8	2021	The upregulated SHP2 contributed to oxaliplatin resistance of the cells, as knockdown of SHP2 decreased the IC50 of oxaliplatin and abated proliferation and survival of SW480/L-OHP and HCT116/L-OHP cells in the presence of oxaliplatin.	Oxaliplatin	116-127	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	16-20
34052504-8	2021	The upregulated SHP2 contributed to oxaliplatin resistance of the cells, as knockdown of SHP2 decreased the IC50 of oxaliplatin and abated proliferation and survival of SW480/L-OHP and HCT116/L-OHP cells in the presence of oxaliplatin.	Oxaliplatin	116-127	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	89-93
34052504-8	2021	The upregulated SHP2 contributed to oxaliplatin resistance of the cells, as knockdown of SHP2 decreased the IC50 of oxaliplatin and abated proliferation and survival of SW480/L-OHP and HCT116/L-OHP cells in the presence of oxaliplatin.	Oxaliplatin	116-127	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	16-20
34052504-8	2021	The upregulated SHP2 contributed to oxaliplatin resistance of the cells, as knockdown of SHP2 decreased the IC50 of oxaliplatin and abated proliferation and survival of SW480/L-OHP and HCT116/L-OHP cells in the presence of oxaliplatin.	Oxaliplatin	116-127	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	89-93
34052504-10	2021	Inhibition of AKT, ERK, or SHP2 sensitized SW480/L-OHP and HCT116/L-OHP cells to oxaliplatin.	Oxaliplatin	49-54	AKT serine/threonine kinase 1	Homo sapiens	14-17
34052504-10	2021	Inhibition of AKT, ERK, or SHP2 sensitized SW480/L-OHP and HCT116/L-OHP cells to oxaliplatin.	Oxaliplatin	49-54	mitogen-activated protein kinase 1	Homo sapiens	19-22
34052504-10	2021	Inhibition of AKT, ERK, or SHP2 sensitized SW480/L-OHP and HCT116/L-OHP cells to oxaliplatin.	Oxaliplatin	49-54	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	27-31
34052504-10	2021	Inhibition of AKT, ERK, or SHP2 sensitized SW480/L-OHP and HCT116/L-OHP cells to oxaliplatin.	Oxaliplatin	81-92	AKT serine/threonine kinase 1	Homo sapiens	14-17
34052504-10	2021	Inhibition of AKT, ERK, or SHP2 sensitized SW480/L-OHP and HCT116/L-OHP cells to oxaliplatin.	Oxaliplatin	81-92	mitogen-activated protein kinase 1	Homo sapiens	19-22
34052504-10	2021	Inhibition of AKT, ERK, or SHP2 sensitized SW480/L-OHP and HCT116/L-OHP cells to oxaliplatin.	Oxaliplatin	81-92	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	27-31
34052504-11	2021	Our results indicate that SHP2 contributes oxaliplatin resistance through AKT and ERK.	Oxaliplatin	43-54	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	26-30
34052504-11	2021	Our results indicate that SHP2 contributes oxaliplatin resistance through AKT and ERK.	Oxaliplatin	43-54	AKT serine/threonine kinase 1	Homo sapiens	74-77
34052504-11	2021	Our results indicate that SHP2 contributes oxaliplatin resistance through AKT and ERK.	Oxaliplatin	43-54	mitogen-activated protein kinase 1	Homo sapiens	82-85
34039363-10	2021	KITENIN-overexpressing CRC cells deregulated certain microRNAs and were resistant to 5-fluorouracil, oxaliplatin, and cetuximab.	Oxaliplatin	101-112	VANGL planar cell polarity protein 1	Homo sapiens	0-7
34052504-12	2021	These results also suggest that SHP2-targeting is a potential strategy for overcoming oxaliplatin resistance of colon cancer cells.	Oxaliplatin	86-97	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	32-36
34032956-0	2021	ZEB1 Induces Ddr1 Promoter Hypermethylation and Contributes to the Chronic Pain in Spinal Cord in Rats Following Oxaliplatin Treatment.	Oxaliplatin	113-124	zinc finger E-box binding homeobox 1	Rattus norvegicus	0-4
34032956-2	2021	Here, Ddr1, which showed an increased methylation in the promoter, was screened from the SRA methylation database (PRJNA587622) after oxaliplatin treatment.	Oxaliplatin	134-145	discoidin domain receptor tyrosine kinase 1	Rattus norvegicus	6-10
34032956-3	2021	qPCR and MeDIP assays verified that oxaliplatin treatment increased the methylation in Ddr1 promoter region and decreased the expression of DDR1 in the neurons of spinal dorsal horn.	Oxaliplatin	36-47	discoidin domain receptor tyrosine kinase 1	Rattus norvegicus	87-91
34032956-3	2021	qPCR and MeDIP assays verified that oxaliplatin treatment increased the methylation in Ddr1 promoter region and decreased the expression of DDR1 in the neurons of spinal dorsal horn.	Oxaliplatin	36-47	discoidin domain receptor tyrosine kinase 1	Rattus norvegicus	140-144
34032956-4	2021	In addition, overexpression of DDR1 by intraspinal injection of AAV-hSyn-Ddr1 significantly alleviated the mechanical allodynia induced by oxaliplatin.	Oxaliplatin	139-150	discoidin domain receptor tyrosine kinase 1	Rattus norvegicus	31-35
34032956-4	2021	In addition, overexpression of DDR1 by intraspinal injection of AAV-hSyn-Ddr1 significantly alleviated the mechanical allodynia induced by oxaliplatin.	Oxaliplatin	139-150	synemin	Homo sapiens	68-72
34032956-4	2021	In addition, overexpression of DDR1 by intraspinal injection of AAV-hSyn-Ddr1 significantly alleviated the mechanical allodynia induced by oxaliplatin.	Oxaliplatin	139-150	discoidin domain receptor tyrosine kinase 1	Rattus norvegicus	73-77
34032956-5	2021	Furthermore, we found that oxaliplatin treatment increased the expression of DNMT3b and ZEB1 in dorsal horn neurons, and promoted the interaction between DNMT3b and ZEB1.	Oxaliplatin	27-38	DNA methyltransferase 3 beta	Rattus norvegicus	77-83
34032956-5	2021	Furthermore, we found that oxaliplatin treatment increased the expression of DNMT3b and ZEB1 in dorsal horn neurons, and promoted the interaction between DNMT3b and ZEB1.	Oxaliplatin	27-38	zinc finger E-box binding homeobox 1	Rattus norvegicus	88-92
34032956-5	2021	Furthermore, we found that oxaliplatin treatment increased the expression of DNMT3b and ZEB1 in dorsal horn neurons, and promoted the interaction between DNMT3b and ZEB1.	Oxaliplatin	27-38	DNA methyltransferase 3 beta	Rattus norvegicus	154-160
34032956-5	2021	Furthermore, we found that oxaliplatin treatment increased the expression of DNMT3b and ZEB1 in dorsal horn neurons, and promoted the interaction between DNMT3b and ZEB1.	Oxaliplatin	27-38	zinc finger E-box binding homeobox 1	Rattus norvegicus	165-169
34032956-6	2021	Intrathecal injection of ZEB1 siRNA inhibited the enhanced recruitment of DNMT3b and the hypermethylation in Ddr1 promoter induced by oxaliplatin.	Oxaliplatin	134-145	zinc finger E-box binding homeobox 1	Rattus norvegicus	25-29
34032956-6	2021	Intrathecal injection of ZEB1 siRNA inhibited the enhanced recruitment of DNMT3b and the hypermethylation in Ddr1 promoter induced by oxaliplatin.	Oxaliplatin	134-145	discoidin domain receptor tyrosine kinase 1	Rattus norvegicus	109-113
34032956-7	2021	Finally, ZEB1 siRNA rescued the DDR1 downregulation and mechanical allodynia induced by oxaliplatin.	Oxaliplatin	88-99	zinc finger E-box binding homeobox 1	Rattus norvegicus	9-13
34032956-7	2021	Finally, ZEB1 siRNA rescued the DDR1 downregulation and mechanical allodynia induced by oxaliplatin.	Oxaliplatin	88-99	discoidin domain receptor tyrosine kinase 1	Rattus norvegicus	32-36
34032956-8	2021	In conclusion, these results suggested that the ZEB1 recruited DNMT3b to the Ddr1 promoter, which induced the DDR1 downregulation and contributed to the oxaliplatin-induced chronic pain.	Oxaliplatin	153-164	zinc finger E-box binding homeobox 1	Rattus norvegicus	48-52
34032956-8	2021	In conclusion, these results suggested that the ZEB1 recruited DNMT3b to the Ddr1 promoter, which induced the DDR1 downregulation and contributed to the oxaliplatin-induced chronic pain.	Oxaliplatin	153-164	DNA methyltransferase 3 beta	Rattus norvegicus	63-69
34032956-8	2021	In conclusion, these results suggested that the ZEB1 recruited DNMT3b to the Ddr1 promoter, which induced the DDR1 downregulation and contributed to the oxaliplatin-induced chronic pain.	Oxaliplatin	153-164	discoidin domain receptor tyrosine kinase 1	Rattus norvegicus	77-81
34032956-8	2021	In conclusion, these results suggested that the ZEB1 recruited DNMT3b to the Ddr1 promoter, which induced the DDR1 downregulation and contributed to the oxaliplatin-induced chronic pain.	Oxaliplatin	153-164	discoidin domain receptor tyrosine kinase 1	Rattus norvegicus	110-114
34015230-8	2021	OXA exposure increased SOD, GPx and GST activities and caused a reduction on NPSH levels, CAT and GR activities.	Oxaliplatin	0-3	hematopoietic prostaglandin D synthase	Mus musculus	36-39
34021129-0	2021	UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer.	Oxaliplatin	33-44	UPF1 RNA helicase and ATPase	Homo sapiens	0-4
34021129-0	2021	UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer.	Oxaliplatin	33-44	DNA topoisomerase II alpha	Homo sapiens	67-72
34021129-2	2021	However, the role of UPF1 in oxaliplatin resistance in colorectal cancer (CRC) remains unknown.	Oxaliplatin	29-40	UPF1 RNA helicase and ATPase	Homo sapiens	21-25
34021129-4	2021	UPF1 promotes chemoresistance to oxaliplatin in vitro and in vivo.	Oxaliplatin	33-44	UPF1 RNA helicase and ATPase	Homo sapiens	0-4
34021129-5	2021	UPF1-induced oxaliplatin resistance can be associated with interaction between zinc finger of UPF1 and Toprim of TOP2A and increasing phosphorylated TOP2A in a SMG1-dependent manner.	Oxaliplatin	13-24	UPF1 RNA helicase and ATPase	Homo sapiens	0-4
34021129-5	2021	UPF1-induced oxaliplatin resistance can be associated with interaction between zinc finger of UPF1 and Toprim of TOP2A and increasing phosphorylated TOP2A in a SMG1-dependent manner.	Oxaliplatin	13-24	UPF1 RNA helicase and ATPase	Homo sapiens	94-98
34021129-5	2021	UPF1-induced oxaliplatin resistance can be associated with interaction between zinc finger of UPF1 and Toprim of TOP2A and increasing phosphorylated TOP2A in a SMG1-dependent manner.	Oxaliplatin	13-24	DNA topoisomerase II alpha	Homo sapiens	113-118
34021129-5	2021	UPF1-induced oxaliplatin resistance can be associated with interaction between zinc finger of UPF1 and Toprim of TOP2A and increasing phosphorylated TOP2A in a SMG1-dependent manner.	Oxaliplatin	13-24	DNA topoisomerase II alpha	Homo sapiens	149-154
34021129-5	2021	UPF1-induced oxaliplatin resistance can be associated with interaction between zinc finger of UPF1 and Toprim of TOP2A and increasing phosphorylated TOP2A in a SMG1-dependent manner.	Oxaliplatin	13-24	SMG1 nonsense mediated mRNA decay associated PI3K related kinase	Homo sapiens	160-164
34021129-8	2021	UPF1 enhanced chemoresistance to oxaliplatin in CRC, which may result from regulation of TOP2A activity and maintenance of stemness.	Oxaliplatin	33-44	UPF1 RNA helicase and ATPase	Homo sapiens	0-4
34021129-8	2021	UPF1 enhanced chemoresistance to oxaliplatin in CRC, which may result from regulation of TOP2A activity and maintenance of stemness.	Oxaliplatin	33-44	DNA topoisomerase II alpha	Homo sapiens	89-94
34015230-8	2021	OXA exposure increased SOD, GPx and GST activities and caused a reduction on NPSH levels, CAT and GR activities.	Oxaliplatin	0-3	catalase	Mus musculus	90-93
34015230-8	2021	OXA exposure increased SOD, GPx and GST activities and caused a reduction on NPSH levels, CAT and GR activities.	Oxaliplatin	0-3	glutathione reductase	Mus musculus	98-100
33691171-8	2021	ERBB2 expression was negatively related to drug sensitivity of Ifosfamide, Imexon, and Oxaliplatin.	Oxaliplatin	87-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
33990575-7	2021	Thus, TGFbeta converts Nur77"s role from destabilizing ID1 protein and cancer inhibition to inducing ID1 mRNA expression and cancer promotion, which is highly relevant to colon cancer stemness, metastasis and oxaliplatin resistance.	Oxaliplatin	209-220	transforming growth factor alpha	Homo sapiens	6-13
33990575-7	2021	Thus, TGFbeta converts Nur77"s role from destabilizing ID1 protein and cancer inhibition to inducing ID1 mRNA expression and cancer promotion, which is highly relevant to colon cancer stemness, metastasis and oxaliplatin resistance.	Oxaliplatin	209-220	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-28
34017210-0	2021	MicroRNA-19b Downregulates NR3C1 and Enhances Oxaliplatin Chemoresistance in Colon Cancer via the PI3K/AKT/mTOR Pathway.	Oxaliplatin	46-57	microRNA 19b-1	Homo sapiens	0-12
33966039-0	2021	TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.	Oxaliplatin	17-28	tripartite motif containing 25	Homo sapiens	0-6
33966039-0	2021	TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.	Oxaliplatin	17-28	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	74-78
33966039-2	2021	Here, we identified TRIM25 as an epigenetic regulator of oxaliplatin (OXA) resistance in CRC.	Oxaliplatin	57-68	tripartite motif containing 25	Homo sapiens	20-26
33966039-2	2021	Here, we identified TRIM25 as an epigenetic regulator of oxaliplatin (OXA) resistance in CRC.	Oxaliplatin	70-73	tripartite motif containing 25	Homo sapiens	20-26
33966039-3	2021	The level of TRIM25 in OXA-resistant patients who experienced recurrence during the follow-up period was significantly higher than in those who had no recurrence.	Oxaliplatin	23-26	tripartite motif containing 25	Homo sapiens	13-19
33966039-5	2021	Downregulation of TRIM25 dramatically inhibited, while overexpression of TRIM25 increased, CRC cell survival after OXA treatment.	Oxaliplatin	115-118	tripartite motif containing 25	Homo sapiens	73-79
33966039-8	2021	Our study contributes to a better understanding of OXA resistance and indicates that inhibitors against TRIM25 might be an excellent strategy for CRC management in clinical practice.	Oxaliplatin	51-54	tripartite motif containing 25	Homo sapiens	104-110
33662352-7	2021	These results indicate that PIK3CA mutation contributes to reduced sensitivity to 5-FU and L-OHP via Akt activation in colon cancer cells.	Oxaliplatin	91-96	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	28-34
33662352-7	2021	These results indicate that PIK3CA mutation contributes to reduced sensitivity to 5-FU and L-OHP via Akt activation in colon cancer cells.	Oxaliplatin	91-96	AKT serine/threonine kinase 1	Homo sapiens	101-104
33662352-8	2021	Perifosine increases the efficacy of 5-FU and L-OHP by suppressing Akt activation.	Oxaliplatin	46-51	AKT serine/threonine kinase 1	Homo sapiens	67-70
33662352-9	2021	Thus, the use of an Akt inhibitor in combination with 5-FU and L-OHP may be beneficial in colon cancer with cells harboring the PIK3CA mutation.	Oxaliplatin	63-68	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	128-134
33986248-0	2021	A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer.	Oxaliplatin	69-80	Kruppel like factor 4	Homo sapiens	2-6
33986248-0	2021	A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer.	Oxaliplatin	69-80	prostate cancer associated transcript 1	Homo sapiens	7-11
33986248-0	2021	A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer.	Oxaliplatin	69-80	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	12-16
33986248-0	2021	A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer.	Oxaliplatin	69-80	high mobility group AT-hook 2	Homo sapiens	17-22
33986248-2	2021	In this study, lncRNA P53 inHibiting LncRNA (PiHL) was shown to be highly induced in oxaliplatin-resistant CRC cells and tumor tissues.	Oxaliplatin	85-96	tumor protein p53	Homo sapiens	22-25
33986248-2	2021	In this study, lncRNA P53 inHibiting LncRNA (PiHL) was shown to be highly induced in oxaliplatin-resistant CRC cells and tumor tissues.	Oxaliplatin	85-96	prostate cancer associated transcript 1	Homo sapiens	45-49
33986248-3	2021	In vitro and in vivo models clarified PiHL"s role in conferring resistance to oxaliplatin-induced apoptosis.	Oxaliplatin	78-89	prostate cancer associated transcript 1	Homo sapiens	38-42
33986248-5	2021	Furthermore, HMGA2 upregulation induced by PiHL promotes PI3K/Akt phosphorylation, which resulted in increased oxaliplatin resistance.	Oxaliplatin	111-122	high mobility group AT-hook 2	Homo sapiens	13-18
33986248-5	2021	Furthermore, HMGA2 upregulation induced by PiHL promotes PI3K/Akt phosphorylation, which resulted in increased oxaliplatin resistance.	Oxaliplatin	111-122	prostate cancer associated transcript 1	Homo sapiens	43-47
33986248-5	2021	Furthermore, HMGA2 upregulation induced by PiHL promotes PI3K/Akt phosphorylation, which resulted in increased oxaliplatin resistance.	Oxaliplatin	111-122	AKT serine/threonine kinase 1	Homo sapiens	62-65
33986248-6	2021	We also found that transcription factor KLF4 was downregulated in oxaliplatin-resistant cells, and KLF4 negatively regulated PiHL expression by binding to PiHL promoter.	Oxaliplatin	66-77	Kruppel like factor 4	Homo sapiens	40-44
33986248-6	2021	We also found that transcription factor KLF4 was downregulated in oxaliplatin-resistant cells, and KLF4 negatively regulated PiHL expression by binding to PiHL promoter.	Oxaliplatin	66-77	prostate cancer associated transcript 1	Homo sapiens	125-129
33986248-6	2021	We also found that transcription factor KLF4 was downregulated in oxaliplatin-resistant cells, and KLF4 negatively regulated PiHL expression by binding to PiHL promoter.	Oxaliplatin	66-77	prostate cancer associated transcript 1	Homo sapiens	155-159
33986248-7	2021	In vivo models further demonstrated that treatment of oxaliplatin-resistant CRC with locked nucleic acids targeting PiHL restored oxaliplatin response.	Oxaliplatin	54-65	prostate cancer associated transcript 1	Homo sapiens	116-120
33986248-7	2021	In vivo models further demonstrated that treatment of oxaliplatin-resistant CRC with locked nucleic acids targeting PiHL restored oxaliplatin response.	Oxaliplatin	130-141	prostate cancer associated transcript 1	Homo sapiens	116-120
33662352-0	2021	Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.	Oxaliplatin	73-84	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	121-127
33662352-4	2021	The use of 5-FU or L-OHP alone or in combination induced significant death of Caco-2 cells (PIK3CA wild type), but only weakly decreased the viability of DLD-1 and SW948 cells harboring the PIK3CA mutation.	Oxaliplatin	19-24	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	92-98
33662352-4	2021	The use of 5-FU or L-OHP alone or in combination induced significant death of Caco-2 cells (PIK3CA wild type), but only weakly decreased the viability of DLD-1 and SW948 cells harboring the PIK3CA mutation.	Oxaliplatin	19-24	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	190-196
33662352-5	2021	The use of 5-FU and L-OHP, either alone or in combination, strongly suppressed Akt activation, Survivin, Bcl-2, and Bcl-xL expression, and enhanced Puma, phospho-p53, and p53 expression in Caco-2 cells than in DLD-1 cells.	Oxaliplatin	20-25	AKT serine/threonine kinase 1	Homo sapiens	79-82
33662352-5	2021	The use of 5-FU and L-OHP, either alone or in combination, strongly suppressed Akt activation, Survivin, Bcl-2, and Bcl-xL expression, and enhanced Puma, phospho-p53, and p53 expression in Caco-2 cells than in DLD-1 cells.	Oxaliplatin	20-25	BCL2 apoptosis regulator	Homo sapiens	105-110
33662352-5	2021	The use of 5-FU and L-OHP, either alone or in combination, strongly suppressed Akt activation, Survivin, Bcl-2, and Bcl-xL expression, and enhanced Puma, phospho-p53, and p53 expression in Caco-2 cells than in DLD-1 cells.	Oxaliplatin	20-25	BCL2 like 1	Homo sapiens	116-122
33662352-5	2021	The use of 5-FU and L-OHP, either alone or in combination, strongly suppressed Akt activation, Survivin, Bcl-2, and Bcl-xL expression, and enhanced Puma, phospho-p53, and p53 expression in Caco-2 cells than in DLD-1 cells.	Oxaliplatin	20-25	BCL2 binding component 3	Homo sapiens	148-152
33662352-5	2021	The use of 5-FU and L-OHP, either alone or in combination, strongly suppressed Akt activation, Survivin, Bcl-2, and Bcl-xL expression, and enhanced Puma, phospho-p53, and p53 expression in Caco-2 cells than in DLD-1 cells.	Oxaliplatin	20-25	tumor protein p53	Homo sapiens	162-165
33662352-5	2021	The use of 5-FU and L-OHP, either alone or in combination, strongly suppressed Akt activation, Survivin, Bcl-2, and Bcl-xL expression, and enhanced Puma, phospho-p53, and p53 expression in Caco-2 cells than in DLD-1 cells.	Oxaliplatin	20-25	tumor protein p53	Homo sapiens	171-174
33662352-6	2021	In addition, perifosine enhanced the cytotoxicity of the 5-FU and L-OHP combination, inhibited Akt activation and the expression of Survivin, Bcl-2, and Bcl-xL, and increased the expression of Puma, phospho-p53, and p53 in DLD-1 cells.	Oxaliplatin	66-71	AKT serine/threonine kinase 1	Homo sapiens	95-98
34017210-2	2021	In this study, we aimed to investigate the biological functions and underlying mechanisms of action of miR-19b and NR3C1, as well as their effects on chemosensitivity to oxaliplatin and prognosis of colon cancer patients.	Oxaliplatin	170-181	microRNA 19b-1	Homo sapiens	103-110
34017210-9	2021	The miR-19b inhibition and NR3C1 overexpression inhibited cell proliferation, and induced G1/S cell cycle blockade, apoptosis, and chemosensitivity to oxaliplatin in vitro.	Oxaliplatin	151-162	microRNA 19b-2	Mus musculus	4-11
34017210-9	2021	The miR-19b inhibition and NR3C1 overexpression inhibited cell proliferation, and induced G1/S cell cycle blockade, apoptosis, and chemosensitivity to oxaliplatin in vitro.	Oxaliplatin	151-162	nuclear receptor subfamily 3, group C, member 1	Mus musculus	27-32
34017210-13	2021	Thus, miR-19b might inhibit apoptosis and enhance oxaliplatin chemoresistance via the PI3K/AKT/mTOR pathway.	Oxaliplatin	50-61	microRNA 19b-2	Mus musculus	6-13
34017210-13	2021	Thus, miR-19b might inhibit apoptosis and enhance oxaliplatin chemoresistance via the PI3K/AKT/mTOR pathway.	Oxaliplatin	50-61	AKT serine/threonine kinase 1	Homo sapiens	91-94
34017210-13	2021	Thus, miR-19b might inhibit apoptosis and enhance oxaliplatin chemoresistance via the PI3K/AKT/mTOR pathway.	Oxaliplatin	50-61	mechanistic target of rapamycin kinase	Homo sapiens	95-99
34017210-14	2021	Conclusions: Our study revealed that miR-19b promotes cell survival and chemoresistance to oxaliplatin via the PI3K/AKT/mTOR pathway by downregulating NR3C1 in colon cancer.	Oxaliplatin	91-102	microRNA 19b-2	Mus musculus	37-44
34017210-14	2021	Conclusions: Our study revealed that miR-19b promotes cell survival and chemoresistance to oxaliplatin via the PI3K/AKT/mTOR pathway by downregulating NR3C1 in colon cancer.	Oxaliplatin	91-102	AKT serine/threonine kinase 1	Homo sapiens	116-119
34017210-14	2021	Conclusions: Our study revealed that miR-19b promotes cell survival and chemoresistance to oxaliplatin via the PI3K/AKT/mTOR pathway by downregulating NR3C1 in colon cancer.	Oxaliplatin	91-102	mechanistic target of rapamycin kinase	Homo sapiens	120-124
34017210-14	2021	Conclusions: Our study revealed that miR-19b promotes cell survival and chemoresistance to oxaliplatin via the PI3K/AKT/mTOR pathway by downregulating NR3C1 in colon cancer.	Oxaliplatin	91-102	nuclear receptor subfamily 3, group C, member 1	Mus musculus	151-156
33995648-0	2021	KIF11 is upregulated in colorectal cancer and silencing of it impairs tumor growth and sensitizes colorectal cancer cells to oxaliplatin via p53/GSK3beta signaling.	Oxaliplatin	125-136	kinesin family member 11	Homo sapiens	0-5
33995648-7	2021	We found that KIF11 was upregulated in CRC tissues and was associated with advanced clinical stage and vessel invasion and that knockdown of KIF11 led to tumor growth arrest and increased sensitivity to oxaliplatin via enhanced DNA damage and apoptosis.	Oxaliplatin	203-214	kinesin family member 11	Homo sapiens	141-146
34017681-0	2021	MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer.	Oxaliplatin	20-31	phosphatase and tensin homolog	Homo sapiens	56-60
34017681-7	2021	Moreover, we determined that miR-454-3p promoted oxaliplatin resistance through targeting PTEN and activating the AKT signaling pathway.	Oxaliplatin	49-60	phosphatase and tensin homolog	Homo sapiens	90-94
34017681-7	2021	Moreover, we determined that miR-454-3p promoted oxaliplatin resistance through targeting PTEN and activating the AKT signaling pathway.	Oxaliplatin	49-60	AKT serine/threonine kinase 1	Homo sapiens	114-117
33995648-9	2021	Thus, our data firmly demonstrated that KIF11 could serve as a potential oncogene and proper biomarker for assessing oxaliplatin sensitivity in CRC.	Oxaliplatin	117-128	kinesin family member 11	Homo sapiens	40-45
33468383-2	2021	The purpose of this study was to determine the clinical significance of the KRAS mutation and ERCC1 overexpression status as predictive factors for resistance against oxaliplatin-based treatment.	Oxaliplatin	167-178	KRAS proto-oncogene, GTPase	Homo sapiens	76-80
33468383-2	2021	The purpose of this study was to determine the clinical significance of the KRAS mutation and ERCC1 overexpression status as predictive factors for resistance against oxaliplatin-based treatment.	Oxaliplatin	167-178	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	94-99
33468383-10	2021	CONCLUSIONS: Our results suggest that CRC with wild-type KRAS and ERCC1 overexpression might be associated with oxaliplatin resistance.	Oxaliplatin	112-123	KRAS proto-oncogene, GTPase	Homo sapiens	57-61
33468383-10	2021	CONCLUSIONS: Our results suggest that CRC with wild-type KRAS and ERCC1 overexpression might be associated with oxaliplatin resistance.	Oxaliplatin	112-123	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	66-71
33468383-11	2021	When considering oxaliplatin-based chemotherapy, the status of both KRAS mutation and ERCC1 overexpression should be evaluated.	Oxaliplatin	17-28	KRAS proto-oncogene, GTPase	Homo sapiens	68-72
33468383-11	2021	When considering oxaliplatin-based chemotherapy, the status of both KRAS mutation and ERCC1 overexpression should be evaluated.	Oxaliplatin	17-28	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	86-91
33592546-4	2021	MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol.	Oxaliplatin	73-84	prominin 1	Homo sapiens	156-161
33592546-4	2021	MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol.	Oxaliplatin	172-183	prominin 1	Homo sapiens	57-62
33905821-0	2021	Exosomal miR-208b Related with Oxaliplatin Resistance Promotes Tregs expansion in Colorectal Cancer.	Oxaliplatin	31-42	microRNA 208b	Homo sapiens	9-17
33931939-6	2021	The ZEB2-dependent EMT transcriptional programme activated nucleotide excision repair (NER) pathway largely via upregulation of the ERCC1 gene and other components in NER pathway, leading to enhanced viability of CRC cells upon oxaliplatin treatment.	Oxaliplatin	228-239	zinc finger E-box binding homeobox 2	Homo sapiens	4-8
33931939-6	2021	The ZEB2-dependent EMT transcriptional programme activated nucleotide excision repair (NER) pathway largely via upregulation of the ERCC1 gene and other components in NER pathway, leading to enhanced viability of CRC cells upon oxaliplatin treatment.	Oxaliplatin	228-239	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	132-137
33755863-1	2021	BACKGROUND: Zolbetuximab plus first-line EOX (epirubicin, oxaliplatin, capecitabine; ZOL/EOX) significantly prolonged progression-free survival and overall survival in the FAST trial vs EOX alone.	Oxaliplatin	58-69	Fas activated serine/threonine kinase	Homo sapiens	172-176
33905821-7	2021	miR-208b in the colon cancer was secreted by the tumor cells in the pattern of exosomes, and oxaliplatin resistant cells showed the most obvious phenomenon of miR-208b increase.	Oxaliplatin	93-104	microRNA 208b	Mus musculus	0-8
33905821-7	2021	miR-208b in the colon cancer was secreted by the tumor cells in the pattern of exosomes, and oxaliplatin resistant cells showed the most obvious phenomenon of miR-208b increase.	Oxaliplatin	93-104	microRNA 208b	Mus musculus	159-167
33905821-9	2021	Furthermore, in vivo studies indicated that Tregs expansion mediated by cancer cell-secreted miR-208b resulted in tumor growth and oxaliplatin resistance.	Oxaliplatin	131-142	microRNA 208b	Mus musculus	93-101
33905821-10	2021	Our results demonstrate that tumor-secreted miR-208b promotes Tregs expansion by targeting PDCD4 and it may be related to decrease of oxaliplatin-based chemosensitivity in CRC.	Oxaliplatin	134-145	microRNA 208b	Mus musculus	44-52
33922007-3	2021	Oxaliplatin treatment resulted in the G2-phase arrest in all CRC lines tested (HCT116p53+/+, HCT116p53-/-, LoVo, SW48 and SW480).	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	85-88
33922007-0	2021	Oxaliplatin-Induced Senescence in Colorectal Cancer Cells Depends on p14ARF-Mediated Sustained p53 Activation.	Oxaliplatin	0-11	cyclin dependent kinase inhibitor 2A	Homo sapiens	69-75
33922007-4	2021	Immunoblot analysis showed that within the p53-competent lines p53 and p21CIP1 are activated at early times upon oxaliplatin treatment.	Oxaliplatin	113-124	tumor protein p53	Homo sapiens	43-46
33922007-0	2021	Oxaliplatin-Induced Senescence in Colorectal Cancer Cells Depends on p14ARF-Mediated Sustained p53 Activation.	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	95-98
33922007-4	2021	Immunoblot analysis showed that within the p53-competent lines p53 and p21CIP1 are activated at early times upon oxaliplatin treatment.	Oxaliplatin	113-124	tumor protein p53	Homo sapiens	63-66
33922007-4	2021	Immunoblot analysis showed that within the p53-competent lines p53 and p21CIP1 are activated at early times upon oxaliplatin treatment.	Oxaliplatin	113-124	cyclin dependent kinase inhibitor 1A	Homo sapiens	71-78
33922007-8	2021	Vice versa, ectopic p14ARF expression enhanced oxaliplatin-induced senescence in SW48 and SW480 cells.	Oxaliplatin	47-58	cyclin dependent kinase inhibitor 2A	Homo sapiens	20-26
33922007-9	2021	Our data show that oxaliplatin-induced senescence in CRC cells is dependent on p53 proficiency; however, a significant induction can only be observed upon p14ARF-mediated p53 stabilization.	Oxaliplatin	19-30	tumor protein p53	Homo sapiens	79-82
33922007-9	2021	Our data show that oxaliplatin-induced senescence in CRC cells is dependent on p53 proficiency; however, a significant induction can only be observed upon p14ARF-mediated p53 stabilization.	Oxaliplatin	19-30	cyclin dependent kinase inhibitor 2A	Homo sapiens	155-161
33922007-9	2021	Our data show that oxaliplatin-induced senescence in CRC cells is dependent on p53 proficiency; however, a significant induction can only be observed upon p14ARF-mediated p53 stabilization.	Oxaliplatin	19-30	tumor protein p53	Homo sapiens	171-174
33963708-10	2021	OBJECTIVE: EPS and Oxa can synergistically inhibit the proliferation of HCT116 cells possibly through the PI3K-Akt, MAPK, VEGF, and p53 signaling pathways.	Oxaliplatin	19-22	AKT serine/threonine kinase 1	Homo sapiens	111-114
33907420-14	2021	MiR-502-5p suppressed OXA resistance, proliferation and metastasis in OXA-resistant GC cells by targeting ADAM9.	Oxaliplatin	22-25	microRNA 502	Homo sapiens	0-7
33907420-14	2021	MiR-502-5p suppressed OXA resistance, proliferation and metastasis in OXA-resistant GC cells by targeting ADAM9.	Oxaliplatin	70-73	microRNA 502	Homo sapiens	0-7
33995628-8	2021	In CRC patients who received either capecitabine or capecitabine combined with oxaliplatin post-surgery, the positive expression of LC3 correlated with worse OS compared to patients who did not express LC3.	Oxaliplatin	79-90	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	132-135
33907420-14	2021	MiR-502-5p suppressed OXA resistance, proliferation and metastasis in OXA-resistant GC cells by targeting ADAM9.	Oxaliplatin	70-73	ADAM metallopeptidase domain 9	Homo sapiens	106-111
33963708-10	2021	OBJECTIVE: EPS and Oxa can synergistically inhibit the proliferation of HCT116 cells possibly through the PI3K-Akt, MAPK, VEGF, and p53 signaling pathways.	Oxaliplatin	19-22	vascular endothelial growth factor A	Homo sapiens	122-126
33963708-10	2021	OBJECTIVE: EPS and Oxa can synergistically inhibit the proliferation of HCT116 cells possibly through the PI3K-Akt, MAPK, VEGF, and p53 signaling pathways.	Oxaliplatin	19-22	tumor protein p53	Homo sapiens	132-135
33898768-0	2021	miR-33a-5p in small extracellular vesicles as non-invasive biomarker for oxaliplatin sensitivity in human colorectal cancer cells.	Oxaliplatin	73-84	microRNA 33a	Homo sapiens	0-7
33948371-0	2021	SLF1 polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer.	Oxaliplatin	39-50	SMC5-SMC6 complex localization factor 1	Homo sapiens	0-4
33948371-8	2021	We conclude that the rs6891545C > A polymorphism may serve as an independent marker of response to oxaliplatin-based adjuvant chemotherapy in patients with stage II and III colon cancer, with improved clinical benefit observed in patients with the A allele possibly attributable to low expression of SLF1 protein resulting in deficient DNA repair capacity.	Oxaliplatin	99-110	SMC5-SMC6 complex localization factor 1	Homo sapiens	300-304
33849565-11	2021	At the molecular level, metallothionein-2 modulated oxaliplatin-induced neuroinflammation, activation of NF-kappaB, and inactive transcriptional expression of IkappaB-alpha promoter, and these processes could be blocked by genetic restoration of metallothionein-2 in the spinal dorsal horn neurons.	Oxaliplatin	52-63	NFKB inhibitor alpha	Rattus norvegicus	159-172
33920318-0	2021	PEA-OXA Mitigates Oxaliplatin-Induced Painful Neuropathy through NF-kappaB/Nrf-2 Axis.	Oxaliplatin	18-29	NFE2 like bZIP transcription factor 2	Rattus norvegicus	75-80
33920318-7	2021	Our findings identify PEA-OXA as a therapeutic target in chemotherapy-induced painful neuropathy, through the biomolecular signaling NF-kappaB/Nrf-2 axis, thanks to its abilities to counteract L-OHP damage.	Oxaliplatin	193-198	NFE2 like bZIP transcription factor 2	Rattus norvegicus	143-148
33898768-7	2021	In microarray and real-time RT-PCR analyses, the intracellular miR-33a-5p, miR-210-3p, and miR-224-5p expressions were lower in acquired and intrinsic L-OHP-resistant CRC cells than sensitive cells.	Oxaliplatin	151-156	microRNA 33a	Homo sapiens	63-70
33898768-7	2021	In microarray and real-time RT-PCR analyses, the intracellular miR-33a-5p, miR-210-3p, and miR-224-5p expressions were lower in acquired and intrinsic L-OHP-resistant CRC cells than sensitive cells.	Oxaliplatin	151-156	microRNA 224	Homo sapiens	91-98
33898768-11	2021	The amount of miR-33a-5p and miR-210-3p in sEVs secreted from acquired and intrinsic L-OHP-resistant cells tended to be small.	Oxaliplatin	85-90	microRNA 33a	Homo sapiens	14-21
33898768-13	2021	To the best of our knowledge, this is the first study demonstrating that miR-33a-5p and/or miR-210-3p in sEVs would be candidates for biomarkers of L-OHP sensitivity.	Oxaliplatin	148-153	microRNA 33a	Homo sapiens	73-80
33898768-14	2021	In particular, miR-33a-5p is a promising candidate because it would be directly involved in L-OHP sensitivity.	Oxaliplatin	92-97	microRNA 33a	Homo sapiens	15-22
33796975-10	2021	It has been shown that melittin and whole honey bee venom are effective in treating paclitaxel and oxaliplatin-induced peripheral neuropathy.	Oxaliplatin	99-110	melittin	Apis mellifera	23-31
33785877-7	2021	In GC cells and organoids, long-term treatment with oxaliplatin suppressed SLFN11 expression while imparting drug resistance.	Oxaliplatin	52-63	schlafen family member 11	Homo sapiens	75-81
33136172-0	2021	Correction to: A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.	Oxaliplatin	119-130	thrombomodulin	Homo sapiens	83-97
33877891-7	2021	GC cell proliferation and the influence of HEIH on the sensitivity of cells to oxaliplatin following HEIH knockdown were assessed using sulforhodamine blue (SRB) assays in the MKN45 and AGS cell lines.	Oxaliplatin	79-90	hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA	Homo sapiens	43-47
33877891-13	2021	Downregulation of HEIH expression inhibited cell proliferation, enhanced oxaliplatin sensitivity, and induced the expression of p53 in MKN45 and AGC cells.	Oxaliplatin	73-84	hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA	Homo sapiens	18-22
33558709-5	2021	In addition, the influence of oxaliplatin and IgG on the ERK1/2-signalling pathway was evaluated by western blots.	Oxaliplatin	30-41	mitogen-activated protein kinase 3	Homo sapiens	57-63
33558709-9	2021	Moreover, while oxaliplatin induced the activation of ERK1/2, the pharmaceutical IgG inhibited ERK1/2 activity.	Oxaliplatin	16-27	mitogen-activated protein kinase 3	Homo sapiens	54-60
33460644-0	2021	Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1-/- mice.	Oxaliplatin	19-30	sterile alpha and HEAT/Armadillo motif containing 1	Mus musculus	82-87
33460644-5	2021	In BL/6 and WldS mice, oxaliplatin induced significant mechanical and cold hypersensitivities which were absent in Sarm1-/- mice.	Oxaliplatin	23-34	wallerian degeneration	Mus musculus	12-16
33460644-5	2021	In BL/6 and WldS mice, oxaliplatin induced significant mechanical and cold hypersensitivities which were absent in Sarm1-/- mice.	Oxaliplatin	23-34	sterile alpha and HEAT/Armadillo motif containing 1	Mus musculus	115-120
33460644-10	2021	Changes in levels of four transcripts - Alas2, Hba-a1, Hba-a2, and Tfrc - correlated with oxaliplatin-induced pain, or absence thereof, across the three genotypes.	Oxaliplatin	90-101	aminolevulinic acid synthase 2, erythroid	Mus musculus	40-45
33460644-10	2021	Changes in levels of four transcripts - Alas2, Hba-a1, Hba-a2, and Tfrc - correlated with oxaliplatin-induced pain, or absence thereof, across the three genotypes.	Oxaliplatin	90-101	hemoglobin alpha, adult chain 1	Mus musculus	47-53
33460644-10	2021	Changes in levels of four transcripts - Alas2, Hba-a1, Hba-a2, and Tfrc - correlated with oxaliplatin-induced pain, or absence thereof, across the three genotypes.	Oxaliplatin	90-101	hemoglobin alpha, adult chain 2	Mus musculus	55-61
33460644-10	2021	Changes in levels of four transcripts - Alas2, Hba-a1, Hba-a2, and Tfrc - correlated with oxaliplatin-induced pain, or absence thereof, across the three genotypes.	Oxaliplatin	90-101	transferrin receptor	Mus musculus	67-71
33460644-11	2021	Our findings suggest that targeting SARM1 could be a viable therapeutic approach to prevent oxaliplatin-induced acute neuropathic pain.	Oxaliplatin	92-103	sterile alpha and HEAT/Armadillo motif containing 1	Mus musculus	36-41
33785877-8	2021	The acquired resistance to oxaliplatin was reversed by reactivation of SLFN11 with epigenetic modifying drugs.	Oxaliplatin	27-38	schlafen family member 11	Homo sapiens	71-77
33828479-6	2021	Furthermore, the SW620 cell viability was inhibited and the expressions of MAPK and the p-ERK/ERK ratio were significantly downregulated by the aqueous extract of BSJPJDD combined with oxaliplatin treatment, compared with oxaliplatin treatment alone (p < 0.05).	Oxaliplatin	185-196	mitogen-activated protein kinase 1	Homo sapiens	90-93
33824865-0	2021	TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell.	Oxaliplatin	16-27	tripartite motif containing 29	Homo sapiens	0-6
33824865-0	2021	TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell.	Oxaliplatin	16-27	tumor protein p53	Homo sapiens	42-45
33824865-3	2021	In our experiments, we aim to elucidate the associations among TRIM29 protein, mutant P53, and the resistance of colon cancer cells to oxaliplatin.	Oxaliplatin	135-146	tripartite motif containing 29	Homo sapiens	63-69
33828479-6	2021	Furthermore, the SW620 cell viability was inhibited and the expressions of MAPK and the p-ERK/ERK ratio were significantly downregulated by the aqueous extract of BSJPJDD combined with oxaliplatin treatment, compared with oxaliplatin treatment alone (p < 0.05).	Oxaliplatin	185-196	mitogen-activated protein kinase 1	Homo sapiens	94-97
33824865-3	2021	In our experiments, we aim to elucidate the associations among TRIM29 protein, mutant P53, and the resistance of colon cancer cells to oxaliplatin.	Oxaliplatin	135-146	tumor protein p53	Homo sapiens	86-89
33824865-10	2021	TRIM29 significantly increased the sensitivity of P53 mutant colon cancer cell HT29 to oxaliplatin.	Oxaliplatin	87-98	tripartite motif containing 29	Homo sapiens	0-6
33824865-10	2021	TRIM29 significantly increased the sensitivity of P53 mutant colon cancer cell HT29 to oxaliplatin.	Oxaliplatin	87-98	tumor protein p53	Homo sapiens	50-53
33824865-11	2021	The oxaliplatin-resistant model of P53 mutant colon cancer cell HT29 was successfully constructed.	Oxaliplatin	4-15	tumor protein p53	Homo sapiens	35-38
33824865-13	2021	In addition, TRIM29 successfully reversed the resistance of HT29-OX resistant cell model to oxaliplatin.	Oxaliplatin	92-103	tripartite motif containing 29	Homo sapiens	13-19
33824865-14	2021	Conclusion: In mutant P53 colon cancer cell HT29, TRIM29 greatly increased the sensitivity of HT29 to oxaliplatin and reverse oxaliplatin resistance.	Oxaliplatin	102-113	tumor protein p53	Homo sapiens	22-25
33824865-14	2021	Conclusion: In mutant P53 colon cancer cell HT29, TRIM29 greatly increased the sensitivity of HT29 to oxaliplatin and reverse oxaliplatin resistance.	Oxaliplatin	102-113	tripartite motif containing 29	Homo sapiens	50-56
33824865-14	2021	Conclusion: In mutant P53 colon cancer cell HT29, TRIM29 greatly increased the sensitivity of HT29 to oxaliplatin and reverse oxaliplatin resistance.	Oxaliplatin	126-137	tumor protein p53	Homo sapiens	22-25
33828479-6	2021	Furthermore, the SW620 cell viability was inhibited and the expressions of MAPK and the p-ERK/ERK ratio were significantly downregulated by the aqueous extract of BSJPJDD combined with oxaliplatin treatment, compared with oxaliplatin treatment alone (p < 0.05).	Oxaliplatin	222-233	mitogen-activated protein kinase 1	Homo sapiens	90-93
33824865-14	2021	Conclusion: In mutant P53 colon cancer cell HT29, TRIM29 greatly increased the sensitivity of HT29 to oxaliplatin and reverse oxaliplatin resistance.	Oxaliplatin	126-137	tripartite motif containing 29	Homo sapiens	50-56
33824865-15	2021	The underlying mechanism is TRIM29 may increase the sensitivity of HT29 to oxaliplatin by blocking the transcriptional function of mutant P53, which inhibits the transcription function of its downstream gene such as MDR1.	Oxaliplatin	75-86	tripartite motif containing 29	Homo sapiens	28-34
33828479-6	2021	Furthermore, the SW620 cell viability was inhibited and the expressions of MAPK and the p-ERK/ERK ratio were significantly downregulated by the aqueous extract of BSJPJDD combined with oxaliplatin treatment, compared with oxaliplatin treatment alone (p < 0.05).	Oxaliplatin	222-233	mitogen-activated protein kinase 1	Homo sapiens	94-97
33824865-15	2021	The underlying mechanism is TRIM29 may increase the sensitivity of HT29 to oxaliplatin by blocking the transcriptional function of mutant P53, which inhibits the transcription function of its downstream gene such as MDR1.	Oxaliplatin	75-86	tumor protein p53	Homo sapiens	138-141
33981825-8	2021	It was indicated that scutellarin resensitizes oxaliplatin-resistant CRC cells to oxaliplatin treatment through inhibition of PKM2.	Oxaliplatin	47-58	pyruvate kinase M1/2	Homo sapiens	126-130
33824865-15	2021	The underlying mechanism is TRIM29 may increase the sensitivity of HT29 to oxaliplatin by blocking the transcriptional function of mutant P53, which inhibits the transcription function of its downstream gene such as MDR1.	Oxaliplatin	75-86	ATP binding cassette subfamily B member 1	Homo sapiens	216-220
33981825-8	2021	It was indicated that scutellarin resensitizes oxaliplatin-resistant CRC cells to oxaliplatin treatment through inhibition of PKM2.	Oxaliplatin	82-93	pyruvate kinase M1/2	Homo sapiens	126-130
33981825-0	2021	Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2.	Oxaliplatin	74-85	pyruvate kinase M1/2	Homo sapiens	118-122
33712895-0	2021	Ultrasensitive and selective molecularly imprinted electrochemical oxaliplatin sensor based on a novel nitrogen-doped carbon nanotubes/Ag@cu MOF as a signal enhancer and reporter nanohybrid.	Oxaliplatin	67-78	lysine acetyltransferase 8	Homo sapiens	141-144
33981825-6	2021	Mechanically, overexpression of pyruvate kinase isoenzyme M2 (PKM2) was responsible for the resistance to oxaliplatin in OR-SW480 and OR-HT29.	Oxaliplatin	106-117	pyruvate kinase M1/2	Homo sapiens	32-60
33981825-6	2021	Mechanically, overexpression of pyruvate kinase isoenzyme M2 (PKM2) was responsible for the resistance to oxaliplatin in OR-SW480 and OR-HT29.	Oxaliplatin	106-117	pyruvate kinase M1/2	Homo sapiens	62-66
33841630-1	2021	First-generation immunological checkpoint inhibitors, such as CTLA-4, PD-L1 and PD-1 exhibit significant advantages over conventional cytotoxic drugs, such as oxaliplatin and 5-FU, for the treatment of colorectal cancer.	Oxaliplatin	159-170	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	62-68
33524870-0	2021	Knockdown of PC4 increases chemosensitivity of Oxaliplatin in triple negative breast cancer by suppressing mTOR pathway.	Oxaliplatin	47-58	SUB1 regulator of transcription	Homo sapiens	13-16
33524870-0	2021	Knockdown of PC4 increases chemosensitivity of Oxaliplatin in triple negative breast cancer by suppressing mTOR pathway.	Oxaliplatin	47-58	mechanistic target of rapamycin kinase	Homo sapiens	107-111
33731881-8	2021	The median expression of oxaliplatin-related genes ATP7B and SRPK1 was significantly reduced in mucinous versus non-mucinous CRC (p = 0.004, p = 0.007, respectively).	Oxaliplatin	25-36	ATPase copper transporting beta	Homo sapiens	51-56
33731881-8	2021	The median expression of oxaliplatin-related genes ATP7B and SRPK1 was significantly reduced in mucinous versus non-mucinous CRC (p = 0.004, p = 0.007, respectively).	Oxaliplatin	25-36	SRSF protein kinase 1	Homo sapiens	61-66
32947545-5	2021	To confirm the role of neuroendocrine stress axes in CIPN, intrathecal administration of antisense oligodeoxynucleotide (AS-ODN) targeting beta2-adrenergic receptor mRNA both prevented and reversed oxaliplatin-induced hyperalgesia, only in males.	Oxaliplatin	198-209	adrenoceptor beta 2	Rattus norvegicus	139-164
33791222-7	2021	We found that miR-1278 was downregulated in CRC samples, correlating with advanced clinical stage, and overexpression of miR-1278 led to tumor growth arrest and increased sensitivity to oxaliplatin via enhanced apoptosis and DNA damage.	Oxaliplatin	186-197	microRNA 1278	Homo sapiens	121-129
33791222-10	2021	In summary, our data demonstrated that miR-1278 may serve as a potential tumor suppressor gene and biomarker for determining sensitivity to oxaliplatin and vitamin D in CRC.	Oxaliplatin	140-151	microRNA 1278	Homo sapiens	39-47
33429333-0	2021	miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.	Oxaliplatin	91-102	C-X-C motif chemokine receptor 4	Homo sapiens	132-137
33650652-8	2021	The results revealed that HIPK2 depletion induced resistance to 5-FU and OXA, and that this resistance was not overcome by brusatol, an inhibitor of the antioxidant response regulator nuclear factor erythroid 2-related factor 2 (NRF2), which is frequently overexpressed in CRC.	Oxaliplatin	73-76	homeodomain interacting protein kinase 2	Homo sapiens	26-31
33650652-9	2021	By contrast, cell sensitivity to 5-FU and OXA was further induced by brusatol supplementation in HIPK2-proficient cells, further supporting the contribution of HIPK2 in chemotherapy response.	Oxaliplatin	42-45	homeodomain interacting protein kinase 2	Homo sapiens	97-102
33650652-9	2021	By contrast, cell sensitivity to 5-FU and OXA was further induced by brusatol supplementation in HIPK2-proficient cells, further supporting the contribution of HIPK2 in chemotherapy response.	Oxaliplatin	42-45	homeodomain interacting protein kinase 2	Homo sapiens	160-165
33720069-5	2021	In human epidermal growth factor receptor 2 (HER2)-positive oesophago-gastric adenocarcinoma, a phase II trial showed improved DFS when pertuzumab and trastuzumab were added to perioperative FLOT (5-fluorouracil/leucovorin, oxaliplatin, docetaxel).	Oxaliplatin	224-235	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
33754020-0	2021	Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy.	Oxaliplatin	100-111	cathepsin S	Homo sapiens	38-49
33754020-7	2021	(2) Oxaliplatin treatment increases CTSS expression by enhancing cytosol translocation of interferon response factor 1 (IRF1), which then facilitates STIM-dependent store-operated Ca2+ entry homeostasis.	Oxaliplatin	4-15	cathepsin S	Mus musculus	36-40
33754020-7	2021	(2) Oxaliplatin treatment increases CTSS expression by enhancing cytosol translocation of interferon response factor 1 (IRF1), which then facilitates STIM-dependent store-operated Ca2+ entry homeostasis.	Oxaliplatin	4-15	interferon regulatory factor 1	Mus musculus	90-118
33754020-7	2021	(2) Oxaliplatin treatment increases CTSS expression by enhancing cytosol translocation of interferon response factor 1 (IRF1), which then facilitates STIM-dependent store-operated Ca2+ entry homeostasis.	Oxaliplatin	4-15	interferon regulatory factor 1	Mus musculus	120-124
33754020-10	2021	(5) Serum CTSS expression is increased in CRC patients with oxaliplatin-induced neurotoxicity.	Oxaliplatin	60-71	cathepsin S	Mus musculus	10-14
33754020-11	2021	Conclusions: We highlighted the critical role of CTSS in OIPN, which provides a therapeutic strategy for the common adverse side effects of oxaliplatin.	Oxaliplatin	140-151	cathepsin S	Homo sapiens	49-53
33653301-15	2021	CONCLUSIONS: According to the evolution model, DNA damage response (DDR)-related ATM or BRCA2 somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin-based chemotherapy.	Oxaliplatin	193-204	ATM serine/threonine kinase	Homo sapiens	81-84
33653301-15	2021	CONCLUSIONS: According to the evolution model, DNA damage response (DDR)-related ATM or BRCA2 somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin-based chemotherapy.	Oxaliplatin	193-204	BRCA2 DNA repair associated	Homo sapiens	88-93
33788740-7	2021	MDM4-transduced NUGC4 cells formed twice as many colonies and had a higher 50% inhibitory concentration for 5-fluorouracil and oxaliplatin than did the control cells.	Oxaliplatin	127-138	MDM4 regulator of p53	Homo sapiens	0-4
33169187-8	2021	However, co-administration of gefitinib and oxaliplatin or cisplatin was frequently antagonistic in cell-based assays in EGFR CNG ESCC, whereas the combination of gefitinib with docetaxel or irinotecan was more efficacious.	Oxaliplatin	44-55	epidermal growth factor receptor	Homo sapiens	121-125
33485079-0	2021	Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.	Oxaliplatin	44-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
33555197-0	2021	Tumor-Associated Macrophages Promote Oxaliplatin Resistance via METTL3-Mediated m6A of TRAF5 and Necroptosis in Colorectal Cancer.	Oxaliplatin	37-48	methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit	Homo sapiens	64-70
33555197-0	2021	Tumor-Associated Macrophages Promote Oxaliplatin Resistance via METTL3-Mediated m6A of TRAF5 and Necroptosis in Colorectal Cancer.	Oxaliplatin	37-48	TNF receptor associated factor 5	Homo sapiens	87-92
33574948-7	2021	AKT1/CTNNB1 mutations were also associated with oxaliplatin, irinotecan, SN-38 and 5-fluorouracil resistance.	Oxaliplatin	48-59	AKT serine/threonine kinase 1	Homo sapiens	0-4
33574948-7	2021	AKT1/CTNNB1 mutations were also associated with oxaliplatin, irinotecan, SN-38 and 5-fluorouracil resistance.	Oxaliplatin	48-59	catenin beta 1	Homo sapiens	5-11
33602823-5	2021	Moreover, we found that two distinct DNA damaging drugs, the platinoid oxaliplatin and the topoisomerase inhibitor mitoxantrone, strongly up-regulate MHC-I AgPP in a manner dependent on activation of nuclear factor kappa B (NF-kappaB), p300/CBP, and other transcription factors, but independently of autocrine IFNgamma signaling.	Oxaliplatin	71-82	nuclear factor kappa B subunit 1	Homo sapiens	200-222
33518493-3	2021	suggest that immunogenic chemotherapeutics such as oxaliplatin can be harnessed to maximize the capacity of CAR T cells to infiltrate and control solid tumors.	Oxaliplatin	51-62	nuclear receptor subfamily 1 group I member 3	Homo sapiens	108-111
33688593-4	2021	Oxaliplatin (L-OHP) has a favorable toxicity profile compared with cisplatin; hence, a phase III clinical trial (G-SOX trial) demonstrated the progression-free survival (PFS) and overall survival in CS was 5.4 and 13.1 months and those in SOX was 5.5 and 14.1 months, respectively.	Oxaliplatin	0-11	citrate synthase	Homo sapiens	199-201
33688593-4	2021	Oxaliplatin (L-OHP) has a favorable toxicity profile compared with cisplatin; hence, a phase III clinical trial (G-SOX trial) demonstrated the progression-free survival (PFS) and overall survival in CS was 5.4 and 13.1 months and those in SOX was 5.5 and 14.1 months, respectively.	Oxaliplatin	13-18	citrate synthase	Homo sapiens	199-201
33658858-0	2021	The Combination Therapy of Fluorouracil and Oxaliplatin Suppress the Progression of Colon Cancer Through miR-183-5p/SOCS3 Axis and Downregulating PD-L1.	Oxaliplatin	44-55	suppressor of cytokine signaling 3	Homo sapiens	116-121
33658858-0	2021	The Combination Therapy of Fluorouracil and Oxaliplatin Suppress the Progression of Colon Cancer Through miR-183-5p/SOCS3 Axis and Downregulating PD-L1.	Oxaliplatin	44-55	CD274 molecule	Homo sapiens	146-151
33658858-1	2021	Purpose: The purpose of this study was to investigate the mechanism of combination of fluorouracil (FU) and oxaliplatin (OXA) on the progression of colon cancer via miR-183-5p/SOCS3 axis and regulating PD-L1.	Oxaliplatin	108-119	suppressor of cytokine signaling 3	Homo sapiens	176-181
33658858-1	2021	Purpose: The purpose of this study was to investigate the mechanism of combination of fluorouracil (FU) and oxaliplatin (OXA) on the progression of colon cancer via miR-183-5p/SOCS3 axis and regulating PD-L1.	Oxaliplatin	108-119	CD274 molecule	Homo sapiens	202-207
33658858-1	2021	Purpose: The purpose of this study was to investigate the mechanism of combination of fluorouracil (FU) and oxaliplatin (OXA) on the progression of colon cancer via miR-183-5p/SOCS3 axis and regulating PD-L1.	Oxaliplatin	121-124	suppressor of cytokine signaling 3	Homo sapiens	176-181
33658858-1	2021	Purpose: The purpose of this study was to investigate the mechanism of combination of fluorouracil (FU) and oxaliplatin (OXA) on the progression of colon cancer via miR-183-5p/SOCS3 axis and regulating PD-L1.	Oxaliplatin	121-124	CD274 molecule	Homo sapiens	202-207
33658858-7	2021	Results: Our study demonstrated that the combination of OXA and FU remarkably suppressed proliferation, promoted apoptosis and arrest cells in G0/G1 phrase of HCT116 cells, and observably downregulated the expression of PD-L1, CCL1, CCL4, CCL7, EGFR, STARD1 and STARD3.	Oxaliplatin	56-59	CD274 molecule	Homo sapiens	220-225
33658858-7	2021	Results: Our study demonstrated that the combination of OXA and FU remarkably suppressed proliferation, promoted apoptosis and arrest cells in G0/G1 phrase of HCT116 cells, and observably downregulated the expression of PD-L1, CCL1, CCL4, CCL7, EGFR, STARD1 and STARD3.	Oxaliplatin	56-59	C-C motif chemokine ligand 1	Homo sapiens	227-231
33658858-7	2021	Results: Our study demonstrated that the combination of OXA and FU remarkably suppressed proliferation, promoted apoptosis and arrest cells in G0/G1 phrase of HCT116 cells, and observably downregulated the expression of PD-L1, CCL1, CCL4, CCL7, EGFR, STARD1 and STARD3.	Oxaliplatin	56-59	C-C motif chemokine ligand 4	Homo sapiens	233-237
33658858-7	2021	Results: Our study demonstrated that the combination of OXA and FU remarkably suppressed proliferation, promoted apoptosis and arrest cells in G0/G1 phrase of HCT116 cells, and observably downregulated the expression of PD-L1, CCL1, CCL4, CCL7, EGFR, STARD1 and STARD3.	Oxaliplatin	56-59	C-C motif chemokine ligand 7	Homo sapiens	239-243
33658858-7	2021	Results: Our study demonstrated that the combination of OXA and FU remarkably suppressed proliferation, promoted apoptosis and arrest cells in G0/G1 phrase of HCT116 cells, and observably downregulated the expression of PD-L1, CCL1, CCL4, CCL7, EGFR, STARD1 and STARD3.	Oxaliplatin	56-59	epidermal growth factor receptor	Homo sapiens	245-249
33658858-7	2021	Results: Our study demonstrated that the combination of OXA and FU remarkably suppressed proliferation, promoted apoptosis and arrest cells in G0/G1 phrase of HCT116 cells, and observably downregulated the expression of PD-L1, CCL1, CCL4, CCL7, EGFR, STARD1 and STARD3.	Oxaliplatin	56-59	steroidogenic acute regulatory protein	Homo sapiens	251-257
33658858-7	2021	Results: Our study demonstrated that the combination of OXA and FU remarkably suppressed proliferation, promoted apoptosis and arrest cells in G0/G1 phrase of HCT116 cells, and observably downregulated the expression of PD-L1, CCL1, CCL4, CCL7, EGFR, STARD1 and STARD3.	Oxaliplatin	56-59	StAR related lipid transfer domain containing 3	Homo sapiens	262-268
33658858-11	2021	Finally, we demonstrated that the combination therapy of OXA and FU inhibited the proliferation, promote apoptosis and arrest cells in G0/G1 phrase by downregulating PD-L1 via miR-183-5p/SOCS3 axis.	Oxaliplatin	57-60	CD274 molecule	Homo sapiens	166-171
33658858-11	2021	Finally, we demonstrated that the combination therapy of OXA and FU inhibited the proliferation, promote apoptosis and arrest cells in G0/G1 phrase by downregulating PD-L1 via miR-183-5p/SOCS3 axis.	Oxaliplatin	57-60	suppressor of cytokine signaling 3	Homo sapiens	187-192
33658858-12	2021	Conclusion: The combination therapy of OXA and FU could suppress the malignant biological behavior, and the mechanism was realized by inhibiting PD-L1 through miR-183-5p/SOCS3 axis.	Oxaliplatin	39-42	CD274 molecule	Homo sapiens	145-150
33658858-12	2021	Conclusion: The combination therapy of OXA and FU could suppress the malignant biological behavior, and the mechanism was realized by inhibiting PD-L1 through miR-183-5p/SOCS3 axis.	Oxaliplatin	39-42	suppressor of cytokine signaling 3	Homo sapiens	170-175
33602823-5	2021	Moreover, we found that two distinct DNA damaging drugs, the platinoid oxaliplatin and the topoisomerase inhibitor mitoxantrone, strongly up-regulate MHC-I AgPP in a manner dependent on activation of nuclear factor kappa B (NF-kappaB), p300/CBP, and other transcription factors, but independently of autocrine IFNgamma signaling.	Oxaliplatin	71-82	nuclear factor kappa B subunit 1	Homo sapiens	224-233
33602823-5	2021	Moreover, we found that two distinct DNA damaging drugs, the platinoid oxaliplatin and the topoisomerase inhibitor mitoxantrone, strongly up-regulate MHC-I AgPP in a manner dependent on activation of nuclear factor kappa B (NF-kappaB), p300/CBP, and other transcription factors, but independently of autocrine IFNgamma signaling.	Oxaliplatin	71-82	E1A binding protein p300	Homo sapiens	236-240
33602823-5	2021	Moreover, we found that two distinct DNA damaging drugs, the platinoid oxaliplatin and the topoisomerase inhibitor mitoxantrone, strongly up-regulate MHC-I AgPP in a manner dependent on activation of nuclear factor kappa B (NF-kappaB), p300/CBP, and other transcription factors, but independently of autocrine IFNgamma signaling.	Oxaliplatin	71-82	CREB binding protein	Homo sapiens	241-244
33602823-5	2021	Moreover, we found that two distinct DNA damaging drugs, the platinoid oxaliplatin and the topoisomerase inhibitor mitoxantrone, strongly up-regulate MHC-I AgPP in a manner dependent on activation of nuclear factor kappa B (NF-kappaB), p300/CBP, and other transcription factors, but independently of autocrine IFNgamma signaling.	Oxaliplatin	71-82	interferon gamma	Homo sapiens	310-318
33602823-7	2021	Drugs like oxaliplatin and mitoxantrone may be used to overcome resistance to PD-(L)1 inhibitors in tumors that had "epigenetically down-regulated," but had not permanently lost MHC-I AgPP activity.	Oxaliplatin	11-22	CD274 molecule	Homo sapiens	78-85
33594312-0	2021	LACTB induced apoptosis of oxaliplatin-resistant gastric cancer through regulating autophagy-mediated mitochondrial apoptosis pathway.	Oxaliplatin	27-38	lactamase beta	Homo sapiens	0-5
33594312-4	2021	Here, we aimed to investigate the function and mechanism of LACTB in OXA-resistant GC.	Oxaliplatin	69-72	lactamase beta	Homo sapiens	60-65
33594312-10	2021	Furthermore, our results certified that RAPA could weaken the function of LACTB on apoptosis and mitochondrial morphology and function in OXA-resistant MGC-803 cells with OXA treatment.	Oxaliplatin	171-174	lactamase beta	Homo sapiens	74-79
33594312-11	2021	Therefore, we demonstrated that LACTB could attenuate the resistance of MGC-803/OXA cells to OXA through autophagy-mediated mitochondrial morphological changes, mitochondrial dysfunction, and apoptosis, suggesting that LACTB, functions as a suppressor, is conducive to the therapy of OXA-resistant GC.	Oxaliplatin	80-83	lactamase beta	Homo sapiens	32-37
33594312-7	2021	We revealed that LACTB was downregulated in OXA-resistant MGC-803 cells, and overexpression of LACTB reduced the resistance of GC cells to OXA.	Oxaliplatin	44-47	lactamase beta	Homo sapiens	17-22
33594312-11	2021	Therefore, we demonstrated that LACTB could attenuate the resistance of MGC-803/OXA cells to OXA through autophagy-mediated mitochondrial morphological changes, mitochondrial dysfunction, and apoptosis, suggesting that LACTB, functions as a suppressor, is conducive to the therapy of OXA-resistant GC.	Oxaliplatin	80-83	lactamase beta	Homo sapiens	219-224
33594312-7	2021	We revealed that LACTB was downregulated in OXA-resistant MGC-803 cells, and overexpression of LACTB reduced the resistance of GC cells to OXA.	Oxaliplatin	139-142	lactamase beta	Homo sapiens	95-100
33594312-8	2021	Besides, our results uncovered that overexpression of LACTB induced apoptosis, reduced the mitochondrial membrane potential (MMP) and accelerated ROS accumulation in OXA-resistant MGC-803 (MGC-803/OXA) cells.	Oxaliplatin	166-169	lactamase beta	Homo sapiens	54-59
33594312-10	2021	Furthermore, our results certified that RAPA could weaken the function of LACTB on apoptosis and mitochondrial morphology and function in OXA-resistant MGC-803 cells with OXA treatment.	Oxaliplatin	138-141	transcriptional regulating factor 1	Homo sapiens	40-44
33594312-10	2021	Furthermore, our results certified that RAPA could weaken the function of LACTB on apoptosis and mitochondrial morphology and function in OXA-resistant MGC-803 cells with OXA treatment.	Oxaliplatin	138-141	lactamase beta	Homo sapiens	74-79
33594312-10	2021	Furthermore, our results certified that RAPA could weaken the function of LACTB on apoptosis and mitochondrial morphology and function in OXA-resistant MGC-803 cells with OXA treatment.	Oxaliplatin	171-174	transcriptional regulating factor 1	Homo sapiens	40-44
33129844-9	2021	The combination of 5-fluorouracil and oxaliplatin reduced MDSCs, increased numbers of intra-tumor CD8+ T cells, and increased the response of tumors to anti-PD1-however, this resulted in increased tumor expression of PDL1.	Oxaliplatin	38-49	programmed cell death 1	Mus musculus	157-160
33357452-5	2021	Adding oxaliplatin (Ox) to the lymphodepletion regimen activates tumor macrophages to express T-cell-recruiting chemokines, resulting in improved CAR-T cell infiltration, remodeling of the tumor microenvironment, and increased tumor sensitivity to anti-PD-L1.	Oxaliplatin	7-18	CD274 molecule	Homo sapiens	253-258
33534373-10	2021	Besides, intrathecal injection of miR-141-5p mimic attenuated OXA-induced neuropathic pain and reduced the expression of TRPA1, a predicted target of miR-141-5p.	Oxaliplatin	62-65	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	121-126
33534373-11	2021	Collectively, the results suggest that TRPA1 may mediate miR-141-5p-alleviated neuropathic pain induced by OXA.	Oxaliplatin	107-110	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	39-44
33534373-11	2021	Collectively, the results suggest that TRPA1 may mediate miR-141-5p-alleviated neuropathic pain induced by OXA.	Oxaliplatin	107-110	microRNA 141	Rattus norvegicus	57-64
33376510-0	2021	Silencing GnT-V reduces oxaliplatin chemosensitivity in human colorectal cancer cells through N-glycan alteration of organic cation transporter member 2.	Oxaliplatin	24-35	alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase	Homo sapiens	10-15
33376510-5	2021	The present study describes a potential novel strategy for enhancing oxaliplatin sensitivity involving the glycosylation of this drug transporter, specifically the modification of beta-1,6-N-acetylglucosamine (GlcNAc) residues by N-acetylglucosaminyltransferase V (GnT-V).	Oxaliplatin	69-80	alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase	Homo sapiens	230-263
33376510-5	2021	The present study describes a potential novel strategy for enhancing oxaliplatin sensitivity involving the glycosylation of this drug transporter, specifically the modification of beta-1,6-N-acetylglucosamine (GlcNAc) residues by N-acetylglucosaminyltransferase V (GnT-V).	Oxaliplatin	69-80	alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase	Homo sapiens	265-270
33603368-1	2021	Background: This study was aimed to prepare a novel magnetic thermosensitive cationic liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA of MDC1 (MDC1-AS) to Cervical cancer cells and evaluate the efficiency of this drug carrier and its antitumor effects on Cervical cancer.	Oxaliplatin	130-141	mediator of DNA damage checkpoint 1	Homo sapiens	178-182
33578797-5	2021	Notably, myristoylated alanine-rich C-kinase substrate (MARCKS) and Wntless homolog protein (WLS) were upregulated in oxaliplatin-resistant cells compared to sensitive cells, as confirmed by qRT-PCR and Western blot analysis.	Oxaliplatin	118-129	myristoylated alanine rich protein kinase C substrate	Homo sapiens	9-54
33578797-5	2021	Notably, myristoylated alanine-rich C-kinase substrate (MARCKS) and Wntless homolog protein (WLS) were upregulated in oxaliplatin-resistant cells compared to sensitive cells, as confirmed by qRT-PCR and Western blot analysis.	Oxaliplatin	118-129	myristoylated alanine rich protein kinase C substrate	Homo sapiens	56-62
33578797-6	2021	We further demonstrated the activation of AKT and beta-catenin signaling (downstream targets of MARCKS and WLS, respectively) in oxaliplatin-resistant PANC-1 cells.	Oxaliplatin	129-140	AKT serine/threonine kinase 1	Homo sapiens	42-45
33578797-6	2021	We further demonstrated the activation of AKT and beta-catenin signaling (downstream targets of MARCKS and WLS, respectively) in oxaliplatin-resistant PANC-1 cells.	Oxaliplatin	129-140	catenin beta 1	Homo sapiens	50-62
33578797-6	2021	We further demonstrated the activation of AKT and beta-catenin signaling (downstream targets of MARCKS and WLS, respectively) in oxaliplatin-resistant PANC-1 cells.	Oxaliplatin	129-140	myristoylated alanine rich protein kinase C substrate	Homo sapiens	96-102
33578797-7	2021	Additionally, we show that the siRNA-mediated suppression of both MARCKS and WLS enhanced oxaliplatin sensitivity in oxaliplatin-resistant PANC-1 cells.	Oxaliplatin	90-101	myristoylated alanine rich protein kinase C substrate	Homo sapiens	66-72
33578797-7	2021	Additionally, we show that the siRNA-mediated suppression of both MARCKS and WLS enhanced oxaliplatin sensitivity in oxaliplatin-resistant PANC-1 cells.	Oxaliplatin	117-128	myristoylated alanine rich protein kinase C substrate	Homo sapiens	66-72
33578797-8	2021	Taken together, our results provide insights into multiple mechanisms of oxaliplatin resistance in pancreatic cancer cells and reveal that MARCKS and WLS might be involved in the oxaliplatin resistance.	Oxaliplatin	179-190	myristoylated alanine rich protein kinase C substrate	Homo sapiens	139-145
33417830-4	2021	in this issue demonstrate that oxaliplatin-based lymphodepleting chemotherapy promotes enhanced CAR T cell recruitment to lung tumors, boosting therapeutic impact in combination with anti-PD-L1.	Oxaliplatin	31-42	CXADR pseudogene 1	Homo sapiens	96-99
33417830-4	2021	in this issue demonstrate that oxaliplatin-based lymphodepleting chemotherapy promotes enhanced CAR T cell recruitment to lung tumors, boosting therapeutic impact in combination with anti-PD-L1.	Oxaliplatin	31-42	CD274 molecule	Homo sapiens	188-193
33534373-0	2021	TRPA1 involved in miR-141-5p-alleviated neuropathic pain induced by oxaliplatin.	Oxaliplatin	68-79	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	0-5
33534373-0	2021	TRPA1 involved in miR-141-5p-alleviated neuropathic pain induced by oxaliplatin.	Oxaliplatin	68-79	microRNA 141	Rattus norvegicus	18-25
33534373-9	2021	By contrast, OXA significantly up-regulated the expression of TRPA1 mRNA and protein.	Oxaliplatin	13-16	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	62-67
33123829-0	2021	Circular RNA circ_0032821 contributes to oxaliplatin (OXA) resistance of gastric cancer cells by regulating SOX9 via miR-515-5p.	Oxaliplatin	41-52	SRY (sex determining region Y)-box 9	Mus musculus	108-112
33123829-0	2021	Circular RNA circ_0032821 contributes to oxaliplatin (OXA) resistance of gastric cancer cells by regulating SOX9 via miR-515-5p.	Oxaliplatin	54-57	SRY (sex determining region Y)-box 9	Mus musculus	108-112
33383348-1	2021	BACKGROUND: The CAO/ARO/AIO trial has shown that oxaliplatin added to preoperative chemoradiotherapy and postoperative chemotherapy significantly improved disease-free survival in locally advanced rectal cancer (LARC).	Oxaliplatin	49-60	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	20-23
33376510-6	2021	The results revealed that the downregulation of GnT-V inhibited the oxaliplatin chemosensitivity of CW-2 cells.	Oxaliplatin	68-79	alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase	Homo sapiens	48-53
33376510-7	2021	Furthermore, the knockdown of GnT-V caused a marked reduction in the presence of beta-1,6-GlcNAc structures on OCT2 and decreased the localization of OCT2 in the cytomembrane, which were associated with a reduced uptake of oxaliplatin in wild-type and oxaliplatin-resistant CW-2 cells.	Oxaliplatin	223-234	alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase	Homo sapiens	30-35
33376510-7	2021	Furthermore, the knockdown of GnT-V caused a marked reduction in the presence of beta-1,6-GlcNAc structures on OCT2 and decreased the localization of OCT2 in the cytomembrane, which were associated with a reduced uptake of oxaliplatin in wild-type and oxaliplatin-resistant CW-2 cells.	Oxaliplatin	252-263	alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase	Homo sapiens	30-35
33376510-8	2021	Overall, the study provides novel insights into the molecular mechanism by which GnT-V regulates the chemosensitivity to oxaliplatin, which involves the modulation of the drug transporter OCT2 by N-glycosylation in CRC cells.	Oxaliplatin	121-132	alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase	Homo sapiens	81-86
33376510-8	2021	Overall, the study provides novel insights into the molecular mechanism by which GnT-V regulates the chemosensitivity to oxaliplatin, which involves the modulation of the drug transporter OCT2 by N-glycosylation in CRC cells.	Oxaliplatin	121-132	solute carrier family 22 member 2	Homo sapiens	188-192
33129844-9	2021	The combination of 5-fluorouracil and oxaliplatin reduced MDSCs, increased numbers of intra-tumor CD8+ T cells, and increased the response of tumors to anti-PD1-however, this resulted in increased tumor expression of PDL1.	Oxaliplatin	38-49	CD274 antigen	Mus musculus	217-221
33129844-12	2021	CONCLUSIONS: In mouse models of gastric cancer, 5-fluorouracil and oxaliplatin reduce numbers of MDSCs to increase the effects of anti-PD1, which promotes tumor infiltration by CD8+ T cells.	Oxaliplatin	67-78	programmed cell death 1	Mus musculus	135-138
33039558-6	2021	STAG3 knockdown inhibited cell migration and increased drug sensitivity to oxaliplatin, 5-fluorouracil, irinotecan hydrochloride hydrate, and BRAF inhibitor in CRC cell lines.	Oxaliplatin	75-86	stromal antigen 3	Homo sapiens	0-5
33753993-0	2021	Cyr61 mediates oxaliplatin resistance in colorectal cancer cells by regulating Bcl-xL expression.	Oxaliplatin	15-26	cellular communication network factor 1	Homo sapiens	0-5
33753993-0	2021	Cyr61 mediates oxaliplatin resistance in colorectal cancer cells by regulating Bcl-xL expression.	Oxaliplatin	15-26	BCL2 like 1	Homo sapiens	79-85
33753993-2	2021	Cysteine-rich protein 61 (Cyr61), a multifunctional extracellular matrix protein, is highly expressed in a variety of tumors; increased Cyr61 expression is known to be closely involved in the chemotherapeutic resistance of many tumors, but its role in the L-OHP resistance of CRC cells has not been studied.	Oxaliplatin	256-261	cellular communication network factor 1	Homo sapiens	0-24
33753993-2	2021	Cysteine-rich protein 61 (Cyr61), a multifunctional extracellular matrix protein, is highly expressed in a variety of tumors; increased Cyr61 expression is known to be closely involved in the chemotherapeutic resistance of many tumors, but its role in the L-OHP resistance of CRC cells has not been studied.	Oxaliplatin	256-261	cellular communication network factor 1	Homo sapiens	26-31
33753993-2	2021	Cysteine-rich protein 61 (Cyr61), a multifunctional extracellular matrix protein, is highly expressed in a variety of tumors; increased Cyr61 expression is known to be closely involved in the chemotherapeutic resistance of many tumors, but its role in the L-OHP resistance of CRC cells has not been studied.	Oxaliplatin	256-261	cellular communication network factor 1	Homo sapiens	136-141
33753993-3	2021	In this study, we aimed to investigate the role of Cyr61 in the L-OHP resistance of CRC cells and examine the underlying mechanism.	Oxaliplatin	64-69	cellular communication network factor 1	Homo sapiens	51-56
33753993-4	2021	Our findings showed that the mRNA and protein levels of Cyr61 in L-OHP-resistant cells were significantly increased compared with those in nonresistant cells.	Oxaliplatin	65-70	cellular communication network factor 1	Homo sapiens	56-61
33753993-5	2021	Knockdown of Cyr61 enhanced the chemosensitivity of L-OHP-resistant cells to L-OHP.	Oxaliplatin	52-57	cellular communication network factor 1	Homo sapiens	13-18
33753993-5	2021	Knockdown of Cyr61 enhanced the chemosensitivity of L-OHP-resistant cells to L-OHP.	Oxaliplatin	77-82	cellular communication network factor 1	Homo sapiens	13-18
33753993-6	2021	Mechanistically, we found that overexpression of Cyr61 decreased L-OHP-induced apoptosis in drug-resistant CRC cells through the regulation of Bcl-xL.	Oxaliplatin	65-70	cellular communication network factor 1	Homo sapiens	49-54
33753993-6	2021	Mechanistically, we found that overexpression of Cyr61 decreased L-OHP-induced apoptosis in drug-resistant CRC cells through the regulation of Bcl-xL.	Oxaliplatin	65-70	BCL2 like 1	Homo sapiens	143-149
33753993-7	2021	Collectively, our results revealed for the first time that Cyr61 plays a crucial role in the resistance of CRC cells to L-OHP and indicated that targeting Cyr61 may be a promising therapeutic strategy to overcome L-OHP resistance in CRC.	Oxaliplatin	120-125	cellular communication network factor 1	Homo sapiens	59-64
33753993-7	2021	Collectively, our results revealed for the first time that Cyr61 plays a crucial role in the resistance of CRC cells to L-OHP and indicated that targeting Cyr61 may be a promising therapeutic strategy to overcome L-OHP resistance in CRC.	Oxaliplatin	213-218	cellular communication network factor 1	Homo sapiens	155-160
33547248-0	2021	Correction: MALAT1 is Associated with Poor Response to Oxaliplatin-based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.	Oxaliplatin	55-66	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	12-18
33547248-0	2021	Correction: MALAT1 is Associated with Poor Response to Oxaliplatin-based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.	Oxaliplatin	55-66	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	153-157
33565716-0	2021	Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR-138-5p and activation of AKT/mTOR signaling pathway.	Oxaliplatin	32-43	urothelial cancer associated 1	Homo sapiens	12-16
33565716-10	2021	Besides, depletion of UCA1 triggered more dramatic regression of HepG2 xenografts than that of HepG2/OXA xenografts with OXA treatment and impaired the p-AKT and p-mTOR levels in vivo.	Oxaliplatin	101-104	urothelial cancer associated 1	Homo sapiens	22-26
33565716-11	2021	In conclusion, our findings provide the evidence that UCA1 may contribute to OXA resistance via miR-138-5p-mediated AK /mTOR activation, suggesting that UCA1 is a potential therapeutic target for HCC.	Oxaliplatin	77-80	urothelial cancer associated 1	Homo sapiens	54-58
33565716-11	2021	In conclusion, our findings provide the evidence that UCA1 may contribute to OXA resistance via miR-138-5p-mediated AK /mTOR activation, suggesting that UCA1 is a potential therapeutic target for HCC.	Oxaliplatin	77-80	mechanistic target of rapamycin kinase	Homo sapiens	120-124
33565716-11	2021	In conclusion, our findings provide the evidence that UCA1 may contribute to OXA resistance via miR-138-5p-mediated AK /mTOR activation, suggesting that UCA1 is a potential therapeutic target for HCC.	Oxaliplatin	77-80	urothelial cancer associated 1	Homo sapiens	153-157
33495407-0	2021	Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS.	Oxaliplatin	0-11	poly(ADP-ribose) polymerase 1	Homo sapiens	24-29
33552961-0	2020	Mechanism and Molecular Network of RBM8A-Mediated Regulation of Oxaliplatin Resistance in Hepatocellular Carcinoma.	Oxaliplatin	64-75	RNA binding motif protein 8A	Homo sapiens	35-40
33552961-2	2020	The EMT plays an important role in the development of drug resistance, suggesting that RBM8A may be involved in the regulation of oxaliplatin (OXA) resistance in HCC.	Oxaliplatin	130-141	RNA binding motif protein 8A	Homo sapiens	87-92
33552961-2	2020	The EMT plays an important role in the development of drug resistance, suggesting that RBM8A may be involved in the regulation of oxaliplatin (OXA) resistance in HCC.	Oxaliplatin	143-146	RNA binding motif protein 8A	Homo sapiens	87-92
33552961-3	2020	Here we examined the potential involvement of RBM8A and its downstream pathways in OXA resistance using in vitro and in vivo models.	Oxaliplatin	83-86	RNA binding motif protein 8A	Homo sapiens	46-51
33552961-4	2020	RBM8A overexpression induced the EMT in OXA-resistant HCC cells, altering cell proliferation, apoptosis, migration, and invasion.	Oxaliplatin	40-43	RNA binding motif protein 8A	Homo sapiens	0-5
33552961-6	2020	In particular, histone deacetylase 9 (HDAC9) emerged as an important mediator of RBM8A activity related to OXA resistance.	Oxaliplatin	107-110	histone deacetylase 9	Homo sapiens	15-36
33552961-6	2020	In particular, histone deacetylase 9 (HDAC9) emerged as an important mediator of RBM8A activity related to OXA resistance.	Oxaliplatin	107-110	histone deacetylase 9	Homo sapiens	38-43
33552961-6	2020	In particular, histone deacetylase 9 (HDAC9) emerged as an important mediator of RBM8A activity related to OXA resistance.	Oxaliplatin	107-110	RNA binding motif protein 8A	Homo sapiens	81-86
33552961-7	2020	These data suggest that RBM8A and its related regulatory pathways represent potential markers of OXA resistance and therapeutic targets in HCC.	Oxaliplatin	97-100	RNA binding motif protein 8A	Homo sapiens	24-29
33495407-6	2021	Further experiments proved that oxaliplatin induced parthanatos in OSCC cells, characterized by depolarization of the mitochondrial membrane potential, up-regulation of PARP1, AIF and MIF in the nucleus, as well as the nuclear translocation of AIF.	Oxaliplatin	32-43	poly(ADP-ribose) polymerase 1	Homo sapiens	169-174
33495407-6	2021	Further experiments proved that oxaliplatin induced parthanatos in OSCC cells, characterized by depolarization of the mitochondrial membrane potential, up-regulation of PARP1, AIF and MIF in the nucleus, as well as the nuclear translocation of AIF.	Oxaliplatin	32-43	apoptosis inducing factor mitochondria associated 1	Homo sapiens	176-179
33495407-6	2021	Further experiments proved that oxaliplatin induced parthanatos in OSCC cells, characterized by depolarization of the mitochondrial membrane potential, up-regulation of PARP1, AIF and MIF in the nucleus, as well as the nuclear translocation of AIF.	Oxaliplatin	32-43	macrophage migration inhibitory factor	Homo sapiens	184-187
33495407-6	2021	Further experiments proved that oxaliplatin induced parthanatos in OSCC cells, characterized by depolarization of the mitochondrial membrane potential, up-regulation of PARP1, AIF and MIF in the nucleus, as well as the nuclear translocation of AIF.	Oxaliplatin	32-43	apoptosis inducing factor mitochondria associated 1	Homo sapiens	244-247
33495407-7	2021	Meanwhile, PARP1 inhibitor rucaparib and siRNA against PARP1 attenuated oxaliplatin-induced parthanatos in OSCC cells.	Oxaliplatin	72-83	poly(ADP-ribose) polymerase 1	Homo sapiens	11-16
33495407-7	2021	Meanwhile, PARP1 inhibitor rucaparib and siRNA against PARP1 attenuated oxaliplatin-induced parthanatos in OSCC cells.	Oxaliplatin	72-83	poly(ADP-ribose) polymerase 1	Homo sapiens	55-60
33495407-8	2021	In addition, we found that oxaliplatin caused oxidative stress in OSCC cells, and antioxidant NAC not only relieved oxaliplatin-induced overproduction of reactive oxygen species (ROS) but also reversed parthanatos caused by oxaliplatin.	Oxaliplatin	116-127	X-linked Kx blood group	Homo sapiens	94-97
33495407-8	2021	In addition, we found that oxaliplatin caused oxidative stress in OSCC cells, and antioxidant NAC not only relieved oxaliplatin-induced overproduction of reactive oxygen species (ROS) but also reversed parthanatos caused by oxaliplatin.	Oxaliplatin	116-127	X-linked Kx blood group	Homo sapiens	94-97
33495407-9	2021	In conclusion, our results indicate that oxaliplatin inhibits OSCC by activating PARP1-mediated parthanatos through increasing the production of ROS.	Oxaliplatin	41-52	poly(ADP-ribose) polymerase 1	Homo sapiens	81-86
33527017-0	2021	MiR-1254 and MEGF6 regulates oxaliplatin resistance in human colorectal cancer cells.	Oxaliplatin	29-40	microRNA 1254-1	Homo sapiens	0-8
33462197-11	2021	NORAD was highly expressed in oxaliplatin-resistant tissues.	Oxaliplatin	30-41	non-coding RNA activated by DNA damage	Homo sapiens	0-5
33462197-13	2021	Oxaliplatin induces oxidative stress and upregulates the expression of NORAD.	Oxaliplatin	0-11	non-coding RNA activated by DNA damage	Homo sapiens	71-76
33462197-18	2021	NORAD may be a potential biomarker for predicting oxaliplatin resistance and mediating oxidative stress, and provides therapeutic targets for reversing oxaliplatin resistance.	Oxaliplatin	50-61	non-coding RNA activated by DNA damage	Homo sapiens	0-5
33462197-18	2021	NORAD may be a potential biomarker for predicting oxaliplatin resistance and mediating oxidative stress, and provides therapeutic targets for reversing oxaliplatin resistance.	Oxaliplatin	152-163	non-coding RNA activated by DNA damage	Homo sapiens	0-5
33527017-7	2021	Furthermore, transfection of miR-1254 inhibitor increased apoptosis, decreased HCT116-R tolerance to oxaliplatin, and reduced MEGF6 expression.	Oxaliplatin	101-112	microRNA 1254-1	Homo sapiens	29-37
33527017-9	2021	In summary, MEGF6 is a latent functional target of miR-1254 in regulating oxaliplatin resistance and apoptosis in human CRC cells, suggesting a potential therapeutic target for CRC.	Oxaliplatin	74-85	multiple EGF like domains 6	Homo sapiens	12-17
33527017-0	2021	MiR-1254 and MEGF6 regulates oxaliplatin resistance in human colorectal cancer cells.	Oxaliplatin	29-40	multiple EGF like domains 6	Homo sapiens	13-18
33527017-9	2021	In summary, MEGF6 is a latent functional target of miR-1254 in regulating oxaliplatin resistance and apoptosis in human CRC cells, suggesting a potential therapeutic target for CRC.	Oxaliplatin	74-85	microRNA 1254-1	Homo sapiens	51-59
33527017-4	2021	The study found that miR-1254 is upregulated in oxaliplatin-resistant CRC cell line HCT116-R compared with its parental cell line HCT116 by transcriptome sequencing and small RNA sequencing.	Oxaliplatin	48-59	microRNA 1254-1	Homo sapiens	21-29
33527017-6	2021	Transient transfection of miR-1254 mimics significantly reduced cell apoptosis, increased HCT116 tolerance to oxaliplatin, and enhanced MEGF6 expression.	Oxaliplatin	110-121	microRNA 1254-1	Homo sapiens	26-34
33665222-0	2021	Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy.	Oxaliplatin	60-71	indoleamine 2,3-dioxygenase 1	Mus musculus	14-43
33428788-0	2021	HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin.	Oxaliplatin	158-169	histone deacetylase 6	Homo sapiens	0-5
33428788-9	2021	The HDAC6 inhibitor ACY1215 increases the chemotherapy effect of gemcitabine and oxaliplatin.	Oxaliplatin	81-92	histone deacetylase 6	Homo sapiens	4-9
33428788-10	2021	ACY1215 could suppress cell proliferation and induce apoptosis of GBC-SD and SGC-996, and increased the chemotherapy effect of gemcitabine and oxaliplatin, which provides a rationale for the combination of HDAC6 selective inhibitors with other anticancer agents in treating gallbladder cancer.	Oxaliplatin	143-154	histone deacetylase 6	Homo sapiens	206-211
33665222-9	2021	OXA-pretreated CT26 cells promoted BMDC maturation and CD8+ T cell expansion.	Oxaliplatin	0-3	CD8a molecule	Homo sapiens	55-58
33665222-10	2021	OXA significantly upregulated indoleamine 2,3-dioxygenase 1 (IDO1) in patient-derived colorectal cancer cells and in combination with the IDO1-specific inhibitor, NLG919, suppressed tumor progression.	Oxaliplatin	0-3	indoleamine 2,3-dioxygenase 1	Homo sapiens	30-59
33665222-10	2021	OXA significantly upregulated indoleamine 2,3-dioxygenase 1 (IDO1) in patient-derived colorectal cancer cells and in combination with the IDO1-specific inhibitor, NLG919, suppressed tumor progression.	Oxaliplatin	0-3	indoleamine 2,3-dioxygenase 1	Homo sapiens	61-65
33665222-10	2021	OXA significantly upregulated indoleamine 2,3-dioxygenase 1 (IDO1) in patient-derived colorectal cancer cells and in combination with the IDO1-specific inhibitor, NLG919, suppressed tumor progression.	Oxaliplatin	0-3	indoleamine 2,3-dioxygenase 1	Homo sapiens	138-142
33665222-12	2021	We demonstrated the upregulation of IDO1 by OXA, which combined with the IDO1 inhibitor, tremendously potentiated therapeutic effects of OXA against colorectal cancer.	Oxaliplatin	44-47	indoleamine 2,3-dioxygenase 1	Homo sapiens	36-40
33665222-12	2021	We demonstrated the upregulation of IDO1 by OXA, which combined with the IDO1 inhibitor, tremendously potentiated therapeutic effects of OXA against colorectal cancer.	Oxaliplatin	137-140	indoleamine 2,3-dioxygenase 1	Homo sapiens	36-40
33665222-12	2021	We demonstrated the upregulation of IDO1 by OXA, which combined with the IDO1 inhibitor, tremendously potentiated therapeutic effects of OXA against colorectal cancer.	Oxaliplatin	137-140	indoleamine 2,3-dioxygenase 1	Homo sapiens	73-77
33271260-8	2021	Interestingly, we also found that DHC-1 enhanced cell proliferation inhibitory effect of oxaliplatin (OXA).	Oxaliplatin	89-100	dynein cytoplasmic 1 heavy chain 1	Homo sapiens	34-39
32698745-0	2021	linc01559 Served as a Potential Oncogene and Promoted Resistance of Hepatocellular Carcinoma to Oxaliplatin by Directly Sponging miR-6783-3p.	Oxaliplatin	96-107	long intergenic non-protein coding RNA 1559	Homo sapiens	0-9
32698745-3	2021	The aim of this study was to investigate the role of linc01559 and miR-6783-3p in regulating resistance to L-OHP.	Oxaliplatin	107-112	long intergenic non-protein coding RNA 1559	Homo sapiens	53-62
32698745-9	2021	Regarding the in vitro tests, linc01559 showed higher expression in L-OHP-resistant cell lines, whereas miR-6783-3p was downregulated.	Oxaliplatin	68-73	long intergenic non-protein coding RNA 1559	Homo sapiens	30-39
32698745-12	2021	Furthermore, linc01559 and miR-6783-3p regulated the viability of L-OHP-resistant cells following treatment with L-OHP.	Oxaliplatin	66-71	long intergenic non-protein coding RNA 1559	Homo sapiens	13-22
32698745-12	2021	Furthermore, linc01559 and miR-6783-3p regulated the viability of L-OHP-resistant cells following treatment with L-OHP.	Oxaliplatin	113-118	long intergenic non-protein coding RNA 1559	Homo sapiens	13-22
32698745-14	2021	This suggests that linc01559/miR6783-3p may be key factors in regulating resistance and response to L-OHP.	Oxaliplatin	100-105	long intergenic non-protein coding RNA 1559	Homo sapiens	19-28
33112824-11	2021	These results suggest that the FGFR/ERK axis is hyperactivated in response to oxaliplatin-based chemotherapeutic strategy.	Oxaliplatin	78-89	mitogen-activated protein kinase 1	Homo sapiens	36-39
33271260-8	2021	Interestingly, we also found that DHC-1 enhanced cell proliferation inhibitory effect of oxaliplatin (OXA).	Oxaliplatin	102-105	dynein cytoplasmic 1 heavy chain 1	Homo sapiens	34-39
32990355-7	2021	Besides, CRC cell lines transfected by miR-488 mimic demonstrated decreases in glucose uptake and lactate secretion, increases in oxaliplatin/5-Fu-sensistivity, as well as diminished capability of proliferating, invading, and migratory (P < .05), which were reversible by extra transfection of pcDNA3.1-PFKFB3 (ie, miR-488 mimic + pcDNA3.1-PFKFB3 group).	Oxaliplatin	130-141	microRNA 488	Homo sapiens	39-46
33468749-4	2021	NAC with FOLFOXIRI(5-fluorouracil/oxaliplatin/leucovorin/irinotecan)plus bevacizumab(BEV)was inisiated as NAC.	Oxaliplatin	34-45	synuclein alpha	Homo sapiens	0-3
33655890-5	2021	Variations at the gene expression level, the protein level and the activity of CYP3A4 protein in 12 cancer cell lines were observed, also different response to drug treatments between cell line HT-29 and oxaliplatin-resistant cell line HT-29-OxR.	Oxaliplatin	204-215	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
33653494-2	2021	Oxaliplatin (OXA), as one of the first-line chemotherapeutic drugs for HCC, abnormally activates the PI3K/AKT/mTOR signaling pathway and DNA damage repair pathway (NHEJ and HR), causing drug resistance and consequnet compromised efficacy.	Oxaliplatin	0-11	AKT serine/threonine kinase 1	Homo sapiens	106-109
33653494-2	2021	Oxaliplatin (OXA), as one of the first-line chemotherapeutic drugs for HCC, abnormally activates the PI3K/AKT/mTOR signaling pathway and DNA damage repair pathway (NHEJ and HR), causing drug resistance and consequnet compromised efficacy.	Oxaliplatin	0-11	mechanistic target of rapamycin kinase	Homo sapiens	110-114
33653494-2	2021	Oxaliplatin (OXA), as one of the first-line chemotherapeutic drugs for HCC, abnormally activates the PI3K/AKT/mTOR signaling pathway and DNA damage repair pathway (NHEJ and HR), causing drug resistance and consequnet compromised efficacy.	Oxaliplatin	13-16	AKT serine/threonine kinase 1	Homo sapiens	106-109
33653494-2	2021	Oxaliplatin (OXA), as one of the first-line chemotherapeutic drugs for HCC, abnormally activates the PI3K/AKT/mTOR signaling pathway and DNA damage repair pathway (NHEJ and HR), causing drug resistance and consequnet compromised efficacy.	Oxaliplatin	13-16	mechanistic target of rapamycin kinase	Homo sapiens	110-114
33653494-4	2021	The hollow structure of H-PDA endowed O/P-HP with high loading efficiencies of OXA and PKI-587-up to 49.6% and 7.0%, respectively.	Oxaliplatin	79-82	SRY-box transcription factor 3	Homo sapiens	40-44
33653494-5	2021	In addition, benefiting from the intracellular delivery of H-PDA as well as the highly concentrated drugs therein, O/P-HP inhibited the proliferation of OXA-resistant HR cells, resulting in a cell viability of only 17.63%.	Oxaliplatin	153-156	SRY-box transcription factor 3	Homo sapiens	117-121
33653494-7	2021	We examined the intrinsic mechanisms of the combination therapy: O/PHP had excellent anti-cancer effects via the simultaneous upstream and downstream action to re-sensitize HR cells to chemotherapy; OXA induced strong apoptosis via the direct platinum lesions on DNA molecules, while PKI-587 normalized the abnormally activated PI3K/AKT/mTOR signaling pathway and DNA damage repair pathway (NHEJ and HR) that could attenuate the effectiveness of OXA, thus resulting in inhibition of cell proliferation, migration and DNA repair enzyme activity and the augment of apoptotic effects.	Oxaliplatin	199-202	AKT serine/threonine kinase 1	Homo sapiens	333-336
33653494-7	2021	We examined the intrinsic mechanisms of the combination therapy: O/PHP had excellent anti-cancer effects via the simultaneous upstream and downstream action to re-sensitize HR cells to chemotherapy; OXA induced strong apoptosis via the direct platinum lesions on DNA molecules, while PKI-587 normalized the abnormally activated PI3K/AKT/mTOR signaling pathway and DNA damage repair pathway (NHEJ and HR) that could attenuate the effectiveness of OXA, thus resulting in inhibition of cell proliferation, migration and DNA repair enzyme activity and the augment of apoptotic effects.	Oxaliplatin	199-202	mechanistic target of rapamycin kinase	Homo sapiens	337-341
33653494-7	2021	We examined the intrinsic mechanisms of the combination therapy: O/PHP had excellent anti-cancer effects via the simultaneous upstream and downstream action to re-sensitize HR cells to chemotherapy; OXA induced strong apoptosis via the direct platinum lesions on DNA molecules, while PKI-587 normalized the abnormally activated PI3K/AKT/mTOR signaling pathway and DNA damage repair pathway (NHEJ and HR) that could attenuate the effectiveness of OXA, thus resulting in inhibition of cell proliferation, migration and DNA repair enzyme activity and the augment of apoptotic effects.	Oxaliplatin	199-202	DNA ligase 4	Homo sapiens	517-534
33147048-0	2021	Exosomal transfer of circular RNA FBXW7 ameliorates the chemoresistance to oxaliplatin in colorectal cancer by sponging miR-18b-5p.	Oxaliplatin	75-86	F-box and WD repeat domain containing 7	Homo sapiens	34-39
33147048-0	2021	Exosomal transfer of circular RNA FBXW7 ameliorates the chemoresistance to oxaliplatin in colorectal cancer by sponging miR-18b-5p.	Oxaliplatin	75-86	microRNA 18b	Homo sapiens	120-127
33147048-10	2021	Our results showed that circ-FBXW7 was decreased in oxaliplatin-resistant CRC patients and cells.	Oxaliplatin	52-63	F-box and WD repeat domain containing 7	Homo sapiens	29-34
33147048-12	2021	Subsequently, in vitro and in vivo studies demonstrated exosomal circ-FBXW7 led resistant cells sensitive to oxaliplatin, increased the oxaliplatin-induced apoptosis, inhibited oxaliplatin-induced epithelial-mesenchymal transition, and suppressed oxaliplatin efflux.	Oxaliplatin	109-120	F-box and WD repeat domain containing 7	Homo sapiens	70-75
33147048-12	2021	Subsequently, in vitro and in vivo studies demonstrated exosomal circ-FBXW7 led resistant cells sensitive to oxaliplatin, increased the oxaliplatin-induced apoptosis, inhibited oxaliplatin-induced epithelial-mesenchymal transition, and suppressed oxaliplatin efflux.	Oxaliplatin	136-147	F-box and WD repeat domain containing 7	Homo sapiens	70-75
33147048-12	2021	Subsequently, in vitro and in vivo studies demonstrated exosomal circ-FBXW7 led resistant cells sensitive to oxaliplatin, increased the oxaliplatin-induced apoptosis, inhibited oxaliplatin-induced epithelial-mesenchymal transition, and suppressed oxaliplatin efflux.	Oxaliplatin	136-147	F-box and WD repeat domain containing 7	Homo sapiens	70-75
32857294-3	2021	Here, we show that the short-term memory deficits and anxiety-like and depression-like behaviors induced by intraperitoneal injections of OXA (4 mg/kg per day for 5 consecutive days) were accompanied by synaptic dysfunction and downregulation of the NR2B subunit of N-methyl-D-aspartate receptors in the hippocampus, which is critically involved in memory and emotion.	Oxaliplatin	138-141	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	250-254
32857294-7	2021	Oral L-TAMS prevented the OXA-induced upregulation of TNF-alpha and p-p65, as well as microglial activation in the hippocampus and the medial prefrontal cortex.	Oxaliplatin	26-29	tumor necrosis factor	Rattus norvegicus	54-63
32857294-7	2021	Oral L-TAMS prevented the OXA-induced upregulation of TNF-alpha and p-p65, as well as microglial activation in the hippocampus and the medial prefrontal cortex.	Oxaliplatin	26-29	synaptotagmin 1	Rattus norvegicus	70-73
33147048-12	2021	Subsequently, in vitro and in vivo studies demonstrated exosomal circ-FBXW7 led resistant cells sensitive to oxaliplatin, increased the oxaliplatin-induced apoptosis, inhibited oxaliplatin-induced epithelial-mesenchymal transition, and suppressed oxaliplatin efflux.	Oxaliplatin	136-147	F-box and WD repeat domain containing 7	Homo sapiens	70-75
33147048-13	2021	miR-18b-5p was increased in oxaliplatin-resistant CRC patients and cells and was confirmed to be a target of circ-FBXW7.	Oxaliplatin	28-39	microRNA 18b	Homo sapiens	0-7
33147048-13	2021	miR-18b-5p was increased in oxaliplatin-resistant CRC patients and cells and was confirmed to be a target of circ-FBXW7.	Oxaliplatin	28-39	F-box and WD repeat domain containing 7	Homo sapiens	114-119
33147048-14	2021	Immediately, the rescue assay showed exosome-mediated transfer of circ-FBXW7 enhanced oxaliplatin sensitivity by binding to miR-18b-5p in vitro and in vivo.	Oxaliplatin	86-97	F-box and WD repeat domain containing 7	Homo sapiens	71-76
33147048-14	2021	Immediately, the rescue assay showed exosome-mediated transfer of circ-FBXW7 enhanced oxaliplatin sensitivity by binding to miR-18b-5p in vitro and in vivo.	Oxaliplatin	86-97	microRNA 18b	Homo sapiens	124-131
32857294-8	2021	Finally, similar to oral L-TAMS, intracerebroventricular injection of PDTC, an NF-kappaB inhibitor, also prevented the OXA-induced memory/emotional deficits and the changes in TNF-alpha, p-p65, and microglia.	Oxaliplatin	119-122	synaptotagmin 1	Rattus norvegicus	189-192
33147048-15	2021	To conclude, the circ-FBXW7 delivery by exosomes could ameliorate chemoresistance to oxaliplatin in CRC by directly binding to miR-128-3p, suggesting a promising therapeutic strategy for oxaliplatin-resistant CRC patients.	Oxaliplatin	85-96	F-box and WD repeat domain containing 7	Homo sapiens	22-27
32857294-9	2021	Taken together, the activation of TNF-alpha/NF-kappaB signaling resulting from reduced brain Mg2+ is responsible for the memory/emotional deficits induced by OXA.	Oxaliplatin	158-161	tumor necrosis factor	Rattus norvegicus	34-43
33147048-15	2021	To conclude, the circ-FBXW7 delivery by exosomes could ameliorate chemoresistance to oxaliplatin in CRC by directly binding to miR-128-3p, suggesting a promising therapeutic strategy for oxaliplatin-resistant CRC patients.	Oxaliplatin	187-198	F-box and WD repeat domain containing 7	Homo sapiens	22-27
33396481-5	2020	Soluble thrombomodulin (TMalpha), known to degrade HMGB1 in a thrombin-dependent manner, prevents CIPN in rodents treated with paclitaxel, oxaliplatin, or vincristine and in patients with colorectal cancer undergoing oxaliplatin-based chemotherapy.	Oxaliplatin	139-150	thrombomodulin	Homo sapiens	8-22
33396481-5	2020	Soluble thrombomodulin (TMalpha), known to degrade HMGB1 in a thrombin-dependent manner, prevents CIPN in rodents treated with paclitaxel, oxaliplatin, or vincristine and in patients with colorectal cancer undergoing oxaliplatin-based chemotherapy.	Oxaliplatin	217-228	thrombomodulin	Homo sapiens	8-22
33292133-5	2020	METHODS: FOXA3 expression in oxaliplatin-resistant CRC tissues and cells was evaluated using RT-qPCR.	Oxaliplatin	29-40	forkhead box A3	Homo sapiens	9-14
33396362-0	2020	Gabapentin and Duloxetine Prevent Oxaliplatin- and Paclitaxel-Induced Peripheral Neuropathy by Inhibiting Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Phosphorylation in Spinal Cords of Mice.	Oxaliplatin	34-45	mitogen-activated protein kinase 3	Mus musculus	106-147
33396362-0	2020	Gabapentin and Duloxetine Prevent Oxaliplatin- and Paclitaxel-Induced Peripheral Neuropathy by Inhibiting Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Phosphorylation in Spinal Cords of Mice.	Oxaliplatin	34-45	mitogen-activated protein kinase 3	Mus musculus	149-155
33396362-11	2020	Moreover, PD0325901 prevented the development of oxaliplatin- and paclitaxel-induced neuropathic-like pain behavior by inhibiting ERK1/2 activation in the spinal cord of mice.	Oxaliplatin	49-60	mitogen-activated protein kinase 3	Mus musculus	130-136
33376237-2	2020	Here, we report the efficacy of anti-programmed death 1 (PD-1) antibody with the P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) regimen in advanced NKTL.	Oxaliplatin	121-132	programmed cell death 1	Homo sapiens	57-61
33376405-11	2020	Silencing of BLACAT1 limited the proliferation, migration, and invasion, facilitated the apoptosis, and re-sensitized OXA-resistance in CRC cells.	Oxaliplatin	118-121	BLACAT1 overlapping LEMD1 locus	Homo sapiens	13-20
33376405-17	2020	Conclusion: BLACAT1 mediated the progression of CRC and OXA-resistance by miR-519d-3p/CREB1 axis.	Oxaliplatin	56-59	BLACAT1 overlapping LEMD1 locus	Homo sapiens	12-19
33376405-17	2020	Conclusion: BLACAT1 mediated the progression of CRC and OXA-resistance by miR-519d-3p/CREB1 axis.	Oxaliplatin	56-59	cAMP responsive element binding protein 1	Homo sapiens	86-91
33292133-12	2020	Mechanistically, the anti-neoplasic effect of FOXA3 was mediated mainly through transcriptional repression of metastasis-associated in colon cancer 1 (MACC1) in oxaliplatin-resistant CRC cells.	Oxaliplatin	161-172	forkhead box A3	Homo sapiens	46-51
33396362-12	2020	In summary, our findings suggest that gabapentin, duloxetine, and PD0325901 prevent the development of oxaliplatin- and paclitaxel-induced neuropathic-like pain behavior by inhibiting ERK1/2 phosphorylation in mice.	Oxaliplatin	103-114	mitogen-activated protein kinase 3	Mus musculus	184-190
33396362-13	2020	Therefore, inhibiting ERK1/2 phosphorylation could be an effective preventive strategy against oxaliplatin- and paclitaxel-induced neuropathy.	Oxaliplatin	95-106	mitogen-activated protein kinase 3	Mus musculus	22-28
33359068-0	2021	Suppression MGP inhibits tumor proliferation and reverses oxaliplatin-resistance in colorectal cancer.	Oxaliplatin	58-69	matrix Gla protein	Homo sapiens	12-15
33359068-4	2021	Here, a comprehensive bioinformatics analysis revealed that MGP, which is overexpressed in CRC, might act as one of the critical genes conferring resistance to oxaliplatin (OXA).	Oxaliplatin	160-171	matrix Gla protein	Homo sapiens	60-63
33359068-4	2021	Here, a comprehensive bioinformatics analysis revealed that MGP, which is overexpressed in CRC, might act as one of the critical genes conferring resistance to oxaliplatin (OXA).	Oxaliplatin	173-176	matrix Gla protein	Homo sapiens	60-63
33359068-7	2021	The knockdown of MGP or inhibition of MGP expression significantly increased the sensitivity of the CRC cell lines to OXA.	Oxaliplatin	118-121	matrix Gla protein	Homo sapiens	17-20
33359068-7	2021	The knockdown of MGP or inhibition of MGP expression significantly increased the sensitivity of the CRC cell lines to OXA.	Oxaliplatin	118-121	matrix Gla protein	Homo sapiens	38-41
33359068-8	2021	Suppression of MGP may reverse OXA resistance by upregulating copper transporter 1 (CTR1) and downregulating ATP7A and ATP7B.	Oxaliplatin	31-34	matrix Gla protein	Homo sapiens	15-18
33359068-8	2021	Suppression of MGP may reverse OXA resistance by upregulating copper transporter 1 (CTR1) and downregulating ATP7A and ATP7B.	Oxaliplatin	31-34	solute carrier family 31 member 1	Homo sapiens	62-82
33359068-8	2021	Suppression of MGP may reverse OXA resistance by upregulating copper transporter 1 (CTR1) and downregulating ATP7A and ATP7B.	Oxaliplatin	31-34	solute carrier family 31 member 1	Homo sapiens	84-88
33359068-8	2021	Suppression of MGP may reverse OXA resistance by upregulating copper transporter 1 (CTR1) and downregulating ATP7A and ATP7B.	Oxaliplatin	31-34	ATPase copper transporting alpha	Homo sapiens	109-114
33359068-8	2021	Suppression of MGP may reverse OXA resistance by upregulating copper transporter 1 (CTR1) and downregulating ATP7A and ATP7B.	Oxaliplatin	31-34	ATPase copper transporting beta	Homo sapiens	119-124
33359068-9	2021	When used in combination with OXA, the inhibition of MGP reduced cancer cell proliferation, invasion, and migration and increased cell apoptosis in vitro.	Oxaliplatin	30-33	matrix Gla protein	Homo sapiens	53-56
33359068-12	2021	In summary, our study is the first to provide evidence that MGP expression confers OXA chemotherapy resistance in CRC and provides novel strategies to overcome chemotherapy resistance in CRC.	Oxaliplatin	83-86	matrix Gla protein	Mus musculus	60-63
33331338-9	2020	The association of TUBA1A with the IC50 of oxaliplatin was analyzed by Pearson correlation test.	Oxaliplatin	43-54	tubulin alpha 1a	Homo sapiens	19-25
33331338-14	2020	Elevated TUBA1A contributes to the infiltration of macrophages to the tumor microenvironment (p<0.001) and increased the IC50 of oxaliplatin in vitro (p<0.05), while hypomethylation was shown to contribute to the upregulation of TUBA1A (p<0.05).	Oxaliplatin	129-140	tubulin alpha 1a	Homo sapiens	9-15
33331338-16	2020	TUBA1A is significantly associated with the infiltration of M2-polarized macrophages in GC, and the IC50 of oxaliplatin.	Oxaliplatin	108-119	tubulin alpha 1a	Homo sapiens	0-6
33292133-12	2020	Mechanistically, the anti-neoplasic effect of FOXA3 was mediated mainly through transcriptional repression of metastasis-associated in colon cancer 1 (MACC1) in oxaliplatin-resistant CRC cells.	Oxaliplatin	161-172	MET transcriptional regulator MACC1	Homo sapiens	110-149
33292133-12	2020	Mechanistically, the anti-neoplasic effect of FOXA3 was mediated mainly through transcriptional repression of metastasis-associated in colon cancer 1 (MACC1) in oxaliplatin-resistant CRC cells.	Oxaliplatin	161-172	MET transcriptional regulator MACC1	Homo sapiens	151-156
33292133-13	2020	CONCLUSION: Our findings establish FOXA3 as a potent tumor suppressor in CRC, which may disrupt the maintenance of stemness and modulate sensitivity to oxaliplatin by inhibiting the transcription of MACC1 within CRC cells.	Oxaliplatin	152-163	forkhead box A3	Homo sapiens	35-40
33292133-6	2020	Effects of FOXA3 manipulation on sensitivity to oxaliplatin were assessed using WST-1, apoptotic ELISA, colony formation and xenograft model.	Oxaliplatin	48-59	forkhead box A3	Homo sapiens	11-16
33292133-9	2020	RESULTS: FOXA3 expression was significantly reduced in tumor samples from oxaliplatin-non-responsive patients compared with that in tumor samples from oxaliplatin-sensitive patients.	Oxaliplatin	74-85	forkhead box A3	Homo sapiens	9-14
33010214-6	2020	Furthermore, this study revealed that oprozomib, a selective beta5 subunit proteasome inhibitor, is able to normalize the spinal prodynorphin gene expression upregulation induced by oxaliplatin, as well as to revert mechanical allodynia and thermal hyperalgesia observed in oxaliplatin-treated rats.	Oxaliplatin	182-193	adaptor related protein complex 5 subunit beta 1	Rattus norvegicus	61-66
33280607-0	2020	Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms.	Oxaliplatin	83-94	dihydropyrimidine dehydrogenase	Homo sapiens	119-123
33280607-0	2020	Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms.	Oxaliplatin	83-94	glutathione S-transferase pi 1	Homo sapiens	128-133
33291076-5	2020	Here, we found that FOXM1 was overexpressed in oxaliplatin- and vincristine-resistant CRC cells (HCT-8/L-OHP and HCT-8/VCR) with enhanced metastatic potential, compared with HCT-8 cells.	Oxaliplatin	47-58	forkhead box M1	Homo sapiens	20-25
33291076-5	2020	Here, we found that FOXM1 was overexpressed in oxaliplatin- and vincristine-resistant CRC cells (HCT-8/L-OHP and HCT-8/VCR) with enhanced metastatic potential, compared with HCT-8 cells.	Oxaliplatin	103-108	forkhead box M1	Homo sapiens	20-25
33291076-6	2020	FOXM1 overexpression increased migration, invasion and drug-resistance to oxaliplatin and vincristine in HCT-8 cells, while FOXM1 knockdown using shFOXM1 impaired metastasis and drug-resistance in HCT-8/L-OHP and HCT-8/VCR cells.	Oxaliplatin	74-85	forkhead box M1	Homo sapiens	0-5
33291076-6	2020	FOXM1 overexpression increased migration, invasion and drug-resistance to oxaliplatin and vincristine in HCT-8 cells, while FOXM1 knockdown using shFOXM1 impaired metastasis and drug-resistance in HCT-8/L-OHP and HCT-8/VCR cells.	Oxaliplatin	203-208	forkhead box M1	Homo sapiens	0-5
33291076-6	2020	FOXM1 overexpression increased migration, invasion and drug-resistance to oxaliplatin and vincristine in HCT-8 cells, while FOXM1 knockdown using shFOXM1 impaired metastasis and drug-resistance in HCT-8/L-OHP and HCT-8/VCR cells.	Oxaliplatin	203-208	forkhead box M1	Homo sapiens	124-129
33158961-12	2020	We demonstrate for the first time that LPC 18:1 contributes to the activation of the ion channels TRPV1 and TRPM8 in sensory neurons and causes mechanical hypersensitivity after peripheral injection in vivo These findings suggest that the LPC-mediated lipid signaling is involved in oxaliplatin-induced acute peripheral pain.	Oxaliplatin	283-294	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	98-103
32981900-0	2020	The pain-relieving effects of lactoferrin on oxaliplatin-induced neuropathic pain.	Oxaliplatin	45-56	lactotransferrin	Mus musculus	30-41
33292253-0	2020	Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer.	Oxaliplatin	45-56	MAD2 mitotic arrest deficient-like 2	Mus musculus	10-14
33292253-9	2020	RESULTS: In this study, we found that expression of REV7, which is a key component of translesion synthesis (TLS) polymerase zeta (POL zeta), is significantly increased in both 5-FU and oxaliplatin resistant CRC cells.	Oxaliplatin	186-197	MAD2 mitotic arrest deficient-like 2	Mus musculus	52-56
33292253-10	2020	TLS efficiency analysis revealed that upregulated REV7 protein level results in enhanced TLS in response to 5-FU and oxaliplatin.	Oxaliplatin	117-128	MAD2 mitotic arrest deficient-like 2	Mus musculus	50-54
33292253-11	2020	Importantly, inhibition of REV7 by CRISPR/Cas9 knockout exhibited significant synergy with 5-FU and oxaliplatin in cell culture and murine xenograft model.	Oxaliplatin	100-111	MAD2 mitotic arrest deficient-like 2	Mus musculus	27-31
32623784-5	2020	In this case report, we describe the use of cisplatin during HIPEC in a patient who previously experienced an HSR to systemic oxaliplatin.	Oxaliplatin	126-137	HSR	Homo sapiens	110-113
32869182-11	2020	The alterations in the activity and expression of the GPx, SOD, CAT and AChE induced by OXA exposure were normalized by 4-PSQ.	Oxaliplatin	88-91	catalase	Mus musculus	64-67
32727666-0	2020	Oxaliplatin and Methylprednisolone-induced Thrombocytopenia and Monocytopenia, Owing to Anti-GPIIbIIIa and -CD36 Antibodies in a Patient With Colorectal Cancer.	Oxaliplatin	0-11	CD36 molecule	Homo sapiens	108-112
32638210-0	2020	MT2A Promotes Oxaliplatin Resistance in Colorectal Cancer Cells.	Oxaliplatin	14-25	metallothionein 2A	Homo sapiens	0-4
32638210-9	2020	Knockdown of MT2A in HT29 OR cells improved sensitivity to Oxaliplatin, while ectopic overexpression of MT2A conferred HT29 cells relative resistance to Oxaliplatin.	Oxaliplatin	59-70	metallothionein 2A	Homo sapiens	13-17
32638210-9	2020	Knockdown of MT2A in HT29 OR cells improved sensitivity to Oxaliplatin, while ectopic overexpression of MT2A conferred HT29 cells relative resistance to Oxaliplatin.	Oxaliplatin	153-164	metallothionein 2A	Homo sapiens	104-108
32638210-11	2020	BARD1 overexpression partially restored the compromised Oxaliplatin resistance elicited by MT2A deficiency in terms of both cell proliferation and viability.	Oxaliplatin	56-67	BRCA1 associated RING domain 1	Homo sapiens	0-5
32638210-11	2020	BARD1 overexpression partially restored the compromised Oxaliplatin resistance elicited by MT2A deficiency in terms of both cell proliferation and viability.	Oxaliplatin	56-67	metallothionein 2A	Homo sapiens	91-95
32638210-12	2020	Our data highlighted the critical contributions of MT2A-BARD1/BRCA1 in Oxaliplatin resistance in colorectal cancer cells.	Oxaliplatin	71-82	metallothionein 2A	Homo sapiens	51-55
32638210-12	2020	Our data highlighted the critical contributions of MT2A-BARD1/BRCA1 in Oxaliplatin resistance in colorectal cancer cells.	Oxaliplatin	71-82	BRCA1 associated RING domain 1	Homo sapiens	56-61
32638210-12	2020	Our data highlighted the critical contributions of MT2A-BARD1/BRCA1 in Oxaliplatin resistance in colorectal cancer cells.	Oxaliplatin	71-82	BRCA1 DNA repair associated	Homo sapiens	62-67
32805281-10	2020	RESULTS: High expression of CCAT2 induced CIN in CRC cell lines and increased resistance to 5-fluorouracil and oxaliplatin.	Oxaliplatin	111-122	colon cancer associated transcript 2	Homo sapiens	28-33
32869182-11	2020	The alterations in the activity and expression of the GPx, SOD, CAT and AChE induced by OXA exposure were normalized by 4-PSQ.	Oxaliplatin	88-91	acetylcholinesterase	Mus musculus	72-76
32710137-12	2020	Oxaliplatin significantly decreased MBP immunoreactivity and increased nitrotyrosine immunoreactivity.	Oxaliplatin	0-11	myelin basic protein	Rattus norvegicus	36-39
33035787-7	2020	In the oxaliplatin group, rs1045642 TT genotype was associated with the need to adjust treatment (OR = 0.32; p = 0.02), ERCC1 rs11615 GG genotype with asthenia (OR = 3.01; p = 0.01) and rs1615 GSTP1 GG genotype with respiratory toxicity (OR = 5.07; p = 0.009).	Oxaliplatin	7-18	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	120-125
33035787-7	2020	In the oxaliplatin group, rs1045642 TT genotype was associated with the need to adjust treatment (OR = 0.32; p = 0.02), ERCC1 rs11615 GG genotype with asthenia (OR = 3.01; p = 0.01) and rs1615 GSTP1 GG genotype with respiratory toxicity (OR = 5.07; p = 0.009).	Oxaliplatin	7-18	glutathione S-transferase pi 1	Homo sapiens	193-198
33035787-8	2020	ABCB1 rs1045642 T-allele reduces the need for treatment modification with both 5FU and oxaliplatin.	Oxaliplatin	87-98	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
33222668-0	2021	OSI-027 alleviates oxaliplatin chemoresistance in gastric cancer cells by suppressing P-gp induction.	Oxaliplatin	19-30	phosphoglycolate phosphatase	Homo sapiens	86-90
33292221-0	2020	LINC00152 upregulates ZEB1 expression and enhances epithelial-mesenchymal transition and oxaliplatin resistance in esophageal cancer by interacting with EZH2.	Oxaliplatin	89-100	cytoskeleton regulator RNA	Homo sapiens	0-9
33292221-1	2020	BACKGROUND: Expression of the long non-coding mRNA LINC00152 has been reported to correlate with cancer cell resistance to oxaliplatin (L-OHP).	Oxaliplatin	123-134	cytoskeleton regulator RNA	Homo sapiens	51-60
33292221-1	2020	BACKGROUND: Expression of the long non-coding mRNA LINC00152 has been reported to correlate with cancer cell resistance to oxaliplatin (L-OHP).	Oxaliplatin	136-141	cytoskeleton regulator RNA	Homo sapiens	51-60
33292221-8	2020	Animal experiments were also conducted to detect the effects of the LINC00152/EZH2/ZEB1 on EMT and L-OHP resistance.	Oxaliplatin	99-104	cytoskeleton regulator RNA	Homo sapiens	68-77
33292221-10	2020	As revealed by assays in vitro and in vivo, LINC00152 positively regulated ZEB1 expression through interaction with EZH2 to enhance EMT and L-OHP resistance in EC cells.	Oxaliplatin	140-145	cytoskeleton regulator RNA	Homo sapiens	44-53
33292221-10	2020	As revealed by assays in vitro and in vivo, LINC00152 positively regulated ZEB1 expression through interaction with EZH2 to enhance EMT and L-OHP resistance in EC cells.	Oxaliplatin	140-145	zinc finger E-box binding homeobox 1	Homo sapiens	75-79
33292221-11	2020	In contrast, silencing of LINC00152 contributed to attenuated EMT and drug resistance of EC cells to L-OHP.	Oxaliplatin	101-106	cytoskeleton regulator RNA	Homo sapiens	26-35
33292221-12	2020	CONCLUSIONS: Our study demonstrates that LINC00152/EZH2/ZEB1 axis can regulate EMT and resistance of EC cells to L-OHP, thus presenting a potential therapeutic target for EC treatment.	Oxaliplatin	113-118	cytoskeleton regulator RNA	Homo sapiens	41-50
33292221-12	2020	CONCLUSIONS: Our study demonstrates that LINC00152/EZH2/ZEB1 axis can regulate EMT and resistance of EC cells to L-OHP, thus presenting a potential therapeutic target for EC treatment.	Oxaliplatin	113-118	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	51-55
33292221-12	2020	CONCLUSIONS: Our study demonstrates that LINC00152/EZH2/ZEB1 axis can regulate EMT and resistance of EC cells to L-OHP, thus presenting a potential therapeutic target for EC treatment.	Oxaliplatin	113-118	zinc finger E-box binding homeobox 1	Homo sapiens	56-60
33257690-12	2020	Collectively, our study demonstrates that IAP inhibition is a promising modulator of response to oxaliplatin/5-FU in colorectal cancers of the CMS1 subtype, and may show promise as in the CMS2 subtype, suggesting that molecular subtyping may aid as a patient stratification tool for IAP antagonists in this disease.	Oxaliplatin	97-108	alkaline phosphatase, intestinal	Homo sapiens	42-45
33222668-8	2021	Additionally, OSI-027 also downregulated P-gp, which enhanced oxaliplatin-induced apoptosis and suppressed multidrug resistance.	Oxaliplatin	62-73	phosphoglycolate phosphatase	Homo sapiens	41-45
32789331-7	2020	By coupling our methods with Pt quantification and cellular profiling in control and hTMEM205-expressing cells, we demonstrate that hTMEM205 mediates Pt(ii)-drug export selectively towards cisplatin and oxaliplatin but not carboplatin.	Oxaliplatin	203-214	transmembrane protein 205	Homo sapiens	85-93
33073974-1	2020	The main objective of this study was to determine whether (E)-3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2) and its structural derivative DM489 produce anti-neuropathic pain activity using the streptozotocin (STZ)- and oxaliplatin-induced neuropathic pain animal models.	Oxaliplatin	215-226	skull morphology 4	Mus musculus	58-63
33177876-0	2020	Down-Regulation of Circ_0032833 Sensitizes Colorectal Cancer to 5-Fluorouracil and Oxaliplatin Partly Depending on the Regulation of miR-125-5p and MSI1.	Oxaliplatin	83-94	musashi RNA-binding protein 1	Mus musculus	148-152
33177876-11	2020	Besides, miR-125-5p targeted Musashi1 (MSI1) to increase the susceptibility of 5-fluorouracil and oxaliplatin in FOLFOX-resistant CRC cells.	Oxaliplatin	98-109	musashi RNA-binding protein 1	Mus musculus	29-37
33177876-11	2020	Besides, miR-125-5p targeted Musashi1 (MSI1) to increase the susceptibility of 5-fluorouracil and oxaliplatin in FOLFOX-resistant CRC cells.	Oxaliplatin	98-109	musashi RNA-binding protein 1	Mus musculus	39-43
33177876-13	2020	Circ_0032833 down-regulation also promoted the 5-fluorouracil and oxaliplatin sensitivities partly through the miR-125-5p/MSI1 axis in vivo.	Oxaliplatin	66-77	musashi RNA-binding protein 1	Mus musculus	122-126
33177876-14	2020	Conclusion: This study illuminated an unambiguous mechanism circ_0032833/miR-125-5p/MSI1 on regulating 5-fluorouracil and oxaliplatin sensitivities in FOLFOX therapy, maybe providing a deep insight of resistance formation and developing a novel strategy to enhance chemosensitivity in CRC.	Oxaliplatin	122-133	musashi RNA-binding protein 1	Mus musculus	84-88
32965539-0	2020	A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.	Oxaliplatin	104-115	thrombomodulin	Homo sapiens	68-82
32965539-1	2020	PURPOSE: The purpose of this clinical study was to be the first to explore whether ART-123, a recombinant human soluble thrombomodulin, prevents oxaliplatin-induced peripheral neuropathy (OIPN).	Oxaliplatin	145-156	thrombomodulin	Homo sapiens	120-134
32428246-0	2020	Oxaliplatin-induced neuropathic pain involves HOXA6 via a TET1-dependent demethylation of the SOX10 promoter.	Oxaliplatin	0-11	homeobox A6	Rattus norvegicus	46-51
32428246-0	2020	Oxaliplatin-induced neuropathic pain involves HOXA6 via a TET1-dependent demethylation of the SOX10 promoter.	Oxaliplatin	0-11	tet methylcytosine dioxygenase 1	Rattus norvegicus	58-62
32428246-0	2020	Oxaliplatin-induced neuropathic pain involves HOXA6 via a TET1-dependent demethylation of the SOX10 promoter.	Oxaliplatin	0-11	SRY-box transcription factor 10	Rattus norvegicus	94-99
32428246-2	2020	Here, we used a whole genome expression microarray and gene ontology analysis to identify the upregulation of a sequence-specific DNA-binding protein, HOXA6, in the spinal dorsal horn on day 10 after injection of rats with oxaliplatin.	Oxaliplatin	223-234	homeobox A6	Rattus norvegicus	151-156
32428246-3	2020	Genetic disruption of HOXA6 with siRNAs alleviated mechanical allodynia after oxaliplatin administration.	Oxaliplatin	78-89	homeobox A6	Rattus norvegicus	22-27
32428246-4	2020	Reduced representation bisulfite sequencing assays indicated that oxaliplatin decreased the methylation levels of the SOX10 promoter but not of HOXA6.	Oxaliplatin	66-77	SRY-box transcription factor 10	Rattus norvegicus	118-123
32428246-5	2020	TET1 was also upregulated by oxaliplatin.	Oxaliplatin	29-40	tet methylcytosine dioxygenase 1	Rattus norvegicus	0-4
32428246-7	2020	Importantly, inhibition of SOX10 by intrathecal application of SOX10 siRNA ameliorated the mechanical allodynia induced by oxaliplatin and downregulated the expression of HOXA6.	Oxaliplatin	123-134	SRY-box transcription factor 10	Rattus norvegicus	27-32
32428246-7	2020	Importantly, inhibition of SOX10 by intrathecal application of SOX10 siRNA ameliorated the mechanical allodynia induced by oxaliplatin and downregulated the expression of HOXA6.	Oxaliplatin	123-134	SRY-box transcription factor 10	Rattus norvegicus	63-68
32428246-9	2020	Moreover, chromatin immunoprecipitation assays demonstrated that oxaliplatin increased the binding of SOX10 to the promoter region of HOXA6.	Oxaliplatin	65-76	SRY-box transcription factor 10	Rattus norvegicus	102-107
32428246-9	2020	Moreover, chromatin immunoprecipitation assays demonstrated that oxaliplatin increased the binding of SOX10 to the promoter region of HOXA6.	Oxaliplatin	65-76	homeobox A6	Rattus norvegicus	134-139
32428246-10	2020	Taken together, our data suggest that HOXA6 upregulation through the TET1-mediated promoter demethylation of SOX10 may contribute to oxaliplatin-induced neuropathic pain.	Oxaliplatin	133-144	homeobox A6	Rattus norvegicus	38-43
32428246-10	2020	Taken together, our data suggest that HOXA6 upregulation through the TET1-mediated promoter demethylation of SOX10 may contribute to oxaliplatin-induced neuropathic pain.	Oxaliplatin	133-144	tet methylcytosine dioxygenase 1	Rattus norvegicus	69-73
32428246-10	2020	Taken together, our data suggest that HOXA6 upregulation through the TET1-mediated promoter demethylation of SOX10 may contribute to oxaliplatin-induced neuropathic pain.	Oxaliplatin	133-144	SRY-box transcription factor 10	Rattus norvegicus	109-114
32118594-2	2020	In addition, we aim to assess the correlation between TS and ERCC-1 expression and the response of these cases to oxaliplatin and 5-fluorouracil chemotherapy (FOLFOX).	Oxaliplatin	114-125	thymidylate synthetase	Homo sapiens	54-56
32118594-2	2020	In addition, we aim to assess the correlation between TS and ERCC-1 expression and the response of these cases to oxaliplatin and 5-fluorouracil chemotherapy (FOLFOX).	Oxaliplatin	114-125	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	61-67
33455104-13	2020	Moreover, IRF-1 was found to be a negative transcription regulator of PVT1-214 and decreased PVT1-214 levels in oxaliplatin-resistant CRC cells.	Oxaliplatin	112-123	interferon regulatory factor 1	Homo sapiens	10-15
33455104-15	2020	CONCLUSIONS: IRF-1/PVT1-214 may markedly boost the oxaliplatin-resistance of CRC, resulting in the late TNM stage and poor survival.	Oxaliplatin	51-62	interferon regulatory factor 1	Homo sapiens	13-18
32818544-0	2020	GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.	Oxaliplatin	27-38	golgi phosphoprotein 3	Homo sapiens	0-6
32818544-0	2020	GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.	Oxaliplatin	27-38	AKT serine/threonine kinase 1	Homo sapiens	96-99
32818544-0	2020	GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.	Oxaliplatin	27-38	mechanistic target of rapamycin kinase	Homo sapiens	100-104
32818544-1	2020	OBJECTIVE: To explore whether GOLPH3 regulated oxaliplatin (L-OHP) resistance of colon cancer cells via PI3K/AKT/mTOR pathway.	Oxaliplatin	47-58	golgi phosphoprotein 3	Homo sapiens	30-36
32818544-1	2020	OBJECTIVE: To explore whether GOLPH3 regulated oxaliplatin (L-OHP) resistance of colon cancer cells via PI3K/AKT/mTOR pathway.	Oxaliplatin	47-58	AKT serine/threonine kinase 1	Homo sapiens	109-112
32818544-1	2020	OBJECTIVE: To explore whether GOLPH3 regulated oxaliplatin (L-OHP) resistance of colon cancer cells via PI3K/AKT/mTOR pathway.	Oxaliplatin	47-58	mechanistic target of rapamycin kinase	Homo sapiens	113-117
32818544-1	2020	OBJECTIVE: To explore whether GOLPH3 regulated oxaliplatin (L-OHP) resistance of colon cancer cells via PI3K/AKT/mTOR pathway.	Oxaliplatin	60-65	golgi phosphoprotein 3	Homo sapiens	30-36
32818544-1	2020	OBJECTIVE: To explore whether GOLPH3 regulated oxaliplatin (L-OHP) resistance of colon cancer cells via PI3K/AKT/mTOR pathway.	Oxaliplatin	60-65	AKT serine/threonine kinase 1	Homo sapiens	109-112
32818544-1	2020	OBJECTIVE: To explore whether GOLPH3 regulated oxaliplatin (L-OHP) resistance of colon cancer cells via PI3K/AKT/mTOR pathway.	Oxaliplatin	60-65	mechanistic target of rapamycin kinase	Homo sapiens	113-117
32818544-7	2020	L-OHP and GOLPH3 shRNA decreased tumor volume and reduced expression of Ki67 in tumor tissues with the increased Caspase-3.	Oxaliplatin	0-5	caspase 3	Homo sapiens	113-122
32818544-9	2020	CONCLUSION: GOLPH3 inhibition reduced proliferation and promoted apoptosis of HCT116/L-OHP cells, and also reversed the L-OHP resistance of HCT116/L-OHP, which may be associated with the suppression of P13K/AKT/mTOR pathway.	Oxaliplatin	85-90	golgi phosphoprotein 3	Homo sapiens	12-18
32818544-9	2020	CONCLUSION: GOLPH3 inhibition reduced proliferation and promoted apoptosis of HCT116/L-OHP cells, and also reversed the L-OHP resistance of HCT116/L-OHP, which may be associated with the suppression of P13K/AKT/mTOR pathway.	Oxaliplatin	120-125	golgi phosphoprotein 3	Homo sapiens	12-18
33120790-4	2020	PATIENT CONCERNS: A 72-year-old man diagnosed with stage IV rectal adenocarcinoma (KRAS mutation) with peritoneal carcinomatosis and liver metastases developed resistance to 2 lines of treatment (bevacizumab/irinotecan/S-1 and bevacizumab/oxaliplatin/HDFL [high-dose 24-hour infusion of 5-fluorouracil and leucovorin regimen]) within 5 months.	Oxaliplatin	239-250	KRAS proto-oncogene, GTPase	Homo sapiens	83-87
33116894-0	2020	LPS Enhances the Chemosensitivity of Oxaliplatin in HT29 Cells via GSDMD-Mediated Pyroptosis.	Oxaliplatin	37-48	gasdermin D	Homo sapiens	67-72
32789331-7	2020	By coupling our methods with Pt quantification and cellular profiling in control and hTMEM205-expressing cells, we demonstrate that hTMEM205 mediates Pt(ii)-drug export selectively towards cisplatin and oxaliplatin but not carboplatin.	Oxaliplatin	203-214	transmembrane protein 205	Homo sapiens	132-140
32893979-0	2020	A new monitoring tool CLIP test for progression of oxaliplatin-induced peripheral neuropathy: A multicenter prospective study.	Oxaliplatin	51-62	CAP-Gly domain containing linker protein 1	Homo sapiens	22-26
33251049-0	2020	LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer.	Oxaliplatin	66-77	tumor protein p53	Homo sapiens	39-42
33251049-3	2020	In this study, we report that the LINC00460-miR-149-5p/miR-150-5p-mutant p53 feedback loop is responsible for oxaliplatin resistance in CRC.	Oxaliplatin	110-121	long intergenic non-protein coding RNA 460	Homo sapiens	34-43
33066568-8	2020	Renal damage in Ru-1 treated mice was lower in comparison with oxaliplatin treated mice, as evaluated by serum levels of urea and creatinine and histological evaluation, but Ru-1 induced higher liver damage than oxaliplatin, evaluated by the serum levels of alanine aminotransferase.	Oxaliplatin	212-223	Scm like with four mbt domains 1	Homo sapiens	16-20
32557982-4	2020	Based on the strong affinity and inhibitory activity for CAIX, CAIXplatins can not only overcome hypoxia and acidic microenvironment, but also inhibit metabolic pathways of hypoxic cancer cells responsible for energy supply and biomacromolecules synthesis, resulting in significantly enhanced therapeutic effect on hypoxic MDA-MB-231 tumors both in vitro and in vivo compared with cisplatin/oxaliplatin, accompanied with excellent anti-metastasis and anti-angiogenesis activities.	Oxaliplatin	391-402	carbonic anhydrase 9	Homo sapiens	57-61
33041328-0	2020	Inhibition of Chk1 by miR-320c increases oxaliplatin responsiveness in triple-negative breast cancer.	Oxaliplatin	41-52	checkpoint kinase 1	Homo sapiens	14-18
33041328-7	2020	We observed that overexpression of miR-320c in TNBC regulated the oxaliplatin responsiveness by mediating DNA damage repair through the negative regulation of Chk1 in vitro.	Oxaliplatin	66-77	checkpoint kinase 1	Homo sapiens	159-163
33082779-4	2020	The data show that Siwei Jianbu Decoction can effectively prevent oxaliplatin-induced neuroinflammation by inhibiting an increase in NF-kappaB expression via downregulation of p-ERK1/2 and p-p38.	Oxaliplatin	66-77	nuclear factor kappa B subunit 1	Homo sapiens	133-142
33082779-4	2020	The data show that Siwei Jianbu Decoction can effectively prevent oxaliplatin-induced neuroinflammation by inhibiting an increase in NF-kappaB expression via downregulation of p-ERK1/2 and p-p38.	Oxaliplatin	66-77	mitogen-activated protein kinase 3	Homo sapiens	178-184
33082779-4	2020	The data show that Siwei Jianbu Decoction can effectively prevent oxaliplatin-induced neuroinflammation by inhibiting an increase in NF-kappaB expression via downregulation of p-ERK1/2 and p-p38.	Oxaliplatin	66-77	mitogen-activated protein kinase 1	Homo sapiens	191-194
33251049-3	2020	In this study, we report that the LINC00460-miR-149-5p/miR-150-5p-mutant p53 feedback loop is responsible for oxaliplatin resistance in CRC.	Oxaliplatin	110-121	microRNA 149	Homo sapiens	44-51
33251049-3	2020	In this study, we report that the LINC00460-miR-149-5p/miR-150-5p-mutant p53 feedback loop is responsible for oxaliplatin resistance in CRC.	Oxaliplatin	110-121	tumor protein p53	Homo sapiens	73-76
33251049-4	2020	First, LINC00460 was found to exhibit higher expression in oxaliplatin-resistant CRC (CRC/OxR) cells compared with parental oxaliplatin-sensitive ones, and this expression pattern depends on mutant p53 (SW480/OxR), not wild-type p53 (HCT116/OxR).	Oxaliplatin	59-70	long intergenic non-protein coding RNA 460	Homo sapiens	7-16
33251049-4	2020	First, LINC00460 was found to exhibit higher expression in oxaliplatin-resistant CRC (CRC/OxR) cells compared with parental oxaliplatin-sensitive ones, and this expression pattern depends on mutant p53 (SW480/OxR), not wild-type p53 (HCT116/OxR).	Oxaliplatin	124-135	long intergenic non-protein coding RNA 460	Homo sapiens	7-16
33251049-5	2020	Oxaliplatin-induced LINC00460 in SW480/OxR cells was mainly located in the cytoplasm and was associated with AGO2 protein.	Oxaliplatin	0-11	long intergenic non-protein coding RNA 460	Homo sapiens	20-29
33251049-5	2020	Oxaliplatin-induced LINC00460 in SW480/OxR cells was mainly located in the cytoplasm and was associated with AGO2 protein.	Oxaliplatin	0-11	argonaute RISC catalytic component 2	Homo sapiens	109-113
33251049-6	2020	LINC00460 functions as a competing endogenous RNA (ceRNA) to promote oxaliplatin resistance through sequestering miR-149-5p/miR-150-5p and upregulating the expression of the microRNA (miRNA) target p53.	Oxaliplatin	69-80	long intergenic non-protein coding RNA 460	Homo sapiens	0-9
33251049-6	2020	LINC00460 functions as a competing endogenous RNA (ceRNA) to promote oxaliplatin resistance through sequestering miR-149-5p/miR-150-5p and upregulating the expression of the microRNA (miRNA) target p53.	Oxaliplatin	69-80	microRNA 149	Homo sapiens	113-120
33251049-6	2020	LINC00460 functions as a competing endogenous RNA (ceRNA) to promote oxaliplatin resistance through sequestering miR-149-5p/miR-150-5p and upregulating the expression of the microRNA (miRNA) target p53.	Oxaliplatin	69-80	tumor protein p53	Homo sapiens	198-201
33251049-7	2020	Knockdown of LINC00460 sensitized SW480/OxR cells to oxaliplatin by modulating p53 in vitro and in vivo.	Oxaliplatin	53-64	long intergenic non-protein coding RNA 460	Homo sapiens	13-22
33251049-7	2020	Knockdown of LINC00460 sensitized SW480/OxR cells to oxaliplatin by modulating p53 in vitro and in vivo.	Oxaliplatin	53-64	tumor protein p53	Homo sapiens	79-82
33251049-10	2020	Our findings uncover a mechanism for the LINC00460-miR-149-5p/miR-150-5p-mutant p53 feedback loop in oxaliplatin resistance of CRC, and they provide potential therapeutic targets for tumor chemoresistance.	Oxaliplatin	101-112	long intergenic non-protein coding RNA 460	Homo sapiens	41-50
33251049-10	2020	Our findings uncover a mechanism for the LINC00460-miR-149-5p/miR-150-5p-mutant p53 feedback loop in oxaliplatin resistance of CRC, and they provide potential therapeutic targets for tumor chemoresistance.	Oxaliplatin	101-112	microRNA 149	Homo sapiens	51-58
33251049-10	2020	Our findings uncover a mechanism for the LINC00460-miR-149-5p/miR-150-5p-mutant p53 feedback loop in oxaliplatin resistance of CRC, and they provide potential therapeutic targets for tumor chemoresistance.	Oxaliplatin	101-112	tumor protein p53	Homo sapiens	80-83
32563943-2	2020	In this study, we construct a bifunctional liposome by self-assembly of oxaliplatin-prodrug (Oxa(IV)) conjugated phospholipid and alkylated NLG919 (aNLG), an IDO1 inhibitor, together with other commercial lipids.	Oxaliplatin	72-83	indoleamine 2,3-dioxygenase 1	Homo sapiens	158-162
32893979-10	2020	CONCLUSION: A positive result on the CLIP test predict is predictive of the risk of progression of OIPN during chemotherapy with oxaliplatin.	Oxaliplatin	129-140	CAP-Gly domain containing linker protein 1	Homo sapiens	37-41
32599983-4	2020	FGFR4-dependent signal pathways involving cell proliferation, invasion, migration, and resistance to oxaliplatin (OXA) in accordance with the SNP were also assessed in transfected GC cell lines.	Oxaliplatin	101-112	fibroblast growth factor receptor 4	Homo sapiens	0-5
32652867-4	2020	Enhanced dbpA promoted the drug resistance of SW620 cells to 5-FU and L-OHP.	Oxaliplatin	70-75	Y-box binding protein 3	Homo sapiens	9-13
32652867-6	2020	Besides, dbpA shRNA enhanced the cytotoxicity of 5-FU and L-OHP to SW620/5-FU and SW620/L-OHP cells.	Oxaliplatin	58-63	Y-box binding protein 3	Homo sapiens	9-13
32652867-6	2020	Besides, dbpA shRNA enhanced the cytotoxicity of 5-FU and L-OHP to SW620/5-FU and SW620/L-OHP cells.	Oxaliplatin	88-93	Y-box binding protein 3	Homo sapiens	9-13
32652867-10	2020	Our study indicated that knockdown of dbpA enhanced the sensitivity of colorectal cancer cells to 5-FU via Wnt/beta-catenin/Chk1 pathway, and DbpA may be a potential therapeutic target to sensitize drug resistance colorectal cancer to 5-FU and L-OHP.	Oxaliplatin	244-249	Y-box binding protein 3	Homo sapiens	38-42
32652867-10	2020	Our study indicated that knockdown of dbpA enhanced the sensitivity of colorectal cancer cells to 5-FU via Wnt/beta-catenin/Chk1 pathway, and DbpA may be a potential therapeutic target to sensitize drug resistance colorectal cancer to 5-FU and L-OHP.	Oxaliplatin	244-249	catenin beta 1	Homo sapiens	111-123
32599983-4	2020	FGFR4-dependent signal pathways involving cell proliferation, invasion, migration, and resistance to oxaliplatin (OXA) in accordance with the SNP were also assessed in transfected GC cell lines.	Oxaliplatin	114-117	fibroblast growth factor receptor 4	Homo sapiens	0-5
32599983-7	2020	In transfected GC cells, the overexpression of FGFR4-Arg388 variant increased proliferation and invasion of GC cells, increasing resistance of GC cells to OXA compared with cells over-expressing the Gly388 allele.	Oxaliplatin	155-158	fibroblast growth factor receptor 4	Homo sapiens	47-52
32652867-10	2020	Our study indicated that knockdown of dbpA enhanced the sensitivity of colorectal cancer cells to 5-FU via Wnt/beta-catenin/Chk1 pathway, and DbpA may be a potential therapeutic target to sensitize drug resistance colorectal cancer to 5-FU and L-OHP.	Oxaliplatin	244-249	checkpoint kinase 1	Homo sapiens	124-128
32384961-11	2020	The results showed that the expression of TXNIP and autophagy related indexes-BECN1 and LC3B in sciatic nerve decreased significantly after oxaliplatin treatment.	Oxaliplatin	140-151	thioredoxin interacting protein	Mus musculus	42-47
32800255-12	2020	Participants with elevated 1-OHP level had higher odds of high RAGE level in the model 1 (OR = 3.466, 95% CI, 1.053-11.412) and model 2 (OR = 3.454, 95% CI, 1.034-11.536).	Oxaliplatin	27-32	advanced glycosylation end-product specific receptor	Homo sapiens	63-67
33155210-13	2020	Oxaliplatin group exhibited notably lower levels of serum TNF-alpha, CRP and IL-1beta (p<0.05) and higher IL-4 level than model group (p<0.05).	Oxaliplatin	0-11	tumor necrosis factor	Rattus norvegicus	58-67
33155210-13	2020	Oxaliplatin group exhibited notably lower levels of serum TNF-alpha, CRP and IL-1beta (p<0.05) and higher IL-4 level than model group (p<0.05).	Oxaliplatin	0-11	C-reactive protein	Rattus norvegicus	69-72
33155210-13	2020	Oxaliplatin group exhibited notably lower levels of serum TNF-alpha, CRP and IL-1beta (p<0.05) and higher IL-4 level than model group (p<0.05).	Oxaliplatin	0-11	interleukin 1 alpha	Rattus norvegicus	77-85
33155210-13	2020	Oxaliplatin group exhibited notably lower levels of serum TNF-alpha, CRP and IL-1beta (p<0.05) and higher IL-4 level than model group (p<0.05).	Oxaliplatin	0-11	interleukin 4	Rattus norvegicus	106-110
33155210-17	2020	Moreover, the expressions of Apaf1, Caspase-9 and Survivin were clearly higher, while that of Bcl-2 was prominently lower in tumor tissues in oxaliplatin group than model group (p<0.05).	Oxaliplatin	142-153	apoptotic peptidase activating factor 1	Rattus norvegicus	29-34
33155210-17	2020	Moreover, the expressions of Apaf1, Caspase-9 and Survivin were clearly higher, while that of Bcl-2 was prominently lower in tumor tissues in oxaliplatin group than model group (p<0.05).	Oxaliplatin	142-153	caspase 9	Rattus norvegicus	36-45
33155210-17	2020	Moreover, the expressions of Apaf1, Caspase-9 and Survivin were clearly higher, while that of Bcl-2 was prominently lower in tumor tissues in oxaliplatin group than model group (p<0.05).	Oxaliplatin	142-153	BCL2, apoptosis regulator	Rattus norvegicus	94-99
32384961-11	2020	The results showed that the expression of TXNIP and autophagy related indexes-BECN1 and LC3B in sciatic nerve decreased significantly after oxaliplatin treatment.	Oxaliplatin	140-151	beclin 1, autophagy related	Mus musculus	78-83
32384961-11	2020	The results showed that the expression of TXNIP and autophagy related indexes-BECN1 and LC3B in sciatic nerve decreased significantly after oxaliplatin treatment.	Oxaliplatin	140-151	microtubule-associated protein 1 light chain 3 beta	Mus musculus	88-92
32384961-13	2020	Thus, our study has identified TXNIP as a novel target for oxaliplatin induced peripheral nerve pain.	Oxaliplatin	59-70	thioredoxin interacting protein	Mus musculus	31-36
32384961-14	2020	We have shown that oxaliplatin inhibits TXNIP expression, regulates autophagy, thereby affecting neuralgia.	Oxaliplatin	19-30	thioredoxin interacting protein	Mus musculus	40-45
32512114-4	2020	Likewise, activation of mTOR by constitutively active 5-HT6 receptors mediates allodynia in oxaliplatin-induced peripheral neuropathy in rats but not mechanical nociception in healthy rats.	Oxaliplatin	92-103	mechanistic target of rapamycin kinase	Rattus norvegicus	24-28
33005106-0	2020	Long non-coding RNA MALAT1 regulates oxaliplatin-resistance via miR-324-3p/ADAM17 axis in colorectal cancer cells.	Oxaliplatin	37-48	metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA)	Mus musculus	20-26
33005106-0	2020	Long non-coding RNA MALAT1 regulates oxaliplatin-resistance via miR-324-3p/ADAM17 axis in colorectal cancer cells.	Oxaliplatin	37-48	a disintegrin and metallopeptidase domain 17	Mus musculus	75-81
33042471-4	2020	The biological significance of CD44 expression in the chemoresistance response to fluorouracil, oxaliplatin or irinotecan, three major anti-cancer agents for colon cancer in the clinical setting, was examined using colon cancer cell lines.	Oxaliplatin	96-107	CD44 molecule (Indian blood group)	Homo sapiens	31-35
33205012-5	2020	Using cell lines harboring patient-specific C4BPA mutations, we show that increasing intracellular C4BPA levels correlate with sensitivity to oxaliplatin-induced apoptosis in vitro and in vivo.	Oxaliplatin	142-153	complement component 4 binding protein alpha	Homo sapiens	44-49
33205012-5	2020	Using cell lines harboring patient-specific C4BPA mutations, we show that increasing intracellular C4BPA levels correlate with sensitivity to oxaliplatin-induced apoptosis in vitro and in vivo.	Oxaliplatin	142-153	complement component 4 binding protein alpha	Homo sapiens	99-104
33014113-2	2020	The resistance mechanism(s) of colorectal tumors to L-OHP may be related to the regulation of ERCC1 by cancer-expressed miRNAs, but no in-depth studies on the miRNAs that affect drug resistance have been performed.	Oxaliplatin	52-57	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	94-99
33014113-12	2020	Conclusion: Curcumin can overcome L-OHP resistance in colorectal cancer cells through its effects on miR-409-3p mediated ERCC1 expression.	Oxaliplatin	34-39	microRNA 409	Homo sapiens	101-108
33014113-12	2020	Conclusion: Curcumin can overcome L-OHP resistance in colorectal cancer cells through its effects on miR-409-3p mediated ERCC1 expression.	Oxaliplatin	34-39	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	121-126
33042471-10	2020	CONCLUSIONS: CD44 enhances chemoresistance in response to anti-cancer drugs (fluorouracil and oxaliplatin) in colon cancer cells.	Oxaliplatin	94-105	CD44 molecule (Indian blood group)	Homo sapiens	13-17
33042471-8	2020	Additionally, CD44 knockdown overcame chemoresistance in response to fluorouracil and oxaliplatin with enhanced apoptosis and p27 upregulation, respectively.	Oxaliplatin	86-97	CD44 molecule (Indian blood group)	Homo sapiens	14-18
33042471-8	2020	Additionally, CD44 knockdown overcame chemoresistance in response to fluorouracil and oxaliplatin with enhanced apoptosis and p27 upregulation, respectively.	Oxaliplatin	86-97	dynactin subunit 6	Homo sapiens	126-129
32900990-5	2020	Overexpression of VDR effectively suppressed the stemness and oxaliplatin resistance of cells in acidosis.	Oxaliplatin	62-73	vitamin D receptor	Homo sapiens	18-21
32982229-3	2020	Methods: The reverse-phase evaporation method (REV) was used to prepare L-OHP loaded LCTL (L-OHP/LCTL).	Oxaliplatin	72-77	lactase-like	Mus musculus	85-89
32982229-3	2020	Methods: The reverse-phase evaporation method (REV) was used to prepare L-OHP loaded LCTL (L-OHP/LCTL).	Oxaliplatin	72-77	lactase-like	Mus musculus	91-101
32982229-8	2020	Conclusively, LCTL could serve as a promising carrier for oxaliplatin delivery to treat solid tumors.	Oxaliplatin	58-69	lactase-like	Mus musculus	14-18
32914380-0	2021	MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway.	Oxaliplatin	17-28	microRNA 325	Homo sapiens	0-7
32914380-0	2021	MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway.	Oxaliplatin	17-28	heat shock protein family A (Hsp70) member 12B	Homo sapiens	88-95
32914380-0	2021	MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway.	Oxaliplatin	17-28	AKT serine/threonine kinase 1	Homo sapiens	101-104
32914380-0	2021	MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway.	Oxaliplatin	17-28	BCL2 apoptosis regulator	Homo sapiens	105-110
32914380-3	2021	AIMS: To investigate the role of miR-325 in changing the oxaliplatin sensitivity to CRC cells.	Oxaliplatin	57-68	microRNA 325	Homo sapiens	33-40
32914380-5	2021	Cytotoxicity of oxaliplatin to control or miR-325-overexpressed HT29 and SW480 cells was evaluated by CCK-8 assays.	Oxaliplatin	16-27	microRNA 325	Homo sapiens	42-49
32914380-9	2021	However, overexpression of miR-325 can decrease the 50% inhibiting concentration of oxaliplatin to colorectal cancer cell lines HT29 and SW480.	Oxaliplatin	84-95	microRNA 325	Homo sapiens	27-34
32914380-11	2021	Therefore, overexpression of miR-325 inhibited the phosphorylation of PI3K and AKT and decreased the expression of Bcl-2 to promote the oxaliplatin-induced mitochondrial apoptosis in colorectal cancer.	Oxaliplatin	136-147	microRNA 325	Homo sapiens	29-36
32914380-11	2021	Therefore, overexpression of miR-325 inhibited the phosphorylation of PI3K and AKT and decreased the expression of Bcl-2 to promote the oxaliplatin-induced mitochondrial apoptosis in colorectal cancer.	Oxaliplatin	136-147	BCL2 apoptosis regulator	Homo sapiens	115-120
32914380-12	2021	CONCLUSIONS: MiR-325 sensitizes the colorectal cancer cells to oxaliplatin-induced cytotoxicity through the HSPA12B/PI3K/AKT/Bcl-2 pathway.	Oxaliplatin	63-74	microRNA 325	Homo sapiens	13-20
32914380-12	2021	CONCLUSIONS: MiR-325 sensitizes the colorectal cancer cells to oxaliplatin-induced cytotoxicity through the HSPA12B/PI3K/AKT/Bcl-2 pathway.	Oxaliplatin	63-74	heat shock protein family A (Hsp70) member 12B	Homo sapiens	108-115
32914380-12	2021	CONCLUSIONS: MiR-325 sensitizes the colorectal cancer cells to oxaliplatin-induced cytotoxicity through the HSPA12B/PI3K/AKT/Bcl-2 pathway.	Oxaliplatin	63-74	AKT serine/threonine kinase 1	Homo sapiens	121-124
32914380-12	2021	CONCLUSIONS: MiR-325 sensitizes the colorectal cancer cells to oxaliplatin-induced cytotoxicity through the HSPA12B/PI3K/AKT/Bcl-2 pathway.	Oxaliplatin	63-74	BCL2 apoptosis regulator	Homo sapiens	125-130
32917936-0	2020	LINC00641/miR-582-5p mediate oxaliplatin resistance by activating autophagy in gastric adenocarcinoma.	Oxaliplatin	29-40	long intergenic non-protein coding RNA 641	Homo sapiens	0-9
32917936-0	2020	LINC00641/miR-582-5p mediate oxaliplatin resistance by activating autophagy in gastric adenocarcinoma.	Oxaliplatin	29-40	microRNA 582	Homo sapiens	10-17
32917936-3	2020	We aim to find the roles that LINC00641 and miR-582-5p play in regulating oxaliplatin resistance.	Oxaliplatin	74-85	long intergenic non-protein coding RNA 641	Homo sapiens	30-39
32917936-6	2020	LINC00641 expression was associated with prognosis and oxaliplatin resistance in patients with gastric adenocarcinoma.	Oxaliplatin	55-66	long intergenic non-protein coding RNA 641	Homo sapiens	0-9
32917936-8	2020	Moreover, LINC00641 was highly expressed in oxaliplatin-resistant cell lines and miR-582-5p was down-regulated.	Oxaliplatin	44-55	long intergenic non-protein coding RNA 641	Homo sapiens	10-19
32917936-11	2020	Further experiments indicated that down-regulation of LINC00641 inhibited the autophagy process, making gastric cancer cells more sensitive to oxaliplatin.	Oxaliplatin	143-154	long intergenic non-protein coding RNA 641	Homo sapiens	54-63
32917936-12	2020	LINC00641 and miR-582-5p are biomarkers for predicting overall survival, as they were involved in regulating oxaliplatin resistance by altering autophagy in gastric adenocarcinoma.	Oxaliplatin	109-120	long intergenic non-protein coding RNA 641	Homo sapiens	0-9
32488710-10	2020	The null state of GSTT1 was significantly associated with high concentrations of 1-OHP in urea (p < 0.01).	Oxaliplatin	81-86	glutathione S-transferase theta 1	Homo sapiens	18-23
32692214-2	2020	Acute neuropathy is caused by the intact L-OHP affecting the function of transient receptor potential vanilloid 1 (TRPV1) channel.	Oxaliplatin	41-46	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	73-113
32692214-2	2020	Acute neuropathy is caused by the intact L-OHP affecting the function of transient receptor potential vanilloid 1 (TRPV1) channel.	Oxaliplatin	41-46	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	115-120
32595209-6	2020	Syntenin-1 knockdown in CRC cells reduced the presence of cancer stem cells (CSCs), oxaliplatin chemoresistance and migration.	Oxaliplatin	84-95	syndecan binding protein	Homo sapiens	0-10
32595209-10	2020	CONCLUSIONS: Our findings suggested that syntenin-1 enhanced CSC expansion, oxaliplatin chemoresistance and migration capability through regulation of PTGER2 expression.	Oxaliplatin	76-87	syndecan binding protein	Homo sapiens	41-51
32488710-11	2020	There was significant association between methylated states of CDKN2A and high concentrations of 1-OHP in urine (p < 0.01).	Oxaliplatin	97-102	cyclin dependent kinase inhibitor 2A	Homo sapiens	63-69
32765688-0	2020	Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1.	Oxaliplatin	76-87	microRNA 96	Homo sapiens	14-20
32765688-4	2020	The present study focused on the roles of microRNA (miR)-96 in the oxaliplatin resistance of CRC cells and the underlying mechanisms.	Oxaliplatin	67-78	microRNA 96	Homo sapiens	42-59
32765688-12	2020	Furthermore, knockdown of miR-96 combined with oxaliplatin reduced the viability and induced apoptosis of CRC cells, which was further verified by decreased expression of Bcl-2 and the increased expression of TPM1 and BAX.	Oxaliplatin	47-58	BCL2 apoptosis regulator	Homo sapiens	171-176
32765688-12	2020	Furthermore, knockdown of miR-96 combined with oxaliplatin reduced the viability and induced apoptosis of CRC cells, which was further verified by decreased expression of Bcl-2 and the increased expression of TPM1 and BAX.	Oxaliplatin	47-58	BCL2 associated X, apoptosis regulator	Homo sapiens	218-221
32765688-13	2020	Taken together, the downregulation of miR-96 enhanced the sensitivity of CRC cells to oxaliplatin.	Oxaliplatin	86-97	microRNA 96	Homo sapiens	38-44
32705170-0	2020	Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming.	Oxaliplatin	122-133	pyruvate dehydrogenase kinase 1	Homo sapiens	14-45
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Oxaliplatin	433-444	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	83-105
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Oxaliplatin	433-444	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	107-110
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Oxaliplatin	433-444	pyruvate dehydrogenase kinase 1	Homo sapiens	142-146
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Oxaliplatin	446-449	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	83-105
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Oxaliplatin	446-449	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	107-110
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Oxaliplatin	446-449	pyruvate dehydrogenase kinase 1	Homo sapiens	142-146
32484793-3	2020	Among candidate transporters investigated in genetically engineered mouse models, we provide evidence for a critical role of the organic cation transporter 2 (OCT2) in satellite glial cells in oxaliplatin-induced neurotoxicity, and demonstrate that targeting OCT2 using genetic and pharmacological approaches ameliorates acute and chronic forms of neurotoxicity.	Oxaliplatin	193-204	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	129-157
33277837-0	2020	IRF-1 mediated long non-coding RNA PVT1-214 promotes oxaliplatin resistance of colorectal cancer via miR-128 inhibition.	Oxaliplatin	53-64	interferon regulatory factor 1	Homo sapiens	0-5
33277837-13	2020	Moreover, IRF-1 was found to be a negative transcription regulator of PVT1-214 and decreased PVT1-214 levels in oxaliplatin-resistant CRC cells.	Oxaliplatin	112-123	interferon regulatory factor 1	Homo sapiens	10-15
33277837-15	2020	CONCLUSIONS: IRF-1/PVT1-214 may markedly boost the oxaliplatin-resistance of CRC, resulting in the late TNM stage and poor survival.	Oxaliplatin	51-62	interferon regulatory factor 1	Homo sapiens	13-18
32484793-3	2020	Among candidate transporters investigated in genetically engineered mouse models, we provide evidence for a critical role of the organic cation transporter 2 (OCT2) in satellite glial cells in oxaliplatin-induced neurotoxicity, and demonstrate that targeting OCT2 using genetic and pharmacological approaches ameliorates acute and chronic forms of neurotoxicity.	Oxaliplatin	193-204	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	159-163
32484793-3	2020	Among candidate transporters investigated in genetically engineered mouse models, we provide evidence for a critical role of the organic cation transporter 2 (OCT2) in satellite glial cells in oxaliplatin-induced neurotoxicity, and demonstrate that targeting OCT2 using genetic and pharmacological approaches ameliorates acute and chronic forms of neurotoxicity.	Oxaliplatin	193-204	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	259-263
32484793-5	2020	These studies suggest that pharmacological targeting of OCT2 could be exploited to afford neuroprotection in cancer patients requiring treatment with oxaliplatin.	Oxaliplatin	150-161	solute carrier family 22 member 2	Homo sapiens	56-60
31851321-3	2020	METHODS: HER2-HER3 dimerization was quantified by "FLIM Histology" in primary tumor samples from 550 COIN trial patients receiving oxaliplatin and fluoropyrimidine chemotherapy +/-cetuximab.	Oxaliplatin	131-142	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
32544411-0	2020	Lycopene protects against central and peripheral neuropathy by inhibiting Oxaliplatin-induced ATF-6 pathway, apoptosis, inflammation and oxidative stress in brains and sciatic tissues of rats.	Oxaliplatin	74-85	activating transcription factor 6	Rattus norvegicus	94-99
32823168-0	2020	Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis.	Oxaliplatin	25-36	kelch-like ECH-associated protein 1	Mus musculus	75-80
32331534-0	2020	The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1.	Oxaliplatin	53-64	AKT serine/threonine kinase 1	Homo sapiens	4-7
32331534-0	2020	The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1.	Oxaliplatin	53-64	snail family transcriptional repressor 2	Homo sapiens	22-26
32331534-0	2020	The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1.	Oxaliplatin	53-64	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	117-122
32331534-3	2020	In this study, we found the chemoresistance in oxaliplatin-resistant HCT116 cells (HCT116/OXA) was mediated by the upregulation of ERCC1 expression.	Oxaliplatin	47-58	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	131-136
32331534-8	2020	Taken together, the simultaneous inhibition of the AKT/GSK3/Slug axis may be of significance for surmounting metastasis and chemoresistance, thereby improving the therapeutic outcome of oxaliplatin.	Oxaliplatin	186-197	AKT serine/threonine kinase 1	Homo sapiens	51-54
32331534-8	2020	Taken together, the simultaneous inhibition of the AKT/GSK3/Slug axis may be of significance for surmounting metastasis and chemoresistance, thereby improving the therapeutic outcome of oxaliplatin.	Oxaliplatin	186-197	snail family transcriptional repressor 2	Homo sapiens	60-64
32544411-6	2020	It was determined that OXL-induced endoplasmic reticulum stress (ERS) decreased because LY administration reduced the expressions of activating transcription factor-6 (ATF6), glucose-regulated protein-78 (GRP78), pancreatic endoplasmic reticulum kinase (PERK) and inositol-requiring enzyme-1 (IRE1).	Oxaliplatin	23-26	activating transcription factor 6	Rattus norvegicus	133-166
32544411-6	2020	It was determined that OXL-induced endoplasmic reticulum stress (ERS) decreased because LY administration reduced the expressions of activating transcription factor-6 (ATF6), glucose-regulated protein-78 (GRP78), pancreatic endoplasmic reticulum kinase (PERK) and inositol-requiring enzyme-1 (IRE1).	Oxaliplatin	23-26	activating transcription factor 6	Rattus norvegicus	168-172
32544411-6	2020	It was determined that OXL-induced endoplasmic reticulum stress (ERS) decreased because LY administration reduced the expressions of activating transcription factor-6 (ATF6), glucose-regulated protein-78 (GRP78), pancreatic endoplasmic reticulum kinase (PERK) and inositol-requiring enzyme-1 (IRE1).	Oxaliplatin	23-26	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	175-203
32544411-6	2020	It was determined that OXL-induced endoplasmic reticulum stress (ERS) decreased because LY administration reduced the expressions of activating transcription factor-6 (ATF6), glucose-regulated protein-78 (GRP78), pancreatic endoplasmic reticulum kinase (PERK) and inositol-requiring enzyme-1 (IRE1).	Oxaliplatin	23-26	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	205-210
32544411-7	2020	LY administration also reduced the damage of OXL-induced brain and sciatic tissue by increasing NCAM levels and decreasing GFAP levels.	Oxaliplatin	45-48	neural cell adhesion molecule 1	Rattus norvegicus	96-100
32544411-7	2020	LY administration also reduced the damage of OXL-induced brain and sciatic tissue by increasing NCAM levels and decreasing GFAP levels.	Oxaliplatin	45-48	glial fibrillary acidic protein	Rattus norvegicus	123-127
32823168-0	2020	Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis.	Oxaliplatin	25-36	nuclear factor, erythroid derived 2, like 2	Mus musculus	81-85
32823168-0	2020	Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis.	Oxaliplatin	25-36	glutathione S-transferase, pi 1	Mus musculus	86-91
32823168-5	2020	Further expression profile sequencing showed that FN exerts its protective effect via the NRF2 downstream-oxaliplatin metabolism enzyme, GSTP1.	Oxaliplatin	106-117	nuclear factor, erythroid derived 2, like 2	Mus musculus	90-94
32823168-5	2020	Further expression profile sequencing showed that FN exerts its protective effect via the NRF2 downstream-oxaliplatin metabolism enzyme, GSTP1.	Oxaliplatin	106-117	glutathione S-transferase, pi 1	Mus musculus	137-142
32825798-8	2020	Finally, p22phox might have binding specificity for the platinum drugs, including CDDP, carboplatin and oxaliplatin.	Oxaliplatin	104-115	cytochrome b-245 alpha chain	Homo sapiens	9-16
32729895-7	2020	Additionally, CD133+CD44+ cells presented significant chemoresistance compared with corresponding nontumorigenic CD133-CD44- cells following exposure to oxaliplatin or 5-FU.	Oxaliplatin	153-164	prominin 1	Homo sapiens	14-19
32729895-7	2020	Additionally, CD133+CD44+ cells presented significant chemoresistance compared with corresponding nontumorigenic CD133-CD44- cells following exposure to oxaliplatin or 5-FU.	Oxaliplatin	153-164	CD44 molecule (Indian blood group)	Homo sapiens	20-24
32859280-0	2021	Prognostic Value of EGFR Expression for Patients with Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy.	Oxaliplatin	177-188	epidermal growth factor receptor	Homo sapiens	20-24
32984059-0	2020	Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin.	Oxaliplatin	139-150	tumor protein p53	Homo sapiens	32-35
32984059-0	2020	Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin.	Oxaliplatin	139-150	tumor protein p53	Homo sapiens	82-85
32984059-3	2020	The current study was aimed to investigate the response of wild-type TP53 harboring HCT 116 and mutant TP53 harboring HT 29 colon cancer cells to chemotherapeutic drug oxaliplatin (OX) and to elucidate the underlying molecular mechanisms of sensitivity/resistance in correlation to their p53 status.	Oxaliplatin	168-179	tumor protein p53	Homo sapiens	69-73
32984059-3	2020	The current study was aimed to investigate the response of wild-type TP53 harboring HCT 116 and mutant TP53 harboring HT 29 colon cancer cells to chemotherapeutic drug oxaliplatin (OX) and to elucidate the underlying molecular mechanisms of sensitivity/resistance in correlation to their p53 status.	Oxaliplatin	168-179	tumor protein p53	Homo sapiens	103-107
32778717-0	2020	Diurnal expression of MRP4 in bone marrow cells underlies the dosing-time dependent changes in the oxaliplatin-induced myelotoxicity.	Oxaliplatin	99-110	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	22-26
32851091-0	2020	AURKA Increase the Chemosensitivity of Colon Cancer Cells to Oxaliplatin by Inhibiting the TP53-Mediated DNA Damage Response Genes.	Oxaliplatin	61-72	tumor protein p53	Homo sapiens	91-95
32851091-6	2020	Moreover, we demonstrated that AURKA overexpression promoted the death of colon cancer cells induced by Oxaliplatin, whereas knockdown of AURKA significantly weakened the chemosensitivity of colon cancer cells to Oxaliplatin.	Oxaliplatin	104-115	aurora kinase A	Homo sapiens	31-36
32851091-6	2020	Moreover, we demonstrated that AURKA overexpression promoted the death of colon cancer cells induced by Oxaliplatin, whereas knockdown of AURKA significantly weakened the chemosensitivity of colon cancer cells to Oxaliplatin.	Oxaliplatin	213-224	aurora kinase A	Homo sapiens	138-143
32778717-3	2020	In this study, we demonstrated that MRP4 was responsible for the extrusion of oxaliplatin (L-OHP), a platinum (Pt)-based chemotherapeutic drug, from BMCs of mice, and that the efflux transporter expression exhibited significant diurnal variation.	Oxaliplatin	78-89	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	36-40
32778717-3	2020	In this study, we demonstrated that MRP4 was responsible for the extrusion of oxaliplatin (L-OHP), a platinum (Pt)-based chemotherapeutic drug, from BMCs of mice, and that the efflux transporter expression exhibited significant diurnal variation.	Oxaliplatin	91-96	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	36-40
32778717-6	2020	Lower Pt accumulation in BMCs was detected in mice after injection of L-OHP at the mid-dark phase, during which the expression levels of MRP4 increased.	Oxaliplatin	70-75	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	137-141
32778717-10	2020	Diurnal expression of MRP4 in BMCs is associated with the dosing time-dependent changes in L-OHP-induced myelotoxicity.	Oxaliplatin	91-96	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	22-26
32459682-0	2020	Pregabalin reduces oxaliplatin-induced oxidative neurotoxicity through modulation of TRPV1 channels in DBTRG neuronal cell line.	Oxaliplatin	19-30	transient receptor potential cation channel subfamily V member 1	Homo sapiens	85-90
32416186-0	2020	Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.	Oxaliplatin	29-40	carboxypeptidase B2	Homo sapiens	92-135
32416186-2	2020	Recently, thrombomodulin alfa, a recombinant human soluble thrombomodulin, was reported to prevent oxaliplatin-induced peripheral neuropathy in a clinical phase 2 study.	Oxaliplatin	99-110	thrombomodulin	Homo sapiens	10-24
32416186-8	2020	These results suggest that thrombomodulin alfa prevents sensory symptoms of oxaliplatin-induced peripheral neuropathy through the activation of TAFI and protein C by modulating thrombin activity, but the effects are independent of an anticoagulant effect.	Oxaliplatin	76-87	carboxypeptidase B2	Homo sapiens	144-148
32416186-8	2020	These results suggest that thrombomodulin alfa prevents sensory symptoms of oxaliplatin-induced peripheral neuropathy through the activation of TAFI and protein C by modulating thrombin activity, but the effects are independent of an anticoagulant effect.	Oxaliplatin	76-87	coagulation factor II, thrombin	Homo sapiens	177-185
32459682-7	2020	In the patch-clamp analyses, OXAL-induced TRPV1 channel activation in the OXAL group also decreased in the PREGAB + OXAL group using the PREGAB and capsazepine treatments.	Oxaliplatin	29-33	transient receptor potential cation channel subfamily V member 1	Homo sapiens	42-47
32658073-1	2020	OBJECTIVES: The objective of this study was to investigate the efficacy and tolerability of 5-fluorouracil-oxaliplatin (FOLFOX) in advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).	Oxaliplatin	107-118	granulin precursor	Homo sapiens	189-192
32380907-0	2020	MiR-153-5p promotes sensibility of colorectal cancer cells to oxaliplatin via targeting Bcl-2-mediated autophagy pathway.	Oxaliplatin	62-73	BCL2 apoptosis regulator	Homo sapiens	88-93
32096264-8	2020	RESULTS: TRIM14 was significantly upregulated in 5-FU- and L-OHP-resistant GC tissues and cells.	Oxaliplatin	59-64	tripartite motif containing 14	Homo sapiens	9-15
32661875-0	2020	The potential impact of trigonelline loaded micelles on Nrf2 suppression to overcome oxaliplatin resistance in colon cancer cells.	Oxaliplatin	85-96	NFE2 like bZIP transcription factor 2	Homo sapiens	56-60
32661875-3	2020	This study investigated the role of trigonelline and trigonelline loaded micelles in Nrf2 inhibition to break down oxaliplatin resistance in colon cancer cells.	Oxaliplatin	115-126	NFE2 like bZIP transcription factor 2	Homo sapiens	85-89
32661875-10	2020	Furthermore, trigonelline loaded 5Block micelle increased oxaliplatin-induced apoptosis in a Nrf2/ARE dependent manner.	Oxaliplatin	58-69	NFE2 like bZIP transcription factor 2	Homo sapiens	93-97
32096264-2	2020	METHODS: The expression of TRIM14 in 5-fluorouracil (5-FU)- and oxaliplation (L-OHP)-resistant GC tissues and cells were determined by qRT-PCR and western blotting.	Oxaliplatin	78-83	tripartite motif containing 14	Homo sapiens	27-33
32742376-5	2020	In HCT116 cells expressing wild-type (wt) TP53, SIRT inhibitors were found to act antagonistically with multiple chemotherapeutic agents (cisplatin, 5-fluorouracil, oxaliplatin, gefitinib, LY294002 and metformin), and decreased the anti-tumor effects of these agents.	Oxaliplatin	165-176	tumor protein p53	Homo sapiens	42-46
32760217-0	2020	Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b.	Oxaliplatin	75-86	GATA binding protein 3	Mus musculus	14-19
32657048-0	2020	Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/beta-catenin signaling pathway.	Oxaliplatin	43-54	catenin beta 1	Homo sapiens	122-134
32657048-18	2020	WHAT THIS STUDY ADDS: Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cells through the Wnt/beta-catenin signaling pathway.	Oxaliplatin	65-76	catenin beta 1	Homo sapiens	149-161
32677671-7	2020	In this study, we investigated the association between CELF1 and ETS2 in CRC tumorigenesis and oxaliplatin (L-OHP) resistance.	Oxaliplatin	95-106	CUGBP Elav-like family member 1	Homo sapiens	55-60
32677671-7	2020	In this study, we investigated the association between CELF1 and ETS2 in CRC tumorigenesis and oxaliplatin (L-OHP) resistance.	Oxaliplatin	108-113	CUGBP Elav-like family member 1	Homo sapiens	55-60
32677671-9	2020	Overexpression of CELF1 increased CRC cell proliferation, migration, and invasion in vitro and in a xenograft tumor growth model in vivo, and induced resistance to L-OHP.	Oxaliplatin	164-169	CUGBP Elav-like family member 1	Homo sapiens	18-23
32677671-10	2020	In contrast, CELF1 knockdown improved the response of CRC cells to L-OHP.	Oxaliplatin	67-72	CUGBP Elav-like family member 1	Homo sapiens	13-18
32677671-11	2020	Overexpression of ETS2 increased the malignant behavior of CRC cells (growth, migration, and invasion) and L-OHP resistance in vitro.	Oxaliplatin	107-112	ETS proto-oncogene 2, transcription factor	Homo sapiens	18-22
32677671-12	2020	Moreover, L-OHP resistance induced by CELF1 overexpression was reversed by ETS2 knockdown.	Oxaliplatin	10-15	CUGBP Elav-like family member 1	Homo sapiens	38-43
32677671-12	2020	Moreover, L-OHP resistance induced by CELF1 overexpression was reversed by ETS2 knockdown.	Oxaliplatin	10-15	ETS proto-oncogene 2, transcription factor	Homo sapiens	75-79
32677671-14	2020	Taken together, our findings have identified that CELF1 regulates ETS2 in a mechanism that results in CRC tumorigenesis and L-OHP resistance, and CELF1 may be a promising target for overcoming chemoresistance in CRC.	Oxaliplatin	124-129	CUGBP Elav-like family member 1	Homo sapiens	50-55
32677671-14	2020	Taken together, our findings have identified that CELF1 regulates ETS2 in a mechanism that results in CRC tumorigenesis and L-OHP resistance, and CELF1 may be a promising target for overcoming chemoresistance in CRC.	Oxaliplatin	124-129	ETS proto-oncogene 2, transcription factor	Homo sapiens	66-70
32722474-0	2020	PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer.	Oxaliplatin	47-58	pyruvate kinase M1/2	Homo sapiens	0-4
32760217-8	2020	Result: Both GATA3 and miR-29b agomir inhibited the activity of the CRC cells, promoted apoptosis and Cleaved caspase3 expression, and reduced the resistance of the cells to chemotherapy drug oxaliplatin.	Oxaliplatin	192-203	GATA binding protein 3	Mus musculus	13-18
32760217-12	2020	Conclusion: GATA3 inhibits the cell viability of CRC cells, promotes apoptosis, and reduces oxaliplatin resistance of CRC cells through regulating miR-29b.	Oxaliplatin	92-103	GATA binding protein 3	Mus musculus	12-17
32622356-6	2020	After biopsy confirmation, patient was initially started on gemcitabine and oxaliplatin combination followed by gene sequencing, which showed Tp53 (exon 7-c.713 G > A and exon 5-c.376-2A > G) and EGFR (exon 20-T790M) mutation, and erlotinib was added to chemotherapy, after 6 cycles of chemotherapy patient showed a 90% partial radiological response as per RECIST criteria.	Oxaliplatin	76-87	tumor protein p53	Homo sapiens	142-146
32622356-7	2020	CONCLUSION: This case reports the possible efficacy of erlotinib in combination with gemcitabine and oxaliplatin in treating an EGFR-mutated GBC with liver metastasis.	Oxaliplatin	101-112	epidermal growth factor receptor	Homo sapiens	128-132
32629861-3	2020	Here, we analyzed whether RPA2 and GTF2H1 SNPs predict the efficacy of oxaliplatin in metastatic CRC (mCRC) patients.	Oxaliplatin	71-82	replication protein A2	Homo sapiens	26-30
32319158-7	2020	The c-FOS protein level and p/t-ERK/PKC were significantly elevated by morphine + OXA.	Oxaliplatin	82-85	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	4-9
32319158-7	2020	The c-FOS protein level and p/t-ERK/PKC were significantly elevated by morphine + OXA.	Oxaliplatin	82-85	mitogen-activated protein kinase 1	Homo sapiens	32-35
32092782-0	2020	miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.	Oxaliplatin	22-33	tubulin beta 3 class III	Homo sapiens	59-64
32092782-2	2020	The aim of the present study was to investigate whether miR-200b-3p could regulate L-OHP resistance via targeting TUBB3 in CRC cells.	Oxaliplatin	83-88	microRNA 200b	Homo sapiens	56-64
32092782-2	2020	The aim of the present study was to investigate whether miR-200b-3p could regulate L-OHP resistance via targeting TUBB3 in CRC cells.	Oxaliplatin	83-88	tubulin beta 3 class III	Homo sapiens	114-119
32092782-4	2020	The effect of miR-200b-3p on L-OHP resistant CRC cells was then evaluated using the CCK8 assay.	Oxaliplatin	29-34	microRNA 200b	Homo sapiens	14-22
32092782-7	2020	RESULTS: miR-200b-3p declined in L-OHP resistant CRC tissues and cell lines, and the overexpression of miR-200b-3p elevated the L-OHP sensitivity in L-OHP resistant HT29 and HCT116 cells.	Oxaliplatin	33-38	microRNA 200b	Homo sapiens	9-17
32092782-8	2020	In addition, we determined the potential mechanisms underlying miR-200b-3p-mediated reversal of L-OHP resistance via mediating its downstream target TUBB3, and the overexpression of miR-200b-3p could induce migration and growth inhibition and apoptosis in L-OHP resistant HT29 and HCT116 cells by silencing betaIII-tubulin protein expression.	Oxaliplatin	96-101	microRNA 200b	Homo sapiens	63-71
32092782-8	2020	In addition, we determined the potential mechanisms underlying miR-200b-3p-mediated reversal of L-OHP resistance via mediating its downstream target TUBB3, and the overexpression of miR-200b-3p could induce migration and growth inhibition and apoptosis in L-OHP resistant HT29 and HCT116 cells by silencing betaIII-tubulin protein expression.	Oxaliplatin	96-101	tubulin beta 3 class III	Homo sapiens	149-154
32092782-8	2020	In addition, we determined the potential mechanisms underlying miR-200b-3p-mediated reversal of L-OHP resistance via mediating its downstream target TUBB3, and the overexpression of miR-200b-3p could induce migration and growth inhibition and apoptosis in L-OHP resistant HT29 and HCT116 cells by silencing betaIII-tubulin protein expression.	Oxaliplatin	256-261	microRNA 200b	Homo sapiens	63-71
32092782-8	2020	In addition, we determined the potential mechanisms underlying miR-200b-3p-mediated reversal of L-OHP resistance via mediating its downstream target TUBB3, and the overexpression of miR-200b-3p could induce migration and growth inhibition and apoptosis in L-OHP resistant HT29 and HCT116 cells by silencing betaIII-tubulin protein expression.	Oxaliplatin	256-261	tubulin beta 3 class III	Homo sapiens	149-154
32092782-8	2020	In addition, we determined the potential mechanisms underlying miR-200b-3p-mediated reversal of L-OHP resistance via mediating its downstream target TUBB3, and the overexpression of miR-200b-3p could induce migration and growth inhibition and apoptosis in L-OHP resistant HT29 and HCT116 cells by silencing betaIII-tubulin protein expression.	Oxaliplatin	256-261	microRNA 200b	Homo sapiens	182-190
32092782-9	2020	However, the overexpression of TUBB3 reversed miR-200b-3p mimics-induced migration and growth inhibition and apoptosis in L-OHP resistant CRC cells.	Oxaliplatin	122-127	tubulin beta 3 class III	Homo sapiens	31-36
32092782-9	2020	However, the overexpression of TUBB3 reversed miR-200b-3p mimics-induced migration and growth inhibition and apoptosis in L-OHP resistant CRC cells.	Oxaliplatin	122-127	microRNA 200b	Homo sapiens	46-54
32092782-10	2020	CONCLUSIONS: miR-200b-3p improved L-OHP resistance and induced growth inhibition and cell apoptosis in L-OHP resistant CRC cells, and the underlying mechanism was mediated, at least partially, through the suppression of betaIII-tubulin protein expression.	Oxaliplatin	34-39	microRNA 200b	Homo sapiens	13-21
32092782-10	2020	CONCLUSIONS: miR-200b-3p improved L-OHP resistance and induced growth inhibition and cell apoptosis in L-OHP resistant CRC cells, and the underlying mechanism was mediated, at least partially, through the suppression of betaIII-tubulin protein expression.	Oxaliplatin	103-108	microRNA 200b	Homo sapiens	13-21
32572830-8	2020	In the dorsal horn of the spinal cord, carbophenyline significantly decreased the oxaliplatin-induced astrocyte activation detected by immunofluorescence staining by the specific labelling with GFAP antibody.	Oxaliplatin	82-93	glial fibrillary acidic protein	Mus musculus	194-198
32572830-10	2020	Therefore, I1-R agonists emerge as a new class of candidates for the management of oxaliplatin-induced neuropathic pain.	Oxaliplatin	83-94	nischarin	Mus musculus	11-15
32665777-10	2020	Moreover, qPCR analyses showed that CASP3 and CASP9 mRNA levels significantly increased after pre-treatment with Pxd followed by 5-Fu and 1-OHP treatments, compared to 5-Fu with 1-OHP alone.	Oxaliplatin	138-143	caspase 9	Homo sapiens	46-51
32665777-10	2020	Moreover, qPCR analyses showed that CASP3 and CASP9 mRNA levels significantly increased after pre-treatment with Pxd followed by 5-Fu and 1-OHP treatments, compared to 5-Fu with 1-OHP alone.	Oxaliplatin	178-183	caspase 3	Homo sapiens	36-41
32665777-10	2020	Moreover, qPCR analyses showed that CASP3 and CASP9 mRNA levels significantly increased after pre-treatment with Pxd followed by 5-Fu and 1-OHP treatments, compared to 5-Fu with 1-OHP alone.	Oxaliplatin	178-183	caspase 9	Homo sapiens	46-51
32629861-3	2020	Here, we analyzed whether RPA2 and GTF2H1 SNPs predict the efficacy of oxaliplatin in metastatic CRC (mCRC) patients.	Oxaliplatin	71-82	general transcription factor IIH subunit 1	Homo sapiens	35-41
32629861-9	2020	CONCLUSION: RPA2 SNPs may serve as predictive and prognostic markers of oxaliplatin responsiveness in a RAS status-dependent manner in mCRC patients receiving FOLFOXIRI + BEV.	Oxaliplatin	72-83	replication protein A2	Homo sapiens	12-16
32665777-10	2020	Moreover, qPCR analyses showed that CASP3 and CASP9 mRNA levels significantly increased after pre-treatment with Pxd followed by 5-Fu and 1-OHP treatments, compared to 5-Fu with 1-OHP alone.	Oxaliplatin	138-143	caspase 3	Homo sapiens	36-41
32169534-3	2020	OXA/DCK-NE showed 3.35-fold increased permeability across a Caco-2 cell monolayer, resulting in 1.73-fold higher oral bioavailability than free OXA.	Oxaliplatin	0-3	deoxycytidine kinase	Homo sapiens	4-7
32169534-5	2020	In a B16F10.OVA tumor-bearing mouse model, treatment with OXA/DCK-NE substantially impeded tumor growth by 63.9 +- 13.3% compared to the control group, which was also greater than the intravenous (IV) OXA group.	Oxaliplatin	58-61	deoxycytidine kinase	Mus musculus	62-65
32165274-0	2020	HCN2 contributes to oxaliplatin-induced neuropathic pain by inducing spinal long-term potentiation via activation of NMDA receptor-mediated CaMKII signaling.	Oxaliplatin	20-31	hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2	Rattus norvegicus	0-4
32444490-1	2020	Metastatic colorectal cancer (mCRC) patients have poor overall survival despite using irinotecan- or oxaliplatin-based chemotherapy combined with anti-EGFR (epidermal growth factor receptor) drugs, especially those with the oncogene mutation of KRAS Metformin has been reported as a potentially novel antitumor agent in many experiments, but its therapeutic activity is discrepant and controversial so far.	Oxaliplatin	101-112	KRAS proto-oncogene, GTPase	Homo sapiens	245-249
32165274-1	2020	Our previous findings indicate that HCN2 contributes to oxaliplatin-induced neuropathic pain, but the mechanisms underlying the development of neuropathic pain are still unclear.	Oxaliplatin	56-67	hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2	Rattus norvegicus	36-40
32165274-4	2020	In addition, oxaliplatin administration induced spinal LTP via activation of the CaMKII-CREB cascade in the rat spinal dorsal horn.	Oxaliplatin	13-24	cAMP responsive element binding protein 1	Rattus norvegicus	88-92
32165274-5	2020	Moreover, we found that administration of oxaliplatin significantly increased the amplitude of excitatory postsynaptic currents and the number of action potentials, but these effects were attenuated by pretreatment with either CaMKII inhibitor KN-93 or NR2B antagonist Ro 25-6981.	Oxaliplatin	42-53	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	253-257
32165274-6	2020	An increase in the phosphorylation of spinal N-methyl-d-aspartate (NMDA) receptor subunit 1 (NR1) after oxaliplatin administration was weakened by ZD7288 pretreatment.	Oxaliplatin	104-115	glutamate ionotropic receptor NMDA type subunit 1	Rattus norvegicus	45-96
32165274-7	2020	Administration of noncompetitive NMDA receptor antagonist MK-801 blocked oxaliplatin-evoked CaMKII-CREB cascade activation and prevented HCN2-mediated spinal-LTP induction in vitro and suppressed neuropathic-pain behaviors of rats.	Oxaliplatin	73-84	cAMP responsive element binding protein 1	Rattus norvegicus	99-103
32248666-0	2020	Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells.	Oxaliplatin	33-44	insulin	Homo sapiens	17-24
32468080-8	2020	This correlated with differential upregulation of p53/p21 pathway, with S and G2/M arrests by cisplatin and satraplatin in contrast to G1 arrest by oxaliplatin and DAP.	Oxaliplatin	148-159	tumor protein p53	Homo sapiens	50-53
32248666-3	2020	This study aimed to elucidate the underlying mechanism by which metformin reverts insulin-induced oxaliplatin resistance in human colon cancer HCT116 cells.	Oxaliplatin	98-109	insulin	Homo sapiens	82-89
32248666-4	2020	METHODS: Two colon cancer cell lines (HCT116 and LoVo) were used to verify whether the expression of insulin receptor substrate 1 (IRS-1) could impact the half maximal inhibitory concentration (IC50) of oxaliplatin after chronic insulin treatment.	Oxaliplatin	203-214	insulin receptor substrate 1	Homo sapiens	101-129
32248666-4	2020	METHODS: Two colon cancer cell lines (HCT116 and LoVo) were used to verify whether the expression of insulin receptor substrate 1 (IRS-1) could impact the half maximal inhibitory concentration (IC50) of oxaliplatin after chronic insulin treatment.	Oxaliplatin	203-214	insulin receptor substrate 1	Homo sapiens	131-136
32248666-4	2020	METHODS: Two colon cancer cell lines (HCT116 and LoVo) were used to verify whether the expression of insulin receptor substrate 1 (IRS-1) could impact the half maximal inhibitory concentration (IC50) of oxaliplatin after chronic insulin treatment.	Oxaliplatin	203-214	insulin	Homo sapiens	101-108
32248666-14	2020	CONCLUSIONS: Insulin-induced oxaliplatin resistance was reversed by metformin-mediated AMPK activation.	Oxaliplatin	29-40	insulin	Homo sapiens	13-20
32248666-14	2020	CONCLUSIONS: Insulin-induced oxaliplatin resistance was reversed by metformin-mediated AMPK activation.	Oxaliplatin	29-40	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	87-91
32468080-8	2020	This correlated with differential upregulation of p53/p21 pathway, with S and G2/M arrests by cisplatin and satraplatin in contrast to G1 arrest by oxaliplatin and DAP.	Oxaliplatin	148-159	H3 histone pseudogene 16	Homo sapiens	54-57
32468080-4	2020	METHODS: We included cisplatin as reference and DAP as a Pt(IV)-prodrug of oxaliplatin to offset Pt(IV) status of satraplatin, and utilized A2780, cisplatin-resistant 2780CP/Cl-16, U2OS, and HCT-116 tumor cells in the investigation.	Oxaliplatin	75-86	death associated protein	Homo sapiens	48-51
32468080-9	2020	Moreover, Rad51 and BRCA1 were severely downregulated by oxaliplatin and DAP, but not cisplatin and satraplatin.	Oxaliplatin	57-68	RAD51 recombinase	Homo sapiens	10-15
32468080-7	2020	RESULTS: Clustering analysis paired oxaliplatin with DAP and, surprisingly, satraplatin with cisplatin.	Oxaliplatin	36-47	death associated protein	Homo sapiens	53-56
32468080-9	2020	Moreover, Rad51 and BRCA1 were severely downregulated by oxaliplatin and DAP, but not cisplatin and satraplatin.	Oxaliplatin	57-68	BRCA1 DNA repair associated	Homo sapiens	20-25
32468080-11	2020	CONCLUSIONS: Oxaliplatin and DAP robustly activate p53 and p21, which downregulate HR proteins to enhance drug activity.	Oxaliplatin	13-24	tumor protein p53	Homo sapiens	51-54
32468080-11	2020	CONCLUSIONS: Oxaliplatin and DAP robustly activate p53 and p21, which downregulate HR proteins to enhance drug activity.	Oxaliplatin	13-24	H3 histone pseudogene 16	Homo sapiens	59-62
32346424-0	2020	miR-454 promotes survival and induces oxaliplatin resistance in gastric carcinoma cells by targeting CYLD.	Oxaliplatin	38-49	microRNA 454	Homo sapiens	0-7
32346424-0	2020	miR-454 promotes survival and induces oxaliplatin resistance in gastric carcinoma cells by targeting CYLD.	Oxaliplatin	38-49	CYLD lysine 63 deubiquitinase	Homo sapiens	101-105
32346424-8	2020	Finally, miR-454 was also demonstrated to induce resistance to oxaliplatin in gastric cancer cells.	Oxaliplatin	63-74	microRNA 454	Homo sapiens	9-16
32661473-1	2020	BACKGROUND AND AIM: Our study aimed to investigate the ways by which HOXB7 affects gastric cancer progression and oxaliplatin (L-OHP) resistance.	Oxaliplatin	127-132	homeobox B7	Homo sapiens	69-74
32661473-2	2020	METHODS: First, the expression of HOXB7 in paired cancer and paracancerous tissues of L-OHP-sensitive and L-OHP-resistant gastric cancer patients was qualitatively and quantitatively analyzed by immunohistochemistry.	Oxaliplatin	86-91	homeobox B7	Homo sapiens	34-39
32661473-4	2020	The expression of HOXB7 in the SGC-7901 L-OHP-resistant gastric cancer cell line was further verified by immunofluorescence, western blot, and RT-qPCR.	Oxaliplatin	40-45	homeobox B7	Homo sapiens	18-23
32661473-7	2020	The proliferation rate of both control and HOXB-7-silenced cells induced by varying concentrations of L-OHP was detected by the CCK-8 assay, while the degree of apoptosis in the same cells induced by 60 microM L-OHP was detected by flow cytometry.	Oxaliplatin	102-107	homeobox B7	Homo sapiens	43-49
32661473-7	2020	The proliferation rate of both control and HOXB-7-silenced cells induced by varying concentrations of L-OHP was detected by the CCK-8 assay, while the degree of apoptosis in the same cells induced by 60 microM L-OHP was detected by flow cytometry.	Oxaliplatin	210-215	homeobox B7	Homo sapiens	43-49
32661473-10	2020	By silencing HOXB7 protein expression, the proliferation rate of L-OHP-resistant gastric cancer cells decreased considerably, while their degree of apoptosis increased significantly.	Oxaliplatin	65-70	homeobox B7	Homo sapiens	13-18
32661473-11	2020	These results showed that HOXB7 promoted gastric cancer progression and L-OHP resistance.	Oxaliplatin	72-77	homeobox B7	Homo sapiens	26-31
32389805-7	2020	Furthermore, reduction of the IR and protein levels and current density were demonstrated using patch-clamp measurements, of Kir4.1 channels after oxaliplatin exposure.	Oxaliplatin	147-158	potassium inwardly rectifying channel subfamily J member 10	Homo sapiens	125-131
32389805-8	2020	Cytokine release in SGCs was measured using enzyme-linked immunosorbent assays (ELISA) after oxaliplatin exposure and indicated an increased release of IL-6 and TNFalpha, while IL-1beta was decreased.	Oxaliplatin	93-104	interleukin 6	Homo sapiens	152-156
32389805-8	2020	Cytokine release in SGCs was measured using enzyme-linked immunosorbent assays (ELISA) after oxaliplatin exposure and indicated an increased release of IL-6 and TNFalpha, while IL-1beta was decreased.	Oxaliplatin	93-104	tumor necrosis factor	Homo sapiens	161-169
32539919-4	2020	A combination of UA and Oxa induced apoptosis in RKO cells and increased the activities of caspase-3, caspase-8, and caspase-9.	Oxaliplatin	24-27	caspase 3	Homo sapiens	91-100
32539919-4	2020	A combination of UA and Oxa induced apoptosis in RKO cells and increased the activities of caspase-3, caspase-8, and caspase-9.	Oxaliplatin	24-27	caspase 8	Homo sapiens	102-111
32539919-4	2020	A combination of UA and Oxa induced apoptosis in RKO cells and increased the activities of caspase-3, caspase-8, and caspase-9.	Oxaliplatin	24-27	caspase 9	Homo sapiens	117-126
32539919-6	2020	In addition, UA and Oxa downregulated the expression of X-linked inhibitor of apoptosis (XIAP) and Survivin in RKO cells.	Oxaliplatin	20-23	X-linked inhibitor of apoptosis	Homo sapiens	56-87
32539919-6	2020	In addition, UA and Oxa downregulated the expression of X-linked inhibitor of apoptosis (XIAP) and Survivin in RKO cells.	Oxaliplatin	20-23	X-linked inhibitor of apoptosis	Homo sapiens	89-93
32371487-8	2020	Accordingly, we found that the stimulation of autophagy on fasting protects Lgr5+ISC against DNA damage and cell death mediated by oxaliplatin and doxorubicin treatments.	Oxaliplatin	131-142	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	76-80
32292957-2	2020	Unlike oxaliplatin which increases the expression of stemness genes (SOX2, KLF4, HES1 and Oct4), these complexes maintain a tight regulation.	Oxaliplatin	7-18	SRY-box transcription factor 2	Homo sapiens	69-73
32222024-0	2020	Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis.	Oxaliplatin	72-83	microRNA 605	Homo sapiens	103-110
32489465-13	2020	Furthermore, we found that oxaliplatin could activate IRE1alpha-XBP1s signaling, and combination with cetuximab partially reversed the activation.	Oxaliplatin	27-38	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	54-63
32489465-14	2020	Inhibition of EGFR signaling could enhance the efficacy of oxaliplatin in vitro and in vivo.	Oxaliplatin	59-70	epidermal growth factor receptor	Homo sapiens	14-18
32489465-17	2020	Cetuximab could partially recover oxaliplatin-induced IRE1alpha-XBP1s activation, and therefore enhance the anti-tumor efficacy of oxaliplatin.	Oxaliplatin	34-45	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	54-63
32359534-0	2020	WASF3 Knockdown Sensitizes Gastric Cancer Cells to Oxaliplatin by Inhibiting ATG12-Mediated Autophagy.	Oxaliplatin	51-62	WASP family member 3	Homo sapiens	0-5
32359534-0	2020	WASF3 Knockdown Sensitizes Gastric Cancer Cells to Oxaliplatin by Inhibiting ATG12-Mediated Autophagy.	Oxaliplatin	51-62	autophagy related 12	Homo sapiens	77-82
32359534-5	2020	In this study, we explored the role of WASF3 in the sensitivity of gastric cancer to oxaliplatin, and the underlying mechanisms.	Oxaliplatin	85-96	WASP family member 3	Homo sapiens	39-44
32359534-8	2020	Moreover, we evaluated the potential mechanism in vitro to determine the sensitization to oxaliplatin induced by WASF3.	Oxaliplatin	90-101	WASP family member 3	Homo sapiens	113-118
32359534-10	2020	We also observed that WASF3 knockdown promoted cell apoptosis and enhanced oxaliplatin sensitivity.	Oxaliplatin	75-86	WASP family member 3	Homo sapiens	22-27
32359534-11	2020	Furthermore, the sensitization to oxaliplatin induced by WASF3 knockdown depended on the inhibition of Atg12-mediated autophagy.	Oxaliplatin	34-45	WASP family member 3	Homo sapiens	57-62
32359534-11	2020	Furthermore, the sensitization to oxaliplatin induced by WASF3 knockdown depended on the inhibition of Atg12-mediated autophagy.	Oxaliplatin	34-45	autophagy related 12	Homo sapiens	103-108
31465111-9	2020	Here, we report that L-OHP-induced mechanical pain in mice with significant MMP-9/2 activation in dorsal root ganglion (DRG) neurons.	Oxaliplatin	21-26	matrix metallopeptidase 9	Mus musculus	76-81
32462912-5	2020	We performed functional validation and observed that by targeting HNF4A, HCT116 cells were more sensitive toward both oxaliplatin and 5-fluorouracil significantly.	Oxaliplatin	118-129	hepatocyte nuclear factor 4 alpha	Homo sapiens	66-71
32163218-4	2020	First, we confirmed that the presence of KRAS/TP53 mutations significantly increased the IC50 of oxaliplatin (L-OHP) and NF-kappaB activity in HCT116 cells in vitro.	Oxaliplatin	97-108	KRAS proto-oncogene, GTPase	Homo sapiens	41-45
32163218-4	2020	First, we confirmed that the presence of KRAS/TP53 mutations significantly increased the IC50 of oxaliplatin (L-OHP) and NF-kappaB activity in HCT116 cells in vitro.	Oxaliplatin	97-108	tumor protein p53	Homo sapiens	46-50
32163218-4	2020	First, we confirmed that the presence of KRAS/TP53 mutations significantly increased the IC50 of oxaliplatin (L-OHP) and NF-kappaB activity in HCT116 cells in vitro.	Oxaliplatin	110-115	KRAS proto-oncogene, GTPase	Homo sapiens	41-45
32163218-4	2020	First, we confirmed that the presence of KRAS/TP53 mutations significantly increased the IC50 of oxaliplatin (L-OHP) and NF-kappaB activity in HCT116 cells in vitro.	Oxaliplatin	110-115	tumor protein p53	Homo sapiens	46-50
32163218-7	2020	With regard to safety, significant bodyweight loss, severe myelosuppression and AST/ALT elevation were observed in L-OHP-treated mice, whereas none of these toxicity was noted in CMG-treated mice.	Oxaliplatin	115-120	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	80-83
32163218-7	2020	With regard to safety, significant bodyweight loss, severe myelosuppression and AST/ALT elevation were observed in L-OHP-treated mice, whereas none of these toxicity was noted in CMG-treated mice.	Oxaliplatin	115-120	glutamic pyruvic transaminase, soluble	Mus musculus	84-87
32243061-8	2020	In conclusion, hsa_circ_0079662, as a ceRNA binding with hsa-mir-324-5p, can regulate target gene HOXA9 and induced the mechanism of chemotherapy drug oxaliplatin resistance in CRC through the TNF-alpha pathway in human colon cancer.	Oxaliplatin	151-162	microRNA 324	Homo sapiens	57-68
32243061-8	2020	In conclusion, hsa_circ_0079662, as a ceRNA binding with hsa-mir-324-5p, can regulate target gene HOXA9 and induced the mechanism of chemotherapy drug oxaliplatin resistance in CRC through the TNF-alpha pathway in human colon cancer.	Oxaliplatin	151-162	homeobox A9	Homo sapiens	98-103
32243061-8	2020	In conclusion, hsa_circ_0079662, as a ceRNA binding with hsa-mir-324-5p, can regulate target gene HOXA9 and induced the mechanism of chemotherapy drug oxaliplatin resistance in CRC through the TNF-alpha pathway in human colon cancer.	Oxaliplatin	151-162	tumor necrosis factor	Homo sapiens	193-202
32222024-0	2020	Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis.	Oxaliplatin	72-83	forkhead box O3	Homo sapiens	111-116
32222024-0	2020	Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis.	Oxaliplatin	72-83	ATP binding cassette subfamily B member 1	Homo sapiens	117-122
32431512-0	2020	MiR-138 Suppresses the PDK1 Expression to Decrease the Oxaliplatin Resistance of Colorectal Cancer.	Oxaliplatin	55-66	pyruvate dehydrogenase kinase 1	Homo sapiens	23-27
32365581-12	2020	This suggests SOX2 may predict response to oxaliplatin treatment, but not 5-FU.	Oxaliplatin	43-54	SRY-box transcription factor 2	Homo sapiens	14-18
32270866-0	2020	MIR600HG suppresses metastasis and enhances oxaliplatin chemosensitivity by targeting ALDH1A3 in colorectal cancer.	Oxaliplatin	44-55	MIR600 host gene	Homo sapiens	0-8
32270866-0	2020	MIR600HG suppresses metastasis and enhances oxaliplatin chemosensitivity by targeting ALDH1A3 in colorectal cancer.	Oxaliplatin	44-55	aldehyde dehydrogenase 1 family member A3	Homo sapiens	86-93
32431512-16	2020	Conclusion: Overexpression of miR-138 suppressed the PDK1 expression to decrease the oxaliplatin resistance of CRC.	Oxaliplatin	85-96	pyruvate dehydrogenase kinase 1	Homo sapiens	53-57
32124922-8	2020	RESULTS: In three chemotherapeutic models, oxaliplatin, paclitaxel or bortezomib accordantly up-regulated the expression of TRPC6 mRNA and protein without affecting the DNA methylation level of TRPC6 gene in DRG.	Oxaliplatin	43-54	transient receptor potential cation channel, subfamily C, member 6	Rattus norvegicus	124-129
32124922-8	2020	RESULTS: In three chemotherapeutic models, oxaliplatin, paclitaxel or bortezomib accordantly up-regulated the expression of TRPC6 mRNA and protein without affecting the DNA methylation level of TRPC6 gene in DRG.	Oxaliplatin	43-54	transient receptor potential cation channel, subfamily C, member 6	Rattus norvegicus	194-199
32029274-7	2020	Moreover, TXNDC9 regulates autophagy and apoptosis in response to oxaliplatin treatment in HT29 cells via the Nrf2 pathway.	Oxaliplatin	66-77	thioredoxin domain containing 9	Homo sapiens	10-16
32363127-0	2020	FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin.	Oxaliplatin	89-100	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	0-6
32363127-3	2020	demonstrates that, in patients receiving a hepatic arterial infusion of oxaliplatin for the treatment of colorectal cancer metastases, an increase in circulating FLT3LG predicts long-term survival of those individuals whose metastases have been rendered resectable.	Oxaliplatin	72-83	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	162-168
32363127-4	2020	Thus, FLT3LG constitutes a potential biomarker of immune activation by immunogenic cell death-inducing chemotherapeutics such as oxaliplatin.	Oxaliplatin	129-140	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	6-12
32382656-0	2020	miR-124 Intensified Oxaliplatin-Based Chemotherapy by Targeting CAPN2 in Colorectal Cancer.	Oxaliplatin	20-31	calpain 2	Homo sapiens	64-69
32382656-8	2020	miR-124 also promoted L-OHP-induced apoptosis and restrained CAPN2 protein expression in xenograft tumors.	Oxaliplatin	22-27	calpain 2	Mus musculus	61-66
32029274-0	2020	Thioredoxin domain-containing protein 9 (TXNDC9) contributes to oxaliplatin resistance through regulation of autophagy-apoptosis in colorectal adenocarcinoma.	Oxaliplatin	64-75	thioredoxin domain containing 9	Homo sapiens	0-39
32029274-0	2020	Thioredoxin domain-containing protein 9 (TXNDC9) contributes to oxaliplatin resistance through regulation of autophagy-apoptosis in colorectal adenocarcinoma.	Oxaliplatin	64-75	thioredoxin domain containing 9	Homo sapiens	41-47
32029274-4	2020	In this study, we anticipated that TXNDC9 might demonstrate a protective role in oxaliplatin-resistant CRC cells.	Oxaliplatin	81-92	thioredoxin domain containing 9	Homo sapiens	35-41
32029274-5	2020	TXNDC9 was found significantly upregulated when treated with oxaliplatin.	Oxaliplatin	61-72	thioredoxin domain containing 9	Homo sapiens	0-6
32029274-6	2020	Manipulation of TXNDC9 expression largely affected the oxaliplatin-induced cell death.	Oxaliplatin	55-66	thioredoxin domain containing 9	Homo sapiens	16-22
32029274-7	2020	Moreover, TXNDC9 regulates autophagy and apoptosis in response to oxaliplatin treatment in HT29 cells via the Nrf2 pathway.	Oxaliplatin	66-77	NFE2 like bZIP transcription factor 2	Homo sapiens	110-114
32029274-8	2020	Taken together, our findings explore the biological role of TXNDC9 in oxaliplatin resistance in CRC cells and may identify a novel therapeutic target to counteract drug resistance to oxaliplatin in CRC.	Oxaliplatin	70-81	thioredoxin domain containing 9	Homo sapiens	60-66
32029274-8	2020	Taken together, our findings explore the biological role of TXNDC9 in oxaliplatin resistance in CRC cells and may identify a novel therapeutic target to counteract drug resistance to oxaliplatin in CRC.	Oxaliplatin	183-194	thioredoxin domain containing 9	Homo sapiens	60-66
32308348-0	2020	Effects of long non-coding RNA Opa-interacting protein 5 antisense RNA 1 on colon cancer cell resistance to oxaliplatin and its regulation of microRNA-137.	Oxaliplatin	108-119	OIP5 antisense RNA 1	Homo sapiens	31-72
32308348-3	2020	Therefore, this study investigated the mechanism of Opa-interacting protein 5 antisense RNA 1 (OIP5-AS1) on L-OHP resistance by determining the expression of OIP5-AS1 and microRNA-137 (miR-137) in CC cells and the effects on L-OHP resistance, with the goal of identifying new targets for the treatment of CC.	Oxaliplatin	108-113	OIP5 antisense RNA 1	Homo sapiens	52-93
32308348-3	2020	Therefore, this study investigated the mechanism of Opa-interacting protein 5 antisense RNA 1 (OIP5-AS1) on L-OHP resistance by determining the expression of OIP5-AS1 and microRNA-137 (miR-137) in CC cells and the effects on L-OHP resistance, with the goal of identifying new targets for the treatment of CC.	Oxaliplatin	108-113	OIP5 antisense RNA 1	Homo sapiens	95-103
32308348-3	2020	Therefore, this study investigated the mechanism of Opa-interacting protein 5 antisense RNA 1 (OIP5-AS1) on L-OHP resistance by determining the expression of OIP5-AS1 and microRNA-137 (miR-137) in CC cells and the effects on L-OHP resistance, with the goal of identifying new targets for the treatment of CC.	Oxaliplatin	225-230	OIP5 antisense RNA 1	Homo sapiens	95-103
32308348-4	2020	AIM: To study the effects of long non-coding RNA OIP5-AS1 on L-OHP resistance in CC cell lines and its regulation of miR-137.	Oxaliplatin	61-66	OIP5 antisense RNA 1	Homo sapiens	49-57
32308348-13	2020	Moreover, silencing OIP5-AS1 and up-regulating miR-137 expression significantly intensified growth inhibition of drug-resistant CC cells and improved the sensitivity of CC cells to L-OHP.	Oxaliplatin	181-186	Opa interacting protein 5	Homo sapiens	20-24
32308348-13	2020	Moreover, silencing OIP5-AS1 and up-regulating miR-137 expression significantly intensified growth inhibition of drug-resistant CC cells and improved the sensitivity of CC cells to L-OHP.	Oxaliplatin	181-186	microRNA 137	Homo sapiens	47-54
32308348-14	2020	OIP5-AS1 targetedly inhibited miR-137 expression, and silencing OIP5-AS1 reversed the resistance of CC cells to L-OHP by promoting the expression of miR-137.	Oxaliplatin	112-117	Opa interacting protein 5	Homo sapiens	64-68
32308348-14	2020	OIP5-AS1 targetedly inhibited miR-137 expression, and silencing OIP5-AS1 reversed the resistance of CC cells to L-OHP by promoting the expression of miR-137.	Oxaliplatin	112-117	prostaglandin D2 receptor	Homo sapiens	69-72
32308348-14	2020	OIP5-AS1 targetedly inhibited miR-137 expression, and silencing OIP5-AS1 reversed the resistance of CC cells to L-OHP by promoting the expression of miR-137.	Oxaliplatin	112-117	microRNA 137	Homo sapiens	149-156
32308348-15	2020	CONCLUSION: Highly expressed in CC, OIP5-AS1 can affect the biological behavior of CC cells, and can also regulate the resistance of CC cells to L-OHP by mediating miR-137 expression.	Oxaliplatin	145-150	Opa interacting protein 5	Homo sapiens	36-40
32308348-15	2020	CONCLUSION: Highly expressed in CC, OIP5-AS1 can affect the biological behavior of CC cells, and can also regulate the resistance of CC cells to L-OHP by mediating miR-137 expression.	Oxaliplatin	145-150	prostaglandin D2 receptor	Homo sapiens	41-44
32308348-15	2020	CONCLUSION: Highly expressed in CC, OIP5-AS1 can affect the biological behavior of CC cells, and can also regulate the resistance of CC cells to L-OHP by mediating miR-137 expression.	Oxaliplatin	145-150	microRNA 137	Homo sapiens	164-171
32329851-0	2020	ANXA3 deletion inhibits the resistance of lung cancer cells to oxaliplatin.	Oxaliplatin	63-74	annexin A3	Homo sapiens	0-5
32329851-1	2020	OBJECTIVE: The purpose of this study was to explore the role of ANXA3 in lung cancer cell resistance to oxaliplatin (OXA).	Oxaliplatin	104-115	annexin A3	Homo sapiens	64-69
32329851-1	2020	OBJECTIVE: The purpose of this study was to explore the role of ANXA3 in lung cancer cell resistance to oxaliplatin (OXA).	Oxaliplatin	117-120	annexin A3	Homo sapiens	64-69
32329851-8	2020	CONCLUSIONS: Knockdown of ANXA3 may be able to inhibit the resistance of LCa cells to OXA.	Oxaliplatin	86-89	annexin A3	Homo sapiens	26-31
32022814-7	2020	Oxamusplatin is more resistant than cisplatin or oxaliplatin towards hydrolysis, thiol binding and sequestration by ATP7B.	Oxaliplatin	49-60	ATPase copper transporting beta	Homo sapiens	116-121
32209726-0	2020	Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.	Oxaliplatin	80-91	microRNA 19a	Homo sapiens	14-21
32209726-0	2020	Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.	Oxaliplatin	80-91	phosphatase and tensin homolog	Homo sapiens	96-100
32209726-0	2020	Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.	Oxaliplatin	80-91	AKT serine/threonine kinase 1	Homo sapiens	106-109
32209726-6	2020	However, combination treatment with anti-miR-19a, an antisense oligonucleotide of miR-19a, was found to resensitize SW480/R and HT29/R cells to oxaliplatin treatment.	Oxaliplatin	144-155	microRNA 19a	Homo sapiens	41-48
32209726-6	2020	However, combination treatment with anti-miR-19a, an antisense oligonucleotide of miR-19a, was found to resensitize SW480/R and HT29/R cells to oxaliplatin treatment.	Oxaliplatin	144-155	microRNA 19a	Homo sapiens	82-89
32209726-9	2020	We demonstrated that PTEN was the target of miR-19a and inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.	Oxaliplatin	136-147	phosphatase and tensin homolog	Homo sapiens	21-25
32209726-9	2020	We demonstrated that PTEN was the target of miR-19a and inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.	Oxaliplatin	136-147	microRNA 19a	Homo sapiens	44-51
32209726-9	2020	We demonstrated that PTEN was the target of miR-19a and inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.	Oxaliplatin	136-147	microRNA 19a	Homo sapiens	70-77
32209726-9	2020	We demonstrated that PTEN was the target of miR-19a and inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.	Oxaliplatin	136-147	phosphatase and tensin homolog	Homo sapiens	152-156
32209726-9	2020	We demonstrated that PTEN was the target of miR-19a and inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.	Oxaliplatin	136-147	AKT serine/threonine kinase 1	Homo sapiens	162-165
32210803-14	2020	LOR17, therefore, may emerge as a novel KOPr agonist displaying functional selectivity toward G protein signaling and eliciting antinociceptive/antihypersensitivity effects in different animal models, including oxaliplatin-induced neuropathy.	Oxaliplatin	211-222	opioid receptor kappa 1	Homo sapiens	40-44
32355746-12	2020	Administration of SLC1A5 or GPT2 inhibitor could prohibit SRCC growth and significantly enhance the sensitivity of SRCC to the treatment of 5-fu and L-OHP.	Oxaliplatin	149-154	solute carrier family 1 member 5	Homo sapiens	18-24
32355746-12	2020	Administration of SLC1A5 or GPT2 inhibitor could prohibit SRCC growth and significantly enhance the sensitivity of SRCC to the treatment of 5-fu and L-OHP.	Oxaliplatin	149-154	glutamic--pyruvic transaminase 2	Homo sapiens	28-32
32271417-10	2020	Conversely, an oxaliplatin-containing regimen should be recommended in KRAS mutated patients.	Oxaliplatin	15-26	KRAS proto-oncogene, GTPase	Homo sapiens	71-75
32269848-7	2020	AGS and NCI-N87 cells transfected with si-RNA-Bcl-3 (si-Bcl-3) showed significantly reduced migratory ability and increased chemosensitivity to oxaliplatin, 5-fluorouracil, and irinotecan.	Oxaliplatin	144-155	BCL3 transcription coactivator	Homo sapiens	46-51
31884801-0	2020	MiR-744 mediates the Oxaliplatin chemoresistance in colorectal cancer through inhibiting BIN1.	Oxaliplatin	21-32	microRNA 744	Homo sapiens	0-7
31884801-0	2020	MiR-744 mediates the Oxaliplatin chemoresistance in colorectal cancer through inhibiting BIN1.	Oxaliplatin	21-32	bridging integrator 1	Homo sapiens	89-93
31884801-3	2020	The aim of this study was to explore the effect and mechanism of miR-744 on the oxaliplatin chemoresistance in CRC.	Oxaliplatin	80-91	microRNA 744	Homo sapiens	65-72
31884801-4	2020	Firstly, the levels of miR-744 were elevated significantly in CRC tissues from patients with oxaliplatin administration before surgery and in oxaliplatin-resistant HCT116 cells.	Oxaliplatin	93-104	microRNA 744	Homo sapiens	23-30
31884801-4	2020	Firstly, the levels of miR-744 were elevated significantly in CRC tissues from patients with oxaliplatin administration before surgery and in oxaliplatin-resistant HCT116 cells.	Oxaliplatin	142-153	microRNA 744	Homo sapiens	23-30
31884801-5	2020	Then, the oxaliplatin chemoresistance was enhanced by miR-744 overexpression, while was attenuated by miR-744 inhibition in HCT116 and T84 cells.	Oxaliplatin	10-21	microRNA 744	Homo sapiens	54-61
31884801-5	2020	Then, the oxaliplatin chemoresistance was enhanced by miR-744 overexpression, while was attenuated by miR-744 inhibition in HCT116 and T84 cells.	Oxaliplatin	10-21	microRNA 744	Homo sapiens	102-109
31884801-6	2020	Additionally, the level of BIN1 protein was found to be regulated negatively by miR-744, and BIN1 overexpression blocked the oxaliplatin chemoresistance induced by miR-744.	Oxaliplatin	125-136	bridging integrator 1	Homo sapiens	27-31
31884801-6	2020	Additionally, the level of BIN1 protein was found to be regulated negatively by miR-744, and BIN1 overexpression blocked the oxaliplatin chemoresistance induced by miR-744.	Oxaliplatin	125-136	microRNA 744	Homo sapiens	80-87
31884801-6	2020	Additionally, the level of BIN1 protein was found to be regulated negatively by miR-744, and BIN1 overexpression blocked the oxaliplatin chemoresistance induced by miR-744.	Oxaliplatin	125-136	bridging integrator 1	Homo sapiens	93-97
31884801-6	2020	Additionally, the level of BIN1 protein was found to be regulated negatively by miR-744, and BIN1 overexpression blocked the oxaliplatin chemoresistance induced by miR-744.	Oxaliplatin	125-136	microRNA 744	Homo sapiens	164-171
31884801-8	2020	Taken together, these findings demonstrated that miR-744 might positively mediate the oxaliplatin chemoresistance through suppressing BIN1 expression in CRC cells, thus suggested a rationale target for the developing more effective strategies to reverse oxaliplatin resistance in CRC treatment.	Oxaliplatin	86-97	microRNA 744	Homo sapiens	49-56
31884801-8	2020	Taken together, these findings demonstrated that miR-744 might positively mediate the oxaliplatin chemoresistance through suppressing BIN1 expression in CRC cells, thus suggested a rationale target for the developing more effective strategies to reverse oxaliplatin resistance in CRC treatment.	Oxaliplatin	254-265	microRNA 744	Homo sapiens	49-56
31884801-8	2020	Taken together, these findings demonstrated that miR-744 might positively mediate the oxaliplatin chemoresistance through suppressing BIN1 expression in CRC cells, thus suggested a rationale target for the developing more effective strategies to reverse oxaliplatin resistance in CRC treatment.	Oxaliplatin	254-265	bridging integrator 1	Homo sapiens	134-138
32167760-3	2020	Here, we demonstrated that beta-sitosterol, the most common dietary phytosterol, recovers oxaliplatin (OXA) sensitivity in drug-resistant colorectal cancer (CRC) cells by inhibiting breast cancer resistance protein (BCRP) expression.	Oxaliplatin	90-101	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	182-214
32167760-3	2020	Here, we demonstrated that beta-sitosterol, the most common dietary phytosterol, recovers oxaliplatin (OXA) sensitivity in drug-resistant colorectal cancer (CRC) cells by inhibiting breast cancer resistance protein (BCRP) expression.	Oxaliplatin	103-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	182-214
32167760-3	2020	Here, we demonstrated that beta-sitosterol, the most common dietary phytosterol, recovers oxaliplatin (OXA) sensitivity in drug-resistant colorectal cancer (CRC) cells by inhibiting breast cancer resistance protein (BCRP) expression.	Oxaliplatin	103-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	216-220
32187976-0	2020	Oxaliplatin-Induced DHX9 Phosphorylation Promotes Oncogenic Circular RNA CCDC66 Expression and Development of Chemoresistance.	Oxaliplatin	0-11	DExH-box helicase 9	Homo sapiens	20-24
32187976-0	2020	Oxaliplatin-Induced DHX9 Phosphorylation Promotes Oncogenic Circular RNA CCDC66 Expression and Development of Chemoresistance.	Oxaliplatin	0-11	coiled-coil domain containing 66	Homo sapiens	73-79
32187976-9	2020	Blockage of phosphorylation by either PI3KK inhibitors or nonphosphorable mutants of DHX9 decreased the oxaliplatin-induced circCCDC66 expression and the ability to develop chemoresistant cells.	Oxaliplatin	104-115	DExH-box helicase 9	Homo sapiens	85-89
32187976-10	2020	Taken together, we demonstrated and linked the functional role of DHX9 phosphorylation to oncogenic circCCDC66 expression during the development of resistance to oxaliplatin, providing a mechanistic insight for the development of therapeutic strategies to recurring/chemoresistant colorectal cancer.	Oxaliplatin	162-173	DExH-box helicase 9	Homo sapiens	66-70
31972222-2	2020	Whether GCS contributes to oxaliplatin resistance in colorectal cancer (CRC) has not yet been determined.	Oxaliplatin	27-38	UDP-glucose ceramide glucosyltransferase	Homo sapiens	8-11
31972222-3	2020	We have addressed this potentially important clinical issue by examining GCS function in two panels of oxaliplatin-resistant, isogenic CRC cell lines.	Oxaliplatin	103-114	UDP-glucose ceramide glucosyltransferase	Homo sapiens	73-76
31972222-4	2020	Compared to parental cell lines, oxaliplatin-resistant cells have increased expression of GCS protein associated with increased levels of the pro-survival ceramide metabolite, glucosylceramide (GlcCer).	Oxaliplatin	33-44	UDP-glucose ceramide glucosyltransferase	Homo sapiens	90-93
31972222-5	2020	Inhibition of GCS expression by RNAi-mediated gene knockdown resulted in a reduction in cellular GlcCer levels, with restored sensitivity to oxaliplatin.	Oxaliplatin	141-152	UDP-glucose ceramide glucosyltransferase	Homo sapiens	14-17
31972222-9	2020	Increased Akt activation was also observed in oxaliplatin-resistant CRC cell lines, together with increased expression of the anti-apoptotic protein survivin.	Oxaliplatin	46-57	AKT serine/threonine kinase 1	Homo sapiens	10-13
31972222-11	2020	These findings uncover an important cellular role for GCS in oxaliplatin chemosensitivity and may provide a novel cellular target for augmenting chemotherapeutic drug effectiveness in CRC.	Oxaliplatin	61-72	UDP-glucose ceramide glucosyltransferase	Homo sapiens	54-57
32271422-0	2020	The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer.	Oxaliplatin	67-78	DEAD/H-box helicase 11	Homo sapiens	24-29
32271422-0	2020	The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer.	Oxaliplatin	67-78	prostaglandin D2 receptor	Homo sapiens	30-33
32271422-0	2020	The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer.	Oxaliplatin	67-78	microRNA 326	Homo sapiens	105-112
32271422-0	2020	The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer.	Oxaliplatin	67-78	insulin receptor substrate 1	Homo sapiens	113-117
32271422-8	2020	RESULTS: DDX11-AS1 was overexpressed in OXA-resistant GC tissues and cells, and DDX11-AS1 knockdown inhibited cell proliferation, migration, invasion and OXA resistance, and promoted apoptosis in OXA-resistant GC cells.	Oxaliplatin	40-43	DEAD/H-box helicase 11	Homo sapiens	9-14
32271422-8	2020	RESULTS: DDX11-AS1 was overexpressed in OXA-resistant GC tissues and cells, and DDX11-AS1 knockdown inhibited cell proliferation, migration, invasion and OXA resistance, and promoted apoptosis in OXA-resistant GC cells.	Oxaliplatin	40-43	prostaglandin D2 receptor	Homo sapiens	15-18
32271422-8	2020	RESULTS: DDX11-AS1 was overexpressed in OXA-resistant GC tissues and cells, and DDX11-AS1 knockdown inhibited cell proliferation, migration, invasion and OXA resistance, and promoted apoptosis in OXA-resistant GC cells.	Oxaliplatin	154-157	DEAD/H-box helicase 11	Homo sapiens	80-85
32271422-8	2020	RESULTS: DDX11-AS1 was overexpressed in OXA-resistant GC tissues and cells, and DDX11-AS1 knockdown inhibited cell proliferation, migration, invasion and OXA resistance, and promoted apoptosis in OXA-resistant GC cells.	Oxaliplatin	154-157	prostaglandin D2 receptor	Homo sapiens	86-89
32271422-8	2020	RESULTS: DDX11-AS1 was overexpressed in OXA-resistant GC tissues and cells, and DDX11-AS1 knockdown inhibited cell proliferation, migration, invasion and OXA resistance, and promoted apoptosis in OXA-resistant GC cells.	Oxaliplatin	154-157	DEAD/H-box helicase 11	Homo sapiens	80-85
32271422-8	2020	RESULTS: DDX11-AS1 was overexpressed in OXA-resistant GC tissues and cells, and DDX11-AS1 knockdown inhibited cell proliferation, migration, invasion and OXA resistance, and promoted apoptosis in OXA-resistant GC cells.	Oxaliplatin	154-157	prostaglandin D2 receptor	Homo sapiens	86-89
32271422-10	2020	Functionally, silencing DDX11-AS1 repressed the progression and OXA resistance in OXA-resistant GC cells by down-modulating IRS1 expression via sponging miR-326 in vitro and in vivo.	Oxaliplatin	64-67	DEAD/H-box helicase 11	Homo sapiens	24-29
32271422-10	2020	Functionally, silencing DDX11-AS1 repressed the progression and OXA resistance in OXA-resistant GC cells by down-modulating IRS1 expression via sponging miR-326 in vitro and in vivo.	Oxaliplatin	64-67	prostaglandin D2 receptor	Homo sapiens	30-33
32271422-10	2020	Functionally, silencing DDX11-AS1 repressed the progression and OXA resistance in OXA-resistant GC cells by down-modulating IRS1 expression via sponging miR-326 in vitro and in vivo.	Oxaliplatin	82-85	DEAD/H-box helicase 11	Homo sapiens	24-29
32271422-10	2020	Functionally, silencing DDX11-AS1 repressed the progression and OXA resistance in OXA-resistant GC cells by down-modulating IRS1 expression via sponging miR-326 in vitro and in vivo.	Oxaliplatin	82-85	prostaglandin D2 receptor	Homo sapiens	30-33
32271422-10	2020	Functionally, silencing DDX11-AS1 repressed the progression and OXA resistance in OXA-resistant GC cells by down-modulating IRS1 expression via sponging miR-326 in vitro and in vivo.	Oxaliplatin	82-85	insulin receptor substrate 1	Homo sapiens	124-128
32271422-10	2020	Functionally, silencing DDX11-AS1 repressed the progression and OXA resistance in OXA-resistant GC cells by down-modulating IRS1 expression via sponging miR-326 in vitro and in vivo.	Oxaliplatin	82-85	microRNA 326	Homo sapiens	153-160
32098629-11	2020	Additionally, up-regulation of MUC5AC resulted in resistance to 5-fluorouracil (5-FU) and oxaliplatin, and its knockout increased sensitivity to these drugs.	Oxaliplatin	90-101	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	31-37
32110058-0	2020	FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer.	Oxaliplatin	15-26	forkhead box C2	Homo sapiens	0-5
32110058-0	2020	FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer.	Oxaliplatin	15-26	mitogen-activated protein kinase 1	Homo sapiens	88-92
32110058-0	2020	FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer.	Oxaliplatin	15-26	mitogen-activated protein kinase 1	Homo sapiens	93-96
32110058-12	2020	Conclusion: FOXC2 induced EMT to promote oxaliplatin resistance by activating the MAPK/ERK signaling pathway.	Oxaliplatin	41-52	forkhead box C2	Homo sapiens	12-17
32110058-12	2020	Conclusion: FOXC2 induced EMT to promote oxaliplatin resistance by activating the MAPK/ERK signaling pathway.	Oxaliplatin	41-52	mitogen-activated protein kinase 1	Homo sapiens	82-86
32110058-12	2020	Conclusion: FOXC2 induced EMT to promote oxaliplatin resistance by activating the MAPK/ERK signaling pathway.	Oxaliplatin	41-52	mitogen-activated protein kinase 1	Homo sapiens	87-90
32127943-4	2020	Moreover, the role of B7-H3/CDC25A axis in regulating chemoresistance in vivo in the xenograft tumor models by intraperitoneal injection of oxaliplatin (L-OHP) and CDC25A inhibitors.	Oxaliplatin	153-158	CD276 antigen	Mus musculus	22-27
32206108-2	2020	Abnormal hypermethylation- mediated silencing of OCT2 results in oxaliplatin resistance in renal cell carcinoma (RCC).	Oxaliplatin	65-76	solute carrier family 22 member 2	Homo sapiens	49-53
32062671-0	2020	Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.	Oxaliplatin	12-23	KRAS proto-oncogene, GTPase	Homo sapiens	101-106
32062671-1	2020	BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer.	Oxaliplatin	91-102	KRAS proto-oncogene, GTPase	Homo sapiens	180-185
32127943-4	2020	Moreover, the role of B7-H3/CDC25A axis in regulating chemoresistance in vivo in the xenograft tumor models by intraperitoneal injection of oxaliplatin (L-OHP) and CDC25A inhibitors.	Oxaliplatin	140-151	CD276 antigen	Mus musculus	22-27
32127943-4	2020	Moreover, the role of B7-H3/CDC25A axis in regulating chemoresistance in vivo in the xenograft tumor models by intraperitoneal injection of oxaliplatin (L-OHP) and CDC25A inhibitors.	Oxaliplatin	140-151	cell division cycle 25A	Mus musculus	28-34
31065671-4	2020	Oxaliplatin stimulation significantly induced the expression of H3K27 lysine demethylase 6A/6B (KDM6A/6B), thus decreasing the level of H3K27me3 in CRC cells.	Oxaliplatin	0-11	lysine demethylase 6A	Homo sapiens	96-101
31065671-5	2020	Elevation of H3K27me3 level through KDM6A/6B depletion or GSK-J4 (a KDM6A/6B inhibitor) treatment significantly enhanced oxaliplatin-induced apoptosis.	Oxaliplatin	121-132	lysine demethylase 6A	Homo sapiens	36-41
31065671-5	2020	Elevation of H3K27me3 level through KDM6A/6B depletion or GSK-J4 (a KDM6A/6B inhibitor) treatment significantly enhanced oxaliplatin-induced apoptosis.	Oxaliplatin	121-132	lysine demethylase 6A	Homo sapiens	68-73
31065671-8	2020	Importantly, we revealed that oxaliplatin treatment dramatically induced NOTCH2 expression, which was caused by downregulation of H3K27me3 level on the NOTCH2 transcription initiation site.	Oxaliplatin	30-41	notch receptor 2	Homo sapiens	73-79
31065671-8	2020	Importantly, we revealed that oxaliplatin treatment dramatically induced NOTCH2 expression, which was caused by downregulation of H3K27me3 level on the NOTCH2 transcription initiation site.	Oxaliplatin	30-41	notch receptor 2	Homo sapiens	152-158
32104001-0	2020	lncRNA MALAT1 modulates oxaliplatin resistance of gastric cancer via sponging miR-22-3p.	Oxaliplatin	24-35	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	7-13
32104001-3	2020	However, the regulatory network of ncRNA and mRNA in GC oxaliplatin (OXA) resistance has not been fully clarified.	Oxaliplatin	56-67	RNANC	Homo sapiens	35-40
32127943-4	2020	Moreover, the role of B7-H3/CDC25A axis in regulating chemoresistance in vivo in the xenograft tumor models by intraperitoneal injection of oxaliplatin (L-OHP) and CDC25A inhibitors.	Oxaliplatin	153-158	cell division cycle 25A	Mus musculus	28-34
32127943-6	2020	We found that B7-H3 could effectively enhance the resistance to a chemotherapeutic drug (oxaliplatin or 5-fluorouracil) via CDC25A.	Oxaliplatin	89-100	CD276 molecule	Homo sapiens	14-19
32127943-6	2020	We found that B7-H3 could effectively enhance the resistance to a chemotherapeutic drug (oxaliplatin or 5-fluorouracil) via CDC25A.	Oxaliplatin	89-100	cell division cycle 25A	Homo sapiens	124-130
32381972-1	2020	There are few reports of using oxaliplatin(L-OHP)for esophageal squamous cell carcinoma.We report a case of long-term disease control after administration of L-OHP for esophagogastric junction squamous cell carcinoma(EG).A woman in her 40s was diagnosed with EG(cT3, cN2, cM0, cStage III).She received thoracoscopic, laparoscopic-assisted, subtotal esophagectomy with 3-field dissection after 3 courses of preoperative chemotherapy with DCF(docetaxel hydrate, cisplatin, 5- fluorouracil).Reconstruction was achieved using a retrosternally shifted gastric tube and transesophageal gastro-tubing.	Oxaliplatin	31-42	carnosine dipeptidase 2	Homo sapiens	267-270
31727675-1	2020	PURPOSE: Aflibercept is a targeted anti-VEGF therapy used to treat patients with metastatic colorectal cancer (mCRC) following progression on oxaliplatin-based regimens.	Oxaliplatin	142-153	vascular endothelial growth factor A	Homo sapiens	40-44
32381986-3	2020	We introduced neoadjuvant chemotherapy(NAC) (cetuximab plus oxaliplatin plus S-1, 4 courses)for this patient and diagnosed ycStage IIIc(ycT4bN3M0)after the therapy.	Oxaliplatin	60-71	X-linked Kx blood group	Homo sapiens	39-42
31935686-0	2020	Improvement of efficacy and decrement cytotoxicity of oxaliplatin anticancer drug using bovine serum albumin nanoparticles: synthesis, characterisation and release behaviour.	Oxaliplatin	54-65	albumin	Homo sapiens	95-108
31935686-1	2020	To sustained release of an anticancer drug, oxaliplatin (OX), a non-toxic and biocompatible nanocarrier based on bovine serum albumin (BSA) were synthesised by desolvation method and characterised using Fourier-transform infrared (FTIR) spectroscopy, field emission scanning electron microscopy (FESEM), atomic force microscopy (AFM) and dynamic light scattering.	Oxaliplatin	44-55	albumin	Homo sapiens	120-133
31756312-7	2020	Moreover, GC cells with high RhCG level had reduced oxaliplatin efficacy suggesting a role for RhCG as a therapeutic target for GC.	Oxaliplatin	52-63	Rh family C glycoprotein	Homo sapiens	29-33
30767651-0	2020	Inhibitory effects of oxali-Platin as a chemotherapeutic drug on the function and structure of bovine liver catalase.	Oxaliplatin	22-34	catalase	Bos taurus	108-116
31916900-3	2020	Previously, we discovered that SDF-2 mediates acquired resistance to oxaliplatin in human gastric cancer cells.	Oxaliplatin	69-80	stromal cell derived factor 2	Homo sapiens	31-36
31916900-4	2020	In this study, we have generated SDF-2-specific monoclonal antibodies (mAbs), using the rat medial iliac lymph node method, as a tool to explore novel mechanisms of oxaliplatin resistance.	Oxaliplatin	165-176	stromal cell derived factor 2	Rattus norvegicus	33-38
31634341-3	2020	We have previously demonstrated that therapeutically relevant concentrations/doses of oxaliplatin lead to a reduction in intracellular pH in mouse dorsal root ganglion (DRG) neurons in vitro and in vivo and that this alteration sensitizes TRPA1 and TRPV1 channels, which most likely mediate the allodynia associated with treatment.	Oxaliplatin	86-97	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	239-244
31634341-3	2020	We have previously demonstrated that therapeutically relevant concentrations/doses of oxaliplatin lead to a reduction in intracellular pH in mouse dorsal root ganglion (DRG) neurons in vitro and in vivo and that this alteration sensitizes TRPA1 and TRPV1 channels, which most likely mediate the allodynia associated with treatment.	Oxaliplatin	86-97	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	249-254
31629935-0	2020	TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.	Oxaliplatin	25-36	toll-like receptor 7	Mus musculus	0-7
31629935-7	2020	In this study, we uncovered novel immunological mechanism of oxaliplatin-resistance and showed the great potential of TLR7/8 agonist as a new immunologic adjuvant in chemotherapy for oxaliplatin-resistant colorectal cancer.	Oxaliplatin	183-194	toll-like receptor 7	Mus musculus	118-124
32194794-4	2020	However, the effect of aminooxyacetic acid (AOAA), which has been widely used as an inhibitor of CBS dependent synthesis of H2S, on the chemotherapeutic effect of oxaliplatin (OXA) and the underlying mechanisms remain to be illustrated.	Oxaliplatin	163-174	cystathionine beta-synthase	Homo sapiens	97-100
32194794-15	2020	Conclusion: The results suggested that CBS is overexpressed in colorectal cancer tissues and AOAA sensitizes colon cancer cells to OXA via exaggerating apoptosis both in vitro and in vivo.	Oxaliplatin	131-134	cystathionine beta-synthase	Homo sapiens	39-42
30838483-2	2020	We conducted a phase I study to determine the maximum tolerated dose of oxaliplatin plus trifluridine/tipiracil (FTD/TPI) in patients with refractory mCRC.	Oxaliplatin	72-83	triosephosphate isomerase 1	Homo sapiens	117-120
30838483-6	2020	Three of six patients in the oxaliplatin 85 mg/m2 cohort had dose-limiting toxicities (DLTs) with treatment delays during the second cycle at &gt;=8 days due to grade &gt;= 2 neutropenia or grade 2 AST/ALT increased.	Oxaliplatin	29-40	solute carrier family 17 member 5	Homo sapiens	198-201
31756312-7	2020	Moreover, GC cells with high RhCG level had reduced oxaliplatin efficacy suggesting a role for RhCG as a therapeutic target for GC.	Oxaliplatin	52-63	Rh family C glycoprotein	Homo sapiens	95-99
32104496-10	2020	MiR-27b-3p could sensitize colorectal cancer cells to oxaliplatin in vitro and in vivo.	Oxaliplatin	54-65	microRNA 27b	Homo sapiens	0-7
32101174-0	2020	Successful desensitization to oxaliplatin after a single initial dose of omalizumab in a patient with elevated IgE levels.	Oxaliplatin	30-41	immunoglobulin heavy constant epsilon	Homo sapiens	111-114
31781855-9	2020	While FOXC1 and NFIC were upregulated in cell lines which were resistant to oxaliplatin, silencing FOXC1 decreased the resistance of SW480 cell line to oxaliplatin.	Oxaliplatin	76-87	forkhead box C1	Homo sapiens	6-11
31781855-9	2020	While FOXC1 and NFIC were upregulated in cell lines which were resistant to oxaliplatin, silencing FOXC1 decreased the resistance of SW480 cell line to oxaliplatin.	Oxaliplatin	76-87	nuclear factor I C	Homo sapiens	16-20
31781855-9	2020	While FOXC1 and NFIC were upregulated in cell lines which were resistant to oxaliplatin, silencing FOXC1 decreased the resistance of SW480 cell line to oxaliplatin.	Oxaliplatin	152-163	forkhead box C1	Homo sapiens	99-104
32021093-0	2020	Curcumin Attenuates Oxaliplatin-Induced Liver Injury and Oxidative Stress by Activating the Nrf2 Pathway.	Oxaliplatin	20-31	NFE2 like bZIP transcription factor 2	Homo sapiens	92-96
32021093-9	2020	Furthermore, Western blotting revealed that CUR treatment reverses the suppression of Nrf2 nuclear translocation and increases the expression of HO-1 and NOQ1 in mice with OXA-induced liver injury.	Oxaliplatin	172-175	heme oxygenase 1	Mus musculus	145-149
32021093-11	2020	Conclusion: Curcumin attenuates oxaliplatin-induced liver injury and oxidative stress by activating the Nrf2 pathway, which suggests that CUR may be potentially used in the prevention and treatment of OXA-induced liver injury.	Oxaliplatin	201-204	nuclear factor, erythroid derived 2, like 2	Mus musculus	104-108
31768696-2	2020	We conducted the first phase II trial among four Japanese study groups to assess the efficacy and safety of T-mab + S-1 and oxaliplatin (T-SOX130) for HER2+ AGC or recurrent gastric cancer.	Oxaliplatin	124-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	151-155
31477841-0	2020	Metabolic targeting of HIF-1alpha potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.	Oxaliplatin	74-85	hypoxia inducible factor 1 subunit alpha	Homo sapiens	23-33
31477841-4	2020	Here, we show that DNMT inhibitors can induce HIF-1alpha degradation to overcome oxaliplatin resistance and enhance anti-CRC therapy.	Oxaliplatin	81-92	DNA methyltransferase 1	Homo sapiens	19-23
31477841-4	2020	Here, we show that DNMT inhibitors can induce HIF-1alpha degradation to overcome oxaliplatin resistance and enhance anti-CRC therapy.	Oxaliplatin	81-92	hypoxia inducible factor 1 subunit alpha	Homo sapiens	46-56
31530934-7	2020	Suppression of AMPKalpha1 by using nano-sized polymeric vector induces a favorable therapeutic effect, especially when in combination with oxaliplatin.	Oxaliplatin	139-150	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	15-25
31477841-5	2020	We found that a low-toxicity DNMT inhibitor, zebularine, could downregulate HIF-1alpha expression and overcome hypoxia-induced oxaliplatin resistance in HCT116 cells and showed efficacy in HCT116 xenograft models and AOM/DSS-induced CRC mouse models.	Oxaliplatin	127-138	DNA methyltransferase 1	Homo sapiens	29-33
31477841-11	2020	This finding provides a new strategy in which an increase in HIF-1alpha hydroxylation could overcome oxaliplatin resistance to enhance anti-CRC therapy.	Oxaliplatin	101-112	hypoxia inducible factor 1 subunit alpha	Homo sapiens	61-71
30861353-0	2019	MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.	Oxaliplatin	21-32	microRNA 483	Homo sapiens	0-7
31856090-4	2020	We present the case of a 44-year-old woman with ATM-mutated PC who achieved stable disease as the best response to first-line fluorouracil, leucovorin, irinotecan, and oxaliplatin, followed by progression on a PARP inhibitor.	Oxaliplatin	168-179	ATM serine/threonine kinase	Homo sapiens	48-51
31490328-3	2020	Our work in male rodents using paclitaxel, oxaliplatin and bortezomib showed robust inhibition of CINP with either S1PR1 antagonists or A3AR agonists.	Oxaliplatin	43-54	sphingosine-1-phosphate receptor 1	Rattus norvegicus	115-120
31490328-5	2020	Our findings reveal that S1PR1 antagonists and A3AR agonists mitigate paclitaxel and oxaliplatin CINP in female and male rodents, but failed to block or reverse bortezomib-induced neuropathic pain (BINP) in females.	Oxaliplatin	85-96	sphingosine-1-phosphate receptor 1	Rattus norvegicus	25-30
31490328-5	2020	Our findings reveal that S1PR1 antagonists and A3AR agonists mitigate paclitaxel and oxaliplatin CINP in female and male rodents, but failed to block or reverse bortezomib-induced neuropathic pain (BINP) in females.	Oxaliplatin	85-96	adenosine A3 receptor	Mus musculus	47-51
30861353-0	2019	MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.	Oxaliplatin	21-32	family with sequence similarity 171 member B	Homo sapiens	57-64
30861353-4	2019	In this work, using small RNA sequencing (small RNA-Seq) and transcriptome sequencing (RNA-Seq), we found that down-regulated miR-483-3p was concurrent with up-regulated FAM171B in oxaliplatin-resistant colorectal cancer cell line HCT116/L as compared with its parental cell line HCT116.	Oxaliplatin	181-192	microRNA 483	Homo sapiens	126-133
30861353-4	2019	In this work, using small RNA sequencing (small RNA-Seq) and transcriptome sequencing (RNA-Seq), we found that down-regulated miR-483-3p was concurrent with up-regulated FAM171B in oxaliplatin-resistant colorectal cancer cell line HCT116/L as compared with its parental cell line HCT116.	Oxaliplatin	181-192	family with sequence similarity 171 member B	Homo sapiens	170-177
30861353-5	2019	Transient transfection of miR-483-3p mimics markedly decreased the levels of FAM171B and restored oxaliplatin responsiveness of HCT116/L cells, and this alteration enhanced cell apoptosis and weakened cell migration.	Oxaliplatin	98-109	microRNA 483	Homo sapiens	26-33
30861353-6	2019	Whereas miR-483-3p inhibitor dramatically promoted the expression of FAM171B and enhanced oxaliplatin resistance of HCT116 cells by repressing cell apoptosis.	Oxaliplatin	90-101	microRNA 483	Homo sapiens	8-15
30861353-7	2019	Furthermore, knockdown of FAM171B in HCT116/L cells could also sensitize its reaction of the treatment with oxaliplatin, which was verified by the reduced cell migration.	Oxaliplatin	108-119	family with sequence similarity 171 member B	Homo sapiens	26-33
30861353-8	2019	These findings demonstrate that FAM171B is a functional target of miR-483-3p in the regulation of oxaliplatin resistance in human CRC cells.	Oxaliplatin	98-109	family with sequence similarity 171 member B	Homo sapiens	32-39
30861353-8	2019	These findings demonstrate that FAM171B is a functional target of miR-483-3p in the regulation of oxaliplatin resistance in human CRC cells.	Oxaliplatin	98-109	microRNA 483	Homo sapiens	66-73
31486252-0	2019	Liability Of The Voltage-Gated Potassium Channel KCNN3 Repeat Polymorphism To Acute Oxaliplatin-Induced Peripheral Neurotoxicity.	Oxaliplatin	84-95	potassium calcium-activated channel subfamily N member 3	Homo sapiens	49-54
31493144-11	2019	Moreover, we found that PL potentiated the antitumor effect of oxaliplatin by inhibiting TrxR1 activity.	Oxaliplatin	63-74	thioredoxin reductase 1	Mus musculus	89-94
31493144-12	2019	PL combined with oxaliplatin markedly suppressed the activity of TrxR1, resulting in the accumulation of ROS and, thereby, DNA damage induction and p38 and JNK signaling pathway activation.	Oxaliplatin	17-28	thioredoxin reductase 1	Mus musculus	65-70
31493144-12	2019	PL combined with oxaliplatin markedly suppressed the activity of TrxR1, resulting in the accumulation of ROS and, thereby, DNA damage induction and p38 and JNK signaling pathway activation.	Oxaliplatin	17-28	mitogen-activated protein kinase 14	Mus musculus	148-151
31493144-12	2019	PL combined with oxaliplatin markedly suppressed the activity of TrxR1, resulting in the accumulation of ROS and, thereby, DNA damage induction and p38 and JNK signaling pathway activation.	Oxaliplatin	17-28	mitogen-activated protein kinase 8	Mus musculus	156-159
31493144-14	2019	Importantly, we found that activation of the p38 and JNK signaling pathways prompted by PL and oxaliplatin was also reversed by NAC pretreatment.	Oxaliplatin	95-106	mitogen-activated protein kinase 14	Mus musculus	45-48
31493144-14	2019	Importantly, we found that activation of the p38 and JNK signaling pathways prompted by PL and oxaliplatin was also reversed by NAC pretreatment.	Oxaliplatin	95-106	mitogen-activated protein kinase 8	Mus musculus	53-56
32156949-2	2019	Herein we report 2 cases of patients with GCC who were successfully treated by surgical resection and oxaliplatin-based adjuvant chemotherapy, without evidence of recurrence.	Oxaliplatin	102-113	guanylate cyclase 2C	Homo sapiens	42-45
32157048-1	2019	We report a case in which recurrent partial HER2-positive gastric cancer showed complete clinical response to capecitabine (Cape)/oxaliplatin(L-OHP/OX)(CapeOX)plus trastuzumab(Tmab)combined chemotherapy for 32months.	Oxaliplatin	130-141	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
32157048-1	2019	We report a case in which recurrent partial HER2-positive gastric cancer showed complete clinical response to capecitabine (Cape)/oxaliplatin(L-OHP/OX)(CapeOX)plus trastuzumab(Tmab)combined chemotherapy for 32months.	Oxaliplatin	142-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
31396953-0	2019	CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.	Oxaliplatin	61-72	CD4 molecule	Homo sapiens	0-3
31396953-5	2019	We demonstrated that oxaliplatin-resistant CRC cell lines overexpressed telomerase reverse transcriptase (TERT), colorectal-associated-tumor antigen-1 (COA-1) and mesothelin tumor-associated antigens.	Oxaliplatin	21-32	telomerase reverse transcriptase	Homo sapiens	72-104
31396953-5	2019	We demonstrated that oxaliplatin-resistant CRC cell lines overexpressed telomerase reverse transcriptase (TERT), colorectal-associated-tumor antigen-1 (COA-1) and mesothelin tumor-associated antigens.	Oxaliplatin	21-32	telomerase reverse transcriptase	Homo sapiens	106-110
31493144-15	2019	In vivo, we found that PL combined with oxaliplatin significantly suppressed tumor growth in a gastric cancer xenograft model, and effectively reduced the activity of TrxR1 in tumor tissues.	Oxaliplatin	40-51	thioredoxin reductase 1	Mus musculus	167-172
31525340-5	2019	Additionally, miR-133b overexpression reduces CRC stemness and overrides chemoresistance to 5-Fluorouracil (5-FU) and oxaliplatin (OXP), indicating a negative role of miR-133b in regulating CRC stemness and chemoresistance.	Oxaliplatin	118-129	microRNA 133b	Homo sapiens	14-22
31525340-5	2019	Additionally, miR-133b overexpression reduces CRC stemness and overrides chemoresistance to 5-Fluorouracil (5-FU) and oxaliplatin (OXP), indicating a negative role of miR-133b in regulating CRC stemness and chemoresistance.	Oxaliplatin	131-134	microRNA 133b	Homo sapiens	14-22
31107542-5	2019	In the overall population, interaction with treatment arm was significant for ERCC2 rs1799787 (pinteraction = 0.05) and XPA rs3176683 (pinteraction = 0.008), suggesting a predictive effect for response to oxaliplatin-based chemoradiotherapy (CRT).	Oxaliplatin	205-216	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	78-83
31107542-5	2019	In the overall population, interaction with treatment arm was significant for ERCC2 rs1799787 (pinteraction = 0.05) and XPA rs3176683 (pinteraction = 0.008), suggesting a predictive effect for response to oxaliplatin-based chemoradiotherapy (CRT).	Oxaliplatin	205-216	XPA, DNA damage recognition and repair factor	Homo sapiens	120-123
31732877-1	2019	PURPOSE: To investigate the influence of organic cation transporter 3 (OCT3) expression on the effect of the combination regimen of 5-fluorouracil, folinic acid and oxaliplatin ((m)FOLFOX6) in colorectal cancer (CRC) patients.	Oxaliplatin	165-176	OCTN3	Homo sapiens	41-69
31732877-1	2019	PURPOSE: To investigate the influence of organic cation transporter 3 (OCT3) expression on the effect of the combination regimen of 5-fluorouracil, folinic acid and oxaliplatin ((m)FOLFOX6) in colorectal cancer (CRC) patients.	Oxaliplatin	165-176	OCTN3	Homo sapiens	71-75
31732877-14	2019	Besides, it was found that the age of patients was negatively correlated with expression level of OCT3, which can explain why patients over 70 years do not benefit from oxaliplatin-containing chemotherapy.	Oxaliplatin	169-180	OCTN3	Homo sapiens	98-102
31907114-0	2019	Verapamil enhances the sensitivity of oxaliplatin to tumor cells by influencing the PARP pathway.	Oxaliplatin	38-49	poly(ADP-ribose) polymerase 1	Homo sapiens	84-88
31907114-3	2019	Moreover, it could enhance the sensitivity of oxaliplatin to low-expression P-glycoprotein (P-gP) tumor cells and strengthen its apoptosis-inducing effect on tumor cells under the reverse drug resistance concentration of tumor cells.	Oxaliplatin	46-57	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
31907114-3	2019	Moreover, it could enhance the sensitivity of oxaliplatin to low-expression P-glycoprotein (P-gP) tumor cells and strengthen its apoptosis-inducing effect on tumor cells under the reverse drug resistance concentration of tumor cells.	Oxaliplatin	46-57	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
31719636-3	2019	The study aimed to elucidate the effects of insulin (INS), an inexpensive drug with a convincing safety profile, on the susceptibility of colon cancer to chemotherapeutic agents: 5-fluorouracil (FU), oxaliplatin (OXA), irinotecan (IRI), cyclophosphamide (CPA) and docetaxel (DOC).	Oxaliplatin	200-211	insulin	Homo sapiens	44-51
31719636-3	2019	The study aimed to elucidate the effects of insulin (INS), an inexpensive drug with a convincing safety profile, on the susceptibility of colon cancer to chemotherapeutic agents: 5-fluorouracil (FU), oxaliplatin (OXA), irinotecan (IRI), cyclophosphamide (CPA) and docetaxel (DOC).	Oxaliplatin	213-216	insulin	Homo sapiens	44-51
31704837-8	2019	These results indicated that the simultaneous expression of APEX1 and Jagged-1 might be associated with chemoresistance toward 5-FU, oxaliplatin, and irinotecan.	Oxaliplatin	133-144	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	60-65
31756062-0	2019	Association of XPD Asp312Asn polymorphism and response to oxaliplatin-based first-line chemotherapy and survival in patients with metastatic colorectal cancer.	Oxaliplatin	58-69	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	15-18
31756062-4	2019	OBJECTIVES: This prospective study was designed to determine the role of the XPD Asp312Asn polymorphism in predicting the response to oxaliplatin-based first-line chemotherapy and survival in patients with metastatic colorectal cancer.	Oxaliplatin	134-145	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	77-80
31704837-8	2019	These results indicated that the simultaneous expression of APEX1 and Jagged-1 might be associated with chemoresistance toward 5-FU, oxaliplatin, and irinotecan.	Oxaliplatin	133-144	jagged canonical Notch ligand 1	Homo sapiens	70-78
31102009-2	2019	S-1 plus oxaliplatin (SOX) is one of the standard regimens for HER2-negative AGC in Japan.	Oxaliplatin	9-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
31465821-6	2019	However, CYP450 enzymes may have affected the mutagenic action of oxaliplatin.	Oxaliplatin	66-77	Cytochrome P450-9b2	Drosophila melanogaster	9-15
30923916-0	2019	Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer.	Oxaliplatin	57-68	replication protein A1	Homo sapiens	20-24
30923916-10	2019	Furthermore, low RPA1 expression increased sensitivity to oxaliplatin in colon cancer cells and inhibited proliferation after oxaliplatin treatment.	Oxaliplatin	58-69	replication protein A1	Homo sapiens	17-21
30923916-10	2019	Furthermore, low RPA1 expression increased sensitivity to oxaliplatin in colon cancer cells and inhibited proliferation after oxaliplatin treatment.	Oxaliplatin	126-137	replication protein A1	Homo sapiens	17-21
30923916-12	2019	RPA1 functions as a putative oncogene in tumorigenesis by reducing sensitivity to oxaliplatin and could serve as a potential prognostic biomarker in colorectal cancer.	Oxaliplatin	82-93	replication protein A1	Homo sapiens	0-4
31436301-0	2019	Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin-resistant cell line to oxaliplatin by inhibiting excision repair cross-complementing group 1 protein expression.	Oxaliplatin	68-79	dehydrogenase/reductase 2	Homo sapiens	0-43
31016687-0	2019	Engagement of MicroRNA-155 in Exaggerated Oxidative Stress Signal and TRPA1 in the Dorsal Horn of the Spinal Cord and Neuropathic Pain During Chemotherapeutic Oxaliplatin.	Oxaliplatin	159-170	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	70-75
31016687-2	2019	The present study was to examine the inhibitory effects of blocking microRNA-155 (miR-155) in the dorsal horn of the spinal cord on neuropathic pain induced by OXL in rats and the underlying mechanisms.	Oxaliplatin	160-163	microRNA 155	Rattus norvegicus	68-80
31016687-2	2019	The present study was to examine the inhibitory effects of blocking microRNA-155 (miR-155) in the dorsal horn of the spinal cord on neuropathic pain induced by OXL in rats and the underlying mechanisms.	Oxaliplatin	160-163	microRNA 155	Rattus norvegicus	82-89
31016687-9	2019	In conclusion, data show the critical role of miR-155 in regulating OXL-induced neuropathic pain likely via oxidative stress-TRPA1 signal pathway, indicating that inhibition of miR-155 has potential benefits in preventing neuropathic pain development during intervention of OXL.	Oxaliplatin	68-71	microRNA 155	Rattus norvegicus	46-53
31016687-9	2019	In conclusion, data show the critical role of miR-155 in regulating OXL-induced neuropathic pain likely via oxidative stress-TRPA1 signal pathway, indicating that inhibition of miR-155 has potential benefits in preventing neuropathic pain development during intervention of OXL.	Oxaliplatin	68-71	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	125-130
31016687-9	2019	In conclusion, data show the critical role of miR-155 in regulating OXL-induced neuropathic pain likely via oxidative stress-TRPA1 signal pathway, indicating that inhibition of miR-155 has potential benefits in preventing neuropathic pain development during intervention of OXL.	Oxaliplatin	68-71	microRNA 155	Rattus norvegicus	177-184
31016687-9	2019	In conclusion, data show the critical role of miR-155 in regulating OXL-induced neuropathic pain likely via oxidative stress-TRPA1 signal pathway, indicating that inhibition of miR-155 has potential benefits in preventing neuropathic pain development during intervention of OXL.	Oxaliplatin	274-277	microRNA 155	Rattus norvegicus	46-53
31016687-9	2019	In conclusion, data show the critical role of miR-155 in regulating OXL-induced neuropathic pain likely via oxidative stress-TRPA1 signal pathway, indicating that inhibition of miR-155 has potential benefits in preventing neuropathic pain development during intervention of OXL.	Oxaliplatin	274-277	microRNA 155	Rattus norvegicus	177-184
31016687-0	2019	Engagement of MicroRNA-155 in Exaggerated Oxidative Stress Signal and TRPA1 in the Dorsal Horn of the Spinal Cord and Neuropathic Pain During Chemotherapeutic Oxaliplatin.	Oxaliplatin	159-170	microRNA 155	Rattus norvegicus	14-26
31436301-0	2019	Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin-resistant cell line to oxaliplatin by inhibiting excision repair cross-complementing group 1 protein expression.	Oxaliplatin	103-114	dehydrogenase/reductase 2	Homo sapiens	0-43
31436301-7	2019	Silencing of DHRS2 in HCT116/Oxa cells effectively restored Oxa-sensitivity by suppressing the expression of excision repair cross-complementing group 1 protein via a p53-dependent pathway, and reversed the EMT phenotype.	Oxaliplatin	29-32	dehydrogenase/reductase 2	Homo sapiens	13-18
31436301-7	2019	Silencing of DHRS2 in HCT116/Oxa cells effectively restored Oxa-sensitivity by suppressing the expression of excision repair cross-complementing group 1 protein via a p53-dependent pathway, and reversed the EMT phenotype.	Oxaliplatin	29-32	tumor protein p53	Homo sapiens	167-170
31671668-0	2019	PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells.	Oxaliplatin	29-40	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	0-6
31671668-4	2019	In addition, whether PFKFB3 affects the cytotoxicity of Oxa has not been investigated.	Oxaliplatin	56-59	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	21-27
31671668-8	2019	Meanwhile, suppression of PFKFB3 attenuated both the basal and Oxa-induced autophagy, by monitoring the autophagic flux and phosphorylated-Ulk1, which play essential roles in autophagy initiation.	Oxaliplatin	63-66	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	26-32
31671668-8	2019	Meanwhile, suppression of PFKFB3 attenuated both the basal and Oxa-induced autophagy, by monitoring the autophagic flux and phosphorylated-Ulk1, which play essential roles in autophagy initiation.	Oxaliplatin	63-66	unc-51 like autophagy activating kinase 1	Homo sapiens	139-143
31671668-10	2019	Collectively, the presented data demonstrated that PFKFB3 inhibition attenuated Oxa-induced autophagy and enhanced its cytotoxicity in colorectal cancer cells.	Oxaliplatin	80-83	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	51-57
31671668-7	2019	Utilizing quantitative PCR and immunoblotting, we observed that Oxa increased PFKFB3 expression in a time- and dose-dependent manner.	Oxaliplatin	64-67	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	78-84
31208913-10	2019	Finally, in a xenograft model, overexpressing miR-338-5p in CRC cells and HIF-1alpha inhibitor PX-478 were able to enhance the sensitivity of CRC to oxaliplatin (OXA) via suppressing the HIF-1alpha/miR-338-5p/IL-6 feedback loop in vivo.	Oxaliplatin	149-160	hypoxia inducible factor 1 subunit alpha	Homo sapiens	74-84
33997167-5	2021	CRISPR/Cas9 silencing of fibroblast growth factor receptor 1 (FGFR1) and oxytocin receptor (OXTR) helped overcome oxaliplatin resistance.	Oxaliplatin	114-125	fibroblast growth factor receptor 1	Homo sapiens	25-60
33997167-5	2021	CRISPR/Cas9 silencing of fibroblast growth factor receptor 1 (FGFR1) and oxytocin receptor (OXTR) helped overcome oxaliplatin resistance.	Oxaliplatin	114-125	fibroblast growth factor receptor 1	Homo sapiens	62-67
33997167-5	2021	CRISPR/Cas9 silencing of fibroblast growth factor receptor 1 (FGFR1) and oxytocin receptor (OXTR) helped overcome oxaliplatin resistance.	Oxaliplatin	114-125	oxytocin receptor	Homo sapiens	73-90
33997167-5	2021	CRISPR/Cas9 silencing of fibroblast growth factor receptor 1 (FGFR1) and oxytocin receptor (OXTR) helped overcome oxaliplatin resistance.	Oxaliplatin	114-125	oxytocin receptor	Homo sapiens	92-96
33997167-6	2021	Similarly, treatment with oxaliplatin in combination with an FGFR1 inhibitor (PD166866) or an antagonist of OXTR (L-368,899) suppressed chemoresistant organoids.	Oxaliplatin	26-37	fibroblast growth factor receptor 1	Homo sapiens	61-66
33997167-6	2021	Similarly, treatment with oxaliplatin in combination with an FGFR1 inhibitor (PD166866) or an antagonist of OXTR (L-368,899) suppressed chemoresistant organoids.	Oxaliplatin	26-37	oxytocin receptor	Homo sapiens	108-112
31208913-10	2019	Finally, in a xenograft model, overexpressing miR-338-5p in CRC cells and HIF-1alpha inhibitor PX-478 were able to enhance the sensitivity of CRC to oxaliplatin (OXA) via suppressing the HIF-1alpha/miR-338-5p/IL-6 feedback loop in vivo.	Oxaliplatin	162-165	hypoxia inducible factor 1 subunit alpha	Homo sapiens	74-84
31208913-10	2019	Finally, in a xenograft model, overexpressing miR-338-5p in CRC cells and HIF-1alpha inhibitor PX-478 were able to enhance the sensitivity of CRC to oxaliplatin (OXA) via suppressing the HIF-1alpha/miR-338-5p/IL-6 feedback loop in vivo.	Oxaliplatin	162-165	hypoxia inducible factor 1 subunit alpha	Homo sapiens	187-197
31208913-10	2019	Finally, in a xenograft model, overexpressing miR-338-5p in CRC cells and HIF-1alpha inhibitor PX-478 were able to enhance the sensitivity of CRC to oxaliplatin (OXA) via suppressing the HIF-1alpha/miR-338-5p/IL-6 feedback loop in vivo.	Oxaliplatin	162-165	interleukin 6	Homo sapiens	209-213
31388734-10	2019	There was a trend towards up-regulation of TNF-alpha mRNA levels in rats treated with oxaliplatin and with oxaliplatin and ibuprofen.	Oxaliplatin	86-97	tumor necrosis factor	Rattus norvegicus	43-52
31326791-7	2019	In vitro studies have demonstrated contribution of MEG3 in defining response to chemotherapeutic agents such as paclitaxel, cisplatin and oxaliplatin.	Oxaliplatin	138-149	maternally expressed 3	Homo sapiens	51-55
31423683-4	2019	LINC is composed of a reduction-responsive heterodimer of photosensitizer pheophorbide A (PPa) and indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, i.e., NLG919, and a light-activatable prodrug of oxaliplatin (OXA).	Oxaliplatin	197-208	indoleamine 2,3-dioxygenase 1	Homo sapiens	130-135
31423683-4	2019	LINC is composed of a reduction-responsive heterodimer of photosensitizer pheophorbide A (PPa) and indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, i.e., NLG919, and a light-activatable prodrug of oxaliplatin (OXA).	Oxaliplatin	210-213	indoleamine 2,3-dioxygenase 1	Homo sapiens	130-135
31388734-10	2019	There was a trend towards up-regulation of TNF-alpha mRNA levels in rats treated with oxaliplatin and with oxaliplatin and ibuprofen.	Oxaliplatin	107-118	tumor necrosis factor	Rattus norvegicus	43-52
31524264-0	2019	Role and mechanism of organic cation transporter 3 in oxaliplatin treatment of colon cancer in vitro and in vivo.	Oxaliplatin	54-65	OCTN3	Homo sapiens	22-50
32184867-10	2019	Furthermore, higher IFN-gamma levels were reported in mice receiving oxaliplatin in comparison with those receiving PBS (p < 0.01).	Oxaliplatin	69-80	interferon gamma	Mus musculus	20-29
32184881-1	2019	This study was designed to evaluate the effect of excision repair cross complementing group 1 (ERCC1) rs11615 codon 118C/T gene polymorphisms on treatment outcomes in Iranian patients receiving oxaliplatin-based regimens for colorectal (CRC) and gastric cancers (GC).	Oxaliplatin	194-205	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	50-93
32184881-1	2019	This study was designed to evaluate the effect of excision repair cross complementing group 1 (ERCC1) rs11615 codon 118C/T gene polymorphisms on treatment outcomes in Iranian patients receiving oxaliplatin-based regimens for colorectal (CRC) and gastric cancers (GC).	Oxaliplatin	194-205	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	95-100
31432188-0	2019	The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis.	Oxaliplatin	81-92	colorectal neoplasia differentially expressed	Homo sapiens	22-27
31432188-0	2019	The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis.	Oxaliplatin	81-92	H19 imprinted maternally expressed transcript	Homo sapiens	29-32
31432188-0	2019	The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis.	Oxaliplatin	81-92	urothelial cancer associated 1	Homo sapiens	34-38
31432188-0	2019	The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis.	Oxaliplatin	81-92	HOX transcript antisense RNA	Homo sapiens	43-49
31524278-0	2019	FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression.	Oxaliplatin	15-26	FKBP prolyl isomerase 3	Homo sapiens	0-5
31524264-4	2019	The results demonstrated that OXA cellular concentration and OXA-induced cytotoxicity were significantly increased in response to high expression of OCT3, whereas OCT3 knockdown directly increased the invasion and migration of colon cancer cells.	Oxaliplatin	30-33	OCTN3	Homo sapiens	149-153
31524278-0	2019	FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression.	Oxaliplatin	15-26	histone deacetylase 2	Homo sapiens	79-84
31524278-4	2019	However, the role of FKBP3 and HDAC2 in oxaliplatin resistance in CRC and the potential molecular mechanisms are still poorly understood.	Oxaliplatin	40-51	FKBP prolyl isomerase 3	Homo sapiens	21-26
31524278-12	2019	Our data revealed that oxaliplatin resistance in CRC cells is positively associated with FKBP3 and HDAC2 expression, and FKBP3 downregulation could attenuate oxaliplatin resistance in CRC cells by reducing HDAC2 expression and possibly through regulation of the PTEN/AKT pathway.	Oxaliplatin	158-169	FKBP prolyl isomerase 3	Homo sapiens	121-126
31524278-12	2019	Our data revealed that oxaliplatin resistance in CRC cells is positively associated with FKBP3 and HDAC2 expression, and FKBP3 downregulation could attenuate oxaliplatin resistance in CRC cells by reducing HDAC2 expression and possibly through regulation of the PTEN/AKT pathway.	Oxaliplatin	158-169	histone deacetylase 2	Homo sapiens	206-211
31524278-4	2019	However, the role of FKBP3 and HDAC2 in oxaliplatin resistance in CRC and the potential molecular mechanisms are still poorly understood.	Oxaliplatin	40-51	histone deacetylase 2	Homo sapiens	31-36
31524264-5	2019	Furthermore, upregulation of OCT3 expression in colon cancer xenografts via treatment with the DNA methyltransferase inhibitor decitabine increased cellular OXA concentration and improved the curative effect of OXA.	Oxaliplatin	157-160	OCTN3	Homo sapiens	29-33
31524278-9	2019	Downregulation of FKBP3 significantly increased the sensitivity of primary CRC cells to oxaliplatin, reduced expression of HDAC2, permeability glycoprotein (P-gp) and phosphorylated AKT (p-AKT), and increased expression of phosphatase and tensin homolog (PTEN) and cleaved caspase-3.	Oxaliplatin	88-99	FKBP prolyl isomerase 3	Homo sapiens	18-23
31524278-11	2019	Furthermore, downregulation of HDAC2 significantly counteracted FKBP3-induced oxaliplatin resistance in CRC cells.	Oxaliplatin	78-89	histone deacetylase 2	Homo sapiens	31-36
31524264-5	2019	Furthermore, upregulation of OCT3 expression in colon cancer xenografts via treatment with the DNA methyltransferase inhibitor decitabine increased cellular OXA concentration and improved the curative effect of OXA.	Oxaliplatin	211-214	OCTN3	Homo sapiens	29-33
31524278-11	2019	Furthermore, downregulation of HDAC2 significantly counteracted FKBP3-induced oxaliplatin resistance in CRC cells.	Oxaliplatin	78-89	FKBP prolyl isomerase 3	Homo sapiens	64-69
31524278-12	2019	Our data revealed that oxaliplatin resistance in CRC cells is positively associated with FKBP3 and HDAC2 expression, and FKBP3 downregulation could attenuate oxaliplatin resistance in CRC cells by reducing HDAC2 expression and possibly through regulation of the PTEN/AKT pathway.	Oxaliplatin	23-34	FKBP prolyl isomerase 3	Homo sapiens	89-94
31524278-12	2019	Our data revealed that oxaliplatin resistance in CRC cells is positively associated with FKBP3 and HDAC2 expression, and FKBP3 downregulation could attenuate oxaliplatin resistance in CRC cells by reducing HDAC2 expression and possibly through regulation of the PTEN/AKT pathway.	Oxaliplatin	23-34	histone deacetylase 2	Homo sapiens	99-104
31325582-9	2019	Oxaliplatin caused a nociceptive response accompanied by the increased expression of c-Fos and ATF3 in the dorsal root ganglia and spinal cord.	Oxaliplatin	0-11	FBJ osteosarcoma oncogene	Mus musculus	85-90
31325582-9	2019	Oxaliplatin caused a nociceptive response accompanied by the increased expression of c-Fos and ATF3 in the dorsal root ganglia and spinal cord.	Oxaliplatin	0-11	activating transcription factor 3	Mus musculus	95-99
31325582-10	2019	In addition, the oxaliplatin-associated nociception was significantly attenuated by metformin (P &lt; 0.05), which also reduced the expression of c-Fos and ATF3 (P &lt; 0.05).	Oxaliplatin	17-28	FBJ osteosarcoma oncogene	Mus musculus	146-151
31325582-10	2019	In addition, the oxaliplatin-associated nociception was significantly attenuated by metformin (P &lt; 0.05), which also reduced the expression of c-Fos and ATF3 (P &lt; 0.05).	Oxaliplatin	17-28	activating transcription factor 3	Mus musculus	156-160
31325582-11	2019	Therefore, metformin protected from the peripheral sensory neuropathy induced by oxaliplatin, which was confirmed by the reduction of c-Fos and ATF3 expression, two known neuronal activation and damage markers, respectively.	Oxaliplatin	81-92	FBJ osteosarcoma oncogene	Mus musculus	134-139
31325582-11	2019	Therefore, metformin protected from the peripheral sensory neuropathy induced by oxaliplatin, which was confirmed by the reduction of c-Fos and ATF3 expression, two known neuronal activation and damage markers, respectively.	Oxaliplatin	81-92	activating transcription factor 3	Mus musculus	144-148
31488078-6	2019	Selectively, the effect of EGF receptor inhibition was augmented by a combination with 5-fluorouracil and oxaliplatin.	Oxaliplatin	106-117	epidermal growth factor receptor	Homo sapiens	27-39
31500349-1	2019	Our recent publications showed that multidrug resistance protein 2 (MRP2, encoded by the ABCC2 gene) conferred oxaliplatin resistance in human liver cancer HepG2 cells.	Oxaliplatin	111-122	ATP binding cassette subfamily C member 2	Homo sapiens	89-94
31500349-3	2019	We investigated the effects of silencing MRP2 by siRNA on oxaliplatin accumulation and sensitivity in human colorectal cancer Caco-2 cells and pancreatic cancer PANC-1 cells.	Oxaliplatin	58-69	ATP binding cassette subfamily C member 2	Homo sapiens	41-45
31500349-4	2019	We characterized the effects of oxaliplatin on MRP2 ATPase activities using membrane vesicles.	Oxaliplatin	32-43	ATP binding cassette subfamily C member 2	Homo sapiens	47-51
31500349-5	2019	Over-expression of MRP2 (endogenously in Caco-2 and PANC-1 cells) was associated with decreased oxaliplatin accumulation and cytotoxicity, but those deficits were reversed by inhibition of MRP2 with myricetin or siRNA knockdown.	Oxaliplatin	96-107	ATP binding cassette subfamily C member 2	Homo sapiens	19-23
31500349-6	2019	Silencing MRP2 by siRNA increased oxaliplatin-induced apoptotic rate in Caco-2 and PANC-1 cells.	Oxaliplatin	34-45	ATP binding cassette subfamily C member 2	Homo sapiens	10-14
31500349-7	2019	Oxaliplatin stimulated MRP2 ATPase activity with a concentration needed to reach 50% of the maximal stimulation (EC50) value of 8.3 +- 0.7 microM and Hill slope 2.7.	Oxaliplatin	0-11	ATP binding cassette subfamily C member 2	Homo sapiens	23-27
31500349-8	2019	In conclusion, oxaliplatin is a substrate of MRP2 with possibly two binding sites, and silencing MRP2 increased oxaliplatin accumulation and cytotoxicity in two widely available gastrointestinal tumour lines (PANC-1 and Caco-2).	Oxaliplatin	15-26	ATP binding cassette subfamily C member 2	Homo sapiens	45-49
31500349-8	2019	In conclusion, oxaliplatin is a substrate of MRP2 with possibly two binding sites, and silencing MRP2 increased oxaliplatin accumulation and cytotoxicity in two widely available gastrointestinal tumour lines (PANC-1 and Caco-2).	Oxaliplatin	112-123	ATP binding cassette subfamily C member 2	Homo sapiens	97-101
31500349-0	2019	Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells.	Oxaliplatin	19-30	ATP binding cassette subfamily C member 2	Homo sapiens	87-91
31500349-1	2019	Our recent publications showed that multidrug resistance protein 2 (MRP2, encoded by the ABCC2 gene) conferred oxaliplatin resistance in human liver cancer HepG2 cells.	Oxaliplatin	111-122	ATP binding cassette subfamily C member 2	Homo sapiens	36-66
31500349-1	2019	Our recent publications showed that multidrug resistance protein 2 (MRP2, encoded by the ABCC2 gene) conferred oxaliplatin resistance in human liver cancer HepG2 cells.	Oxaliplatin	111-122	ATP binding cassette subfamily C member 2	Homo sapiens	68-72
31497229-0	2019	PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway.	Oxaliplatin	37-48	AKT serine/threonine kinase 1	Homo sapiens	146-149
31486238-10	2019	In a systematic investigation conducted on Chinese patients with GC, CLDN18-ARHGAP26/6 fusion was associated with signet-ring cell content and was prognostic for a worse outcome and predictive for no benefit from oxaliplatin/fluoropyrimidine-based chemotherapy.	Oxaliplatin	213-224	claudin 18	Homo sapiens	69-75
31272718-11	2019	PLAC8 conferred resistance to GEM and OXA by upregulating PD-L1 expression, and PLAC8 or PD-L1 blockade may have potential for overcoming chemotherapy resistance, providing therapeutic options for chemotherapy-refractory GBC patients.	Oxaliplatin	38-41	placenta associated 8	Homo sapiens	0-5
31272718-11	2019	PLAC8 conferred resistance to GEM and OXA by upregulating PD-L1 expression, and PLAC8 or PD-L1 blockade may have potential for overcoming chemotherapy resistance, providing therapeutic options for chemotherapy-refractory GBC patients.	Oxaliplatin	38-41	CD274 molecule	Homo sapiens	58-63
30998268-0	2019	Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.	Oxaliplatin	45-56	annexin A3	Homo sapiens	0-10
30998268-3	2019	This study aimed to investigate the effects and potential mechanisms of ANXA3 on oxaliplatin (Ox) resistance in CRC.	Oxaliplatin	81-92	annexin A3	Homo sapiens	72-77
30998268-3	2019	This study aimed to investigate the effects and potential mechanisms of ANXA3 on oxaliplatin (Ox) resistance in CRC.	Oxaliplatin	94-96	annexin A3	Homo sapiens	72-77
31181314-5	2019	Treatment with oxaliplatin, tetraplatin, cisplatin, and carboplatin mediated the upregulation of CASC11 in cells of OSCC cell line.	Oxaliplatin	15-26	cancer susceptibility 11	Homo sapiens	97-103
31181314-6	2019	In addition, overexpression of CASC11 led to increased cancer cell viability under oxaliplatin, tetraplatin, cisplatin, and carboplatin treatment, while CASC11 siRNA silencing played an opposite role.	Oxaliplatin	83-94	cancer susceptibility 11	Homo sapiens	31-37
31467597-11	2019	Conclusions: Hyperglycemia can affect clinical outcomes in stage III CRC patients receiving adjuvant chemotherapy, and the mechanism underlying oxaliplatin resistance is possibly associated with increased phosphorylation of SMAD3 and MYC and upregulation of EHMT2 expression.	Oxaliplatin	144-155	SMAD family member 3	Homo sapiens	224-229
31467597-11	2019	Conclusions: Hyperglycemia can affect clinical outcomes in stage III CRC patients receiving adjuvant chemotherapy, and the mechanism underlying oxaliplatin resistance is possibly associated with increased phosphorylation of SMAD3 and MYC and upregulation of EHMT2 expression.	Oxaliplatin	144-155	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	234-237
31467597-11	2019	Conclusions: Hyperglycemia can affect clinical outcomes in stage III CRC patients receiving adjuvant chemotherapy, and the mechanism underlying oxaliplatin resistance is possibly associated with increased phosphorylation of SMAD3 and MYC and upregulation of EHMT2 expression.	Oxaliplatin	144-155	euchromatic histone lysine methyltransferase 2	Homo sapiens	258-263
31497229-0	2019	PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway.	Oxaliplatin	37-48	mechanistic target of rapamycin kinase	Homo sapiens	150-154
31497229-3	2019	In this research, we evaluated the effect of the dual PI3K/mTOR inhibitor, PKI-587, on the sensitivity of oxaliplatin in HCC.	Oxaliplatin	106-117	mechanistic target of rapamycin kinase	Homo sapiens	59-63
31497229-10	2019	We conclude that PKI-587 enhances chemosensitivity of oxaliplatin in HCC through suppressing the PI3K/AKT/mTOR signalling pathway and inhibiting the DNA damage repair pathway.	Oxaliplatin	54-65	AKT serine/threonine kinase 1	Homo sapiens	102-105
31497229-10	2019	We conclude that PKI-587 enhances chemosensitivity of oxaliplatin in HCC through suppressing the PI3K/AKT/mTOR signalling pathway and inhibiting the DNA damage repair pathway.	Oxaliplatin	54-65	mechanistic target of rapamycin kinase	Homo sapiens	106-110
31409858-4	2019	Exposure to oxaliplatin triggers alterations in peripheral neuropathic pathways previously linked to IL-8 pathway.	Oxaliplatin	12-23	C-X-C motif chemokine ligand 8	Homo sapiens	101-105
31296923-8	2019	Use of oxaliplatin showed survival benefit only in patients with high-risk stage II CC and post-operative CEA &gt; 2.35 ng/ml (interaction term P = 0.09 and 0.03 for DFS and OS).	Oxaliplatin	7-18	CEA cell adhesion molecule 3	Homo sapiens	106-109
31382983-9	2019	GKN2 also inhibited xenograft tumor growth and was an independent and significant prognostic factor for patients with gastric cancer treated with oxaliplatin.	Oxaliplatin	146-157	gastrokine 2	Homo sapiens	0-4
31382983-12	2019	GKN2 overexpression could be used to determine the subgroup of patients to obtain the more favorable outcome of oxaliplatin treatment and may be used as biomarker of the prognosis of this cancer.	Oxaliplatin	112-123	gastrokine 2	Homo sapiens	0-4
31428584-0	2019	High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma.	Oxaliplatin	49-60	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	25-30
31428584-4	2019	The purpose of this study was to synthesise a humanized antibody against c-Met (anti-c-Met IgG) and conjugate it to oxaliplatin to develop a novel antibody-drug conjugate (ADC).	Oxaliplatin	116-127	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	73-78
31428584-4	2019	The purpose of this study was to synthesise a humanized antibody against c-Met (anti-c-Met IgG) and conjugate it to oxaliplatin to develop a novel antibody-drug conjugate (ADC).	Oxaliplatin	116-127	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	85-90
31428584-5	2019	Anti-c-Met IgG was detected to be loaded with ~4.35 moles oxaliplatin per mole of antibody.	Oxaliplatin	58-69	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	5-10
31296923-10	2019	In the MOSAIC trial, only high-risk stage II CC patients with post-operative CEA &gt; 2.35 ng/mL benefited from the addition of oxaliplatin to LV5FU2.	Oxaliplatin	128-139	CEA cell adhesion molecule 3	Homo sapiens	77-80
31467537-9	2019	Cox regression analysis revealed that middle age (61-78 years old, P=0.003) and oxaliplatin cumulative dose &lt;850 mg/m2 (P=0.002) were associated with patient mortality.	Oxaliplatin	80-91	cytochrome c oxidase subunit 8A	Homo sapiens	0-3
31088315-2	2019	Previous studies have shown that loss of the human organic cation transporter OCT2 is the main factor contributing to oxaliplatin resistance in RCC, and that DNA hypermethylation and histone methylation play important roles in the transcriptional repression of OCT2 in RCC.	Oxaliplatin	118-129	POU class 2 homeobox 2	Homo sapiens	78-82
31088315-6	2019	We found that combined treatment using the DNA methylation inhibitor decitabine and the histone deacetylase inhibitor vorinostat significantly increased the expression of OCT2 in RCC cell lines, which sensitized these cells to oxaliplatin.	Oxaliplatin	227-238	POU class 2 homeobox 2	Homo sapiens	171-175
30649440-1	2019	Background: Constitutional loss of function (LOF) single nucleotide polymorphisms (SNPs) in pattern recognition receptors FPR1, TLR3, and TLR4 have previously been reported to predict oxaliplatin benefit in colorectal cancer.	Oxaliplatin	184-195	formyl peptide receptor 1	Homo sapiens	122-126
30649440-1	2019	Background: Constitutional loss of function (LOF) single nucleotide polymorphisms (SNPs) in pattern recognition receptors FPR1, TLR3, and TLR4 have previously been reported to predict oxaliplatin benefit in colorectal cancer.	Oxaliplatin	184-195	toll like receptor 3	Homo sapiens	128-132
30649440-1	2019	Background: Constitutional loss of function (LOF) single nucleotide polymorphisms (SNPs) in pattern recognition receptors FPR1, TLR3, and TLR4 have previously been reported to predict oxaliplatin benefit in colorectal cancer.	Oxaliplatin	184-195	toll like receptor 4	Homo sapiens	138-142
30859572-0	2019	Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.	Oxaliplatin	80-91	Meis homeobox 2	Homo sapiens	34-39
30859572-5	2019	Among these genes, Meis Homeobox 2 (MEIS2) had the highest correlation with L-OHP resistance (r = -0.443) and was deregulated in L-OHP resistant tissues compared with L-OHP sensitive tissues in both our own dataset and GSE104645 testing dataset.	Oxaliplatin	76-81	Meis homeobox 2	Homo sapiens	19-34
30859572-5	2019	Among these genes, Meis Homeobox 2 (MEIS2) had the highest correlation with L-OHP resistance (r = -0.443) and was deregulated in L-OHP resistant tissues compared with L-OHP sensitive tissues in both our own dataset and GSE104645 testing dataset.	Oxaliplatin	76-81	Meis homeobox 2	Homo sapiens	36-41
30859572-5	2019	Among these genes, Meis Homeobox 2 (MEIS2) had the highest correlation with L-OHP resistance (r = -0.443) and was deregulated in L-OHP resistant tissues compared with L-OHP sensitive tissues in both our own dataset and GSE104645 testing dataset.	Oxaliplatin	129-134	Meis homeobox 2	Homo sapiens	19-34
30859572-5	2019	Among these genes, Meis Homeobox 2 (MEIS2) had the highest correlation with L-OHP resistance (r = -0.443) and was deregulated in L-OHP resistant tissues compared with L-OHP sensitive tissues in both our own dataset and GSE104645 testing dataset.	Oxaliplatin	129-134	Meis homeobox 2	Homo sapiens	36-41
30859572-5	2019	Among these genes, Meis Homeobox 2 (MEIS2) had the highest correlation with L-OHP resistance (r = -0.443) and was deregulated in L-OHP resistant tissues compared with L-OHP sensitive tissues in both our own dataset and GSE104645 testing dataset.	Oxaliplatin	129-134	Meis homeobox 2	Homo sapiens	19-34
30859572-5	2019	Among these genes, Meis Homeobox 2 (MEIS2) had the highest correlation with L-OHP resistance (r = -0.443) and was deregulated in L-OHP resistant tissues compared with L-OHP sensitive tissues in both our own dataset and GSE104645 testing dataset.	Oxaliplatin	129-134	Meis homeobox 2	Homo sapiens	36-41
30859572-6	2019	The receiver operating characteristic curve validated that MEIS2 had a good ability in predicting L-OHP response in both our own dataset (area under the curve [AUC] = 0.802) and GSE104645 dataset (AUC = 0.746).	Oxaliplatin	98-103	Meis homeobox 2	Homo sapiens	59-64
30859572-12	2019	In the overall view, MEIS2 had increased promoter hypermethylation and was downregulated in poor L-OHP response mCRC tissues.	Oxaliplatin	97-102	Meis homeobox 2	Homo sapiens	21-26
30859572-13	2019	MEIS2 might be involved in the Wnt/beta-catenin pathway to maintain CRC stemness, which leads to L-OHP resistance.	Oxaliplatin	97-102	Meis homeobox 2	Homo sapiens	0-5
30859572-13	2019	MEIS2 might be involved in the Wnt/beta-catenin pathway to maintain CRC stemness, which leads to L-OHP resistance.	Oxaliplatin	97-102	catenin beta 1	Homo sapiens	35-47
31345380-5	2019	RESULTS: Cisplatin and oxaliplatin both increased cell surface levels of calreticulin, HSP70, MHC class I and PD-L1 in multiple cell lines.	Oxaliplatin	23-34	calreticulin	Mus musculus	73-85
31345380-5	2019	RESULTS: Cisplatin and oxaliplatin both increased cell surface levels of calreticulin, HSP70, MHC class I and PD-L1 in multiple cell lines.	Oxaliplatin	23-34	heat shock protein 1B	Mus musculus	87-92
31233200-8	2019	However, in the resistant cells, the oxaliplatin-triggered extrinsic apoptotic pathway appeared to be suppressed by decreased lipid raft formation, and recruitment of death receptor 5 and FADD into lipid rafts.	Oxaliplatin	37-48	TNF receptor superfamily member 10b	Homo sapiens	167-183
31345380-5	2019	RESULTS: Cisplatin and oxaliplatin both increased cell surface levels of calreticulin, HSP70, MHC class I and PD-L1 in multiple cell lines.	Oxaliplatin	23-34	CD274 antigen	Mus musculus	110-115
31423269-0	2019	Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling.	Oxaliplatin	0-11	glucagon like peptide 1 receptor	Homo sapiens	25-31
31233200-8	2019	However, in the resistant cells, the oxaliplatin-triggered extrinsic apoptotic pathway appeared to be suppressed by decreased lipid raft formation, and recruitment of death receptor 5 and FADD into lipid rafts.	Oxaliplatin	37-48	Fas associated via death domain	Homo sapiens	188-192
31283225-6	2019	We show that cisplatin and an oxaliplatin analogue can specifically bind to the heterodimeric complex Atox1-Cu(I)-Mnk1 (Mnk1 is the first soluble domain of Atp7a), thus leading to a kinetically stable adduct that has been structurally characterized by solution NMR and X-ray crystallography.	Oxaliplatin	30-41	antioxidant 1 copper chaperone	Homo sapiens	102-107
31242722-4	2019	LINC00525 knockdown decreased stemness properties and increased sensitivities to oxaliplatin.	Oxaliplatin	81-92	long intergenic non-protein coding RNA 525	Homo sapiens	0-9
31423269-0	2019	Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling.	Oxaliplatin	0-11	forkhead box O1	Homo sapiens	98-103
31423269-5	2019	It was also indicated that following oxaliplatin treatment, the effects of GLP-1R on EMT and invasion were reversed.	Oxaliplatin	37-48	glucagon like peptide 1 receptor	Homo sapiens	75-81
31423269-5	2019	It was also indicated that following oxaliplatin treatment, the effects of GLP-1R on EMT and invasion were reversed.	Oxaliplatin	37-48	IL2 inducible T cell kinase	Homo sapiens	85-88
31423282-7	2019	The high expression of alpha-SMA, p-AKT and survivin in patients with aCRC were associated with oxaliplatin plus 5-FU resistance (P&lt;0.001, P=0.023 and P=0.001, respectively).	Oxaliplatin	96-107	AKT serine/threonine kinase 1	Homo sapiens	36-39
31423282-11	2019	In conclusion, the multifactorial predictive biomarker model of alpha-SMA, p-AKT, p-ERK and survivin expression for patients with aCRC to predict intrinsic resistance to oxaliplatin plus 5-FU regimens is of great efficiency and accuracy.	Oxaliplatin	170-181	AKT serine/threonine kinase 1	Homo sapiens	77-80
31423282-11	2019	In conclusion, the multifactorial predictive biomarker model of alpha-SMA, p-AKT, p-ERK and survivin expression for patients with aCRC to predict intrinsic resistance to oxaliplatin plus 5-FU regimens is of great efficiency and accuracy.	Oxaliplatin	170-181	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	82-87
31283225-6	2019	We show that cisplatin and an oxaliplatin analogue can specifically bind to the heterodimeric complex Atox1-Cu(I)-Mnk1 (Mnk1 is the first soluble domain of Atp7a), thus leading to a kinetically stable adduct that has been structurally characterized by solution NMR and X-ray crystallography.	Oxaliplatin	30-41	MAPK interacting serine/threonine kinase 1	Homo sapiens	114-118
31283225-6	2019	We show that cisplatin and an oxaliplatin analogue can specifically bind to the heterodimeric complex Atox1-Cu(I)-Mnk1 (Mnk1 is the first soluble domain of Atp7a), thus leading to a kinetically stable adduct that has been structurally characterized by solution NMR and X-ray crystallography.	Oxaliplatin	30-41	MAPK interacting serine/threonine kinase 1	Homo sapiens	120-124
31283225-6	2019	We show that cisplatin and an oxaliplatin analogue can specifically bind to the heterodimeric complex Atox1-Cu(I)-Mnk1 (Mnk1 is the first soluble domain of Atp7a), thus leading to a kinetically stable adduct that has been structurally characterized by solution NMR and X-ray crystallography.	Oxaliplatin	30-41	ATPase copper transporting alpha	Homo sapiens	156-161
31358014-8	2019	RESULTS: We observed significant associations of smoking and 1-OHP co-exposure with CYP1A1 hypomethylation (OR: 1.87, 95% CI: 1.01-3.47) and high 8-OHdG (OR: 2.13, 95% CI: 1.14-3.97).	Oxaliplatin	61-66	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	84-90
31358014-10	2019	In addition, mediation analysis suggested CYP1A1 hypomethylation could explain 13.6% of effect of high 8-OHdG related to smoking and 1-OHP co-exposure.	Oxaliplatin	133-138	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	42-48
31344863-4	2019	Cellular oxaliplatin accumulation and DNA-adduct formation were decreased and related to OCT1-3 and ATP7A expression.	Oxaliplatin	9-20	solute carrier family 22 member 1	Homo sapiens	89-93
31344863-4	2019	Cellular oxaliplatin accumulation and DNA-adduct formation were decreased and related to OCT1-3 and ATP7A expression.	Oxaliplatin	9-20	ATPase copper transporting alpha	Homo sapiens	100-105
31336636-7	2019	The results showed 1-OHPH is specifically correlated with CpG4 and CpG6 of the imprinted gene H19, CpG1 and CpG2 of PEG3, and CpG2 of MEG3; whereas 1-OHP is positively correlated with PEG3 at CpG1.	Oxaliplatin	19-24	H19 imprinted maternally expressed transcript	Homo sapiens	94-97
31336636-7	2019	The results showed 1-OHPH is specifically correlated with CpG4 and CpG6 of the imprinted gene H19, CpG1 and CpG2 of PEG3, and CpG2 of MEG3; whereas 1-OHP is positively correlated with PEG3 at CpG1.	Oxaliplatin	19-24	paternally expressed 3	Homo sapiens	116-120
31336636-7	2019	The results showed 1-OHPH is specifically correlated with CpG4 and CpG6 of the imprinted gene H19, CpG1 and CpG2 of PEG3, and CpG2 of MEG3; whereas 1-OHP is positively correlated with PEG3 at CpG1.	Oxaliplatin	19-24	maternally expressed 3	Homo sapiens	134-138
31336636-7	2019	The results showed 1-OHPH is specifically correlated with CpG4 and CpG6 of the imprinted gene H19, CpG1 and CpG2 of PEG3, and CpG2 of MEG3; whereas 1-OHP is positively correlated with PEG3 at CpG1.	Oxaliplatin	19-24	paternally expressed 3	Homo sapiens	184-188
31054938-0	2019	MiR-30b-5p attenuates oxaliplatin-induced peripheral neuropathic pain through the voltage-gated sodium channel Nav1.6 in rats.	Oxaliplatin	22-33	microRNA 30b	Rattus norvegicus	0-7
31242722-11	2019	Conclusions: LINC00525 enhanced stemness properties and increased sensitivities of CRC cells to oxaliplatin by targeting miR-507/ELK3 axis.	Oxaliplatin	96-107	long intergenic non-protein coding RNA 525	Homo sapiens	13-22
31320608-0	2019	Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer.	Oxaliplatin	119-130	heterogeneous nuclear ribonucleoprotein L	Homo sapiens	0-41
31320608-0	2019	Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer.	Oxaliplatin	119-130	tumor protein p53 binding protein 1	Homo sapiens	69-74
31320608-0	2019	Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer.	Oxaliplatin	119-130	BRCA1 DNA repair associated	Homo sapiens	79-84
31320608-3	2019	Our study aims to uncover an unidentified mechanism of regulating DNA double-strand breaks (DSBs) by hnRNP L in CRC cells treated by oxaliplatin.	Oxaliplatin	133-144	heterogeneous nuclear ribonucleoprotein L	Homo sapiens	101-108
31320608-4	2019	In present study, we observed that knockdown of hnRNP L enhanced the level of DNA breakage and sensitivity of CRC cells to oxaliplatin.	Oxaliplatin	123-134	heterogeneous nuclear ribonucleoprotein L	Homo sapiens	48-55
31320608-9	2019	Analysis of cell death indicated that the RRMs of hnRNP L are required for cell survival under incubation with oxaliplatin.	Oxaliplatin	111-122	heterogeneous nuclear ribonucleoprotein L	Homo sapiens	50-57
31320608-10	2019	In conclusion, hnRNP L is critical for the recruitment of the DNA repair factors in oxaliplatin-induced DSBs.	Oxaliplatin	84-95	heterogeneous nuclear ribonucleoprotein L	Homo sapiens	15-22
31320608-11	2019	Targeting hnRNP L is a promising new clinical approach that could enhance the effectiveness of current chemotherapeutic treatment in patients with resistance to oxaliplatin.	Oxaliplatin	161-172	heterogeneous nuclear ribonucleoprotein L	Homo sapiens	10-17
31337142-0	2019	Docosahexaenoic Acid Enhances Oxaliplatin-Induced Autophagic Cell Death via the ER Stress/Sesn2 Pathway in Colorectal Cancer.	Oxaliplatin	30-41	sestrin 2	Homo sapiens	90-95
31337142-5	2019	Oxaliplatin and DHA also increased the expression of Sestrin 2 (SESN2) and endoplasmic reticulum (ER) stress related C/EBP homologous protein (CHOP).	Oxaliplatin	0-11	sestrin 2	Homo sapiens	53-62
31337142-5	2019	Oxaliplatin and DHA also increased the expression of Sestrin 2 (SESN2) and endoplasmic reticulum (ER) stress related C/EBP homologous protein (CHOP).	Oxaliplatin	0-11	sestrin 2	Homo sapiens	64-69
31181310-0	2019	MiRNA-204-5p and oxaliplatin-loaded silica nanoparticles for enhanced tumor suppression effect in CD44-overexpressed colon adenocarcinoma.	Oxaliplatin	17-28	CD44 molecule (Indian blood group)	Homo sapiens	98-102
31054938-0	2019	MiR-30b-5p attenuates oxaliplatin-induced peripheral neuropathic pain through the voltage-gated sodium channel Nav1.6 in rats.	Oxaliplatin	22-33	neuron navigator 1	Rattus norvegicus	111-115
31054938-8	2019	Overexpression of miR-30b using an miR-30b agomir attenuated neuropathic pain induced by oxaliplatin and inhibited both the mRNA and protein expression levels of Nav1.6 both in vitro and in vivo.	Oxaliplatin	89-100	microRNA 30b	Rattus norvegicus	18-25
31054938-8	2019	Overexpression of miR-30b using an miR-30b agomir attenuated neuropathic pain induced by oxaliplatin and inhibited both the mRNA and protein expression levels of Nav1.6 both in vitro and in vivo.	Oxaliplatin	89-100	microRNA 30b	Rattus norvegicus	35-42
31337142-5	2019	Oxaliplatin and DHA also increased the expression of Sestrin 2 (SESN2) and endoplasmic reticulum (ER) stress related C/EBP homologous protein (CHOP).	Oxaliplatin	0-11	DNA damage inducible transcript 3	Homo sapiens	117-141
31337142-5	2019	Oxaliplatin and DHA also increased the expression of Sestrin 2 (SESN2) and endoplasmic reticulum (ER) stress related C/EBP homologous protein (CHOP).	Oxaliplatin	0-11	DNA damage inducible transcript 3	Homo sapiens	143-147
31054938-11	2019	These data suggest that miR-30b contributes to oxaliplatin-induced chronic neuropathic pain through Nav1.6 downregulation and could be a novel therapeutic target for the treatment of oxaliplatin-induced neuropathic pain as a side effect of chemotherapy in cancer patients.	Oxaliplatin	47-58	microRNA 30b	Homo sapiens	24-31
31337142-6	2019	Additionally, treatment with Oxaliplatin and DHA enhanced the binding of CHOP to the promotor region of SESN2, increasing SESN2 expression.	Oxaliplatin	29-40	DNA damage inducible transcript 3	Homo sapiens	73-77
31337142-6	2019	Additionally, treatment with Oxaliplatin and DHA enhanced the binding of CHOP to the promotor region of SESN2, increasing SESN2 expression.	Oxaliplatin	29-40	sestrin 2	Homo sapiens	104-109
31054938-11	2019	These data suggest that miR-30b contributes to oxaliplatin-induced chronic neuropathic pain through Nav1.6 downregulation and could be a novel therapeutic target for the treatment of oxaliplatin-induced neuropathic pain as a side effect of chemotherapy in cancer patients.	Oxaliplatin	47-58	sodium voltage-gated channel alpha subunit 8	Homo sapiens	100-106
31337142-6	2019	Additionally, treatment with Oxaliplatin and DHA enhanced the binding of CHOP to the promotor region of SESN2, increasing SESN2 expression.	Oxaliplatin	29-40	sestrin 2	Homo sapiens	122-127
31337142-7	2019	These results suggested that DHA enhanced Oxaliplatin-induced reduction in cell viability and increase in autophagy via activating SESN2 and increasing ER stress.	Oxaliplatin	42-53	sestrin 2	Homo sapiens	131-136
31054938-11	2019	These data suggest that miR-30b contributes to oxaliplatin-induced chronic neuropathic pain through Nav1.6 downregulation and could be a novel therapeutic target for the treatment of oxaliplatin-induced neuropathic pain as a side effect of chemotherapy in cancer patients.	Oxaliplatin	183-194	microRNA 30b	Homo sapiens	24-31
31054938-11	2019	These data suggest that miR-30b contributes to oxaliplatin-induced chronic neuropathic pain through Nav1.6 downregulation and could be a novel therapeutic target for the treatment of oxaliplatin-induced neuropathic pain as a side effect of chemotherapy in cancer patients.	Oxaliplatin	183-194	sodium voltage-gated channel alpha subunit 8	Homo sapiens	100-106
31102316-4	2019	Depletion of HAS2 in HCT116 and DLD1 cells, which express high levels of HAS2, critically increased sensitivity of radiation/oxaliplatin-mediated apoptotic cell death.	Oxaliplatin	125-136	hyaluronan synthase 2	Homo sapiens	13-17
31380428-8	2019	TF expression and MMP-9/2 activity in sciatic nerve and blood are significantly increased by L-OHP.	Oxaliplatin	93-98	coagulation factor III	Mus musculus	0-2
31380428-8	2019	TF expression and MMP-9/2 activity in sciatic nerve and blood are significantly increased by L-OHP.	Oxaliplatin	93-98	matrix metallopeptidase 9	Mus musculus	18-25
31380428-9	2019	L-OHP increased the release of HSP70 from macrophage and enhanced the expression of p-p38 and HIF-1alpha in vivo and in vitro.	Oxaliplatin	0-5	mitogen-activated protein kinase 14	Mus musculus	86-89
31380428-9	2019	L-OHP increased the release of HSP70 from macrophage and enhanced the expression of p-p38 and HIF-1alpha in vivo and in vitro.	Oxaliplatin	0-5	hypoxia inducible factor 1, alpha subunit	Mus musculus	94-104
31380428-10	2019	Hirudin significantly suppressed the overexpression of p38, HIF-1alpha and activation of MMP-9/2 induced by L-OHP and attenuated CIPN in mice.	Oxaliplatin	108-113	mitogen-activated protein kinase 14	Mus musculus	55-58
31380428-10	2019	Hirudin significantly suppressed the overexpression of p38, HIF-1alpha and activation of MMP-9/2 induced by L-OHP and attenuated CIPN in mice.	Oxaliplatin	108-113	matrix metallopeptidase 9	Mus musculus	89-96
30797942-5	2019	Non-transplantation-related chemotherapies associated with increased risk for VOD/SOS include oxaliplatin and 5-fluorouracil chemotherapies.	Oxaliplatin	94-105	xylosyltransferase 2	Homo sapiens	82-85
31219617-1	2019	The protein binding rates (PBR) of platinum-containing agents cisplatin (CDDP), carboplatin (CBDCA) and oxaliplatin (L-OHP) have been reported as 98%, 25-50% and 98%, respectively.	Oxaliplatin	104-115	translocator protein	Rattus norvegicus	27-30
31219617-1	2019	The protein binding rates (PBR) of platinum-containing agents cisplatin (CDDP), carboplatin (CBDCA) and oxaliplatin (L-OHP) have been reported as 98%, 25-50% and 98%, respectively.	Oxaliplatin	117-122	translocator protein	Rattus norvegicus	27-30
31219617-4	2019	The ratios of PBR to irreversible PBR, of cisplatin and oxaliplatin were 98%:98% and 90%:87%, respectively, indicating a higher affinity for irreversible binding with albumin.	Oxaliplatin	56-67	translocator protein	Rattus norvegicus	34-37
30698845-6	2019	Besides, multivariate linear regression analyses revealed that miR-126[beta = 0.61; 95% confidence interval (0.32-0.90)] and miR-155 [beta = 0.45; 95% confidence interval (0.13-0.84)] expression levels were significantly associated with urinary 1-OHP concentrations after being adjusted by traditional risk factors (P &lt; 0.05).	Oxaliplatin	245-250	microRNA 126	Homo sapiens	63-70
30698845-6	2019	Besides, multivariate linear regression analyses revealed that miR-126[beta = 0.61; 95% confidence interval (0.32-0.90)] and miR-155 [beta = 0.45; 95% confidence interval (0.13-0.84)] expression levels were significantly associated with urinary 1-OHP concentrations after being adjusted by traditional risk factors (P &lt; 0.05).	Oxaliplatin	245-250	microRNA 155	Homo sapiens	125-132
31258699-0	2019	Reversal effect of ginsenoside Rh2 on oxaliplatin-resistant colon cancer cells and its mechanism.	Oxaliplatin	38-49	Rh associated glycoprotein	Homo sapiens	31-34
31258699-3	2019	The present study examined the effect of G-Rh2 on oxaliplatin (L-OHP)-resistant colon cancer cells and its potential mechanism.	Oxaliplatin	50-61	Rh associated glycoprotein	Homo sapiens	43-46
31258699-3	2019	The present study examined the effect of G-Rh2 on oxaliplatin (L-OHP)-resistant colon cancer cells and its potential mechanism.	Oxaliplatin	63-68	Rh associated glycoprotein	Homo sapiens	43-46
31258699-13	2019	Treatment with G-Rh2 + L-OHP significantly reduced the expression of P-gp and Bcl-2, and enhanced the expression levels of Smad4, Bax and caspase-3.	Oxaliplatin	23-28	Rh associated glycoprotein	Homo sapiens	17-20
31258699-13	2019	Treatment with G-Rh2 + L-OHP significantly reduced the expression of P-gp and Bcl-2, and enhanced the expression levels of Smad4, Bax and caspase-3.	Oxaliplatin	23-28	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
31258699-13	2019	Treatment with G-Rh2 + L-OHP significantly reduced the expression of P-gp and Bcl-2, and enhanced the expression levels of Smad4, Bax and caspase-3.	Oxaliplatin	23-28	BCL2 apoptosis regulator	Homo sapiens	78-83
31258699-13	2019	Treatment with G-Rh2 + L-OHP significantly reduced the expression of P-gp and Bcl-2, and enhanced the expression levels of Smad4, Bax and caspase-3.	Oxaliplatin	23-28	SMAD family member 4	Homo sapiens	123-128
31258699-13	2019	Treatment with G-Rh2 + L-OHP significantly reduced the expression of P-gp and Bcl-2, and enhanced the expression levels of Smad4, Bax and caspase-3.	Oxaliplatin	23-28	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
31258699-13	2019	Treatment with G-Rh2 + L-OHP significantly reduced the expression of P-gp and Bcl-2, and enhanced the expression levels of Smad4, Bax and caspase-3.	Oxaliplatin	23-28	caspase 3	Homo sapiens	138-147
31258699-14	2019	These findings demonstrated that G-Rh2 reversed the drug resistance of LoVo/L-OHP cells to L-OHP, and this may be mediated by inhibiting cell proliferation and promoting apoptosis and regulating the expression of drug resistance genes.	Oxaliplatin	76-81	Rh associated glycoprotein	Homo sapiens	35-38
31325295-9	2019	Carriers of the variant allele (Gln) of XRCC1 had the highest levels of 1-OHP, DNA adducts and 8-OHdG, and the lowest level of CYP2E1 gene expression.	Oxaliplatin	72-77	X-ray repair cross complementing 1	Homo sapiens	40-45
31250351-0	2019	CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma.	Oxaliplatin	82-93	cellular communication network factor 2	Homo sapiens	0-4
31250351-0	2019	CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma.	Oxaliplatin	82-93	inhibitor of DNA binding 1, HLH protein	Homo sapiens	10-14
31250351-6	2019	Finally, the role of downstream signaling of MAPK/Id-1 signaling pathway in oxaliplatin resistance were also explored.	Oxaliplatin	76-87	inhibitor of DNA binding 1, HLH protein	Homo sapiens	50-54
31250351-7	2019	RESULTS: The increased expression of Id-1 and CCN2 were closely related to oxaliplatin resistance in HCC.	Oxaliplatin	75-86	inhibitor of DNA binding 1, HLH protein	Homo sapiens	37-41
31250351-7	2019	RESULTS: The increased expression of Id-1 and CCN2 were closely related to oxaliplatin resistance in HCC.	Oxaliplatin	75-86	cellular communication network factor 2	Homo sapiens	46-50
31250351-8	2019	Upregulation of CCN2 and Id-1 was independently associated with shorter survival and increased recurrence in HCC patients, and significantly enhanced oxaliplatin resistance and promoted lung metastasis in vivo, whereas knock-down of their expression significantly reversed the chemo-resistance and inhibited HCC cell stemness.	Oxaliplatin	150-161	cellular communication network factor 2	Homo sapiens	16-20
31250351-10	2019	CCN2 significantly enhanced oxaliplatin resistance by activating the MAPK/Id-1 signaling pathway, and Id-1 could upregulate CCN2 in a positive feedback manner.	Oxaliplatin	28-39	cellular communication network factor 2	Homo sapiens	0-4
31250351-11	2019	CONCLUSIONS: CCN2/MAPK/Id-1 loop feedback amplification is involved in oxaliplatin resistance, and the combination of oxaliplatin with inhibitor of CCN2 or MAPK signaling could provide a promising approach to ameliorating oxaliplatin resistance in HCC.	Oxaliplatin	71-82	cellular communication network factor 2	Homo sapiens	13-17
31250351-11	2019	CONCLUSIONS: CCN2/MAPK/Id-1 loop feedback amplification is involved in oxaliplatin resistance, and the combination of oxaliplatin with inhibitor of CCN2 or MAPK signaling could provide a promising approach to ameliorating oxaliplatin resistance in HCC.	Oxaliplatin	71-82	inhibitor of DNA binding 1, HLH protein	Homo sapiens	23-27
31250351-11	2019	CONCLUSIONS: CCN2/MAPK/Id-1 loop feedback amplification is involved in oxaliplatin resistance, and the combination of oxaliplatin with inhibitor of CCN2 or MAPK signaling could provide a promising approach to ameliorating oxaliplatin resistance in HCC.	Oxaliplatin	71-82	cellular communication network factor 2	Homo sapiens	148-152
31250351-11	2019	CONCLUSIONS: CCN2/MAPK/Id-1 loop feedback amplification is involved in oxaliplatin resistance, and the combination of oxaliplatin with inhibitor of CCN2 or MAPK signaling could provide a promising approach to ameliorating oxaliplatin resistance in HCC.	Oxaliplatin	118-129	inhibitor of DNA binding 1, HLH protein	Homo sapiens	23-27
31250351-11	2019	CONCLUSIONS: CCN2/MAPK/Id-1 loop feedback amplification is involved in oxaliplatin resistance, and the combination of oxaliplatin with inhibitor of CCN2 or MAPK signaling could provide a promising approach to ameliorating oxaliplatin resistance in HCC.	Oxaliplatin	118-129	cellular communication network factor 2	Homo sapiens	148-152
31250351-11	2019	CONCLUSIONS: CCN2/MAPK/Id-1 loop feedback amplification is involved in oxaliplatin resistance, and the combination of oxaliplatin with inhibitor of CCN2 or MAPK signaling could provide a promising approach to ameliorating oxaliplatin resistance in HCC.	Oxaliplatin	118-129	inhibitor of DNA binding 1, HLH protein	Homo sapiens	23-27
31250351-11	2019	CONCLUSIONS: CCN2/MAPK/Id-1 loop feedback amplification is involved in oxaliplatin resistance, and the combination of oxaliplatin with inhibitor of CCN2 or MAPK signaling could provide a promising approach to ameliorating oxaliplatin resistance in HCC.	Oxaliplatin	118-129	cellular communication network factor 2	Homo sapiens	148-152
31325295-11	2019	There was a significant negative correlation between 1-OHP level and CYP2E1 gene expression.	Oxaliplatin	53-58	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	69-75
31289684-10	2019	and oxaliplatin-resistant AGS cells compared with those in untreated cells included telomerase reverse transcriptase (TERT), apolipoprotein C1 (APOC1) and serine/threonine/tyrosine kinase 1 (STYK1), whereas genes commonly expressed at lower levels in the three drug-resistant cell types compared with the untreated cells included defensin beta4A (DEFB4A).	Oxaliplatin	4-15	telomerase reverse transcriptase	Homo sapiens	84-116
31064870-0	2019	The RNA-Binding Protein HuR Confers Oxaliplatin Resistance of Colorectal Cancer By Upregulating CDC6.	Oxaliplatin	36-47	ELAV like RNA binding protein 1	Homo sapiens	24-27
31064870-0	2019	The RNA-Binding Protein HuR Confers Oxaliplatin Resistance of Colorectal Cancer By Upregulating CDC6.	Oxaliplatin	36-47	cell division cycle 6	Homo sapiens	96-100
31064870-5	2019	HuR overexpression increased colorectal cancer cell proliferation in vitro and xenograft tumor growth in vivo, and induced resistance to L-OHP.	Oxaliplatin	137-142	ELAV like RNA binding protein 1	Homo sapiens	0-3
31064870-6	2019	In contrast, HuR knockdown sensitized colorectal cancer cells to L-OHP.	Oxaliplatin	65-70	ELAV like RNA binding protein 1	Homo sapiens	13-16
31064870-7	2019	CDC6 overexpression increased while CDC6 knockdown decreased colorectal cancer cell malignant behaviors (growth, DNA synthesis, EMT, migration, and invasion) and L-OHP resistance in vitro Moreover, L-OHP resistance induced by HuR overexpression was reversed by CDC6 knockdown.	Oxaliplatin	198-203	cell division cycle 6	Homo sapiens	0-4
31064870-7	2019	CDC6 overexpression increased while CDC6 knockdown decreased colorectal cancer cell malignant behaviors (growth, DNA synthesis, EMT, migration, and invasion) and L-OHP resistance in vitro Moreover, L-OHP resistance induced by HuR overexpression was reversed by CDC6 knockdown.	Oxaliplatin	198-203	cell division cycle 6	Homo sapiens	36-40
31064870-7	2019	CDC6 overexpression increased while CDC6 knockdown decreased colorectal cancer cell malignant behaviors (growth, DNA synthesis, EMT, migration, and invasion) and L-OHP resistance in vitro Moreover, L-OHP resistance induced by HuR overexpression was reversed by CDC6 knockdown.	Oxaliplatin	198-203	ELAV like RNA binding protein 1	Homo sapiens	226-229
31064870-7	2019	CDC6 overexpression increased while CDC6 knockdown decreased colorectal cancer cell malignant behaviors (growth, DNA synthesis, EMT, migration, and invasion) and L-OHP resistance in vitro Moreover, L-OHP resistance induced by HuR overexpression was reversed by CDC6 knockdown.	Oxaliplatin	198-203	cell division cycle 6	Homo sapiens	36-40
31289684-10	2019	and oxaliplatin-resistant AGS cells compared with those in untreated cells included telomerase reverse transcriptase (TERT), apolipoprotein C1 (APOC1) and serine/threonine/tyrosine kinase 1 (STYK1), whereas genes commonly expressed at lower levels in the three drug-resistant cell types compared with the untreated cells included defensin beta4A (DEFB4A).	Oxaliplatin	4-15	telomerase reverse transcriptase	Homo sapiens	118-122
31064870-9	2019	Taken together, our findings identified HuR"s regulation of CDC6 as an essential mechanism driving colorectal cancer tumorigenesis and L-OHP resistance, and this mechanism may represent a potential target for overcoming drug resistance in colorectal cancer.	Oxaliplatin	135-140	ELAV like RNA binding protein 1	Homo sapiens	40-43
31064870-9	2019	Taken together, our findings identified HuR"s regulation of CDC6 as an essential mechanism driving colorectal cancer tumorigenesis and L-OHP resistance, and this mechanism may represent a potential target for overcoming drug resistance in colorectal cancer.	Oxaliplatin	135-140	cell division cycle 6	Homo sapiens	60-64
31289684-10	2019	and oxaliplatin-resistant AGS cells compared with those in untreated cells included telomerase reverse transcriptase (TERT), apolipoprotein C1 (APOC1) and serine/threonine/tyrosine kinase 1 (STYK1), whereas genes commonly expressed at lower levels in the three drug-resistant cell types compared with the untreated cells included defensin beta4A (DEFB4A).	Oxaliplatin	4-15	apolipoprotein C1	Homo sapiens	125-142
31290727-1	2019	Aim: PD-L1 monoclonal antibody-conjugated miR-130a/oxaliplatin-loaded immunoliposomes were constructed for enhanced therapeutic efficacy against gastric cancer.	Oxaliplatin	51-62	CD274 molecule	Homo sapiens	5-10
31289684-10	2019	and oxaliplatin-resistant AGS cells compared with those in untreated cells included telomerase reverse transcriptase (TERT), apolipoprotein C1 (APOC1) and serine/threonine/tyrosine kinase 1 (STYK1), whereas genes commonly expressed at lower levels in the three drug-resistant cell types compared with the untreated cells included defensin beta4A (DEFB4A).	Oxaliplatin	4-15	serine/threonine/tyrosine kinase 1	Homo sapiens	191-196
31289684-10	2019	and oxaliplatin-resistant AGS cells compared with those in untreated cells included telomerase reverse transcriptase (TERT), apolipoprotein C1 (APOC1) and serine/threonine/tyrosine kinase 1 (STYK1), whereas genes commonly expressed at lower levels in the three drug-resistant cell types compared with the untreated cells included defensin beta4A (DEFB4A).	Oxaliplatin	4-15	defensin beta 4A	Homo sapiens	330-345
31289684-10	2019	and oxaliplatin-resistant AGS cells compared with those in untreated cells included telomerase reverse transcriptase (TERT), apolipoprotein C1 (APOC1) and serine/threonine/tyrosine kinase 1 (STYK1), whereas genes commonly expressed at lower levels in the three drug-resistant cell types compared with the untreated cells included defensin beta4A (DEFB4A).	Oxaliplatin	4-15	defensin beta 4A	Homo sapiens	347-353
31309123-12	2019	Platinum drugs cisplatin and oxaliplatin significantly inhibited phosphorylation of STAT6 during differentiation and maturation.	Oxaliplatin	29-40	signal transducer and activator of transcription 6	Homo sapiens	84-89
30927036-2	2019	However, as demonstrated in HER2-negative AGC, oxaliplatin-based regimens could improve tolerance remaining effective.	Oxaliplatin	47-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
31195721-6	2019	Additionally, phosphorylation of nitric oxide synthase 3 (NOS3) was increased in oxaliplatin-resistant cells compared to that in parent cells.	Oxaliplatin	81-92	nitric oxide synthase 3	Homo sapiens	33-56
31195721-6	2019	Additionally, phosphorylation of nitric oxide synthase 3 (NOS3) was increased in oxaliplatin-resistant cells compared to that in parent cells.	Oxaliplatin	81-92	nitric oxide synthase 3	Homo sapiens	58-62
31195721-7	2019	Combined treatment with oxaliplatin and CBD reduced phospho-NOS3 levels and nitric oxide (NO) production and resulted in the production of reactive oxygen species (ROS) by reducing the levels of superoxide dismutase 2, an antioxidant present in the mitochondria, causing mitochondrial dysfunction.	Oxaliplatin	24-35	nitric oxide synthase 3	Homo sapiens	60-64
31195721-8	2019	Taken together, these results suggest that elevated phosphorylation of NOS3 is essential for oxaliplatin resistance.	Oxaliplatin	93-104	nitric oxide synthase 3	Homo sapiens	71-75
31195721-9	2019	The combination of oxaliplatin and CBD decreased NOS3 phosphorylation, which resulted in autophagy, by inducing the overproduction of ROS through mitochondrial dysfunction, thus overcoming oxaliplatin resistance.	Oxaliplatin	19-30	nitric oxide synthase 3	Homo sapiens	49-53
31195721-9	2019	The combination of oxaliplatin and CBD decreased NOS3 phosphorylation, which resulted in autophagy, by inducing the overproduction of ROS through mitochondrial dysfunction, thus overcoming oxaliplatin resistance.	Oxaliplatin	189-200	nitric oxide synthase 3	Homo sapiens	49-53
30930425-0	2019	Ginsenoside Rg3 Combined with Oxaliplatin Inhibits the Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells via Downregulating PCNA and Cyclin D1.	Oxaliplatin	30-41	proliferating cell nuclear antigen	Homo sapiens	145-149
30930425-0	2019	Ginsenoside Rg3 Combined with Oxaliplatin Inhibits the Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells via Downregulating PCNA and Cyclin D1.	Oxaliplatin	30-41	cyclin D1	Homo sapiens	154-163
30930425-6	2019	Meanwhile, ginsenoside Rg3, oxaliplatin or ginsenoside Rg3 + oxaliplatin also significantly inhibited the expressions of PCNA and cyclin D1.	Oxaliplatin	28-39	proliferating cell nuclear antigen	Homo sapiens	121-125
30930425-6	2019	Meanwhile, ginsenoside Rg3, oxaliplatin or ginsenoside Rg3 + oxaliplatin also significantly inhibited the expressions of PCNA and cyclin D1.	Oxaliplatin	28-39	cyclin D1	Homo sapiens	130-139
30930425-6	2019	Meanwhile, ginsenoside Rg3, oxaliplatin or ginsenoside Rg3 + oxaliplatin also significantly inhibited the expressions of PCNA and cyclin D1.	Oxaliplatin	61-72	proliferating cell nuclear antigen	Homo sapiens	121-125
30930425-6	2019	Meanwhile, ginsenoside Rg3, oxaliplatin or ginsenoside Rg3 + oxaliplatin also significantly inhibited the expressions of PCNA and cyclin D1.	Oxaliplatin	61-72	cyclin D1	Homo sapiens	130-139
30930425-8	2019	Taken together, cells treated with oxaliplatin+ ginsenoside enhanced the anti-tumor effect and may inhibit the proliferation and promoted apoptosis of hepatocellular carcinoma via regulating the expression of PCNA and cyclin D1.	Oxaliplatin	35-46	proliferating cell nuclear antigen	Homo sapiens	209-213
30930425-8	2019	Taken together, cells treated with oxaliplatin+ ginsenoside enhanced the anti-tumor effect and may inhibit the proliferation and promoted apoptosis of hepatocellular carcinoma via regulating the expression of PCNA and cyclin D1.	Oxaliplatin	35-46	cyclin D1	Homo sapiens	218-227
30927036-3	2019	The aim of this trial was to explore the potential activity and safety of capecitabine, oxaliplatin (XELOX) and trastuzumab in patients with HER-2 positive advanced gastric cancer.	Oxaliplatin	88-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-146
30807913-6	2019	OGG1 methylation was not only positively correlated with urinary 1-OHP in a dose-responsive manner (P trend = 0.008) but was also associated with G0/G1 phase arrest (OR: 0.63, 95% CI: 0.41-0.97), S phase arrest (OR: 1.55, 95% CI: 1.01-2.40) and oxidative DNA damage (OR: 1.71, 95% CI: 1.02-2.86).	Oxaliplatin	65-70	8-oxoguanine DNA glycosylase	Homo sapiens	0-4
30987998-0	2019	Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.	Oxaliplatin	77-88	ATM serine/threonine kinase	Homo sapiens	14-60
30987998-0	2019	Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.	Oxaliplatin	77-88	ATR serine/threonine kinase	Homo sapiens	62-65
30987998-3	2019	We found that silencing of ataxia-telangiectasia mutated and RAD3-related (ATR), a serine/threonine protein kinase involved in the response to DNA stress, restored oxaliplatin sensitivity in a cellular model of oxaliplatin resistance.	Oxaliplatin	164-175	ATR serine/threonine kinase	Homo sapiens	27-79
30807913-7	2019	Mediation analysis estimated that OGG1 methylation mediated about 20% of associations between urinary 1-OHP levels and cell cycle arrest and oxidative DNA damage, respectively (all P &lt; 0.05).	Oxaliplatin	102-107	8-oxoguanine DNA glycosylase	Homo sapiens	34-38
30987998-3	2019	We found that silencing of ataxia-telangiectasia mutated and RAD3-related (ATR), a serine/threonine protein kinase involved in the response to DNA stress, restored oxaliplatin sensitivity in a cellular model of oxaliplatin resistance.	Oxaliplatin	211-222	ATR serine/threonine kinase	Homo sapiens	27-79
30987998-4	2019	Combined application of the ATR inhibitor VE-822 and oxaliplatin resulted in strong synergistic effects in six different colorectal cancer cell lines and their oxaliplatin-resistant subclones, promoted DNA single- and double-strand break formation, growth arrest, and apoptosis.	Oxaliplatin	53-64	ATR serine/threonine kinase	Homo sapiens	28-31
30807913-8	2019	Our findings suggested that urinary 1-OHP concentrations were associated with cell cycle arrest and oxidative DNA damage by a mechanism partly involving OGG1 methylation.	Oxaliplatin	36-41	8-oxoguanine DNA glycosylase	Homo sapiens	153-157
30987998-4	2019	Combined application of the ATR inhibitor VE-822 and oxaliplatin resulted in strong synergistic effects in six different colorectal cancer cell lines and their oxaliplatin-resistant subclones, promoted DNA single- and double-strand break formation, growth arrest, and apoptosis.	Oxaliplatin	160-171	ATR serine/threonine kinase	Homo sapiens	28-31
31078520-8	2019	In vitro, Gain- and lose-of-function assays showed miR-567 not only weakened cells proliferative ability, but also sensitized GC cells to 5-FU and oxaliplatin.	Oxaliplatin	147-158	microRNA 567	Homo sapiens	51-58
30987998-9	2019	SIGNIFICANCE: These findings demonstrate that resistance to oxaliplatin in colorectal cancer cells can be overcome with inhibitors of ATR and that combined treatment with both agents exerts synergistic antitumor effects.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/11/2933/F1.large.jpg.	Oxaliplatin	60-71	ATR serine/threonine kinase	Homo sapiens	134-137
31190888-0	2019	Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-beta/Smad2/3 signaling pathway.	Oxaliplatin	18-29	SMAD family member 2	Homo sapiens	95-100
30942432-5	2019	OXA also induced the upregulation of hepatic inflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and interleukin (IL)-17, in NAFLD mice.	Oxaliplatin	0-3	tumor necrosis factor	Mus musculus	77-110
30942432-5	2019	OXA also induced the upregulation of hepatic inflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and interleukin (IL)-17, in NAFLD mice.	Oxaliplatin	0-3	interferon gamma	Mus musculus	112-134
30942432-5	2019	OXA also induced the upregulation of hepatic inflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and interleukin (IL)-17, in NAFLD mice.	Oxaliplatin	0-3	interleukin 17A	Mus musculus	139-158
30942432-6	2019	Furthermore, collagen fiber deposition in liver tissues was increased and the expression of transforming growth factor (TGF)-beta, alpha-smooth muscle actin (SMA) and tissue inhibitor of metallopeptidase (TIMP)-1 was upregulated in the livers of OXA-treated NAFLD mice.	Oxaliplatin	246-249	immunoglobulin mu binding protein 2	Mus musculus	131-156
30942432-6	2019	Furthermore, collagen fiber deposition in liver tissues was increased and the expression of transforming growth factor (TGF)-beta, alpha-smooth muscle actin (SMA) and tissue inhibitor of metallopeptidase (TIMP)-1 was upregulated in the livers of OXA-treated NAFLD mice.	Oxaliplatin	246-249	immunoglobulin mu binding protein 2	Mus musculus	158-161
30942432-6	2019	Furthermore, collagen fiber deposition in liver tissues was increased and the expression of transforming growth factor (TGF)-beta, alpha-smooth muscle actin (SMA) and tissue inhibitor of metallopeptidase (TIMP)-1 was upregulated in the livers of OXA-treated NAFLD mice.	Oxaliplatin	246-249	tissue inhibitor of metalloproteinase 1	Mus musculus	167-203
30942432-6	2019	Furthermore, collagen fiber deposition in liver tissues was increased and the expression of transforming growth factor (TGF)-beta, alpha-smooth muscle actin (SMA) and tissue inhibitor of metallopeptidase (TIMP)-1 was upregulated in the livers of OXA-treated NAFLD mice.	Oxaliplatin	246-249	tissue inhibitor of metalloproteinase 1	Mus musculus	205-209
30942432-8	2019	However, GSH treatment did not inhibit collagen fiber deposition, although it reduced the levels of IFN-gamma, IL-17, TGF-beta, alpha-SMA and TIMP-1 in the livers of OXA-treated NAFLD mice.	Oxaliplatin	166-169	transforming growth factor, beta 1	Mus musculus	118-126
30942432-8	2019	However, GSH treatment did not inhibit collagen fiber deposition, although it reduced the levels of IFN-gamma, IL-17, TGF-beta, alpha-SMA and TIMP-1 in the livers of OXA-treated NAFLD mice.	Oxaliplatin	166-169	tissue inhibitor of metalloproteinase 1	Mus musculus	142-148
30640294-0	2019	Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance.	Oxaliplatin	94-105	X inactive specific transcript	Homo sapiens	19-49
30640294-5	2019	XIST knockdown inhibited proliferation and migration in MM cells and increased the oxaliplatin sensitivity of oxaliplatin-resistant MM cells.	Oxaliplatin	83-94	X inactive specific transcript	Homo sapiens	0-4
30640294-5	2019	XIST knockdown inhibited proliferation and migration in MM cells and increased the oxaliplatin sensitivity of oxaliplatin-resistant MM cells.	Oxaliplatin	110-121	X inactive specific transcript	Homo sapiens	0-4
30640294-8	2019	In short, the current study showed that XIST was a crucial regulator in progression and oxaliplatin resistance of MM, providing a novel insight into the pathogenesis and underlying therapeutic target for MM.	Oxaliplatin	88-99	X inactive specific transcript	Homo sapiens	40-44
31213923-0	2019	Connexin 32 downregulation is critical for chemoresistance in oxaliplatin-resistant HCC cells associated with EMT.	Oxaliplatin	62-73	gap junction protein beta 1	Homo sapiens	0-11
31116985-6	2019	In a human CD39 knockin mouse preclinical model, IPH5201 increased the anti-tumor activity of the ATP-inducing chemotherapeutic drug oxaliplatin.	Oxaliplatin	133-144	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	11-15
30951957-12	2019	The changes in 8-OHdG, Foxp3 and TGF-beta were significantly associated with the increase of 1-OHP.	Oxaliplatin	93-98	forkhead box P3	Homo sapiens	23-28
30951957-12	2019	The changes in 8-OHdG, Foxp3 and TGF-beta were significantly associated with the increase of 1-OHP.	Oxaliplatin	93-98	transforming growth factor alpha	Homo sapiens	33-41
30792218-8	2019	Moreover, knockdown of LGR5 resensitizes DAP3-depleted gastric cancer cells to 5-fluorouracil (5-FU) and oxaliplatin.	Oxaliplatin	105-116	leucine rich repeat containing G protein-coupled receptor 5	Homo sapiens	23-27
30792218-8	2019	Moreover, knockdown of LGR5 resensitizes DAP3-depleted gastric cancer cells to 5-fluorouracil (5-FU) and oxaliplatin.	Oxaliplatin	105-116	death associated protein 3	Homo sapiens	41-45
30792218-9	2019	We also observed that ectopic expression of LGR5 reduces apoptosis in gastric cancer cells on treatment with 5-FU and oxaliplatin, which is accompanied by prevention of caspase-3 cleavage.	Oxaliplatin	118-129	leucine rich repeat containing G protein-coupled receptor 5	Homo sapiens	44-48
31441696-8	2019	Results: Oxaliplatin induced robust ICD in LLC cells, activated dendritic cells (DCs, CD80+CD86+) and enhanced cytotoxic T cells (CD8+) in LLC tumor tissues, which resulted in tumor regression.	Oxaliplatin	9-20	CD80 antigen	Mus musculus	86-90
31441696-8	2019	Results: Oxaliplatin induced robust ICD in LLC cells, activated dendritic cells (DCs, CD80+CD86+) and enhanced cytotoxic T cells (CD8+) in LLC tumor tissues, which resulted in tumor regression.	Oxaliplatin	9-20	CD86 antigen	Mus musculus	91-95
30596962-5	2019	We further confirmed that co-treatment with OPCs sensitized the chemoresistant cells to 5FU and oxaliplatin, as observed by improvement in cell cycle arrest, double-strand breaks and p53 accumulation in these cells.	Oxaliplatin	96-107	tumor protein p53	Homo sapiens	183-186
31002510-5	2019	Compound 14 arrested the cell cycle at S and G2 phases and up-regulated thymidylate synthase and p53, consistent with the results of the combination, suggesting 14 adopted a collaborative mode of 5-FU and oxaliplatin to kill cancer cells.	Oxaliplatin	205-216	tumor protein p53	Homo sapiens	97-100
31088567-0	2019	Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.	Oxaliplatin	70-81	eukaryotic translation initiation factor 4A2	Homo sapiens	0-32
31088567-6	2019	In vitro and in vivo cell-biological assays were performed to study the biological functions of EIF4A2 on experimental metastasis and sensitivity to oxaliplatin treatment.	Oxaliplatin	149-160	eukaryotic translation initiation factor 4A2	Homo sapiens	96-102
31088567-10	2019	Dysfunction of EIF4A2 by genetic knock-down or small-molecule inhibitor silvestrol dramatically inhibited CRC invasion and migration, sphere formation and enhanced sensitivity to oxaliplatin treatment in vitro and in vivo.	Oxaliplatin	179-190	eukaryotic translation initiation factor 4A2	Homo sapiens	15-21
31088567-14	2019	CONCLUSIONS: EIF4A2 promotes experimental metastasis and oxaliplatin resistance in CRC.	Oxaliplatin	57-68	eukaryotic translation initiation factor 4A2	Homo sapiens	13-19
30486697-7	2019	Besides, we found a significant association (p &lt; 0.01) between miR-126 and miR-155 expression levels and CIES and urinary 1-OHP concentrations.	Oxaliplatin	125-130	microRNA 126	Homo sapiens	66-73
31002492-4	2019	In this work, we designed a nanocarrier (PEG-Por-CD: oxliPt(IV)-ada) assembled with oxaliplatin prodrug (oxliPt(IV)-ada) and porphyrin photosensitizer (PEG-Por-CD) through host-guest interaction to achieve stimulus-responsive combination therapy.	Oxaliplatin	84-95	cytochrome p450 oxidoreductase	Mus musculus	45-48
31002492-4	2019	In this work, we designed a nanocarrier (PEG-Por-CD: oxliPt(IV)-ada) assembled with oxaliplatin prodrug (oxliPt(IV)-ada) and porphyrin photosensitizer (PEG-Por-CD) through host-guest interaction to achieve stimulus-responsive combination therapy.	Oxaliplatin	84-95	cytochrome p450 oxidoreductase	Mus musculus	156-159
30898612-6	2019	Interestingly, co-treatment with nutlin-3a and certain chemotherapeutic drug such as irinotecan and oxaliplatin resulted in antagonistic effects in cells both lacking and containing WT-TP53 activity.	Oxaliplatin	100-111	tumor protein p53	Homo sapiens	185-189
31060282-3	2019	Here, we report that alphaO-conotoxin GeXIVA[1,2], a highly potent and selective antagonist of the alpha9alpha10 nicotinic acetylcholine receptor (nAChR) subtype, can relieve and reverse oxaliplatin-induced mechanical and cold allodynia after single and repeated intramuscular (IM) injections in rats.	Oxaliplatin	187-198	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	147-152
30486697-7	2019	Besides, we found a significant association (p &lt; 0.01) between miR-126 and miR-155 expression levels and CIES and urinary 1-OHP concentrations.	Oxaliplatin	125-130	microRNA 155	Homo sapiens	78-85
30724469-7	2019	In pancreatic cancer cells, SRPK2 downregulation or overexpression led to modulation of Numb and wild-type p53 protein expression in response to oxaliplatin treatment.	Oxaliplatin	145-156	SRSF protein kinase 2	Homo sapiens	28-33
30724469-7	2019	In pancreatic cancer cells, SRPK2 downregulation or overexpression led to modulation of Numb and wild-type p53 protein expression in response to oxaliplatin treatment.	Oxaliplatin	145-156	NUMB endocytic adaptor protein	Homo sapiens	88-92
30724469-7	2019	In pancreatic cancer cells, SRPK2 downregulation or overexpression led to modulation of Numb and wild-type p53 protein expression in response to oxaliplatin treatment.	Oxaliplatin	145-156	tumor protein p53	Homo sapiens	107-110
30724469-10	2019	SRPK2 overexpression promoted cell invasion and migration, and decreased chemosensitivity of cancer cells to gemcitabine or oxaliplatin treatment.	Oxaliplatin	124-135	SRSF protein kinase 2	Homo sapiens	0-5
30724469-11	2019	Conversely, SRPK2 silencing decreased cell invasion and migration and increased chemosensitivity; these effects were reversed by silencing p53 in oxaliplatin-treated pancreatic cancer cells.	Oxaliplatin	146-157	SRSF protein kinase 2	Homo sapiens	12-17
30724469-11	2019	Conversely, SRPK2 silencing decreased cell invasion and migration and increased chemosensitivity; these effects were reversed by silencing p53 in oxaliplatin-treated pancreatic cancer cells.	Oxaliplatin	146-157	tumor protein p53	Homo sapiens	139-142
30926638-7	2019	Knockdown of Rac1b or Rac inhibition increases the sensitivity of the cells to oxaliplatin.	Oxaliplatin	79-90	AKT serine/threonine kinase 1	Homo sapiens	13-16
30947381-4	2019	Intriguingly, depletion of PTPRK significantly reduced sensitivity to the anti-cancer drug oxaliplatin and was accompanied by up-regulation of phosphorylation of Bad, a downstream target of AKT.	Oxaliplatin	91-102	protein tyrosine phosphatase receptor type K	Homo sapiens	27-32
30926638-8	2019	When used in combination, inhibition of Rac prevents the increase in NF-kappaB activity associated with chemotherapy treatment and increases the sensitivity of the cells to oxaliplatin.	Oxaliplatin	173-184	AKT serine/threonine kinase 1	Homo sapiens	40-43
31105879-3	2019	Acute and chronic exposition of colon cancer cell lines to CT/CTE PEDF-derived peptides decreased drug-resistance to conventional colorectal cancer treatments, such as oxaliplatin or irinotecan.	Oxaliplatin	168-179	serpin family F member 1	Homo sapiens	66-70
30724953-0	2019	Computational insight into the interaction of oxaliplatin with insulin.	Oxaliplatin	46-57	insulin	Homo sapiens	63-70
31413915-2	2019	Thus, certain classes of cytotoxic compounds, for example, anthracyclines, oxaliplatin and taxanes are endowed with the capacity to act on cancer cells to ignite premortem stress pathways that lead to the surface exposure of calreticulin (CALR) and the cellular release of adenosine triphosphate, annexin A1, high mobility group B1 and type-1 interferons.	Oxaliplatin	75-86	calreticulin	Homo sapiens	225-237
31413915-2	2019	Thus, certain classes of cytotoxic compounds, for example, anthracyclines, oxaliplatin and taxanes are endowed with the capacity to act on cancer cells to ignite premortem stress pathways that lead to the surface exposure of calreticulin (CALR) and the cellular release of adenosine triphosphate, annexin A1, high mobility group B1 and type-1 interferons.	Oxaliplatin	75-86	calreticulin	Homo sapiens	239-243
30724953-4	2019	However, despite the interest in understanding the nature of the oxaliplatin-insulin adducts, no 3D models have been achieved so far.	Oxaliplatin	65-76	insulin	Homo sapiens	77-84
30879295-4	2019	The complex ( OC-6-44)-acetatodichlorido(cyclohexane-1 R,2 R-diamine)( rac-2-(2-propynyl)octanoato)platinum(IV) showed higher tumor mass Pt accumulation than oxaliplatin, due to its higher lipophilicity, with negligible nephro- and hepatotoxicities when administered intravenously.	Oxaliplatin	158-169	Rac family small GTPase 2	Mus musculus	71-76
30965636-3	2019	We showed the expression levels of both beta-catenin and RAS were significantly increased and correlated in tissues of 756 gastric cancer (GC) patients and tissues of primary- and acquired-resistance patient-derived xenograft tumors treated with 5-fluorouracil and oxaliplatin modulated with leucovorin (FOLFOX).	Oxaliplatin	265-276	catenin beta 1	Homo sapiens	40-52
31040703-0	2019	lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway.	Oxaliplatin	48-59	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	7-15
31040703-0	2019	lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway.	Oxaliplatin	48-59	microRNA 34a	Homo sapiens	93-100
31040703-0	2019	lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway.	Oxaliplatin	48-59	autophagy related 4B cysteine peptidase	Homo sapiens	101-106
31040703-10	2019	Using colon cancer cell lines HCT116 and SW480, it was demonstrated that knockdown of KCNQ1OT1 decreased the cell viability and increased the apoptosis rates upon L-OHP treatment.	Oxaliplatin	163-168	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	86-94
30282452-10	2019	CONCLUSION: This study shows that high TS expression is a predictive factor for worse outcomes on capecitabine plus oxaliplatin adjuvant chemotherapy, whereas PD-L1 expression is a favorable prognostic factor in locally advanced gastric cancer patients.	Oxaliplatin	116-127	thymidylate synthetase	Homo sapiens	39-41
30894685-0	2019	p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	142-153	tumor protein p53	Homo sapiens	0-3
31040701-0	2019	SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway.	Oxaliplatin	18-29	SET and MYND domain containing 2	Homo sapiens	0-5
31040701-0	2019	SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway.	Oxaliplatin	18-29	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
31040701-0	2019	SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway.	Oxaliplatin	18-29	ATP binding cassette subfamily B member 1	Homo sapiens	70-84
31040701-0	2019	SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway.	Oxaliplatin	18-29	mitogen-activated protein kinase kinase 7	Homo sapiens	89-92
31040701-0	2019	SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway.	Oxaliplatin	18-29	mitogen-activated protein kinase 1	Homo sapiens	93-96
31040701-0	2019	SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway.	Oxaliplatin	18-29	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	97-100
31040701-5	2019	In this study, we investigated the relationship of SMYD2-OE expression and L-OHP resistance in colon cancer and further explored the underlying mechanism linking SMYD2-OE, L-OHP resistance, and colon cancer.	Oxaliplatin	75-80	SET and MYND domain containing 2	Homo sapiens	51-56
31040701-7	2019	In vitro and in vivo assays were conducted to explore the function and mechanism of SMYD2-OE in colon cancer sensitivity to L-OHP.	Oxaliplatin	124-129	SET and MYND domain containing 2	Homo sapiens	84-89
31040701-8	2019	Results: SMYD2-OE was overexpressed in colon cancer tissues compared with non-neoplastic tissues and associated with poor prognosis of patients with colon cancer after L-OHP-based chemotherapy.	Oxaliplatin	168-173	SET and MYND domain containing 2	Homo sapiens	9-14
31040701-9	2019	Knockdown of SMYD2-OE increased colon cancer sensitivity to L-OHP in vitro and in vivo.	Oxaliplatin	60-65	SET and MYND domain containing 2	Homo sapiens	13-18
31040701-12	2019	Conclusion: These results imply that SMYD2-OE promotes L-OHP resistance in colon cancer by regulating MDR1/P-glycoprotein through MEK/ERK/AP-1 signaling pathway, providing a potential strategy to sensitize chemotherapy by SMYD2-OE knockdown in colon cancer treatment.	Oxaliplatin	55-60	SET and MYND domain containing 2	Homo sapiens	37-42
31040701-12	2019	Conclusion: These results imply that SMYD2-OE promotes L-OHP resistance in colon cancer by regulating MDR1/P-glycoprotein through MEK/ERK/AP-1 signaling pathway, providing a potential strategy to sensitize chemotherapy by SMYD2-OE knockdown in colon cancer treatment.	Oxaliplatin	55-60	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
31040701-12	2019	Conclusion: These results imply that SMYD2-OE promotes L-OHP resistance in colon cancer by regulating MDR1/P-glycoprotein through MEK/ERK/AP-1 signaling pathway, providing a potential strategy to sensitize chemotherapy by SMYD2-OE knockdown in colon cancer treatment.	Oxaliplatin	55-60	ATP binding cassette subfamily B member 1	Homo sapiens	107-121
31040701-12	2019	Conclusion: These results imply that SMYD2-OE promotes L-OHP resistance in colon cancer by regulating MDR1/P-glycoprotein through MEK/ERK/AP-1 signaling pathway, providing a potential strategy to sensitize chemotherapy by SMYD2-OE knockdown in colon cancer treatment.	Oxaliplatin	55-60	mitogen-activated protein kinase kinase 7	Homo sapiens	130-133
31040701-12	2019	Conclusion: These results imply that SMYD2-OE promotes L-OHP resistance in colon cancer by regulating MDR1/P-glycoprotein through MEK/ERK/AP-1 signaling pathway, providing a potential strategy to sensitize chemotherapy by SMYD2-OE knockdown in colon cancer treatment.	Oxaliplatin	55-60	mitogen-activated protein kinase 1	Homo sapiens	134-137
31040701-12	2019	Conclusion: These results imply that SMYD2-OE promotes L-OHP resistance in colon cancer by regulating MDR1/P-glycoprotein through MEK/ERK/AP-1 signaling pathway, providing a potential strategy to sensitize chemotherapy by SMYD2-OE knockdown in colon cancer treatment.	Oxaliplatin	55-60	SET and MYND domain containing 2	Homo sapiens	222-227
30987009-5	2019	Intriguingly, 25 muM luteolin reduced cell viability through apoptotic induction, which was intensified in p53-expressing cells while 1 muM oxaliplatin caused cell cycle arrest at G0/G1-phase via the p53/p21-dependent mechanism.	Oxaliplatin	140-151	tumor protein p53	Homo sapiens	200-203
30987009-5	2019	Intriguingly, 25 muM luteolin reduced cell viability through apoptotic induction, which was intensified in p53-expressing cells while 1 muM oxaliplatin caused cell cycle arrest at G0/G1-phase via the p53/p21-dependent mechanism.	Oxaliplatin	140-151	H3 histone pseudogene 16	Homo sapiens	204-207
30987009-6	2019	Moreover, luteolin treatment was found to reduce oxaliplatin-treated p53-null cell viability and colony counts further, thereby demonstrating an additional effect of luteolin in the killing of human colorectal tumor HCT116 cells not expressing functional p53 protein.	Oxaliplatin	49-60	tumor protein p53	Homo sapiens	69-72
30987009-7	2019	The findings suggest that luteolin can induce p53-mediated apoptosis regardless of oxaliplatin treatment and may eliminate oxaliplatin-resistant p53-null colorectal cells.	Oxaliplatin	123-134	tumor protein p53	Homo sapiens	145-148
30690837-8	2019	Furthermore, knockdown of LUCAT1 rendered CRC cells hypersensitive to oxaliplatin treatment.	Oxaliplatin	70-81	lung cancer associated transcript 1	Homo sapiens	26-32
30936724-0	2019	Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer.	Oxaliplatin	73-84	non-homologous end joining factor 1	Homo sapiens	37-40
30787174-0	2019	Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer.	Oxaliplatin	44-55	BCL2 like 11	Homo sapiens	72-75
30787174-5	2019	Our study showed that a combination of genipin and oxaliplatin exerts synergistic antitumor effects in vitro and in vivo in colorectal cancer cell lines through the reactive oxygen species (ROS)/endoplasmic reticulum (ER) stress/BIM pathway.	Oxaliplatin	51-62	BCL2 like 11	Homo sapiens	229-232
30962765-7	2019	Under oxaliplatin treatment, cell death was measured using MTT and annexin V/propidium iodide assays.	Oxaliplatin	6-17	annexin A5	Homo sapiens	67-76
30962765-14	2019	Suppression of autophagy using RNA interference of ATG5 in HCC cells promoted the oxaliplatin cytotoxicity in the co-culture system.	Oxaliplatin	82-93	autophagy related 5	Homo sapiens	51-55
30894570-6	2019	RNAi knockdown of microsomal prostaglandin E synthase-1, the rate-limiting enzyme in PGE2 synthesis, sensitized OXR cells to oxaliplatin.	Oxaliplatin	125-136	prostaglandin E synthase	Homo sapiens	18-55
30894570-10	2019	The accumulation of intracellular reactive oxygen species (ROS), a key component of oxaliplatin cytotoxicity, was significantly increased by EP4 inhibition (2.4 -fold; P < 0.0001).	Oxaliplatin	84-95	prostaglandin E receptor 4	Homo sapiens	141-144
30894570-11	2019	Overall, our findings uncover an important role for the COX-2/PGE2/EP4 signaling axis in oxaliplatin resistance via regulation of oxidative stress.	Oxaliplatin	89-100	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	56-61
30894570-11	2019	Overall, our findings uncover an important role for the COX-2/PGE2/EP4 signaling axis in oxaliplatin resistance via regulation of oxidative stress.	Oxaliplatin	89-100	prostaglandin E receptor 4	Homo sapiens	67-70
30639170-0	2019	LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.	Oxaliplatin	29-40	ATP binding cassette subfamily C member 1	Homo sapiens	98-103
30890168-0	2019	Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.	Oxaliplatin	60-71	membrane associated ring-CH-type finger 8	Homo sapiens	20-23
30890168-5	2019	METHODS: Oxaliplatin-resistant CRC and normal intestinal FHC cells were transfected with a miR-128-3p expression lentivirus.	Oxaliplatin	9-20	membrane associated ring-CH-type finger 8	Homo sapiens	91-94
30890168-11	2019	RESULTS: In our established stable oxaliplatin-resistant CRC cell lines, in vitro and vivo studies revealed miR-128-3p suppressed EMT and increased intracellular oxaliplatin accumulation.	Oxaliplatin	35-46	membrane associated ring-CH-type finger 8	Homo sapiens	108-111
30890168-11	2019	RESULTS: In our established stable oxaliplatin-resistant CRC cell lines, in vitro and vivo studies revealed miR-128-3p suppressed EMT and increased intracellular oxaliplatin accumulation.	Oxaliplatin	162-173	membrane associated ring-CH-type finger 8	Homo sapiens	108-111
30890168-12	2019	Importantly, our results indicated that lower miR-128-3p expression was associated with poor oxaliplatin response in advanced human CRC patients.	Oxaliplatin	93-104	membrane associated ring-CH-type finger 8	Homo sapiens	46-49
30890168-13	2019	Moreover, data showed that miR-128-3p-transfected FHC cells effectively packaged miR-128-3p into secreted exosomes and mediated miR-128-3p delivery to oxaliplatin-resistant cells, improving oxaliplatin response in CRC cells both in vitro and in vivo.	Oxaliplatin	151-162	membrane associated ring-CH-type finger 8	Homo sapiens	27-30
30890168-13	2019	Moreover, data showed that miR-128-3p-transfected FHC cells effectively packaged miR-128-3p into secreted exosomes and mediated miR-128-3p delivery to oxaliplatin-resistant cells, improving oxaliplatin response in CRC cells both in vitro and in vivo.	Oxaliplatin	151-162	membrane associated ring-CH-type finger 8	Homo sapiens	81-84
30890168-13	2019	Moreover, data showed that miR-128-3p-transfected FHC cells effectively packaged miR-128-3p into secreted exosomes and mediated miR-128-3p delivery to oxaliplatin-resistant cells, improving oxaliplatin response in CRC cells both in vitro and in vivo.	Oxaliplatin	151-162	membrane associated ring-CH-type finger 8	Homo sapiens	81-84
30890168-13	2019	Moreover, data showed that miR-128-3p-transfected FHC cells effectively packaged miR-128-3p into secreted exosomes and mediated miR-128-3p delivery to oxaliplatin-resistant cells, improving oxaliplatin response in CRC cells both in vitro and in vivo.	Oxaliplatin	190-201	membrane associated ring-CH-type finger 8	Homo sapiens	27-30
30890168-13	2019	Moreover, data showed that miR-128-3p-transfected FHC cells effectively packaged miR-128-3p into secreted exosomes and mediated miR-128-3p delivery to oxaliplatin-resistant cells, improving oxaliplatin response in CRC cells both in vitro and in vivo.	Oxaliplatin	190-201	membrane associated ring-CH-type finger 8	Homo sapiens	81-84
30890168-13	2019	Moreover, data showed that miR-128-3p-transfected FHC cells effectively packaged miR-128-3p into secreted exosomes and mediated miR-128-3p delivery to oxaliplatin-resistant cells, improving oxaliplatin response in CRC cells both in vitro and in vivo.	Oxaliplatin	190-201	membrane associated ring-CH-type finger 8	Homo sapiens	81-84
30890168-14	2019	In addition, miR-128-3p overexpression up-regulated E-cadherin levels and inhibited oxaliplatin-induced EMT by suppressing Bmi1 expression in resistant cells.	Oxaliplatin	84-95	membrane associated ring-CH-type finger 8	Homo sapiens	13-16
30890168-14	2019	In addition, miR-128-3p overexpression up-regulated E-cadherin levels and inhibited oxaliplatin-induced EMT by suppressing Bmi1 expression in resistant cells.	Oxaliplatin	84-95	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	123-127
30890168-15	2019	Meanwhile, it also decreased oxaliplatin efflux through suppressed expression of the drug transporter MRP5.	Oxaliplatin	29-40	ATP binding cassette subfamily C member 5	Homo sapiens	102-106
30890168-17	2019	Moreover, miR-128-3p may be a promising diagnostic and prognostic marker for oxaliplatin-based chemotherapy.	Oxaliplatin	77-88	membrane associated ring-CH-type finger 8	Homo sapiens	10-13
30639170-0	2019	LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.	Oxaliplatin	29-40	microRNA 145	Homo sapiens	121-128
30639170-3	2019	In this work, we aimed to investigate the functional role of lncRNA cancer susceptibility candidate 15 (CASC15) in oxaliplatin (OXA) resistance of CRC and reveal the underlying molecular mechanism.	Oxaliplatin	115-126	cancer susceptibility 15	Homo sapiens	104-110
30639170-8	2019	miR-145 overexpression or ABCC1 knockdown could mimic the functional role of down-regulated CACS15 in OXA resistance, which was counteracted by CASC15 overexpression.	Oxaliplatin	102-105	microRNA 145	Homo sapiens	0-7
30639170-8	2019	miR-145 overexpression or ABCC1 knockdown could mimic the functional role of down-regulated CACS15 in OXA resistance, which was counteracted by CASC15 overexpression.	Oxaliplatin	102-105	ATP binding cassette subfamily C member 1	Homo sapiens	26-31
30639170-8	2019	miR-145 overexpression or ABCC1 knockdown could mimic the functional role of down-regulated CACS15 in OXA resistance, which was counteracted by CASC15 overexpression.	Oxaliplatin	102-105	cancer susceptibility 15	Homo sapiens	144-150
30854066-11	2019	The aforementioned indicated that GSTP1 genetic polymorphism is associated with peripheral neuropathy induced by oxaliplatin treatment for colorectal cancer, and therefore serves as a predictive marker.	Oxaliplatin	113-124	glutathione S-transferase pi 1	Homo sapiens	34-39
30418550-6	2019	P53 was dispensable for the G2/M arrest in HCT116 cells but required for induction of a senescence-like phenotype upon long-term exposure and for the observed synergism with oxaliplatin.	Oxaliplatin	174-185	tumor protein p53	Homo sapiens	0-3
30915355-7	2019	In addition, Ubenimex downregulates expression of membrane transport proteins, such as P-gp and MRP1, by inhibiting phosphorylation in the PI3K/AKT/mTOR pathway to increase intracellular accumulations of 5-fluorouracil and oxaliplatin, a process for which downregulation of CD13 expression is essential.	Oxaliplatin	223-234	phosphoglycolate phosphatase	Homo sapiens	87-91
30709915-10	2019	Overall, the Poleta-oxaliplatin-GpG structure provides a structural basis for TLS-mediated bypass of the major oxaliplatin-DNA adducts and insights into resistance to platinum-based chemotherapy in humans.	Oxaliplatin	20-31	FUS RNA binding protein	Homo sapiens	78-81
30709915-10	2019	Overall, the Poleta-oxaliplatin-GpG structure provides a structural basis for TLS-mediated bypass of the major oxaliplatin-DNA adducts and insights into resistance to platinum-based chemotherapy in humans.	Oxaliplatin	111-122	FUS RNA binding protein	Homo sapiens	78-81
30787271-0	2019	ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance.	Oxaliplatin	92-103	ataxin 2 like	Homo sapiens	0-6
30787271-0	2019	ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance.	Oxaliplatin	92-103	epidermal growth factor	Homo sapiens	22-45
30787271-8	2019	When adding the chemotherapeutic agent oxaliplatin to induce stress, silencing ATXN2L sensitized GC cells to oxaliplatin.	Oxaliplatin	39-50	ataxin 2 like	Homo sapiens	79-85
30787271-8	2019	When adding the chemotherapeutic agent oxaliplatin to induce stress, silencing ATXN2L sensitized GC cells to oxaliplatin.	Oxaliplatin	109-120	ataxin 2 like	Homo sapiens	79-85
30787271-9	2019	Interestingly, oxaliplatin was found to in turn promote ATXN2L expression and stress granule assembly.	Oxaliplatin	15-26	ataxin 2 like	Homo sapiens	56-62
30915355-7	2019	In addition, Ubenimex downregulates expression of membrane transport proteins, such as P-gp and MRP1, by inhibiting phosphorylation in the PI3K/AKT/mTOR pathway to increase intracellular accumulations of 5-fluorouracil and oxaliplatin, a process for which downregulation of CD13 expression is essential.	Oxaliplatin	223-234	CD9 molecule	Homo sapiens	96-100
30787271-11	2019	The oxaliplatin-resistant strains presented with elevated ATXN2L levels, while silencing ATXN2L in the strains reversed the oxaliplatin resistance by increasing reactive oxygen species production and apoptosis.	Oxaliplatin	4-15	ataxin 2 like	Homo sapiens	58-64
30787271-11	2019	The oxaliplatin-resistant strains presented with elevated ATXN2L levels, while silencing ATXN2L in the strains reversed the oxaliplatin resistance by increasing reactive oxygen species production and apoptosis.	Oxaliplatin	124-135	ataxin 2 like	Homo sapiens	89-95
30783141-0	2019	Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer.	Oxaliplatin	55-66	ATP binding cassette subfamily C member 2	Homo sapiens	18-22
30787271-12	2019	These results suggested that ATXN2L was responsible for not only intrinsic but also acquired oxaliplatin chemoresistance.	Oxaliplatin	93-104	ataxin 2 like	Homo sapiens	29-35
30787271-14	2019	Blocking EGFR/ATXN2L signaling reversed GC cell oxaliplatin resistance and inhibited migration.	Oxaliplatin	48-59	epidermal growth factor receptor	Homo sapiens	9-13
30787271-14	2019	Blocking EGFR/ATXN2L signaling reversed GC cell oxaliplatin resistance and inhibited migration.	Oxaliplatin	48-59	ataxin 2 like	Homo sapiens	14-20
30787271-15	2019	In conclusion, ATXN2L promotes cell invasiveness and oxaliplatin resistance and can be upregulated by EGF via PI3K/Akt signaling.	Oxaliplatin	53-64	ataxin 2 like	Homo sapiens	15-21
30787271-16	2019	ATXN2L may be an indicator and therapeutic target in GC, especially for oxaliplatin-based chemotherapy.	Oxaliplatin	72-83	ataxin 2 like	Homo sapiens	0-6
30672917-0	2019	Cyanidin inhibits EMT induced by oxaliplatin via targeting the PDK1-PI3K/Akt signaling pathway.	Oxaliplatin	33-44	IL2 inducible T cell kinase	Homo sapiens	18-21
30672917-0	2019	Cyanidin inhibits EMT induced by oxaliplatin via targeting the PDK1-PI3K/Akt signaling pathway.	Oxaliplatin	33-44	3-phosphoinositide dependent protein kinase 1	Homo sapiens	63-67
30672917-0	2019	Cyanidin inhibits EMT induced by oxaliplatin via targeting the PDK1-PI3K/Akt signaling pathway.	Oxaliplatin	33-44	AKT serine/threonine kinase 1	Homo sapiens	73-76
30783141-5	2019	Over-expression of MRP2 (endogenously in HepG2 and PANC-1 cells, or induced by stable transfection of HEK293 cells) decreased oxaliplatin accumulation and cytotoxicity but those deficits were reversed by inhibition of MRP2 with myricetin or siRNA knockdown.	Oxaliplatin	126-137	ATP binding cassette subfamily C member 2	Homo sapiens	19-23
30783141-7	2019	In conclusion, MRP2 limits oxaliplatin accumulation and response in human gastrointestinal cancer.	Oxaliplatin	27-38	ATP binding cassette subfamily C member 2	Homo sapiens	15-19
30783141-8	2019	Screening tumour MRP2 expression levels, to select patients for treatment with oxaliplatin-based chemotherapy alone or in combination with a MRP2 inhibitor, could improve treatment outcomes.	Oxaliplatin	79-90	ATP binding cassette subfamily C member 2	Homo sapiens	17-21
30592963-0	2019	L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-kappaB pathways.	Oxaliplatin	29-40	NFE2 like bZIP transcription factor 2	Homo sapiens	129-134
30906773-8	2019	Results: Oxaliplatin treatment reduced spleen size and cellularity (CD45+ cells), increased the proportion of CD4+, CD8+, and Treg cells, and elevated TNF-alpha expression.	Oxaliplatin	9-20	CD4 antigen	Mus musculus	68-71
30906773-8	2019	Results: Oxaliplatin treatment reduced spleen size and cellularity (CD45+ cells), increased the proportion of CD4+, CD8+, and Treg cells, and elevated TNF-alpha expression.	Oxaliplatin	9-20	tumor necrosis factor	Mus musculus	151-160
30592963-0	2019	L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-kappaB pathways.	Oxaliplatin	29-40	nuclear factor kappa B subunit 1	Homo sapiens	139-148
30592963-8	2019	CONCLUSION: L-Carnosine exerted a neuroprotective effect against oxaliplatin-induced peripheral neuropathy in colorectal cancer patients by targeting Nrf-2 and NF-kappaB pathways.	Oxaliplatin	65-76	NFE2 like bZIP transcription factor 2	Homo sapiens	150-155
30592963-8	2019	CONCLUSION: L-Carnosine exerted a neuroprotective effect against oxaliplatin-induced peripheral neuropathy in colorectal cancer patients by targeting Nrf-2 and NF-kappaB pathways.	Oxaliplatin	65-76	nuclear factor kappa B subunit 1	Homo sapiens	160-169
30739089-2	2019	We report a case of an 83-year-old Hispanic man, non-smoker, with KRAS/NRAS wild-type mCRC of the liver who was treated with 9 cycles of FOLFOX4 (fluorouracil, leucovorin and oxaliplatin) and cetuximab.	Oxaliplatin	175-186	KRAS proto-oncogene, GTPase	Homo sapiens	66-70
30736824-10	2019	IL-11 can reduce the efficacy of oxaliplatin-mediated inhibition of cell viability.	Oxaliplatin	33-44	interleukin 11	Homo sapiens	0-5
30736824-12	2019	Its combination with oxaliplatin attenuated DLD-1 xenograft tumor burden and reduced p-STAT3 in vivo.	Oxaliplatin	21-32	signal transducer and activator of transcription 3	Homo sapiens	87-92
30682002-4	2019	OBJECTIVES: This article reviews the symptoms of HSRs associated with oxaliplatin, the specific management of HSRs associated with oxaliplatin, the role of desensitization, and the potential use of skin testing to better identify patients at risk for HSR.	Oxaliplatin	70-81	HSR	Homo sapiens	49-52
30447099-2	2019	We undertook this study to investigate the association between UGT1A1 genetic polymorphisms and toxicity in patients treated with the FOLFIRINOX (comprising oxaliplatin, irinotecan, fluorouracil, and leucovorin) chemotherapy regimen in the JASPAC 06 study.	Oxaliplatin	157-168	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	63-69
30539797-0	2019	miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/beta-catenin pathway.	Oxaliplatin	60-71	microRNA 122	Homo sapiens	0-7
30539797-0	2019	miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/beta-catenin pathway.	Oxaliplatin	60-71	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
30539797-0	2019	miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/beta-catenin pathway.	Oxaliplatin	60-71	catenin beta 1	Homo sapiens	109-121
30539797-12	2019	CONCLUSION: Our study fully demonstrated that miR-122 inhibits MDR1 expression via suppression of Wnt/beta-catenin pathway, thereby enhancing HCC sensitivity to OXA.	Oxaliplatin	161-164	microRNA 122	Homo sapiens	46-53
30539797-12	2019	CONCLUSION: Our study fully demonstrated that miR-122 inhibits MDR1 expression via suppression of Wnt/beta-catenin pathway, thereby enhancing HCC sensitivity to OXA.	Oxaliplatin	161-164	ATP binding cassette subfamily B member 1	Homo sapiens	63-67
30539797-12	2019	CONCLUSION: Our study fully demonstrated that miR-122 inhibits MDR1 expression via suppression of Wnt/beta-catenin pathway, thereby enhancing HCC sensitivity to OXA.	Oxaliplatin	161-164	catenin beta 1	Homo sapiens	102-114
30535504-0	2019	MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells.	Oxaliplatin	47-58	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
30295925-8	2019	Octn1/2- and Mate1-expressing cells showed the intracellular accumulation of oxaliplatin.	Oxaliplatin	77-88	solute carrier family 22 member 4	Rattus norvegicus	0-5
30295925-8	2019	Octn1/2- and Mate1-expressing cells showed the intracellular accumulation of oxaliplatin.	Oxaliplatin	77-88	solute carrier family 47 member 1	Rattus norvegicus	13-18
30295925-12	2019	These results indicate that Octn1 and Mate1 are involved in platinum accumulation at DRG and oxaliplatin-induced peripheral neuropathy.	Oxaliplatin	93-104	solute carrier family 22 member 4	Rattus norvegicus	28-33
30295925-12	2019	These results indicate that Octn1 and Mate1 are involved in platinum accumulation at DRG and oxaliplatin-induced peripheral neuropathy.	Oxaliplatin	93-104	solute carrier family 47 member 1	Rattus norvegicus	38-43
30535504-0	2019	MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells.	Oxaliplatin	47-58	mitogen-activated protein kinase kinase 1	Homo sapiens	81-85
30535504-5	2019	The results suggested that MEK inhibitors in combination with oxaliplatin/5-FU may offer an improved therapeutic effect in patients with MEK-mutant CRC.	Oxaliplatin	62-73	mitogen-activated protein kinase kinase 7	Homo sapiens	137-140
30307354-2	2019	CASE PRESENTATION: Here we present a KRAS/NRAS/BRAF wild-type mCRC patient who has been previously treated with FOLFIRI (fluorouracil, leucovorin, and irinotecan), XELOX (capecitabine and oxaliplatin), cetuximab and bevacizumab, and then received the next generation sequencing (NGS) and whose metastatic subcutaneous nodule was resected to generate patient-derived xenograft (PDX) models.	Oxaliplatin	188-199	KRAS proto-oncogene, GTPase	Homo sapiens	37-41
30244138-8	2019	This prophylactic effect of Huachansu was associated with suppressed oxaliplatin-induced TRPV1 up-regulation in the dorsal root ganglia and spinal astrocyte activation.	Oxaliplatin	69-80	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	89-94
30581001-3	2019	DAC at very low concentration below its IC20 synergistically enhanced cytotoxicity of oxaliplatin (L-OHP), and the enhancement was the most remarkable for L-OHP among several anti-cancer drugs tested.	Oxaliplatin	86-97	arylacetamide deacetylase	Homo sapiens	0-3
30581001-3	2019	DAC at very low concentration below its IC20 synergistically enhanced cytotoxicity of oxaliplatin (L-OHP), and the enhancement was the most remarkable for L-OHP among several anti-cancer drugs tested.	Oxaliplatin	99-104	arylacetamide deacetylase	Homo sapiens	0-3
30581001-3	2019	DAC at very low concentration below its IC20 synergistically enhanced cytotoxicity of oxaliplatin (L-OHP), and the enhancement was the most remarkable for L-OHP among several anti-cancer drugs tested.	Oxaliplatin	155-160	arylacetamide deacetylase	Homo sapiens	0-3
30581001-6	2019	On the other hand, although DAC alone did not produce reactive oxygen species (ROS), DAC significantly enhanced ROS production by L-OHP in HT29 cells.	Oxaliplatin	130-135	arylacetamide deacetylase	Homo sapiens	85-88
30581001-7	2019	Furthermore, enhanced cytotoxicity of L-OHP by DAC was cancelled with the presence of N-acetyl-l-cysteine, a ROS scavenger.	Oxaliplatin	38-43	arylacetamide deacetylase	Homo sapiens	47-50
30581001-9	2019	Taken together, indirect enhancement of ROS production by DAC at the low concentration with negligible cytotoxicity should be at least involved in synergistic effects with L-OHP in HT29 cells with intrinsic resistance to DAC.	Oxaliplatin	172-177	arylacetamide deacetylase	Homo sapiens	58-61
30657060-7	2019	In oxaliplatin-treated mice, MBP expression, confocal and electronic microscopy of the sciatic nerves revealed a demyelination and confirmed the alteration of the myelinated axons morphology when compared to animals injected with oxaliplatin plus benztropine.	Oxaliplatin	3-14	myelin basic protein	Mus musculus	29-32
30509090-0	2019	Suppressing the secretion of exosomal miR-19b by gw4869 could regulate oxaliplatin sensitivity in colorectal cancer.	Oxaliplatin	71-82	microRNA 19b-1	Homo sapiens	38-45
30509090-3	2019	In this study, we investigate how exosomal miR-19b participates in oxaliplatin sensitivity and then prove that miR-19b down-regulates oxaliplatin sensitivity of sw480 cells.	Oxaliplatin	67-78	microRNA 19b-1	Homo sapiens	43-50
30509090-3	2019	In this study, we investigate how exosomal miR-19b participates in oxaliplatin sensitivity and then prove that miR-19b down-regulates oxaliplatin sensitivity of sw480 cells.	Oxaliplatin	134-145	microRNA 19b-1	Homo sapiens	111-118
30509090-4	2019	We found that suppressing the secretion of exosomal miR-19b with gw4869 promotes sw480 cell oxaliplatin sensitivity.	Oxaliplatin	92-103	microRNA 19b-1	Homo sapiens	52-59
30509090-5	2019	Our combined results demonstrate for the first time that miR-19b regulates the oxaliplatin sensitivity of sw480 cells and provides a unique mechanism mediated by gw4869 to modulate oxaliplatin sensitivity by suppressing exosomal miR-19b release.	Oxaliplatin	79-90	microRNA 19b-1	Homo sapiens	57-64
30509090-5	2019	Our combined results demonstrate for the first time that miR-19b regulates the oxaliplatin sensitivity of sw480 cells and provides a unique mechanism mediated by gw4869 to modulate oxaliplatin sensitivity by suppressing exosomal miR-19b release.	Oxaliplatin	181-192	microRNA 19b-1	Homo sapiens	57-64
30509090-5	2019	Our combined results demonstrate for the first time that miR-19b regulates the oxaliplatin sensitivity of sw480 cells and provides a unique mechanism mediated by gw4869 to modulate oxaliplatin sensitivity by suppressing exosomal miR-19b release.	Oxaliplatin	181-192	microRNA 19b-1	Homo sapiens	229-236
30792807-0	2019	Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.	Oxaliplatin	88-99	KRAS proto-oncogene, GTPase	Homo sapiens	135-139
30792807-0	2019	Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.	Oxaliplatin	88-99	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	140-144
30792807-0	2019	Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.	Oxaliplatin	88-99	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	159-164
30792807-0	2019	Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.	Oxaliplatin	88-99	tumor protein p53	Homo sapiens	165-168
30792807-1	2019	Ammonium tetrathiomolybdate (TTM) and disulfiram (DSF) are copper (Cu) chelators in cancer clinical trials partly because Cu chelation: a) restricts the activity of Cu-binding MEK1/2 enzymes which drive tumourigenesis by KRAS or BRAF oncogenic mutations and b) enhances uptake of oxaliplatin (OxPt), clinically used in advanced KRAS-mutant colorectal carcinomas (CRC).	Oxaliplatin	280-291	mitogen-activated protein kinase kinase 1	Homo sapiens	176-182
30792807-1	2019	Ammonium tetrathiomolybdate (TTM) and disulfiram (DSF) are copper (Cu) chelators in cancer clinical trials partly because Cu chelation: a) restricts the activity of Cu-binding MEK1/2 enzymes which drive tumourigenesis by KRAS or BRAF oncogenic mutations and b) enhances uptake of oxaliplatin (OxPt), clinically used in advanced KRAS-mutant colorectal carcinomas (CRC).	Oxaliplatin	293-297	mitogen-activated protein kinase kinase 1	Homo sapiens	176-182
30307354-2	2019	CASE PRESENTATION: Here we present a KRAS/NRAS/BRAF wild-type mCRC patient who has been previously treated with FOLFIRI (fluorouracil, leucovorin, and irinotecan), XELOX (capecitabine and oxaliplatin), cetuximab and bevacizumab, and then received the next generation sequencing (NGS) and whose metastatic subcutaneous nodule was resected to generate patient-derived xenograft (PDX) models.	Oxaliplatin	188-199	NRAS proto-oncogene, GTPase	Homo sapiens	42-46
30307354-2	2019	CASE PRESENTATION: Here we present a KRAS/NRAS/BRAF wild-type mCRC patient who has been previously treated with FOLFIRI (fluorouracil, leucovorin, and irinotecan), XELOX (capecitabine and oxaliplatin), cetuximab and bevacizumab, and then received the next generation sequencing (NGS) and whose metastatic subcutaneous nodule was resected to generate patient-derived xenograft (PDX) models.	Oxaliplatin	188-199	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	47-51
30305341-5	2019	Specifically, the role of PRKRA/PACT in oxaliplatin resistance was interrogated.	Oxaliplatin	40-51	protein kinase, interferon inducible double stranded RNA dependent activator	Mus musculus	26-31
30592157-10	2019	Oxaliplatin treatment diminished the expression of the immunosuppressive functional mediators arginase 1 (ARG1) and NADPH oxidase 2 (NOX2) in MDSCs, while an MDSC-depleting agent, gemcitabine, did not downregulate these factors significantly.	Oxaliplatin	0-11	arginase 1	Homo sapiens	94-104
30592157-10	2019	Oxaliplatin treatment diminished the expression of the immunosuppressive functional mediators arginase 1 (ARG1) and NADPH oxidase 2 (NOX2) in MDSCs, while an MDSC-depleting agent, gemcitabine, did not downregulate these factors significantly.	Oxaliplatin	0-11	arginase 1	Homo sapiens	106-110
30592157-10	2019	Oxaliplatin treatment diminished the expression of the immunosuppressive functional mediators arginase 1 (ARG1) and NADPH oxidase 2 (NOX2) in MDSCs, while an MDSC-depleting agent, gemcitabine, did not downregulate these factors significantly.	Oxaliplatin	0-11	cytochrome b-245 beta chain	Homo sapiens	116-131
30592157-10	2019	Oxaliplatin treatment diminished the expression of the immunosuppressive functional mediators arginase 1 (ARG1) and NADPH oxidase 2 (NOX2) in MDSCs, while an MDSC-depleting agent, gemcitabine, did not downregulate these factors significantly.	Oxaliplatin	0-11	cytochrome b-245 beta chain	Homo sapiens	133-137
30422156-4	2019	The main eligibility criterion was disease progression after bevacizumab plus fluorouracil with irinotecan or oxaliplatin in patients with wild-type KRAS exon 2 metastatic colorectal cancer.	Oxaliplatin	110-121	KRAS proto-oncogene, GTPase	Homo sapiens	149-153
30253135-8	2019	Here, we show that oxaliplatin induces the interaction of NMDARs with PSD-95.	Oxaliplatin	19-30	discs large MAGUK scaffold protein 4	Rattus norvegicus	70-76
30468657-0	2019	Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K/Akt/MTOR pathway.	Oxaliplatin	48-59	AKT serine/threonine kinase 1	Homo sapiens	68-71
30468657-0	2019	Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K/Akt/MTOR pathway.	Oxaliplatin	48-59	mechanistic target of rapamycin kinase	Homo sapiens	72-76
30468657-6	2019	Meanwhile, nobiletin promoted oxaliplatin-induced apoptosis of CRC cells, as demonstrated by the increased expression of pro-apoptotic proteins (Bax and cleaved-caspse3) and the down-regulation of anti-apoptotic protein Bcl-2.	Oxaliplatin	30-41	BCL2 apoptosis regulator	Homo sapiens	220-225
30198601-5	2019	Oxaliplatin-induced neuropathy presented with a cross-sectional area (CSA) increase of mostly the tibial and fibular nerve, which developed parallel or prior to clinical signs and electrophysiological changes.	Oxaliplatin	0-11	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	70-73
30305341-10	2019	The PRKRA/PACT axis represents an important therapeutic target in MOC to enhance sensitivity to oxaliplatin.	Oxaliplatin	96-107	protein kinase, interferon inducible double stranded RNA dependent activator	Mus musculus	10-14
30305341-5	2019	Specifically, the role of PRKRA/PACT in oxaliplatin resistance was interrogated.	Oxaliplatin	40-51	protein kinase, interferon inducible double stranded RNA dependent activator	Mus musculus	32-36
30305341-8	2019	In addition, expression of miR-515-3p was regulated by PACT-Dicer interaction, and miR-515-3p increased the sensitivity of MOC to oxaliplatin.	Oxaliplatin	130-141	protein kinase, interferon inducible double stranded RNA dependent activator	Mus musculus	55-59
30305341-10	2019	The PRKRA/PACT axis represents an important therapeutic target in MOC to enhance sensitivity to oxaliplatin.	Oxaliplatin	96-107	protein kinase, interferon inducible double stranded RNA dependent activator	Mus musculus	4-9
30372807-13	2018	In conclusion, upregulation of ABCB1 can be considered as the crucial component of poor response to oxaliplatin which is likely controlled by miR-302c-5p.	Oxaliplatin	100-111	ATP binding cassette subfamily B member 1	Homo sapiens	31-36
30219676-0	2018	PTBP1 knockdown overcomes the resistance to vincristine and oxaliplatin in drug-resistant colon cancer cells through regulation of glycolysis.	Oxaliplatin	60-71	polypyrimidine tract binding protein 1	Homo sapiens	0-5
30219676-3	2018	Herein, we found that PTBP1 was highly expressed in two drug-resistant colon cancer cell lines, vincristine-resistant HCT-8 cell line (HCT-8/V) and oxaliplatin-resistant HCT116 cell line (HCT116/L-OHP).	Oxaliplatin	148-159	polypyrimidine tract binding protein 1	Homo sapiens	22-27
30219676-5	2018	PTBP1 knockdown enhanced the sensitivity of HCT-8/V and HCT116/L-OHP cells to vincristine and oxaliplatin, and caused reduction in glucose consumption and lactate production.	Oxaliplatin	94-105	polypyrimidine tract binding protein 1	Homo sapiens	0-5
30219676-9	2018	In conclusion, PTBP1 knockdown enhanced the sensitivity of drug-resistant colon cancer cells to vincristine and oxaliplatin through repression of glycolysis.	Oxaliplatin	112-123	polypyrimidine tract binding protein 1	Homo sapiens	15-20
30643454-0	2019	Polymorphisms in DNA repair pathway genes and ABCG2 gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy.	Oxaliplatin	151-162	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	46-51
30643454-6	2019	Of these six SNPs, XPA rs10817938 CT/ TT genotypes retained its significant association with longer overall survival (OS) (P=0.008) in CRC patients receiving oxaliplatin-based chemotherapy (n=580).	Oxaliplatin	158-169	XPA, DNA damage recognition and repair factor	Homo sapiens	19-22
30643454-11	2019	Conclusion: The current data indicated that the XPA gene and ABCG2 gene had significant interaction with environmental factors and prognosis, which could provide a comprehensive understanding of the implications of those SNPs in the prediction of prognosis in advanced CRC patients receiving oxaliplatin-based chemotherapy.	Oxaliplatin	292-303	XPA, DNA damage recognition and repair factor	Homo sapiens	48-51
30643454-11	2019	Conclusion: The current data indicated that the XPA gene and ABCG2 gene had significant interaction with environmental factors and prognosis, which could provide a comprehensive understanding of the implications of those SNPs in the prediction of prognosis in advanced CRC patients receiving oxaliplatin-based chemotherapy.	Oxaliplatin	292-303	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	61-66
30547773-5	2018	CONCLUSIONS: This case indicated an association of BRCA2 mutation with high mutation loads and an excellent response of oxaliplatin-based chemotherapy regimen for LARC.	Oxaliplatin	120-131	BRCA2 DNA repair associated	Homo sapiens	51-56
30517302-0	2018	Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China.	Oxaliplatin	123-134	ERCC excision repair 5, endonuclease	Homo sapiens	88-93
30517302-1	2018	OBJECTIVES: To study the relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer (CRC) in China.	Oxaliplatin	148-159	ERCC excision repair 5, endonuclease	Homo sapiens	113-118
30517302-8	2018	CONCLUSIONS: The Asp1104His polymorphism of ERCC5 was associated with the risk and 5-year survival rate of CRC as well as treatment sensitivity to oxaliplatin.	Oxaliplatin	147-158	ERCC excision repair 5, endonuclease	Homo sapiens	44-49
30662802-6	2018	Moreover, knockdown of YEATS4 improved chemosensitivity for CDDP and L-OHP.	Oxaliplatin	69-74	YEATS domain containing 4	Homo sapiens	23-29
30372807-0	2018	Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p.	Oxaliplatin	8-19	ATP binding cassette subfamily B member 1	Homo sapiens	80-85
30372807-0	2018	Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p.	Oxaliplatin	8-19	microRNA 1295a	Homo sapiens	153-163
30372807-4	2018	There are different genes like GSTP1 and ABCB1 which are responsible for oxaliplatin resistance.	Oxaliplatin	73-84	glutathione S-transferase pi 1	Homo sapiens	31-36
30372807-4	2018	There are different genes like GSTP1 and ABCB1 which are responsible for oxaliplatin resistance.	Oxaliplatin	73-84	ATP binding cassette subfamily B member 1	Homo sapiens	41-46
30042009-8	2018	ATM loss was associated with superior overall survival after first-line oxaliplatin-based therapy (49 vs. 32 months; hazard ratio [HR], 2.52) but not with irinotecan-based therapy (24 vs. 33 months; HR, 0.72).	Oxaliplatin	72-83	ATM serine/threonine kinase	Homo sapiens	0-3
30454021-10	2018	In this context, anti-EGFR and oxaliplatin based chemotherapy are the most powerful to induce CD8+ cells mobilization within the metastatic site.	Oxaliplatin	31-42	CD8a molecule	Homo sapiens	94-97
30316683-0	2018	ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer.	Oxaliplatin	34-45	ATM serine/threonine kinase	Homo sapiens	0-3
30248604-7	2018	The similar associations were also found between urinary 1-OHP and high-AhR expressions (4th vs. 1st quartile = 3.50, 95% CI: 1.24-9.87, P for trend = 0.029).	Oxaliplatin	57-62	aryl hydrocarbon receptor	Homo sapiens	72-75
30132163-9	2018	In addition, there was evidence of immunogenic cell death (elevated EIF2alpha phosphorylation and calreticulin exposure) following prolonged OXA treatment.	Oxaliplatin	141-144	eukaryotic translation initiation factor 2A	Mus musculus	68-77
30132163-10	2018	Notably, inhibition of ER stress reversed the OXA-mediated inhibition of STAT3 activity and MGMT expression in the tumor cells.	Oxaliplatin	46-49	signal transducer and activator of transcription 3	Mus musculus	73-78
30132163-10	2018	Notably, inhibition of ER stress reversed the OXA-mediated inhibition of STAT3 activity and MGMT expression in the tumor cells.	Oxaliplatin	46-49	O-6-methylguanine-DNA methyltransferase	Mus musculus	92-96
30587732-0	2018	[A Case of Complete Response to Trastuzumab plus S-1 and Oxaliplatin for a HER2-Positive Recurrence of Gastric Cancer].	Oxaliplatin	57-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
30467535-0	2018	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.	Oxaliplatin	100-111	amphiregulin	Homo sapiens	0-12
30336979-8	2018	We found that OXA treatment inhibited Dicer expression through decreasing the protein stability.	Oxaliplatin	14-17	dicer 1, ribonuclease III	Homo sapiens	38-43
30336979-11	2018	Knockdown of Dicer resensitized CRC cells to OXA treatment.	Oxaliplatin	45-48	dicer 1, ribonuclease III	Homo sapiens	13-18
30336979-0	2018	Role of Dicer in regulating oxaliplatin resistance of colon cancer cells.	Oxaliplatin	28-39	dicer 1, ribonuclease III	Homo sapiens	8-13
30467535-0	2018	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.	Oxaliplatin	100-111	epiregulin	Homo sapiens	24-34
30467535-0	2018	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.	Oxaliplatin	100-111	epiregulin	Homo sapiens	36-40
32913994-0	2018	Temporal Dynamics of Genomic Alterations in a BRCA1 Germline-Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorouracil, Oxaliplatin, Leucovorin, and Irinotecan.	Oxaliplatin	165-176	BRCA1 DNA repair associated	Homo sapiens	46-51
30410004-6	2018	In contrast, oxaliplatin-enhanced responsiveness to subsequent treatment with cetuximab was associated with increased apoptosis, inhibition of STAT3 activity and increased EGFR down-regulation.	Oxaliplatin	13-24	signal transducer and activator of transcription 3	Homo sapiens	143-148
30410004-6	2018	In contrast, oxaliplatin-enhanced responsiveness to subsequent treatment with cetuximab was associated with increased apoptosis, inhibition of STAT3 activity and increased EGFR down-regulation.	Oxaliplatin	13-24	epidermal growth factor receptor	Homo sapiens	172-176
30409714-5	2018	Moreover, riluzole prevented cold allodynia and increase in levels of TRPM8 mRNA in oxaliplatin-treated rats.	Oxaliplatin	84-95	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	70-75
30409714-6	2018	These results suggest that riluzole prevents oxaliplatin-induced cold allodynia via inhibition of TRPM8 overexpression in the DRG.	Oxaliplatin	45-56	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	98-103
30400960-8	2018	RESULTS: Reintroduction of miR-31-5p into miR-31-5p-null Hep3B cells significantly enhanced clonogenic resistance to oxaliplatin.	Oxaliplatin	117-128	microRNA 31	Homo sapiens	27-33
30400960-8	2018	RESULTS: Reintroduction of miR-31-5p into miR-31-5p-null Hep3B cells significantly enhanced clonogenic resistance to oxaliplatin.	Oxaliplatin	117-128	microRNA 31	Homo sapiens	42-48
30400960-9	2018	Although miR-31-5p re-expression increased chemoresistance, it paradoxically increased the relative intracellular accumulation of oxaliplatin.	Oxaliplatin	130-141	microRNA 31	Homo sapiens	9-15
30400960-10	2018	This effect was coupled with a significantly decreased intranuclear concentration of oxaliplatin by ICP-MS. miR-31-5p prevents the nuclear location of PARP1 detected by immunofluorescence, histological analysis and Western blotting analysis.	Oxaliplatin	85-96	microRNA 31	Homo sapiens	108-114
30400960-10	2018	This effect was coupled with a significantly decreased intranuclear concentration of oxaliplatin by ICP-MS. miR-31-5p prevents the nuclear location of PARP1 detected by immunofluorescence, histological analysis and Western blotting analysis.	Oxaliplatin	85-96	poly(ADP-ribose) polymerase 1	Homo sapiens	151-156
30400960-11	2018	We subsequently identified an indirect miR-31-5p-mediated upregulation of ABCB9, which is a transporter associated with drug accumulation in lysosomes, along with an increased uptake of oxaliplatin to lysosomes; these phenomena were associated with a downregulation of PARP1, a bipotential transcriptional regulator with multiple miR-31-5p binding sites.	Oxaliplatin	186-197	microRNA 31	Homo sapiens	39-45
30400960-11	2018	We subsequently identified an indirect miR-31-5p-mediated upregulation of ABCB9, which is a transporter associated with drug accumulation in lysosomes, along with an increased uptake of oxaliplatin to lysosomes; these phenomena were associated with a downregulation of PARP1, a bipotential transcriptional regulator with multiple miR-31-5p binding sites.	Oxaliplatin	186-197	ATP binding cassette subfamily B member 9	Homo sapiens	74-79
30400960-11	2018	We subsequently identified an indirect miR-31-5p-mediated upregulation of ABCB9, which is a transporter associated with drug accumulation in lysosomes, along with an increased uptake of oxaliplatin to lysosomes; these phenomena were associated with a downregulation of PARP1, a bipotential transcriptional regulator with multiple miR-31-5p binding sites.	Oxaliplatin	186-197	poly(ADP-ribose) polymerase 1	Homo sapiens	269-274
30400960-11	2018	We subsequently identified an indirect miR-31-5p-mediated upregulation of ABCB9, which is a transporter associated with drug accumulation in lysosomes, along with an increased uptake of oxaliplatin to lysosomes; these phenomena were associated with a downregulation of PARP1, a bipotential transcriptional regulator with multiple miR-31-5p binding sites.	Oxaliplatin	186-197	microRNA 31	Homo sapiens	330-336
30257334-3	2018	The MTT assay was used to detect growth inhibition of differentially-expressed KDM5c colon cancer cells, for which L-OHP or CPT-11 were added.	Oxaliplatin	115-120	lysine demethylase 5C	Homo sapiens	79-84
30257334-7	2018	RESULTS: KDM5c expression upregulation in colon cancer cells had significantly reduced L-OHP and CPT-111/2 inhibitory concentrations (IC50 s) and decreased the ABCC1mRNA and protein expression.	Oxaliplatin	87-92	lysine demethylase 5C	Homo sapiens	9-14
30257334-8	2018	The IC50 s of L-OHP and CPT-11 were significantly increased in colon cancer cells with downregulated KDM5c expression.	Oxaliplatin	14-19	lysine demethylase 5C	Homo sapiens	101-106
30409714-0	2018	Riluzole prevents oxaliplatin-induced cold allodynia via inhibition of overexpression of transient receptor potential melastatin 8 in rats.	Oxaliplatin	18-29	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	89-130
30409714-2	2018	We previously reported oxalate derived from oxaliplatin induced cold allodynia via overexpression of transient receptor potential melastatin 8 (TRPM8) in the dorsal root ganglion (DRG) in rats.	Oxaliplatin	44-55	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	101-142
30409714-2	2018	We previously reported oxalate derived from oxaliplatin induced cold allodynia via overexpression of transient receptor potential melastatin 8 (TRPM8) in the dorsal root ganglion (DRG) in rats.	Oxaliplatin	44-55	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	144-149
30565584-1	2018	This is a "best practice" case report of a non-uncommon clinical scenario, referring to an early liver relapse, judged as technically resectable, following adjuvant oxaliplatin-based treatment for left-sided, RAS and BRAF wild-type colon cancer.	Oxaliplatin	165-176	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	217-221
30355278-11	2018	The potential predictive role of PODXL was further strengthened for TTR in Cox regression analyses, especially for patients treated with neoadjuvant fluoropyrimidine and oxaliplatin for a minimum of 8 weeks, with a significant interaction term in both unadjusted (p = 0.006) and adjusted (p = 0.024) analyses.	Oxaliplatin	170-181	podocalyxin like	Homo sapiens	33-38
30355278-13	2018	CONCLUSIONS: Patients with resectable gastric or esophageal adenocarcinoma with high PODXL expression in their diagnostic biopsies have an excellent prognosis when treated with neoadjuvant +- adjuvant fluoropyrimidine- and oxaliplatin-based chemotherapy.	Oxaliplatin	223-234	podocalyxin like	Homo sapiens	85-90
30410600-0	2018	Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma.	Oxaliplatin	53-64	Yes1 associated transcriptional regulator	Homo sapiens	87-90
30410600-5	2018	Subsequently, in Bel-7404 and SMMC-7721 cells after treated with Oxa, it was verified that the expression of Cyr61 and Yes-associated protein (YAP) was increased.	Oxaliplatin	65-68	cellular communication network factor 1	Homo sapiens	109-114
30305703-2	2018	It has been previously shown that pharmacological or genetic ablation of TRPA1 responses reduces oxaliplatin-induced peripheral neurotoxicity in mouse models.	Oxaliplatin	97-108	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	73-78
30305703-3	2018	In the present report, we show that treatment with concentrations of oxaliplatin similar to those found in plasma of treated patients leads to an acidification of the cytosol of mouse dorsal root ganglia neurons in culture and this in turn is responsible for sensitization of TRPA1 channels, thereby providing a mechanistic explanation to toxicity of oxaliplatin.	Oxaliplatin	69-80	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	276-281
30410600-5	2018	Subsequently, in Bel-7404 and SMMC-7721 cells after treated with Oxa, it was verified that the expression of Cyr61 and Yes-associated protein (YAP) was increased.	Oxaliplatin	65-68	Yes1 associated transcriptional regulator	Homo sapiens	119-141
30410600-5	2018	Subsequently, in Bel-7404 and SMMC-7721 cells after treated with Oxa, it was verified that the expression of Cyr61 and Yes-associated protein (YAP) was increased.	Oxaliplatin	65-68	Yes1 associated transcriptional regulator	Homo sapiens	143-146
30059758-4	2018	Here, we show that in human wild-type (wt) p53 HCT-116 colon cancer cells treatment with oxaliplatin or 5-fluorouracil (5-FU) leads to a strong increase in ceramide synthase 5 (CerS5) expression and C16:0-ceramide levels, which was not shown in HCT-116 lacking p53 expression (HCT-116 p53-/-).	Oxaliplatin	89-100	tumor protein p53	Homo sapiens	43-46
30245393-8	2018	In turn, the pure TRPA1 antagonists 16 and 27 revealed a statistically significant antiallodynic effect in the formalin test and in the von Frey test performed in both phases of oxaliplatin-induced allodynia.	Oxaliplatin	178-189	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	18-23
30059758-4	2018	Here, we show that in human wild-type (wt) p53 HCT-116 colon cancer cells treatment with oxaliplatin or 5-fluorouracil (5-FU) leads to a strong increase in ceramide synthase 5 (CerS5) expression and C16:0-ceramide levels, which was not shown in HCT-116 lacking p53 expression (HCT-116 p53-/-).	Oxaliplatin	89-100	ceramide synthase 5	Homo sapiens	156-175
30059758-4	2018	Here, we show that in human wild-type (wt) p53 HCT-116 colon cancer cells treatment with oxaliplatin or 5-fluorouracil (5-FU) leads to a strong increase in ceramide synthase 5 (CerS5) expression and C16:0-ceramide levels, which was not shown in HCT-116 lacking p53 expression (HCT-116 p53-/-).	Oxaliplatin	89-100	ceramide synthase 5	Homo sapiens	177-182
30059758-4	2018	Here, we show that in human wild-type (wt) p53 HCT-116 colon cancer cells treatment with oxaliplatin or 5-fluorouracil (5-FU) leads to a strong increase in ceramide synthase 5 (CerS5) expression and C16:0-ceramide levels, which was not shown in HCT-116 lacking p53 expression (HCT-116 p53-/-).	Oxaliplatin	89-100	tumor protein p53	Homo sapiens	261-264
30059758-4	2018	Here, we show that in human wild-type (wt) p53 HCT-116 colon cancer cells treatment with oxaliplatin or 5-fluorouracil (5-FU) leads to a strong increase in ceramide synthase 5 (CerS5) expression and C16:0-ceramide levels, which was not shown in HCT-116 lacking p53 expression (HCT-116 p53-/-).	Oxaliplatin	89-100	tumor protein p53	Homo sapiens	261-264
30119236-0	2018	Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.	Oxaliplatin	61-72	maternally expressed 3	Homo sapiens	18-22
30059758-7	2018	Stable knockdown of CerS5 expression using CerS5-targeting shRNA led to an increased sensitivity of HCT-116 p53wt cells, but not of p53-/- cells, to oxaliplatin and 5-FU.	Oxaliplatin	149-160	ceramide synthase 5	Homo sapiens	20-25
30059758-7	2018	Stable knockdown of CerS5 expression using CerS5-targeting shRNA led to an increased sensitivity of HCT-116 p53wt cells, but not of p53-/- cells, to oxaliplatin and 5-FU.	Oxaliplatin	149-160	ceramide synthase 5	Homo sapiens	43-48
30119236-0	2018	Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.	Oxaliplatin	61-72	microRNA 141	Homo sapiens	95-102
30119236-0	2018	Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.	Oxaliplatin	61-72	programmed cell death 4	Homo sapiens	103-108
30059758-7	2018	Stable knockdown of CerS5 expression using CerS5-targeting shRNA led to an increased sensitivity of HCT-116 p53wt cells, but not of p53-/- cells, to oxaliplatin and 5-FU.	Oxaliplatin	149-160	tumor protein p53	Homo sapiens	108-111
30119236-3	2018	In the present study, we aimed to identify the role of MEG3 in oxaliplatin-resistant colorectal cancer (CRC) and its potential mechanisms.	Oxaliplatin	63-74	maternally expressed 3	Homo sapiens	55-59
30059758-10	2018	In conclusion, in p53wt colon cancer cells chemosensitivity against oxaliplatin or 5-FU could be enhanced by downregulation of CerS5 expression leading to reduced autophagy and mitochondrial respiration.	Oxaliplatin	68-79	tumor protein p53	Homo sapiens	18-21
30119236-4	2018	MEG3 was down-regulated in oxaliplatin-resistant CRC tissues and cell lines.	Oxaliplatin	27-38	maternally expressed 3	Homo sapiens	0-4
30059758-10	2018	In conclusion, in p53wt colon cancer cells chemosensitivity against oxaliplatin or 5-FU could be enhanced by downregulation of CerS5 expression leading to reduced autophagy and mitochondrial respiration.	Oxaliplatin	68-79	ceramide synthase 5	Homo sapiens	127-132
30119236-6	2018	Overexpression of MEG3 improved oxaliplatin sensitivity of HT29/OXA and HCT116/OXA cells.	Oxaliplatin	32-43	maternally expressed 3	Homo sapiens	18-22
30119236-9	2018	miR-141 inhibition or PDCD4 up-regulation could mimic the functional role in oxaliplatin resistance, which was counteracted by overexpression of MEG3.	Oxaliplatin	77-88	microRNA 141	Homo sapiens	0-7
29920241-0	2018	Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and beta1 integrin/FAK-mediated signalling.	Oxaliplatin	66-77	N-acylsphingosine amidohydrolase 1	Homo sapiens	0-15
30119236-9	2018	miR-141 inhibition or PDCD4 up-regulation could mimic the functional role in oxaliplatin resistance, which was counteracted by overexpression of MEG3.	Oxaliplatin	77-88	programmed cell death 4	Homo sapiens	22-27
30119236-9	2018	miR-141 inhibition or PDCD4 up-regulation could mimic the functional role in oxaliplatin resistance, which was counteracted by overexpression of MEG3.	Oxaliplatin	77-88	maternally expressed 3	Homo sapiens	145-149
30119236-10	2018	Collectively, MEG3 facilitated the sensitivity of CRC cells to oxaliplatin by regulating miR-141/PDCD4 axis, providing a novel therapeutic strategy for CRC.	Oxaliplatin	63-74	maternally expressed 3	Homo sapiens	14-18
30119236-10	2018	Collectively, MEG3 facilitated the sensitivity of CRC cells to oxaliplatin by regulating miR-141/PDCD4 axis, providing a novel therapeutic strategy for CRC.	Oxaliplatin	63-74	microRNA 141	Homo sapiens	89-96
30119236-10	2018	Collectively, MEG3 facilitated the sensitivity of CRC cells to oxaliplatin by regulating miR-141/PDCD4 axis, providing a novel therapeutic strategy for CRC.	Oxaliplatin	63-74	programmed cell death 4	Homo sapiens	97-102
30345013-3	2018	In patients with pN1 and pT1-pT3 tumors, 3 months of treatment with 5-fluorouracil and oxaliplatin is comparable with respect to 3-year survival rate to 6 months of treatment.	Oxaliplatin	87-98	zinc finger protein 77	Homo sapiens	25-28
30345013-3	2018	In patients with pN1 and pT1-pT3 tumors, 3 months of treatment with 5-fluorouracil and oxaliplatin is comparable with respect to 3-year survival rate to 6 months of treatment.	Oxaliplatin	87-98	zinc finger protein 135	Homo sapiens	29-32
29966655-0	2018	Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ ABCC1 axis.	Oxaliplatin	39-50	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	20-28
29966655-0	2018	Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ ABCC1 axis.	Oxaliplatin	39-50	microRNA 7-2	Homo sapiens	98-106
29966655-0	2018	Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ ABCC1 axis.	Oxaliplatin	39-50	ATP binding cassette subfamily C member 1	Homo sapiens	108-113
29966655-3	2018	In this study, we concentrated on the function and mechanism of KCNQ1OT1 on oxaliplatin resistance in hepatocellular carcinoma.	Oxaliplatin	76-87	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	64-72
29966655-4	2018	Results showed that KCNQ1OT1 was significantly up-regulated in oxaliplatin-resistant HepG2 and Huh7 cells.	Oxaliplatin	63-74	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	20-28
29966655-7	2018	Conclusively, KCNQ1OT1 modulated oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ABCC1 axis, indicating a novel approach for the treatment of hepatocellular carcinoma.	Oxaliplatin	33-44	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	14-22
29966655-7	2018	Conclusively, KCNQ1OT1 modulated oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ABCC1 axis, indicating a novel approach for the treatment of hepatocellular carcinoma.	Oxaliplatin	33-44	microRNA 7-2	Homo sapiens	92-100
29966655-7	2018	Conclusively, KCNQ1OT1 modulated oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ABCC1 axis, indicating a novel approach for the treatment of hepatocellular carcinoma.	Oxaliplatin	33-44	ATP binding cassette subfamily C member 1	Homo sapiens	101-106
30056126-0	2018	Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin.	Oxaliplatin	112-123	potassium two pore domain channel subfamily K member 2	Homo sapiens	14-20
29964008-0	2018	Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.	Oxaliplatin	62-73	ADAM metallopeptidase domain 17	Homo sapiens	13-19
29964008-1	2018	We investigated the role of a disintegrin and metalloproteinase 17 (ADAM17) in chemo resistance, and to clarify the mechanism underlying reverse of L-OHP resistance by knockdown of ADAM17.	Oxaliplatin	148-153	ADAM metallopeptidase domain 17	Homo sapiens	181-187
29964008-9	2018	Moreover, ADAM17 shRNA, AG1478 and LY294002 could inhibit cell proliferation, induce apoptosis and increase oxaliplatin sensitivity in HCT-8/L-OHP and parental colorectal cancer cell line, but nonsense shRNA did not show this effect.	Oxaliplatin	108-119	ADAM metallopeptidase domain 17	Homo sapiens	10-16
29964008-11	2018	The present study provides the evidence that downregulation of ADAM17 could increase the sensitivity to chemotherapy, inhibit cell proliferation, induce apoptosis, and reverse oxaliplatin resistance via suppression of the EGFR/PI3K/AKT signaling pathway in CRC.	Oxaliplatin	176-187	ADAM metallopeptidase domain 17	Homo sapiens	63-69
29964008-11	2018	The present study provides the evidence that downregulation of ADAM17 could increase the sensitivity to chemotherapy, inhibit cell proliferation, induce apoptosis, and reverse oxaliplatin resistance via suppression of the EGFR/PI3K/AKT signaling pathway in CRC.	Oxaliplatin	176-187	epidermal growth factor receptor	Homo sapiens	222-226
30911664-0	2018	Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design.	Oxaliplatin	20-31	pipecolic acid and sarcosine oxidase	Homo sapiens	132-137
30126848-7	2018	Transfection with ZNF139-siRNA into SGC7901/ADR cells markedly increased expression of miR-185, and treating with chemotherapeutic drugs ADR, 5-FU, L-OHP, the survival rate of SGC7901/ADR cells obviously decreased after ZNF139-siRNA transfection.	Oxaliplatin	148-153	zinc finger with KRAB and SCAN domains 1	Homo sapiens	18-24
30126848-8	2018	On the other hand, transfection with pcDNA-ZNF139 in GC cell line SGC7901 resulted in an increased expression level of ZNF139 and a decline in the expression level of miR-185, meanwhile drug resistance of GC cells was clearly enhanced to ADR, 5-FU, L-OHP.	Oxaliplatin	249-254	zinc finger with KRAB and SCAN domains 1	Homo sapiens	43-49
29920241-0	2018	Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and beta1 integrin/FAK-mediated signalling.	Oxaliplatin	66-77	transglutaminase 2	Homo sapiens	104-122
29920241-0	2018	Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and beta1 integrin/FAK-mediated signalling.	Oxaliplatin	66-77	integrin subunit beta 1	Homo sapiens	127-141
29920241-0	2018	Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and beta1 integrin/FAK-mediated signalling.	Oxaliplatin	66-77	protein tyrosine kinase 2	Homo sapiens	142-145
29920241-4	2018	Finally, we have explored the role of ASAH1 in response and resistance mechanisms to oxaliplatin (OXA) in HCT 116 colon cancer cells.	Oxaliplatin	85-96	N-acylsphingosine amidohydrolase 1	Homo sapiens	38-43
29920241-7	2018	Obtained data revealed that ASAH1 was involved in HCT 116 cell response to OXA and that anti-proliferative, pro-apoptotic, anti-migratory and anti-clonogenic effects of OXA could be significantly increased by combination treatment with ASAH1 inhibitor carmofur.	Oxaliplatin	75-78	N-acylsphingosine amidohydrolase 1	Homo sapiens	28-33
30073902-1	2018	INTRODUCTION: Ramucirumab, a human monoclonal antibody against vascular endothelial growth factor receptor 2 (VEGFR-2), is an antiangiogenic therapy that has been approved in combination with FOLFIRI in second-line treatment of metastatic colorectal cancer (mCRC), after progression on or after therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.	Oxaliplatin	321-332	kinase insert domain receptor	Homo sapiens	63-108
30126982-6	2018	The advillin-containing focal-adhesion protein complex was shed from neurite tips during neurite retraction and was detectable in cerebrospinal fluid in experimental autoimmune encephalomyelitis, oxaliplatin-induced peripheral neuropathy, and chronic constriction injury of the sciatic nerve.	Oxaliplatin	196-207	advillin	Homo sapiens	4-12
29936608-0	2018	Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients.	Oxaliplatin	59-70	cyclin H	Homo sapiens	25-33
30073902-1	2018	INTRODUCTION: Ramucirumab, a human monoclonal antibody against vascular endothelial growth factor receptor 2 (VEGFR-2), is an antiangiogenic therapy that has been approved in combination with FOLFIRI in second-line treatment of metastatic colorectal cancer (mCRC), after progression on or after therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.	Oxaliplatin	321-332	kinase insert domain receptor	Homo sapiens	110-117
30249901-4	2018	Cell viability assay, colony formation and xenograft experiments assay were performed to detect effect of FHL1 on Paclitaxel or Oxaliplatin resistance in vitro and in vivo.	Oxaliplatin	128-139	four and a half LIM domains 1	Homo sapiens	106-110
28229371-6	2018	In the KRAS-mutated group, the longest median OS was observed with oxaliplatin with or without bevacizumab (34 months).	Oxaliplatin	67-78	KRAS proto-oncogene, GTPase	Homo sapiens	7-11
29876924-4	2018	We found that CypB is a novel wild-type p53 (p53WT)-inducible gene but a negative regulator of p53WT in response to oxaliplatin treatment.	Oxaliplatin	116-127	peptidylprolyl isomerase B	Homo sapiens	14-18
29807243-6	2018	In vivo tests showed that Cou-platin, at equimolar dose to cisplatin, could inhibit tumor growth in nude mouse HCT116 tumor xenograft models almost as cisplatin and oxaliplatin, but with less toxicity.	Oxaliplatin	165-176	brachyury, T-box transcription factor T	Mus musculus	26-29
29876924-5	2018	Overexpression of CypB shortens the half-life of p53WT and inhibits oxaliplatin-induced apoptosis in CRC cells, whereas knockdown of CypB lengthens the half-life of p53WT and stimulates p53WT-dependent apoptosis.	Oxaliplatin	68-79	peptidylprolyl isomerase B	Homo sapiens	18-22
30031110-0	2018	Oxaliplatin treatment impairs extension of sensory neuron neurites in vitro through miR-204 overexpression.	Oxaliplatin	0-11	microRNA 204	Homo sapiens	84-91
30031110-10	2018	Taken together, our data indicate that oxaliplatin impairs sensory neurons arborization through up-regulation of miR-204 that decreases PlexinA2 expression and neurite length.	Oxaliplatin	39-50	microRNA 204	Homo sapiens	113-120
30031110-10	2018	Taken together, our data indicate that oxaliplatin impairs sensory neurons arborization through up-regulation of miR-204 that decreases PlexinA2 expression and neurite length.	Oxaliplatin	39-50	plexin A2	Homo sapiens	136-144
30214685-8	2018	Of the chemotherapeutic protocols applied, gemcitabine plus oxaliplatin (GEMOX) significantly increased circulating TSLP levels.	Oxaliplatin	60-71	thymic stromal lymphopoietin	Homo sapiens	116-120
30015936-0	2018	High expression of microRNA-31 and its host gene LOC554202 predict favorable outcomes in patients with colorectal cancer treated with oxaliplatin.	Oxaliplatin	134-145	microRNA 31	Homo sapiens	19-30
30015936-12	2018	These data indicated that miR-31 and LOC554202 may be potential markers for evaluation of the prognosis of patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	129-140	microRNA 31	Homo sapiens	26-32
29925895-0	2018	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.	Oxaliplatin	60-71	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	18-22
29925895-2	2018	We hypothesized that genetic polymorphisms in PIN1-related pathways may affect tumor sensitivity to oxaliplatin or irinotecan in metastatic colorectal cancer (mCRC) patients.	Oxaliplatin	100-111	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	46-50
29925895-5	2018	In the oxaliplatin cohort 1, patients carrying any PIN1 rs2233678 C allele had shorter progression-free survival (PFS) and overall survival (OS) than the G/G variant (PFS, 7.4 vs. 15.0 months, hazard ratio [HR] 3.24, P &lt; 0.001; OS, 16.9 vs. 31.5 months, HR: 2.38, P = 0.003).	Oxaliplatin	7-18	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	51-55
29925895-9	2018	Germline PIN1 polymorphisms may predict clinical outcomes in mCRC patients receiving oxaliplatin-based or irinotecan-based therapy, and identify specific populations favorable to oxaliplatin plus irinotecan combination therapy.	Oxaliplatin	85-96	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	9-13
29925895-9	2018	Germline PIN1 polymorphisms may predict clinical outcomes in mCRC patients receiving oxaliplatin-based or irinotecan-based therapy, and identify specific populations favorable to oxaliplatin plus irinotecan combination therapy.	Oxaliplatin	179-190	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	9-13
30143606-0	2018	Correction to: MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy.	Oxaliplatin	38-49	eva-1 homolog A, regulator of programmed cell death	Homo sapiens	114-119
29980405-5	2018	Upon introduction of the WT-TP53 gene into the MIA-PaCa-2 pancreatic cancer cell line, the sensitivity to drugs used to treat pancreatic cancer cells such as: gemcitabine, fluorouracil (5FU), cisplatin, irinotecan, oxaliplatin, and paclitaxel increased significantly.	Oxaliplatin	215-226	tumor protein p53	Homo sapiens	28-32
30143021-11	2018	More importantly, they were resistant to cisplatin, oxaliplatin and cyclophosphamide exhibiting high cross-resistance along with alterations in expression of cancer-stem cell markers such as CD133, CD166, CD24, CD26, CXCR4, CD271 and CD274.	Oxaliplatin	52-63	chemokine (C-X-C motif) receptor 4	Mus musculus	217-222
30143021-11	2018	More importantly, they were resistant to cisplatin, oxaliplatin and cyclophosphamide exhibiting high cross-resistance along with alterations in expression of cancer-stem cell markers such as CD133, CD166, CD24, CD26, CXCR4, CD271 and CD274.	Oxaliplatin	52-63	CD274 antigen	Mus musculus	234-239
30108309-7	2018	Finally, we show that arginase antagonizes chemotherapeutic drugs oxaliplatin and 5-fluorouracil (5-FU), whereas ADI-PEG20 synergizes with oxaliplatin in ASS1-negative cell lines and appears to interact with 5-fluorouracil independently of ASS1 status.	Oxaliplatin	139-150	argininosuccinate synthase 1	Homo sapiens	154-158
30175154-2	2018	Here, we report for the first time that miR-34a expression was significantly downregulated in clinical CCa samples from oxaliplatin-resistant patients and in experimentally established multidrug-resistant CCa cells.	Oxaliplatin	120-131	microRNA 34a	Homo sapiens	40-47
30175154-4	2018	Functionally, ectopic expression of exogenous miR-34a resensitized multidrug-resistant HCT-8/OR cells to oxaliplatin treatment, whereas miR-34a inhibition augmented the oxaliplatin resistance in chemosensitive HCT-8 cells.	Oxaliplatin	105-116	microRNA 34a	Homo sapiens	46-53
30175154-4	2018	Functionally, ectopic expression of exogenous miR-34a resensitized multidrug-resistant HCT-8/OR cells to oxaliplatin treatment, whereas miR-34a inhibition augmented the oxaliplatin resistance in chemosensitive HCT-8 cells.	Oxaliplatin	169-180	microRNA 34a	Homo sapiens	136-143
30120227-6	2018	ZFL-mediated ER stress enhanced anti-cancer drug-induced apoptotic cell death, and pretreatment with chemical chaperones or down-regulation of ATF4 and CHOP by small interfering RNA markedly reduced ZFL plus oxaliplatin-induced apoptosis.	Oxaliplatin	208-219	activating transcription factor 4	Homo sapiens	143-147
30120227-6	2018	ZFL-mediated ER stress enhanced anti-cancer drug-induced apoptotic cell death, and pretreatment with chemical chaperones or down-regulation of ATF4 and CHOP by small interfering RNA markedly reduced ZFL plus oxaliplatin-induced apoptosis.	Oxaliplatin	208-219	DNA damage inducible transcript 3	Homo sapiens	152-156
30008940-13	2018	Downregulated hCTP1 and upregulated ATP7A and ATP7B were associated with L-OHP resistance, and GA reversed the resistance by increasing levels of hCTR1 and decreasing levels of ATP7A and ATP7B.	Oxaliplatin	73-78	ATPase copper transporting alpha	Homo sapiens	36-41
29873684-1	2018	Background: The German rectal cancer trial CAO/ARO/AIO-04 has shown a significant benefit in 3-year disease-free survival (DFS) of adding oxaliplatin to a standard preoperative 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) and adjuvant chemotherapy in patients with locally advanced rectal cancer.	Oxaliplatin	138-149	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	47-50
29574322-4	2018	The aim of our study was to illustrate electrochemotherapy as an effective treatment for pancreatic cancer along with the expression change in stemness genes (Nanog, Sox2 and Oct3/4) in pancreatic cancer cells post electrochemotherapy with bleomycin, cisplatin and oxaliplatin.	Oxaliplatin	265-276	Nanog homeobox	Homo sapiens	159-164
29574322-4	2018	The aim of our study was to illustrate electrochemotherapy as an effective treatment for pancreatic cancer along with the expression change in stemness genes (Nanog, Sox2 and Oct3/4) in pancreatic cancer cells post electrochemotherapy with bleomycin, cisplatin and oxaliplatin.	Oxaliplatin	265-276	SRY-box transcription factor 2	Homo sapiens	166-170
29574322-4	2018	The aim of our study was to illustrate electrochemotherapy as an effective treatment for pancreatic cancer along with the expression change in stemness genes (Nanog, Sox2 and Oct3/4) in pancreatic cancer cells post electrochemotherapy with bleomycin, cisplatin and oxaliplatin.	Oxaliplatin	265-276	POU class 5 homeobox 1	Homo sapiens	175-181
29869834-7	2018	Our results also showed that clinical drug oxaliplatin suppresses colon carcinoma cell proliferation by inhibiting the YY1/GLUT3 axis.	Oxaliplatin	43-54	YY1 transcription factor	Homo sapiens	119-122
29869834-7	2018	Our results also showed that clinical drug oxaliplatin suppresses colon carcinoma cell proliferation by inhibiting the YY1/GLUT3 axis.	Oxaliplatin	43-54	solute carrier family 2 member 3	Homo sapiens	123-128
29749542-0	2018	The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells.	Oxaliplatin	65-76	histone deacetylase 6	Homo sapiens	4-9
29323702-0	2018	Sirtuin 3 silencing improves oxaliplatin efficacy through acetylation of MnSOD in colon cancer.	Oxaliplatin	29-40	sirtuin 3	Homo sapiens	0-9
29323702-0	2018	Sirtuin 3 silencing improves oxaliplatin efficacy through acetylation of MnSOD in colon cancer.	Oxaliplatin	29-40	superoxide dismutase 2	Homo sapiens	73-78
29323702-9	2018	In conclusion, SIRT3 could be a target for colon cancer, since it regulates the antioxidant response and its knockdown improves the efficacy of oxaliplatin treatment.	Oxaliplatin	144-155	sirtuin 3	Homo sapiens	15-20
30170406-0	2018	miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study.	Oxaliplatin	60-71	miR-17-92a-1 cluster host gene	Homo sapiens	0-9
30106061-12	2018	These findings confirm that AG490 can attenuate oxaliplatin-induced acute neuropathic pain and is associated with the inhibition in the JAK/STAT3 signaling pathway.	Oxaliplatin	48-59	signal transducer and activator of transcription 3	Rattus norvegicus	140-145
30008904-13	2018	Trastuzumab combined with oxaliplatin and capecitabine as a conversion therapy regime for ERBB2-overexpressing advanced gastric adenocarcinoma increased the likelihood of successful surgical resection, and prolonged progression-free survival.	Oxaliplatin	26-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-95
29845565-9	2018	Additionally, the heterozygote variants of CYP1A1-m1 and CYP1A1-m2 significantly increased the urinary excretion of 1-OHP, and the GSTM1 null variant was inversely associated with the comet parameters evaluated.	Oxaliplatin	116-121	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	43-49
29845565-9	2018	Additionally, the heterozygote variants of CYP1A1-m1 and CYP1A1-m2 significantly increased the urinary excretion of 1-OHP, and the GSTM1 null variant was inversely associated with the comet parameters evaluated.	Oxaliplatin	116-121	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	57-63
29845565-9	2018	Additionally, the heterozygote variants of CYP1A1-m1 and CYP1A1-m2 significantly increased the urinary excretion of 1-OHP, and the GSTM1 null variant was inversely associated with the comet parameters evaluated.	Oxaliplatin	116-121	glutathione S-transferase mu 1	Homo sapiens	131-136
30008940-13	2018	Downregulated hCTP1 and upregulated ATP7A and ATP7B were associated with L-OHP resistance, and GA reversed the resistance by increasing levels of hCTR1 and decreasing levels of ATP7A and ATP7B.	Oxaliplatin	73-78	ATPase copper transporting beta	Homo sapiens	46-51
33168516-8	2018	CONCLUSIONS: Dex can alleviate oxaliplatin-induced neuropathic pain in rats by inhibiting the phosphorylation of STAT3 in the spinal cord.	Oxaliplatin	31-42	signal transducer and activator of transcription 3	Rattus norvegicus	113-118
29737584-0	2018	Metformin increases the cytotoxicity of oxaliplatin in human DLD-1 colorectal cancer cells through down-regulating HMGB1 expression.	Oxaliplatin	40-51	high mobility group box 1	Homo sapiens	115-120
29737584-8	2018	The results showed that treatment with OXA increased HMGB1 expression in the ERK1/2- and Akt-dependent manners in DLD-1 cells.	Oxaliplatin	39-42	high mobility group box 1	Homo sapiens	53-58
29737584-8	2018	The results showed that treatment with OXA increased HMGB1 expression in the ERK1/2- and Akt-dependent manners in DLD-1 cells.	Oxaliplatin	39-42	mitogen-activated protein kinase 3	Homo sapiens	77-83
29737584-8	2018	The results showed that treatment with OXA increased HMGB1 expression in the ERK1/2- and Akt-dependent manners in DLD-1 cells.	Oxaliplatin	39-42	AKT serine/threonine kinase 1	Homo sapiens	89-92
29737584-11	2018	Compared to a single agent, OXA combined with metformin administration resulted in cytotoxicity and cell growth inhibition synergistically, accompanied with reduced HMGB1 level.	Oxaliplatin	28-31	high mobility group box 1	Homo sapiens	165-170
30029680-0	2018	Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.	Oxaliplatin	104-115	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	14-18
30131854-8	2018	Moreover, FSTL1 knockdown made CRC cells more susceptible to oxaliplatin and irinotecan-induced death.	Oxaliplatin	61-72	follistatin like 1	Homo sapiens	10-15
30029680-0	2018	Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.	Oxaliplatin	104-115	tumor protein p53	Homo sapiens	46-49
30029680-13	2018	CONCLUSION: Our results show that oxaliplatin mediates differential cellular responses in colon cancer cells depending on their p53 status, and demonstrate that the ROS-p53 axis is important for regulating POU3F2 and its downstream target, tNOX.	Oxaliplatin	34-45	tumor protein p53	Homo sapiens	128-131
30029680-13	2018	CONCLUSION: Our results show that oxaliplatin mediates differential cellular responses in colon cancer cells depending on their p53 status, and demonstrate that the ROS-p53 axis is important for regulating POU3F2 and its downstream target, tNOX.	Oxaliplatin	34-45	tumor protein p53	Homo sapiens	169-172
30029680-0	2018	Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.	Oxaliplatin	104-115	POU class 3 homeobox 2	Homo sapiens	50-56
30029680-13	2018	CONCLUSION: Our results show that oxaliplatin mediates differential cellular responses in colon cancer cells depending on their p53 status, and demonstrate that the ROS-p53 axis is important for regulating POU3F2 and its downstream target, tNOX.	Oxaliplatin	34-45	POU class 3 homeobox 2	Homo sapiens	206-212
30029680-3	2018	We recently established that oxaliplatin also exert its anti-cancer activity in gastric cancer cell lines by targeting tumor-associated NADH oxidase (tNOX), attenuate NAD+ generation and reduce NAD+-dependent sirtuin 1 (SIRT1) deacetylase activity, which in turn enhances p53 acetylation and apoptosis.	Oxaliplatin	29-40	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	119-148
30029680-13	2018	CONCLUSION: Our results show that oxaliplatin mediates differential cellular responses in colon cancer cells depending on their p53 status, and demonstrate that the ROS-p53 axis is important for regulating POU3F2 and its downstream target, tNOX.	Oxaliplatin	34-45	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	240-244
30029680-14	2018	Notably, the depletion of tNOX sensitizes p53-null cells to both spontaneous and oxaliplatin-induced apoptosis.	Oxaliplatin	81-92	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	26-30
30029680-3	2018	We recently established that oxaliplatin also exert its anti-cancer activity in gastric cancer cell lines by targeting tumor-associated NADH oxidase (tNOX), attenuate NAD+ generation and reduce NAD+-dependent sirtuin 1 (SIRT1) deacetylase activity, which in turn enhances p53 acetylation and apoptosis.	Oxaliplatin	29-40	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	150-154
30029680-14	2018	Notably, the depletion of tNOX sensitizes p53-null cells to both spontaneous and oxaliplatin-induced apoptosis.	Oxaliplatin	81-92	tumor protein p53	Homo sapiens	42-45
30029680-3	2018	We recently established that oxaliplatin also exert its anti-cancer activity in gastric cancer cell lines by targeting tumor-associated NADH oxidase (tNOX), attenuate NAD+ generation and reduce NAD+-dependent sirtuin 1 (SIRT1) deacetylase activity, which in turn enhances p53 acetylation and apoptosis.	Oxaliplatin	29-40	sirtuin 1	Homo sapiens	209-218
30029680-3	2018	We recently established that oxaliplatin also exert its anti-cancer activity in gastric cancer cell lines by targeting tumor-associated NADH oxidase (tNOX), attenuate NAD+ generation and reduce NAD+-dependent sirtuin 1 (SIRT1) deacetylase activity, which in turn enhances p53 acetylation and apoptosis.	Oxaliplatin	29-40	sirtuin 1	Homo sapiens	220-225
30029680-3	2018	We recently established that oxaliplatin also exert its anti-cancer activity in gastric cancer cell lines by targeting tumor-associated NADH oxidase (tNOX), attenuate NAD+ generation and reduce NAD+-dependent sirtuin 1 (SIRT1) deacetylase activity, which in turn enhances p53 acetylation and apoptosis.	Oxaliplatin	29-40	tumor protein p53	Homo sapiens	272-275
30029680-4	2018	METHODS: In this study, differential cellular outcomes in response to oxaliplatin exposure of p53-wild-type versus p53-null HCT116 human colon cancer cells were examined.	Oxaliplatin	70-81	tumor protein p53	Homo sapiens	94-97
30029680-4	2018	METHODS: In this study, differential cellular outcomes in response to oxaliplatin exposure of p53-wild-type versus p53-null HCT116 human colon cancer cells were examined.	Oxaliplatin	70-81	tumor protein p53	Homo sapiens	115-118
30029680-6	2018	The engagement between oxaliplatin and tNOX protein was studied by cellular thermal shift assay.	Oxaliplatin	23-34	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	39-43
30029680-8	2018	RESULTS: In p53-wild-type cells, we found that oxaliplatin inhibited cell growth by inducing apoptosis and concurrently down-regulating tNOX at both the transcriptional and translational levels.	Oxaliplatin	47-58	tumor protein p53	Homo sapiens	12-15
30029680-8	2018	RESULTS: In p53-wild-type cells, we found that oxaliplatin inhibited cell growth by inducing apoptosis and concurrently down-regulating tNOX at both the transcriptional and translational levels.	Oxaliplatin	47-58	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	136-140
30029680-9	2018	In p53-null cells, in contrast, oxaliplatin moderately up-regulated tNOX expression and yielded no apoptosis and much less cytotoxicity.	Oxaliplatin	32-43	tumor protein p53	Homo sapiens	3-6
30029680-9	2018	In p53-null cells, in contrast, oxaliplatin moderately up-regulated tNOX expression and yielded no apoptosis and much less cytotoxicity.	Oxaliplatin	32-43	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	68-72
30029680-10	2018	Further experiments revealed that in p53-wild-type cells, oxaliplatin enhanced ROS generation and p53 transcriptional activation, leading to down-regulation of the transcriptional factor, POU3F2, which enhances the expression of tNOX.	Oxaliplatin	58-69	tumor protein p53	Homo sapiens	37-40
30029680-10	2018	Further experiments revealed that in p53-wild-type cells, oxaliplatin enhanced ROS generation and p53 transcriptional activation, leading to down-regulation of the transcriptional factor, POU3F2, which enhances the expression of tNOX.	Oxaliplatin	58-69	tumor protein p53	Homo sapiens	98-101
30029680-10	2018	Further experiments revealed that in p53-wild-type cells, oxaliplatin enhanced ROS generation and p53 transcriptional activation, leading to down-regulation of the transcriptional factor, POU3F2, which enhances the expression of tNOX.	Oxaliplatin	58-69	POU class 3 homeobox 2	Homo sapiens	188-194
30029680-10	2018	Further experiments revealed that in p53-wild-type cells, oxaliplatin enhanced ROS generation and p53 transcriptional activation, leading to down-regulation of the transcriptional factor, POU3F2, which enhances the expression of tNOX.	Oxaliplatin	58-69	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	229-233
30029680-11	2018	Moreover, the addition of a ROS scavenger reversed the p53 activation, POU3F2 down-regulation, and apoptosis induced by oxaliplatin in p53-wild-type cells.	Oxaliplatin	120-131	tumor protein p53	Homo sapiens	55-58
30029680-11	2018	Moreover, the addition of a ROS scavenger reversed the p53 activation, POU3F2 down-regulation, and apoptosis induced by oxaliplatin in p53-wild-type cells.	Oxaliplatin	120-131	POU class 3 homeobox 2	Homo sapiens	71-77
30029680-11	2018	Moreover, the addition of a ROS scavenger reversed the p53 activation, POU3F2 down-regulation, and apoptosis induced by oxaliplatin in p53-wild-type cells.	Oxaliplatin	120-131	tumor protein p53	Homo sapiens	135-138
30029680-12	2018	In the p53-null line, on the other hand, oxaliplatin treatment triggered less ROS generation and no p53 protein, such that POU3F2 and tNOX were not down-regulated and oxaliplatin-mediated cytotoxicity was attenuated.	Oxaliplatin	41-52	tumor protein p53	Homo sapiens	7-10
30029680-12	2018	In the p53-null line, on the other hand, oxaliplatin treatment triggered less ROS generation and no p53 protein, such that POU3F2 and tNOX were not down-regulated and oxaliplatin-mediated cytotoxicity was attenuated.	Oxaliplatin	41-52	tumor protein p53	Homo sapiens	100-103
30029680-12	2018	In the p53-null line, on the other hand, oxaliplatin treatment triggered less ROS generation and no p53 protein, such that POU3F2 and tNOX were not down-regulated and oxaliplatin-mediated cytotoxicity was attenuated.	Oxaliplatin	41-52	POU class 3 homeobox 2	Homo sapiens	123-129
30029680-12	2018	In the p53-null line, on the other hand, oxaliplatin treatment triggered less ROS generation and no p53 protein, such that POU3F2 and tNOX were not down-regulated and oxaliplatin-mediated cytotoxicity was attenuated.	Oxaliplatin	41-52	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	134-138
30029680-12	2018	In the p53-null line, on the other hand, oxaliplatin treatment triggered less ROS generation and no p53 protein, such that POU3F2 and tNOX were not down-regulated and oxaliplatin-mediated cytotoxicity was attenuated.	Oxaliplatin	167-178	tumor protein p53	Homo sapiens	7-10
30042932-9	2018	Corroborating recombinant soluble DLL1 and Notch activator oxaliplatin stimulate STAT3 phosphorylation and expression of immune-suppressive PD-L1.	Oxaliplatin	59-70	signal transducer and activator of transcription 3	Homo sapiens	81-86
30014319-3	2018	The present study is based on evaluation of anti-proliferative potential, pharmacokinetics parameters, safety profile, biodistribution and efficacy of 5-FU/oxaliplatin loaded lactoferrin nanoparticles in cell lines and wistar rats in order to overcome the above limitation.	Oxaliplatin	156-167	lactotransferrin	Rattus norvegicus	175-186
30014319-8	2018	Lactoferrin nanoparticles also improve the pharmacokinetics profile, safety parameters and efficacy of 5-FU and Oxaliplatin.	Oxaliplatin	112-123	lactotransferrin	Rattus norvegicus	0-11
30014319-9	2018	CONCLUSION: Lactoferrin nanoparticles demonstrated an attractive drug delivery module to manage the colon adenocarcinoma as it has improved the antiproliferative activity of 5-FU and Oxaliplatin against colon adenocarcinoma cells.	Oxaliplatin	183-194	lactotransferrin	Rattus norvegicus	12-23
30042932-9	2018	Corroborating recombinant soluble DLL1 and Notch activator oxaliplatin stimulate STAT3 phosphorylation and expression of immune-suppressive PD-L1.	Oxaliplatin	59-70	CD274 molecule	Homo sapiens	140-145
30094097-6	2018	We found that trametinib, an MEK inhibitor, suppressed oxaliplatin-, paclitaxel-, vincristine-, and bortezomib-induced cold and mechanical allodynia in mice.	Oxaliplatin	55-66	midkine	Mus musculus	29-32
29978335-6	2018	The patient was treated with S-1 plus oxaliplatin based on negative immunohistochemical staining of the resected specimens for human epidermal growth factor receptor 2 (HER2).	Oxaliplatin	38-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-167
29978335-6	2018	The patient was treated with S-1 plus oxaliplatin based on negative immunohistochemical staining of the resected specimens for human epidermal growth factor receptor 2 (HER2).	Oxaliplatin	38-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-173
30094097-8	2018	In conclusion, we demonstrated that the disruption of this pathway by MEK inhibitors suppresses oxaliplatin-, paclitaxel-, vincristine-, and bortezomib-induced neuropathy.	Oxaliplatin	96-107	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
30094097-7	2018	In addition, treatment with oxaliplatin, paclitaxel, vincristine, or bortezomib enhanced ERK1/2 and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord lumbar segments 4-6, and when combined with trametinib, can prevent chemotherapy-induced neuropathy via the suppression of ERK1/2 activation, but does not affect JNK activation.	Oxaliplatin	28-39	mitogen-activated protein kinase 3	Homo sapiens	89-95
30094097-7	2018	In addition, treatment with oxaliplatin, paclitaxel, vincristine, or bortezomib enhanced ERK1/2 and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord lumbar segments 4-6, and when combined with trametinib, can prevent chemotherapy-induced neuropathy via the suppression of ERK1/2 activation, but does not affect JNK activation.	Oxaliplatin	28-39	mitogen-activated protein kinase 8	Homo sapiens	100-123
30094097-7	2018	In addition, treatment with oxaliplatin, paclitaxel, vincristine, or bortezomib enhanced ERK1/2 and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord lumbar segments 4-6, and when combined with trametinib, can prevent chemotherapy-induced neuropathy via the suppression of ERK1/2 activation, but does not affect JNK activation.	Oxaliplatin	28-39	mitogen-activated protein kinase 8	Homo sapiens	125-128
30094097-7	2018	In addition, treatment with oxaliplatin, paclitaxel, vincristine, or bortezomib enhanced ERK1/2 and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord lumbar segments 4-6, and when combined with trametinib, can prevent chemotherapy-induced neuropathy via the suppression of ERK1/2 activation, but does not affect JNK activation.	Oxaliplatin	28-39	mitogen-activated protein kinase 3	Homo sapiens	288-294
30094097-7	2018	In addition, treatment with oxaliplatin, paclitaxel, vincristine, or bortezomib enhanced ERK1/2 and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord lumbar segments 4-6, and when combined with trametinib, can prevent chemotherapy-induced neuropathy via the suppression of ERK1/2 activation, but does not affect JNK activation.	Oxaliplatin	28-39	mitogen-activated protein kinase 8	Homo sapiens	327-330
29928420-9	2018	Cell death induced by oxaliplatin and sorafenib was significantly increased following GSTM1-knockdown in MHCC97-H and Huh-7 cells.	Oxaliplatin	22-33	glutathione S-transferase mu 1	Homo sapiens	86-91
29684854-0	2018	The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells.	Oxaliplatin	43-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-16
29684854-0	2018	The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells.	Oxaliplatin	43-54	NFE2 like bZIP transcription factor 2	Homo sapiens	17-21
29684854-3	2018	The aim of this study was to investigate the possible cross talk between Nrf2 and Her2 mediated signaling pathways in development of oxaliplatin resistance in colon cancer cells.	Oxaliplatin	133-144	NFE2 like bZIP transcription factor 2	Homo sapiens	73-77
29684854-3	2018	The aim of this study was to investigate the possible cross talk between Nrf2 and Her2 mediated signaling pathways in development of oxaliplatin resistance in colon cancer cells.	Oxaliplatin	133-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
29684854-4	2018	We first generated oxaliplatin-resistant LS174T and SW480 colon cancer cells with different Her2 expression levels by employing IC50 concentrations followed by a resting period.	Oxaliplatin	19-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
29684854-10	2018	Inhibition of either Nrf2 or Her2 alone and in combination caused a significant increase in oxaliplatin-induced cytotoxicity and apoptosis with maximum effects in SW480/Res cells with low Her2 and Nrf2 expression levels.	Oxaliplatin	92-103	NFE2 like bZIP transcription factor 2	Homo sapiens	21-25
29684854-10	2018	Inhibition of either Nrf2 or Her2 alone and in combination caused a significant increase in oxaliplatin-induced cytotoxicity and apoptosis with maximum effects in SW480/Res cells with low Her2 and Nrf2 expression levels.	Oxaliplatin	92-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
29684854-10	2018	Inhibition of either Nrf2 or Her2 alone and in combination caused a significant increase in oxaliplatin-induced cytotoxicity and apoptosis with maximum effects in SW480/Res cells with low Her2 and Nrf2 expression levels.	Oxaliplatin	92-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	188-192
29684854-10	2018	Inhibition of either Nrf2 or Her2 alone and in combination caused a significant increase in oxaliplatin-induced cytotoxicity and apoptosis with maximum effects in SW480/Res cells with low Her2 and Nrf2 expression levels.	Oxaliplatin	92-103	NFE2 like bZIP transcription factor 2	Homo sapiens	197-201
29684854-11	2018	Altogether, our results suggest that inhibition of Nrf2 signaling in colon cancer patients with Her2 overexpression can be considered as an important strategy to overcome oxaliplatin resistance.	Oxaliplatin	171-182	NFE2 like bZIP transcription factor 2	Homo sapiens	51-55
29684854-11	2018	Altogether, our results suggest that inhibition of Nrf2 signaling in colon cancer patients with Her2 overexpression can be considered as an important strategy to overcome oxaliplatin resistance.	Oxaliplatin	171-182	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
29774408-0	2018	Possible association of CAG repeat polymorphism in KCNN3 encoding the potassium channel SK3 with oxaliplatin-induced neurotoxicity.	Oxaliplatin	97-108	potassium calcium-activated channel subfamily N member 3	Homo sapiens	51-56
29774408-0	2018	Possible association of CAG repeat polymorphism in KCNN3 encoding the potassium channel SK3 with oxaliplatin-induced neurotoxicity.	Oxaliplatin	97-108	potassium calcium-activated channel subfamily N member 3	Homo sapiens	88-91
29774408-1	2018	INTRODUCTION: Data suggest a role of the potassium channel SK3 (KCNN3 gene) in oxaliplatin-induced neurotoxicity (OIN).	Oxaliplatin	79-90	potassium calcium-activated channel subfamily N member 3	Homo sapiens	59-62
29774408-1	2018	INTRODUCTION: Data suggest a role of the potassium channel SK3 (KCNN3 gene) in oxaliplatin-induced neurotoxicity (OIN).	Oxaliplatin	79-90	potassium calcium-activated channel subfamily N member 3	Homo sapiens	64-69
29247488-0	2018	Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.	Oxaliplatin	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	80-85
29637602-8	2018	HES1 silencing increased viability of HCT116 and its chemoresistant sublines after 5-FU or OxaPt treatment.	Oxaliplatin	91-96	hes family bHLH transcription factor 1	Homo sapiens	0-4
29637602-9	2018	The results of HES1 downregulation coincide with RO and XAV effects on cell viability of OxaPt-treated cells.	Oxaliplatin	89-94	hes family bHLH transcription factor 1	Homo sapiens	15-19
29977534-0	2018	Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases.	Oxaliplatin	124-135	thymidylate synthetase	Homo sapiens	0-20
29928420-11	2018	The results of the present study suggest that GSTM1 may protect HCC cells against the effect of oxaliplatin treatment through activating autophagy.	Oxaliplatin	96-107	glutathione S-transferase mu 1	Homo sapiens	46-51
29554018-0	2018	Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity.	Oxaliplatin	79-90	C-C motif chemokine ligand 2	Homo sapiens	10-14
29927360-0	2018	The interference between oxaliplatin &amp; anti-EGFR therapies: a different hypothesis to explain the "unexplainable".	Oxaliplatin	25-36	epidermal growth factor receptor	Homo sapiens	48-52
29554018-0	2018	Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity.	Oxaliplatin	79-90	C-C motif chemokine receptor 2	Homo sapiens	32-36
29554018-5	2018	Immunohistochemical showed that the expression of CCL2/CCR2 started to increase by 4 hours after oxaliplatin treatment, was significantly increased at day 4, and then both signals became normalized by day 15.	Oxaliplatin	97-108	C-C motif chemokine ligand 2	Homo sapiens	50-54
29554018-5	2018	Immunohistochemical showed that the expression of CCL2/CCR2 started to increase by 4 hours after oxaliplatin treatment, was significantly increased at day 4, and then both signals became normalized by day 15.	Oxaliplatin	97-108	C-C motif chemokine receptor 2	Homo sapiens	55-59
29554018-6	2018	Cotreatment with intrathecal anti-CCL2 antibodies prevented the development of oxaliplatin-induced mechanical hyperresponsiveness, and transiently reversed established hyperalgesia when given 1 week after chemotherapy.	Oxaliplatin	79-90	C-C motif chemokine ligand 2	Homo sapiens	34-38
29554018-7	2018	This is the first study to demonstrate CCL2/CCR2 signaling in a model of oxaliplatin-related CIPN; and it further shows that blocking of this signal can attenuate the development of oxaliplatin-induced mechanical hyperalgesia.	Oxaliplatin	73-84	C-C motif chemokine ligand 2	Homo sapiens	39-43
29554018-7	2018	This is the first study to demonstrate CCL2/CCR2 signaling in a model of oxaliplatin-related CIPN; and it further shows that blocking of this signal can attenuate the development of oxaliplatin-induced mechanical hyperalgesia.	Oxaliplatin	73-84	C-C motif chemokine receptor 2	Homo sapiens	44-48
29554018-7	2018	This is the first study to demonstrate CCL2/CCR2 signaling in a model of oxaliplatin-related CIPN; and it further shows that blocking of this signal can attenuate the development of oxaliplatin-induced mechanical hyperalgesia.	Oxaliplatin	182-193	C-C motif chemokine ligand 2	Homo sapiens	39-43
29554018-7	2018	This is the first study to demonstrate CCL2/CCR2 signaling in a model of oxaliplatin-related CIPN; and it further shows that blocking of this signal can attenuate the development of oxaliplatin-induced mechanical hyperalgesia.	Oxaliplatin	182-193	C-C motif chemokine receptor 2	Homo sapiens	44-48
29927360-1	2018	This paper has been written because we have a differing idea concerning the suspected negative interference between oxaliplatin and anti-EGFR therapies in cancer patients.	Oxaliplatin	116-127	epidermal growth factor receptor	Homo sapiens	137-141
29803994-5	2018	In a mice model of neuropathic pain induced by oxaliplatin, some of the strong CA II/VII inhibitors induced a long lasting pain relieving effect.	Oxaliplatin	47-58	carbonic anhydrase 2	Mus musculus	79-84
29949874-6	2018	Knockout of GPRC5a reduced the proliferation and migration ability of PaCa cell lines and suppressed the chemotherapy drug resistance of gemcitabine, oxaliplatin, and fluorouracil in PaCa cells.	Oxaliplatin	150-161	G protein-coupled receptor class C group 5 member A	Homo sapiens	12-18
29963241-5	2018	Compared to CPT-11, L-OHP is a stronger inducer of caspases and p53-dependent apoptosis.	Oxaliplatin	20-25	tumor protein p53	Homo sapiens	64-67
29894476-0	2018	Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon.	Oxaliplatin	0-11	toll-like receptor 4	Mus musculus	43-47
29894476-0	2018	Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon.	Oxaliplatin	0-11	high mobility group box 1	Mus musculus	68-73
29963241-7	2018	We additionally show that L-OHP suppresses survivin through p53 and its downstream target p21, which stalls cell cycle progression as a cyclin-dependent kinase inhibitor (CDKi).	Oxaliplatin	26-31	tumor protein p53	Homo sapiens	60-63
29894476-6	2018	We studied effects of oxaliplatin treatment on 1) TLR4 and high-mobility group box 1 expression within the colon; 2) gastrointestinal microbiota composition; 3) inflammation within the colon; 4) changes in Peyer"s patches and mesenteric lymph nodes immune populations in mice.	Oxaliplatin	22-33	toll-like receptor 4	Mus musculus	50-54
29894476-6	2018	We studied effects of oxaliplatin treatment on 1) TLR4 and high-mobility group box 1 expression within the colon; 2) gastrointestinal microbiota composition; 3) inflammation within the colon; 4) changes in Peyer"s patches and mesenteric lymph nodes immune populations in mice.	Oxaliplatin	22-33	high mobility group box 1	Mus musculus	59-84
29963241-7	2018	We additionally show that L-OHP suppresses survivin through p53 and its downstream target p21, which stalls cell cycle progression as a cyclin-dependent kinase inhibitor (CDKi).	Oxaliplatin	26-31	cyclin dependent kinase inhibitor 1A	Homo sapiens	90-93
29894476-7	2018	TLR4+ cells displayed pseudopodia-like extensions characteristic of antigen sampling co-localised with high-mobility group box 1 -overexpressing cells in the colonic lamina propria from oxaliplatin-treated animals.	Oxaliplatin	186-197	toll-like receptor 4	Mus musculus	0-4
29894476-7	2018	TLR4+ cells displayed pseudopodia-like extensions characteristic of antigen sampling co-localised with high-mobility group box 1 -overexpressing cells in the colonic lamina propria from oxaliplatin-treated animals.	Oxaliplatin	186-197	high mobility group box 1	Mus musculus	103-128
29844803-0	2018	Sphingosine kinase 1 overexpression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma.	Oxaliplatin	74-85	sphingosine kinase 1	Homo sapiens	0-20
29894476-10	2018	In conclusion, oxaliplatin treatment caused morphological changes in TLR4+ cells, increase in gram-negative microbiota and enhanced HMGB1 expression associated with immunosuppression in the colon.	Oxaliplatin	15-26	toll-like receptor 4	Mus musculus	69-73
29894476-10	2018	In conclusion, oxaliplatin treatment caused morphological changes in TLR4+ cells, increase in gram-negative microbiota and enhanced HMGB1 expression associated with immunosuppression in the colon.	Oxaliplatin	15-26	high mobility group box 1	Mus musculus	132-137
29879147-9	2018	Addition of bev to oxaliplatin-based chemotherapy resulted in differential changes in hepatic CDH5, HEY1, IL16, JAG1, MMP9, NOTCH4 and TIMP1 expression.	Oxaliplatin	19-30	cadherin 5	Homo sapiens	94-98
29879147-9	2018	Addition of bev to oxaliplatin-based chemotherapy resulted in differential changes in hepatic CDH5, HEY1, IL16, JAG1, MMP9, NOTCH4 and TIMP1 expression.	Oxaliplatin	19-30	hes related family bHLH transcription factor with YRPW motif 1	Homo sapiens	100-104
29879147-9	2018	Addition of bev to oxaliplatin-based chemotherapy resulted in differential changes in hepatic CDH5, HEY1, IL16, JAG1, MMP9, NOTCH4 and TIMP1 expression.	Oxaliplatin	19-30	interleukin 16	Homo sapiens	106-110
29879147-9	2018	Addition of bev to oxaliplatin-based chemotherapy resulted in differential changes in hepatic CDH5, HEY1, IL16, JAG1, MMP9, NOTCH4 and TIMP1 expression.	Oxaliplatin	19-30	jagged canonical Notch ligand 1	Homo sapiens	112-116
29879147-9	2018	Addition of bev to oxaliplatin-based chemotherapy resulted in differential changes in hepatic CDH5, HEY1, IL16, JAG1, MMP9, NOTCH4 and TIMP1 expression.	Oxaliplatin	19-30	matrix metallopeptidase 9	Homo sapiens	118-122
29879147-9	2018	Addition of bev to oxaliplatin-based chemotherapy resulted in differential changes in hepatic CDH5, HEY1, IL16, JAG1, MMP9, NOTCH4 and TIMP1 expression.	Oxaliplatin	19-30	notch receptor 4	Homo sapiens	124-130
29879147-9	2018	Addition of bev to oxaliplatin-based chemotherapy resulted in differential changes in hepatic CDH5, HEY1, IL16, JAG1, MMP9, NOTCH4 and TIMP1 expression.	Oxaliplatin	19-30	TIMP metallopeptidase inhibitor 1	Homo sapiens	135-140
29602203-0	2018	LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.	Oxaliplatin	52-63	nuclear receptor subfamily 2 group F member 1	Homo sapiens	7-12
29602203-0	2018	LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.	Oxaliplatin	52-63	prostaglandin D2 receptor	Homo sapiens	13-16
29602203-0	2018	LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.	Oxaliplatin	52-63	ATP binding cassette subfamily C member 1	Homo sapiens	88-93
29602203-0	2018	LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.	Oxaliplatin	52-63	microRNA 363	Homo sapiens	98-105
29602203-2	2018	In the present study, we investigate the function of lncRNA NR2F1-AS1 on oxaliplatin (OXA) resistance of hepatocellular carcinoma (HCC) and discover the underlying molecular mechanism.	Oxaliplatin	73-84	nuclear receptor subfamily 2 group F member 1	Homo sapiens	60-65
29602203-2	2018	In the present study, we investigate the function of lncRNA NR2F1-AS1 on oxaliplatin (OXA) resistance of hepatocellular carcinoma (HCC) and discover the underlying molecular mechanism.	Oxaliplatin	73-84	prostaglandin D2 receptor	Homo sapiens	66-69
29602203-2	2018	In the present study, we investigate the function of lncRNA NR2F1-AS1 on oxaliplatin (OXA) resistance of hepatocellular carcinoma (HCC) and discover the underlying molecular mechanism.	Oxaliplatin	86-89	nuclear receptor subfamily 2 group F member 1	Homo sapiens	60-65
29602203-2	2018	In the present study, we investigate the function of lncRNA NR2F1-AS1 on oxaliplatin (OXA) resistance of hepatocellular carcinoma (HCC) and discover the underlying molecular mechanism.	Oxaliplatin	86-89	prostaglandin D2 receptor	Homo sapiens	66-69
29602203-3	2018	Results revealed that lncRNA NR2F1-AS1 was up-regulated in oxaliplatin-resistant HCC tissue and cells using microarray analysis and RT-PCR.	Oxaliplatin	59-70	nuclear receptor subfamily 2 group F member 1	Homo sapiens	29-34
29602203-3	2018	Results revealed that lncRNA NR2F1-AS1 was up-regulated in oxaliplatin-resistant HCC tissue and cells using microarray analysis and RT-PCR.	Oxaliplatin	59-70	prostaglandin D2 receptor	Homo sapiens	35-38
29805687-0	2018	Suppression of GRP78 sensitizes human colorectal cancer cells to oxaliplatin by downregulation of CD24.	Oxaliplatin	65-76	heat shock protein family A (Hsp70) member 5	Homo sapiens	15-20
29805687-0	2018	Suppression of GRP78 sensitizes human colorectal cancer cells to oxaliplatin by downregulation of CD24.	Oxaliplatin	65-76	CD24 molecule	Homo sapiens	98-102
29805687-4	2018	In the present study, oxaliplatin (L-OHP) was demonstrated to decrease the expression of CD24 in HT29 cells.	Oxaliplatin	22-33	CD24 molecule	Homo sapiens	89-93
29805687-4	2018	In the present study, oxaliplatin (L-OHP) was demonstrated to decrease the expression of CD24 in HT29 cells.	Oxaliplatin	35-40	CD24 molecule	Homo sapiens	89-93
29805687-5	2018	Knockdown of CD24 using small interfering RNA resulted in sensitization of HT29 cells to L-OHP.	Oxaliplatin	89-94	CD24 molecule	Homo sapiens	13-17
29805687-6	2018	By contrast, overexpression of CD24 rendered SW480 cells resistant to L-OHP, which indicated that CD24 antagonized L-OHP-induced cytotoxicity.	Oxaliplatin	70-75	CD24 molecule	Homo sapiens	31-35
29805687-6	2018	By contrast, overexpression of CD24 rendered SW480 cells resistant to L-OHP, which indicated that CD24 antagonized L-OHP-induced cytotoxicity.	Oxaliplatin	70-75	CD24 molecule	Homo sapiens	98-102
29805687-6	2018	By contrast, overexpression of CD24 rendered SW480 cells resistant to L-OHP, which indicated that CD24 antagonized L-OHP-induced cytotoxicity.	Oxaliplatin	115-120	CD24 molecule	Homo sapiens	31-35
29805687-6	2018	By contrast, overexpression of CD24 rendered SW480 cells resistant to L-OHP, which indicated that CD24 antagonized L-OHP-induced cytotoxicity.	Oxaliplatin	115-120	CD24 molecule	Homo sapiens	98-102
29805687-8	2018	L-OHP suppresses the expression of GRP78 and CD24, in part come from the inhibition of interaction between the two.	Oxaliplatin	0-5	heat shock protein family A (Hsp70) member 5	Homo sapiens	35-40
29805687-8	2018	L-OHP suppresses the expression of GRP78 and CD24, in part come from the inhibition of interaction between the two.	Oxaliplatin	0-5	CD24 molecule	Homo sapiens	45-49
29805687-9	2018	Suppression of GRP78 caused downregulation of CD24 expression and enhanced L-OHP-induced CD24 inhibition.	Oxaliplatin	75-80	heat shock protein family A (Hsp70) member 5	Homo sapiens	15-20
29805687-9	2018	Suppression of GRP78 caused downregulation of CD24 expression and enhanced L-OHP-induced CD24 inhibition.	Oxaliplatin	75-80	CD24 molecule	Homo sapiens	89-93
29805687-10	2018	Furthermore, down-regulation of GPR78 with a pharmacological inhibitor sensitized the CRC cells to L-OHP.	Oxaliplatin	99-104	G protein-coupled receptor 78	Homo sapiens	32-37
29884866-3	2018	We demonstrate that oxaliplatin (OxP) boosts anti-PD-L1 mAb therapy against murine colorectal cancer.	Oxaliplatin	20-31	CD274 antigen	Mus musculus	50-55
29859044-8	2018	Moreover, Slit3-repression induced chemoresistance to sorafenib, oxaliplatin and 5-FU through impairment of beta-catenin degradation and induction of cyclin D3 and survivin levels.	Oxaliplatin	65-76	slit guidance ligand 3	Homo sapiens	10-15
29805687-11	2018	Collectively, the present results indicate that CD24 antagonizes L-OHP-induced cytotoxicity and that GRP78 is involved in this process.	Oxaliplatin	65-70	CD24 molecule	Homo sapiens	48-52
29805687-13	2018	Use of a combination of compounds which suppress GRP78 may help to improve the effectiveness of L-OHP in the treatment of CRC.	Oxaliplatin	96-101	heat shock protein family A (Hsp70) member 5	Homo sapiens	49-54
29419652-6	2018	We now demonstrate that chemotherapy (oxaliplatin) in rodents caused ADK overexpression in reactive astrocytes and reduced adenosine signaling at the A3AR subtype (A3AR) within the spinal cord.	Oxaliplatin	38-49	adenosine kinase	Rattus norvegicus	69-72
29419652-7	2018	Dysregulation of ADK and A3AR signaling was associated with increased proinflammatory and neuroexcitatory interleukin-1beta expression and activation of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome, but not putative oxaliplatin-associated GSK3beta transcriptional regulation.	Oxaliplatin	250-261	adenosine kinase	Rattus norvegicus	17-20
29928496-0	2018	Correction: Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway.	Oxaliplatin	39-50	NADPH oxidase 1	Homo sapiens	139-143
29844803-2	2018	However, the role of SphK1 in the resistance of hepatocellular carcinoma (HCC) to oxaliplatin remains unclear.	Oxaliplatin	82-93	sphingosine kinase 1	Homo sapiens	21-26
29844803-5	2018	Furthermore, SphK1 expression levels and activity were analyzed in a series of HCC cell lines and they were both demonstrated to be associated with resistance to oxaliplatin.	Oxaliplatin	162-173	sphingosine kinase 1	Homo sapiens	13-18
29844803-6	2018	Conversely, the knockdown of SphK1 protein expression resulted in decreased oxaliplatin resistance in SK-Hep1 and HCCLM3 cell lines.	Oxaliplatin	76-87	sphingosine kinase 1	Homo sapiens	29-34
29844803-6	2018	Conversely, the knockdown of SphK1 protein expression resulted in decreased oxaliplatin resistance in SK-Hep1 and HCCLM3 cell lines.	Oxaliplatin	76-87	DNL-type zinc finger	Homo sapiens	105-109
29844803-7	2018	In addition, the results of the current study demonstrated that the downregulation of SphK1 decreased the levels of phosphorylated AKT serine/threonine kinase (Akt) and glycogen synthase kinase-3beta (GSK3beta), suggesting that SphK1 promotes oxaliplatin resistance of HCC cells via modulation of the Akt/GSK3beta signaling pathway.	Oxaliplatin	243-254	sphingosine kinase 1	Homo sapiens	86-91
29844803-7	2018	In addition, the results of the current study demonstrated that the downregulation of SphK1 decreased the levels of phosphorylated AKT serine/threonine kinase (Akt) and glycogen synthase kinase-3beta (GSK3beta), suggesting that SphK1 promotes oxaliplatin resistance of HCC cells via modulation of the Akt/GSK3beta signaling pathway.	Oxaliplatin	243-254	AKT serine/threonine kinase 1	Homo sapiens	131-134
29844803-8	2018	To the best of our knowledge, the present study is the first to report that SphK1 is associated with poor prognosis and oxaliplatin resistance in HCC.	Oxaliplatin	120-131	sphingosine kinase 1	Homo sapiens	76-81
29896290-4	2018	This study outlines the regulatory effects of oxaliplatin on miRNAs expression in colon cancer cells and correlates it with the changing microRNA expression with p53 and p73 expression status in cells.	Oxaliplatin	46-57	tumor protein p53	Homo sapiens	162-165
29899829-0	2018	Inhibition of Fas associated phosphatase 1 (Fap1) facilitates apoptosis of colon cancer stem cells and enhances the effects of oxaliplatin.	Oxaliplatin	127-138	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	44-48
29899829-6	2018	We determined that CD133+ cells were relatively resistant to Fas or oxaliplatin induced apoptosis, but this was reversed by Fap1-knockdown or a Fap1-blocking tripeptide (SLV).	Oxaliplatin	68-79	prominin 1	Mus musculus	19-24
29896290-4	2018	This study outlines the regulatory effects of oxaliplatin on miRNAs expression in colon cancer cells and correlates it with the changing microRNA expression with p53 and p73 expression status in cells.	Oxaliplatin	46-57	tumor protein p73	Homo sapiens	170-173
29896290-6	2018	p73 was knocked down using siRNA and the tumor cells were then treated with oxaliplatin.	Oxaliplatin	76-87	tumor protein p73	Homo sapiens	0-3
29896290-10	2018	A selective set of miRNAs were either up-regulated or down-regulated in response to the oxaliplatin treatment with a presumable role of p53 and p73 proteins.	Oxaliplatin	88-99	tumor protein p53	Homo sapiens	136-139
29896290-10	2018	A selective set of miRNAs were either up-regulated or down-regulated in response to the oxaliplatin treatment with a presumable role of p53 and p73 proteins.	Oxaliplatin	88-99	tumor protein p73	Homo sapiens	144-147
29896290-11	2018	The miRNAs expression is known to influence the pharmacodynamic mechanisms of oxaliplatin and these effects have been observed to be regulated by p53 and p73.	Oxaliplatin	78-89	tumor protein p53	Homo sapiens	146-149
29896290-11	2018	The miRNAs expression is known to influence the pharmacodynamic mechanisms of oxaliplatin and these effects have been observed to be regulated by p53 and p73.	Oxaliplatin	78-89	tumor protein p73	Homo sapiens	154-157
29436100-0	2018	Lupeol alters ER stress-signaling pathway by downregulating ABCG2 expression to induce Oxaliplatin-resistant LoVo colorectal cancer cell apoptosis.	Oxaliplatin	87-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	60-65
29530794-0	2018	Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function.	Oxaliplatin	14-25	nuclear factor, erythroid derived 2, like 2	Mus musculus	0-4
29739952-0	2018	Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.	Oxaliplatin	74-85	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	31-34
29739952-0	2018	Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.	Oxaliplatin	74-85	MUS81 structure-specific endonuclease subunit	Homo sapiens	39-44
29739952-7	2018	In cell lines in vitro, we showed the mechanism of action related to repair of oxaliplatin-induced DNA damage by depletion and knockout of protein binding partners of the candidate biomarkers, XPF and MUS81 respectively.	Oxaliplatin	79-90	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	193-196
29805744-6	2018	We found that the administration of 10 muM oxaliplatin for 8 and 16 h induced alterations of the tight junction (TJs) proteins zonula occludens-1 (ZO-1) and of F-actin, thus highlighting BBB alteration.	Oxaliplatin	43-54	tight junction protein 1	Rattus norvegicus	127-145
29805744-6	2018	We found that the administration of 10 muM oxaliplatin for 8 and 16 h induced alterations of the tight junction (TJs) proteins zonula occludens-1 (ZO-1) and of F-actin, thus highlighting BBB alteration.	Oxaliplatin	43-54	tight junction protein 1	Rattus norvegicus	147-151
29805744-7	2018	Furthermore, we reported that intracellular oxaliplatin rapidly induced increased levels of reactive oxygen species and endoplasmic reticulum stress, assessed by the evaluation of glucose-regulated protein GRP78 expression levels.	Oxaliplatin	44-55	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	206-211
29888105-0	2018	Natural killer cells inhibit oxaliplatin-resistant colorectal cancer by repressing WBSCR22 via upregulating microRNA-146b-5p.	Oxaliplatin	29-40	BUD23, rRNA methyltransferase and ribosome maturation factor	Mus musculus	83-90
29888105-5	2018	Expression of WBSCR22 gene was assessed in the oxaliplatin-resistant colorectal cancer cells following NK cell treatment to elucidate the mechanism.	Oxaliplatin	47-58	BUD23, rRNA methyltransferase and ribosome maturation factor	Mus musculus	14-21
29888105-8	2018	MicroRNA-146b-5p directly targeted WBSCR22 mRNA 3"-UTR to inhibit its expression, which was required for NK cell-induced inhibition of oxaliplatin-resistant colorectal cancer cell lines.	Oxaliplatin	135-146	BUD23, rRNA methyltransferase and ribosome maturation factor	Mus musculus	35-42
29888105-9	2018	NK cells inhibit oxaliplatin-resistant colorectal cancer by repressing WBSCR22 via upregulating microRNA-146b-5p, both of which could serve as candidates for targeted therapy against oxaliplatin-resistant colorectal cancer.	Oxaliplatin	17-28	BUD23, rRNA methyltransferase and ribosome maturation factor	Mus musculus	71-78
29695770-3	2018	METHODS: In two high-risk patient cohorts, we assessed the circulating levels of the fms-like tyrosine kinase 3 ligand (Flt3L), a factor reflecting both therapy-induced myelosuppression and activation of tumour antigen-presenting dendritic cells, at baseline and following induction chemotherapy and sequential chemoradiotherapy, both modalities containing oxaliplatin.	Oxaliplatin	357-368	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	85-118
29695770-3	2018	METHODS: In two high-risk patient cohorts, we assessed the circulating levels of the fms-like tyrosine kinase 3 ligand (Flt3L), a factor reflecting both therapy-induced myelosuppression and activation of tumour antigen-presenting dendritic cells, at baseline and following induction chemotherapy and sequential chemoradiotherapy, both modalities containing oxaliplatin.	Oxaliplatin	357-368	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	120-125
29530794-6	2018	Furthermore, Nrf2 knockout aggravated oxaliplatin-induced reactive oxygen species production, decreased the mitochondrial membrane potential, led to abnormal intracellular calcium levels, and induced cytochrome c-related apoptosis and overexpression of the TRP protein family.	Oxaliplatin	38-49	nuclear factor, erythroid derived 2, like 2	Mus musculus	13-17
29772714-2	2018	Drug importing, intracellular shuffling, and exporting-carried out by the high-affinity copper (Cu) transporter (hCtr1), Cu chaperone (Ato x1), and Cu exporters (ATP7A and ATP7B), respectively-cumulatively contribute to the chemosensitivity of Pt drugs including cisplatin and carboplatin, but not oxaliplatin.	Oxaliplatin	298-309	solute carrier family 31 member 1	Homo sapiens	113-118
29772714-2	2018	Drug importing, intracellular shuffling, and exporting-carried out by the high-affinity copper (Cu) transporter (hCtr1), Cu chaperone (Ato x1), and Cu exporters (ATP7A and ATP7B), respectively-cumulatively contribute to the chemosensitivity of Pt drugs including cisplatin and carboplatin, but not oxaliplatin.	Oxaliplatin	298-309	antioxidant 1 copper chaperone	Homo sapiens	135-141
29772714-2	2018	Drug importing, intracellular shuffling, and exporting-carried out by the high-affinity copper (Cu) transporter (hCtr1), Cu chaperone (Ato x1), and Cu exporters (ATP7A and ATP7B), respectively-cumulatively contribute to the chemosensitivity of Pt drugs including cisplatin and carboplatin, but not oxaliplatin.	Oxaliplatin	298-309	ATPase copper transporting alpha	Homo sapiens	162-167
29739952-7	2018	In cell lines in vitro, we showed the mechanism of action related to repair of oxaliplatin-induced DNA damage by depletion and knockout of protein binding partners of the candidate biomarkers, XPF and MUS81 respectively.	Oxaliplatin	79-90	MUS81 structure-specific endonuclease subunit	Homo sapiens	201-206
29739952-9	2018	XPF and MUS81 merit further validation in prospective clinical trials as biomarkers that may predict clinical response of EAC to oxaliplatin-based chemotherapy.	Oxaliplatin	129-140	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	0-3
29739952-9	2018	XPF and MUS81 merit further validation in prospective clinical trials as biomarkers that may predict clinical response of EAC to oxaliplatin-based chemotherapy.	Oxaliplatin	129-140	MUS81 structure-specific endonuclease subunit	Homo sapiens	8-13
29749374-0	2018	MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy.	Oxaliplatin	23-34	eva-1 homolog A, regulator of programmed cell death	Homo sapiens	99-104
29749374-4	2018	EVA1A expression was shown to be upregulated in tissue samples from oxaliplatin-resistant HCC patients, and its ectopic expression partially induced autophagy and reversed the effect of miR-125b on inhibiting the growth of oxaliplatin-resistant cell lines and xenograft tumors.	Oxaliplatin	68-79	eva-1 homolog A, regulator of programmed cell death	Homo sapiens	0-5
29749374-4	2018	EVA1A expression was shown to be upregulated in tissue samples from oxaliplatin-resistant HCC patients, and its ectopic expression partially induced autophagy and reversed the effect of miR-125b on inhibiting the growth of oxaliplatin-resistant cell lines and xenograft tumors.	Oxaliplatin	223-234	eva-1 homolog A, regulator of programmed cell death	Homo sapiens	0-5
29568868-13	2018	Knocking down the expression of Plk2 resulted in elevated cellular apoptosis induced by oxaliplatin.	Oxaliplatin	88-99	polo like kinase 2	Homo sapiens	32-36
29731915-0	2018	Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells in vivo using oxaliplatin-au-fe3o4-herceptin nanoparticles.	Oxaliplatin	28-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
29721050-0	2018	Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.	Oxaliplatin	29-40	growth arrest and DNA damage inducible alpha	Homo sapiens	60-67
29534961-0	2018	Z-FL-COCHO, a cathepsin S inhibitor, enhances oxaliplatin-induced apoptosis through upregulation of Bim expression.	Oxaliplatin	46-57	BCL2 like 11	Homo sapiens	100-103
29534961-5	2018	ZFL enhances oxaliplatin-mediated apoptosis through ER stress-induced Bim upregulation in cancer cells.	Oxaliplatin	13-24	BCL2 like 11	Homo sapiens	70-73
29721050-0	2018	Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.	Oxaliplatin	29-40	AKT serine/threonine kinase 1	Homo sapiens	73-76
29393491-0	2018	beta3GnT8 regulates oxaliplatin resistance by altering integrin beta1 glycosylation in colon cancer cells.	Oxaliplatin	20-31	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8	Homo sapiens	0-9
29599315-3	2018	MATERIALS AND METHODS: The level of cellular prion protein (PrPC) in oxaliplatin-resistant colorectal cancer (SNU-C5/Oxal-R) cells was assessed.	Oxaliplatin	69-80	prion protein	Homo sapiens	60-64
29599315-6	2018	Treatment of SNU-C5/Oxal-R cells with oxaliplatin and melatonin reduced PrPC expression, while suppressing antioxidant enzyme activity and increasing superoxide anion generation.	Oxaliplatin	38-49	prion protein	Homo sapiens	72-76
29599315-8	2018	CONCLUSION: Co-treatment with oxaliplatin and melatonin increased endoplasmic reticulum stress in and apoptosis of SNU-C5/Oxal-R cells through inhibition of PrPC, suggesting that PrPC could be a key molecule in oxaliplatin resistance of colorectal cancer cells.	Oxaliplatin	30-41	prion protein	Homo sapiens	157-161
29599315-8	2018	CONCLUSION: Co-treatment with oxaliplatin and melatonin increased endoplasmic reticulum stress in and apoptosis of SNU-C5/Oxal-R cells through inhibition of PrPC, suggesting that PrPC could be a key molecule in oxaliplatin resistance of colorectal cancer cells.	Oxaliplatin	30-41	prion protein	Homo sapiens	179-183
29599315-8	2018	CONCLUSION: Co-treatment with oxaliplatin and melatonin increased endoplasmic reticulum stress in and apoptosis of SNU-C5/Oxal-R cells through inhibition of PrPC, suggesting that PrPC could be a key molecule in oxaliplatin resistance of colorectal cancer cells.	Oxaliplatin	211-222	prion protein	Homo sapiens	179-183
29030979-9	2018	Furthermore, pioglitazone enhanced the cytotoxic effect of cisplatin and oxaliplatin by suppressing Survivin and increasing AIF expression.	Oxaliplatin	73-84	apoptosis inducing factor mitochondria associated 1	Homo sapiens	124-127
28881481-8	2018	Mice receiving extended oxaliplatin treatment demonstrated reduced hindlimb muscle mass with upregulation of myopathy-associated genes Foxo3, MAFbx, and Bnip3.	Oxaliplatin	24-35	forkhead box O3	Mus musculus	135-140
28881481-8	2018	Mice receiving extended oxaliplatin treatment demonstrated reduced hindlimb muscle mass with upregulation of myopathy-associated genes Foxo3, MAFbx, and Bnip3.	Oxaliplatin	24-35	F-box protein 32	Mus musculus	142-147
28881481-8	2018	Mice receiving extended oxaliplatin treatment demonstrated reduced hindlimb muscle mass with upregulation of myopathy-associated genes Foxo3, MAFbx, and Bnip3.	Oxaliplatin	24-35	BCL2/adenovirus E1B interacting protein 3	Mus musculus	153-158
29541216-9	2018	BRAF V600E and beta-catenin T41A double mutations were identified in one cell line, and were associated with a lack of response to 5-fluorouracil, oxaliplatin and cetuximab treatment.	Oxaliplatin	147-158	catenin (cadherin associated protein), beta 1	Mus musculus	15-27
29861605-8	2018	Results: 5-Fu/oxaliplatin exerted no significant effect on the expression of the stimulating phenotypes of DCs in vitro, while it could reduce the expression of programmed death ligand 1/2 (PD-L1/L2) and promote interleukin-12 (IL-12) secretion by DCs.	Oxaliplatin	14-25	CD274 antigen	Mus musculus	190-195
29861605-10	2018	5-Fu/oxaliplatin further enhanced the stimulating phenotypic expression of DCs in tumor bearing mice, decreased PD-L1/L2 expression, and specifically activated the lymphocytes.	Oxaliplatin	5-16	CD274 antigen	Mus musculus	112-117
29861605-11	2018	The CD1d-MC38/alpha-GC tumor vaccine combined with 5-Fu/oxaliplatin could exert a synergistic role that resulted in a significant delay of the tumor growth rate, and an increase in the survival time of tumor bearing mice.	Oxaliplatin	56-67	CD1d1 antigen	Mus musculus	4-8
29861605-12	2018	Conclusions: 5-Fu/oxaliplatin decreased the expression of the DC inhibitory phenotypes PD-L1/L2, promoted DC phenotypic maturation in tumor bearing mice, activated the lymphocytes of tumor bearing mice, and exerted synergistic effects with the CD1d-MC38/alpha-GC colon cancer tumor vaccine.	Oxaliplatin	18-29	CD274 antigen	Mus musculus	87-92
29861605-12	2018	Conclusions: 5-Fu/oxaliplatin decreased the expression of the DC inhibitory phenotypes PD-L1/L2, promoted DC phenotypic maturation in tumor bearing mice, activated the lymphocytes of tumor bearing mice, and exerted synergistic effects with the CD1d-MC38/alpha-GC colon cancer tumor vaccine.	Oxaliplatin	18-29	CD1d1 antigen	Mus musculus	244-248
29650829-1	2018	We report a case of Stage IV gastric cancer showing pathological complete response(pCR)after neo-adjuvant chemotherapy( NAC)using S-1 and oxaliplatin(SOX).A woman 73-year-old was diagnosed as harming type 3 Stage IV gastric cancer with para-aortic lymph node(PAN)metastasis.She underwent 4 courses of NAC with SOX regimen.After the treatment, both the primary tumor and the metastatic PAN decreased in size remarkably.She underwent distal gastrectomy with D2 plus PAN dissection with curative intent.Pathological diagnosis revealed complete disappearance of cancer cells in both the primary lesion of the stomach and all dissected lymph nodes, confirming pCR.She is alive without recurrence 4 months after surgery.	Oxaliplatin	138-149	synuclein alpha	Homo sapiens	120-123
29434366-6	2018	This oncolytic-virus-induced subversion of tumour-associated immunosuppression can potentiate the effectiveness of current immunotherapeutics, including immune checkpoint inhibitors (for example, antibodies against programmed cell death protein 1 (PD1), programmed cell death 1 ligand 1 (PDL1), and cytotoxic T lymphocyte antigen 4 (CTLA4)) and chemotherapeutics that induce immunogenic cell death (for example, doxorubicin and oxaliplatin).	Oxaliplatin	428-439	programmed cell death 1	Sus scrofa	248-251
29393491-5	2018	Using an RNA interference strategy, we revealed that the silencing of beta3GnT8 in SW620R cells resulted in increased chemosensitivity to oxaliplatin.	Oxaliplatin	138-149	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8	Homo sapiens	70-79
29393491-6	2018	Conversely, the engineered overexpression of beta3GnT8 in SW620 cells enhanced resistance to oxaliplatin.	Oxaliplatin	93-104	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8	Homo sapiens	45-54
29393491-8	2018	These results revealed that beta3GnT8 may play a key role in the development of oxaliplatin resistance in colon cancer cells possibly through the alteration of the glycosylation of integrin beta1.	Oxaliplatin	80-91	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8	Homo sapiens	28-37
29393491-8	2018	These results revealed that beta3GnT8 may play a key role in the development of oxaliplatin resistance in colon cancer cells possibly through the alteration of the glycosylation of integrin beta1.	Oxaliplatin	80-91	integrin subunit beta 1	Homo sapiens	181-195
29339292-0	2018	Selective HCN1 block as a strategy to control oxaliplatin-induced neuropathy.	Oxaliplatin	46-57	hyperpolarization-activated cyclic nucleotide-gated potassium channel 1	Rattus norvegicus	10-14
29241656-9	2018	In oxaliplatin-treated rats, the plasma concentration of vascular endothelial growth factor (pan VEGF-A) was increased while the isoform VEGF165b was upregulated in the spinal cord.	Oxaliplatin	3-14	vascular endothelial growth factor A	Rattus norvegicus	97-103
29241656-11	2018	The anti-VEGF-A monoclonal antibody bevacizumab (intraperitoneally) reduced oxaliplatin-dependent pain.	Oxaliplatin	76-87	vascular endothelial growth factor A	Rattus norvegicus	9-15
29491106-0	2018	Case Report: CEA Elevation Can Be a Marker of Increased Inflammation During Treatment with Oxaliplatin.	Oxaliplatin	91-102	CEA cell adhesion molecule 3	Homo sapiens	13-16
29491106-4	2018	His CEA level increased significantly during oxaliplatin-based chemotherapy and declined to a near normal level after completion of therapy.	Oxaliplatin	45-56	CEA cell adhesion molecule 3	Homo sapiens	4-7
29491106-7	2018	We postulate that this patient"s rising CEA level was secondary to an inflammatory response to oxaliplatin-based therapy, which is further supported by the subsequent decrease after completion of chemotherapy.	Oxaliplatin	95-106	CEA cell adhesion molecule 3	Homo sapiens	40-43
29491106-8	2018	To our knowledge, this is the first published case of oxaliplatin-induced rising CEA level.	Oxaliplatin	54-65	CEA cell adhesion molecule 3	Homo sapiens	81-84
29496692-6	2018	ILK inhibition increases sensitivity of resistant cells to 5-FU and oxaliplatin and reduces the levels of EMT and CSC markers in 5-FU resistant cells.	Oxaliplatin	68-79	integrin linked kinase	Homo sapiens	0-3
29277064-9	2018	In the validation set, the concentration of serum CC16 in the PM2.5 exposed group was 22.42% lower than that of the controls and an IQR (1.24mumol/mol creatinine) increase in urinary 1-OHP concentration was associated with a 12.24% decrease in serum CC16 levels in the DEE cohort.	Oxaliplatin	183-188	secretoglobin family 1A member 1	Homo sapiens	50-54
29339292-8	2018	In this work, we show an HCN current gain of function in DRG neurons from oxaliplatin-treated rats.	Oxaliplatin	74-85	cyclic nucleotide gated channel subunit alpha 1	Rattus norvegicus	25-28
29339292-10	2018	Finally, we report the efficacy of the selective HCN1 inhibitor MEL57A in reducing hyperalgesia and allodynia in oxaliplatin-treated rats without cardiac effects.	Oxaliplatin	113-124	hyperpolarization-activated cyclic nucleotide-gated potassium channel 1	Rattus norvegicus	49-53
29286074-17	2018	The results of the H&amp;E and IHC staining confirmed the inhibition of autophagy (LC3 and Beclin-1) and activation of p65 by treatment with the high dose of cbFeD and oxaliplatin.	Oxaliplatin	168-179	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	83-86
29710482-0	2018	Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361.	Oxaliplatin	54-65	BLACAT1 overlapping LEMD1 locus	Homo sapiens	19-26
29710482-0	2018	Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361.	Oxaliplatin	54-65	ATP binding cassette subfamily B member 1	Homo sapiens	37-42
29710482-0	2018	Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361.	Oxaliplatin	54-65	microRNA 361	Homo sapiens	108-115
29710482-4	2018	Results showed that BLACAT1 expression was up-regulated in the oxaliplatin (OXA) resistant gastric cancer tissue and cells compared with OXA-sensitive tissue and parental cell lines.	Oxaliplatin	63-74	BLACAT1 overlapping LEMD1 locus	Homo sapiens	20-27
29710482-4	2018	Results showed that BLACAT1 expression was up-regulated in the oxaliplatin (OXA) resistant gastric cancer tissue and cells compared with OXA-sensitive tissue and parental cell lines.	Oxaliplatin	76-79	BLACAT1 overlapping LEMD1 locus	Homo sapiens	20-27
29710482-6	2018	Besides, BLACAT1 knockdown significantly promoted apoptosis and down-regulated the invasion and the IC50 value of oxaliplatin.	Oxaliplatin	114-125	BLACAT1 overlapping LEMD1 locus	Homo sapiens	9-16
29710482-9	2018	In summary, our results conclude that BLACAT1 accelerates the oxaliplatin-resistance of gastric cancer via promoting ABCB1 protein expression by targeting miR-361, providing a novel insight for the chemoresistance of gastric cancer.	Oxaliplatin	62-73	BLACAT1 overlapping LEMD1 locus	Homo sapiens	38-45
29286074-17	2018	The results of the H&amp;E and IHC staining confirmed the inhibition of autophagy (LC3 and Beclin-1) and activation of p65 by treatment with the high dose of cbFeD and oxaliplatin.	Oxaliplatin	168-179	beclin 1	Homo sapiens	91-99
29286074-17	2018	The results of the H&amp;E and IHC staining confirmed the inhibition of autophagy (LC3 and Beclin-1) and activation of p65 by treatment with the high dose of cbFeD and oxaliplatin.	Oxaliplatin	168-179	RELA proto-oncogene, NF-kB subunit	Homo sapiens	119-122
29421658-5	2018	Mechanistically, L-OHP incubation stimulated upregulation of an ABC family protein, ABCF2, and the expression was inhibited by PPC.	Oxaliplatin	17-22	ATP binding cassette subfamily F member 2	Homo sapiens	84-89
29417972-0	2018	Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells.	Oxaliplatin	74-85	solute carrier family 31 member 1	Homo sapiens	13-69
29417972-5	2018	The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells.	Oxaliplatin	135-146	solute carrier family 31 member 1	Homo sapiens	58-78
29417972-5	2018	The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells.	Oxaliplatin	135-146	solute carrier family 31 member 1	Homo sapiens	80-84
29417972-5	2018	The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells.	Oxaliplatin	135-146	solute carrier family 22 member 1	Homo sapiens	90-121
29417972-5	2018	The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells.	Oxaliplatin	135-146	solute carrier family 22 member 1	Homo sapiens	123-129
29417972-5	2018	The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells.	Oxaliplatin	198-209	solute carrier family 31 member 1	Homo sapiens	58-78
29417972-5	2018	The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells.	Oxaliplatin	198-209	solute carrier family 31 member 1	Homo sapiens	80-84
29417972-5	2018	The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells.	Oxaliplatin	198-209	solute carrier family 22 member 1	Homo sapiens	90-121
29417972-5	2018	The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells.	Oxaliplatin	198-209	solute carrier family 22 member 1	Homo sapiens	123-129
29417972-6	2018	Co-incubation with copper(ii) sulfate, a CTR1 substrate, significantly decreased oxaliplatin accumulation but not cytotoxicity in both cell lines.	Oxaliplatin	81-92	solute carrier family 31 member 1	Homo sapiens	41-45
29417972-7	2018	Pre- as well as co-incubation with the OCT1 inhibitor atropine led to a significant reduction in oxaliplatin accumulation in sensitive but not in resistant cells.	Oxaliplatin	97-108	solute carrier family 22 member 1	Homo sapiens	39-43
29417972-9	2018	Cimetidine, an inhibitor of OCT2, induced a significant reduction in the cellular accumulation and potency of oxaliplatin in sensitive and resistant cells.	Oxaliplatin	110-121	solute carrier family 22 member 2	Homo sapiens	28-32
29417972-12	2018	A fluorescent oxaliplatin derivative CFDA-oxPt co-localized with CTR1, OCT1 and OCT2 in sensitive cells, but only with CTR1 and OCT2 in the resistant cell line.	Oxaliplatin	14-25	solute carrier family 31 member 1	Homo sapiens	65-69
29417972-12	2018	A fluorescent oxaliplatin derivative CFDA-oxPt co-localized with CTR1, OCT1 and OCT2 in sensitive cells, but only with CTR1 and OCT2 in the resistant cell line.	Oxaliplatin	14-25	solute carrier family 22 member 1	Homo sapiens	71-75
29417972-12	2018	A fluorescent oxaliplatin derivative CFDA-oxPt co-localized with CTR1, OCT1 and OCT2 in sensitive cells, but only with CTR1 and OCT2 in the resistant cell line.	Oxaliplatin	14-25	solute carrier family 22 member 2	Homo sapiens	80-84
29417972-12	2018	A fluorescent oxaliplatin derivative CFDA-oxPt co-localized with CTR1, OCT1 and OCT2 in sensitive cells, but only with CTR1 and OCT2 in the resistant cell line.	Oxaliplatin	14-25	solute carrier family 22 member 2	Homo sapiens	128-132
29417972-13	2018	Our results suggest that oxaliplatin is transported into the cell by CTR1 in both cell lines.	Oxaliplatin	25-36	solute carrier family 31 member 1	Homo sapiens	69-73
29417972-15	2018	Uptake of oxaliplatin via OCT1 appears to take place in the sensitive but not in the resistant cell line underscoring the transporter relevance for oxaliplatin resistance.	Oxaliplatin	10-21	solute carrier family 22 member 1	Homo sapiens	26-30
29417972-15	2018	Uptake of oxaliplatin via OCT1 appears to take place in the sensitive but not in the resistant cell line underscoring the transporter relevance for oxaliplatin resistance.	Oxaliplatin	148-159	solute carrier family 22 member 1	Homo sapiens	26-30
29417972-16	2018	OCT2 is likely to be involved in the uptake of oxaliplatin to a similar extent in both cell lines suggesting no major contribution of this transporter to resistance.	Oxaliplatin	47-58	solute carrier family 22 member 2	Homo sapiens	0-4
29134439-11	2018	In summary, previously unreported stromal expression of claudin-2 in CAFs of human CRC was detected together with significant association between high claudin-2 expression in CAFs and shorter survival in 5-FU+oxaliplatin-treated mCRC patients.	Oxaliplatin	209-220	claudin 2	Homo sapiens	56-65
29203250-0	2018	NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.	Oxaliplatin	52-63	nuclear transcription factor Y subunit beta	Homo sapiens	0-4
29203250-0	2018	NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.	Oxaliplatin	52-63	E2F transcription factor 1	Homo sapiens	32-36
29203250-2	2018	In the present study, we found that the nuclear transcription factor Y subunit beta (NFYB) and E2F transcription factor 1 (E2F1) expression levels were significantly higher in oxaliplatin-resistant DLD1 and RKO CRC (OR-CRC) cells than in non-resistant cells.	Oxaliplatin	176-187	nuclear transcription factor Y subunit beta	Homo sapiens	40-83
29203250-2	2018	In the present study, we found that the nuclear transcription factor Y subunit beta (NFYB) and E2F transcription factor 1 (E2F1) expression levels were significantly higher in oxaliplatin-resistant DLD1 and RKO CRC (OR-CRC) cells than in non-resistant cells.	Oxaliplatin	176-187	nuclear transcription factor Y subunit beta	Homo sapiens	85-89
29203250-2	2018	In the present study, we found that the nuclear transcription factor Y subunit beta (NFYB) and E2F transcription factor 1 (E2F1) expression levels were significantly higher in oxaliplatin-resistant DLD1 and RKO CRC (OR-CRC) cells than in non-resistant cells.	Oxaliplatin	176-187	E2F transcription factor 1	Homo sapiens	95-121
29203250-2	2018	In the present study, we found that the nuclear transcription factor Y subunit beta (NFYB) and E2F transcription factor 1 (E2F1) expression levels were significantly higher in oxaliplatin-resistant DLD1 and RKO CRC (OR-CRC) cells than in non-resistant cells.	Oxaliplatin	176-187	E2F transcription factor 1	Homo sapiens	123-127
29203250-3	2018	Additionally, highly expressed NFYB transactivated the E2F1 gene, which is important to maintain oxaliplatin resistance in OR-CRC cells.	Oxaliplatin	97-108	nuclear transcription factor Y subunit beta	Homo sapiens	31-35
29203250-3	2018	Additionally, highly expressed NFYB transactivated the E2F1 gene, which is important to maintain oxaliplatin resistance in OR-CRC cells.	Oxaliplatin	97-108	E2F transcription factor 1	Homo sapiens	55-59
29203250-6	2018	Deprivation of CHK1 sensitized OR-CRC cells to oxaliplatin.	Oxaliplatin	47-58	checkpoint kinase 1	Homo sapiens	15-19
29203250-9	2018	Consistently, a high level of NFYB, E2F1, or CHK1 predicted poor survival in CRC patients, especially with oxaliplatin treatment.	Oxaliplatin	107-118	nuclear transcription factor Y subunit beta	Homo sapiens	30-34
29203250-9	2018	Consistently, a high level of NFYB, E2F1, or CHK1 predicted poor survival in CRC patients, especially with oxaliplatin treatment.	Oxaliplatin	107-118	checkpoint kinase 1	Homo sapiens	45-49
29203250-10	2018	Collectively, the NFYB-E2F1 pathway displays a crucial role in the chemoresistance of OR-CRC by inducing the expression and activation of CHK1, providing a possible therapeutic target for oxaliplatin resistance in CRC.	Oxaliplatin	188-199	nuclear transcription factor Y subunit beta	Homo sapiens	18-22
29203250-10	2018	Collectively, the NFYB-E2F1 pathway displays a crucial role in the chemoresistance of OR-CRC by inducing the expression and activation of CHK1, providing a possible therapeutic target for oxaliplatin resistance in CRC.	Oxaliplatin	188-199	E2F transcription factor 1	Homo sapiens	23-27
29203250-10	2018	Collectively, the NFYB-E2F1 pathway displays a crucial role in the chemoresistance of OR-CRC by inducing the expression and activation of CHK1, providing a possible therapeutic target for oxaliplatin resistance in CRC.	Oxaliplatin	188-199	checkpoint kinase 1	Homo sapiens	138-142
28392193-12	2018	CONCLUSION: The change in AFP levels 2-4 weeks after initiating oxaliplatin-based chemotherapy is useful to predict treatment response and survival.	Oxaliplatin	64-75	alpha fetoprotein	Homo sapiens	26-29
29368506-4	2018	The oxaliplatin-loaded AF conjugated with panitumumab (AFPO) was designed to specifically target cell lines expressing epidermal growth factor receptor (EGFR).	Oxaliplatin	4-15	epidermal growth factor receptor	Homo sapiens	119-151
29368506-4	2018	The oxaliplatin-loaded AF conjugated with panitumumab (AFPO) was designed to specifically target cell lines expressing epidermal growth factor receptor (EGFR).	Oxaliplatin	4-15	epidermal growth factor receptor	Homo sapiens	153-157
29396485-0	2018	hnRNP A1/A2 and Sam68 collaborate with SRSF10 to control the alternative splicing response to oxaliplatin-mediated DNA damage.	Oxaliplatin	94-105	heterogeneous nuclear ribonucleoprotein A1	Homo sapiens	0-8
29396485-0	2018	hnRNP A1/A2 and Sam68 collaborate with SRSF10 to control the alternative splicing response to oxaliplatin-mediated DNA damage.	Oxaliplatin	94-105	KH RNA binding domain containing, signal transduction associated 1	Homo sapiens	16-21
29396485-0	2018	hnRNP A1/A2 and Sam68 collaborate with SRSF10 to control the alternative splicing response to oxaliplatin-mediated DNA damage.	Oxaliplatin	94-105	serine and arginine rich splicing factor 10	Homo sapiens	39-45
29396485-2	2018	We have shown previously that SRSF10 plays an important role in the Bcl-x splicing response to DNA damage elicited by oxaliplatin in 293 cells.	Oxaliplatin	118-129	serine and arginine rich splicing factor 10	Homo sapiens	30-36
29396485-2	2018	We have shown previously that SRSF10 plays an important role in the Bcl-x splicing response to DNA damage elicited by oxaliplatin in 293 cells.	Oxaliplatin	118-129	BCL2 like 1	Homo sapiens	68-73
29497313-0	2018	Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell.	Oxaliplatin	28-39	kallikrein related peptidase 11	Homo sapiens	13-18
29497313-0	2018	Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell.	Oxaliplatin	28-39	AKT serine/threonine kinase 1	Homo sapiens	129-132
29497313-1	2018	Introduction: Kallikrein 11 (KLK11) plays a crucial role in drug-resistance to oxaliplatin (L-OHP) in the treatment of metastatic colorectal cancer (mCRC).	Oxaliplatin	79-90	kallikrein related peptidase 11	Homo sapiens	14-27
29497313-1	2018	Introduction: Kallikrein 11 (KLK11) plays a crucial role in drug-resistance to oxaliplatin (L-OHP) in the treatment of metastatic colorectal cancer (mCRC).	Oxaliplatin	79-90	kallikrein related peptidase 11	Homo sapiens	29-34
29497313-1	2018	Introduction: Kallikrein 11 (KLK11) plays a crucial role in drug-resistance to oxaliplatin (L-OHP) in the treatment of metastatic colorectal cancer (mCRC).	Oxaliplatin	92-97	kallikrein related peptidase 11	Homo sapiens	14-27
29497313-1	2018	Introduction: Kallikrein 11 (KLK11) plays a crucial role in drug-resistance to oxaliplatin (L-OHP) in the treatment of metastatic colorectal cancer (mCRC).	Oxaliplatin	92-97	kallikrein related peptidase 11	Homo sapiens	29-34
29497313-2	2018	The study aimed to investigate the role of KLK11 in chemoresistance, and to clarify the mechanism underlying reverse of L-OHP resistance by knockdown of KLK11.	Oxaliplatin	120-125	kallikrein related peptidase 11	Homo sapiens	153-158
29497313-9	2018	Moreover, the activated PI3K/AKT pathway was related to L-OHP-resistance.	Oxaliplatin	56-61	AKT serine/threonine kinase 1	Homo sapiens	29-32
29497313-10	2018	Knockdown of KLK11 in HCT-8/L-OHP cell reversed L-OHP-resistance by inhibiting cell growth and activating apoptosis via suppressing the PI3K/AKT signaling pathway.	Oxaliplatin	28-33	kallikrein related peptidase 11	Homo sapiens	13-18
29497313-10	2018	Knockdown of KLK11 in HCT-8/L-OHP cell reversed L-OHP-resistance by inhibiting cell growth and activating apoptosis via suppressing the PI3K/AKT signaling pathway.	Oxaliplatin	28-33	AKT serine/threonine kinase 1	Homo sapiens	141-144
29497313-13	2018	Moreover, L-OHP resistance was associated with activated PI3K/AKT signal pathway.	Oxaliplatin	10-15	AKT serine/threonine kinase 1	Homo sapiens	62-65
29497313-14	2018	Knockdown of KLK11 can reverse L-OHP resistance by blocking PI3K/AKT signaling pathway.	Oxaliplatin	31-36	kallikrein related peptidase 11	Homo sapiens	13-18
29497313-14	2018	Knockdown of KLK11 can reverse L-OHP resistance by blocking PI3K/AKT signaling pathway.	Oxaliplatin	31-36	AKT serine/threonine kinase 1	Homo sapiens	65-68
29145602-2	2018	TYMS-3" untranslated region (UTR) 6 bp ins/del and ERCC1-118C/T polymorphisms were previously reported to facilitate selecting patients for fluoropyrimidine-based treatment in combination with oxaliplatin as first-line therapy.	Oxaliplatin	193-204	thymidylate synthetase	Homo sapiens	0-4
29145602-2	2018	TYMS-3" untranslated region (UTR) 6 bp ins/del and ERCC1-118C/T polymorphisms were previously reported to facilitate selecting patients for fluoropyrimidine-based treatment in combination with oxaliplatin as first-line therapy.	Oxaliplatin	193-204	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56
29434844-9	2018	The results of the present study indicated that TNF-alpha was increased in the tumor tissue of patients with colon cancer who were resistant to OXA and also in OXA-resistant colon cancer cell lines.	Oxaliplatin	144-147	tumor necrosis factor	Homo sapiens	48-57
29247884-5	2018	Experiments using xenograft models revealed that SL-1 was more potent than 5-fluorouracil (5-FU) and oxaliplatin for suppressing the growth of RKO and RKO-E6 (oxaliplatin-resistant subline) cells as well as metastatic SW620 cells.	Oxaliplatin	159-170	TATA-box binding protein associated factor, RNA polymerase I subunit A	Homo sapiens	49-53
29274843-6	2018	Double-staining immunohistochemistry showed that 4days after oxaliplatin treatment, there was increased co-expression of TRPA1 and TRPV1 in isolectin B4-positive small-sized DRG neurons, as well as a significant increase in the co-localization of TRPM8 and neurofilament 200 in medium-sized DRG neurons.	Oxaliplatin	61-72	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	121-126
29274843-6	2018	Double-staining immunohistochemistry showed that 4days after oxaliplatin treatment, there was increased co-expression of TRPA1 and TRPV1 in isolectin B4-positive small-sized DRG neurons, as well as a significant increase in the co-localization of TRPM8 and neurofilament 200 in medium-sized DRG neurons.	Oxaliplatin	61-72	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	131-136
29274843-6	2018	Double-staining immunohistochemistry showed that 4days after oxaliplatin treatment, there was increased co-expression of TRPA1 and TRPV1 in isolectin B4-positive small-sized DRG neurons, as well as a significant increase in the co-localization of TRPM8 and neurofilament 200 in medium-sized DRG neurons.	Oxaliplatin	61-72	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	247-252
29274843-7	2018	In addition, in situ hybridization revealed that TRPV1 protein was co-expressed with TRPA1 mRNA on day 4 after oxaliplatin administration.	Oxaliplatin	111-122	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	49-54
29274843-7	2018	In addition, in situ hybridization revealed that TRPV1 protein was co-expressed with TRPA1 mRNA on day 4 after oxaliplatin administration.	Oxaliplatin	111-122	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	85-90
29274843-8	2018	Thus, at an early stage following oxaliplatin treatment there is an increased expression of TRPA1 and TRPV1 in small-sized DRG neurons and of TRPM8 in medium-sized DRG neurons.	Oxaliplatin	34-45	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	92-97
29274843-8	2018	Thus, at an early stage following oxaliplatin treatment there is an increased expression of TRPA1 and TRPV1 in small-sized DRG neurons and of TRPM8 in medium-sized DRG neurons.	Oxaliplatin	34-45	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	102-107
29274843-8	2018	Thus, at an early stage following oxaliplatin treatment there is an increased expression of TRPA1 and TRPV1 in small-sized DRG neurons and of TRPM8 in medium-sized DRG neurons.	Oxaliplatin	34-45	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	142-147
29403564-10	2018	When GSH was used to treat OXA-induced ALI mice, the pathological injury of liver tissues was alleviated, and serum ALT and AST were significantly decreased.	Oxaliplatin	27-30	glutamic pyruvic transaminase, soluble	Mus musculus	116-119
29403564-10	2018	When GSH was used to treat OXA-induced ALI mice, the pathological injury of liver tissues was alleviated, and serum ALT and AST were significantly decreased.	Oxaliplatin	27-30	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	124-127
29552311-8	2018	On the other hand, expression plasmid of SIRT1, N-acetyl cysteine or SP600125 (JNK specific inhibitor) abolished the effect of miR-29b on oxaliplatin-treated OR-SW480.	Oxaliplatin	138-149	sirtuin 1	Homo sapiens	41-46
29552311-0	2018	MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1.	Oxaliplatin	17-28	microRNA 29b-1	Homo sapiens	0-7
29552311-8	2018	On the other hand, expression plasmid of SIRT1, N-acetyl cysteine or SP600125 (JNK specific inhibitor) abolished the effect of miR-29b on oxaliplatin-treated OR-SW480.	Oxaliplatin	138-149	mitogen-activated protein kinase 8	Homo sapiens	79-82
29552311-8	2018	On the other hand, expression plasmid of SIRT1, N-acetyl cysteine or SP600125 (JNK specific inhibitor) abolished the effect of miR-29b on oxaliplatin-treated OR-SW480.	Oxaliplatin	138-149	microRNA 29b-1	Homo sapiens	127-134
29552311-9	2018	We therefore demonstrated that miR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1/ROS/JNK pathway.	Oxaliplatin	48-59	microRNA 29b-1	Homo sapiens	31-38
29552311-0	2018	MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1.	Oxaliplatin	17-28	sirtuin 1	Homo sapiens	74-79
29552311-9	2018	We therefore demonstrated that miR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1/ROS/JNK pathway.	Oxaliplatin	48-59	sirtuin 1	Homo sapiens	105-110
29552311-9	2018	We therefore demonstrated that miR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1/ROS/JNK pathway.	Oxaliplatin	48-59	mitogen-activated protein kinase 8	Homo sapiens	115-118
29552311-4	2018	We found that intracellular expression of miR-29b was decreased when the SW480 cells became oxaliplatin-resistant.	Oxaliplatin	92-103	microRNA 29b-1	Homo sapiens	42-49
29552311-5	2018	More importantly, overexpression of miR-29b resensitized OR-SW480 cells to oxaliplatin treatment.	Oxaliplatin	75-86	microRNA 29b-1	Homo sapiens	36-43
29552311-7	2018	Overexpression of miR-29b in oxaliplatin-treated OR-SW480 decreased the expression of SIRT1 to enhance the ROS production and JNK phosphorylation, and thus promoting apoptosis via activation of caspase 9, 7 and 3.	Oxaliplatin	29-40	microRNA 29b-1	Homo sapiens	18-25
29552311-7	2018	Overexpression of miR-29b in oxaliplatin-treated OR-SW480 decreased the expression of SIRT1 to enhance the ROS production and JNK phosphorylation, and thus promoting apoptosis via activation of caspase 9, 7 and 3.	Oxaliplatin	29-40	sirtuin 1	Homo sapiens	86-91
29552311-7	2018	Overexpression of miR-29b in oxaliplatin-treated OR-SW480 decreased the expression of SIRT1 to enhance the ROS production and JNK phosphorylation, and thus promoting apoptosis via activation of caspase 9, 7 and 3.	Oxaliplatin	29-40	mitogen-activated protein kinase 8	Homo sapiens	126-129
29552311-7	2018	Overexpression of miR-29b in oxaliplatin-treated OR-SW480 decreased the expression of SIRT1 to enhance the ROS production and JNK phosphorylation, and thus promoting apoptosis via activation of caspase 9, 7 and 3.	Oxaliplatin	29-40	caspase 9	Homo sapiens	194-212
29378575-6	2018	DHA, Omegaven  and oxaliplatin were associated with significant downregulation of VEGF and p53 protein, and upregulation of p21 protein.	Oxaliplatin	19-30	vascular endothelial growth factor A	Homo sapiens	82-86
29307816-8	2018	c-Fos, ATF3 and iNOS expressions were increased in neuronal cells during and after the end of the injections in animals treated with oxaliplatin and LLC-1402 (P&lt;0.05), even though oxaliplatin lead to an earlier increase.	Oxaliplatin	133-144	FBJ osteosarcoma oncogene	Mus musculus	0-5
29307816-8	2018	c-Fos, ATF3 and iNOS expressions were increased in neuronal cells during and after the end of the injections in animals treated with oxaliplatin and LLC-1402 (P&lt;0.05), even though oxaliplatin lead to an earlier increase.	Oxaliplatin	133-144	activating transcription factor 3	Mus musculus	7-11
29307816-8	2018	c-Fos, ATF3 and iNOS expressions were increased in neuronal cells during and after the end of the injections in animals treated with oxaliplatin and LLC-1402 (P&lt;0.05), even though oxaliplatin lead to an earlier increase.	Oxaliplatin	133-144	nitric oxide synthase 2, inducible	Mus musculus	16-20
29307816-10	2018	c-Fos expression was also shown in glial satellite cells only in the oxaliplatin-treated animals.	Oxaliplatin	69-80	FBJ osteosarcoma oncogene	Mus musculus	0-5
29378575-7	2018	DHA, Omegaven  and Oxaliplatin also led to significant downregulation of the total ERK1/2 and Akt proteins.	Oxaliplatin	19-30	AKT serine/threonine kinase 1	Homo sapiens	94-97
29378575-6	2018	DHA, Omegaven  and oxaliplatin were associated with significant downregulation of VEGF and p53 protein, and upregulation of p21 protein.	Oxaliplatin	19-30	tumor protein p53	Homo sapiens	91-94
29378575-8	2018	CONCLUSION: DHA, Omegaven  and oxaliplatin were associated with downregulation of p53 and VEGF in both cells.	Oxaliplatin	31-42	tumor protein p53	Homo sapiens	82-85
29378575-8	2018	CONCLUSION: DHA, Omegaven  and oxaliplatin were associated with downregulation of p53 and VEGF in both cells.	Oxaliplatin	31-42	vascular endothelial growth factor A	Homo sapiens	90-94
29378575-6	2018	DHA, Omegaven  and oxaliplatin were associated with significant downregulation of VEGF and p53 protein, and upregulation of p21 protein.	Oxaliplatin	19-30	H3 histone pseudogene 16	Homo sapiens	124-127
29378575-7	2018	DHA, Omegaven  and Oxaliplatin also led to significant downregulation of the total ERK1/2 and Akt proteins.	Oxaliplatin	19-30	mitogen-activated protein kinase 3	Homo sapiens	83-89
29433678-5	2018	Interestingly, the combined treatment of wogonin and oxaliplatin modulated the expression of phospho-JNK (Thr183/Tyr185), phospho-ULK1 (Ser555) and the formation of LC3II.	Oxaliplatin	53-64	mitogen-activated protein kinase 8	Homo sapiens	101-104
29371831-7	2018	Results: In cervical cancer, we found that SHP-2 suppressed apoptosis induced by Oxaliplatin and 5-FU.	Oxaliplatin	81-92	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	43-48
29360852-10	2018	Moreover, miR-143 overexpression increased oxaliplatin-induced apoptosis associated with reactive oxygen species generation, which was abrogated by genetic and pharmacological inhibition of oxidative stress.	Oxaliplatin	43-54	microRNA 143	Homo sapiens	10-17
29360852-11	2018	Overall, miR-143 might circumvent resistance of colon cancer cells to oxaliplatin via increased oxidative stress in HCT116 human colon cancer cells.	Oxaliplatin	70-81	microRNA 143	Homo sapiens	9-16
29433678-5	2018	Interestingly, the combined treatment of wogonin and oxaliplatin modulated the expression of phospho-JNK (Thr183/Tyr185), phospho-ULK1 (Ser555) and the formation of LC3II.	Oxaliplatin	53-64	unc-51 like autophagy activating kinase 1	Homo sapiens	130-134
29301327-5	2018	Moreover, non-replicative, TLS-capable DNA polymerases can negatively impact cancer treatment by synthesizing DNA past lesions generated from treatments such as cisplatin, oxaliplatin, etoposide, bleomycin, and radiotherapy.	Oxaliplatin	172-183	FUS RNA binding protein	Homo sapiens	27-30
29310611-0	2018	Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.	Oxaliplatin	66-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
29310611-2	2018	The current research involves a single-arm, prospective, phase II clinical trial to examine the efficacy and safety of oxaliplatin + S-1 with an oxaliplatin dose of 130 mg/m2 to treat HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy in Japan.	Oxaliplatin	119-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-188
29310611-8	2018	Verifying the efficacy and safety of oxaliplatin + S-1 with an oxaliplatin dose of 130 mg is an important task that the current trial has set out to achieve.	Oxaliplatin	63-74	proteasome 26S subunit, non-ATPase 1	Homo sapiens	51-54
29239146-8	2018	Vorinostat suppressed the expression of BRCA1 induced by oxaliplatin.	Oxaliplatin	57-68	BRCA1 DNA repair associated	Homo sapiens	40-45
29793414-0	2018	Oxaliplatin Regulates Chemotherapy Induced Peripheral Neuropathic Pain in the Dorsal Horn and Dorsal Root Ganglion via the Calcineurin/NFAT Pathway.	Oxaliplatin	0-11	nuclear factor of activated T-cells 5	Rattus norvegicus	135-139
29793414-12	2018	CONCLUSION: It was the first time to prove that oxaliplatin-induced neuropathic pain was correlated to the activation of the CaN/NFAT pathway in our rat model.	Oxaliplatin	48-59	nuclear factor of activated T-cells 5	Rattus norvegicus	129-133
28939924-3	2018	METHODS: This pilot study examined PAH exposure by measuring 1-hydroxypyrene (1-OHP) in urine samples using high-performance liquid chromatography and fluorescence detection from 75 women and men in the Ecuadorian and Peruvian Amazon living near oil drilling operations and who answered a questionnaire collecting socio-demographic, occupational and dietary information.	Oxaliplatin	78-83	phenylalanine hydroxylase	Homo sapiens	35-38
30071508-0	2018	Knockdown of Mir-135b Sensitizes Colorectal Cancer Cells to Oxaliplatin-Induced Apoptosis Through Increase of FOXO1.	Oxaliplatin	60-71	microRNA 135b	Homo sapiens	13-21
30071508-0	2018	Knockdown of Mir-135b Sensitizes Colorectal Cancer Cells to Oxaliplatin-Induced Apoptosis Through Increase of FOXO1.	Oxaliplatin	60-71	forkhead box O1	Homo sapiens	110-115
30071508-5	2018	MTT assays were used to evaluate the effect of anti-miR-135b on oxaliplatin-induced cell death in CRC cell lines.	Oxaliplatin	64-75	microRNA 135b	Homo sapiens	52-60
30071508-6	2018	Western blot, flow cytometry and luciferase reporter assays were performed to evaluate the potential mechanism and pathway of anti-miR-135b-promoted apoptosis in oxaliplatin-treated CRC cells.	Oxaliplatin	162-173	microRNA 135b	Homo sapiens	131-139
30071508-8	2018	Knockdown of miR-135b was found to sensitize colorectal cancer cells to oxaliplatin-induced cytotoxicity.	Oxaliplatin	72-83	microRNA 135b	Homo sapiens	13-21
30071508-11	2018	Since Bim and Noxa act as key pro-apoptotic proteins in mitochondrial apoptosis, anti-miR-135b was able to enhance the oxaliplatin-induced apoptosis dependent on the anti-miR-135b/FOXO1 axis.	Oxaliplatin	119-130	BCL2 like 11	Homo sapiens	6-9
30071508-11	2018	Since Bim and Noxa act as key pro-apoptotic proteins in mitochondrial apoptosis, anti-miR-135b was able to enhance the oxaliplatin-induced apoptosis dependent on the anti-miR-135b/FOXO1 axis.	Oxaliplatin	119-130	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	14-18
30071508-11	2018	Since Bim and Noxa act as key pro-apoptotic proteins in mitochondrial apoptosis, anti-miR-135b was able to enhance the oxaliplatin-induced apoptosis dependent on the anti-miR-135b/FOXO1 axis.	Oxaliplatin	119-130	microRNA 135b	Homo sapiens	86-94
30071508-11	2018	Since Bim and Noxa act as key pro-apoptotic proteins in mitochondrial apoptosis, anti-miR-135b was able to enhance the oxaliplatin-induced apoptosis dependent on the anti-miR-135b/FOXO1 axis.	Oxaliplatin	119-130	microRNA 135b	Homo sapiens	171-179
30071508-11	2018	Since Bim and Noxa act as key pro-apoptotic proteins in mitochondrial apoptosis, anti-miR-135b was able to enhance the oxaliplatin-induced apoptosis dependent on the anti-miR-135b/FOXO1 axis.	Oxaliplatin	119-130	forkhead box O1	Homo sapiens	180-185
30071508-12	2018	CONCLUSIONS: Anti-miR-135b enhanced the anti-tumor effect of oxaliplatin on CRC.	Oxaliplatin	61-72	microRNA 135b	Homo sapiens	18-26
30071508-13	2018	Combination with miR-135b antisense nucleotides may represent a novel strategy to sensitize CRC to oxaliplatin-based treatment.	Oxaliplatin	99-110	microRNA 135b	Homo sapiens	17-25
30522111-0	2018	miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.	Oxaliplatin	69-80	microRNA 122	Homo sapiens	0-7
30522111-0	2018	miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.	Oxaliplatin	69-80	X-linked inhibitor of apoptosis	Homo sapiens	16-55
30522111-0	2018	miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.	Oxaliplatin	118-129	microRNA 122	Homo sapiens	0-7
30522111-0	2018	miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.	Oxaliplatin	118-129	X-linked inhibitor of apoptosis	Homo sapiens	16-55
30522111-3	2018	The aim of this study was to explore the effect of microRNA-122 (miR-122) on reversing oxaliplatin resistance in CRC.	Oxaliplatin	87-98	microRNA 122	Homo sapiens	51-63
30522111-3	2018	The aim of this study was to explore the effect of microRNA-122 (miR-122) on reversing oxaliplatin resistance in CRC.	Oxaliplatin	87-98	microRNA 122	Homo sapiens	65-72
30522111-8	2018	RESULTS: Established oxaliplatin-resistant SW480 and HT29 cells (SW480/OR and HT29/OR) expressed significantly higher levels of X-linked inhibitor of apoptosis protein (XIAP) and lower levels of miR-122 compared with normal SW480 and HT29 cells, respectively.	Oxaliplatin	21-32	X-linked inhibitor of apoptosis	Homo sapiens	128-167
30522111-8	2018	RESULTS: Established oxaliplatin-resistant SW480 and HT29 cells (SW480/OR and HT29/OR) expressed significantly higher levels of X-linked inhibitor of apoptosis protein (XIAP) and lower levels of miR-122 compared with normal SW480 and HT29 cells, respectively.	Oxaliplatin	21-32	X-linked inhibitor of apoptosis	Homo sapiens	169-173
30522111-8	2018	RESULTS: Established oxaliplatin-resistant SW480 and HT29 cells (SW480/OR and HT29/OR) expressed significantly higher levels of X-linked inhibitor of apoptosis protein (XIAP) and lower levels of miR-122 compared with normal SW480 and HT29 cells, respectively.	Oxaliplatin	21-32	microRNA 122	Homo sapiens	195-202
30522111-9	2018	Our results showed that the downregulation of miR-122 was responsible for the overexpression of XIAP in these oxaliplatin-resistant CRC cells.	Oxaliplatin	110-121	microRNA 122	Homo sapiens	46-53
30522111-9	2018	Our results showed that the downregulation of miR-122 was responsible for the overexpression of XIAP in these oxaliplatin-resistant CRC cells.	Oxaliplatin	110-121	X-linked inhibitor of apoptosis	Homo sapiens	96-100
30522111-10	2018	We then found that the recovery of miR-122 expression can sensitize SW480/OR and HT29/OR cells to oxaliplatin-mediated apoptosis through the inhibition of XIAP expression.	Oxaliplatin	98-109	microRNA 122	Homo sapiens	35-42
30522111-10	2018	We then found that the recovery of miR-122 expression can sensitize SW480/OR and HT29/OR cells to oxaliplatin-mediated apoptosis through the inhibition of XIAP expression.	Oxaliplatin	98-109	X-linked inhibitor of apoptosis	Homo sapiens	155-159
30522111-11	2018	CONCLUSION: Upregulation of XIAP in CRC cells is responsible for the acquired resistance to oxaliplatin.	Oxaliplatin	92-103	X-linked inhibitor of apoptosis	Homo sapiens	28-32
30522111-12	2018	Furthermore, miR-122 reversed oxaliplatin resistance in CRC by targeting XIAP.	Oxaliplatin	30-41	microRNA 122	Homo sapiens	13-20
30522111-12	2018	Furthermore, miR-122 reversed oxaliplatin resistance in CRC by targeting XIAP.	Oxaliplatin	30-41	X-linked inhibitor of apoptosis	Homo sapiens	73-77
30041169-6	2018	We found higher values for the basophil activation percentage and mean stimulation index for CD203c expression with all oxaliplatin concentrations tested (most significant at 150 mug/mL: p = 0,0087; p = 0.0222) in the patients than in controls.	Oxaliplatin	120-131	ectonucleotide pyrophosphatase/phosphodiesterase 3	Homo sapiens	93-99
29115606-0	2018	DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53-deficient pancreatic cancer cells.	Oxaliplatin	71-82	DNA methyltransferase 3 alpha	Homo sapiens	0-24
29115606-0	2018	DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53-deficient pancreatic cancer cells.	Oxaliplatin	71-82	AKT serine/threonine kinase 1	Homo sapiens	96-99
29115606-3	2018	However, its regulation of chemosensitivity to gemcitabine (GEM) and oxaliplatin (OXA) in p53-deficient PDAC remains unclear.	Oxaliplatin	69-80	tumor protein p53	Homo sapiens	90-93
29454708-7	2018	The HSR incidence was 15.2% among oxaliplatin-naive patients but increased to 31.9% among those with a history of asymptomatic exposure and 75.0% among those with a history of oxaliplatin HSRs during the previous exposure, despite prophylaxis.	Oxaliplatin	34-45	HSR	Homo sapiens	4-7
29454708-7	2018	The HSR incidence was 15.2% among oxaliplatin-naive patients but increased to 31.9% among those with a history of asymptomatic exposure and 75.0% among those with a history of oxaliplatin HSRs during the previous exposure, despite prophylaxis.	Oxaliplatin	176-187	HSR	Homo sapiens	4-7
29454708-11	2018	CONCLUSIONS: Previous exposure to oxaliplatin is a risk factor for earlier HSR onset and more severe and frequent HSR episodes, even if prior therapy was well tolerated.	Oxaliplatin	34-45	HSR	Homo sapiens	75-78
29454708-11	2018	CONCLUSIONS: Previous exposure to oxaliplatin is a risk factor for earlier HSR onset and more severe and frequent HSR episodes, even if prior therapy was well tolerated.	Oxaliplatin	34-45	HSR	Homo sapiens	114-117
29115606-0	2018	DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53-deficient pancreatic cancer cells.	Oxaliplatin	71-82	checkpoint kinase 1	Homo sapiens	87-91
29115606-3	2018	However, its regulation of chemosensitivity to gemcitabine (GEM) and oxaliplatin (OXA) in p53-deficient PDAC remains unclear.	Oxaliplatin	82-85	tumor protein p53	Homo sapiens	90-93
29115606-7	2018	DNMT3a depletion distinctly abolished S phase arrest induced by GEM and OXA.	Oxaliplatin	72-75	DNA methyltransferase 3 alpha	Homo sapiens	0-6
29313436-0	2018	Down-regulation of Kv4.3 channels and a-type K+ currents in V2 trigeminal ganglion neurons of rats following oxaliplatin treatment.	Oxaliplatin	109-120	potassium voltage-gated channel subfamily D member 3	Rattus norvegicus	19-24
29115606-8	2018	Further research demonstrated that activation inhibition of CHK1 and AKT, as well as an increase in apoptosis, were involved in DNMT3a-mediated chemosensitivity to GEM and OXA.	Oxaliplatin	172-175	checkpoint kinase 1	Homo sapiens	60-64
29115606-8	2018	Further research demonstrated that activation inhibition of CHK1 and AKT, as well as an increase in apoptosis, were involved in DNMT3a-mediated chemosensitivity to GEM and OXA.	Oxaliplatin	172-175	AKT serine/threonine kinase 1	Homo sapiens	69-72
29115606-8	2018	Further research demonstrated that activation inhibition of CHK1 and AKT, as well as an increase in apoptosis, were involved in DNMT3a-mediated chemosensitivity to GEM and OXA.	Oxaliplatin	172-175	DNA methyltransferase 3 alpha	Homo sapiens	128-134
29115606-9	2018	Taken together, these data demonstrated that DNMT3a serves a crucial role in the regulation of chemosensitivity to GEM and OXA, and suggests a promising therapeutic target for p53-deficient PDAC.	Oxaliplatin	123-126	DNA methyltransferase 3 alpha	Homo sapiens	45-51
29806529-0	2018	HCN2 contributes to oxaliplatin-induced neuropathic pain through activation of the CaMKII/CREB cascade in spinal neurons.	Oxaliplatin	20-31	hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2	Rattus norvegicus	0-4
29313436-6	2018	The numbers of Kv4.3-ir positive V2 TG neurons were significantly reduced in oxaliplatin-treated rats, suggesting down-regulation of Kv4.3 channel expression on V2 TG neurons by the chemotherapy drug.	Oxaliplatin	77-88	potassium voltage-gated channel subfamily D member 3	Rattus norvegicus	15-20
29806529-0	2018	HCN2 contributes to oxaliplatin-induced neuropathic pain through activation of the CaMKII/CREB cascade in spinal neurons.	Oxaliplatin	20-31	cAMP responsive element binding protein 1	Rattus norvegicus	90-94
29806529-3	2018	Here, we found that HCN2 expression was upregulated in a rat model of oxaliplatin-induced neuropathic pain.	Oxaliplatin	70-81	hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2	Rattus norvegicus	20-24
29313436-6	2018	The numbers of Kv4.3-ir positive V2 TG neurons were significantly reduced in oxaliplatin-treated rats, suggesting down-regulation of Kv4.3 channel expression on V2 TG neurons by the chemotherapy drug.	Oxaliplatin	77-88	potassium voltage-gated channel subfamily D member 3	Rattus norvegicus	133-138
29806529-9	2018	In a word, HCN2 is conducive to oxaliplatin-induced neuropathic pain by activating the neuronal CaMKII/CREB cascade.	Oxaliplatin	32-43	hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2	Rattus norvegicus	11-15
29806529-9	2018	In a word, HCN2 is conducive to oxaliplatin-induced neuropathic pain by activating the neuronal CaMKII/CREB cascade.	Oxaliplatin	32-43	cAMP responsive element binding protein 1	Rattus norvegicus	103-107
29900804-6	2018	Results IL-1beta, IL-6, and TNF-alpha were elevated within the periaqueductal gray of oxaliplatin rats.	Oxaliplatin	86-97	interleukin 1 beta	Rattus norvegicus	8-16
29900804-6	2018	Results IL-1beta, IL-6, and TNF-alpha were elevated within the periaqueductal gray of oxaliplatin rats.	Oxaliplatin	86-97	interleukin 6	Rattus norvegicus	18-22
29313436-10	2018	These findings raise a possibility that down-regulation of Kv4.3 channels and IA currents in nociceptive V2 TG neurons is an underlying mechanism of oxaliplatin-induced orofacial neuropathic pain.	Oxaliplatin	149-160	potassium voltage-gated channel subfamily D member 3	Rattus norvegicus	59-64
29900804-6	2018	Results IL-1beta, IL-6, and TNF-alpha were elevated within the periaqueductal gray of oxaliplatin rats.	Oxaliplatin	86-97	tumor necrosis factor	Rattus norvegicus	28-37
29900804-7	2018	Protein expression of IL-1beta, IL-6, and TNF-alpha receptors (namely, IL-1R, IL-6R, and TNFR subtype TNFR1) in the plasma membrane periaqueductal gray of oxaliplatin rats was upregulated, whereas the total expression of pro-inflammatory cytokine receptors was not altered.	Oxaliplatin	155-166	interleukin 1 beta	Rattus norvegicus	22-30
29587559-2	2018	The purpose of this study was to examine the underlying mechanisms by which mammalian target of rapamycin (mTOR) and its signal are responsible for oxaliplatin-evoked neuropathic pain.	Oxaliplatin	148-159	mechanistic target of rapamycin kinase	Homo sapiens	76-105
29900804-7	2018	Protein expression of IL-1beta, IL-6, and TNF-alpha receptors (namely, IL-1R, IL-6R, and TNFR subtype TNFR1) in the plasma membrane periaqueductal gray of oxaliplatin rats was upregulated, whereas the total expression of pro-inflammatory cytokine receptors was not altered.	Oxaliplatin	155-166	interleukin 6	Rattus norvegicus	32-36
29900804-7	2018	Protein expression of IL-1beta, IL-6, and TNF-alpha receptors (namely, IL-1R, IL-6R, and TNFR subtype TNFR1) in the plasma membrane periaqueductal gray of oxaliplatin rats was upregulated, whereas the total expression of pro-inflammatory cytokine receptors was not altered.	Oxaliplatin	155-166	tumor necrosis factor	Rattus norvegicus	42-51
29900804-7	2018	Protein expression of IL-1beta, IL-6, and TNF-alpha receptors (namely, IL-1R, IL-6R, and TNFR subtype TNFR1) in the plasma membrane periaqueductal gray of oxaliplatin rats was upregulated, whereas the total expression of pro-inflammatory cytokine receptors was not altered.	Oxaliplatin	155-166	interleukin 6 receptor	Rattus norvegicus	78-83
29900804-7	2018	Protein expression of IL-1beta, IL-6, and TNF-alpha receptors (namely, IL-1R, IL-6R, and TNFR subtype TNFR1) in the plasma membrane periaqueductal gray of oxaliplatin rats was upregulated, whereas the total expression of pro-inflammatory cytokine receptors was not altered.	Oxaliplatin	155-166	TNF receptor superfamily member 1A	Rattus norvegicus	102-107
29587559-2	2018	The purpose of this study was to examine the underlying mechanisms by which mammalian target of rapamycin (mTOR) and its signal are responsible for oxaliplatin-evoked neuropathic pain.	Oxaliplatin	148-159	mechanistic target of rapamycin kinase	Homo sapiens	107-111
29587559-6	2018	Oxaliplatin also amplified the expression of p-mTOR and mTOR-mediated phosphorylation of p70 ribosomal S6 protein kinase 1 and 4E-binding protein 1 in the lumbar dorsal root ganglion.	Oxaliplatin	0-11	mechanistic target of rapamycin kinase	Rattus norvegicus	47-51
29587559-6	2018	Oxaliplatin also amplified the expression of p-mTOR and mTOR-mediated phosphorylation of p70 ribosomal S6 protein kinase 1 and 4E-binding protein 1 in the lumbar dorsal root ganglion.	Oxaliplatin	0-11	mechanistic target of rapamycin kinase	Rattus norvegicus	56-60
29587559-7	2018	Blocking mTOR using rapamycin attenuated peripheral painful neuropathy observed in oxaliplatin rats ( P &lt; 0.05 vs. vehicle control).	Oxaliplatin	83-94	mechanistic target of rapamycin kinase	Rattus norvegicus	9-13
29587559-9	2018	In addition, inhibition of phosphatidylinositide 3-kinase (p-PI3K) attenuated the expression of p-mTOR and the levels of pro-inflammatory cytokines in oxaliplatin rats, and this further attenuated mechanical and cold hypersensitivity.	Oxaliplatin	151-162	mechanistic target of rapamycin kinase	Rattus norvegicus	98-102
29587559-10	2018	Conclusions The data revealed specific signaling pathways leading to oxaliplatin-induced peripheral neuropathic pain, including the activation of PI3K-mTOR and pro-inflammatory cytokine signal.	Oxaliplatin	69-80	mechanistic target of rapamycin kinase	Rattus norvegicus	151-155
29138869-3	2018	Mutated p53 in CRC was reported to be associated with resistance to commonly used chemotherapeutic agents including, 5-fluorouracil, oxaliplatin and irinotecan.	Oxaliplatin	133-144	tumor protein p53	Homo sapiens	8-11
29153096-2	2017	While, single nucleotide polymorphisms (SNP) of ERCC1 and XRCC1 have be proved to influence clinical outcome of colorectal cancer patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	152-163	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	48-53
28987388-0	2017	BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.	Oxaliplatin	14-25	bone morphogenetic protein 4	Homo sapiens	0-4
28987388-0	2017	BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.	Oxaliplatin	14-25	mitogen-activated protein kinase kinase 1	Homo sapiens	94-98
28987388-0	2017	BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.	Oxaliplatin	14-25	mitogen-activated protein kinase 1	Homo sapiens	99-102
28987388-0	2017	BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.	Oxaliplatin	14-25	ETS transcription factor ELK1	Homo sapiens	103-107
29423057-9	2018	Consistently, IL-34 knockdown in HT-29 cells with a specific IL-34 antisense oligonucleotide reduced ERK1/2 activation, cell proliferation and enhanced the susceptibility of cells to Oxaliplatin-induced death.	Oxaliplatin	183-194	interleukin 34	Homo sapiens	14-19
29423057-9	2018	Consistently, IL-34 knockdown in HT-29 cells with a specific IL-34 antisense oligonucleotide reduced ERK1/2 activation, cell proliferation and enhanced the susceptibility of cells to Oxaliplatin-induced death.	Oxaliplatin	183-194	interleukin 34	Homo sapiens	61-66
29326595-3	2017	Accumulating evidences indicates that antagonists of TRPA1 and TRPM8 may protect against cisplatin, oxaliplatin, and paclitaxel-induced mitochondrial oxidative stress, inflammation, cold allodynia, and hyperalgesia.	Oxaliplatin	100-111	transient receptor potential cation channel subfamily A member 1	Homo sapiens	53-58
29326595-3	2017	Accumulating evidences indicates that antagonists of TRPA1 and TRPM8 may protect against cisplatin, oxaliplatin, and paclitaxel-induced mitochondrial oxidative stress, inflammation, cold allodynia, and hyperalgesia.	Oxaliplatin	100-111	transient receptor potential cation channel subfamily M member 8	Homo sapiens	63-68
29326595-6	2017	There is a debate on direct or oxaliplatin-induced oxidative cold stress dependent TRPA1 and TRPV4 activation in the DRG.	Oxaliplatin	31-42	transient receptor potential cation channel subfamily A member 1	Homo sapiens	83-88
29326595-6	2017	There is a debate on direct or oxaliplatin-induced oxidative cold stress dependent TRPA1 and TRPV4 activation in the DRG.	Oxaliplatin	31-42	transient receptor potential cation channel subfamily V member 4	Homo sapiens	93-98
29326595-7	2017	Involvement of molecular pathways such as cysteine groups, glutathione metabolism, anandamide, cAMP, lipopolysaccharide, proteinase-activated receptor 2, and mitogen-activated protein kinase were also indicated in the oxaliplatin and paclitaxel-induced cold allodynia.	Oxaliplatin	218-229	F2R like trypsin receptor 1	Homo sapiens	121-152
29024195-9	2017	Furthermore, knockdown of ZIC5 or PDGFD enhanced death of PCa and CRC cells induced by the anti-cancer drugs docetaxel or oxaliplatin, respectively.	Oxaliplatin	122-133	Zic family member 5	Homo sapiens	26-30
29024195-9	2017	Furthermore, knockdown of ZIC5 or PDGFD enhanced death of PCa and CRC cells induced by the anti-cancer drugs docetaxel or oxaliplatin, respectively.	Oxaliplatin	122-133	platelet derived growth factor D	Homo sapiens	34-39
30048976-0	2018	Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells.	Oxaliplatin	38-49	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	53-98
30048976-4	2018	However, -ERCC1-transfected HCT-116 cells showed paradoxical behaviour in vivo with increased growth in mice treated with oxaliplatin as compared to untreated mice.	Oxaliplatin	122-133	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	10-15
29484125-8	2018	The in vitro study showed that the knockdown of YTHDF1 resulted in the suppression of cancer proliferation and sensitization to the exposure of anticancer drugs such as fluorouracil and oxaliplatin.	Oxaliplatin	186-197	YTH N6-methyladenosine RNA binding protein 1	Homo sapiens	48-54
29383202-5	2017	Silencing Dishevelled1-3 resensitized HCT-8/VCR cells to multiple drugs including vincristine, 5-fluorouracil and oxaliplatin.	Oxaliplatin	114-125	dishevelled segment polarity protein 1	Homo sapiens	10-22
29153096-2	2017	While, single nucleotide polymorphisms (SNP) of ERCC1 and XRCC1 have be proved to influence clinical outcome of colorectal cancer patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	152-163	X-ray repair cross complementing 1	Homo sapiens	58-63
29206996-6	2017	Results: With a median follow-up of 50 months, the addition of oxaliplatin to fluorouracil-based CRT led to statistically significantly improved three-year DFS (75.9%, 95% CI = 72.3 to 79.5, vs 71.3%, 95% CI = 67.6 to 74.9, P = .04, PC 1) and a shift toward more advanced TRG groups ( P &lt; .001, PC 2) compared with CRT with fluorouracil alone.	Oxaliplatin	63-74	proprotein convertase subtilisin/kexin type 1	Homo sapiens	233-237
28812173-12	2017	Oxaliplatin injection also enhanced the messenger RNA (mRNA) expressions of cytokines including interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) and chemokines including monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1 (MIP-1alpha) in the spinal dorsal horn, which could be significantly repressed by melatonin.	Oxaliplatin	0-11	tumor necrosis factor	Rattus norvegicus	158-167
28812173-12	2017	Oxaliplatin injection also enhanced the messenger RNA (mRNA) expressions of cytokines including interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) and chemokines including monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1 (MIP-1alpha) in the spinal dorsal horn, which could be significantly repressed by melatonin.	Oxaliplatin	0-11	C-C motif chemokine ligand 2	Rattus norvegicus	194-228
28812173-12	2017	Oxaliplatin injection also enhanced the messenger RNA (mRNA) expressions of cytokines including interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) and chemokines including monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1 (MIP-1alpha) in the spinal dorsal horn, which could be significantly repressed by melatonin.	Oxaliplatin	0-11	C-C motif chemokine ligand 2	Rattus norvegicus	230-235
28812173-12	2017	Oxaliplatin injection also enhanced the messenger RNA (mRNA) expressions of cytokines including interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) and chemokines including monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1 (MIP-1alpha) in the spinal dorsal horn, which could be significantly repressed by melatonin.	Oxaliplatin	0-11	C-C motif chemokine ligand 3	Rattus norvegicus	274-284
28812173-9	2017	Immunohistochemistry showed that oxaliplatin induced a significant increase of glial fibrillary acidic protein (GFAP) immunodensities, which could be suppressed by melatonin.	Oxaliplatin	33-44	glial fibrillary acidic protein	Rattus norvegicus	79-110
28812173-9	2017	Immunohistochemistry showed that oxaliplatin induced a significant increase of glial fibrillary acidic protein (GFAP) immunodensities, which could be suppressed by melatonin.	Oxaliplatin	33-44	glial fibrillary acidic protein	Rattus norvegicus	112-116
28812173-10	2017	Western blotting showed that GFAP protein levels were significantly elevated in the oxaliplatin-vehicle group.	Oxaliplatin	84-95	glial fibrillary acidic protein	Rattus norvegicus	29-33
28812173-11	2017	Melatonin significantly decreased oxaliplatin-induced upregulation of GFAP expressions.	Oxaliplatin	34-45	glial fibrillary acidic protein	Rattus norvegicus	70-74
28812173-12	2017	Oxaliplatin injection also enhanced the messenger RNA (mRNA) expressions of cytokines including interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) and chemokines including monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1 (MIP-1alpha) in the spinal dorsal horn, which could be significantly repressed by melatonin.	Oxaliplatin	0-11	interleukin 1 beta	Rattus norvegicus	96-113
28812173-12	2017	Oxaliplatin injection also enhanced the messenger RNA (mRNA) expressions of cytokines including interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) and chemokines including monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1 (MIP-1alpha) in the spinal dorsal horn, which could be significantly repressed by melatonin.	Oxaliplatin	0-11	interleukin 1 beta	Rattus norvegicus	115-123
28812173-12	2017	Oxaliplatin injection also enhanced the messenger RNA (mRNA) expressions of cytokines including interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) and chemokines including monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1 (MIP-1alpha) in the spinal dorsal horn, which could be significantly repressed by melatonin.	Oxaliplatin	0-11	tumor necrosis factor	Rattus norvegicus	129-156
28551160-0	2017	Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity.	Oxaliplatin	109-120	solute carrier family 31 member 1	Homo sapiens	0-20
29206996-6	2017	Results: With a median follow-up of 50 months, the addition of oxaliplatin to fluorouracil-based CRT led to statistically significantly improved three-year DFS (75.9%, 95% CI = 72.3 to 79.5, vs 71.3%, 95% CI = 67.6 to 74.9, P = .04, PC 1) and a shift toward more advanced TRG groups ( P &lt; .001, PC 2) compared with CRT with fluorouracil alone.	Oxaliplatin	63-74	chromobox 4	Homo sapiens	298-302
29344221-8	2017	It was also revealed that knockdown of livin by siRNA increased the apoptotic rate, suppressed invasion of LoVo cells, and decreased the half-maximal inhibitory concentration of oxaliplatin and 5-fluorouracil by ~50% in LoVo cells significantly compared with control groups.	Oxaliplatin	178-189	baculoviral IAP repeat containing 7	Homo sapiens	39-44
28551160-5	2017	In a colorectal cancer cell-line background (DLD-1), stable transfection of the hCtr1 gene enhanced hCTR1 protein expression and increased the sensitivity of the cells to the cytotoxicity of copper and oxaliplatin.	Oxaliplatin	202-213	solute carrier family 31 member 1	Homo sapiens	80-85
28551160-6	2017	Treatment with copper chelators (ammonium tetrathiomolybdate, bathocuproinedisulfonic acid and D-penicillamine) increased expression of hCTR1 protein in DLD-1 and SW620 cells, and potentiated the cytotoxicity of oxaliplatin in DLD-1 but not SW620 cells.	Oxaliplatin	212-223	solute carrier family 31 member 1	Homo sapiens	136-141
28551160-9	2017	Genetic or pharmacological modification of hCTR1 protein expression may potentiate oxaliplatin sensitivity in some but not all colorectal cancer cell lines.	Oxaliplatin	83-94	solute carrier family 31 member 1	Homo sapiens	43-48
28733220-11	2017	Gemcitabine/oxaliplatin had limited efficacy in treating late stage AKT/YapS127A ICC.	Oxaliplatin	12-23	thymoma viral proto-oncogene 1	Mus musculus	68-71
28733220-15	2017	CONCLUSIONS: This study suggests that mTOR kinase inhibitors may be beneficial for the treatment of ICC, even in tumors that are resistant to standard of care chemotherapeutics, such as gemcitabine/oxaliplatin-based regimens, especially in the subset of tumors exhibiting activated AKT/mTOR cascade.	Oxaliplatin	198-209	mechanistic target of rapamycin kinase	Mus musculus	38-42
28733220-15	2017	CONCLUSIONS: This study suggests that mTOR kinase inhibitors may be beneficial for the treatment of ICC, even in tumors that are resistant to standard of care chemotherapeutics, such as gemcitabine/oxaliplatin-based regimens, especially in the subset of tumors exhibiting activated AKT/mTOR cascade.	Oxaliplatin	198-209	thymoma viral proto-oncogene 1	Mus musculus	282-285
28733220-15	2017	CONCLUSIONS: This study suggests that mTOR kinase inhibitors may be beneficial for the treatment of ICC, even in tumors that are resistant to standard of care chemotherapeutics, such as gemcitabine/oxaliplatin-based regimens, especially in the subset of tumors exhibiting activated AKT/mTOR cascade.	Oxaliplatin	198-209	mechanistic target of rapamycin kinase	Mus musculus	286-290
29204180-9	2017	Drug interactions were analyzed using Chou-Talalay method to calculate the combination index (CI).The data revealed that 17-AAG shows a potent synergistic interaction (CI &lt; 1) with oxaliplatin and capecitabine in double combinations (0.5 x IC50) in both cell lines.	Oxaliplatin	184-195	N-methylpurine DNA glycosylase	Homo sapiens	124-127
29209153-7	2017	5-Fluorouracil and oxaliplatin treatment lead to an enhanced caspase 3-dependent apoptosis and produce an increase of autophagy.	Oxaliplatin	19-30	caspase 3	Homo sapiens	61-70
29128865-0	2017	Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy.	Oxaliplatin	118-129	Ras association domain family member 1	Homo sapiens	24-31
29169374-14	2017	CONCLUSIONS: Our study provided the first evidence that ID1 conferred oxaliplatin resistance in HCC by activating the PPP.	Oxaliplatin	70-81	inhibitor of DNA binding 1, HLH protein	Homo sapiens	56-59
28708932-0	2017	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.	Oxaliplatin	97-108	HIC ZBTB transcriptional repressor 1	Homo sapiens	33-37
28708932-0	2017	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.	Oxaliplatin	97-108	HIC ZBTB transcriptional repressor 1	Homo sapiens	39-66
28708932-1	2017	BACKGROUND: The hypermethylated in cancer 1/sirtuin 1 (HIC1/SIRT1) axis plays an important role in regulating the nucleotide excision repair pathway, which is the main oxaliplatin-induced damage-repair system.	Oxaliplatin	168-179	HIC ZBTB transcriptional repressor 1	Homo sapiens	16-43
28708932-1	2017	BACKGROUND: The hypermethylated in cancer 1/sirtuin 1 (HIC1/SIRT1) axis plays an important role in regulating the nucleotide excision repair pathway, which is the main oxaliplatin-induced damage-repair system.	Oxaliplatin	168-179	sirtuin 1	Homo sapiens	44-53
28708932-2	2017	On the basis of prior evidence that the variable number of tandem repeat (VNTR) sequence located near the promoter lesion of HIC1 is associated with HIC1 gene expression, the authors tested the hypothesis that this VNTR is associated with clinical outcome in patients with metastatic colorectal cancer who receive oxaliplatin-based chemotherapy.	Oxaliplatin	314-325	HIC ZBTB transcriptional repressor 1	Homo sapiens	125-129
28708932-9	2017	CONCLUSIONS: The current findings suggest that the VNTR sequence near HIC1 could be a predictive marker for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.	Oxaliplatin	108-119	HIC ZBTB transcriptional repressor 1	Homo sapiens	70-74
29133897-0	2017	WBSCR22 confers oxaliplatin resistance in human colorectal cancer.	Oxaliplatin	16-27	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	0-7
29133897-4	2017	Knockdown of WBSCR22 significantly sensitized CRC cells to oxaliplatin in vitro and in vivo, while overexpression of WBSCR22 led to cellular resistance to oxaliplatin treatment.	Oxaliplatin	59-70	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	13-20
29133897-4	2017	Knockdown of WBSCR22 significantly sensitized CRC cells to oxaliplatin in vitro and in vivo, while overexpression of WBSCR22 led to cellular resistance to oxaliplatin treatment.	Oxaliplatin	155-166	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	117-124
29133897-5	2017	Although WBSCR22 knockdown did not change cell cycle, it increased the oxaliplatin-induced cellular apoptosis.	Oxaliplatin	71-82	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	9-16
29133897-6	2017	WBSCR22 knockdown augmented the oxaliplatin-induced intracellular reactive oxygen species (ROS) production and ROS-induced 8-oxoguanine (8-oxoG) oxidative lesion accumulation, likely sensitizing oxaliplatin treatment.	Oxaliplatin	32-43	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	0-7
29133897-6	2017	WBSCR22 knockdown augmented the oxaliplatin-induced intracellular reactive oxygen species (ROS) production and ROS-induced 8-oxoguanine (8-oxoG) oxidative lesion accumulation, likely sensitizing oxaliplatin treatment.	Oxaliplatin	195-206	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	0-7
29133897-7	2017	These results demonstrate that WBSCR22 is involved in CRC resistance to oxaliplatin, suggesting WBSCR22 may represent a novel oxaliplatin resistance biomarker as well as a potentail target for CRC therapeutics.	Oxaliplatin	72-83	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	31-38
29133897-7	2017	These results demonstrate that WBSCR22 is involved in CRC resistance to oxaliplatin, suggesting WBSCR22 may represent a novel oxaliplatin resistance biomarker as well as a potentail target for CRC therapeutics.	Oxaliplatin	72-83	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	96-103
29133897-7	2017	These results demonstrate that WBSCR22 is involved in CRC resistance to oxaliplatin, suggesting WBSCR22 may represent a novel oxaliplatin resistance biomarker as well as a potentail target for CRC therapeutics.	Oxaliplatin	126-137	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	31-38
29133897-7	2017	These results demonstrate that WBSCR22 is involved in CRC resistance to oxaliplatin, suggesting WBSCR22 may represent a novel oxaliplatin resistance biomarker as well as a potentail target for CRC therapeutics.	Oxaliplatin	126-137	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	96-103
29169374-0	2017	ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.	Oxaliplatin	83-94	inhibitor of DNA binding 1, HLH protein	Homo sapiens	0-3
29169374-2	2017	The aim of the present study was to determine whether aberrant high expression of the inhibitor of differentiation 1(ID1) confers oxaliplatin-resistance to HCC by activating the pentose phosphate pathway (PPP).	Oxaliplatin	130-141	inhibitor of DNA binding 1, HLH protein	Homo sapiens	117-120
29169374-3	2017	METHODS: Aberrant high expression of ID1 was detected in two oxaliplatin-resistant cell lines MHCC97H-OXA(97H-OXA) and Hep3B-OXA(3B-OXA).	Oxaliplatin	61-72	inhibitor of DNA binding 1, HLH protein	Homo sapiens	37-40
29169374-6	2017	The molecular signaling mechanism underlying the induction of HCC proliferation and oxaliplatin resistance by ID1 was explored.	Oxaliplatin	84-95	inhibitor of DNA binding 1, HLH protein	Homo sapiens	110-113
29169374-8	2017	RESULTS: ID1 was upregulated in oxaliplaitin-resistant HCC cells and promoted HCC cell proliferation and oxaliplatin resistance.	Oxaliplatin	105-116	inhibitor of DNA binding 1, HLH protein	Homo sapiens	9-12
29128865-1	2017	BACKGROUND The purpose of this study was to investigate the prognostic significance of methylation of RAS association domain family protein 1 (RASSF1A) in the promoter region for patients with stage II and III colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy.	Oxaliplatin	244-255	Ras association domain family member 1	Homo sapiens	143-150
29128865-10	2017	Cox regression analysis indicated that RASSF1A methylation (HR=2.471, 95% CI=1.125-5.428, p=0.024) and OR (HR=2.678, 95% CI=1.085-6.610, p 0.033) were independently correlated with prognosis for patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	217-228	Ras association domain family member 1	Homo sapiens	39-46
29128865-11	2017	CONCLUSIONS Promoter methylation of RASSF1A can influence sensitivity to oxaliplatin-based chemotherapy, which can be used to predict outcomes for patients with stage II and III CRC.	Oxaliplatin	73-84	Ras association domain family member 1	Homo sapiens	36-43
29163216-0	2017	Distinct Mechanism of Cysteine Oxidation-Dependent Activation and Cold Sensitization of Human Transient Receptor Potential Ankyrin 1 Channel by High and Low Oxaliplatin.	Oxaliplatin	157-168	transient receptor potential cation channel subfamily A member 1	Homo sapiens	94-132
28692052-4	2017	High expression of G6PD predicts poor prognosis and correlated with poor outcome of oxaliplatin-based first-line chemotherapy in patients with CRC.	Oxaliplatin	84-95	glucose-6-phosphate dehydrogenase	Homo sapiens	19-23
28692052-5	2017	Suppressing G6PD decreases NADPH production, lowers GSH levels, impairs the ability to scavenge ROS levels, and enhances oxaliplatin-induced apoptosis in CRC via ROS-mediated damage in vitro.	Oxaliplatin	121-132	glucose-6-phosphate dehydrogenase	Homo sapiens	12-16
28692052-6	2017	In vivo experiments further shows that silencing G6PD with lentivirus or non-viral gene delivery vector enhances oxaliplatin anti-tumor effects in cell based xenografts and PDX models.	Oxaliplatin	113-124	glucose-6-phosphate dehydrogenase	Homo sapiens	49-53
28692052-7	2017	In summary, our finding indicated that disrupting G6PD-mediated NADPH homeostasis enhances oxaliplatin-induced apoptosis in CRC through redox modulation.	Oxaliplatin	91-102	glucose-6-phosphate dehydrogenase	Homo sapiens	50-54
29394602-0	2017	[A Case of HER2-Positive Unresectable Gastric Cancer with Multiple Lymph Node and Liver Metastases Controlled Effectively by Combination Chemotherapy with Capecitabine, Oxaliplatin, and Trastuzumab].	Oxaliplatin	169-180	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
29048889-0	2017	Lipoyl-Homotaurine Derivative (ADM_12) Reverts Oxaliplatin-Induced Neuropathy and Reduces Cancer Cells Malignancy by Inhibiting Carbonic Anhydrase IX (CAIX).	Oxaliplatin	47-58	carbonic anhydrase 9	Homo sapiens	151-155
29163216-8	2017	By contrast, a lower concentration of oxaliplatin (100 muM) did not increase the intracellular Ca2+ concentration but did confer cold sensitivity on hTRPA1-expressing cells, and this was inhibited by PHD2 co-overexpression.	Oxaliplatin	38-49	latexin	Homo sapiens	55-58
29163216-8	2017	By contrast, a lower concentration of oxaliplatin (100 muM) did not increase the intracellular Ca2+ concentration but did confer cold sensitivity on hTRPA1-expressing cells, and this was inhibited by PHD2 co-overexpression.	Oxaliplatin	38-49	transient receptor potential cation channel subfamily A member 1	Homo sapiens	149-155
29163216-8	2017	By contrast, a lower concentration of oxaliplatin (100 muM) did not increase the intracellular Ca2+ concentration but did confer cold sensitivity on hTRPA1-expressing cells, and this was inhibited by PHD2 co-overexpression.	Oxaliplatin	38-49	egl-9 family hypoxia inducible factor 1	Homo sapiens	200-204
29163216-1	2017	Oxaliplatin, a third-generation platinum-based chemotherapeutic agent, displays unique acute peripheral neuropathy triggered or enhanced by cold, and accumulating evidence suggests that transient receptor potential ankyrin 1 (TRPA1) is responsible.	Oxaliplatin	0-11	transient receptor potential cation channel subfamily A member 1	Homo sapiens	186-224
29163216-10	2017	Thus, high oxaliplatin evokes ROS-mediated cysteine oxidation-dependent hTRPA1 activation independent of PHD activity, while a lower concentration induces cold-induced cysteine oxidation-dependent opening of hTRPA1 via PHD inhibition.	Oxaliplatin	11-22	transient receptor potential cation channel subfamily A member 1	Homo sapiens	72-78
29394847-0	2017	[A Case in Which S-1/Oxaliplatin(SOX)/Trastuzumab Therapy Was Effective for Unresectable HER2 Positive Advanced Gastric Cancer and Radical Resection Could Be Performed].	Oxaliplatin	21-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
29163216-1	2017	Oxaliplatin, a third-generation platinum-based chemotherapeutic agent, displays unique acute peripheral neuropathy triggered or enhanced by cold, and accumulating evidence suggests that transient receptor potential ankyrin 1 (TRPA1) is responsible.	Oxaliplatin	0-11	transient receptor potential cation channel subfamily A member 1	Homo sapiens	226-231
29163216-2	2017	TRPA1 is activated by oxaliplatin via a glutathione-sensitive mechanism.	Oxaliplatin	22-33	transient receptor potential cation channel subfamily A member 1	Homo sapiens	0-5
29163216-3	2017	However, oxaliplatin interrupts hydroxylation of a proline residue located in the N-terminal region of TRPA1 via inhibition of prolyl hydroxylase (PHD), which causes sensitization of TRPA1 to reactive oxygen species (ROS).	Oxaliplatin	9-20	transient receptor potential cation channel subfamily A member 1	Homo sapiens	103-108
29163216-3	2017	However, oxaliplatin interrupts hydroxylation of a proline residue located in the N-terminal region of TRPA1 via inhibition of prolyl hydroxylase (PHD), which causes sensitization of TRPA1 to reactive oxygen species (ROS).	Oxaliplatin	9-20	transient receptor potential cation channel subfamily A member 1	Homo sapiens	183-188
29163216-5	2017	Since cysteine oxidation and proline hydroxylation regulate its activity, their association with oxaliplatin-induced TRPA1 activation and acquirement of cold sensitivity were investigated in the present study.	Oxaliplatin	97-108	transient receptor potential cation channel subfamily A member 1	Homo sapiens	117-122
29163216-6	2017	A high concentration of oxaliplatin (1 mM) induced outward-rectifier whole-cell currents and increased the intracellular Ca2+ concentration in hTRPA1-expressing HEK293 cells, but did not increase the probability of hTRPA1 channel opening in the inside-out configuration.	Oxaliplatin	24-35	transient receptor potential cation channel subfamily A member 1	Homo sapiens	143-149
29163216-7	2017	Oxaliplatin also induced the rapid generation of hydrogen peroxide, and the resultant Ca2+ influx was prevented in the presence of glutathione and in cysteine-mutated hTRPA1 (Cys641Ser)-expressing cells, whereas proline-mutated hTRPA1 (Pro394Ala)-expressing cells showed similar whole-cell currents and Ca2+ influx.	Oxaliplatin	0-11	transient receptor potential cation channel subfamily A member 1	Homo sapiens	167-173
29163216-7	2017	Oxaliplatin also induced the rapid generation of hydrogen peroxide, and the resultant Ca2+ influx was prevented in the presence of glutathione and in cysteine-mutated hTRPA1 (Cys641Ser)-expressing cells, whereas proline-mutated hTRPA1 (Pro394Ala)-expressing cells showed similar whole-cell currents and Ca2+ influx.	Oxaliplatin	0-11	transient receptor potential cation channel subfamily A member 1	Homo sapiens	228-234
28614905-0	2017	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).	Oxaliplatin	58-69	keratin 20	Homo sapiens	140-144
29262595-0	2017	Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway.	Oxaliplatin	27-38	mitogen-activated protein kinase 14	Homo sapiens	56-59
29262595-2	2017	Our previous work has shown that oxaliplatin efficacy depends on the reactive oxygen species (ROS) produced by Nox1.	Oxaliplatin	33-44	NADPH oxidase 1	Homo sapiens	111-115
29262595-3	2017	In this report, we investigated Nox1 involvement in the survival mechanisms of oxaliplatin resistant cell lines that we have selected.	Oxaliplatin	79-90	NADPH oxidase 1	Homo sapiens	32-36
29262595-5	2017	Whereas the transitory Nox1-dependent production of superoxide contributes to the cytotoxicity of oxaliplatin in sensitive cells, oxaliplatin treatment of resistant cells leads to a decrease in the production of superoxide associated with an increase of H2O2 and a decreased cytotoxicity of oxaliplatin.	Oxaliplatin	98-109	NADPH oxidase 1	Homo sapiens	23-27
29262595-6	2017	We have shown that calpains regulate differently Nox1 according to the sensitivity of the cells to oxaliplatin.	Oxaliplatin	99-110	NADPH oxidase 1	Homo sapiens	49-53
29262595-7	2017	In sensitive cells, calpains inhibit Nox1 by cleaving NoxA1 leading to a transient ROS production necessary for oxaliplatin cytotoxic effects.	Oxaliplatin	112-123	NADPH oxidase 1	Homo sapiens	37-41
29262595-7	2017	In sensitive cells, calpains inhibit Nox1 by cleaving NoxA1 leading to a transient ROS production necessary for oxaliplatin cytotoxic effects.	Oxaliplatin	112-123	NADPH oxidase activator 1	Homo sapiens	54-59
29262595-11	2017	However, a strategy to maximize Nox1 activation while inhibiting the p38 MAPK-dependent escape routes appears to be an option of choice to optimize oxaliplatin efficiency.	Oxaliplatin	148-159	NADPH oxidase 1	Homo sapiens	32-36
29262595-11	2017	However, a strategy to maximize Nox1 activation while inhibiting the p38 MAPK-dependent escape routes appears to be an option of choice to optimize oxaliplatin efficiency.	Oxaliplatin	148-159	mitogen-activated protein kinase 14	Homo sapiens	69-72
28708138-7	2017	Interestingly, treatment with macitentan, a dual ETAR and ETBR antagonist, able to interfere with tumor and microenvironment, disrupts the ET-1R/beta-arr1-beta-catenin interaction impairing pathways involved in cell survival, EMT, invasion, and enhancing sensitivity to oxaliplatin (OX) and 5-fluorouracil (5-FU).	Oxaliplatin	270-281	arrestin beta 1	Homo sapiens	145-154
27866426-5	2017	On one hand, oxaliplatin induces significantly more chromosomal abnormalities than carboplatin at concentrations of 12.5 and 25 muM.	Oxaliplatin	13-24	latexin	Homo sapiens	128-131
29066704-1	2017	We report 2 unusual cases of Stage IV rectal cancer for which pathological complete response was achieved with neoadjuvant chemotherapy(NAC)consisting of a combination of 5-fluorouracil(5-FU), oxaliplatin, Leucovorin(mFOLFOX6)or irinotecan(FOLFIRI), and bevacizumab, without radiotherapy.	Oxaliplatin	193-204	X-linked Kx blood group	Homo sapiens	136-139
28902369-0	2017	Synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 and oxaliplatin via p53-independent pathway in vitro and in vivo.	Oxaliplatin	103-114	tumor protein p53	Homo sapiens	119-122
28902369-1	2017	The present study was designed to investigate the synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 (Aspp2-ad) and oxaliplatin via p53-independent pathway in vitro and in vivo.	Oxaliplatin	164-175	tumor protein p53	Homo sapiens	180-183
28902369-12	2017	In conclusion, Aspp2-ad, in P53-independent manner, regulated ERK and STAT3 signal moleculars to inhibit hepatocarcinoma in coordination with oxaliplatin by influencing the protein expression of proliferation, apoptosis, autophagy and vascular growth.	Oxaliplatin	142-153	tumor protein p53 binding protein 2	Homo sapiens	15-20
28731151-0	2017	MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis.	Oxaliplatin	79-90	maternally expressed 3	Homo sapiens	0-4
29151941-0	2017	ZEB1 Promotes Oxaliplatin Resistance through the Induction of Epithelial - Mesenchymal Transition in Colon Cancer Cells.	Oxaliplatin	14-25	zinc finger E-box binding homeobox 1	Homo sapiens	0-4
29151941-9	2017	ZEB1 knockdown using small interfering RNA (siRNA) was used to determine the ZEB1 contribution to OXA-sensitivity in vitro and in vivo (in a nude mice xenograft model).	Oxaliplatin	98-101	zinc finger E-box binding homeobox 1	Mus musculus	77-81
29151941-12	2017	Transfection of Si-ZEB1 into HCT116/OXA cells significantly reversed the EMT phenotype and enhanced OXA-sensitivity in vitro and in vivo.	Oxaliplatin	36-39	zinc finger E-box binding homeobox 1	Homo sapiens	19-23
29151941-14	2017	ZEB1 knockdown effectively restored OXA-sensitivity by reversing EMT.	Oxaliplatin	36-39	zinc finger E-box binding homeobox 1	Homo sapiens	0-4
28938919-0	2017	miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses.	Oxaliplatin	51-62	SMAD family member 4	Homo sapiens	98-103
28938919-11	2017	In addition, we confirmed that miR-19b-3p mediates resistance to oxaliplatin-based chemotherapy via SMAD4.	Oxaliplatin	65-76	SMAD family member 4	Homo sapiens	100-105
28870205-2	2017	In our previous study, oxaliplatin-resistant HCC is found to exhibit an enhanced stemness, and increased levels of CCN2 and LRP6, while the role of CCN2 and LRP6 in the prognosis of HCC patients, and the interaction regulation mechanism between CCN2 and LRP6 are still unclear.	Oxaliplatin	23-34	cellular communication network factor 2	Homo sapiens	115-119
28870205-2	2017	In our previous study, oxaliplatin-resistant HCC is found to exhibit an enhanced stemness, and increased levels of CCN2 and LRP6, while the role of CCN2 and LRP6 in the prognosis of HCC patients, and the interaction regulation mechanism between CCN2 and LRP6 are still unclear.	Oxaliplatin	23-34	LDL receptor related protein 6	Homo sapiens	124-128
28870205-2	2017	In our previous study, oxaliplatin-resistant HCC is found to exhibit an enhanced stemness, and increased levels of CCN2 and LRP6, while the role of CCN2 and LRP6 in the prognosis of HCC patients, and the interaction regulation mechanism between CCN2 and LRP6 are still unclear.	Oxaliplatin	23-34	cellular communication network factor 2	Homo sapiens	148-152
28870205-2	2017	In our previous study, oxaliplatin-resistant HCC is found to exhibit an enhanced stemness, and increased levels of CCN2 and LRP6, while the role of CCN2 and LRP6 in the prognosis of HCC patients, and the interaction regulation mechanism between CCN2 and LRP6 are still unclear.	Oxaliplatin	23-34	LDL receptor related protein 6	Homo sapiens	157-161
28870205-2	2017	In our previous study, oxaliplatin-resistant HCC is found to exhibit an enhanced stemness, and increased levels of CCN2 and LRP6, while the role of CCN2 and LRP6 in the prognosis of HCC patients, and the interaction regulation mechanism between CCN2 and LRP6 are still unclear.	Oxaliplatin	23-34	cellular communication network factor 2	Homo sapiens	148-152
28870205-2	2017	In our previous study, oxaliplatin-resistant HCC is found to exhibit an enhanced stemness, and increased levels of CCN2 and LRP6, while the role of CCN2 and LRP6 in the prognosis of HCC patients, and the interaction regulation mechanism between CCN2 and LRP6 are still unclear.	Oxaliplatin	23-34	LDL receptor related protein 6	Homo sapiens	157-161
28870205-8	2017	LMWH enhanced the therapeutic effect of oxaliplatin on HCC with a high CCN2 expression.	Oxaliplatin	40-51	cellular communication network factor 2	Homo sapiens	71-75
28928806-0	2017	Alterations in IQGAP1 expression and localization in colorectal carcinoma and liver metastases following oxaliplatin-based chemotherapy.	Oxaliplatin	105-116	IQ motif containing GTPase activating protein 1	Homo sapiens	15-21
28928806-3	2017	In addition, screening studies have reported that IQ-motif containing GTPase activating protein 1 (IQGAP1) transcriptional expression levels varied from "off" to "on" following oxaliplatin CT.	Oxaliplatin	177-188	IQ motif containing GTPase activating protein 1	Homo sapiens	50-97
28928806-3	2017	In addition, screening studies have reported that IQ-motif containing GTPase activating protein 1 (IQGAP1) transcriptional expression levels varied from "off" to "on" following oxaliplatin CT.	Oxaliplatin	177-188	IQ motif containing GTPase activating protein 1	Homo sapiens	99-105
28245171-9	2017	Low expression of miR-181a was closely related to cervical cancer growth and oxaliplatin resistance.	Oxaliplatin	77-88	microRNA 181a-2	Mus musculus	18-26
28245171-11	2017	Upregulation of GRP78 led to a high cell proliferation rate and oxaliplatin resistance in cervical cancer models.	Oxaliplatin	64-75	heat shock protein family A (Hsp70) member 5	Homo sapiens	16-21
28662900-2	2017	In the present study we revisit and evaluate critical preclinical parameters important for the therapeutic potential and safety of platinum drugs, here oxaliplatin (L-OHP), formulated in sPLA2 sensitive liposomes.	Oxaliplatin	152-163	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	187-192
28662900-2	2017	In the present study we revisit and evaluate critical preclinical parameters important for the therapeutic potential and safety of platinum drugs, here oxaliplatin (L-OHP), formulated in sPLA2 sensitive liposomes.	Oxaliplatin	165-170	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	187-192
28927129-0	2017	Deficiency of gap junction composed of connexin43 contributes to oxaliplatin resistance in colon cancer cells.	Oxaliplatin	65-76	gap junction protein alpha 1	Homo sapiens	39-49
28927129-4	2017	The present study mainly investigated the effect of the gap junction (GJ) composed of connexin43 (Cx43) on oxaliplatin cytotoxicity in colon cancer cells.	Oxaliplatin	107-118	gap junction protein alpha 1	Homo sapiens	86-96
28927129-4	2017	The present study mainly investigated the effect of the gap junction (GJ) composed of connexin43 (Cx43) on oxaliplatin cytotoxicity in colon cancer cells.	Oxaliplatin	107-118	gap junction protein alpha 1	Homo sapiens	98-102
28927129-5	2017	Three different methods with distinct mechanisms were used to change the function of Cx43 GJs, including cell culture at different densities, pretreatment with a specific inhibitor or enhancer, and special gene knockdown, to observe the cytotoxicity of oxaliplatin and the level of reactive oxygen species (ROS) mediated by Cx43 GJs.	Oxaliplatin	253-264	gap junction protein alpha 1	Homo sapiens	85-89
28731151-5	2017	Moreover, decreased serum MEG3 expression was associated with poor chemoresponse and low survival rate in CRC patients receiving oxaliplatin treatment.	Oxaliplatin	129-140	maternally expressed 3	Homo sapiens	26-30
28731151-7	2017	In addition, overexpression of MEG3 with pMEG3 reversed oxaliplatin resistance in both CRC cell lines.	Oxaliplatin	56-67	maternally expressed 3	Homo sapiens	31-35
28731151-9	2017	More importantly, MEG3 enhanced oxaliplatin-induced cell cytotoxicity in CRC.	Oxaliplatin	32-43	maternally expressed 3	Homo sapiens	18-22
28927129-6	2017	The results revealed that the cytotoxicity of oxaliplatin and the level of ROS were decreased with the downregulation of Cx43 GJ function, but exacerbated with the upregulation of Cx43 GJ function.	Oxaliplatin	46-57	gap junction protein alpha 1	Homo sapiens	121-125
28927129-6	2017	The results revealed that the cytotoxicity of oxaliplatin and the level of ROS were decreased with the downregulation of Cx43 GJ function, but exacerbated with the upregulation of Cx43 GJ function.	Oxaliplatin	46-57	gap junction protein alpha 1	Homo sapiens	180-184
28731151-10	2017	In conclusion, our integrated approach demonstrated that decreased expression of lncRNA MEG3 in CRC confers potent poor therapeutic efficacy, and that MEG3 promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis.	Oxaliplatin	195-206	maternally expressed 3	Homo sapiens	151-155
28927129-8	2017	We concluded that the loss of GJ composed of Cx43 contributed to the resistance of oxaliplatin in colon cancer cells, and the mechanism was associated with intracellular ROS alternation.	Oxaliplatin	83-94	gap junction protein alpha 1	Homo sapiens	45-49
28731151-11	2017	Thus, overexpression of MEG3 may be a future direction by which to develop a novel therapeutic strategy to overcome oxaliplatin resistance of CRC patients.	Oxaliplatin	116-127	maternally expressed 3	Homo sapiens	24-28
28850174-24	2017	For HER-2 negative people, all different two-and three-drug combinations including irinotecan, docetaxel, oxaliplatin or oral 5-FU prodrugs are valid treatment options for advanced gastric cancer, and consideration of the side effects of each regimen is essential in the treatment decision.	Oxaliplatin	106-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-9
28676400-5	2017	The silencing of X-ray repair cross complementing group 1 (XRCC1), upregulated in B7-H3 overexpressing cells, induced an increase in cell death following oxaliplatin treatment.	Oxaliplatin	154-165	X-ray repair complementing defective repair in Chinese hamster cells 1	Mus musculus	17-57
28676400-5	2017	The silencing of X-ray repair cross complementing group 1 (XRCC1), upregulated in B7-H3 overexpressing cells, induced an increase in cell death following oxaliplatin treatment.	Oxaliplatin	154-165	X-ray repair complementing defective repair in Chinese hamster cells 1	Mus musculus	59-64
28676400-0	2017	Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells.	Oxaliplatin	29-40	CD276 molecule	Homo sapiens	14-19
28676400-5	2017	The silencing of X-ray repair cross complementing group 1 (XRCC1), upregulated in B7-H3 overexpressing cells, induced an increase in cell death following oxaliplatin treatment.	Oxaliplatin	154-165	CD276 molecule	Homo sapiens	82-87
28676400-2	2017	Here, we investigated the role of B7-H3 in oxaliplatin resistance in colorectal cancer (CRC) cells.	Oxaliplatin	43-54	CD276 molecule	Homo sapiens	34-39
28676400-3	2017	Transient silencing of B7-H3 enhanced oxaliplatin sensitivity by increasing oxaliplatin-induced DNA damage.	Oxaliplatin	38-49	CD276 molecule	Homo sapiens	23-28
28676400-7	2017	In conclusion, B7-H3 promotes the oxaliplatin resistance in CRC cells upregulating the expression of XRCC1 via PI3K-AKT pathway.	Oxaliplatin	34-45	CD276 molecule	Homo sapiens	15-20
28676400-3	2017	Transient silencing of B7-H3 enhanced oxaliplatin sensitivity by increasing oxaliplatin-induced DNA damage.	Oxaliplatin	76-87	CD276 molecule	Homo sapiens	23-28
28676400-7	2017	In conclusion, B7-H3 promotes the oxaliplatin resistance in CRC cells upregulating the expression of XRCC1 via PI3K-AKT pathway.	Oxaliplatin	34-45	X-ray repair cross complementing 1	Homo sapiens	101-106
28676400-4	2017	The overexpression of B7-H3 increased oxaliplatin resistance reducing the formation of phosphorylated histone H2AX (gammaH2AX) loci.	Oxaliplatin	38-49	CD276 molecule	Homo sapiens	22-27
28687498-5	2017	High PAK6 expression was associated with poor prognosis and increased chemoresistance to 5-FU/oxaliplatin chemotherapy.	Oxaliplatin	94-105	p21 (RAC1) activated kinase 6	Homo sapiens	5-9
28676400-4	2017	The overexpression of B7-H3 increased oxaliplatin resistance reducing the formation of phosphorylated histone H2AX (gammaH2AX) loci.	Oxaliplatin	38-49	H2A.X variant histone	Homo sapiens	102-114
28800641-0	2017	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.	Oxaliplatin	65-76	RNA binding motif protein 3	Homo sapiens	5-9
28800641-6	2017	PFS was significantly longer in patients with high RBM3 expression who had received first-line oxaliplatin based treatment, compared to those who had received irinotecan based treatment, both regarding nuclear and cytoplasmic expression (p-value 0.020 and 0.022 respectively).	Oxaliplatin	95-106	RNA binding motif protein 3	Homo sapiens	51-55
28800641-7	2017	CONCLUSION: High RBM3 expression is an independent predictor of prolonged survival in mCRC patients, in particular in patients treated with first-line oxaliplatin based chemotherapy.	Oxaliplatin	151-162	RNA binding motif protein 3	Homo sapiens	17-21
29696197-1	2017	Introduction: The combination of a fluoropyrimidine [5-fluorouracil (5-FU), capecitabine, or S-1] with a platinum analog (cisplatin or oxaliplatin) is the most widely accepted first-line chemotherapy regimen for metastatic or recurrent advanced gastric cancer (AGC), based on the results of clinical trials.	Oxaliplatin	135-146	proteasome 26S subunit, non-ATPase 1	Homo sapiens	93-96
28688823-0	2017	PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy.	Oxaliplatin	129-140	p21 (RAC1) activated kinase 6	Homo sapiens	0-4
28729624-3	2017	Exposure of primary cultured rat Schwann cells to paclitaxel (0.01 muM), cisplatin (1 muM), or oxaliplatin (3 muM) for 48 h induced cytotoxicity and reduced myelin basic protein expression at concentrations lower than those required to induce neurotoxicity in cultured rat dorsal root ganglion (DRG) neurons.	Oxaliplatin	95-106	myelin basic protein	Rattus norvegicus	157-177
28511060-0	2017	A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin.	Oxaliplatin	84-95	ribonuclease pancreatic	Bos taurus	22-29
28511060-3	2017	Here, we verify the ability of carboplatin and oxaliplatin to induce RNase A oligomerization under the same experimental conditions.	Oxaliplatin	47-58	ribonuclease pancreatic	Bos taurus	69-76
28511060-10	2017	Although platinated oligomers of RNase A formed upon reaction with CDDP, carboplatin and oxaliplatin retain a residual ribonuclease activity, they do not show cytotoxic action, suggesting that protein aggregation processes induced by Pt-based drugs can represent a collateral drawback, which affects the functional state of protein targets and reduces the efficacy of Pt-based drug treatment.	Oxaliplatin	89-100	ribonuclease pancreatic	Bos taurus	33-40
28811232-0	2017	CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.	Oxaliplatin	57-68	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	0-6
28811232-2	2017	To identify predictive markers for gastric cancer treatment in Chinese patients, we evaluated the association between polymorphisms of the gene encoding cytochrome P450 2A6 (CYP2A6) and outcomes of S-1 plus oxaliplatin (SOX) chemotherapy treatment.	Oxaliplatin	207-218	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	153-172
28283541-3	2017	METHODS: We analysed 54 potentially functional, common, inherited EGFR pathway variants in 815 patients with aCRC treated with oxaliplatin-fluoropyrimidine chemotherapy plus cetuximab.	Oxaliplatin	127-138	epidermal growth factor receptor	Homo sapiens	66-70
28624791-0	2017	EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells.	Oxaliplatin	33-44	EPH receptor A2	Homo sapiens	0-5
28724889-4	2017	When combined with the conventional chemotherapeutic agents, the aptamer-guided survivin RNAi was able to enhance the sensitivity towards 5-FU or oxaliplatin in colorectal cancer stem cells, increase apoptosis, inhibit tumour growth and improve the overall survival of mice bearing xenograft colorectal cancer.	Oxaliplatin	146-157	baculoviral IAP repeat-containing 5	Mus musculus	80-88
28624791-0	2017	EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells.	Oxaliplatin	64-75	EPH receptor A2	Homo sapiens	0-5
28537875-0	2017	N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.	Oxaliplatin	43-54	BCL2 apoptosis regulator	Homo sapiens	138-143
28624791-2	2017	The current study was designed to establish the oxaliplatin-resistant human gastric cancer cell line SGC-7901/L-OHP, to determine if EMT in these cells could be reversed, and to determine if the susceptibility of these cells to oxaliplatin was affected by silencing EphA2 expression.	Oxaliplatin	48-59	EPH receptor A2	Homo sapiens	266-271
28537875-7	2017	NDRG1 over-expression promoted apoptosis in colorectal cancer cells whereas depletion of NDRG1 resulted in resistance to oxaliplatin treatment.	Oxaliplatin	121-132	N-myc downstream regulated 1	Homo sapiens	89-94
28537875-11	2017	In conclusion,NDRG1 promotes oxaliplatin-triggered apoptosis in colorectal cancer.	Oxaliplatin	29-40	N-myc downstream regulated 1	Homo sapiens	14-19
28624791-5	2017	Moreover, silencing of EphA2 inhibited cell migration and invasion, and significantly enhanced the sensitivity of oxaliplatin-resistant gastric cancer cells to oxaliplatin.	Oxaliplatin	114-125	EPH receptor A2	Homo sapiens	23-28
28537875-13	2017	NDRG1-positive patients may benefit from oxaliplatin-containing chemotherapy regimens whereas those with negative NDRG1 expression should avoid the usage of this cytotoxic drug.	Oxaliplatin	41-52	N-myc downstream regulated 1	Homo sapiens	0-5
28624791-5	2017	Moreover, silencing of EphA2 inhibited cell migration and invasion, and significantly enhanced the sensitivity of oxaliplatin-resistant gastric cancer cells to oxaliplatin.	Oxaliplatin	160-171	EPH receptor A2	Homo sapiens	23-28
28624791-6	2017	These observations demonstrate that EphA2 affects the sensitivity to oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells.	Oxaliplatin	69-80	EPH receptor A2	Homo sapiens	36-41
28624791-6	2017	These observations demonstrate that EphA2 affects the sensitivity to oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells.	Oxaliplatin	100-111	EPH receptor A2	Homo sapiens	36-41
28528980-7	2017	Furthermore, PLCdelta1 overexpression suppresses the autophagy induced by the anti-cancer drug oxaliplatin and promotes cell death under oxaliplatin treatment.	Oxaliplatin	95-106	phospholipase C, delta 1	Rattus norvegicus	13-22
28528980-7	2017	Furthermore, PLCdelta1 overexpression suppresses the autophagy induced by the anti-cancer drug oxaliplatin and promotes cell death under oxaliplatin treatment.	Oxaliplatin	137-148	phospholipase C, delta 1	Rattus norvegicus	13-22
28498807-0	2017	Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.	Oxaliplatin	64-75	pyruvate kinase M1/2	Homo sapiens	13-17
28498807-11	2017	Taken together, the present findings enriched our knowledge by demonstrating a significant association of PKM2 and GLS1 with oxaliplatin-resistance in CRC.	Oxaliplatin	125-136	pyruvate kinase M1/2	Homo sapiens	106-110
28498807-0	2017	Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.	Oxaliplatin	64-75	glutaminase	Homo sapiens	22-26
28498807-11	2017	Taken together, the present findings enriched our knowledge by demonstrating a significant association of PKM2 and GLS1 with oxaliplatin-resistance in CRC.	Oxaliplatin	125-136	glutaminase	Homo sapiens	115-119
28591705-5	2017	Chaperone-mediated autophagy induced tolerance to oxaliplatin treatment by reducing cyclin D1 expression; thus, cyclin D1 overexpression stimulated oxaliplatin-induced apoptosis.	Oxaliplatin	50-61	cyclin D1	Homo sapiens	84-93
28591705-5	2017	Chaperone-mediated autophagy induced tolerance to oxaliplatin treatment by reducing cyclin D1 expression; thus, cyclin D1 overexpression stimulated oxaliplatin-induced apoptosis.	Oxaliplatin	148-159	cyclin D1	Homo sapiens	112-121
28498807-3	2017	This study aimed to explore the possible association of oxaliplatin-resistance with aerobic glycolysis/glutaminolysis indexed by PKM2/GLS1 expression.	Oxaliplatin	56-67	pyruvate kinase M1/2	Homo sapiens	129-133
28498807-3	2017	This study aimed to explore the possible association of oxaliplatin-resistance with aerobic glycolysis/glutaminolysis indexed by PKM2/GLS1 expression.	Oxaliplatin	56-67	glutaminase	Homo sapiens	134-138
28498807-8	2017	In the THC8307 cell line, PKM2 and GLS1 can accelerate malignant behaviors, increase oxaliplatin-resistance, upregulate Pgp expression, and inhibit cell apoptosis.	Oxaliplatin	85-96	pyruvate kinase M1/2	Homo sapiens	26-30
28498807-8	2017	In the THC8307 cell line, PKM2 and GLS1 can accelerate malignant behaviors, increase oxaliplatin-resistance, upregulate Pgp expression, and inhibit cell apoptosis.	Oxaliplatin	85-96	glutaminase	Homo sapiens	35-39
28498807-9	2017	Contrastingly in the THC8307/Oxa cell line, knockdown of PKM2/GLS1 expression can restrain malignant behaviors, reestablish oxaliplatin-sensitivity, downregulate Pgp expression, and induce cell apoptosis.	Oxaliplatin	124-135	pyruvate kinase M1/2	Homo sapiens	57-61
28498807-9	2017	Contrastingly in the THC8307/Oxa cell line, knockdown of PKM2/GLS1 expression can restrain malignant behaviors, reestablish oxaliplatin-sensitivity, downregulate Pgp expression, and induce cell apoptosis.	Oxaliplatin	124-135	glutaminase	Homo sapiens	62-66
28340461-5	2017	Highest urinary 1-OHP concentration was observed in digestive tract cancer patients (median 1.25 mumol/mol-Cr) with GSTM-1 genotype.	Oxaliplatin	16-21	glutathione S-transferase mu 1	Homo sapiens	116-122
27918237-5	2017	We find GPX3 promoter region methylation in approximately one third of CRC samples and GPX3 methylation leads to reduced GPX3 expression and increased oxaliplatin and cisplatin sensitivity.	Oxaliplatin	151-162	glutathione peroxidase 3	Homo sapiens	87-91
27918237-5	2017	We find GPX3 promoter region methylation in approximately one third of CRC samples and GPX3 methylation leads to reduced GPX3 expression and increased oxaliplatin and cisplatin sensitivity.	Oxaliplatin	151-162	glutathione peroxidase 3	Homo sapiens	87-91
28475688-0	2017	Oxaliplatin inhibits proliferation and migration of human hepatocellular carcinoma cells via GAS7C and the N-WASP/FAK/F-actin pathway.	Oxaliplatin	0-11	WASP like actin nucleation promoting factor	Homo sapiens	107-113
28475688-0	2017	Oxaliplatin inhibits proliferation and migration of human hepatocellular carcinoma cells via GAS7C and the N-WASP/FAK/F-actin pathway.	Oxaliplatin	0-11	protein tyrosine kinase 2	Homo sapiens	114-117
28475688-4	2017	Interestingly, western blot analysis showed that treatment with oxaliplatin increased GAS7C and N-WASP protein levels and decreased the levels of proteins involved in the fibronectin/integrin/FAK pathway, such as FAK, in both HCC cell lines.	Oxaliplatin	64-75	WASP like actin nucleation promoting factor	Homo sapiens	96-102
28475688-4	2017	Interestingly, western blot analysis showed that treatment with oxaliplatin increased GAS7C and N-WASP protein levels and decreased the levels of proteins involved in the fibronectin/integrin/FAK pathway, such as FAK, in both HCC cell lines.	Oxaliplatin	64-75	fibronectin 1	Homo sapiens	171-182
28475688-4	2017	Interestingly, western blot analysis showed that treatment with oxaliplatin increased GAS7C and N-WASP protein levels and decreased the levels of proteins involved in the fibronectin/integrin/FAK pathway, such as FAK, in both HCC cell lines.	Oxaliplatin	64-75	protein tyrosine kinase 2	Homo sapiens	192-195
28475688-4	2017	Interestingly, western blot analysis showed that treatment with oxaliplatin increased GAS7C and N-WASP protein levels and decreased the levels of proteins involved in the fibronectin/integrin/FAK pathway, such as FAK, in both HCC cell lines.	Oxaliplatin	64-75	protein tyrosine kinase 2	Homo sapiens	213-216
28475688-9	2017	Taken together, our results showed that oxaliplatin inhibits HCC cell proliferation and migration ability by up-regulating GAS7C and activating the N-WASP/FAK/F-actin pathway.	Oxaliplatin	40-51	WASP like actin nucleation promoting factor	Homo sapiens	148-154
28475688-9	2017	Taken together, our results showed that oxaliplatin inhibits HCC cell proliferation and migration ability by up-regulating GAS7C and activating the N-WASP/FAK/F-actin pathway.	Oxaliplatin	40-51	protein tyrosine kinase 2	Homo sapiens	155-158
28418176-2	2017	In particular, the combination of Panitumumab and the platinum (Pt)-derived chemotherapeutic drug Oxaliplatin is clinically effective against KRAS and BRAF wild-type colorectal cancer (CRC) cells that overexpress epidermal growth factor receptors, and significantly greater efficacy is observed than with either drug alone.	Oxaliplatin	98-109	KRAS proto-oncogene, GTPase	Homo sapiens	142-146
28418176-2	2017	In particular, the combination of Panitumumab and the platinum (Pt)-derived chemotherapeutic drug Oxaliplatin is clinically effective against KRAS and BRAF wild-type colorectal cancer (CRC) cells that overexpress epidermal growth factor receptors, and significantly greater efficacy is observed than with either drug alone.	Oxaliplatin	98-109	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	151-155
28714373-7	2017	Finally, we assessed the role of miR-21 in mediating renal cell carcinoma chemoresistance and further showed that miR-21 silencing significantly (1) increased chemosensitivity of paclitaxel, 5-fluorouracil, oxaliplatin, and dovitinib; (2) decreased expression of multi-drug resistance genes; and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression.	Oxaliplatin	207-218	microRNA 21	Homo sapiens	114-120
28560442-2	2017	In the present study, we investigated whether elevated levels of induced or normal ACBP in MKN-45 gastric cancer (GC) cells may reduce their toxicity to oxaliplatin (L-OHP) in a dose-dependent manner.	Oxaliplatin	153-164	diazepam binding inhibitor	Mus musculus	83-87
28560442-2	2017	In the present study, we investigated whether elevated levels of induced or normal ACBP in MKN-45 gastric cancer (GC) cells may reduce their toxicity to oxaliplatin (L-OHP) in a dose-dependent manner.	Oxaliplatin	166-171	diazepam binding inhibitor	Mus musculus	83-87
28560442-4	2017	Compared with normal ACBP, induced ACBP alone significantly enhanced the anticancer activity of L-OHP-mediated apoptosis and reduced the amount and side-effects of L-OHP (P&lt;0.05).	Oxaliplatin	96-101	diazepam binding inhibitor	Mus musculus	35-39
28560442-4	2017	Compared with normal ACBP, induced ACBP alone significantly enhanced the anticancer activity of L-OHP-mediated apoptosis and reduced the amount and side-effects of L-OHP (P&lt;0.05).	Oxaliplatin	164-169	diazepam binding inhibitor	Mus musculus	35-39
28560442-6	2017	In addition, for the first time, we examined the potential of a combination of induced ACBP and L-OHP to increase L-OHP sensitivity in human gastric carcinoma xenograft tumors.	Oxaliplatin	114-119	diazepam binding inhibitor	Mus musculus	87-91
28560442-9	2017	The combination of induced ACBP and L-OHP also significantly improved the quality of life of the nude mice and reduced the toxicity of L-OHP.	Oxaliplatin	135-140	diazepam binding inhibitor	Mus musculus	27-31
28433438-5	2017	Oxaliplatin-related increases in protein levels of TRPM8 in DRG and SP in the dorsal horn were also reduced after TUS.	Oxaliplatin	0-11	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	51-56
28586033-0	2017	Sufentanil attenuates oxaliplatin cytotoxicity via inhibiting connexin 43-composed gap junction function.	Oxaliplatin	22-33	gap junction protein alpha 1	Homo sapiens	62-73
28586033-7	2017	The results demonstrated that in the cell lines expressing Cx43 (Lovo and Colo320), the cytotoxicity of oxaliplatin was attenuated and Cx43 GJ function was inhibited.	Oxaliplatin	104-115	gap junction protein alpha 1	Homo sapiens	59-63
28586033-10	2017	These results suggested that alternation of Cx43 GJ function may regulate the cytotoxicity of oxaliplatin in regard to CRC.	Oxaliplatin	94-105	gap junction protein alpha 1	Homo sapiens	44-48
28586033-11	2017	Furthermore, sufentanil, not fentanyl or remifentanil, suppressed the cytotoxicity of oxaliplatin through inhibition of Cx43 GJ function.	Oxaliplatin	86-97	gap junction protein alpha 1	Homo sapiens	120-124
28693217-0	2017	Transforming growth factor-beta1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transition.	Oxaliplatin	48-59	transforming growth factor beta 1	Homo sapiens	0-32
28693217-2	2017	The present study aimed to analyze the effects and mechanisms underlying TGF-beta1-induced chemoresistance to oxaliplatin (LOH) in human colorectal cancer (CRC) cell lines.	Oxaliplatin	110-121	transforming growth factor beta 1	Homo sapiens	73-82
28461099-4	2017	In this study, therefore, we intended to investigate the efficacy of using liposomal oxaliplatin (liposomal l-OHP) to guarantee the efficient delivery of RNAi molecules, namely shRNA against thymidylate synthase (TS shRNA) complexed with cationic liposome (TS shRNA-lipoplex), to solid tumors, and to suppress the immunostimulatory effect of RNAi molecules, TS shRNA, following intravenous administration.	Oxaliplatin	85-96	thymidylate synthetase	Homo sapiens	191-211
28490629-9	2017	Using an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that gammaH2AX and monoubiquitinated PCNA and FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that gammaH2AX, PCNA, and FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells.	Oxaliplatin	47-58	proliferating cell nuclear antigen	Homo sapiens	124-128
28490629-9	2017	Using an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that gammaH2AX and monoubiquitinated PCNA and FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that gammaH2AX, PCNA, and FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells.	Oxaliplatin	47-58	FA complementation group D2	Homo sapiens	133-139
28490629-9	2017	Using an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that gammaH2AX and monoubiquitinated PCNA and FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that gammaH2AX, PCNA, and FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells.	Oxaliplatin	175-186	proliferating cell nuclear antigen	Homo sapiens	124-128
28490629-9	2017	Using an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that gammaH2AX and monoubiquitinated PCNA and FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that gammaH2AX, PCNA, and FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells.	Oxaliplatin	175-186	FA complementation group D2	Homo sapiens	133-139
28490629-9	2017	Using an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that gammaH2AX and monoubiquitinated PCNA and FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that gammaH2AX, PCNA, and FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells.	Oxaliplatin	175-186	proliferating cell nuclear antigen	Homo sapiens	243-247
28490629-9	2017	Using an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that gammaH2AX and monoubiquitinated PCNA and FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that gammaH2AX, PCNA, and FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells.	Oxaliplatin	175-186	FA complementation group D2	Homo sapiens	253-259
28490629-9	2017	Using an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that gammaH2AX and monoubiquitinated PCNA and FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that gammaH2AX, PCNA, and FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells.	Oxaliplatin	175-186	proliferating cell nuclear antigen	Homo sapiens	124-128
28490629-9	2017	Using an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that gammaH2AX and monoubiquitinated PCNA and FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that gammaH2AX, PCNA, and FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells.	Oxaliplatin	175-186	FA complementation group D2	Homo sapiens	133-139
28490629-9	2017	Using an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that gammaH2AX and monoubiquitinated PCNA and FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that gammaH2AX, PCNA, and FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells.	Oxaliplatin	175-186	proliferating cell nuclear antigen	Homo sapiens	243-247
28490629-9	2017	Using an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that gammaH2AX and monoubiquitinated PCNA and FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that gammaH2AX, PCNA, and FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells.	Oxaliplatin	175-186	FA complementation group D2	Homo sapiens	253-259
28166203-3	2017	In this study, we for the first time demonstrated that treatment with antitumor reagents such as oxaliplatin, 5-fluorouracil and pirarubicin (THP) dramatically induced HULC expression and protective autophagy.	Oxaliplatin	97-108	hepatocellular carcinoma up-regulated long non-coding RNA	Homo sapiens	168-172
27517624-5	2017	Moreover, miR-199b led to PP2A activation through a direct SET inhibition, impaired cell viability and enhanced oxaliplatin sensitivity in CRC cells.	Oxaliplatin	112-123	microRNA 199b	Homo sapiens	10-18
27517624-5	2017	Moreover, miR-199b led to PP2A activation through a direct SET inhibition, impaired cell viability and enhanced oxaliplatin sensitivity in CRC cells.	Oxaliplatin	112-123	protein phosphatase 2 phosphatase activator	Homo sapiens	26-30
27517624-7	2017	Furthermore, low miR-199b levels determined shorter overall (p &lt; 0.001), progression-free survival (p = 0.003) and predicted clinical benefit to oxaliplatin treatment.	Oxaliplatin	148-159	microRNA 199b	Homo sapiens	17-25
28461099-4	2017	In this study, therefore, we intended to investigate the efficacy of using liposomal oxaliplatin (liposomal l-OHP) to guarantee the efficient delivery of RNAi molecules, namely shRNA against thymidylate synthase (TS shRNA) complexed with cationic liposome (TS shRNA-lipoplex), to solid tumors, and to suppress the immunostimulatory effect of RNAi molecules, TS shRNA, following intravenous administration.	Oxaliplatin	108-113	thymidylate synthetase	Homo sapiens	191-211
28695301-7	2017	The influence of the chemotherapy backbone on anti-EGFR mAb efficacy, evaluated with meta-regression, indicated a higher ORR with irinotecan-based versus oxaliplatin-based regimens, but comparable PFS and OS.	Oxaliplatin	154-165	epidermal growth factor receptor	Homo sapiens	51-55
28217977-0	2017	miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.	Oxaliplatin	69-80	microRNA 506	Homo sapiens	0-7
28217977-0	2017	miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.	Oxaliplatin	69-80	ATP binding cassette subfamily B member 1	Homo sapiens	96-100
28217977-0	2017	miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.	Oxaliplatin	69-80	phosphoglycolate phosphatase	Homo sapiens	101-105
28217977-2	2017	The aim of this study was to elucidate the mechanism by which miR-506 reverses oxaliplatin chemoresistance in CRC.	Oxaliplatin	79-90	microRNA 506	Homo sapiens	62-69
28217977-5	2017	MTT assay demonstrated the fractional survival rates and cell viability of HCT116-OxR, HCT116-OxR-miR-Ctrl and HCT116-OxR-miR-506 cells treated with oxaliplatin at different concentrations.	Oxaliplatin	149-160	MLX interacting protein	Homo sapiens	122-125
28217977-12	2017	miR-506 overexpression inhibited cell growth and increased oxaliplatin-induced cell apoptosis in HCT116-OxR cells, as shown via FCM and apoptosis assay.	Oxaliplatin	59-70	microRNA 506	Homo sapiens	0-7
28217977-15	2017	CONCLUSION: Taken together, the findings of our study demonstrate that miR-506 overexpression in HCT116-OxR cells enhances oxaliplatin sensitivity by inhibiting MDR1/P-gp expression via down-regulation of the Wnt/beta-catenin pathway and thus provide a rationale for the development of miRNA-based strategies to reverse oxaliplatin resistance in CRC cells.	Oxaliplatin	123-134	microRNA 506	Homo sapiens	71-78
28217977-15	2017	CONCLUSION: Taken together, the findings of our study demonstrate that miR-506 overexpression in HCT116-OxR cells enhances oxaliplatin sensitivity by inhibiting MDR1/P-gp expression via down-regulation of the Wnt/beta-catenin pathway and thus provide a rationale for the development of miRNA-based strategies to reverse oxaliplatin resistance in CRC cells.	Oxaliplatin	123-134	ATP binding cassette subfamily B member 1	Homo sapiens	161-165
28217977-15	2017	CONCLUSION: Taken together, the findings of our study demonstrate that miR-506 overexpression in HCT116-OxR cells enhances oxaliplatin sensitivity by inhibiting MDR1/P-gp expression via down-regulation of the Wnt/beta-catenin pathway and thus provide a rationale for the development of miRNA-based strategies to reverse oxaliplatin resistance in CRC cells.	Oxaliplatin	123-134	phosphoglycolate phosphatase	Homo sapiens	166-170
28217977-15	2017	CONCLUSION: Taken together, the findings of our study demonstrate that miR-506 overexpression in HCT116-OxR cells enhances oxaliplatin sensitivity by inhibiting MDR1/P-gp expression via down-regulation of the Wnt/beta-catenin pathway and thus provide a rationale for the development of miRNA-based strategies to reverse oxaliplatin resistance in CRC cells.	Oxaliplatin	123-134	catenin beta 1	Homo sapiens	213-225
28217977-15	2017	CONCLUSION: Taken together, the findings of our study demonstrate that miR-506 overexpression in HCT116-OxR cells enhances oxaliplatin sensitivity by inhibiting MDR1/P-gp expression via down-regulation of the Wnt/beta-catenin pathway and thus provide a rationale for the development of miRNA-based strategies to reverse oxaliplatin resistance in CRC cells.	Oxaliplatin	320-331	microRNA 506	Homo sapiens	71-78
28618970-3	2017	investigated the association between germline genetic polymorphisms in DPYD, the gene encoding dihydropyrimidine dehydrogenase, and (1) the risk of developing pediatric acute lymphoblastic leukemia and (2) outcome of acute lymphoblastic leukemia following the treatment with 5-fluorouracil plus oxaliplatin (FOLFOX).	Oxaliplatin	295-306	dihydropyrimidine dehydrogenase	Homo sapiens	71-75
28209329-0	2017	Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: Toward routine preoperative dosage of Von Willebrand factor?	Oxaliplatin	54-65	von Willebrand factor	Homo sapiens	153-174
28621236-2	2017	We have recently published that in vitro, chronically oxaliplatin resistance upregulates soluble vascular endothelial growth factor receptor 1, downregulates vascular endothelial growth factor, and also promotes c-MET, b-catenin/transcription factor 4, and AKT activation.	Oxaliplatin	54-65	fms related receptor tyrosine kinase 1	Homo sapiens	97-142
28618970-3	2017	investigated the association between germline genetic polymorphisms in DPYD, the gene encoding dihydropyrimidine dehydrogenase, and (1) the risk of developing pediatric acute lymphoblastic leukemia and (2) outcome of acute lymphoblastic leukemia following the treatment with 5-fluorouracil plus oxaliplatin (FOLFOX).	Oxaliplatin	295-306	dihydropyrimidine dehydrogenase	Homo sapiens	95-126
28621236-2	2017	We have recently published that in vitro, chronically oxaliplatin resistance upregulates soluble vascular endothelial growth factor receptor 1, downregulates vascular endothelial growth factor, and also promotes c-MET, b-catenin/transcription factor 4, and AKT activation.	Oxaliplatin	54-65	vascular endothelial growth factor A	Homo sapiens	97-131
28621236-2	2017	We have recently published that in vitro, chronically oxaliplatin resistance upregulates soluble vascular endothelial growth factor receptor 1, downregulates vascular endothelial growth factor, and also promotes c-MET, b-catenin/transcription factor 4, and AKT activation.	Oxaliplatin	54-65	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	212-217
28534337-1	2017	OBJECTIVE: To predict and identify the target gene of miR-145, and to explore the underlying mechanism of the inhibition of miR-145 on drug resistance to Oxaliplatin (L-OHP) in human colorectal cancer cells.	Oxaliplatin	167-172	microRNA 145	Homo sapiens	124-131
28621236-2	2017	We have recently published that in vitro, chronically oxaliplatin resistance upregulates soluble vascular endothelial growth factor receptor 1, downregulates vascular endothelial growth factor, and also promotes c-MET, b-catenin/transcription factor 4, and AKT activation.	Oxaliplatin	54-65	catenin beta 1	Homo sapiens	219-228
28621236-2	2017	We have recently published that in vitro, chronically oxaliplatin resistance upregulates soluble vascular endothelial growth factor receptor 1, downregulates vascular endothelial growth factor, and also promotes c-MET, b-catenin/transcription factor 4, and AKT activation.	Oxaliplatin	54-65	AKT serine/threonine kinase 1	Homo sapiens	257-260
28383086-2	2017	The copper transport protein, hCTR1, is proposed to facilitate the cellular uptake of cisplatin, whereas organic cation transport (OCT) is more important for oxaliplatin.	Oxaliplatin	158-169	solute carrier family 31 member 1	Homo sapiens	30-35
28534337-0	2017	[MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].	Oxaliplatin	37-48	microRNA 145	Homo sapiens	1-8
28539468-0	2017	Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin".	Oxaliplatin	98-109	POU class 2 homeobox 2	Homo sapiens	58-62
28534337-1	2017	OBJECTIVE: To predict and identify the target gene of miR-145, and to explore the underlying mechanism of the inhibition of miR-145 on drug resistance to Oxaliplatin (L-OHP) in human colorectal cancer cells.	Oxaliplatin	154-165	microRNA 145	Homo sapiens	124-131
28539476-0	2017	Response to Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin".	Oxaliplatin	110-121	POU class 2 homeobox 2	Homo sapiens	70-74
28442401-9	2017	In sum, our findings indicate that TRIB3 plays an anti-apoptotic role in doxorubicin-treated gastric cancer cell lines, perhaps indicating that the status of TRIB3 expression in response to anticancer drugs, such as doxorubicin, irinotecan or oxaliplatin, may reflect the efficiency for cancer therapy.	Oxaliplatin	243-254	tribbles pseudokinase 3	Homo sapiens	35-40
28442401-9	2017	In sum, our findings indicate that TRIB3 plays an anti-apoptotic role in doxorubicin-treated gastric cancer cell lines, perhaps indicating that the status of TRIB3 expression in response to anticancer drugs, such as doxorubicin, irinotecan or oxaliplatin, may reflect the efficiency for cancer therapy.	Oxaliplatin	243-254	tribbles pseudokinase 3	Homo sapiens	158-163
28463955-8	2017	Oxaliplatin combined with CPS-C decreased the expressions of PI3K, phospho-Akt, phospho-mTOR, Bcl-2, and Bcl-XL, and increased the expression of Bax and caspase-3 significantly compared to oxaliplatin-only treatment.	Oxaliplatin	0-11	AKT serine/threonine kinase 1	Homo sapiens	75-78
28463955-0	2017	Capilliposide C Sensitizes Esophageal Squamous Carcinoma Cells to Oxaliplatin by Inducing Apoptosis Through the PI3K/Akt/mTOR Pathway.	Oxaliplatin	66-77	AKT serine/threonine kinase 1	Homo sapiens	117-120
28463955-8	2017	Oxaliplatin combined with CPS-C decreased the expressions of PI3K, phospho-Akt, phospho-mTOR, Bcl-2, and Bcl-XL, and increased the expression of Bax and caspase-3 significantly compared to oxaliplatin-only treatment.	Oxaliplatin	0-11	mechanistic target of rapamycin kinase	Homo sapiens	88-92
28463955-0	2017	Capilliposide C Sensitizes Esophageal Squamous Carcinoma Cells to Oxaliplatin by Inducing Apoptosis Through the PI3K/Akt/mTOR Pathway.	Oxaliplatin	66-77	mechanistic target of rapamycin kinase	Homo sapiens	121-125
28463955-8	2017	Oxaliplatin combined with CPS-C decreased the expressions of PI3K, phospho-Akt, phospho-mTOR, Bcl-2, and Bcl-XL, and increased the expression of Bax and caspase-3 significantly compared to oxaliplatin-only treatment.	Oxaliplatin	0-11	BCL2 apoptosis regulator	Homo sapiens	94-99
28463955-8	2017	Oxaliplatin combined with CPS-C decreased the expressions of PI3K, phospho-Akt, phospho-mTOR, Bcl-2, and Bcl-XL, and increased the expression of Bax and caspase-3 significantly compared to oxaliplatin-only treatment.	Oxaliplatin	0-11	BCL2 like 1	Homo sapiens	105-111
28463955-8	2017	Oxaliplatin combined with CPS-C decreased the expressions of PI3K, phospho-Akt, phospho-mTOR, Bcl-2, and Bcl-XL, and increased the expression of Bax and caspase-3 significantly compared to oxaliplatin-only treatment.	Oxaliplatin	0-11	BCL2 associated X, apoptosis regulator	Homo sapiens	145-148
28463955-8	2017	Oxaliplatin combined with CPS-C decreased the expressions of PI3K, phospho-Akt, phospho-mTOR, Bcl-2, and Bcl-XL, and increased the expression of Bax and caspase-3 significantly compared to oxaliplatin-only treatment.	Oxaliplatin	0-11	caspase 3	Homo sapiens	153-162
28463955-8	2017	Oxaliplatin combined with CPS-C decreased the expressions of PI3K, phospho-Akt, phospho-mTOR, Bcl-2, and Bcl-XL, and increased the expression of Bax and caspase-3 significantly compared to oxaliplatin-only treatment.	Oxaliplatin	189-200	BCL2 associated X, apoptosis regulator	Homo sapiens	145-148
28463955-10	2017	CONCLUSIONS The results indicated that CPS-C enhanced the anti-proliferative and apoptotic effect of oxaliplatin by modulating the PI3K/Akt/mTOR pathway on ESCC in vitro and in vivo.	Oxaliplatin	101-112	AKT serine/threonine kinase 1	Homo sapiens	136-139
28463955-10	2017	CONCLUSIONS The results indicated that CPS-C enhanced the anti-proliferative and apoptotic effect of oxaliplatin by modulating the PI3K/Akt/mTOR pathway on ESCC in vitro and in vivo.	Oxaliplatin	101-112	mechanistic target of rapamycin kinase	Homo sapiens	140-144
28160544-5	2017	The antioxidant potential of extract was first evaluated in cell-free models by the thiobarbituric acid-reactive substances assay and nitro blue tetrazolium oxidation test; the ability of H. perforatum extract to reduce oxaliplatin-induced caspase-3 activity in rat astrocytes and its potential interference with the cytotoxic effects of oxaliplatin in a colorectal cancer in vitro model (HT-29 cells) were also evaluated.	Oxaliplatin	220-231	caspase 3	Rattus norvegicus	240-249
27853901-1	2017	BACKGROUND: The impact of microsatellite instability (MSI) on survival in stage III colon cancer treated with adjuvant 5-fluorouracil-oxaliplatin combination (FOLFOX) chemotherapy is not clear.	Oxaliplatin	134-145	RB binding protein 4, chromatin remodeling factor	Homo sapiens	54-57
28447739-0	2017	Neural precursor cell expressed, developmentally downregulated 8-activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis.	Oxaliplatin	139-150	NEDD8 ubiquitin like modifier	Homo sapiens	0-64
28447739-8	2017	p-CHK2 protein expression levels were increased following combined treatment with MLN4924 and oxaliplatin, whereas p21/p53 protein expression levels were not.	Oxaliplatin	94-105	checkpoint kinase 2	Homo sapiens	2-6
28447739-9	2017	In conclusion, MLN4924 treatment may sensitize CRC cells to oxaliplatin treatment by inducing the DDR and increasing protein expression levels of p-CHK2, leading to G2 cell cycle arrest and apoptosis.	Oxaliplatin	60-71	checkpoint kinase 2	Homo sapiens	148-152
28391355-1	2017	PURPOSE: Although hypersensitivity reactions (HSRs) to oxaliplatin (L-OHP) therapy are well-documented, few reports have compared different therapies in terms of HSR occurrence.	Oxaliplatin	55-66	HSR	Homo sapiens	46-49
28391355-1	2017	PURPOSE: Although hypersensitivity reactions (HSRs) to oxaliplatin (L-OHP) therapy are well-documented, few reports have compared different therapies in terms of HSR occurrence.	Oxaliplatin	68-73	HSR	Homo sapiens	46-49
28391355-7	2017	Treatment method or cumulative dosage was not identified as a risk factor for HSR; however, the incidence of &gt;=grade-2 HSR was higher in cases where the cumulative L-OHP dosage was &gt;=600 mg/m2 and in patients in whom dexamethasone was not co-infused with L-OHP.	Oxaliplatin	167-172	HSR	Homo sapiens	122-125
28391355-7	2017	Treatment method or cumulative dosage was not identified as a risk factor for HSR; however, the incidence of &gt;=grade-2 HSR was higher in cases where the cumulative L-OHP dosage was &gt;=600 mg/m2 and in patients in whom dexamethasone was not co-infused with L-OHP.	Oxaliplatin	261-266	HSR	Homo sapiens	122-125
28339092-0	2017	MACC1 decreases the chemosensitivity of gastric cancer cells to oxaliplatin by regulating FASN expression.	Oxaliplatin	64-75	MET transcriptional regulator MACC1	Homo sapiens	0-5
28339092-0	2017	MACC1 decreases the chemosensitivity of gastric cancer cells to oxaliplatin by regulating FASN expression.	Oxaliplatin	64-75	fatty acid synthase	Homo sapiens	90-94
28339092-4	2017	Bioinformatic analysis revealed that MACC1 is positively associated with fatty acid synthase (FASN), a major enzyme of lipogenesis, and drives chemoresistance to oxaliplatin in GC.	Oxaliplatin	162-173	MET transcriptional regulator MACC1	Homo sapiens	37-42
28339092-4	2017	Bioinformatic analysis revealed that MACC1 is positively associated with fatty acid synthase (FASN), a major enzyme of lipogenesis, and drives chemoresistance to oxaliplatin in GC.	Oxaliplatin	162-173	fatty acid synthase	Homo sapiens	73-92
28339092-4	2017	Bioinformatic analysis revealed that MACC1 is positively associated with fatty acid synthase (FASN), a major enzyme of lipogenesis, and drives chemoresistance to oxaliplatin in GC.	Oxaliplatin	162-173	fatty acid synthase	Homo sapiens	94-98
28339092-6	2017	We next employed FASN inhibitor C75 or siFASN (small interfering RNA targeted to FASN) to block endogenous fatty acid metabolism and it was revealed that cell proliferation and chemoresistance to oxaliplatin induced by MACC1 upregulation were attenuated by FASN blockade to various extents.	Oxaliplatin	196-207	fatty acid synthase	Homo sapiens	17-21
28339092-6	2017	We next employed FASN inhibitor C75 or siFASN (small interfering RNA targeted to FASN) to block endogenous fatty acid metabolism and it was revealed that cell proliferation and chemoresistance to oxaliplatin induced by MACC1 upregulation were attenuated by FASN blockade to various extents.	Oxaliplatin	196-207	fatty acid synthase	Homo sapiens	41-45
28339092-6	2017	We next employed FASN inhibitor C75 or siFASN (small interfering RNA targeted to FASN) to block endogenous fatty acid metabolism and it was revealed that cell proliferation and chemoresistance to oxaliplatin induced by MACC1 upregulation were attenuated by FASN blockade to various extents.	Oxaliplatin	196-207	MET transcriptional regulator MACC1	Homo sapiens	219-224
28339092-6	2017	We next employed FASN inhibitor C75 or siFASN (small interfering RNA targeted to FASN) to block endogenous fatty acid metabolism and it was revealed that cell proliferation and chemoresistance to oxaliplatin induced by MACC1 upregulation were attenuated by FASN blockade to various extents.	Oxaliplatin	196-207	fatty acid synthase	Homo sapiens	41-45
28339092-7	2017	Conclusively, these outcomes highlight a novel role of MACC1 in GC cell lipogenesis, and suggest that MACC1 may be an attractive target to decrease oxaliplatin resistance in GC.	Oxaliplatin	148-159	MET transcriptional regulator MACC1	Homo sapiens	102-107
28459196-9	2017	The L-OHP resistance rate in vascular endothelial growth factor positive patients was significantly higher than that in negative patients (p = 0.031).	Oxaliplatin	4-9	vascular endothelial growth factor A	Homo sapiens	29-63
28459196-10	2017	The L-OHP resistance rate in E-cadherin negative patients was significantly higher than that in positive patients (p = 0.014).	Oxaliplatin	4-9	cadherin 1	Homo sapiens	29-39
28459196-13	2017	Positive expression of vascular endothelial growth factor and negative expression of E-cadherin were associated with L-OHP resistance.	Oxaliplatin	117-122	vascular endothelial growth factor A	Homo sapiens	23-57
28459196-13	2017	Positive expression of vascular endothelial growth factor and negative expression of E-cadherin were associated with L-OHP resistance.	Oxaliplatin	117-122	cadherin 1	Homo sapiens	85-95
27834032-9	2017	CD107a+/ROSlow cells were enriched in HT29 and DLD1 cultures after treatments with oxaliplatin, 5-fluorouracil, and the irinotecan metabolite SN38.	Oxaliplatin	83-94	lysosomal associated membrane protein 1	Homo sapiens	0-6
28478804-0	2017	Connexin 43 enhances oxaliplatin cytotoxicity in colorectal cancer cell lines.	Oxaliplatin	21-32	gap junction protein alpha 1	Homo sapiens	0-11
28478804-6	2017	The purpose of this study was to investigate the role of connexin 43 in oxaliplatin activity by using colorectal cancer cell lines.	Oxaliplatin	72-83	gap junction protein alpha 1	Homo sapiens	57-68
28478804-9	2017	MTT, western blot, "Parachute" dye-coupling assays and reactive oxygen species measurement were used to detect cytotoxicity and the inhibition of connexin 43 expression induced by oxaliplatin.	Oxaliplatin	180-191	gap junction protein alpha 1	Homo sapiens	146-157
28478804-10	2017	Results showed that connexin 43 enhanced oxaliplatin cytotoxicity through gap junctional communication function and high concentration of oxaliplatin inhibited connexin 43 expression to counteract its cytotoxicity.	Oxaliplatin	41-52	gap junction protein alpha 1	Homo sapiens	20-31
28478804-10	2017	Results showed that connexin 43 enhanced oxaliplatin cytotoxicity through gap junctional communication function and high concentration of oxaliplatin inhibited connexin 43 expression to counteract its cytotoxicity.	Oxaliplatin	138-149	gap junction protein alpha 1	Homo sapiens	160-171
28478804-11	2017	This study suggested that connexin 43 could be considered a molecular target of oxaliplatin activity in colorectal cancer.	Oxaliplatin	80-91	gap junction protein alpha 1	Homo sapiens	26-37
28441737-2	2017	We report the pattern of cellular and subcellular expression of scaffoldins angiomotin-like 2 (AmotL2), FK506 binding protein 5 (FKBP51) and IQ motif containing GTPase-activating protein 1 (IQGAP1) in colorectal cancer (CRC) and metastases in liver resected after oxaliplatin-based chemotherapy (CT).	Oxaliplatin	264-275	angiomotin like 2	Homo sapiens	76-93
28441737-2	2017	We report the pattern of cellular and subcellular expression of scaffoldins angiomotin-like 2 (AmotL2), FK506 binding protein 5 (FKBP51) and IQ motif containing GTPase-activating protein 1 (IQGAP1) in colorectal cancer (CRC) and metastases in liver resected after oxaliplatin-based chemotherapy (CT).	Oxaliplatin	264-275	IQ motif containing GTPase activating protein 1	Homo sapiens	190-196
28443020-4	2017	Here we investigate the effects of oxaliplatin (OXA) treatment in mice on the skeletal muscle and mitochondria, and the capacity for the Poly ADP-ribose polymerase (PARP) inhibitor, BGP-15, to ameliorate any pathological side-effects induced by OXA.	Oxaliplatin	245-248	poly (ADP-ribose) polymerase family, member 1	Mus musculus	165-169
28373425-11	2017	CONCLUSION: ME-143 alone and in combination with 5FU and oxaliplatin effectively inhibits the WNT/beta-catenin pathway in colorectal cancer cells of diverse genetic background.	Oxaliplatin	57-68	catenin beta 1	Homo sapiens	98-110
28175985-5	2017	Urine biomarker of PAH exposure (1-OHP levels) was measured by UPLC-MS/MS and a marker of oxidative stress (8OHdG) was measured by ELISA.	Oxaliplatin	33-38	phenylalanine hydroxylase	Homo sapiens	19-22
28175985-10	2017	Similar results were also found for 1-OHP levels with IgE levels (per ln-unit: beta = 0.27 kU/l, p = 0.027).	Oxaliplatin	36-41	immunoglobulin heavy constant epsilon	Homo sapiens	54-57
28685553-12	2017	Thus, it can be concluded that oxaliplatin in combination with epirubicin can improve survival quality, extend survival time, and decrease the serum AFP and CEA levels in the treatment of primary liver carcinoma, with definite effects but without aggravating toxic and side effects.	Oxaliplatin	31-42	alpha fetoprotein	Homo sapiens	149-152
28685553-12	2017	Thus, it can be concluded that oxaliplatin in combination with epirubicin can improve survival quality, extend survival time, and decrease the serum AFP and CEA levels in the treatment of primary liver carcinoma, with definite effects but without aggravating toxic and side effects.	Oxaliplatin	31-42	CEA cell adhesion molecule 3	Homo sapiens	157-160
28356150-4	2017	The roles of PXR on cancer cell proliferation, apoptosis and tumor growth with L-OHP-treated were investigated by MTS, colony formation, flow cytometry and xenograft tumor assays.	Oxaliplatin	79-84	nuclear receptor subfamily 1 group I member 2	Homo sapiens	13-16
28284059-0	2017	Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.	Oxaliplatin	163-174	tumor protein p53	Homo sapiens	13-16
28284059-0	2017	Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.	Oxaliplatin	163-174	RBPJ interacting and tubulin associated 1	Homo sapiens	47-51
28284059-0	2017	Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.	Oxaliplatin	163-174	RBPJ interacting and tubulin associated 1	Homo sapiens	78-82
28284059-10	2017	Sensitivity to RITA appeared independent of p53 status and was associated with an increase in antiproliferative response to 5FU and oxaliplatin, a transcriptional increase of p53 targets p21 and NOXA, and a decrease in MYC mRNA.	Oxaliplatin	132-143	RBPJ interacting and tubulin associated 1	Homo sapiens	15-19
28284059-13	2017	We found a substantial number of RITA-sensitive CRC cells within both panels of established CRC cell lines and primary patient-derived CRC cell lines (6/14) that provide a rationale for combining RITA with 5FU or oxaliplatin to enhance the antiproliferative response to both chemotherapeutic agents.	Oxaliplatin	213-224	RBPJ interacting and tubulin associated 1	Homo sapiens	33-37
28454407-8	2017	These results indicated that inhibition of NPM, as a Her-2 downstream signal, may be a novel strategy to overcome oxaliplatin-resistant gastric cancer, and that trastuzumab and oxaliplatin may exhibit a synergistic antitumor effect in Her-2-positive gastric cancer cells.	Oxaliplatin	177-188	erb-b2 receptor tyrosine kinase 2	Homo sapiens	235-240
28069878-0	2017	MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.	Oxaliplatin	43-54	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	0-6
28069878-4	2017	In this study, we aim to investigate the prognostic and therapeutic role of lncRNA MALAT1 in colorectal cancer patients receiving oxaliplatin-based therapy and further explore the potential transcriptional regulation through interaction with EZH2 based on the established HT29 oxaliplatin-resistant cells.	Oxaliplatin	130-141	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	83-89
28069878-4	2017	In this study, we aim to investigate the prognostic and therapeutic role of lncRNA MALAT1 in colorectal cancer patients receiving oxaliplatin-based therapy and further explore the potential transcriptional regulation through interaction with EZH2 based on the established HT29 oxaliplatin-resistant cells.	Oxaliplatin	277-288	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	242-246
28069878-5	2017	Our results showed that high MALAT1 expression was associated with reduced patient survival and poor response to oxaliplatin-based chemotherapy in advanced colorectal cancer patients.	Oxaliplatin	113-124	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	29-35
28069878-6	2017	Oxaliplatin-resistant colorectal cancer cells exhibited high MALAT1 expression and EMT.	Oxaliplatin	0-11	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	61-67
28069878-7	2017	LncRNA MALAT1 knockdown enhances E-cadherin expression and inhibits oxaliplatin-induced EMT in colorectal cancer cells.	Oxaliplatin	68-79	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	7-13
28069878-9	2017	Furthermore, targeted inhibition of MALAT1 or EZH2 reversed EMT and chemoresistance induced by oxaliplatin.	Oxaliplatin	95-106	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	36-42
28069878-9	2017	Furthermore, targeted inhibition of MALAT1 or EZH2 reversed EMT and chemoresistance induced by oxaliplatin.	Oxaliplatin	95-106	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	46-50
28069878-10	2017	Finally, the interaction between lncRNA MALAT1 and miR-218 was observed, which further indicated its prognostic value in patients who received standard FOLFOX (oxaliplatin combine with 5-fluorouracil and leucovorin) treatment.	Oxaliplatin	160-171	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	40-46
28069878-11	2017	In conclusion, this study illuminates the prognostic role of lncRNA MALAT1 in colorectal cancer patients receiving oxaliplatin-based treatment and further demonstrates how lncRNA MALAT1 confers a chemoresistant function in colorectal cancer.	Oxaliplatin	115-126	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	68-74
28069878-11	2017	In conclusion, this study illuminates the prognostic role of lncRNA MALAT1 in colorectal cancer patients receiving oxaliplatin-based treatment and further demonstrates how lncRNA MALAT1 confers a chemoresistant function in colorectal cancer.	Oxaliplatin	115-126	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	179-185
28454407-0	2017	Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin.	Oxaliplatin	82-93	nucleophosmin 1	Homo sapiens	18-21
28454407-0	2017	Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin.	Oxaliplatin	82-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-41
28454407-6	2017	Cell counting kit-8 assays demonstrated that the cell sensitivity to oxaliplatin decreased simultaneously with an increase in NPM expression.	Oxaliplatin	69-80	nucleophosmin 1	Homo sapiens	126-129
28454407-7	2017	Furthermore, inhibition of Her-2 expression using trastuzumab significantly increased the sensitivity of the cells to oxaliplatin, which occurred simultaneously with the downregulation of NPM.	Oxaliplatin	118-129	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-32
28454407-7	2017	Furthermore, inhibition of Her-2 expression using trastuzumab significantly increased the sensitivity of the cells to oxaliplatin, which occurred simultaneously with the downregulation of NPM.	Oxaliplatin	118-129	nucleophosmin 1	Homo sapiens	188-191
28454407-8	2017	These results indicated that inhibition of NPM, as a Her-2 downstream signal, may be a novel strategy to overcome oxaliplatin-resistant gastric cancer, and that trastuzumab and oxaliplatin may exhibit a synergistic antitumor effect in Her-2-positive gastric cancer cells.	Oxaliplatin	114-125	nucleophosmin 1	Homo sapiens	43-46
28366950-7	2017	In conclusion, GSTM1 genotypes may affect the urinary 1-OHP in the non-occupationally exposed general population, and micronucleus frequency in both occupational workers and non-occupational population.	Oxaliplatin	54-59	glutathione S-transferase mu 1	Homo sapiens	15-20
28356150-8	2017	RESULTS: PXR over-expression significantly increased oxaliplatin (L-OHP) transport capacity with a reduction of its content and repressed the effects of L-OHP on tumour cell proliferation and apoptosis.	Oxaliplatin	53-64	nuclear receptor subfamily 1 group I member 2	Homo sapiens	9-12
28356150-8	2017	RESULTS: PXR over-expression significantly increased oxaliplatin (L-OHP) transport capacity with a reduction of its content and repressed the effects of L-OHP on tumour cell proliferation and apoptosis.	Oxaliplatin	66-71	nuclear receptor subfamily 1 group I member 2	Homo sapiens	9-12
28356150-8	2017	RESULTS: PXR over-expression significantly increased oxaliplatin (L-OHP) transport capacity with a reduction of its content and repressed the effects of L-OHP on tumour cell proliferation and apoptosis.	Oxaliplatin	153-158	nuclear receptor subfamily 1 group I member 2	Homo sapiens	9-12
28356150-9	2017	Conversely, PXR knockdown augments L-OHP-mediated cellular proliferation and apoptosis.	Oxaliplatin	35-40	nuclear receptor subfamily 1 group I member 2	Homo sapiens	12-15
28356150-10	2017	Moreover, PXR significantly reduced the therapeutic effects of L-OHP on tumor growth in nude mice.	Oxaliplatin	63-68	nuclear receptor subfamily 1, group I, member 2	Mus musculus	10-13
28356150-17	2017	CONCLUSIONS: PXR is a potential biomarker for predicting outcome and activates MRP3 transcription by directly binding to its promoter resulting in an increased L-OHP efflux capacity, and resistance to L-OHP or platinum drugs in CRC.	Oxaliplatin	160-165	nuclear receptor subfamily 1 group I member 2	Homo sapiens	13-16
28356150-17	2017	CONCLUSIONS: PXR is a potential biomarker for predicting outcome and activates MRP3 transcription by directly binding to its promoter resulting in an increased L-OHP efflux capacity, and resistance to L-OHP or platinum drugs in CRC.	Oxaliplatin	160-165	ATP binding cassette subfamily C member 3	Homo sapiens	79-83
28356150-17	2017	CONCLUSIONS: PXR is a potential biomarker for predicting outcome and activates MRP3 transcription by directly binding to its promoter resulting in an increased L-OHP efflux capacity, and resistance to L-OHP or platinum drugs in CRC.	Oxaliplatin	201-206	nuclear receptor subfamily 1 group I member 2	Homo sapiens	13-16
28356150-17	2017	CONCLUSIONS: PXR is a potential biomarker for predicting outcome and activates MRP3 transcription by directly binding to its promoter resulting in an increased L-OHP efflux capacity, and resistance to L-OHP or platinum drugs in CRC.	Oxaliplatin	201-206	ATP binding cassette subfamily C member 3	Homo sapiens	79-83
29108296-1	2017	Aims: To compare the safety and efficacy of TACE using raltitrexed, oxaliplatin and epirubicin with 5-fluorouracil, oxaliplatin and epirubicin for patients with unresectable hepatocelluar carcinoma.	Oxaliplatin	68-79	ADAM metallopeptidase domain 17	Homo sapiens	44-48
28103584-4	2017	TACE was administered three times once a month, using lipiodol 10ml, oxaliplatin 150mg, and tegafur 1g.	Oxaliplatin	69-80	ADAM metallopeptidase domain 17	Homo sapiens	0-4
28348394-0	2017	The G2A receptor (GPR132) contributes to oxaliplatin-induced mechanical pain hypersensitivity.	Oxaliplatin	41-52	G protein-coupled receptor 132	Mus musculus	4-7
28348394-0	2017	The G2A receptor (GPR132) contributes to oxaliplatin-induced mechanical pain hypersensitivity.	Oxaliplatin	41-52	G protein-coupled receptor 132	Mus musculus	18-24
28348394-4	2017	Here, we report the involvement of the G-protein coupled receptor G2A (GPR132) in oxaliplatin-induced neuropathic pain in mice.	Oxaliplatin	82-93	G protein-coupled receptor 132	Mus musculus	66-69
28348394-4	2017	Here, we report the involvement of the G-protein coupled receptor G2A (GPR132) in oxaliplatin-induced neuropathic pain in mice.	Oxaliplatin	82-93	G protein-coupled receptor 132	Mus musculus	71-77
28348394-5	2017	We found that mice deficient in the G2A-receptor show decreased mechanical hypersensitivity after oxaliplatin treatment.	Oxaliplatin	98-109	G protein-coupled receptor 132	Mus musculus	36-39
28348394-6	2017	Lipid ligands of G2A were found in increased concentrations in the sciatic nerve and dorsal root ganglia of oxaliplatin treated mice.	Oxaliplatin	108-119	G protein-coupled receptor 132	Mus musculus	17-20
28348394-8	2017	Based on these findings, we conclude that targeting G2A may be a promising approach to reduce oxaliplatin-induced TRPV1-sensitization and the hyperexcitability of sensory neurons and thereby to reduce pain in patients treated with this chemotherapeutic agent.	Oxaliplatin	94-105	G protein-coupled receptor 132	Homo sapiens	52-55
28348394-8	2017	Based on these findings, we conclude that targeting G2A may be a promising approach to reduce oxaliplatin-induced TRPV1-sensitization and the hyperexcitability of sensory neurons and thereby to reduce pain in patients treated with this chemotherapeutic agent.	Oxaliplatin	94-105	transient receptor potential cation channel subfamily V member 1	Homo sapiens	114-119
28259288-1	2017	Excision repair cross-complementation group 1 (ERCC1) is a key component in DNA repair mechanisms and may influence the tumor DNA-targeting effect of the chemotherapeutic agent oxaliplatin.	Oxaliplatin	177-188	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
28348487-0	2017	miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-beta/Smad4 pathway.	Oxaliplatin	17-28	microRNA 34a	Homo sapiens	0-7
28348487-0	2017	miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-beta/Smad4 pathway.	Oxaliplatin	17-28	SMAD family member 4	Homo sapiens	132-137
28003121-0	2017	Silencing peroxiredoxin-2 sensitizes human colorectal cancer cells to ionizing radiation and oxaliplatin.	Oxaliplatin	93-104	peroxiredoxin 2	Homo sapiens	10-25
28003121-7	2017	In addition, we showed that administration of IR plus oxaliplatin in down regulated Prx2 HCT116 cells has higher citotoxic effect than in control cells.	Oxaliplatin	54-65	peroxiredoxin 2	Homo sapiens	84-88
28348487-1	2017	AIM: To investigate whether microRNA (miR)-34a mediates oxaliplatin (OXA) resistance of colorectal cancer (CRC) cells by inhibiting macroautophagy via the transforming growth factor (TGF)-beta/Smad4 pathway.	Oxaliplatin	56-67	microRNA 34a	Homo sapiens	28-46
28348487-6	2017	RESULTS: Expression of miR-34a was significantly reduced while expression of TGF-beta and Smad4 was increased in CRC patients treated with OXA-based chemotherapy.	Oxaliplatin	139-142	microRNA 34a	Homo sapiens	23-30
28348487-6	2017	RESULTS: Expression of miR-34a was significantly reduced while expression of TGF-beta and Smad4 was increased in CRC patients treated with OXA-based chemotherapy.	Oxaliplatin	139-142	transforming growth factor beta 1	Homo sapiens	77-85
28348487-6	2017	RESULTS: Expression of miR-34a was significantly reduced while expression of TGF-beta and Smad4 was increased in CRC patients treated with OXA-based chemotherapy.	Oxaliplatin	139-142	SMAD family member 4	Homo sapiens	90-95
28348487-10	2017	OXA-induced downregulation of miR-34a and increased drug resistance by activating macroautophagy in CRC cells.	Oxaliplatin	0-3	microRNA 34a	Homo sapiens	30-37
28229139-0	2017	PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features.	Oxaliplatin	35-46	dachshund family transcription factor 1	Homo sapiens	5-9
28229139-3	2017	In search of novel and more efficacious Pt-based drugs for CRC treatment, we synthesized and characterised PtI2(DACH), an oxaliplatin analogue.	Oxaliplatin	122-133	dachshund family transcription factor 1	Homo sapiens	112-116
28012171-0	2017	miR-15b mediates oxaliplatin-induced chronic neuropathic pain through BACE1 down-regulation.	Oxaliplatin	17-28	microRNA 15b	Rattus norvegicus	0-7
28012171-0	2017	miR-15b mediates oxaliplatin-induced chronic neuropathic pain through BACE1 down-regulation.	Oxaliplatin	17-28	beta-secretase 1	Rattus norvegicus	70-75
28012171-8	2017	KEY RESULTS: Among the miRNAs examined in the DRG in the late phase of oxaliplatin-induced neuropathic pain, miR-15b was most robustly increased.	Oxaliplatin	71-82	microRNA 15b	Rattus norvegicus	109-116
28012171-13	2017	CONCLUSIONS AND IMPLICATIONS: These findings suggest that miR-15b contributes to oxaliplatin-induced chronic neuropathic pain at least in part through the down-regulation of BACE1.	Oxaliplatin	81-92	microRNA 15b	Rattus norvegicus	58-65
28012171-13	2017	CONCLUSIONS AND IMPLICATIONS: These findings suggest that miR-15b contributes to oxaliplatin-induced chronic neuropathic pain at least in part through the down-regulation of BACE1.	Oxaliplatin	81-92	beta-secretase 1	Rattus norvegicus	174-179
28031409-3	2017	The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2.	Oxaliplatin	74-85	tumor protein p53	Homo sapiens	159-162
28166401-3	2017	Here, we used detailed spectroscopic characterization to demonstrate rapid formation of Pt-guanosine adducts within 30 min after coincubation of oxaliplatin [OxaPt(II)] or cisplatin [CisPt(II)] with either guanosine monophosphate or B-cell lymphoma 2 (BCL-2) siRNA.	Oxaliplatin	145-156	BCL2 apoptosis regulator	Homo sapiens	233-250
28166401-3	2017	Here, we used detailed spectroscopic characterization to demonstrate rapid formation of Pt-guanosine adducts within 30 min after coincubation of oxaliplatin [OxaPt(II)] or cisplatin [CisPt(II)] with either guanosine monophosphate or B-cell lymphoma 2 (BCL-2) siRNA.	Oxaliplatin	145-156	BCL2 apoptosis regulator	Homo sapiens	252-257
28031409-3	2017	The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2.	Oxaliplatin	74-85	tumor protein p53	Homo sapiens	214-217
28031409-3	2017	The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2.	Oxaliplatin	74-85	cyclin dependent kinase inhibitor 1A	Homo sapiens	259-262
28031409-3	2017	The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2.	Oxaliplatin	74-85	cyclin dependent kinase inhibitor 1A	Homo sapiens	264-270
28031409-3	2017	The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2.	Oxaliplatin	74-85	MDM2 proto-oncogene	Homo sapiens	276-280
28454268-8	2017	In the present study, it was demonstrated that TCRP1 contributed to the resistance to DDP and L-OHP in human lung and ovarian cancer cells.	Oxaliplatin	94-99	family with sequence similarity 168 member A	Homo sapiens	47-52
28454268-10	2017	The present study identified a positive correlation between TCRP1 expression and primary resistance to DDP and L-OHP in lung cancer cells.	Oxaliplatin	111-116	family with sequence similarity 168 member A	Homo sapiens	60-65
28454268-11	2017	In addition, it was observed that cells treated with nuclear factor (NF)-kappaB inhibitor BAY 11-7082 displayed increased sensitivity to DDP and L-OHP.	Oxaliplatin	145-150	nuclear factor kappa B subunit 1	Homo sapiens	53-79
28041630-9	2017	Intracerebroventricularly administered orexin-A dose-dependently attenuated oxaliplatin-induced mechanical allodynia and increased tail flick latencies.	Oxaliplatin	76-87	hypocretin	Mus musculus	39-47
27980217-1	2017	Copper transporter 1 (CTR1), copper transporter 2 (CTR2), copper-transporting p-type adenosine triphosphatase 1 and 2 (ATP7A and ATP7B) are key mediators of cellular cisplatin, carboplatin and oxaliplatin accumulation.	Oxaliplatin	193-204	solute carrier family 31 member 1	Homo sapiens	0-20
27980217-1	2017	Copper transporter 1 (CTR1), copper transporter 2 (CTR2), copper-transporting p-type adenosine triphosphatase 1 and 2 (ATP7A and ATP7B) are key mediators of cellular cisplatin, carboplatin and oxaliplatin accumulation.	Oxaliplatin	193-204	solute carrier family 31 member 1	Homo sapiens	22-26
27980217-1	2017	Copper transporter 1 (CTR1), copper transporter 2 (CTR2), copper-transporting p-type adenosine triphosphatase 1 and 2 (ATP7A and ATP7B) are key mediators of cellular cisplatin, carboplatin and oxaliplatin accumulation.	Oxaliplatin	193-204	solute carrier family 31 member 2	Homo sapiens	29-49
27980217-1	2017	Copper transporter 1 (CTR1), copper transporter 2 (CTR2), copper-transporting p-type adenosine triphosphatase 1 and 2 (ATP7A and ATP7B) are key mediators of cellular cisplatin, carboplatin and oxaliplatin accumulation.	Oxaliplatin	193-204	solute carrier family 31 member 2	Homo sapiens	51-55
27980217-1	2017	Copper transporter 1 (CTR1), copper transporter 2 (CTR2), copper-transporting p-type adenosine triphosphatase 1 and 2 (ATP7A and ATP7B) are key mediators of cellular cisplatin, carboplatin and oxaliplatin accumulation.	Oxaliplatin	193-204	ATPase copper transporting alpha	Homo sapiens	119-124
27980217-1	2017	Copper transporter 1 (CTR1), copper transporter 2 (CTR2), copper-transporting p-type adenosine triphosphatase 1 and 2 (ATP7A and ATP7B) are key mediators of cellular cisplatin, carboplatin and oxaliplatin accumulation.	Oxaliplatin	193-204	ATPase copper transporting beta	Homo sapiens	129-134
28076324-11	2017	Knockdown of PCBP1 sensitized HT-29/L-OHP and HT-29 cells to L-OHP, while overexpression of PCBP1 increased L-OHP resistance in HT-29 cells.	Oxaliplatin	36-41	poly(rC) binding protein 1	Homo sapiens	13-18
28076324-11	2017	Knockdown of PCBP1 sensitized HT-29/L-OHP and HT-29 cells to L-OHP, while overexpression of PCBP1 increased L-OHP resistance in HT-29 cells.	Oxaliplatin	61-66	poly(rC) binding protein 1	Homo sapiens	13-18
28076324-12	2017	In addition, PCBP1 expression was significantly higher in tumor samples from L-OHP refractory patients than in those from L-OHP responsive patients.	Oxaliplatin	77-82	poly(rC) binding protein 1	Homo sapiens	13-18
28076324-12	2017	In addition, PCBP1 expression was significantly higher in tumor samples from L-OHP refractory patients than in those from L-OHP responsive patients.	Oxaliplatin	122-127	poly(rC) binding protein 1	Homo sapiens	13-18
28143584-0	2017	Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.	Oxaliplatin	167-178	tumor protein, translationally-controlled 1	Homo sapiens	42-46
28143584-3	2017	Here we study the early increase of TCTP levels in human colorectal cancer (CRC) and the regulation of TCTP expression in HCT116 colon cancer cells, in response to treatment with the anti-cancer drugs 5-FU and oxaliplatin.	Oxaliplatin	210-221	tumor protein, translationally-controlled 1	Homo sapiens	103-107
28143584-5	2017	We also studied the regulation of TCTP in HCT116 colon cancer cells in response to 5-FU and oxaliplatin by western blotting.	Oxaliplatin	92-103	tumor protein, translationally-controlled 1	Homo sapiens	34-38
28143584-12	2017	TCTP protein levels are about 4-fold upregulated in HCT116 colon cancer cells, in response to 5-FU and oxaliplatin treatment, whereas TCTP mRNA levels are down regulated.	Oxaliplatin	103-114	tumor protein, translationally-controlled 1	Homo sapiens	0-4
28143584-16	2017	Using two cellular assay systems, we demonstrated that TCTP-knockdown sensitises HCT116 cells to the cytotoxicity caused by 5-FU and oxaliplatin.	Oxaliplatin	133-144	tumor protein, translationally-controlled 1	Homo sapiens	55-59
27856287-5	2017	Importantly, we found that incubation of low concentration oxaliplatin at dose of 6.6nM (the detected concentration in CSF following a single intraperitoneal injection of oxaliplatin) also significantly inhibited the AMPKalpha activation and increased the amplitude of sEPSCs, the number of action potential, and the expression of p-mTOR and p-p70S6K in spinal cord slices.	Oxaliplatin	59-70	mechanistic target of rapamycin kinase	Homo sapiens	333-337
27856287-5	2017	Importantly, we found that incubation of low concentration oxaliplatin at dose of 6.6nM (the detected concentration in CSF following a single intraperitoneal injection of oxaliplatin) also significantly inhibited the AMPKalpha activation and increased the amplitude of sEPSCs, the number of action potential, and the expression of p-mTOR and p-p70S6K in spinal cord slices.	Oxaliplatin	59-70	ribosomal protein S6 kinase B1	Homo sapiens	344-350
27856287-8	2017	Local application of metformin significantly decreased the mTOR and p70S6K activation induced by tetanus stimulation or oxaliplatin (i.p.).	Oxaliplatin	120-131	mechanistic target of rapamycin kinase	Homo sapiens	59-63
27856287-8	2017	Local application of metformin significantly decreased the mTOR and p70S6K activation induced by tetanus stimulation or oxaliplatin (i.p.).	Oxaliplatin	120-131	ribosomal protein S6 kinase B1	Homo sapiens	68-74
27856287-9	2017	These results suggested that the decreased AMPKalpha activity via negatively regulating mTOR/p70S6K signal pathway enhanced the synaptic plasticity and contributed to acute pain induced by low concentration of oxaliplatin entering CNS.	Oxaliplatin	210-221	mechanistic target of rapamycin kinase	Homo sapiens	88-92
27856287-9	2017	These results suggested that the decreased AMPKalpha activity via negatively regulating mTOR/p70S6K signal pathway enhanced the synaptic plasticity and contributed to acute pain induced by low concentration of oxaliplatin entering CNS.	Oxaliplatin	210-221	ribosomal protein S6 kinase B1	Homo sapiens	93-99
28356957-0	2017	Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway.	Oxaliplatin	21-32	interleukin 17A	Homo sapiens	75-80
28356957-0	2017	Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway.	Oxaliplatin	21-32	interleukin 17 receptor A	Homo sapiens	81-87
28356957-0	2017	Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway.	Oxaliplatin	21-32	Janus kinase 2	Homo sapiens	88-92
28356957-0	2017	Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway.	Oxaliplatin	21-32	signal transducer and activator of transcription 3	Homo sapiens	93-98
28356957-2	2017	The present study demonstrated that oxaliplatin was able to increase the levels of IL-17/IL-17R in hepatocellular carcinoma (HCC) patients and cells lines, and that it had important roles in reducing the susceptibility of the cells to oxaliplatin-induced apoptosis.	Oxaliplatin	36-47	interleukin 17A	Homo sapiens	83-88
28356957-2	2017	The present study demonstrated that oxaliplatin was able to increase the levels of IL-17/IL-17R in hepatocellular carcinoma (HCC) patients and cells lines, and that it had important roles in reducing the susceptibility of the cells to oxaliplatin-induced apoptosis.	Oxaliplatin	36-47	interleukin 17 receptor A	Homo sapiens	89-95
28122359-0	2017	Tumor-associated NADH oxidase (tNOX)-NAD+-sirtuin 1 axis contributes to oxaliplatin-induced apoptosis of gastric cancer cells.	Oxaliplatin	72-83	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	0-29
28122359-0	2017	Tumor-associated NADH oxidase (tNOX)-NAD+-sirtuin 1 axis contributes to oxaliplatin-induced apoptosis of gastric cancer cells.	Oxaliplatin	72-83	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	31-35
28122359-0	2017	Tumor-associated NADH oxidase (tNOX)-NAD+-sirtuin 1 axis contributes to oxaliplatin-induced apoptosis of gastric cancer cells.	Oxaliplatin	72-83	sirtuin 1	Homo sapiens	42-51
28122359-4	2017	We explored the effects of oxaliplatin on a tumor-associated NADH oxidase (tNOX) in gastric cancer lines.	Oxaliplatin	27-38	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	44-73
28122359-4	2017	We explored the effects of oxaliplatin on a tumor-associated NADH oxidase (tNOX) in gastric cancer lines.	Oxaliplatin	27-38	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	75-79
28122359-5	2017	In AGS cells, we found that the oxaliplatin-inhibited tNOX effectively attenuated the NAD+/NADH ratio and reduced the deacetylase activity of an NAD+-dependent sirtuin 1, thereby enhancing p53 acetylation and apoptosis.	Oxaliplatin	32-43	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	54-58
28122359-5	2017	In AGS cells, we found that the oxaliplatin-inhibited tNOX effectively attenuated the NAD+/NADH ratio and reduced the deacetylase activity of an NAD+-dependent sirtuin 1, thereby enhancing p53 acetylation and apoptosis.	Oxaliplatin	32-43	sirtuin 1	Homo sapiens	160-169
28122359-5	2017	In AGS cells, we found that the oxaliplatin-inhibited tNOX effectively attenuated the NAD+/NADH ratio and reduced the deacetylase activity of an NAD+-dependent sirtuin 1, thereby enhancing p53 acetylation and apoptosis.	Oxaliplatin	32-43	tumor protein p53	Homo sapiens	189-192
28122359-8	2017	However, the downregulation of either sirtuin 1 or tNOX sensitized TMK-1 cells to oxaliplatin-induced apoptosis.	Oxaliplatin	82-93	sirtuin 1	Homo sapiens	38-47
28122359-8	2017	However, the downregulation of either sirtuin 1 or tNOX sensitized TMK-1 cells to oxaliplatin-induced apoptosis.	Oxaliplatin	82-93	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	51-55
28122359-10	2017	Together, our results demonstrate that oxaliplatin targets tNOX and SIRT1, and that the tNOX-NAD+-sirtuin 1 axis is essential for oxaliplatin-induced apoptosis.	Oxaliplatin	39-50	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	59-63
28122359-10	2017	Together, our results demonstrate that oxaliplatin targets tNOX and SIRT1, and that the tNOX-NAD+-sirtuin 1 axis is essential for oxaliplatin-induced apoptosis.	Oxaliplatin	39-50	sirtuin 1	Homo sapiens	68-73
28122359-10	2017	Together, our results demonstrate that oxaliplatin targets tNOX and SIRT1, and that the tNOX-NAD+-sirtuin 1 axis is essential for oxaliplatin-induced apoptosis.	Oxaliplatin	130-141	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	88-92
28122359-10	2017	Together, our results demonstrate that oxaliplatin targets tNOX and SIRT1, and that the tNOX-NAD+-sirtuin 1 axis is essential for oxaliplatin-induced apoptosis.	Oxaliplatin	130-141	sirtuin 1	Homo sapiens	98-107
28076324-7	2017	PCBP1 expression level in 20 cases of L-OHP sensitive patients and 20 cases of L-OHP refractory patients was analyzed by immunohistochemistry.	Oxaliplatin	38-43	poly(rC) binding protein 1	Homo sapiens	0-5
28076324-7	2017	PCBP1 expression level in 20 cases of L-OHP sensitive patients and 20 cases of L-OHP refractory patients was analyzed by immunohistochemistry.	Oxaliplatin	79-84	poly(rC) binding protein 1	Homo sapiens	0-5
28192521-2	2017	Here, we introduce a novel model of acquired oxaliplatin resistance, a sub-line of the non-MYCN-amplified neuroblastoma cell line SK-N-AS that was adapted to growth in the presence of 4000 ng/mL oxaliplatin (SK-N-ASrOXALI4000).	Oxaliplatin	45-56	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	91-95
28881609-5	2017	In combination, they affected the activation of Erk1/2 and counteracted the intrinsic and the extrinsic pathway of apoptosis, the DNA damage and the generation of ROS induced by oxaliplatin.	Oxaliplatin	178-189	mitogen-activated protein kinase 3	Homo sapiens	48-54
28088319-0	2017	ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.	Oxaliplatin	44-55	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
28088319-0	2017	ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.	Oxaliplatin	44-55	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	10-15
28088319-1	2017	BACKGROUND: The impact of Excision repair cross-complementation group 1 (ERCC1) and group 2 (ERCC2) expression levels on the efficacy of oxaliplatin-based chemotherapy is still controversial.	Oxaliplatin	137-148	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	73-78
28088319-1	2017	BACKGROUND: The impact of Excision repair cross-complementation group 1 (ERCC1) and group 2 (ERCC2) expression levels on the efficacy of oxaliplatin-based chemotherapy is still controversial.	Oxaliplatin	137-148	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	93-98
28088319-11	2017	CONCLUSIONS: ERCC1 expression levels may help in selecting patients who benefit from oxaliplatin chemotherapy in stage III &amp; IV CRC.	Oxaliplatin	85-96	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-18
27980107-13	2017	Niclosamide prevents oxaliplatin-induced increased levels of IL6, TNFalpha, and advanced oxidized protein products.	Oxaliplatin	21-32	interleukin 6	Mus musculus	61-64
27980107-13	2017	Niclosamide prevents oxaliplatin-induced increased levels of IL6, TNFalpha, and advanced oxidized protein products.	Oxaliplatin	21-32	tumor necrosis factor	Mus musculus	66-74
28356957-3	2017	Furthermore, the expression of autophagy-related proteins was induced by IL-17/IL-17R and autophagy was shown to induce resistance to oxaliplatin in HCC.	Oxaliplatin	134-145	interleukin 17A	Homo sapiens	73-78
28356957-3	2017	Furthermore, the expression of autophagy-related proteins was induced by IL-17/IL-17R and autophagy was shown to induce resistance to oxaliplatin in HCC.	Oxaliplatin	134-145	interleukin 17 receptor A	Homo sapiens	79-85
28356957-4	2017	In addition, the janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway was shown to be an important pathway in the induction of autophagy in response to oxaliplatin.	Oxaliplatin	188-199	Janus kinase 2	Homo sapiens	17-31
28356957-4	2017	In addition, the janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway was shown to be an important pathway in the induction of autophagy in response to oxaliplatin.	Oxaliplatin	188-199	Janus kinase 2	Homo sapiens	33-37
28356957-4	2017	In addition, the janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway was shown to be an important pathway in the induction of autophagy in response to oxaliplatin.	Oxaliplatin	188-199	signal transducer and activator of transcription 3	Homo sapiens	39-89
28356957-4	2017	In addition, the janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway was shown to be an important pathway in the induction of autophagy in response to oxaliplatin.	Oxaliplatin	188-199	signal transducer and activator of transcription 3	Homo sapiens	91-96
28356957-5	2017	Autopjhagy was inhibited by 3-methyladenine and JAK2/STAT3 signaling was blocked by AG490, which induced apoptosis in SMMC7721 cells treated with oxaliplatin.	Oxaliplatin	146-157	Janus kinase 2	Homo sapiens	48-52
28356957-5	2017	Autopjhagy was inhibited by 3-methyladenine and JAK2/STAT3 signaling was blocked by AG490, which induced apoptosis in SMMC7721 cells treated with oxaliplatin.	Oxaliplatin	146-157	signal transducer and activator of transcription 3	Homo sapiens	53-58
28125674-6	2017	OXA caused a significant increase in the percentage of interleukin-4+ lymphocytes in the spleen and significant down-regulation of regulatory T (T-reg) cells in the inguinal lymph nodes.	Oxaliplatin	0-3	interleukin 4	Mus musculus	55-68
28041630-10	2017	Oxaliplatin-induced mechanical allodynia was completely reversed by orexin-A at a low dose that did not increase tail flick latency.	Oxaliplatin	0-11	hypocretin	Mus musculus	68-76
28041630-12	2017	The analgesic effect of orexin-A on oxaliplatin-induced mechanical allodynia was completely antagonized by prior intraperitoneal injection of SB-408124 (orexin type-1 receptor antagonist), but not by prior intraperitoneal injection of TCS-OX2-29 (orexin type-2 receptor antagonist).	Oxaliplatin	36-47	hypocretin	Mus musculus	24-32
28060954-0	2017	Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis.	Oxaliplatin	34-45	mechanistic target of rapamycin kinase	Homo sapiens	18-22
28103821-0	2017	Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy.	Oxaliplatin	51-62	sodium voltage-gated channel alpha subunit 9	Homo sapiens	25-30
28103821-6	2017	In this study we investigated whether SCN9A genetic variants were associated with risk of neurotoxicity in patients diagnosed of cancer on treatment with oxaliplatin.	Oxaliplatin	154-165	sodium voltage-gated channel alpha subunit 9	Homo sapiens	38-43
28103821-14	2017	CONCLUSION: SCN9A rs6746030 was associated with protection for severe oxaliplatin-induced peripheral neuropathy.	Oxaliplatin	70-81	sodium voltage-gated channel alpha subunit 9	Homo sapiens	12-17
28088201-12	2017	Immunohistochemical analysis showed the activation of astrocytes and microglia and the increase of the IL-1beta and TNF-alpha levels in the spinal cord after an oxaliplatin injection.	Oxaliplatin	161-172	interleukin 1 beta	Rattus norvegicus	103-111
28088201-12	2017	Immunohistochemical analysis showed the activation of astrocytes and microglia and the increase of the IL-1beta and TNF-alpha levels in the spinal cord after an oxaliplatin injection.	Oxaliplatin	161-172	tumor necrosis factor	Rattus norvegicus	116-125
28060954-5	2017	RESULTS: Gene set enrichment analysis revealed that the mTOR pathway was activated in patients receiving oxaliplatin based therapy.	Oxaliplatin	105-116	mechanistic target of rapamycin kinase	Homo sapiens	56-60
28060954-6	2017	Treatment of early passaged colorectal cancer lines and patient derived xenografts with oxaliplatin resulted in activation of the mTOR pathway.	Oxaliplatin	88-99	mechanistic target of rapamycin kinase	Homo sapiens	130-134
28060954-7	2017	Combination therapy with oxaliplatin and a mTOR inhibitor resulted in a synergistic effect both in vitro and in vivo.	Oxaliplatin	25-36	mechanistic target of rapamycin kinase	Homo sapiens	43-47
28011495-8	2017	Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l.	Oxaliplatin	155-166	colony stimulating factor 3	Homo sapiens	0-37
28115855-0	2017	Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer.	Oxaliplatin	91-102	colorectal neoplasia differentially expressed	Homo sapiens	19-24
28115855-0	2017	Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer.	Oxaliplatin	91-102	microRNA 136	Homo sapiens	126-133
28115855-1	2017	Colorectal neoplasia differentially expressed (CRNDE) is a novel gene recognized as a long noncoding RNA (lncRNA) that is highly elevated in colorectal cancer and many other solid tumors but its functions on metastasis and oxaliplatin (OXA) resistance are unknown.	Oxaliplatin	223-234	colorectal neoplasia differentially expressed	Homo sapiens	47-52
28115855-1	2017	Colorectal neoplasia differentially expressed (CRNDE) is a novel gene recognized as a long noncoding RNA (lncRNA) that is highly elevated in colorectal cancer and many other solid tumors but its functions on metastasis and oxaliplatin (OXA) resistance are unknown.	Oxaliplatin	236-239	colorectal neoplasia differentially expressed	Homo sapiens	47-52
28115855-6	2017	Knockdown of CRNDE with OXA treatment decreased cell viability and promoted DNA damage and cell apoptosis, while the overexpression of CRNDE with OXA treatment reduced DNA damage and cell apoptosis.	Oxaliplatin	24-27	colorectal neoplasia differentially expressed	Homo sapiens	13-18
28115855-6	2017	Knockdown of CRNDE with OXA treatment decreased cell viability and promoted DNA damage and cell apoptosis, while the overexpression of CRNDE with OXA treatment reduced DNA damage and cell apoptosis.	Oxaliplatin	146-149	colorectal neoplasia differentially expressed	Homo sapiens	135-140
28011495-8	2017	Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l.	Oxaliplatin	155-166	colony stimulating factor 3	Homo sapiens	39-44
28035913-0	2017	MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1.	Oxaliplatin	77-88	Y-box binding protein 1	Homo sapiens	108-112
28674258-4	2017	In this review, we focus on the specific roles of redox-sensitive TRP ankyrin 1 (TRPA1), which was first reported to be a cold nociceptor, in acute cold hypersensitivity induced by oxaliplatin, a platinum-based agent, because it induces a peculiar cold-triggered CIPN during or within hours after its infusion.	Oxaliplatin	181-192	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	66-79
28674258-4	2017	In this review, we focus on the specific roles of redox-sensitive TRP ankyrin 1 (TRPA1), which was first reported to be a cold nociceptor, in acute cold hypersensitivity induced by oxaliplatin, a platinum-based agent, because it induces a peculiar cold-triggered CIPN during or within hours after its infusion.	Oxaliplatin	181-192	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	81-86
28674258-5	2017	Oxaliplatin-induced rapid-onset cold hypersensitivity is ameliorated by TRPA1 blockade or deficiency in mice.	Oxaliplatin	0-11	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	72-77
28674258-6	2017	Consistent with this, oxaliplatin enhances the responsiveness of TRPA1 stimulation, but not of TRP melastatin 8 (TRPM8) and TRP vanilloid 1 (TRPV1), in mice and cultured mouse dorsal root ganglion neurons.	Oxaliplatin	22-33	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	65-70
28674258-8	2017	In human TRPA1 (hTRPA1)-expressing cells, oxaliplatin or oxalate causes TRPA1 sensitization to reactive oxygen species (ROS) by inhibiting prolyl hydroxylases (PHDs).	Oxaliplatin	42-53	transient receptor potential cation channel subfamily A member 1	Homo sapiens	9-14
28674258-8	2017	In human TRPA1 (hTRPA1)-expressing cells, oxaliplatin or oxalate causes TRPA1 sensitization to reactive oxygen species (ROS) by inhibiting prolyl hydroxylases (PHDs).	Oxaliplatin	42-53	transient receptor potential cation channel subfamily A member 1	Homo sapiens	16-22
28674258-8	2017	In human TRPA1 (hTRPA1)-expressing cells, oxaliplatin or oxalate causes TRPA1 sensitization to reactive oxygen species (ROS) by inhibiting prolyl hydroxylases (PHDs).	Oxaliplatin	42-53	transient receptor potential cation channel subfamily A member 1	Homo sapiens	17-22
28674258-10	2017	This review discusses these findings and summarizes the evidence demonstrating that oxaliplatin-induced acute cold hypersensitivity is caused by TRPA1 sensitization to ROS via PHD inhibition, which enables TRPA1 to convert ROS signaling into cold sensitivity.	Oxaliplatin	84-95	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	145-150
28674258-10	2017	This review discusses these findings and summarizes the evidence demonstrating that oxaliplatin-induced acute cold hypersensitivity is caused by TRPA1 sensitization to ROS via PHD inhibition, which enables TRPA1 to convert ROS signaling into cold sensitivity.	Oxaliplatin	84-95	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	206-211
28035913-0	2017	MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1.	Oxaliplatin	90-93	Y-box binding protein 1	Homo sapiens	108-112
28035913-5	2017	Blocking miR-137 caused a significant inhibition of OXA-induced cytotoxicity, therefore, miR-137 was chosen for further research.	Oxaliplatin	52-55	microRNA 137	Homo sapiens	9-16
28035913-6	2017	An in vitro cell viability assay showed that knockdown of miR-137 in HCT-15 and SW480 cells caused a marked inhibition of OXA-induced cytotoxicity.	Oxaliplatin	122-125	microRNA 137	Homo sapiens	58-65
28040715-4	2017	This report describes a patient with KRAS, NRAS, and BRAF wild-type mCRC who experienced disease progression on first-line treatment with FOLFIRI and cetuximab after only 5 months, and subsequently experienced progression on second-line treatment with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline.	Oxaliplatin	269-280	KRAS proto-oncogene, GTPase	Homo sapiens	37-41
29041002-7	2017	Moreover, AS-IV and miR-134 increased the sensitivity of CRC tumors to oxaliplatin (OXA) chemotherapy.	Oxaliplatin	71-82	microRNA 134	Homo sapiens	20-27
29041002-7	2017	Moreover, AS-IV and miR-134 increased the sensitivity of CRC tumors to oxaliplatin (OXA) chemotherapy.	Oxaliplatin	84-87	microRNA 134	Homo sapiens	20-27
27796996-7	2017	Moreover, a significant association (p &lt; 0.001) was found between urinary 1-OHP levels and serum FABP4 concentrations in women after adjusting for potential confounding variables.	Oxaliplatin	77-82	fatty acid binding protein 4	Homo sapiens	100-105
28040715-4	2017	This report describes a patient with KRAS, NRAS, and BRAF wild-type mCRC who experienced disease progression on first-line treatment with FOLFIRI and cetuximab after only 5 months, and subsequently experienced progression on second-line treatment with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline.	Oxaliplatin	269-280	NRAS proto-oncogene, GTPase	Homo sapiens	43-47
28040715-4	2017	This report describes a patient with KRAS, NRAS, and BRAF wild-type mCRC who experienced disease progression on first-line treatment with FOLFIRI and cetuximab after only 5 months, and subsequently experienced progression on second-line treatment with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline.	Oxaliplatin	269-280	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	53-57
28741430-0	2017	Orofacial neuropathic pain induced by oxaliplatin: downregulation of KCNQ2 channels in V2 trigeminal ganglion neurons and treatment by the KCNQ2 channel potentiator retigabine.	Oxaliplatin	38-49	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	69-74
28849713-0	2017	Upregulation of CX3CL1 mediated by NF-kappaB activation in dorsal root ganglion contributes to peripheral sensitization and chronic pain induced by oxaliplatin administration.	Oxaliplatin	148-159	C-X3-C motif chemokine ligand 1	Homo sapiens	16-22
28849713-0	2017	Upregulation of CX3CL1 mediated by NF-kappaB activation in dorsal root ganglion contributes to peripheral sensitization and chronic pain induced by oxaliplatin administration.	Oxaliplatin	148-159	nuclear factor kappa B subunit 1	Homo sapiens	35-44
28849713-4	2017	Furthermore, the CX3CL1 expression was significantly increased after oxaliplatin treatment, and intrathecal injection of a neutralizing antibody against CX3CL1 markedly attenuated the enhanced excitability of dorsal root ganglion neurons and thermal hyperalgesia.	Oxaliplatin	69-80	C-X3-C motif chemokine ligand 1	Homo sapiens	17-23
28849713-4	2017	Furthermore, the CX3CL1 expression was significantly increased after oxaliplatin treatment, and intrathecal injection of a neutralizing antibody against CX3CL1 markedly attenuated the enhanced excitability of dorsal root ganglion neurons and thermal hyperalgesia.	Oxaliplatin	69-80	C-X3-C motif chemokine ligand 1	Homo sapiens	153-159
28849713-5	2017	Importantly, the upregulated CX3CL1 is mediated by the NF-kappaB signaling pathway, as inhibition of NF-kappaB p65 activation with pyrrolidine dithiocarbamate or p65 siRNA inhibited the upregulation of CX3CL1, the enhanced excitability of dorsal root ganglion neurons, and thermal hyperalgesia induced by oxaliplatin.	Oxaliplatin	305-316	C-X3-C motif chemokine ligand 1	Homo sapiens	29-35
28741430-8	2017	Immunostaining shows strong KCNQ2 immunoreactivity in small-sized V2 trigeminal ganglion neurons in controls, and the numbers of KCNQ2 immunoreactivity positive V2 trigeminal ganglion neurons are significantly reduced in oxaliplatin-treated animals.	Oxaliplatin	221-232	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	129-134
28741430-10	2017	We further show with the operant behavioral test that oxaliplatin-induced orofacial mechanical allodynia can be alleviated by the KCNQ2 potentiator retigabine.	Oxaliplatin	54-65	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	130-135
28741430-11	2017	Taken together, these findings suggest that KCNQ2 downregulation may be a cause of oxaliplatin-induced orofacial neuropathic pain and KCNQ2 potentiators may be useful for alleviating the neuropathic pain.	Oxaliplatin	83-94	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	44-49
28849713-5	2017	Importantly, the upregulated CX3CL1 is mediated by the NF-kappaB signaling pathway, as inhibition of NF-kappaB p65 activation with pyrrolidine dithiocarbamate or p65 siRNA inhibited the upregulation of CX3CL1, the enhanced excitability of dorsal root ganglion neurons, and thermal hyperalgesia induced by oxaliplatin.	Oxaliplatin	305-316	nuclear factor kappa B subunit 1	Homo sapiens	55-64
28849713-5	2017	Importantly, the upregulated CX3CL1 is mediated by the NF-kappaB signaling pathway, as inhibition of NF-kappaB p65 activation with pyrrolidine dithiocarbamate or p65 siRNA inhibited the upregulation of CX3CL1, the enhanced excitability of dorsal root ganglion neurons, and thermal hyperalgesia induced by oxaliplatin.	Oxaliplatin	305-316	nuclear factor kappa B subunit 1	Homo sapiens	101-110
28741430-0	2017	Orofacial neuropathic pain induced by oxaliplatin: downregulation of KCNQ2 channels in V2 trigeminal ganglion neurons and treatment by the KCNQ2 channel potentiator retigabine.	Oxaliplatin	38-49	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	139-144
28849713-5	2017	Importantly, the upregulated CX3CL1 is mediated by the NF-kappaB signaling pathway, as inhibition of NF-kappaB p65 activation with pyrrolidine dithiocarbamate or p65 siRNA inhibited the upregulation of CX3CL1, the enhanced excitability of dorsal root ganglion neurons, and thermal hyperalgesia induced by oxaliplatin.	Oxaliplatin	305-316	RELA proto-oncogene, NF-kB subunit	Homo sapiens	111-114
28849713-5	2017	Importantly, the upregulated CX3CL1 is mediated by the NF-kappaB signaling pathway, as inhibition of NF-kappaB p65 activation with pyrrolidine dithiocarbamate or p65 siRNA inhibited the upregulation of CX3CL1, the enhanced excitability of dorsal root ganglion neurons, and thermal hyperalgesia induced by oxaliplatin.	Oxaliplatin	305-316	RELA proto-oncogene, NF-kB subunit	Homo sapiens	162-165
28849713-6	2017	Further studies with chromatin immunoprecipitation found that oxaliplatin treatment increased the recruitment of NF-kappaB p65 to the CX3Cl1 promoter region.	Oxaliplatin	62-73	nuclear factor kappa B subunit 1	Homo sapiens	113-122
28849713-6	2017	Further studies with chromatin immunoprecipitation found that oxaliplatin treatment increased the recruitment of NF-kappaB p65 to the CX3Cl1 promoter region.	Oxaliplatin	62-73	RELA proto-oncogene, NF-kB subunit	Homo sapiens	123-126
29166835-0	2017	Activation of STAT3-mediated CXCL12 up-regulation in the dorsal root ganglion contributes to oxaliplatin-induced chronic pain.	Oxaliplatin	93-104	signal transducer and activator of transcription 3	Homo sapiens	14-19
29166835-3	2017	In the present study, we found that the intraperitoneal administration of oxaliplatin at 4 mg/kg for five consecutive days noticeably upregulated the expression of CXC motif ligand 12 (CXCL12) in the dorsal root ganglion, and the intrathecal injection of an anti-CXCL12 neutralizing antibody or CXCL12 siRNA attenuated the mechanical allodynia and thermal hyperalgesia induced by oxaliplatin.	Oxaliplatin	74-85	C-X-C motif chemokine ligand 12	Homo sapiens	164-183
29166835-0	2017	Activation of STAT3-mediated CXCL12 up-regulation in the dorsal root ganglion contributes to oxaliplatin-induced chronic pain.	Oxaliplatin	93-104	C-X-C motif chemokine ligand 12	Homo sapiens	29-35
29166835-3	2017	In the present study, we found that the intraperitoneal administration of oxaliplatin at 4 mg/kg for five consecutive days noticeably upregulated the expression of CXC motif ligand 12 (CXCL12) in the dorsal root ganglion, and the intrathecal injection of an anti-CXCL12 neutralizing antibody or CXCL12 siRNA attenuated the mechanical allodynia and thermal hyperalgesia induced by oxaliplatin.	Oxaliplatin	74-85	C-X-C motif chemokine ligand 12	Homo sapiens	185-191
28849713-6	2017	Further studies with chromatin immunoprecipitation found that oxaliplatin treatment increased the recruitment of NF-kappaB p65 to the CX3Cl1 promoter region.	Oxaliplatin	62-73	C-X3-C motif chemokine ligand 1	Homo sapiens	134-140
29166835-3	2017	In the present study, we found that the intraperitoneal administration of oxaliplatin at 4 mg/kg for five consecutive days noticeably upregulated the expression of CXC motif ligand 12 (CXCL12) in the dorsal root ganglion, and the intrathecal injection of an anti-CXCL12 neutralizing antibody or CXCL12 siRNA attenuated the mechanical allodynia and thermal hyperalgesia induced by oxaliplatin.	Oxaliplatin	74-85	C-X-C motif chemokine ligand 12	Homo sapiens	263-269
28849713-7	2017	Our results suggest that upregulation of CX3CL1 in dorsal root ganglion mediated by NF-kappaB activation contributes to the peripheral sensitization and chronic pain induced by oxaliplatin administration.	Oxaliplatin	177-188	C-X3-C motif chemokine ligand 1	Homo sapiens	41-47
28849713-7	2017	Our results suggest that upregulation of CX3CL1 in dorsal root ganglion mediated by NF-kappaB activation contributes to the peripheral sensitization and chronic pain induced by oxaliplatin administration.	Oxaliplatin	177-188	nuclear factor kappa B subunit 1	Homo sapiens	84-93
29166835-3	2017	In the present study, we found that the intraperitoneal administration of oxaliplatin at 4 mg/kg for five consecutive days noticeably upregulated the expression of CXC motif ligand 12 (CXCL12) in the dorsal root ganglion, and the intrathecal injection of an anti-CXCL12 neutralizing antibody or CXCL12 siRNA attenuated the mechanical allodynia and thermal hyperalgesia induced by oxaliplatin.	Oxaliplatin	74-85	C-X-C motif chemokine ligand 12	Homo sapiens	263-269
29166835-3	2017	In the present study, we found that the intraperitoneal administration of oxaliplatin at 4 mg/kg for five consecutive days noticeably upregulated the expression of CXC motif ligand 12 (CXCL12) in the dorsal root ganglion, and the intrathecal injection of an anti-CXCL12 neutralizing antibody or CXCL12 siRNA attenuated the mechanical allodynia and thermal hyperalgesia induced by oxaliplatin.	Oxaliplatin	380-391	C-X-C motif chemokine ligand 12	Homo sapiens	164-183
29166835-3	2017	In the present study, we found that the intraperitoneal administration of oxaliplatin at 4 mg/kg for five consecutive days noticeably upregulated the expression of CXC motif ligand 12 (CXCL12) in the dorsal root ganglion, and the intrathecal injection of an anti-CXCL12 neutralizing antibody or CXCL12 siRNA attenuated the mechanical allodynia and thermal hyperalgesia induced by oxaliplatin.	Oxaliplatin	380-391	C-X-C motif chemokine ligand 12	Homo sapiens	185-191
29166835-4	2017	We also found that the signal transducers and transcription activator 3 (STAT3) was activated in the dorsal root ganglion, and inhibition of STAT3 with S3I-201 or the injection of AAV-Cre-GFP into STAT3flox/flox mice prevented the upregulation of CXCL12 expression in the dorsal root ganglion and chronic pain following oxaliplatin administration.	Oxaliplatin	320-331	signal transducer and activator of transcription 3	Mus musculus	23-71
29166835-4	2017	We also found that the signal transducers and transcription activator 3 (STAT3) was activated in the dorsal root ganglion, and inhibition of STAT3 with S3I-201 or the injection of AAV-Cre-GFP into STAT3flox/flox mice prevented the upregulation of CXCL12 expression in the dorsal root ganglion and chronic pain following oxaliplatin administration.	Oxaliplatin	320-331	signal transducer and activator of transcription 3	Mus musculus	73-78
29166835-4	2017	We also found that the signal transducers and transcription activator 3 (STAT3) was activated in the dorsal root ganglion, and inhibition of STAT3 with S3I-201 or the injection of AAV-Cre-GFP into STAT3flox/flox mice prevented the upregulation of CXCL12 expression in the dorsal root ganglion and chronic pain following oxaliplatin administration.	Oxaliplatin	320-331	signal transducer and activator of transcription 3	Mus musculus	141-146
29166835-4	2017	We also found that the signal transducers and transcription activator 3 (STAT3) was activated in the dorsal root ganglion, and inhibition of STAT3 with S3I-201 or the injection of AAV-Cre-GFP into STAT3flox/flox mice prevented the upregulation of CXCL12 expression in the dorsal root ganglion and chronic pain following oxaliplatin administration.	Oxaliplatin	320-331	signal transducer and activator of transcription 3	Mus musculus	141-146
29166835-6	2017	Furthermore, the results of a chromatin immunoprecipitation assay revealed that p-STAT3 might be essential for oxaliplatin-induced CXCL12 upregulation via binding directly to the specific position of the CXCL12 gene promoter.	Oxaliplatin	111-122	signal transducer and activator of transcription 3	Homo sapiens	82-87
29166835-6	2017	Furthermore, the results of a chromatin immunoprecipitation assay revealed that p-STAT3 might be essential for oxaliplatin-induced CXCL12 upregulation via binding directly to the specific position of the CXCL12 gene promoter.	Oxaliplatin	111-122	C-X-C motif chemokine ligand 12	Homo sapiens	131-137
29166835-6	2017	Furthermore, the results of a chromatin immunoprecipitation assay revealed that p-STAT3 might be essential for oxaliplatin-induced CXCL12 upregulation via binding directly to the specific position of the CXCL12 gene promoter.	Oxaliplatin	111-122	C-X-C motif chemokine ligand 12	Homo sapiens	204-210
29166835-7	2017	Finally, we found that cytokine TNF-alpha and IL-1beta increases mediated the STAT3 activation following oxaliplatin treatment.	Oxaliplatin	105-116	tumor necrosis factor	Homo sapiens	32-41
29166835-7	2017	Finally, we found that cytokine TNF-alpha and IL-1beta increases mediated the STAT3 activation following oxaliplatin treatment.	Oxaliplatin	105-116	interleukin 1 beta	Homo sapiens	46-54
29166835-7	2017	Finally, we found that cytokine TNF-alpha and IL-1beta increases mediated the STAT3 activation following oxaliplatin treatment.	Oxaliplatin	105-116	signal transducer and activator of transcription 3	Homo sapiens	78-83
29166835-8	2017	Taken together, these findings suggested that the upregulation of CXCL12 via TNF-alpha/IL-1beta-dependent STAT3 activation contributes to oxaliplatin-induced chronic pain.	Oxaliplatin	138-149	C-X-C motif chemokine ligand 12	Homo sapiens	66-72
29166835-8	2017	Taken together, these findings suggested that the upregulation of CXCL12 via TNF-alpha/IL-1beta-dependent STAT3 activation contributes to oxaliplatin-induced chronic pain.	Oxaliplatin	138-149	tumor necrosis factor	Homo sapiens	77-86
29166835-8	2017	Taken together, these findings suggested that the upregulation of CXCL12 via TNF-alpha/IL-1beta-dependent STAT3 activation contributes to oxaliplatin-induced chronic pain.	Oxaliplatin	138-149	interleukin 1 beta	Homo sapiens	87-95
29166835-8	2017	Taken together, these findings suggested that the upregulation of CXCL12 via TNF-alpha/IL-1beta-dependent STAT3 activation contributes to oxaliplatin-induced chronic pain.	Oxaliplatin	138-149	signal transducer and activator of transcription 3	Homo sapiens	106-111
27904848-9	2016	CONCLUSION: siRNA-mediated down-regulation of livin gene expression could significantly suppress colon cancer growth and enhance the cytotoxic effects of anticancer drugs such as 5-FU and L-OHP.	Oxaliplatin	188-193	baculoviral IAP repeat containing 7	Homo sapiens	46-51
28004750-3	2016	Depletion of SNHG5 induces cell cycle arrest and apoptosis in vitro and limits tumour outgrowth in vivo, whereas SNHG5 overexpression counteracts oxaliplatin-induced apoptosis.	Oxaliplatin	146-157	small nucleolar RNA host gene 5	Homo sapiens	113-118
27671687-0	2016	Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.	Oxaliplatin	58-69	thymoma viral proto-oncogene 1	Mus musculus	102-105
27510316-5	2017	However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained.	Oxaliplatin	12-23	tachykinin receptor 1	Homo sapiens	80-92
28035331-7	2016	Immunogenic cell death marker high-mobility group box 1 protein (HMGB1) and adenosine triphosphate in culture medium were higher after Ad881 infection (24.3 ng/ml and 48.2 nmol/l, respectively) than after Ad884 infection (8.6 ng/ml and 15.4 nmol/l, respectively) or oxaliplatin treatment (3.7 ng/ml and 1.8 nmol/l, respectively).	Oxaliplatin	266-277	high mobility group box 1	Mus musculus	30-55
28035331-7	2016	Immunogenic cell death marker high-mobility group box 1 protein (HMGB1) and adenosine triphosphate in culture medium were higher after Ad881 infection (24.3 ng/ml and 48.2 nmol/l, respectively) than after Ad884 infection (8.6 ng/ml and 15.4 nmol/l, respectively) or oxaliplatin treatment (3.7 ng/ml and 1.8 nmol/l, respectively).	Oxaliplatin	266-277	high mobility group box 1	Mus musculus	65-70
27633443-0	2016	Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer.	Oxaliplatin	60-71	cytoskeleton regulator RNA	Homo sapiens	0-9
26697734-2	2016	Hence, the aim of the study was to prepare oxaliplatin solid lipid nanoparticles (OP-SLN) by microemulsion method optimizing it by Box-Behnken design and then covalently conjugated to TRAIL (CD-253) monoclonal antibody (TR-OP-SLN) for targeting colorectal cancer cells.	Oxaliplatin	43-54	TNF superfamily member 10	Homo sapiens	184-189
27671687-0	2016	Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.	Oxaliplatin	58-69	mechanistic target of rapamycin kinase	Mus musculus	106-110
27671687-5	2016	Co-treatment with OMT and OXA caused G0/G1 phase arrest by upregulating P21, P27 and downregulating cyclin D, and induced apoptosis through decreasing the expression of p-PI3K, p-AKT, p-mTOR, p-p70S6K.	Oxaliplatin	26-29	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	72-75
27671687-5	2016	Co-treatment with OMT and OXA caused G0/G1 phase arrest by upregulating P21, P27 and downregulating cyclin D, and induced apoptosis through decreasing the expression of p-PI3K, p-AKT, p-mTOR, p-p70S6K.	Oxaliplatin	26-29	cyclin-dependent kinase inhibitor 1B	Mus musculus	77-80
27671687-5	2016	Co-treatment with OMT and OXA caused G0/G1 phase arrest by upregulating P21, P27 and downregulating cyclin D, and induced apoptosis through decreasing the expression of p-PI3K, p-AKT, p-mTOR, p-p70S6K.	Oxaliplatin	26-29	thymoma viral proto-oncogene 1	Mus musculus	179-182
27671687-5	2016	Co-treatment with OMT and OXA caused G0/G1 phase arrest by upregulating P21, P27 and downregulating cyclin D, and induced apoptosis through decreasing the expression of p-PI3K, p-AKT, p-mTOR, p-p70S6K.	Oxaliplatin	26-29	mechanistic target of rapamycin kinase	Mus musculus	186-190
27671687-5	2016	Co-treatment with OMT and OXA caused G0/G1 phase arrest by upregulating P21, P27 and downregulating cyclin D, and induced apoptosis through decreasing the expression of p-PI3K, p-AKT, p-mTOR, p-p70S6K.	Oxaliplatin	26-29	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	194-200
27671687-6	2016	In addition, pretreatment with a specific PI3K/AKT activator (IGF-1) significantly neutralized the pro-apoptotic activity of OXA + OMT, demonstrating the important role of PI3K/AKT in this process.	Oxaliplatin	125-128	thymoma viral proto-oncogene 1	Mus musculus	47-50
27671687-6	2016	In addition, pretreatment with a specific PI3K/AKT activator (IGF-1) significantly neutralized the pro-apoptotic activity of OXA + OMT, demonstrating the important role of PI3K/AKT in this process.	Oxaliplatin	125-128	insulin-like growth factor 1	Mus musculus	62-67
27671687-6	2016	In addition, pretreatment with a specific PI3K/AKT activator (IGF-1) significantly neutralized the pro-apoptotic activity of OXA + OMT, demonstrating the important role of PI3K/AKT in this process.	Oxaliplatin	125-128	thymoma viral proto-oncogene 1	Mus musculus	177-180
27671687-9	2016	In conclusion, our findings highlight that the combination therapy with OMT and OXA exerted synergistic antitumor effects in colon cancer cells through PI3K/AKT/mTOR pathway and combination treatment with OMT and OXA would be a promising therapeutic strategy for colon carcinoma treatment.	Oxaliplatin	80-83	thymoma viral proto-oncogene 1	Mus musculus	157-160
27671687-9	2016	In conclusion, our findings highlight that the combination therapy with OMT and OXA exerted synergistic antitumor effects in colon cancer cells through PI3K/AKT/mTOR pathway and combination treatment with OMT and OXA would be a promising therapeutic strategy for colon carcinoma treatment.	Oxaliplatin	80-83	mechanistic target of rapamycin kinase	Mus musculus	161-165
27546011-0	2016	Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment?	Oxaliplatin	21-32	cancer antigen 1	Homo sapiens	85-88
27633443-2	2016	This study showed that a novel lncRNA, long intergenic noncoding RNA 152 (Linc00152 ), promoted tumor progression and conferred resistance to oxaliplatin (L-OHP)-induced apoptosis in vitro and in vivo.	Oxaliplatin	142-153	cytoskeleton regulator RNA	Homo sapiens	74-83
27633443-2	2016	This study showed that a novel lncRNA, long intergenic noncoding RNA 152 (Linc00152 ), promoted tumor progression and conferred resistance to oxaliplatin (L-OHP)-induced apoptosis in vitro and in vivo.	Oxaliplatin	155-160	cytoskeleton regulator RNA	Homo sapiens	74-83
27633443-4	2016	Knockdown of ERBB4 in colon cancer cells decreased AKT phosphorylation, which resulted in decreased L-OHP resistance.	Oxaliplatin	100-105	erb-b2 receptor tyrosine kinase 4	Homo sapiens	13-18
27633443-4	2016	Knockdown of ERBB4 in colon cancer cells decreased AKT phosphorylation, which resulted in decreased L-OHP resistance.	Oxaliplatin	100-105	AKT serine/threonine kinase 1	Homo sapiens	51-54
27633443-5	2016	Consistent with above findings, the specific AKT signaling inhibitor and activator were used, respectively, which demonstrated that Linc00152 contributed to L-OHP resistance at least partly through activating AKT pathway.	Oxaliplatin	157-162	cytoskeleton regulator RNA	Homo sapiens	132-141
27633443-5	2016	Consistent with above findings, the specific AKT signaling inhibitor and activator were used, respectively, which demonstrated that Linc00152 contributed to L-OHP resistance at least partly through activating AKT pathway.	Oxaliplatin	157-162	AKT serine/threonine kinase 1	Homo sapiens	209-212
27633443-6	2016	Further studies indicated that Linc00152 was increased and appeared to be an independent prognostic factor for decreased survival and increased disease recurrence in stage II and III colon cancer patients undergoing L-OHP-based chemotherapy after surgery.	Oxaliplatin	216-221	cytoskeleton regulator RNA	Homo sapiens	31-40
27748887-0	2016	Gefitinib enhances oxaliplatin-induced apoptosis mediated by Src and PKC-modulated gap junction function.	Oxaliplatin	19-30	Rous sarcoma oncogene	Mus musculus	61-64
27748887-6	2016	Furthermore, the ratio of Bcl-2/Bax and the cleavage of caspase-3 and -9 were increased by gefitinib during oxaliplatin-induced apoptosis.	Oxaliplatin	108-119	B cell leukemia/lymphoma 2	Mus musculus	26-31
27748887-6	2016	Furthermore, the ratio of Bcl-2/Bax and the cleavage of caspase-3 and -9 were increased by gefitinib during oxaliplatin-induced apoptosis.	Oxaliplatin	108-119	BCL2-associated X protein	Mus musculus	32-35
27748887-6	2016	Furthermore, the ratio of Bcl-2/Bax and the cleavage of caspase-3 and -9 were increased by gefitinib during oxaliplatin-induced apoptosis.	Oxaliplatin	108-119	caspase 3	Mus musculus	56-72
28101205-9	2016	In microsatellite stable SW480 cells, MSH2 levels markedly increased in the nucleus following 150 microM oxaliplatin treatment for 3 days.	Oxaliplatin	105-116	mutS homolog 2	Homo sapiens	38-42
27779719-0	2016	Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy.	Oxaliplatin	74-79	YEATS domain containing 4	Homo sapiens	18-24
27748887-7	2016	The oxaliplatin-induced apoptosis was enhanced through the upregulation of gap junction (GJ) channels composed of connexin 43 (Cx43) by gefitinib.	Oxaliplatin	4-15	gap junction protein, alpha 1	Mus musculus	114-125
27779719-10	2016	Furthermore, YEATS4 overexpression without the 3"-untranslated region (3"-UTR) restored miR-218-inhibited YEATS4 and LC3 II expression, and abolished miR-218-stimulated cell viability loss and cell apoptosis increase in response to L-OHP.	Oxaliplatin	232-237	YEATS domain containing 4	Homo sapiens	13-19
27779719-11	2016	In conclusion, miR-218 sensitized HCT-116/L-OHP cells to L-OHP-induced cell apoptosis via inhibition of cytoprotective autophagy by targeting YEATS4 expression.	Oxaliplatin	42-47	YEATS domain containing 4	Homo sapiens	142-148
28101205-11	2016	The results of the present study suggest that it is important to identify patients with CRC who may benefit from adjuvant chemotherapy with 5-FU or oxaliplatin, particularly CRC patients with MSS and mutated KRAS or BRAF, who have poorer overall survival rates than patients with microsatellite instability.	Oxaliplatin	148-159	KRAS proto-oncogene, GTPase	Homo sapiens	208-212
28101205-11	2016	The results of the present study suggest that it is important to identify patients with CRC who may benefit from adjuvant chemotherapy with 5-FU or oxaliplatin, particularly CRC patients with MSS and mutated KRAS or BRAF, who have poorer overall survival rates than patients with microsatellite instability.	Oxaliplatin	148-159	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	216-220
28101212-7	2016	Furthermore, PPC stimulated the growth of SGC-7901 cells and greatly promoted their apoptosis induced by L-OHP, which was supported by the upregulation of cytochrome c and the downstream activation of caspases 3 and 9.	Oxaliplatin	105-110	cytochrome c, somatic	Homo sapiens	155-167
27748887-7	2016	The oxaliplatin-induced apoptosis was enhanced through the upregulation of gap junction (GJ) channels composed of connexin 43 (Cx43) by gefitinib.	Oxaliplatin	4-15	gap junction protein, alpha 1	Mus musculus	127-131
28101212-8	2016	Finally, following treatment with a combination of PPC and L-OHP, the expression of cyclins D1 and E was downregulated; however, PPC did not alter the production of reactive oxygen species caused by L-OHP (P=0.88).	Oxaliplatin	59-64	cyclin D1	Homo sapiens	84-100
28074043-0	2016	Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.	Oxaliplatin	92-103	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	25-28
27942212-11	2016	Furthermore, tumor growth in CT26 tumor-bearing mice given the oral OXA/DCK- and 5-FU-loaded nanoemulsion was maximally inhibited by 73.9%, 48.5%, and 38.1%, compared with tumor volumes in the control group and the oral OXA and 5-FU groups, respectively.	Oxaliplatin	68-71	deoxycytidine kinase	Mus musculus	72-75
27942212-4	2016	We constructed an ion-pairing complex of OXA with a deoxycholic acid derivative (Nalpha-deoxycholyl-l-lysyl-methylester, DCK) (OXA/DCK) as a permeation enhancer.	Oxaliplatin	41-44	deoxycytidine kinase	Homo sapiens	121-124
27942212-4	2016	We constructed an ion-pairing complex of OXA with a deoxycholic acid derivative (Nalpha-deoxycholyl-l-lysyl-methylester, DCK) (OXA/DCK) as a permeation enhancer.	Oxaliplatin	41-44	deoxycytidine kinase	Homo sapiens	131-134
27942212-10	2016	The oral absorption of OXA/DCK and 5-FU from the nanoemulsion also increased significantly, and the resulting oral bioavailability values of OXA/DCK and 5-FU in the nanoemulsive system were 9.19- and 1.39-fold higher than those of free OXA and 5-FU, respectively.	Oxaliplatin	23-26	deoxycytidine kinase	Mus musculus	145-148
27942212-10	2016	The oral absorption of OXA/DCK and 5-FU from the nanoemulsion also increased significantly, and the resulting oral bioavailability values of OXA/DCK and 5-FU in the nanoemulsive system were 9.19- and 1.39-fold higher than those of free OXA and 5-FU, respectively.	Oxaliplatin	141-144	deoxycytidine kinase	Mus musculus	27-30
28074043-0	2016	Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.	Oxaliplatin	92-103	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	142-145
27295176-0	2016	Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles.	Oxaliplatin	32-43	TNF receptor superfamily member 10b	Homo sapiens	69-72
27851963-2	2016	DNA damage promoted by oxaliplatin increases the level of pro-apoptotic Bcl-xS in an ATM/CHK2-dependent manner, but how this shift is enforced is not known.	Oxaliplatin	23-34	ATM serine/threonine kinase	Homo sapiens	85-88
27851963-2	2016	DNA damage promoted by oxaliplatin increases the level of pro-apoptotic Bcl-xS in an ATM/CHK2-dependent manner, but how this shift is enforced is not known.	Oxaliplatin	23-34	checkpoint kinase 2	Homo sapiens	89-93
27851963-4	2016	Oxaliplatin abrogates the interaction of SRSF10 with hnRNP F/H and decreases the association of SRSF10 and hnRNP K with the Bcl-x pre-mRNA.	Oxaliplatin	0-11	serine and arginine rich splicing factor 10	Homo sapiens	41-47
27851963-4	2016	Oxaliplatin abrogates the interaction of SRSF10 with hnRNP F/H and decreases the association of SRSF10 and hnRNP K with the Bcl-x pre-mRNA.	Oxaliplatin	0-11	heterogeneous nuclear ribonucleoprotein F	Homo sapiens	53-60
27851963-4	2016	Oxaliplatin abrogates the interaction of SRSF10 with hnRNP F/H and decreases the association of SRSF10 and hnRNP K with the Bcl-x pre-mRNA.	Oxaliplatin	0-11	serine and arginine rich splicing factor 10	Homo sapiens	96-102
27851963-4	2016	Oxaliplatin abrogates the interaction of SRSF10 with hnRNP F/H and decreases the association of SRSF10 and hnRNP K with the Bcl-x pre-mRNA.	Oxaliplatin	0-11	heterogeneous nuclear ribonucleoprotein K	Homo sapiens	107-114
27851963-4	2016	Oxaliplatin abrogates the interaction of SRSF10 with hnRNP F/H and decreases the association of SRSF10 and hnRNP K with the Bcl-x pre-mRNA.	Oxaliplatin	0-11	BCL2 like 1	Homo sapiens	124-129
27882231-5	2016	The two L-OHP-resistant sublines showed cross resistance to CDDP and L-OHP, and a decreased expression of OCT6.	Oxaliplatin	8-13	solute carrier family 22 member 16	Homo sapiens	106-110
27882231-8	2016	Using the PC-14/CDDP cell line engineered to overexpress OCT6, we confirmed that the intracellular L-OHP concentration was increased concomitantly with OCT6 overexpression compared with the parental cell line.	Oxaliplatin	99-104	solute carrier family 22 member 16	Homo sapiens	57-61
27882085-0	2016	Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer.	Oxaliplatin	61-72	kallikrein related peptidase 11	Homo sapiens	13-18
27882085-3	2016	The aim of the present study was to investigate the role of KLK11 and the effects of KLK11 on oxaliplatin (L-OHP) chemosensitivity by knocking down KLK11 in LOVO and HCT-8 cells.	Oxaliplatin	94-105	kallikrein related peptidase 11	Homo sapiens	85-90
27882085-3	2016	The aim of the present study was to investigate the role of KLK11 and the effects of KLK11 on oxaliplatin (L-OHP) chemosensitivity by knocking down KLK11 in LOVO and HCT-8 cells.	Oxaliplatin	94-105	kallikrein related peptidase 11	Homo sapiens	85-90
27882085-6	2016	KLK11 inhibition of increased L-OHP-induced apoptosis may be associated with activation of caspase-3 cleavage and the apoptosis signaling pathway.	Oxaliplatin	30-35	kallikrein related peptidase 11	Homo sapiens	0-5
27882085-6	2016	KLK11 inhibition of increased L-OHP-induced apoptosis may be associated with activation of caspase-3 cleavage and the apoptosis signaling pathway.	Oxaliplatin	30-35	caspase 3	Homo sapiens	91-100
27644195-0	2016	Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN.	Oxaliplatin	53-64	phosphatase and tensin homolog	Homo sapiens	127-131
26524393-6	2016	The results of this study revealed that 2-DG conjugated platinum (II) complexes are GLUT1 transportable substrates and exhibit improved cytotoxicities in cancer cell lines that over express GLUT1 when compared to the clinical drug, Oxaliplatin.	Oxaliplatin	232-243	solute carrier family 2 member 1	Homo sapiens	190-195
28133108-1	2016	We report a case of pathological complete response after neoadjuvant chemotherapy(NAC)(S-1 plus oxaliplatin)for rectal cancer.	Oxaliplatin	96-107	synuclein alpha	Homo sapiens	82-85
27774979-12	2016	Silencing of HMGB3 enhanced sensitive to cisplatin and paclitaxel, and reduced sensitive to oxaliplatin.	Oxaliplatin	92-103	high mobility group box 3	Homo sapiens	13-18
27748862-0	2016	Gap junction composed of connexin43 modulates 5-fluorouracil, oxaliplatin and irinotecan resistance on colorectal cancers.	Oxaliplatin	62-73	gap junction protein alpha 1	Homo sapiens	25-35
27748862-4	2016	The current study investigated the effects of connexin43 (Cx43) gap junctions on 5-fluorouracil (5-FU), oxaliplatin and irinotecan in colon cancer cells.	Oxaliplatin	104-115	gap junction protein alpha 1	Homo sapiens	58-62
27748862-7	2016	Downregulation of Cx43 gap junction functioning attenuated 5-FU, oxaliplatin and irinotecan toxicity in colon cancer cells, which was increased in cells treated with a Cx43 gap junction function enhancer.	Oxaliplatin	65-76	gap junction protein alpha 1	Homo sapiens	18-22
27748862-7	2016	Downregulation of Cx43 gap junction functioning attenuated 5-FU, oxaliplatin and irinotecan toxicity in colon cancer cells, which was increased in cells treated with a Cx43 gap junction function enhancer.	Oxaliplatin	65-76	gap junction protein alpha 1	Homo sapiens	168-172
27899980-0	2016	Treatment effects of oxaliplatin combined with gemcitabine on colorectal cancer and its influence on HMGB1 expression.	Oxaliplatin	21-32	high mobility group box 1	Homo sapiens	101-106
27899980-1	2016	In the present study, we analyzed the supra-additive effect of oxaliplatin in combination with gemcitabine on terminal colorectal cancer and its influence on high-mobility group box 1 (HMGB1) expression.	Oxaliplatin	63-74	high mobility group box 1	Homo sapiens	158-183
27899980-1	2016	In the present study, we analyzed the supra-additive effect of oxaliplatin in combination with gemcitabine on terminal colorectal cancer and its influence on high-mobility group box 1 (HMGB1) expression.	Oxaliplatin	63-74	high mobility group box 1	Homo sapiens	185-190
27899980-12	2016	We conclude that the reduced expression rate of HMGB1 in terminal colorectal cancer cases was probably related to the effects of oxaliplatin combined with gemcitabine.	Oxaliplatin	129-140	high mobility group box 1	Homo sapiens	48-53
28375128-1	2016	To investigate the combined effects of indomethacin and oxaliplatin on expressions of epidermal growth factor receptor (EGFR), E-cadherin (E-cad), intercellular adhesion molecule-1 (ICAM-1) and CD44v6 related to lymph node metastasis of human lung cancer cell lines.	Oxaliplatin	56-67	epidermal growth factor receptor	Homo sapiens	86-118
28375128-1	2016	To investigate the combined effects of indomethacin and oxaliplatin on expressions of epidermal growth factor receptor (EGFR), E-cadherin (E-cad), intercellular adhesion molecule-1 (ICAM-1) and CD44v6 related to lymph node metastasis of human lung cancer cell lines.	Oxaliplatin	56-67	epidermal growth factor receptor	Homo sapiens	120-124
28375128-1	2016	To investigate the combined effects of indomethacin and oxaliplatin on expressions of epidermal growth factor receptor (EGFR), E-cadherin (E-cad), intercellular adhesion molecule-1 (ICAM-1) and CD44v6 related to lymph node metastasis of human lung cancer cell lines.	Oxaliplatin	56-67	cadherin 1	Homo sapiens	127-132
28375128-6	2016	Compared to control group, the protein and mRNA expressions of EGFR, ICAM-1 and CD44v6 in the indomethacin, oxaliplatin, and combination therapy groups were significantly reduced (P&lt;0.05) and the protein and mRNA expressions of E-cad expression were significantly increased (P&lt;0.05).	Oxaliplatin	108-119	epidermal growth factor receptor	Homo sapiens	63-67
28375128-6	2016	Compared to control group, the protein and mRNA expressions of EGFR, ICAM-1 and CD44v6 in the indomethacin, oxaliplatin, and combination therapy groups were significantly reduced (P&lt;0.05) and the protein and mRNA expressions of E-cad expression were significantly increased (P&lt;0.05).	Oxaliplatin	108-119	intercellular adhesion molecule 1	Homo sapiens	69-75
28375128-6	2016	Compared to control group, the protein and mRNA expressions of EGFR, ICAM-1 and CD44v6 in the indomethacin, oxaliplatin, and combination therapy groups were significantly reduced (P&lt;0.05) and the protein and mRNA expressions of E-cad expression were significantly increased (P&lt;0.05).	Oxaliplatin	108-119	cadherin 1	Homo sapiens	231-236
28375128-7	2016	Compared to indomethacin group and oxaliplatin group, the protein and mRNA expressions of EGFR, ICAM-1 and CD44v6 in combination therapy groups were significantly reduced (P&lt;0.05), and the protein and mRNA expressions of E-cad expression were significantly increased (P&lt;0.05).	Oxaliplatin	35-46	epidermal growth factor receptor	Homo sapiens	90-94
28375128-7	2016	Compared to indomethacin group and oxaliplatin group, the protein and mRNA expressions of EGFR, ICAM-1 and CD44v6 in combination therapy groups were significantly reduced (P&lt;0.05), and the protein and mRNA expressions of E-cad expression were significantly increased (P&lt;0.05).	Oxaliplatin	35-46	intercellular adhesion molecule 1	Homo sapiens	96-102
28375128-7	2016	Compared to indomethacin group and oxaliplatin group, the protein and mRNA expressions of EGFR, ICAM-1 and CD44v6 in combination therapy groups were significantly reduced (P&lt;0.05), and the protein and mRNA expressions of E-cad expression were significantly increased (P&lt;0.05).	Oxaliplatin	35-46	cadherin 1	Homo sapiens	224-229
27822036-3	2016	Recently, we have reported that metronomic S-1, orally available tegafur formulation, dosing synergistically augmented the therapeutic efficacy of oxaliplatin (l-OHP)-containing PEGylated liposome without increasing the toxicity in animal model.	Oxaliplatin	147-158	proteasome 26S subunit, non-ATPase 1	Homo sapiens	43-46
27822036-3	2016	Recently, we have reported that metronomic S-1, orally available tegafur formulation, dosing synergistically augmented the therapeutic efficacy of oxaliplatin (l-OHP)-containing PEGylated liposome without increasing the toxicity in animal model.	Oxaliplatin	160-165	proteasome 26S subunit, non-ATPase 1	Homo sapiens	43-46
27895768-1	2016	The present study aimed to investigate the interaction between miR-196 and its target gene homeobox B8 (HoxB8) in colorectal cancer (CRC) cells, and the sensitivity of miR-196 and HoxB8 to fluorouracil, leucovorin and oxaliplatin (FOLFOX4) chemotherapy (1,200 mg/m2 fluorouracil, 200 mg/m2 leucovorin and 85 mg/m2 oxaliplatin).	Oxaliplatin	218-229	homeobox B8	Homo sapiens	91-102
27895768-1	2016	The present study aimed to investigate the interaction between miR-196 and its target gene homeobox B8 (HoxB8) in colorectal cancer (CRC) cells, and the sensitivity of miR-196 and HoxB8 to fluorouracil, leucovorin and oxaliplatin (FOLFOX4) chemotherapy (1,200 mg/m2 fluorouracil, 200 mg/m2 leucovorin and 85 mg/m2 oxaliplatin).	Oxaliplatin	218-229	homeobox B8	Homo sapiens	104-109
27895768-1	2016	The present study aimed to investigate the interaction between miR-196 and its target gene homeobox B8 (HoxB8) in colorectal cancer (CRC) cells, and the sensitivity of miR-196 and HoxB8 to fluorouracil, leucovorin and oxaliplatin (FOLFOX4) chemotherapy (1,200 mg/m2 fluorouracil, 200 mg/m2 leucovorin and 85 mg/m2 oxaliplatin).	Oxaliplatin	314-325	homeobox B8	Homo sapiens	91-102
27895768-1	2016	The present study aimed to investigate the interaction between miR-196 and its target gene homeobox B8 (HoxB8) in colorectal cancer (CRC) cells, and the sensitivity of miR-196 and HoxB8 to fluorouracil, leucovorin and oxaliplatin (FOLFOX4) chemotherapy (1,200 mg/m2 fluorouracil, 200 mg/m2 leucovorin and 85 mg/m2 oxaliplatin).	Oxaliplatin	314-325	homeobox B8	Homo sapiens	104-109
27613096-4	2016	Knockdown of hHR23A decreased cell growth and increased the resistance in A549 cells to the DNA-damaging agents, cisplatin and oxaliplatin.	Oxaliplatin	127-138	RAD23 homolog A, nucleotide excision repair protein	Homo sapiens	13-19
27877224-6	2016	Results: We found that DDP-resistant cell sublines EC109/DDP (8.490 folds) showed cross-resistance to carboplatin (5.27 folds) and oxaliplatin (4.12 folds).	Oxaliplatin	131-142	translocase of inner mitochondrial membrane 8A	Homo sapiens	23-26
27877224-6	2016	Results: We found that DDP-resistant cell sublines EC109/DDP (8.490 folds) showed cross-resistance to carboplatin (5.27 folds) and oxaliplatin (4.12 folds).	Oxaliplatin	131-142	translocase of inner mitochondrial membrane 8A	Homo sapiens	57-60
27760932-8	2016	So far, 2 courses of S-1 plus CDDP or 3 courses of S-1 plus oxaliplatin can be recommended as candidates for the test arm of future phase III studies of NAC.	Oxaliplatin	60-71	synuclein alpha	Homo sapiens	153-156
27821910-0	2016	Celecoxib alleviates oxaliplatin-induced hyperalgesia through inhibition of spinal ERK1/2 signaling.	Oxaliplatin	21-32	mitogen-activated protein kinase 3	Homo sapiens	83-89
27821910-4	2016	Our previous data showed that Akt2 in the dorsal root ganglion (DRG) participated in the regulation of OXA-induced neuropathic pain.	Oxaliplatin	103-106	AKT serine/threonine kinase 2	Homo sapiens	30-34
27821910-5	2016	But it is still unclear whether spinal ERK1/2 signaling is involved in the regulation of OXA-induced hyperalgesia, and the linkage between COX-2 and ERK1/2 signaling in mediating OXA-induced hyperalgesia also remains unclear.	Oxaliplatin	179-182	prostaglandin-endoperoxide synthase 2	Homo sapiens	139-144
27821910-5	2016	But it is still unclear whether spinal ERK1/2 signaling is involved in the regulation of OXA-induced hyperalgesia, and the linkage between COX-2 and ERK1/2 signaling in mediating OXA-induced hyperalgesia also remains unclear.	Oxaliplatin	179-182	mitogen-activated protein kinase 3	Homo sapiens	149-155
27821910-10	2016	Administration of celecoxib for 7 days suppressed the increase in expression of COX-2 and pERK1/2 induced by OXA.	Oxaliplatin	109-112	prostaglandin-endoperoxide synthase 2	Homo sapiens	80-85
27821910-11	2016	Our findings suggested that COX-2 and ERK1/2 signaling in spinal cord contributed to the OXA-induced neuropathic pain.	Oxaliplatin	89-92	prostaglandin-endoperoxide synthase 2	Homo sapiens	28-33
27821910-11	2016	Our findings suggested that COX-2 and ERK1/2 signaling in spinal cord contributed to the OXA-induced neuropathic pain.	Oxaliplatin	89-92	mitogen-activated protein kinase 3	Homo sapiens	38-44
27573002-7	2016	Moreover, the overexpression of TRIM32 in cells accelerated the G1-S phase transition, promoted cell proliferation rates, and induced the resistance of HCC patients to oxaliplatin.	Oxaliplatin	168-179	tripartite motif containing 32	Homo sapiens	32-38
27498955-0	2016	Kidney cancer: OCT2 demethylation cracks open oxaliplatin resistance.	Oxaliplatin	46-57	POU class 2 homeobox 2	Homo sapiens	15-19
27723906-0	2016	AFP-producing adenocarcinoma of the esophagogastric junction: report of a case with atypical immunohistochemical findings responding to palliative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT regime).	Oxaliplatin	193-204	alpha fetoprotein	Homo sapiens	0-3
27468920-13	2016	CONCLUSIONS: Combination therapy with cetuximab and S-1 was effective and well tolerated in patients with irinotecan-, oxaliplatin-, and fluoropyrimidine-refractory metastatic colorectal cancer.	Oxaliplatin	119-130	proteasome 26S subunit, non-ATPase 1	Homo sapiens	52-55
27322737-7	2016	Furthermore, nafamostat mesilate could reverse oxaliplatin induced NF-kappaB and Erk activation in CRC cells, and enhance the sensitivity of CRC cells to oxaliplatin.	Oxaliplatin	47-58	nuclear factor kappa B subunit 1	Homo sapiens	67-76
27322737-7	2016	Furthermore, nafamostat mesilate could reverse oxaliplatin induced NF-kappaB and Erk activation in CRC cells, and enhance the sensitivity of CRC cells to oxaliplatin.	Oxaliplatin	47-58	mitogen-activated protein kinase 1	Homo sapiens	81-84
27657030-6	2016	WECC at 200 mg/kg significantly suppressed the activation of astrocytes and microglia and decreased the expression levels of IL-1beta and TNF in the spinal cord after injection with oxaliplatin.	Oxaliplatin	182-193	interleukin 1 beta	Rattus norvegicus	125-133
27657030-6	2016	WECC at 200 mg/kg significantly suppressed the activation of astrocytes and microglia and decreased the expression levels of IL-1beta and TNF in the spinal cord after injection with oxaliplatin.	Oxaliplatin	182-193	tumor necrosis factor	Rattus norvegicus	138-141
27456785-4	2016	We then showed that structurally diverse ERbeta-selective agonists also relieved allodynia in CINP caused by taxol, oxaliplatin, and vincristine.	Oxaliplatin	116-127	estrogen receptor 2	Homo sapiens	41-47
27609465-0	2016	Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines.	Oxaliplatin	26-37	cytochrome P450 family 2 subfamily S member 1	Homo sapiens	16-22
27609465-0	2016	Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines.	Oxaliplatin	26-37	tumor protein p53	Homo sapiens	57-60
27609465-3	2016	In the present study, oxaliplatin was found to strongly inhibit the growth of HCT116 cells harboring wild-type p53 but to only weakly inhibit SW480 cells, HT29 cells or p53-/- HCT116 cells, which all lack p53 expression.	Oxaliplatin	22-33	tumor protein p53	Homo sapiens	111-114
27609465-3	2016	In the present study, oxaliplatin was found to strongly inhibit the growth of HCT116 cells harboring wild-type p53 but to only weakly inhibit SW480 cells, HT29 cells or p53-/- HCT116 cells, which all lack p53 expression.	Oxaliplatin	22-33	tumor protein p53	Homo sapiens	169-172
27609465-3	2016	In the present study, oxaliplatin was found to strongly inhibit the growth of HCT116 cells harboring wild-type p53 but to only weakly inhibit SW480 cells, HT29 cells or p53-/- HCT116 cells, which all lack p53 expression.	Oxaliplatin	22-33	tumor protein p53	Homo sapiens	169-172
27609465-4	2016	Administration of oxaliplatin significantly induced p53 accumulation and enhanced expression of CYP2S1 in HCT116 cells with wild-type p53.	Oxaliplatin	18-29	tumor protein p53	Homo sapiens	52-55
27609465-4	2016	Administration of oxaliplatin significantly induced p53 accumulation and enhanced expression of CYP2S1 in HCT116 cells with wild-type p53.	Oxaliplatin	18-29	cytochrome P450 family 2 subfamily S member 1	Homo sapiens	96-102
27609465-4	2016	Administration of oxaliplatin significantly induced p53 accumulation and enhanced expression of CYP2S1 in HCT116 cells with wild-type p53.	Oxaliplatin	18-29	tumor protein p53	Homo sapiens	134-137
27609465-5	2016	CYP2S1 knockdown conferred a cell survival advantage after oxaliplatin treatment to cells harboring wild-type p53 in vitro and in vivo.	Oxaliplatin	59-70	cytochrome P450 family 2 subfamily S member 1	Homo sapiens	0-6
27609465-6	2016	Interestingly, enzyme immunoassays, TOPFlash/FOPFlash reporter activity assays and western blotting analysis demonstrated oxaliplatin-mediated downregulation of PGE2 and Wnt/beta-catenin signaling in a manner dependent on p53.	Oxaliplatin	122-133	catenin beta 1	Homo sapiens	174-186
27609465-6	2016	Interestingly, enzyme immunoassays, TOPFlash/FOPFlash reporter activity assays and western blotting analysis demonstrated oxaliplatin-mediated downregulation of PGE2 and Wnt/beta-catenin signaling in a manner dependent on p53.	Oxaliplatin	122-133	tumor protein p53	Homo sapiens	222-225
27609465-7	2016	Moreover, oxaliplatin treatment of mice with subcutaneous tumor xenografts drastically reduced the volume of wild-type p53 HCT116 tumors but had no effect on isogenic p53-/- HCT116 tumors.	Oxaliplatin	10-21	transformation related protein 53, pseudogene	Mus musculus	119-122
27609465-8	2016	These results suggest that oxaliplatin exerts its inhibitory effects in human CRC cells via upregulation of CYP2S1 expression in a p53-dependent manner.	Oxaliplatin	27-38	cytochrome P450 family 2 subfamily S member 1	Homo sapiens	108-114
27609465-8	2016	These results suggest that oxaliplatin exerts its inhibitory effects in human CRC cells via upregulation of CYP2S1 expression in a p53-dependent manner.	Oxaliplatin	27-38	tumor protein p53	Homo sapiens	131-134
27245421-0	2016	Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by upregulating P-glycoprotein.	Oxaliplatin	24-35	stanniocalcin 2	Homo sapiens	0-15
27245421-0	2016	Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by upregulating P-glycoprotein.	Oxaliplatin	24-35	ATP binding cassette subfamily B member 1	Homo sapiens	90-104
27245421-4	2016	STC2 knockdown sensitized chemoresistant CRC cells to oxaliplatin.	Oxaliplatin	54-65	stanniocalcin 2	Homo sapiens	0-4
27245421-5	2016	Moreover, the expression of exogenous STC2 in chemonaive CRC cells induced oxaliplatin resistance.	Oxaliplatin	75-86	stanniocalcin 2	Homo sapiens	38-42
27245421-8	2016	To our knowledge, this is the first report to demonstrate the induction of oxaliplatin resistance in CRC cells in response to STC2 stimulation of P-gp via the PI3K/Akt signaling pathway.	Oxaliplatin	75-86	stanniocalcin 2	Homo sapiens	126-130
27245421-8	2016	To our knowledge, this is the first report to demonstrate the induction of oxaliplatin resistance in CRC cells in response to STC2 stimulation of P-gp via the PI3K/Akt signaling pathway.	Oxaliplatin	75-86	ATP binding cassette subfamily B member 1	Homo sapiens	146-150
27245421-8	2016	To our knowledge, this is the first report to demonstrate the induction of oxaliplatin resistance in CRC cells in response to STC2 stimulation of P-gp via the PI3K/Akt signaling pathway.	Oxaliplatin	75-86	AKT serine/threonine kinase 1	Homo sapiens	164-167
27526785-0	2016	miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells.	Oxaliplatin	21-32	mitogen-activated protein kinase kinase 6	Homo sapiens	57-63
27530650-5	2016	Synergy between oxaliplatin and pyrolipid-induced PDT kills tumour cells and provokes an immune response, resulting in calreticulin exposure on the cell surface, antitumour vaccination and an abscopal effect.	Oxaliplatin	16-27	calreticulin	Homo sapiens	119-131
27602102-1	2016	The current study aimed to determine the association between protein kinase Calpha (PKCalpha) and Kirsten rat sarcoma viral oncogene homolog (KRAS) expression and the response to folinic acid, 5-fluorouracil and oxaliplatin (FOLFOX regimen) in patients with colorectal cancer (CRC).	Oxaliplatin	212-223	protein kinase C, alpha	Rattus norvegicus	61-82
27602102-1	2016	The current study aimed to determine the association between protein kinase Calpha (PKCalpha) and Kirsten rat sarcoma viral oncogene homolog (KRAS) expression and the response to folinic acid, 5-fluorouracil and oxaliplatin (FOLFOX regimen) in patients with colorectal cancer (CRC).	Oxaliplatin	212-223	protein kinase C, alpha	Rattus norvegicus	84-92
27602102-1	2016	The current study aimed to determine the association between protein kinase Calpha (PKCalpha) and Kirsten rat sarcoma viral oncogene homolog (KRAS) expression and the response to folinic acid, 5-fluorouracil and oxaliplatin (FOLFOX regimen) in patients with colorectal cancer (CRC).	Oxaliplatin	212-223	KRAS proto-oncogene, GTPase	Rattus norvegicus	142-146
27526785-0	2016	miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells.	Oxaliplatin	21-32	mitogen-activated protein kinase 14	Homo sapiens	64-67
27526785-4	2016	We show that the p38 MAPK activator MAP2K6 is a direct target of miR-625-3p, and, accordingly, is downregulated in non-responder patients of oxaliplatin therapy.	Oxaliplatin	141-152	mitogen-activated protein kinase 14	Homo sapiens	17-20
27526785-4	2016	We show that the p38 MAPK activator MAP2K6 is a direct target of miR-625-3p, and, accordingly, is downregulated in non-responder patients of oxaliplatin therapy.	Oxaliplatin	141-152	mitogen-activated protein kinase kinase 6	Homo sapiens	36-42
27526785-6	2016	In addition, reduction of p38 signalling by using siRNAs, chemical inhibitors or expression of a dominant-negative MAP2K6 protein induces resistance to oxaliplatin.	Oxaliplatin	152-163	mitogen-activated protein kinase 14	Homo sapiens	26-29
27526785-6	2016	In addition, reduction of p38 signalling by using siRNAs, chemical inhibitors or expression of a dominant-negative MAP2K6 protein induces resistance to oxaliplatin.	Oxaliplatin	152-163	mitogen-activated protein kinase kinase 6	Homo sapiens	115-121
27526785-7	2016	Transcriptome, proteome and phosphoproteome profiles confirm inactivation of MAP2K6-p38 signalling as one likely mechanism of oxaliplatin resistance.	Oxaliplatin	126-137	mitogen-activated protein kinase kinase 6	Homo sapiens	77-83
27526785-7	2016	Transcriptome, proteome and phosphoproteome profiles confirm inactivation of MAP2K6-p38 signalling as one likely mechanism of oxaliplatin resistance.	Oxaliplatin	126-137	mitogen-activated protein kinase 14	Homo sapiens	84-87
27526785-8	2016	Our study shows that miR-625-3p induces oxaliplatin resistance by abrogating MAP2K6-p38-regulated apoptosis and cell cycle control networks, and corroborates the predictive power of miR-625-3p.	Oxaliplatin	40-51	mitogen-activated protein kinase kinase 6	Homo sapiens	77-83
27526785-8	2016	Our study shows that miR-625-3p induces oxaliplatin resistance by abrogating MAP2K6-p38-regulated apoptosis and cell cycle control networks, and corroborates the predictive power of miR-625-3p.	Oxaliplatin	40-51	mitogen-activated protein kinase 14	Homo sapiens	84-87
27330076-4	2016	Knockdown of PDK4 expression sensitizes colon cancer cells to 5-FU or oxaliplatin-induced apoptosis in vitro and increases the effectiveness of 5-FU in the inhibition of tumor growth in a mouse xenograft model in vivo In addition, we demonstrate for the first time that TGFbeta mediates drug resistance by regulating PDK4 expression and that 5-FU induces PDK4 expression in a TGFbeta signaling-dependent manner.	Oxaliplatin	70-81	pyruvate dehydrogenase kinase, isoenzyme 4	Mus musculus	13-17
27330076-4	2016	Knockdown of PDK4 expression sensitizes colon cancer cells to 5-FU or oxaliplatin-induced apoptosis in vitro and increases the effectiveness of 5-FU in the inhibition of tumor growth in a mouse xenograft model in vivo In addition, we demonstrate for the first time that TGFbeta mediates drug resistance by regulating PDK4 expression and that 5-FU induces PDK4 expression in a TGFbeta signaling-dependent manner.	Oxaliplatin	70-81	transforming growth factor, beta 1	Mus musculus	270-277
27330076-4	2016	Knockdown of PDK4 expression sensitizes colon cancer cells to 5-FU or oxaliplatin-induced apoptosis in vitro and increases the effectiveness of 5-FU in the inhibition of tumor growth in a mouse xenograft model in vivo In addition, we demonstrate for the first time that TGFbeta mediates drug resistance by regulating PDK4 expression and that 5-FU induces PDK4 expression in a TGFbeta signaling-dependent manner.	Oxaliplatin	70-81	pyruvate dehydrogenase kinase, isoenzyme 4	Mus musculus	317-321
27330076-4	2016	Knockdown of PDK4 expression sensitizes colon cancer cells to 5-FU or oxaliplatin-induced apoptosis in vitro and increases the effectiveness of 5-FU in the inhibition of tumor growth in a mouse xenograft model in vivo In addition, we demonstrate for the first time that TGFbeta mediates drug resistance by regulating PDK4 expression and that 5-FU induces PDK4 expression in a TGFbeta signaling-dependent manner.	Oxaliplatin	70-81	pyruvate dehydrogenase kinase, isoenzyme 4	Mus musculus	317-321
27330076-4	2016	Knockdown of PDK4 expression sensitizes colon cancer cells to 5-FU or oxaliplatin-induced apoptosis in vitro and increases the effectiveness of 5-FU in the inhibition of tumor growth in a mouse xenograft model in vivo In addition, we demonstrate for the first time that TGFbeta mediates drug resistance by regulating PDK4 expression and that 5-FU induces PDK4 expression in a TGFbeta signaling-dependent manner.	Oxaliplatin	70-81	transforming growth factor, beta 1	Mus musculus	376-383
26392056-7	2016	The observed synergistic interaction of both PBOX-15/Oxaliplatin and PBOX-15/5FU may involve activation of p38 MAPK and JNK pathway, which in turn significantly increased caspase-3 cleavage in DLD-1 cells, treated with PBOX-5/Oxaliplatin but not with PBOX-15/5FU.	Oxaliplatin	53-64	mitogen-activated protein kinase 14	Homo sapiens	107-110
26392056-7	2016	The observed synergistic interaction of both PBOX-15/Oxaliplatin and PBOX-15/5FU may involve activation of p38 MAPK and JNK pathway, which in turn significantly increased caspase-3 cleavage in DLD-1 cells, treated with PBOX-5/Oxaliplatin but not with PBOX-15/5FU.	Oxaliplatin	53-64	mitogen-activated protein kinase 8	Homo sapiens	120-123
26392056-7	2016	The observed synergistic interaction of both PBOX-15/Oxaliplatin and PBOX-15/5FU may involve activation of p38 MAPK and JNK pathway, which in turn significantly increased caspase-3 cleavage in DLD-1 cells, treated with PBOX-5/Oxaliplatin but not with PBOX-15/5FU.	Oxaliplatin	53-64	caspase 3	Homo sapiens	171-180
26392056-7	2016	The observed synergistic interaction of both PBOX-15/Oxaliplatin and PBOX-15/5FU may involve activation of p38 MAPK and JNK pathway, which in turn significantly increased caspase-3 cleavage in DLD-1 cells, treated with PBOX-5/Oxaliplatin but not with PBOX-15/5FU.	Oxaliplatin	226-237	mitogen-activated protein kinase 14	Homo sapiens	107-110
26392056-7	2016	The observed synergistic interaction of both PBOX-15/Oxaliplatin and PBOX-15/5FU may involve activation of p38 MAPK and JNK pathway, which in turn significantly increased caspase-3 cleavage in DLD-1 cells, treated with PBOX-5/Oxaliplatin but not with PBOX-15/5FU.	Oxaliplatin	226-237	mitogen-activated protein kinase 8	Homo sapiens	120-123
27384479-9	2016	Taken together, these results demonstrated that the combination of desferal with oxaliplatin can overcome oxaliplatin resistance through the regulation of hCtr1 and TfR1, and may have beneficial effect for treatment of patient with oxaliplatin-refractory tumors.	Oxaliplatin	81-92	solute carrier family 31 member 1	Homo sapiens	155-160
27384479-9	2016	Taken together, these results demonstrated that the combination of desferal with oxaliplatin can overcome oxaliplatin resistance through the regulation of hCtr1 and TfR1, and may have beneficial effect for treatment of patient with oxaliplatin-refractory tumors.	Oxaliplatin	106-117	transferrin receptor	Homo sapiens	165-169
26746689-3	2016	We conducted a phase II trial to evaluate the efficacy and safety of the combination of S-1 and irinotecan plus bevacizumab as a second-line treatment for oxaliplatin-refractory mCRC.	Oxaliplatin	155-166	proteasome 26S subunit, non-ATPase 1	Homo sapiens	88-91
27157913-0	2016	Protection of stromal cell-derived factor 2 by heat shock protein 72 prevents oxaliplatin-induced cell death in oxaliplatin-resistant human gastric cancer cells.	Oxaliplatin	78-89	stromal cell derived factor 2	Homo sapiens	14-43
27157913-0	2016	Protection of stromal cell-derived factor 2 by heat shock protein 72 prevents oxaliplatin-induced cell death in oxaliplatin-resistant human gastric cancer cells.	Oxaliplatin	78-89	heat shock protein family A (Hsp70) member 1A	Homo sapiens	47-68
27157913-0	2016	Protection of stromal cell-derived factor 2 by heat shock protein 72 prevents oxaliplatin-induced cell death in oxaliplatin-resistant human gastric cancer cells.	Oxaliplatin	112-123	stromal cell derived factor 2	Homo sapiens	14-43
27157913-0	2016	Protection of stromal cell-derived factor 2 by heat shock protein 72 prevents oxaliplatin-induced cell death in oxaliplatin-resistant human gastric cancer cells.	Oxaliplatin	112-123	heat shock protein family A (Hsp70) member 1A	Homo sapiens	47-68
27157913-5	2016	Here, we aimed to identify proteins that are critical for oxaliplatin (OXA) resistance by analyzing human gastric cancer cell lines, as well as OXA-resistant cells via a mass spectrometry-based proteomic approach combined with affinity purification using anti-Hsp72 antibodies.	Oxaliplatin	71-74	heat shock protein family A (Hsp70) member 1A	Homo sapiens	260-265
27157913-7	2016	SDF-2 was overexpressed in OXA-resistant cells and SDF-2 silencing promoted the apoptotic effects of OXA.	Oxaliplatin	27-30	stromal cell derived factor 2	Homo sapiens	0-5
27384479-9	2016	Taken together, these results demonstrated that the combination of desferal with oxaliplatin can overcome oxaliplatin resistance through the regulation of hCtr1 and TfR1, and may have beneficial effect for treatment of patient with oxaliplatin-refractory tumors.	Oxaliplatin	81-92	transferrin receptor	Homo sapiens	165-169
27384479-9	2016	Taken together, these results demonstrated that the combination of desferal with oxaliplatin can overcome oxaliplatin resistance through the regulation of hCtr1 and TfR1, and may have beneficial effect for treatment of patient with oxaliplatin-refractory tumors.	Oxaliplatin	106-117	transferrin receptor	Homo sapiens	165-169
27107996-5	2016	Using CRC cell lines expressing exogenous c-myb we show that c-Myb protects CRC cells from the cisplatin-, oxaliplatin-, and doxorubicin-induced apoptosis, elevates reactive oxygen species via up-regulation of NOX1, and sustains the pro-survival p38 MAPK pathway.	Oxaliplatin	107-118	MYB proto-oncogene, transcription factor	Homo sapiens	42-47
27107996-5	2016	Using CRC cell lines expressing exogenous c-myb we show that c-Myb protects CRC cells from the cisplatin-, oxaliplatin-, and doxorubicin-induced apoptosis, elevates reactive oxygen species via up-regulation of NOX1, and sustains the pro-survival p38 MAPK pathway.	Oxaliplatin	107-118	MYB proto-oncogene, transcription factor	Homo sapiens	61-66
26746689-15	2016	CONCLUSIONS: The findings suggest that the combination of S-1 and irinotecan plus bevacizumab is effective and tolerable as second-line chemotherapy for patients with oxaliplatin-refractory mCRC.	Oxaliplatin	167-178	proteasome 26S subunit, non-ATPase 1	Homo sapiens	58-61
27216154-1	2016	UNLABELLED: Inhibition of hypoxia-induced stress signaling through JNK potentiates the effects of oxaliplatin.	Oxaliplatin	98-109	mitogen-activated protein kinase 8	Homo sapiens	67-70
27562704-0	2016	5-HT1A receptor agonists, xaliproden and tandospirone, inhibit the increase in the number of cutaneous mast cells involved in the exacerbation of mechanical allodynia in oxaliplatin-treated mice.	Oxaliplatin	170-181	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-15
27562704-2	2016	This study was designed to investigate whether prophylactic repetitive administration of 5-HT1A receptor agonists inhibits oxaliplatin-induced mechanical allodynia in mice.	Oxaliplatin	123-134	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	89-104
27562704-3	2016	Repetitive administration of 5-HT1A receptor agonists (xaliproden and tandospirone) inhibited mechanical allodynia induced by a single intraperitoneal injection of oxaliplatin.	Oxaliplatin	164-175	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	29-44
27562704-5	2016	These results suggest that the prophylactic repetitive administration of 5-HT1A receptor agonists attenuates oxaliplatin-induced mechanical allodynia by inhibiting the cutaneous mast cell migration.	Oxaliplatin	109-120	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	73-88
27216154-2	2016	The JNK pathway plays a role in both autophagy and apoptosis; therefore, it was determined how much of the effect of JNK inhibition on oxaliplatin sensitivity is dependent on its effect on autophagy.	Oxaliplatin	135-146	mitogen-activated protein kinase 8	Homo sapiens	4-7
27216154-2	2016	The JNK pathway plays a role in both autophagy and apoptosis; therefore, it was determined how much of the effect of JNK inhibition on oxaliplatin sensitivity is dependent on its effect on autophagy.	Oxaliplatin	135-146	mitogen-activated protein kinase 8	Homo sapiens	117-120
27216154-3	2016	We studied the impact of JNK isoform downregulation in the HT29 colon adenocarcinoma cell line on hypoxia- and oxaliplatin-induced responses.	Oxaliplatin	111-122	mitogen-activated protein kinase 8	Homo sapiens	25-28
27216154-4	2016	Electron microscopic analyses demonstrated that both oxaliplatin- and hypoxia-induced formations of autophagosomes were reduced significantly in HT29 cells treated with the JNK inhibitor SP600125.	Oxaliplatin	53-64	mitogen-activated protein kinase 8	Homo sapiens	173-176
27216154-9	2016	Consistent with this, knockdown of Bcl-XL in HT29 cells did not significantly affect the induction of autophagy, but abrogated hypoxic resistance to oxaliplatin due to the faster and more robust activation of apoptosis.	Oxaliplatin	149-160	BCL2 like 1	Homo sapiens	35-41
27216154-10	2016	IMPLICATIONS: These data suggest that balance between autophagy and apoptosis is shifted toward apoptosis by downregulation of JNK1, contributing to oxaliplatin sensitization.	Oxaliplatin	149-160	mitogen-activated protein kinase 8	Homo sapiens	127-131
27283986-5	2016	Increased expression of HDAC2 correlated with drug resistance, and depletion by shRNA sensitised the multi-drug resistance cell line HT-29 to CRC chemotherapeutic drugs such as 5-fluorouracil (5-FU) and oxaliplatin (Oxa).	Oxaliplatin	203-214	histone deacetylase 2	Homo sapiens	24-29
27446402-3	2016	In a previous study, it was demonstrated that STK17A, a proapoptotic gene, was significantly downregulated in acquired resistance phenotypes of colon cancer cells that are resistant to oxaliplatin and 5-fluorouracil.	Oxaliplatin	185-196	serine/threonine kinase 17a	Homo sapiens	46-52
27384995-0	2016	Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells.	Oxaliplatin	22-33	repulsive guidance molecule BMP co-receptor b	Homo sapiens	8-12
27384995-8	2016	Mechanistically, Dragon inhibited oxaliplatin-induced JNK and p38 MAPK activation, and caspase-3 and PARP cleavages.	Oxaliplatin	34-45	mitogen-activated protein kinase 8	Homo sapiens	54-57
27384995-8	2016	Mechanistically, Dragon inhibited oxaliplatin-induced JNK and p38 MAPK activation, and caspase-3 and PARP cleavages.	Oxaliplatin	34-45	mitogen-activated protein kinase 14	Homo sapiens	62-65
27384995-8	2016	Mechanistically, Dragon inhibited oxaliplatin-induced JNK and p38 MAPK activation, and caspase-3 and PARP cleavages.	Oxaliplatin	34-45	caspase 3	Homo sapiens	87-96
27468218-11	2016	CONCLUSION: Our data show that the ratio of not BV-bound VEGF to total VEGF serum and BV plasma concentrations for predicting the response to BV plus oxaliplatin-based chemotherapy could be a promising biomarker of response to BV.	Oxaliplatin	150-161	vascular endothelial growth factor A	Homo sapiens	71-75
27440728-0	2016	Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin.	Oxaliplatin	86-97	POU class 2 homeobox 2	Homo sapiens	46-50
27440728-2	2016	Using data obtained from the cancer transcriptome database Oncomine and the proteome database The Human Protein Atlas, we identified the repression of organic cation transporter OCT2 as a potential factor contributing to oxaliplatin resistance in RCC.	Oxaliplatin	221-232	POU class 2 homeobox 2	Homo sapiens	178-182
27440728-6	2016	Targeting this mechanism, we designed a sequential combination therapy and demonstrated that epigenetic activation of OCT2 by decitabine sensitizes RCC cells to oxaliplatin both in vitro and in xenografts.	Oxaliplatin	161-172	POU class 2 homeobox 2	Homo sapiens	118-122
27283986-5	2016	Increased expression of HDAC2 correlated with drug resistance, and depletion by shRNA sensitised the multi-drug resistance cell line HT-29 to CRC chemotherapeutic drugs such as 5-fluorouracil (5-FU) and oxaliplatin (Oxa).	Oxaliplatin	216-219	histone deacetylase 2	Homo sapiens	24-29
27283986-6	2016	Combined treatment with the HDACi suberoylanilide hydroxamic acid plus 5-FU or Oxa reduced the level of HDAC2 expression, modified chromatin structure and induced mitotic cell death in HT-29 cells.	Oxaliplatin	79-82	histone deacetylase 2	Homo sapiens	104-109
27445823-7	2016	Moreover, the results of cell viability assay imply that three phytochemicals probably induce OCTN2 expression leading to the enhanced uptake of its substrate, oxaliplatin, thereby making cells more sensitive to oxaliplatin.	Oxaliplatin	160-171	solute carrier family 22 member 5	Homo sapiens	94-99
27305454-0	2016	Oxaliplatin Binding to Human Copper Chaperone Atox1 and Protein Dimerization.	Oxaliplatin	0-11	antioxidant 1 copper chaperone	Homo sapiens	46-51
27305454-2	2016	We investigated the reaction of the chaperone Atox1 with an activated form of oxaliplatin, the third platinum drug to reach worldwide approval.	Oxaliplatin	78-89	antioxidant 1 copper chaperone	Homo sapiens	46-51
27445823-7	2016	Moreover, the results of cell viability assay imply that three phytochemicals probably induce OCTN2 expression leading to the enhanced uptake of its substrate, oxaliplatin, thereby making cells more sensitive to oxaliplatin.	Oxaliplatin	212-223	solute carrier family 22 member 5	Homo sapiens	94-99
27347942-0	2016	Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position.	Oxaliplatin	59-70	translocator protein	Homo sapiens	98-102
27347942-1	2016	The first Pt(IV) derivative of oxaliplatin carrying a ligand for TSPO (the 18-kDa mitochondrial translocator protein) has been developed.	Oxaliplatin	31-42	translocator protein	Homo sapiens	65-69
27347942-1	2016	The first Pt(IV) derivative of oxaliplatin carrying a ligand for TSPO (the 18-kDa mitochondrial translocator protein) has been developed.	Oxaliplatin	31-42	translocator protein	Homo sapiens	96-116
27340349-2	2016	In addition, the combined strategies of administering EGFR mAbs and traditional cytotoxic agents, such as 5-fluorouracil, oxaliplatin and irinotecan, have resulted in a more complicated management of CRC treatment-related side effects compared with EGFR mAb monotherapy.	Oxaliplatin	122-133	epidermal growth factor receptor	Homo sapiens	54-58
27155924-3	2016	Nevertheless, several retrospective studies suggest a greater efficacy of oxaliplatin in mCRC with KRAS mutation.	Oxaliplatin	74-85	KRAS proto-oncogene, GTPase	Homo sapiens	99-103
27366083-4	2016	RESULTS: ERCC1-positive patients who received oxaliplatin-based chemotherapy had a shorter MST than ERCC1-negative patients (P&lt;0.05), whereas there is no difference of MST between BRCA1-positive and -negative patients.	Oxaliplatin	46-57	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	9-14
27145368-6	2016	Functional assays results indicated that the restoration of miR-199b considerably reduced cell invasion and migration in vitro and in vivo, and increased the sensitivity to 5-FU and oxaliplatin.	Oxaliplatin	182-193	microRNA 199b	Homo sapiens	60-68
27145458-0	2016	Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.	Oxaliplatin	43-54	TNF receptor superfamily member 11b	Homo sapiens	20-35
27143148-1	2016	PURPOSE: Patients with unresectable wild-type KRAS metastatic colorectal cancer benefit from fluoropyrimidines (FP), oxaliplatin (O), irinotecan (I), bevacizumab (Bev), and epithelial growth factor receptor inhibitors (EGFRI).	Oxaliplatin	117-128	KRAS proto-oncogene, GTPase	Homo sapiens	46-50
26983912-0	2016	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).	Oxaliplatin	113-124	fibroblast growth factor receptor 2	Homo sapiens	9-14
27197163-6	2016	Loss-of-function alleles in TLR4 and FPR1 also affect the prognosis of colorectal cancer patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	111-122	toll like receptor 4	Homo sapiens	28-32
27197163-6	2016	Loss-of-function alleles in TLR4 and FPR1 also affect the prognosis of colorectal cancer patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	111-122	formyl peptide receptor 1	Homo sapiens	37-41
26377238-3	2016	Here, we formulated oxaliplatin immunohybrid nanoparticles (OIHNPs) to deliver oxaliplatin and anti-TRAIL for colorectal cancer treatment in xenograft tumor models.	Oxaliplatin	20-31	TNF superfamily member 10	Homo sapiens	100-105
27031051-2	2016	Cold-sensitive transient receptor potential channels (TRPM8 and TRPA1) have been implicated as candidates to mediate oxaliplatin-induced cold allodynia and hyperalgesia, but precise roles of these channels remain unclear.	Oxaliplatin	117-128	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	54-59
26983880-0	2016	TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.	Oxaliplatin	122-133	twist family bHLH transcription factor 1	Homo sapiens	0-6
27313765-1	2016	The present study aimed to investigate the impact of indomethacin treatment combined with oxaliplatin treatment on the expression of cluster of differentiation 44 variant 6 (CD44v6), matrix metalloproteinase-2 (MMP-2) and survivin in human lung cancer-nude mouse transplanted tumors.	Oxaliplatin	90-101	matrix metallopeptidase 2	Homo sapiens	183-209
27313765-1	2016	The present study aimed to investigate the impact of indomethacin treatment combined with oxaliplatin treatment on the expression of cluster of differentiation 44 variant 6 (CD44v6), matrix metalloproteinase-2 (MMP-2) and survivin in human lung cancer-nude mouse transplanted tumors.	Oxaliplatin	90-101	matrix metallopeptidase 2	Homo sapiens	211-216
27313765-1	2016	The present study aimed to investigate the impact of indomethacin treatment combined with oxaliplatin treatment on the expression of cluster of differentiation 44 variant 6 (CD44v6), matrix metalloproteinase-2 (MMP-2) and survivin in human lung cancer-nude mouse transplanted tumors.	Oxaliplatin	90-101	baculoviral IAP repeat-containing 5	Mus musculus	222-230
27313765-8	2016	The present study provides evidence that the administration of indomethacin alone, or in combination with oxaliplatin, may significantly inhibit the growth of lung cancer-nude mouse transplanted tumors and the expression of CD44v6, MMP-2 and survivin inside the tumor.	Oxaliplatin	106-117	matrix metallopeptidase 2	Mus musculus	232-237
27313765-8	2016	The present study provides evidence that the administration of indomethacin alone, or in combination with oxaliplatin, may significantly inhibit the growth of lung cancer-nude mouse transplanted tumors and the expression of CD44v6, MMP-2 and survivin inside the tumor.	Oxaliplatin	106-117	baculoviral IAP repeat-containing 5	Mus musculus	242-250
26261061-0	2016	AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.	Oxaliplatin	125-136	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	0-4
26261061-0	2016	AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.	Oxaliplatin	125-136	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	9-14
27031051-2	2016	Cold-sensitive transient receptor potential channels (TRPM8 and TRPA1) have been implicated as candidates to mediate oxaliplatin-induced cold allodynia and hyperalgesia, but precise roles of these channels remain unclear.	Oxaliplatin	117-128	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	64-69
27031051-3	2016	In this study, we investigated the role of TRPM8 in oxaliplatin-induced cold allodynia.	Oxaliplatin	52-63	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	43-48
27031051-7	2016	RESULTS: Oxaliplatin-induced cold allodynia was alleviated by the TRPM8 blockers N-(2-aminoethyl)-N-[4-(benzyloxy)-3-methoxybenzyl]-N"-(1S)-1-(phenyl) ethyl] urea and TC-I 2014.	Oxaliplatin	9-20	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	66-71
27031051-8	2016	Oxaliplatin increased the expression levels of TRPM8 mRNA and protein in the dorsal root ganglia and plantar skin, respectively.	Oxaliplatin	0-11	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	47-52
27031051-9	2016	Prophylactic administration of the c-Myc inhibitor 10058-F4 prevented cold allodynia and the increase of TRPM8 mRNA after oxaliplatin injection.	Oxaliplatin	122-133	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	105-110
27031051-10	2016	CONCLUSION: These results suggest that oxaliplatin induces cold allodynia through the increase of c-Myc-mediated TRPM8 expression in primary sensory neurons.	Oxaliplatin	39-50	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	113-118
27246726-1	2016	BACKGROUND: Patients with metastatic colorectal cancer whose disease has progressed on oxaliplatin- and irinotecan-containing regimens may benefit from EGFR-inhibiting monoclonal antibodies if they do not contain mutations in the KRAS gene (are "wild type").	Oxaliplatin	87-98	epidermal growth factor receptor	Homo sapiens	152-156
26733168-6	2016	Following oxaliplatin treatment, the messenger RNA (mRNA) levels of most peroxiredoxin family genes, except for peroxiredoxin 1 (prdx1) gene, were constant or even decreased, resulting in ROS abundance.	Oxaliplatin	10-21	peroxiredoxin 1	Homo sapiens	73-86
26733168-6	2016	Following oxaliplatin treatment, the messenger RNA (mRNA) levels of most peroxiredoxin family genes, except for peroxiredoxin 1 (prdx1) gene, were constant or even decreased, resulting in ROS abundance.	Oxaliplatin	10-21	peroxiredoxin 1	Homo sapiens	112-127
26733168-6	2016	Following oxaliplatin treatment, the messenger RNA (mRNA) levels of most peroxiredoxin family genes, except for peroxiredoxin 1 (prdx1) gene, were constant or even decreased, resulting in ROS abundance.	Oxaliplatin	10-21	peroxiredoxin 1	Homo sapiens	129-134
26733168-7	2016	And the antioxidant guardian Nrf2 was unconspicuously raised both transcriptionally and translationally with oxaliplatin treatment as compared to those induced by topotecan treatment, which has been proved with no induced metastasis.	Oxaliplatin	109-120	NFE2 like bZIP transcription factor 2	Homo sapiens	29-33
26733168-9	2016	Using the Akt inhibitor LY294002 or knocking down Snail expression via RNA interference (RNAi) reversed the effects of oxaliplatin on the EMT and metastasis.	Oxaliplatin	119-130	AKT serine/threonine kinase 1	Homo sapiens	10-13
26733168-9	2016	Using the Akt inhibitor LY294002 or knocking down Snail expression via RNA interference (RNAi) reversed the effects of oxaliplatin on the EMT and metastasis.	Oxaliplatin	119-130	snail family transcriptional repressor 1	Homo sapiens	50-55
27165126-21	2016	Our data shows that BRCA2 is mutated in our PACC model, which could contribute to the oxaliplatin sensitivity observed.	Oxaliplatin	86-97	BRCA2 DNA repair associated	Homo sapiens	20-25
27105527-0	2016	Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.	Oxaliplatin	80-91	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	13-16
27105527-0	2016	Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.	Oxaliplatin	80-91	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	130-133
27105527-3	2016	In the present work, we determined that high levels of activated Src kinase, measured as phospho-Src at the Tyr419 residue in CRC cell lines, can promote colorectal carcinoma cell resistance to oxaliplatin, but not to 5-fluorouracil (5FU), and that inhibition of this protein restores sensitivity to oxaliplatin.	Oxaliplatin	194-205	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	65-68
27105527-3	2016	In the present work, we determined that high levels of activated Src kinase, measured as phospho-Src at the Tyr419 residue in CRC cell lines, can promote colorectal carcinoma cell resistance to oxaliplatin, but not to 5-fluorouracil (5FU), and that inhibition of this protein restores sensitivity to oxaliplatin.	Oxaliplatin	194-205	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	97-100
27105527-3	2016	In the present work, we determined that high levels of activated Src kinase, measured as phospho-Src at the Tyr419 residue in CRC cell lines, can promote colorectal carcinoma cell resistance to oxaliplatin, but not to 5-fluorouracil (5FU), and that inhibition of this protein restores sensitivity to oxaliplatin.	Oxaliplatin	300-311	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	65-68
27105527-3	2016	In the present work, we determined that high levels of activated Src kinase, measured as phospho-Src at the Tyr419 residue in CRC cell lines, can promote colorectal carcinoma cell resistance to oxaliplatin, but not to 5-fluorouracil (5FU), and that inhibition of this protein restores sensitivity to oxaliplatin.	Oxaliplatin	300-311	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	97-100
27105527-5	2016	In PDX tumor lines derived from human CRC liver metastasis, dasatinib, a Src inhibitor, increases sensitivity to oxaliplatin only in tumors with high p-Src.	Oxaliplatin	113-124	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	73-76
27105527-5	2016	In PDX tumor lines derived from human CRC liver metastasis, dasatinib, a Src inhibitor, increases sensitivity to oxaliplatin only in tumors with high p-Src.	Oxaliplatin	113-124	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	152-155
27105527-7	2016	Our data suggest that chemoresistance induced by p-Src is specific to oxaliplatin, and that p-Src levels can be used to identify patients who may benefit from this combination therapy.	Oxaliplatin	70-81	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	51-54
27135196-1	2016	Methyl 6-aminodeoxy-d-pyranoside-derived platinum(II) glycoconjugates were designed and synthesized based on the clinical drug oxaliplatin for glucose transporter (GLUT)-mediated tumor targeting.	Oxaliplatin	127-138	solute carrier family 2 member 1	Homo sapiens	143-162
27135196-1	2016	Methyl 6-aminodeoxy-d-pyranoside-derived platinum(II) glycoconjugates were designed and synthesized based on the clinical drug oxaliplatin for glucose transporter (GLUT)-mediated tumor targeting.	Oxaliplatin	127-138	solute carrier family 2 member 1	Homo sapiens	164-168
26978408-6	2016	Spinal application of oxaliplatin at the detected concentration (6.6 nM) significantly increased the field potentials in the dorsal horn, induced acute mechanical allodynia (n = 12 each) and thermal hyperalgesia (n = 12 each), and enhanced the evoked excitatory postsynaptic currents and spontaneous excitatory postsynaptic currents in the projection neurokinin 1 receptor-expressing lamina I to II neurons.	Oxaliplatin	22-33	tachykinin receptor 1	Rattus norvegicus	351-372
26978408-7	2016	The authors further found that oxaliplatin significantly increased the nuclear factor-kappaB p65 binding and histone H4 acetylation in cx3cl1 promoter region.	Oxaliplatin	31-42	C-X3-C motif chemokine ligand 1	Rattus norvegicus	135-141
26978408-8	2016	Thus, the upregulated spinal CX3CL1 markedly mediated the induction of central sensitization and acute pain behavior after oxaliplatin administration.	Oxaliplatin	123-134	C-X3-C motif chemokine ligand 1	Rattus norvegicus	29-35
26387536-8	2016	Importantly, pharmacological inhibition of HuR by MS-444 inhibits HuR homodimerization and its cytoplasmic translocation, abrogates hypoxia-induced PIM1 overexpression and markedly enhances PDA cell sensitivity to oxaliplatin and 5-fluorouracil under physiologic low oxygen conditions.	Oxaliplatin	214-225	ELAV like RNA binding protein 1	Homo sapiens	43-46
25647613-0	2016	LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET.	Oxaliplatin	37-48	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	61-66
25647613-0	2016	LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET.	Oxaliplatin	37-48	fms related receptor tyrosine kinase 1	Homo sapiens	71-78
25647613-0	2016	LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET.	Oxaliplatin	37-48	vascular endothelial growth factor A	Homo sapiens	71-75
25647613-0	2016	LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET.	Oxaliplatin	37-48	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	125-130
25647613-1	2016	Oxaliplatin-resistant LoVo colon cancer cells overexpressing c-MET and VEGFR-1 were selected to study several signaling pathways involved in chemoresistance, as well as the effect of increasing amounts of VEGF in the regulation of c-MET.	Oxaliplatin	0-11	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	61-66
25647613-1	2016	Oxaliplatin-resistant LoVo colon cancer cells overexpressing c-MET and VEGFR-1 were selected to study several signaling pathways involved in chemoresistance, as well as the effect of increasing amounts of VEGF in the regulation of c-MET.	Oxaliplatin	0-11	fms related receptor tyrosine kinase 1	Homo sapiens	71-78
25647613-1	2016	Oxaliplatin-resistant LoVo colon cancer cells overexpressing c-MET and VEGFR-1 were selected to study several signaling pathways involved in chemoresistance, as well as the effect of increasing amounts of VEGF in the regulation of c-MET.	Oxaliplatin	0-11	vascular endothelial growth factor A	Homo sapiens	71-75
25647613-1	2016	Oxaliplatin-resistant LoVo colon cancer cells overexpressing c-MET and VEGFR-1 were selected to study several signaling pathways involved in chemoresistance, as well as the effect of increasing amounts of VEGF in the regulation of c-MET.	Oxaliplatin	0-11	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	231-236
25647613-2	2016	In comparison with chemosensitive LoVo colon cancer cells, oxaliplatin-resistant cells (LoVoR) overexpress and phosphorylate c-MET, upregulate the expression of transmembrane and soluble VEGFR-1 and, unexpectedly, downregulate VEGF.	Oxaliplatin	59-70	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	125-130
25647613-2	2016	In comparison with chemosensitive LoVo colon cancer cells, oxaliplatin-resistant cells (LoVoR) overexpress and phosphorylate c-MET, upregulate the expression of transmembrane and soluble VEGFR-1 and, unexpectedly, downregulate VEGF.	Oxaliplatin	59-70	fms related receptor tyrosine kinase 1	Homo sapiens	187-194
25647613-2	2016	In comparison with chemosensitive LoVo colon cancer cells, oxaliplatin-resistant cells (LoVoR) overexpress and phosphorylate c-MET, upregulate the expression of transmembrane and soluble VEGFR-1 and, unexpectedly, downregulate VEGF.	Oxaliplatin	59-70	vascular endothelial growth factor A	Homo sapiens	187-191
26794347-3	2016	Objective: To determine the impact of DPYD variants on fluorouracil AEs in patients with stage III CC treated with a fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) regimen.	Oxaliplatin	147-158	dihydropyrimidine dehydrogenase	Homo sapiens	38-42
27175691-0	2016	Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy.	Oxaliplatin	102-113	ERCC excision repair 5, endonuclease	Homo sapiens	35-40
27175691-2	2016	The aim of the study was to determine whether genetic variations at excision repair cross complementation group 5 (ERCC5) promoter could affect transcription factor binding and whether such single nucleotide polymorphism (SNP)-dependent binding could affect gene expression, drug response, and clinical outcome.A total of 170 patients who were cytologically or histologically confirmed with advanced colorectal cancer (CRC), at least 1 measurable lesion, and underwent oxaliplatin-based chemotherapy were studied.	Oxaliplatin	469-480	ERCC excision repair 5, endonuclease	Homo sapiens	115-120
27175691-10	2016	At multivariate analysis, patients with risk genotypes (-763AA or +25GG genotype) demonstrated a significantly increasing risk of progression (P = 0.01) or worse OS (P = 0.001).The ERCC5 promoter polymorphisms at -763 and +25 may be important functional variants and predictors of clinical outcome of CRC patients who received oxaliplatin chemotherapy.	Oxaliplatin	327-338	ERCC excision repair 5, endonuclease	Homo sapiens	181-186
27017918-6	2016	Observation of ROCK II cleavage after ouabain, digoxin and oxaliplatin treatments in HeLa and/or HepG2 cells suggested that cleavage is independent of cell type and cell death induction.	Oxaliplatin	59-70	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	15-22
27091625-6	2016	Moreover, CXCL8 and CXCL1 gene silencing made resistant cells more sensitive to OXA through the inhibition of the Akt/NF-kappaB pathway.	Oxaliplatin	80-83	C-X-C motif chemokine ligand 8	Homo sapiens	10-15
26643894-6	2016	Ectopic SNX1 expression repressed CRC cell growth and promoted tumor sensitivity to most commonly used chemotherapeutic drugs (oxaliplatin and 5-Fluorouracil).	Oxaliplatin	127-138	sorting nexin 1	Homo sapiens	8-12
27091625-6	2016	Moreover, CXCL8 and CXCL1 gene silencing made resistant cells more sensitive to OXA through the inhibition of the Akt/NF-kappaB pathway.	Oxaliplatin	80-83	C-X-C motif chemokine ligand 1	Homo sapiens	20-25
27091625-0	2016	Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-kappaB signalling pathway.	Oxaliplatin	18-29	nuclear factor kappa B subunit 1	Homo sapiens	128-137
27091625-3	2016	Here, we show that NF-kappaB was hyperactivated in in vitro models of OXA-acquired resistance but was attenuated by the addition of Curcumin, a non-toxic NF-kappaB inhibitor.	Oxaliplatin	70-73	nuclear factor kappa B subunit 1	Homo sapiens	19-28
27091625-6	2016	Moreover, CXCL8 and CXCL1 gene silencing made resistant cells more sensitive to OXA through the inhibition of the Akt/NF-kappaB pathway.	Oxaliplatin	80-83	AKT serine/threonine kinase 1	Homo sapiens	114-117
27091625-3	2016	Here, we show that NF-kappaB was hyperactivated in in vitro models of OXA-acquired resistance but was attenuated by the addition of Curcumin, a non-toxic NF-kappaB inhibitor.	Oxaliplatin	70-73	nuclear factor kappa B subunit 1	Homo sapiens	154-163
27091625-6	2016	Moreover, CXCL8 and CXCL1 gene silencing made resistant cells more sensitive to OXA through the inhibition of the Akt/NF-kappaB pathway.	Oxaliplatin	80-83	nuclear factor kappa B subunit 1	Homo sapiens	118-127
27091625-4	2016	The concomitant combination of Curcumin + OXA was more effective and synergistic in cell lines with acquired resistance to OXA, leading to the reversion of their resistant phenotype, through the inhibition of the NF-kappaB signalling cascade.	Oxaliplatin	42-45	nuclear factor kappa B subunit 1	Homo sapiens	213-222
27091625-4	2016	The concomitant combination of Curcumin + OXA was more effective and synergistic in cell lines with acquired resistance to OXA, leading to the reversion of their resistant phenotype, through the inhibition of the NF-kappaB signalling cascade.	Oxaliplatin	123-126	nuclear factor kappa B subunit 1	Homo sapiens	213-222
27091625-7	2016	High expression of CXCL1 in FFPE samples from explant cultures of CRC patients-derived liver metastases was associated with response to OXA + Curcumin.	Oxaliplatin	136-139	C-X-C motif chemokine ligand 1	Homo sapiens	19-24
27091625-5	2016	Transcriptomic profiling revealed the up-regulation of three NF-kappaB-regulated CXC-chemokines, CXCL8, CXCL1 and CXCL2, in the resistant cells that were more efficiently down-regulated after OXA + Curcumin treatment as compared to the sensitive cells.	Oxaliplatin	192-195	nuclear factor kappa B subunit 1	Homo sapiens	61-70
27091625-5	2016	Transcriptomic profiling revealed the up-regulation of three NF-kappaB-regulated CXC-chemokines, CXCL8, CXCL1 and CXCL2, in the resistant cells that were more efficiently down-regulated after OXA + Curcumin treatment as compared to the sensitive cells.	Oxaliplatin	192-195	C-X-C motif chemokine ligand 8	Homo sapiens	97-102
27091625-8	2016	In conclusion, we suggest that combination of OXA + Curcumin could be an effective treatment, for which CXCL1 could be used as a predictive marker, in CRC patients.	Oxaliplatin	46-49	C-X-C motif chemokine ligand 1	Homo sapiens	104-109
27091625-5	2016	Transcriptomic profiling revealed the up-regulation of three NF-kappaB-regulated CXC-chemokines, CXCL8, CXCL1 and CXCL2, in the resistant cells that were more efficiently down-regulated after OXA + Curcumin treatment as compared to the sensitive cells.	Oxaliplatin	192-195	C-X-C motif chemokine ligand 1	Homo sapiens	104-109
27091625-5	2016	Transcriptomic profiling revealed the up-regulation of three NF-kappaB-regulated CXC-chemokines, CXCL8, CXCL1 and CXCL2, in the resistant cells that were more efficiently down-regulated after OXA + Curcumin treatment as compared to the sensitive cells.	Oxaliplatin	192-195	C-X-C motif chemokine ligand 2	Homo sapiens	114-119
26828020-6	2016	Incubation with 100 microM oxaliplatin increased superoxide anion production and caspase 3/7 activity in the neuronal cell line SH-SY5Y and cortical astrocytes.	Oxaliplatin	27-38	caspase 3	Rattus norvegicus	81-90
27149123-2	2016	We aimed to examine the anti-proliferative effects of the flavopiridol and oxaliplatin combination on p16INK4A deficient melanoma cells B16F10 and also its apoptotic effects on a subcutaneously injected B16F10 allograft melanoma tumor model.	Oxaliplatin	75-86	cyclin dependent kinase inhibitor 2A	Mus musculus	102-110
27124048-0	2016	GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.	Oxaliplatin	84-95	polypeptide N-acetylgalactosaminyltransferase 14	Homo sapiens	0-7
26935807-0	2016	miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy.	Oxaliplatin	44-55	microRNA 409	Homo sapiens	0-7
26935807-0	2016	miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy.	Oxaliplatin	44-55	beclin 1	Homo sapiens	70-78
26935807-3	2016	In the present study, we examined the role of miR-409-3p in colon cancer as well as the effects of miR-409-3p on the sensitivity of colon cancer cells to oxaliplatin.	Oxaliplatin	154-165	microRNA 409	Homo sapiens	99-106
26935807-6	2016	Moreover, we observed a negative correlation between the miR-409-3p levels and resistance to oxaliplatin: the oxaliplatin-resistant colon cancer cells exhibited significantly downregulated miR-409-3p levels, but higher autophagic activity than the oxaliplatin-sensitive cells.	Oxaliplatin	93-104	microRNA 409	Homo sapiens	57-64
26935807-6	2016	Moreover, we observed a negative correlation between the miR-409-3p levels and resistance to oxaliplatin: the oxaliplatin-resistant colon cancer cells exhibited significantly downregulated miR-409-3p levels, but higher autophagic activity than the oxaliplatin-sensitive cells.	Oxaliplatin	93-104	microRNA 409	Homo sapiens	189-196
26935807-6	2016	Moreover, we observed a negative correlation between the miR-409-3p levels and resistance to oxaliplatin: the oxaliplatin-resistant colon cancer cells exhibited significantly downregulated miR-409-3p levels, but higher autophagic activity than the oxaliplatin-sensitive cells.	Oxaliplatin	110-121	microRNA 409	Homo sapiens	57-64
26935807-6	2016	Moreover, we observed a negative correlation between the miR-409-3p levels and resistance to oxaliplatin: the oxaliplatin-resistant colon cancer cells exhibited significantly downregulated miR-409-3p levels, but higher autophagic activity than the oxaliplatin-sensitive cells.	Oxaliplatin	110-121	microRNA 409	Homo sapiens	189-196
26935807-6	2016	Moreover, we observed a negative correlation between the miR-409-3p levels and resistance to oxaliplatin: the oxaliplatin-resistant colon cancer cells exhibited significantly downregulated miR-409-3p levels, but higher autophagic activity than the oxaliplatin-sensitive cells.	Oxaliplatin	110-121	microRNA 409	Homo sapiens	57-64
26935807-6	2016	Moreover, we observed a negative correlation between the miR-409-3p levels and resistance to oxaliplatin: the oxaliplatin-resistant colon cancer cells exhibited significantly downregulated miR-409-3p levels, but higher autophagic activity than the oxaliplatin-sensitive cells.	Oxaliplatin	110-121	microRNA 409	Homo sapiens	189-196
26935807-9	2016	In addition, the overexpression of miR-409-3p enhanced the chemosensitivity of the oxaliplatin-sensitive and oxaliplatin-resistant colon cancer cells.	Oxaliplatin	83-94	microRNA 409	Homo sapiens	35-42
26935807-9	2016	In addition, the overexpression of miR-409-3p enhanced the chemosensitivity of the oxaliplatin-sensitive and oxaliplatin-resistant colon cancer cells.	Oxaliplatin	109-120	microRNA 409	Homo sapiens	35-42
26979622-6	2016	Yes1 inhibition in vivo diminished OCT2 activity, significantly mitigating oxaliplatin-induced acute sensory neuropathy.	Oxaliplatin	75-86	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	0-4
26515332-7	2016	Our studies supported the conclusions that rs61764370 and rs712 polymorphisms of the KRAS are functional and it may play an important role in the development of CRC and oxaliplatin-based chemotherapy efficiency and prognosis of CRC.	Oxaliplatin	169-180	KRAS proto-oncogene, GTPase	Homo sapiens	85-89
26975868-1	2016	UNLABELLED: We report a case of a 31-year-old man with metastatic fibrolamellar hepatocellular carcinoma (FLHCC) treated with gemcitabine and oxaliplatin complicated by hyperammonemic encephalopathy biochemically consistent with acquired ornithine transcarbamylase deficiency.	Oxaliplatin	142-153	ornithine transcarbamylase	Homo sapiens	238-264
27186286-6	2016	Th17/Treg balance was reversed by HCT in oxaliplatin-treated rats by regulating PI3K/Akt/mTOR signaling pathway.	Oxaliplatin	41-52	AKT serine/threonine kinase 1	Rattus norvegicus	85-88
26515494-10	2016	Furthermore, ch282-5 could potentiate the effectiveness of oxaliplatin and rescue ABT-263 efficacy by downregulation of Mcl-1 and elevation of platelet number.	Oxaliplatin	59-70	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	120-125
27186286-6	2016	Th17/Treg balance was reversed by HCT in oxaliplatin-treated rats by regulating PI3K/Akt/mTOR signaling pathway.	Oxaliplatin	41-52	mechanistic target of rapamycin kinase	Rattus norvegicus	89-93
27471616-2	2016	Here, we show that anthracyclines and oxaliplatin can trigger necroptosis in murine cancer cell lines expressing receptor-interacting serine-threonine kinase 3 (RIP3) and mixed lineage kinase domain-like (MLKL).	Oxaliplatin	38-49	receptor-interacting serine-threonine kinase 3	Mus musculus	113-159
27471616-2	2016	Here, we show that anthracyclines and oxaliplatin can trigger necroptosis in murine cancer cell lines expressing receptor-interacting serine-threonine kinase 3 (RIP3) and mixed lineage kinase domain-like (MLKL).	Oxaliplatin	38-49	receptor-interacting serine-threonine kinase 3	Mus musculus	161-165
27471616-2	2016	Here, we show that anthracyclines and oxaliplatin can trigger necroptosis in murine cancer cell lines expressing receptor-interacting serine-threonine kinase 3 (RIP3) and mixed lineage kinase domain-like (MLKL).	Oxaliplatin	38-49	mixed lineage kinase domain-like	Mus musculus	171-203
27471616-2	2016	Here, we show that anthracyclines and oxaliplatin can trigger necroptosis in murine cancer cell lines expressing receptor-interacting serine-threonine kinase 3 (RIP3) and mixed lineage kinase domain-like (MLKL).	Oxaliplatin	38-49	mixed lineage kinase domain-like	Mus musculus	205-209
27014726-3	2016	Data from the flow cytometric transporter efflux assay showed specific inhibition of ABCC2 activity by vatalanib in stable transfected cells and ABCC2-overexpressing oxaliplatin-resistant colon cancer cells HCT116/Oxa.	Oxaliplatin	166-177	ATP binding cassette subfamily C member 2	Homo sapiens	145-150
29997781-6	2016	Pt(iv) derivatives of cisplatin with either two axial PhB or valproate ligands are more potent than their oxaliplatin analogs.	Oxaliplatin	106-117	prohibitin 1	Homo sapiens	54-57
26998002-0	2016	Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin.	Oxaliplatin	91-102	proline rich 13	Homo sapiens	11-34
26998002-0	2016	Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin.	Oxaliplatin	91-102	sarcoglycan beta	Homo sapiens	73-76
26998002-1	2016	The present study aimed to evaluate the role of taxol resistance gene 1 (Txr1) in the development of oxaliplatin (L-OHP) resistance in gastric cancer (GC).	Oxaliplatin	101-112	proline rich 13	Homo sapiens	48-71
26998002-1	2016	The present study aimed to evaluate the role of taxol resistance gene 1 (Txr1) in the development of oxaliplatin (L-OHP) resistance in gastric cancer (GC).	Oxaliplatin	101-112	proline rich 13	Homo sapiens	73-77
26998002-1	2016	The present study aimed to evaluate the role of taxol resistance gene 1 (Txr1) in the development of oxaliplatin (L-OHP) resistance in gastric cancer (GC).	Oxaliplatin	114-119	proline rich 13	Homo sapiens	48-71
26998002-1	2016	The present study aimed to evaluate the role of taxol resistance gene 1 (Txr1) in the development of oxaliplatin (L-OHP) resistance in gastric cancer (GC).	Oxaliplatin	114-119	proline rich 13	Homo sapiens	73-77
26998002-5	2016	Txr1-knockdown significantly increased the sensitivity of the SGC-7901 cells to L-OHP, whereas Txr1 overexpression promoted the resistance of the SGC-7901 cells to L-OHP.	Oxaliplatin	80-85	proline rich 13	Homo sapiens	0-4
26998002-5	2016	Txr1-knockdown significantly increased the sensitivity of the SGC-7901 cells to L-OHP, whereas Txr1 overexpression promoted the resistance of the SGC-7901 cells to L-OHP.	Oxaliplatin	164-169	proline rich 13	Homo sapiens	95-99
26998002-6	2016	Exogenous Txr1 expression in the SGC-7901 cells induced L-OHP resistance, and the siRNA knockdown of Txr1 sensitized the human GC cells to L-OHP.	Oxaliplatin	56-61	proline rich 13	Homo sapiens	10-14
26998002-6	2016	Exogenous Txr1 expression in the SGC-7901 cells induced L-OHP resistance, and the siRNA knockdown of Txr1 sensitized the human GC cells to L-OHP.	Oxaliplatin	139-144	proline rich 13	Homo sapiens	101-105
26628478-1	2016	PURPOSE: To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma.	Oxaliplatin	74-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-173
26782761-12	2016	In addition, Twist-overexpressing CRC cells were more chemo-resistant to oxaliplatin than control cells.	Oxaliplatin	73-84	twist family bHLH transcription factor 1	Homo sapiens	13-18
26804251-0	2016	Involvement of mast cells and proteinase-activated receptor 2 in oxaliplatin-induced mechanical allodynia in mice.	Oxaliplatin	65-76	coagulation factor II (thrombin) receptor-like 1	Mus musculus	30-61
26804251-7	2016	The serine protease inhibitor camostat mesilate and the proteinase-activated receptor 2 (PAR2) antagonist FSLLRY-NH2 significantly inhibited oxaliplatin-induced mechanical allodynia.	Oxaliplatin	141-152	complement component 1, s subcomponent 1	Mus musculus	4-19
26804251-7	2016	The serine protease inhibitor camostat mesilate and the proteinase-activated receptor 2 (PAR2) antagonist FSLLRY-NH2 significantly inhibited oxaliplatin-induced mechanical allodynia.	Oxaliplatin	141-152	coagulation factor II (thrombin) receptor-like 1	Mus musculus	56-87
26804251-7	2016	The serine protease inhibitor camostat mesilate and the proteinase-activated receptor 2 (PAR2) antagonist FSLLRY-NH2 significantly inhibited oxaliplatin-induced mechanical allodynia.	Oxaliplatin	141-152	coagulation factor II (thrombin) receptor-like 1	Mus musculus	89-93
26804251-11	2016	These results suggest that serine protease(s) released from mast cells and PAR2 are involved in oxaliplatin-induced mechanical allodynia.	Oxaliplatin	96-107	complement component 1, s subcomponent 1	Mus musculus	27-42
26804251-11	2016	These results suggest that serine protease(s) released from mast cells and PAR2 are involved in oxaliplatin-induced mechanical allodynia.	Oxaliplatin	96-107	coagulation factor II (thrombin) receptor-like 1	Mus musculus	75-79
28053885-0	2017	Shakuyakukanzoto attenuates oxaliplatin-induced cold dysesthesia by inhibiting the expression of transient receptor potential melastatin 8 in mice.	Oxaliplatin	28-39	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	97-138
28053885-5	2017	Our previous report has shown that the mRNA expression of transient receptor potential melastatin 8 (TRPM8), characterized as a cold-sensing cation channel, is increased in the dorsal root ganglia of mice treated with oxaliplatin.	Oxaliplatin	218-229	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	58-99
28053885-5	2017	Our previous report has shown that the mRNA expression of transient receptor potential melastatin 8 (TRPM8), characterized as a cold-sensing cation channel, is increased in the dorsal root ganglia of mice treated with oxaliplatin.	Oxaliplatin	218-229	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	101-106
28053885-6	2017	In addition, TRPM8 antagonist TC-I 2014 (10 and 30 mg/kg) also attenuated cold dysesthesia in oxaliplatin-treated mice.	Oxaliplatin	94-105	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	13-18
28053885-7	2017	Taken together, it is suggested that TRPM8 is involved in the cold dysesthesia induced by oxaliplatin.	Oxaliplatin	90-101	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	37-42
28053885-8	2017	Repetitive administration of SKT inhibited the mRNA expression of TRPM8 induced by oxaliplatin in the dorsal root ganglia.	Oxaliplatin	83-94	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	66-71
28053885-9	2017	These results suggested that prophylactic repetitive administration of SKT is effective in preventing the exacerbation of oxaliplatin-induced cold dysesthesia by inhibiting the mRNA expression of TRPM8 in the dorsal root ganglia.	Oxaliplatin	122-133	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	196-201
26867799-0	2016	beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.	Oxaliplatin	58-69	solute carrier family 31, member 1	Mus musculus	119-139
26867799-0	2016	beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.	Oxaliplatin	84-95	solute carrier family 31, member 1	Mus musculus	119-139
26867799-4	2016	Western blot and laser scanning confocal microscopy studies indicated that beta-elemene enhanced the sensitivity of HCC cells to oxaliplatin by upregulating copper transporter 1 (CTR1), a major controller of intracellular platinum accumulation.	Oxaliplatin	129-140	solute carrier family 31, member 1	Mus musculus	157-177
26867799-4	2016	Western blot and laser scanning confocal microscopy studies indicated that beta-elemene enhanced the sensitivity of HCC cells to oxaliplatin by upregulating copper transporter 1 (CTR1), a major controller of intracellular platinum accumulation.	Oxaliplatin	129-140	solute carrier family 31, member 1	Mus musculus	179-183
26867799-7	2016	Taken together, our findings show that beta-elemene can block the reduction of CTR1 resulting from oxaliplatin treatment, and therefore has a synergistic anti-HCC effect with oxaliplatin by enhancing cellular uptake of oxaliplatin.	Oxaliplatin	99-110	solute carrier family 31, member 1	Mus musculus	79-83
26846566-4	2016	Furthermore, the xenograft tumor tissues of mice treated with oxaliplatin and PT-100 contained lower numbers of tumor-associated macrophages and dendritic cells, expressed lower levels of cytokines associated with CAFs and had a lower density of CD31+ endothelial cells.	Oxaliplatin	62-73	platelet/endothelial cell adhesion molecule 1	Mus musculus	246-250
26804244-0	2016	Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma.	Oxaliplatin	69-80	dual specificity tyrosine phosphorylation regulated kinase 2	Homo sapiens	14-19
26804244-1	2016	We aimed to investigate the molecular mechanisms of DYRK2 and the HCC sensitivity to Oxaliplatin in DYRK2-depleted HCC cells.	Oxaliplatin	85-96	dual specificity tyrosine phosphorylation regulated kinase 2	Homo sapiens	100-105
26804244-4	2016	Flow cytometry and CCK-8 assay were detected in cell cycle progression, cell proliferation and the efficacy of Oxaliplatin, DYRK2 was down-regulated in HCC tissues, compared with adjacent nontumor ones.	Oxaliplatin	111-122	dual specificity tyrosine phosphorylation regulated kinase 2	Homo sapiens	124-129
26804244-8	2016	The depletion of DYRK2 promoted HCC cell proliferation, and increased resistance to Oxaliplatin.	Oxaliplatin	84-95	dual specificity tyrosine phosphorylation regulated kinase 2	Homo sapiens	17-22
26804244-10	2016	In addition, reducing DYRK2 expression was associated with poor prognosis and Oxaliplatin resistance in HCC.	Oxaliplatin	78-89	dual specificity tyrosine phosphorylation regulated kinase 2	Homo sapiens	22-27
26867764-0	2016	A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.	Oxaliplatin	34-45	DNA topoisomerase II alpha	Homo sapiens	103-108
26628478-1	2016	PURPOSE: To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma.	Oxaliplatin	74-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
26656794-5	2016	Oxaliplatin and cisplatin were most cytotoxic with IC50 values of 1.7 muM+-0.8 and 4.1 muM+-0.1, respectively.	Oxaliplatin	0-11	latexin	Homo sapiens	70-73
26859833-3	2016	The intracellular distribution of oxaliplatin is mediated by organic cation transporters 1, 2 and 3 (OCT1, 2 and 3), copper transporter 1 (CTR1) and ATPase Cu2+ transporting beta polypeptide (ATP7B) and may modulate the efficacy of oxaliplatin-based chemotherapy.	Oxaliplatin	34-45	solute carrier family 22 member 1	Homo sapiens	61-99
26859833-3	2016	The intracellular distribution of oxaliplatin is mediated by organic cation transporters 1, 2 and 3 (OCT1, 2 and 3), copper transporter 1 (CTR1) and ATPase Cu2+ transporting beta polypeptide (ATP7B) and may modulate the efficacy of oxaliplatin-based chemotherapy.	Oxaliplatin	34-45	solute carrier family 22 member 1	Homo sapiens	101-114
26859833-3	2016	The intracellular distribution of oxaliplatin is mediated by organic cation transporters 1, 2 and 3 (OCT1, 2 and 3), copper transporter 1 (CTR1) and ATPase Cu2+ transporting beta polypeptide (ATP7B) and may modulate the efficacy of oxaliplatin-based chemotherapy.	Oxaliplatin	34-45	solute carrier family 31 member 1	Homo sapiens	117-137
26859833-3	2016	The intracellular distribution of oxaliplatin is mediated by organic cation transporters 1, 2 and 3 (OCT1, 2 and 3), copper transporter 1 (CTR1) and ATPase Cu2+ transporting beta polypeptide (ATP7B) and may modulate the efficacy of oxaliplatin-based chemotherapy.	Oxaliplatin	34-45	solute carrier family 31 member 1	Homo sapiens	139-143
26859833-3	2016	The intracellular distribution of oxaliplatin is mediated by organic cation transporters 1, 2 and 3 (OCT1, 2 and 3), copper transporter 1 (CTR1) and ATPase Cu2+ transporting beta polypeptide (ATP7B) and may modulate the efficacy of oxaliplatin-based chemotherapy.	Oxaliplatin	34-45	ATPase copper transporting beta	Homo sapiens	149-190
26859833-3	2016	The intracellular distribution of oxaliplatin is mediated by organic cation transporters 1, 2 and 3 (OCT1, 2 and 3), copper transporter 1 (CTR1) and ATPase Cu2+ transporting beta polypeptide (ATP7B) and may modulate the efficacy of oxaliplatin-based chemotherapy.	Oxaliplatin	34-45	ATPase copper transporting beta	Homo sapiens	192-197
26859833-3	2016	The intracellular distribution of oxaliplatin is mediated by organic cation transporters 1, 2 and 3 (OCT1, 2 and 3), copper transporter 1 (CTR1) and ATPase Cu2+ transporting beta polypeptide (ATP7B) and may modulate the efficacy of oxaliplatin-based chemotherapy.	Oxaliplatin	232-243	ATPase copper transporting beta	Homo sapiens	192-197
26857702-3	2016	To further improve treatment options for patients with advanced gastric cancer, we initiated a study to evaluate the efficacy and safety of trastuzumab plus oxaliplatin/capecitabine in patients with HER2-positive advanced gastric cancer.	Oxaliplatin	157-168	erb-b2 receptor tyrosine kinase 2	Homo sapiens	199-203
26656794-5	2016	Oxaliplatin and cisplatin were most cytotoxic with IC50 values of 1.7 muM+-0.8 and 4.1 muM+-0.1, respectively.	Oxaliplatin	0-11	latexin	Homo sapiens	87-90
26673998-6	2016	Further research showed that HY-PDT-mediated resensitization of resistance cells towards L-OHP was dependent on regulation of MRP-2, instead of p-gp.	Oxaliplatin	89-94	ATP binding cassette subfamily C member 2	Homo sapiens	126-131
27433728-1	2016	To prepare orally available oxaliplatin (OXA), nanocomplexes were formed by ionic conjugation of OXA with the deoxycholic acid derivative, Nalpha-deoxycholy-L-lysyl-methylester (DCK), as an oral absorption enhancer.	Oxaliplatin	28-39	deoxycytidine kinase	Homo sapiens	178-181
27433728-8	2016	An in vivo pharmacokinetic study revealed that the Cm value of the OXA/DCK nanocomplex was 3.18-fold higher than that of OXA (32.22 +/- 10.24 ng/mL), and the resulting oral bioavailability of the OXA/DCK nanocomplex was 39.3-fold more than that of OXA.	Oxaliplatin	67-70	deoxycytidine kinase	Homo sapiens	200-203
27433728-10	2016	These findings demonstrate the therapeutic potential of the OXA/DCK nanocomplex as an oral anti-cancer therapy because it improves the oral absorption of OXA, which may improve patient compliance and expand the therapeutic applications of OXA to the prevention of recurrence and metastasis.	Oxaliplatin	60-63	deoxycytidine kinase	Homo sapiens	64-67
26637483-6	2016	RESULTS: Knockdown of SMC1A protein and mRNA levels resulted in the inhibition of cell proliferation, an increased rate of apoptosis and enhanced chemosensitivity to oxaliplatin in HT-29 cells.	Oxaliplatin	166-177	structural maintenance of chromosomes 1A	Homo sapiens	22-27
27433728-1	2016	To prepare orally available oxaliplatin (OXA), nanocomplexes were formed by ionic conjugation of OXA with the deoxycholic acid derivative, Nalpha-deoxycholy-L-lysyl-methylester (DCK), as an oral absorption enhancer.	Oxaliplatin	41-44	deoxycytidine kinase	Homo sapiens	178-181
27433728-10	2016	These findings demonstrate the therapeutic potential of the OXA/DCK nanocomplex as an oral anti-cancer therapy because it improves the oral absorption of OXA, which may improve patient compliance and expand the therapeutic applications of OXA to the prevention of recurrence and metastasis.	Oxaliplatin	154-157	deoxycytidine kinase	Homo sapiens	64-67
27433728-2	2016	We characterized the DCK-conjugated OXA nanocomplexes by differential scanning calorimetry, particle size determination, and morphological analysis.	Oxaliplatin	36-39	deoxycytidine kinase	Homo sapiens	21-24
27433728-6	2016	The solubility of OXA in water was approximately 7.07 mg/mL, whereas the water solubility of OXA/DCK was approximately 2.04 mg/mL and its partition coefficient was approximately 1.2-fold higher than that of OXA.	Oxaliplatin	93-96	deoxycytidine kinase	Homo sapiens	97-100
27433728-7	2016	The in vitro intestinal membrane permeability of OXA was significantly enhanced by complex formation with DCK.	Oxaliplatin	49-52	deoxycytidine kinase	Homo sapiens	106-109
27433728-8	2016	An in vivo pharmacokinetic study revealed that the Cm value of the OXA/DCK nanocomplex was 3.18-fold higher than that of OXA (32.22 +/- 10.24 ng/mL), and the resulting oral bioavailability of the OXA/DCK nanocomplex was 39.3-fold more than that of OXA.	Oxaliplatin	67-70	deoxycytidine kinase	Homo sapiens	71-74
26768731-10	2016	Moreover, they showed reduced apoptosis, increased proliferation and different response to 5-fluorouracil and oxaliplatin upon CRY1 and CRY2 ectopic expression.	Oxaliplatin	110-121	cryptochrome circadian regulator 1	Homo sapiens	127-131
26797636-0	2016	Preventive Effects of Bee Venom Derived Phospholipase A2 on Oxaliplatin-Induced Neuropathic Pain in Mice.	Oxaliplatin	60-71	phospholipase A2, group IB, pancreas	Mus musculus	40-56
26797636-2	2016	Here we examined the preventive effects of Bee Venom (BV) derived phospholipase A2 (bvPLA2) on oxaliplatin-induced neuropathic pain in mice and its immunological mechanism.	Oxaliplatin	95-106	phospholipase A2, group IB, pancreas	Mus musculus	66-82
26768731-10	2016	Moreover, they showed reduced apoptosis, increased proliferation and different response to 5-fluorouracil and oxaliplatin upon CRY1 and CRY2 ectopic expression.	Oxaliplatin	110-121	cryptochrome circadian regulator 2	Homo sapiens	136-140
28356789-4	2016	The aim of our study was to evaluate the incidence of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving first line oxaliplatin based chemotherapy with or without bevacizumab and to evaluate their prognostic and predictive significance.	Oxaliplatin	154-165	KRAS proto-oncogene, GTPase	Homo sapiens	54-58
26729828-3	2016	Genetic evaluation determined that he had the GSTT1-null and GSTM1-null genotype, known to be an independent risk factor for developing oxaliplatin-induced SOS.	Oxaliplatin	136-147	glutathione S-transferase mu 1	Homo sapiens	61-66
26254603-2	2016	The structures of oxaliplatin/CDs were confirmed by NMR, FTIR, TGA, XRD as well as SEM analysis.	Oxaliplatin	18-29	T-box transcription factor 1	Homo sapiens	63-66
26729828-3	2016	Genetic evaluation determined that he had the GSTT1-null and GSTM1-null genotype, known to be an independent risk factor for developing oxaliplatin-induced SOS.	Oxaliplatin	136-147	glutathione S-transferase theta 1	Homo sapiens	46-51
28356789-4	2016	The aim of our study was to evaluate the incidence of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving first line oxaliplatin based chemotherapy with or without bevacizumab and to evaluate their prognostic and predictive significance.	Oxaliplatin	154-165	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	75-81
26575609-7	2016	The Fat4-silenced cells which were treated with 5-FU, Cisplatin, Oxaliplatin and Paclitaxel individually demonstrated less sensitivities to these chemotherapy drugs compared with the control cells.	Oxaliplatin	65-76	FAT atypical cadherin 4	Homo sapiens	4-8
26546510-0	2016	Celecoxib reverts oxaliplatin-induced neuropathic pain through inhibiting PI3K/Akt2 pathway in the mouse dorsal root ganglion.	Oxaliplatin	18-29	thymoma viral proto-oncogene 2	Mus musculus	79-83
26695693-7	2016	Overexpression of miR-1914* and -1915 in chemoresistant CRC cells reduced resistance to 5-FU and Oxaliplatin in vitro.	Oxaliplatin	97-108	microRNA 1914	Homo sapiens	18-26
26474693-1	2016	It has been demonstrated that COX-2-selective inhibitor celecoxib shows synergy with oxaliplatin for suppressing tumor growth.	Oxaliplatin	85-96	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	30-35
27262300-0	2016	TRPA1 and TRPM8 Receptors May Promote Local Vasodilation that Aggravates Oxaliplatin-Induced Peripheral Neuropathy Amenable to 17beta-Estradiol Treatment.	Oxaliplatin	73-84	transient receptor potential cation channel subfamily A member 1	Homo sapiens	0-5
27262300-0	2016	TRPA1 and TRPM8 Receptors May Promote Local Vasodilation that Aggravates Oxaliplatin-Induced Peripheral Neuropathy Amenable to 17beta-Estradiol Treatment.	Oxaliplatin	73-84	transient receptor potential cation channel subfamily M member 8	Homo sapiens	10-15
26474693-5	2016	Celecoxib alone or combined with oxaliplatin substantially reduced the expression of organic cation transporter 2 (OCT2).	Oxaliplatin	33-44	solute carrier family 22 member 2	Homo sapiens	85-113
26474693-5	2016	Celecoxib alone or combined with oxaliplatin substantially reduced the expression of organic cation transporter 2 (OCT2).	Oxaliplatin	33-44	solute carrier family 22 member 2	Homo sapiens	115-119
26474693-6	2016	To this end, OCT2 knockdown was sufficient to reduce oxaliplatin uptake, connecting OCT2 expression to oxaliplatin accumulation.	Oxaliplatin	53-64	solute carrier family 22 member 2	Homo sapiens	13-17
26474693-6	2016	To this end, OCT2 knockdown was sufficient to reduce oxaliplatin uptake, connecting OCT2 expression to oxaliplatin accumulation.	Oxaliplatin	103-114	solute carrier family 22 member 2	Homo sapiens	13-17
26546510-7	2016	We found that OXA increased the expression of cyclooxygenase-2 (COX-2) and Akt2 in the lumbar 4-5 (L4-5) dorsal root ganglion (DRG).	Oxaliplatin	14-17	thymoma viral proto-oncogene 2	Mus musculus	75-79
26546510-9	2016	Our findings showed that COX-2 and PI3K/Akt2 signaling in DRG contributed to the OXA-induced neuropathic pain.	Oxaliplatin	81-84	prostaglandin-endoperoxide synthase 2	Mus musculus	25-30
26546510-9	2016	Our findings showed that COX-2 and PI3K/Akt2 signaling in DRG contributed to the OXA-induced neuropathic pain.	Oxaliplatin	81-84	thymoma viral proto-oncogene 2	Mus musculus	40-44
26546510-7	2016	We found that OXA increased the expression of cyclooxygenase-2 (COX-2) and Akt2 in the lumbar 4-5 (L4-5) dorsal root ganglion (DRG).	Oxaliplatin	14-17	prostaglandin-endoperoxide synthase 2	Mus musculus	46-62
26546510-7	2016	We found that OXA increased the expression of cyclooxygenase-2 (COX-2) and Akt2 in the lumbar 4-5 (L4-5) dorsal root ganglion (DRG).	Oxaliplatin	14-17	prostaglandin-endoperoxide synthase 2	Mus musculus	64-69
26892017-7	2016	Oxaliplatin LP-EGF decreased IC50 between 48 and 13% in cell EGFR+.	Oxaliplatin	0-11	epidermal growth factor receptor	Homo sapiens	61-65
27340400-9	2016	Apoptotic and necrotic rates of CD4+ cells and CD8+ cells correlated well within the 2 Gy, 8 Gy, and 2 Gy and Oxaliplatin arrangements (p &lt;= 0.009).	Oxaliplatin	110-121	CD4 molecule	Homo sapiens	32-35
27340400-9	2016	Apoptotic and necrotic rates of CD4+ cells and CD8+ cells correlated well within the 2 Gy, 8 Gy, and 2 Gy and Oxaliplatin arrangements (p &lt;= 0.009).	Oxaliplatin	110-121	CD8a molecule	Homo sapiens	47-50
27340400-10	2016	High apoptotic CD8+ rates after 2 Gy, 8 Gy, and 2 Gy + Oxaliplatin treatment were prognostically favorable for metastasis-free survival (p = 0.009, p = 0.038, and p = 0.009) and disease-free survival (p = 0.013, p = 0.098, and p = 0.013).	Oxaliplatin	55-66	CD8a molecule	Homo sapiens	15-18
27301172-0	2016	Improved Treatment of MT-3 Breast Cancer and Brain Metastases in a Mouse Xenograft by LRP-Targeted Oxaliplatin Liposomes.	Oxaliplatin	99-110	low density lipoprotein receptor-related protein 1	Mus musculus	86-89
27229742-3	2016	METHODS: Subjects were mCRC patients with mutated KRAS who showed disease aggravation even after two regimens with oxaliplatin and irinotecan.	Oxaliplatin	115-126	KRAS proto-oncogene, GTPase	Homo sapiens	50-54
27565326-1	2016	The presented study aimed to investigate the antitumor efficacy of combination of oxaliplatin with rapamycin, an mTOR inhibitor, in hepatocellular carcinoma (HCC).	Oxaliplatin	82-93	mechanistic target of rapamycin kinase	Homo sapiens	113-117
27565326-10	2016	The ratios of Bax/Bcl-2 in cells exposed to both oxaliplatin and rapamycin were significantly increased compared to those in cells subjected to oxaliplatin or rapamycin alone treatment.	Oxaliplatin	49-60	BCL2 associated X, apoptosis regulator	Homo sapiens	14-17
27565326-10	2016	The ratios of Bax/Bcl-2 in cells exposed to both oxaliplatin and rapamycin were significantly increased compared to those in cells subjected to oxaliplatin or rapamycin alone treatment.	Oxaliplatin	49-60	BCL2 apoptosis regulator	Homo sapiens	18-23
27565326-10	2016	The ratios of Bax/Bcl-2 in cells exposed to both oxaliplatin and rapamycin were significantly increased compared to those in cells subjected to oxaliplatin or rapamycin alone treatment.	Oxaliplatin	144-155	BCL2 associated X, apoptosis regulator	Homo sapiens	14-17
26931435-7	2016	After HIF-1alpha-siRNA transfection, inhibition rates of 5-FU and L-OHP to tumor cells increased significantly.	Oxaliplatin	66-71	hypoxia inducible factor 1 subunit alpha	Homo sapiens	6-16
27229742-12	2016	CONCLUSIONS: The results suggest that third-line chemotherapy with combined bevacizumab and S-1 is safe and may delay the progression of mCRC resistant to oxaliplatin and irinotecan with mutated KRAS.	Oxaliplatin	155-166	proteasome 26S subunit, non-ATPase 1	Homo sapiens	92-95
26006084-3	2016	The purpose of the present study was to investigate the antiallodynic effect of LLLT in an oxaliplatin-treated animal model by assessing sensory behavioral responses, levels of nerve growth factor (NGF), and transient receptor potential M8 (TRPM8) in dorsal root ganglia (DRG) neurons, as well as substance P (SP) in the spinal dorsal horn.	Oxaliplatin	91-102	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	241-246
26006084-9	2016	Oxaliplatin-related increases in protein levels of NGF and TRPM8 in DRG and SP in the dorsal horn were also reduced after LLLT.	Oxaliplatin	0-11	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	59-64
26728375-0	2016	[Keratin 18 phosphorylation increases autophagy of colorectal cancer HCT116 cells and enhanced its sensitivity to oxaliplatin].	Oxaliplatin	114-125	keratin 18	Homo sapiens	1-11
26831807-9	2016	(2) TRPA1 expression via activation of p38 mitogen-activated protein kinase in small-diameter DRG neurons, at least in part, contributes to the development of oxaliplatin-induced acute cold hyperalgesia.	Oxaliplatin	159-170	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	4-9
26831807-9	2016	(2) TRPA1 expression via activation of p38 mitogen-activated protein kinase in small-diameter DRG neurons, at least in part, contributes to the development of oxaliplatin-induced acute cold hyperalgesia.	Oxaliplatin	159-170	mitogen activated protein kinase 14	Rattus norvegicus	39-42
26728375-1	2016	OBJECTIVE: To study the correlation between the phosphorylation of keratin 18 (K18) and the autophagy and apoptosis of HCT116 cells under the effect of oxaliplatin (OXA) and investigate its possible mechanism.	Oxaliplatin	152-163	keratin 18	Homo sapiens	67-77
26728375-1	2016	OBJECTIVE: To study the correlation between the phosphorylation of keratin 18 (K18) and the autophagy and apoptosis of HCT116 cells under the effect of oxaliplatin (OXA) and investigate its possible mechanism.	Oxaliplatin	152-163	keratin 18	Homo sapiens	79-82
26728375-1	2016	OBJECTIVE: To study the correlation between the phosphorylation of keratin 18 (K18) and the autophagy and apoptosis of HCT116 cells under the effect of oxaliplatin (OXA) and investigate its possible mechanism.	Oxaliplatin	165-168	keratin 18	Homo sapiens	67-77
26728375-1	2016	OBJECTIVE: To study the correlation between the phosphorylation of keratin 18 (K18) and the autophagy and apoptosis of HCT116 cells under the effect of oxaliplatin (OXA) and investigate its possible mechanism.	Oxaliplatin	165-168	keratin 18	Homo sapiens	79-82
26728375-5	2016	After treated with OXA, the apoptosis rate of K18 plasmid transfected group was significantly higher than that of empty plasmid transfected group, while the apoptosis rate of Ser33/52A plasmid transfected HCT116 cells was significantly lower than that of empty plasmid or K18 plasmid transfected group.	Oxaliplatin	19-22	keratin 18	Homo sapiens	46-49
26728375-7	2016	CONCLUSION: K18 overexpression enhanced the autophagy in HCT116 cells and increased its sensitivity to OXA.	Oxaliplatin	103-106	keratin 18	Homo sapiens	12-15
26674205-17	2015	Besides, Res exerted a synergistic effect with Oxa in a miR-34c dependent manner.	Oxaliplatin	47-50	microRNA 34c	Homo sapiens	56-63
26719345-9	2016	RESULTS: Cetuximab and oxaliplatin exhibited antagonistic effects on cellular proliferation and apoptosis (caspase 3/7 activity reduced by 1.4-fold, 95% confidence interval [CI] = 0.78 to 2.11, P = .003) as opposed to synergistic effects observed with the irinotecan metabolite 7-Ethyl-10-hydroxycamptothecin (SN-38).	Oxaliplatin	23-34	caspase 3	Homo sapiens	107-116
26719345-11	2016	Production of ROS by oxaliplatin was secondary to STAT1-mediated transcriptional upregulation of DUOX2 (3.1-fold, 95% CI = 1.75 to 2.41, P &lt; .001).	Oxaliplatin	21-32	signal transducer and activator of transcription 1	Homo sapiens	50-55
26719345-11	2016	Production of ROS by oxaliplatin was secondary to STAT1-mediated transcriptional upregulation of DUOX2 (3.1-fold, 95% CI = 1.75 to 2.41, P &lt; .001).	Oxaliplatin	21-32	dual oxidase 2	Homo sapiens	97-102
26719345-12	2016	Inhibition of DUOX2 induction and p38 activation by cetuximab reduced oxaliplatin cytotoxicity.	Oxaliplatin	70-81	dual oxidase 2	Homo sapiens	14-19
26719345-12	2016	Inhibition of DUOX2 induction and p38 activation by cetuximab reduced oxaliplatin cytotoxicity.	Oxaliplatin	70-81	mitogen-activated protein kinase 14	Homo sapiens	34-37
26719345-13	2016	CONCLUSIONS: Inhibition of STAT1 and DUOX2-mediated ROS generation by cetuximab impairs p38-dependent apoptosis by oxaliplatin in preclinical models and may contribute to reduced efficacy in clinical settings.	Oxaliplatin	115-126	signal transducer and activator of transcription 1	Homo sapiens	27-32
26719345-13	2016	CONCLUSIONS: Inhibition of STAT1 and DUOX2-mediated ROS generation by cetuximab impairs p38-dependent apoptosis by oxaliplatin in preclinical models and may contribute to reduced efficacy in clinical settings.	Oxaliplatin	115-126	dual oxidase 2	Homo sapiens	37-42
26719345-13	2016	CONCLUSIONS: Inhibition of STAT1 and DUOX2-mediated ROS generation by cetuximab impairs p38-dependent apoptosis by oxaliplatin in preclinical models and may contribute to reduced efficacy in clinical settings.	Oxaliplatin	115-126	mitogen-activated protein kinase 14	Homo sapiens	88-91
26662383-0	2015	Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	123-134	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	15-20
26674867-7	2015	Consistently, systemic treatment with donepezil, a centrally active acetylcholinesterase inhibitor, prevented and reversed oxaliplatin-induced cold and mechanical allodynia as well as social interaction impairment.	Oxaliplatin	123-134	acetylcholinesterase	Rattus norvegicus	68-88
26514681-3	2015	Here we utilize N-bromosuccinimide (NBS) and carry out oxidative bromination on platinum(II) drugs, namely cisplatin, carboplatin, and oxaliplatin, to obtain asymmetric and mono-bromo platinum(IV) prodrugs.	Oxaliplatin	135-146	nibrin	Homo sapiens	36-39
26318481-5	2015	The influences of Cx43 infection on sensitivity of chemotherapy (including Doxorubicin, fluorouracil, oxaliplatin) were detected by MTT assay.	Oxaliplatin	102-113	gap junction protein alpha 1	Homo sapiens	18-22
26318481-12	2015	The data of MTT assay revealed that infection with Cx43 adenovirus, cell proliferation ability decreased and sensitivity to chemotherapy drugs (including doxorubicin, fluorouracil, oxaliplatin) increased.	Oxaliplatin	181-192	gap junction protein alpha 1	Homo sapiens	51-55
26662383-2	2015	The present study aimed to evaluate the effects of ERCC1 expression in peripheral blood lymphocytes (PBLs) on the outcome of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	167-178	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56
26662383-10	2015	Patients with gastric cancer exhibiting negative expression of ERCC1 are more likely to benefit from oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	101-112	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	63-68
26282442-5	2015	Strong associations between some red cell indices (MCH, MCHC, RDW) and 1-OHP concentration were found.	Oxaliplatin	71-76	pro-melanin concentrating hormone	Homo sapiens	51-54
26636340-0	2015	Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107.	Oxaliplatin	82-93	lin-28 homolog A	Homo sapiens	18-23
26636340-3	2015	In this study, we found that transfection of Lin28 into gastric cancer cells (MKN45 and MKN28) increased their resistance to the chemo-drugs oxaliplatin (OXA), paclitaxel (PTX), doxorubicin (ADM), and fluorouracil (5-Fu) compared with gastric cancer cells transfected with a control vector.	Oxaliplatin	141-152	lin-28 homolog A	Homo sapiens	45-50
26636340-3	2015	In this study, we found that transfection of Lin28 into gastric cancer cells (MKN45 and MKN28) increased their resistance to the chemo-drugs oxaliplatin (OXA), paclitaxel (PTX), doxorubicin (ADM), and fluorouracil (5-Fu) compared with gastric cancer cells transfected with a control vector.	Oxaliplatin	154-157	lin-28 homolog A	Homo sapiens	45-50
26399480-7	2015	GSH enhances the reactivity of three anti-cancer drugs (cisplatin, carboplatin and oxaliplatin) to Cox17, but suppresses the reaction of transplatin.	Oxaliplatin	83-94	cytochrome c oxidase copper chaperone COX17	Homo sapiens	99-104
27551256-4	2015	The decoy vascular endothelial growth factor receptor aflibercept has been approved in combination with 5-fluorouracil, leucovorin and irinotecan-based chemotherapy in metastatic colorectal cancer patients whose disease has progressed on a prior oxaliplatin-based chemotherapy regimen.	Oxaliplatin	246-257	vascular endothelial growth factor A	Homo sapiens	10-44
26138671-4	2015	The results indicated that treatment of tumor cells with oxaliplatin induced the production of type I interferons and chemokines and enhanced the expression of major histocompatibility complex class I-related chains (MIC) A/B, UL16-binding protein (ULBP)-3, CD155 and TNF-related apoptosis-inducing ligand (TRAIL)-R1/R2.	Oxaliplatin	57-68	UL16 binding protein 3	Homo sapiens	227-256
26138671-4	2015	The results indicated that treatment of tumor cells with oxaliplatin induced the production of type I interferons and chemokines and enhanced the expression of major histocompatibility complex class I-related chains (MIC) A/B, UL16-binding protein (ULBP)-3, CD155 and TNF-related apoptosis-inducing ligand (TRAIL)-R1/R2.	Oxaliplatin	57-68	PVR cell adhesion molecule	Homo sapiens	258-263
26138671-4	2015	The results indicated that treatment of tumor cells with oxaliplatin induced the production of type I interferons and chemokines and enhanced the expression of major histocompatibility complex class I-related chains (MIC) A/B, UL16-binding protein (ULBP)-3, CD155 and TNF-related apoptosis-inducing ligand (TRAIL)-R1/R2.	Oxaliplatin	57-68	TNF receptor superfamily member 10a	Homo sapiens	268-319
26239545-2	2015	Here, the X-ray structures of the adducts formed upon reaction of carboplatin and oxaliplatin with bovine pancreatic ribonuclease (RNase A) are reported and compared with results obtained for the structure of the RNase A-cisplatin adduct derived from isomorphous crystals, under the same experimental conditions.	Oxaliplatin	82-93	ribonuclease pancreatic	Bos taurus	131-138
25899918-6	2015	Congruently, NUPR1L gene expression is activated in response to DNA damage induced by oxaliplatin treatment or cell cycle arrest induced by serum starvation, two well-validated methods to achieve p53 activation.	Oxaliplatin	86-97	nuclear protein 2, transcriptional regulator	Homo sapiens	13-19
26239545-2	2015	Here, the X-ray structures of the adducts formed upon reaction of carboplatin and oxaliplatin with bovine pancreatic ribonuclease (RNase A) are reported and compared with results obtained for the structure of the RNase A-cisplatin adduct derived from isomorphous crystals, under the same experimental conditions.	Oxaliplatin	82-93	ribonuclease pancreatic	Bos taurus	213-220
25778469-6	2015	Patients carrying variant alleles of rs3783819 (MNAT1) and rs1043953 (XPC) experienced a longer overall survival after treatment with oxaliplatin than patients who did not carry the variant allele, while the opposite association was found in patients who were not treated with oxaliplatin (false discovery rate-adjusted P-values for heterogeneity 0.0047 and 0.0237, respectively).	Oxaliplatin	134-145	MNAT1 component of CDK activating kinase	Homo sapiens	48-53
25778469-6	2015	Patients carrying variant alleles of rs3783819 (MNAT1) and rs1043953 (XPC) experienced a longer overall survival after treatment with oxaliplatin than patients who did not carry the variant allele, while the opposite association was found in patients who were not treated with oxaliplatin (false discovery rate-adjusted P-values for heterogeneity 0.0047 and 0.0237, respectively).	Oxaliplatin	277-288	MNAT1 component of CDK activating kinase	Homo sapiens	48-53
25778469-6	2015	Patients carrying variant alleles of rs3783819 (MNAT1) and rs1043953 (XPC) experienced a longer overall survival after treatment with oxaliplatin than patients who did not carry the variant allele, while the opposite association was found in patients who were not treated with oxaliplatin (false discovery rate-adjusted P-values for heterogeneity 0.0047 and 0.0237, respectively).	Oxaliplatin	277-288	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	70-73
26644081-3	2015	In this study, we showed that combination of imatinib with platinum (Pt)-based anticancer agents, including cisplatin and oxaliplatin, exhibited synergistic cytotoxic effect specifically in Bcr-Abl+ human chronic myeloid leukemia cell line K562 but not in Bcr-Abl- RPMI8226 cells.	Oxaliplatin	122-133	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	190-197
26644081-3	2015	In this study, we showed that combination of imatinib with platinum (Pt)-based anticancer agents, including cisplatin and oxaliplatin, exhibited synergistic cytotoxic effect specifically in Bcr-Abl+ human chronic myeloid leukemia cell line K562 but not in Bcr-Abl- RPMI8226 cells.	Oxaliplatin	122-133	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	256-263
26398480-6	2015	Additionally, OCT4B1 was able to reduce sensitivity to oxaliplatin by altering the expression of two important mediators in drug resistance, P-gp and ABCG2 [ATP-binding cassette, sub-family G (WHITE), member 2].	Oxaliplatin	55-66	phosphoglycolate phosphatase	Mus musculus	141-145
26398480-6	2015	Additionally, OCT4B1 was able to reduce sensitivity to oxaliplatin by altering the expression of two important mediators in drug resistance, P-gp and ABCG2 [ATP-binding cassette, sub-family G (WHITE), member 2].	Oxaliplatin	55-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	150-155
26398480-6	2015	Additionally, OCT4B1 was able to reduce sensitivity to oxaliplatin by altering the expression of two important mediators in drug resistance, P-gp and ABCG2 [ATP-binding cassette, sub-family G (WHITE), member 2].	Oxaliplatin	55-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	157-209
25778469-6	2015	Patients carrying variant alleles of rs3783819 (MNAT1) and rs1043953 (XPC) experienced a longer overall survival after treatment with oxaliplatin than patients who did not carry the variant allele, while the opposite association was found in patients who were not treated with oxaliplatin (false discovery rate-adjusted P-values for heterogeneity 0.0047 and 0.0237, respectively).	Oxaliplatin	134-145	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	70-73
26124005-2	2015	In this study, the effects of resveratrol on the expression of P-glycoprotein/multi-drug resistance protein 1 (P-gp/MDR1), and the underlying molecular mechanisms, were investigated in oxaliplatin (L-OHP)-resistant colorectal cancer cells (HCT116/L-OHP).	Oxaliplatin	185-196	phosphoglycolate phosphatase	Homo sapiens	111-115
26124005-2	2015	In this study, the effects of resveratrol on the expression of P-glycoprotein/multi-drug resistance protein 1 (P-gp/MDR1), and the underlying molecular mechanisms, were investigated in oxaliplatin (L-OHP)-resistant colorectal cancer cells (HCT116/L-OHP).	Oxaliplatin	185-196	ATP binding cassette subfamily B member 1	Homo sapiens	116-120
26552750-7	2015	Orthotopic HT-29 xenografts treated with standard CRC chemotherapeutics 5-fluorouracil, irinotecan, or oxaliplatin showed dramatic increases in CD26 compared to untreated tumors.	Oxaliplatin	103-114	dipeptidyl peptidase 4	Homo sapiens	144-148
26552750-9	2015	Analysis of cancer-initiating cell CD44 and CD133 subsets revealed drug-dependent responses of CD26/CD44/CD133 populations, suggesting that the benefits of combining standard chemotherapies 5-fluoruracil and oxaliplatin may be derived from their complementary elimination of cell populations.	Oxaliplatin	208-219	dipeptidyl peptidase 4	Homo sapiens	95-99
26552750-9	2015	Analysis of cancer-initiating cell CD44 and CD133 subsets revealed drug-dependent responses of CD26/CD44/CD133 populations, suggesting that the benefits of combining standard chemotherapies 5-fluoruracil and oxaliplatin may be derived from their complementary elimination of cell populations.	Oxaliplatin	208-219	CD44 molecule (Indian blood group)	Homo sapiens	100-104
26196680-8	2015	SW480 CRC cells that naturally express Lgr5 are those that are floating, and they are more sensitive to the chemotherapeutic compounds irinotecan (maximum difference approximately two times, 0.0001&lt;P&lt;0.0052) and oxaliplatin (maximum difference ~1.5 times, 0.0001&lt;P&lt;0.0024) than Lgr5-negative (attached) SW480 cells.	Oxaliplatin	218-229	leucine rich repeat containing G protein-coupled receptor 5	Homo sapiens	39-43
26567040-6	2015	Real-time PCR showed that oxaliplatin (6 mg/kg) significantly increased TRPA1 mRNA expression in DRGs at days 1, 2, and 4.	Oxaliplatin	26-37	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	72-77
26567040-7	2015	Western blotting revealed that oxaliplatin significantly increased TRPA1 protein expression in DRGs at days 2, 4, and 7.	Oxaliplatin	31-42	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	67-72
26567040-9	2015	Oxaliplatin significantly increased co-localization of TRPA1 expression and isolectin B4 binding in DRG neurons.	Oxaliplatin	0-11	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	55-60
26567040-10	2015	Oxaliplatin induced a significant increase in the percent of TRPA1 mRNA-positive small neurons in DRGs at days 1, 2, and 4.	Oxaliplatin	0-11	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	61-66
26567040-11	2015	In addition, we found that intrathecal administration of TRPA1 antisense, but not TRPA1 mismatched oligodeoxynucleotides, knocked down TRPA1 expression and decreased oxaliplatin-induced cold hyperalgesia.	Oxaliplatin	166-177	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	57-62
26567040-12	2015	Double labeling showed that p-p38 mitogen-activated protein kinase (MAPK) was co-expressed in TRPA1 mRNA-labeled neurons at day 2 after oxaliplatin administration.	Oxaliplatin	136-147	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	94-99
26567040-14	2015	CONCLUSIONS: Together, these results demonstrate that TRPA1 expression via activation of p38 MAPK in DRG neurons, at least in part, contributes to the development of oxaliplatin-induced acute cold hyperalgesia.	Oxaliplatin	166-177	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	54-59
26450087-6	2015	In oxaliplatin-treated rats, 0.3 nmol morphine induced the reversion of the mechanical hypersensitivity (Paw-pressure test), nociceptin/orphanin FQ (N/OFQ; 0.3-3 nmol) significantly increased the pain threshold without reaching the values of the control animals.	Oxaliplatin	3-14	prepronociceptin	Rattus norvegicus	125-135
26450087-6	2015	In oxaliplatin-treated rats, 0.3 nmol morphine induced the reversion of the mechanical hypersensitivity (Paw-pressure test), nociceptin/orphanin FQ (N/OFQ; 0.3-3 nmol) significantly increased the pain threshold without reaching the values of the control animals.	Oxaliplatin	3-14	prepronociceptin	Rattus norvegicus	136-147
26298407-4	2015	METHODS: A 5-year retrospective review of patients referred to Massachusetts General Hospital with carboplatin- or oxaliplatin-induced HSR was performed.	Oxaliplatin	115-126	HSR	Homo sapiens	135-138
26298407-11	2015	For carboplatin and oxaliplatin, ST conversion was associated with an interval of at least 6 months from the HSR to the initial ST (carboplatin, P = .002; oxaliplatin, P = .045).	Oxaliplatin	155-166	HSR	Homo sapiens	109-112
26123838-0	2015	Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.	Oxaliplatin	67-78	homeobox C8	Homo sapiens	12-17
26123838-11	2015	HOXC8 siRNA knockdown delayed the G1-S phase transition, inhibited cell proliferation, and attenuated resistance to oxaliplatin.	Oxaliplatin	116-127	homeobox C8	Homo sapiens	0-5
26123838-13	2015	Furthermore, upregulated HOXC8 expression was associated with oxaliplatin resistance in hepatocellular carcinoma.	Oxaliplatin	62-73	homeobox C8	Homo sapiens	25-30
26372896-1	2015	Our previous study showed that administering oxaliplatin as first-line chemotherapy increased ERCC1 and DPD levels in liver colorectal cancers (CRCs) metastases.	Oxaliplatin	45-56	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	94-99
26372896-1	2015	Our previous study showed that administering oxaliplatin as first-line chemotherapy increased ERCC1 and DPD levels in liver colorectal cancers (CRCs) metastases.	Oxaliplatin	45-56	dihydropyrimidine dehydrogenase	Homo sapiens	104-107
26372896-9	2015	This study confirmed that first-line oxaliplatin-based chemotherapy increases ERCC1 and DPYD expression levels, potentially enhancing chemosensitivity to subsequent therapy.	Oxaliplatin	37-48	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	78-83
26372896-9	2015	This study confirmed that first-line oxaliplatin-based chemotherapy increases ERCC1 and DPYD expression levels, potentially enhancing chemosensitivity to subsequent therapy.	Oxaliplatin	37-48	dihydropyrimidine dehydrogenase	Homo sapiens	88-92
26460489-0	2015	Down-Regulating Receptor Interacting Protein Kinase 1 (RIP1) Promotes Oxaliplatin-Induced Tca8113 Cell Apoptosis.	Oxaliplatin	70-81	receptor interacting serine/threonine kinase 1	Homo sapiens	16-53
26460489-0	2015	Down-Regulating Receptor Interacting Protein Kinase 1 (RIP1) Promotes Oxaliplatin-Induced Tca8113 Cell Apoptosis.	Oxaliplatin	70-81	receptor interacting serine/threonine kinase 1	Homo sapiens	55-59
26460489-7	2015	RESULTS: We found that 1 mumol/L oxaliplatin could inhibit Tca8113 cell growth (cell survival rate was 19.3%), reduce mitochondrial membrane potential (reduce 82.3%) and phosphatidylserine eversion (positive rate was 62.7%), and activate caspase-3 (increased 2.6 times).	Oxaliplatin	33-44	caspase 3	Homo sapiens	238-247
26460489-8	2015	We also found that 1 mumol/L oxaliplatin treatment could increase RIP1 expression in Tca8113 cells.	Oxaliplatin	29-40	receptor interacting serine/threonine kinase 1	Homo sapiens	66-70
26460489-9	2015	Cell apoptosis rate increased after siRNA RIP1 and 1 mumol/L oxaliplatin treatment (apoptosis rate was 90.2%).	Oxaliplatin	61-72	receptor interacting serine/threonine kinase 1	Homo sapiens	42-52
26460489-10	2015	CONCLUSIONS: Down-regulating RIP1 promotes oxaliplatin induced Tca8113 cells apoptosis.	Oxaliplatin	43-54	receptor interacting serine/threonine kinase 1	Homo sapiens	29-33
26567040-0	2015	Transient receptor potential ankyrin 1 that is induced in dorsal root ganglion neurons contributes to acute cold hypersensitivity after oxaliplatin administration.	Oxaliplatin	136-147	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	0-38
26567040-3	2015	In the present study, we investigated the effects of oxaliplatin on transient receptor potential ankyrin 1 (TRPA1) in dorsal root ganglion (DRG) neurons of rats.	Oxaliplatin	53-64	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	68-106
26567040-3	2015	In the present study, we investigated the effects of oxaliplatin on transient receptor potential ankyrin 1 (TRPA1) in dorsal root ganglion (DRG) neurons of rats.	Oxaliplatin	53-64	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	108-113
26525741-0	2015	High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment.	Oxaliplatin	134-145	schlafen family member 11	Homo sapiens	5-11
26525741-0	2015	High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment.	Oxaliplatin	134-145	KRAS proto-oncogene, GTPase	Homo sapiens	66-70
26525741-2	2015	The study was to investigate whether SLFN11 expression is related to sensitivity to adjuvant oxaliplatin-based treatment in colorectal cancer.	Oxaliplatin	93-104	schlafen family member 11	Homo sapiens	37-43
26525741-11	2015	CONCLUSIONS: SLFN11 expression predicts good better survival in colorectal cancer patients with KRAS exon 2 wild type who have received oxaliplatin based adjuvant chemotherapy.	Oxaliplatin	136-147	schlafen family member 11	Homo sapiens	13-19
26525741-11	2015	CONCLUSIONS: SLFN11 expression predicts good better survival in colorectal cancer patients with KRAS exon 2 wild type who have received oxaliplatin based adjuvant chemotherapy.	Oxaliplatin	136-147	KRAS proto-oncogene, GTPase	Homo sapiens	96-100
26160429-0	2015	Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin.	Oxaliplatin	77-88	semenogelin 1	Homo sapiens	15-18
26160429-5	2015	Pretreatment with low doses of SGI-110 significantly synergized with oxaliplatin yielding enhanced cytotoxicity.	Oxaliplatin	69-80	semenogelin 1	Homo sapiens	31-34
26160429-6	2015	The combination of SGI-110 and oxaliplatin was well tolerated and significantly delayed tumor growth in mice compared to oxaliplatin alone.	Oxaliplatin	121-132	chromogranin B	Mus musculus	19-22
26160429-10	2015	In conclusion, SGI-110 priming sensitizes HCC cells to oxaliplatin by inhibiting distinct signaling pathways.	Oxaliplatin	55-66	semenogelin 1	Homo sapiens	15-18
26616804-0	2015	[Association between RIPK4 relative copy number and prognosis of colorectal cancer patient after oxaliplatin-based chemotherapy].	Oxaliplatin	97-108	receptor interacting serine/threonine kinase 4	Homo sapiens	21-26
26616804-1	2015	OBJECTIVE: To investigate the association between receptor-interacting kinase protein 4 (RIPK4) relative copy number (RCN) and prognosis of stage III( colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	197-208	receptor interacting serine/threonine kinase 4	Homo sapiens	89-94
26616804-10	2015	Multivariate analysis revealed that high RIPK4 RCN was an independent prognostic factor of OS in stage III( CRC patients treated with oxaliplatin-based chemotherapy (HR=2.903, 95% CI: 1.275 to 6.610).	Oxaliplatin	134-145	receptor interacting serine/threonine kinase 4	Homo sapiens	41-46
26616804-11	2015	CONCLUSION: RIPK4 RCN is significantly associated with OS in stage III( colon cancer patients receiving oxaliplatin-based chemotherapy and may be a novel biomarker that can predict the efficacy of oxaliplatin in colon cancer patients.	Oxaliplatin	104-115	receptor interacting serine/threonine kinase 4	Homo sapiens	12-17
26616804-11	2015	CONCLUSION: RIPK4 RCN is significantly associated with OS in stage III( colon cancer patients receiving oxaliplatin-based chemotherapy and may be a novel biomarker that can predict the efficacy of oxaliplatin in colon cancer patients.	Oxaliplatin	197-208	receptor interacting serine/threonine kinase 4	Homo sapiens	12-17
26490659-4	2015	This study aimed to evaluate the predictive significance of the serum p53 antibody status in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy.	Oxaliplatin	169-180	tumor protein p53	Homo sapiens	70-73
26543375-2	2015	The purpose of this study was to investigate the effect of PARP1 inhibitor on oxaliplatin treatment for colorectal cancer (CRC).	Oxaliplatin	78-89	poly(ADP-ribose) polymerase 1	Homo sapiens	59-64
26770441-0	2015	Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy.	Oxaliplatin	108-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-22
26770441-0	2015	Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy.	Oxaliplatin	108-119	X-ray repair cross complementing 1	Homo sapiens	27-32
26770441-1	2015	The aim of the present study was to evaluate the clinical outcome of excision repair cross-complementing protein 1 (ERCC1) and X-ray repair cross-complementing protein 1 (XRCC1) gene polymorphisms in 89 patients receiving oxaliplatin/5-fluorouracil-based chemotherapy as a first-line treatment regimen for advanced gastric cancer.	Oxaliplatin	222-233	X-ray repair cross complementing 1	Homo sapiens	127-169
26770441-1	2015	The aim of the present study was to evaluate the clinical outcome of excision repair cross-complementing protein 1 (ERCC1) and X-ray repair cross-complementing protein 1 (XRCC1) gene polymorphisms in 89 patients receiving oxaliplatin/5-fluorouracil-based chemotherapy as a first-line treatment regimen for advanced gastric cancer.	Oxaliplatin	222-233	X-ray repair cross complementing 1	Homo sapiens	171-176
26186063-3	2015	In this work, we described the design, synthesis, and characterization of conjugates combining trastuzumab with a platinum (IV) analog of oxaliplatin, in which the trastuzumab acted as an active targeting agent for HER2-positive cancer cells.	Oxaliplatin	138-149	erb-b2 receptor tyrosine kinase 2	Homo sapiens	215-219
26196680-11	2015	Transfected Lgr5-overexpressing attached cells showed similar results with irinotecan and oxaliplatin, confirming that the detected differences in sensitivity to these drugs were Lgr5 driven.	Oxaliplatin	90-101	leucine rich repeat containing G protein-coupled receptor 5	Homo sapiens	12-16
26632544-7	2015	Randomized controlled EACH study and retrospective AGEO study for systemic chemotherapy showed that oxaliplatin-based or gemcitabine-based regimen was effective for advanced HCC patients.	Oxaliplatin	100-111	HCC	Homo sapiens	174-177
26239822-0	2015	Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.	Oxaliplatin	92-103	DLC1 Rho GTPase activating protein	Homo sapiens	18-22
26208523-5	2015	In this study, we found that oxaliplatin and dachplatin, platinum-based drugs containing the 1,2-diaminocyclohexane (DACH) carrier ligand, repressed the expression of nuclear isoform of dUTPase (DUT-N), whereas cisplatin and carboplatin did not.	Oxaliplatin	29-40	Deoxyuridine triphosphatase	Drosophila melanogaster	186-193
26208523-5	2015	In this study, we found that oxaliplatin and dachplatin, platinum-based drugs containing the 1,2-diaminocyclohexane (DACH) carrier ligand, repressed the expression of nuclear isoform of dUTPase (DUT-N), whereas cisplatin and carboplatin did not.	Oxaliplatin	29-40	deoxyuridine triphosphatase	Homo sapiens	195-198
26208523-6	2015	Oxaliplatin induced early p53 accumulation, upregulation of primary miR-34a transcript expression, and subsequent downregulation of E2F3 and E2F1.	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	26-29
26208523-6	2015	Oxaliplatin induced early p53 accumulation, upregulation of primary miR-34a transcript expression, and subsequent downregulation of E2F3 and E2F1.	Oxaliplatin	0-11	microRNA 34a	Homo sapiens	68-75
26208523-6	2015	Oxaliplatin induced early p53 accumulation, upregulation of primary miR-34a transcript expression, and subsequent downregulation of E2F3 and E2F1.	Oxaliplatin	0-11	E2F transcription factor 3	Homo sapiens	132-136
26208523-6	2015	Oxaliplatin induced early p53 accumulation, upregulation of primary miR-34a transcript expression, and subsequent downregulation of E2F3 and E2F1.	Oxaliplatin	0-11	E2F transcription factor 1	Homo sapiens	141-145
26208523-9	2015	In addition to DUT-N, oxaliplatin repressed, in a p53-dependent manner, the expression of genes encoding enzymes involved in thymidylate biosynthesis.	Oxaliplatin	22-33	tumor protein p53	Homo sapiens	50-53
26208523-10	2015	Consequently, oxaliplatin significantly decreased the level of dTTP in the dNTP pool in a p53-dependent manner.	Oxaliplatin	14-25	tumor protein p53	Homo sapiens	90-93
25809905-11	2015	In MGC-803 cells, CD44 stimulated proliferation and colony formation, antagonized oxaliplatin-induced apoptosis, but did not affect migration.	Oxaliplatin	82-93	CD44 molecule (Indian blood group)	Homo sapiens	18-22
26208523-0	2015	The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis.	Oxaliplatin	45-56	tumor protein p53	Homo sapiens	65-68
26208523-3	2015	In the p53-proficient colorectal cancer cell line HCT116, oxaliplatin represses the expression of deoxyuridine triphosphatase (dUTPase), a ubiquitous pyrophosphatase that catalyzes the hydrolysis of dUTP to dUMP and inhibits dUTP-mediated cytotoxicity.	Oxaliplatin	58-69	tumor protein p53	Homo sapiens	7-10
26208523-3	2015	In the p53-proficient colorectal cancer cell line HCT116, oxaliplatin represses the expression of deoxyuridine triphosphatase (dUTPase), a ubiquitous pyrophosphatase that catalyzes the hydrolysis of dUTP to dUMP and inhibits dUTP-mediated cytotoxicity.	Oxaliplatin	58-69	deoxyuridine triphosphatase	Homo sapiens	98-125
26208523-3	2015	In the p53-proficient colorectal cancer cell line HCT116, oxaliplatin represses the expression of deoxyuridine triphosphatase (dUTPase), a ubiquitous pyrophosphatase that catalyzes the hydrolysis of dUTP to dUMP and inhibits dUTP-mediated cytotoxicity.	Oxaliplatin	58-69	Deoxyuridine triphosphatase	Drosophila melanogaster	127-134
26547331-0	2015	[Effect of bafilomycin A1 on proliferation and oxaliplatin sensitivity in gastric cancer MGC-803 cells].	Oxaliplatin	47-58	BAF nuclear assembly factor 1	Homo sapiens	11-25
26208523-11	2015	These data indicate that the DACH carrier ligand in oxaliplatin triggers signaling via the p53-miR-34a-E2F axis, leading to transcriptional regulation that ultimately results in accumulation of dUTP and reduced dTTP biosynthesis, potentially enhancing 5-FU cytotoxicity.	Oxaliplatin	52-63	tumor protein p53	Homo sapiens	91-94
26208523-11	2015	These data indicate that the DACH carrier ligand in oxaliplatin triggers signaling via the p53-miR-34a-E2F axis, leading to transcriptional regulation that ultimately results in accumulation of dUTP and reduced dTTP biosynthesis, potentially enhancing 5-FU cytotoxicity.	Oxaliplatin	52-63	microRNA 34a	Homo sapiens	95-102
26547331-1	2015	OBJECTIVE: To investigate the effect of bafilomycin A1 (BAF) on the cell proliferation, invasiveness, apoptosis, and oxaliplatin sensitivity in gastric cancer MGC-803 cells.	Oxaliplatin	117-128	BAF nuclear assembly factor 1	Homo sapiens	40-54
26547331-1	2015	OBJECTIVE: To investigate the effect of bafilomycin A1 (BAF) on the cell proliferation, invasiveness, apoptosis, and oxaliplatin sensitivity in gastric cancer MGC-803 cells.	Oxaliplatin	117-128	BAF nuclear assembly factor 1	Homo sapiens	56-59
26547331-8	2015	Compared with cells treated with oxaliplatin alone, the cells treated with both BAF and oxaliplatin showed significantly lowered autophagosome accumulation, suppressed cell proliferation, migration and invasion, increased cell apoptosis, increased Bax expression and lowered Bcl-2 expression.	Oxaliplatin	33-44	BAF nuclear assembly factor 1	Homo sapiens	80-83
26547331-8	2015	Compared with cells treated with oxaliplatin alone, the cells treated with both BAF and oxaliplatin showed significantly lowered autophagosome accumulation, suppressed cell proliferation, migration and invasion, increased cell apoptosis, increased Bax expression and lowered Bcl-2 expression.	Oxaliplatin	88-99	BCL2 associated X, apoptosis regulator	Homo sapiens	248-251
26071109-0	2015	Oxaliplatin evokes P2X7-dependent glutamate release in the cerebral cortex: A pain mechanism mediated by Pannexin 1.	Oxaliplatin	0-11	Pannexin 1	Rattus norvegicus	105-115
26044641-7	2015	Oxaliplatin also accelerated neurobiotin uptake in HeLa cells expressing the human ortholog of Cx29, Cx31.3, as well as dye transfer between cells expressing the human Cx32, and this effect was blocked by octanol.	Oxaliplatin	0-11	gap junction protein gamma 3	Homo sapiens	95-99
26071109-7	2015	Finally, the influence of the P2X7R-Panx1 system blockade on oxaliplatin anticancer activity was evaluated on the human colon cancer cell line HT-29.	Oxaliplatin	61-72	pannexin 1	Homo sapiens	30-41
26547331-8	2015	Compared with cells treated with oxaliplatin alone, the cells treated with both BAF and oxaliplatin showed significantly lowered autophagosome accumulation, suppressed cell proliferation, migration and invasion, increased cell apoptosis, increased Bax expression and lowered Bcl-2 expression.	Oxaliplatin	88-99	BCL2 apoptosis regulator	Homo sapiens	275-280
26071109-10	2015	It is concluded that glutamate release dependent on P2X7R is increased in cerebrocortical nerve terminals from oxaliplatin-treated rats; the increase is mediated by functional recruitment of Panx1; P2X7R antagonists and Panx1 inhibitors revert oxaliplatin-induced neuropathic pain; Panx1 inhibitors do not alter the oxaliplatin-induced mortality of cancer cells HT-29.	Oxaliplatin	111-122	Pannexin 1	Rattus norvegicus	191-196
26044641-7	2015	Oxaliplatin also accelerated neurobiotin uptake in HeLa cells expressing the human ortholog of Cx29, Cx31.3, as well as dye transfer between cells expressing the human Cx32, and this effect was blocked by octanol.	Oxaliplatin	0-11	gap junction protein gamma 3	Homo sapiens	101-107
26044641-7	2015	Oxaliplatin also accelerated neurobiotin uptake in HeLa cells expressing the human ortholog of Cx29, Cx31.3, as well as dye transfer between cells expressing the human Cx32, and this effect was blocked by octanol.	Oxaliplatin	0-11	gap junction protein beta 1	Homo sapiens	168-172
26071109-10	2015	It is concluded that glutamate release dependent on P2X7R is increased in cerebrocortical nerve terminals from oxaliplatin-treated rats; the increase is mediated by functional recruitment of Panx1; P2X7R antagonists and Panx1 inhibitors revert oxaliplatin-induced neuropathic pain; Panx1 inhibitors do not alter the oxaliplatin-induced mortality of cancer cells HT-29.	Oxaliplatin	111-122	Pannexin 1	Rattus norvegicus	220-225
26044641-9	2015	Our study indicates that oxaliplatin causes forced opening of Cx32 channels and Cx29 hemichannels in peripheral myelinated fibers leading to disruption of axonal K(+) homeostasis.	Oxaliplatin	25-36	gap junction protein beta 1	Homo sapiens	62-66
26547331-9	2015	CONCLUSION: BAF can inhibit the proliferation and invasiveness of MGC-803 cells, promote cell apoptosis by inhibiting autophagy, and enhances the sensitivity of the cells to oxaliplatin.	Oxaliplatin	174-185	BAF nuclear assembly factor 1	Homo sapiens	12-15
26044641-9	2015	Our study indicates that oxaliplatin causes forced opening of Cx32 channels and Cx29 hemichannels in peripheral myelinated fibers leading to disruption of axonal K(+) homeostasis.	Oxaliplatin	25-36	gap junction protein gamma 3	Homo sapiens	80-84
26071109-10	2015	It is concluded that glutamate release dependent on P2X7R is increased in cerebrocortical nerve terminals from oxaliplatin-treated rats; the increase is mediated by functional recruitment of Panx1; P2X7R antagonists and Panx1 inhibitors revert oxaliplatin-induced neuropathic pain; Panx1 inhibitors do not alter the oxaliplatin-induced mortality of cancer cells HT-29.	Oxaliplatin	111-122	Pannexin 1	Rattus norvegicus	220-225
26071109-10	2015	It is concluded that glutamate release dependent on P2X7R is increased in cerebrocortical nerve terminals from oxaliplatin-treated rats; the increase is mediated by functional recruitment of Panx1; P2X7R antagonists and Panx1 inhibitors revert oxaliplatin-induced neuropathic pain; Panx1 inhibitors do not alter the oxaliplatin-induced mortality of cancer cells HT-29.	Oxaliplatin	244-255	Pannexin 1	Rattus norvegicus	191-196
26071109-10	2015	It is concluded that glutamate release dependent on P2X7R is increased in cerebrocortical nerve terminals from oxaliplatin-treated rats; the increase is mediated by functional recruitment of Panx1; P2X7R antagonists and Panx1 inhibitors revert oxaliplatin-induced neuropathic pain; Panx1 inhibitors do not alter the oxaliplatin-induced mortality of cancer cells HT-29.	Oxaliplatin	244-255	Pannexin 1	Rattus norvegicus	220-225
25707392-0	2015	Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	115-126	vascular endothelial growth factor A	Homo sapiens	26-30
26071109-10	2015	It is concluded that glutamate release dependent on P2X7R is increased in cerebrocortical nerve terminals from oxaliplatin-treated rats; the increase is mediated by functional recruitment of Panx1; P2X7R antagonists and Panx1 inhibitors revert oxaliplatin-induced neuropathic pain; Panx1 inhibitors do not alter the oxaliplatin-induced mortality of cancer cells HT-29.	Oxaliplatin	244-255	Pannexin 1	Rattus norvegicus	220-225
26071109-10	2015	It is concluded that glutamate release dependent on P2X7R is increased in cerebrocortical nerve terminals from oxaliplatin-treated rats; the increase is mediated by functional recruitment of Panx1; P2X7R antagonists and Panx1 inhibitors revert oxaliplatin-induced neuropathic pain; Panx1 inhibitors do not alter the oxaliplatin-induced mortality of cancer cells HT-29.	Oxaliplatin	244-255	Pannexin 1	Rattus norvegicus	191-196
26071109-10	2015	It is concluded that glutamate release dependent on P2X7R is increased in cerebrocortical nerve terminals from oxaliplatin-treated rats; the increase is mediated by functional recruitment of Panx1; P2X7R antagonists and Panx1 inhibitors revert oxaliplatin-induced neuropathic pain; Panx1 inhibitors do not alter the oxaliplatin-induced mortality of cancer cells HT-29.	Oxaliplatin	244-255	Pannexin 1	Rattus norvegicus	220-225
26071109-10	2015	It is concluded that glutamate release dependent on P2X7R is increased in cerebrocortical nerve terminals from oxaliplatin-treated rats; the increase is mediated by functional recruitment of Panx1; P2X7R antagonists and Panx1 inhibitors revert oxaliplatin-induced neuropathic pain; Panx1 inhibitors do not alter the oxaliplatin-induced mortality of cancer cells HT-29.	Oxaliplatin	244-255	Pannexin 1	Rattus norvegicus	220-225
25707392-4	2015	This study evaluates the influence of common genetic variations within the VEGF pathway in the clinical outcomes of 172 metastatic colorectal cancer (mCRC) patients treated with first-line oxaliplatin/5-fluorouracil chemotherapy.	Oxaliplatin	189-200	vascular endothelial growth factor A	Homo sapiens	75-79
25707392-9	2015	This study provides evidence that functional germline polymorphisms in the VEGF pathway may help to predict outcome in mCRC patients who undergo oxaliplatin/5-fluorouracil chemotherapy.	Oxaliplatin	145-156	vascular endothelial growth factor A	Homo sapiens	75-79
26302162-0	2015	Ontogenic expression profiles and oxaliplatin regulation of leptin expression in mice dorsal root ganglion.	Oxaliplatin	34-45	leptin	Mus musculus	60-66
26302162-14	2015	In the current study, we found that the expression of leptin was increased in the lumbar 4-6 DRG of OXA-treated mice.	Oxaliplatin	100-103	leptin	Mus musculus	54-60
26023085-5	2015	RESULTS: Hypoxia-induced JNK activation was associated with resistance to oxaliplatin.	Oxaliplatin	74-85	mitogen-activated protein kinase 8	Homo sapiens	25-28
26396533-0	2015	Polymorphism in miR-146a associated with clinical characteristics and outcomes in gastric cancer patients treated with adjuvant oxaliplatin and fluoropyrimidines.	Oxaliplatin	128-139	microRNA 146a	Homo sapiens	16-24
26023085-10	2015	Finally, stable introduction of a dominant negative JNK1, but not JNK2, construct into HT29 cells rendered them more sensitive to oxaliplatin under hypoxia, suggesting differing input of JNK isoforms in cellular responses to chemotherapy.	Oxaliplatin	130-141	mitogen-activated protein kinase 8	Homo sapiens	52-56
26023085-10	2015	Finally, stable introduction of a dominant negative JNK1, but not JNK2, construct into HT29 cells rendered them more sensitive to oxaliplatin under hypoxia, suggesting differing input of JNK isoforms in cellular responses to chemotherapy.	Oxaliplatin	130-141	mitogen-activated protein kinase 8	Homo sapiens	52-55
25782327-0	2015	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.	Oxaliplatin	111-122	dihydropyrimidine dehydrogenase	Homo sapiens	0-3
25782327-0	2015	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.	Oxaliplatin	111-122	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	8-14
26063742-10	2015	Similarly, colon tumor cells are rendered less viable when cosuppression of MCM complexes occurs during exposure to the crosslinking agent oxaliplatin or topoisomerase inhibitor etoposide.	Oxaliplatin	139-150	methylmalonyl-CoA mutase	Homo sapiens	76-79
25943534-9	2015	The antitumor activity of anti-PD-L1 was enhanced by combination with oxaliplatin, which resulted in increased release of HMGB1 within CT26 tumors.	Oxaliplatin	70-81	CD274 molecule	Homo sapiens	31-36
25943534-9	2015	The antitumor activity of anti-PD-L1 was enhanced by combination with oxaliplatin, which resulted in increased release of HMGB1 within CT26 tumors.	Oxaliplatin	70-81	high mobility group box 1	Homo sapiens	122-127
25782915-6	2015	The signal transduction pathway involving cAMP/VEGF was activated after treatment with oxaliplatin and/or OA-GcMAF in both cell lines.	Oxaliplatin	87-98	vascular endothelial growth factor A	Mus musculus	47-51
26017781-8	2015	Atoh1 protein also enriched cancer stem cells with upregulated Lgr5 expression and cells in G0/G1 cell cycle phase, resulting in both the chemoresistance to 5-fluorouracil and oxaliplatin and the promotion of cell migration.	Oxaliplatin	176-187	atonal bHLH transcription factor 1	Homo sapiens	0-5
26623038-6	2015	In this model, treatment with trastuzumab alone or trastuzumab plus oxaliplatin enhanced the expression of thymidine phosphorylase (TP), a key enzyme in the generation of 5-FU from capecitabine in tumor tissues.	Oxaliplatin	68-79	thymidine phosphorylase	Homo sapiens	107-130
26623038-6	2015	In this model, treatment with trastuzumab alone or trastuzumab plus oxaliplatin enhanced the expression of thymidine phosphorylase (TP), a key enzyme in the generation of 5-FU from capecitabine in tumor tissues.	Oxaliplatin	68-79	thymidine phosphorylase	Homo sapiens	132-134
25979230-6	2015	Addition of curcumin to oxaliplatin/5-FU enhanced anti-proliferative and pro-apoptotic effects in a proportion of patient-derived explants, whilst reducing expression of stem cell-associated markers ALDH and CD133.	Oxaliplatin	24-35	prominin 1	Homo sapiens	208-213
26292288-7	2015	Compared to non-transfected cells, the survival rate was significantly reduced in the cells transfected with HIF-1alpha-siRNA after treatment with L-OHP.	Oxaliplatin	147-152	hypoxia inducible factor 1 subunit alpha	Homo sapiens	109-119
26017781-8	2015	Atoh1 protein also enriched cancer stem cells with upregulated Lgr5 expression and cells in G0/G1 cell cycle phase, resulting in both the chemoresistance to 5-fluorouracil and oxaliplatin and the promotion of cell migration.	Oxaliplatin	176-187	leucine rich repeat containing G protein-coupled receptor 5	Homo sapiens	63-67
25998052-0	2015	Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.	Oxaliplatin	10-21	epidermal growth factor receptor	Homo sapiens	36-68
26189067-0	2015	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.	Oxaliplatin	0-11	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	152-155
26189067-14	2015	INTERPRETATION: Adding oxaliplatin to fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy (at the doses and intensities used in this trial) significantly improved disease-free survival of patients with clinically staged cT3-4 or cN1-2 rectal cancer compared with our former fluorouracil-based combined modality regimen (based on CAO/ARO/AIO-94).	Oxaliplatin	23-34	dickkopf like acrosomal protein 1	Homo sapiens	243-248
26189067-14	2015	INTERPRETATION: Adding oxaliplatin to fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy (at the doses and intensities used in this trial) significantly improved disease-free survival of patients with clinically staged cT3-4 or cN1-2 rectal cancer compared with our former fluorouracil-based combined modality regimen (based on CAO/ARO/AIO-94).	Oxaliplatin	23-34	5'-nucleotidase, cytosolic IA	Homo sapiens	252-255
26189067-14	2015	INTERPRETATION: Adding oxaliplatin to fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy (at the doses and intensities used in this trial) significantly improved disease-free survival of patients with clinically staged cT3-4 or cN1-2 rectal cancer compared with our former fluorouracil-based combined modality regimen (based on CAO/ARO/AIO-94).	Oxaliplatin	23-34	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	356-359
25998052-1	2015	Oxaliplatin (L-OH), a platinum derivative with good tolerability is currently combined with Cetuximab (CTX), a monoclonal antibody (mAb), for the treatment of certain (wild-type KRAS) metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR).	Oxaliplatin	0-11	KRAS proto-oncogene, GTPase	Homo sapiens	178-182
25998052-1	2015	Oxaliplatin (L-OH), a platinum derivative with good tolerability is currently combined with Cetuximab (CTX), a monoclonal antibody (mAb), for the treatment of certain (wild-type KRAS) metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR).	Oxaliplatin	0-11	epidermal growth factor receptor	Homo sapiens	230-262
25998052-1	2015	Oxaliplatin (L-OH), a platinum derivative with good tolerability is currently combined with Cetuximab (CTX), a monoclonal antibody (mAb), for the treatment of certain (wild-type KRAS) metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR).	Oxaliplatin	0-11	epidermal growth factor receptor	Homo sapiens	264-268
26136074-8	2015	The combination of thiostrepton and oxaliplatin eradicated both CD44(+) HCT-15 and HT-29 cells more efficiently than either drug alone.	Oxaliplatin	36-47	CD44 molecule (Indian blood group)	Homo sapiens	64-68
25862460-10	2015	These findings provide direct evidences that the miR-492/CD147 axis might play an essential role in the Oxaliplatin resistance of colon cancer cells, suggesting that the miR-492/CD147 signaling cohort could be served as a novel therapeutic target for the treatment of chemotherapy resistant in colon cancer.	Oxaliplatin	104-115	microRNA 492	Homo sapiens	170-177
25937522-1	2015	BACKGROUND: The OPUS study demonstrated that addition of cetuximab to 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX4) significantly improved objective response and progression-free survival (PFS) in the first-line treatment of patients with KRAS exon 2 wild-type metastatic colorectal cancer (mCRC).	Oxaliplatin	103-114	KRAS proto-oncogene, GTPase	Homo sapiens	248-252
25430564-0	2015	PKC/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects.	Oxaliplatin	28-39	proline rich transmembrane protein 2	Homo sapiens	0-3
25430564-0	2015	PKC/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects.	Oxaliplatin	28-39	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
25430564-4	2015	Oxaliplatin-induced neuropathy was recently reported to be associated with protein kinase C (PKC) activation.	Oxaliplatin	0-11	proline rich transmembrane protein 2	Homo sapiens	75-91
25430564-4	2015	Oxaliplatin-induced neuropathy was recently reported to be associated with protein kinase C (PKC) activation.	Oxaliplatin	0-11	proline rich transmembrane protein 2	Homo sapiens	93-96
25430564-6	2015	In our current studies, we found that a PKC inhibitor, tamoxifen, inhibited oxaliplatin-induced neuropathy via the PKC/extracellular signal-regulated kinase (ERK)/c-Fos pathway in lumbar spinal cords (lumbar segments 4-6).	Oxaliplatin	76-87	proline rich transmembrane protein 2	Homo sapiens	40-43
25430564-6	2015	In our current studies, we found that a PKC inhibitor, tamoxifen, inhibited oxaliplatin-induced neuropathy via the PKC/extracellular signal-regulated kinase (ERK)/c-Fos pathway in lumbar spinal cords (lumbar segments 4-6).	Oxaliplatin	76-87	mitogen-activated protein kinase 1	Homo sapiens	158-161
25430564-6	2015	In our current studies, we found that a PKC inhibitor, tamoxifen, inhibited oxaliplatin-induced neuropathy via the PKC/extracellular signal-regulated kinase (ERK)/c-Fos pathway in lumbar spinal cords (lumbar segments 4-6).	Oxaliplatin	76-87	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	163-168
25430564-8	2015	Moreover, mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, PD0325901, suppressed oxaliplatin-induced neuropathy and enhanced oxaliplatin efficacy.	Oxaliplatin	93-104	mitogen-activated protein kinase kinase 1	Homo sapiens	10-59
25430564-8	2015	Moreover, mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, PD0325901, suppressed oxaliplatin-induced neuropathy and enhanced oxaliplatin efficacy.	Oxaliplatin	137-148	mitogen-activated protein kinase kinase 1	Homo sapiens	10-59
25430564-9	2015	Our results indicate that oxaliplatin-induced neuropathy is associated with PKC/ERK/c-Fos pathway in lumbar spinal cord.	Oxaliplatin	26-37	proline rich transmembrane protein 2	Homo sapiens	76-79
25430564-9	2015	Our results indicate that oxaliplatin-induced neuropathy is associated with PKC/ERK/c-Fos pathway in lumbar spinal cord.	Oxaliplatin	26-37	mitogen-activated protein kinase 1	Homo sapiens	80-83
25430564-9	2015	Our results indicate that oxaliplatin-induced neuropathy is associated with PKC/ERK/c-Fos pathway in lumbar spinal cord.	Oxaliplatin	26-37	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	84-89
25430564-10	2015	Additionally, we demonstrate that disruption of this pathway by PKC and MEK inhibitors suppresses oxaliplatin-induced neuropathy, thereby suggesting that PKC and MEK inhibitors may be therapeutically useful in preventing oxaliplatin-induced neuropathy and could aid in combination antitumor pharmacotherapy.	Oxaliplatin	98-109	proline rich transmembrane protein 2	Homo sapiens	64-67
25430564-10	2015	Additionally, we demonstrate that disruption of this pathway by PKC and MEK inhibitors suppresses oxaliplatin-induced neuropathy, thereby suggesting that PKC and MEK inhibitors may be therapeutically useful in preventing oxaliplatin-induced neuropathy and could aid in combination antitumor pharmacotherapy.	Oxaliplatin	98-109	mitogen-activated protein kinase kinase 7	Homo sapiens	72-75
25430564-10	2015	Additionally, we demonstrate that disruption of this pathway by PKC and MEK inhibitors suppresses oxaliplatin-induced neuropathy, thereby suggesting that PKC and MEK inhibitors may be therapeutically useful in preventing oxaliplatin-induced neuropathy and could aid in combination antitumor pharmacotherapy.	Oxaliplatin	98-109	proline rich transmembrane protein 2	Homo sapiens	154-157
25430564-10	2015	Additionally, we demonstrate that disruption of this pathway by PKC and MEK inhibitors suppresses oxaliplatin-induced neuropathy, thereby suggesting that PKC and MEK inhibitors may be therapeutically useful in preventing oxaliplatin-induced neuropathy and could aid in combination antitumor pharmacotherapy.	Oxaliplatin	98-109	mitogen-activated protein kinase kinase 7	Homo sapiens	162-165
25430564-10	2015	Additionally, we demonstrate that disruption of this pathway by PKC and MEK inhibitors suppresses oxaliplatin-induced neuropathy, thereby suggesting that PKC and MEK inhibitors may be therapeutically useful in preventing oxaliplatin-induced neuropathy and could aid in combination antitumor pharmacotherapy.	Oxaliplatin	221-232	proline rich transmembrane protein 2	Homo sapiens	64-67
25430564-10	2015	Additionally, we demonstrate that disruption of this pathway by PKC and MEK inhibitors suppresses oxaliplatin-induced neuropathy, thereby suggesting that PKC and MEK inhibitors may be therapeutically useful in preventing oxaliplatin-induced neuropathy and could aid in combination antitumor pharmacotherapy.	Oxaliplatin	221-232	mitogen-activated protein kinase kinase 7	Homo sapiens	72-75
25430564-10	2015	Additionally, we demonstrate that disruption of this pathway by PKC and MEK inhibitors suppresses oxaliplatin-induced neuropathy, thereby suggesting that PKC and MEK inhibitors may be therapeutically useful in preventing oxaliplatin-induced neuropathy and could aid in combination antitumor pharmacotherapy.	Oxaliplatin	221-232	proline rich transmembrane protein 2	Homo sapiens	154-157
25430564-10	2015	Additionally, we demonstrate that disruption of this pathway by PKC and MEK inhibitors suppresses oxaliplatin-induced neuropathy, thereby suggesting that PKC and MEK inhibitors may be therapeutically useful in preventing oxaliplatin-induced neuropathy and could aid in combination antitumor pharmacotherapy.	Oxaliplatin	221-232	mitogen-activated protein kinase kinase 7	Homo sapiens	162-165
25777765-5	2015	In the present study, it was demonstrated that NPRL2 overexpression increases the sensitivity of HCT116 cells to L-OHP.	Oxaliplatin	113-118	NPR2 like, GATOR1 complex subunit	Homo sapiens	47-52
25777765-6	2015	The IC50 of L-OHP was decreased in cells transduced with NPRL2 compared with negative control (NC) cells and the effect of NPRL2 on L-OHP sensitivity was time dependent.	Oxaliplatin	12-17	NPR2 like, GATOR1 complex subunit	Homo sapiens	57-62
25777765-6	2015	The IC50 of L-OHP was decreased in cells transduced with NPRL2 compared with negative control (NC) cells and the effect of NPRL2 on L-OHP sensitivity was time dependent.	Oxaliplatin	132-137	NPR2 like, GATOR1 complex subunit	Homo sapiens	57-62
25777765-6	2015	The IC50 of L-OHP was decreased in cells transduced with NPRL2 compared with negative control (NC) cells and the effect of NPRL2 on L-OHP sensitivity was time dependent.	Oxaliplatin	132-137	NPR2 like, GATOR1 complex subunit	Homo sapiens	123-128
25777765-9	2015	The mechanism through which NPRL2 overexpression enhances L-OHP sensitivity involves downregulation of the functions of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin network.	Oxaliplatin	58-63	NPR2 like, GATOR1 complex subunit	Homo sapiens	28-33
25777765-9	2015	The mechanism through which NPRL2 overexpression enhances L-OHP sensitivity involves downregulation of the functions of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin network.	Oxaliplatin	58-63	AKT serine/threonine kinase 1	Homo sapiens	154-157
25777765-9	2015	The mechanism through which NPRL2 overexpression enhances L-OHP sensitivity involves downregulation of the functions of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin network.	Oxaliplatin	58-63	mechanistic target of rapamycin kinase	Homo sapiens	158-187
25777765-10	2015	Furthermore, L-OHP upregulated caspase-3 and caspase-9 to promote apoptosis in NPRL2-overexpressing cells compared with cells that were transduced with NPRL2 or treated with L-OHP and NC cells (P&lt;0.01).	Oxaliplatin	13-18	caspase 9	Homo sapiens	45-54
25777765-10	2015	Furthermore, L-OHP upregulated caspase-3 and caspase-9 to promote apoptosis in NPRL2-overexpressing cells compared with cells that were transduced with NPRL2 or treated with L-OHP and NC cells (P&lt;0.01).	Oxaliplatin	13-18	NPR2 like, GATOR1 complex subunit	Homo sapiens	79-84
25862460-0	2015	MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147.	Oxaliplatin	36-47	microRNA 492	Homo sapiens	0-7
25862460-0	2015	MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147.	Oxaliplatin	36-47	basigin (Ok blood group)	Homo sapiens	125-130
25862460-6	2015	In the present study, we found that lower level of miR-492 is accompanied with increased expression of CD147 in Oxaliplatin-resistant colon cancer cell line LS174T/L-OHP as compared with its parental cell line LS174T.	Oxaliplatin	112-123	microRNA 492	Homo sapiens	51-58
25862460-6	2015	In the present study, we found that lower level of miR-492 is accompanied with increased expression of CD147 in Oxaliplatin-resistant colon cancer cell line LS174T/L-OHP as compared with its parental cell line LS174T.	Oxaliplatin	112-123	basigin (Ok blood group)	Homo sapiens	103-108
25862460-7	2015	Exogenous expression of miR-492 in LS174T/L-OHP could sensitize its reaction on the treatment of Oxaliplatin, which is coincided with its directly reducing the expression of CD147.	Oxaliplatin	97-108	microRNA 492	Homo sapiens	24-31
25862460-7	2015	Exogenous expression of miR-492 in LS174T/L-OHP could sensitize its reaction on the treatment of Oxaliplatin, which is coincided with its directly reducing the expression of CD147.	Oxaliplatin	97-108	basigin (Ok blood group)	Homo sapiens	174-179
25862460-8	2015	Furthermore, we found that knockdown of CD147 in LS174T/L-OHP could also sensitize its reaction of the treatment with Oxaliplatin.	Oxaliplatin	118-129	basigin (Ok blood group)	Homo sapiens	40-45
25862460-9	2015	Besides, intratumoral delivering of miR-492 could also restore Oxaliplatin treatment response in Oxaliplatin-resistant xenografts in vivo.	Oxaliplatin	63-74	microRNA 492	Homo sapiens	36-43
25862460-9	2015	Besides, intratumoral delivering of miR-492 could also restore Oxaliplatin treatment response in Oxaliplatin-resistant xenografts in vivo.	Oxaliplatin	97-108	microRNA 492	Homo sapiens	36-43
25862460-10	2015	These findings provide direct evidences that the miR-492/CD147 axis might play an essential role in the Oxaliplatin resistance of colon cancer cells, suggesting that the miR-492/CD147 signaling cohort could be served as a novel therapeutic target for the treatment of chemotherapy resistant in colon cancer.	Oxaliplatin	104-115	microRNA 492	Homo sapiens	49-56
25862460-10	2015	These findings provide direct evidences that the miR-492/CD147 axis might play an essential role in the Oxaliplatin resistance of colon cancer cells, suggesting that the miR-492/CD147 signaling cohort could be served as a novel therapeutic target for the treatment of chemotherapy resistant in colon cancer.	Oxaliplatin	104-115	basigin (Ok blood group)	Homo sapiens	57-62
25862460-10	2015	These findings provide direct evidences that the miR-492/CD147 axis might play an essential role in the Oxaliplatin resistance of colon cancer cells, suggesting that the miR-492/CD147 signaling cohort could be served as a novel therapeutic target for the treatment of chemotherapy resistant in colon cancer.	Oxaliplatin	104-115	basigin (Ok blood group)	Homo sapiens	178-183
26146058-0	2015	[ASPP2 inhibits oxaliplatin-induced autophagy and promotes apoptosis of colon cancer cells].	Oxaliplatin	16-27	tumor protein p53 binding protein 2	Homo sapiens	1-6
26131551-7	2015	MRP2 inhibitors (myricetin and MK571) reduced the ATP-dependent accumulation of oxaliplatin-derived platinum in MRP2-expressing membrane vesicles in a concentration-dependent manner.	Oxaliplatin	80-91	ATP binding cassette subfamily C member 2	Homo sapiens	0-4
26131551-7	2015	MRP2 inhibitors (myricetin and MK571) reduced the ATP-dependent accumulation of oxaliplatin-derived platinum in MRP2-expressing membrane vesicles in a concentration-dependent manner.	Oxaliplatin	80-91	ATP binding cassette subfamily C member 2	Homo sapiens	112-116
26131551-9	2015	In conclusion, MRP2 mediates the ATP-dependent active membrane transport of oxaliplatin-derived platinum.	Oxaliplatin	76-87	ATP binding cassette subfamily C member 2	Homo sapiens	15-19
26131551-10	2015	Intact oxaliplatin and its anionic monochloro oxalate ring-opened intermediate appear likely candidates as substrates for MRP2-mediated transport.	Oxaliplatin	7-18	ATP binding cassette subfamily C member 2	Homo sapiens	122-126
26131551-0	2015	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles.	Oxaliplatin	71-82	ATP binding cassette subfamily C member 2	Homo sapiens	0-41
26131551-0	2015	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles.	Oxaliplatin	71-82	ATP binding cassette subfamily C member 2	Homo sapiens	43-47
26131551-2	2015	However, the role of multidrug resistance-associated protein 2 (MRP2) in controlling oxaliplatin membrane transport, in vivo handling, toxicity and therapeutic responses is unclear.	Oxaliplatin	85-96	ATP binding cassette subfamily C member 2	Homo sapiens	21-62
26131551-2	2015	However, the role of multidrug resistance-associated protein 2 (MRP2) in controlling oxaliplatin membrane transport, in vivo handling, toxicity and therapeutic responses is unclear.	Oxaliplatin	85-96	ATP binding cassette subfamily C member 2	Homo sapiens	64-68
26131551-3	2015	In the current study, preparations of MRP2-expressing and control membrane vesicles, containing inside-out orientated vesicles, were used to directly characterise the membrane transport of oxaliplatin-derived platinum measured by inductively coupled plasma mass spectrometry.	Oxaliplatin	189-200	ATP binding cassette subfamily C member 2	Homo sapiens	38-42
26131551-5	2015	MRP2-expressing membrane vesicles accumulated up to 19-fold more platinum during their incubation with oxaliplatin and ATP as compared to control membrane vesicles and in the absence of ATP.	Oxaliplatin	103-114	ATP binding cassette subfamily C member 2	Homo sapiens	0-4
26146058-10	2015	CONCLUSION: OXA can induce autophagy of colorectal cancer cells, while ASPP2 over-expression can suppress the OXA-induced autophagy.	Oxaliplatin	110-113	tumor protein p53 binding protein 2	Homo sapiens	71-76
26146058-1	2015	OBJECTIVE: To investigate the role of apoptosis stimulating p53 binding protein 2 (ASPP2)-induced p53-dependent and p53-independent autophagy inhibition in apoptosis-promoting function of oxaliplatin (OXA).	Oxaliplatin	188-199	tumor protein p53	Homo sapiens	60-63
26146058-1	2015	OBJECTIVE: To investigate the role of apoptosis stimulating p53 binding protein 2 (ASPP2)-induced p53-dependent and p53-independent autophagy inhibition in apoptosis-promoting function of oxaliplatin (OXA).	Oxaliplatin	188-199	tumor protein p53 binding protein 2	Homo sapiens	83-88
26146058-1	2015	OBJECTIVE: To investigate the role of apoptosis stimulating p53 binding protein 2 (ASPP2)-induced p53-dependent and p53-independent autophagy inhibition in apoptosis-promoting function of oxaliplatin (OXA).	Oxaliplatin	201-204	tumor protein p53	Homo sapiens	60-63
26146058-1	2015	OBJECTIVE: To investigate the role of apoptosis stimulating p53 binding protein 2 (ASPP2)-induced p53-dependent and p53-independent autophagy inhibition in apoptosis-promoting function of oxaliplatin (OXA).	Oxaliplatin	201-204	tumor protein p53 binding protein 2	Homo sapiens	83-88
26161372-0	2015	ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy.	Oxaliplatin	65-76	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
25904054-8	2015	The copy numbers of MAP4K1 and CDKL4 can predict clinical outcomes in CRC patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	96-107	mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens	20-26
25904054-8	2015	The copy numbers of MAP4K1 and CDKL4 can predict clinical outcomes in CRC patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	96-107	cyclin dependent kinase like 4	Homo sapiens	31-36
26131771-0	2015	Analgesic Effects of Bee Venom Derived Phospholipase A(2) in a Mouse Model of Oxaliplatin-Induced Neuropathic Pain.	Oxaliplatin	78-89	phospholipase A2, group IB, pancreas	Mus musculus	39-57
25855785-5	2015	Knockdown of CRY2 increased colorectal cancer sensitivity to oxaliplatin in colorectal cancer cells.	Oxaliplatin	61-72	cryptochrome circadian regulator 2	Homo sapiens	13-17
25666295-9	2015	CONCLUSION: These findings support those from recent studies that RAS and BRAF mutations are associated with poor outcome in patients receiving an epidermal growth factor receptor-targeted monoclonal antibody in combination with oxaliplatin-based chemotherapy.	Oxaliplatin	229-240	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	74-78
25899086-6	2015	Furthermore, CD19(+) B cells were more sensitive to capecitabine plus oxaliplatin stimulation in vitro than other immune cells, displaying higher frequency of apoptosis in a dose-dependent way.	Oxaliplatin	70-81	CD19 molecule	Homo sapiens	13-17
26025411-3	2015	The aim of this study was to investigate the effect of a specific MDR1 small interference RNA (siRNA) on sensitivity of oxaliplatin&amp;mdash;resistant SW480 human colon cancer cell line (SW480/OxR) to the chemotherapeutic drug oxaliplatin.	Oxaliplatin	228-239	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
25331073-0	2015	MTHFR-1298 A&gt;C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.	Oxaliplatin	183-194	methylenetetrahydrofolate reductase	Homo sapiens	0-5
26025411-0	2015	siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.	Oxaliplatin	60-71	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
25043306-6	2015	In an HCT116 xenograft model, PHF2 was found to be required for the anticancer effects of oxaliplatin and doxorubicin.	Oxaliplatin	90-101	PHD finger protein 2	Homo sapiens	30-34
26025411-10	2015	MDR1 down&amp;mdash;regulation synergistically increased the cytotoxic effects of oxaliplatin and spontaneous apoptosis SW480/OxR.	Oxaliplatin	82-93	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
26025411-3	2015	The aim of this study was to investigate the effect of a specific MDR1 small interference RNA (siRNA) on sensitivity of oxaliplatin&amp;mdash;resistant SW480 human colon cancer cell line (SW480/OxR) to the chemotherapeutic drug oxaliplatin.	Oxaliplatin	120-131	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
25940438-6	2015	Downregulation of S100A11 by RNAi resulted in enhanced sensitivity of NSCLC cells to cisplatin, oxaliplatin and 5-fluouracil.	Oxaliplatin	96-107	S100 calcium binding protein A11	Homo sapiens	18-25
25829079-0	2015	Blocking PAR2 attenuates oxaliplatin-induced neuropathic pain via TRPV1 and releases of substance P and CGRP in superficial dorsal horn of spinal cord.	Oxaliplatin	25-36	F2R like trypsin receptor 1	Rattus norvegicus	9-13
25959819-6	2015	Disrupting Nav1.9 expression in rodents also alleviates cold pain hypersensitivity induced by the antineoplastic agent oxaliplatin.	Oxaliplatin	119-130	sodium channel, voltage-gated, type XI, alpha	Mus musculus	11-17
26269759-4	2015	The molecular mechanisms of Twist1 expression and its effects on chemosensitivity to 5-Fluorouracil and oxaliplatin were also explored by MTT assay, colony forming assay, flow cytometry assay.	Oxaliplatin	104-115	twist family bHLH transcription factor 1	Homo sapiens	28-34
25829079-0	2015	Blocking PAR2 attenuates oxaliplatin-induced neuropathic pain via TRPV1 and releases of substance P and CGRP in superficial dorsal horn of spinal cord.	Oxaliplatin	25-36	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	66-71
25829079-0	2015	Blocking PAR2 attenuates oxaliplatin-induced neuropathic pain via TRPV1 and releases of substance P and CGRP in superficial dorsal horn of spinal cord.	Oxaliplatin	25-36	calcitonin-related polypeptide alpha	Rattus norvegicus	104-108
25829079-5	2015	Blocking PAR2 also attenuated a heightened cold sensitivity evoked by OXL; whereas blocking TRPV1 had little effects on OXL-evoked hypersensitive cold response.	Oxaliplatin	70-73	F2R like trypsin receptor 1	Rattus norvegicus	9-13
25829079-8	2015	Overall, our data suggest that upregulated expression of PAR2 in the superficial dorsal horn contributes to mechanical hyperalgesia and cold hypersensitivity; whereas amplified TRPV1 plays a role in regulating mechanical hyperalgesia, but not cold hypersensitivity after administration of OXL.	Oxaliplatin	289-292	F2R like trypsin receptor 1	Rattus norvegicus	57-61
25829079-9	2015	We further suggest that TRPV1 is likely one of the signaling pathways for PAR2 to play a role in regulating OXL-induced neuropathic pain.	Oxaliplatin	108-111	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	24-29
25829079-9	2015	We further suggest that TRPV1 is likely one of the signaling pathways for PAR2 to play a role in regulating OXL-induced neuropathic pain.	Oxaliplatin	108-111	F2R like trypsin receptor 1	Rattus norvegicus	74-78
24372557-2	2015	Reverse-transcription polymerase chain reaction and Western blot analyses were employed to detect periostin expression in SW480 and HT-29 colon cancer cells treated with oxaliplatin or fluorouracil (5-FU).	Oxaliplatin	170-181	periostin	Homo sapiens	98-107
25955657-0	2015	PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.	Oxaliplatin	45-56	pyruvate kinase M1/2	Homo sapiens	0-4
25955657-3	2015	In a previous work we identified low levels of PKM2 as a putative oxaliplatin-resistance marker in HT29 CRC cell lines and also in patients.	Oxaliplatin	66-77	pyruvate kinase M1/2	Homo sapiens	47-51
25955657-8	2015	Fluorescence microscopy revealed PKM2 nuclear translocation in response to oxaliplatin in HCT116 and HT29 cells but not in OXA-resistant HTOXAR3 cells.	Oxaliplatin	75-86	pyruvate kinase M1/2	Homo sapiens	33-37
25955657-9	2015	Finally, by using a qPCR Array we demonstrated that oxaliplatin and PKM2 silencing altered cell death gene expression patterns including those of BMF, which was significantly increased in HT29 cells in response to oxaliplatin, in a dose and time-dependent manner, but not in siPKM2-HT29 and HTOXAR3 cells.	Oxaliplatin	214-225	pyruvate kinase M1/2	Homo sapiens	68-72
25955657-11	2015	In conclusion, our data report new non-glycolytic roles of PKM2 in response to genotoxic damage and proposes BMF as a possible target gene of PKM2 to be involved in oxaliplatin response and resistance in CRC cells.	Oxaliplatin	165-176	pyruvate kinase M1/2	Homo sapiens	142-146
25767076-7	2015	Oxaliplatin administration did not stimulate reactive oxygen species (ROS) production and autophagy, but elevated the protein level of Bmf.	Oxaliplatin	0-11	Bcl2 modifying factor	Homo sapiens	135-138
25767076-10	2015	Oxaliplatin treatment resulted in poly(ADP-ribose) polymerase-1 (PARP-1) overactivation, as indicated by the increase of poly(ADP-ribose) (PAR), which led to NAD(+) and ATP depletion.	Oxaliplatin	0-11	poly(ADP-ribose) polymerase 1	Homo sapiens	34-63
25767076-10	2015	Oxaliplatin treatment resulted in poly(ADP-ribose) polymerase-1 (PARP-1) overactivation, as indicated by the increase of poly(ADP-ribose) (PAR), which led to NAD(+) and ATP depletion.	Oxaliplatin	0-11	poly(ADP-ribose) polymerase 1	Homo sapiens	65-71
25767076-11	2015	PARP-1 inhibitor, olaparib, could significantly block oxaliplatin-induced cell death, thus confirming that PARP-1 activation is mainly responsible for the cytotoxicity of oxaliplatin.	Oxaliplatin	54-65	poly(ADP-ribose) polymerase 1	Homo sapiens	0-6
25767076-11	2015	PARP-1 inhibitor, olaparib, could significantly block oxaliplatin-induced cell death, thus confirming that PARP-1 activation is mainly responsible for the cytotoxicity of oxaliplatin.	Oxaliplatin	54-65	poly(ADP-ribose) polymerase 1	Homo sapiens	107-113
25767076-11	2015	PARP-1 inhibitor, olaparib, could significantly block oxaliplatin-induced cell death, thus confirming that PARP-1 activation is mainly responsible for the cytotoxicity of oxaliplatin.	Oxaliplatin	171-182	poly(ADP-ribose) polymerase 1	Homo sapiens	0-6
25767076-11	2015	PARP-1 inhibitor, olaparib, could significantly block oxaliplatin-induced cell death, thus confirming that PARP-1 activation is mainly responsible for the cytotoxicity of oxaliplatin.	Oxaliplatin	171-182	poly(ADP-ribose) polymerase 1	Homo sapiens	107-113
24372557-5	2015	The results showed that treatment with oxaliplatin or 5-FU elevated both the mRNA and protein levels of periostin in SW480 and HT-29 cells.	Oxaliplatin	39-50	periostin	Homo sapiens	104-113
25801007-11	2015	Taken together, this study provides insight into that the co-manipulation of hCtrl and ATP7A by D-penicillamine could increase the therapeutic efficacy of platinum drugs in oxaliplatin resistant tumors, especially in resistant phenotype with downexpression of hCtrl and overexpression of ATP7A.	Oxaliplatin	173-184	ATPase copper transporting alpha	Homo sapiens	87-92
25690281-7	2015	Results showed that Trp/Trp genotype of XRCC1 Arg194Trp and AA genotype of ERCC1 rs2336219 have a significantly increased risk of CRC; Trp allele of XRCC1 Arg194Trp and CC genotype of ERCC1 rs735482 were associated with lower response to oxaliplatin-based chemotherapy, a shorter survival and a higher risk of relapse or metastasis.	Oxaliplatin	238-249	X-ray repair cross complementing 1	Homo sapiens	40-45
26027741-8	2015	Heritable genetic variants in the ABC and SLC transport pathways; in the CYP450, GST, and UGT-mediated phase I and II metabolism; in the folate metabolic pathway; as well as in the EGF and VEGF signaling pathways, have been associated with a distinct tumor sensitivity phenotype in CRC patients treated with fluoropyrimidines combined with either irinotecan, oxaliplatin or targeted biological agents.	Oxaliplatin	359-370	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	34-37
26027741-8	2015	Heritable genetic variants in the ABC and SLC transport pathways; in the CYP450, GST, and UGT-mediated phase I and II metabolism; in the folate metabolic pathway; as well as in the EGF and VEGF signaling pathways, have been associated with a distinct tumor sensitivity phenotype in CRC patients treated with fluoropyrimidines combined with either irinotecan, oxaliplatin or targeted biological agents.	Oxaliplatin	359-370	C-C motif chemokine ligand 21	Homo sapiens	42-45
26027741-8	2015	Heritable genetic variants in the ABC and SLC transport pathways; in the CYP450, GST, and UGT-mediated phase I and II metabolism; in the folate metabolic pathway; as well as in the EGF and VEGF signaling pathways, have been associated with a distinct tumor sensitivity phenotype in CRC patients treated with fluoropyrimidines combined with either irinotecan, oxaliplatin or targeted biological agents.	Oxaliplatin	359-370	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	90-93
26027741-8	2015	Heritable genetic variants in the ABC and SLC transport pathways; in the CYP450, GST, and UGT-mediated phase I and II metabolism; in the folate metabolic pathway; as well as in the EGF and VEGF signaling pathways, have been associated with a distinct tumor sensitivity phenotype in CRC patients treated with fluoropyrimidines combined with either irinotecan, oxaliplatin or targeted biological agents.	Oxaliplatin	359-370	vascular endothelial growth factor A	Homo sapiens	189-193
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	Oxaliplatin	150-161	solute carrier family 22 member 16	Homo sapiens	13-17
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	Oxaliplatin	150-161	solute carrier family 22 member 16	Homo sapiens	64-68
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	Oxaliplatin	150-161	solute carrier family 22 member 16	Homo sapiens	75-83
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	Oxaliplatin	163-168	solute carrier family 22 member 16	Homo sapiens	13-17
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	Oxaliplatin	163-168	solute carrier family 22 member 16	Homo sapiens	64-68
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	Oxaliplatin	163-168	solute carrier family 22 member 16	Homo sapiens	75-83
26124936-8	2015	Significant increase in the expression of BDNF was found in the dorsal horn in rats receiving oxaliplatin, which was prevented by gabapentin.	Oxaliplatin	94-105	brain-derived neurotrophic factor	Rattus norvegicus	42-46
26124936-9	2015	Further studies also observed a significant increase in the expression of GluR1 and NR2B, as well as enhanced glutamatergic transmission in the dorsal horn neurons in rats treated with oxaliplatin.	Oxaliplatin	185-196	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	74-79
26124936-9	2015	Further studies also observed a significant increase in the expression of GluR1 and NR2B, as well as enhanced glutamatergic transmission in the dorsal horn neurons in rats treated with oxaliplatin.	Oxaliplatin	185-196	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	84-88
26124936-11	2015	CONCLUSION: These results illustrated an increased expression of BDNF and enhanced glutamatergic transmission in rats with oxaliplatin-induced neuropathic pain, which was markedly attenuated by gabapentin.	Oxaliplatin	123-134	brain-derived neurotrophic factor	Rattus norvegicus	65-69
25690281-7	2015	Results showed that Trp/Trp genotype of XRCC1 Arg194Trp and AA genotype of ERCC1 rs2336219 have a significantly increased risk of CRC; Trp allele of XRCC1 Arg194Trp and CC genotype of ERCC1 rs735482 were associated with lower response to oxaliplatin-based chemotherapy, a shorter survival and a higher risk of relapse or metastasis.	Oxaliplatin	238-249	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	75-80
25690281-7	2015	Results showed that Trp/Trp genotype of XRCC1 Arg194Trp and AA genotype of ERCC1 rs2336219 have a significantly increased risk of CRC; Trp allele of XRCC1 Arg194Trp and CC genotype of ERCC1 rs735482 were associated with lower response to oxaliplatin-based chemotherapy, a shorter survival and a higher risk of relapse or metastasis.	Oxaliplatin	238-249	X-ray repair cross complementing 1	Homo sapiens	149-154
25690281-7	2015	Results showed that Trp/Trp genotype of XRCC1 Arg194Trp and AA genotype of ERCC1 rs2336219 have a significantly increased risk of CRC; Trp allele of XRCC1 Arg194Trp and CC genotype of ERCC1 rs735482 were associated with lower response to oxaliplatin-based chemotherapy, a shorter survival and a higher risk of relapse or metastasis.	Oxaliplatin	238-249	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	184-189
25766630-5	2015	In a mice model of neuropathic pain induced by oxaliplatin, one of the strong CA II/VII inhibitors reported here induced a long lasting pain relieving effect, a fact never observed earlier.	Oxaliplatin	47-58	carbonic anhydrase 2	Mus musculus	78-83
25928068-0	2015	Oxaliplatin-Induced Peripheral Neuropathy via TRPA1 Stimulation in Mice Dorsal Root Ganglion Is Correlated with Aluminum Accumulation.	Oxaliplatin	0-11	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	46-51
25860929-9	2015	FBXW7 loss in HCT116 cells promoted resistance to oxaliplatin.	Oxaliplatin	50-61	F-box and WD repeat domain containing 7	Homo sapiens	0-5
25892894-3	2015	In this study, we report the development of t-acute promyelocytic leukemia in a cT4N1M0 gastric cancer patient after an approximate 44 mo latency period following treatment with 4 cycles of oxaliplatin (OXP) (85 mg/m(2) on day 1) plus capecitabine (1250 mg/m(2) orally twice daily on days 1-14) in combination with recombinant human granulocyte-colony stimulating factor treatment.	Oxaliplatin	190-201	colony stimulating factor 3	Homo sapiens	333-370
25892894-3	2015	In this study, we report the development of t-acute promyelocytic leukemia in a cT4N1M0 gastric cancer patient after an approximate 44 mo latency period following treatment with 4 cycles of oxaliplatin (OXP) (85 mg/m(2) on day 1) plus capecitabine (1250 mg/m(2) orally twice daily on days 1-14) in combination with recombinant human granulocyte-colony stimulating factor treatment.	Oxaliplatin	203-206	colony stimulating factor 3	Homo sapiens	333-370
25723812-0	2015	The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver.	Oxaliplatin	39-50	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	23-28
25862901-0	2015	Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.	Oxaliplatin	142-153	CEA cell adhesion molecule 3	Homo sapiens	22-25
25723812-1	2015	Increased expression of excision repair cross-complementing 1 (ERCC1) in mCRC patients could be related to their response to Oxaliplatin based chemotherapy.	Oxaliplatin	125-136	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	24-61
25723812-1	2015	Increased expression of excision repair cross-complementing 1 (ERCC1) in mCRC patients could be related to their response to Oxaliplatin based chemotherapy.	Oxaliplatin	125-136	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	63-68
25723812-5	2015	Further study is needed to assess the promising role of ERCC1 expression as a predictive marker benefiting subgroups for Oxaliplatin.	Oxaliplatin	121-132	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	56-61
24748501-11	2015	In oxaliplatin-treated gastric cancer patients, resistance to oxaliplatin was found in MLH1 methylated patients (HR 2.988, 95% CI, 1.064-8.394, p = 0.038), and overall survival was longer in the MLH1 unmethylated group compared with the MLH1 methylated group (log-rank, p = 0.046).	Oxaliplatin	3-14	mutL homolog 1	Homo sapiens	87-91
24748501-11	2015	In oxaliplatin-treated gastric cancer patients, resistance to oxaliplatin was found in MLH1 methylated patients (HR 2.988, 95% CI, 1.064-8.394, p = 0.038), and overall survival was longer in the MLH1 unmethylated group compared with the MLH1 methylated group (log-rank, p = 0.046).	Oxaliplatin	3-14	mutL homolog 1	Homo sapiens	195-199
24748501-11	2015	In oxaliplatin-treated gastric cancer patients, resistance to oxaliplatin was found in MLH1 methylated patients (HR 2.988, 95% CI, 1.064-8.394, p = 0.038), and overall survival was longer in the MLH1 unmethylated group compared with the MLH1 methylated group (log-rank, p = 0.046).	Oxaliplatin	3-14	mutL homolog 1	Homo sapiens	195-199
24748501-11	2015	In oxaliplatin-treated gastric cancer patients, resistance to oxaliplatin was found in MLH1 methylated patients (HR 2.988, 95% CI, 1.064-8.394, p = 0.038), and overall survival was longer in the MLH1 unmethylated group compared with the MLH1 methylated group (log-rank, p = 0.046).	Oxaliplatin	62-73	mutL homolog 1	Homo sapiens	87-91
24748501-11	2015	In oxaliplatin-treated gastric cancer patients, resistance to oxaliplatin was found in MLH1 methylated patients (HR 2.988, 95% CI, 1.064-8.394, p = 0.038), and overall survival was longer in the MLH1 unmethylated group compared with the MLH1 methylated group (log-rank, p = 0.046).	Oxaliplatin	62-73	mutL homolog 1	Homo sapiens	195-199
24748501-11	2015	In oxaliplatin-treated gastric cancer patients, resistance to oxaliplatin was found in MLH1 methylated patients (HR 2.988, 95% CI, 1.064-8.394, p = 0.038), and overall survival was longer in the MLH1 unmethylated group compared with the MLH1 methylated group (log-rank, p = 0.046).	Oxaliplatin	62-73	mutL homolog 1	Homo sapiens	195-199
24748501-13	2015	MLH1 methylation was related to oxaliplatin resistance in gastric cancer patients.	Oxaliplatin	32-43	mutL homolog 1	Homo sapiens	0-4
24839048-11	2015	CONCLUSION: This phase I trial of preoperative S-1 in combination with oxaliplatin and radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis revealed that the recommended dose of oxaliplatin was 60 mg/m(2) weekly.	Oxaliplatin	208-219	proteasome 26S subunit, non-ATPase 1	Homo sapiens	47-50
25806091-11	2015	Oxaliplatin (D2) and azacitidine (D1 and 5) mean systemic exposure based on plasma AUCall showed dose-dependent interaction whereby increasing the dose of oxaliplatin reduced the mean azacitidine exposure and vice versa; however, no significant differences in other non-compartmental modeled parameters were observed.	Oxaliplatin	155-166	leiomodin 1	Homo sapiens	34-42
25103530-6	2015	(4) CWQ could restore OXA-mediated deregulation of copper transporter genes, hCTR1, ATP7A and ATP7B.	Oxaliplatin	22-25	solute carrier family 31 member 1	Homo sapiens	77-82
25103530-6	2015	(4) CWQ could restore OXA-mediated deregulation of copper transporter genes, hCTR1, ATP7A and ATP7B.	Oxaliplatin	22-25	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	84-89
25103530-6	2015	(4) CWQ could restore OXA-mediated deregulation of copper transporter genes, hCTR1, ATP7A and ATP7B.	Oxaliplatin	22-25	ATPase, Cu++ transporting, beta polypeptide	Mus musculus	94-99
26148595-12	2015	Therefore, S-1 could be used to substitute Xeloda in combined chemotherapy with oxaliplatin for the treatment of advanced or recurrent colorectal cancer.	Oxaliplatin	80-91	proteasome 26S subunit, non-ATPase 1	Homo sapiens	11-14
25940182-6	2015	Processed by 17-DMAG 100 nmol/L, oxaliplatin 50 mg/L and half-dose combination of 2 drugs, transcription level of the apoptosis inhibitory gene (Bcl-2) in SW480 and HCT116 cells was decreased, the level of apoptosis promoting gene (Bax) transcription and protein PARP-1 spliceosome expression was increased, and the above trend was more obvious when using half-dose combination of 2 drugs.	Oxaliplatin	33-44	BCL2 apoptosis regulator	Homo sapiens	145-150
25870609-5	2015	In this study, we propose to analyze the different clinical outcomes and disease prognosis of patients with stage IV CRC treated with FOLFOX chemotherapy (fluorouracil, leucovorin, oxaliplatin) based on different Kirsten ras (KRAS) mutation patterns.	Oxaliplatin	181-192	KRAS proto-oncogene, GTPase	Homo sapiens	213-224
25870609-5	2015	In this study, we propose to analyze the different clinical outcomes and disease prognosis of patients with stage IV CRC treated with FOLFOX chemotherapy (fluorouracil, leucovorin, oxaliplatin) based on different Kirsten ras (KRAS) mutation patterns.	Oxaliplatin	181-192	KRAS proto-oncogene, GTPase	Homo sapiens	226-230
28123794-0	2015	Role of PAR2 in regulating oxaliplatin-induced neuropathic pain via TRPA1.	Oxaliplatin	27-38	F2R like trypsin receptor 1	Rattus norvegicus	8-12
28123794-0	2015	Role of PAR2 in regulating oxaliplatin-induced neuropathic pain via TRPA1.	Oxaliplatin	27-38	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	68-73
25616665-3	2015	Ectopic expression of miR-520g conferred resistance to 5-fluorouracil (5-FU)- or oxaliplatin-induced apoptosis in vitro and reduced the effectiveness of 5-FU in the inhibition of tumor growth in a mouse xenograft model in vivo.	Oxaliplatin	81-92	microRNA 520g	Homo sapiens	22-30
25834456-0	2015	Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis.	Oxaliplatin	76-87	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	24-29
25834456-1	2015	PURPOSE: The relationship between the excision repair cross-complementing 1 (ERCC1) rs11615 polymorphism (C/T) and responses to oxaliplatin-based chemotherapy for gastric cancer (GC) and colorectal cancer (CRC) patients is controversial.	Oxaliplatin	128-139	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	38-75
25834456-1	2015	PURPOSE: The relationship between the excision repair cross-complementing 1 (ERCC1) rs11615 polymorphism (C/T) and responses to oxaliplatin-based chemotherapy for gastric cancer (GC) and colorectal cancer (CRC) patients is controversial.	Oxaliplatin	128-139	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	77-82
25834456-4	2015	A systematic review and meta-analysis was performed to evaluate the predictive value of the ERCC1 rs11615 polymorphism for the clinical outcomes of GC and CRC patients receiving oxaliplatin-based chemotherapy.	Oxaliplatin	178-189	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	92-97
25834456-9	2015	CONCLUSION: The ERCC1 rs11615 polymorphism was closely associated with the clinical outcomes of GC and CRC patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	129-140	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
25565603-9	2015	Mitotic index of NKR-52E and RGE cells was worst affected by OxaliPt.	Oxaliplatin	61-68	tachykinin receptor 3	Rattus norvegicus	17-20
25482013-0	2015	The FOXM1-induced resistance to oxaliplatin is partially mediated by its novel target gene Mcl-1 in gastric cancer cells.	Oxaliplatin	32-43	forkhead box M1	Homo sapiens	4-9
25534115-0	2015	ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy.	Oxaliplatin	15-26	tumor protein p53 binding protein 2	Homo sapiens	0-5
25482013-0	2015	The FOXM1-induced resistance to oxaliplatin is partially mediated by its novel target gene Mcl-1 in gastric cancer cells.	Oxaliplatin	32-43	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	91-96
25482013-4	2015	In this study, we first found that Forkhead box M1 (FOXM1) and Mcl-1 expression levels were positively correlated in human gastric cancer specimens and that both are associated with poor prognosis of patients treated with oxaliplatin.	Oxaliplatin	222-233	forkhead box M1	Homo sapiens	35-50
25482013-4	2015	In this study, we first found that Forkhead box M1 (FOXM1) and Mcl-1 expression levels were positively correlated in human gastric cancer specimens and that both are associated with poor prognosis of patients treated with oxaliplatin.	Oxaliplatin	222-233	forkhead box M1	Homo sapiens	52-57
25482013-4	2015	In this study, we first found that Forkhead box M1 (FOXM1) and Mcl-1 expression levels were positively correlated in human gastric cancer specimens and that both are associated with poor prognosis of patients treated with oxaliplatin.	Oxaliplatin	222-233	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	63-68
25482013-8	2015	Moreover, CCK-8 assays and analyses of apoptosis revealed that the suppression of the FOXM1/Mcl-1 pathway induced apoptosis and thus increased sensitivity to oxaliplatin in gastric cancer cells, whereas the enhancement of the FOXM1/Mcl-1 pathway inhibited apoptosis and decreased sensitivity to oxaliplatin in gastric cancer cells.	Oxaliplatin	158-169	forkhead box M1	Homo sapiens	86-91
25482013-8	2015	Moreover, CCK-8 assays and analyses of apoptosis revealed that the suppression of the FOXM1/Mcl-1 pathway induced apoptosis and thus increased sensitivity to oxaliplatin in gastric cancer cells, whereas the enhancement of the FOXM1/Mcl-1 pathway inhibited apoptosis and decreased sensitivity to oxaliplatin in gastric cancer cells.	Oxaliplatin	158-169	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	92-97
25482013-8	2015	Moreover, CCK-8 assays and analyses of apoptosis revealed that the suppression of the FOXM1/Mcl-1 pathway induced apoptosis and thus increased sensitivity to oxaliplatin in gastric cancer cells, whereas the enhancement of the FOXM1/Mcl-1 pathway inhibited apoptosis and decreased sensitivity to oxaliplatin in gastric cancer cells.	Oxaliplatin	295-306	forkhead box M1	Homo sapiens	86-91
25482013-8	2015	Moreover, CCK-8 assays and analyses of apoptosis revealed that the suppression of the FOXM1/Mcl-1 pathway induced apoptosis and thus increased sensitivity to oxaliplatin in gastric cancer cells, whereas the enhancement of the FOXM1/Mcl-1 pathway inhibited apoptosis and decreased sensitivity to oxaliplatin in gastric cancer cells.	Oxaliplatin	295-306	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	92-97
25482013-9	2015	Taken together, this study is the first to not only show that Mcl-1 is a novel target gene of FOXM1 but also suggest that targeting FOXM1/Mcl-1 may be a novel strategy to enhance sensitivity to oxaliplatin in gastric cancer.	Oxaliplatin	194-205	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	62-67
25482013-9	2015	Taken together, this study is the first to not only show that Mcl-1 is a novel target gene of FOXM1 but also suggest that targeting FOXM1/Mcl-1 may be a novel strategy to enhance sensitivity to oxaliplatin in gastric cancer.	Oxaliplatin	194-205	forkhead box M1	Homo sapiens	94-99
25482013-9	2015	Taken together, this study is the first to not only show that Mcl-1 is a novel target gene of FOXM1 but also suggest that targeting FOXM1/Mcl-1 may be a novel strategy to enhance sensitivity to oxaliplatin in gastric cancer.	Oxaliplatin	194-205	forkhead box M1	Homo sapiens	132-137
25482013-9	2015	Taken together, this study is the first to not only show that Mcl-1 is a novel target gene of FOXM1 but also suggest that targeting FOXM1/Mcl-1 may be a novel strategy to enhance sensitivity to oxaliplatin in gastric cancer.	Oxaliplatin	194-205	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	138-143
25534115-0	2015	ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy.	Oxaliplatin	28-33	tumor protein p53 binding protein 2	Homo sapiens	0-5
25534115-0	2015	ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy.	Oxaliplatin	28-33	tumor protein p53	Homo sapiens	81-84
25534115-4	2015	In this study, ASPP2 was found to enhance L-OHP-induced apoptosis in HCT116 p53(-/-) cells in a p53-independent manner.	Oxaliplatin	42-47	tumor protein p53 binding protein 2	Homo sapiens	15-20
25534115-4	2015	In this study, ASPP2 was found to enhance L-OHP-induced apoptosis in HCT116 p53(-/-) cells in a p53-independent manner.	Oxaliplatin	42-47	tumor protein p53	Homo sapiens	76-79
26148739-6	2015	In Cox proportional hazards regression model-based univariate and multivariate analyses, pT category (pT1-3 vs pT4) was the only significant prognostic factor in patients receiving non-oxaliplatin-based adjuvant chemotherapy, whereas pT category, signet ring cell histology and cribriform comedo histology remained independent prognostic factors in patients receiving oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	368-379	zinc finger protein 77	Homo sapiens	102-105
25798259-9	2015	PPAR- gammapositivity was associated with oxaliplatin use, surgical margins &gt;=1 mm and a trend towards a lesser degree of fibrosis.	Oxaliplatin	42-53	peroxisome proliferator activated receptor alpha	Homo sapiens	0-4
25304987-0	2015	Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin.	Oxaliplatin	91-102	GC vitamin D binding protein	Homo sapiens	0-47
25603057-6	2015	Using the MTT cell viability assay, we observed that cotreatment with ABCG2 blocker Nicardipine and platinum-based drugs Cisplatin, Oxaliplatin or Carboplatin significantly decreased cell viability of tumor cells.	Oxaliplatin	132-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	70-75
25304987-3	2015	In this study we evaluated the roles of a proven immunotherapeutic agent [Gc-protein-derived macrophage activating factor (GcMAF)] in preventing or decreasing oxaliplatin-induced neuronal damage and in modulating microglia activation following oxaliplatin-induced damage.	Oxaliplatin	159-170	GC vitamin D binding protein	Homo sapiens	74-121
25304987-3	2015	In this study we evaluated the roles of a proven immunotherapeutic agent [Gc-protein-derived macrophage activating factor (GcMAF)] in preventing or decreasing oxaliplatin-induced neuronal damage and in modulating microglia activation following oxaliplatin-induced damage.	Oxaliplatin	159-170	GC vitamin D binding protein	Homo sapiens	123-128
25304987-3	2015	In this study we evaluated the roles of a proven immunotherapeutic agent [Gc-protein-derived macrophage activating factor (GcMAF)] in preventing or decreasing oxaliplatin-induced neuronal damage and in modulating microglia activation following oxaliplatin-induced damage.	Oxaliplatin	244-255	GC vitamin D binding protein	Homo sapiens	74-121
25304987-3	2015	In this study we evaluated the roles of a proven immunotherapeutic agent [Gc-protein-derived macrophage activating factor (GcMAF)] in preventing or decreasing oxaliplatin-induced neuronal damage and in modulating microglia activation following oxaliplatin-induced damage.	Oxaliplatin	244-255	GC vitamin D binding protein	Homo sapiens	123-128
25304987-6	2015	OA-GcMAF reverted the damage inflicted by oxaliplatin on human neurons and preserved their viability.	Oxaliplatin	42-53	GC vitamin D binding protein	Homo sapiens	3-8
25304987-9	2015	However, it increased microglial activation following oxaliplatin-induced damage, resulting in an increased expression of the markers Iba1 and B7-2 without any concomitant increase in cell number.	Oxaliplatin	54-65	allograft inflammatory factor 1	Homo sapiens	134-138
25304987-9	2015	However, it increased microglial activation following oxaliplatin-induced damage, resulting in an increased expression of the markers Iba1 and B7-2 without any concomitant increase in cell number.	Oxaliplatin	54-65	CD86 molecule	Homo sapiens	143-147
25304987-10	2015	When neurons and microglial cells were co-cultured, the presence of OA-GcMAF significantly counteracted the toxic effects of oxaliplatin.	Oxaliplatin	125-136	GC vitamin D binding protein	Homo sapiens	71-76
25304987-11	2015	Our results demonstrate that OA-GcMAF, already used in the immunotherapy of advanced cancers, may significantly contribute to neutralizing the neurotoxicity induced by oxaliplatin, at the same time possibly concurring to an integrated anticancer effect.	Oxaliplatin	168-179	GC vitamin D binding protein	Homo sapiens	32-37
24998225-3	2015	We monitored the 1-hydroxypyrene (1-OHP) as biomarkers of exposure to PAHs and its probable association with catalase (CAT), glutathione (GSH) glutathione peroxidase (GSHPx) activity as biomarkers of oxidative stress in selected cohorts from the city Lahore.	Oxaliplatin	34-39	catalase	Homo sapiens	109-117
25220279-5	2015	Our results herein demonstrate that the development of oxaliplatin-induced mechano-hypersensitivity (allodynia and hyperalgesia) in rats is associated with the hyperactivation of astrocytes, but not microglial cells, increased production of pro-inflammatory and neuroexcitatory cytokines (TNF, IL-1beta), and reductions in the levels of anti-inflammatory/neuroprotective cytokines (IL-10, IL-4) in the dorsal horn of the spinal cord.	Oxaliplatin	55-66	tumor necrosis factor	Rattus norvegicus	289-292
25220279-5	2015	Our results herein demonstrate that the development of oxaliplatin-induced mechano-hypersensitivity (allodynia and hyperalgesia) in rats is associated with the hyperactivation of astrocytes, but not microglial cells, increased production of pro-inflammatory and neuroexcitatory cytokines (TNF, IL-1beta), and reductions in the levels of anti-inflammatory/neuroprotective cytokines (IL-10, IL-4) in the dorsal horn of the spinal cord.	Oxaliplatin	55-66	interleukin 1 beta	Rattus norvegicus	294-302
25220279-5	2015	Our results herein demonstrate that the development of oxaliplatin-induced mechano-hypersensitivity (allodynia and hyperalgesia) in rats is associated with the hyperactivation of astrocytes, but not microglial cells, increased production of pro-inflammatory and neuroexcitatory cytokines (TNF, IL-1beta), and reductions in the levels of anti-inflammatory/neuroprotective cytokines (IL-10, IL-4) in the dorsal horn of the spinal cord.	Oxaliplatin	55-66	interleukin 10	Rattus norvegicus	382-387
25220279-5	2015	Our results herein demonstrate that the development of oxaliplatin-induced mechano-hypersensitivity (allodynia and hyperalgesia) in rats is associated with the hyperactivation of astrocytes, but not microglial cells, increased production of pro-inflammatory and neuroexcitatory cytokines (TNF, IL-1beta), and reductions in the levels of anti-inflammatory/neuroprotective cytokines (IL-10, IL-4) in the dorsal horn of the spinal cord.	Oxaliplatin	55-66	interleukin 4	Rattus norvegicus	389-393
25444914-0	2015	Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells.	Oxaliplatin	61-72	AKT serine/threonine kinase 1	Homo sapiens	140-143
25444914-3	2015	We found that WA enhanced oxaliplatin-induced growth suppression and apoptosis in PC cells dramatically through a mechanism involving mitochondrial dysfunction and inactivation of the PI3K/AKT pathway.	Oxaliplatin	26-37	AKT serine/threonine kinase 1	Homo sapiens	189-192
24998225-3	2015	We monitored the 1-hydroxypyrene (1-OHP) as biomarkers of exposure to PAHs and its probable association with catalase (CAT), glutathione (GSH) glutathione peroxidase (GSHPx) activity as biomarkers of oxidative stress in selected cohorts from the city Lahore.	Oxaliplatin	34-39	catalase	Homo sapiens	119-122
25451013-7	2015	Through comprehensive proteomic analysis, three of the tested compounds, oxaliplatin, ginsenoside 20(S)-Rg3 and curcumin, were revealed to have a suppressive effect on FASN and histone H4 expression.	Oxaliplatin	73-84	fatty acid synthase	Homo sapiens	168-172
25624920-0	2015	Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins.	Oxaliplatin	86-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
25624920-4	2015	Treatment with 1.0mug/ml trastuzumab for 48 h significantly increased the sensitivity of NCI-N87 cells with HER2 amplification to oxaliplatin (Oxa) and DDP.	Oxaliplatin	130-141	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
25451013-7	2015	Through comprehensive proteomic analysis, three of the tested compounds, oxaliplatin, ginsenoside 20(S)-Rg3 and curcumin, were revealed to have a suppressive effect on FASN and histone H4 expression.	Oxaliplatin	73-84	H4 clustered histone 9	Homo sapiens	177-187
25785104-0	2015	PIK3C2G copy number is associated with clinical outcomes of colorectal cancer patients treated with oxaliplatin.	Oxaliplatin	100-111	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma	Homo sapiens	0-7
25785104-1	2015	PURPOSE: To investigate whether the copy number of PIK3C2G is associated with clinical outcomes for stage III colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	156-167	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma	Homo sapiens	51-58
25451013-12	2015	Three tested drugs, namely, oxaliplatin, ginsenoside 20(S)-Rg3 and curcumin were revealed to possess suppressive effects on fatty acid synthase and histone H4 and reduce metastasis as determined by cell migration assay.	Oxaliplatin	28-39	H4 clustered histone 9	Homo sapiens	148-158
25785104-8	2015	CONCLUSIONS: PIK3C2G is capable of predicting the recurrence and overall survival of stage III CRC patients receiving oxaliplatin-based therapy.	Oxaliplatin	118-129	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma	Homo sapiens	13-20
24889488-2	2015	The purpose of this study was to assess the prognostic impact of KRAS and BRAF mutation in patients treated with adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX).	Oxaliplatin	148-159	KRAS proto-oncogene, GTPase	Homo sapiens	65-69
24889488-2	2015	The purpose of this study was to assess the prognostic impact of KRAS and BRAF mutation in patients treated with adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX).	Oxaliplatin	148-159	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	74-78
25448804-1	2015	BACKGROUND: Whether hepatic arterial infusion (HAI) of oxaliplatin influences the rates of complete pathologic response (CPR) and severe oxaliplatin-related lesions (SOxL) in patients with colorectal liver metastases (CRLM) is unknown.	Oxaliplatin	55-66	high mobility group 20B	Homo sapiens	166-170
25307448-0	2015	A novel oxaliplatin derivative, Ht-2, triggers mitochondrion-dependent apoptosis in human colon cancer cells.	Oxaliplatin	8-19	hypothermia due to alcohol sensitivity 2	Mus musculus	32-36
25448804-10	2015	Patients with SOxL did not experience different outcome (median OS of 42 vs. 50 months, respectively; P = 0.92) CONCLUSIONS: HAI of oxaliplatin increases the likelihood of a CPR at the cost of a higher incidence of SOxL in patients with initially unresectable CRLM.	Oxaliplatin	132-143	high mobility group 20B	Homo sapiens	14-18
25448804-10	2015	Patients with SOxL did not experience different outcome (median OS of 42 vs. 50 months, respectively; P = 0.92) CONCLUSIONS: HAI of oxaliplatin increases the likelihood of a CPR at the cost of a higher incidence of SOxL in patients with initially unresectable CRLM.	Oxaliplatin	132-143	high mobility group 20B	Homo sapiens	215-219
24999837-0	2015	Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis.	Oxaliplatin	60-71	interleukin 1 receptor antagonist	Mus musculus	10-16
25307448-1	2015	Ht-2 is a novel oxaliplatin derivative previously identified in a compound screen performed by our laboratory.	Oxaliplatin	16-27	hypothermia due to alcohol sensitivity 2	Mus musculus	0-4
24999837-0	2015	Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis.	Oxaliplatin	60-71	transformation related protein 53, pseudogene	Mus musculus	114-117
25307448-4	2015	The IC50 of Ht-2 was 2-10-fold lower than oxaliplatin in all of the cancer cell lines tested except MCF-7 cells, whereas, the value was threefold higher than cisplatin or oxaliplatin in normal HUVEC cells.	Oxaliplatin	171-182	hypothermia due to alcohol sensitivity 2	Mus musculus	12-16
26179333-0	2015	Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells.	Oxaliplatin	85-96	microRNA 200c	Homo sapiens	61-69
25757925-0	2015	Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.	Oxaliplatin	94-105	microRNA 200c	Homo sapiens	70-78
25757925-0	2015	Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.	Oxaliplatin	94-105	microRNA 141	Homo sapiens	83-90
25757925-4	2015	The IC50 value of L-OHP was increased 16-fold in L-OHP-resistant SW620 cells, which also displayed mesenchymal cell-like characteristics, such as the down-regulation of E-cadherin and up-regulation of vimentin.	Oxaliplatin	18-23	cadherin 1	Homo sapiens	169-179
25757925-4	2015	The IC50 value of L-OHP was increased 16-fold in L-OHP-resistant SW620 cells, which also displayed mesenchymal cell-like characteristics, such as the down-regulation of E-cadherin and up-regulation of vimentin.	Oxaliplatin	49-54	cadherin 1	Homo sapiens	169-179
25757925-7	2015	The expression levels of miR-200c and miR-141 were significantly lower in L-OHP-resistant SW620 cells than in control SW620 cells.	Oxaliplatin	74-79	microRNA 200c	Homo sapiens	25-33
25757925-7	2015	The expression levels of miR-200c and miR-141 were significantly lower in L-OHP-resistant SW620 cells than in control SW620 cells.	Oxaliplatin	74-79	microRNA 141	Homo sapiens	38-45
25757925-9	2015	These results suggest that the down-regulated expression of miR-200c and miR-141 plays a role in selective resistance to L-OHP and EMT in CRC cells during repeated treatments with L-OHP.	Oxaliplatin	121-126	microRNA 200c	Homo sapiens	60-68
25757925-9	2015	These results suggest that the down-regulated expression of miR-200c and miR-141 plays a role in selective resistance to L-OHP and EMT in CRC cells during repeated treatments with L-OHP.	Oxaliplatin	121-126	microRNA 141	Homo sapiens	73-80
25757925-9	2015	These results suggest that the down-regulated expression of miR-200c and miR-141 plays a role in selective resistance to L-OHP and EMT in CRC cells during repeated treatments with L-OHP.	Oxaliplatin	180-185	microRNA 200c	Homo sapiens	60-68
26179333-0	2015	Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells.	Oxaliplatin	85-96	microRNA 141	Homo sapiens	74-81
25757925-9	2015	These results suggest that the down-regulated expression of miR-200c and miR-141 plays a role in selective resistance to L-OHP and EMT in CRC cells during repeated treatments with L-OHP.	Oxaliplatin	180-185	microRNA 141	Homo sapiens	73-80
25778491-0	2015	HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.	Oxaliplatin	77-88	high mobility group box 1	Homo sapiens	0-5
25778491-0	2015	HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.	Oxaliplatin	77-88	mitogen-activated protein kinase kinase 7	Homo sapiens	93-96
25778491-0	2015	HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.	Oxaliplatin	77-88	mitogen-activated protein kinase 1	Homo sapiens	97-100
25778491-3	2015	Administration of oxaliplatin to human CRC cells significantly enhanced the expression of HMGB1, which regulated the autophagy response and negatively regulate the cell apoptosis.	Oxaliplatin	18-29	high mobility group box 1	Homo sapiens	90-95
25778491-4	2015	Moreover, a decreased oxaliplatin -induced autophagy response and an increased apoptosis level were detected in stable CRC cells harboring HMGB1 shRNA.	Oxaliplatin	22-33	high mobility group box 1	Homo sapiens	139-144
25778491-6	2015	Taken together, these data suggest that HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.	Oxaliplatin	117-128	high mobility group box 1	Homo sapiens	40-45
25778491-6	2015	Taken together, these data suggest that HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.	Oxaliplatin	117-128	mitogen-activated protein kinase kinase 7	Homo sapiens	133-136
26126066-0	2015	The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy.	Oxaliplatin	119-130	SLC9A3 regulator 1	Homo sapiens	41-47
25778491-6	2015	Taken together, these data suggest that HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.	Oxaliplatin	117-128	mitogen-activated protein kinase 1	Homo sapiens	137-140
26126066-3	2015	Herein, we aimed to analyze the potential association between NHERF1 expression and P-gp, sorcin and HIF-1alpha MDR-related proteins in advanced GC patients treated with epirubicin/oxaliplatin/capecitabine (EOX) chemotherapy regimen, and its relation to response.	Oxaliplatin	181-192	SLC9A3 regulator 1	Homo sapiens	62-68
25553091-0	2015	ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas.	Oxaliplatin	22-33	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
26126066-3	2015	Herein, we aimed to analyze the potential association between NHERF1 expression and P-gp, sorcin and HIF-1alpha MDR-related proteins in advanced GC patients treated with epirubicin/oxaliplatin/capecitabine (EOX) chemotherapy regimen, and its relation to response.	Oxaliplatin	181-192	phosphoglycolate phosphatase	Homo sapiens	84-88
26126066-3	2015	Herein, we aimed to analyze the potential association between NHERF1 expression and P-gp, sorcin and HIF-1alpha MDR-related proteins in advanced GC patients treated with epirubicin/oxaliplatin/capecitabine (EOX) chemotherapy regimen, and its relation to response.	Oxaliplatin	181-192	sorcin	Homo sapiens	90-96
26126066-3	2015	Herein, we aimed to analyze the potential association between NHERF1 expression and P-gp, sorcin and HIF-1alpha MDR-related proteins in advanced GC patients treated with epirubicin/oxaliplatin/capecitabine (EOX) chemotherapy regimen, and its relation to response.	Oxaliplatin	181-192	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-111
26646579-7	2015	RESULTS: A 48 hours exposure of human erythrocytes to oxaliplatin (10 microg/ml) significantly increased the percentage of annexin-V-binding cells, significantly decreased forward scatter, significantly increased Fluo-3 fluorescence, and significantly increased DCFDA fluorescence.	Oxaliplatin	54-65	annexin A5	Homo sapiens	123-132
26646579-8	2015	The effect of oxaliplatin on annexin-V-binding and forward scatter was rather augmented by removal of extracellular Ca2+, but was significantly blunted in the presence of the antioxidant N-acetyl-cysteine (1 mM).	Oxaliplatin	14-25	annexin A5	Homo sapiens	29-38
25553091-9	2015	The basal levels of ERCC1 did not show significant differences between KRAS mt and wt cell lines, however, after 24 h exposure to Oxa, only the wt KRAS lines showed the ability to induce ERCC1, with a statistically significant difference (OR 42.9 IC 95% 17.260-106.972 p&lt;0.0005).	Oxaliplatin	130-133	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	187-192
25553091-12	2015	CONCLUSION: KRAS mutated cell lines were more sensitive to Oxa.	Oxaliplatin	59-62	KRAS proto-oncogene, GTPase	Homo sapiens	12-16
25553091-0	2015	ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas.	Oxaliplatin	22-33	KRAS proto-oncogene, GTPase	Homo sapiens	57-61
25553091-9	2015	The basal levels of ERCC1 did not show significant differences between KRAS mt and wt cell lines, however, after 24 h exposure to Oxa, only the wt KRAS lines showed the ability to induce ERCC1, with a statistically significant difference (OR 42.9 IC 95% 17.260-106.972 p&lt;0.0005).	Oxaliplatin	130-133	KRAS proto-oncogene, GTPase	Homo sapiens	147-151
25444672-0	2015	Silencing of CD59 enhanced the sensitivity of HT29 cells to 5-Fluorouracil and Oxaliplatin.	Oxaliplatin	79-90	CD59 molecule (CD59 blood group)	Homo sapiens	13-17
25976336-8	2015	Rapamycin slightly induced cell apoptosis but significantly enhanced the effect of oxaliplatin in soliciting apoptosis of A2780cis cells, which might be ascribed to its ability in further increasing the levels of cleaved caspase-8 and -3 and PARP induced by oxaliplatin.	Oxaliplatin	83-94	caspase 8	Homo sapiens	221-237
25976336-8	2015	Rapamycin slightly induced cell apoptosis but significantly enhanced the effect of oxaliplatin in soliciting apoptosis of A2780cis cells, which might be ascribed to its ability in further increasing the levels of cleaved caspase-8 and -3 and PARP induced by oxaliplatin.	Oxaliplatin	83-94	poly(ADP-ribose) polymerase 1	Homo sapiens	242-246
25444672-1	2015	Complement regulatory proteins (CD55 and CD59) were known to be expressed in many tumors and tumor cell lines including colorectal carcinoma, and were proposed as immunotherapy targets, however whether knocking down of CD55 and CD59 will affect the sensitivity of HT-29 cells to chemotherapy drugs for example, 5-Fluorouracil and Oxaliplatin and their possible mechanisms haven"t been studied.	Oxaliplatin	330-341	CD55 molecule (Cromer blood group)	Homo sapiens	32-36
25444672-1	2015	Complement regulatory proteins (CD55 and CD59) were known to be expressed in many tumors and tumor cell lines including colorectal carcinoma, and were proposed as immunotherapy targets, however whether knocking down of CD55 and CD59 will affect the sensitivity of HT-29 cells to chemotherapy drugs for example, 5-Fluorouracil and Oxaliplatin and their possible mechanisms haven"t been studied.	Oxaliplatin	330-341	CD59 molecule (CD59 blood group)	Homo sapiens	41-45
25444672-1	2015	Complement regulatory proteins (CD55 and CD59) were known to be expressed in many tumors and tumor cell lines including colorectal carcinoma, and were proposed as immunotherapy targets, however whether knocking down of CD55 and CD59 will affect the sensitivity of HT-29 cells to chemotherapy drugs for example, 5-Fluorouracil and Oxaliplatin and their possible mechanisms haven"t been studied.	Oxaliplatin	330-341	CD55 molecule (Cromer blood group)	Homo sapiens	219-223
25444672-1	2015	Complement regulatory proteins (CD55 and CD59) were known to be expressed in many tumors and tumor cell lines including colorectal carcinoma, and were proposed as immunotherapy targets, however whether knocking down of CD55 and CD59 will affect the sensitivity of HT-29 cells to chemotherapy drugs for example, 5-Fluorouracil and Oxaliplatin and their possible mechanisms haven"t been studied.	Oxaliplatin	330-341	CD59 molecule (CD59 blood group)	Homo sapiens	228-232
25444672-5	2015	We found that silencing CD59 in HT-29 cells could significantly enhance their sensitivity to 5-FU (P &lt; 0.05) and Oxaliplatin (P &lt; 0.05), and significantly reduced their IC50 concentration.	Oxaliplatin	116-127	CD59 molecule (CD59 blood group)	Homo sapiens	24-28
26106421-0	2015	Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer.	Oxaliplatin	76-87	secreted phosphoprotein 1	Homo sapiens	0-11
26146570-5	2015	Oxaliplatin (1 muM, 48 h) reduced cell viability and increased caspase-3 activity of neuron monocultures without damaging astrocytes.	Oxaliplatin	0-11	caspase 3	Rattus norvegicus	63-72
26146570-10	2015	The alpha7 nAChR stimulation protects neurons from oxaliplatin toxicity through an astrocyte-mediated mechanism.	Oxaliplatin	51-62	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	11-16
25355463-3	2015	The aim of the present study was to determine the role of gap junction intercellular communication (GJIC) composed of Cx43 on oxaliplatin-induced survival/apoptosis in mouse leydig normal and cancer cells using MTT, Annexin V/PI double staining assays and western blot analysis.	Oxaliplatin	126-137	gap junction protein, alpha 3	Mus musculus	118-122
25355463-9	2015	Furthermore, this converse oxaliplatin-inducing apoptosis exerted through the functional gap junction was correlated with the mitochondrial pathway-related protein Bcl-2/Bax and caspase-3/9.	Oxaliplatin	27-38	B cell leukemia/lymphoma 2	Mus musculus	164-169
25355463-9	2015	Furthermore, this converse oxaliplatin-inducing apoptosis exerted through the functional gap junction was correlated with the mitochondrial pathway-related protein Bcl-2/Bax and caspase-3/9.	Oxaliplatin	27-38	BCL2-associated X protein	Mus musculus	170-173
25355463-9	2015	Furthermore, this converse oxaliplatin-inducing apoptosis exerted through the functional gap junction was correlated with the mitochondrial pathway-related protein Bcl-2/Bax and caspase-3/9.	Oxaliplatin	27-38	caspase 3	Mus musculus	178-189
26113782-0	2015	PPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based Chemotherapy.	Oxaliplatin	85-96	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	0-8
26113782-1	2015	AIM: To investigate the correlation between PPP1R12A gene copy number and clinical outcomes of oxaliplatin-based regimen in stage III colorectal cancer (CRC).	Oxaliplatin	95-106	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	44-52
26113782-7	2015	CONCLUSION: Our findings suggest the copy number of PPP1R12A can independently predict recurrence and overall survival of stage III colorectal cancer patients receiving oxaliplatin-based chemotherapy.	Oxaliplatin	169-180	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	52-60
25322862-11	2015	The MTT experiment showed that SOCS1 interference caused the median inhibitory concentration (IC50) of oxaliplatin in Mel526 cells to decrease significantly.	Oxaliplatin	103-114	suppressor of cytokine signaling 1	Homo sapiens	31-36
26106421-9	2015	In addition, DLD1-OPN overexpressing cells showed enhanced ability to survive upon oxaliplatin treatment, and OPN expression was higher in CRC patients who were resistant to oxaliplatin-involved chemotherapy treatment.	Oxaliplatin	83-94	secreted phosphoprotein 1	Homo sapiens	18-21
26106421-9	2015	In addition, DLD1-OPN overexpressing cells showed enhanced ability to survive upon oxaliplatin treatment, and OPN expression was higher in CRC patients who were resistant to oxaliplatin-involved chemotherapy treatment.	Oxaliplatin	174-185	secreted phosphoprotein 1	Homo sapiens	18-21
26106421-9	2015	In addition, DLD1-OPN overexpressing cells showed enhanced ability to survive upon oxaliplatin treatment, and OPN expression was higher in CRC patients who were resistant to oxaliplatin-involved chemotherapy treatment.	Oxaliplatin	174-185	secreted phosphoprotein 1	Homo sapiens	110-113
25239074-8	2014	TREK2 is involved in the cold allodynia that characterizes the neuropathy commonly associated with treatments with the anticancer drug oxaliplatin.	Oxaliplatin	135-146	potassium channel, subfamily K, member 10	Mus musculus	0-5
25516776-7	2014	Rodel et al reported on the CAO/ARO/AIO-04 randomized phase III trial that compared standard treatment with 5-FU and radiation therapy, to oxaliplatin plus 5-FU in association with radiation therapy.	Oxaliplatin	139-150	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	32-35
25430880-6	2014	Activity of SGC7901/ADR cells transfected with Vav3-siRNA combined with 5-fluorouracil/oxaliplatin was much lower than that of control groups, and MDR1/P-gp, GST-pi and Bcl-2, Bax genes were significantly downregulated in Vav3-siRNA transfection group.	Oxaliplatin	87-98	aldo-keto reductase family 1 member B	Homo sapiens	20-23
25430880-6	2014	Activity of SGC7901/ADR cells transfected with Vav3-siRNA combined with 5-fluorouracil/oxaliplatin was much lower than that of control groups, and MDR1/P-gp, GST-pi and Bcl-2, Bax genes were significantly downregulated in Vav3-siRNA transfection group.	Oxaliplatin	87-98	vav guanine nucleotide exchange factor 3	Homo sapiens	47-51
25474278-1	2014	PURPOSE: The aim of this study was to evaluate the prognostic value of MSI-H and p53 overexpression in metastatic colorectal cancer (mCRC) treated with oxaliplatin and fluoropyrimidine-based first line chemotherapy.	Oxaliplatin	152-163	tumor protein p53	Homo sapiens	81-84
25474278-11	2014	mCRC patients with p53 overexpression undergoing an irinotecan containing second- or third-line chemotherapy after oxaliplatin failure have a significantly longer post-progression survival compared to patients without p53 overexpression.	Oxaliplatin	115-126	tumor protein p53	Homo sapiens	19-22
25360631-6	2014	LIN28B suppression inhibited the migration of SW480 colon cancer cells and facilitated the cytotoxicity induced by oxaliplatin in SW480 and HCT116 colon cancer cells.	Oxaliplatin	115-126	lin-28 homolog B	Homo sapiens	0-6
25473889-0	2014	Human rpL3 plays a crucial role in cell response to nucleolar stress induced by 5-FU and L-OHP.	Oxaliplatin	89-94	ribosomal protein L3	Homo sapiens	6-10
25473889-2	2014	Here, we demonstrate that in lung and colon cancer cell lines devoid of p53, the efficacy of 5-FU and L-OHP chemotherapy depends on rpL3 status.	Oxaliplatin	102-107	ribosomal protein L3	Homo sapiens	132-136
25473889-3	2014	Specifically, we demonstrate that ribosomal stress induced by 5-FU and L-OHP is associated to up-regulation of rpL3 and its accumulation as ribosome-free form.	Oxaliplatin	71-76	ribosomal protein L3	Homo sapiens	111-115
25731304-7	2014	After 7 courses of capecitabine plus oxaliplatin (XELOX) treatment, the right #283 lymph node increased to 8 mm in October 2011 and the patient was diagnosed with a re-recurrence of the original tumor (CEA level, 4.6).	Oxaliplatin	37-48	CEA cell adhesion molecule 3	Homo sapiens	202-205
25321193-5	2014	Patients with high preoperative Sdc-1 serum levels were less responsive to 5-Fluorouracil, Oxaliplatin, Irintecan, Cisplatin or Paclitaxel chemotherapy.	Oxaliplatin	91-102	syndecan 1	Homo sapiens	32-37
25199623-0	2014	Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin-induced Src activation in gastric cancer cells.	Oxaliplatin	67-78	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	116-119
25199623-0	2014	Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin-induced Src activation in gastric cancer cells.	Oxaliplatin	96-107	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	116-119
25199623-10	2014	In addition, combined exposure to oxaliplatin and SAHA increased gammaH2AX expression and decreased Bcl-2 expression.	Oxaliplatin	34-45	BCL2 apoptosis regulator	Homo sapiens	100-105
25199623-12	2014	Oxaliplatin-induced Src phosphorylation was detected in gastric cancer cells, as we have previously reported.	Oxaliplatin	0-11	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	20-23
25199623-14	2014	The oxaliplatin-induced Src phosphorylation was not impaired with Akt inhibition.	Oxaliplatin	4-15	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	24-27
25199623-16	2014	The reversal of oxaliplatin-induced Src activation may be responsible for this positive interaction.	Oxaliplatin	16-27	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	36-39
25075794-0	2014	Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPARgamma/OCTN2 pathway.	Oxaliplatin	72-83	peroxisome proliferator activated receptor gamma	Homo sapiens	96-105
25075794-0	2014	Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPARgamma/OCTN2 pathway.	Oxaliplatin	72-83	solute carrier family 22 member 5	Homo sapiens	106-111
25075794-3	2014	Organic cation/carnitine transporter 2 (OCTN2) is a member of the solute carrier superfamily and is a determinant of oxaliplatin uptake.	Oxaliplatin	117-128	solute carrier family 22 member 5	Homo sapiens	0-38
25075794-3	2014	Organic cation/carnitine transporter 2 (OCTN2) is a member of the solute carrier superfamily and is a determinant of oxaliplatin uptake.	Oxaliplatin	117-128	solute carrier family 22 member 5	Homo sapiens	40-45
25075794-6	2014	Thus, we hypothesize that luteolin-mediated OCTN2 expression and activity potentiate the sensitivity of cancer cells to oxaliplatin.	Oxaliplatin	120-131	solute carrier family 22 member 5	Homo sapiens	44-49
25075794-9	2014	In uptake studies, luteolin increased the binding affinity of OCTN2 toward oxaliplatin and enhanced intracellular concentration of oxaliplatin.	Oxaliplatin	75-86	solute carrier family 22 member 5	Homo sapiens	62-67
25075794-12	2014	Thus, our study showed that luteolin increased the sensitivity of colorectal cancer SW480 cells to oxaliplatin, likely through the PPARgamma/OCTN2 pathway.	Oxaliplatin	99-110	peroxisome proliferator activated receptor gamma	Homo sapiens	131-140
25075794-12	2014	Thus, our study showed that luteolin increased the sensitivity of colorectal cancer SW480 cells to oxaliplatin, likely through the PPARgamma/OCTN2 pathway.	Oxaliplatin	99-110	solute carrier family 22 member 5	Homo sapiens	141-146
25232273-10	2014	Trastuzumab as perioperative and adjuvant medication, in combination with oxaliplatin and capecitabine for a HER2-overexpressing advanced gastric adenocarcinoma, led to recurrence-free survival of at least 18 mo after surgery.	Oxaliplatin	74-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
25174808-2	2014	The aim of the present study was to investigate the effects of polyethylene glycol (PEG)-liposomal oxaliplatin (L-OHP) on the induction of apoptosis in human colorectal cancer SW480 cells and how the nuclear factor-kappaB (NF-kappaB) pathway may contribute to mediating PEG-liposomal L-OHP-induced apoptosis.	Oxaliplatin	99-110	nuclear factor kappa B subunit 1	Homo sapiens	200-221
25174808-2	2014	The aim of the present study was to investigate the effects of polyethylene glycol (PEG)-liposomal oxaliplatin (L-OHP) on the induction of apoptosis in human colorectal cancer SW480 cells and how the nuclear factor-kappaB (NF-kappaB) pathway may contribute to mediating PEG-liposomal L-OHP-induced apoptosis.	Oxaliplatin	99-110	nuclear factor kappa B subunit 1	Homo sapiens	223-232
25174808-2	2014	The aim of the present study was to investigate the effects of polyethylene glycol (PEG)-liposomal oxaliplatin (L-OHP) on the induction of apoptosis in human colorectal cancer SW480 cells and how the nuclear factor-kappaB (NF-kappaB) pathway may contribute to mediating PEG-liposomal L-OHP-induced apoptosis.	Oxaliplatin	112-117	nuclear factor kappa B subunit 1	Homo sapiens	200-221
25174808-2	2014	The aim of the present study was to investigate the effects of polyethylene glycol (PEG)-liposomal oxaliplatin (L-OHP) on the induction of apoptosis in human colorectal cancer SW480 cells and how the nuclear factor-kappaB (NF-kappaB) pathway may contribute to mediating PEG-liposomal L-OHP-induced apoptosis.	Oxaliplatin	112-117	nuclear factor kappa B subunit 1	Homo sapiens	223-232
25174808-12	2014	Moreover, NF-kappaB signaling pathways may contribute to mediating PEG-liposomal L-OHP-induced apoptosis.	Oxaliplatin	81-86	nuclear factor kappa B subunit 1	Homo sapiens	10-19
25128218-11	2014	These results demonstrated that GIRK1 channels differentially contribute to antinociceptive effects of MOR agonists, and that action site of GIRK1 channels is also different between morphine and oxycodone in oxaliplatin model.	Oxaliplatin	208-219	potassium inwardly-rectifying channel, subfamily J, member 3	Rattus norvegicus	141-146
25128218-12	2014	This study suggests the possibility that GIRK1 channels have a crucial role for antinociception of MOR agonists in oxaliplatin-induced neuropathy.	Oxaliplatin	115-126	potassium inwardly-rectifying channel, subfamily J, member 3	Rattus norvegicus	41-46
25222248-8	2014	We found that the XPF rs6498486 and XPF rs2276465 polymorphisms are mark-ers of response to oxaliplatin/5-fluorouracil-based chemotherapy in gastric cancer patients.	Oxaliplatin	92-103	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	18-21
25208577-0	2014	Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.	Oxaliplatin	29-40	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
25222248-8	2014	We found that the XPF rs6498486 and XPF rs2276465 polymorphisms are mark-ers of response to oxaliplatin/5-fluorouracil-based chemotherapy in gastric cancer patients.	Oxaliplatin	92-103	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	36-39
25208577-3	2014	However, activation of Src and its substrate focal adhesion kinase (FAK) in metastatic colorectal cancer treated with oxaliplatin has not been investigated.	Oxaliplatin	118-129	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	23-26
25208577-3	2014	However, activation of Src and its substrate focal adhesion kinase (FAK) in metastatic colorectal cancer treated with oxaliplatin has not been investigated.	Oxaliplatin	118-129	protein tyrosine kinase 2	Homo sapiens	45-66
25208577-3	2014	However, activation of Src and its substrate focal adhesion kinase (FAK) in metastatic colorectal cancer treated with oxaliplatin has not been investigated.	Oxaliplatin	118-129	protein tyrosine kinase 2	Homo sapiens	68-71
25208577-4	2014	We retrospectively evaluated the activation of Src and FAK in hepatic metastases of colorectal cancer and correlated these findings with the clinical outcomes of patients treated with oxaliplatin.	Oxaliplatin	184-195	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	47-50
25208577-10	2014	Total Src expression was associated with the number of neoadjuvant cycles of oxaliplatin (P = 0.047).	Oxaliplatin	77-88	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	6-9
25208577-14	2014	CONCLUSIONS: Patients administered neoadjuvant oxaliplatin demonstrated higher levels of Src pathway signaling in hepatic metastases, a finding associated with poorer relapse-free survival.	Oxaliplatin	47-58	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	89-92
25257356-5	2014	1-OHP levels were increased in post-infarct patients compared to controls (p &lt; 0.05) and were correlated to MDA (r = 0.426, p &lt; 0.01), CAT (r = 0.474, p &lt; 0.001) and beta-carotene (r = -0.309; p &lt; 0.05) in non-smokers.	Oxaliplatin	0-5	catalase	Homo sapiens	141-144
25186747-7	2014	Both mechanical and cold hypersensitivity were reduced in VGluT3(-/-) mice in neuropathic pain evoked by the chemotherapeutic oxaliplatin, but not in the chronic constriction injury (CCI) model of the sciatic nerve.	Oxaliplatin	126-137	solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 8	Mus musculus	58-64
25186747-8	2014	Further, we provide direct evidence that, despite not mediating painful stimuli in naive mice, activation of VGluT3(+) sensory fibers by light elicits pain behavior in the oxaliplatin but not the CCI model.	Oxaliplatin	172-183	solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 8	Mus musculus	109-115
25232494-2	2014	Organic anion transporter 2 (OAT2) and organic cation transporter 2 (OCT2) are critical determinants in uptake of 5-FU and oxaliplatin, respectively.	Oxaliplatin	123-134	solute carrier family 22 member 7	Homo sapiens	0-27
25232494-2	2014	Organic anion transporter 2 (OAT2) and organic cation transporter 2 (OCT2) are critical determinants in uptake of 5-FU and oxaliplatin, respectively.	Oxaliplatin	123-134	solute carrier family 22 member 7	Homo sapiens	29-33
25232494-2	2014	Organic anion transporter 2 (OAT2) and organic cation transporter 2 (OCT2) are critical determinants in uptake of 5-FU and oxaliplatin, respectively.	Oxaliplatin	123-134	solute carrier family 22 member 2	Homo sapiens	39-67
25232494-2	2014	Organic anion transporter 2 (OAT2) and organic cation transporter 2 (OCT2) are critical determinants in uptake of 5-FU and oxaliplatin, respectively.	Oxaliplatin	123-134	solute carrier family 22 member 2	Homo sapiens	69-73
25188410-6	2014	As previously observed with cisplatin, oxaliplatin and carboplatin also increased DNA damage as indicated by an increase in phospho-H2AX and reduced the capsaicin-evoked release of CGRP from neuronal cultures.	Oxaliplatin	39-50	calcitonin-related polypeptide alpha	Rattus norvegicus	181-185
24869759-0	2014	TCF4 silencing sensitizes the colon cancer cell line to oxaliplatin as a common chemotherapeutic drug.	Oxaliplatin	56-67	transcription factor 4	Homo sapiens	0-4
24869759-3	2014	Hence, we aimed to determine the effect of RNA-mediated silencing of tcf4, the downstream effector of the wnt signaling pathway, on the response of the SW480 cell line to oxaliplatin, a common chemotherapeutic drug.	Oxaliplatin	171-182	transcription factor 4	Homo sapiens	69-73
24869759-12	2014	Although silencing the tcf4 gene would confer sensitivity to oxaliplatin in SW1874 and especially SW1396, in SW480 and SW-Sc, the lethal effect of oxaliplatin was compensated by its effect in increasing the proliferation of cells.	Oxaliplatin	61-72	transcription factor 4	Homo sapiens	23-27
24869759-12	2014	Although silencing the tcf4 gene would confer sensitivity to oxaliplatin in SW1874 and especially SW1396, in SW480 and SW-Sc, the lethal effect of oxaliplatin was compensated by its effect in increasing the proliferation of cells.	Oxaliplatin	147-158	transcription factor 4	Homo sapiens	23-27
24980946-8	2014	Our findings suggest that the SELE rs3917412 and MTHFR rs1801133 SNPs could serve as pharmacogenetic predictors of tumor recurrence in patients with early-stage colon cancer treated with oxaliplatin-based adjuvant chemotherapy, thus allowing personalized selection of treatment to optimize clinical outcomes.	Oxaliplatin	187-198	selectin E	Homo sapiens	30-34
25328987-6	2014	Finally, miR-378 increased cell apoptosis induced by the chemotherapeutic drug L-OHP.	Oxaliplatin	79-84	microRNA 378a	Homo sapiens	9-16
25175730-0	2014	Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.	Oxaliplatin	111-122	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	20-25
25175730-1	2014	BACKGROUND: Aim was to explore the association of ERCC1 and TS mRNA levels with the disease free survival (DFS) in Chinese colorectal cancer (CRC) patients receiving oxaliplatin and 5-FU based adjuvant chemotherapy.	Oxaliplatin	166-177	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	50-55
24980946-8	2014	Our findings suggest that the SELE rs3917412 and MTHFR rs1801133 SNPs could serve as pharmacogenetic predictors of tumor recurrence in patients with early-stage colon cancer treated with oxaliplatin-based adjuvant chemotherapy, thus allowing personalized selection of treatment to optimize clinical outcomes.	Oxaliplatin	187-198	methylenetetrahydrofolate reductase	Homo sapiens	49-54
25134433-4	2014	METHODS: NF-kappaB reporter cells were established and treated with 5-fluorouracil (5-FU, DNA/RNA damaging), oxaliplatin (DNA damaging), camptothecin (CTP, topoisomerase inhibitor), phleomycin (radiomimetic), or erlotinib (EGFR inhibitor).	Oxaliplatin	109-120	nuclear factor kappa B subunit 1	Homo sapiens	9-18
24960403-3	2014	We report the combination of panitumumab with gemcitabine (GEM) and oxaliplatin (OX) as first-line therapy for KRAS wild-type biliary tract cancer.	Oxaliplatin	68-79	KRAS proto-oncogene, GTPase	Homo sapiens	111-115
23543356-4	2014	Secondly, the variation of intracellular concentration of oxaliplatin (L-OHP) was evaluated by the inductively coupled plasma mass spectroscopy (ICPMS) in HCT8/V and its COX-2 siRNA cells; the concentration of JJR combined with chemotherapeutic drugs and the reverse effect of multidrug resistance (MDR) in HCT8/V cells was evaluated by the MTT assay.	Oxaliplatin	58-69	prostaglandin-endoperoxide synthase 2	Homo sapiens	170-175
23543356-4	2014	Secondly, the variation of intracellular concentration of oxaliplatin (L-OHP) was evaluated by the inductively coupled plasma mass spectroscopy (ICPMS) in HCT8/V and its COX-2 siRNA cells; the concentration of JJR combined with chemotherapeutic drugs and the reverse effect of multidrug resistance (MDR) in HCT8/V cells was evaluated by the MTT assay.	Oxaliplatin	71-76	prostaglandin-endoperoxide synthase 2	Homo sapiens	170-175
24960403-11	2014	CONCLUSIONS: The combination of gemcitabine, oxaliplatin and panitumumab in KRAS wild type metastatic biliary tract cancer showed encouraging efficacy, additional efforts of genetic stratification and targeted therapy is warranted in biliary tract cancer.	Oxaliplatin	45-56	KRAS proto-oncogene, GTPase	Homo sapiens	76-80
24264800-8	2014	In addition, CRT knockdown significantly decreased pho-ERK expression and cell chemoresistance independent of activated p53 and caspase-3-related apoptosis in gemcitabine- or oxaliplatin-treated Capan-2 cells.	Oxaliplatin	175-186	calreticulin	Homo sapiens	13-16
24876379-6	2014	Noteworthy, systemic administration of the S1PR1 modulator FTY720 (Food and Drug Administration- approved for multiple sclerosis) attenuated the activation of these neuroinflammatory processes and abrogated neuropathic pain without altering anticancer properties of paclitaxel and with beneficial effects extended to oxaliplatin.	Oxaliplatin	317-328	sphingosine-1-phosphate receptor 1	Homo sapiens	43-48
25036594-8	2014	Five day incubation with the selective Peroxisome Proliferator Activated Receptor-gamma (PPAR-gamma) antagonist G3335 (30 microM) induced a similar peroxisomal impairment suggesting a relationship between PPARgamma signaling and oxaliplatin neurotoxicity.	Oxaliplatin	229-240	peroxisome proliferator activated receptor gamma	Homo sapiens	39-87
25036594-8	2014	Five day incubation with the selective Peroxisome Proliferator Activated Receptor-gamma (PPAR-gamma) antagonist G3335 (30 microM) induced a similar peroxisomal impairment suggesting a relationship between PPARgamma signaling and oxaliplatin neurotoxicity.	Oxaliplatin	229-240	peroxisome proliferator activated receptor gamma	Homo sapiens	89-99
25036594-8	2014	Five day incubation with the selective Peroxisome Proliferator Activated Receptor-gamma (PPAR-gamma) antagonist G3335 (30 microM) induced a similar peroxisomal impairment suggesting a relationship between PPARgamma signaling and oxaliplatin neurotoxicity.	Oxaliplatin	229-240	peroxisome proliferator activated receptor gamma	Homo sapiens	205-214
25036594-9	2014	The PPARgamma agonist rosiglitazone (10 microM) reduced the harmful effects induced both by G3335 and oxaliplatin.	Oxaliplatin	102-113	peroxisome proliferator activated receptor gamma	Homo sapiens	4-13
25036594-14	2014	These results highlight the role of peroxisomes in oxaliplatin-dependent nervous damage and suggest PPARgamma stimulation as a candidate to counteract oxaliplatin neurotoxicity.	Oxaliplatin	151-162	peroxisome proliferator activated receptor gamma	Homo sapiens	100-109
25009397-6	2014	Finally, the cytotoxic effect of simultaneous treatment with oxaliplatin and adriamycin (an inhibitor of a significantly downregulated gene after Girdin suppression in DLD1 cells) was examined by MTT assay.	Oxaliplatin	61-72	coiled-coil domain containing 88A	Homo sapiens	146-152
25009397-8	2014	Compared with the scramble control, DLD1 cells infected with the Girdin shRNA displayed decreased Girdin mRNA and protein levels (P &lt; 0.05), and Girdin knockdown significantly enhanced chemosensitivity to oxaliplatin in colorectal cancer cells (P &lt; 0.05).	Oxaliplatin	208-219	coiled-coil domain containing 88A	Homo sapiens	65-71
25009397-11	2014	CONCLUSION: Girdin knockdown enhances chemosensitivity of colorectal cancer cells to oxaliplatin via TOP2B down-regulation.	Oxaliplatin	85-96	coiled-coil domain containing 88A	Homo sapiens	12-18
25009397-11	2014	CONCLUSION: Girdin knockdown enhances chemosensitivity of colorectal cancer cells to oxaliplatin via TOP2B down-regulation.	Oxaliplatin	85-96	DNA topoisomerase II beta	Homo sapiens	101-106
24786153-6	2014	Ex vivo analysis revealed that oxaliplatin increased the 5-HT2C receptor mRNA expression and protein levels in the SC and PAG.	Oxaliplatin	31-42	5-hydroxytryptamine receptor 2C	Rattus norvegicus	57-63
24786153-8	2014	While oxaliplatin decreased the 5-HT2C mRNA expression levels in the Amy, fluoxetine increased their protein levels in this area.	Oxaliplatin	6-17	5-hydroxytryptamine receptor 2C	Rattus norvegicus	32-38
24786153-9	2014	Fluoxetine impaired the oxaliplatin effects on the 5-HT2C receptor mRNA expression in the SC and Amy and protein levels in the SC.	Oxaliplatin	24-35	5-hydroxytryptamine receptor 2C	Rattus norvegicus	51-57
24786153-11	2014	These results suggest that the effects of fluoxetine on neuropathic pain induced by oxaliplatin are associated with quantitative changes in the 5-HT2C receptors located within important areas of the nociceptive system.	Oxaliplatin	84-95	5-hydroxytryptamine receptor 2C	Rattus norvegicus	144-150
25009397-0	2014	Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin.	Oxaliplatin	77-88	coiled-coil domain containing 88A	Homo sapiens	14-20
25009397-1	2014	AIM: To investigate the effect of Girdin knockdown on the chemosensitivity of colorectal cancer cells to oxaliplatin and the possible mechanisms involved.	Oxaliplatin	105-116	coiled-coil domain containing 88A	Homo sapiens	34-40
24981311-0	2014	VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).	Oxaliplatin	96-107	fms related receptor tyrosine kinase 4	Homo sapiens	0-7
24842074-0	2014	Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin.	Oxaliplatin	162-173	glutathione S-transferase kappa 1	Homo sapiens	24-49
24842074-7	2014	RESULTS: Compared with noncarriers, CRC patients who were homozygote carriers of GSTM1 had significantly poorer survival after treatment with oxaliplatin [hazard ratio (HR) 2.25, 95% confidence interval (CI) 0.93-5.44] than those not treated with oxaliplatin (HR 0.64, 95% CI 0.30-1.34; P for heterogeneity=0.031).	Oxaliplatin	142-153	glutathione S-transferase mu 1	Homo sapiens	81-86
24726707-7	2014	RESULTS: In OXPT-treated mice LPP1 and pregabalin dose-dependently reduced tactile allodynia (41-106% and 6-122%, respectively, p&lt;0.01).	Oxaliplatin	12-16	phospholipid phosphatase 1	Mus musculus	30-34
24842074-7	2014	RESULTS: Compared with noncarriers, CRC patients who were homozygote carriers of GSTM1 had significantly poorer survival after treatment with oxaliplatin [hazard ratio (HR) 2.25, 95% confidence interval (CI) 0.93-5.44] than those not treated with oxaliplatin (HR 0.64, 95% CI 0.30-1.34; P for heterogeneity=0.031).	Oxaliplatin	247-258	glutathione S-transferase mu 1	Homo sapiens	81-86
24842074-10	2014	CONCLUSION: Our data suggest that GSTM1 may be a predictive marker for oxaliplatin therapy; however, independent large studies are warranted to confirm these results.	Oxaliplatin	71-82	glutathione S-transferase mu 1	Homo sapiens	34-39
24515389-5	2014	It"s found the inhibition rate of 5-FU, L-OHP to well-differentiated GC tissues and cell line was lower than that in the poorly differentiated tissues and cell line; expressions of ZNF139 and MDR1/P-gp, MRP1 and Bcl-2 in well-differentiated GC tissues and cell line MKN28 were higher, while Bax expression was lower.	Oxaliplatin	40-45	zinc finger with KRAB and SCAN domains 1	Homo sapiens	181-187
24924344-5	2014	Specifically, ATP-binding cassette, sub-family C, member 5 (ABCC5), metallothionein 1A (MT1A) and NAD(P)H dehydrogenase quinone1 (NQO1) were significantly associated with oxaliplatin drug response.	Oxaliplatin	171-182	ATP binding cassette subfamily C member 5	Homo sapiens	14-58
24924344-5	2014	Specifically, ATP-binding cassette, sub-family C, member 5 (ABCC5), metallothionein 1A (MT1A) and NAD(P)H dehydrogenase quinone1 (NQO1) were significantly associated with oxaliplatin drug response.	Oxaliplatin	171-182	ATP binding cassette subfamily C member 5	Homo sapiens	60-65
24924344-5	2014	Specifically, ATP-binding cassette, sub-family C, member 5 (ABCC5), metallothionein 1A (MT1A) and NAD(P)H dehydrogenase quinone1 (NQO1) were significantly associated with oxaliplatin drug response.	Oxaliplatin	171-182	metallothionein 1A	Homo sapiens	68-86
24924344-5	2014	Specifically, ATP-binding cassette, sub-family C, member 5 (ABCC5), metallothionein 1A (MT1A) and NAD(P)H dehydrogenase quinone1 (NQO1) were significantly associated with oxaliplatin drug response.	Oxaliplatin	171-182	metallothionein 1A	Homo sapiens	88-92
24924344-5	2014	Specifically, ATP-binding cassette, sub-family C, member 5 (ABCC5), metallothionein 1A (MT1A) and NAD(P)H dehydrogenase quinone1 (NQO1) were significantly associated with oxaliplatin drug response.	Oxaliplatin	171-182	NAD(P)H quinone dehydrogenase 1	Homo sapiens	98-128
24924344-5	2014	Specifically, ATP-binding cassette, sub-family C, member 5 (ABCC5), metallothionein 1A (MT1A) and NAD(P)H dehydrogenase quinone1 (NQO1) were significantly associated with oxaliplatin drug response.	Oxaliplatin	171-182	NAD(P)H quinone dehydrogenase 1	Homo sapiens	130-134
24924344-6	2014	The significant SNP on NQO1 (rs1800566) has been linked with poor survival rates in patients with non-small cell lung cancer treated with cisplatin (which belongs to the same class of drugs as oxaliplatin).	Oxaliplatin	193-204	NAD(P)H quinone dehydrogenase 1	Homo sapiens	23-27
24468885-2	2014	Therefore, we designed a study using simvastatin/cetuximab/irinotecan for KRAS mutant CRC patients who are refractory to irinotecan and oxaliplatin-based chemotherapy.	Oxaliplatin	136-147	KRAS proto-oncogene, GTPase	Homo sapiens	74-78
24515389-5	2014	It"s found the inhibition rate of 5-FU, L-OHP to well-differentiated GC tissues and cell line was lower than that in the poorly differentiated tissues and cell line; expressions of ZNF139 and MDR1/P-gp, MRP1 and Bcl-2 in well-differentiated GC tissues and cell line MKN28 were higher, while Bax expression was lower.	Oxaliplatin	40-45	ATP binding cassette subfamily B member 1	Homo sapiens	192-196
24515389-5	2014	It"s found the inhibition rate of 5-FU, L-OHP to well-differentiated GC tissues and cell line was lower than that in the poorly differentiated tissues and cell line; expressions of ZNF139 and MDR1/P-gp, MRP1 and Bcl-2 in well-differentiated GC tissues and cell line MKN28 were higher, while Bax expression was lower.	Oxaliplatin	40-45	ATP binding cassette subfamily C member 1	Homo sapiens	203-207
24515389-5	2014	It"s found the inhibition rate of 5-FU, L-OHP to well-differentiated GC tissues and cell line was lower than that in the poorly differentiated tissues and cell line; expressions of ZNF139 and MDR1/P-gp, MRP1 and Bcl-2 in well-differentiated GC tissues and cell line MKN28 were higher, while Bax expression was lower.	Oxaliplatin	40-45	BCL2 apoptosis regulator	Homo sapiens	212-217
24515389-5	2014	It"s found the inhibition rate of 5-FU, L-OHP to well-differentiated GC tissues and cell line was lower than that in the poorly differentiated tissues and cell line; expressions of ZNF139 and MDR1/P-gp, MRP1 and Bcl-2 in well-differentiated GC tissues and cell line MKN28 were higher, while Bax expression was lower.	Oxaliplatin	40-45	BCL2 associated X, apoptosis regulator	Homo sapiens	291-294
24515389-6	2014	After ZNF139-siRNA was transfected into MKN28, ZNF139 expression in GC cells was inhibited by 90%; inhibition rate of 5-FU, L-OHP to tumor cells increased, and expressions of MDR1/P-gp, MRP1 and Bcl-2 were down-regulated, while Bax was up-regulated.	Oxaliplatin	124-129	zinc finger with KRAB and SCAN domains 1	Homo sapiens	6-12
23821376-0	2014	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.	Oxaliplatin	134-145	KRAS proto-oncogene, GTPase	Homo sapiens	8-12
23821376-0	2014	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.	Oxaliplatin	134-145	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	20-24
23821376-10	2014	Patients with KRAS/NRAS, BRAF and TP53 wild-type tumours could derive the maximal benefits from treatment with cetuximab, oxaliplatin and UFT.	Oxaliplatin	122-133	KRAS proto-oncogene, GTPase	Homo sapiens	14-18
23821376-0	2014	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.	Oxaliplatin	134-145	tumor protein p53	Homo sapiens	29-33
23821376-10	2014	Patients with KRAS/NRAS, BRAF and TP53 wild-type tumours could derive the maximal benefits from treatment with cetuximab, oxaliplatin and UFT.	Oxaliplatin	122-133	NRAS proto-oncogene, GTPase	Homo sapiens	19-23
23821376-10	2014	Patients with KRAS/NRAS, BRAF and TP53 wild-type tumours could derive the maximal benefits from treatment with cetuximab, oxaliplatin and UFT.	Oxaliplatin	122-133	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	25-29
24755081-7	2014	Overexpression of KIN enhanced, while silencing KIN impaired, chemoresistance to oxaliplatin (Ox) or 5-fluorouracil (5-FU) in CRC cell lines.	Oxaliplatin	81-92	Kin17 DNA and RNA binding protein	Homo sapiens	18-21
23821376-10	2014	Patients with KRAS/NRAS, BRAF and TP53 wild-type tumours could derive the maximal benefits from treatment with cetuximab, oxaliplatin and UFT.	Oxaliplatin	122-133	tumor protein p53	Homo sapiens	34-38
25241782-0	2014	[Phosphorylation status of ASPP2 modulates p53 apoptotic function in oxaliplatin-induced apoptosis of colorectal cancer HCT116 cells].	Oxaliplatin	69-80	tumor protein p53 binding protein 2	Homo sapiens	27-32
25241782-0	2014	[Phosphorylation status of ASPP2 modulates p53 apoptotic function in oxaliplatin-induced apoptosis of colorectal cancer HCT116 cells].	Oxaliplatin	69-80	tumor protein p53	Homo sapiens	43-46
25241782-7	2014	RESULTS: Oxaliplatin induced cell apoptosis and caused phosphorylation of ASPP2 at ser92/ser361 in the HCT116 cells.	Oxaliplatin	9-20	tumor protein p53 binding protein 2	Homo sapiens	74-79
25241782-10	2014	These results indicate that phosphorylated ASPP2 promoted the oxaliplatin-induced apoptosis of HCT116 cells through a p53-dependent pathway.	Oxaliplatin	62-73	tumor protein p53 binding protein 2	Homo sapiens	43-48
25241782-10	2014	These results indicate that phosphorylated ASPP2 promoted the oxaliplatin-induced apoptosis of HCT116 cells through a p53-dependent pathway.	Oxaliplatin	62-73	tumor protein p53	Homo sapiens	118-121
25241782-12	2014	CONCLUSION: Phosphorylation status of ASPP2 modulates p53 apoptotic function in oxaliplatin-induced apoptosis of colorectal cancer HCT116 cells.	Oxaliplatin	80-91	tumor protein p53 binding protein 2	Homo sapiens	38-43
25241782-12	2014	CONCLUSION: Phosphorylation status of ASPP2 modulates p53 apoptotic function in oxaliplatin-induced apoptosis of colorectal cancer HCT116 cells.	Oxaliplatin	80-91	tumor protein p53	Homo sapiens	54-57
24590266-0	2014	XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis.	Oxaliplatin	98-109	X-ray repair cross complementing 1	Homo sapiens	0-5
24590266-0	2014	XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis.	Oxaliplatin	98-109	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	10-13
24590266-1	2014	This meta-analysis aimed to obtain a comprehensive and reliable assessment of the relationships between XRCC1 Arg399Gln and XPD Lys751Gln polymorphisms and the clinical outcomes of gastric cancer (GC) patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	223-234	X-ray repair cross complementing 1	Homo sapiens	104-109
24590266-1	2014	This meta-analysis aimed to obtain a comprehensive and reliable assessment of the relationships between XRCC1 Arg399Gln and XPD Lys751Gln polymorphisms and the clinical outcomes of gastric cancer (GC) patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	223-234	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	124-127
24590266-10	2014	Results from the current meta-analysis indicate that XRCC1 Arg399Gln polymorphism may be associated with poor clinical outcomes in GC patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	156-167	X-ray repair cross complementing 1	Homo sapiens	53-58
24851084-0	2014	Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells.	Oxaliplatin	52-63	S100 calcium binding protein A10	Homo sapiens	21-28
24884501-0	2014	FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.	Oxaliplatin	150-161	Fc gamma receptor IIa	Homo sapiens	0-6
24884501-0	2014	FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.	Oxaliplatin	150-161	Fc gamma receptor IIIa	Homo sapiens	11-17
24851084-2	2014	Our recent proteomics studies have demonstrated that intracellular protein expression levels of S100A10 are significantly correlated with the sensitivity of colorectal cancer (CRC) cells to L-OHP, but not 5-FU, suggesting that S100A10 is a candidate predictive marker for the response to L-OHP.	Oxaliplatin	190-195	S100 calcium binding protein A10	Homo sapiens	96-103
24851084-2	2014	Our recent proteomics studies have demonstrated that intracellular protein expression levels of S100A10 are significantly correlated with the sensitivity of colorectal cancer (CRC) cells to L-OHP, but not 5-FU, suggesting that S100A10 is a candidate predictive marker for the response to L-OHP.	Oxaliplatin	190-195	S100 calcium binding protein A10	Homo sapiens	227-234
24851084-2	2014	Our recent proteomics studies have demonstrated that intracellular protein expression levels of S100A10 are significantly correlated with the sensitivity of colorectal cancer (CRC) cells to L-OHP, but not 5-FU, suggesting that S100A10 is a candidate predictive marker for the response to L-OHP.	Oxaliplatin	288-293	S100 calcium binding protein A10	Homo sapiens	96-103
24851084-2	2014	Our recent proteomics studies have demonstrated that intracellular protein expression levels of S100A10 are significantly correlated with the sensitivity of colorectal cancer (CRC) cells to L-OHP, but not 5-FU, suggesting that S100A10 is a candidate predictive marker for the response to L-OHP.	Oxaliplatin	288-293	S100 calcium binding protein A10	Homo sapiens	227-234
24851084-4	2014	RESULTS: Forced expression of S100A10 in COLO-320 CRC cells significantly increased the 50% inhibitory concentration (IC50) for L-OHP (P = 0.003), but did not change that for 5-FU, indicating that S100A10 is more specific to L-OHP than 5-FU.	Oxaliplatin	128-133	S100 calcium binding protein A10	Homo sapiens	30-37
24851084-4	2014	RESULTS: Forced expression of S100A10 in COLO-320 CRC cells significantly increased the 50% inhibitory concentration (IC50) for L-OHP (P = 0.003), but did not change that for 5-FU, indicating that S100A10 is more specific to L-OHP than 5-FU.	Oxaliplatin	225-230	S100 calcium binding protein A10	Homo sapiens	30-37
24851084-8	2014	CONCLUSIONS: The present results have shown that protein expression of S100A10 was associated with resistance to L-OHP, but not 5-FU, supporting the hypothesis that S100A10 expression may predict L-OHP sensitivity.	Oxaliplatin	113-118	S100 calcium binding protein A10	Homo sapiens	71-78
24851084-8	2014	CONCLUSIONS: The present results have shown that protein expression of S100A10 was associated with resistance to L-OHP, but not 5-FU, supporting the hypothesis that S100A10 expression may predict L-OHP sensitivity.	Oxaliplatin	196-201	S100 calcium binding protein A10	Homo sapiens	71-78
24851084-8	2014	CONCLUSIONS: The present results have shown that protein expression of S100A10 was associated with resistance to L-OHP, but not 5-FU, supporting the hypothesis that S100A10 expression may predict L-OHP sensitivity.	Oxaliplatin	196-201	S100 calcium binding protein A10	Homo sapiens	165-172
24851084-9	2014	Thus, our present study provides basic findings to support that S100A10 expression can be used as a predictive marker for tumor sensitivity to L-OHP.	Oxaliplatin	143-148	S100 calcium binding protein A10	Homo sapiens	64-71
24702224-0	2014	Cisplatin and oxaliplatin are toxic to cochlear outer hair cells and both target thioredoxin reductase in organ of Corti cultures.	Oxaliplatin	14-25	peroxiredoxin 5	Homo sapiens	81-102
24847383-0	2014	ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy.	Oxaliplatin	108-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
24847383-0	2014	ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy.	Oxaliplatin	108-119	glutathione S-transferase pi 1	Homo sapiens	17-22
24702224-11	2014	An animal model was used to evaluate the effect on TrxR after treatment with cisplatin and oxaliplatin in vivo.	Oxaliplatin	91-102	peroxiredoxin 5	Homo sapiens	51-55
24702224-12	2014	RESULTS: Direct exposure of cochlear organotypic cultures to either cisplatin or oxaliplatin induced comparable levels of outer hair cell loss and inhibition of TrxR, demonstrating that both drugs are similarly ototoxic provided that the cochlea becomes directly exposed.	Oxaliplatin	81-92	peroxiredoxin 5	Homo sapiens	161-165
24772300-5	2014	The median progression-free survival (mPFS) of the wild-type and mutated KRAS subgroups that had received oxaliplatin-based treatment was 8.6 and 6.8 months, respectively (P=0.41), whereas the mPFS of the wild-type KRAS, BRAF, PIK3CA, NRAS and AKT1 subgroups and that of their respective mutant subgroups was 9.7 and 7.2 months, respectively (P=0.10).	Oxaliplatin	106-117	KRAS proto-oncogene, GTPase	Homo sapiens	73-77
24923572-3	2014	METHODS: From March 2009 to December 2010, among the 614 patients diagnosed with gastric cancer in a medical center, 49 patients with unresectable advanced or metastatic gastric adenocarcinoma were treated with oxaliplatin (85 mg/m 2 ) on Day 1 and capecitabine (1000 mg/m 2 BID) for 10 days every 2 weeks (mXELOX).	Oxaliplatin	211-222	BH3 interacting domain death agonist	Homo sapiens	275-278
24585249-8	2014	Enforced expression of SCGB2A1 in CRC-derived cell lines promoted proliferation (DLD1, SW480 and LoVo cells; p&lt;0.05), decreased chemosensitivity to 5-fluorouracil and oxaliplatin (DLD1 and SW480 cell lines; p&lt;0.05), and significantly increased the viability of irradiated cells (DLD1, SW480 and LoVo cell lines; p&lt;0.05).	Oxaliplatin	170-181	secretoglobin family 2A member 1	Homo sapiens	23-30
24361534-0	2014	Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.	Oxaliplatin	140-151	eukaryotic translation elongation factor 1 alpha 2	Mus musculus	80-83
24361534-8	2014	In conclusion, 1-OHP-containing PEGylated liposome together with S-1 enhanced intratumor influx, leading to improved antitumor activity of subsequently injected 1-OHP-containing PEGylated liposomes and/or S-1.	Oxaliplatin	15-20	eukaryotic translation elongation factor 1 alpha 2	Mus musculus	205-208
24361534-8	2014	In conclusion, 1-OHP-containing PEGylated liposome together with S-1 enhanced intratumor influx, leading to improved antitumor activity of subsequently injected 1-OHP-containing PEGylated liposomes and/or S-1.	Oxaliplatin	161-166	eukaryotic translation elongation factor 1 alpha 2	Mus musculus	65-68
24556415-0	2014	Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.	Oxaliplatin	0-11	kelch-like ECH-associated protein 1	Mus musculus	26-31
24556415-0	2014	Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.	Oxaliplatin	0-11	nuclear factor, erythroid derived 2, like 2	Mus musculus	32-36
24556415-3	2014	Here, we report that oxaliplatin is an activator of the Nrf2 signaling pathway, with upregulation of ARE-driven genes and glutathione elevation.	Oxaliplatin	21-32	nuclear factor, erythroid derived 2, like 2	Mus musculus	56-60
24556415-4	2014	An injection of oxaliplatin into mice enhanced the expression of glutathione transferases and antioxidant enzymes in the small and large intestines of wild-type (WT) mice but not Nrf2(-/-) mice, indicating that oxaliplatin activates Nrf2 in vivo.	Oxaliplatin	16-27	nuclear factor, erythroid derived 2, like 2	Mus musculus	233-237
24556415-6	2014	However, forced expression of WT mKeap1 restored the ability of oxaliplatin to activate the transcription factor.	Oxaliplatin	64-75	kelch-like ECH-associated protein 1	Mus musculus	33-39
24556415-7	2014	Cys(151) in Keap1 was required for the response stimulated by oxaliplatin.	Oxaliplatin	62-73	kelch-like ECH-associated protein 1	Mus musculus	12-17
24556415-10	2014	Furthermore, activation of Nrf2 by oxaliplatin reduced the sensitivity of colon cancer cells to therapeutic drugs.	Oxaliplatin	35-46	nuclear factor, erythroid derived 2, like 2	Mus musculus	27-31
24556415-11	2014	Conversely, knockdown of Nrf2 by Nrf2 siRNA reduced oxaliplatin-induced chemoresistance.	Oxaliplatin	52-63	nuclear factor, erythroid derived 2, like 2	Mus musculus	25-29
24556415-11	2014	Conversely, knockdown of Nrf2 by Nrf2 siRNA reduced oxaliplatin-induced chemoresistance.	Oxaliplatin	52-63	nuclear factor, erythroid derived 2, like 2	Mus musculus	33-37
24556415-12	2014	Our study showed that oxaliplatin exerts protection against the cytotoxicity of anticancer drugs via Nrf2, indicating an important role of Nrf2 in oxaliplatin-based chemotherapy.	Oxaliplatin	22-33	nuclear factor, erythroid derived 2, like 2	Mus musculus	101-105
24556415-12	2014	Our study showed that oxaliplatin exerts protection against the cytotoxicity of anticancer drugs via Nrf2, indicating an important role of Nrf2 in oxaliplatin-based chemotherapy.	Oxaliplatin	22-33	nuclear factor, erythroid derived 2, like 2	Mus musculus	139-143
24556415-12	2014	Our study showed that oxaliplatin exerts protection against the cytotoxicity of anticancer drugs via Nrf2, indicating an important role of Nrf2 in oxaliplatin-based chemotherapy.	Oxaliplatin	147-158	nuclear factor, erythroid derived 2, like 2	Mus musculus	101-105
24556415-12	2014	Our study showed that oxaliplatin exerts protection against the cytotoxicity of anticancer drugs via Nrf2, indicating an important role of Nrf2 in oxaliplatin-based chemotherapy.	Oxaliplatin	147-158	nuclear factor, erythroid derived 2, like 2	Mus musculus	139-143
24634414-2	2014	In this article, we show that overexpression of the MT1G isoform sensitizes colorectal cell lines to the chemotherapeutic agents oxaliplatin (OXA) and 5-fluorouracil (5-FU), in part through enhancing p53 and repressing NF-kappaB activity.	Oxaliplatin	129-140	metallothionein 1G	Homo sapiens	52-56
24634414-2	2014	In this article, we show that overexpression of the MT1G isoform sensitizes colorectal cell lines to the chemotherapeutic agents oxaliplatin (OXA) and 5-fluorouracil (5-FU), in part through enhancing p53 and repressing NF-kappaB activity.	Oxaliplatin	142-145	metallothionein 1G	Homo sapiens	52-56
24634414-6	2014	We show for the first time that OXA and 5-FU induce higher levels of intracellular labile zinc, as measured using the fluorescent probe FLUOZIN-3, and that such zinc contributes to the activation of p53 and repression of NF-kappaB.	Oxaliplatin	32-35	tumor protein p53	Homo sapiens	199-202
24634414-6	2014	We show for the first time that OXA and 5-FU induce higher levels of intracellular labile zinc, as measured using the fluorescent probe FLUOZIN-3, and that such zinc contributes to the activation of p53 and repression of NF-kappaB.	Oxaliplatin	32-35	nuclear factor kappa B subunit 1	Homo sapiens	221-230
24765164-0	2014	Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: Association between neurotoxicity and the GSTP1 polymorphism.	Oxaliplatin	41-52	glutathione S-transferase pi 1	Homo sapiens	150-155
24765164-12	2014	Therefore, correlation between the GSTP1 polymorphism and oxaliplatin-induced neurotoxicity remains controversial.	Oxaliplatin	58-69	glutathione S-transferase pi 1	Homo sapiens	35-40
24764664-10	2014	The update showed that for patients with non-mutated KRAS exon 2 but other RAS mutations, panitumumab-fluorouracil, leucovorin, and oxaliplatin (FOLFOX)4 treatment led to inferior PFS (HR = 1.28, 95%CI: 0.79-2.07) and OS (HR = 1.29, 95%CI: 0.79-2.10), which was consistent with the findings in patients with KRAS mutations in exon 2.	Oxaliplatin	132-143	KRAS proto-oncogene, GTPase	Homo sapiens	53-57
24690178-8	2014	Oxaliplatin treatment produced only minimal changes in ROS levels and activation of the JNK/p38 pathway.	Oxaliplatin	0-11	mitogen-activated protein kinase 14	Homo sapiens	92-95
24764664-10	2014	The update showed that for patients with non-mutated KRAS exon 2 but other RAS mutations, panitumumab-fluorouracil, leucovorin, and oxaliplatin (FOLFOX)4 treatment led to inferior PFS (HR = 1.28, 95%CI: 0.79-2.07) and OS (HR = 1.29, 95%CI: 0.79-2.10), which was consistent with the findings in patients with KRAS mutations in exon 2.	Oxaliplatin	132-143	KRAS proto-oncogene, GTPase	Homo sapiens	308-312
23739764-0	2014	Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.	Oxaliplatin	46-57	TEF transcription factor, PAR bZIP family member	Homo sapiens	59-62
23739764-5	2014	TEF was administered as follows: docetaxel (50 mg/m(2)), oxaliplatin (85 mg/m(2)), and leucovorin (40 mg/m(2)) on day 1, and 5-FU continuous infusion for 48 h (2400 mg/m(2)) every 2 weeks.	Oxaliplatin	57-68	TEF transcription factor, PAR bZIP family member	Homo sapiens	0-3
23982883-0	2014	XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.	Oxaliplatin	72-83	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	0-3
24254404-2	2014	Oxaliplatin is released from the polymer-drug conjugate within cancer cell by reduction to attack nuclear DNA, while a dose of DMC is also hydrolyzed subsequently to block DNA damage-induced defense mechanisms by serine/threonine phosphatase 2A (PP2A) inhibition.	Oxaliplatin	0-11	protein phosphatase 2 phosphatase activator	Homo sapiens	246-250
24361454-12	2014	Among the various markers investigated, only TRPA1 transcript was upregulated in ganglia of oxaliplatin-treated rats.	Oxaliplatin	92-103	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	45-50
24318989-10	2014	This study reported a carriage of ERCC1 rs11615, and rs2298881 polymorphism can be used as a predictor of response to folinic acid/5-fluorouracil (5-FU)/oxaliplatin (FOLFOX)-based chemotherapy in gastric cancer patients.	Oxaliplatin	153-164	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	34-39
24846979-0	2014	[Roles of hMMS2 gene in reversing the oxaliplatin tolerance of human colon carcinoma cells].	Oxaliplatin	38-49	ubiquitin conjugating enzyme E2 V2	Homo sapiens	10-15
24846979-1	2014	In this study, the roles of hMMS2 (human methyl methanesulfonate sensitive mutant 2) gene encoding the human ubiquitin-conjugating enzyme E2 variant 2 in the drug resistance in human colon carcinoma were investigated by using a well-differentiated human colorectal carcinoma L-OHP-resistant cell line, THC8307/L-OHP.	Oxaliplatin	275-280	ubiquitin conjugating enzyme E2 V2	Homo sapiens	28-33
24846979-1	2014	In this study, the roles of hMMS2 (human methyl methanesulfonate sensitive mutant 2) gene encoding the human ubiquitin-conjugating enzyme E2 variant 2 in the drug resistance in human colon carcinoma were investigated by using a well-differentiated human colorectal carcinoma L-OHP-resistant cell line, THC8307/L-OHP.	Oxaliplatin	275-280	ubiquitin conjugating enzyme E2 V2	Homo sapiens	109-150
24846979-3	2014	Compared with untransfected or pcDNA6.2-GW/EmGFP vector-transfected cells, the hMMS2-depleted cells displayed significantly (P&lt;0.05) reduced half inhibition concentration(IC50) resistance index (RI) and colony-forming efficiency (CFE) upon treatment with oxaliplatin (L-OHP), while its relative reverse efficiency(RRE) was significantly higher (P&lt;0.05) than the control cells, indicating compromised ability of cell proliferation.	Oxaliplatin	258-269	ubiquitin conjugating enzyme E2 V2	Homo sapiens	79-84
24846979-3	2014	Compared with untransfected or pcDNA6.2-GW/EmGFP vector-transfected cells, the hMMS2-depleted cells displayed significantly (P&lt;0.05) reduced half inhibition concentration(IC50) resistance index (RI) and colony-forming efficiency (CFE) upon treatment with oxaliplatin (L-OHP), while its relative reverse efficiency(RRE) was significantly higher (P&lt;0.05) than the control cells, indicating compromised ability of cell proliferation.	Oxaliplatin	271-276	ubiquitin conjugating enzyme E2 V2	Homo sapiens	79-84
24846979-5	2014	The above observations collec-tively indicate that suppression of hMMS2 reverses L-OHP tolerance in differentiated human colorectal carcinoma cells by promoting apoptosis.	Oxaliplatin	81-86	ubiquitin conjugating enzyme E2 V2	Homo sapiens	66-71
23494222-2	2014	PATIENTS AND METHODS: S-1 was orally administered for 14 days at a dose of 80-120 mg/body/day to 7 patients with recurrent adenocarcinoma of the uterine cervix, with oxaliplatin being administered intravenously at a dose of 100 mg/m(2) on day 1.	Oxaliplatin	166-177	proteasome 26S subunit, non-ATPase 1	Homo sapiens	22-25
24548858-9	2014	Colorectal cancer cells with RAD21 knockdown exhibited enhanced sensitivity to 5-fluorouracil, either alone or in combination with oxaliplatin.	Oxaliplatin	131-142	RAD21 cohesin complex component	Homo sapiens	29-34
23982883-3	2014	In this study, we have shown that oxaliplatin forms interstrand crosslinks (ICLs) in cellular DNA and that loss of the heterodimeric structure-specific endonuclease XPF-ERCC1 causes hypersensitivity to oxaliplatin in mammalian cells.	Oxaliplatin	34-45	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	165-168
23982883-3	2014	In this study, we have shown that oxaliplatin forms interstrand crosslinks (ICLs) in cellular DNA and that loss of the heterodimeric structure-specific endonuclease XPF-ERCC1 causes hypersensitivity to oxaliplatin in mammalian cells.	Oxaliplatin	34-45	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	169-174
24486574-0	2014	Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death.	Oxaliplatin	72-83	BCL2 like 1	Homo sapiens	8-14
24486574-0	2014	Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death.	Oxaliplatin	72-83	beclin 1	Homo sapiens	15-23
23982883-3	2014	In this study, we have shown that oxaliplatin forms interstrand crosslinks (ICLs) in cellular DNA and that loss of the heterodimeric structure-specific endonuclease XPF-ERCC1 causes hypersensitivity to oxaliplatin in mammalian cells.	Oxaliplatin	202-213	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	165-168
24486574-5	2014	The combinational treatment of oxaliplatin and bortezomib promoted the JNK-Bcl-xL-Bax pathway which modulated the synergistic effect through the mitochondria-dependent apoptotic pathway.	Oxaliplatin	31-42	mitogen-activated protein kinase 8	Homo sapiens	71-74
23982883-3	2014	In this study, we have shown that oxaliplatin forms interstrand crosslinks (ICLs) in cellular DNA and that loss of the heterodimeric structure-specific endonuclease XPF-ERCC1 causes hypersensitivity to oxaliplatin in mammalian cells.	Oxaliplatin	202-213	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	169-174
24486574-5	2014	The combinational treatment of oxaliplatin and bortezomib promoted the JNK-Bcl-xL-Bax pathway which modulated the synergistic effect through the mitochondria-dependent apoptotic pathway.	Oxaliplatin	31-42	BCL2 like 1	Homo sapiens	75-81
24486574-5	2014	The combinational treatment of oxaliplatin and bortezomib promoted the JNK-Bcl-xL-Bax pathway which modulated the synergistic effect through the mitochondria-dependent apoptotic pathway.	Oxaliplatin	31-42	BCL2 associated X, apoptosis regulator	Homo sapiens	82-85
23982883-5	2014	In a panel of 12 MM cell lines, oxaliplatin sensitivity correlated with XPF and ERCC1 protein levels.	Oxaliplatin	32-43	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	72-75
24486574-9	2014	Beclin-1 was dissociated from Bcl-xL and initiated autophagy during treatment with oxaliplatin and bortezomib.	Oxaliplatin	83-94	beclin 1	Homo sapiens	0-8
23982883-5	2014	In a panel of 12 MM cell lines, oxaliplatin sensitivity correlated with XPF and ERCC1 protein levels.	Oxaliplatin	32-43	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	80-85
24486574-11	2014	A combinatorial treatment of oxaliplatin and bortezomib-induced Beclin-1 cleavage was abolished in Beclin-1 double mutant (D133AA/D149A) knock-in HCT116 cells, restoring the autophagy-promoting function of Beclin-1 and suppressing the apoptosis induced by the combination therapy.	Oxaliplatin	29-40	beclin 1	Homo sapiens	64-72
23982883-6	2014	The knockdown of ERCC1 and XPF protein levels by RNA interference increased sensitivity of cancer cells to oxaliplatin; overexpression of exogenous ERCC1 significantly decreased drug sensitivity.	Oxaliplatin	107-118	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-22
24486574-11	2014	A combinatorial treatment of oxaliplatin and bortezomib-induced Beclin-1 cleavage was abolished in Beclin-1 double mutant (D133AA/D149A) knock-in HCT116 cells, restoring the autophagy-promoting function of Beclin-1 and suppressing the apoptosis induced by the combination therapy.	Oxaliplatin	29-40	beclin 1	Homo sapiens	99-107
24486574-11	2014	A combinatorial treatment of oxaliplatin and bortezomib-induced Beclin-1 cleavage was abolished in Beclin-1 double mutant (D133AA/D149A) knock-in HCT116 cells, restoring the autophagy-promoting function of Beclin-1 and suppressing the apoptosis induced by the combination therapy.	Oxaliplatin	29-40	beclin 1	Homo sapiens	99-107
23982883-6	2014	The knockdown of ERCC1 and XPF protein levels by RNA interference increased sensitivity of cancer cells to oxaliplatin; overexpression of exogenous ERCC1 significantly decreased drug sensitivity.	Oxaliplatin	107-118	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	27-30
23982883-10	2014	Moreover, we show that XPF-ERCC1 protein levels are a key determinant of the sensitivity of melanoma cells to oxaliplatin in vitro.	Oxaliplatin	110-121	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	23-26
23982883-10	2014	Moreover, we show that XPF-ERCC1 protein levels are a key determinant of the sensitivity of melanoma cells to oxaliplatin in vitro.	Oxaliplatin	110-121	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	27-32
23982883-11	2014	Immunohistochemical detection of XPF appears suitable for development as a tissue biomarker for potentially selecting patients for oxaliplatin treatment in a prospective clinical trial.	Oxaliplatin	131-142	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	33-36
24632571-0	2014	Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1.	Oxaliplatin	27-38	insulin-like growth factor 1	Mus musculus	116-120
24632571-14	2014	CONCLUSION: Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma cells is associated with increased autocrine of IGF1.	Oxaliplatin	39-50	insulin-like growth factor 1	Mus musculus	134-138
24300914-4	2014	In MTT assays, combination treatment with oxaliplatin and trastuzumab significantly decreased the concentration of oxaliplatin required to induce 50% growth inhibition in HER2-positive gastric cancer cells.	Oxaliplatin	42-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	171-175
24606760-1	2014	BACKGROUND: Translationally controlled tumor protein (TCTP), alternatively called fortilin, is believed to be involved in the development of the chemoresistance of tumor cells against anticancer drugs such as etoposide, taxol, and oxaliplatin, the underlying mechanisms of which still remain elusive.	Oxaliplatin	231-242	tumor protein, translationally-controlled 1	Homo sapiens	12-52
24606760-1	2014	BACKGROUND: Translationally controlled tumor protein (TCTP), alternatively called fortilin, is believed to be involved in the development of the chemoresistance of tumor cells against anticancer drugs such as etoposide, taxol, and oxaliplatin, the underlying mechanisms of which still remain elusive.	Oxaliplatin	231-242	tumor protein, translationally-controlled 1	Homo sapiens	54-58
24606760-1	2014	BACKGROUND: Translationally controlled tumor protein (TCTP), alternatively called fortilin, is believed to be involved in the development of the chemoresistance of tumor cells against anticancer drugs such as etoposide, taxol, and oxaliplatin, the underlying mechanisms of which still remain elusive.	Oxaliplatin	231-242	tumor protein, translationally-controlled 1	Homo sapiens	82-90
24300914-4	2014	In MTT assays, combination treatment with oxaliplatin and trastuzumab significantly decreased the concentration of oxaliplatin required to induce 50% growth inhibition in HER2-positive gastric cancer cells.	Oxaliplatin	115-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	171-175
24300914-5	2014	Further investigation revealed that the trastuzumab-oxaliplatin combination induced cell cycle arrest and decreased expression of both p-AKT and p-ERK.	Oxaliplatin	52-63	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	145-150
24300914-6	2014	Notably, this treatment combination induced downregulation of the excision repair cross-complementation group 1 (ERCC1) protein, which is involved in the key repair process of the oxaliplatin-DNA platinum adduct at the protein level.	Oxaliplatin	180-191	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	66-111
24300914-6	2014	Notably, this treatment combination induced downregulation of the excision repair cross-complementation group 1 (ERCC1) protein, which is involved in the key repair process of the oxaliplatin-DNA platinum adduct at the protein level.	Oxaliplatin	180-191	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	113-118
24300914-8	2014	These findings suggest that trastuzumab synergizes the cytotoxic effect of oxaliplatin on HER2-positive gastric and breast cancer cells.	Oxaliplatin	75-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
24530887-0	2014	Oxaliplatin induces hypomyelination and reduced neuregulin 1 expression in the rat sciatic nerve.	Oxaliplatin	0-11	neuregulin 1	Rattus norvegicus	48-60
24362470-5	2014	After OXA/5-Fu therapy, the sera of CRC patients also exhibited increased levels of HMGB1 and HSP70, both of which are well-known DAMPs.	Oxaliplatin	6-9	high mobility group box 1	Homo sapiens	84-89
24362470-5	2014	After OXA/5-Fu therapy, the sera of CRC patients also exhibited increased levels of HMGB1 and HSP70, both of which are well-known DAMPs.	Oxaliplatin	6-9	heat shock protein family A (Hsp70) member 4	Homo sapiens	94-99
24362470-6	2014	The supernatants of dying CRC cells treated with OXA/5-Fu promoted mouse and human DC maturation, with upregulation of HLA-DR, CD80 and CD86 expression and enhancement of IL-1beta, TNF-alpha, MIP-1alpha, MIP-1beta, RANTES and IP-10 production.	Oxaliplatin	49-52	CD80 molecule	Homo sapiens	127-131
24362470-6	2014	The supernatants of dying CRC cells treated with OXA/5-Fu promoted mouse and human DC maturation, with upregulation of HLA-DR, CD80 and CD86 expression and enhancement of IL-1beta, TNF-alpha, MIP-1alpha, MIP-1beta, RANTES and IP-10 production.	Oxaliplatin	49-52	CD86 molecule	Homo sapiens	136-140
24362470-6	2014	The supernatants of dying CRC cells treated with OXA/5-Fu promoted mouse and human DC maturation, with upregulation of HLA-DR, CD80 and CD86 expression and enhancement of IL-1beta, TNF-alpha, MIP-1alpha, MIP-1beta, RANTES and IP-10 production.	Oxaliplatin	49-52	interleukin 1 beta	Homo sapiens	171-179
24362470-6	2014	The supernatants of dying CRC cells treated with OXA/5-Fu promoted mouse and human DC maturation, with upregulation of HLA-DR, CD80 and CD86 expression and enhancement of IL-1beta, TNF-alpha, MIP-1alpha, MIP-1beta, RANTES and IP-10 production.	Oxaliplatin	49-52	tumor necrosis factor	Homo sapiens	181-190
24362470-6	2014	The supernatants of dying CRC cells treated with OXA/5-Fu promoted mouse and human DC maturation, with upregulation of HLA-DR, CD80 and CD86 expression and enhancement of IL-1beta, TNF-alpha, MIP-1alpha, MIP-1beta, RANTES and IP-10 production.	Oxaliplatin	49-52	C-C motif chemokine ligand 3	Homo sapiens	192-202
24362470-6	2014	The supernatants of dying CRC cells treated with OXA/5-Fu promoted mouse and human DC maturation, with upregulation of HLA-DR, CD80 and CD86 expression and enhancement of IL-1beta, TNF-alpha, MIP-1alpha, MIP-1beta, RANTES and IP-10 production.	Oxaliplatin	49-52	C-C motif chemokine ligand 4	Homo sapiens	204-213
24362470-6	2014	The supernatants of dying CRC cells treated with OXA/5-Fu promoted mouse and human DC maturation, with upregulation of HLA-DR, CD80 and CD86 expression and enhancement of IL-1beta, TNF-alpha, MIP-1alpha, MIP-1beta, RANTES and IP-10 production.	Oxaliplatin	49-52	C-C motif chemokine ligand 5	Homo sapiens	215-221
24362470-6	2014	The supernatants of dying CRC cells treated with OXA/5-Fu promoted mouse and human DC maturation, with upregulation of HLA-DR, CD80 and CD86 expression and enhancement of IL-1beta, TNF-alpha, MIP-1alpha, MIP-1beta, RANTES and IP-10 production.	Oxaliplatin	49-52	C-X-C motif chemokine ligand 10	Homo sapiens	226-231
24318863-5	2014	Target genes were XPD-751, GSTP-1-105, XRCC1-399 for oxaliplatin, UGT1A1 for irinotecan.	Oxaliplatin	53-64	X-ray repair cross complementing 1	Homo sapiens	39-44
24362470-4	2014	Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70).	Oxaliplatin	63-74	high mobility group box 1	Homo sapiens	134-159
24362470-4	2014	Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70).	Oxaliplatin	63-74	high mobility group box 1	Homo sapiens	161-166
24362470-4	2014	Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70).	Oxaliplatin	63-74	heat shock protein family A (Hsp70) member 4	Homo sapiens	172-193
24362470-4	2014	Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70).	Oxaliplatin	63-74	heat shock protein family A (Hsp70) member 4	Homo sapiens	195-200
24362470-4	2014	Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70).	Oxaliplatin	76-79	high mobility group box 1	Homo sapiens	134-159
24362470-4	2014	Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70).	Oxaliplatin	76-79	high mobility group box 1	Homo sapiens	161-166
24362470-4	2014	Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70).	Oxaliplatin	76-79	heat shock protein family A (Hsp70) member 4	Homo sapiens	172-193
24362470-4	2014	Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70).	Oxaliplatin	76-79	heat shock protein family A (Hsp70) member 4	Homo sapiens	195-200
25818736-7	2014	Adding cetuximab to oxaliplatin-based chemotherapy regime can significant increase response rate in K-RAS mutation metastatic colorectal patients (odds ratio [OR]: 1.45, 95% confidence interval [CI]: 1.17-1.80, Z = 3.38, P = 0.001) and metastatic colorectal patients without knowing the K-RAS status (OR: 1.36, 95% CI: 1.11-1.65, Z = 1.89, P = 0.003).	Oxaliplatin	20-31	KRAS proto-oncogene, GTPase	Homo sapiens	100-105
25818736-7	2014	Adding cetuximab to oxaliplatin-based chemotherapy regime can significant increase response rate in K-RAS mutation metastatic colorectal patients (odds ratio [OR]: 1.45, 95% confidence interval [CI]: 1.17-1.80, Z = 3.38, P = 0.001) and metastatic colorectal patients without knowing the K-RAS status (OR: 1.36, 95% CI: 1.11-1.65, Z = 1.89, P = 0.003).	Oxaliplatin	20-31	KRAS proto-oncogene, GTPase	Homo sapiens	287-292
24598096-4	2014	Her platelet count increased to approximately 10.0x10(4)/muL during chemotherapy with oxaliplatin plus capecitabine, and she developed deep venous thrombosis requiring inferior vena cava filter placement and anticoagulation.	Oxaliplatin	86-97	tripartite motif containing 37	Homo sapiens	57-60
24530887-5	2014	Moreover, oxaliplatin reduced NRG1 mRNA levels in the DRG and decreased levels of cleaved NRG1 type III protein in the sciatic nerve.	Oxaliplatin	10-21	neuregulin 1	Rattus norvegicus	30-34
24530887-5	2014	Moreover, oxaliplatin reduced NRG1 mRNA levels in the DRG and decreased levels of cleaved NRG1 type III protein in the sciatic nerve.	Oxaliplatin	10-21	neuregulin 1	Rattus norvegicus	90-94
24530887-6	2014	Our results indicate that oxaliplatin induces hypomyelination and reduced NRG1 expression.	Oxaliplatin	26-37	neuregulin 1	Rattus norvegicus	74-78
24277452-0	2014	Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.	Oxaliplatin	74-85	clock circadian regulator	Homo sapiens	32-37
24215868-4	2014	Synergism was evident between LT-626 and cisplatin, oxaliplatin and SN-38 suggesting that PARP inhibitors in combination with DNA damaging agents may be a successful strategy for treatment of CRC.	Oxaliplatin	52-63	poly(ADP-ribose) polymerase 1	Homo sapiens	90-94
24503538-6	2014	A synergistic interaction was also observed between FGFR4 silencing and 5-fluorouracil (5-FU) and oxaliplatin chemotherapy in colon cancer cell lines.	Oxaliplatin	98-109	fibroblast growth factor receptor 4	Homo sapiens	52-57
24503538-9	2014	A similar phenotype and downstream pathway changes were observed following FGFR4 silencing in cell lines resistant to 5-FU, oxaliplatin and SN38 and upon exposure of parental cells to the FGFR small-molecule inhibitor BGJ398.	Oxaliplatin	124-135	fibroblast growth factor receptor 4	Homo sapiens	75-80
24277452-0	2014	Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.	Oxaliplatin	74-85	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	43-48
24277452-2	2014	The aim of this study was to explore the effect of Bmal1 on oxaliplatin sensitivity and to determine its clinical significance in colorectal cancer.	Oxaliplatin	60-71	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	51-56
24277452-9	2014	RESULTS: Bmal1 overexpression inhibited colorectal cancer cell proliferation and increased colorectal cancer sensitivity to oxaliplatin in three colorectal cancer cell lines and HCT116 cells model in vivo.	Oxaliplatin	124-135	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	9-14
24495750-7	2014	RESULTS: The combination of dovitinib and oxaliplatin showed higher in vitro cytotoxicity in colon cell lines irrespective of their RAS-RAF status as compared to either of the drugs alone.	Oxaliplatin	42-53	zinc fingers and homeoboxes 2	Homo sapiens	136-139
24495750-11	2014	CONCLUSIONS: This study demonstrates the synergistic antitumor activity of combination of dovitinib and oxaliplatin against colon cancer with different RAS-RAF status.	Oxaliplatin	104-115	zinc fingers and homeoboxes 2	Homo sapiens	156-159
24505265-0	2014	Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.	Oxaliplatin	0-11	KRAS proto-oncogene, GTPase	Homo sapiens	53-57
24351404-9	2014	CONCLUSIONS: Our results suggest that SNPs in CCNH and ABCG2 can modulate the development of severe OXPN among stage II-III CC patients who received oxaliplatin-based CT, thus enabling the individualization of adjuvant treatment.	Oxaliplatin	149-160	cyclin H	Homo sapiens	46-50
24505265-0	2014	Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.	Oxaliplatin	0-11	KRAS proto-oncogene, GTPase	Homo sapiens	73-77
24505265-4	2014	In KRAS mutant patients who had used oxaliplatin-based regimens (N = 131), the OS was significantly longer than that in KRAS mutant patients who had never-used oxaliplatin-based regimens (N = 38).	Oxaliplatin	37-48	KRAS proto-oncogene, GTPase	Homo sapiens	3-7
24505265-5	2014	The OS was 28.8 months [95% confidence interval (CI): 23.2-34.4] in KRAS mutant patients who had used oxaliplatin-based regimens versus 17.8 months [95% CI: 6.5-29.1] in KRAS mutant patients who had never-used oxaliplatin-based regimens (P = 0.026).	Oxaliplatin	102-113	KRAS proto-oncogene, GTPase	Homo sapiens	68-72
24505265-5	2014	The OS was 28.8 months [95% confidence interval (CI): 23.2-34.4] in KRAS mutant patients who had used oxaliplatin-based regimens versus 17.8 months [95% CI: 6.5-29.1] in KRAS mutant patients who had never-used oxaliplatin-based regimens (P = 0.026).	Oxaliplatin	210-221	KRAS proto-oncogene, GTPase	Homo sapiens	68-72
24505265-8	2014	In multivariate analyses, patients who had used oxaliplatin-based regimens remains an independent prognostic factor for longer OS in KRAS mutant mCRC patients.	Oxaliplatin	48-59	KRAS proto-oncogene, GTPase	Homo sapiens	133-137
24505265-9	2014	In conclusion, oxaliplatin-based regimens are more beneficial in KRAS mutant than in KRAS wild-type mCRC patients.	Oxaliplatin	15-26	KRAS proto-oncogene, GTPase	Homo sapiens	65-69
24505265-9	2014	In conclusion, oxaliplatin-based regimens are more beneficial in KRAS mutant than in KRAS wild-type mCRC patients.	Oxaliplatin	15-26	KRAS proto-oncogene, GTPase	Homo sapiens	85-89
24761411-11	2014	In addition to survivin restoration, resveratrol cotreatment also induced restoration of Bcl-2/caspase-3 expression suppressed by oxaliplatin only treatment.	Oxaliplatin	130-141	BCL2 apoptosis regulator	Homo sapiens	89-94
24761411-11	2014	In addition to survivin restoration, resveratrol cotreatment also induced restoration of Bcl-2/caspase-3 expression suppressed by oxaliplatin only treatment.	Oxaliplatin	130-141	caspase 3	Homo sapiens	95-104
24498368-0	2014	Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.	Oxaliplatin	84-95	chitinase 3 like 1	Homo sapiens	7-13
24498368-1	2014	BACKGROUND: We aim to test the hypothesis that high plasma YKL-40 is associated with short progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with first-line oxaliplatin and 5-flourouracil with or without cetuximab.	Oxaliplatin	226-237	chitinase 3 like 1	Homo sapiens	59-65
24498368-9	2014	CONCLUSIONS: Plasma YKL-40 is an independent prognostic biomarker in patients with mCRC treated with first-line oxaliplatin-based therapy alone or combined with cetuximab.	Oxaliplatin	112-123	chitinase 3 like 1	Homo sapiens	20-26
24351404-9	2014	CONCLUSIONS: Our results suggest that SNPs in CCNH and ABCG2 can modulate the development of severe OXPN among stage II-III CC patients who received oxaliplatin-based CT, thus enabling the individualization of adjuvant treatment.	Oxaliplatin	149-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	55-60
24701697-2	2014	Several recent phase III trials reported median overall survival data exceeding 30 months, an achievement inconceivable only 5 years ago.The first major step forward in the medical management of mCRC was provided by the addition of irinotecan and oxaliplatin to fluorouracil-based therapy; this increased survival from about 12 months to about 20 months.The introduction of biologic agents such as vascular endothelial growth factor inhibitors and epidermal growth factor inhibitors further increased survival--to more than 2 years in prospective trials.	Oxaliplatin	247-258	vascular endothelial growth factor A	Homo sapiens	398-432
24362794-8	2014	In oxaliplatin-resistant SGC7901/L-OHP cells, the main expression location of Txr1 shifted from the nucleus to cytoplasm, and both the mRNA and protein expression of Txr1 were higher than that of the parental cells, whereas expression of thrombospondin-1 (TSP1) decreased.	Oxaliplatin	3-14	thrombospondin 1	Homo sapiens	238-254
24362794-8	2014	In oxaliplatin-resistant SGC7901/L-OHP cells, the main expression location of Txr1 shifted from the nucleus to cytoplasm, and both the mRNA and protein expression of Txr1 were higher than that of the parental cells, whereas expression of thrombospondin-1 (TSP1) decreased.	Oxaliplatin	3-14	thrombospondin 1	Homo sapiens	256-260
24145123-0	2014	miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.	Oxaliplatin	16-27	microRNA 203a	Homo sapiens	0-7
24145123-0	2014	miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.	Oxaliplatin	16-27	ATM serine/threonine kinase	Homo sapiens	91-94
24145123-4	2014	In this study, unbiased microRNA array screening revealed that the miR-203 microRNA is up-regulated in three of three oxaliplatin-resistant CRC cell lines, and therefore we investigated the role of miR-203 in chemoresistance.	Oxaliplatin	118-129	microRNA 203a	Homo sapiens	67-74
24145123-5	2014	Exogenous expression of miR-203 in chemo-naive CRC cells induced oxaliplatin resistance.	Oxaliplatin	65-76	microRNA 203a	Homo sapiens	24-31
24145123-6	2014	Knockdown of miR-203 sensitized chemoresistant CRC cells to oxaliplatin.	Oxaliplatin	60-71	microRNA 203a	Homo sapiens	13-20
24145123-8	2014	ATM mRNA and protein levels were significantly down-regulated in CRC cells with acquired resistance to oxaliplatin.	Oxaliplatin	103-114	ATM serine/threonine kinase	Homo sapiens	0-3
24145123-12	2014	Furthermore, stable knockdown of ATM induced resistance to oxaliplatin in chemo-naive CRC cells.	Oxaliplatin	59-70	ATM serine/threonine kinase	Homo sapiens	33-36
24145123-13	2014	This is the first report of oxaliplatin resistance in CRC cells induced by miR-203-mediated suppression of ATM.	Oxaliplatin	28-39	microRNA 203a	Homo sapiens	75-82
24145123-13	2014	This is the first report of oxaliplatin resistance in CRC cells induced by miR-203-mediated suppression of ATM.	Oxaliplatin	28-39	ATM serine/threonine kinase	Homo sapiens	107-110
24052105-0	2014	Gosha-jinki-gan reduced oxaliplatin-induced hypersensitivity to cold sensation and its effect would be related to suppression of the expression of TRPM8 and TRPA1 in rats.	Oxaliplatin	24-35	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	147-152
24239815-8	2014	CONCLUSIONS: Both 1-OHP and 1-OHPG can be used to assess the relatively low PAH levels to which the general population is exposed.	Oxaliplatin	18-23	phenylalanine hydroxylase	Homo sapiens	76-79
24415827-1	2014	The crystal structure of the anticancer drug oxaliplatin, [Pt(R,R-DACH)(oxalate)] (DACH = diaminocyclohexane), was first reported in the non-centrosymmetric space group P21, confirming the sole presence of the R,R enantiomer of the DACH ligand [M. A. Bruck et al., Inorg.	Oxaliplatin	45-56	H3 histone pseudogene 16	Homo sapiens	169-172
24052105-0	2014	Gosha-jinki-gan reduced oxaliplatin-induced hypersensitivity to cold sensation and its effect would be related to suppression of the expression of TRPM8 and TRPA1 in rats.	Oxaliplatin	24-35	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	157-162
24403498-2	2014	Oxaliplatin-based regimens can be further strengthened by the addition of a third component, either a traditional drug such as irinotecan or targeted agents such as anti-vascular endothelial growth factor (VEGF) drugs, bevacizumab and aflibercept, or the anti-epidermal growth factor receptor (EGFR), cetuximab and panitumumab.	Oxaliplatin	0-11	vascular endothelial growth factor A	Homo sapiens	165-204
24052105-4	2014	We hypothesized that the effect of GJG on Oxp-induced cold hypersensitivity may be associated with the expression of the transient receptor potential melastatin 8 (TRPM8) and transient receptor potential ankyrin 1 (TRPA1) channels, which are cold-gated ion channels.	Oxaliplatin	42-45	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	121-162
24403498-2	2014	Oxaliplatin-based regimens can be further strengthened by the addition of a third component, either a traditional drug such as irinotecan or targeted agents such as anti-vascular endothelial growth factor (VEGF) drugs, bevacizumab and aflibercept, or the anti-epidermal growth factor receptor (EGFR), cetuximab and panitumumab.	Oxaliplatin	0-11	vascular endothelial growth factor A	Homo sapiens	206-210
24521151-3	2014	In the present study, we demonstrated that aurora B kinase (AURKB) is overexpressed in both cisplatin- and oxaliplatin-resistant cells.	Oxaliplatin	107-118	aurora kinase B	Homo sapiens	60-65
24521151-4	2014	Downregulation of AURKB sensitized cells to both cisplatin and oxaliplatin, but not to paclitaxel, 5-FU or hydrogen peroxide.	Oxaliplatin	63-74	aurora kinase B	Homo sapiens	18-23
24403498-2	2014	Oxaliplatin-based regimens can be further strengthened by the addition of a third component, either a traditional drug such as irinotecan or targeted agents such as anti-vascular endothelial growth factor (VEGF) drugs, bevacizumab and aflibercept, or the anti-epidermal growth factor receptor (EGFR), cetuximab and panitumumab.	Oxaliplatin	0-11	epidermal growth factor receptor	Homo sapiens	255-292
24052105-4	2014	We hypothesized that the effect of GJG on Oxp-induced cold hypersensitivity may be associated with the expression of the transient receptor potential melastatin 8 (TRPM8) and transient receptor potential ankyrin 1 (TRPA1) channels, which are cold-gated ion channels.	Oxaliplatin	42-45	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	164-169
24403498-2	2014	Oxaliplatin-based regimens can be further strengthened by the addition of a third component, either a traditional drug such as irinotecan or targeted agents such as anti-vascular endothelial growth factor (VEGF) drugs, bevacizumab and aflibercept, or the anti-epidermal growth factor receptor (EGFR), cetuximab and panitumumab.	Oxaliplatin	0-11	epidermal growth factor receptor	Homo sapiens	294-298
24052105-4	2014	We hypothesized that the effect of GJG on Oxp-induced cold hypersensitivity may be associated with the expression of the transient receptor potential melastatin 8 (TRPM8) and transient receptor potential ankyrin 1 (TRPA1) channels, which are cold-gated ion channels.	Oxaliplatin	42-45	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	175-213
24052105-4	2014	We hypothesized that the effect of GJG on Oxp-induced cold hypersensitivity may be associated with the expression of the transient receptor potential melastatin 8 (TRPM8) and transient receptor potential ankyrin 1 (TRPA1) channels, which are cold-gated ion channels.	Oxaliplatin	42-45	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	215-220
24052105-10	2014	These results suggest that coadministration of GJG may improve Oxp-induced cold hypersensitivity by suppressing the overexpression of TRPM8 and TRPA1 mRNA.	Oxaliplatin	63-66	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	134-139
24052105-10	2014	These results suggest that coadministration of GJG may improve Oxp-induced cold hypersensitivity by suppressing the overexpression of TRPM8 and TRPA1 mRNA.	Oxaliplatin	63-66	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	144-149
24172061-7	2014	In all 4 CRC cell lines, the cytotoxicity of L-OHP was enhanced in a synergic manner by co-treatment with DAC.	Oxaliplatin	45-50	arylacetamide deacetylase	Homo sapiens	106-109
25520091-0	2014	The XPD Lys751Gln polymorphism has predictive value in colorectal cancer patients receiving oxaliplatin-based chemotherapy: a systemic review and meta-analysis.	Oxaliplatin	92-103	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	4-7
25520091-1	2014	BACKGROUND: The predictive value of the xeroderma pigmentosum group D (XPD) Lys751Gln polymorphism regarding clinical outcomes of patients with colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy has been evaluated in numerous published studies, but the results remain inconclusive.	Oxaliplatin	178-189	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	40-69
25520091-1	2014	BACKGROUND: The predictive value of the xeroderma pigmentosum group D (XPD) Lys751Gln polymorphism regarding clinical outcomes of patients with colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy has been evaluated in numerous published studies, but the results remain inconclusive.	Oxaliplatin	178-189	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	71-74
25520091-6	2014	Overall, the XPD 751Gln allele was associated with a non-significant reduced objective response to oxaliplatin-based chemotherapy in all patients or in the Asian and Caucasian subgroups.	Oxaliplatin	99-110	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	13-16
25520091-7	2014	However, poor PFS and OS of CRC patients treated with oxaliplatin-based regimens were significantly related to the XPD 751Gln allele in the dominant model (PFS: HR=2.10, 95%CI: 1.65-2.67; OS: HR=3.18, 95%CI: 1.57-6.47).	Oxaliplatin	54-65	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	115-118
25520091-9	2014	CONCLUSIONS: The XPD Lys751Gln polymorphism may have prognostic value in patients with CRC undergoing oxaliplatin-based chemotherapy.	Oxaliplatin	102-113	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	17-20
24761924-3	2014	Compared with parental cell lines, IC50s for various chemotherapeutic agents (oxaliplatin, cisplatin and doxorubicin) were increased in oxaliplatin-resistant cell lines and this was accompanied by activation of nuclear factor erythroid-2 p45-related factor 2 (Nrf2) and NADPH quinone oxidoreductase 1 (NQO1).	Oxaliplatin	78-89	nuclear factor, erythroid derived 2, like 2	Mus musculus	260-264
24761924-3	2014	Compared with parental cell lines, IC50s for various chemotherapeutic agents (oxaliplatin, cisplatin and doxorubicin) were increased in oxaliplatin-resistant cell lines and this was accompanied by activation of nuclear factor erythroid-2 p45-related factor 2 (Nrf2) and NADPH quinone oxidoreductase 1 (NQO1).	Oxaliplatin	78-89	NAD(P)H dehydrogenase, quinone 1	Mus musculus	302-306
24761924-3	2014	Compared with parental cell lines, IC50s for various chemotherapeutic agents (oxaliplatin, cisplatin and doxorubicin) were increased in oxaliplatin-resistant cell lines and this was accompanied by activation of nuclear factor erythroid-2 p45-related factor 2 (Nrf2) and NADPH quinone oxidoreductase 1 (NQO1).	Oxaliplatin	136-147	nuclear factor, erythroid derived 2, like 2	Mus musculus	260-264
24761924-3	2014	Compared with parental cell lines, IC50s for various chemotherapeutic agents (oxaliplatin, cisplatin and doxorubicin) were increased in oxaliplatin-resistant cell lines and this was accompanied by activation of nuclear factor erythroid-2 p45-related factor 2 (Nrf2) and NADPH quinone oxidoreductase 1 (NQO1).	Oxaliplatin	136-147	NAD(P)H dehydrogenase, quinone 1	Mus musculus	302-306
24761924-4	2014	Furthermore, luteolin inhibited the Nrf2 pathway in oxaliplatin-resistant cell lines in a dose-dependent manner.	Oxaliplatin	52-63	nuclear factor, erythroid derived 2, like 2	Mus musculus	36-40
25339033-0	2014	The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.	Oxaliplatin	96-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-9
25339033-1	2014	BACKGROUND: Although the predictive value of the excision repair cross-complementing group 1 (ERCC1) C118T polymorphism in clinical outcomes of patients with colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy has been evaluated in numerous published studies, the conclusions are conflicting.	Oxaliplatin	192-203	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	49-92
25339033-1	2014	BACKGROUND: Although the predictive value of the excision repair cross-complementing group 1 (ERCC1) C118T polymorphism in clinical outcomes of patients with colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy has been evaluated in numerous published studies, the conclusions are conflicting.	Oxaliplatin	192-203	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	94-99
25339033-10	2014	CONCLUSIONS: The ERCC1 C118T polymorphism may have prognostic value in patients with CRC undergoing oxaliplatin-based chemotherapy.	Oxaliplatin	100-111	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-22
24368879-2	2014	Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF); it was approved in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing fluoropyrimidine-based regimen.	Oxaliplatin	361-372	placental growth factor	Homo sapiens	153-157
24427340-0	2014	Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	135-146	solute carrier family 22 member 2	Homo sapiens	0-28
24520224-0	2014	Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil.	Oxaliplatin	114-125	TNF receptor associated protein 1	Homo sapiens	15-20
24520224-0	2014	Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil.	Oxaliplatin	114-125	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	25-30
24520224-2	2014	Excision repair cross-complementation group 1 (ERCC1) expression levels in tumor tissues also predict clinical outcomes in metastatic CRC patients receiving combination oxaliplatin and 5-fluorouracil treatment.	Oxaliplatin	169-180	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
24520224-2	2014	Excision repair cross-complementation group 1 (ERCC1) expression levels in tumor tissues also predict clinical outcomes in metastatic CRC patients receiving combination oxaliplatin and 5-fluorouracil treatment.	Oxaliplatin	169-180	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
24520224-12	2014	CONCLUSION: The present study demonstrates that the combination of TRAP1 and ERCC1 expression predicts the survival of metastatic CRC patients who were treated with oxaliplatin/5-fluorouracil.	Oxaliplatin	165-176	TNF receptor associated protein 1	Homo sapiens	67-72
24520224-12	2014	CONCLUSION: The present study demonstrates that the combination of TRAP1 and ERCC1 expression predicts the survival of metastatic CRC patients who were treated with oxaliplatin/5-fluorouracil.	Oxaliplatin	165-176	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	77-82
25505922-8	2014	Immunoreactivities of glial fibrillary acidic protein (GFAP, astrocyte marker) and OX-42 (microglia marker) in the spinal dorsal horn were significantly increased by an oxaliplatin injection, which were restored by GBT administration.	Oxaliplatin	169-180	glial fibrillary acidic protein	Rattus norvegicus	22-53
25505922-8	2014	Immunoreactivities of glial fibrillary acidic protein (GFAP, astrocyte marker) and OX-42 (microglia marker) in the spinal dorsal horn were significantly increased by an oxaliplatin injection, which were restored by GBT administration.	Oxaliplatin	169-180	glial fibrillary acidic protein	Rattus norvegicus	55-59
24273214-0	2014	Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.	Oxaliplatin	71-82	BRCA1 DNA repair associated	Homo sapiens	31-36
24273214-8	2014	RESULTS: We found that oxaliplatin resistance in colorectal cancer cells depends on the DNA methylation-associated inactivation of the BRCA1 interactor SRBC gene.	Oxaliplatin	23-34	BRCA1 DNA repair associated	Homo sapiens	135-140
24273214-8	2014	RESULTS: We found that oxaliplatin resistance in colorectal cancer cells depends on the DNA methylation-associated inactivation of the BRCA1 interactor SRBC gene.	Oxaliplatin	23-34	caveolae associated protein 3	Homo sapiens	152-156
24273214-9	2014	SRBC overexpression or depletion gives rise to sensitivity or resistance to oxaliplatin, respectively.	Oxaliplatin	76-87	caveolae associated protein 3	Homo sapiens	0-4
24273214-10	2014	SRBC epigenetic inactivation occurred in primary tumors from a discovery cohort of colorectal cancer patients (29.8%; n = 39 of 131), where it predicted shorter PFS (hazard ratio [HR] = 1.83; 95% confidence interval [CI] = 1.15 to 2.92; log-rank P = .01), particularly in oxaliplatin-treated case subjects for which metastasis surgery was not indicated (HR = 1.96; 95% CI = 1.13 to 3.40; log-rank P = .01).	Oxaliplatin	272-283	caveolae associated protein 3	Homo sapiens	0-4
24273214-11	2014	In a validation cohort of unresectable colorectal tumors treated with oxaliplatin (n = 58), SRBC hypermethylation was also associated with shorter PFS (HR = 1.90; 95% CI = 1.01 to 3.60; log-rank P = .045).	Oxaliplatin	70-81	caveolae associated protein 3	Homo sapiens	92-96
24273214-12	2014	CONCLUSIONS: These results provide a basis for future clinical studies to validate SRBC hypermethylation as a predictive marker for oxaliplatin resistance in colorectal cancer.	Oxaliplatin	132-143	caveolae associated protein 3	Homo sapiens	83-87
24784702-6	2014	Application of menthol, a TRPA1/TRPM8 agonist, or allyl isothiocyanate (AITC), a selective TRPA1 agonist, to the hind paw of oxaliplatin-treated rats enhanced the nocifensive behaviors evoked by each agonist, whereas oxaliplatin had no significant effect on nocifensive behaviors evoked by capsaicin, a TRPV1 agonist.	Oxaliplatin	125-136	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	26-31
24784702-6	2014	Application of menthol, a TRPA1/TRPM8 agonist, or allyl isothiocyanate (AITC), a selective TRPA1 agonist, to the hind paw of oxaliplatin-treated rats enhanced the nocifensive behaviors evoked by each agonist, whereas oxaliplatin had no significant effect on nocifensive behaviors evoked by capsaicin, a TRPV1 agonist.	Oxaliplatin	125-136	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	91-96
24784702-6	2014	Application of menthol, a TRPA1/TRPM8 agonist, or allyl isothiocyanate (AITC), a selective TRPA1 agonist, to the hind paw of oxaliplatin-treated rats enhanced the nocifensive behaviors evoked by each agonist, whereas oxaliplatin had no significant effect on nocifensive behaviors evoked by capsaicin, a TRPV1 agonist.	Oxaliplatin	125-136	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	303-308
24220697-1	2014	AIMS: ERCC1 is involved in the repair of oxaliplatin-induced DNA damage.	Oxaliplatin	41-52	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	6-11
24220697-3	2014	We investigated the ERCC1 C118T SNP with respect to overall and progression-free survival in patients with advanced colorectal cancer (ACC) treated with oxaliplatin and in vitro DNA repair capacity after oxaliplatin exposure.	Oxaliplatin	153-164	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	20-25
24220697-3	2014	We investigated the ERCC1 C118T SNP with respect to overall and progression-free survival in patients with advanced colorectal cancer (ACC) treated with oxaliplatin and in vitro DNA repair capacity after oxaliplatin exposure.	Oxaliplatin	204-215	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	20-25
25136686-4	2014	For the dose-response relationship of IgG, IgA, IgM, and IgE by 1-OHP, each one percentage increase in urinary 1-OHP generates a 0.109%, 0.472%, 0.051%, and 0.067% decrease in control group and generates a 0.312%, 0.538%, 0.062%, and 0.071% decrease in exposed group, respectively.	Oxaliplatin	64-69	CD79a molecule	Homo sapiens	43-46
25136686-4	2014	For the dose-response relationship of IgG, IgA, IgM, and IgE by 1-OHP, each one percentage increase in urinary 1-OHP generates a 0.109%, 0.472%, 0.051%, and 0.067% decrease in control group and generates a 0.312%, 0.538%, 0.062%, and 0.071% decrease in exposed group, respectively.	Oxaliplatin	111-116	CD79a molecule	Homo sapiens	43-46
24548447-15	2013	Patients with down-regulated ERCC1 on Oxaliplatin or up-regulated TOPO Ion Irinotecan have longer survival and better curative effect.	Oxaliplatin	38-49	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	29-34
24351817-12	2013	Combination treatment with oxaliplatin and Exendin4 can significantly decrease Ki67 and PCNA proteins" expression in subcutaneous tumors of nude mice.	Oxaliplatin	27-38	antigen identified by monoclonal antibody Ki 67	Mus musculus	79-83
24351817-12	2013	Combination treatment with oxaliplatin and Exendin4 can significantly decrease Ki67 and PCNA proteins" expression in subcutaneous tumors of nude mice.	Oxaliplatin	27-38	proliferating cell nuclear antigen	Mus musculus	88-92
24351817-14	2013	In addition, Combination treatment with oxaliplatin and Exendin4 can significantly increase Caspase3 protein positive expression.	Oxaliplatin	40-51	caspase 3	Mus musculus	92-100
24784702-8	2014	Furthermore, GJG suppressed the increase of TRPA1 and TRPM8 mRNA expression induced by oxaliplatin in dorsal root ganglia.	Oxaliplatin	87-98	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	44-49
24784702-8	2014	Furthermore, GJG suppressed the increase of TRPA1 and TRPM8 mRNA expression induced by oxaliplatin in dorsal root ganglia.	Oxaliplatin	87-98	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	54-59
24784702-9	2014	These findings suggest that GJG prevented oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels, especially TRPA1 and TRPM8.	Oxaliplatin	42-53	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	155-160
24784702-9	2014	These findings suggest that GJG prevented oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels, especially TRPA1 and TRPM8.	Oxaliplatin	42-53	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	165-170
25427581-0	2014	Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.	Oxaliplatin	50-61	zinc fingers and homeoboxes 2	Homo sapiens	148-151
24362578-1	2013	We carried out molecular dynamics simulations and free energy calculations for a series of binary and ternary models of the cisplatin, transplatin and oxaliplatin agents binding to a monomeric Atox1 protein and a dimeric Atox1 protein to investigate their interaction mechanisms.	Oxaliplatin	151-162	antioxidant 1 copper chaperone	Homo sapiens	193-198
24362578-1	2013	We carried out molecular dynamics simulations and free energy calculations for a series of binary and ternary models of the cisplatin, transplatin and oxaliplatin agents binding to a monomeric Atox1 protein and a dimeric Atox1 protein to investigate their interaction mechanisms.	Oxaliplatin	151-162	antioxidant 1 copper chaperone	Homo sapiens	221-226
24362578-3	2013	The results suggested that the extra interaction from the oxaliplatin ligand-Atox1 protein interface increases its affinity only for the OxaliPt + Atox1 model.	Oxaliplatin	58-69	antioxidant 1 copper chaperone	Homo sapiens	77-82
24362578-3	2013	The results suggested that the extra interaction from the oxaliplatin ligand-Atox1 protein interface increases its affinity only for the OxaliPt + Atox1 model.	Oxaliplatin	58-69	antioxidant 1 copper chaperone	Homo sapiens	147-152
24362578-4	2013	The binding of the oxaliplatin agent to the Atox1 protein might cause larger deformation of the protein than those of the cisplatin and transplatin agents due to the larger size of the oxaliplatin ligand.	Oxaliplatin	19-30	antioxidant 1 copper chaperone	Homo sapiens	44-49
24362578-4	2013	The binding of the oxaliplatin agent to the Atox1 protein might cause larger deformation of the protein than those of the cisplatin and transplatin agents due to the larger size of the oxaliplatin ligand.	Oxaliplatin	185-196	antioxidant 1 copper chaperone	Homo sapiens	44-49
24070812-9	2013	In contrast, oxaliplatin significantly increased the mRNA expression of 5-HT1A receptor in the spinal dorsal horn, but not in the dorsal root ganglia.	Oxaliplatin	13-24	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	72-87
24427340-11	2014	These results suggest that high levels of OCT2 indicate severe invasion, but also better prognosis in mCRC patients treated with oxaliplatin-based chemotherapy, possibly because of its role in oxaliplatin susceptibility.	Oxaliplatin	129-140	solute carrier family 22 member 2	Homo sapiens	42-46
24427340-11	2014	These results suggest that high levels of OCT2 indicate severe invasion, but also better prognosis in mCRC patients treated with oxaliplatin-based chemotherapy, possibly because of its role in oxaliplatin susceptibility.	Oxaliplatin	193-204	solute carrier family 22 member 2	Homo sapiens	42-46
24427340-12	2014	Combined analysis of OCT2 and TB status may guide the selection of patients for successful oxaliplatin-based chemotherapy.	Oxaliplatin	91-102	solute carrier family 22 member 2	Homo sapiens	21-25
24118195-8	2013	While oxaliplatin induced p53- and p21-dependent G2 -phase arrest associated with downregulation of cyclin B1 and Cdk1, LA-12 allowed cells to enter M-phase of the cell cycle regardless of p53/p21 status.	Oxaliplatin	6-17	tumor protein p53	Homo sapiens	26-29
24328669-0	2013	Statement of retraction: Hongying Lv, Qicai Li, Wengsheng Qiu, Jinyu Xiang, Hongjun Wei, Hua Liang, Aihua Sui and Jun Liang "Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer".	Oxaliplatin	183-194	X-ray repair cross complementing 1	Homo sapiens	149-154
24286410-16	2013	CONCLUSION: The oxaliplatin-based IAP regimen is potentially effective for salvage chemotherapy in patients with recurrent and drug-resistant ovarian cancer, with a better therapeutic effect and tolerable side effects.	Oxaliplatin	16-27	alkaline phosphatase, intestinal	Homo sapiens	34-37
24118195-8	2013	While oxaliplatin induced p53- and p21-dependent G2 -phase arrest associated with downregulation of cyclin B1 and Cdk1, LA-12 allowed cells to enter M-phase of the cell cycle regardless of p53/p21 status.	Oxaliplatin	6-17	cyclin dependent kinase inhibitor 1A	Homo sapiens	35-38
24118195-8	2013	While oxaliplatin induced p53- and p21-dependent G2 -phase arrest associated with downregulation of cyclin B1 and Cdk1, LA-12 allowed cells to enter M-phase of the cell cycle regardless of p53/p21 status.	Oxaliplatin	6-17	cyclin dependent kinase 1	Homo sapiens	114-118
24394004-4	2013	The relationship between the MSI status and the efficacy of first- line oxaliplatin-based chemotherapy was retrospectively examined.	Oxaliplatin	72-83	RB binding protein 4, chromatin remodeling factor	Homo sapiens	29-32
23809767-3	2013	METHODS: NR4A2 was transfected into CRC cells to investigate its effects on chemo-resistance to 5-fluorouracil and oxaliplatin and chemotherapeutics-induced apoptosis.	Oxaliplatin	115-126	nuclear receptor subfamily 4, group A, member 2	Mus musculus	9-14
24114122-0	2013	UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.	Oxaliplatin	52-63	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-6
24222149-0	2013	C-reactive protein is a negative independent factor in patients with stage IV colorectal cancer undergoing oxaliplatin-based chemotherapy.	Oxaliplatin	107-118	C-reactive protein	Homo sapiens	0-18
24222149-1	2013	BACKGROUND/AIM: To determine the clinical significance of C-reactive protein (CRP) concentration in patients with stage IV colorectal cancer (CRC) undergoing oxaliplatin-based chemotherapy.	Oxaliplatin	158-169	C-reactive protein	Homo sapiens	58-76
24222149-1	2013	BACKGROUND/AIM: To determine the clinical significance of C-reactive protein (CRP) concentration in patients with stage IV colorectal cancer (CRC) undergoing oxaliplatin-based chemotherapy.	Oxaliplatin	158-169	C-reactive protein	Homo sapiens	78-81
23809767-11	2013	High NR4A2 expression specifically predicted a shorter DSS of colon cancer patients (dichotomisation, HR=2.55, log-rank test P=0.011), especially for those who received postoperative 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) chemotherapy (3-score range, HR=1.86, log-rank test P=0.020).	Oxaliplatin	214-225	nuclear receptor subfamily 4 group A member 2	Homo sapiens	5-10
24204988-8	2013	As a validation that the oxaliplatin-induced hypersensitivity could be due to an increased activity of the spinal glutamate system, an intrathecal administration of the specific NR2B antagonist, ifenprodil, totally reversed oxaliplatin-induced mechanical and cold hypersensitivity.	Oxaliplatin	25-36	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	178-182
24204988-8	2013	As a validation that the oxaliplatin-induced hypersensitivity could be due to an increased activity of the spinal glutamate system, an intrathecal administration of the specific NR2B antagonist, ifenprodil, totally reversed oxaliplatin-induced mechanical and cold hypersensitivity.	Oxaliplatin	224-235	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	178-182
24098947-0	2013	RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.	Oxaliplatin	58-69	phosphatidylethanolamine binding protein 1	Homo sapiens	0-4
24098947-0	2013	RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.	Oxaliplatin	58-69	signal transducer and activator of transcription 3	Homo sapiens	25-30
24098947-4	2013	The aim of this study was to evaluate the regulation of RKIP and STAT3 after treatment with clinically relevant chemotherapeutic agents (camptothecin (CPT) and oxaliplatin (OXP)) and the cytokine interleukin-6 (IL-6) in HCT116 colon cancer cells as well as evaluate the association between RKIP and STAT3 with clinical outcome of Stage II colon cancer patients.	Oxaliplatin	160-171	signal transducer and activator of transcription 3	Homo sapiens	65-70
24098947-4	2013	The aim of this study was to evaluate the regulation of RKIP and STAT3 after treatment with clinically relevant chemotherapeutic agents (camptothecin (CPT) and oxaliplatin (OXP)) and the cytokine interleukin-6 (IL-6) in HCT116 colon cancer cells as well as evaluate the association between RKIP and STAT3 with clinical outcome of Stage II colon cancer patients.	Oxaliplatin	160-171	phosphatidylethanolamine binding protein 1	Homo sapiens	56-60
23933386-2	2013	We previously demonstrated that increased DNA repair capacity and copper-transporting ATPase 1 (ATP7A) level contributed to oxaliplatin resistance in the human gastric carcinoma cell line TSGH-S3 (S3).	Oxaliplatin	124-135	ATPase copper transporting alpha	Homo sapiens	66-94
24146874-1	2013	Organic cation/carnitine transporter 2 (OCTN2) is responsible for the cellular uptake of the antineoplastic agent, oxaliplatin.	Oxaliplatin	115-126	solute carrier family 22 member 5	Homo sapiens	0-38
24146874-1	2013	Organic cation/carnitine transporter 2 (OCTN2) is responsible for the cellular uptake of the antineoplastic agent, oxaliplatin.	Oxaliplatin	115-126	solute carrier family 22 member 5	Homo sapiens	40-45
23887890-0	2013	Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.	Oxaliplatin	38-49	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	86-91
23887890-0	2013	Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.	Oxaliplatin	38-49	BCL2 like 1	Homo sapiens	99-105
23887890-4	2013	In this study, we analyzed the effect of MRK-003 (Merck), a potent inhibitor of gamma-secretase, on oxaliplatin-induced apoptosis in colon cancer.	Oxaliplatin	100-111	ciliogenesis associated kinase 1	Homo sapiens	41-44
23887890-7	2013	Blocking of Mcl-1 and/or Bcl-xL through siRNA or the small molecule inhibitor obatoclax restored the apoptotic potential of cells treated with both oxaliplatin and MRK-003.	Oxaliplatin	148-159	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	12-17
23887890-7	2013	Blocking of Mcl-1 and/or Bcl-xL through siRNA or the small molecule inhibitor obatoclax restored the apoptotic potential of cells treated with both oxaliplatin and MRK-003.	Oxaliplatin	148-159	BCL2 like 1	Homo sapiens	25-31
23933386-2	2013	We previously demonstrated that increased DNA repair capacity and copper-transporting ATPase 1 (ATP7A) level contributed to oxaliplatin resistance in the human gastric carcinoma cell line TSGH-S3 (S3).	Oxaliplatin	124-135	ATPase copper transporting alpha	Homo sapiens	96-101
23933386-9	2013	Knockdown of Nrf2 not only decreased the levels of AKR1C1, AKR1C2, and AKR1C3 mRNA and protein but also reversed oxaliplatin resistance in S3 cells.	Oxaliplatin	113-124	NFE2 like bZIP transcription factor 2	Homo sapiens	13-17
23822592-2	2013	This meta-analysis was performed to determine whether the addition of monoclonal antibodies (mAbs) of epidermal growth factor receptor (EGFR) to oxaliplatin-based chemotherapy treatment improves efficacy in KRAS wild-type metastatic colorectal cancer (mCRC), and whether infusional 5-fluorouracil (5-FU) and oxaliplatin is a preferred combination for EGFR mAbs.	Oxaliplatin	145-156	KRAS proto-oncogene, GTPase	Homo sapiens	207-211
23822592-2	2013	This meta-analysis was performed to determine whether the addition of monoclonal antibodies (mAbs) of epidermal growth factor receptor (EGFR) to oxaliplatin-based chemotherapy treatment improves efficacy in KRAS wild-type metastatic colorectal cancer (mCRC), and whether infusional 5-fluorouracil (5-FU) and oxaliplatin is a preferred combination for EGFR mAbs.	Oxaliplatin	308-319	epidermal growth factor receptor	Homo sapiens	102-134
23822592-2	2013	This meta-analysis was performed to determine whether the addition of monoclonal antibodies (mAbs) of epidermal growth factor receptor (EGFR) to oxaliplatin-based chemotherapy treatment improves efficacy in KRAS wild-type metastatic colorectal cancer (mCRC), and whether infusional 5-fluorouracil (5-FU) and oxaliplatin is a preferred combination for EGFR mAbs.	Oxaliplatin	308-319	epidermal growth factor receptor	Homo sapiens	136-140
23921441-5	2013	Results from experiments designed to test such hypothesis demonstrate that, as expected, mt-PCPH expression in human colorectal carcinoma (CRC) cells decreased their ATP levels and conferred resistance to oxaliplatin, a colorectal cancer-relevant chemotherapeutic agent.	Oxaliplatin	205-216	ectonucleoside triphosphate diphosphohydrolase 5 (inactive)	Homo sapiens	92-96
24344031-4	2013	RESULTS: CDP-choline significantly reduced OXA-induced mechanical hyperalgesia, in a dose- and time-dependent manner.	Oxaliplatin	43-46	cut-like homeobox 1	Rattus norvegicus	9-12
24344031-6	2013	CONCLUSION: These findings indicate that CDP-choline exerts an antihyperalgesic effect in OXA-induced neuropatic pain and it can be tested in clinical trials.	Oxaliplatin	90-93	cut-like homeobox 1	Rattus norvegicus	41-44
23822592-9	2013	EGFR mAbs combined with oxaliplatin and an infusional 5-FU regimen was associated with significantly improved RR, PFS and OS as first-line treatment in KRAS wild-type mCRC.	Oxaliplatin	24-35	KRAS proto-oncogene, GTPase	Homo sapiens	152-156
24634931-7	2013	In patients with colorectal cancer (n = 67) treated with HAl oxaliplatin or irinotecan combination therapy, the rates of PR and SD &gt;= 4 months were 7.5% and 34.3%, respectively.	Oxaliplatin	61-72	histidine ammonia-lyase	Homo sapiens	57-60
24344031-0	2013	Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain.	Oxaliplatin	73-84	cut-like homeobox 1	Rattus norvegicus	58-61
24344031-1	2013	PURPOSE: This study was designed to evaluate the antihyperalgesic effect of CDP-choline (cytidine-5"-diphosphate- choline; citicoline) in a rat model of neuropathic pain produced by oxaliplatin (OXA).	Oxaliplatin	182-193	cut-like homeobox 1	Rattus norvegicus	76-79
24344031-1	2013	PURPOSE: This study was designed to evaluate the antihyperalgesic effect of CDP-choline (cytidine-5"-diphosphate- choline; citicoline) in a rat model of neuropathic pain produced by oxaliplatin (OXA).	Oxaliplatin	195-198	cut-like homeobox 1	Rattus norvegicus	76-79
23933386-10	2013	Taken together, these results suggest that activation of the Nrf2/AKR1C axis may contribute to oxaliplatin resistance in S3 cells but that the IL-6 signaling pathway did not contribute to resistance.	Oxaliplatin	95-106	NFE2 like bZIP transcription factor 2	Homo sapiens	61-65
23933386-11	2013	Manipulation of Nrf2/AKR1Cs activity may be useful for management of oxaliplatin-refractory gastric cancers.	Oxaliplatin	69-80	NFE2 like bZIP transcription factor 2	Homo sapiens	16-20
26217113-5	2013	However, randomised phase III trials, evaluating the addition of oxaliplatin at low doses plus preoperative fluoropyrimidine-based chemoradiotherapy (CRT), have in the main failed to show a significant improvement on early pathological response, with the exception of the German CAO/ARO/AIO-04 study.	Oxaliplatin	65-76	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	283-286
24098083-0	2013	Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment.	Oxaliplatin	98-109	baculoviral IAP repeat containing 3	Homo sapiens	26-31
24098083-0	2013	Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment.	Oxaliplatin	98-109	baculoviral IAP repeat containing 7	Homo sapiens	36-41
24098083-6	2013	RESULTS: The caspase 3 and 9 inhibitors of apoptosis 2 (cIAP2) and LIVIN were found to be the most dose-responsive genes during the period of oxaliplatin treatment.	Oxaliplatin	142-153	baculoviral IAP repeat containing 3	Homo sapiens	56-61
24098083-6	2013	RESULTS: The caspase 3 and 9 inhibitors of apoptosis 2 (cIAP2) and LIVIN were found to be the most dose-responsive genes during the period of oxaliplatin treatment.	Oxaliplatin	142-153	baculoviral IAP repeat containing 7	Homo sapiens	67-72
24098083-7	2013	Two-fold sensitization of cells to oxaliplatin was observed with independent knockdown of either cIAP2 or LIVIN expression.	Oxaliplatin	35-46	baculoviral IAP repeat containing 3	Homo sapiens	97-102
24098083-7	2013	Two-fold sensitization of cells to oxaliplatin was observed with independent knockdown of either cIAP2 or LIVIN expression.	Oxaliplatin	35-46	baculoviral IAP repeat containing 7	Homo sapiens	106-111
23786838-8	2013	Oxaliplatin combined with honokiol improved the apoptosis rate of HT-29 cell and reduced PGE2 and VEGF secretion levels.	Oxaliplatin	0-11	vascular endothelial growth factor A	Homo sapiens	98-102
24023346-8	2013	CONCLUSION: Oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with initially unresectable metastases from colorectal cancer is safe and feasible.	Oxaliplatin	12-23	proteasome 26S subunit, non-ATPase 1	Homo sapiens	34-37
23747051-6	2013	Arm 2: docetaxel+oxaliplatin+cetuximab (DOCOX+C)=DOCOX with C 400mg/m(2) first dose then 250 mg/m(2) weekly.	Oxaliplatin	17-28	Jupiter microtubule associated homolog 1	Homo sapiens	0-5
23711479-0	2013	An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways.	Oxaliplatin	19-30	sodium channel, voltage-gated, type VIII, alpha	Mus musculus	81-87
23867956-4	2013	Both 1-OHP concentration and urinary mutagenicity tested by TA98+S9 were significantly higher in individuals with EPHX1 (exon 4) Arg/Arg genotype than in individuals with other genotype.	Oxaliplatin	5-10	epoxide hydrolase 1	Homo sapiens	114-119
23867956-7	2013	XRCC3 Met/Met genotype was associated with significantly higher levels of 1-OHP in urine compared with only The/Met genotype.	Oxaliplatin	74-79	X-ray repair cross complementing 3	Homo sapiens	0-5
24137384-11	2013	GSTP1-105 and GSTM1 genotypes may be useful markers of severe peripheral neuropathy in MCRC patients treated with 5-FU/oxaliplatin as first-line chemotherapy.	Oxaliplatin	119-130	glutathione S-transferase pi 1	Homo sapiens	0-5
23836292-10	2013	Our findings suggest that oxaliplatin-induced mechanical allodynia is associated with spinal NR2B up-regulation, which may be attenuated by mirtazapine administration.	Oxaliplatin	26-37	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	93-97
23711479-4	2013	Consistent with a crucial role for delayed-rectifier potassium channels in excitability in response to cold, intraplantar administration of the K(+)-channel blocker 4-aminopyridine mimicked oxaliplatin-induced cold allodynia and was also inhibited by Nav1.6 blockers.	Oxaliplatin	190-201	neuron navigator 1	Mus musculus	251-255
23969971-2	2013	Because oxaliplatin and nedaplatin are effective against cisplatin-resistant ovarian cancer in clinical trials and signal transducer and activator of transcription 3 (STAT3) is associated with cisplatin resistance, we investigated whether overcoming cisplatin resistance by oxaliplatin and nedaplatin was associated with the STAT3 pathway in ovarian cancer.	Oxaliplatin	274-285	signal transducer and activator of transcription 3	Homo sapiens	167-172
22643568-2	2013	In this study, we evaluated if there is any difference between first-line irinotecan-based and oxaliplatin-based chemotherapies in the duration of time to disease progression (TTP) in CRC patients with only liver metastasis.	Oxaliplatin	95-106	ZFP36 ring finger protein	Homo sapiens	176-179
23629479-1	2013	Both S1 and XELOX (capecitabine+oxaliplatin) have been recommended as an adjuvant treatment for gastric cancer according to the guidelines of the National Comprehensive Cancer Network (NCCN).	Oxaliplatin	32-43	proteasome 26S subunit, non-ATPase 1	Homo sapiens	5-17
23737485-6	2013	CatmAb promoted tumor cell death associated with ATP release and strongly synergized with oxaliplatin for the exposure of the three hallmarks of immunogenic cell death (calreticulin, HMGB1, and ATP).	Oxaliplatin	90-101	calreticulin	Homo sapiens	169-181
23737485-6	2013	CatmAb promoted tumor cell death associated with ATP release and strongly synergized with oxaliplatin for the exposure of the three hallmarks of immunogenic cell death (calreticulin, HMGB1, and ATP).	Oxaliplatin	90-101	high mobility group box 1	Homo sapiens	183-188
24013390-2	2013	Searching for the most clinically relevant approaches for treating colorectal metastatic disease by isolated hepatic perfusion (IHP), we developed the application of oxaliplatin concomitantly with hyperthermia and humanized death receptor 4 (DR4) antibody mapatumumab (Mapa), and investigated the molecular mechanisms of this multimodality treatment in human colon cancer cell lines CX-1 and HCT116 as well as human colon cancer stem cells Tu-12, Tu-21 and Tu-22.	Oxaliplatin	166-177	fatty acid desaturase 1	Homo sapiens	440-445
23695028-0	2013	Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis.	Oxaliplatin	53-64	glutathione S-transferase pi 1	Homo sapiens	20-25
23695028-1	2013	BACKGROUND AND AIMS: The association between glutathione-S-transferase P1 (GSTP1) Ile105Val polymorphism and oxaliplatin-induced neuropathy has been investigated in a number of published studies.	Oxaliplatin	109-120	glutathione S-transferase pi 1	Homo sapiens	45-73
23695028-1	2013	BACKGROUND AND AIMS: The association between glutathione-S-transferase P1 (GSTP1) Ile105Val polymorphism and oxaliplatin-induced neuropathy has been investigated in a number of published studies.	Oxaliplatin	109-120	glutathione S-transferase pi 1	Homo sapiens	75-80
23695028-3	2013	To assess the relationship between GSTP1 gene Ile105Val polymorphism and its susceptibility to oxaliplatin-induced neuropathy, a meta-analysis of previous studies was conducted.	Oxaliplatin	95-106	glutathione S-transferase pi 1	Homo sapiens	35-40
23548635-10	2013	These antioxidants fully protected astrocytes from the caspase 3 apoptotic signaling activation induced by oxaliplatin.	Oxaliplatin	107-118	caspase 3	Homo sapiens	55-64
23741067-2	2013	EXPERIMENTAL DESIGN: We used Sequenom and Pyrosequencing for high-throughput somatic profiling of the EGFR pathway in 1,976 tumors from patients with advanced colorectal cancer from the COIN trial (oxaliplatin and fluoropyrimidine chemotherapy +- cetuximab).	Oxaliplatin	198-209	epidermal growth factor receptor	Homo sapiens	102-106
23754252-5	2013	Oxaliplatin induced activation of the p53-p21 pathway and p38.	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	38-41
23754252-6	2013	In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin.	Oxaliplatin	208-219	H3 histone pseudogene 16	Homo sapiens	69-72
23458185-11	2013	Polymorphisms in the ATP7B gene may explain varying susceptibility to SOS among patients following oxaliplatin-based chemotherapy.	Oxaliplatin	99-110	ATPase copper transporting beta	Homo sapiens	21-26
23504997-11	2013	Finally, actopaxin down-regulation enhanced the chemosensitivity of HCC cells towards oxaliplatin treatment by way of a collective result of suppression of survivin protein, beta-catenin, and mammalian target of rapamycin pathways and up-regulation of p53.	Oxaliplatin	86-97	parvin alpha	Homo sapiens	9-18
23504997-11	2013	Finally, actopaxin down-regulation enhanced the chemosensitivity of HCC cells towards oxaliplatin treatment by way of a collective result of suppression of survivin protein, beta-catenin, and mammalian target of rapamycin pathways and up-regulation of p53.	Oxaliplatin	86-97	catenin beta 1	Homo sapiens	174-186
23504997-11	2013	Finally, actopaxin down-regulation enhanced the chemosensitivity of HCC cells towards oxaliplatin treatment by way of a collective result of suppression of survivin protein, beta-catenin, and mammalian target of rapamycin pathways and up-regulation of p53.	Oxaliplatin	86-97	tumor protein p53	Homo sapiens	252-255
23754252-6	2013	In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin.	Oxaliplatin	208-219	tumor protein p53	Homo sapiens	65-68
23754252-6	2013	In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin.	Oxaliplatin	208-219	mitogen-activated protein kinase 14	Homo sapiens	85-88
23754252-6	2013	In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin.	Oxaliplatin	208-219	caspase 3	Homo sapiens	145-154
23754252-8	2013	Based on these studies, inhibiting fatty acid synthase would be an effective strategy to treat unresectable colorectal cancer tumors in combination with oxaliplatin.	Oxaliplatin	153-164	fatty acid synthase	Homo sapiens	35-54
23754252-9	2013	Fatty acid synthase inhibitor would be one of the best counterparts of oxaliplatin, which reduces the dose and side-effects of oxaliplatin and would make it possible to endure the chemotherapy over a longer period.	Oxaliplatin	71-82	fatty acid synthase	Homo sapiens	0-19
23754252-9	2013	Fatty acid synthase inhibitor would be one of the best counterparts of oxaliplatin, which reduces the dose and side-effects of oxaliplatin and would make it possible to endure the chemotherapy over a longer period.	Oxaliplatin	127-138	fatty acid synthase	Homo sapiens	0-19
23754252-5	2013	Oxaliplatin induced activation of the p53-p21 pathway and p38.	Oxaliplatin	0-11	H3 histone pseudogene 16	Homo sapiens	42-45
23754252-5	2013	Oxaliplatin induced activation of the p53-p21 pathway and p38.	Oxaliplatin	0-11	mitogen-activated protein kinase 14	Homo sapiens	58-61
23754252-6	2013	In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin.	Oxaliplatin	34-45	tumor protein p53	Homo sapiens	65-68
23754252-6	2013	In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin.	Oxaliplatin	34-45	H3 histone pseudogene 16	Homo sapiens	69-72
23754252-6	2013	In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin.	Oxaliplatin	34-45	mitogen-activated protein kinase 14	Homo sapiens	85-88
23754252-6	2013	In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin.	Oxaliplatin	34-45	caspase 3	Homo sapiens	145-154
23894315-7	2013	Difluorinated curcumin (CDF), a novel analog of the dietary ingredient curcumin, which has been shown to inhibit the growth of 5-Flurouracil + Oxaliplatin resistant colon cancer cells, downregulated miR-21 in chemo-resistant colon cancer HCT116 and HT-29 cells and restored PTEN levels with subsequent reduction in Akt phosphorylation.	Oxaliplatin	143-154	LIF interleukin 6 family cytokine	Homo sapiens	24-27
23757163-3	2013	Surprisingly, OATP1B3 gene expression in a panel of 60 human tumor cell lines was linked with sensitivity to multiple cytotoxic agents, including the platinum anticancer drugs cisplatin, carboplatin, and oxaliplatin.	Oxaliplatin	204-215	solute carrier organic anion transporter family member 1B3	Homo sapiens	14-21
23712327-1	2013	PURPOSE: The aim of this study is to investigate whether dasatinib, a Src inhibitor, has the synergistic effect with oxaliplatin in treating gastric cancer cells.	Oxaliplatin	117-128	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	70-73
23776246-0	2013	Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.	Oxaliplatin	0-11	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	81-85
23776246-2	2013	We found that the organic cation transporter 2 (OCT2) is expressed on dorsal root ganglia cells within the nervous system where oxaliplatin is known to accumulate.	Oxaliplatin	128-139	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	18-46
23776246-2	2013	We found that the organic cation transporter 2 (OCT2) is expressed on dorsal root ganglia cells within the nervous system where oxaliplatin is known to accumulate.	Oxaliplatin	128-139	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	48-52
23776246-3	2013	Cellular uptake of oxaliplatin was increased by 16- to 35-fold in cells overexpressing mouse Oct2 or human OCT2, and this process was associated with increased DNA platination and oxaliplatin-induced cytotoxicity.	Oxaliplatin	19-30	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	93-97
23776246-3	2013	Cellular uptake of oxaliplatin was increased by 16- to 35-fold in cells overexpressing mouse Oct2 or human OCT2, and this process was associated with increased DNA platination and oxaliplatin-induced cytotoxicity.	Oxaliplatin	19-30	solute carrier family 22 member 2	Homo sapiens	107-111
23776246-3	2013	Cellular uptake of oxaliplatin was increased by 16- to 35-fold in cells overexpressing mouse Oct2 or human OCT2, and this process was associated with increased DNA platination and oxaliplatin-induced cytotoxicity.	Oxaliplatin	180-191	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	93-97
23776246-4	2013	Furthermore, genetic or pharmacologic knockout of Oct2 protected mice from hypersensitivity to cold or mechanical-induced allodynia, which are established tests to assess acute oxaliplatin-induced neurotoxicity.	Oxaliplatin	177-188	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	50-54
23525071-0	2013	Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.	Oxaliplatin	138-149	heterogeneous nuclear ribonucleoprotein A2/B1	Homo sapiens	153-164
23525071-8	2013	Inhibition of hnRNP A2/B1 expression significantly reduced the IC(50) of gemcitabine, 5-FU, and oxaliplatin (P&lt;0.01).	Oxaliplatin	96-107	heterogeneous nuclear ribonucleoprotein A2/B1	Homo sapiens	14-25
23525071-9	2013	hnRNP A2/B1 siRNA combined with gemcitabine, 5-FU and oxaliplatin significantly increased (P&lt;0.01) apoptosis of pancreatic cancer cell lines SW1990 and BxPC-3, increased the expression level of Bax mRNA, decreased Bcl-2 mRNA and MDR1 mRNA expression (P&lt;0.01), and induced no change in p53, TRAIL, and Survivin mRNA expression in SW1990.	Oxaliplatin	54-65	heterogeneous nuclear ribonucleoprotein A2/B1	Homo sapiens	0-11
23525071-9	2013	hnRNP A2/B1 siRNA combined with gemcitabine, 5-FU and oxaliplatin significantly increased (P&lt;0.01) apoptosis of pancreatic cancer cell lines SW1990 and BxPC-3, increased the expression level of Bax mRNA, decreased Bcl-2 mRNA and MDR1 mRNA expression (P&lt;0.01), and induced no change in p53, TRAIL, and Survivin mRNA expression in SW1990.	Oxaliplatin	54-65	BCL2 associated X, apoptosis regulator	Homo sapiens	197-200
23525071-9	2013	hnRNP A2/B1 siRNA combined with gemcitabine, 5-FU and oxaliplatin significantly increased (P&lt;0.01) apoptosis of pancreatic cancer cell lines SW1990 and BxPC-3, increased the expression level of Bax mRNA, decreased Bcl-2 mRNA and MDR1 mRNA expression (P&lt;0.01), and induced no change in p53, TRAIL, and Survivin mRNA expression in SW1990.	Oxaliplatin	54-65	BCL2 apoptosis regulator	Homo sapiens	217-222
23525071-9	2013	hnRNP A2/B1 siRNA combined with gemcitabine, 5-FU and oxaliplatin significantly increased (P&lt;0.01) apoptosis of pancreatic cancer cell lines SW1990 and BxPC-3, increased the expression level of Bax mRNA, decreased Bcl-2 mRNA and MDR1 mRNA expression (P&lt;0.01), and induced no change in p53, TRAIL, and Survivin mRNA expression in SW1990.	Oxaliplatin	54-65	ATP binding cassette subfamily B member 1	Homo sapiens	232-236
23525071-9	2013	hnRNP A2/B1 siRNA combined with gemcitabine, 5-FU and oxaliplatin significantly increased (P&lt;0.01) apoptosis of pancreatic cancer cell lines SW1990 and BxPC-3, increased the expression level of Bax mRNA, decreased Bcl-2 mRNA and MDR1 mRNA expression (P&lt;0.01), and induced no change in p53, TRAIL, and Survivin mRNA expression in SW1990.	Oxaliplatin	54-65	tumor protein p53	Homo sapiens	291-294
23525071-9	2013	hnRNP A2/B1 siRNA combined with gemcitabine, 5-FU and oxaliplatin significantly increased (P&lt;0.01) apoptosis of pancreatic cancer cell lines SW1990 and BxPC-3, increased the expression level of Bax mRNA, decreased Bcl-2 mRNA and MDR1 mRNA expression (P&lt;0.01), and induced no change in p53, TRAIL, and Survivin mRNA expression in SW1990.	Oxaliplatin	54-65	TNF superfamily member 10	Homo sapiens	296-301
23525071-13	2013	Inhibition of hnRNP A2/B1 expression can induce apoptosis in pancreatic cancer cells and improve chemosensitivity to gemcitabine, 5-FU, and oxaliplatin.	Oxaliplatin	140-151	heterogeneous nuclear ribonucleoprotein A2/B1	Homo sapiens	14-25
23636450-7	2013	MSH3-proficient HCT116+5 or HCT116+3+5 cells, which were more resistant to oxaliplatin and PARPi in comparison with their MSH3-deficient counterparts, expressed higher levels of the nucleotide excision repair ERCC1 and XPF proteins, involved in the resistance to platinum compounds, and lower PARP-1 levels.	Oxaliplatin	75-86	mutS homolog 3	Homo sapiens	0-4
23792648-0	2013	Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells.	Oxaliplatin	23-34	BCL2 apoptosis regulator	Homo sapiens	103-108
23874836-3	2013	In the present study, we used the TUNEL assay and FACS analysis to demonstrate that oxaliplatin induced apoptosis was significantly increased in cells with silenced Pokemon.	Oxaliplatin	84-95	zinc finger and BTB domain containing 7A	Homo sapiens	165-172
23874836-6	2013	In addition, upon oxaliplatin treatment of Pokemon-silenced cells, the FAS receptor, FADD and their downstream targets caspase-10 and caspase-8 were activated, causing increased release of caspase-8 active fragments p18 and p10.	Oxaliplatin	18-29	zinc finger and BTB domain containing 7A	Homo sapiens	43-50
23874836-6	2013	In addition, upon oxaliplatin treatment of Pokemon-silenced cells, the FAS receptor, FADD and their downstream targets caspase-10 and caspase-8 were activated, causing increased release of caspase-8 active fragments p18 and p10.	Oxaliplatin	18-29	Fas associated via death domain	Homo sapiens	85-89
23874836-6	2013	In addition, upon oxaliplatin treatment of Pokemon-silenced cells, the FAS receptor, FADD and their downstream targets caspase-10 and caspase-8 were activated, causing increased release of caspase-8 active fragments p18 and p10.	Oxaliplatin	18-29	caspase 10	Homo sapiens	119-129
23874836-6	2013	In addition, upon oxaliplatin treatment of Pokemon-silenced cells, the FAS receptor, FADD and their downstream targets caspase-10 and caspase-8 were activated, causing increased release of caspase-8 active fragments p18 and p10.	Oxaliplatin	18-29	caspase 8	Homo sapiens	134-143
23874836-6	2013	In addition, upon oxaliplatin treatment of Pokemon-silenced cells, the FAS receptor, FADD and their downstream targets caspase-10 and caspase-8 were activated, causing increased release of caspase-8 active fragments p18 and p10.	Oxaliplatin	18-29	caspase 8	Homo sapiens	189-198
23874836-6	2013	In addition, upon oxaliplatin treatment of Pokemon-silenced cells, the FAS receptor, FADD and their downstream targets caspase-10 and caspase-8 were activated, causing increased release of caspase-8 active fragments p18 and p10.	Oxaliplatin	18-29	H3 histone pseudogene 12	Homo sapiens	216-219
23874836-6	2013	In addition, upon oxaliplatin treatment of Pokemon-silenced cells, the FAS receptor, FADD and their downstream targets caspase-10 and caspase-8 were activated, causing increased release of caspase-8 active fragments p18 and p10.	Oxaliplatin	18-29	S100 calcium binding protein A10	Homo sapiens	224-227
23689915-3	2013	METHODS: Newly diagnosed K-RAS wild-type colorectal cancer patients with unresectable liver-only metastases were treated with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) plus cetuximab every 2 weeks for a maximum of 12 cycles.	Oxaliplatin	158-169	KRAS proto-oncogene, GTPase	Homo sapiens	25-30
23712327-3	2013	The changes of Src and p-Src expression after oxaliplatin exposure were evaluated by WB.	Oxaliplatin	46-57	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	15-18
23712327-3	2013	The changes of Src and p-Src expression after oxaliplatin exposure were evaluated by WB.	Oxaliplatin	46-57	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	25-28
23712327-7	2013	RESULTS: The different levels of Src expression in gastric cancer cells were related with their different sensitivity to oxaliplatin.	Oxaliplatin	121-132	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	33-36
23712327-8	2013	The expression of p-Src, but not total Src, was elevated after oxaliplatin exposure both in vitro and in vivo.	Oxaliplatin	63-74	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	20-23
23712327-9	2013	Dasatinib could dramatically inhibit p-Src expression, and combination indices demonstrated that dasatinib and oxaliplatin were synergistic in inhibiting gastric cancer cell growth.	Oxaliplatin	111-122	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	39-42
23712327-12	2013	CONCLUSIONS: Dasatinib plays synergistic role with oxaliplatin in inhibiting gastric cancer cell growth both in vitro and in vivo, via inhibiting Src activity stimulated by oxaliplatin.	Oxaliplatin	51-62	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	146-149
23712327-12	2013	CONCLUSIONS: Dasatinib plays synergistic role with oxaliplatin in inhibiting gastric cancer cell growth both in vitro and in vivo, via inhibiting Src activity stimulated by oxaliplatin.	Oxaliplatin	173-184	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	146-149
23180349-2	2013	Bax proapoptotic protein may correlate to chemosensitivity and differential response to irinotecan or oxaliplatin-based combinations.	Oxaliplatin	102-113	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
23180349-3	2013	METHODS: Bax expression was assessed by immunohistochemistry in 49 advanced colorectal cancer patients enrolled at our institution from 2002 to 2004 within a multicenter, phase II, randomized trial of first-line UFT/leucovorin/irinotecan (TEGAFIRI) versus UFT/leucovorin/oxaliplatin (TEGAFOX).	Oxaliplatin	271-282	BCL2 associated X, apoptosis regulator	Homo sapiens	9-12
22968820-12	2013	MKN45 cells showed increased sensitivity to oxaliplatin when FANCJ was knocked down by short interfering (si) RNA.	Oxaliplatin	44-55	BRCA1 interacting helicase 1	Homo sapiens	61-66
22968820-14	2013	CONCLUSION: These results strongly suggest that the decrease in FANCJ caused by 5FU treatment leads to an increase in sensitivity to oxaliplatin, thus indicating that the FANCJ protein plays an important role in the synergism of the combination of 5FU and oxaliplatin.	Oxaliplatin	133-144	BRCA1 interacting helicase 1	Homo sapiens	64-69
22968820-0	2013	Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells.	Oxaliplatin	74-85	BRCA1 interacting helicase 1	Homo sapiens	10-15
22968820-14	2013	CONCLUSION: These results strongly suggest that the decrease in FANCJ caused by 5FU treatment leads to an increase in sensitivity to oxaliplatin, thus indicating that the FANCJ protein plays an important role in the synergism of the combination of 5FU and oxaliplatin.	Oxaliplatin	133-144	BRCA1 interacting helicase 1	Homo sapiens	171-176
22968820-14	2013	CONCLUSION: These results strongly suggest that the decrease in FANCJ caused by 5FU treatment leads to an increase in sensitivity to oxaliplatin, thus indicating that the FANCJ protein plays an important role in the synergism of the combination of 5FU and oxaliplatin.	Oxaliplatin	256-267	BRCA1 interacting helicase 1	Homo sapiens	64-69
22968820-14	2013	CONCLUSION: These results strongly suggest that the decrease in FANCJ caused by 5FU treatment leads to an increase in sensitivity to oxaliplatin, thus indicating that the FANCJ protein plays an important role in the synergism of the combination of 5FU and oxaliplatin.	Oxaliplatin	256-267	BRCA1 interacting helicase 1	Homo sapiens	171-176
23895841-1	2013	OBJECTIVE: To investigate the effect of small interfering RNA-mediated receptor-interacting protein kinase 1 (RIP1) knockdown on the sensitivity of human oral squamous carcinoma cells to to oxaliplatin (L-OHP)-induced apoptosis and explore a new target for clinical treatment of oral squamous carcinoma.	Oxaliplatin	190-201	receptor interacting serine/threonine kinase 1	Homo sapiens	71-108
23863744-5	2013	After 8 courses of adjuvant chemotherapy with modified 5-fluorouracil/Leucovorin/oxaliplatin(mFOLFOX6), carcinoembryonic antigen( CEA)decreased to a normal level, and positron emission tomography-computed tomography(PET-CT)showed no abnormal accumulation that suggested metastasis.	Oxaliplatin	81-92	CEA cell adhesion molecule 3	Homo sapiens	130-133
25250123-0	2013	The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine.	Oxaliplatin	165-176	thymocyte selection associated high mobility group box	Homo sapiens	23-26
23895841-1	2013	OBJECTIVE: To investigate the effect of small interfering RNA-mediated receptor-interacting protein kinase 1 (RIP1) knockdown on the sensitivity of human oral squamous carcinoma cells to to oxaliplatin (L-OHP)-induced apoptosis and explore a new target for clinical treatment of oral squamous carcinoma.	Oxaliplatin	190-201	receptor interacting serine/threonine kinase 1	Homo sapiens	110-114
23895841-1	2013	OBJECTIVE: To investigate the effect of small interfering RNA-mediated receptor-interacting protein kinase 1 (RIP1) knockdown on the sensitivity of human oral squamous carcinoma cells to to oxaliplatin (L-OHP)-induced apoptosis and explore a new target for clinical treatment of oral squamous carcinoma.	Oxaliplatin	203-208	receptor interacting serine/threonine kinase 1	Homo sapiens	71-108
23895841-1	2013	OBJECTIVE: To investigate the effect of small interfering RNA-mediated receptor-interacting protein kinase 1 (RIP1) knockdown on the sensitivity of human oral squamous carcinoma cells to to oxaliplatin (L-OHP)-induced apoptosis and explore a new target for clinical treatment of oral squamous carcinoma.	Oxaliplatin	203-208	receptor interacting serine/threonine kinase 1	Homo sapiens	110-114
23895841-6	2013	KB cells transfected with pSH1Si-RIP1 showed an apoptotic rate of 9.4%, which increased to 29.1% following L-OHP exposure.	Oxaliplatin	107-112	receptor interacting serine/threonine kinase 1	Homo sapiens	33-37
23895841-7	2013	RIP1 expression was first up-regulated and then down-regulated in KB cells treated with L-OHP, and was significantly reduced after cell transfection with pSH1Si-RIP1.	Oxaliplatin	88-93	receptor interacting serine/threonine kinase 1	Homo sapiens	0-4
23895841-7	2013	RIP1 expression was first up-regulated and then down-regulated in KB cells treated with L-OHP, and was significantly reduced after cell transfection with pSH1Si-RIP1.	Oxaliplatin	88-93	receptor interacting serine/threonine kinase 1	Homo sapiens	161-165
23556474-0	2013	Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo.	Oxaliplatin	104-115	solute carrier family 31 member 1	Rattus norvegicus	45-65
23923647-0	2013	Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin.	Oxaliplatin	78-89	ATP binding cassette subfamily C member 3	Homo sapiens	21-24
23923647-2	2013	In this study the effects of modulating multidrug resistance-associated protein (MRP)-mediated efflux and glutathione (GSH) depletion on the cytotoxicity of oxaliplatin were assessed in a human ileocecal colorectal adenocarcinoma cell line and its oxaliplatin-resistant variant.	Oxaliplatin	157-168	ATP binding cassette subfamily C member 3	Homo sapiens	40-79
23923647-2	2013	In this study the effects of modulating multidrug resistance-associated protein (MRP)-mediated efflux and glutathione (GSH) depletion on the cytotoxicity of oxaliplatin were assessed in a human ileocecal colorectal adenocarcinoma cell line and its oxaliplatin-resistant variant.	Oxaliplatin	157-168	ATP binding cassette subfamily C member 3	Homo sapiens	81-84
23923647-2	2013	In this study the effects of modulating multidrug resistance-associated protein (MRP)-mediated efflux and glutathione (GSH) depletion on the cytotoxicity of oxaliplatin were assessed in a human ileocecal colorectal adenocarcinoma cell line and its oxaliplatin-resistant variant.	Oxaliplatin	248-259	ATP binding cassette subfamily C member 3	Homo sapiens	81-84
23923647-3	2013	Upon oxaliplatin exposure, DNA platination was elevated by co-incubation with Gu83, a MRP1 and MRP2 inhibitor, but cytotoxicity was not increased.	Oxaliplatin	5-16	ATP binding cassette subfamily C member 1	Homo sapiens	86-90
23923647-3	2013	Upon oxaliplatin exposure, DNA platination was elevated by co-incubation with Gu83, a MRP1 and MRP2 inhibitor, but cytotoxicity was not increased.	Oxaliplatin	5-16	ATP binding cassette subfamily C member 2	Homo sapiens	95-99
24022933-6	2013	L-OHP induced S cell cycle arrest in HepG2 cell; down-regulated the levels of CDK4, cyclinD1 and up-regulated the levels of p21, p53.	Oxaliplatin	0-5	cyclin dependent kinase 4	Homo sapiens	78-82
24022933-6	2013	L-OHP induced S cell cycle arrest in HepG2 cell; down-regulated the levels of CDK4, cyclinD1 and up-regulated the levels of p21, p53.	Oxaliplatin	0-5	cyclin D1	Homo sapiens	84-92
24022933-6	2013	L-OHP induced S cell cycle arrest in HepG2 cell; down-regulated the levels of CDK4, cyclinD1 and up-regulated the levels of p21, p53.	Oxaliplatin	0-5	H3 histone pseudogene 16	Homo sapiens	124-127
24022933-6	2013	L-OHP induced S cell cycle arrest in HepG2 cell; down-regulated the levels of CDK4, cyclinD1 and up-regulated the levels of p21, p53.	Oxaliplatin	0-5	tumor protein p53	Homo sapiens	129-132
23788041-8	2013	Conditioned medium from miR-21-overexpressing fibroblasts protected CRC cells from oxaliplatin-induced apoptosis and increased their proliferative capacity.	Oxaliplatin	83-94	microRNA 21	Homo sapiens	24-30
23348695-2	2013	In combination treatment with nafamostat mesilate and oxaliplatin, NF-kappaB activation was inhibited by suppressing IkappaBalpha phosphorylation, and caspase-8-mediated apoptosis was more prominent than that treated with oxaliplatin alone, both in vitro and in vivo.	Oxaliplatin	54-65	NFKB inhibitor alpha	Homo sapiens	117-129
23348695-2	2013	In combination treatment with nafamostat mesilate and oxaliplatin, NF-kappaB activation was inhibited by suppressing IkappaBalpha phosphorylation, and caspase-8-mediated apoptosis was more prominent than that treated with oxaliplatin alone, both in vitro and in vivo.	Oxaliplatin	54-65	caspase 8	Homo sapiens	151-160
23348695-2	2013	In combination treatment with nafamostat mesilate and oxaliplatin, NF-kappaB activation was inhibited by suppressing IkappaBalpha phosphorylation, and caspase-8-mediated apoptosis was more prominent than that treated with oxaliplatin alone, both in vitro and in vivo.	Oxaliplatin	222-233	caspase 8	Homo sapiens	151-160
23461901-9	2013	Inhibition of autophagy, either with chloroquine or by downregulation of beclin1 or of ATG5, enhanced sensitivity to oxaliplatin under normal and hypoxic conditions in a synergistic manner.	Oxaliplatin	117-128	beclin 1, autophagy related	Mus musculus	73-80
23461901-9	2013	Inhibition of autophagy, either with chloroquine or by downregulation of beclin1 or of ATG5, enhanced sensitivity to oxaliplatin under normal and hypoxic conditions in a synergistic manner.	Oxaliplatin	117-128	autophagy related 5	Mus musculus	87-91
23826152-7	2013	Additionally, OXA caused concentration-dependent P2X7 receptor activation, increased chromatin condensation and caspase-3 activation associated with TNF-alpha and IL-6 release.	Oxaliplatin	14-17	purinergic receptor P2X 7	Homo sapiens	49-62
23826152-7	2013	Additionally, OXA caused concentration-dependent P2X7 receptor activation, increased chromatin condensation and caspase-3 activation associated with TNF-alpha and IL-6 release.	Oxaliplatin	14-17	caspase 3	Homo sapiens	112-121
23826152-7	2013	Additionally, OXA caused concentration-dependent P2X7 receptor activation, increased chromatin condensation and caspase-3 activation associated with TNF-alpha and IL-6 release.	Oxaliplatin	14-17	tumor necrosis factor	Homo sapiens	149-158
23826152-7	2013	Additionally, OXA caused concentration-dependent P2X7 receptor activation, increased chromatin condensation and caspase-3 activation associated with TNF-alpha and IL-6 release.	Oxaliplatin	14-17	interleukin 6	Homo sapiens	163-167
23826152-11	2013	Our study suggests that targeting P2X7 receptor activation and mitochondrial impairment might be a potential therapeutic strategy against OXA-induced neuropathic pain.	Oxaliplatin	138-141	purinergic receptor P2X 7	Homo sapiens	34-47
23426175-1	2013	Our previous study has shown that the activity and expression of sphingosine kinase (SPHK) regulated the sensitivity of human colon cancer cells to the chemotherapeutic oxaliplatin (L-OHP).	Oxaliplatin	169-180	sphingosine kinase 1	Homo sapiens	65-83
23426175-1	2013	Our previous study has shown that the activity and expression of sphingosine kinase (SPHK) regulated the sensitivity of human colon cancer cells to the chemotherapeutic oxaliplatin (L-OHP).	Oxaliplatin	169-180	sphingosine kinase 1	Homo sapiens	85-89
23426175-1	2013	Our previous study has shown that the activity and expression of sphingosine kinase (SPHK) regulated the sensitivity of human colon cancer cells to the chemotherapeutic oxaliplatin (L-OHP).	Oxaliplatin	182-187	sphingosine kinase 1	Homo sapiens	65-83
23426175-1	2013	Our previous study has shown that the activity and expression of sphingosine kinase (SPHK) regulated the sensitivity of human colon cancer cells to the chemotherapeutic oxaliplatin (L-OHP).	Oxaliplatin	182-187	sphingosine kinase 1	Homo sapiens	85-89
23426175-3	2013	Here, we use colon cancer cell lines to examine the relationship between SPHK1 activity and CD44 expression.CD44 expression was measured by western blotting and quantitative PCR in two human colon cancer cell lines: L-OHP-resistant RKO and L-OHP-sensitive HCT116.	Oxaliplatin	216-221	sphingosine kinase 1	Homo sapiens	73-78
23543295-5	2013	One copy number variant (GSTT1) and nine polymorphisms in irinotecan and oxaliplatin metabolism, transport or DNA repair genes (ABCB1, UGT1A1, XRCC1, ERCC1, ERCC2, GSTP1) were genotyped by SNaPshot, polymerase chain reactions" length fragments, or copy number assays.	Oxaliplatin	73-84	ATP binding cassette subfamily B member 1	Homo sapiens	128-133
23543295-7	2013	In oxaliplatin-treated patients, carriers of one or two T variants of Asn118Asn ERCC1 SNP had a lower risk for neutropenia(OR = 0.205; 95 % CI = 0.061-0.690; P = 0.01) [corrected].	Oxaliplatin	3-14	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	80-85
23332421-11	2013	TS and ERCC1 expression was inversely related to response to 5-FU-and/or oxaliplatin-containing regimens.	Oxaliplatin	73-84	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	7-12
23556474-7	2013	In conclusion, copper histidine inhibited cellular uptake of oxaliplatin mediated by Ctr1 in vitro without altering the accumulation of platinum or neurotoxicity of oxaliplatin in DRG tissue in vivo at doses tolerated in combination with oxaliplatin treatment.	Oxaliplatin	61-72	solute carrier family 31 member 1	Rattus norvegicus	85-89
23556474-1	2013	The purpose of the present study was to determine whether copper histidine could inhibit copper transporter 1 (Ctr1)-mediated transport of oxaliplatin in vitro and thereby limit the accumulation of platinum and neurotoxicity of oxaliplatin in dorsal root ganglion (DRG) tissue in vivo.	Oxaliplatin	139-150	solute carrier family 31 member 1	Rattus norvegicus	89-109
23556474-1	2013	The purpose of the present study was to determine whether copper histidine could inhibit copper transporter 1 (Ctr1)-mediated transport of oxaliplatin in vitro and thereby limit the accumulation of platinum and neurotoxicity of oxaliplatin in dorsal root ganglion (DRG) tissue in vivo.	Oxaliplatin	139-150	solute carrier family 31 member 1	Rattus norvegicus	111-115
23556474-1	2013	The purpose of the present study was to determine whether copper histidine could inhibit copper transporter 1 (Ctr1)-mediated transport of oxaliplatin in vitro and thereby limit the accumulation of platinum and neurotoxicity of oxaliplatin in dorsal root ganglion (DRG) tissue in vivo.	Oxaliplatin	228-239	solute carrier family 31 member 1	Rattus norvegicus	89-109
23556474-1	2013	The purpose of the present study was to determine whether copper histidine could inhibit copper transporter 1 (Ctr1)-mediated transport of oxaliplatin in vitro and thereby limit the accumulation of platinum and neurotoxicity of oxaliplatin in dorsal root ganglion (DRG) tissue in vivo.	Oxaliplatin	228-239	solute carrier family 31 member 1	Rattus norvegicus	111-115
23556474-2	2013	In HEK293 cells overexpressing rat Ctr1, copper histidine was shown to be transported by Ctr1 and to inhibit their Ctr1-mediated uptake of oxaliplatin.	Oxaliplatin	139-150	solute carrier family 31 member 1	Rattus norvegicus	35-39
23556474-2	2013	In HEK293 cells overexpressing rat Ctr1, copper histidine was shown to be transported by Ctr1 and to inhibit their Ctr1-mediated uptake of oxaliplatin.	Oxaliplatin	139-150	solute carrier family 31 member 1	Rattus norvegicus	89-93
23556474-2	2013	In HEK293 cells overexpressing rat Ctr1, copper histidine was shown to be transported by Ctr1 and to inhibit their Ctr1-mediated uptake of oxaliplatin.	Oxaliplatin	139-150	solute carrier family 31 member 1	Rattus norvegicus	89-93
23746184-5	2013	Moreover, ABCB1 C1236T variant carriers displayed a longer overall survival after postoperative oxaliplatin-based chemotherapy (adjusted HR [95% CI]: 0.354 [0.182-0.692], 0.646 [0.458-0.910], respectively).	Oxaliplatin	96-107	ATP binding cassette subfamily B member 1	Homo sapiens	10-15
23506979-6	2013	Finally, we also found that these miRNAs were up-regulated in oxaliplatin resistant HCT116/oxPt (miR-625-3p, miR-181b and miR-27b) and LoVo/oxPt (miR-181b) colon cancer cell lines as compared with their isogenic parental cells.	Oxaliplatin	62-73	microRNA 27b	Homo sapiens	122-129
23604281-0	2013	Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	138-149	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	25-30
23604281-0	2013	Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	138-149	X-ray repair cross complementing 1	Homo sapiens	36-41
23604281-0	2013	Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	138-149	glutathione S-transferase pi 1	Homo sapiens	50-55
23604281-8	2013	Our data suggested that gastric cancer patients harboring ERCC1-118 C/C and XRCC1-399 A/G or A/A genotypes may benefit from receiving OXA-based adjuvant chemotherapy, and carrying at least one variant XRCC1 Arg399Gln or GSTP1 Ile105Val allele may contribute to the occurrence of adverse drug effects associated with OXA-based chemotherapy.	Oxaliplatin	134-137	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	58-63
23604281-8	2013	Our data suggested that gastric cancer patients harboring ERCC1-118 C/C and XRCC1-399 A/G or A/A genotypes may benefit from receiving OXA-based adjuvant chemotherapy, and carrying at least one variant XRCC1 Arg399Gln or GSTP1 Ile105Val allele may contribute to the occurrence of adverse drug effects associated with OXA-based chemotherapy.	Oxaliplatin	134-137	X-ray repair cross complementing 1	Homo sapiens	76-81
23604281-8	2013	Our data suggested that gastric cancer patients harboring ERCC1-118 C/C and XRCC1-399 A/G or A/A genotypes may benefit from receiving OXA-based adjuvant chemotherapy, and carrying at least one variant XRCC1 Arg399Gln or GSTP1 Ile105Val allele may contribute to the occurrence of adverse drug effects associated with OXA-based chemotherapy.	Oxaliplatin	316-319	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	58-63
23604281-8	2013	Our data suggested that gastric cancer patients harboring ERCC1-118 C/C and XRCC1-399 A/G or A/A genotypes may benefit from receiving OXA-based adjuvant chemotherapy, and carrying at least one variant XRCC1 Arg399Gln or GSTP1 Ile105Val allele may contribute to the occurrence of adverse drug effects associated with OXA-based chemotherapy.	Oxaliplatin	316-319	X-ray repair cross complementing 1	Homo sapiens	76-81
23746184-7	2013	CONCLUSION: The ABCB1 polymorphisms might be a candidate pharmacogenomic factor to assess susceptibility and prognosis after oxaliplatin-based chemotherapy for CRC patients.	Oxaliplatin	125-136	ATP binding cassette subfamily B member 1	Homo sapiens	16-21
23730417-0	2013	Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer.	Oxaliplatin	0-11	KRAS proto-oncogene, GTPase	Homo sapiens	81-85
23730417-6	2013	In patients who received first-line oxaliplatin-based regimens, the PFS was significantly longer in KRAS mutant patients (N = 32) than that in KRAS wild-type patients (N = 51).	Oxaliplatin	36-47	KRAS proto-oncogene, GTPase	Homo sapiens	100-104
23730417-6	2013	In patients who received first-line oxaliplatin-based regimens, the PFS was significantly longer in KRAS mutant patients (N = 32) than that in KRAS wild-type patients (N = 51).	Oxaliplatin	36-47	KRAS proto-oncogene, GTPase	Homo sapiens	143-147
23730417-11	2013	In multivariate analyses, KRAS mutation remains an independent predictive factor for longer PFS in first-line oxaliplatin-based regimens.	Oxaliplatin	110-121	KRAS proto-oncogene, GTPase	Homo sapiens	26-30
23730417-12	2013	In conclusion, oxaliplatin-based chemotherapy in KRAS mutant mCRC might result in longer PFS than in KRAS wild-type mCRC.	Oxaliplatin	15-26	KRAS proto-oncogene, GTPase	Homo sapiens	49-53
23730417-12	2013	In conclusion, oxaliplatin-based chemotherapy in KRAS mutant mCRC might result in longer PFS than in KRAS wild-type mCRC.	Oxaliplatin	15-26	KRAS proto-oncogene, GTPase	Homo sapiens	101-105
23801206-6	2013	RESULTS: After treatment of different oxaliplatin concentrations in human colon carcinoma cells SW480 line, the cell growth was inhibited in a dose-dependent manner, while Bim and PUMA expressions were significantly up-regulated.	Oxaliplatin	38-49	BCL2 like 11	Homo sapiens	172-175
23801206-11	2013	Induction of apoptosis of colon cancer cells by oxaliplatin may be associated with the up-regulation of BH3-only proteins, Bim and PUMA.	Oxaliplatin	48-59	BCL2 like 11	Homo sapiens	123-126
23724141-7	2013	RESULTS: MSH3-deficient vs proficient CRC cells showed increased sensitivity to the irinotecan metabolite SN-38 and to oxaliplatin, but not 5-FU, as shown in assays for apoptosis and clonogenic survival.	Oxaliplatin	119-130	mutS homolog 3	Homo sapiens	9-13
23724141-9	2013	The impact of MSH3 knockdown on chemosensitivity to SN-38 and oxaliplatin was maintained independent of MLH1 status.	Oxaliplatin	62-73	mutS homolog 3	Homo sapiens	14-18
23724141-10	2013	In MSH3-deficient vs proficient cells, SN-38 and oxaliplatin induced higher levels of phosphorylated histone H2AX and Chk2, and similar results were found in MLH1-proficient SW480 cells.	Oxaliplatin	49-60	mutS homolog 3	Homo sapiens	3-7
23724141-10	2013	In MSH3-deficient vs proficient cells, SN-38 and oxaliplatin induced higher levels of phosphorylated histone H2AX and Chk2, and similar results were found in MLH1-proficient SW480 cells.	Oxaliplatin	49-60	checkpoint kinase 2	Homo sapiens	118-122
23724141-10	2013	In MSH3-deficient vs proficient cells, SN-38 and oxaliplatin induced higher levels of phosphorylated histone H2AX and Chk2, and similar results were found in MLH1-proficient SW480 cells.	Oxaliplatin	49-60	mutL homolog 1	Homo sapiens	158-162
23347235-9	2013	For the first time, our data suggest that MDM2 is a potent prognostic and predictive factor for benefit from adjuvant fluorouracil-leucovorin-oxaliplatin chemotherapy in resectable gastric cancer.	Oxaliplatin	142-153	MDM2 proto-oncogene	Homo sapiens	42-46
23477783-3	2013	In this study, we evaluated whether TRPA1 acted as a critical mediator of CIPN by bortezomib or oxaliplatin in a mouse model system.	Oxaliplatin	96-107	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	36-41
23477783-8	2013	Administration of bortezomib or oxaliplatin, which also elicits TRPA1-dependent hypersensitivity, produced a rapid, transient increase in plasma of carboxy-methyl-lysine, a by-product of oxidative stress.	Oxaliplatin	32-43	transient receptor potential cation channel subfamily A member 1	Homo sapiens	64-69
23574723-0	2013	MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers.	Oxaliplatin	87-98	microRNA 143	Homo sapiens	0-12
23574723-6	2013	Overexpression of miR-143 inhibited cell proliferation, migration, tumor growth and angiogenesis and increased chemosensitivity to oxaliplatin treatment in an IGF-IR-dependent manner.	Oxaliplatin	131-142	microRNA 143	Homo sapiens	18-25
23574723-6	2013	Overexpression of miR-143 inhibited cell proliferation, migration, tumor growth and angiogenesis and increased chemosensitivity to oxaliplatin treatment in an IGF-IR-dependent manner.	Oxaliplatin	131-142	insulin like growth factor 1 receptor	Homo sapiens	159-165
23486839-3	2013	In this study, neuronal loss and changes to the structure and immunoreactivity of myenteric neuronal nitric oxide synthase (nNOS) neurons were examined in colonic segments from mice following exposure to oxaliplatin ex vivo and following repeated intraperitoneal injections of oxaliplatin over 3 weeks in vivo, using immunohistochemistry and confocal microscopy.	Oxaliplatin	204-215	nitric oxide synthase 1, neuronal	Mus musculus	124-128
23262037-0	2013	Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma.	Oxaliplatin	66-77	forkhead box M1	Homo sapiens	44-49
23262037-0	2013	Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma.	Oxaliplatin	66-77	tumor protein p53	Homo sapiens	53-56
23262037-2	2013	In the present study, we revealed that oxaliplatin could induce senescence in HCC cells, since advanced HCC patients with lower expression of FoxM1 were more sensitive to oxaliplatin therapy.	Oxaliplatin	39-50	forkhead box M1	Homo sapiens	142-147
23262037-2	2013	In the present study, we revealed that oxaliplatin could induce senescence in HCC cells, since advanced HCC patients with lower expression of FoxM1 were more sensitive to oxaliplatin therapy.	Oxaliplatin	171-182	forkhead box M1	Homo sapiens	142-147
23262037-3	2013	Our data indicated that due to the repression by p53, FoxM1 played a critical role in oxaliplatin-induced senescence via regulating cycle-related proteins p21, p27, cyclins B1 and D1.	Oxaliplatin	86-97	tumor protein p53	Homo sapiens	49-52
23262037-3	2013	Our data indicated that due to the repression by p53, FoxM1 played a critical role in oxaliplatin-induced senescence via regulating cycle-related proteins p21, p27, cyclins B1 and D1.	Oxaliplatin	86-97	forkhead box M1	Homo sapiens	54-59
23262037-3	2013	Our data indicated that due to the repression by p53, FoxM1 played a critical role in oxaliplatin-induced senescence via regulating cycle-related proteins p21, p27, cyclins B1 and D1.	Oxaliplatin	86-97	H3 histone pseudogene 16	Homo sapiens	155-158
23262037-3	2013	Our data indicated that due to the repression by p53, FoxM1 played a critical role in oxaliplatin-induced senescence via regulating cycle-related proteins p21, p27, cyclins B1 and D1.	Oxaliplatin	86-97	interferon alpha inducible protein 27	Homo sapiens	160-182
23262037-5	2013	Taken together, our findings suggest that FoxM1 may represent a promising therapeutic target for the medication of the chemosensitivity to oxaliplatin in HCC patients.	Oxaliplatin	139-150	forkhead box M1	Homo sapiens	42-47
23618903-12	2013	Finally, active pCREB is elevated in colorectal cancer (CRC) cells and adenomas, and is required for the expression of drug transporter, MRP2, associated with resistance to Oxaliplatin as well as several chromatin cohesion protein that are relevant to CRC therapy.	Oxaliplatin	173-184	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	137-141
23481186-0	2013	ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	123-134	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
23481186-1	2013	BACKGROUND: Excision repair cross-complementation group 1 (ERCC1) expression status has been identified as a candidate marker for predicting efficacy of oxaliplatin (OX) treatment for metastatic colorectal cancer (CRC) in several trials.	Oxaliplatin	153-164	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	12-57
23481186-1	2013	BACKGROUND: Excision repair cross-complementation group 1 (ERCC1) expression status has been identified as a candidate marker for predicting efficacy of oxaliplatin (OX) treatment for metastatic colorectal cancer (CRC) in several trials.	Oxaliplatin	153-164	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	59-64
23279642-0	2013	Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.	Oxaliplatin	35-46	AKT serine/threonine kinase 1	Homo sapiens	72-75
22648527-7	2013	Oxaliplatin (4 mg/kg) and cisplatin (2 mg/kg) [each given twice weekly, in a total of nine intraperitoneal injections over 4.5 weeks] significantly increased plasma neurotensin concentration, caused specific damage in the histology of the sciatic nerve and produced variable effects in the motor and behavioral tests.	Oxaliplatin	0-11	neurotensin	Rattus norvegicus	165-176
23299794-0	2013	XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.	Oxaliplatin	47-58	X-ray repair cross complementing 1	Homo sapiens	0-5
23299794-0	2013	XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.	Oxaliplatin	47-58	glutathione S-transferase pi 1	Homo sapiens	10-15
23299794-2	2013	The aim was to explore the influences of X-ray repair cross-complementing 1(XRCC1) and Glutathione S-transferase P1 (GSTP1) genetic variants on prognosis of oxaliplatin-based chemotherapy in colorectal cancer patients.	Oxaliplatin	157-168	X-ray repair cross complementing 1	Homo sapiens	41-75
23299794-2	2013	The aim was to explore the influences of X-ray repair cross-complementing 1(XRCC1) and Glutathione S-transferase P1 (GSTP1) genetic variants on prognosis of oxaliplatin-based chemotherapy in colorectal cancer patients.	Oxaliplatin	157-168	X-ray repair cross complementing 1	Homo sapiens	76-81
23299794-2	2013	The aim was to explore the influences of X-ray repair cross-complementing 1(XRCC1) and Glutathione S-transferase P1 (GSTP1) genetic variants on prognosis of oxaliplatin-based chemotherapy in colorectal cancer patients.	Oxaliplatin	157-168	glutathione S-transferase pi 1	Homo sapiens	87-115
23299794-2	2013	The aim was to explore the influences of X-ray repair cross-complementing 1(XRCC1) and Glutathione S-transferase P1 (GSTP1) genetic variants on prognosis of oxaliplatin-based chemotherapy in colorectal cancer patients.	Oxaliplatin	157-168	glutathione S-transferase pi 1	Homo sapiens	117-122
23299794-8	2013	CONCLUSION: In our meta-analysis, XRCC1 Arg399Gln polymorphism may be a valuable genetic marker for oxaliplatin-based chemotherapy in colorectal cancer, and the results still need further confirmation.	Oxaliplatin	100-111	X-ray repair cross complementing 1	Homo sapiens	34-39
23287989-0	2013	Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer.	Oxaliplatin	69-80	glutathione S-transferase mu 1	Homo sapiens	0-28
23426424-0	2013	The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	159-170	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	15-20
23426424-6	2013	The results demonstrated that the expression levels of ERCC1 mRNA were correlated with the chemosensitivity of platinum agents, and depletion of ERCC1 sensitized the relatively resistant MKN45 cells to cisplatin and oxaliplatin.	Oxaliplatin	216-227	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	55-60
23426424-6	2013	The results demonstrated that the expression levels of ERCC1 mRNA were correlated with the chemosensitivity of platinum agents, and depletion of ERCC1 sensitized the relatively resistant MKN45 cells to cisplatin and oxaliplatin.	Oxaliplatin	216-227	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	145-150
23426424-9	2013	These results suggest that overexpression of ERCC1 is correlated with platinum drug resistance in gastric cancer cells, and that depletion of ERCC1 sensitizes gastric cancer cell lines to cisplatin and oxaliplatin.	Oxaliplatin	202-213	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	142-147
23426424-10	2013	Gastric cancer patients with low levels of ERCC1 expression demonstrate a benefit from oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	87-98	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	43-48
24892667-1	2013	OBJECTIVE: Quantifying polycyclic aromatic hydrocarbon levels in urine samples taken from a population of traffic police working in the metropolitan area of Bogota who were occupationally exposed to 1-hydroxypyrene (1-OHP) and 3-hydroxy-benzo[a]pyrene (3-BaP) metabolites from polycyclic aromatic hydrocarbons (PAH) having toxicological interest, related to their detection, and a degree of exposure to particulate material having a size less than 10 micrometres (PM10) and/or other factors.	Oxaliplatin	216-221	prohibitin 2	Homo sapiens	255-258
23393334-7	2013	VDR and RXRalpha expressions were up-regulated by PRI-2191 analog, as compared to oxaliplatin alone.	Oxaliplatin	82-93	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	0-3
23393334-7	2013	VDR and RXRalpha expressions were up-regulated by PRI-2191 analog, as compared to oxaliplatin alone.	Oxaliplatin	82-93	retinoid X receptor alpha	Mus musculus	8-16
23393334-9	2013	However, the regulation of ERK1/2 expression by both analogs and oxaliplatin may explain the observed antagonistic interactions.	Oxaliplatin	65-76	mitogen-activated protein kinase 3	Mus musculus	27-33
22820863-2	2013	An adenovirus armed with Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24; abbreviated to "IL-24" here) was shown to reverse the MDR of colon cancer cells to oxaliplatin and doxorubicin.	Oxaliplatin	180-191	interleukin 24	Mus musculus	84-89
23374220-1	2013	BACKGROUND: The aim of this study is to evaluate the associations between vascular endothelial growth factor (VEGF) Single-nucleotide polymorphisms (SNPs) and clinical outcome in advanced gastric cancer patients treated with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX).	Oxaliplatin	225-236	vascular endothelial growth factor A	Homo sapiens	74-108
23374220-1	2013	BACKGROUND: The aim of this study is to evaluate the associations between vascular endothelial growth factor (VEGF) Single-nucleotide polymorphisms (SNPs) and clinical outcome in advanced gastric cancer patients treated with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX).	Oxaliplatin	225-236	vascular endothelial growth factor A	Homo sapiens	110-114
22820863-2	2013	An adenovirus armed with Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24; abbreviated to "IL-24" here) was shown to reverse the MDR of colon cancer cells to oxaliplatin and doxorubicin.	Oxaliplatin	180-191	interleukin 24	Mus musculus	90-95
22820863-2	2013	An adenovirus armed with Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24; abbreviated to "IL-24" here) was shown to reverse the MDR of colon cancer cells to oxaliplatin and doxorubicin.	Oxaliplatin	180-191	interleukin 24	Mus musculus	113-118
22820863-2	2013	An adenovirus armed with Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24; abbreviated to "IL-24" here) was shown to reverse the MDR of colon cancer cells to oxaliplatin and doxorubicin.	Oxaliplatin	180-191	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	151-154
23149912-7	2013	Accordingly, Egr1 downregulation reduced oxaliplatin-induced apoptosis, whereas E2F1 downregulation reduced doxorubicin-induced apoptosis.	Oxaliplatin	41-52	early growth response 1	Mus musculus	13-17
23391546-0	2013	[Roles of TRPA1 in acute peripheral neuropathy characteristically induced by oxaliplatin].	Oxaliplatin	77-88	transient receptor potential cation channel subfamily A member 1	Homo sapiens	10-15
23484700-10	2013	It is concluded that the oxaliplatin can induce apoptosis of RPMI-8226 cells, activating the death receptor pathway and arresting cell cycle may be two of the related mechanisms, Bcl-2 gene has unobservable effects in the process of oxaliplatin-induced cell apoptosis.	Oxaliplatin	25-36	BCL2 apoptosis regulator	Homo sapiens	179-184
23484700-10	2013	It is concluded that the oxaliplatin can induce apoptosis of RPMI-8226 cells, activating the death receptor pathway and arresting cell cycle may be two of the related mechanisms, Bcl-2 gene has unobservable effects in the process of oxaliplatin-induced cell apoptosis.	Oxaliplatin	233-244	BCL2 apoptosis regulator	Homo sapiens	179-184
23123662-3	2013	Heterologous expression of rCtr1 in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.	Oxaliplatin	116-127	solute carrier family 31 member 1	Rattus norvegicus	27-32
23123662-3	2013	Heterologous expression of rCtr1 in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.	Oxaliplatin	116-127	solute carrier family 31 member 1	Rattus norvegicus	54-59
23123662-7	2013	The accumulation of platinum by both cultured rat DRG neurons and HEK/rCtr1 cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/rCtr1 cells.	Oxaliplatin	90-101	solute carrier family 31 member 1	Rattus norvegicus	70-75
23374942-3	2013	The expression of glial fibrillary acidic protein (GFAP) in spinal dorsal horn was significantly increased at day 7 but recovered at day 14 after oxaliplatin treatment, suggesting a transient activation of spinal astrocytes by chemotherapy.	Oxaliplatin	146-157	glial fibrillary acidic protein	Homo sapiens	18-49
23374942-3	2013	The expression of glial fibrillary acidic protein (GFAP) in spinal dorsal horn was significantly increased at day 7 but recovered at day 14 after oxaliplatin treatment, suggesting a transient activation of spinal astrocytes by chemotherapy.	Oxaliplatin	146-157	glial fibrillary acidic protein	Homo sapiens	51-55
23374942-6	2013	These results suggest that oxaliplatin chemotherapy induces the activation of spinal astrocytes and this is accompanied by increased expression of astrocyte-astrocyte gap junction connections via Cx43.	Oxaliplatin	27-38	gap junction protein alpha 1	Homo sapiens	196-200
23149912-5	2013	Both ultraviolet (UV) and the UV mimetic compound oxaliplatin and the radiomimetic compound doxorubicin promoted apoptosis by upregulating the tumor suppressor p73.	Oxaliplatin	50-61	transformation related protein 73	Mus musculus	160-163
23149912-6	2013	However, only the UV and oxaliplatin-induced upregulation of p73 mediated by the transcription factor Egr1, but not the doxorubicin-induced upregulation mediated by the transcription factor E2F1, was enhanced by Cry1/Cry2 double mutation.	Oxaliplatin	25-36	transformation related protein 73	Mus musculus	61-64
23149912-6	2013	However, only the UV and oxaliplatin-induced upregulation of p73 mediated by the transcription factor Egr1, but not the doxorubicin-induced upregulation mediated by the transcription factor E2F1, was enhanced by Cry1/Cry2 double mutation.	Oxaliplatin	25-36	early growth response 1	Mus musculus	102-106
23149912-6	2013	However, only the UV and oxaliplatin-induced upregulation of p73 mediated by the transcription factor Egr1, but not the doxorubicin-induced upregulation mediated by the transcription factor E2F1, was enhanced by Cry1/Cry2 double mutation.	Oxaliplatin	25-36	cryptochrome 1 (photolyase-like)	Mus musculus	212-216
23175150-0	2013	KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.	Oxaliplatin	31-42	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
23149912-6	2013	However, only the UV and oxaliplatin-induced upregulation of p73 mediated by the transcription factor Egr1, but not the doxorubicin-induced upregulation mediated by the transcription factor E2F1, was enhanced by Cry1/Cry2 double mutation.	Oxaliplatin	25-36	cryptochrome 2 (photolyase-like)	Mus musculus	217-221
23175150-1	2013	BACKGROUND: In this study, we evaluated the possibility that KRAS mutational status might be predictive of oxaliplatin (OXA) efficacy.	Oxaliplatin	107-118	KRAS proto-oncogene, GTPase	Homo sapiens	61-65
23175150-1	2013	BACKGROUND: In this study, we evaluated the possibility that KRAS mutational status might be predictive of oxaliplatin (OXA) efficacy.	Oxaliplatin	120-123	KRAS proto-oncogene, GTPase	Homo sapiens	61-65
23803084-5	2013	Kaplan-Meier curves showed that the ABCB1 C3435T variant was associated with a tendency toward longer progression-free survival (PFS) (n=343, Log-rank test: P=0.063), and the G2677T/A variant genotypes (GT+TT+GA+AA) with a tendency for longer OS in postoperative oxaliplatin-based patients (n=343, Log-rank test: P=0.082).	Oxaliplatin	263-274	ATP binding cassette subfamily B member 1	Homo sapiens	36-41
23327191-0	2013	Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.	Oxaliplatin	58-69	X-ray repair cross complementing 1	Homo sapiens	24-29
23327191-1	2013	In this study, we investigated the association between genetic polymorphisms of XRCC1 Arg399Gln (G A) and response to oxaliplatin-based chemotherapy in advanced colorectal cancer.	Oxaliplatin	118-129	X-ray repair cross complementing 1	Homo sapiens	80-85
23736016-3	2013	OBJECTIVE: To study the possible mechanisms of S100P enhanced the chemosensitivity to oxaliplatin in gastric cancer cell lines.	Oxaliplatin	86-97	S100 calcium binding protein P	Homo sapiens	47-52
23327191-2	2013	XRCC1 genotypes of totally 99 patients (37 stage III and 62 stage IV) with advanced colorectal cancer treated with oxaliplatin-based chemotherapy were detected by the TaqMan-MGB probe allelic discrimination method, and clinical response of 62 patients in stage IV after 2 to 3 cycles of chemotherapy were evaluated.	Oxaliplatin	115-126	X-ray repair cross complementing 1	Homo sapiens	0-5
23736016-9	2013	CONCLUSIONS: S100P contributes to oxaliplatin chemosensitivity in gastric cell lines by increasing drug inflow.	Oxaliplatin	34-45	S100 calcium binding protein P	Homo sapiens	13-18
23066038-2	2012	We investigated the ability of various common chemotherapeutic drugs to induce p21 expression in p53-negative cancer cells and showed that the induction of p21 expression by oxaliplatin is caused by the derepression of a previously unrecognized negative regulatory element with a Sp1/Sp3 palindrome sequence core at -216 to -236 of the p21 proximal promoter.	Oxaliplatin	174-185	tumor protein p53	Homo sapiens	97-100
22535375-15	2013	Oxaliplatin, a clinically acceptable cisplatin alternative, may represent a potential therapeutic option for BMP4-positive GCs.	Oxaliplatin	0-11	bone morphogenetic protein 4	Homo sapiens	109-113
24247529-6	2013	Following the initial episode, oxaliplatin was reintroduced to 39 patients, resulting in HSR relapse in 89.7% of the patients, including 4 patients (10.3%) with grade 3 reactions.	Oxaliplatin	31-42	HSR	Homo sapiens	89-92
23774285-0	2013	A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain.	Oxaliplatin	27-38	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	2-7
23355248-10	2013	Both oxaliplatin alone and combination therapy down-regulated expressions of procaspase-3, 9, and PARP protein.	Oxaliplatin	5-16	caspase 3	Homo sapiens	77-89
23355248-10	2013	Both oxaliplatin alone and combination therapy down-regulated expressions of procaspase-3, 9, and PARP protein.	Oxaliplatin	5-16	poly(ADP-ribose) polymerase 1	Homo sapiens	98-102
23169295-0	2012	Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.	Oxaliplatin	48-59	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
23169295-0	2012	Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.	Oxaliplatin	48-59	dihydropyrimidine dehydrogenase	Homo sapiens	26-29
23169295-9	2012	Resistant cells to oxaliplatin showed significantly higher ERCC1 and DPD expression than sensitive cells.	Oxaliplatin	19-30	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	59-64
23169295-9	2012	Resistant cells to oxaliplatin showed significantly higher ERCC1 and DPD expression than sensitive cells.	Oxaliplatin	19-30	dihydropyrimidine dehydrogenase	Homo sapiens	69-72
23169295-10	2012	In validation study, ERCC1 and DPD but not TOP1 expressions in cancer cells were significantly higher in FOLFOX (oxaliplatin, folinic acid, and 5-FU)-treated patients (N=24) than nontreated patients (N=21).	Oxaliplatin	113-124	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	21-26
23169295-10	2012	In validation study, ERCC1 and DPD but not TOP1 expressions in cancer cells were significantly higher in FOLFOX (oxaliplatin, folinic acid, and 5-FU)-treated patients (N=24) than nontreated patients (N=21).	Oxaliplatin	113-124	dihydropyrimidine dehydrogenase	Homo sapiens	31-34
23169295-12	2012	CONCLUSION: The ERCC1 and DPD expression levels at both mRNA and protein levels were significantly higher in patients with oxaliplatin as a first-line chemotherapy than those without oxaliplatin.	Oxaliplatin	123-134	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
23169295-12	2012	CONCLUSION: The ERCC1 and DPD expression levels at both mRNA and protein levels were significantly higher in patients with oxaliplatin as a first-line chemotherapy than those without oxaliplatin.	Oxaliplatin	123-134	dihydropyrimidine dehydrogenase	Homo sapiens	26-29
23169295-12	2012	CONCLUSION: The ERCC1 and DPD expression levels at both mRNA and protein levels were significantly higher in patients with oxaliplatin as a first-line chemotherapy than those without oxaliplatin.	Oxaliplatin	183-194	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
23169295-12	2012	CONCLUSION: The ERCC1 and DPD expression levels at both mRNA and protein levels were significantly higher in patients with oxaliplatin as a first-line chemotherapy than those without oxaliplatin.	Oxaliplatin	183-194	dihydropyrimidine dehydrogenase	Homo sapiens	26-29
23169295-13	2012	The IRIS regimens with the DPD inhibitory fluoropyrimidine may show superior activity against DPD-high tumours (e.g., tumours treated with oxaliplatin) compared with FOLFIRI.	Oxaliplatin	139-150	dihydropyrimidine dehydrogenase	Homo sapiens	27-30
23066038-2	2012	We investigated the ability of various common chemotherapeutic drugs to induce p21 expression in p53-negative cancer cells and showed that the induction of p21 expression by oxaliplatin is caused by the derepression of a previously unrecognized negative regulatory element with a Sp1/Sp3 palindrome sequence core at -216 to -236 of the p21 proximal promoter.	Oxaliplatin	174-185	cyclin dependent kinase inhibitor 1A	Homo sapiens	79-82
24480791-0	2013	Association between high antitumor activity of oxaliplatin and cyclophosphamide and constitutional GSTM1 homozygous deletion in an advanced ovarian cancer patient.	Oxaliplatin	47-58	glutathione S-transferase mu 1	Homo sapiens	99-104
24480791-2	2013	In cells, oxaliplatin is metabolized by the enzymes belonging to the glutathione-S-transferase (GST) family.	Oxaliplatin	10-21	glutathione S-transferase kappa 1	Homo sapiens	69-94
24480791-2	2013	In cells, oxaliplatin is metabolized by the enzymes belonging to the glutathione-S-transferase (GST) family.	Oxaliplatin	10-21	glutathione S-transferase kappa 1	Homo sapiens	96-99
24480791-8	2013	CONCLUSION: The association of a homozygous deletion of GSTM1 with hypersensitivity to oxaliplatin and cyclophosphamide combination chemotherapy has not been described to date in ovarian cancer.	Oxaliplatin	87-98	glutathione S-transferase mu 1	Homo sapiens	56-61
23066038-2	2012	We investigated the ability of various common chemotherapeutic drugs to induce p21 expression in p53-negative cancer cells and showed that the induction of p21 expression by oxaliplatin is caused by the derepression of a previously unrecognized negative regulatory element with a Sp1/Sp3 palindrome sequence core at -216 to -236 of the p21 proximal promoter.	Oxaliplatin	174-185	cyclin dependent kinase inhibitor 1A	Homo sapiens	156-159
23066038-2	2012	We investigated the ability of various common chemotherapeutic drugs to induce p21 expression in p53-negative cancer cells and showed that the induction of p21 expression by oxaliplatin is caused by the derepression of a previously unrecognized negative regulatory element with a Sp1/Sp3 palindrome sequence core at -216 to -236 of the p21 proximal promoter.	Oxaliplatin	174-185	Sp3 transcription factor	Homo sapiens	284-287
23066038-2	2012	We investigated the ability of various common chemotherapeutic drugs to induce p21 expression in p53-negative cancer cells and showed that the induction of p21 expression by oxaliplatin is caused by the derepression of a previously unrecognized negative regulatory element with a Sp1/Sp3 palindrome sequence core at -216 to -236 of the p21 proximal promoter.	Oxaliplatin	174-185	cyclin dependent kinase inhibitor 1A	Homo sapiens	156-159
23066038-3	2012	Electrophoretic mobility shift and antibody super-shift assays confirmed the specific binding of Sp1/Sp3, and showed that the oxaliplatin-mediated derepression of p21 transcription was associated with an increased Sp1/Sp3 phosphorylation and binding affinity to the oxaliplatin-responsive element.	Oxaliplatin	126-137	Sp3 transcription factor	Homo sapiens	101-104
23066038-3	2012	Electrophoretic mobility shift and antibody super-shift assays confirmed the specific binding of Sp1/Sp3, and showed that the oxaliplatin-mediated derepression of p21 transcription was associated with an increased Sp1/Sp3 phosphorylation and binding affinity to the oxaliplatin-responsive element.	Oxaliplatin	126-137	cyclin dependent kinase inhibitor 1A	Homo sapiens	163-166
23066038-3	2012	Electrophoretic mobility shift and antibody super-shift assays confirmed the specific binding of Sp1/Sp3, and showed that the oxaliplatin-mediated derepression of p21 transcription was associated with an increased Sp1/Sp3 phosphorylation and binding affinity to the oxaliplatin-responsive element.	Oxaliplatin	126-137	Sp3 transcription factor	Homo sapiens	218-221
23066038-3	2012	Electrophoretic mobility shift and antibody super-shift assays confirmed the specific binding of Sp1/Sp3, and showed that the oxaliplatin-mediated derepression of p21 transcription was associated with an increased Sp1/Sp3 phosphorylation and binding affinity to the oxaliplatin-responsive element.	Oxaliplatin	266-277	cyclin dependent kinase inhibitor 1A	Homo sapiens	163-166
23051936-0	2012	The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer.	Oxaliplatin	76-87	BCL2 like 1	Homo sapiens	12-18
23205118-3	2012	To address its potential as a therapeutic target for chemosensitisation, this study investigated the effect of BNIP3 expression on chemosensitivity and reversal of oxaliplatin (L-OHP) resistance in human colon cancer cell lines.	Oxaliplatin	164-175	BCL2 interacting protein 3	Homo sapiens	111-116
23051936-4	2012	Oxaliplatin and hyperthermia sensitized colon cancer cells to mapatumumab in the mitochondrial-dependent apoptotic pathway and increased reactive oxygen species (ROS) production, leading to Bcl-xL phosphorylation at serine 62 in a c-jun-NH2-kinase (JNK)-dependent manner.	Oxaliplatin	0-11	BCL2 like 1	Homo sapiens	190-196
23051936-4	2012	Oxaliplatin and hyperthermia sensitized colon cancer cells to mapatumumab in the mitochondrial-dependent apoptotic pathway and increased reactive oxygen species (ROS) production, leading to Bcl-xL phosphorylation at serine 62 in a c-jun-NH2-kinase (JNK)-dependent manner.	Oxaliplatin	0-11	mitogen-activated protein kinase 8	Homo sapiens	231-247
23051936-4	2012	Oxaliplatin and hyperthermia sensitized colon cancer cells to mapatumumab in the mitochondrial-dependent apoptotic pathway and increased reactive oxygen species (ROS) production, leading to Bcl-xL phosphorylation at serine 62 in a c-jun-NH2-kinase (JNK)-dependent manner.	Oxaliplatin	0-11	mitogen-activated protein kinase 8	Homo sapiens	249-252
23205118-3	2012	To address its potential as a therapeutic target for chemosensitisation, this study investigated the effect of BNIP3 expression on chemosensitivity and reversal of oxaliplatin (L-OHP) resistance in human colon cancer cell lines.	Oxaliplatin	177-182	BCL2 interacting protein 3	Homo sapiens	111-116
23205118-4	2012	A plasmid expressing the BNIP3 gene was transfected into human parental colon cancer cell lines (SW620 and colo320) and L-OHP-resistant colon cancer cell lines (SW620/L-OHP and colo320/L-OHP) using Lipofectamine  2000, and the transfection efficiency was determined using fluorescence optics.	Oxaliplatin	120-125	BCL2 interacting protein 3	Homo sapiens	25-30
23205118-7	2012	Following transfection with pDsRed-BNIP3, the chemosensitivity of parental and L-OHP-resistant cell lines to L-OHP was increased (P&lt;0.01), as detected by the Cell Counting Kit-8 (CCK8) assay.	Oxaliplatin	79-84	BCL2 interacting protein 3	Homo sapiens	35-40
23205118-7	2012	Following transfection with pDsRed-BNIP3, the chemosensitivity of parental and L-OHP-resistant cell lines to L-OHP was increased (P&lt;0.01), as detected by the Cell Counting Kit-8 (CCK8) assay.	Oxaliplatin	109-114	BCL2 interacting protein 3	Homo sapiens	35-40
23205118-8	2012	Hoechst 33342 staining and flow cytometry revealed that the effects on L-OHP-induced apoptosis were enhanced by the overexpression of BNIP3.	Oxaliplatin	71-76	BCL2 interacting protein 3	Homo sapiens	134-139
23205118-10	2012	The results of this study suggest that BNIP3 is a potential therapeutic target for reversing the resistance of L-OHP-resistant colon cancer cells to L-OHP.	Oxaliplatin	111-116	BCL2 interacting protein 3	Homo sapiens	39-44
23205118-10	2012	The results of this study suggest that BNIP3 is a potential therapeutic target for reversing the resistance of L-OHP-resistant colon cancer cells to L-OHP.	Oxaliplatin	149-154	BCL2 interacting protein 3	Homo sapiens	39-44
23192191-2	2012	In this work, the interactions of two selected pyrene derivatives (1-OHP and 1-PBO) and human tumor-related DNA (p53 DNA and C-myc DNA) are investigated by spectroscopic and non-native polyacrylamide gel electrophoresis (PAGE) methods.	Oxaliplatin	67-72	tumor protein p53	Homo sapiens	113-116
22948777-4	2012	By aiming to explore how the molecular profile of KLK13 is modified in stomach cancer cells treated with antineoplastic drugs, we examined, for the first time, the mRNA alterations of this gene following gastric cancer cells" exposure to the prominent chemotherapeutic substances epirubicin, oxaliplatin, or methotrexate.	Oxaliplatin	292-303	kallikrein related peptidase 13	Homo sapiens	50-55
23192191-2	2012	In this work, the interactions of two selected pyrene derivatives (1-OHP and 1-PBO) and human tumor-related DNA (p53 DNA and C-myc DNA) are investigated by spectroscopic and non-native polyacrylamide gel electrophoresis (PAGE) methods.	Oxaliplatin	67-72	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	125-130
23192191-5	2012	The binding constants of 1-OHP are 1.16 x 10(6) L x mol(-1) and 4.04 x 10(5) L x mol(-1) for p53 DNA and C-myc DNA, respectively, while that of 1-PBO are only 2.04 x 10(3) L x mol(-1) and 1.39 x 10(3) L x mol(-1) for p53 DNA and C-myc DNA, respectively.	Oxaliplatin	25-30	tumor protein p53	Homo sapiens	93-96
23192191-5	2012	The binding constants of 1-OHP are 1.16 x 10(6) L x mol(-1) and 4.04 x 10(5) L x mol(-1) for p53 DNA and C-myc DNA, respectively, while that of 1-PBO are only 2.04 x 10(3) L x mol(-1) and 1.39 x 10(3) L x mol(-1) for p53 DNA and C-myc DNA, respectively.	Oxaliplatin	25-30	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	105-110
23192191-5	2012	The binding constants of 1-OHP are 1.16 x 10(6) L x mol(-1) and 4.04 x 10(5) L x mol(-1) for p53 DNA and C-myc DNA, respectively, while that of 1-PBO are only 2.04 x 10(3) L x mol(-1) and 1.39 x 10(3) L x mol(-1) for p53 DNA and C-myc DNA, respectively.	Oxaliplatin	25-30	tumor protein p53	Homo sapiens	217-220
23192191-5	2012	The binding constants of 1-OHP are 1.16 x 10(6) L x mol(-1) and 4.04 x 10(5) L x mol(-1) for p53 DNA and C-myc DNA, respectively, while that of 1-PBO are only 2.04 x 10(3) L x mol(-1) and 1.39 x 10(3) L x mol(-1) for p53 DNA and C-myc DNA, respectively.	Oxaliplatin	25-30	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	229-234
22873218-13	2012	The positive effect of testing BCT100 with oxaliplatin in PLC/PRF/5 tumours also supports the rationale of combining BCT-100 and oxaliplatin in the clinical treatment of HCC.	Oxaliplatin	43-54	heparan sulfate proteoglycan 2	Homo sapiens	58-61
22909976-0	2012	K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy.	Oxaliplatin	126-137	KRAS proto-oncogene, GTPase	Homo sapiens	0-5
22909976-7	2012	Multivariate analysis revealed a predictive significance for K-Ras mutations with respect to time to progression in patients treated with irinotecan and oxaliplatin as first-line chemotherapy.	Oxaliplatin	153-164	KRAS proto-oncogene, GTPase	Homo sapiens	61-66
22909976-11	2012	Also, K-Ras mutation status may predict time to progression in patients treated with irinotecan and oxaliplatin.	Oxaliplatin	100-111	KRAS proto-oncogene, GTPase	Homo sapiens	6-11
23152059-8	2012	miR-204 targeted Bcl-2 messenger RNA and increased responsiveness of GC cells to 5-fluorouracil and oxaliplatin treatment.	Oxaliplatin	100-111	microRNA 204	Homo sapiens	0-7
23152059-8	2012	miR-204 targeted Bcl-2 messenger RNA and increased responsiveness of GC cells to 5-fluorouracil and oxaliplatin treatment.	Oxaliplatin	100-111	BCL2 apoptosis regulator	Homo sapiens	17-22
23268018-0	2012	[Clinical outcomes in refractory colorectal cancer patients with wild-type K-ras treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment].	Oxaliplatin	110-121	KRAS proto-oncogene, GTPase	Homo sapiens	75-80
23268018-1	2012	The clinical outcomes, including adverse events, in 34 unresectable advanced colorectal cancer patients with wild-type K-ras, who were treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment, were analyzed for confirmation of the effectiveness and safety of this treatment.	Oxaliplatin	164-175	KRAS proto-oncogene, GTPase	Homo sapiens	119-124
22770988-4	2012	Interestingly, when gef gene expression was combined with drugs of choice in the clinical treatment of colon cancer (5-fluorouracil, oxaliplatin and irinotecan), a strong synergistic effect was observed with approximately a 15-20% enhancement of the antiproliferative effect.	Oxaliplatin	133-144	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	20-23
23110695-0	2012	Phosphorylation of p68 RNA helicase by p38 MAP kinase contributes to colon cancer cells apoptosis induced by oxaliplatin.	Oxaliplatin	109-120	DEAD-box helicase 5	Homo sapiens	19-22
23110695-0	2012	Phosphorylation of p68 RNA helicase by p38 MAP kinase contributes to colon cancer cells apoptosis induced by oxaliplatin.	Oxaliplatin	109-120	mitogen-activated protein kinase 14	Homo sapiens	39-42
23110695-2	2012	RESULTS: In this report, we characterized the role of p68 phosphorylation in apoptosis induction under the treatment of oxaliplatin in the colon cancer cells.	Oxaliplatin	120-131	DEAD-box helicase 5	Homo sapiens	54-57
23110695-3	2012	Our data suggest that oxaliplatin treatment activates p38 MAP kinase, which subsequently phosphorylates p68 at T564 and/or T446.	Oxaliplatin	22-33	mitogen-activated protein kinase 14	Homo sapiens	54-57
23110695-3	2012	Our data suggest that oxaliplatin treatment activates p38 MAP kinase, which subsequently phosphorylates p68 at T564 and/or T446.	Oxaliplatin	22-33	DEAD-box helicase 5	Homo sapiens	104-107
22476768-7	2012	MiR-21 silencing in DLD1 cell line had no effect on the cell viability; however, when combined with chemotherapeutics (5-FU, L-OHP, and SN38), it contributed to the decrease of cell viability.	Oxaliplatin	125-130	microRNA 21	Homo sapiens	0-6
23291126-9	2012	A decreased expression of E-cadherin and increased expression of N-cadherin, vimentin and transcription factor Snail were detected in the oxaliplatin pre-treated tumors by immunohistochemistry, which provided the evidence of epithelial mesenchymal transition (EMT) in these tumors.	Oxaliplatin	138-149	cadherin 1	Mus musculus	26-36
23291126-9	2012	A decreased expression of E-cadherin and increased expression of N-cadherin, vimentin and transcription factor Snail were detected in the oxaliplatin pre-treated tumors by immunohistochemistry, which provided the evidence of epithelial mesenchymal transition (EMT) in these tumors.	Oxaliplatin	138-149	cadherin 2	Mus musculus	65-75
23291126-9	2012	A decreased expression of E-cadherin and increased expression of N-cadherin, vimentin and transcription factor Snail were detected in the oxaliplatin pre-treated tumors by immunohistochemistry, which provided the evidence of epithelial mesenchymal transition (EMT) in these tumors.	Oxaliplatin	138-149	vimentin	Mus musculus	77-85
23291126-9	2012	A decreased expression of E-cadherin and increased expression of N-cadherin, vimentin and transcription factor Snail were detected in the oxaliplatin pre-treated tumors by immunohistochemistry, which provided the evidence of epithelial mesenchymal transition (EMT) in these tumors.	Oxaliplatin	138-149	snail family zinc finger 1	Mus musculus	111-116
22192364-3	2012	Anti-EGFR agents can be added to first-line FOLFIRI (5-fluorouracil, leucovorin [folinic acid], irinotecan) or FOLFOX (5-fluorouracil, leucovorin [folinic acid], oxaliplatin) in patients whose tumors express wild-type KRAS.	Oxaliplatin	162-173	epidermal growth factor receptor	Homo sapiens	5-9
22213216-0	2012	DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	115-126	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	17-20
22213216-0	2012	DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	115-126	ERCC excision repair 5, endonuclease	Homo sapiens	22-25
22213216-6	2012	Moreover a significantly longer progression-free survival (PFS) after Oxaliplatin-based adjuvant chemotherapy was observed in patients with XPG Asp1104His wide-type GG genotype (n = 432, Log-rank test: P = 0.033).	Oxaliplatin	70-81	ERCC excision repair 5, endonuclease	Homo sapiens	140-143
22549274-0	2012	Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.	Oxaliplatin	58-69	X-ray repair cross complementing 1	Homo sapiens	24-29
22549274-1	2012	To examine the association between genetic polymorphisms of XRCC1 Arg399Gln(G A) and response to oxaliplatin-based chemotherapy in advanced colorectal cancer.	Oxaliplatin	97-108	X-ray repair cross complementing 1	Homo sapiens	60-65
22549274-2	2012	XRCC1 genotypes of totally 99 patients(37 stage III, 62 stage IV)with advanced colorectal cancer treated with oxaliplatin-based chemotherapy were detected by TaqMan-MGB probe allelic discrimination method.	Oxaliplatin	110-121	X-ray repair cross complementing 1	Homo sapiens	0-5
22549274-11	2012	The results suggest that XRCC1 Arg399Gln polymorphisms is associated with the response to oxaliplatin-based chemotherapy and time to progression in advanced colorectal cancer in Chinese population.	Oxaliplatin	90-101	X-ray repair cross complementing 1	Homo sapiens	25-30
22549274-12	2012	It is proposed that the XRCC1 Arg399Gln polymorphism should be routinely detected to screen patients who are more likely benefit from oxaliplatin-based treatment.	Oxaliplatin	134-145	X-ray repair cross complementing 1	Homo sapiens	24-29
23167110-0	2012	[Preliminary study on mechanisms of granulocyte macrophage-colony stimulating factor in enhancing impaired colonic anastomotic healing in rats treated with intraperitoneal oxaliplatin].	Oxaliplatin	172-183	colony stimulating factor 2	Rattus norvegicus	36-84
23167110-1	2012	OBJECTIVE: To investigate the mechanisms of local application of granulocyte macrophage-colony stimulating factor (GM-CSF) on healing of colonic anastomoses impaired by intraperitoneal oxaliplatin in rats.	Oxaliplatin	185-196	colony stimulating factor 2	Rattus norvegicus	65-113
23167110-1	2012	OBJECTIVE: To investigate the mechanisms of local application of granulocyte macrophage-colony stimulating factor (GM-CSF) on healing of colonic anastomoses impaired by intraperitoneal oxaliplatin in rats.	Oxaliplatin	185-196	colony stimulating factor 2	Rattus norvegicus	115-121
23291066-9	2012	Compared with the control group, statistical analysis of variance showed that the expression levels of COX-2, VEGF-C and VEGFR-3 of the oxaliplatin group were significantly increased (P &lt; 0.05), the expression levels of survivin and beta-catenin protein and mRNA of the oxaliplatin group were significantly reduced (P &lt; 0.05).	Oxaliplatin	136-147	cytochrome c oxidase II, mitochondrial	Mus musculus	103-108
23291066-9	2012	Compared with the control group, statistical analysis of variance showed that the expression levels of COX-2, VEGF-C and VEGFR-3 of the oxaliplatin group were significantly increased (P &lt; 0.05), the expression levels of survivin and beta-catenin protein and mRNA of the oxaliplatin group were significantly reduced (P &lt; 0.05).	Oxaliplatin	136-147	vascular endothelial growth factor C	Mus musculus	110-116
23291066-9	2012	Compared with the control group, statistical analysis of variance showed that the expression levels of COX-2, VEGF-C and VEGFR-3 of the oxaliplatin group were significantly increased (P &lt; 0.05), the expression levels of survivin and beta-catenin protein and mRNA of the oxaliplatin group were significantly reduced (P &lt; 0.05).	Oxaliplatin	136-147	FMS-like tyrosine kinase 4	Mus musculus	121-128
23291066-9	2012	Compared with the control group, statistical analysis of variance showed that the expression levels of COX-2, VEGF-C and VEGFR-3 of the oxaliplatin group were significantly increased (P &lt; 0.05), the expression levels of survivin and beta-catenin protein and mRNA of the oxaliplatin group were significantly reduced (P &lt; 0.05).	Oxaliplatin	136-147	baculoviral IAP repeat-containing 5	Mus musculus	223-231
23291066-9	2012	Compared with the control group, statistical analysis of variance showed that the expression levels of COX-2, VEGF-C and VEGFR-3 of the oxaliplatin group were significantly increased (P &lt; 0.05), the expression levels of survivin and beta-catenin protein and mRNA of the oxaliplatin group were significantly reduced (P &lt; 0.05).	Oxaliplatin	136-147	catenin (cadherin associated protein), beta 1	Mus musculus	236-248
23291066-10	2012	Compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide + oxaliplatin group were significantly reduced (all P &lt; 0.05).	Oxaliplatin	128-139	baculoviral IAP repeat-containing 5	Mus musculus	82-90
23291066-10	2012	Compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide + oxaliplatin group were significantly reduced (all P &lt; 0.05).	Oxaliplatin	128-139	catenin (cadherin associated protein), beta 1	Mus musculus	95-107
23291066-11	2012	CONCLUSIONS: Both nimesulide alone or in combination with oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice and the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin.	Oxaliplatin	58-69	cytochrome c oxidase II, mitochondrial	Mus musculus	175-180
23291066-11	2012	CONCLUSIONS: Both nimesulide alone or in combination with oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice and the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin.	Oxaliplatin	58-69	vascular endothelial growth factor C	Mus musculus	182-188
23291066-11	2012	CONCLUSIONS: Both nimesulide alone or in combination with oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice and the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin.	Oxaliplatin	58-69	FMS-like tyrosine kinase 4	Mus musculus	190-197
23291066-11	2012	CONCLUSIONS: Both nimesulide alone or in combination with oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice and the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin.	Oxaliplatin	58-69	baculoviral IAP repeat-containing 5	Mus musculus	199-207
23291066-11	2012	CONCLUSIONS: Both nimesulide alone or in combination with oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice and the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin.	Oxaliplatin	58-69	catenin (cadherin associated protein), beta 1	Mus musculus	212-224
23291066-12	2012	Oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice, and the expression of survivin and beta-catenin.	Oxaliplatin	0-11	baculoviral IAP repeat-containing 5	Mus musculus	111-119
23291066-12	2012	Oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice, and the expression of survivin and beta-catenin.	Oxaliplatin	0-11	catenin (cadherin associated protein), beta 1	Mus musculus	124-136
23170132-1	2012	This study aimed to investigate the impact of the combined use of the nuclear factor-kappaB (NF-kappaB) inhibitors pyrrolidine dithiocarbamate (PDTC), bortezomib or SN50, and the chemotherapy agents arsenic acid (As(2)O(3)), fluorouracil (5FU), oxaliplatin or paclitaxel on the growth and apoptosis of HT-29 cells.	Oxaliplatin	245-256	nuclear factor kappa B subunit 1	Homo sapiens	70-91
22700002-12	2012	In our experience, gemcitabine-oxaliplatin was feasible and induced effective palliation in PS2 patients with advanced BTC.	Oxaliplatin	31-42	taste 2 receptor member 64 pseudogene	Homo sapiens	92-95
22612279-3	2012	CuL3, the most active superoxide scavenger, was further studied as a modulator of the cytotoxicity of oxaliplatin in epithelial breast MCF10A cells and in MCF7 breast cancer cells.	Oxaliplatin	102-113	cullin 3	Homo sapiens	0-4
22612279-4	2012	Our results show that CuL3 enhances the therapeutic window of oxaliplatin, by both protecting non-tumour cells and increasing its cytotoxic effect in breast carcinoma cells.	Oxaliplatin	62-73	cullin 3	Homo sapiens	22-26
22333669-8	2012	Aspartate aminotransferase and alanine aminotransferase decreased after two additional weeks off therapy and during cycle 3 in which oxaliplatin was held.	Oxaliplatin	133-144	glutamic--pyruvic transaminase	Homo sapiens	31-55
22710939-4	2012	Sec61beta knockdown (KD) resulted in 8-, 16.8-, and 9-fold resistance to cisplatin (cDDP), carboplatin, and oxaliplatin, respectively.	Oxaliplatin	108-119	SEC61 translocon subunit beta	Homo sapiens	0-9
22710431-8	2012	Moreover, expression of Cyclin D1 increased, whereas expression of Cyclin A decreased after treatment with PEG-liposomal oxaliplatin.	Oxaliplatin	121-132	cyclin D1	Homo sapiens	24-33
22710431-8	2012	Moreover, expression of Cyclin D1 increased, whereas expression of Cyclin A decreased after treatment with PEG-liposomal oxaliplatin.	Oxaliplatin	121-132	cyclin A2	Homo sapiens	67-75
22710431-11	2012	The effect of PEG-liposomal oxaliplatin on apoptosis of SW480 human colorectal cancer cells may be through regulation of expression of Cyclin A or Cyclin D1, as well as pro-apoptotic and anti-apoptotic proteins.	Oxaliplatin	28-39	cyclin A2	Homo sapiens	135-143
22710431-11	2012	The effect of PEG-liposomal oxaliplatin on apoptosis of SW480 human colorectal cancer cells may be through regulation of expression of Cyclin A or Cyclin D1, as well as pro-apoptotic and anti-apoptotic proteins.	Oxaliplatin	28-39	cyclin D1	Homo sapiens	147-156
22876876-0	2012	Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy.	Oxaliplatin	98-109	KRAS proto-oncogene, GTPase	Homo sapiens	10-14
22876876-2	2012	BACKGROUND: To evaluate the value of KRAS codon 13 mutations in patients with advanced colorectal cancer (advanced CRC) treated with oxaliplatin and fluoropyrimidines.	Oxaliplatin	133-144	KRAS proto-oncogene, GTPase	Homo sapiens	37-41
22876876-11	2012	CONCLUSIONS: Our data suggest that the type of KRAS mutation may be of clinical relevance under oxaliplatin combination chemotherapies without the addition of monoclonal antibodies in particular when overall response rates are important.	Oxaliplatin	96-107	KRAS proto-oncogene, GTPase	Homo sapiens	47-51
23342249-13	2012	Furthermore, the Snail-overexpressing CRC cells were more chemoresistant to oxaliplatin than control cells.	Oxaliplatin	76-87	snail family transcriptional repressor 1	Homo sapiens	17-22
22839205-11	2012	CONCLUSIONS: Taken together, these results suggest that a brief treatment with oxaliplatin or its metabolite oxalate is sufficient to enhance the responsiveness of TRPA1 but not that of TRPM8 and TRPV1 expressed by DRG neurons, which may contribute to the characteristic acute peripheral neuropathy induced by oxaliplatin.	Oxaliplatin	310-321	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	164-169
22652385-6	2012	Quantification of the magnitude of neuronal extracellular signal-regulated kinase (ERK) phosphorylation in cortical neurons as a marker of neuronal activity revealed a 10-fold increase induced by oxaliplatin treatment, suggesting that neurons of cortical areas involved in transmission of painful stimuli undergo a chronic cortical excitability.	Oxaliplatin	196-207	mitogen-activated protein kinase 1	Homo sapiens	44-81
22652385-6	2012	Quantification of the magnitude of neuronal extracellular signal-regulated kinase (ERK) phosphorylation in cortical neurons as a marker of neuronal activity revealed a 10-fold increase induced by oxaliplatin treatment, suggesting that neurons of cortical areas involved in transmission of painful stimuli undergo a chronic cortical excitability.	Oxaliplatin	196-207	mitogen-activated protein kinase 1	Homo sapiens	83-86
22839205-0	2012	Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice.	Oxaliplatin	58-69	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	114-119
22839205-3	2012	In this study, the involvement of thermosensitive transient receptor potential channels (TRPA1, TRPM8 and TRPV1) in oxaliplatin-induced acute hypersensitivity was investigated in mice.	Oxaliplatin	116-127	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	89-94
22193989-9	2012	The oxaliplatin induced upregulation of PD-L1 and downregulation of costimulatory molecules CD80 and CD86 resulted in decreased T-cell proliferation.	Oxaliplatin	4-15	CD80 molecule	Homo sapiens	92-96
22839205-3	2012	In this study, the involvement of thermosensitive transient receptor potential channels (TRPA1, TRPM8 and TRPV1) in oxaliplatin-induced acute hypersensitivity was investigated in mice.	Oxaliplatin	116-127	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	96-101
22839205-3	2012	In this study, the involvement of thermosensitive transient receptor potential channels (TRPA1, TRPM8 and TRPV1) in oxaliplatin-induced acute hypersensitivity was investigated in mice.	Oxaliplatin	116-127	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	106-111
22839205-6	2012	The oxaliplatin-induced acute cold hypersensitivity was abolished by the TRPA1 antagonist HC-030031 (100 mg/kg) and by TRPA1 deficiency.	Oxaliplatin	4-15	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	73-78
22839205-6	2012	The oxaliplatin-induced acute cold hypersensitivity was abolished by the TRPA1 antagonist HC-030031 (100 mg/kg) and by TRPA1 deficiency.	Oxaliplatin	4-15	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	119-124
22839205-7	2012	The nocifensive behaviors evoked by intraplantar injections of allyl-isothiocyanate (AITC; TRPA1 agonist) were significantly enhanced in mice treated for 2 h with oxaliplatin (1-10 mg/kg) in a dose-dependent manner, while capsaicin (TRPV1 agonist)-evoked nocifensive behaviors were not affected.	Oxaliplatin	163-174	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	91-96
22839205-7	2012	The nocifensive behaviors evoked by intraplantar injections of allyl-isothiocyanate (AITC; TRPA1 agonist) were significantly enhanced in mice treated for 2 h with oxaliplatin (1-10 mg/kg) in a dose-dependent manner, while capsaicin (TRPV1 agonist)-evoked nocifensive behaviors were not affected.	Oxaliplatin	163-174	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	233-238
22839205-8	2012	Menthol (TRPM8/TRPA1 agonist)-evoked nocifensive-like behaviors were also enhanced by oxaliplatin pretreatment, which were inhibited by TRPA1 deficiency.	Oxaliplatin	86-97	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	9-14
22839205-8	2012	Menthol (TRPM8/TRPA1 agonist)-evoked nocifensive-like behaviors were also enhanced by oxaliplatin pretreatment, which were inhibited by TRPA1 deficiency.	Oxaliplatin	86-97	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	15-20
22839205-8	2012	Menthol (TRPM8/TRPA1 agonist)-evoked nocifensive-like behaviors were also enhanced by oxaliplatin pretreatment, which were inhibited by TRPA1 deficiency.	Oxaliplatin	86-97	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	136-141
22839205-11	2012	CONCLUSIONS: Taken together, these results suggest that a brief treatment with oxaliplatin or its metabolite oxalate is sufficient to enhance the responsiveness of TRPA1 but not that of TRPM8 and TRPV1 expressed by DRG neurons, which may contribute to the characteristic acute peripheral neuropathy induced by oxaliplatin.	Oxaliplatin	79-90	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	164-169
22402811-11	2012	CD34 positive areas were likely situated at the peripheral area of SOS, and both SOS score and number of cycles of oxaliplatin-based chemotherapy significantly correlated with CD34 expression (r=0.629, P&lt;0.001 and r=0.522, P&lt;0.001, respectively).	Oxaliplatin	115-126	CD34 molecule	Homo sapiens	176-180
22193989-7	2012	Exposure to oxaliplatin markedly increased expression of the T-cell inhibitory molecule programmed death receptor-ligand 1 (PD-L1) on human pDCs and also TLR9-induced IFNalpha secretion.	Oxaliplatin	12-23	CD274 molecule	Homo sapiens	124-129
22193989-7	2012	Exposure to oxaliplatin markedly increased expression of the T-cell inhibitory molecule programmed death receptor-ligand 1 (PD-L1) on human pDCs and also TLR9-induced IFNalpha secretion.	Oxaliplatin	12-23	toll like receptor 9	Homo sapiens	154-158
22193989-7	2012	Exposure to oxaliplatin markedly increased expression of the T-cell inhibitory molecule programmed death receptor-ligand 1 (PD-L1) on human pDCs and also TLR9-induced IFNalpha secretion.	Oxaliplatin	12-23	interferon alpha 1	Homo sapiens	167-175
22193989-8	2012	Furthermore, oxaliplatin decreased TLR-induced STAT1 and STAT3 expression, and NF-kappaB-mediated responses.	Oxaliplatin	13-24	signal transducer and activator of transcription 1	Homo sapiens	47-52
22193989-9	2012	The oxaliplatin induced upregulation of PD-L1 and downregulation of costimulatory molecules CD80 and CD86 resulted in decreased T-cell proliferation.	Oxaliplatin	4-15	CD86 molecule	Homo sapiens	101-105
22193989-8	2012	Furthermore, oxaliplatin decreased TLR-induced STAT1 and STAT3 expression, and NF-kappaB-mediated responses.	Oxaliplatin	13-24	signal transducer and activator of transcription 3	Homo sapiens	57-62
22193989-9	2012	The oxaliplatin induced upregulation of PD-L1 and downregulation of costimulatory molecules CD80 and CD86 resulted in decreased T-cell proliferation.	Oxaliplatin	4-15	CD274 molecule	Homo sapiens	40-45
22627104-2	2012	With the aim of improving disease-free survival (DFS), this phase 3 study (CAO/ARO/AIO-04) integrated oxaliplatin into standard treatment.	Oxaliplatin	102-113	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	79-82
22524576-1	2012	AIM: To examine the relationship between changes in serum carcinoembryonic antigen (CEA) levels and survival during oxaliplatin-based chemotherapy for metastatic colorectal cancer (mCRC).	Oxaliplatin	116-127	CEA cell adhesion molecule 3	Homo sapiens	58-82
22698403-5	2012	Additionally, silencing of ID1 and ID3 increases sensitivity of CC-ICs to the chemotherapeutic agent oxaliplatin, linking tumor initiation function with chemotherapy resistance.	Oxaliplatin	101-112	inhibitor of DNA binding 1, HLH protein	Homo sapiens	27-30
22698403-5	2012	Additionally, silencing of ID1 and ID3 increases sensitivity of CC-ICs to the chemotherapeutic agent oxaliplatin, linking tumor initiation function with chemotherapy resistance.	Oxaliplatin	101-112	inhibitor of DNA binding 3, HLH protein	Homo sapiens	35-38
22690072-12	2012	We further detected the expression of E-cadherin and vimentin in cells treated with nigericin and oxaliplatin.	Oxaliplatin	98-109	cadherin 1	Homo sapiens	38-48
22690072-12	2012	We further detected the expression of E-cadherin and vimentin in cells treated with nigericin and oxaliplatin.	Oxaliplatin	98-109	vimentin	Homo sapiens	53-61
22690072-14	2012	In contrast, oxaliplatin downregulated the expression of E-cadherin and upregulated the expression of vimentin in HT29 cells relative to vehicle controls.	Oxaliplatin	13-24	cadherin 1	Homo sapiens	57-67
22690072-14	2012	In contrast, oxaliplatin downregulated the expression of E-cadherin and upregulated the expression of vimentin in HT29 cells relative to vehicle controls.	Oxaliplatin	13-24	vimentin	Homo sapiens	102-110
22494465-4	2012	Furthermore, detection of platinum accumulation in wt CHO, mutant CHO-pgsD-677 (lacking HS), and CHO-pgsA (lacking HS/CS) cells confirms that HSPG-mediated interactions are an important mechanism for PPC internalization but not so for uncharged cisplatin and oxaliplatin.	Oxaliplatin	259-270	syndecan 2	Homo sapiens	142-146
22524576-1	2012	AIM: To examine the relationship between changes in serum carcinoembryonic antigen (CEA) levels and survival during oxaliplatin-based chemotherapy for metastatic colorectal cancer (mCRC).	Oxaliplatin	116-127	CEA cell adhesion molecule 3	Homo sapiens	84-87
22524576-12	2012	A CEA response of &gt;=50% at 3 months and good ECOG were independent predictors of OS of patients with mCRC treated with oxaliplatin-based chemotherapies.	Oxaliplatin	122-133	CEA cell adhesion molecule 3	Homo sapiens	2-5
21487682-7	2012	RESULTS: Under normoxic conditions, clusterin overexpressing cells were more sensitive to FOLFOX treatment (p = 0.01); under 3% and 1% hypoxic conditions, overexpressing clusterin cells were more sensitive to 5-FU, oxaliplatin and FOLFOX, p values &lt;0.05 for all conditions.	Oxaliplatin	215-226	clusterin	Homo sapiens	170-179
22580644-8	2012	CONCLUSIONS: This study is first to report that the XRCC1 and XRCC3 gene polymorphisms are useful as a surrogate marker of clinical outcome in colorectal cancer with 5-FU/oxaliplatin combination chemotherapy in the Chinese population.	Oxaliplatin	171-182	X-ray repair cross complementing 1	Homo sapiens	52-57
22580644-8	2012	CONCLUSIONS: This study is first to report that the XRCC1 and XRCC3 gene polymorphisms are useful as a surrogate marker of clinical outcome in colorectal cancer with 5-FU/oxaliplatin combination chemotherapy in the Chinese population.	Oxaliplatin	171-182	X-ray repair cross complementing 3	Homo sapiens	62-67
21221710-1	2012	This study sought to measure the degree of synergy induced by specific small molecule inhibitors of DNA-PK [NU7026 and IC486241 (ICC)], a major component of the non-homologous end-joining (NHEJ) pathway, with SN38 or oxaliplatin.	Oxaliplatin	217-228	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	100-106
21487682-2	2012	The aim of this study was to assess the effect of clusterin overexpression in CRC cells on sensitivity to 5-fluorouracil (5-FU), oxaliplatin and FOLFOX treatment under normoxic and graded hypoxic conditions.	Oxaliplatin	129-140	clusterin	Homo sapiens	50-59
22391039-0	2012	The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.	Oxaliplatin	83-94	C-X-C motif chemokine receptor 2	Homo sapiens	4-9
21487682-5	2012	The response of parental and clusterin overexpressing cells to 5-FU, oxaliplatin and FOLFOX was examined using a crystal violet-based proliferation assay under normoxic conditions, 3% and 1% hypoxic conditions.	Oxaliplatin	69-80	clusterin	Homo sapiens	29-38
22391039-4	2012	The aim of this study was to investigate whether the CXCR2 antagonist, SCH-527123, inhibits colorectal cancer proliferation and if it can sensitize colorectal cancer cells to oxaliplatin both in vitro and in vivo.	Oxaliplatin	175-186	C-X-C motif chemokine receptor 2	Homo sapiens	53-58
22387291-3	2012	Because oxaliplatin, satraplatin, and picoplatin contain bulkier chemical groups attached to the platinum core compared with cisplatin, we hypothesized that these chemical additions may impede replicative bypass by TLS polymerases and reduce tolerance to platinum-containing adducts.	Oxaliplatin	8-19	FUS RNA binding protein	Homo sapiens	215-218
22391039-11	2012	In addition, CXCR2 blockade may further sensitize colorectal cancer to oxaliplatin treatment.	Oxaliplatin	71-82	C-X-C motif chemokine receptor 2	Homo sapiens	13-18
22741034-0	2012	Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen.	Oxaliplatin	133-144	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
22741034-2	2012	The purpose of this study was to evaluate the prognostic role of Bax in patients with advanced gastric cancer treated with triplet chemotherapy COI regimen (capecitabine, oxaliplatin, and irinotecan).	Oxaliplatin	171-182	BCL2 associated X, apoptosis regulator	Homo sapiens	65-68
22737602-4	2012	TLR4 loss-of-function alleles also have a negative impact on the therapeutic outcome of oxaliplatin in colorectal cancer patients.	Oxaliplatin	88-99	toll like receptor 4	Homo sapiens	0-4
22438565-11	2012	In both genders, AR was the main driver of TUBB3/TUBB6 expression, as constitutive silencing of AR was associated with downregulation of TUBB3/TUBB6 expression and increased sensitivity to oxaliplatin and SN-38.	Oxaliplatin	189-200	androgen receptor	Homo sapiens	96-98
22328001-10	2012	Knockdown of CIP2A decreased the resistance of the cells to 5-fluorouracil, oxaliplatin, and SN38 (an active metabolite of irinotecan).	Oxaliplatin	76-87	cellular inhibitor of PP2A	Homo sapiens	13-18
22328001-11	2012	Treatment with 5-fluorouracil, oxaliplatin, and SN38 decreased CIP2A expression.	Oxaliplatin	31-42	cellular inhibitor of PP2A	Homo sapiens	63-68
22328001-13	2012	The knockdown of CIP2A reduced proliferation and anchorage-independent colony formation and increased 5-fluorouracil, oxaliplatin, and SN38 efficacy in colon cancer cell lines.	Oxaliplatin	118-129	cellular inhibitor of PP2A	Homo sapiens	17-22
22510452-2	2012	We previously reported that oxaliplatin (4 mg/kg, i.p., twice a week) induces mechanical allodynia in the late phase in rats, and that spinal NR2B-containing N-methyl-D-aspartate (NMDA) receptors are involved in the oxaliplatin-induced mechanical allodynia.	Oxaliplatin	28-39	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	142-146
22493249-0	2012	Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current.	Oxaliplatin	16-27	sodium channel, voltage-gated, type VIII, alpha	Mus musculus	99-107
22493249-9	2012	This finding suggests that Na(V)1.6 plays a central role in mediating acute cooling-exacerbated symptoms following oxaliplatin, and that enhanced resurgent and persistent sodium currents may provide a general mechanistic basis for cold-aggravated symptoms of neuropathy.	Oxaliplatin	115-126	sodium channel, voltage-gated, type VIII, alpha	Mus musculus	27-35
22510452-2	2012	We previously reported that oxaliplatin (4 mg/kg, i.p., twice a week) induces mechanical allodynia in the late phase in rats, and that spinal NR2B-containing N-methyl-D-aspartate (NMDA) receptors are involved in the oxaliplatin-induced mechanical allodynia.	Oxaliplatin	216-227	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	142-146
22493351-11	2012	VEGF expression in the tumors was significantly reduced by oxaliplatin and COT treatment.	Oxaliplatin	59-70	vascular endothelial growth factor A	Mus musculus	0-4
22261548-8	2012	RESULTS: iDEB-TACE resulted in PFS of 3.9 months and overall survival (OS) of 11.7 months, compared with a PFS of 1.8 months and OS of 5.7 months, respectively, in patients treated with cTACE, and a PFS of 6.2 months and OS of 11.0 months, respectively, in patients treated with oxaliplatin and gemcitabine.	Oxaliplatin	279-290	ADAM metallopeptidase domain 17	Homo sapiens	14-18
22528234-0	2012	Down-regulation of p110beta expression increases chemosensitivity of colon cancer cell lines to oxaliplatin.	Oxaliplatin	96-107	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	19-27
22528234-8	2012	Moreover, inhibition of p110beta expression increased oxaliplatin-induced cell apoptosis and cell cycle arrest in HT29, HCT116 and SW620 cell lines.	Oxaliplatin	54-65	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	24-32
22528234-10	2012	It is concluded that down-regulated expression of p110beta could inhibit colon cancer cells proliferation and result in increased chemosensitivity of colorectal cancer cells to oxaliplatin through augmentation of oxaliplatin-induced cell apoptosis and cell cycle arrest.	Oxaliplatin	177-188	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	50-58
22528234-10	2012	It is concluded that down-regulated expression of p110beta could inhibit colon cancer cells proliferation and result in increased chemosensitivity of colorectal cancer cells to oxaliplatin through augmentation of oxaliplatin-induced cell apoptosis and cell cycle arrest.	Oxaliplatin	213-224	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	50-58
22528234-9	2012	In addition, increases of cleaved caspase-3 and cleaved PARP induced by oxaliplatin treatment were determined by immunoblotting in p110beta knockdown group compared with normal control group and wild-type group.	Oxaliplatin	72-83	poly(ADP-ribose) polymerase 1	Homo sapiens	56-60
22528234-9	2012	In addition, increases of cleaved caspase-3 and cleaved PARP induced by oxaliplatin treatment were determined by immunoblotting in p110beta knockdown group compared with normal control group and wild-type group.	Oxaliplatin	72-83	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	131-139
22469241-7	2012	For irinotecan-, oxaliplatin-, and bevacizumab-treated tumors, a significant correlation was established between the radiotracer uptake and caspase-3 immunostaining (r  =  .8, p &lt; .05; r  =  .9, p &lt; .001; r  =  .9, p &lt; .001, respectively).	Oxaliplatin	17-28	caspase 3	Mus musculus	140-149
22207655-6	2012	Mean IC(50) among the five cell lines was 6.2 +- 1.9 muM for cisplatin and 11.6 +- 4.2 muM for oxaliplatin, whereas carboplatin showed significantly lower proliferation inhibition (IC(50) 107.5 +- 21.2 muM).	Oxaliplatin	95-106	latexin	Homo sapiens	87-90
22207655-6	2012	Mean IC(50) among the five cell lines was 6.2 +- 1.9 muM for cisplatin and 11.6 +- 4.2 muM for oxaliplatin, whereas carboplatin showed significantly lower proliferation inhibition (IC(50) 107.5 +- 21.2 muM).	Oxaliplatin	95-106	latexin	Homo sapiens	87-90
22408359-5	2012	RESULTS: The overexpression of IL-8 resulted in an increased cell adhesion, migration and invasion, and a significant resistance to oxaliplatin in MKN-45 cells.	Oxaliplatin	132-143	C-X-C motif chemokine ligand 8	Homo sapiens	31-35
22258694-3	2012	We recently showed that TRP ankyrin 1 (TRPA1) channel mediates oxaliplatin-evoked cold and mechanical allodynia, and the drug targets TRPA1 via generation of oxidative stress.	Oxaliplatin	63-74	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	24-37
22258694-3	2012	We recently showed that TRP ankyrin 1 (TRPA1) channel mediates oxaliplatin-evoked cold and mechanical allodynia, and the drug targets TRPA1 via generation of oxidative stress.	Oxaliplatin	63-74	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	39-44
22258694-3	2012	We recently showed that TRP ankyrin 1 (TRPA1) channel mediates oxaliplatin-evoked cold and mechanical allodynia, and the drug targets TRPA1 via generation of oxidative stress.	Oxaliplatin	63-74	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	134-139
22397399-0	2012	The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.	Oxaliplatin	95-106	microRNA 126	Homo sapiens	24-36
22397399-2	2012	The aim of the present study was to analyse the possible predictive value of miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer (mCRC).	Oxaliplatin	130-141	microRNA 126	Homo sapiens	77-86
22408359-6	2012	Inhibition of IL-8 expression with small interfering RNA decreased the adhesion, migration and invasion functions and oxaliplatin resistance in KATO-III cells.	Oxaliplatin	118-129	C-X-C motif chemokine ligand 8	Homo sapiens	14-18
22399593-1	2012	BACKGROUND: Clinical studies have suggested that the epidermal growth factor receptor (EGFR)-inhibiting antibody cetuximab may have better effect in the third-line treatment of metastatic colorectal cancer, after failure of standard chemotherapy including oxaliplatin, compared to using it up-front in the first line.	Oxaliplatin	256-267	epidermal growth factor receptor	Homo sapiens	53-85
22065348-3	2012	Only ETD allowed the simultaneous and exact determination of Met1 and His68 residues as binding partners for oxaliplatin.	Oxaliplatin	109-120	granzyme M	Homo sapiens	61-65
22399593-1	2012	BACKGROUND: Clinical studies have suggested that the epidermal growth factor receptor (EGFR)-inhibiting antibody cetuximab may have better effect in the third-line treatment of metastatic colorectal cancer, after failure of standard chemotherapy including oxaliplatin, compared to using it up-front in the first line.	Oxaliplatin	256-267	epidermal growth factor receptor	Homo sapiens	87-91
22399593-5	2012	RESULTS: A marked increase in sensitivity to cetuximab, accompanied by an up-regulation of EGFR, was observed in the oxaliplatin-resistant cell lines.	Oxaliplatin	117-128	epidermal growth factor receptor	Homo sapiens	91-95
21503888-0	2012	PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.	Oxaliplatin	40-51	PML nuclear body scaffold	Homo sapiens	0-3
21888623-0	2012	PEG-liposomal oxaliplatin induces apoptosis in human colorectal cancer cells via Fas/FasL and caspase-8.	Oxaliplatin	14-25	Fas ligand	Homo sapiens	85-89
21888623-0	2012	PEG-liposomal oxaliplatin induces apoptosis in human colorectal cancer cells via Fas/FasL and caspase-8.	Oxaliplatin	14-25	caspase 8	Homo sapiens	94-103
21888623-9	2012	These findings indicate that PEG-liposomal L-OHP enhances the anticancer potency of the chemotherapeutic agent; moreover, Fas/FasL and caspase-8 signalling pathways play a key role in mediating PEG-liposomal L-OHP-induced apoptosis.	Oxaliplatin	43-48	Fas ligand	Homo sapiens	126-130
21888623-9	2012	These findings indicate that PEG-liposomal L-OHP enhances the anticancer potency of the chemotherapeutic agent; moreover, Fas/FasL and caspase-8 signalling pathways play a key role in mediating PEG-liposomal L-OHP-induced apoptosis.	Oxaliplatin	43-48	caspase 8	Homo sapiens	135-144
21503888-1	2012	PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity.	Oxaliplatin	140-151	PML nuclear body scaffold	Homo sapiens	0-3
21503888-2	2012	The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy.	Oxaliplatin	79-90	PML nuclear body scaffold	Homo sapiens	38-41
21503888-10	2012	This study represents the first evidence of a possible correlation between PML protein expression and outcome of metastatic colorectal cancer patients treated with oxaliplatin/fluoropyrimidine-based first line therapy.	Oxaliplatin	164-175	PML nuclear body scaffold	Homo sapiens	75-78
22624338-6	2012	Western blot analysis demonstrated that oxaliplatin could induce apoptosis of L02 cells by reducing the Bcl-2/Bim ratio, stimulating the cytochrome c release, and activating caspase-3.	Oxaliplatin	40-51	BCL2 like 11	Homo sapiens	110-113
22181013-8	2012	The overall conclusions were as follows: Several promising biomarker candidates were identified, notably thymidylate synthase for 5-FU, topoisomerase I for irinotecan and ERCC1 for oxaliplatin.	Oxaliplatin	181-192	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	171-176
22624338-6	2012	Western blot analysis demonstrated that oxaliplatin could induce apoptosis of L02 cells by reducing the Bcl-2/Bim ratio, stimulating the cytochrome c release, and activating caspase-3.	Oxaliplatin	40-51	BCL2 apoptosis regulator	Homo sapiens	104-109
22624338-6	2012	Western blot analysis demonstrated that oxaliplatin could induce apoptosis of L02 cells by reducing the Bcl-2/Bim ratio, stimulating the cytochrome c release, and activating caspase-3.	Oxaliplatin	40-51	cytochrome c, somatic	Homo sapiens	137-149
22624338-6	2012	Western blot analysis demonstrated that oxaliplatin could induce apoptosis of L02 cells by reducing the Bcl-2/Bim ratio, stimulating the cytochrome c release, and activating caspase-3.	Oxaliplatin	40-51	caspase 3	Homo sapiens	174-183
22198330-9	2012	We observed higher 1-OHP concentrations in children with CYP1A1*2C or GSTM1*0 polymorphisms, and a positive influence of CYP1A1*2C on OTM values in children with the highest PAH exposure.	Oxaliplatin	19-24	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	57-63
22198330-9	2012	We observed higher 1-OHP concentrations in children with CYP1A1*2C or GSTM1*0 polymorphisms, and a positive influence of CYP1A1*2C on OTM values in children with the highest PAH exposure.	Oxaliplatin	19-24	glutathione S-transferase mu 1	Homo sapiens	70-75
22209414-0	2012	Synthesis, antiproliferative activity and estrogen receptor alpha affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin.	Oxaliplatin	149-160	estrogen receptor 1	Homo sapiens	42-65
22048643-9	2012	The levels of miR-638 were correlated with the concentration of urinary 1-hydroxypyrene (1-OHP) and external levels of PAHs.	Oxaliplatin	89-94	microRNA 638	Homo sapiens	14-21
22740893-0	2012	Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation.	Oxaliplatin	50-61	KRAS proto-oncogene, GTPase	Homo sapiens	148-152
22455966-12	2012	Immunohistochemical studies showed an increase in the expression of VEGF-C in the oxaliplatin group (20 825 +- 2067) as compared to the control group (16 075 +- 875, F = 97.24, P &lt; 0.05), but no significant differences in beta-catenin and MLD (17 396 +- 1693, 9666 +- 978) as compared with the control group (9824 +- 1181, 17 588 +- 1698)respectively, P &gt; 0.05.	Oxaliplatin	82-93	vascular endothelial growth factor C	Mus musculus	68-74
22455966-12	2012	Immunohistochemical studies showed an increase in the expression of VEGF-C in the oxaliplatin group (20 825 +- 2067) as compared to the control group (16 075 +- 875, F = 97.24, P &lt; 0.05), but no significant differences in beta-catenin and MLD (17 396 +- 1693, 9666 +- 978) as compared with the control group (9824 +- 1181, 17 588 +- 1698)respectively, P &gt; 0.05.	Oxaliplatin	82-93	catenin (cadherin associated protein), beta 1	Mus musculus	225-237
22455966-15	2012	CONCLUSION: The combined use of indomethacin and oxaliplatin promoted antitumor lymphangiogenesis activity, possible by inhibiting the VEGF-C/VEGFR-3 and Wnt pathways.	Oxaliplatin	49-60	vascular endothelial growth factor C	Mus musculus	135-141
22455966-15	2012	CONCLUSION: The combined use of indomethacin and oxaliplatin promoted antitumor lymphangiogenesis activity, possible by inhibiting the VEGF-C/VEGFR-3 and Wnt pathways.	Oxaliplatin	49-60	FMS-like tyrosine kinase 4	Mus musculus	142-149
22994779-0	2012	GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.	Oxaliplatin	73-84	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	17-22
22292988-10	2012	RESULTS: Oxaliplatin (4 mg/kg) induced cold hyperalgesia and increased in the transient receptor potential melastatin 8 (TRPM8) mRNA levels in the dorsal root ganglia (DRG).	Oxaliplatin	9-20	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	78-119
22292988-10	2012	RESULTS: Oxaliplatin (4 mg/kg) induced cold hyperalgesia and increased in the transient receptor potential melastatin 8 (TRPM8) mRNA levels in the dorsal root ganglia (DRG).	Oxaliplatin	9-20	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	121-126
22292988-12	2012	Treatment with oxaliplatin and oxalate (500 muM for each) also increased the TRPM8 mRNA levels and induced Ca2+ influx and nuclear factor of activated T-cell (NFAT) nuclear translocation in cultured DRG cells.	Oxaliplatin	15-26	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	77-82
22292988-12	2012	Treatment with oxaliplatin and oxalate (500 muM for each) also increased the TRPM8 mRNA levels and induced Ca2+ influx and nuclear factor of activated T-cell (NFAT) nuclear translocation in cultured DRG cells.	Oxaliplatin	15-26	nuclear factor of activated T-cells 5	Rattus norvegicus	159-163
22292988-15	2012	CONCLUSIONS: These data suggest that the L type Ca2+ channels/NFAT/TRPM8 pathway is a downstream mediator for oxaliplatin-induced cold hyperalgesia, and that Ca2+ channel blockers have prophylactic potential for acute neuropathy.	Oxaliplatin	110-121	nuclear factor of activated T-cells 5	Rattus norvegicus	62-66
22292988-15	2012	CONCLUSIONS: These data suggest that the L type Ca2+ channels/NFAT/TRPM8 pathway is a downstream mediator for oxaliplatin-induced cold hyperalgesia, and that Ca2+ channel blockers have prophylactic potential for acute neuropathy.	Oxaliplatin	110-121	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	67-72
22901134-0	2012	Effect of tissue factor on invasion inhibition and apoptosis inducing effect of oxaliplatin in human gastric cancer cell.	Oxaliplatin	80-91	coagulation factor III, tissue factor	Homo sapiens	10-23
22901134-2	2012	The aim of this study was to construct a human gastric cancer cell line SGC7901 stably-transfected with human TF, and observe effects on oxaliplatin-dependent inhibition of invasion and the apoptosis induction.	Oxaliplatin	137-148	coagulation factor III, tissue factor	Homo sapiens	110-112
22994779-2	2012	We assessed whether single nucleotide polymorphisms (SNPs) in GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln might predict the overall survival in patients receiving oxaliplatin-based chemotherapy in a Chinese population.	Oxaliplatin	162-173	glutathione S-transferase pi 1	Homo sapiens	62-67
22994779-2	2012	We assessed whether single nucleotide polymorphisms (SNPs) in GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln might predict the overall survival in patients receiving oxaliplatin-based chemotherapy in a Chinese population.	Oxaliplatin	162-173	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	69-74
22994779-2	2012	We assessed whether single nucleotide polymorphisms (SNPs) in GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln might predict the overall survival in patients receiving oxaliplatin-based chemotherapy in a Chinese population.	Oxaliplatin	162-173	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	89-94
22994779-8	2012	CONCLUSION: GSTP1, GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln genotyping might facilitate tailored oxaliplatin-based chemotherapy for colorectal cancer patients.	Oxaliplatin	99-110	glutathione S-transferase pi 1	Homo sapiens	12-17
22994779-8	2012	CONCLUSION: GSTP1, GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln genotyping might facilitate tailored oxaliplatin-based chemotherapy for colorectal cancer patients.	Oxaliplatin	99-110	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	26-31
22994779-8	2012	CONCLUSION: GSTP1, GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln genotyping might facilitate tailored oxaliplatin-based chemotherapy for colorectal cancer patients.	Oxaliplatin	99-110	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	46-51
22994781-0	2012	Oxaliplatin sensitizes OS cells to TRAIL-induced apoptosis via down-regulation of Mcl1.	Oxaliplatin	0-11	TNF superfamily member 10	Homo sapiens	35-40
22994781-0	2012	Oxaliplatin sensitizes OS cells to TRAIL-induced apoptosis via down-regulation of Mcl1.	Oxaliplatin	0-11	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	82-86
22994781-4	2012	RESULTS: The survival inhibition rate of combined application of 100 mug/ml TRAIL and 1 mug/ml oxaliplatin on OS-732 cells was significantly higher than that of either agent singly (p&lt;0.01).	Oxaliplatin	95-106	TNF superfamily member 10	Homo sapiens	76-87
22994781-6	2012	Oxaliplatin had the effect of down-regulating Mcl1 expression and sensitizing OS cells to TRAIL-induced apoptosis.	Oxaliplatin	0-11	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	46-50
22994781-6	2012	Oxaliplatin had the effect of down-regulating Mcl1 expression and sensitizing OS cells to TRAIL-induced apoptosis.	Oxaliplatin	0-11	TNF superfamily member 10	Homo sapiens	90-95
22994781-7	2012	CONCLUSION: A combination of TRAIL and oxaliplatin exerts strong killing effects on OS-732 cells which might be related to down-regulation of Mcl1 expression.	Oxaliplatin	39-50	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	142-146
22236191-0	2012	CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.	Oxaliplatin	110-121	CEA cell adhesion molecule 3	Homo sapiens	0-3
22028397-5	2012	The relationships between p16(INK4alpha) methylation and the level of urinary 1-hydroxypyrene (1-OHP) or the frequency of cytokinesis block micronucleus (CBMN) were analyzed.	Oxaliplatin	95-100	cyclin dependent kinase inhibitor 2A	Homo sapiens	26-29
22574275-0	2012	Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation.	Oxaliplatin	0-11	transient receptor potential cation channel subfamily M member 8	Homo sapiens	43-48
22574275-2	2012	We hypothesized that the transient receptor potential melastatin 8 (TRPM8), a putative cold and menthol receptor, contributes to oxaliplatin cold hypersensitivity.	Oxaliplatin	129-140	transient receptor potential cation channel subfamily M member 8	Homo sapiens	25-66
22574275-2	2012	We hypothesized that the transient receptor potential melastatin 8 (TRPM8), a putative cold and menthol receptor, contributes to oxaliplatin cold hypersensitivity.	Oxaliplatin	129-140	transient receptor potential cation channel subfamily M member 8	Homo sapiens	68-73
22574275-8	2012	Further, the mean baseline CDT in oxaliplatin-treated patients was significantly higher than that of chemotherapy-naive patients and healthy subjects (0.151% vs. 0.066%, P = 0.0225), suggesting that acute sensory changes may be concealed by progressive abnormalities in sensory axons in severe neurotoxicity, and that TRPM8 is subject to desensitization on repeat stimulation.	Oxaliplatin	34-45	transient receptor potential cation channel subfamily M member 8	Homo sapiens	318-323
21953494-9	2012	Furthermore, HMGB1 silencing sensitized cells to apoptosis that was induced by oxaliplatin and mediated by the caspase-3 pathway.	Oxaliplatin	79-90	high mobility group box 1	Homo sapiens	13-18
23481572-8	2012	While 5-florouracil did not inhibit the VEGF secretion of HT-29 cell line, irinotecan, oxaliplatin, docetaxel and paclitaxel significantly decreased the levels of secreted VEGF.	Oxaliplatin	87-98	vascular endothelial growth factor A	Homo sapiens	172-176
21999765-2	2012	We showed that ectopic expression of BMI-1 in B-cell lymphoma cell lines, HT and RL, conferred resistance to etoposide and oxaliplatin, known to enhance sensitivity by targeting the survivin gene, but not to irinotecan, which is not relevant to the downregulation of survivin expression.	Oxaliplatin	123-134	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	37-42
22678405-3	2012	METHODS: Following our published data from S-adenosylmethionine (SAMe), oxaliplatin and sorafenib were further used to stimulate GADD45beta expression in cultured HepG2 (p53 wild type) and Hep3B (p53 null) hepatoma cells in vitro.	Oxaliplatin	72-83	growth arrest and DNA damage inducible beta	Homo sapiens	129-139
22678405-3	2012	METHODS: Following our published data from S-adenosylmethionine (SAMe), oxaliplatin and sorafenib were further used to stimulate GADD45beta expression in cultured HepG2 (p53 wild type) and Hep3B (p53 null) hepatoma cells in vitro.	Oxaliplatin	72-83	tumor protein p53	Homo sapiens	170-173
23295255-4	2012	The aim of this study was to evaluate the prognostic significance of serum VEGF and IGF-1 levels in advanced gastric cancer patients who were treated with oxaliplatin/5-fluorouracil (FOLFOX).	Oxaliplatin	155-166	vascular endothelial growth factor A	Homo sapiens	75-79
22678405-3	2012	METHODS: Following our published data from S-adenosylmethionine (SAMe), oxaliplatin and sorafenib were further used to stimulate GADD45beta expression in cultured HepG2 (p53 wild type) and Hep3B (p53 null) hepatoma cells in vitro.	Oxaliplatin	72-83	tumor protein p53	Homo sapiens	196-199
23295255-4	2012	The aim of this study was to evaluate the prognostic significance of serum VEGF and IGF-1 levels in advanced gastric cancer patients who were treated with oxaliplatin/5-fluorouracil (FOLFOX).	Oxaliplatin	155-166	insulin like growth factor 1	Homo sapiens	84-89
22678405-5	2012	RESULTS: Oxaliplatin and sorafenib could induce GADD45beta in both HepG2 and Hep3B in a dose-dependent manner with rapid and direct cytotoxic effect.	Oxaliplatin	9-20	growth arrest and DNA damage inducible beta	Homo sapiens	48-58
22678405-6	2012	Transcriptional activity of NF-kB and E2F-1 were both enhanced by oxaliplatin and sorafenib.	Oxaliplatin	66-77	E2F transcription factor 1	Homo sapiens	38-43
21940361-0	2012	Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.	Oxaliplatin	70-81	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	34-40
21940361-0	2012	Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.	Oxaliplatin	70-81	glutathione S-transferase pi 1	Homo sapiens	45-50
21940361-9	2012	CONCLUSIONS: Immunohistochemical studies for ERCC-1 and GST-p may be useful in prediction of the response to 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer patients.	Oxaliplatin	124-135	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-51
21940361-9	2012	CONCLUSIONS: Immunohistochemical studies for ERCC-1 and GST-p may be useful in prediction of the response to 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer patients.	Oxaliplatin	124-135	glutathione S-transferase pi 1	Homo sapiens	56-61
22466962-4	2012	Repeated administration of amitriptyline (5 and 10 mg/kg, p.o., once a day) reduced the oxaliplatin-induced mechanical allodynia but not cold hyperalgesia and reversed the oxaliplatin-induced increase in the expression of NR2B protein and mRNA in rat spinal cord.	Oxaliplatin	172-183	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	222-226
24833529-0	2012	ERCC1 and XPD/ERCC2 polymorphisms" predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.	Oxaliplatin	55-66	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
24833529-0	2012	ERCC1 and XPD/ERCC2 polymorphisms" predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.	Oxaliplatin	55-66	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	10-19
24833529-1	2012	Our purpose is to evaluate the predictive value of the genetic polymorphisms of Excision repair cross-complementing group 1 (ERCC1) and xeroderma pigmentosum group D/excision repair cross-complementing group 2 (XPD/ERCC2) in patients with advanced colorectal cancer receiving oxaliplatin-based chemotherapy, and we performed a meta-analysis in order to obtain a more precise estimation for a more optimizing individual chemotherapy.	Oxaliplatin	276-287	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	80-123
24833529-1	2012	Our purpose is to evaluate the predictive value of the genetic polymorphisms of Excision repair cross-complementing group 1 (ERCC1) and xeroderma pigmentosum group D/excision repair cross-complementing group 2 (XPD/ERCC2) in patients with advanced colorectal cancer receiving oxaliplatin-based chemotherapy, and we performed a meta-analysis in order to obtain a more precise estimation for a more optimizing individual chemotherapy.	Oxaliplatin	276-287	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	211-220
24833529-7	2012	For ERCC1 codon C118T polymorphism, the ORR to oxaliplatin-based chemotherapy in patients with C/C wild genotype was 77.27% and it was 69.30% for C/T and T/T variant genotype.	Oxaliplatin	47-58	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-9
24833529-11	2012	The results indicated that Oxaliplatin sensitivity was significantly associated with ERCC1 C118T polymorphism in Asian people.	Oxaliplatin	27-38	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	85-90
21935576-3	2012	We found             that exposure to oxaliplatin induced a significant increase in LC3 lipidation             and subsequent LC3 puncta formation.	Oxaliplatin	38-49	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	84-87
21935576-3	2012	We found             that exposure to oxaliplatin induced a significant increase in LC3 lipidation             and subsequent LC3 puncta formation.	Oxaliplatin	38-49	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	126-129
22948721-6	2012	An interaction model illustrated that KRAS p.G12C was associated with unfavorable outcome when treated with oxaliplatin plus cetuximab.	Oxaliplatin	108-119	KRAS proto-oncogene, GTPase	Homo sapiens	38-42
21963225-8	2011	Moreover, lunasin potentiated the effect of oxaliplatin in modifying expression of proteins involved in apoptosis and metastasis including Bax, Bcl-2, IKK-alpha and p-p65.	Oxaliplatin	44-55	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142
23226426-4	2012	Eligible studies were randomized controlled trials (RCTs) which evaluated oxaliplatin-based chemotherapy with or without anti-EGFR drugs (cetuximab or panitumumab) in untreated KRAS wild type patients with mCRC.	Oxaliplatin	74-85	KRAS proto-oncogene, GTPase	Homo sapiens	177-181
23226467-5	2012	The suppression of autophagy using either pharmacologic inhibitors (3-methyladenine, bafilomycin A1) or RNA interference in essential autophagy genes (ATG5 or Beclin1) enhanced the cell death and reactive oxygen species (ROS) production induced by oxaliplatin in Caco-2 cells.	Oxaliplatin	248-259	autophagy related 5	Homo sapiens	151-155
23226467-5	2012	The suppression of autophagy using either pharmacologic inhibitors (3-methyladenine, bafilomycin A1) or RNA interference in essential autophagy genes (ATG5 or Beclin1) enhanced the cell death and reactive oxygen species (ROS) production induced by oxaliplatin in Caco-2 cells.	Oxaliplatin	248-259	beclin 1	Homo sapiens	159-166
23226467-6	2012	Blocking oxaliplatin-induced ROS production by using ROS scavengers (NAC or Tiron) decreased autophagy.	Oxaliplatin	9-20	X-linked Kx blood group	Homo sapiens	69-72
23226467-7	2012	Furthermore, numerous dilated endoplasmic reticula (ER) were present in oxaliplatin-treated Caco-2 cells, and blocking ER stress by RNA interference against candidate of metastasis-1 (P8) and C/EBP-homologous protein (CHOP) decreased autophagy and ROS production.	Oxaliplatin	72-83	DNA damage inducible transcript 3	Homo sapiens	218-222
23071744-0	2012	Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116.	Oxaliplatin	62-73	C-X-C motif chemokine receptor 4	Homo sapiens	100-105
23071744-3	2012	In this study, we report for the first time that the chemokine receptor CXCR4 and the hypoxia-inducible transcription factors (HIF)-1alpha and HIF-2alpha are involved in these synergistic antitumor effects in human colorectal cancer SW1116 cells in vitro when endostar treatment is combined with the cytotoxic drug oxaliplatin.	Oxaliplatin	315-326	C-X-C motif chemokine receptor 4	Homo sapiens	72-77
23071744-3	2012	In this study, we report for the first time that the chemokine receptor CXCR4 and the hypoxia-inducible transcription factors (HIF)-1alpha and HIF-2alpha are involved in these synergistic antitumor effects in human colorectal cancer SW1116 cells in vitro when endostar treatment is combined with the cytotoxic drug oxaliplatin.	Oxaliplatin	315-326	hypoxia inducible factor 1 subunit alpha	Homo sapiens	86-138
23071744-3	2012	In this study, we report for the first time that the chemokine receptor CXCR4 and the hypoxia-inducible transcription factors (HIF)-1alpha and HIF-2alpha are involved in these synergistic antitumor effects in human colorectal cancer SW1116 cells in vitro when endostar treatment is combined with the cytotoxic drug oxaliplatin.	Oxaliplatin	315-326	endothelial PAS domain protein 1	Homo sapiens	143-153
23071744-4	2012	Under normoxia, we demonstrate that endostar and oxaliplatin treatments synergize to inhibit SW1116 cell proliferation, Matrigel adhesion and invasion by reduction of CXCR4 expression.	Oxaliplatin	49-60	C-X-C motif chemokine receptor 4	Homo sapiens	167-172
23071744-5	2012	Consistently, these antitumor abilities of endostar and oxaliplatin were markedly reduced by silencing of CXCR4 in SW1116 cells.	Oxaliplatin	56-67	C-X-C motif chemokine receptor 4	Homo sapiens	106-111
23071744-8	2012	CXCR4, is only dependent on HIF-2alpha, which promotes more aggressive phenotype and more significant for oxaliplatin resistance in SW1116 cells.	Oxaliplatin	106-117	C-X-C motif chemokine receptor 4	Homo sapiens	0-5
23071744-8	2012	CXCR4, is only dependent on HIF-2alpha, which promotes more aggressive phenotype and more significant for oxaliplatin resistance in SW1116 cells.	Oxaliplatin	106-117	endothelial PAS domain protein 1	Homo sapiens	28-38
22206547-0	2011	S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cells.	Oxaliplatin	46-57	S100 calcium binding protein A10	Homo sapiens	0-7
22206547-7	2011	We verified its differential expression and the correlation between S100A10 protein expression levels in drug-untreated CRC cells and their L-OHP sensitivities by Western blot analyses.	Oxaliplatin	140-145	S100 calcium binding protein A10	Homo sapiens	68-75
22206547-8	2011	In addition, S100A10 protein expression levels were not correlated with sensitivity to 5-fluorouracil, suggesting that S100A10 is more specific to L-OHP than to 5-fluorouracil in CRC cells.	Oxaliplatin	147-152	S100 calcium binding protein A10	Homo sapiens	119-126
22206547-10	2011	CONCLUSIONS: By proteomic approaches including SELDI technology, we have demonstrated that intracellular S100A10 protein expression levels in drug-untreated CRC cells differ according to cell lines and are significantly correlated with sensitivity of CRC cells to L-OHP exposure.	Oxaliplatin	264-269	S100 calcium binding protein A10	Homo sapiens	105-112
23209813-0	2012	KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.	Oxaliplatin	32-43	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
23209813-2	2012	We tested our hypothesis that KRAS mutation may be a predictor of oxaliplatin sensitivity in CRC.	Oxaliplatin	66-77	KRAS proto-oncogene, GTPase	Homo sapiens	30-34
23209813-6	2012	In KRAS-wild-type CRC cells (COLO320DM), KRAS overexpression by mutant vectors caused excision repair cross-complementation group 1 (ERCC1) downregulation in protein and mRNA levels, and enhanced oxaliplatin sensitivity.	Oxaliplatin	196-207	KRAS proto-oncogene, GTPase	Homo sapiens	41-45
23209813-7	2012	In contrast, in KRAS-mutant CRC cells (DLD-1(G13D) and SW480(G12V)), KRAS knocked-down by KRAS-siRNA led to ERCC1 upregulation and increased oxaliplatin resistance.	Oxaliplatin	141-152	KRAS proto-oncogene, GTPase	Homo sapiens	69-73
23209813-7	2012	In contrast, in KRAS-mutant CRC cells (DLD-1(G13D) and SW480(G12V)), KRAS knocked-down by KRAS-siRNA led to ERCC1 upregulation and increased oxaliplatin resistance.	Oxaliplatin	141-152	KRAS proto-oncogene, GTPase	Homo sapiens	69-73
23209813-9	2012	To validate ERCC1 as a predictor of sensitivity for oxaliplatin, ERCC1 was knocked-down by siRNA in KRAS-wild-type CRC cells, which restored oxaliplatin sensitivity.	Oxaliplatin	141-152	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	65-70
23209813-10	2012	In contrast, ERCC1 was overexpressed by ERCC1-expressing vectors in KRAS-mutant CRC cells, and caused oxaliplatin resistance.	Oxaliplatin	102-113	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-18
23209813-10	2012	In contrast, ERCC1 was overexpressed by ERCC1-expressing vectors in KRAS-mutant CRC cells, and caused oxaliplatin resistance.	Oxaliplatin	102-113	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	40-45
23209813-11	2012	Overall, our findings suggest that KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells by the mechanism of ERCC1 downregulation.	Oxaliplatin	67-78	KRAS proto-oncogene, GTPase	Homo sapiens	35-39
23209813-11	2012	Overall, our findings suggest that KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells by the mechanism of ERCC1 downregulation.	Oxaliplatin	67-78	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	133-138
23029137-3	2012	Our results show that, compared to beta-catenin knockdown, Tcf-4 knockdown more effectively inhibited colony formation, induced apoptosis, and increased 5-FU and oxaliplatin-mediated cytotoxicity in colon cancer cells.	Oxaliplatin	162-173	transcription factor 4	Homo sapiens	59-64
23123720-8	2012	Oxaliplatin, which was a superior substrate of the luminal efflux transporter, MATE2-K as well as OCT2, did not show nephrotoxicity.	Oxaliplatin	0-11	solute carrier family 47 member 2	Homo sapiens	79-86
21963225-0	2011	Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to alpha5beta1 integrin and suppresses FAK/ERK/NF-kappaB signaling.	Oxaliplatin	34-45	protein tyrosine kinase 2	Homo sapiens	140-143
21963225-0	2011	Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to alpha5beta1 integrin and suppresses FAK/ERK/NF-kappaB signaling.	Oxaliplatin	34-45	mitogen-activated protein kinase 1	Homo sapiens	144-147
21963225-0	2011	Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to alpha5beta1 integrin and suppresses FAK/ERK/NF-kappaB signaling.	Oxaliplatin	34-45	nuclear factor kappa B subunit 1	Homo sapiens	148-157
21963225-8	2011	Moreover, lunasin potentiated the effect of oxaliplatin in modifying expression of proteins involved in apoptosis and metastasis including Bax, Bcl-2, IKK-alpha and p-p65.	Oxaliplatin	44-55	BCL2 apoptosis regulator	Homo sapiens	144-149
21963225-8	2011	Moreover, lunasin potentiated the effect of oxaliplatin in modifying expression of proteins involved in apoptosis and metastasis including Bax, Bcl-2, IKK-alpha and p-p65.	Oxaliplatin	44-55	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	151-160
22118625-13	2011	Furthermore, depletion of NONO or RALY sensitized otherwise oxaliplatin resistant overexpressing YB-1 SW480 or HT29 cells.	Oxaliplatin	60-71	non-POU domain containing octamer binding	Homo sapiens	26-30
21787270-6	2011	Oxaliplatin effectiveness is principally regulated by nucleotide excision repair (NER) pathway, including excision repair cross-complementation group 1 (ERCC1), X-ray cross-complementing group 1 (XRCC1) and xeroderma pigmentosum group D (XDP).	Oxaliplatin	0-11	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	106-151
21787270-6	2011	Oxaliplatin effectiveness is principally regulated by nucleotide excision repair (NER) pathway, including excision repair cross-complementation group 1 (ERCC1), X-ray cross-complementing group 1 (XRCC1) and xeroderma pigmentosum group D (XDP).	Oxaliplatin	0-11	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	153-158
21787270-6	2011	Oxaliplatin effectiveness is principally regulated by nucleotide excision repair (NER) pathway, including excision repair cross-complementation group 1 (ERCC1), X-ray cross-complementing group 1 (XRCC1) and xeroderma pigmentosum group D (XDP).	Oxaliplatin	0-11	X-ray repair cross complementing 1	Homo sapiens	161-194
21787270-6	2011	Oxaliplatin effectiveness is principally regulated by nucleotide excision repair (NER) pathway, including excision repair cross-complementation group 1 (ERCC1), X-ray cross-complementing group 1 (XRCC1) and xeroderma pigmentosum group D (XDP).	Oxaliplatin	0-11	X-ray repair cross complementing 1	Homo sapiens	196-201
21787270-7	2011	The major oxaliplatin toxicity marker is represented by glutathione S-transferase (GST).	Oxaliplatin	10-21	glutathione S-transferase kappa 1	Homo sapiens	56-81
21788403-12	2011	Knockdown of BIRC6 sensitized colon cancer stem cells against the chemotherapeutic drugs oxaliplatin and cisplatin.	Oxaliplatin	89-100	baculoviral IAP repeat containing 6	Homo sapiens	13-18
21788403-14	2011	We identified BIRC6 as an important mediator of cancer stem cell resistance against cisplatin and oxaliplatin.	Oxaliplatin	98-109	baculoviral IAP repeat containing 6	Homo sapiens	14-19
22118625-0	2011	NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines.	Oxaliplatin	45-56	non-POU domain containing octamer binding	Homo sapiens	0-4
22118625-13	2011	Furthermore, depletion of NONO or RALY sensitized otherwise oxaliplatin resistant overexpressing YB-1 SW480 or HT29 cells.	Oxaliplatin	60-71	RALY heterogeneous nuclear ribonucleoprotein	Homo sapiens	34-38
22118625-0	2011	NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines.	Oxaliplatin	45-56	RALY heterogeneous nuclear ribonucleoprotein	Homo sapiens	9-13
22118625-0	2011	NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines.	Oxaliplatin	45-56	Y-box binding protein 1	Homo sapiens	40-44
22118625-4	2011	In this study, we tested the hypothesis that YB-1 also confers oxaliplatin resistance in colorectal adenocarcinomas.	Oxaliplatin	63-74	Y-box binding protein 1	Homo sapiens	45-49
22118625-5	2011	RESULTS: We show for the first time that transfection of YB-1 cDNA confers oxaliplatin resistance in two colorectal cancer cell lines (SW480 and HT29 cell lines).	Oxaliplatin	75-86	Y-box binding protein 1	Homo sapiens	57-61
22118625-6	2011	Furthermore, we identified by mass spectrometry analyses important YB-1 interactors required for such oxaliplatin resistance in these colorectal cancer cell lines.	Oxaliplatin	102-113	Y-box binding protein 1	Homo sapiens	67-71
22118625-10	2011	From these analyses, we obtained a list of proteins interacting with YB-1 and potentially involved in oxaliplatin resistance.	Oxaliplatin	102-113	Y-box binding protein 1	Homo sapiens	69-73
22118625-13	2011	Furthermore, depletion of NONO or RALY sensitized otherwise oxaliplatin resistant overexpressing YB-1 SW480 or HT29 cells.	Oxaliplatin	60-71	Y-box binding protein 1	Homo sapiens	97-101
22118625-14	2011	CONCLUSION: These results suggest knocking down NONO or RALY significant counteracts oxaliplatin resistance in colorectal cancers overexpressing the YB-1 protein.	Oxaliplatin	85-96	non-POU domain containing octamer binding	Homo sapiens	48-52
22118625-11	2011	Oxaliplatin dose response curves of SW480 and HT29 colorectal cancer cell lines transfected with several siRNAs corresponding to each of these YB-1 interactors were obtained to identify proteins significantly affecting oxaliplatin sensitivity upon gene silencing.	Oxaliplatin	0-11	Y-box binding protein 1	Homo sapiens	143-147
22118625-14	2011	CONCLUSION: These results suggest knocking down NONO or RALY significant counteracts oxaliplatin resistance in colorectal cancers overexpressing the YB-1 protein.	Oxaliplatin	85-96	RALY heterogeneous nuclear ribonucleoprotein	Homo sapiens	56-60
22118625-11	2011	Oxaliplatin dose response curves of SW480 and HT29 colorectal cancer cell lines transfected with several siRNAs corresponding to each of these YB-1 interactors were obtained to identify proteins significantly affecting oxaliplatin sensitivity upon gene silencing.	Oxaliplatin	219-230	Y-box binding protein 1	Homo sapiens	143-147
22118625-12	2011	Only the depletion of either NONO or RALY sensitized both colorectal cancer cell lines to oxaliplatin.	Oxaliplatin	90-101	non-POU domain containing octamer binding	Homo sapiens	29-33
21981408-7	2011	The NGF-induced upregulation of growth-associated protein-43 (GAP-43) was suppressed by oxaliplatin and oxalate.	Oxaliplatin	88-99	growth associated protein 43	Rattus norvegicus	32-60
22118625-14	2011	CONCLUSION: These results suggest knocking down NONO or RALY significant counteracts oxaliplatin resistance in colorectal cancers overexpressing the YB-1 protein.	Oxaliplatin	85-96	Y-box binding protein 1	Homo sapiens	149-153
21981408-7	2011	The NGF-induced upregulation of growth-associated protein-43 (GAP-43) was suppressed by oxaliplatin and oxalate.	Oxaliplatin	88-99	growth associated protein 43	Rattus norvegicus	62-68
22110208-1	2011	AIM: The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively.	Oxaliplatin	252-263	thymidylate synthetase	Homo sapiens	89-109
22110208-1	2011	AIM: The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively.	Oxaliplatin	252-263	thymidylate synthetase	Homo sapiens	111-115
22110208-1	2011	AIM: The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively.	Oxaliplatin	252-263	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	125-162
22110208-1	2011	AIM: The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively.	Oxaliplatin	252-263	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	164-169
22110208-7	2011	The mean level of ERCC1 mRNA expression in the groups with low and high response to oxaliplatin was 13.92x10(-3) +- 9.90x10(-3) 2(-(DeltaCt)) and 23.59x10(-3) +- 5.88x10(-3) 2(-(DeltaCt)), respectively.	Oxaliplatin	84-95	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	18-23
22110208-8	2011	Groups with high response to 5-FU and oxaliplatin had significantly higher expression of TYMS and ERCC1 mRNA, respectively (p&lt;0.01 and p=0.01, respectively).	Oxaliplatin	38-49	thymidylate synthetase	Homo sapiens	89-93
22110208-8	2011	Groups with high response to 5-FU and oxaliplatin had significantly higher expression of TYMS and ERCC1 mRNA, respectively (p&lt;0.01 and p=0.01, respectively).	Oxaliplatin	38-49	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	98-103
22110208-9	2011	CONCLUSION: High expression of TYMS and ERCC1 mRNA was associated with better in vitro chemosensitivity to 5-FU and oxaliplatin, respectively, in patients with colorectal cancer.	Oxaliplatin	116-127	thymidylate synthetase	Homo sapiens	31-35
22110208-9	2011	CONCLUSION: High expression of TYMS and ERCC1 mRNA was associated with better in vitro chemosensitivity to 5-FU and oxaliplatin, respectively, in patients with colorectal cancer.	Oxaliplatin	116-127	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	40-45
22202337-1	2011	It has been reported that thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), and excision repair cross-complementing-1 (ERCC-1) were useful markers to predict the efficacy of anti cancer agents including 5-fluorouracil (5-FU) and oxaliplatin for unresectable advanced colorectal cancer.	Oxaliplatin	275-286	thymidylate synthetase	Homo sapiens	26-46
22202337-1	2011	It has been reported that thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), and excision repair cross-complementing-1 (ERCC-1) were useful markers to predict the efficacy of anti cancer agents including 5-fluorouracil (5-FU) and oxaliplatin for unresectable advanced colorectal cancer.	Oxaliplatin	275-286	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	165-171
21999595-3	2011	METHODS: Quantitative reverse transcriptase-polymerase chain reaction methodology (q-RT-PCR) was employed to quantify mRNA expression of nucleotide excision repair genes ERCC1 and ERCC2, relevant in the neutralization of damage induced by oxaliplatin, and genes encoding enzymes relevant to 5-flurouracil metabolism, [thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD)] in 233 hepatic resection samples.	Oxaliplatin	239-250	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	170-175
21999595-3	2011	METHODS: Quantitative reverse transcriptase-polymerase chain reaction methodology (q-RT-PCR) was employed to quantify mRNA expression of nucleotide excision repair genes ERCC1 and ERCC2, relevant in the neutralization of damage induced by oxaliplatin, and genes encoding enzymes relevant to 5-flurouracil metabolism, [thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD)] in 233 hepatic resection samples.	Oxaliplatin	239-250	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	180-185
21769549-3	2011	By top-down analysis and fragmentation of the intact insulin-oxaliplatin adduct using nano-electrospray ionisation quadrupole time-of-flight mass spectrometry (nESI-Q-ToF-MS), the major binding site was assigned to histidine5 on the insulin B chain.	Oxaliplatin	61-72	insulin	Homo sapiens	233-240
21298384-8	2011	On the other hand, in patients treated with oxaliplatin-containing regimens, median PFS and OS tended to be longer in ERCC1-positive group, but these did not reach statistical significances.	Oxaliplatin	44-55	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	118-123
21769549-0	2011	Determination of the binding sites for oxaliplatin on insulin using mass spectrometry-based approaches.	Oxaliplatin	39-50	insulin	Homo sapiens	54-61
21769549-6	2011	Digestion of insulin-oxaliplatin with endoproteinase Glu-C (GluC) followed by reduction led to the formation of five peptides with Pt(dach) attached.	Oxaliplatin	21-32	insulin	Homo sapiens	13-20
21769549-1	2011	Using insulin as a model protein for binding of oxaliplatin to proteins, various mass spectrometric approaches and techniques were compared.	Oxaliplatin	48-59	insulin	Homo sapiens	6-13
21791631-2	2011	We investigated germline polymorphisms in genes involved in VEGF-dependent and -independent angiogenesis pathways to predict clinical outcome and tumor response in metastatic colorectal cancer (mCRC) patients treated with bevacizumab and oxaliplatin-based chemotherapy.	Oxaliplatin	238-249	vascular endothelial growth factor A	Homo sapiens	60-64
21769549-3	2011	By top-down analysis and fragmentation of the intact insulin-oxaliplatin adduct using nano-electrospray ionisation quadrupole time-of-flight mass spectrometry (nESI-Q-ToF-MS), the major binding site was assigned to histidine5 on the insulin B chain.	Oxaliplatin	61-72	insulin	Homo sapiens	53-60
21791631-9	2011	CONCLUSION: In this study, we identified common germline variants in VEGF-dependent and -independent angiogenesis genes predicting clinical outcome and tumor response in patients with mCRC receiving first-line bevacizumab and oxaliplatin-based chemotherapy.	Oxaliplatin	226-237	vascular endothelial growth factor A	Homo sapiens	69-73
21699898-0	2011	Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation.	Oxaliplatin	0-11	mitogen-activated protein kinase 8	Homo sapiens	17-20
21855036-7	2011	This review will focus on the preclinical and clinical evidences supporting ERCC1 as a major molecule in oxaliplatin resistance.	Oxaliplatin	105-116	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	76-81
21737505-7	2011	Moreover, oxaliplatin treatment induced phosphorylation of Src kinase.	Oxaliplatin	10-21	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	59-62
21737505-12	2011	Targeting Src kinase with a combination of dasatinib and oxaliplatin may be an attractive approach for this disease.	Oxaliplatin	57-68	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	10-13
21813700-3	2011	Intrathecal administration of oligodeoxynucleotide antisense against Drp1 produced a decrease in its expression in peripheral nerve and markedly attenuated neuropathic mechanical hyperalgesia caused by HIV/AIDS antiretroviral [ddC (2",3"-dideoxycytidine)] and anticancer (oxaliplatin) chemotherapy in male Sprague Dawley rats.	Oxaliplatin	272-283	dynamin 1-like	Rattus norvegicus	69-73
21596996-3	2011	The present investigation was undertaken to examine whether Slfn-3 plays a role in regulating differentiation of FOLFOX-resistant (5-fluorouracil + oxaliplatin) colon cancer cells that are highly enriched in cancer stem cells (CSCs).	Oxaliplatin	148-159	schlafen family member 12	Homo sapiens	60-66
20972872-3	2011	The aim of this study was to evaluate the association between k-ras status and addition of oxaliplatin to fluorouracil plus leucovorin (FOLFOX) chemotherapy in CRC patients with curative surgical resection.	Oxaliplatin	91-102	KRAS proto-oncogene, GTPase	Homo sapiens	62-67
21468686-2	2011	Our previous work shows that oxaliplatin induces the pro-apoptotic protein Noxa in CRC cells.	Oxaliplatin	29-40	phorbol-12-myristate-13-acetate-induced protein 1	Mus musculus	75-79
21468686-8	2011	RESULTS: Oxaliplatin and ABT-737 displayed a strong synergistic apoptotic response, which was dependent on wildtype TP53 and oncogenic KRAS.	Oxaliplatin	9-20	transformation related protein 53	Mus musculus	116-120
21468686-8	2011	RESULTS: Oxaliplatin and ABT-737 displayed a strong synergistic apoptotic response, which was dependent on wildtype TP53 and oncogenic KRAS.	Oxaliplatin	9-20	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	135-139
21468686-10	2011	Oxaliplatin, but not ABT-737, induced p53 accumulation, but both drugs stimulated Noxa expression.	Oxaliplatin	0-11	transformation related protein 53	Mus musculus	38-41
21683075-6	2011	RESULTS: Oxaliplatin-induced sensitivity to TRAIL required activation of the mitochondrial apoptotic pathway; reduced expression of Bax, Bak, and caspase-9, and stable overexpression of Bcl-xL, reduced TRAIL-induced death of cells incubated with oxaliplatin.	Oxaliplatin	246-257	TNF superfamily member 10	Homo sapiens	44-49
21683075-0	2011	Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.	Oxaliplatin	0-11	TNF superfamily member 10	Homo sapiens	51-56
21699898-0	2011	Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation.	Oxaliplatin	0-11	TNF superfamily member 10	Homo sapiens	32-37
21683075-0	2011	Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.	Oxaliplatin	0-11	mitogen-activated protein kinase 8	Homo sapiens	65-68
21683075-0	2011	Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.	Oxaliplatin	0-11	BCL2 like 1	Homo sapiens	98-104
21683075-6	2011	RESULTS: Oxaliplatin-induced sensitivity to TRAIL required activation of the mitochondrial apoptotic pathway; reduced expression of Bax, Bak, and caspase-9, and stable overexpression of Bcl-xL, reduced TRAIL-induced death of cells incubated with oxaliplatin.	Oxaliplatin	246-257	BCL2 like 1	Homo sapiens	186-192
21683075-7	2011	Mitochondrial priming was induced in cells that were sensitized by oxaliplatin and required signaling via c-Jun N-terminal kinase and phosphorylation of Bcl-xL.	Oxaliplatin	67-78	BCL2 like 1	Homo sapiens	153-159
21699898-0	2011	Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation.	Oxaliplatin	0-11	BCL2 like 1	Homo sapiens	74-80
21683075-9	2011	Co-immunoprecipitation experiments showed that oxaliplatin-induced phosphorylation of Bcl-xL disrupted its ability to sequestrate Bax, allowing Bax to interact with Bak to induce TRAIL-mediated apoptosis.	Oxaliplatin	47-58	BCL2 like 1	Homo sapiens	86-92
21683075-1	2011	BACKGROUND &amp; AIMS: Oxaliplatin sensitizes drug-resistant colon cancer cell lines to tumor necrosis factor-related apoptosis inducing ligand (TRAIL), a death receptor ligand that is selective for cancer cells.	Oxaliplatin	23-34	TNF superfamily member 10	Homo sapiens	88-143
21606177-0	2011	Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.	Oxaliplatin	0-11	solute carrier family 22 member 4	Homo sapiens	72-77
21683075-1	2011	BACKGROUND &amp; AIMS: Oxaliplatin sensitizes drug-resistant colon cancer cell lines to tumor necrosis factor-related apoptosis inducing ligand (TRAIL), a death receptor ligand that is selective for cancer cells.	Oxaliplatin	23-34	TNF superfamily member 10	Homo sapiens	145-150
21683075-2	2011	We investigated the molecular mechanisms by which oxaliplatin sensitizes cancer cells to TRAIL-induced apoptosis.	Oxaliplatin	50-61	TNF superfamily member 10	Homo sapiens	89-94
21683075-6	2011	RESULTS: Oxaliplatin-induced sensitivity to TRAIL required activation of the mitochondrial apoptotic pathway; reduced expression of Bax, Bak, and caspase-9, and stable overexpression of Bcl-xL, reduced TRAIL-induced death of cells incubated with oxaliplatin.	Oxaliplatin	9-20	TNF superfamily member 10	Homo sapiens	44-49
21683075-6	2011	RESULTS: Oxaliplatin-induced sensitivity to TRAIL required activation of the mitochondrial apoptotic pathway; reduced expression of Bax, Bak, and caspase-9, and stable overexpression of Bcl-xL, reduced TRAIL-induced death of cells incubated with oxaliplatin.	Oxaliplatin	9-20	BCL2 associated X, apoptosis regulator	Homo sapiens	132-135
21683075-6	2011	RESULTS: Oxaliplatin-induced sensitivity to TRAIL required activation of the mitochondrial apoptotic pathway; reduced expression of Bax, Bak, and caspase-9, and stable overexpression of Bcl-xL, reduced TRAIL-induced death of cells incubated with oxaliplatin.	Oxaliplatin	9-20	BCL2 antagonist/killer 1	Homo sapiens	137-140
21683075-6	2011	RESULTS: Oxaliplatin-induced sensitivity to TRAIL required activation of the mitochondrial apoptotic pathway; reduced expression of Bax, Bak, and caspase-9, and stable overexpression of Bcl-xL, reduced TRAIL-induced death of cells incubated with oxaliplatin.	Oxaliplatin	9-20	caspase 9	Homo sapiens	146-155
21683075-6	2011	RESULTS: Oxaliplatin-induced sensitivity to TRAIL required activation of the mitochondrial apoptotic pathway; reduced expression of Bax, Bak, and caspase-9, and stable overexpression of Bcl-xL, reduced TRAIL-induced death of cells incubated with oxaliplatin.	Oxaliplatin	9-20	BCL2 like 1	Homo sapiens	186-192
21683075-6	2011	RESULTS: Oxaliplatin-induced sensitivity to TRAIL required activation of the mitochondrial apoptotic pathway; reduced expression of Bax, Bak, and caspase-9, and stable overexpression of Bcl-xL, reduced TRAIL-induced death of cells incubated with oxaliplatin.	Oxaliplatin	9-20	TNF superfamily member 10	Homo sapiens	202-207
21683075-9	2011	Co-immunoprecipitation experiments showed that oxaliplatin-induced phosphorylation of Bcl-xL disrupted its ability to sequestrate Bax, allowing Bax to interact with Bak to induce TRAIL-mediated apoptosis.	Oxaliplatin	47-58	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
21683075-9	2011	Co-immunoprecipitation experiments showed that oxaliplatin-induced phosphorylation of Bcl-xL disrupted its ability to sequestrate Bax, allowing Bax to interact with Bak to induce TRAIL-mediated apoptosis.	Oxaliplatin	47-58	BCL2 associated X, apoptosis regulator	Homo sapiens	144-147
21683075-9	2011	Co-immunoprecipitation experiments showed that oxaliplatin-induced phosphorylation of Bcl-xL disrupted its ability to sequestrate Bax, allowing Bax to interact with Bak to induce TRAIL-mediated apoptosis.	Oxaliplatin	47-58	BCL2 antagonist/killer 1	Homo sapiens	165-168
21683075-9	2011	Co-immunoprecipitation experiments showed that oxaliplatin-induced phosphorylation of Bcl-xL disrupted its ability to sequestrate Bax, allowing Bax to interact with Bak to induce TRAIL-mediated apoptosis.	Oxaliplatin	47-58	TNF superfamily member 10	Homo sapiens	179-184
21683075-10	2011	CONCLUSIONS: Oxaliplatin facilitates TRAIL-induced apoptosis in colon cancer cells by activating c-Jun N-terminal kinase signaling and phosphorylation of Bcl-xL.	Oxaliplatin	13-24	TNF superfamily member 10	Homo sapiens	37-42
21683075-10	2011	CONCLUSIONS: Oxaliplatin facilitates TRAIL-induced apoptosis in colon cancer cells by activating c-Jun N-terminal kinase signaling and phosphorylation of Bcl-xL.	Oxaliplatin	13-24	BCL2 like 1	Homo sapiens	154-160
21683075-11	2011	Oxaliplatin-induced sensitivity to TRAIL might be developed as an approach to cancer therapy.	Oxaliplatin	0-11	TNF superfamily member 10	Homo sapiens	35-40
21606177-0	2011	Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.	Oxaliplatin	0-11	solute carrier family 22 member 5	Homo sapiens	82-87
21606177-1	2011	The organic cation/carnitine transporters OCTN1 and OCTN2 are related to other organic cation transporters (OCT1, OCT2, and OCT3) known for transporting oxaliplatin, an anticancer drug with dose-limiting neurotoxicity.	Oxaliplatin	153-164	solute carrier family 22 member 4	Rattus norvegicus	42-47
21606177-1	2011	The organic cation/carnitine transporters OCTN1 and OCTN2 are related to other organic cation transporters (OCT1, OCT2, and OCT3) known for transporting oxaliplatin, an anticancer drug with dose-limiting neurotoxicity.	Oxaliplatin	153-164	solute carrier family 22 member 5	Rattus norvegicus	52-57
21606177-1	2011	The organic cation/carnitine transporters OCTN1 and OCTN2 are related to other organic cation transporters (OCT1, OCT2, and OCT3) known for transporting oxaliplatin, an anticancer drug with dose-limiting neurotoxicity.	Oxaliplatin	153-164	solute carrier family 22 member 1	Rattus norvegicus	108-112
21606177-1	2011	The organic cation/carnitine transporters OCTN1 and OCTN2 are related to other organic cation transporters (OCT1, OCT2, and OCT3) known for transporting oxaliplatin, an anticancer drug with dose-limiting neurotoxicity.	Oxaliplatin	153-164	solute carrier family 22 member 2	Rattus norvegicus	114-118
21606177-1	2011	The organic cation/carnitine transporters OCTN1 and OCTN2 are related to other organic cation transporters (OCT1, OCT2, and OCT3) known for transporting oxaliplatin, an anticancer drug with dose-limiting neurotoxicity.	Oxaliplatin	153-164	solute carrier family 22 member 8	Rattus norvegicus	124-128
21606177-2	2011	In this study, we sought to determine whether OCTN1 and OCTN2 also transported oxaliplatin and to characterize their functional expression and contributions to its neuronal accumulation and neurotoxicity in dorsal root ganglion (DRG) neurons relative to those of OCTs.	Oxaliplatin	79-90	solute carrier family 22 member 4	Homo sapiens	46-51
21606177-2	2011	In this study, we sought to determine whether OCTN1 and OCTN2 also transported oxaliplatin and to characterize their functional expression and contributions to its neuronal accumulation and neurotoxicity in dorsal root ganglion (DRG) neurons relative to those of OCTs.	Oxaliplatin	79-90	solute carrier family 22 member 5	Homo sapiens	56-61
21606177-5	2011	HEK293 cells overexpressing rOctn1, rOctn2, human OCTN1, and human OCTN2 showed increased uptake and cytotoxicity of oxaliplatin compared with mock-transfected HEK293 controls; in addition, both uptake and cytotoxicity were inhibited by ergothioneine and L-carnitine.	Oxaliplatin	117-128	solute carrier family 22 member 4	Rattus norvegicus	28-34
21606177-5	2011	HEK293 cells overexpressing rOctn1, rOctn2, human OCTN1, and human OCTN2 showed increased uptake and cytotoxicity of oxaliplatin compared with mock-transfected HEK293 controls; in addition, both uptake and cytotoxicity were inhibited by ergothioneine and L-carnitine.	Oxaliplatin	117-128	solute carrier family 22 member 5	Rattus norvegicus	36-42
21606177-5	2011	HEK293 cells overexpressing rOctn1, rOctn2, human OCTN1, and human OCTN2 showed increased uptake and cytotoxicity of oxaliplatin compared with mock-transfected HEK293 controls; in addition, both uptake and cytotoxicity were inhibited by ergothioneine and L-carnitine.	Oxaliplatin	117-128	solute carrier family 22 member 4	Homo sapiens	50-55
21606177-5	2011	HEK293 cells overexpressing rOctn1, rOctn2, human OCTN1, and human OCTN2 showed increased uptake and cytotoxicity of oxaliplatin compared with mock-transfected HEK293 controls; in addition, both uptake and cytotoxicity were inhibited by ergothioneine and L-carnitine.	Oxaliplatin	117-128	solute carrier family 22 member 5	Homo sapiens	67-72
21606177-6	2011	The uptake of ergothioneine mediated by OCTN1 and of L-carnitine mediated by OCTN2 was decreased during oxaliplatin exposure.	Oxaliplatin	104-115	solute carrier family 22 member 5	Rattus norvegicus	77-82
21606177-10	2011	OCTN1 and OCTN2 both transport oxaliplatin and are functionally expressed by DRG neurons.	Oxaliplatin	31-42	solute carrier family 22 member 4	Rattus norvegicus	0-5
21606177-10	2011	OCTN1 and OCTN2 both transport oxaliplatin and are functionally expressed by DRG neurons.	Oxaliplatin	31-42	solute carrier family 22 member 5	Rattus norvegicus	10-15
21606177-11	2011	OCTN1-mediated transport of oxaliplatin appears to contribute to its neuronal accumulation and treatment-limiting neurotoxicity more so than OCTN2 or OCTs.	Oxaliplatin	28-39	solute carrier family 22 member 4	Rattus norvegicus	0-5
21632856-0	2011	Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.	Oxaliplatin	78-89	DNA repair endonuclease XPF	Cricetulus griseus	122-125
20839263-2	2011	Oxaliplatin-resistant HCT116 p53wt and p53(-/-) cell lines were generated, and the effects of oxaliplatin in combination with curcumin on resistance- and proliferation-associated proteins investigated.	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	29-32
20839263-5	2011	Curcumin in combination with oxaliplatin was able to decrease proliferative capacity of oxaliplatin-resistant p53 wildtype and p53(-/-) cell lines more effectively than oxaliplatin alone.	Oxaliplatin	29-40	tumor protein p53	Homo sapiens	110-113
20839263-5	2011	Curcumin in combination with oxaliplatin was able to decrease proliferative capacity of oxaliplatin-resistant p53 wildtype and p53(-/-) cell lines more effectively than oxaliplatin alone.	Oxaliplatin	29-40	tumor protein p53	Homo sapiens	127-130
20839263-5	2011	Curcumin in combination with oxaliplatin was able to decrease proliferative capacity of oxaliplatin-resistant p53 wildtype and p53(-/-) cell lines more effectively than oxaliplatin alone.	Oxaliplatin	88-99	tumor protein p53	Homo sapiens	110-113
20839263-5	2011	Curcumin in combination with oxaliplatin was able to decrease proliferative capacity of oxaliplatin-resistant p53 wildtype and p53(-/-) cell lines more effectively than oxaliplatin alone.	Oxaliplatin	88-99	tumor protein p53	Homo sapiens	110-113
21632856-6	2011	Oxaliplatin induced DNA synthesis in CLL cells, which was inhibited by fludarabine and was eliminated by knockdown of XPF, the NER 5"-endonuclease.	Oxaliplatin	0-11	DNA repair endonuclease XPF	Cricetulus griseus	118-121
21632856-10	2011	CONCLUSIONS: The synergistic cell killing is caused by a mechanistic interaction that requires the initiation of XPF-dependent excision repair in response to oxaliplatin adducts, and the inhibition of that process by fludarabine incorporation into the repair patch.	Oxaliplatin	158-169	DNA repair endonuclease XPF	Cricetulus griseus	113-116
21691217-1	2011	OBJECTIVES: The object of this study was to assess the modulating effects of genetic polymorphisms of glycine N-methyltransferase (GNMT) genotypes on 1-hydroxypyrene (1-OHP) and 8-hydroxy-2"-deoxyguanosine (8-OHdG) in urine from coke-oven workers, consistently exposed to polycyclic aromatic hydrocarbons (PAHs).	Oxaliplatin	167-172	glycine N-methyltransferase	Homo sapiens	131-135
21228335-1	2011	BACKGROUND: The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC).	Oxaliplatin	42-53	KRAS proto-oncogene, GTPase	Homo sapiens	149-153
21228335-1	2011	BACKGROUND: The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC).	Oxaliplatin	244-255	KRAS proto-oncogene, GTPase	Homo sapiens	149-153
21555371-3	2011	We show here that exposure of tumor cells to TGFbeta and TNFalpha induces EMT and, more importantly, generates cells with a stable BCSC phenotype which is shown by increased self-renewing capacity, greatly increased tumorigenicity, and increased resistance to oxaliplatin, etoposide, and paclitaxel.	Oxaliplatin	260-271	transforming growth factor beta 1	Homo sapiens	45-52
21555371-3	2011	We show here that exposure of tumor cells to TGFbeta and TNFalpha induces EMT and, more importantly, generates cells with a stable BCSC phenotype which is shown by increased self-renewing capacity, greatly increased tumorigenicity, and increased resistance to oxaliplatin, etoposide, and paclitaxel.	Oxaliplatin	260-271	tumor necrosis factor	Homo sapiens	57-65
21718595-10	2011	Furthermore, when MGC803 cells were treated with oxaliplatin for 24 h, an accumulation of punctate LC3 and an increase of LC3-II protein were also detected, indicating the activation of autophagy.	Oxaliplatin	49-60	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	99-102
21718595-10	2011	Furthermore, when MGC803 cells were treated with oxaliplatin for 24 h, an accumulation of punctate LC3 and an increase of LC3-II protein were also detected, indicating the activation of autophagy.	Oxaliplatin	49-60	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	122-125
21718595-11	2011	Phosphorylation of Akt and mTOR were inhibited by oxaliplatin.	Oxaliplatin	50-61	AKT serine/threonine kinase 1	Homo sapiens	19-22
21718595-11	2011	Phosphorylation of Akt and mTOR were inhibited by oxaliplatin.	Oxaliplatin	50-61	mechanistic target of rapamycin kinase	Homo sapiens	27-31
21691217-5	2011	CONCLUSIONS: This study suggests that GNMT STRP1 could modulate urinary 1-OHP and 8-OHdG levels in coke-oven workers exposed to PAHs.	Oxaliplatin	72-77	glycine N-methyltransferase	Homo sapiens	38-42
22848242-10	2011	The combination of L-OHP (1 muM) and RAPA (10 nM) induced 19.76% Annexin V-positive cells, which was found to be higher than L-OHP (11.45%, p&lt;0.01) or RAPA (6.89%, p&lt;0.01) alone.	Oxaliplatin	19-24	annexin A5	Homo sapiens	65-74
21628572-5	2011	As a consequence, when tumors arising from oncogenic Ras-transformed p53(-/-) and p53(-/-)Cry1(-/-)Cry2(-/-) cells are treated with the anticancer drug oxaliplatin, p53(-/-) tumors continue to grow whereas p53(-/-)Cry1(-/-)Cry2(-/-) tumors exhibit extensive apoptosis and stop growing.	Oxaliplatin	152-163	tumor protein p53	Homo sapiens	82-85
21481532-0	2011	Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation.	Oxaliplatin	0-11	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	65-70
21481532-4	2011	We hypothesized that the transient receptor potential ankyrin 1 (TRPA1), a cation channel activated by oxidative stress and cold temperature, contributes to mechanical and cold hypersensitivity caused by oxaliplatin and cisplatin.	Oxaliplatin	204-215	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	25-63
21481532-4	2011	We hypothesized that the transient receptor potential ankyrin 1 (TRPA1), a cation channel activated by oxidative stress and cold temperature, contributes to mechanical and cold hypersensitivity caused by oxaliplatin and cisplatin.	Oxaliplatin	204-215	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	65-70
21481532-5	2011	Oxaliplatin and cisplatin evoked glutathione-sensitive relaxation, mediated by TRPA1 stimulation and the release of calcitonin gene-related peptide from sensory nerve terminals in isolated guinea pig pulmonary arteries.	Oxaliplatin	0-11	transient receptor potential cation channel subfamily A member 1	Cavia porcellus	79-84
21481532-7	2011	However, oxaliplatin, and with lower potency, cisplatin, evoked a glutathione-sensitive calcium response in CHO cells expressing mouse TRPA1.	Oxaliplatin	9-20	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	135-140
21481532-8	2011	One single administration of oxaliplatin produced mechanical and cold hyperalgesia in rats, an effect selectively abated by the TRPA1 antagonist HC-030031.	Oxaliplatin	29-40	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	128-133
21481532-12	2011	TRPA1 is therefore required for oxaliplatin-evoked mechanical and cold hypersensitivity, and contributes to cisplatin-evoked mechanical allodynia.	Oxaliplatin	32-43	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	0-5
21866627-0	2011	[The effect of small GTPase Cdc42 on the multidrug resistance of oxaliplatin-resistant colon cancer cell lines].	Oxaliplatin	65-76	cell division cycle 42	Homo sapiens	28-33
21866627-1	2011	OBJECTIVE: To determine the effect of cell division cycle42 (Cdc42) on the multidrug resistance of oxaliplatin-resistant human colon cancer cells.	Oxaliplatin	99-110	cell division cycle 42	Homo sapiens	61-66
21866627-2	2011	METHODS: The protein expression levels of Cdc42 in oxaliplatin-resistant colon cancer cells and parental cells were examined with Western blot.	Oxaliplatin	51-62	cell division cycle 42	Homo sapiens	42-47
21628572-5	2011	As a consequence, when tumors arising from oncogenic Ras-transformed p53(-/-) and p53(-/-)Cry1(-/-)Cry2(-/-) cells are treated with the anticancer drug oxaliplatin, p53(-/-) tumors continue to grow whereas p53(-/-)Cry1(-/-)Cry2(-/-) tumors exhibit extensive apoptosis and stop growing.	Oxaliplatin	152-163	tumor protein p53	Homo sapiens	82-85
21628572-5	2011	As a consequence, when tumors arising from oncogenic Ras-transformed p53(-/-) and p53(-/-)Cry1(-/-)Cry2(-/-) cells are treated with the anticancer drug oxaliplatin, p53(-/-) tumors continue to grow whereas p53(-/-)Cry1(-/-)Cry2(-/-) tumors exhibit extensive apoptosis and stop growing.	Oxaliplatin	152-163	tumor protein p53	Homo sapiens	82-85
21464406-1	2011	PURPOSE: PTK787/ZK 222584 (PTK/ZK; vatalanib), an orally active, multitargeted angiogenesis inhibitor, has shown tolerability and promising activity in early-phase studies, which led to a phase III trial in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4).	Oxaliplatin	224-235	protein tyrosine kinase 2 beta	Homo sapiens	27-33
20734047-11	2011	The data suggest that the loss of p53 can increase oxaliplatin resistance but not satraplatin resistance.	Oxaliplatin	51-62	tumor protein p53	Homo sapiens	34-37
26189347-7	2011	On the basis of a lymphocyte stimulation test (DLST), oxaliplatin-induced IP was diagnosed.	Oxaliplatin	54-65	dihydrolipoamide S-succinyltransferase	Homo sapiens	47-51
22096847-7	2011	In the coke-oven workers, after adjusting the sex, age, cigarettes per day and urinary 1-OHP, RTL (1.25 +/- 0.93) of workers with CT genotype at the CYP1A1 3801 T &gt; C was significantly longer than that (0.93 +/- 0.51) of workers with TT genotype (P &lt; 0.05).	Oxaliplatin	87-92	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	149-155
21461444-3	2011	We here use electrospray-trap mass spectrometry to show that carboplatin and oxaliplatin are self-associated at concentrations in their ready-to-use infusion solutions (~27 mM and 13 mM, respectively) and, as expected, when the drug concentration is reduced to more physiologically relevant concentrations (100 muM and 5 muM, respectively) the association equilibrium is shifted in favor of the monomeric forms of these drugs.	Oxaliplatin	77-88	latexin	Homo sapiens	311-314
21461444-3	2011	We here use electrospray-trap mass spectrometry to show that carboplatin and oxaliplatin are self-associated at concentrations in their ready-to-use infusion solutions (~27 mM and 13 mM, respectively) and, as expected, when the drug concentration is reduced to more physiologically relevant concentrations (100 muM and 5 muM, respectively) the association equilibrium is shifted in favor of the monomeric forms of these drugs.	Oxaliplatin	77-88	latexin	Homo sapiens	321-324
20872144-3	2011	As the SK3 gene is characterized in Caucasians by a highly polymorphic CAG motif within the exon 1, we hypothesize that SK3 gene polymorphism may influence the development of acute nerve hyperexcitability in oxaliplatin-treated patients.	Oxaliplatin	208-219	potassium calcium-activated channel subfamily N member 3	Homo sapiens	120-123
21452186-0	2011	Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.	Oxaliplatin	96-107	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	22-25
21452186-0	2011	Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.	Oxaliplatin	96-107	ERCC excision repair 5, endonuclease	Homo sapiens	30-33
20872144-3	2011	As the SK3 gene is characterized in Caucasians by a highly polymorphic CAG motif within the exon 1, we hypothesize that SK3 gene polymorphism may influence the development of acute nerve hyperexcitability in oxaliplatin-treated patients.	Oxaliplatin	208-219	potassium calcium-activated channel subfamily N member 3	Homo sapiens	7-10
21327679-0	2011	The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?	Oxaliplatin	47-58	potassium calcium-activated channel subfamily N member 3	Homo sapiens	20-23
20872144-0	2011	Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.	Oxaliplatin	63-74	potassium calcium-activated channel subfamily N member 3	Homo sapiens	29-32
21623005-9	2011	Individually silencing central nodes in these five hubsinterfered with MI-219-oxaliplatin activity confirming their critical role in aiding p53 mediated apoptotic response.	Oxaliplatin	78-89	tumor protein p53	Homo sapiens	140-143
21438154-5	2011	Mechanistically, oxaliplatin promotes over-excitability by drastically lowering the expression of distinct potassium channels (TREK1, TRAAK) and by increasing the expression of pro-excitatory channels such as the hyperpolarization-activated channels (HCNs).	Oxaliplatin	17-28	potassium two pore domain channel subfamily K member 2	Homo sapiens	127-132
21438154-5	2011	Mechanistically, oxaliplatin promotes over-excitability by drastically lowering the expression of distinct potassium channels (TREK1, TRAAK) and by increasing the expression of pro-excitatory channels such as the hyperpolarization-activated channels (HCNs).	Oxaliplatin	17-28	potassium two pore domain channel subfamily K member 4	Homo sapiens	134-139
20648559-8	2011	Growth inhibition studies showed that IL-8 overexpression lead to a significant resistance to oxaliplatin (p &lt; 0.0001).	Oxaliplatin	94-105	C-X-C motif chemokine ligand 8	Homo sapiens	38-42
20648559-9	2011	Inhibition of IL-8 overexpression with small interfering RNA reversed the observed increases in tumorigenic functions and oxaliplatin resistance, suggesting that IL-8 not only provides a proliferative advantage but also promotes the metastatic potential of colon cancer cells.	Oxaliplatin	122-133	C-X-C motif chemokine ligand 8	Homo sapiens	14-18
20648559-9	2011	Inhibition of IL-8 overexpression with small interfering RNA reversed the observed increases in tumorigenic functions and oxaliplatin resistance, suggesting that IL-8 not only provides a proliferative advantage but also promotes the metastatic potential of colon cancer cells.	Oxaliplatin	122-133	C-X-C motif chemokine ligand 8	Homo sapiens	162-166
21623005-0	2011	Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors.	Oxaliplatin	35-46	MDM2 proto-oncogene	Homo sapiens	20-24
21623005-0	2011	Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors.	Oxaliplatin	35-46	tumor protein p53	Homo sapiens	92-95
21430067-7	2011	Furthermore, knockdown of mTORC1 and mTORC2 induced a mesenchymal-epithelial transition (MET) and enhanced chemosensitivity of CRCs to oxaliplatin.	Oxaliplatin	135-146	CREB regulated transcription coactivator 1	Mus musculus	26-32
21430067-7	2011	Furthermore, knockdown of mTORC1 and mTORC2 induced a mesenchymal-epithelial transition (MET) and enhanced chemosensitivity of CRCs to oxaliplatin.	Oxaliplatin	135-146	CREB regulated transcription coactivator 2	Mus musculus	37-43
21508389-2	2011	Preclinical work has shown that the Kirsten ras (KRAS) oncogene sensitizes colorectal tumour cells to oxaliplatin and capecitabine in a wild-type tumour suppressor p53 (TP53)-dependent manner.	Oxaliplatin	102-113	KRAS proto-oncogene, GTPase	Homo sapiens	36-47
21285347-0	2011	MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.	Oxaliplatin	69-80	mutS homolog 3	Homo sapiens	0-4
21285347-4	2011	In this study, we first examined the effects of MSH3 deficiency on cytotoxicity caused by cisplatin and oxaliplatin, another ICL-inducing platinum drug.	Oxaliplatin	104-115	mutS homolog 3	Homo sapiens	48-52
21285347-7	2011	Furthermore, MSH3-deficient cells maintained higher levels of phosphorylated histone H2AX and 53BP1 after oxaliplatin treatment in comparison with MSH3-proficient cells, suggesting that MSH3 plays an important role in repairing DNA double strand breaks (DSBs).	Oxaliplatin	106-117	mutS homolog 3	Homo sapiens	13-17
21285347-7	2011	Furthermore, MSH3-deficient cells maintained higher levels of phosphorylated histone H2AX and 53BP1 after oxaliplatin treatment in comparison with MSH3-proficient cells, suggesting that MSH3 plays an important role in repairing DNA double strand breaks (DSBs).	Oxaliplatin	106-117	tumor protein p53 binding protein 1	Homo sapiens	94-99
21508389-2	2011	Preclinical work has shown that the Kirsten ras (KRAS) oncogene sensitizes colorectal tumour cells to oxaliplatin and capecitabine in a wild-type tumour suppressor p53 (TP53)-dependent manner.	Oxaliplatin	102-113	KRAS proto-oncogene, GTPase	Homo sapiens	49-53
21508389-2	2011	Preclinical work has shown that the Kirsten ras (KRAS) oncogene sensitizes colorectal tumour cells to oxaliplatin and capecitabine in a wild-type tumour suppressor p53 (TP53)-dependent manner.	Oxaliplatin	102-113	tumor protein p53	Homo sapiens	169-173
21161336-3	2011	The current study examines whether difluorinated-curcumin (CDF), a novel analog of the dietary ingredient of curcumin, in combination with 5-fluorouracil and oxaliplatin (5-FU + Ox), the mainstay of colon cancer chemotherapeutic, would be effective in eliminating colon CSCs.	Oxaliplatin	158-169	interleukin 6	Homo sapiens	59-62
21635994-6	2011	RESULTS: For the metastatic colorectal cancer LLD population with K-ras wild-type genotype, mean overall survival estimates were 37.7 months for first-line treatment with cetuximab plus FOLFIRI (irinotecan, leucovorin, fluorouracil) and 30.4 months for bevacizumab plus FOLFOX (oxaliplatin, leucovorin, fluorouracil).	Oxaliplatin	278-289	KRAS proto-oncogene, GTPase	Homo sapiens	66-71
21298326-7	2011	Furthermore, the CD26 effect was enhanced when apigenin was paired with chemotherapeutic agents utilized in the treatment of advanced colorectal cancer including irinotecan, 5-fluorouracil and oxaliplatin.	Oxaliplatin	193-204	dipeptidyl peptidase 4	Homo sapiens	17-21
21278243-0	2011	ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.	Oxaliplatin	59-70	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
21278243-0	2011	ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.	Oxaliplatin	59-70	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	10-15
21278243-2	2011	To summarize published data on the association between polymorphisms of NER genes (ERCC1 and ERCC2) and responses to oxaliplatin-based chemotherapies, we carried out a meta-analysis of gastric and colorectal cancer for commonly studied polymorphisms ERCC1 rs11615C&gt;T and ERCC2 rs13181T&gt;G. PATIENTS AND METHODS: In 17 previously published studies, 1,787 cancer patients were treated with the oxaliplatin-based regimen.	Oxaliplatin	117-128	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	83-88
21278243-2	2011	To summarize published data on the association between polymorphisms of NER genes (ERCC1 and ERCC2) and responses to oxaliplatin-based chemotherapies, we carried out a meta-analysis of gastric and colorectal cancer for commonly studied polymorphisms ERCC1 rs11615C&gt;T and ERCC2 rs13181T&gt;G. PATIENTS AND METHODS: In 17 previously published studies, 1,787 cancer patients were treated with the oxaliplatin-based regimen.	Oxaliplatin	117-128	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	93-98
21278243-2	2011	To summarize published data on the association between polymorphisms of NER genes (ERCC1 and ERCC2) and responses to oxaliplatin-based chemotherapies, we carried out a meta-analysis of gastric and colorectal cancer for commonly studied polymorphisms ERCC1 rs11615C&gt;T and ERCC2 rs13181T&gt;G. PATIENTS AND METHODS: In 17 previously published studies, 1,787 cancer patients were treated with the oxaliplatin-based regimen.	Oxaliplatin	397-408	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	83-88
21278243-8	2011	CONCLUSIONS: NER ERCC1 rs11615C&gt;T and ERCC2 rs13181T&gt;G polymorphisms are useful prognostic factors in oxaliplatin-based treatment of gastric and colorectal cancer.	Oxaliplatin	108-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-22
21278243-8	2011	CONCLUSIONS: NER ERCC1 rs11615C&gt;T and ERCC2 rs13181T&gt;G polymorphisms are useful prognostic factors in oxaliplatin-based treatment of gastric and colorectal cancer.	Oxaliplatin	108-119	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	41-46
20125120-2	2011	The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs, in patients with metastatic colorectal cancer (mCRC) treated with first-line capecitabine and oxaliplatin (XELOX).	Oxaliplatin	185-196	vascular endothelial growth factor A	Homo sapiens	78-84
22811824-0	2011	Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29.	Oxaliplatin	34-45	insulin	Homo sapiens	0-7
22811824-2	2011	This study tested insulin-caused resistance to oxaliplatin via activation of PI3K/Akt pathway in HT29 cells.	Oxaliplatin	47-58	insulin	Homo sapiens	18-25
22811824-2	2011	This study tested insulin-caused resistance to oxaliplatin via activation of PI3K/Akt pathway in HT29 cells.	Oxaliplatin	47-58	AKT serine/threonine kinase 1	Homo sapiens	82-85
22811824-3	2011	METHODS: The effect of insulin on oxaliplatin cytotoxicity was tested by pre-incubation with 1microM insulin followed by addition of oxaliplatin.	Oxaliplatin	34-45	insulin	Homo sapiens	23-30
22811824-3	2011	METHODS: The effect of insulin on oxaliplatin cytotoxicity was tested by pre-incubation with 1microM insulin followed by addition of oxaliplatin.	Oxaliplatin	34-45	insulin	Homo sapiens	101-108
22811824-3	2011	METHODS: The effect of insulin on oxaliplatin cytotoxicity was tested by pre-incubation with 1microM insulin followed by addition of oxaliplatin.	Oxaliplatin	133-144	insulin	Homo sapiens	23-30
22811824-5	2011	RESULTS: Addition of 1microM insulin decreased the cytotoxicity of oxaliplatin.	Oxaliplatin	67-78	insulin	Homo sapiens	29-36
22811824-8	2011	CONCLUSION: Insulin decreased drug efficacy of oxaliplatin in HT29 cells, which could be mediated by the activation of the PI3K/Akt pathway.	Oxaliplatin	47-58	insulin	Homo sapiens	12-19
22811824-8	2011	CONCLUSION: Insulin decreased drug efficacy of oxaliplatin in HT29 cells, which could be mediated by the activation of the PI3K/Akt pathway.	Oxaliplatin	47-58	AKT serine/threonine kinase 1	Homo sapiens	128-131
20643864-1	2011	BACKGROUND: The aim was to evaluate the association between plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) and serum carcinoembryonic antigen (CEA) levels and outcome in patients with metastatic colorectal cancer (mCRC) receiving XELOX (combination chemotherapy with capecitabine and oxaliplatin) as first-line treatment.	Oxaliplatin	293-304	TIMP metallopeptidase inhibitor 1	Homo sapiens	67-106
20643864-1	2011	BACKGROUND: The aim was to evaluate the association between plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) and serum carcinoembryonic antigen (CEA) levels and outcome in patients with metastatic colorectal cancer (mCRC) receiving XELOX (combination chemotherapy with capecitabine and oxaliplatin) as first-line treatment.	Oxaliplatin	293-304	TIMP metallopeptidase inhibitor 1	Homo sapiens	108-114
20443003-1	2011	PURPOSE: To understand the mechanisms behind platinum drug/DENSPM-induced inhibition of cancer cell growth, we compared the effects of oxaliplatin and cisplatin when combined with DENSPM on the induction of SSAT mRNA, activity, polyamines and cell growth in A2780 human ovarian carcinoma cells and their oxaliplatin- and cisplatin-resistant variants A2780/C10B and A2780/CP, respectively.	Oxaliplatin	135-146	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	207-211
21169384-7	2011	We used cDNA transfection to overexpress two genes (LTBR and TMEM30A) that were identified in the siRNA screen as mediators of oxaliplatin sensitivity.	Oxaliplatin	127-138	lymphotoxin beta receptor	Homo sapiens	52-56
21169384-7	2011	We used cDNA transfection to overexpress two genes (LTBR and TMEM30A) that were identified in the siRNA screen as mediators of oxaliplatin sensitivity.	Oxaliplatin	127-138	transmembrane protein 30A	Homo sapiens	61-68
21383056-1	2011	By triggering immunogenic cell death, some anticancer compounds, including anthracyclines and oxaliplatin, elicit tumor-specific, interferon-gamma-producing CD8(+) alphabeta T lymphocytes (Tc1 CTLs) that are pivotal for an optimal therapeutic outcome.	Oxaliplatin	94-105	interferon gamma	Mus musculus	130-146
21609932-0	2011	Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.	Oxaliplatin	97-108	SMAD family member 4	Homo sapiens	28-33
21609932-2	2011	We investigated the prognostic value of reduced SMAD4 expression in patients with metastatic (mCRC) under first-line oxaliplatin-containing combination chemotherapy.	Oxaliplatin	117-128	SMAD family member 4	Homo sapiens	48-53
21609932-9	2011	CONCLUSION: Our data demonstrate the importance of reduced SMAD4 expression in patients with mCRC receiving chemotherapy with oxaliplatin and 5-FU.	Oxaliplatin	126-137	SMAD family member 4	Homo sapiens	59-64
21468552-7	2011	A similar reaction has also been observed in patients with the XRCC1 Arg399Gln polymorphism, while patients with the GSTP1 Ile105Val polymorphism have an improved response to oxaliplatin/5FU therapy.	Oxaliplatin	175-186	X-ray repair cross complementing 1	Homo sapiens	63-68
21468552-7	2011	A similar reaction has also been observed in patients with the XRCC1 Arg399Gln polymorphism, while patients with the GSTP1 Ile105Val polymorphism have an improved response to oxaliplatin/5FU therapy.	Oxaliplatin	175-186	glutathione S-transferase pi 1	Homo sapiens	117-122
21104302-0	2011	Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice.	Oxaliplatin	128-139	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	8-36
21104302-1	2011	PURPOSE: The goal of this study was to test the hypothesis that by controlling intracellular uptake, organic cation transporter 1, Oct1 is a key determinant of the disposition and toxicity of cis-diammine(pyridine)chloroplatinum(II)(CDPCP) and oxaliplatin.	Oxaliplatin	244-255	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	101-129
21104302-1	2011	PURPOSE: The goal of this study was to test the hypothesis that by controlling intracellular uptake, organic cation transporter 1, Oct1 is a key determinant of the disposition and toxicity of cis-diammine(pyridine)chloroplatinum(II)(CDPCP) and oxaliplatin.	Oxaliplatin	244-255	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	131-135
21104302-7	2011	In contrast, the effect of Oct1 on the pharmacokinetics and toxicity of oxaliplatin in the mice was minimal.	Oxaliplatin	72-83	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	27-31
20878461-8	2011	The BRCA1 ubiquitin ligase activity was inhibited by transplatin &gt; cisplatin &gt; oxaliplatin &gt; carboplatin in that order.	Oxaliplatin	85-96	BRCA1 DNA repair associated	Homo sapiens	4-9
21087353-0	2011	Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines.	Oxaliplatin	45-56	nuclear factor I B	Homo sapiens	23-41
21087353-4	2011	Oxaliplatin-resistant DLD1 OX1 and DLD1 OX2 cell lines were approximately 16.3-fold and 17.8-fold more resistant to oxaliplatin than the parent cell lines, respectively, and had 1.7- and 2.2-fold higher cross-resistance to cisplatin, respectively.	Oxaliplatin	0-11	NAD(P)H dehydrogenase, quinone 1	Mus musculus	27-30
21087353-4	2011	Oxaliplatin-resistant DLD1 OX1 and DLD1 OX2 cell lines were approximately 16.3-fold and 17.8-fold more resistant to oxaliplatin than the parent cell lines, respectively, and had 1.7- and 2.2-fold higher cross-resistance to cisplatin, respectively.	Oxaliplatin	0-11	CD200 antigen	Mus musculus	40-43
21087353-4	2011	Oxaliplatin-resistant DLD1 OX1 and DLD1 OX2 cell lines were approximately 16.3-fold and 17.8-fold more resistant to oxaliplatin than the parent cell lines, respectively, and had 1.7- and 2.2-fold higher cross-resistance to cisplatin, respectively.	Oxaliplatin	116-127	NAD(P)H dehydrogenase, quinone 1	Mus musculus	27-30
21087353-5	2011	Oxaliplatin-resistant T24 OX2 and T24 OX3 cell lines were approximately 5.0-fold more resistant to oxaliplatin than the parent cell line and had 1.9-fold higher cross-resistance to cisplatin.	Oxaliplatin	0-11	CD200 antigen	Mus musculus	26-29
21087353-5	2011	Oxaliplatin-resistant T24 OX2 and T24 OX3 cell lines were approximately 5.0-fold more resistant to oxaliplatin than the parent cell line and had 1.9-fold higher cross-resistance to cisplatin.	Oxaliplatin	99-110	CD200 antigen	Mus musculus	26-29
21087353-8	2011	Of these, nuclear factor I/B (NFIB) was upregulated in all oxaliplatin-resistant cells.	Oxaliplatin	59-70	nuclear factor I B	Homo sapiens	10-28
21087353-8	2011	Of these, nuclear factor I/B (NFIB) was upregulated in all oxaliplatin-resistant cells.	Oxaliplatin	59-70	nuclear factor I B	Homo sapiens	30-34
21087353-9	2011	Downregulation of NFIB rendered cells sensitive to oxaliplatin, but not to cisplatin.	Oxaliplatin	51-62	nuclear factor I B	Homo sapiens	18-22
21087353-10	2011	Forced expression of NFIB induced resistance to oxaliplatin, but not to cisplatin.	Oxaliplatin	48-59	nuclear factor I B	Homo sapiens	21-25
21087353-11	2011	Taken together, these results suggest that NFIB is a novel and specific biomarker for oxaliplatin resistance in human cancers.	Oxaliplatin	86-97	nuclear factor I B	Homo sapiens	43-47
21194879-5	2011	The chemosensitivity of cell lines with various expression levels of PTEN was evaluated using 5-flurouracil (5-FU), oxaliplatin and irinotecan (CPT), and clinical significance was evaluated by immunohistochemical analysis of 133 CRC specimens.	Oxaliplatin	116-127	phosphatase and tensin homolog	Homo sapiens	69-73
21194879-7	2011	HT-29 and LoVo PTEN expression was suppressed by a low concentration of 5-FU and oxaliplatin; however, SW480 was insensitive to these chemotherapeutic agents.	Oxaliplatin	81-92	phosphatase and tensin homolog	Homo sapiens	15-19
21194879-10	2011	CONCLUSION: Cell lines with a high expression of PTEN are sensitive to chemotherapy with 5-FU and oxaliplatin.	Oxaliplatin	98-109	phosphatase and tensin homolog	Homo sapiens	49-53
21245990-8	2011	In MKN45 and AGS cells, oxaliplatin treatment promoted both protein kinase B (Akt) and NFkappaB activation, while pretreatment with LY294002 significantly attenuated oxaliplatin-induced Akt activity and NFkappaB binding.	Oxaliplatin	24-35	protein tyrosine kinase 2 beta	Homo sapiens	60-76
21418871-9	2011	CONCLUSION: Gastric cancer patients with ERCC1-118 C/C genotype and XRCC1-399A/G or A/A genotype may benefit from an oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	117-128	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	41-46
21418871-9	2011	CONCLUSION: Gastric cancer patients with ERCC1-118 C/C genotype and XRCC1-399A/G or A/A genotype may benefit from an oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	117-128	X-ray repair cross complementing 1	Homo sapiens	68-73
21247499-0	2011	Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats.	Oxaliplatin	56-67	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	22-26
21247499-4	2011	In the present study, we investigated the involvement of NR2B-containing N-methyl-D-aspartate (NMDA) receptors in oxaliplatin-induced mechanical allodynia in rats.	Oxaliplatin	114-125	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	57-61
21247499-9	2011	In addition, the expression of NR2B protein and mRNA in the rat spinal cord was increased by oxaliplatin on Day 25 (late phase) but not on Day 5 (early phase).	Oxaliplatin	93-104	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	31-35
21247499-11	2011	L-NAME, a non-selective NOS inhibitor, and 7-nitroindazole, a neuronal NOS (nNOS) inhibitor, significantly suppressed the oxaliplatin-induced pain behavior.	Oxaliplatin	122-133	nitric oxide synthase 1	Rattus norvegicus	62-74
21247499-11	2011	L-NAME, a non-selective NOS inhibitor, and 7-nitroindazole, a neuronal NOS (nNOS) inhibitor, significantly suppressed the oxaliplatin-induced pain behavior.	Oxaliplatin	122-133	nitric oxide synthase 1	Rattus norvegicus	76-80
21247499-13	2011	CONCLUSION: These results indicated that spinal NR2B-containing NMDA receptors are involved in the oxaliplatin-induced mechanical allodynia.	Oxaliplatin	99-110	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	48-52
21245990-8	2011	In MKN45 and AGS cells, oxaliplatin treatment promoted both protein kinase B (Akt) and NFkappaB activation, while pretreatment with LY294002 significantly attenuated oxaliplatin-induced Akt activity and NFkappaB binding.	Oxaliplatin	24-35	nuclear factor kappa B subunit 1	Homo sapiens	87-95
21245990-8	2011	In MKN45 and AGS cells, oxaliplatin treatment promoted both protein kinase B (Akt) and NFkappaB activation, while pretreatment with LY294002 significantly attenuated oxaliplatin-induced Akt activity and NFkappaB binding.	Oxaliplatin	24-35	nuclear factor kappa B subunit 1	Homo sapiens	203-211
21245990-8	2011	In MKN45 and AGS cells, oxaliplatin treatment promoted both protein kinase B (Akt) and NFkappaB activation, while pretreatment with LY294002 significantly attenuated oxaliplatin-induced Akt activity and NFkappaB binding.	Oxaliplatin	166-177	AKT serine/threonine kinase 1	Homo sapiens	186-189
21245990-8	2011	In MKN45 and AGS cells, oxaliplatin treatment promoted both protein kinase B (Akt) and NFkappaB activation, while pretreatment with LY294002 significantly attenuated oxaliplatin-induced Akt activity and NFkappaB binding.	Oxaliplatin	166-177	nuclear factor kappa B subunit 1	Homo sapiens	203-211
21245990-8	2011	In MKN45 and AGS cells, oxaliplatin treatment promoted both protein kinase B (Akt) and NFkappaB activation, while pretreatment with LY294002 significantly attenuated oxaliplatin-induced Akt activity and NFkappaB binding.	Oxaliplatin	24-35	AKT serine/threonine kinase 1	Homo sapiens	78-81
21245990-9	2011	LY294002 promoted oxaliplatin-induced Fas ligand (FasL) expression, Fas-associated death domain protein recruitment, caspase-8, Bid, and caspase-3 activation, and the short form of cellular caspase-8/FLICE-inhibitory protein (c-FLIP(S)) inhibition.	Oxaliplatin	18-29	Fas ligand	Homo sapiens	38-48
21245990-9	2011	LY294002 promoted oxaliplatin-induced Fas ligand (FasL) expression, Fas-associated death domain protein recruitment, caspase-8, Bid, and caspase-3 activation, and the short form of cellular caspase-8/FLICE-inhibitory protein (c-FLIP(S)) inhibition.	Oxaliplatin	18-29	Fas ligand	Homo sapiens	50-54
20980256-4	2011	Here we show that the genotoxic stress induced by oxaliplatin elicits an ATM-, CHK2-, and p53-dependent splicing switch that favors the production of the proapoptotic Bcl-x(S) variant.	Oxaliplatin	50-61	ATM serine/threonine kinase	Homo sapiens	73-76
21245990-9	2011	LY294002 promoted oxaliplatin-induced Fas ligand (FasL) expression, Fas-associated death domain protein recruitment, caspase-8, Bid, and caspase-3 activation, and the short form of cellular caspase-8/FLICE-inhibitory protein (c-FLIP(S)) inhibition.	Oxaliplatin	18-29	caspase 8	Homo sapiens	117-126
21245990-9	2011	LY294002 promoted oxaliplatin-induced Fas ligand (FasL) expression, Fas-associated death domain protein recruitment, caspase-8, Bid, and caspase-3 activation, and the short form of cellular caspase-8/FLICE-inhibitory protein (c-FLIP(S)) inhibition.	Oxaliplatin	18-29	caspase 3	Homo sapiens	137-146
21245990-9	2011	LY294002 promoted oxaliplatin-induced Fas ligand (FasL) expression, Fas-associated death domain protein recruitment, caspase-8, Bid, and caspase-3 activation, and the short form of cellular caspase-8/FLICE-inhibitory protein (c-FLIP(S)) inhibition.	Oxaliplatin	18-29	caspase 8	Homo sapiens	190-199
21245990-9	2011	LY294002 promoted oxaliplatin-induced Fas ligand (FasL) expression, Fas-associated death domain protein recruitment, caspase-8, Bid, and caspase-3 activation, and the short form of cellular caspase-8/FLICE-inhibitory protein (c-FLIP(S)) inhibition.	Oxaliplatin	18-29	CASP8 and FADD like apoptosis regulator	Homo sapiens	226-232
21245990-10	2011	In vivo, LY294002 inhibited oxaliplatin-induced activation of Akt and NFkappaB, and increased oxaliplatin-induced expression of FasL, inhibition of c-FLIP(S), and activation of caspase-8, Bid, and caspase-3.	Oxaliplatin	28-39	AKT serine/threonine kinase 1	Homo sapiens	62-65
21245990-10	2011	In vivo, LY294002 inhibited oxaliplatin-induced activation of Akt and NFkappaB, and increased oxaliplatin-induced expression of FasL, inhibition of c-FLIP(S), and activation of caspase-8, Bid, and caspase-3.	Oxaliplatin	28-39	nuclear factor kappa B subunit 1	Homo sapiens	70-78
21245990-10	2011	In vivo, LY294002 inhibited oxaliplatin-induced activation of Akt and NFkappaB, and increased oxaliplatin-induced expression of FasL, inhibition of c-FLIP(S), and activation of caspase-8, Bid, and caspase-3.	Oxaliplatin	94-105	Fas ligand	Homo sapiens	128-132
21245990-10	2011	In vivo, LY294002 inhibited oxaliplatin-induced activation of Akt and NFkappaB, and increased oxaliplatin-induced expression of FasL, inhibition of c-FLIP(S), and activation of caspase-8, Bid, and caspase-3.	Oxaliplatin	94-105	caspase 8	Homo sapiens	177-186
21245990-10	2011	In vivo, LY294002 inhibited oxaliplatin-induced activation of Akt and NFkappaB, and increased oxaliplatin-induced expression of FasL, inhibition of c-FLIP(S), and activation of caspase-8, Bid, and caspase-3.	Oxaliplatin	94-105	BH3 interacting domain death agonist	Homo sapiens	188-191
21245990-10	2011	In vivo, LY294002 inhibited oxaliplatin-induced activation of Akt and NFkappaB, and increased oxaliplatin-induced expression of FasL, inhibition of c-FLIP(S), and activation of caspase-8, Bid, and caspase-3.	Oxaliplatin	94-105	caspase 3	Homo sapiens	197-206
20980256-4	2011	Here we show that the genotoxic stress induced by oxaliplatin elicits an ATM-, CHK2-, and p53-dependent splicing switch that favors the production of the proapoptotic Bcl-x(S) variant.	Oxaliplatin	50-61	checkpoint kinase 2	Homo sapiens	79-83
20980256-4	2011	Here we show that the genotoxic stress induced by oxaliplatin elicits an ATM-, CHK2-, and p53-dependent splicing switch that favors the production of the proapoptotic Bcl-x(S) variant.	Oxaliplatin	50-61	tumor protein p53	Homo sapiens	90-93
20980256-4	2011	Here we show that the genotoxic stress induced by oxaliplatin elicits an ATM-, CHK2-, and p53-dependent splicing switch that favors the production of the proapoptotic Bcl-x(S) variant.	Oxaliplatin	50-61	BCL2 like 1	Homo sapiens	167-172
20980256-6	2011	Interestingly, the ATM/CHK2/p53/tyrosine phosphatases pathway activated by oxaliplatin regulates Bcl-x splicing through the same regulatory sequence element (SB1) that receives signals from the PKC pathway.	Oxaliplatin	75-86	ATM serine/threonine kinase	Homo sapiens	19-22
20980256-6	2011	Interestingly, the ATM/CHK2/p53/tyrosine phosphatases pathway activated by oxaliplatin regulates Bcl-x splicing through the same regulatory sequence element (SB1) that receives signals from the PKC pathway.	Oxaliplatin	75-86	checkpoint kinase 2	Homo sapiens	23-27
20980256-6	2011	Interestingly, the ATM/CHK2/p53/tyrosine phosphatases pathway activated by oxaliplatin regulates Bcl-x splicing through the same regulatory sequence element (SB1) that receives signals from the PKC pathway.	Oxaliplatin	75-86	tumor protein p53	Homo sapiens	28-31
20980803-0	2011	Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death.	Oxaliplatin	81-92	matrix metallopeptidase 7	Homo sapiens	27-31
20980256-6	2011	Interestingly, the ATM/CHK2/p53/tyrosine phosphatases pathway activated by oxaliplatin regulates Bcl-x splicing through the same regulatory sequence element (SB1) that receives signals from the PKC pathway.	Oxaliplatin	75-86	BCL2 like 1	Homo sapiens	97-102
20980256-6	2011	Interestingly, the ATM/CHK2/p53/tyrosine phosphatases pathway activated by oxaliplatin regulates Bcl-x splicing through the same regulatory sequence element (SB1) that receives signals from the PKC pathway.	Oxaliplatin	75-86	SH3KBP1 binding protein 1	Homo sapiens	158-161
22238500-0	2011	Combination treatment with oxaliplatin and mangiferin causes increased apoptosis and downregulation of NFkappaB in cancer cell lines.	Oxaliplatin	27-38	nuclear factor kappa B subunit 1	Homo sapiens	103-111
20980803-7	2011	Accordingly, viability of oxaliplatin-treated RHT29 cells under beta-catenin silencing was decreased.	Oxaliplatin	26-37	catenin beta 1	Homo sapiens	64-76
20980803-1	2011	BACKGROUND: We have previously shown that metalloproteinase 7 (MMP7) expression is increased during the acquisition of resistance to oxaliplatin in colon cancer cells.	Oxaliplatin	133-144	matrix metallopeptidase 7	Homo sapiens	63-67
20980803-8	2011	On the other hand, EGFR siRNA induced contradictory effects, decreasing PEA3 and MMP7 expression in control and oxaliplatin-treated RHCT116 p53-/- cells but increasing basal- and oxaliplatin-induced PEA3 and MMP7 in the HT29 and RHT29 cells.	Oxaliplatin	112-123	epidermal growth factor receptor	Homo sapiens	19-23
20980803-8	2011	On the other hand, EGFR siRNA induced contradictory effects, decreasing PEA3 and MMP7 expression in control and oxaliplatin-treated RHCT116 p53-/- cells but increasing basal- and oxaliplatin-induced PEA3 and MMP7 in the HT29 and RHT29 cells.	Oxaliplatin	112-123	matrix metallopeptidase 7	Homo sapiens	81-85
20980803-2	2011	Now we have analyzed the implication of beta-catenin and EGFR pathways in the up-regulation of MMP7 in the oxaliplatin-resistant human colon cancer cell lines RHT29 and RHCT116 p53-/-, derived from the HT29 and HCT116 p53-/- cells, respectively.	Oxaliplatin	107-118	catenin beta 1	Homo sapiens	40-52
20980803-8	2011	On the other hand, EGFR siRNA induced contradictory effects, decreasing PEA3 and MMP7 expression in control and oxaliplatin-treated RHCT116 p53-/- cells but increasing basal- and oxaliplatin-induced PEA3 and MMP7 in the HT29 and RHT29 cells.	Oxaliplatin	112-123	tumor protein p53	Homo sapiens	140-143
20980803-8	2011	On the other hand, EGFR siRNA induced contradictory effects, decreasing PEA3 and MMP7 expression in control and oxaliplatin-treated RHCT116 p53-/- cells but increasing basal- and oxaliplatin-induced PEA3 and MMP7 in the HT29 and RHT29 cells.	Oxaliplatin	179-190	epidermal growth factor receptor	Homo sapiens	19-23
20980803-2	2011	Now we have analyzed the implication of beta-catenin and EGFR pathways in the up-regulation of MMP7 in the oxaliplatin-resistant human colon cancer cell lines RHT29 and RHCT116 p53-/-, derived from the HT29 and HCT116 p53-/- cells, respectively.	Oxaliplatin	107-118	epidermal growth factor receptor	Homo sapiens	57-61
20980803-8	2011	On the other hand, EGFR siRNA induced contradictory effects, decreasing PEA3 and MMP7 expression in control and oxaliplatin-treated RHCT116 p53-/- cells but increasing basal- and oxaliplatin-induced PEA3 and MMP7 in the HT29 and RHT29 cells.	Oxaliplatin	179-190	ETS variant transcription factor 4	Homo sapiens	199-203
20980803-2	2011	Now we have analyzed the implication of beta-catenin and EGFR pathways in the up-regulation of MMP7 in the oxaliplatin-resistant human colon cancer cell lines RHT29 and RHCT116 p53-/-, derived from the HT29 and HCT116 p53-/- cells, respectively.	Oxaliplatin	107-118	matrix metallopeptidase 7	Homo sapiens	95-99
20980803-8	2011	On the other hand, EGFR siRNA induced contradictory effects, decreasing PEA3 and MMP7 expression in control and oxaliplatin-treated RHCT116 p53-/- cells but increasing basal- and oxaliplatin-induced PEA3 and MMP7 in the HT29 and RHT29 cells.	Oxaliplatin	179-190	matrix metallopeptidase 7	Homo sapiens	208-212
20980803-9	2011	CONCLUSIONS: Oxaliplatin-induced MMP7 up-regulation is differentially achieved in colon cancer cell lines, as a result of EGFR and beta-catenin cross-talk on MMP7 gene transcription.	Oxaliplatin	13-24	matrix metallopeptidase 7	Homo sapiens	33-37
20980803-3	2011	RESULTS: Oxaliplatin treatment increased EGFR expression and induced its activation in all the cell lines.	Oxaliplatin	9-20	epidermal growth factor receptor	Homo sapiens	41-45
20980803-9	2011	CONCLUSIONS: Oxaliplatin-induced MMP7 up-regulation is differentially achieved in colon cancer cell lines, as a result of EGFR and beta-catenin cross-talk on MMP7 gene transcription.	Oxaliplatin	13-24	epidermal growth factor receptor	Homo sapiens	122-126
20980803-4	2011	However, beta-catenin mRNA was only upregulated in the HT29 and RHT29 cells, with a marked increase in the nuclear/cytoplasmic beta-catenin protein ratio in the oxaliplatin-resistant RHT29 cells.	Oxaliplatin	161-172	catenin beta 1	Homo sapiens	9-21
20980803-9	2011	CONCLUSIONS: Oxaliplatin-induced MMP7 up-regulation is differentially achieved in colon cancer cell lines, as a result of EGFR and beta-catenin cross-talk on MMP7 gene transcription.	Oxaliplatin	13-24	catenin beta 1	Homo sapiens	131-143
20980803-9	2011	CONCLUSIONS: Oxaliplatin-induced MMP7 up-regulation is differentially achieved in colon cancer cell lines, as a result of EGFR and beta-catenin cross-talk on MMP7 gene transcription.	Oxaliplatin	13-24	matrix metallopeptidase 7	Homo sapiens	158-162
20980803-4	2011	However, beta-catenin mRNA was only upregulated in the HT29 and RHT29 cells, with a marked increase in the nuclear/cytoplasmic beta-catenin protein ratio in the oxaliplatin-resistant RHT29 cells.	Oxaliplatin	161-172	catenin beta 1	Homo sapiens	127-139
20980803-6	2011	beta-catenin abrogation only prevented the induction of MMP7 by oxaliplatin in HT29 and RHT29 cells.	Oxaliplatin	64-75	catenin beta 1	Homo sapiens	0-12
20980803-6	2011	beta-catenin abrogation only prevented the induction of MMP7 by oxaliplatin in HT29 and RHT29 cells.	Oxaliplatin	64-75	matrix metallopeptidase 7	Homo sapiens	56-60
21844655-2	2011	In this study, to elucidate the haplotype structures of the two closely related alpha-class genes GSTA1 and GSTA2, we screened for genetic variation in 214 Japanese colorectal cancer patients who received oxaliplatin-based chemotherapy.	Oxaliplatin	205-216	glutathione S-transferase alpha 1	Homo sapiens	98-103
20503071-0	2011	Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.	Oxaliplatin	93-104	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
21844655-2	2011	In this study, to elucidate the haplotype structures of the two closely related alpha-class genes GSTA1 and GSTA2, we screened for genetic variation in 214 Japanese colorectal cancer patients who received oxaliplatin-based chemotherapy.	Oxaliplatin	205-216	glutathione S-transferase alpha 2	Homo sapiens	108-113
20951698-11	2011	Administration of BMP4 to immunocompromised mice with tumors that arose from CRC-SCs increased the antitumor effects of 5-fluorouracil and oxaliplatin.	Oxaliplatin	139-150	bone morphogenetic protein 4	Mus musculus	18-22
21787681-4	2011	The objectives of this study were to evaluate association of 1-OHP concentration with genetic polymorphisms of CYP1A1 and GSTs in Thai bus drivers.	Oxaliplatin	61-66	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	111-117
21787681-4	2011	The objectives of this study were to evaluate association of 1-OHP concentration with genetic polymorphisms of CYP1A1 and GSTs in Thai bus drivers.	Oxaliplatin	61-66	hematopoietic prostaglandin D synthase	Homo sapiens	122-126
21787681-7	2011	Significantly increasing of 1-OHP levels were observed in bus drivers with CYP1A1 MspI and exon 7 variants.	Oxaliplatin	28-33	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	75-81
21787681-8	2011	Whereas, bus drivers with GSTP1 Val and GSTM1 null genotypes showed decreasing in excretion of 1-OHP.	Oxaliplatin	95-100	glutathione S-transferase pi 1	Homo sapiens	26-31
21787681-8	2011	Whereas, bus drivers with GSTP1 Val and GSTM1 null genotypes showed decreasing in excretion of 1-OHP.	Oxaliplatin	95-100	glutathione S-transferase mu 1	Homo sapiens	40-45
21787681-10	2011	This study indicated that 1-OHP concentrations were associated with exposure to air pollution, cigarette smoking and polymorphisms of CYP1A1, GSTM1 and GSTP1 genes.	Oxaliplatin	26-31	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	134-140
21787681-10	2011	This study indicated that 1-OHP concentrations were associated with exposure to air pollution, cigarette smoking and polymorphisms of CYP1A1, GSTM1 and GSTP1 genes.	Oxaliplatin	26-31	glutathione S-transferase mu 1	Homo sapiens	142-147
21787681-10	2011	This study indicated that 1-OHP concentrations were associated with exposure to air pollution, cigarette smoking and polymorphisms of CYP1A1, GSTM1 and GSTP1 genes.	Oxaliplatin	26-31	glutathione S-transferase pi 1	Homo sapiens	152-157
21196321-9	2011	Separate treatments and drug combinations significantly decreased DNA binding activity of NF-kappaB which led to the potentiation of cell death induced by the colon cancer drugs oxaliplatin and 5-FU.	Oxaliplatin	178-189	nuclear factor kappa B subunit 1	Homo sapiens	90-99
20709029-4	2010	The cellular uptake of complex 2, like that of oxaliplatin, occurred mainly via organic cation transporters (OCT-1/2; ~32%) and copper transporter related proteins (Ctr1; ~24%), whereas that of chalcone 1 was dependent on endocytosis (~80%).	Oxaliplatin	47-58	solute carrier family 22 member 1	Homo sapiens	109-116
21574897-5	2011	The results show that at both acute (60 min) and chronic (24 h) durations of incubation, cisplatin and oxaliplatin induced oxidative stress as evidenced by significant inhibition of the activities of SOD, CAT, and GPX enzymes as well as significant reduction of the concentrations of GSH and TAC.	Oxaliplatin	103-114	superoxide dismutase 1	Homo sapiens	200-203
21574897-5	2011	The results show that at both acute (60 min) and chronic (24 h) durations of incubation, cisplatin and oxaliplatin induced oxidative stress as evidenced by significant inhibition of the activities of SOD, CAT, and GPX enzymes as well as significant reduction of the concentrations of GSH and TAC.	Oxaliplatin	103-114	catalase	Homo sapiens	205-208
21619788-1	2011	OBJECTIVE: To investigate the modification of GSTM1, GSTT1 and GSTP1 gene polymorphisms on urinary 1-hydroxypyrene (1-OHP) excretions in workers under different exposure levels.	Oxaliplatin	116-121	glutathione S-transferase mu 1	Homo sapiens	46-51
21619788-1	2011	OBJECTIVE: To investigate the modification of GSTM1, GSTT1 and GSTP1 gene polymorphisms on urinary 1-hydroxypyrene (1-OHP) excretions in workers under different exposure levels.	Oxaliplatin	116-121	glutathione S-transferase pi 1	Homo sapiens	63-68
21619788-5	2011	After controlling potential confounders, decreased excretion of urinary 1-OHP was associated with GSTP1 I105V AG + GG genotype in coke oven workers (single-gene model, P = 0.012; multi-gene model, P = 0.011) and with GSTT1 null type in the analysis including all subjects (P = 0.055 in both single-gene and multi-gene models).	Oxaliplatin	72-77	glutathione S-transferase pi 1	Homo sapiens	98-103
21619788-5	2011	After controlling potential confounders, decreased excretion of urinary 1-OHP was associated with GSTP1 I105V AG + GG genotype in coke oven workers (single-gene model, P = 0.012; multi-gene model, P = 0.011) and with GSTT1 null type in the analysis including all subjects (P = 0.055 in both single-gene and multi-gene models).	Oxaliplatin	72-77	glutathione S-transferase theta 1	Homo sapiens	217-222
21619788-6	2011	GSTT1 and GSTP1 were interacted on the urinary concentrations of 1-OHP.	Oxaliplatin	65-70	glutathione S-transferase theta 1	Homo sapiens	0-5
21619788-6	2011	GSTT1 and GSTP1 were interacted on the urinary concentrations of 1-OHP.	Oxaliplatin	65-70	glutathione S-transferase pi 1	Homo sapiens	10-15
21619788-7	2011	CONCLUSION: Urinary 1-OHP concentrations can be modified by GSTM1, GSTT1 and GSTP1 gene polymorphisms, indicating that these genes are involved in the metabolism of polycyclic aromatic hydrocarbons.	Oxaliplatin	20-25	glutathione S-transferase mu 1	Homo sapiens	60-65
21619788-7	2011	CONCLUSION: Urinary 1-OHP concentrations can be modified by GSTM1, GSTT1 and GSTP1 gene polymorphisms, indicating that these genes are involved in the metabolism of polycyclic aromatic hydrocarbons.	Oxaliplatin	20-25	glutathione S-transferase theta 1	Homo sapiens	67-72
21619788-7	2011	CONCLUSION: Urinary 1-OHP concentrations can be modified by GSTM1, GSTT1 and GSTP1 gene polymorphisms, indicating that these genes are involved in the metabolism of polycyclic aromatic hydrocarbons.	Oxaliplatin	20-25	glutathione S-transferase pi 1	Homo sapiens	77-82
20708607-0	2010	Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells.	Oxaliplatin	0-11	mitogen-activated protein kinase 14	Homo sapiens	39-53
20708607-6	2010	The survivin blockage of oxaliplatin elevated caspase-3 activation and apoptosis in RKO cells.	Oxaliplatin	25-36	caspase 3	Homo sapiens	46-55
20708607-9	2010	SB202190, a specific p38 MAP kinase inhibitor, restored the survivin protein level and attenuated oxaliplatin-induced cancer cell death.	Oxaliplatin	98-109	mitogen-activated protein kinase 14	Homo sapiens	21-35
20708607-10	2010	In addition, oxaliplatin increased the levels of phospho-p53 (Ser-15) and total p53 proteins.	Oxaliplatin	13-24	tumor protein p53	Homo sapiens	57-60
20708607-10	2010	In addition, oxaliplatin increased the levels of phospho-p53 (Ser-15) and total p53 proteins.	Oxaliplatin	13-24	tumor protein p53	Homo sapiens	80-83
20708607-11	2010	Inhibition of p53 expression by a specific p53 inhibitor pifithrin-alpha reduced the phosphorylated p38 MAP kinase and active caspase-3 proteins in the oxaliplatin-exposed RKO cells.	Oxaliplatin	152-163	tumor protein p53	Homo sapiens	14-17
20708607-11	2010	Inhibition of p53 expression by a specific p53 inhibitor pifithrin-alpha reduced the phosphorylated p38 MAP kinase and active caspase-3 proteins in the oxaliplatin-exposed RKO cells.	Oxaliplatin	152-163	tumor protein p53	Homo sapiens	43-46
20708607-11	2010	Inhibition of p53 expression by a specific p53 inhibitor pifithrin-alpha reduced the phosphorylated p38 MAP kinase and active caspase-3 proteins in the oxaliplatin-exposed RKO cells.	Oxaliplatin	152-163	mitogen-activated protein kinase 14	Homo sapiens	100-114
20708607-11	2010	Inhibition of p53 expression by a specific p53 inhibitor pifithrin-alpha reduced the phosphorylated p38 MAP kinase and active caspase-3 proteins in the oxaliplatin-exposed RKO cells.	Oxaliplatin	152-163	caspase 3	Homo sapiens	126-135
20708607-14	2010	Taken together, our results demonstrate for the first time that survivin is down-regulated by p38 MAP kinase and proteasome degradation pathway after treatment with oxaliplatin in the human colon cancer cells.	Oxaliplatin	165-176	mitogen-activated protein kinase 14	Homo sapiens	94-108
22811812-3	2010	In this study, we aimed to address the impact of KRAS on the pattern of metastatic disease at presentation and on RR and PFS with first-line 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy.	Oxaliplatin	173-184	KRAS proto-oncogene, GTPase	Homo sapiens	49-53
21106058-4	2010	RESULTS: 48 hour exposure to oxaliplatin resulted in dose related reduction in neurite length, density, and number of neurons compared to vehicle treated controls, using Gap43 immunostaining.	Oxaliplatin	29-40	growth associated protein 43	Rattus norvegicus	170-175
21106058-8	2010	Similarly, second responses to icilin (TRPA1/TRPM8 agonist), were enhanced after acute (143.85 +- 7%, P = 0.004, unpaired t test, n = 3), and chronic (119.7 +- 11.8%, P &lt; 0.05, n = 3) oxaliplatin treatment, compared to control (85.3 +- 1.7%).	Oxaliplatin	187-198	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	39-44
21106058-11	2010	These effects may be mitigated by co-treatment with adenylyl cyclase inhibitors, like CB2 agonists, to alleviate the neurotoxic effects of oxaliplatin.	Oxaliplatin	139-150	cannabinoid receptor 2	Rattus norvegicus	86-89
21894049-0	2011	KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.	Oxaliplatin	152-163	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
20850503-0	2010	NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2.	Oxaliplatin	47-58	mitogen-activated protein kinase 8	Homo sapiens	73-81
20850503-2	2010	In particular, it has been evidenced that in Dorsal Root Ganglion (DRG) neurons prolonged exposure to oxaliplatin (OHP) induces early activation of p38 and ERK1/2, which mediate neuronal apoptosis, while the neuroprotective action of JNK/Sapk is downregulated by the drug treatment.	Oxaliplatin	102-113	mitogen-activated protein kinase 1	Homo sapiens	148-151
20850503-2	2010	In particular, it has been evidenced that in Dorsal Root Ganglion (DRG) neurons prolonged exposure to oxaliplatin (OHP) induces early activation of p38 and ERK1/2, which mediate neuronal apoptosis, while the neuroprotective action of JNK/Sapk is downregulated by the drug treatment.	Oxaliplatin	102-113	mitogen-activated protein kinase 3	Homo sapiens	156-162
20850503-2	2010	In particular, it has been evidenced that in Dorsal Root Ganglion (DRG) neurons prolonged exposure to oxaliplatin (OHP) induces early activation of p38 and ERK1/2, which mediate neuronal apoptosis, while the neuroprotective action of JNK/Sapk is downregulated by the drug treatment.	Oxaliplatin	102-113	mitogen-activated protein kinase 8	Homo sapiens	234-242
21110884-0	2010	DNA polymerase eta protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	138-149	DNA polymerase eta	Homo sapiens	0-18
21110884-1	2010	BACKGROUND: DNA polymerase eta (pol eta) is capable of bypassing DNA adducts produced by cisplatin or oxaliplatin and is associated with cellular tolerance to platinum.	Oxaliplatin	102-113	DNA polymerase eta	Homo sapiens	12-30
20709029-4	2010	The cellular uptake of complex 2, like that of oxaliplatin, occurred mainly via organic cation transporters (OCT-1/2; ~32%) and copper transporter related proteins (Ctr1; ~24%), whereas that of chalcone 1 was dependent on endocytosis (~80%).	Oxaliplatin	47-58	solute carrier family 31 member 1	Homo sapiens	165-169
21166887-9	2010	PX24 also displayed sensitivity to other platinum drugs, oxaliplatin and ZD0473, whereas PX2 acquired significant resistance to both of them.	Oxaliplatin	57-68	pannexin 2	Homo sapiens	0-3
21224630-1	2010	Thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) were known to be important biomarkers to predict a tumor response to 5-fluorouracil (5-FU) and oxaliplatin, but the relationship between these expressions and tumor response were still unclear.	Oxaliplatin	166-177	thymidylate synthetase	Homo sapiens	0-20
21224630-1	2010	Thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) were known to be important biomarkers to predict a tumor response to 5-fluorouracil (5-FU) and oxaliplatin, but the relationship between these expressions and tumor response were still unclear.	Oxaliplatin	166-177	thymidylate synthetase	Homo sapiens	22-24
21224630-1	2010	Thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) were known to be important biomarkers to predict a tumor response to 5-fluorouracil (5-FU) and oxaliplatin, but the relationship between these expressions and tumor response were still unclear.	Oxaliplatin	166-177	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	63-69
21151408-2	2010	This paper uses a case-based approach to summarize the consensus recommendations developed during that meeting.These are the consensus recommendations:Testing for the KRAS status of the tumour should be performed as soon as an egfr inhibitor is being considered as an option for treatment.Anti-egfr therapies are not recommended for the treatment of patients with tumours showing mutated KRAS status.For a patient with wild-type KRAS and an Eastern Cooperative Oncology Group status of 0-2, whose mcrc has previously been treated with a fluoropyrimidine, irinotecan, and oxaliplatin, switching to an egfr inhibitor is a recommended strategy.Cetuximab, cetuximab plus irinotecan, and panitumumab are all options for third-line therapy in patients with wild-type KRAS, provided that tolerability is acceptable.	Oxaliplatin	571-582	KRAS proto-oncogene, GTPase	Homo sapiens	167-171
20690802-0	2010	A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.	Oxaliplatin	20-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
20979931-0	2010	Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.	Oxaliplatin	21-32	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	88-93
20979931-0	2010	Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.	Oxaliplatin	21-32	glutathione S-transferase pi 1	Homo sapiens	98-103
20979931-2	2010	METHODS: We retrospectively studied 51 Japanese adults with colorectal cancer who had received oxaliplatin-based chemotherapy to explore the pharmacogenetic association between oxaliplatin-induced neuropathy and polymorphisms of the excision repair cross-complementation Group 1 (ERCC1) and glutathione-S-transferases pi 1 (GSTP1) genes.	Oxaliplatin	177-188	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	233-278
20690802-1	2010	We investigated the feasibility/efficacy of oxaliplatin in combination with trastuzumab as first-/second-line treatment of HER2-positive metastatic breast cancer (MBC).	Oxaliplatin	44-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
20626587-0	2010	Protective effect of melatonin on oxaliplatin-induced apoptosis through sustained Mcl-1 expression and anti-oxidant action in renal carcinoma Caki cells.	Oxaliplatin	34-45	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	82-87
20626587-7	2010	Interestingly, we also found the involvement of myeloid cell leukemia-1 (Mcl-1) downregulation in oxaliplatin-induced apoptosis; thus, pretreatment with melatonin inhibited Mcl-1 downregulation, and ectopic expression of Mcl-1 attenuated oxaliplatin-induced apoptosis.	Oxaliplatin	238-249	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	173-178
20626587-7	2010	Interestingly, we also found the involvement of myeloid cell leukemia-1 (Mcl-1) downregulation in oxaliplatin-induced apoptosis; thus, pretreatment with melatonin inhibited Mcl-1 downregulation, and ectopic expression of Mcl-1 attenuated oxaliplatin-induced apoptosis.	Oxaliplatin	238-249	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	173-178
20626587-8	2010	Taken together, the results demonstrate that melatonin attenuates oxaliplatin-induced apoptosis in cancer cells by inhibition of GSH depletion and Mcl-1 downregulation.	Oxaliplatin	66-77	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	147-152
20626587-7	2010	Interestingly, we also found the involvement of myeloid cell leukemia-1 (Mcl-1) downregulation in oxaliplatin-induced apoptosis; thus, pretreatment with melatonin inhibited Mcl-1 downregulation, and ectopic expression of Mcl-1 attenuated oxaliplatin-induced apoptosis.	Oxaliplatin	98-109	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	48-71
20626587-7	2010	Interestingly, we also found the involvement of myeloid cell leukemia-1 (Mcl-1) downregulation in oxaliplatin-induced apoptosis; thus, pretreatment with melatonin inhibited Mcl-1 downregulation, and ectopic expression of Mcl-1 attenuated oxaliplatin-induced apoptosis.	Oxaliplatin	98-109	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	73-78
20626587-7	2010	Interestingly, we also found the involvement of myeloid cell leukemia-1 (Mcl-1) downregulation in oxaliplatin-induced apoptosis; thus, pretreatment with melatonin inhibited Mcl-1 downregulation, and ectopic expression of Mcl-1 attenuated oxaliplatin-induced apoptosis.	Oxaliplatin	98-109	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	173-178
20626587-7	2010	Interestingly, we also found the involvement of myeloid cell leukemia-1 (Mcl-1) downregulation in oxaliplatin-induced apoptosis; thus, pretreatment with melatonin inhibited Mcl-1 downregulation, and ectopic expression of Mcl-1 attenuated oxaliplatin-induced apoptosis.	Oxaliplatin	98-109	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	173-178
20819205-8	2010	The caspase studies revealed significantly less expression and activity of caspase 3 in HT29 cells pre-treated with doxycycline compared to the cells treated with cisplatin and oxaliplatin alone.	Oxaliplatin	177-188	caspase 3	Homo sapiens	75-84
20622903-6	2010	In this setting, reducible HMGB1 binds to the receptor for advanced glycation end products (RAGEs), but not to Toll-like receptor 4, induces Beclin1-dependent autophagy and promotes tumor resistance to alkylators (melphalan), tubulin disrupting agents (paclitaxel), DNA crosslinkers (ultraviolet light) and DNA intercalators (oxaliplatin or adriamycin).	Oxaliplatin	326-337	high mobility group box 1	Homo sapiens	27-32
21364678-3	2010	The downregulation of Orai1, and consequently SOCE, protects the cells from diverse apoptosis-inducing pathways, such as those induced by thapsigargin (Tg), tumor necrosis factor alpha, and cisplatin/oxaliplatin.	Oxaliplatin	200-211	ORAI calcium release-activated calcium modulator 1	Homo sapiens	22-27
20836889-6	2010	Oxaliplatin treatment did not alter the size profile of strongly ATP7A-immunoreactive neurons but significantly reduced the size profile of strongly CTR1-immunoreactive neurons.	Oxaliplatin	0-11	solute carrier family 31 member 1	Rattus norvegicus	149-153
20836889-9	2010	The neuron subtype-specific and largely non-overlapping distribution of ATP7A and CTR1 within rat DRG tissue may be required to support the potentially differing cuproenzyme requirements of distinct subsets of sensory neurons, and could influence the transport and neurotoxicity of oxaliplatin.	Oxaliplatin	282-293	ATPase copper transporting alpha	Rattus norvegicus	72-77
20836889-9	2010	The neuron subtype-specific and largely non-overlapping distribution of ATP7A and CTR1 within rat DRG tissue may be required to support the potentially differing cuproenzyme requirements of distinct subsets of sensory neurons, and could influence the transport and neurotoxicity of oxaliplatin.	Oxaliplatin	282-293	solute carrier family 31 member 1	Rattus norvegicus	82-86
20564148-9	2010	The maximum tolerated dose (MTD) of HAI oxaliplatin was 140 mg/m(2).	Oxaliplatin	40-51	metallothionein 1E	Homo sapiens	28-31
20091185-0	2010	MGMT -535G&gt;T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.	Oxaliplatin	118-129	O-6-methylguanine-DNA methyltransferase	Homo sapiens	0-4
19960344-0	2010	The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.	Oxaliplatin	90-101	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	19-24
19960344-0	2010	The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.	Oxaliplatin	90-101	X-ray repair cross complementing 1	Homo sapiens	29-34
20020129-1	2010	PURPOSE: Oxaliplatin effect in the treatment of colorectal cancer is improved upon combination with thymidylate synthase (TS) inhibitors.	Oxaliplatin	9-20	thymidylate synthetase	Homo sapiens	100-120
20020129-1	2010	PURPOSE: Oxaliplatin effect in the treatment of colorectal cancer is improved upon combination with thymidylate synthase (TS) inhibitors.	Oxaliplatin	9-20	thymidylate synthetase	Homo sapiens	122-124
20799994-3	2010	METHODS: After producing oxaliplatin-resistant gastric cancer cells, cell morphology, growth and doubling time were observed, followed by detection of cell cycle distribution and apoptosis, drug sensitivity (e.g., L-OHP) and expression of P-gp and livin.	Oxaliplatin	25-36	phosphoglycolate phosphatase	Homo sapiens	239-243
20799994-3	2010	METHODS: After producing oxaliplatin-resistant gastric cancer cells, cell morphology, growth and doubling time were observed, followed by detection of cell cycle distribution and apoptosis, drug sensitivity (e.g., L-OHP) and expression of P-gp and livin.	Oxaliplatin	25-36	baculoviral IAP repeat containing 7	Homo sapiens	248-253
20799994-5	2010	RESULTS: Compared with parental gastric cancer cells, oxaliplatin-resistant gastric cancer cells in S phase were reduced and cell apoptosis rate was increased (P &lt; 0.05), the inhibition rate of 10 chemotherapeutics on oxaliplatin-resistant gastric cancer cells was significantly lower and the expression of P-gp was significantly higher (P &lt; 0.05).	Oxaliplatin	54-65	phosphoglycolate phosphatase	Homo sapiens	310-314
20799994-10	2010	CONCLUSIONS: The mechanism of oxaliplatin-resistant cell secondary multidrug resistance was correlated with the variation of cell cycle distribution, extension of doubling time and upregulation of P-gp expression.	Oxaliplatin	30-41	phosphoglycolate phosphatase	Homo sapiens	197-201
20221600-2	2010	CRT exposure has been found to be induced by anthracyclins and oxaliplatin, but not by other proapoptotic antineoplastic agents including etoposide, camptothecin and cisplatin.	Oxaliplatin	63-74	calreticulin	Homo sapiens	0-3
20631077-7	2010	Platinum incorporation into tumor DNA and the antitumor efficacy of transferrin-conjugated liposome-delivered oxaliplatin could be enhanced by drug administration at times when TfR1 expression increased.	Oxaliplatin	110-121	transferrin	Mus musculus	68-79
20631077-7	2010	Platinum incorporation into tumor DNA and the antitumor efficacy of transferrin-conjugated liposome-delivered oxaliplatin could be enhanced by drug administration at times when TfR1 expression increased.	Oxaliplatin	110-121	transferrin receptor	Mus musculus	177-181
20091185-6	2010	In a logistic regression analysis adjusted to age, sex, primary site, disease status, and regimen, the POLR2C rs4937 and MSH2 rs3732183 polymorphisms were statistically associated with the response to the oxaliplatin-based chemotherapy.	Oxaliplatin	205-216	RNA polymerase II subunit C	Homo sapiens	103-109
20091185-6	2010	In a logistic regression analysis adjusted to age, sex, primary site, disease status, and regimen, the POLR2C rs4937 and MSH2 rs3732183 polymorphisms were statistically associated with the response to the oxaliplatin-based chemotherapy.	Oxaliplatin	205-216	mutS homolog 2	Homo sapiens	121-125
20091185-8	2010	CONCLUSION: The MGMT -535G&gt;T polymorphism (rs1625649) was found to be correlated with PFS in patients with advanced colorectal cancer treated with oxaliplatin-based chemotherapy.	Oxaliplatin	150-161	O-6-methylguanine-DNA methyltransferase	Homo sapiens	16-20
20551056-6	2010	Saracatinib resembles the pharmacophore of known organic cation transporter (OCT) inhibitors and reduced oxaliplatin efficacy maximally in cells overexpressing OCT2.	Oxaliplatin	105-116	solute carrier family 22 member 2	Homo sapiens	160-164
20597995-8	2010	These results support the idea that isolating survivin and MRP5+ CTCs may help in the selection of metastatic colorectal cancer patients resistant to standard 5-FU and L-OHP based chemotherapy, for which alternative regimens may be appropriate.	Oxaliplatin	168-173	ATP binding cassette subfamily C member 5	Homo sapiens	59-63
20638740-6	2010	Oxaliplatin treatment significantly decreased expression of survivin in cancer cells within 24-72 h. Apoptotic cells and caspase-3 activity were increased parallely with decrease in cell viability, if irradiated during this sensitive period.	Oxaliplatin	0-11	caspase 3	Homo sapiens	121-130
20550106-9	2010	PARP-1 also binds to DNA damaged by other platinum compounds, including oxaliplatin and pyriplatin, indicating protein affinity for the damage in an adduct-specific manner rather than recognition of distorted DNA.	Oxaliplatin	72-83	poly(ADP-ribose) polymerase 1	Homo sapiens	0-6
20551056-7	2010	These data suggest that oxaliplatin uptake in CRC is attenuated by saracatinib via inhibition of OCT2, a potential consideration for the clinical development of this SFK inhibitor.	Oxaliplatin	24-35	solute carrier family 22 member 2	Homo sapiens	97-101
20682979-0	2010	Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.	Oxaliplatin	0-11	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	34-39
20682979-4	2010	Four sensitive and resistant cell lines were analyzed for oxaliplatin effect on ERCC1 expression and two resistant cell lines were subjected to siRNA-mediated gene silencing.	Oxaliplatin	58-69	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	80-85
20527722-5	2010	PLGA-oxaliplatin microspheres significantly restrained tumor growth and this effect correlated with decreased expression of proliferating cell nuclear antigen and increased expression of terminal deoxynucleotidyltransferase dUTP nick end labeling in tumor cells.	Oxaliplatin	5-16	deoxynucleotidyltransferase, terminal	Mus musculus	187-223
20682979-6	2010	ERCC1 mRNA was induced at 24, 48, and 72 hours (71-264%, p&lt;0.05) and ERCC1 protein at 48 hours (123-521%, p&lt;0.05) post-oxaliplatin treatment in resistant cells only.	Oxaliplatin	125-136	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
20682979-6	2010	ERCC1 mRNA was induced at 24, 48, and 72 hours (71-264%, p&lt;0.05) and ERCC1 protein at 48 hours (123-521%, p&lt;0.05) post-oxaliplatin treatment in resistant cells only.	Oxaliplatin	125-136	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	72-77
20682979-7	2010	siRNA-mediated silencing of ERCC1 sensitized the CRC cells to oxaliplatin-induced apoptosis, and increased cleaved PARP.	Oxaliplatin	62-73	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	28-33
20682979-8	2010	CONCLUSION: ERCC1 gene expression is inducible, contributes to oxaliplatin resistance, and is reversible by targeted suppression of ERCC1, identifying ERCC1 as a potential target for drug development.	Oxaliplatin	63-74	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	12-17
20591218-10	2010	The expression of MRP2 in the oxaliplatin-resistant cells was up-regulated, while those of P-gp and MRP1 had no significant change.	Oxaliplatin	30-41	ATP binding cassette subfamily C member 2	Homo sapiens	18-22
20192979-1	2010	AIM: To assess the significance of the ITGB3 polymorphism at residue 33 (ITGB3 L33P) in the development of chronic oxaliplatin-induced peripheral neuropathy (OXLIPN).	Oxaliplatin	115-126	integrin subunit beta 3	Homo sapiens	39-44
20192979-1	2010	AIM: To assess the significance of the ITGB3 polymorphism at residue 33 (ITGB3 L33P) in the development of chronic oxaliplatin-induced peripheral neuropathy (OXLIPN).	Oxaliplatin	115-126	integrin subunit beta 3	Homo sapiens	73-78
20573240-2	2010	During the acquisition of chemoresistance to oxaliplatin there is a progressive loss of CD95 expression in colon cancer cells and a decreased ability of this receptor to induce cell death.	Oxaliplatin	45-56	Fas cell surface death receptor	Homo sapiens	88-92
21029695-0	2010	[Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].	Oxaliplatin	128-139	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	46-51
21029695-0	2010	[Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].	Oxaliplatin	128-139	glutathione S-transferase pi 1	Homo sapiens	60-65
21029695-10	2010	CONCLUSION: Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with TTP and OS of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based combination chemotherapy as the first-line chemotherapy.	Oxaliplatin	152-163	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	37-42
21029695-10	2010	CONCLUSION: Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with TTP and OS of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based combination chemotherapy as the first-line chemotherapy.	Oxaliplatin	152-163	X-ray repair cross complementing 1	Homo sapiens	48-53
21029695-10	2010	CONCLUSION: Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with TTP and OS of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based combination chemotherapy as the first-line chemotherapy.	Oxaliplatin	152-163	glutathione S-transferase pi 1	Homo sapiens	62-67
20557839-0	2010	Contribution of glutathione and MRP-mediated efflux to intracellular oxaliplatin accumulation.	Oxaliplatin	69-80	ATP binding cassette subfamily C member 1	Homo sapiens	32-35
21054985-0	2010	[Impact of S100P expression on clinical outcomes of gastric cancer patients with adjuvant chemotherapy of oxaliplatin and its mechanisms].	Oxaliplatin	106-117	S100 calcium binding protein P	Homo sapiens	11-16
21054985-6	2010	The chemosensitivity of BGC823-S100P cell line to oxaliplatin was detected by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay.	Oxaliplatin	50-61	S100 calcium binding protein P	Homo sapiens	31-36
21054985-11	2010	It indicated with MTT assay that the half-inhibitory concentration (IC(50)) to oxaliplatin decreased in BGC823-S100P cells, and was significantly lower than that in vector-only transfected cells [(142 +- 16) mg/L vs. (266 +- 11) mg/L, P = 0.032].	Oxaliplatin	79-90	S100 calcium binding protein P	Homo sapiens	111-116
20573240-3	2010	The aim of this study was to characterize some key cellular responses controlled by CD95 signaling in oxaliplatin-resistant colon cancer cells.	Oxaliplatin	102-113	Fas cell surface death receptor	Homo sapiens	84-88
20573240-5	2010	Moreover, oxaliplatin treatment itself stimulates cell migration and decreases cell adhesion through CD95 activation, since CD95 expression inhibition by siRNA blocks the promigratory effects of oxaliplatin.	Oxaliplatin	10-21	Fas cell surface death receptor	Homo sapiens	101-105
20573240-5	2010	Moreover, oxaliplatin treatment itself stimulates cell migration and decreases cell adhesion through CD95 activation, since CD95 expression inhibition by siRNA blocks the promigratory effects of oxaliplatin.	Oxaliplatin	195-206	Fas cell surface death receptor	Homo sapiens	124-128
20573240-7	2010	CONCLUSIONS: We conclude that oxaliplatin treatment in cells that have acquired resistance to oxaliplatin-induced apoptosis results in tumor-promoting effects through the activation of CD95 signaling and by inducing EMT, all these events jointly contributing to a metastatic phenotype.	Oxaliplatin	30-41	Fas cell surface death receptor	Homo sapiens	185-189
20573240-7	2010	CONCLUSIONS: We conclude that oxaliplatin treatment in cells that have acquired resistance to oxaliplatin-induced apoptosis results in tumor-promoting effects through the activation of CD95 signaling and by inducing EMT, all these events jointly contributing to a metastatic phenotype.	Oxaliplatin	94-105	Fas cell surface death receptor	Homo sapiens	185-189
20514304-0	2010	Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.	Oxaliplatin	65-76	glutathione S-transferase pi 1	Homo sapiens	24-29
20424169-0	2010	Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin.	Oxaliplatin	203-214	nuclear factor kappa B subunit 1	Homo sapiens	14-23
20424169-8	2010	Similarly, overexpression of IkappaBalpha mutant (IkappaBalphaM) or treatment with the IKK inhibitor, BMS-345541, also sensitized these cells to TRAIL and L-OHP.	Oxaliplatin	155-160	NFKB inhibitor alpha	Homo sapiens	29-41
20424169-11	2010	Short hairpin RNA-mediated knockdown of c-FLIP or Mcl-1 significantly sensitized these cells to TRAIL and L-OHP.	Oxaliplatin	106-111	CASP8 and FADD like apoptosis regulator	Homo sapiens	40-46
20424169-11	2010	Short hairpin RNA-mediated knockdown of c-FLIP or Mcl-1 significantly sensitized these cells to TRAIL and L-OHP.	Oxaliplatin	106-111	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	50-55
20168208-12	2010	ABCB1 was highly overexpressed in the three most oxaliplatin-resistant sublines, but significantly underexpressed in the two most cisplatin-resistant cell lines.	Oxaliplatin	49-60	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
20514304-1	2010	The aim of this study was to evaluate the predictive value of the polymorphism Glutathione S-transferase P1 (GSTP1) Ile(105)Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.	Oxaliplatin	131-142	glutathione S-transferase pi 1	Homo sapiens	79-107
20514304-1	2010	The aim of this study was to evaluate the predictive value of the polymorphism Glutathione S-transferase P1 (GSTP1) Ile(105)Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.	Oxaliplatin	131-142	glutathione S-transferase pi 1	Homo sapiens	109-114
20740189-4	2010	Case Reports: Here we describe the cases of 2 patients with metastatic KRAS wild-type colorectal cancer who received a fourth-line monotherapy with panitumumab after failure of 5-fluorouracil, irinotecan, oxaliplatin, and bevacizumab.	Oxaliplatin	205-216	KRAS proto-oncogene, GTPase	Homo sapiens	71-75
20159940-3	2010	The major copper influx transporter, copper transporter 1 (CTR1), has now been shown to control the tumor cell accumulation and cytotoxic effect of cisplatin, carboplatin, and oxaliplatin.	Oxaliplatin	176-187	solute carrier family 31 member 1	Homo sapiens	59-63
20385995-6	2010	The effect of oxaliplatin on tumor response increased with the number of MTHFR-1298C alleles (test for trend, P = .008).	Oxaliplatin	14-25	methylenetetrahydrofolate reductase	Homo sapiens	73-78
20121626-1	2010	BACKGROUND AND OBJECTIVE: Oxaliplatin (OXA)-induced carcinoembryonic antigen (CEA) surge was reported to be associated with a clinical benefit.	Oxaliplatin	26-37	CEA cell adhesion molecule 3	Homo sapiens	52-76
20121626-1	2010	BACKGROUND AND OBJECTIVE: Oxaliplatin (OXA)-induced carcinoembryonic antigen (CEA) surge was reported to be associated with a clinical benefit.	Oxaliplatin	26-37	CEA cell adhesion molecule 3	Homo sapiens	78-81
20121626-1	2010	BACKGROUND AND OBJECTIVE: Oxaliplatin (OXA)-induced carcinoembryonic antigen (CEA) surge was reported to be associated with a clinical benefit.	Oxaliplatin	39-42	CEA cell adhesion molecule 3	Homo sapiens	52-76
20121626-1	2010	BACKGROUND AND OBJECTIVE: Oxaliplatin (OXA)-induced carcinoembryonic antigen (CEA) surge was reported to be associated with a clinical benefit.	Oxaliplatin	39-42	CEA cell adhesion molecule 3	Homo sapiens	78-81
19833818-5	2010	RESULTS: In univariate analyses, addition of oxaliplatin significantly improved DFS provided that tumour overexpressed p53 [hazard ratio (HR) 0.39; 95% confidence interval (CI) 0.19-0.82; P = 0.01] or displayed MSI phenotype (HR 0.17; 95% CI 0.04-0.68; P = 0.01).	Oxaliplatin	45-56	tumor protein p53	Homo sapiens	119-122
20005867-6	2010	The observed N-glycosylation defect of oxaliplatin-resistant cells was linked to reduced levels of N-acetylglucosamine-1-phosphotransferase (GNPTG) and mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase (MGAT5).	Oxaliplatin	39-50	N-acetylglucosamine-1-phosphate transferase subunit gamma	Homo sapiens	141-146
20005867-6	2010	The observed N-glycosylation defect of oxaliplatin-resistant cells was linked to reduced levels of N-acetylglucosamine-1-phosphotransferase (GNPTG) and mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase (MGAT5).	Oxaliplatin	39-50	alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase	Homo sapiens	230-235
20005867-8	2010	In addition, the overexpression of fully glycosylated MRP1 or MRP4 in tumor cell line of ovarian origin was associated with resistance to oxaliplatin and cisplatin.	Oxaliplatin	138-149	ATP binding cassette subfamily C member 1	Homo sapiens	54-58
20005867-8	2010	In addition, the overexpression of fully glycosylated MRP1 or MRP4 in tumor cell line of ovarian origin was associated with resistance to oxaliplatin and cisplatin.	Oxaliplatin	138-149	ATP binding cassette subfamily C member 4	Homo sapiens	62-66
20005867-9	2010	Our findings, showing that development of resistance to oxaliplatin results in up-regulation of MRPs, support that patients with oxaliplatin-refractory ovarian carcinomas may benefit from non-Pt-based regimens which do not contain MRP1 and MRP4 substrates.	Oxaliplatin	56-67	ATP binding cassette subfamily C member 1	Homo sapiens	231-235
20005867-9	2010	Our findings, showing that development of resistance to oxaliplatin results in up-regulation of MRPs, support that patients with oxaliplatin-refractory ovarian carcinomas may benefit from non-Pt-based regimens which do not contain MRP1 and MRP4 substrates.	Oxaliplatin	56-67	ATP binding cassette subfamily C member 4	Homo sapiens	240-244
20180626-13	2010	DISCUSSION: Potential reasons for the disappointing results of EGFR inhibition with fluoropyrimidine-based preoperative chemoradiation include a less critical role of repopulation in rectal adenocarcinoma using a non-curative radiation dose; or antagonistic effects on 5FU-based chemoradiation and oxaliplatin, if some cells arrest in G1 or G2-M and fail to pass through S phase.	Oxaliplatin	298-309	epidermal growth factor receptor	Homo sapiens	63-67
20354524-5	2010	A multiplexed RT-PCR assay was used to identify KRAS-controlled apoptosis regulators after exposure to 5-FU or oxaliplatin.	Oxaliplatin	111-122	KRAS proto-oncogene, GTPase	Homo sapiens	48-52
20354524-7	2010	RESULTS: Oncogenic KRAS sensitised colorectal tumour cells to oxaliplatin and 5-FU in a p53-dependent manner and promoted p53 phosphorylation at Ser37 and Ser392, without affecting p53 stabilisation, p21 induction, or cell-cycle arrest.	Oxaliplatin	62-73	KRAS proto-oncogene, GTPase	Homo sapiens	19-23
20354524-7	2010	RESULTS: Oncogenic KRAS sensitised colorectal tumour cells to oxaliplatin and 5-FU in a p53-dependent manner and promoted p53 phosphorylation at Ser37 and Ser392, without affecting p53 stabilisation, p21 induction, or cell-cycle arrest.	Oxaliplatin	62-73	tumor protein p53	Homo sapiens	88-91
20354524-11	2010	CONCLUSION: Oncogenic KRAS determines the cellular response to p53 activation by oxaliplatin or 5-FU, by facilitating apoptosis induction through Noxa.	Oxaliplatin	81-92	KRAS proto-oncogene, GTPase	Homo sapiens	22-26
20354524-11	2010	CONCLUSION: Oncogenic KRAS determines the cellular response to p53 activation by oxaliplatin or 5-FU, by facilitating apoptosis induction through Noxa.	Oxaliplatin	81-92	tumor protein p53	Homo sapiens	63-66
20354524-11	2010	CONCLUSION: Oncogenic KRAS determines the cellular response to p53 activation by oxaliplatin or 5-FU, by facilitating apoptosis induction through Noxa.	Oxaliplatin	81-92	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	146-150
19833818-7	2010	CONCLUSION: Our observations indicate that MSI status and p53 expression may influence the impact of oxaliplatin on adjuvant treatment of stage III colon cancer patients.	Oxaliplatin	101-112	tumor protein p53	Homo sapiens	58-61
20085586-8	2010	Patients that were homozygous for the reference alleles SSTR4 rs2567608 (AA) and EPHA7 rs2278107 (TT) showed lower disease control rates in response to irinotecan and oxaliplatin regimens, respectively, than those with substitution alleles (P = 0.022 and 0.014, respectively).	Oxaliplatin	167-178	somatostatin receptor 4	Homo sapiens	56-61
20530432-2	2010	MATERIALS AND METHODS: We evaluated the influence of hepatocyte growth factor, vascular endothelial growth factor and epidermal growth factor on the effect of 5-fluorouracil, oxaliplatin and SN-38 (the active metabolite of irinotecan) on WiDr cells.	Oxaliplatin	175-186	epidermal growth factor	Homo sapiens	118-141
20308030-2	2010	In this study, we investigated the associations between oxaliplatin-induced neuropathy and the following polymorphisms: glutathione S-transferase pi (GSTP1) Ile(105)Val, and glyoxylate aminotransferase (AGXT) Pro(11)Leu and AGXT Ile(340)Met.	Oxaliplatin	56-67	glutathione S-transferase pi 1	Homo sapiens	150-155
20308030-2	2010	In this study, we investigated the associations between oxaliplatin-induced neuropathy and the following polymorphisms: glutathione S-transferase pi (GSTP1) Ile(105)Val, and glyoxylate aminotransferase (AGXT) Pro(11)Leu and AGXT Ile(340)Met.	Oxaliplatin	56-67	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	203-207
20308030-2	2010	In this study, we investigated the associations between oxaliplatin-induced neuropathy and the following polymorphisms: glutathione S-transferase pi (GSTP1) Ile(105)Val, and glyoxylate aminotransferase (AGXT) Pro(11)Leu and AGXT Ile(340)Met.	Oxaliplatin	56-67	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	224-228
20085586-8	2010	Patients that were homozygous for the reference alleles SSTR4 rs2567608 (AA) and EPHA7 rs2278107 (TT) showed lower disease control rates in response to irinotecan and oxaliplatin regimens, respectively, than those with substitution alleles (P = 0.022 and 0.014, respectively).	Oxaliplatin	167-178	EPH receptor A7	Homo sapiens	81-86
20205720-6	2010	RESULTS: In this study, using real-time, reverse transcriptase, polymerase chain reaction (RT-PCR), we analyzed the expression of TRPV1, TRPM8, and TRPA1 induced by cisplatin or oxaliplatin in vitro and in vivo.	Oxaliplatin	178-189	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	130-135
19728331-0	2010	Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma.	Oxaliplatin	30-41	tumor protein p53	Homo sapiens	136-139
19728331-0	2010	Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma.	Oxaliplatin	30-41	caspase 8	Homo sapiens	140-149
19728331-10	2010	In conclusion, UDCA switches oxaliplatin-induced necrosis to apoptosis via inhibition of ROS production and activation of the p53-caspase 8 pathway in HepG2 cells.	Oxaliplatin	29-40	caspase 8	Homo sapiens	130-139
20205720-6	2010	RESULTS: In this study, using real-time, reverse transcriptase, polymerase chain reaction (RT-PCR), we analyzed the expression of TRPV1, TRPM8, and TRPA1 induced by cisplatin or oxaliplatin in vitro and in vivo.	Oxaliplatin	178-189	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	148-153
20205720-9	2010	We show that cisplatin and oxaliplatin-treated DRG neurons had significantly increased in TRPV1, TRPA1, and TRPM8 mRNA expression.	Oxaliplatin	27-38	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	90-95
20205720-9	2010	We show that cisplatin and oxaliplatin-treated DRG neurons had significantly increased in TRPV1, TRPA1, and TRPM8 mRNA expression.	Oxaliplatin	27-38	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	97-102
20205720-9	2010	We show that cisplatin and oxaliplatin-treated DRG neurons had significantly increased in TRPV1, TRPA1, and TRPM8 mRNA expression.	Oxaliplatin	27-38	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	108-113
20205720-10	2010	TG neurons from cisplatin treated mice had significant increases in TRPV1 and TRPA1 mRNA expression while oxaliplatin strongly induced only TRPA1.	Oxaliplatin	106-117	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	140-145
19850635-1	2010	BACKGROUND: The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX).	Oxaliplatin	128-139	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	215-220
19850635-1	2010	BACKGROUND: The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX).	Oxaliplatin	298-309	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	171-213
19774508-0	2010	Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-kappaB activation and induction of apoptosis.	Oxaliplatin	97-108	nuclear factor kappa B subunit 1	Homo sapiens	127-136
20146801-5	2010	RESULTS: We found that mRNA and TAp73 protein were decreased in cells treated with oxaliplatin (in monotherapy or combined with cetuximab) when B-Raf is mutated.	Oxaliplatin	83-94	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	144-149
20146801-7	2010	CONCLUSIONS: Here, for the first time we report, that there is a signaling loop between B-Raf activation and p73 function.Low expression of TAp73 in colorectal cancer cell lines with mutated B-Raf may be involved in the lack of response to oxaliplatin in monotherapy or combined with cetuximab.	Oxaliplatin	240-251	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	88-93
20146801-7	2010	CONCLUSIONS: Here, for the first time we report, that there is a signaling loop between B-Raf activation and p73 function.Low expression of TAp73 in colorectal cancer cell lines with mutated B-Raf may be involved in the lack of response to oxaliplatin in monotherapy or combined with cetuximab.	Oxaliplatin	240-251	tumor protein p73	Homo sapiens	109-112
20067471-7	2010	KEY RESULTS: HEK293/hSLC22A2 cells, compared with HEK293/Neo control cells, displayed significant increases in oxaliplatin (28.6-fold), Pt[DACH]Cl(2) (20.6-fold), ormaplatin (8.1-fold), tetraplatin (4.5-fold), transplatin (3.7-fold) and cisplatin (1.3-fold), but not carboplatin.	Oxaliplatin	111-122	solute carrier family 22 member 2	Homo sapiens	20-28
20067471-9	2010	Furthermore, hSLC22A2-mediated oxaliplatin and cisplatin accumulation was time- and concentration-dependent, but non-saturable.	Oxaliplatin	31-42	solute carrier family 22 member 2	Homo sapiens	13-21
20067471-10	2010	Expression of hSLC22A2 in HEK293 cells resulted in enhanced sensitivity to oxaliplatin (12-fold) and cisplatin (1.8-fold).	Oxaliplatin	75-86	solute carrier family 22 member 2	Homo sapiens	14-22
20067471-12	2010	CONCLUSIONS AND IMPLICATIONS: The hSLC22A2 drug transporter is a critical determinant in the uptake and cytotoxicity of various platinum compounds, particularly oxaliplatin.	Oxaliplatin	161-172	solute carrier family 22 member 2	Homo sapiens	34-42
20086177-2	2010	Anthracyclines, oxaliplatin, and ionizing irradiation activate a type of tumor cell death that elicits efficient anticancer immune responses depending on interferon gamma (IFNgamma) and the IFNgamma receptor.	Oxaliplatin	16-27	interferon gamma	Homo sapiens	154-181
20086177-2	2010	Anthracyclines, oxaliplatin, and ionizing irradiation activate a type of tumor cell death that elicits efficient anticancer immune responses depending on interferon gamma (IFNgamma) and the IFNgamma receptor.	Oxaliplatin	16-27	interferon gamma	Homo sapiens	172-180
19736245-9	2010	Direct inhibition of OCTN2 expressed in L6 cells by cisplatin, oxaliplatin or platinum(2+) could not be demonstrated, and experiments using urine from patients treated with cisplatin inhibited OCTN2 activity no more than expected from the carnitine content in the respective urine sample.	Oxaliplatin	63-74	solute carrier family 22 member 5	Homo sapiens	21-26
20128802-0	2010	Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors.	Oxaliplatin	0-11	checkpoint kinase 2	Homo sapiens	66-70
20128802-3	2010	EXPERIMENTAL APPROACH: We evaluated the ability of CHK2 small molecule inhibitors to potentiate oxaliplatin-induced toxicity.	Oxaliplatin	96-107	checkpoint kinase 2	Homo sapiens	51-55
20128802-4	2010	The role of CHK2 in oxaliplatin-induced apoptosis was investigated in HCT116 cells that were wild-type (WT) or KO for CHK2.	Oxaliplatin	20-31	checkpoint kinase 2	Homo sapiens	12-16
20128802-5	2010	Small molecule inhibitors of CHK2 were used in combination studies with oxaliplatin in this cell model.	Oxaliplatin	72-83	checkpoint kinase 2	Homo sapiens	29-33
20128802-6	2010	KEY RESULTS: In oxaliplatin-treated CHK2 KO cells, accelerated apoptosis was accompanied by attenuated p53 stabilization and p21(WAF-1) up-regulation correlating with increased Bax expression, cytochrome c release and elevated caspase activity.	Oxaliplatin	16-27	checkpoint kinase 2	Homo sapiens	36-40
20128802-6	2010	KEY RESULTS: In oxaliplatin-treated CHK2 KO cells, accelerated apoptosis was accompanied by attenuated p53 stabilization and p21(WAF-1) up-regulation correlating with increased Bax expression, cytochrome c release and elevated caspase activity.	Oxaliplatin	16-27	tumor protein p53	Homo sapiens	103-106
20128802-6	2010	KEY RESULTS: In oxaliplatin-treated CHK2 KO cells, accelerated apoptosis was accompanied by attenuated p53 stabilization and p21(WAF-1) up-regulation correlating with increased Bax expression, cytochrome c release and elevated caspase activity.	Oxaliplatin	16-27	cyclin dependent kinase inhibitor 1A	Homo sapiens	125-128
20128802-6	2010	KEY RESULTS: In oxaliplatin-treated CHK2 KO cells, accelerated apoptosis was accompanied by attenuated p53 stabilization and p21(WAF-1) up-regulation correlating with increased Bax expression, cytochrome c release and elevated caspase activity.	Oxaliplatin	16-27	cyclin dependent kinase inhibitor 1A	Homo sapiens	129-134
20128802-6	2010	KEY RESULTS: In oxaliplatin-treated CHK2 KO cells, accelerated apoptosis was accompanied by attenuated p53 stabilization and p21(WAF-1) up-regulation correlating with increased Bax expression, cytochrome c release and elevated caspase activity.	Oxaliplatin	16-27	BCL2 associated X, apoptosis regulator	Homo sapiens	177-180
20128802-6	2010	KEY RESULTS: In oxaliplatin-treated CHK2 KO cells, accelerated apoptosis was accompanied by attenuated p53 stabilization and p21(WAF-1) up-regulation correlating with increased Bax expression, cytochrome c release and elevated caspase activity.	Oxaliplatin	16-27	cytochrome c, somatic	Homo sapiens	193-205
20128802-8	2010	This "uncoupling" of p53 stabilization and Bax up-regulation in CHK2 KO cells suggested oxaliplatin-induced apoptosis was due to a p53-independent response.	Oxaliplatin	88-99	tumor protein p53	Homo sapiens	21-24
20128802-8	2010	This "uncoupling" of p53 stabilization and Bax up-regulation in CHK2 KO cells suggested oxaliplatin-induced apoptosis was due to a p53-independent response.	Oxaliplatin	88-99	BCL2 associated X, apoptosis regulator	Homo sapiens	43-46
20128802-8	2010	This "uncoupling" of p53 stabilization and Bax up-regulation in CHK2 KO cells suggested oxaliplatin-induced apoptosis was due to a p53-independent response.	Oxaliplatin	88-99	checkpoint kinase 2	Homo sapiens	64-68
20128802-8	2010	This "uncoupling" of p53 stabilization and Bax up-regulation in CHK2 KO cells suggested oxaliplatin-induced apoptosis was due to a p53-independent response.	Oxaliplatin	88-99	tumor protein p53	Homo sapiens	131-134
20128802-9	2010	Combination studies revealed that CHK2 inhibitor II or debromohymenialdisine antagonized the responses to oxaliplatin.	Oxaliplatin	106-117	checkpoint kinase 2	Homo sapiens	34-38
20128802-11	2010	CONCLUSIONS AND IMPLICATIONS: Combinations of CHK2 inhibitors with oxaliplatin should further sensitize cells to oxaliplatin treatment.	Oxaliplatin	113-124	checkpoint kinase 2	Homo sapiens	46-50
20128802-12	2010	However, these inhibitors produced an antagonistic effect on the response to oxaliplatin, which was reversed on the re-introduction of CHK2.	Oxaliplatin	77-88	checkpoint kinase 2	Homo sapiens	135-139
20078321-3	2010	We describe a patient with acute abdominal symptoms and evidence of PCI with PBG under cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy for metastatic adenocarcinoma of the rectosigmoid junction.	Oxaliplatin	98-109	serpin family A member 5	Homo sapiens	68-71
20078321-9	2010	CONCLUSIONS: This is probably the first report of PCI with PBG related to intestinal toxicity during cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy in a patient with advanced rectal carcinoma, followed by delayed small bowel perforation.	Oxaliplatin	112-123	serpin family A member 5	Homo sapiens	50-53
20146801-2	2010	There is little research on the relationship between p73 gene transcription and its protein expression and the response to certain drugs such as oxaliplatin and cetuximab, which are drugs currently used in colorectal cancer.The purpose of this study was to evaluate the impact of TAp73 expression on oxaliplatin and cetuximab-based chemotherapy in colorectal cancer cell lines with different K-Ras and B-Raf mutational status.	Oxaliplatin	145-156	tumor protein p73	Homo sapiens	53-56
19922504-10	2010	I105V polymorphism in GSTP1, by reducing its enzymatic activity and consequential detoxification to oxaliplatin, could be a key determinant for a better outcome, but more neurotoxicity, to FOLFOX-4 treatment.	Oxaliplatin	100-111	glutathione S-transferase pi 1	Homo sapiens	22-27
19774508-8	2010	These findings indicate that parthenolide could markedly enhance sensitivity of A549 cells to low-dose oxaliplatin by inhibiting NF-kappaB activation and inducing apoptosis.	Oxaliplatin	103-114	nuclear factor kappa B subunit 1	Homo sapiens	129-138
19881547-2	2010	Here, we show that both oxaliplatin (OXP) and cisplatin (CDDP) were equally efficient in triggering HMGB1 release.	Oxaliplatin	24-35	high mobility group box 1	Mus musculus	100-105
19881547-2	2010	Here, we show that both oxaliplatin (OXP) and cisplatin (CDDP) were equally efficient in triggering HMGB1 release.	Oxaliplatin	37-40	high mobility group box 1	Mus musculus	100-105
19838217-0	2010	Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy.	Oxaliplatin	96-107	DNA polymerase beta	Homo sapiens	53-72
19838217-4	2010	DNA damage induced by oxaliplatin treatment of HCT116 and HT29 colon cancer cells was observed to be associated with the stabilization of Pol beta protein on chromatin.	Oxaliplatin	22-33	DNA polymerase beta	Homo sapiens	138-146
19838217-5	2010	In comparison with HCT116 colon cancer cells, isogenic oxaliplatin-resistant (HCT-OR) cells were found to have higher constitutive levels of Pol beta protein, faster in vitro repair of a DNA substrate containing a single nucleotide gap and faster repair of 1,2-GG oxaliplatin adduct levels in cells.	Oxaliplatin	55-66	DNA polymerase beta	Homo sapiens	141-149
19838217-6	2010	In HCT-OR cells, small interfering RNA knockdown of Pol beta delayed the repair of oxaliplatin-induced DNA damage.	Oxaliplatin	83-94	DNA polymerase beta	Homo sapiens	52-60
19838217-7	2010	In a different model system, Pol beta-deficient fibroblasts were less able to repair 1,2-GG oxaliplatin adducts and were hypersensitive to oxaliplatin treatment compared with isogenic Pol beta-expressing cells.	Oxaliplatin	92-103	DNA polymerase beta	Homo sapiens	29-37
19838217-7	2010	In a different model system, Pol beta-deficient fibroblasts were less able to repair 1,2-GG oxaliplatin adducts and were hypersensitive to oxaliplatin treatment compared with isogenic Pol beta-expressing cells.	Oxaliplatin	139-150	DNA polymerase beta	Homo sapiens	29-37
19838217-9	2010	These data provide the first link between oxaliplatin sensitivity and DNA repair involving Pol beta.	Oxaliplatin	42-53	DNA polymerase beta	Homo sapiens	91-99
19838217-10	2010	They demonstrate that Pol beta modulates the sensitivity of cells to oxaliplatin treatment.	Oxaliplatin	69-80	DNA polymerase beta	Homo sapiens	22-30
20110784-4	2010	Due to the development of subsequent recurrences (infravesical relapse, bone and lung progression) associated with CEA progression and pain worsening, the patient received treatment by every available agent for the metastatic colorectal cancer, including oxaliplatin and radiotherapy; irinotecan; FOLFOX schema; oral capecitabine; raltitrexed; irinotecan and cetuximab; cetuximab as a single agent; always in combination with zolendronic acid-based treatment for pain control.	Oxaliplatin	255-266	CEA cell adhesion molecule 3	Homo sapiens	115-118
20039457-0	2010	Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin.	Oxaliplatin	111-122	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	10-38
20039457-1	2010	AIM: To investigate whether silencing Fas-associated phosphatase 1 (FAP-1) expression enhances the efficiency of chemotherapy for colon carcinoma with oxaliplatin.	Oxaliplatin	151-162	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	38-66
20039457-1	2010	AIM: To investigate whether silencing Fas-associated phosphatase 1 (FAP-1) expression enhances the efficiency of chemotherapy for colon carcinoma with oxaliplatin.	Oxaliplatin	151-162	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	68-73
20039457-6	2010	RESULTS: The expression of FAP-1 was increased in SW480 cells after chemotherapy with oxaliplatin.	Oxaliplatin	86-97	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	27-32
20039457-7	2010	Transfection of FAP-1 siRNA into SW480 cells silenced the expression of FAP-1 and consequently abolished the inhibitory function of Fas/FasL-mediated apoptosis pathway, thus increasing the efficacy of chemotherapy for colon carcinoma with oxaliplatin.	Oxaliplatin	239-250	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	16-21
20233520-7	2010	MVD was strongly inhibited in the treatment groups compared with the controls, although only YH-16 combined with L-OHP or L-OHP alone decreased VEGF expression.	Oxaliplatin	113-118	vascular endothelial growth factor A	Homo sapiens	144-148
20078613-3	2010	* Only polymorphisms of genes related to oxaliplatin pharmacodynamics (GSTpi 105Ile--&gt;Val and XPD 751Ly--&gt;Gln) influenced progression-free survival.	Oxaliplatin	41-52	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	97-100
20001430-2	2010	AREAS COVERED IN THIS REVIEW: Oxaliplatin and irinotecan have widened the chemotherapy alternatives available in this setting and effective targeted agents against vascular endothelial growth factor and epidermal growth factor receptor have further improved treatment efficacy.	Oxaliplatin	30-41	epidermal growth factor receptor	Homo sapiens	203-235
20233520-7	2010	MVD was strongly inhibited in the treatment groups compared with the controls, although only YH-16 combined with L-OHP or L-OHP alone decreased VEGF expression.	Oxaliplatin	122-127	vascular endothelial growth factor A	Homo sapiens	144-148
20067946-3	2010	Cetuximab, a chimeric monoclonal antibody (mAb) against the epidermal growth factor receptor (EGFR) is FDA approved as a single agent, or in combination with irinotecan, in both irinotecan-naive and refractory patients, and has additional efficacy in combination with oxaliplatin.	Oxaliplatin	268-279	epidermal growth factor receptor	Homo sapiens	60-92
21072377-5	2010	In these studies, we use liquid chromatography and mass spectrometry to compare the binding interactions between cisplatin, carboplatin and oxaliplatin with synthetic peptides corresponding to hCtr1 Mets motifs.	Oxaliplatin	140-151	solute carrier family 31 member 1	Homo sapiens	193-198
20067946-3	2010	Cetuximab, a chimeric monoclonal antibody (mAb) against the epidermal growth factor receptor (EGFR) is FDA approved as a single agent, or in combination with irinotecan, in both irinotecan-naive and refractory patients, and has additional efficacy in combination with oxaliplatin.	Oxaliplatin	268-279	epidermal growth factor receptor	Homo sapiens	94-98
20047135-0	2009	Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients.	Oxaliplatin	59-70	glutathione S-transferase pi 1	Homo sapiens	25-30
20175229-5	2010	RESULT: MTS assay results showed the enhanced cytotoxicity of anticancer drugs (Oxaliplatin, Doxorubicin and Etopside) to the H460 cell line with keap1 overexpression compared to the control cell line.	Oxaliplatin	80-91	kelch like ECH associated protein 1	Homo sapiens	146-151
20175229-7	2010	A Nrf2 down-regulated cell line H460-N5 and a control cell line with GFP over-expression have been identified.Down-regulation of Nrf2 enhanced the cytotoxicity of Oxaliplatin, Doxorubicin and Etopside.	Oxaliplatin	163-174	NFE2 like bZIP transcription factor 2	Homo sapiens	2-6
20175229-7	2010	A Nrf2 down-regulated cell line H460-N5 and a control cell line with GFP over-expression have been identified.Down-regulation of Nrf2 enhanced the cytotoxicity of Oxaliplatin, Doxorubicin and Etopside.	Oxaliplatin	163-174	NFE2 like bZIP transcription factor 2	Homo sapiens	129-133
20175229-10	2010	Down-regulation of Nrf2 enhanced the cytotoxicity of Oxaliplatin, Doxorubicin and Etopside.	Oxaliplatin	53-64	NFE2 like bZIP transcription factor 2	Homo sapiens	19-23
20175230-0	2010	[Down-regulation of Nrf2 enhances the cytotoxicity of Oxaliplatin to H460 cells].	Oxaliplatin	54-65	NFE2 like bZIP transcription factor 2	Homo sapiens	20-24
20175230-1	2010	OBJECTIVE: To establish a stable H460 cell line with Nrf2 down-regulation to study the role of Nrf2 in Oxaliplatin resistance.	Oxaliplatin	103-114	NFE2 like bZIP transcription factor 2	Homo sapiens	95-99
20175230-6	2010	Down-regulation of Nrf2 in H460 sensitized the anti-cancer effect of Oxaliplatin and Doxorubicin.	Oxaliplatin	69-80	NFE2 like bZIP transcription factor 2	Homo sapiens	19-23
20175230-8	2010	Down regulation of Nrf2 in H460 cell enhances cytotoxicity of Oxaliplatin.	Oxaliplatin	62-73	NFE2 like bZIP transcription factor 2	Homo sapiens	19-23
19735649-0	2009	Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.	Oxaliplatin	0-11	H2A.X variant histone	Homo sapiens	26-30
19735649-0	2009	Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	51-54
19735649-4	2009	In this study, we investigated the roles of p53 and gamma-H2AX following oxaliplatin treatment, as they are important effector proteins for apoptosis and DSB repair, respectively.	Oxaliplatin	73-84	tumor protein p53	Homo sapiens	44-47
19735649-5	2009	Both phosphorylated-p53 (Ser-15) and gamma-H2AX were up-regulated and accumulated in the nuclei of p53-wild type human colorectal cancer HCT116 cells after exposure to oxaliplatin.	Oxaliplatin	168-179	tumor protein p53	Homo sapiens	20-23
19735649-5	2009	Both phosphorylated-p53 (Ser-15) and gamma-H2AX were up-regulated and accumulated in the nuclei of p53-wild type human colorectal cancer HCT116 cells after exposure to oxaliplatin.	Oxaliplatin	168-179	H2A.X variant histone	Homo sapiens	43-47
19735649-5	2009	Both phosphorylated-p53 (Ser-15) and gamma-H2AX were up-regulated and accumulated in the nuclei of p53-wild type human colorectal cancer HCT116 cells after exposure to oxaliplatin.	Oxaliplatin	168-179	tumor protein p53	Homo sapiens	99-102
19735649-6	2009	Concomitantly, oxaliplatin-induced G2/M arrest was associated with a reduction in both cyclin B1 expression and phosphorylated-CDC2 (Thr-161).	Oxaliplatin	15-26	cyclin B1	Homo sapiens	87-96
19735649-6	2009	Concomitantly, oxaliplatin-induced G2/M arrest was associated with a reduction in both cyclin B1 expression and phosphorylated-CDC2 (Thr-161).	Oxaliplatin	15-26	cyclin dependent kinase 1	Homo sapiens	127-131
19735649-8	2009	Furthermore, inhibition of p53 phosphorylation by pifithrin-alpha was sufficient to reduce the oxaliplatin-induced up-regulation of gamma-H2AX and apoptosis.	Oxaliplatin	95-106	tumor protein p53	Homo sapiens	27-30
19735649-8	2009	Furthermore, inhibition of p53 phosphorylation by pifithrin-alpha was sufficient to reduce the oxaliplatin-induced up-regulation of gamma-H2AX and apoptosis.	Oxaliplatin	95-106	H2A.X variant histone	Homo sapiens	138-142
19735649-9	2009	Oxaliplatin-induced gamma-H2AX via a p53-independent pathway but did not cause caspase-3 activation in p53-null HCT116 cells.	Oxaliplatin	0-11	H2A.X variant histone	Homo sapiens	26-30
19735649-9	2009	Oxaliplatin-induced gamma-H2AX via a p53-independent pathway but did not cause caspase-3 activation in p53-null HCT116 cells.	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	37-40
19735649-11	2009	Taken together, these data indicate that a molecular pathway involving p53, gamma-H2AX and cell cycle arrest plays a pivotal role in the cellular response to oxaliplatin.	Oxaliplatin	158-169	tumor protein p53	Homo sapiens	71-74
19735649-11	2009	Taken together, these data indicate that a molecular pathway involving p53, gamma-H2AX and cell cycle arrest plays a pivotal role in the cellular response to oxaliplatin.	Oxaliplatin	158-169	H2A.X variant histone	Homo sapiens	82-86
20047135-8	2009	CONCLUSION: The GSTP1 105Val/105Val genotype is associated with a higher clinical response rate to oxaliplatin-based chemotherapy and with increased survival of patients with advanced colo-rectal cancer, receiving 5-FU/oxaliplatin chemotherapy.	Oxaliplatin	99-110	glutathione S-transferase pi 1	Homo sapiens	16-21
20047135-8	2009	CONCLUSION: The GSTP1 105Val/105Val genotype is associated with a higher clinical response rate to oxaliplatin-based chemotherapy and with increased survival of patients with advanced colo-rectal cancer, receiving 5-FU/oxaliplatin chemotherapy.	Oxaliplatin	219-230	glutathione S-transferase pi 1	Homo sapiens	16-21
19622348-9	2009	Over-expression of certain ABC-transporters (BCRP/ABCG2, MRP2/ABCC2 or MRP3/ABCC3) was demonstrated to be beneficial for the efficacy of oxaliplatin.	Oxaliplatin	137-148	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	45-49
19622348-9	2009	Over-expression of certain ABC-transporters (BCRP/ABCG2, MRP2/ABCC2 or MRP3/ABCC3) was demonstrated to be beneficial for the efficacy of oxaliplatin.	Oxaliplatin	137-148	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	50-55
19622348-9	2009	Over-expression of certain ABC-transporters (BCRP/ABCG2, MRP2/ABCC2 or MRP3/ABCC3) was demonstrated to be beneficial for the efficacy of oxaliplatin.	Oxaliplatin	137-148	ATP binding cassette subfamily C member 2	Homo sapiens	57-61
19622348-9	2009	Over-expression of certain ABC-transporters (BCRP/ABCG2, MRP2/ABCC2 or MRP3/ABCC3) was demonstrated to be beneficial for the efficacy of oxaliplatin.	Oxaliplatin	137-148	ATP binding cassette subfamily C member 2	Homo sapiens	62-67
19622348-9	2009	Over-expression of certain ABC-transporters (BCRP/ABCG2, MRP2/ABCC2 or MRP3/ABCC3) was demonstrated to be beneficial for the efficacy of oxaliplatin.	Oxaliplatin	137-148	ATP binding cassette subfamily C member 3	Homo sapiens	71-75
19622348-9	2009	Over-expression of certain ABC-transporters (BCRP/ABCG2, MRP2/ABCC2 or MRP3/ABCC3) was demonstrated to be beneficial for the efficacy of oxaliplatin.	Oxaliplatin	137-148	ATP binding cassette subfamily C member 3	Homo sapiens	76-81
19709902-7	2009	Our results show that IL-21 therapy can be successfully combined with agents from different chemotherapeutic drug classes, i.e. topoisomerase II inhibitors (PLD), anti-metabolites (5-FU) and platinum analogs (oxaliplatin) provided that IL-21 therapy is delayed relative to chemotherapy.	Oxaliplatin	209-220	interleukin 21	Mus musculus	22-27
19415279-6	2009	The DLT level was reached at the doses of paclitaxel 110 mg/m(2), gemcitabine 1,150 mg/m(2) and LOHP 70 mg/m(2).	Oxaliplatin	96-100	codanin 1	Homo sapiens	4-7
19070448-0	2009	Human serum albumin interaction with oxaliplatin studied by capillary isoelectric focusing with the whole column imaging detection and spectroscopic method.	Oxaliplatin	37-48	albumin	Homo sapiens	12-19
19915942-3	2009	The immoglobulin (Ig) G1 EGFR-targeting monoclonal antibody (mAb), cetuximab, has been shown to provide significant clinical benefits when added to standard irinotecan- and oxaliplatin-containing chemotherapy regimens, first-line, in patients with KRAS wild-type mCRC.	Oxaliplatin	173-184	epidermal growth factor receptor	Homo sapiens	25-29
19816189-8	2009	Gemcitabine with 5-fluorouracil or oxaliplatin, but not alone, increased IL-18 and free IL-18 levels statistically significantly, without affecting IL-18BPa.	Oxaliplatin	35-46	interleukin 18	Homo sapiens	73-78
19816189-8	2009	Gemcitabine with 5-fluorouracil or oxaliplatin, but not alone, increased IL-18 and free IL-18 levels statistically significantly, without affecting IL-18BPa.	Oxaliplatin	35-46	interleukin 18	Homo sapiens	88-93
19816189-8	2009	Gemcitabine with 5-fluorouracil or oxaliplatin, but not alone, increased IL-18 and free IL-18 levels statistically significantly, without affecting IL-18BPa.	Oxaliplatin	35-46	interleukin 18 binding protein	Homo sapiens	148-156
19922644-3	2009	RESULTS: After treatment with oxaliplatin, phosphorylated neurofilament heavy subunit (pNF-H) immunoreactivity was reduced in neuronal cell bodies, but unchanged in nerve fibres, of the L5 DRG.	Oxaliplatin	30-41	neurofilament heavy chain	Rattus norvegicus	58-85
19727937-4	2009	We evaluated the feasibility and safety of oxaliplatin-eluting microspheres transarterial chemoembolization (OEM-TACE) associated with chemotherapy (ChT) in patients affected by unresectable ICC.	Oxaliplatin	43-54	ADAM metallopeptidase domain 17	Homo sapiens	113-117
19727937-6	2009	All patients had undergone OEM-TACE associated with chemotherapy with oxaliplatin and gemcitabine.	Oxaliplatin	70-81	ADAM metallopeptidase domain 17	Homo sapiens	31-35
19917537-1	2009	Therapy for metastatic colorectal cancer has been improved in terms of response rate, time to progression and overall survival by the emergence of anti-EGFR monoclonal antibodies (cetuximab and panitumumab) in combination with standard cytotoxic chemotherapy (oxaliplatin or CPT-11-based combinations).	Oxaliplatin	260-271	epidermal growth factor receptor	Homo sapiens	152-156
19070448-2	2009	This study was designed to examine the interaction between the platinum-based anticancer drug, oxaliplatin, with human serum albumin (HSA) in aqueous solution at physiological pH with drug concentrations of 10 to 100 microM and a constant concentration of HSA (5.0 x 10(-5)M).	Oxaliplatin	95-106	albumin	Homo sapiens	125-132
21475919-5	2009	Responses to CDDP and oxaliplatin (OXA) in ESCC cell lines were evaluated using the WST-8 colorimetric assay by comparing ERCC1 levels.	Oxaliplatin	22-33	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	122-127
19713356-0	2009	Bid and calpains cooperate to trigger oxaliplatin-induced apoptosis of cervical carcinoma HeLa cells.	Oxaliplatin	38-49	BH3 interacting domain death agonist	Homo sapiens	0-3
19713356-3	2009	Here, we characterized the role of Bid and the mechanism of Bid activation during oxaliplatin-induced apoptosis of HeLa cervical cancer cells.	Oxaliplatin	82-93	BH3 interacting domain death agonist	Homo sapiens	35-38
19713356-3	2009	Here, we characterized the role of Bid and the mechanism of Bid activation during oxaliplatin-induced apoptosis of HeLa cervical cancer cells.	Oxaliplatin	82-93	BH3 interacting domain death agonist	Homo sapiens	60-63
19713356-4	2009	Small hairpin RNA-mediated silencing of Bid protected HeLa cells against both death receptor- and oxaliplatin-induced apoptosis.	Oxaliplatin	98-109	BH3 interacting domain death agonist	Homo sapiens	40-43
19713356-5	2009	Expression of a Bid mutant in which caspase-8 cleavage site was mutated (D59A) reactivated oxaliplatin-induced apoptosis in Bid-deficient cells but failed to reactivate death receptor-induced apoptosis, suggesting that caspase-8-mediated Bid cleavage did not contribute to oxaliplatin-induced apoptosis.	Oxaliplatin	91-102	BH3 interacting domain death agonist	Homo sapiens	16-19
19713356-5	2009	Expression of a Bid mutant in which caspase-8 cleavage site was mutated (D59A) reactivated oxaliplatin-induced apoptosis in Bid-deficient cells but failed to reactivate death receptor-induced apoptosis, suggesting that caspase-8-mediated Bid cleavage did not contribute to oxaliplatin-induced apoptosis.	Oxaliplatin	91-102	caspase 8	Homo sapiens	36-45
19713356-5	2009	Expression of a Bid mutant in which caspase-8 cleavage site was mutated (D59A) reactivated oxaliplatin-induced apoptosis in Bid-deficient cells but failed to reactivate death receptor-induced apoptosis, suggesting that caspase-8-mediated Bid cleavage did not contribute to oxaliplatin-induced apoptosis.	Oxaliplatin	91-102	BH3 interacting domain death agonist	Homo sapiens	124-127
19713356-5	2009	Expression of a Bid mutant in which caspase-8 cleavage site was mutated (D59A) reactivated oxaliplatin-induced apoptosis in Bid-deficient cells but failed to reactivate death receptor-induced apoptosis, suggesting that caspase-8-mediated Bid cleavage did not contribute to oxaliplatin-induced apoptosis.	Oxaliplatin	91-102	BH3 interacting domain death agonist	Homo sapiens	124-127
19713356-5	2009	Expression of a Bid mutant in which caspase-8 cleavage site was mutated (D59A) reactivated oxaliplatin-induced apoptosis in Bid-deficient cells but failed to reactivate death receptor-induced apoptosis, suggesting that caspase-8-mediated Bid cleavage did not contribute to oxaliplatin-induced apoptosis.	Oxaliplatin	273-284	BH3 interacting domain death agonist	Homo sapiens	16-19
19713356-6	2009	Overexpression of bcl-2 or treatment with the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-dl-Asp-fluoromethylketone abolished caspase-2, -8, -9, and -3 activation as well as Bid cleavage in response to oxaliplatin, suggesting that Bid cleavage occurred downstream of mitochondrial permeabilization and was predominantly mediated by caspases.	Oxaliplatin	208-219	BCL2 apoptosis regulator	Homo sapiens	18-23
19713356-6	2009	Overexpression of bcl-2 or treatment with the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-dl-Asp-fluoromethylketone abolished caspase-2, -8, -9, and -3 activation as well as Bid cleavage in response to oxaliplatin, suggesting that Bid cleavage occurred downstream of mitochondrial permeabilization and was predominantly mediated by caspases.	Oxaliplatin	208-219	caspase 2	Homo sapiens	50-57
19713356-8	2009	Calpain inhibition reduced Bid cleavage, mitochondrial depolarization, and activation of caspase-9, -3, -2, and -8 in response to oxaliplatin.	Oxaliplatin	130-141	BH3 interacting domain death agonist	Homo sapiens	27-30
19713356-11	2009	In conclusion, our data suggest that calpains and Bid act in a cooperative, but mutually independent, manner to mediate oxaliplatin-induced apoptosis of HeLa cells.	Oxaliplatin	120-131	BH3 interacting domain death agonist	Homo sapiens	50-53
21475919-9	2009	ESCC cell lines with lower ERCC1 showed significantly greater sensitivity to clinically relevant concentrations of CDDP and OXA compared to lines with higher ERCC1 (p&lt;0.01).	Oxaliplatin	124-127	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	27-32
19713356-8	2009	Calpain inhibition reduced Bid cleavage, mitochondrial depolarization, and activation of caspase-9, -3, -2, and -8 in response to oxaliplatin.	Oxaliplatin	130-141	caspase 9	Homo sapiens	89-114
19565301-0	2009	Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.	Oxaliplatin	72-83	tissue inhibitor of metalloproteinase 1	Mus musculus	97-103
19755992-0	2009	Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.	Oxaliplatin	45-56	hypoxia inducible factor 1 subunit alpha	Homo sapiens	16-21
19755992-11	2009	CONCLUSION: Overall, data show that drug penetration, DNA damage levels and HIF-1-dependent processes, all contribute to the resistance of hypoxic cells to oxaliplatin.	Oxaliplatin	156-167	hypoxia inducible factor 1 subunit alpha	Homo sapiens	76-81
19808866-5	2009	Here, we report the therapeutic activity of the poly (ADP ribose) polymerase-1 inhibitor BSI-401, as a single agent and in combination with oxaliplatin in orthotopic nude mouse models of pancreatic cancer, and its effect on oxaliplatin-induced acute neurotoxicity.	Oxaliplatin	140-151	poly (ADP-ribose) polymerase family, member 1	Mus musculus	48-78
19808866-5	2009	Here, we report the therapeutic activity of the poly (ADP ribose) polymerase-1 inhibitor BSI-401, as a single agent and in combination with oxaliplatin in orthotopic nude mouse models of pancreatic cancer, and its effect on oxaliplatin-induced acute neurotoxicity.	Oxaliplatin	224-235	poly (ADP-ribose) polymerase family, member 1	Mus musculus	48-78
19219602-0	2009	Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T&gt;C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.	Oxaliplatin	171-182	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-41
19219602-0	2009	Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T&gt;C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.	Oxaliplatin	171-182	prostaglandin-endoperoxide synthase 2	Homo sapiens	43-48
19219602-0	2009	Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T&gt;C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.	Oxaliplatin	171-182	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	49-53
19683395-6	2009	Phosphorylation was reversed when PKC activity was inhibited by Calphostin C. Distinct PKC-activated MAPK pathways, including p38MAPK, ERK1/2 and JNK, were investigated in chronic oxaliplatin rat.	Oxaliplatin	180-191	mitogen activated protein kinase 3	Rattus norvegicus	101-105
19247656-0	2009	Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	107-118	tumor protein p53	Homo sapiens	17-20
19247656-0	2009	Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	107-118	glutathione S-transferase pi 1	Homo sapiens	22-27
19247656-0	2009	Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	107-118	X-ray repair cross complementing 1	Homo sapiens	32-37
19247656-6	2009	CONCLUSION: Testing for p53 Arg72Pro, GSTP1 Ile105Val, and XRCC1 Arg399Gln polymorphisms may allow identification of gastric cancer patients who will benefit from oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	163-174	tumor protein p53	Homo sapiens	24-27
19247656-6	2009	CONCLUSION: Testing for p53 Arg72Pro, GSTP1 Ile105Val, and XRCC1 Arg399Gln polymorphisms may allow identification of gastric cancer patients who will benefit from oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	163-174	glutathione S-transferase pi 1	Homo sapiens	38-43
19247656-6	2009	CONCLUSION: Testing for p53 Arg72Pro, GSTP1 Ile105Val, and XRCC1 Arg399Gln polymorphisms may allow identification of gastric cancer patients who will benefit from oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	163-174	X-ray repair cross complementing 1	Homo sapiens	59-64
19732064-7	2009	KEY RESULTS: Combination of oxaliplatin and cetuximab was less cytotoxic than oxaliplatin alone in colorectal cells harbouring wild-type Ras and membrane expression of receptors for epidermal growth factor receptor (EGFR), such as HT29-D4 and Caco-2 cells.	Oxaliplatin	28-39	epidermal growth factor receptor	Homo sapiens	182-214
19724867-5	2009	The purpose with this study was to evaluate if ASNA1 expression influenced cisplatin, carboplatin, oxaliplatin or arsenite sensitivity in ovarian cancer.	Oxaliplatin	99-110	guided entry of tail-anchored proteins factor 3, ATPase	Homo sapiens	47-52
19724867-9	2009	Down-regulated ASNA1 expression was associated with retarded growth and increased sensitivity to cisplatin, carboplatin, oxaliplatin and arsenite whereas the cisplatin resistant 2008/A overexpresses ASNA1.	Oxaliplatin	121-132	guided entry of tail-anchored proteins factor 3, ATPase	Homo sapiens	15-20
19581934-0	2009	Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells.	Oxaliplatin	95-106	tumor protein p53	Homo sapiens	9-12
19581934-2	2009	Drug-resistant KB cells selected with cisplatin or oxaliplatin were found to have increased p53 levels and in oxaliplatin-selected cells, a larger p53 predominantly in the cytoplasm.	Oxaliplatin	51-62	tumor protein p53	Homo sapiens	92-95
19581934-2	2009	Drug-resistant KB cells selected with cisplatin or oxaliplatin were found to have increased p53 levels and in oxaliplatin-selected cells, a larger p53 predominantly in the cytoplasm.	Oxaliplatin	51-62	tumor protein p53	Homo sapiens	147-150
19581934-2	2009	Drug-resistant KB cells selected with cisplatin or oxaliplatin were found to have increased p53 levels and in oxaliplatin-selected cells, a larger p53 predominantly in the cytoplasm.	Oxaliplatin	110-121	tumor protein p53	Homo sapiens	147-150
19581934-3	2009	In oxaliplatin-selected cells a single nucleotide deletion in the sequence-encoding amino acid 382, part of NLSIII, resulted in a frame shift and a 420 amino acid protein (p53(420)).	Oxaliplatin	3-14	tumor protein p53	Homo sapiens	172-175
18571892-4	2009	The oxaliplatin-resistant cell line, KFR, was established by using KF-1 cells derived from human serous cystadenocarcinoma of the ovary.	Oxaliplatin	4-15	ring finger protein 103	Homo sapiens	67-71
19466412-6	2009	After treatment with platinum drugs, the cell bodies of these CTR1-positive neurons became atrophied, with oxaliplatin causing the greatest percentage reduction in the mean cell body area relative to controls (42%; P &lt; 0.05), followed by cisplatin (18%; P &lt; 0.05) and carboplatin causing the least reduction (3.2%; P = NS).	Oxaliplatin	107-118	solute carrier family 31 member 1	Rattus norvegicus	62-66
19785749-1	2009	BACKGROUND: The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC).	Oxaliplatin	80-91	vascular endothelial growth factor A	Homo sapiens	21-25
19732064-7	2009	KEY RESULTS: Combination of oxaliplatin and cetuximab was less cytotoxic than oxaliplatin alone in colorectal cells harbouring wild-type Ras and membrane expression of receptors for epidermal growth factor receptor (EGFR), such as HT29-D4 and Caco-2 cells.	Oxaliplatin	28-39	epidermal growth factor receptor	Homo sapiens	216-220
19732064-9	2009	Transfection of HT29-D4 with K-Ras(V12) decreased oxaliplatin IC(50) and impaired cetuximab sensitivity, without affecting expression of membrane EGFR compared with HT29-D4 control.	Oxaliplatin	50-61	immunoglobulin lambda variable 2-8	Homo sapiens	29-38
19732064-12	2009	Oxaliplatin efficacy was impaired by short hairpin RNA for Nox1 and by catalase (H(2)O(2) scavenger).	Oxaliplatin	0-11	NADPH oxidase 1	Homo sapiens	59-63
19732064-13	2009	CONCLUSIONS AND IMPLICATIONS: Cetuximab limited oxaliplatin efficiency by affecting the redox status of cancer cells through Nox1.	Oxaliplatin	48-59	NADPH oxidase 1	Homo sapiens	125-129
19330779-5	2009	We determined the susceptibility of POLB-suppressed cells to cisplatin and oxaliplatin.	Oxaliplatin	75-86	DNA polymerase beta	Homo sapiens	36-40
19723892-2	2009	A clear p53-dependent expression pattern of PDF was shown in a panel of colorectal cancer cell lines following acute exposure to oxaliplatin, 5-fluorouracil, and SN38.	Oxaliplatin	129-140	tumor protein p53	Homo sapiens	8-11
19723892-2	2009	A clear p53-dependent expression pattern of PDF was shown in a panel of colorectal cancer cell lines following acute exposure to oxaliplatin, 5-fluorouracil, and SN38.	Oxaliplatin	129-140	peptide deformylase, mitochondrial	Homo sapiens	44-47
19578762-7	2009	Furthermore, the antitumor activity of bevacizumab in combination with capecitabine + oxaliplatin was significantly superior to that of capecitabine + oxaliplatin (COL-16-JCK).	Oxaliplatin	151-162	NIMA related kinase 8	Homo sapiens	171-174
19387877-7	2009	Celecoxib in combination with oxaliplatin could further promote cell apoptosis and reduce beta-catenin protein expression.	Oxaliplatin	30-41	catenin (cadherin associated protein), beta 1	Mus musculus	90-102
19536092-8	2009	The results suggest that the ATM and ERCC5 genes may be associated with oxaliplatin efficacy in ACC.	Oxaliplatin	72-83	ATM serine/threonine kinase	Homo sapiens	29-32
19536092-8	2009	The results suggest that the ATM and ERCC5 genes may be associated with oxaliplatin efficacy in ACC.	Oxaliplatin	72-83	ERCC excision repair 5, endonuclease	Homo sapiens	37-42
19375484-0	2009	Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice.	Oxaliplatin	84-95	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	39-80
19375484-2	2009	In the present study, we investigated in mice whether transient receptor potential melastatin 8 (TRPM8), which is activated by cooling temperature, would be involved in cold allodynia induced by oxaliplatin.	Oxaliplatin	195-206	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	54-95
19375484-2	2009	In the present study, we investigated in mice whether transient receptor potential melastatin 8 (TRPM8), which is activated by cooling temperature, would be involved in cold allodynia induced by oxaliplatin.	Oxaliplatin	195-206	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	97-102
19375484-8	2009	Oxaliplatin increased wet-dog shake and jumping behaviors evoked by the TRPM8 agonist icilin.	Oxaliplatin	0-11	transient receptor potential cation channel subfamily M member 8	Canis lupus familiaris	72-77
19375484-9	2009	An injection of oxaliplatin increased the expression level of TRPM8 mRNA at day 3 after injection and the expression was decreased to the near-normal level on days 10 and 25.	Oxaliplatin	16-27	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	62-67
19375484-10	2009	These results suggest that cold allodynia induced by oxaliplatin is at least partly due to the increased expression of TRPM8 in the primary afferents.	Oxaliplatin	53-64	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	119-124
19458483-0	2009	ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.	Oxaliplatin	69-80	ERCC excision repair 5, endonuclease	Homo sapiens	0-5
19458483-1	2009	This study aimed to investigate whether single nucleotide polymorphisms (SNPs) in the promoter of the excision repair cross complementation group 5 (ERCC5) gene influences response to oxaliplatin-based chemotherapy.	Oxaliplatin	184-195	ERCC excision repair 5, endonuclease	Homo sapiens	102-147
19458483-1	2009	This study aimed to investigate whether single nucleotide polymorphisms (SNPs) in the promoter of the excision repair cross complementation group 5 (ERCC5) gene influences response to oxaliplatin-based chemotherapy.	Oxaliplatin	184-195	ERCC excision repair 5, endonuclease	Homo sapiens	149-154
19458483-10	2009	Therefore, these data suggest that ERCC5 promoter polymorphisms at -763 and +25 may be important predictors of response to oxaliplatin chemotherapy.	Oxaliplatin	123-134	ERCC excision repair 5, endonuclease	Homo sapiens	35-40
19432884-2	2009	We analyzed the influence of codon 751 Lys--&gt;Gln polymorphism of XPD on its protein expression levels, clinico-pathological features, and outcome of 188 Chinese patients with metastatic colorectal carcinoma (CRC) that had been treated with first-line Oxaliplatin + Leucovorin + 5-Fluorouracil (FOLFOX-4) chemotherapy.	Oxaliplatin	254-265	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	68-71
19432884-8	2009	These data suggest that Asian populations have a significantly lower prevalence of codon 751 Lys/Gln polymorphism in XPD, which could be a key determinant for good response to oxaliplatin-based treatment and favorable outcomes.	Oxaliplatin	176-187	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	117-120
19513514-9	2009	However, significant genotypic variation of TS, GST and ERCC1, which was assumed to affect the activity of oxaliplatin, was not observed to affect RR, toxicity and overall survival.	Oxaliplatin	107-118	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	56-61
19328230-2	2009	We show here that the DNA-damaging cisplatin-derived anticancer agent oxaliplatin induced both mitochondrial translocation and subsequent Bcl-xL interaction, whereas cisplatin did neither.	Oxaliplatin	70-81	BCL2 like 1	Homo sapiens	138-144
19217207-3	2009	Accordingly, TRAP1 levels were increased in HT-29 colorectal carcinoma cells resistant to 5-fluorouracil, oxaliplatin and irinotecan.	Oxaliplatin	106-117	TNF receptor associated protein 1	Homo sapiens	13-18
19217207-5	2009	Interestingly, TRAP1 overexpression leads to 5-fluorouracil-, oxaliplatin- and irinotecan-resistant phenotypes in different neoplastic cells.	Oxaliplatin	62-73	TNF receptor associated protein 1	Homo sapiens	15-20
19217207-6	2009	Conversely, the inhibition of TRAP1 activity by TRAP1 ATPase antagonist, shepherdin, increased the sensitivity to oxaliplatin and irinotecan in colorectal carcinoma cells resistant to the single agents.	Oxaliplatin	114-125	TNF receptor associated protein 1	Homo sapiens	30-35
19217207-6	2009	Conversely, the inhibition of TRAP1 activity by TRAP1 ATPase antagonist, shepherdin, increased the sensitivity to oxaliplatin and irinotecan in colorectal carcinoma cells resistant to the single agents.	Oxaliplatin	114-125	TNF receptor associated protein 1	Homo sapiens	48-53
19217207-6	2009	Conversely, the inhibition of TRAP1 activity by TRAP1 ATPase antagonist, shepherdin, increased the sensitivity to oxaliplatin and irinotecan in colorectal carcinoma cells resistant to the single agents.	Oxaliplatin	114-125	dynein axonemal heavy chain 8	Homo sapiens	54-60
19328230-6	2009	Conversely, oxaliplatin-induced translocation of p53 was prevented by cotreatment with an exogenous NO donor.	Oxaliplatin	12-23	tumor protein p53	Homo sapiens	49-52
19378397-4	2009	With cisplatin and oxaliplatin, a minor inhibition of CYP2C9 enzyme (75% of control at 400 miromol/l of these complexes) was seen; cisplatin also inhibited slightly the CYP2B6 activity (85% of control).	Oxaliplatin	19-30	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	54-60
19296535-0	2009	Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.	Oxaliplatin	125-136	ATPase copper transporting beta	Homo sapiens	46-51
19296535-6	2009	Furthermore, patients with low levels of both protein and mRNA of ATP7B derived the maximum benefit from oxaliplatin/5FU with the longest TTP as compared with patients with high levels of ATP7B protein and mRNA (14.64 months vs. 4.63 months, respectively, p = 0.01) and showed a nonsignificant trend toward a lower response rate (37.5% and 75%, respectively).	Oxaliplatin	105-116	ATPase copper transporting beta	Homo sapiens	66-71
19296535-7	2009	In conclusion, ATP7B mRNA and protein expression in colorectal tumors is associated with clinical outcome to oxaliplatin/5FU.	Oxaliplatin	109-120	ATPase copper transporting beta	Homo sapiens	15-20
19509588-14	2009	Oxaliplatin modulated radiation-induced DNA double-strand breaks, as indicated by delayed abrogation of gamma-H2AX, attenuation of radiation-induced phosphorylation of ataxia telangiectasia-mutated kinase and checkpoint kinase 2.	Oxaliplatin	0-11	checkpoint kinase 2	Homo sapiens	209-228
19581859-0	2009	Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.	Oxaliplatin	186-197	epidermal growth factor receptor	Homo sapiens	0-32
19383922-0	2009	Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.	Oxaliplatin	70-81	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	28-31
19383922-2	2009	One potential mediator of oxaliplatin sensitivity is the nonreceptor protein tyrosine kinase, Src, the activity of which correlates with disease stage and patient survival.	Oxaliplatin	26-37	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	94-97
19383922-3	2009	Therefore, we investigated the effects of Src inhibition using the tyrosine kinase inhibitor dasatinib on oxaliplatin sensitivity.	Oxaliplatin	106-117	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	42-45
19383922-4	2009	We show that oxaliplatin acutely activates Src and that combination treatment with dasatinib is synergistic in a cell-line dependent manner, with the level of Src activation correlating with extent of synergy in a panel of six cell lines.	Oxaliplatin	13-24	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	43-46
19383922-5	2009	Intracellular reactive oxygen species (ROS) are generated after oxaliplatin treatment, and ROS potently activates Src.	Oxaliplatin	64-75	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	114-117
19383922-6	2009	Pretreatment with antioxidants inhibits oxaliplatin-induced Src activation.	Oxaliplatin	40-51	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	60-63
19383922-7	2009	In oxaliplatin-resistant cell lines, Src activity is constitutively increased.	Oxaliplatin	3-14	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	37-40
19383922-8	2009	In a mouse model of colorectal liver metastases, treatment with oxaliplatin also results in chronic Src activation.	Oxaliplatin	64-75	Rous sarcoma oncogene	Mus musculus	100-103
19383922-10	2009	Therefore, we conclude that oxaliplatin activates Src through a ROS-dependent mechanism.	Oxaliplatin	28-39	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	50-53
19383922-11	2009	Src inhibition increases oxaliplatin activity both in vitro and in vivo.	Oxaliplatin	25-36	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
19223002-5	2009	Furthermore, the expression of the casitas B-lineage lymphoma (Cbl) family was downregulated by oxaliplatin.	Oxaliplatin	96-107	Cbl proto-oncogene	Homo sapiens	35-61
19240026-0	2009	Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation.	Oxaliplatin	37-48	sphingosine kinase 1	Homo sapiens	0-18
19240026-0	2009	Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation.	Oxaliplatin	37-48	AKT serine/threonine kinase 1	Homo sapiens	123-126
19240026-6	2009	In contrast, in l-OHP-resistant RKO cells, treatment with an SPHK inhibitor or SPHK1 and SPHK2 silencing by RNA interference suppressed cell viability and increased caspase activity and cellular ceramide formation after l-OHP treatment.	Oxaliplatin	16-21	sphingosine kinase 1	Homo sapiens	61-65
19240026-6	2009	In contrast, in l-OHP-resistant RKO cells, treatment with an SPHK inhibitor or SPHK1 and SPHK2 silencing by RNA interference suppressed cell viability and increased caspase activity and cellular ceramide formation after l-OHP treatment.	Oxaliplatin	16-21	sphingosine kinase 1	Homo sapiens	79-84
19240026-6	2009	In contrast, in l-OHP-resistant RKO cells, treatment with an SPHK inhibitor or SPHK1 and SPHK2 silencing by RNA interference suppressed cell viability and increased caspase activity and cellular ceramide formation after l-OHP treatment.	Oxaliplatin	16-21	sphingosine kinase 2	Homo sapiens	89-94
19240026-6	2009	In contrast, in l-OHP-resistant RKO cells, treatment with an SPHK inhibitor or SPHK1 and SPHK2 silencing by RNA interference suppressed cell viability and increased caspase activity and cellular ceramide formation after l-OHP treatment.	Oxaliplatin	220-225	sphingosine kinase 1	Homo sapiens	61-65
19240026-6	2009	In contrast, in l-OHP-resistant RKO cells, treatment with an SPHK inhibitor or SPHK1 and SPHK2 silencing by RNA interference suppressed cell viability and increased caspase activity and cellular ceramide formation after l-OHP treatment.	Oxaliplatin	220-225	sphingosine kinase 1	Homo sapiens	79-84
19240026-6	2009	In contrast, in l-OHP-resistant RKO cells, treatment with an SPHK inhibitor or SPHK1 and SPHK2 silencing by RNA interference suppressed cell viability and increased caspase activity and cellular ceramide formation after l-OHP treatment.	Oxaliplatin	220-225	sphingosine kinase 2	Homo sapiens	89-94
19240026-9	2009	Either SPHK1 or SPHK2 silencing in RKO cells decreased phosphorylated Akt levels and increased p53 and p21 protein levels as well as poly(ADP-ribose) polymerase cleavage in response to l-OHP treatment.	Oxaliplatin	185-190	sphingosine kinase 1	Homo sapiens	7-12
19240026-9	2009	Either SPHK1 or SPHK2 silencing in RKO cells decreased phosphorylated Akt levels and increased p53 and p21 protein levels as well as poly(ADP-ribose) polymerase cleavage in response to l-OHP treatment.	Oxaliplatin	185-190	sphingosine kinase 2	Homo sapiens	16-21
19372549-0	2009	A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines.	Oxaliplatin	70-81	pyruvate kinase M1/2	Homo sapiens	37-55
19372549-4	2009	In a panel of eight colorectal cancer cell lines, we found a negative correlation between oxaliplatin resistance and PK-M2 mRNA levels (Spearman r=-0.846, P=0.008).	Oxaliplatin	90-101	pyruvate kinase M1/2	Homo sapiens	117-122
19372549-5	2009	Oxaliplatin exposure in both HT29 and HTOXAR3 led to PK-M2 mRNA up-regulation.	Oxaliplatin	0-11	pyruvate kinase M1/2	Homo sapiens	53-58
19372549-6	2009	PK-M2 mRNA levels were measured by real-time quantitative PCR in 41 tumors treated with oxaliplatin/5-fluorouracil.	Oxaliplatin	88-99	pyruvate kinase M1/2	Homo sapiens	0-5
19372549-9	2009	In conclusion, the data provided clearly link PK-M2 expression and oxaliplatin resistance mechanisms and further implicate PK-M2 as a predictive marker of response in patients with oxaliplatin-treated colorectal cancer.	Oxaliplatin	67-78	pyruvate kinase M1/2	Homo sapiens	46-51
19372549-9	2009	In conclusion, the data provided clearly link PK-M2 expression and oxaliplatin resistance mechanisms and further implicate PK-M2 as a predictive marker of response in patients with oxaliplatin-treated colorectal cancer.	Oxaliplatin	181-192	pyruvate kinase M1/2	Homo sapiens	46-51
19372549-9	2009	In conclusion, the data provided clearly link PK-M2 expression and oxaliplatin resistance mechanisms and further implicate PK-M2 as a predictive marker of response in patients with oxaliplatin-treated colorectal cancer.	Oxaliplatin	181-192	pyruvate kinase M1/2	Homo sapiens	123-128
19223002-0	2009	Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts.	Oxaliplatin	0-11	TNF superfamily member 10	Homo sapiens	21-26
19223002-0	2009	Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts.	Oxaliplatin	0-11	Cbl proto-oncogene	Homo sapiens	72-75
19223002-3	2009	In the present study, we show that oxaliplatin enhanced TRAIL-induced apoptosis of MGC803, BGC823, and SGC7901 cells.	Oxaliplatin	35-46	TNF superfamily member 10	Homo sapiens	56-61
19223002-4	2009	Oxaliplatin promoted death receptor 4 (DR4) and death receptor 5 (DR5) clustering into aggregated lipid rafts, while the cholesterol-sequestering agent nystatin partially prevented lipid raft aggregation, DR4 and DR5 clustering, and reduced apoptosis.	Oxaliplatin	0-11	TNF receptor superfamily member 10a	Homo sapiens	21-37
19223002-4	2009	Oxaliplatin promoted death receptor 4 (DR4) and death receptor 5 (DR5) clustering into aggregated lipid rafts, while the cholesterol-sequestering agent nystatin partially prevented lipid raft aggregation, DR4 and DR5 clustering, and reduced apoptosis.	Oxaliplatin	0-11	TNF receptor superfamily member 10a	Homo sapiens	39-42
19223002-4	2009	Oxaliplatin promoted death receptor 4 (DR4) and death receptor 5 (DR5) clustering into aggregated lipid rafts, while the cholesterol-sequestering agent nystatin partially prevented lipid raft aggregation, DR4 and DR5 clustering, and reduced apoptosis.	Oxaliplatin	0-11	TNF receptor superfamily member 10b	Homo sapiens	48-64
19223002-4	2009	Oxaliplatin promoted death receptor 4 (DR4) and death receptor 5 (DR5) clustering into aggregated lipid rafts, while the cholesterol-sequestering agent nystatin partially prevented lipid raft aggregation, DR4 and DR5 clustering, and reduced apoptosis.	Oxaliplatin	0-11	TNF receptor superfamily member 10b	Homo sapiens	66-69
19548560-0	2009	[Influence of PAHs exposure and GSTT1, GSTM1 genotypes on urinary 1-OHP as exposure biomarker].	Oxaliplatin	66-71	glutathione S-transferase theta 1	Homo sapiens	32-37
19548560-0	2009	[Influence of PAHs exposure and GSTT1, GSTM1 genotypes on urinary 1-OHP as exposure biomarker].	Oxaliplatin	66-71	glutathione S-transferase mu 1	Homo sapiens	39-44
19548560-1	2009	OBJECTIVE: To study the influence of polycyclic aromatic hydrocarbons (PAHs) exposure (ambient concentration and smoking) and GSTT1, GSTM1, genotypes on urinary 1-OHP as exposure biomarker.	Oxaliplatin	161-166	glutathione S-transferase theta 1	Homo sapiens	126-131
19192254-3	2009	Studies were performed to determine the presence of oxaliplatin-dependent antibodies in addition to oxaliplatin-induced NIPA.	Oxaliplatin	100-111	zinc finger C3HC-type containing 1	Homo sapiens	120-124
19192254-9	2009	RBCs treated with oxaliplatin, cisplatin, and carboplatin all demonstrated NIPA (pooled normal sera and anti-human albumin were reactive to low titers).	Oxaliplatin	18-29	zinc finger C3HC-type containing 1	Homo sapiens	75-79
19192254-10	2009	NIPA was also detected in tests with untreated RBCs in the presence of oxaliplatin and cisplatin.	Oxaliplatin	71-82	zinc finger C3HC-type containing 1	Homo sapiens	0-4
19192254-14	2009	Oxaliplatin was also shown to cause NIPA.	Oxaliplatin	0-11	zinc finger C3HC-type containing 1	Homo sapiens	36-40
19223002-5	2009	Furthermore, the expression of the casitas B-lineage lymphoma (Cbl) family was downregulated by oxaliplatin.	Oxaliplatin	96-107	Cbl proto-oncogene	Homo sapiens	63-66
19223002-6	2009	Transfection of c-Cbl or Cbl-b partially reversed oxaliplatin-induced lipid raft aggregation.	Oxaliplatin	50-61	Cbl proto-oncogene	Homo sapiens	16-21
19223002-6	2009	Transfection of c-Cbl or Cbl-b partially reversed oxaliplatin-induced lipid raft aggregation.	Oxaliplatin	50-61	Cbl proto-oncogene B	Homo sapiens	25-30
19223002-7	2009	These results indicated that oxaliplatin enhanced TRAIL-induced gastric cancer cell apoptosis at least partially through Cbl-regulated death receptor redistribution in lipid rafts.	Oxaliplatin	29-40	TNF superfamily member 10	Homo sapiens	50-55
19223002-7	2009	These results indicated that oxaliplatin enhanced TRAIL-induced gastric cancer cell apoptosis at least partially through Cbl-regulated death receptor redistribution in lipid rafts.	Oxaliplatin	29-40	Cbl proto-oncogene	Homo sapiens	121-124
19084393-1	2009	PURPOSE: Oxaliplatin is detoxified by conjugation to glutathione via the enzyme Glutathione-S-transferase pi (GSTP1).	Oxaliplatin	9-20	glutathione S-transferase pi 1	Homo sapiens	110-115
19354063-6	2009	Platinum agents (cisplatin, carboplatin, oxaliplatin) are associated with IgE-mediated hypersensitivity reactions, and skin testing may be indicated.	Oxaliplatin	41-52	immunoglobulin heavy constant epsilon	Homo sapiens	74-77
19084393-2	2009	The aim of this study is to investigate the association of GSTP1 Ile105Val genetic polymorphism with oxaliplatin efficacy and toxicity in advanced colorectal cancer (ACC) patients.	Oxaliplatin	101-112	glutathione S-transferase pi 1	Homo sapiens	59-64
19428505-4	2009	Both oxaliplatin and cisplatin induced a dose-dependent neuronal apoptosis, modulated by the proteins of Bcl-2 family.	Oxaliplatin	5-16	BCL2 apoptosis regulator	Homo sapiens	105-110
19428505-6	2009	Both oxaliplatin and cisplatin activated ERKs at early stages, although they behaved differently at later stages.	Oxaliplatin	5-16	mitogen-activated protein kinase 3	Homo sapiens	41-45
19084386-0	2009	Spectroscopic investigation on the binding of antineoplastic drug oxaliplatin to human serum albumin and molecular modeling.	Oxaliplatin	66-77	albumin	Homo sapiens	87-100
19084386-1	2009	This study was designed to examine the interaction of oxaliplatin with human serum albumin (HSA) under physiological conditions by using fluorescence, absorption, FT-IR and circular dichroism (CD) spectroscopic techniques in combination with molecular docking study.	Oxaliplatin	54-65	albumin	Homo sapiens	77-90
19068092-5	2009	These data suggest that Asian populations have a significantly higher prevalence of the C/C genotype in ERCC1 codon 118, which could be a key determinant for good responses to oxaliplatin-based treatment and favorable outcomes.	Oxaliplatin	176-187	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	104-109
19194123-1	2009	BACKGROUND: The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy.	Oxaliplatin	297-308	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	81-118
19194123-1	2009	BACKGROUND: The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy.	Oxaliplatin	297-308	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	120-125
19194123-1	2009	BACKGROUND: The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy.	Oxaliplatin	297-308	thymidylate synthetase	Homo sapiens	128-148
19194123-12	2009	CONCLUSION: Immunohistochemical study of ERCC1 and TS may be useful for the prediction of clinical outcome in patients with advanced colorectal cancer treated with 5-FU and oxaliplatin.	Oxaliplatin	173-184	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	41-46
19194123-12	2009	CONCLUSION: Immunohistochemical study of ERCC1 and TS may be useful for the prediction of clinical outcome in patients with advanced colorectal cancer treated with 5-FU and oxaliplatin.	Oxaliplatin	173-184	thymidylate synthetase	Homo sapiens	51-53
19147571-0	2009	gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.	Oxaliplatin	36-47	notch receptor 1	Homo sapiens	74-81
18996970-5	2009	Loss of CTR1 almost completely eliminated the initial influx of CBDCA and reduced the initial uptake of L-OHP by 68% but had no effect on the influx of transplatin.	Oxaliplatin	104-109	solute carrier family 31 member 1	Homo sapiens	8-12
18996970-8	2009	We conclude that CTR1 mediates the initial influx of DDP, CBDCA, and L-OHP and is a major determinant of responsiveness to DDP both in vitro and in vivo.	Oxaliplatin	69-74	solute carrier family 31 member 1	Homo sapiens	17-21
19147571-3	2009	We then report that chemotherapy induces Notch-1, as oxaliplatin, 5-fluorouracil (5-FU), or SN-38 (the active metabolite of irinotecan) induced Notch-1 intracellular domain (NICD) protein and activated Hes-1.	Oxaliplatin	53-64	notch receptor 1	Homo sapiens	144-151
19147571-3	2009	We then report that chemotherapy induces Notch-1, as oxaliplatin, 5-fluorouracil (5-FU), or SN-38 (the active metabolite of irinotecan) induced Notch-1 intracellular domain (NICD) protein and activated Hes-1.	Oxaliplatin	53-64	notch receptor 1	Homo sapiens	41-48
19147571-3	2009	We then report that chemotherapy induces Notch-1, as oxaliplatin, 5-fluorouracil (5-FU), or SN-38 (the active metabolite of irinotecan) induced Notch-1 intracellular domain (NICD) protein and activated Hes-1.	Oxaliplatin	53-64	hes family bHLH transcription factor 1	Homo sapiens	202-207
19147571-6	2009	Blocking the activation of Notch signaling with GSI34 sensitized cells to chemotherapy and was synergistic with oxaliplatin, 5-FU, and SN-38.	Oxaliplatin	112-123	notch receptor 1	Homo sapiens	27-32
19147571-8	2009	Down-regulation of Notch signaling also prevented the induction of prosurvival pathways, most notably phosphoinositide kinase-3/Akt, after oxaliplatin.	Oxaliplatin	139-150	notch receptor 1	Homo sapiens	19-24
19128511-6	2009	RESULTS: After exposing the cholangiocarcinoma cell lines RMCCA1 and KKU100 to oxaliplatin, the levels of Akt and mTOR phosphorylation increased, as shown by western blot analysis.	Oxaliplatin	79-90	AKT serine/threonine kinase 1	Homo sapiens	106-109
19126215-10	2009	RESULTS: The results revealed increased caspase 3 gene expressions and activities in HT 29 cells treated with cisplatin, oxaliplatin and doxycycline; however the combination of doxycycline with cisplatin and oxaliplatin did not report increased caspase 3 gene expressions and activity compared to cisplatin and oxaliplatin alone.	Oxaliplatin	121-132	caspase 3	Homo sapiens	40-49
19128511-6	2009	RESULTS: After exposing the cholangiocarcinoma cell lines RMCCA1 and KKU100 to oxaliplatin, the levels of Akt and mTOR phosphorylation increased, as shown by western blot analysis.	Oxaliplatin	79-90	mechanistic target of rapamycin kinase	Homo sapiens	114-118
19128511-9	2009	Deactivation of mTOR by RAD001 was also synergistic with oxaliplatin, although to a lesser extent.	Oxaliplatin	57-68	mechanistic target of rapamycin kinase	Homo sapiens	16-20
19128511-12	2009	Although the inhibition of PI3K and the inhibition of mTOR both enhance oxaliplatin-induced cytotoxicity, PI3K inhibition has a greater effect.	Oxaliplatin	72-83	mechanistic target of rapamycin kinase	Homo sapiens	54-58
19126215-10	2009	RESULTS: The results revealed increased caspase 3 gene expressions and activities in HT 29 cells treated with cisplatin, oxaliplatin and doxycycline; however the combination of doxycycline with cisplatin and oxaliplatin did not report increased caspase 3 gene expressions and activity compared to cisplatin and oxaliplatin alone.	Oxaliplatin	121-132	caspase 3	Homo sapiens	245-254
19126215-10	2009	RESULTS: The results revealed increased caspase 3 gene expressions and activities in HT 29 cells treated with cisplatin, oxaliplatin and doxycycline; however the combination of doxycycline with cisplatin and oxaliplatin did not report increased caspase 3 gene expressions and activity compared to cisplatin and oxaliplatin alone.	Oxaliplatin	208-219	caspase 3	Homo sapiens	40-49
19126215-10	2009	RESULTS: The results revealed increased caspase 3 gene expressions and activities in HT 29 cells treated with cisplatin, oxaliplatin and doxycycline; however the combination of doxycycline with cisplatin and oxaliplatin did not report increased caspase 3 gene expressions and activity compared to cisplatin and oxaliplatin alone.	Oxaliplatin	208-219	caspase 3	Homo sapiens	40-49
19414151-7	2009	Efficacy of oxaliplatin is influenced by polymorphisms in components of DNA repair systems, such as ERCC1 and XRCC1.	Oxaliplatin	12-23	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	100-105
19343004-0	2009	Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin.	Oxaliplatin	130-141	alpha fetoprotein	Homo sapiens	0-17
19414151-7	2009	Efficacy of oxaliplatin is influenced by polymorphisms in components of DNA repair systems, such as ERCC1 and XRCC1.	Oxaliplatin	12-23	X-ray repair cross complementing 1	Homo sapiens	110-115
19738391-0	2009	Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy.	Oxaliplatin	78-89	sodium voltage-gated channel alpha subunit 2	Homo sapiens	51-56
22276017-7	2009	ERCC1 (excision repair cross-complementation group 1) mediated nucleotide excision repair pathway appears to be the major pathway involved in processing oxaliplatin, because the loss of mismatch repair does not lead to oxaliplatin resistance.	Oxaliplatin	153-164	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
19015155-6	2009	Treatment of HCT116 p53(+/+) cells with the DNA-damaging agent oxaliplatin induced a p53-dependent transcriptional downregulation of dUTPase not observed in the isogenic null cell line.	Oxaliplatin	63-74	tumor protein p53	Homo sapiens	20-23
19015155-6	2009	Treatment of HCT116 p53(+/+) cells with the DNA-damaging agent oxaliplatin induced a p53-dependent transcriptional downregulation of dUTPase not observed in the isogenic null cell line.	Oxaliplatin	63-74	tumor protein p53	Homo sapiens	85-88
19015155-6	2009	Treatment of HCT116 p53(+/+) cells with the DNA-damaging agent oxaliplatin induced a p53-dependent transcriptional downregulation of dUTPase not observed in the isogenic null cell line.	Oxaliplatin	63-74	Deoxyuridine triphosphatase	Drosophila melanogaster	133-140
19015155-7	2009	Oxaliplatin treatment induced enrichment of p53 at the dUTPase promoter with a concomitant reduction in Sp1.	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	44-47
19015155-7	2009	Oxaliplatin treatment induced enrichment of p53 at the dUTPase promoter with a concomitant reduction in Sp1.	Oxaliplatin	0-11	Deoxyuridine triphosphatase	Drosophila melanogaster	55-62
19015155-8	2009	The suppression of dUTPase by oxaliplatin promoted increased levels of dUTP that was enhanced by subsequent addition of fluoropyrimidines.	Oxaliplatin	30-41	Deoxyuridine triphosphatase	Drosophila melanogaster	19-26
19015155-9	2009	The novel observation that oxaliplatin downregulates dUTPase expression may provide a mechanistic basis contributing to the synergy observed between 5-FU and oxaliplatin in the clinic.	Oxaliplatin	27-38	Deoxyuridine triphosphatase	Drosophila melanogaster	53-60
19015155-9	2009	The novel observation that oxaliplatin downregulates dUTPase expression may provide a mechanistic basis contributing to the synergy observed between 5-FU and oxaliplatin in the clinic.	Oxaliplatin	158-169	Deoxyuridine triphosphatase	Drosophila melanogaster	53-60
19203538-0	2009	Influence of the hOCT2 inhibitor cimetidine on the cellular accumulation and cytotoxicity of oxaliplatin.	Oxaliplatin	93-104	POU class 2 homeobox 2	Homo sapiens	17-22
19015155-0	2009	Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage.	Oxaliplatin	103-114	Deoxyuridine triphosphatase	Drosophila melanogaster	20-27
19015155-0	2009	Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage.	Oxaliplatin	103-114	tumor protein p53	Homo sapiens	48-51
19738391-1	2009	AIM: It was the aim of this study to test the hypothesis that the voltage-gated sodium channel gene SCN2A R19K polymorphism confers liability to oxaliplatin-induced peripheral neuropathy (OXLIPN).	Oxaliplatin	145-156	sodium voltage-gated channel alpha subunit 2	Homo sapiens	100-105
19266094-0	2009	The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.	Oxaliplatin	106-117	matrix metallopeptidase 7	Homo sapiens	12-16
19266094-0	2009	The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.	Oxaliplatin	106-117	Fas ligand	Homo sapiens	49-53
19266094-4	2009	The aim of the present study was to analyze the role of MMP7 and its cross-talk with the Fas/FasL system during the acquisition of oxaliplatin resistance in colon cancer cells.	Oxaliplatin	131-142	matrix metallopeptidase 7	Homo sapiens	56-60
19266094-4	2009	The aim of the present study was to analyze the role of MMP7 and its cross-talk with the Fas/FasL system during the acquisition of oxaliplatin resistance in colon cancer cells.	Oxaliplatin	131-142	Fas ligand	Homo sapiens	93-97
19266094-7	2009	MMP7 was also upregulated by oxaliplatin in both HT29 (p53 mutant) and RHCT116 p53(-/-) but not in the RHCT116 p53(+/+).	Oxaliplatin	29-40	matrix metallopeptidase 7	Homo sapiens	0-4
19266094-7	2009	MMP7 was also upregulated by oxaliplatin in both HT29 (p53 mutant) and RHCT116 p53(-/-) but not in the RHCT116 p53(+/+).	Oxaliplatin	29-40	tumor protein p53	Homo sapiens	55-58
19266094-7	2009	MMP7 was also upregulated by oxaliplatin in both HT29 (p53 mutant) and RHCT116 p53(-/-) but not in the RHCT116 p53(+/+).	Oxaliplatin	29-40	tumor protein p53	Homo sapiens	79-82
19266094-7	2009	MMP7 was also upregulated by oxaliplatin in both HT29 (p53 mutant) and RHCT116 p53(-/-) but not in the RHCT116 p53(+/+).	Oxaliplatin	29-40	tumor protein p53	Homo sapiens	79-82
19266094-8	2009	Inhibition of MMP by 1,10-phenantroline monohydrate or siRNA of MMP7 restores cell sensitivity to oxaliplatin-induced apoptosis in both HT29 and RHCT116 p53(-/-) but not in the RHCT116 p53(+/+).	Oxaliplatin	98-109	matrix metallopeptidase 7	Homo sapiens	64-68
19266094-8	2009	Inhibition of MMP by 1,10-phenantroline monohydrate or siRNA of MMP7 restores cell sensitivity to oxaliplatin-induced apoptosis in both HT29 and RHCT116 p53(-/-) but not in the RHCT116 p53(+/+).	Oxaliplatin	98-109	tumor protein p53	Homo sapiens	153-156
19266094-8	2009	Inhibition of MMP by 1,10-phenantroline monohydrate or siRNA of MMP7 restores cell sensitivity to oxaliplatin-induced apoptosis in both HT29 and RHCT116 p53(-/-) but not in the RHCT116 p53(+/+).	Oxaliplatin	98-109	tumor protein p53	Homo sapiens	185-188
19266094-13	2009	CONCLUSIONS: Taking together, these results suggest that MMP7 is related to the acquisition of oxaliplatin-resistance and that its inhibition restores drug sensitivity by increasing Fas receptor.	Oxaliplatin	95-106	matrix metallopeptidase 7	Homo sapiens	57-61
18780829-5	2008	In addition, oxaliplatin increased the transcription and secretion of CXCL8 and the related CXC-chemokine CXCL1 and increased the transcription and expression of CXC-chemokine receptors, especially CXC-chemokine receptor (CXCR) 2, which transduces the biological effects of CXCL8 and CXCL1.	Oxaliplatin	13-24	C-X-C motif chemokine ligand 1	Homo sapiens	284-289
19047118-1	2008	PURPOSE: Recently, an objective response rate of 12% was reported in a phase II study of cetuximab in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (IMC-0144).	Oxaliplatin	236-247	epidermal growth factor receptor	Homo sapiens	116-148
19047118-1	2008	PURPOSE: Recently, an objective response rate of 12% was reported in a phase II study of cetuximab in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (IMC-0144).	Oxaliplatin	236-247	epidermal growth factor receptor	Homo sapiens	150-154
19098406-0	2008	[Single nucleotide polymorphism analysis in the GSTP1 and ABCC2 genes about neuropathy by the Oxaliplatin].	Oxaliplatin	94-105	glutathione S-transferase pi 1	Homo sapiens	48-53
19098406-0	2008	[Single nucleotide polymorphism analysis in the GSTP1 and ABCC2 genes about neuropathy by the Oxaliplatin].	Oxaliplatin	94-105	ATP binding cassette subfamily C member 2	Homo sapiens	58-63
19098406-11	2008	As for a successful rate of the treatment, the wild type and hetero type of GSTP1, a metabolism enzyme of Oxaliplatin, were 53.3% and 41.7%, respectively.	Oxaliplatin	106-117	glutathione S-transferase pi 1	Homo sapiens	76-81
19020759-2	2008	The expression levels of thymidylate synthase (TS) and excision repair cross-complementing factor 1 (ERCC1) have been reported to be prognostic markers for patients with 5-FU/oxaliplatin chemotherapy.	Oxaliplatin	175-186	thymidylate synthetase	Homo sapiens	25-45
19020759-2	2008	The expression levels of thymidylate synthase (TS) and excision repair cross-complementing factor 1 (ERCC1) have been reported to be prognostic markers for patients with 5-FU/oxaliplatin chemotherapy.	Oxaliplatin	175-186	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	55-99
19020759-2	2008	The expression levels of thymidylate synthase (TS) and excision repair cross-complementing factor 1 (ERCC1) have been reported to be prognostic markers for patients with 5-FU/oxaliplatin chemotherapy.	Oxaliplatin	175-186	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	101-106
18780829-3	2008	This study sought to determine the significance of CXCL8 signaling in regulating the response of AIPC cells to oxaliplatin, a drug whose activity is reportedly sensitive to NF-kappaB activity.	Oxaliplatin	111-122	C-X-C motif chemokine ligand 8	Homo sapiens	51-56
18780829-4	2008	Administration of oxaliplatin to PC3 and DU145 cells increased NF-kappaB activity, promoting antiapoptotic gene transcription.	Oxaliplatin	18-29	chromobox 8	Homo sapiens	33-36
18780829-5	2008	In addition, oxaliplatin increased the transcription and secretion of CXCL8 and the related CXC-chemokine CXCL1 and increased the transcription and expression of CXC-chemokine receptors, especially CXC-chemokine receptor (CXCR) 2, which transduces the biological effects of CXCL8 and CXCL1.	Oxaliplatin	13-24	C-X-C motif chemokine ligand 8	Homo sapiens	70-75
18780829-7	2008	Coadministration of a CXCR2-selective antagonist, AZ10397767 (Bioorg Med Chem Lett 18:798-803, 2008), attenuated oxaliplatin-induced NF-kappaB activation, increased oxaliplatin cytotoxicity, and potentiated oxaliplatin-induced apoptosis in AIPC cells.	Oxaliplatin	113-124	C-X-C motif chemokine receptor 2	Homo sapiens	22-27
18780829-5	2008	In addition, oxaliplatin increased the transcription and secretion of CXCL8 and the related CXC-chemokine CXCL1 and increased the transcription and expression of CXC-chemokine receptors, especially CXC-chemokine receptor (CXCR) 2, which transduces the biological effects of CXCL8 and CXCL1.	Oxaliplatin	13-24	C-X-C motif chemokine ligand 1	Homo sapiens	106-111
18780829-5	2008	In addition, oxaliplatin increased the transcription and secretion of CXCL8 and the related CXC-chemokine CXCL1 and increased the transcription and expression of CXC-chemokine receptors, especially CXC-chemokine receptor (CXCR) 2, which transduces the biological effects of CXCL8 and CXCL1.	Oxaliplatin	13-24	C-X-C motif chemokine receptor 2	Homo sapiens	198-229
18780829-7	2008	Coadministration of a CXCR2-selective antagonist, AZ10397767 (Bioorg Med Chem Lett 18:798-803, 2008), attenuated oxaliplatin-induced NF-kappaB activation, increased oxaliplatin cytotoxicity, and potentiated oxaliplatin-induced apoptosis in AIPC cells.	Oxaliplatin	165-176	C-X-C motif chemokine receptor 2	Homo sapiens	22-27
18780829-5	2008	In addition, oxaliplatin increased the transcription and secretion of CXCL8 and the related CXC-chemokine CXCL1 and increased the transcription and expression of CXC-chemokine receptors, especially CXC-chemokine receptor (CXCR) 2, which transduces the biological effects of CXCL8 and CXCL1.	Oxaliplatin	13-24	C-X-C motif chemokine ligand 8	Homo sapiens	274-279
18780829-7	2008	Coadministration of a CXCR2-selective antagonist, AZ10397767 (Bioorg Med Chem Lett 18:798-803, 2008), attenuated oxaliplatin-induced NF-kappaB activation, increased oxaliplatin cytotoxicity, and potentiated oxaliplatin-induced apoptosis in AIPC cells.	Oxaliplatin	165-176	C-X-C motif chemokine receptor 2	Homo sapiens	22-27
18780829-8	2008	Pharmacological inhibition of NF-kappaBorRNA interference-mediated suppression of Bcl-2 and survivin was also shown to sensitize AIPC cells to oxaliplatin.	Oxaliplatin	143-154	BCL2 apoptosis regulator	Homo sapiens	82-87
18594845-4	2008	Our study investigated the value of high degree of MSI (MSI-H) in patients treated with 5-FU/oxaliplatin-based chemotherapy which has been done by only one further study recently.	Oxaliplatin	93-104	RB binding protein 4, chromatin remodeling factor	Homo sapiens	51-54
18801423-4	2008	Cytotoxicity of cisplatin (CIP), carboplatin (CAP) and oxaliplatin (OXP) was significantly lowered in MDCKII cells transfected with ABCG2 transporter and EGFP reporter.	Oxaliplatin	55-66	ATP binding cassette subfamily G member 2	Canis lupus familiaris	132-137
18801423-4	2008	Cytotoxicity of cisplatin (CIP), carboplatin (CAP) and oxaliplatin (OXP) was significantly lowered in MDCKII cells transfected with ABCG2 transporter and EGFP reporter.	Oxaliplatin	68-71	ATP binding cassette subfamily G member 2	Canis lupus familiaris	132-137
19009659-0	2008	ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.	Oxaliplatin	55-66	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
19009659-1	2008	AIM: To determine the influence of excision repair cross complementing group 1 (ERCC1) codon 118 polymorphism and mRNA level on the clinical outcome of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	189-200	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	35-78
19009659-1	2008	AIM: To determine the influence of excision repair cross complementing group 1 (ERCC1) codon 118 polymorphism and mRNA level on the clinical outcome of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.	Oxaliplatin	189-200	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	80-85
19009659-7	2008	Multivariate analysis also showed that ERCC1 mRNA level was a potential predictor for relapse and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy (P&lt;0.05).	Oxaliplatin	147-158	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	39-44
18710896-10	2008	In conclusion, the hOCT3-mediated uptake of oxaliplatin into the cancers was suggested to be important for its cytotoxicity, and hOCT3 expression may be a marker for cancer chemotherapy including oxaliplatin.	Oxaliplatin	44-55	solute carrier family 22 member 3	Homo sapiens	19-24
18710896-10	2008	In conclusion, the hOCT3-mediated uptake of oxaliplatin into the cancers was suggested to be important for its cytotoxicity, and hOCT3 expression may be a marker for cancer chemotherapy including oxaliplatin.	Oxaliplatin	196-207	solute carrier family 22 member 3	Homo sapiens	19-24
19000447-9	2008	The inhibition rates of paclitaxel (PTX), oxaliplatin (OXA) or cisplatin (DDP) on cancer cells were significantly lower in the group with strong P-gp expression than that with weak P-gp expression (all P&lt;0.05).	Oxaliplatin	42-53	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
19000447-9	2008	The inhibition rates of paclitaxel (PTX), oxaliplatin (OXA) or cisplatin (DDP) on cancer cells were significantly lower in the group with strong P-gp expression than that with weak P-gp expression (all P&lt;0.05).	Oxaliplatin	55-58	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
19000447-9	2008	The inhibition rates of paclitaxel (PTX), oxaliplatin (OXA) or cisplatin (DDP) on cancer cells were significantly lower in the group with strong P-gp expression than that with weak P-gp expression (all P&lt;0.05).	Oxaliplatin	55-58	ATP binding cassette subfamily B member 1	Homo sapiens	181-185
18710896-0	2008	Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.	Oxaliplatin	94-105	OCTN3	Homo sapiens	16-44
18710896-0	2008	Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.	Oxaliplatin	94-105	solute carrier family 22 member 3	Homo sapiens	46-53
18710896-2	2008	We found previously that oxaliplatin, but not cisplatin, was transported by human (h) and rat organic cation transporter 3 (OCT3)/SLC22A3.	Oxaliplatin	25-36	solute carrier family 22 member 3	Rattus norvegicus	94-122
18710896-2	2008	We found previously that oxaliplatin, but not cisplatin, was transported by human (h) and rat organic cation transporter 3 (OCT3)/SLC22A3.	Oxaliplatin	25-36	solute carrier family 22 member 3	Rattus norvegicus	124-128
18710896-2	2008	We found previously that oxaliplatin, but not cisplatin, was transported by human (h) and rat organic cation transporter 3 (OCT3)/SLC22A3.	Oxaliplatin	25-36	solute carrier family 22 member 3	Rattus norvegicus	130-137
18710896-3	2008	In the present study, we examined whether hOCT3 was significantly involved in the oxaliplatin-induced cytotoxicity and accumulation of platinum in colorectal cancer.	Oxaliplatin	82-93	solute carrier family 22 member 3	Homo sapiens	42-47
18710896-6	2008	The release of lactate dehydrogenase (LDH) and accumulation of platinum with oxaliplatin treatment were increased in SW480 cells transfected with hOCT3 cDNA compared with empty vector-transfected cells.	Oxaliplatin	77-88	solute carrier family 22 member 3	Homo sapiens	146-151
18955806-3	2008	Oxaliplatin was the most sensitive drug based on the ATP-CRA where the specimen obtained by ultrasound- guided percutaneous liver biopsy was used.	Oxaliplatin	0-11	myotubularin related protein 11	Homo sapiens	57-60
18767116-0	2008	Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells.	Oxaliplatin	34-45	CASP8 and FADD like apoptosis regulator	Homo sapiens	18-24
18767116-0	2008	Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells.	Oxaliplatin	34-45	X-linked inhibitor of apoptosis	Homo sapiens	82-86
18767116-0	2008	Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells.	Oxaliplatin	34-45	AKT serine/threonine kinase 1	Homo sapiens	101-104
18767116-2	2008	We observed that oxaliplatin induced apoptosis, the activation of DEVDase activity, DNA fragmentation, and cleavage of PLC-gamma1 and degradation of XIAP protein in dose-dependent manners, which was prevented by pretreatment with z-VAD or NAC, suggesting that oxaliplatin-induced apoptosis was mediated by caspase- or reactive oxygen species (ROS)-dependent pathways.	Oxaliplatin	17-28	phospholipase C gamma 1	Homo sapiens	119-129
18767116-2	2008	We observed that oxaliplatin induced apoptosis, the activation of DEVDase activity, DNA fragmentation, and cleavage of PLC-gamma1 and degradation of XIAP protein in dose-dependent manners, which was prevented by pretreatment with z-VAD or NAC, suggesting that oxaliplatin-induced apoptosis was mediated by caspase- or reactive oxygen species (ROS)-dependent pathways.	Oxaliplatin	17-28	X-linked inhibitor of apoptosis	Homo sapiens	149-153
18767116-2	2008	We observed that oxaliplatin induced apoptosis, the activation of DEVDase activity, DNA fragmentation, and cleavage of PLC-gamma1 and degradation of XIAP protein in dose-dependent manners, which was prevented by pretreatment with z-VAD or NAC, suggesting that oxaliplatin-induced apoptosis was mediated by caspase- or reactive oxygen species (ROS)-dependent pathways.	Oxaliplatin	17-28	X-linked Kx blood group	Homo sapiens	239-242
18767116-2	2008	We observed that oxaliplatin induced apoptosis, the activation of DEVDase activity, DNA fragmentation, and cleavage of PLC-gamma1 and degradation of XIAP protein in dose-dependent manners, which was prevented by pretreatment with z-VAD or NAC, suggesting that oxaliplatin-induced apoptosis was mediated by caspase- or reactive oxygen species (ROS)-dependent pathways.	Oxaliplatin	260-271	X-linked Kx blood group	Homo sapiens	239-242
18767116-3	2008	Furthermore, ectopic expression of cFLIPs potently attenuated oxaliplatin-induced apoptosis, whereas cFLIP(L) had less effect.	Oxaliplatin	62-73	CASP8 and FADD like apoptosis regulator	Homo sapiens	35-41
18767116-4	2008	Interestingly, we found that the protein level of XIAP was sustained in oxaliplatin-treated cFLIPs overexpressing cell, which was caused by the increased XIAP protein stability and that the phospho-Akt level was high compared to vector-transfected cell.	Oxaliplatin	72-83	X-linked inhibitor of apoptosis	Homo sapiens	50-54
18767116-4	2008	Interestingly, we found that the protein level of XIAP was sustained in oxaliplatin-treated cFLIPs overexpressing cell, which was caused by the increased XIAP protein stability and that the phospho-Akt level was high compared to vector-transfected cell.	Oxaliplatin	72-83	CASP8 and FADD like apoptosis regulator	Homo sapiens	92-98
18767116-4	2008	Interestingly, we found that the protein level of XIAP was sustained in oxaliplatin-treated cFLIPs overexpressing cell, which was caused by the increased XIAP protein stability and that the phospho-Akt level was high compared to vector-transfected cell.	Oxaliplatin	72-83	X-linked inhibitor of apoptosis	Homo sapiens	154-158
18767116-4	2008	Interestingly, we found that the protein level of XIAP was sustained in oxaliplatin-treated cFLIPs overexpressing cell, which was caused by the increased XIAP protein stability and that the phospho-Akt level was high compared to vector-transfected cell.	Oxaliplatin	72-83	AKT serine/threonine kinase 1	Homo sapiens	198-201
18767116-6	2008	Thus, our findings imply that the anti-apoptotic functions of cFLIPs may be attributed to inhibit oxaliplatin-induced apoptosis through the sustained XIAP protein level and Akt activation.	Oxaliplatin	98-109	CASP8 and FADD like apoptosis regulator	Homo sapiens	62-68
18767116-6	2008	Thus, our findings imply that the anti-apoptotic functions of cFLIPs may be attributed to inhibit oxaliplatin-induced apoptosis through the sustained XIAP protein level and Akt activation.	Oxaliplatin	98-109	X-linked inhibitor of apoptosis	Homo sapiens	150-154
18767116-6	2008	Thus, our findings imply that the anti-apoptotic functions of cFLIPs may be attributed to inhibit oxaliplatin-induced apoptosis through the sustained XIAP protein level and Akt activation.	Oxaliplatin	98-109	AKT serine/threonine kinase 1	Homo sapiens	173-176
18788725-1	2008	The liver-specific organic cation transport protein (OCT1; SLC22A1) transports several cationic drugs including the antidiabetic drug metformin and the anticancer agents oxaliplatin and imatinib.	Oxaliplatin	170-181	solute carrier family 22 member 1	Homo sapiens	53-57
18788725-1	2008	The liver-specific organic cation transport protein (OCT1; SLC22A1) transports several cationic drugs including the antidiabetic drug metformin and the anticancer agents oxaliplatin and imatinib.	Oxaliplatin	170-181	solute carrier family 22 member 1	Homo sapiens	59-66
17684476-0	2008	Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?	Oxaliplatin	169-180	thymidylate synthetase	Homo sapiens	42-62
18790747-6	2008	Inhibition of c-FLIP expression was shown to induce spontaneous apoptosis in both cell lines and to sensitize these prostate cancer cells to treatment with TRAIL, oxaliplatin, and docetaxel.	Oxaliplatin	163-174	CASP8 and FADD like apoptosis regulator	Homo sapiens	14-20
18030470-10	2008	In addition, the cellular accumulation of platinum and level of ATP7A mRNA may be factors affecting the cytotoxicity of cisplatin, while the cytotoxicity of oxaliplatin was suggested to be affected by the levels of ATP7A and hOCT1 mRNAs.	Oxaliplatin	157-168	ATPase copper transporting alpha	Homo sapiens	215-220
18030470-10	2008	In addition, the cellular accumulation of platinum and level of ATP7A mRNA may be factors affecting the cytotoxicity of cisplatin, while the cytotoxicity of oxaliplatin was suggested to be affected by the levels of ATP7A and hOCT1 mRNAs.	Oxaliplatin	157-168	solute carrier family 22 member 1	Homo sapiens	225-230
19102417-2	2008	We retrospectively evaluated neoadjuvant chemotherapy with oxaliplatin, leucovorin and 5-flurouracil (OLF) in patients with locally advanced gastric cancer to determine its feasibility, as well as impact on the curative resection rate and patients" survival.	Oxaliplatin	59-70	transmembrane O-mannosyltransferase targeting cadherins 1	Homo sapiens	102-105
18845990-2	2008	Preclinical studies indicate synergism between the EGFR inhibitor gefitinib and oxaliplatin or radiotherapy (RT).	Oxaliplatin	80-91	epidermal growth factor receptor	Homo sapiens	51-55
18790786-5	2008	The effect of oxaliplatin on VEGF-A transcriptional activity was determined by promoter assays.	Oxaliplatin	14-25	vascular endothelial growth factor A	Homo sapiens	29-35
18790786-6	2008	Acute exposure of human colorectal cancer cells to oxaliplatin led to a marked induction of VEGF-A mRNA and protein, whereas 5-fluorouracil alone or when added to oxaliplatin did not cause a further increase in VEGF levels.	Oxaliplatin	51-62	vascular endothelial growth factor A	Homo sapiens	92-98
18790786-6	2008	Acute exposure of human colorectal cancer cells to oxaliplatin led to a marked induction of VEGF-A mRNA and protein, whereas 5-fluorouracil alone or when added to oxaliplatin did not cause a further increase in VEGF levels.	Oxaliplatin	51-62	vascular endothelial growth factor A	Homo sapiens	92-96
18790786-7	2008	VEGF-A promoter activity was induced by oxaliplatin exposure.	Oxaliplatin	40-51	vascular endothelial growth factor A	Homo sapiens	0-6
18790786-8	2008	Expression of VEGF-C, placental growth factor, VEGFR-1, and neuropilin-1 levels were also increased when cells were treated with oxaliplatin.	Oxaliplatin	129-140	vascular endothelial growth factor C	Homo sapiens	14-20
18790786-8	2008	Expression of VEGF-C, placental growth factor, VEGFR-1, and neuropilin-1 levels were also increased when cells were treated with oxaliplatin.	Oxaliplatin	129-140	fms related receptor tyrosine kinase 1	Homo sapiens	47-54
18790786-8	2008	Expression of VEGF-C, placental growth factor, VEGFR-1, and neuropilin-1 levels were also increased when cells were treated with oxaliplatin.	Oxaliplatin	129-140	neuropilin 1	Homo sapiens	60-72
18790786-9	2008	Oxaliplatin led to an increase in Akt and Src activation in HT29 cells.	Oxaliplatin	0-11	AKT serine/threonine kinase 1	Homo sapiens	34-37
18790786-9	2008	Oxaliplatin led to an increase in Akt and Src activation in HT29 cells.	Oxaliplatin	0-11	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	42-45
18790786-10	2008	In contrast, Akt activation did not change in RKO cells whereas phospho-Src and phospho-p44/42 mitogen-activated protein kinase was dramatic increased by oxaliplatin.	Oxaliplatin	154-165	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	72-75
18790786-11	2008	Inhibition of Akt or Src activation with wortmannin or PP2 blocked induction of VEGF-A by oxaliplatin in HT29 or RKO cells, respectively.	Oxaliplatin	90-101	AKT serine/threonine kinase 1	Homo sapiens	14-17
18790786-11	2008	Inhibition of Akt or Src activation with wortmannin or PP2 blocked induction of VEGF-A by oxaliplatin in HT29 or RKO cells, respectively.	Oxaliplatin	90-101	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	21-24
18790786-11	2008	Inhibition of Akt or Src activation with wortmannin or PP2 blocked induction of VEGF-A by oxaliplatin in HT29 or RKO cells, respectively.	Oxaliplatin	90-101	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	55-58
18790786-11	2008	Inhibition of Akt or Src activation with wortmannin or PP2 blocked induction of VEGF-A by oxaliplatin in HT29 or RKO cells, respectively.	Oxaliplatin	90-101	vascular endothelial growth factor A	Homo sapiens	80-86
18472019-9	2008	Moreover, the in vivo studies on xenografted mice further confirmed the antitumor efficacy and low toxicity of NCX 4040 in colon cancer and highlighted its role as sensitizing agent of oxaliplatin cytotoxicity.	Oxaliplatin	185-196	T cell leukemia, homeobox 2	Mus musculus	111-114
17987291-1	2008	PURPOSE: Our previous studies showed that combined treatment of oxaliplatin and N(1), N(11) diethyl-norspermine (DENSPM) results in massive induction of spermidine/spermine N(1)-acetyltransferase (SSAT) mRNA and activity.	Oxaliplatin	64-75	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	153-195
18594218-13	2008	When combined with a fixed dose of S-1 80 mg/m, oxaliplatin administered at a dose of 130 mg/m is tolerable and recommended for phase II study.	Oxaliplatin	48-59	proteasome 26S subunit, non-ATPase 1	Homo sapiens	35-38
17987291-1	2008	PURPOSE: Our previous studies showed that combined treatment of oxaliplatin and N(1), N(11) diethyl-norspermine (DENSPM) results in massive induction of spermidine/spermine N(1)-acetyltransferase (SSAT) mRNA and activity.	Oxaliplatin	64-75	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	197-201
17987291-2	2008	Since oxaliplatin and 5-fluorouracil (5FU) are used clinically in treatment of colorectal cancers, this study examines the effect of adding DENSPM to oxaliplatin/5FU combination on SSAT and spermine oxidase (SMO) in HCT-116 cells.	Oxaliplatin	150-161	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	181-185
17987291-6	2008	RESULTS: Oxaliplatin + 5FU + DENSPM produced significantly higher levels of SSAT and SMO mRNA, protein and activity than those seen with oxaliplatin+5FU with a significant depletion of cellular spermine and spermidine pools.	Oxaliplatin	9-20	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	76-80
17987291-6	2008	RESULTS: Oxaliplatin + 5FU + DENSPM produced significantly higher levels of SSAT and SMO mRNA, protein and activity than those seen with oxaliplatin+5FU with a significant depletion of cellular spermine and spermidine pools.	Oxaliplatin	9-20	spermine oxidase	Homo sapiens	85-88
18632807-0	2008	Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.	Oxaliplatin	42-53	hexokinase 1	Homo sapiens	139-149
18636193-5	2008	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay indicated that overexpression of S100P sensitized OVCAR3 cells for chemotherapeutic drugs (paclitaxel, oxaliplatin, 5-fluorouracil, etoposide and epirubicin) induced cytotoxicity more than vector-only controls.	Oxaliplatin	168-179	S100 calcium binding protein P	Homo sapiens	98-103
18665234-6	2008	While Bid-deficient cells were equally sensitive to ER stress-induced apoptosis, they showed moderate, but significantly reduced levels of apoptosis, as well as increased clonogenic survival in response to the genotoxic drugs Etoposide, Oxaliplatin, and Doxorubicin.	Oxaliplatin	237-248	BH3 interacting domain death agonist	Homo sapiens	6-9
19094468-0	2008	[ERCC1 mRNA expression levels and outcome of gastric cancer patients receiving oxaliplatin-based chemotherapy].	Oxaliplatin	79-90	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	1-6
18665234-8	2008	Interestingly, Bid-deficient cells were dramatically protected from apoptosis when subtoxic concentrations of ER stressors, Etoposide or Oxaliplatin were combined with subtoxic TRAIL concentrations.	Oxaliplatin	137-148	BH3 interacting domain death agonist	Homo sapiens	15-18
18508032-9	2008	Cell cycle distribution after exposure to oxaliplatin showed arrest in G2/M (A2780) or in S-phase (LoVo-92) for wt-p53 cells.	Oxaliplatin	42-53	tumor protein p53	Homo sapiens	115-118
18345033-0	2008	P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.	Oxaliplatin	42-53	tumor protein p53	Homo sapiens	0-3
18345033-0	2008	P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.	Oxaliplatin	42-53	TNF receptor superfamily member 10c	Homo sapiens	29-33
18345033-1	2008	Oxaliplatin has emerged as a major chemotherapeutic drug in the treatment of advanced colorectal cancer, yet like most conventional cancer therapeutics, its efficacy is often compromised due to p53 mutations.	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	194-197
18345033-3	2008	Using a panel of colon cancer cell lines, we assessed the ability of oxaliplatin to sensitize to TRAIL-induced apoptosis.	Oxaliplatin	69-80	TNF superfamily member 10	Homo sapiens	97-102
18345033-5	2008	Impaired TRAIL-induced cell death resulted from a strong p53 dependent, oxaliplatin-mediated, DcR1 receptor expression increase.	Oxaliplatin	72-83	TNF superfamily member 10	Homo sapiens	9-14
18345033-5	2008	Impaired TRAIL-induced cell death resulted from a strong p53 dependent, oxaliplatin-mediated, DcR1 receptor expression increase.	Oxaliplatin	72-83	tumor protein p53	Homo sapiens	57-60
18345033-5	2008	Impaired TRAIL-induced cell death resulted from a strong p53 dependent, oxaliplatin-mediated, DcR1 receptor expression increase.	Oxaliplatin	72-83	TNF receptor superfamily member 10c	Homo sapiens	94-98
18345033-6	2008	According to our finding, downregulation of DcR1 using siRNA, in p53 wild-type colon cancer cells, restored oxaliplatin/TRAIL synergistic apoptotic activity.	Oxaliplatin	108-119	TNF receptor superfamily member 10c	Homo sapiens	44-48
18345033-6	2008	According to our finding, downregulation of DcR1 using siRNA, in p53 wild-type colon cancer cells, restored oxaliplatin/TRAIL synergistic apoptotic activity.	Oxaliplatin	108-119	tumor protein p53	Homo sapiens	65-68
18345033-8	2008	Altogether we demonstrate for the first time that p53 negatively regulates oxaliplatin-mediated TRAIL-induced apoptotic activity through DcR1 upregulation.	Oxaliplatin	75-86	tumor protein p53	Homo sapiens	50-53
18345033-8	2008	Altogether we demonstrate for the first time that p53 negatively regulates oxaliplatin-mediated TRAIL-induced apoptotic activity through DcR1 upregulation.	Oxaliplatin	75-86	TNF superfamily member 10	Homo sapiens	96-101
18345033-8	2008	Altogether we demonstrate for the first time that p53 negatively regulates oxaliplatin-mediated TRAIL-induced apoptotic activity through DcR1 upregulation.	Oxaliplatin	75-86	TNF receptor superfamily member 10c	Homo sapiens	137-141
18345033-9	2008	Our findings could have important implications for future therapeutic strategies, and suggest that the association oxaliplatin/TRAIL should be restricted to patients harbouring a non-functional p53 protein.	Oxaliplatin	115-126	TNF superfamily member 10	Homo sapiens	127-132
18345033-9	2008	Our findings could have important implications for future therapeutic strategies, and suggest that the association oxaliplatin/TRAIL should be restricted to patients harbouring a non-functional p53 protein.	Oxaliplatin	115-126	tumor protein p53	Homo sapiens	194-197
18751412-1	2008	The case of a young man with stage IV chemoresistant pure seminoma overexpressing KIT, who achieved complete remission (CR) after the administration of imatinib mesylate (400 mg once daily), along with a third-line chemotherapy regimen, consisting of paclitaxel (150 mg/m2), oxaliplatin (100 mg/m2) and gemcitabine (800 mg/m2) every 2 weeks with granulocyte colony-stimulating factor (G-CSF) support is reported.	Oxaliplatin	275-286	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	82-85
18508032-11	2008	The cell cycle related proteins Cyclins A and B1 and (p)CDC25C were marginally affected by oxaliplatin.	Oxaliplatin	91-102	cyclin A2	Homo sapiens	32-48
18508032-11	2008	The cell cycle related proteins Cyclins A and B1 and (p)CDC25C were marginally affected by oxaliplatin.	Oxaliplatin	91-102	cell division cycle 25C	Homo sapiens	56-62
18508032-15	2008	Oxaliplatin accumulation was related to hCTR1 and, at low concentration, ATP7A to DNA adducts formation while the retention was related to hCTR1, OCT2 and ATP7B.	Oxaliplatin	0-11	calcitonin receptor	Homo sapiens	40-45
18508032-15	2008	Oxaliplatin accumulation was related to hCTR1 and, at low concentration, ATP7A to DNA adducts formation while the retention was related to hCTR1, OCT2 and ATP7B.	Oxaliplatin	0-11	ATPase copper transporting alpha	Homo sapiens	73-78
18633248-0	2008	[Impact of single nucleotide polymorphisms in glutathione S transferase gene GSTP1 in the treatment with oxaliplatin based chemotherapy].	Oxaliplatin	105-116	glutathione S-transferase pi 1	Homo sapiens	77-82
18628420-4	2008	In this study, we investigated the association of aryl hydrocarbon receptor (AhR) gene polymorphisms and urinary 1-OHP.	Oxaliplatin	113-118	aryl hydrocarbon receptor	Homo sapiens	50-75
18628420-4	2008	In this study, we investigated the association of aryl hydrocarbon receptor (AhR) gene polymorphisms and urinary 1-OHP.	Oxaliplatin	113-118	aryl hydrocarbon receptor	Homo sapiens	77-80
18633248-5	2008	Specific roles for the single nucleotide polymorphisms in GST-pi gene GSTP1 in the treatment with oxaliplatin based chemotherapy, have been demonstrated in recent years.	Oxaliplatin	98-109	glutathione S-transferase pi 1	Homo sapiens	70-75
18436711-0	2008	Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin.	Oxaliplatin	119-130	mitogen-activated protein kinase kinase 4	Homo sapiens	32-36
18436711-0	2008	Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin.	Oxaliplatin	119-130	mitogen-activated protein kinase kinase 7	Homo sapiens	41-45
18436711-6	2008	Inhibition of SEK1 rendered hypoxic cells more sensitive to oxaliplatin in vitro, whereas the opposite effect was observed in MKK7-deficient cells.	Oxaliplatin	60-71	mitogen-activated protein kinase kinase 4	Homo sapiens	14-18
18436711-9	2008	These data support a positive contribution of MKK7/JNK to oxaliplatin cytotoxicity and identify SEK1 as a potential target for reversal of hypoxic resistance to oxaliplatin.	Oxaliplatin	58-69	mitogen-activated protein kinase kinase 7	Homo sapiens	46-50
18436711-9	2008	These data support a positive contribution of MKK7/JNK to oxaliplatin cytotoxicity and identify SEK1 as a potential target for reversal of hypoxic resistance to oxaliplatin.	Oxaliplatin	58-69	mitogen-activated protein kinase 8	Homo sapiens	51-54
18436711-9	2008	These data support a positive contribution of MKK7/JNK to oxaliplatin cytotoxicity and identify SEK1 as a potential target for reversal of hypoxic resistance to oxaliplatin.	Oxaliplatin	161-172	mitogen-activated protein kinase kinase 4	Homo sapiens	96-100
18499365-0	2008	Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells.	Oxaliplatin	64-75	H2A.X variant histone	Homo sapiens	20-24
18499365-0	2008	Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells.	Oxaliplatin	64-75	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	29-36
18499365-0	2008	Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells.	Oxaliplatin	64-75	mitogen-activated protein kinase 14	Homo sapiens	82-118
18499365-5	2008	Treatment of oxaliplatin (1-10 microM for 6-24h) persistently induced gamma-H2AX formation and inhibited securin protein expression via a time- and concentration-dependent manner in HCT116 securin-wild type colorectal cancer cells.	Oxaliplatin	13-24	H2A.X variant histone	Homo sapiens	76-80
18499365-5	2008	Treatment of oxaliplatin (1-10 microM for 6-24h) persistently induced gamma-H2AX formation and inhibited securin protein expression via a time- and concentration-dependent manner in HCT116 securin-wild type colorectal cancer cells.	Oxaliplatin	13-24	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	105-112
18499365-5	2008	Treatment of oxaliplatin (1-10 microM for 6-24h) persistently induced gamma-H2AX formation and inhibited securin protein expression via a time- and concentration-dependent manner in HCT116 securin-wild type colorectal cancer cells.	Oxaliplatin	13-24	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	189-196
18499365-6	2008	Compared with HCT116 securin-wild type cells, the induction of apoptosis and persistent gamma-H2AX formation by oxaliplatin was reduced in the HCT116 securin-null colorectal cancer cells.	Oxaliplatin	112-123	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	21-28
18609706-11	2008	Furthermore, cells with reduced Bcl-x(L) or Mcl-1 expression was more sensitive towards oxaliplatin- and irinotecan-induced apoptosis, and in the case of Bcl-x(L) also towards 5-FU-induced apoptosis.	Oxaliplatin	88-99	BCL2 like 1	Homo sapiens	32-40
18499365-6	2008	Compared with HCT116 securin-wild type cells, the induction of apoptosis and persistent gamma-H2AX formation by oxaliplatin was reduced in the HCT116 securin-null colorectal cancer cells.	Oxaliplatin	112-123	H2A.X variant histone	Homo sapiens	94-98
18609706-11	2008	Furthermore, cells with reduced Bcl-x(L) or Mcl-1 expression was more sensitive towards oxaliplatin- and irinotecan-induced apoptosis, and in the case of Bcl-x(L) also towards 5-FU-induced apoptosis.	Oxaliplatin	88-99	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	44-49
18499365-6	2008	Compared with HCT116 securin-wild type cells, the induction of apoptosis and persistent gamma-H2AX formation by oxaliplatin was reduced in the HCT116 securin-null colorectal cancer cells.	Oxaliplatin	112-123	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	150-157
18499365-7	2008	Furthermore, the blockage of caspases by specific caspase inhibitors reduced the levels of gamma-H2AX proteins and cytotoxicity but increased securin protein expression in the oxaliplatin-exposed cells.	Oxaliplatin	176-187	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	142-149
18499365-8	2008	The gene knockdown of H2AX by transfection with a short interfering RNA of H2AX enhanced the oxaliplatin-induced cell death.	Oxaliplatin	93-104	H2A.X variant histone	Homo sapiens	22-26
18499365-8	2008	The gene knockdown of H2AX by transfection with a short interfering RNA of H2AX enhanced the oxaliplatin-induced cell death.	Oxaliplatin	93-104	H2A.X variant histone	Homo sapiens	75-79
18499365-9	2008	Interestingly, the phosphorylation of p38 mitogen-activated protein kinase (MAPK) was markedly increased by oxaliplatin.	Oxaliplatin	108-119	mitogen-activated protein kinase 14	Homo sapiens	38-74
18499365-10	2008	Pre-treatment of a specific p38 MAPK inhibitor SB202190 reduced gamma-H2AX proteins and increased securin protein expression in the oxaliplatin-treated cells.	Oxaliplatin	132-143	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	98-105
18499365-11	2008	Our findings suggest that p38 MAPK may oppositely regulate securin protein expression and gamma-H2AX formation in the oxaliplatin-induced apoptosis of human colorectal cancer cells.	Oxaliplatin	118-129	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	59-66
18499365-11	2008	Our findings suggest that p38 MAPK may oppositely regulate securin protein expression and gamma-H2AX formation in the oxaliplatin-induced apoptosis of human colorectal cancer cells.	Oxaliplatin	118-129	H2A.X variant histone	Homo sapiens	96-100
18577244-0	2008	Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy.	Oxaliplatin	53-64	CEA cell adhesion molecule 3	Homo sapiens	86-110
18577244-4	2008	Thus, we investigated whether FUL in combination with OXA according to 2 different schedules may influence CEA expression in human colon cancer cells in vitro.	Oxaliplatin	54-57	CEA cell adhesion molecule 3	Homo sapiens	107-110
18577244-8	2008	However, when target cells were exposed to OXA before but not after FUL treatment, the up-regulation of CEA was partially inhibited.	Oxaliplatin	43-46	CEA cell adhesion molecule 3	Homo sapiens	104-107
18289945-0	2008	Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin.	Oxaliplatin	122-133	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	9-15
18289945-0	2008	Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin.	Oxaliplatin	122-133	replication protein A2	Homo sapiens	25-29
18289945-0	2008	Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin.	Oxaliplatin	122-133	DNA polymerase eta	Homo sapiens	54-72
18289945-3	2008	We have investigated the effect of expression of DNA polymerase eta (poleta), a translesion synthesis (TLS) enzyme, on the response of human cell lines to cisplatin and oxaliplatin.	Oxaliplatin	169-180	DNA polymerase eta	Homo sapiens	49-67
18289945-6	2008	Cisplatin- and oxaliplatin-induced hyperphosphorylation of RPA2, and association of the hyperphosphorylated protein with chromatin, is elevated in poleta-deficient cells.	Oxaliplatin	15-26	replication protein A2	Homo sapiens	59-63
18289945-10	2008	Thus, increased sensitivity to cisplatin and oxaliplatin in DNA poleta-deficient cells is associated with prolonged S-phase arrest, and enhanced PIKK-signalling, in particular activation of DNA-PK-dependent hyperphosphorylation of RPA2 on serines 4 and 8.	Oxaliplatin	45-56	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	190-196
18289945-10	2008	Thus, increased sensitivity to cisplatin and oxaliplatin in DNA poleta-deficient cells is associated with prolonged S-phase arrest, and enhanced PIKK-signalling, in particular activation of DNA-PK-dependent hyperphosphorylation of RPA2 on serines 4 and 8.	Oxaliplatin	45-56	replication protein A2	Homo sapiens	231-235
18376310-7	2008	Overexpression of TXNIP in the Panc-1 cells resulted in a higher basal apoptosis and increased sensitivity to cisplatin and oxaliplatin.	Oxaliplatin	124-135	thioredoxin interacting protein	Homo sapiens	18-23
17918158-0	2008	Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.	Oxaliplatin	52-63	epidermal growth factor receptor	Homo sapiens	131-135
20727268-5	2008	RESULTS: The resistance index of A549/Gem" to gemcitabine was 163.228, and the cell line also exhibited cross-resistance to vinorelbine, taxotere, fluorouraci, etoposide and cisplatin, but kept sensitivity to paclitaxol and oxaliplatin.	Oxaliplatin	224-235	GTP binding protein overexpressed in skeletal muscle	Homo sapiens	38-41
18221502-7	2008	Moreover, the SW480-PSAT1 cell line was more resistant to oxaliplatin treatment than the non-transfected SW480 cell line.	Oxaliplatin	58-69	phosphoserine aminotransferase 1	Homo sapiens	20-25
17918158-0	2008	Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.	Oxaliplatin	52-63	insulin like growth factor 1 receptor	Homo sapiens	140-146
18085999-2	2007	The SNPs, Ile105Val for GSTP1 and Lys751Gln for ERCC2, may affect the efficiency of oxaliplatin in patients treated with an oxaliplatin-based regimen for metastatic colorectal carcinoma.	Oxaliplatin	84-95	glutathione S-transferase pi 1	Homo sapiens	24-29
17640835-0	2008	Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.	Oxaliplatin	33-44	transferrin	Homo sapiens	61-72
17640835-5	2008	The present study examines tumor-selective delivery of L-OHP using liposomes modified with transferrin-conjugated polyethyleneglycol (TF-PEG-liposomes).	Oxaliplatin	55-60	transferrin	Homo sapiens	91-102
18179697-0	2008	Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis.	Oxaliplatin	0-11	high mobility group box 1	Mus musculus	20-25
18179697-6	2008	Oxaliplatin is an antineoplastic platinum-based compound that generates DNA adducts which tightly bind HMGB1.	Oxaliplatin	0-11	high mobility group box 1	Mus musculus	103-108
18179697-8	2008	RESULTS: Intraperitoneal injections of oxaliplatin in early collagen type II-induced arthritis trapped HMGB1 with a distinct biphasic response pattern.	Oxaliplatin	39-50	high mobility group box 1	Mus musculus	103-108
18179697-10	2008	Microscopic evaluation of synovitis during this period showed strong nuclear HMGB1 staining in the oxaliplatin treated animals with much lower quantities of extracellular HMGB1 when compared to control treated animals.	Oxaliplatin	99-110	high mobility group box 1	Mus musculus	77-82
18179697-10	2008	Microscopic evaluation of synovitis during this period showed strong nuclear HMGB1 staining in the oxaliplatin treated animals with much lower quantities of extracellular HMGB1 when compared to control treated animals.	Oxaliplatin	99-110	high mobility group box 1	Mus musculus	171-176
18179697-12	2008	A dramatic and as yet unexplained clinical relapse occurred later in the oxaliplatin exposed animals, which coincided with a massive synovial tissue expression of extracellular HMGB1 in all treated animals.	Oxaliplatin	73-84	high mobility group box 1	Mus musculus	177-182
18179697-16	2008	CONCLUSION: Therapeutic compounds like oxaliplatin and gold salts share a capacity to inhibit nuclear HMGB1 release and to ameliorate the course of synovial inflammation.	Oxaliplatin	39-50	high mobility group box 1	Mus musculus	102-107
18778115-1	2008	Bevacizumab (Avastin) is a recombinant, humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to inhibit VEGF function in vascular endothelial cells and thereby inhibit tumor angiogenesis, upon which solid tumors depend for growth and metastasis.The addition of bevacizumab to fluoropyrimidine-based chemotherapy, with or without irinotecan or oxaliplatin, in both the first- and second-line treatment of metastatic colorectal cancer, significantly increased median progression-free survival or time to disease progression in most randomized controlled trials.	Oxaliplatin	383-394	vascular endothelial growth factor A	Homo sapiens	78-112
18778115-1	2008	Bevacizumab (Avastin) is a recombinant, humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to inhibit VEGF function in vascular endothelial cells and thereby inhibit tumor angiogenesis, upon which solid tumors depend for growth and metastasis.The addition of bevacizumab to fluoropyrimidine-based chemotherapy, with or without irinotecan or oxaliplatin, in both the first- and second-line treatment of metastatic colorectal cancer, significantly increased median progression-free survival or time to disease progression in most randomized controlled trials.	Oxaliplatin	383-394	vascular endothelial growth factor A	Homo sapiens	114-118
17786445-7	2008	Patients who received regimens containing oxaliplatin and infusional 5-fluorouracil (5-FU) demonstrated mTTP up to 7 months and a mOS of 16 months.	Oxaliplatin	42-53	zinc finger protein 36	Mus musculus	104-108
17786445-7	2008	Patients who received regimens containing oxaliplatin and infusional 5-fluorouracil (5-FU) demonstrated mTTP up to 7 months and a mOS of 16 months.	Oxaliplatin	42-53	Moloney sarcoma oncogene	Mus musculus	130-133
18560229-8	2008	In terms of activating caspase 3, the order was cisplatin &gt; nedaplatin &gt; oxaliplatin &gt; carboplatin.	Oxaliplatin	79-90	caspase 3	Homo sapiens	23-32
18182978-4	2008	The major changes we found in HCT-8 were a stimulation of oxaliplatin-DNA adduct formation associated with reduced expression of the key enzyme (excision repair cross complementation group1: ERCC1) in the key repair process of oxaliplatin-DNA platinum adduct, the nucleotide excision repair (NER), both at the mRNA and protein levels.	Oxaliplatin	227-238	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	191-196
17949450-6	2008	Further investigations indicated that survivin promoter activity was also inhibited by oxaliplatin.	Oxaliplatin	87-98	baculoviral IAP repeat-containing 5	Mus musculus	38-46
17949450-10	2008	Mechanistic studies showed that downregulation of survivin by oxaliplatin in TE7 cells was partially due to the proteasome-mediated protein degradation pathway and partially due to the downregulation of Sp1 transcription factor.	Oxaliplatin	62-73	baculoviral IAP repeat-containing 5	Mus musculus	50-58
17949450-11	2008	Similar results were obtained for another gastric adenocarcinoma cell line, MKN45, in which survivin was previously shown to be inhibited by oxaliplatin.	Oxaliplatin	141-152	baculoviral IAP repeat-containing 5	Mus musculus	92-100
17949450-12	2008	These data indicate that survivin may be a key target for oxaliplatin.	Oxaliplatin	58-69	baculoviral IAP repeat-containing 5	Mus musculus	25-33
18094427-1	2007	PURPOSE: To establish whether cetuximab, a chimeric IgG1 antibody targeting epidermal growth factor receptor, has the potential to restore responsiveness to oxaliplatin in preclinical cancer models, as has been shown with irinotecan in irinotecan refractory metastatic colorectal cancer patients.	Oxaliplatin	157-168	epidermal growth factor receptor	Homo sapiens	76-108
18094427-8	2007	In line with effects on DNA repair protein expression, cetuximab increased the accumulation of platinum and apurinic/apyrimidinic sites on DNA during oxaliplatin treatment.	Oxaliplatin	150-161	X-ray repair cross complementing 6 pseudogene 5	Homo sapiens	24-42
18085999-2	2007	The SNPs, Ile105Val for GSTP1 and Lys751Gln for ERCC2, may affect the efficiency of oxaliplatin in patients treated with an oxaliplatin-based regimen for metastatic colorectal carcinoma.	Oxaliplatin	84-95	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	48-53
18085999-2	2007	The SNPs, Ile105Val for GSTP1 and Lys751Gln for ERCC2, may affect the efficiency of oxaliplatin in patients treated with an oxaliplatin-based regimen for metastatic colorectal carcinoma.	Oxaliplatin	124-135	glutathione S-transferase pi 1	Homo sapiens	24-29
18085999-2	2007	The SNPs, Ile105Val for GSTP1 and Lys751Gln for ERCC2, may affect the efficiency of oxaliplatin in patients treated with an oxaliplatin-based regimen for metastatic colorectal carcinoma.	Oxaliplatin	124-135	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	48-53
18085999-9	2007	Event-free survival was significantly different as a function of the ERCC2 genotype only in patients receiving oxaliplatin: patients having at least one variant allele had a shorter median event-free survival (6 months) than those having no variant allele (11.6 months, p = 0.008).	Oxaliplatin	111-122	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	69-74
18085999-11	2007	Using univariate analysis, ERCC2 genotype, hemoglobinemia and carbohydrate antigen 19.9 plasma levels were significantly related to overall and event-free survival in patients receiving oxaliplatin.	Oxaliplatin	186-197	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	27-32
18085999-12	2007	CONCLUSION: The ERCC2 genotype appears as an important predictive factor of the survival of patients treated with oxaliplatin in first-line therapy for metastatic colorectal cancer.	Oxaliplatin	114-125	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	16-21
17653802-13	2007	Anti-IGF-IR MoAB, alone and in combination with oxaliplatin, led to a significant increase in tumor cell apoptosis, and a significant inhibition of tumor cell proliferation and angiogenesis.	Oxaliplatin	48-59	insulin like growth factor 1 receptor	Homo sapiens	5-11
18025273-3	2007	Moreover, in vitro studies suggested that blocking Hsp90 could overcome p53-mediated resistance of cancer cells to oxaliplatin.	Oxaliplatin	115-126	heat shock protein 90 alpha family class A member 1	Homo sapiens	51-56
18025273-3	2007	Moreover, in vitro studies suggested that blocking Hsp90 could overcome p53-mediated resistance of cancer cells to oxaliplatin.	Oxaliplatin	115-126	tumor protein p53	Homo sapiens	72-75
18025273-4	2007	We therefore hypothesized that blocking oncogenic signaling with a Hsp90 inhibitor would impair metastatic behavior of colon cancer cells and also improve the efficacy of oxaliplatin in vivo.	Oxaliplatin	171-182	heat shock protein 90 alpha family class A member 1	Homo sapiens	67-72
18025273-11	2007	Importantly, combining oxaliplatin with 17-DMAG in vivo significantly improved growth inhibitory and proapoptotic effects on p53-deficient cells, compared with either substance alone.	Oxaliplatin	23-34	tumor protein p53	Homo sapiens	125-128
18025273-13	2007	Hence, targeting Hsp90 could prove valuable for treatment of advanced colorectal cancer by effectively inhibiting colon cancer growth and hepatic metastasis and improving the efficacy of oxaliplatin.	Oxaliplatin	187-198	heat shock protein 90 alpha family class A member 1	Homo sapiens	17-22
17593927-0	2007	Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.	Oxaliplatin	85-96	X-ray repair cross complementing 1	Homo sapiens	16-21
17593927-11	2007	XRCC1 genotyping might make tailor chemotherapy possible for gastric cancer patients treated with oxaliplatin-based chemotherapy.	Oxaliplatin	98-109	X-ray repair cross complementing 1	Homo sapiens	0-5
17559811-0	2007	p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.	Oxaliplatin	45-56	tumor protein p53	Homo sapiens	0-3
17667523-6	2007	Rather, we observed that tumor cells incubated with the platinating agent oxaliplatin, retained HMGB1 within the nucleus for significantly longer periods than other agents used at comparable cytotoxic concentrations or even with potent cytolytic cells.	Oxaliplatin	74-85	high mobility group box 1	Homo sapiens	96-101
17609664-8	2007	Partial reversal of the resistance of S3 cells to oxaliplatin and CDDP was observed by treating cell with ATP7A-targeted siRNA oligonucleotides or P-type ATPase-inhibitor sodium orthovanadate.	Oxaliplatin	50-61	ATPase copper transporting alpha	Homo sapiens	106-111
17609664-10	2007	Together, our results show that the mechanism responsible for oxaliplatin and CDDP resistance in S3 cells is the combination of increased DNA repair and overexpression of ATP7A.	Oxaliplatin	62-73	ATPase copper transporting alpha	Homo sapiens	171-176
17582384-7	2007	In the in vitro study, the cellular accumulation of cisplatin and oxaliplatin was stimulated by the expression of rat (r) OCT2.	Oxaliplatin	66-77	POU class 2 homeobox 2	Rattus norvegicus	122-126
17582384-8	2007	Oxaliplatin was also transported by rOCT3.	Oxaliplatin	0-11	solute carrier family 22 member 8	Rattus norvegicus	36-41
17762433-12	2007	CONCLUSIONS: Oxaliplatin 50 mg/m2 and docetaxel 30 mg/m2 day 1 and 8 with capecitabine 750 mg/m2 BID for 10 days in 21-day cycles may represent a promising, easily administered regimen for metastatic esophageal and gastric cancer.	Oxaliplatin	13-24	BH3 interacting domain death agonist	Homo sapiens	97-100
17559811-5	2007	Exposure to oxaliplatin resulted in G0/G1 arrest in p53 wild-type cell lines, and in S phase in p53-mutated cell lines.	Oxaliplatin	12-23	tumor protein p53	Homo sapiens	52-55
17559811-5	2007	Exposure to oxaliplatin resulted in G0/G1 arrest in p53 wild-type cell lines, and in S phase in p53-mutated cell lines.	Oxaliplatin	12-23	tumor protein p53	Homo sapiens	96-99
17559811-7	2007	The major role of the p53-p21 pathway in oxaliplatin sensitivity was confirmed in the p53 wild-type HCT116 cell line, using siRNA duplex, and knockdown of the TAp73 protein also enhanced resistance to oxaliplatin in this cell line.	Oxaliplatin	41-52	tumor protein p53	Homo sapiens	22-25
17582384-9	2007	A luminal H(+)/organic cation antiporter, rMATE1 (multidrug and toxin extrusion) as well as human (h) MATE1 and hMATE2-K, stimulated the H(+)-gradient-dependent antiport of oxaliplatin, but not of cisplatin.	Oxaliplatin	173-184	solute carrier family 47 member 1	Rattus norvegicus	42-48
17559811-7	2007	The major role of the p53-p21 pathway in oxaliplatin sensitivity was confirmed in the p53 wild-type HCT116 cell line, using siRNA duplex, and knockdown of the TAp73 protein also enhanced resistance to oxaliplatin in this cell line.	Oxaliplatin	41-52	H3 histone pseudogene 16	Homo sapiens	26-29
17559811-7	2007	The major role of the p53-p21 pathway in oxaliplatin sensitivity was confirmed in the p53 wild-type HCT116 cell line, using siRNA duplex, and knockdown of the TAp73 protein also enhanced resistance to oxaliplatin in this cell line.	Oxaliplatin	41-52	tumor protein p53	Homo sapiens	86-89
17559811-9	2007	Persistent sensitivity to oxaliplatin of the p53-mutated V9P cell line was associated with oxalipatin-induced apoptosis but TAp73 was not the responsible alternative pathway.	Oxaliplatin	26-37	tumor protein p53	Homo sapiens	45-48
17582384-9	2007	A luminal H(+)/organic cation antiporter, rMATE1 (multidrug and toxin extrusion) as well as human (h) MATE1 and hMATE2-K, stimulated the H(+)-gradient-dependent antiport of oxaliplatin, but not of cisplatin.	Oxaliplatin	173-184	solute carrier family 47 member 1	Homo sapiens	43-48
17582384-9	2007	A luminal H(+)/organic cation antiporter, rMATE1 (multidrug and toxin extrusion) as well as human (h) MATE1 and hMATE2-K, stimulated the H(+)-gradient-dependent antiport of oxaliplatin, but not of cisplatin.	Oxaliplatin	173-184	solute carrier family 47 member 2	Homo sapiens	112-118
17559811-3	2007	Sensitivity to oxaliplatin was a characteristic of p53 wild-type colon cancer cells.	Oxaliplatin	15-26	tumor protein p53	Homo sapiens	51-54
17559811-4	2007	In contrast, all p53-mutated cell lines had a high IC50 to oxaliplatin, with the exception of the V9P cell line.	Oxaliplatin	59-70	tumor protein p53	Homo sapiens	17-20
17343830-5	2007	Consistent with these, an HCT116 p53(-/-) line, lacking p21, showed resistance to oxaliplatin, failure to enter apoptosis, and an accumulation of cells in S-phase.	Oxaliplatin	82-93	tumor protein p53	Homo sapiens	33-36
17498780-6	2007	GSTT1 present carriers had a significantly higher urinary 1-OHP level than that in null carriers in the case with AhR R554K GA/AA carriers (5.17 vs. 3.64 micromol/mol creatinine, p=0.038), as well as in the case with UGT1A1 -3263T&gt;G TG/GG carriers (5.67 vs. 3.38 micromol/mol creatinine, p=0.001).	Oxaliplatin	58-63	glutathione S-transferase theta 1	Homo sapiens	0-5
17498780-6	2007	GSTT1 present carriers had a significantly higher urinary 1-OHP level than that in null carriers in the case with AhR R554K GA/AA carriers (5.17 vs. 3.64 micromol/mol creatinine, p=0.038), as well as in the case with UGT1A1 -3263T&gt;G TG/GG carriers (5.67 vs. 3.38 micromol/mol creatinine, p=0.001).	Oxaliplatin	58-63	aryl hydrocarbon receptor	Homo sapiens	114-117
17498780-7	2007	These results showed that AhR, UGT1A1, GSTP1 and GSTT1 polymorphisms were associated with urinary 1-OHP concentrations in Chinese coke oven workers.	Oxaliplatin	98-103	aryl hydrocarbon receptor	Homo sapiens	26-29
17498780-7	2007	These results showed that AhR, UGT1A1, GSTP1 and GSTT1 polymorphisms were associated with urinary 1-OHP concentrations in Chinese coke oven workers.	Oxaliplatin	98-103	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	31-37
17498780-7	2007	These results showed that AhR, UGT1A1, GSTP1 and GSTT1 polymorphisms were associated with urinary 1-OHP concentrations in Chinese coke oven workers.	Oxaliplatin	98-103	glutathione S-transferase pi 1	Homo sapiens	39-44
17498780-7	2007	These results showed that AhR, UGT1A1, GSTP1 and GSTT1 polymorphisms were associated with urinary 1-OHP concentrations in Chinese coke oven workers.	Oxaliplatin	98-103	glutathione S-transferase theta 1	Homo sapiens	49-54
17343830-6	2007	Introduction of p21 in these cells caused reversal of that phenotype, including restoration of the G1 block and re-sensitization to oxaliplatin.	Oxaliplatin	132-143	cyclin dependent kinase inhibitor 1A	Homo sapiens	16-19
17343830-7	2007	Inhibition of G1/S progression using cdk2 inhibitor also enhanced oxaliplatin cytotoxicity.	Oxaliplatin	66-77	cyclin dependent kinase 2	Homo sapiens	37-41
17343830-8	2007	We conclude that in colon cancer cells with impaired p53 function, interventions directed to cycle arrest in G1 may potentiate oxaliplatin activity.	Oxaliplatin	127-138	tumor protein p53	Homo sapiens	53-56
17322540-1	2007	BACKGROUND: The aim of this study was to determine whether expressions of the excision repair cross-complementing (ERCC1), thymidylate synthase (TS), and glutathione S-transferase P1 (GSTP1) predict clinical outcome in patients with advanced gastric cancer treated with fluorouracil (5-fluorouracil)/oxaliplatin chemotherapy.	Oxaliplatin	300-311	glutathione S-transferase pi 1	Homo sapiens	184-189
17575954-7	2007	In contrast, while oxaliplatin treatment had no apparent effect on caspase-3 expression, it significantly decreased the cIAP1 (p &lt; 0.005), cIAP2 (p &lt; 0.008) and XIAP (p &lt; 0.02) proteins levels.	Oxaliplatin	19-30	baculoviral IAP repeat-containing 3	Mus musculus	120-125
17575954-7	2007	In contrast, while oxaliplatin treatment had no apparent effect on caspase-3 expression, it significantly decreased the cIAP1 (p &lt; 0.005), cIAP2 (p &lt; 0.008) and XIAP (p &lt; 0.02) proteins levels.	Oxaliplatin	19-30	baculoviral IAP repeat-containing 3	Mus musculus	142-147
17575954-7	2007	In contrast, while oxaliplatin treatment had no apparent effect on caspase-3 expression, it significantly decreased the cIAP1 (p &lt; 0.005), cIAP2 (p &lt; 0.008) and XIAP (p &lt; 0.02) proteins levels.	Oxaliplatin	19-30	X-linked inhibitor of apoptosis	Mus musculus	167-171
17021820-10	2007	Here, the effects of oxaliplatin exposure on SAMDC and ODC observed by Affymetix are validated with real time QRT-PCR.	Oxaliplatin	21-32	adenosylmethionine decarboxylase 1	Homo sapiens	45-50
17021820-10	2007	Here, the effects of oxaliplatin exposure on SAMDC and ODC observed by Affymetix are validated with real time QRT-PCR.	Oxaliplatin	21-32	ornithine decarboxylase 1	Homo sapiens	55-58
17322540-0	2007	Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.	Oxaliplatin	115-126	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	34-39
17322540-0	2007	Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.	Oxaliplatin	115-126	glutathione S-transferase pi 1	Homo sapiens	67-95
17322540-12	2007	CONCLUSION: Immunohistochemical studies for ERCC1 may be useful in prediction of the clinical outcome in advanced gastric cancer patients treated with 5-FU and oxaliplatin.	Oxaliplatin	160-171	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	44-49
17429172-12	2007	Traffic exhaust exposure, smoking and CYP1A1 MspI genotype contributed to the variation in levels of urinary 1-OHP excretion.	Oxaliplatin	109-114	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	38-44
17429172-9	2007	The subjects with the m1/m2 or m2/m2 genotype of CYP1A1 MspI or GSTM1 deficiency had significantly higher urinary 1-OHP levels than those with other CYP1A1 MspI and GSTM1 genotypes.	Oxaliplatin	114-119	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	49-55
17429172-9	2007	The subjects with the m1/m2 or m2/m2 genotype of CYP1A1 MspI or GSTM1 deficiency had significantly higher urinary 1-OHP levels than those with other CYP1A1 MspI and GSTM1 genotypes.	Oxaliplatin	114-119	glutathione S-transferase mu 1	Homo sapiens	64-69
17273745-1	2007	The aim of this study was to investigate the influence of combining thymidylate synthase (TS), X-ray cross complementing factor 1 (XRCC1) and uridine diphosphate glucoronosyltransferase (UGT1A1 *28) polymorphism genotypes in response rate and time to progression (TTP) in metastatic colorectal cancer patients treated with 5-fluorouracil (5-FU) plus irinotecan or oxaliplatin (OXA).	Oxaliplatin	364-375	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	187-193
17273745-1	2007	The aim of this study was to investigate the influence of combining thymidylate synthase (TS), X-ray cross complementing factor 1 (XRCC1) and uridine diphosphate glucoronosyltransferase (UGT1A1 *28) polymorphism genotypes in response rate and time to progression (TTP) in metastatic colorectal cancer patients treated with 5-fluorouracil (5-FU) plus irinotecan or oxaliplatin (OXA).	Oxaliplatin	377-380	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	187-193
17273745-4	2007	In the OXA + 5-FU group, patients with the TS 5" single nucleotide polymorphism and/or XRCC1 genotypes favourable to treatment had a better TTP (log-rank p=0.02).	Oxaliplatin	7-10	thymidylate synthetase	Homo sapiens	43-45
17273745-4	2007	In the OXA + 5-FU group, patients with the TS 5" single nucleotide polymorphism and/or XRCC1 genotypes favourable to treatment had a better TTP (log-rank p=0.02).	Oxaliplatin	7-10	X-ray repair cross complementing 1	Homo sapiens	87-92
17318448-4	2007	Ctr1, the major copper influx transporter, has been convincingly demonstrated to transport cisplatin and its analogues, carboplatin, and oxaliplatin.	Oxaliplatin	137-148	solute carrier family 31 member 1	Homo sapiens	0-4
16516375-0	2007	Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.	Oxaliplatin	43-54	homeobox C10	Homo sapiens	99-102
17237273-3	2007	SSAT was shown to be inducible in response to 5-fluorouracil (5-FU) or oxaliplatin in parental and drug-resistant HCT116 cell lines.	Oxaliplatin	71-82	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	0-4
16406813-8	2007	CONCLUSION: Our study shows that exposure to urban traffic, dietary habits, and the nonnull GSTT1 genotype may contribute to interindividual variation in background levels of 1-OHP urinary excretion in subjects without occupational exposure to PAHs.	Oxaliplatin	175-180	glutathione S-transferase theta 1	Homo sapiens	92-97
17237273-4	2007	It was also shown that SSAT mRNA was up-regulated in response to 5-FU or oxaliplatin in a panel of six colorectal cancer cell lines.	Oxaliplatin	73-84	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	23-27
17237273-7	2007	Western blot analyses showed that SSAT protein expression was dramatically enhanced when DENSpm was combined with oxaliplatin or 5-FU in HCT116 p53(+/+) cells.	Oxaliplatin	114-125	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	34-38
17237273-7	2007	Western blot analyses showed that SSAT protein expression was dramatically enhanced when DENSpm was combined with oxaliplatin or 5-FU in HCT116 p53(+/+) cells.	Oxaliplatin	114-125	tumor protein p53	Homo sapiens	144-147
17097066-2	2006	The selected TRAIL-resistant cells were cross-resistant to TNF-alpha/cycloheximide but remained sensitive to DNA-damage drugs such as oxaliplatin and etoposide.	Oxaliplatin	134-145	TNF superfamily member 10	Homo sapiens	13-18
17998790-6	2007	The DLT level was reached at paclitaxel 110 mg/m2, LOHP 50 mg/m2 and capecitabine 1,000 mg/m2/day.	Oxaliplatin	51-55	codanin 1	Homo sapiens	4-7
18204222-2	2007	XPA, XPD, ERCC1 and XPG genes are involved in DNA repair, and single nucleotide polymorphisms (SNPs) in these genes can influence the efficacy of oxaliplatin.	Oxaliplatin	146-157	XPA, DNA damage recognition and repair factor	Homo sapiens	0-3
18204222-0	2007	Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.	Oxaliplatin	155-166	XPA, DNA damage recognition and repair factor	Homo sapiens	68-71
18204222-0	2007	Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.	Oxaliplatin	155-166	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	73-76
18204222-0	2007	Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.	Oxaliplatin	155-166	ERCC excision repair 5, endonuclease	Homo sapiens	78-81
18204222-0	2007	Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.	Oxaliplatin	155-166	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	86-91
18204222-2	2007	XPA, XPD, ERCC1 and XPG genes are involved in DNA repair, and single nucleotide polymorphisms (SNPs) in these genes can influence the efficacy of oxaliplatin.	Oxaliplatin	146-157	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	5-8
18204222-2	2007	XPA, XPD, ERCC1 and XPG genes are involved in DNA repair, and single nucleotide polymorphisms (SNPs) in these genes can influence the efficacy of oxaliplatin.	Oxaliplatin	146-157	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	10-15
18204222-2	2007	XPA, XPD, ERCC1 and XPG genes are involved in DNA repair, and single nucleotide polymorphisms (SNPs) in these genes can influence the efficacy of oxaliplatin.	Oxaliplatin	146-157	ERCC excision repair 5, endonuclease	Homo sapiens	20-23
18204222-7	2007	CONCLUSION: Polymorphism in XPG combined with XPA may be an important prognosticator of clinical outcome following oxaliplatin/ fluoropyrimidine chemotherapy.	Oxaliplatin	115-126	ERCC excision repair 5, endonuclease	Homo sapiens	28-31
18204222-7	2007	CONCLUSION: Polymorphism in XPG combined with XPA may be an important prognosticator of clinical outcome following oxaliplatin/ fluoropyrimidine chemotherapy.	Oxaliplatin	115-126	XPA, DNA damage recognition and repair factor	Homo sapiens	46-49
17106441-1	2006	This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens.	Oxaliplatin	137-148	proteasome 26S subunit, non-ATPase 1	Homo sapiens	36-39
17045763-0	2006	Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells.	Oxaliplatin	51-62	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	9-16
17045763-5	2006	The phospho-p53 (Ser-15), total p53, and p21 proteins were elevated by oxaliplatin in RKO cells; conversely, oxaliplatin decreased the securin protein expression.	Oxaliplatin	109-120	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	135-142
17045763-0	2006	Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells.	Oxaliplatin	51-62	tumor protein p53	Homo sapiens	21-24
17045763-6	2006	The p53-functional RKO cells were higher on the cytotoxicity and cell cycle arrest at the G1 and G2/M phases than the p53-mutational SW480 cells after treatment with oxaliplatin.	Oxaliplatin	166-177	tumor protein p53	Homo sapiens	4-7
17045763-6	2006	The p53-functional RKO cells were higher on the cytotoxicity and cell cycle arrest at the G1 and G2/M phases than the p53-mutational SW480 cells after treatment with oxaliplatin.	Oxaliplatin	166-177	tumor protein p53	Homo sapiens	118-121
17045763-5	2006	The phospho-p53 (Ser-15), total p53, and p21 proteins were elevated by oxaliplatin in RKO cells; conversely, oxaliplatin decreased the securin protein expression.	Oxaliplatin	71-82	tumor protein p53	Homo sapiens	12-15
17045763-7	2006	Oxaliplatin inhibited the securin protein expression in the p53-functional cells but not in the p53-mutational cells.	Oxaliplatin	0-11	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	26-33
17045763-5	2006	The phospho-p53 (Ser-15), total p53, and p21 proteins were elevated by oxaliplatin in RKO cells; conversely, oxaliplatin decreased the securin protein expression.	Oxaliplatin	71-82	tumor protein p53	Homo sapiens	32-35
17045763-7	2006	Oxaliplatin inhibited the securin protein expression in the p53-functional cells but not in the p53-mutational cells.	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	60-63
17045763-8	2006	The securin-wild type cells were more sensitive than the securin-null cells on the increases of cytotoxicity and sub-G1 fractions following treatment with oxaliplatin.	Oxaliplatin	155-166	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	4-11
17045763-8	2006	The securin-wild type cells were more sensitive than the securin-null cells on the increases of cytotoxicity and sub-G1 fractions following treatment with oxaliplatin.	Oxaliplatin	155-166	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	57-64
17045763-9	2006	Nevertheless, oxaliplatin elevated the activation of p53 in both securin-wild type and securin-null cells.	Oxaliplatin	14-25	tumor protein p53	Homo sapiens	53-56
17045763-9	2006	Nevertheless, oxaliplatin elevated the activation of p53 in both securin-wild type and securin-null cells.	Oxaliplatin	14-25	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	65-72
17045763-5	2006	The phospho-p53 (Ser-15), total p53, and p21 proteins were elevated by oxaliplatin in RKO cells; conversely, oxaliplatin decreased the securin protein expression.	Oxaliplatin	71-82	H3 histone pseudogene 16	Homo sapiens	41-44
17045763-9	2006	Nevertheless, oxaliplatin elevated the activation of p53 in both securin-wild type and securin-null cells.	Oxaliplatin	14-25	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	87-94
17009149-3	2006	The aim of the investigation reported here was to identify which gene polymorphism is a dominant factor in FOLFOX chemotherapy-the methylenetetrahydrofolate reductase (MTHFR) gene for 5-fluorouracil or the X-ray cross-complementing1 (XRCC1) gene for oxaliplatin.	Oxaliplatin	250-261	methylenetetrahydrofolate reductase	Homo sapiens	131-166
17045763-10	2006	As a whole, it is the first time to demonstrate that oxaliplatin inhibits the securin protein expression via a p53-dependent pathway, and p53 and securin may modulate the oxaliplatin-induced cytotoxicity in human colorectal cancer cells.	Oxaliplatin	53-64	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	78-85
17045763-10	2006	As a whole, it is the first time to demonstrate that oxaliplatin inhibits the securin protein expression via a p53-dependent pathway, and p53 and securin may modulate the oxaliplatin-induced cytotoxicity in human colorectal cancer cells.	Oxaliplatin	53-64	tumor protein p53	Homo sapiens	111-114
17045763-10	2006	As a whole, it is the first time to demonstrate that oxaliplatin inhibits the securin protein expression via a p53-dependent pathway, and p53 and securin may modulate the oxaliplatin-induced cytotoxicity in human colorectal cancer cells.	Oxaliplatin	171-182	tumor protein p53	Homo sapiens	138-141
17045763-10	2006	As a whole, it is the first time to demonstrate that oxaliplatin inhibits the securin protein expression via a p53-dependent pathway, and p53 and securin may modulate the oxaliplatin-induced cytotoxicity in human colorectal cancer cells.	Oxaliplatin	171-182	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	146-153
17009149-3	2006	The aim of the investigation reported here was to identify which gene polymorphism is a dominant factor in FOLFOX chemotherapy-the methylenetetrahydrofolate reductase (MTHFR) gene for 5-fluorouracil or the X-ray cross-complementing1 (XRCC1) gene for oxaliplatin.	Oxaliplatin	250-261	methylenetetrahydrofolate reductase	Homo sapiens	168-173
17009149-3	2006	The aim of the investigation reported here was to identify which gene polymorphism is a dominant factor in FOLFOX chemotherapy-the methylenetetrahydrofolate reductase (MTHFR) gene for 5-fluorouracil or the X-ray cross-complementing1 (XRCC1) gene for oxaliplatin.	Oxaliplatin	250-261	X-ray repair cross complementing 1	Homo sapiens	206-232
17009149-3	2006	The aim of the investigation reported here was to identify which gene polymorphism is a dominant factor in FOLFOX chemotherapy-the methylenetetrahydrofolate reductase (MTHFR) gene for 5-fluorouracil or the X-ray cross-complementing1 (XRCC1) gene for oxaliplatin.	Oxaliplatin	250-261	X-ray repair cross complementing 1	Homo sapiens	234-239
16914559-0	2006	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).	Oxaliplatin	14-25	solute carrier family 22 member 1	Homo sapiens	117-124
16914559-2	2006	Both the cytotoxicity and accumulation of cisplatin were enhanced by the expression of hOCT2 and weakly by hOCT1, and those of oxaliplatin were also enhanced by the expression of hOCT2 and weakly by hOCT3.	Oxaliplatin	127-138	solute carrier family 22 member 2	Homo sapiens	179-184
16847145-1	2006	The goal of this study was to determine the ability of the major copper influx transporter CTR1 to mediate the cellular accumulation of cisplatin (DDP), carboplatin (CBDCA), and oxaliplatin (L-OHP).	Oxaliplatin	191-196	solute carrier family 31, member 1	Mus musculus	91-95
16914559-2	2006	Both the cytotoxicity and accumulation of cisplatin were enhanced by the expression of hOCT2 and weakly by hOCT1, and those of oxaliplatin were also enhanced by the expression of hOCT2 and weakly by hOCT3.	Oxaliplatin	127-138	solute carrier family 22 member 3	Homo sapiens	199-204
16914559-5	2006	The hMATE1 and hMATE2-K, but not hOCTN1 and OCTN2, mediated the cellular accumulation of cisplatin and oxaliplatin without a marked release of lactate dehydrogenase.	Oxaliplatin	103-114	solute carrier family 47 member 1	Homo sapiens	4-10
16914559-5	2006	The hMATE1 and hMATE2-K, but not hOCTN1 and OCTN2, mediated the cellular accumulation of cisplatin and oxaliplatin without a marked release of lactate dehydrogenase.	Oxaliplatin	103-114	solute carrier family 47 member 2	Homo sapiens	15-21
16914559-6	2006	Oxaliplatin, but not cisplatin, markedly decreased the hMATE2-K-mediated TEA uptake.	Oxaliplatin	0-11	solute carrier family 47 member 2	Homo sapiens	55-61
16914559-7	2006	However, the inhibitory effect of cisplatin and oxaliplatin against the hMATE1-mediated TEA uptake was similar.	Oxaliplatin	48-59	solute carrier family 47 member 1	Homo sapiens	72-78
16914559-9	2006	These results indicate that cisplatin is a relatively good substrate of hOCT1, hOCT2, and hMATE1, and oxaliplatin is of hOCT2, hOCT3, hMATE1, and hMATE2-K.	Oxaliplatin	102-113	solute carrier family 22 member 2	Homo sapiens	120-125
16914559-9	2006	These results indicate that cisplatin is a relatively good substrate of hOCT1, hOCT2, and hMATE1, and oxaliplatin is of hOCT2, hOCT3, hMATE1, and hMATE2-K.	Oxaliplatin	102-113	solute carrier family 22 member 3	Homo sapiens	127-132
16914559-9	2006	These results indicate that cisplatin is a relatively good substrate of hOCT1, hOCT2, and hMATE1, and oxaliplatin is of hOCT2, hOCT3, hMATE1, and hMATE2-K.	Oxaliplatin	102-113	solute carrier family 47 member 1	Homo sapiens	134-140
16914559-9	2006	These results indicate that cisplatin is a relatively good substrate of hOCT1, hOCT2, and hMATE1, and oxaliplatin is of hOCT2, hOCT3, hMATE1, and hMATE2-K.	Oxaliplatin	102-113	solute carrier family 47 member 2	Homo sapiens	146-152
16847145-0	2006	Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.	Oxaliplatin	117-128	solute carrier family 31, member 1	Mus musculus	52-56
16847145-1	2006	The goal of this study was to determine the ability of the major copper influx transporter CTR1 to mediate the cellular accumulation of cisplatin (DDP), carboplatin (CBDCA), and oxaliplatin (L-OHP).	Oxaliplatin	178-189	solute carrier family 31, member 1	Mus musculus	91-95
16847145-6	2006	When exposed to DDP, CBDCA, or L-OHP at 2 microM, accumulation in the CTR1-/- cells was only 35 to 36% of that in the CTR1+/+ cells.	Oxaliplatin	31-36	solute carrier family 31, member 1	Mus musculus	70-74
16847145-6	2006	When exposed to DDP, CBDCA, or L-OHP at 2 microM, accumulation in the CTR1-/- cells was only 35 to 36% of that in the CTR1+/+ cells.	Oxaliplatin	31-36	solute carrier family 31, member 1	Mus musculus	118-122
16847145-9	2006	The CTR1-/- cells were 3.2-fold resistant to DDP, 2.0-fold resistant to CBDCA, but only 1.7-fold resistant to L-OHP.	Oxaliplatin	110-115	solute carrier family 31, member 1	Mus musculus	4-8
16773204-4	2006	Particularly, OXA resistance is accompanied by defects in drug uptake (downregulation of the hCTR1 transporter) and enhanced DNA repair (upregulation of the XPD gene).	Oxaliplatin	14-17	solute carrier family 31 member 1	Homo sapiens	93-98
16951202-3	2006	This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters.	Oxaliplatin	229-240	solute carrier family 22 member 1	Homo sapiens	32-73
16951202-3	2006	This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters.	Oxaliplatin	229-240	solute carrier family 22 member 1	Homo sapiens	75-82
16951202-3	2006	This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters.	Oxaliplatin	229-240	solute carrier family 22 member 2	Homo sapiens	87-94
16951202-6	2006	These results indicate that OCT1 and OCT2 are major determinants of the anticancer activity of oxaliplatin and may contribute to its antitumor specificity.	Oxaliplatin	95-106	solute carrier family 22 member 1	Homo sapiens	28-32
16951202-6	2006	These results indicate that OCT1 and OCT2 are major determinants of the anticancer activity of oxaliplatin and may contribute to its antitumor specificity.	Oxaliplatin	95-106	solute carrier family 22 member 2	Homo sapiens	37-41
16292536-0	2006	Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.	Oxaliplatin	38-49	dihydropyrimidine dehydrogenase	Homo sapiens	98-130
16951202-3	2006	This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters.	Oxaliplatin	114-125	solute carrier family 22 member 1	Homo sapiens	32-73
16951202-3	2006	This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters.	Oxaliplatin	114-125	solute carrier family 22 member 1	Homo sapiens	75-82
16951202-3	2006	This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters.	Oxaliplatin	114-125	solute carrier family 22 member 2	Homo sapiens	87-94
16907658-2	2006	However, the recent rising incidence of HSR to oxaliplatin observed is the result of increasing clinical use.	Oxaliplatin	47-58	HSR	Homo sapiens	40-43
16907658-3	2006	HSR to oxaliplatin may manifest as facial flushing, rash/hives, tachycardia, dyspnoea, erythema, pruritus, fever, tongue swelling, headache, chills, weakness, vomiting, burning sensations, dizziness and oedema.	Oxaliplatin	7-18	HSR	Homo sapiens	0-3
16907658-5	2006	No definitive approaches to prevent and treat HSR associated with oxaliplatin are available; however, few successful strategies have been reported.	Oxaliplatin	66-77	HSR	Homo sapiens	46-49
16907658-7	2006	Successful implementation of oxaliplatin desensitisation protocols based on other platinum-containing compounds have been reported, which could enable a small number of patients who experience severe HSR to further receive an effective therapy for CRC.	Oxaliplatin	29-40	HSR	Homo sapiens	200-203
16907658-12	2006	In this article, the author discusses the incidence, clinical presentation, pathogenesis, risk factors and current strategies of management of HSR associated with oxaliplatin.	Oxaliplatin	163-174	HSR	Homo sapiens	143-146
16773204-4	2006	Particularly, OXA resistance is accompanied by defects in drug uptake (downregulation of the hCTR1 transporter) and enhanced DNA repair (upregulation of the XPD gene).	Oxaliplatin	14-17	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	157-160
16773204-5	2006	Our data also confirmed that copper transporters and chaperones are involved in OXA resistance in colorectal cancer cells as evidenced by the overexpression of ATP7A and CCS in response to OXA exposure.	Oxaliplatin	80-83	ATPase copper transporting alpha	Homo sapiens	160-165
16716446-6	2006	In the gemcitabine/oxaliplatin group response rate was 38% and 0% (p=0.04) for patients with or without loss of hMSH2 expression.	Oxaliplatin	19-30	mutS homolog 2	Homo sapiens	112-117
16794239-3	2006	DESIGN: This review summarizes current clinical data for EGFR-TKIs as monotherapy or in combination with 5-fluorouracil/leucovorin, irinotecan, or oxaliplatin, focusing on the rapidly developing area of colorectal, gastroesophageal, and pancreatic cancers.	Oxaliplatin	147-158	epidermal growth factor receptor	Homo sapiens	57-61
16891475-9	2006	Thus, expression of total and active phosphorylated EGFR, as well as AKT and extracellular signal-regulated kinase, was markedly increased by oxaliplatin.	Oxaliplatin	142-153	epidermal growth factor receptor	Homo sapiens	52-56
16891475-9	2006	Thus, expression of total and active phosphorylated EGFR, as well as AKT and extracellular signal-regulated kinase, was markedly increased by oxaliplatin.	Oxaliplatin	142-153	AKT serine/threonine kinase 1	Homo sapiens	69-72
16804963-5	2006	RESULTS: Tumor growth inhibitory rate, the positive expression rate of PCNA, Bax and Bcl-2 were 49.3%, 58.2%, 65.2% and 59.2% in rhGH+L-OHP group respectively; 46.6%, 62.5%, 59.7% and 64.7% in L-OHP group; 5.0%, 82.7%, 23.2% and 82.2% in rhGH group and 0, 77.8%, 23.5% and 80.3% in control group.	Oxaliplatin	134-139	BCL2 associated X, apoptosis regulator	Homo sapiens	77-80
16804963-5	2006	RESULTS: Tumor growth inhibitory rate, the positive expression rate of PCNA, Bax and Bcl-2 were 49.3%, 58.2%, 65.2% and 59.2% in rhGH+L-OHP group respectively; 46.6%, 62.5%, 59.7% and 64.7% in L-OHP group; 5.0%, 82.7%, 23.2% and 82.2% in rhGH group and 0, 77.8%, 23.5% and 80.3% in control group.	Oxaliplatin	134-139	BCL2 apoptosis regulator	Homo sapiens	85-90
16187112-3	2006	The aim of this study was to ascertain whether two polymorphisms in the MTHFR gene (677C&gt;T and 1298 A&gt;C) could be used as genomic predictors of clinical response to fluoropyrimidine-based chemotherapy (in combination with irinotecan or oxaliplatin).	Oxaliplatin	242-253	methylenetetrahydrofolate reductase	Homo sapiens	72-77
16320055-0	2006	In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.	Oxaliplatin	43-54	epidermal growth factor receptor	Homo sapiens	152-156
16320055-2	2006	In vitro, cetuximab combined with oxaliplatin significantly decreased the IC50 values of oxaliplatin in HCT-8 (EGF-R moderate) and HT-29 (EGF-R weak) cell lines, while SW620 (EGF-R negative) and HCT-116 (EGFR strong) cell lines remained unresponsive.	Oxaliplatin	34-45	epidermal growth factor receptor	Homo sapiens	204-208
16897986-6	2006	Clinical trials of S-1 with oxaliplatin or CPT-11 combination chemotherapy are ongoing in Japan.	Oxaliplatin	28-39	proteasome 26S subunit, non-ATPase 1	Homo sapiens	19-22
16707468-0	2006	KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand.	Oxaliplatin	80-91	KRAS proto-oncogene, GTPase	Homo sapiens	0-8
16836929-8	2006	Using an IC(50) dose of oxaliplatin and 5-FU combined with (MDR1) anti-sense RNA, 75 percent of 8348R cells were killed, which was significant higher than that of the control cells.	Oxaliplatin	24-35	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
16836929-9	2006	CONCLUSIONS: Combined MDR1 antisense RNA with oxaliplatin and 5-FU has a synergistic effect of killing drug-resistant cancer cells and may be a promising method for treating drug-resistant rectal carcinoma.	Oxaliplatin	46-57	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
16707468-8	2006	Likewise, KRAS(D13)- or p53-deficient cells display reduced sensitivity to oxaliplatin but not to death receptor activation by TRAIL.	Oxaliplatin	75-86	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	10-14
16707468-8	2006	Likewise, KRAS(D13)- or p53-deficient cells display reduced sensitivity to oxaliplatin but not to death receptor activation by TRAIL.	Oxaliplatin	75-86	transformation related protein 53, pseudogene	Mus musculus	24-27
16707601-0	2006	Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy.	Oxaliplatin	107-118	glutathione S-transferase pi 1	Homo sapiens	0-28
16707601-9	2006	The oxaliplatin-related cumulative neuropathy scored grade 3 was significantly more frequent in patients homozygous for the GSTP1 105Ile allele than in patients homozygous or heterozygous for the GSTP1 105Val allele (odds ratio, 5.75; 95% confidence interval, 1.08-30.74; P = 0.02).	Oxaliplatin	4-15	glutathione S-transferase pi 1	Homo sapiens	124-129
16648562-5	2006	Sequential NCX 4040--&gt;oxaliplatin treatment produced a strong synergism in three cell lines, with a ratio index ranging from 3.7 to 4.	Oxaliplatin	25-36	T cell leukemia homeobox 2	Homo sapiens	11-14
16707601-9	2006	The oxaliplatin-related cumulative neuropathy scored grade 3 was significantly more frequent in patients homozygous for the GSTP1 105Ile allele than in patients homozygous or heterozygous for the GSTP1 105Val allele (odds ratio, 5.75; 95% confidence interval, 1.08-30.74; P = 0.02).	Oxaliplatin	4-15	glutathione S-transferase pi 1	Homo sapiens	196-201
16707601-11	2006	CONCLUSIONS: The results of the current study suggest that the 105Val allele variant of the GSTP1 gene at exon 5 confers a significantly decreased risk of developing severe oxaliplatin-related cumulative neuropathy.	Oxaliplatin	173-184	glutathione S-transferase pi 1	Homo sapiens	92-97
16684860-0	2006	Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.	Oxaliplatin	20-31	MAX network transcriptional repressor	Homo sapiens	89-92
16638878-8	2006	Strikingly, cotreatment of day 4 PHH with cisplatin sensitized for TRAIL-induced apoptosis whereas 5-fluorouracil, etoposide, gemcitabine, irinotecan, or oxaliplatin, which are commonly used in the treatment of gastrointestinal cancers, did not.	Oxaliplatin	154-165	TNF superfamily member 10	Homo sapiens	67-72
17163168-9	2006	Tumors with high TS, TP, and DPD expression levels should be treated with such non-TS-directed anticancer drugs as irinotecan or oxaliplatin, or in combination with 5-FU.	Oxaliplatin	129-140	dihydropyrimidine dehydrogenase	Homo sapiens	29-32
16084535-4	2006	However, significant differences of regression coefficient were found for the relation between urinary log 1-OHP and urinary 8-OHdG concentrations in the presence of different MnSOD or MPO genotypes by multiple regression after controlling for age, sex, body mass index, cotinine, and smoking.	Oxaliplatin	107-112	superoxide dismutase 2	Homo sapiens	176-181
16084535-4	2006	However, significant differences of regression coefficient were found for the relation between urinary log 1-OHP and urinary 8-OHdG concentrations in the presence of different MnSOD or MPO genotypes by multiple regression after controlling for age, sex, body mass index, cotinine, and smoking.	Oxaliplatin	107-112	myeloperoxidase	Homo sapiens	185-188
16317265-14	2005	CONCLUSION: The addition of oxaliplatin to IFL as second-line treatment rendered a prolongation of survival and a response rate of 38.9% in patients in whom IFL pretreatment had failed.	Oxaliplatin	28-39	interferon alpha 1	Homo sapiens	157-160
17641537-5	2006	RESULTS: MTD was defined at PLD 45 mg/m(2) and oxaliplatin 130 mg/m(2).	Oxaliplatin	47-58	metallothionein 1E	Homo sapiens	9-12
16273226-4	2005	Clonogenic data demonstrated that sublethal concentrations of radicicol increased the sensitivity to cisplatin and to oxaliplatin in both MLH1-proficient cells and MLH1-deficient cells.	Oxaliplatin	118-129	mutL homolog 1	Homo sapiens	138-142
16270098-4	2005	For the treatment of metastatic colorectal cancer, improved response rates and prolonged survival have been reported when irinotecan or oxaliplatin was added to 5-FU/FA; a further increase in efficacy was shown when bevacizumab, an antibody to vascular endothelial growth factor, was added to chemotherapy.	Oxaliplatin	136-147	vascular endothelial growth factor A	Homo sapiens	244-278
16373718-2	2005	We assessed the roles of p53, TRAIL receptors, and cellular Fas-associated death domain-like interleukin-1beta-converting enzyme inhibitory protein (c-FLIP) in regulating the cytotoxic effects of recombinant TRAIL (rTRAIL) alone and in combination with chemotherapy [5-fluorouracil (5-FU), oxaliplatin, and irinotecan] in a panel of colon cancer cell lines.	Oxaliplatin	290-301	CASP8 and FADD like apoptosis regulator	Homo sapiens	149-155
16336754-0	2005	Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.	Oxaliplatin	10-21	epidermal growth factor receptor	Homo sapiens	76-108
16277025-0	2005	Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.	Oxaliplatin	49-60	interleukin 2	Homo sapiens	102-106
16243822-7	2005	Furthermore, in cell lines exhibiting low constitutive EGFR phosphorylation, an antagonistic interaction between gefitinib and oxaliplatin was observed, whereas in cell lines with high basal EGFR phosphorylation, the interaction was synergistic.	Oxaliplatin	127-138	epidermal growth factor receptor	Homo sapiens	55-59
16243796-10	2005	Cell lines in which MIF was inducible by hypoxia were more sensitive to oxaliplatin.	Oxaliplatin	72-83	macrophage migration inhibitory factor	Homo sapiens	20-23
16243822-8	2005	In addition, oxaliplatin treatment increased EGFR phosphorylation in those cell lines in which oxaliplatin and gefitinib were synergistic but down-regulated EGFR phosphorylation in those lines in which oxaliplatin and gefitinib were antagonistic.	Oxaliplatin	13-24	epidermal growth factor receptor	Homo sapiens	45-49
16243822-8	2005	In addition, oxaliplatin treatment increased EGFR phosphorylation in those cell lines in which oxaliplatin and gefitinib were synergistic but down-regulated EGFR phosphorylation in those lines in which oxaliplatin and gefitinib were antagonistic.	Oxaliplatin	95-106	epidermal growth factor receptor	Homo sapiens	45-49
16243822-8	2005	In addition, oxaliplatin treatment increased EGFR phosphorylation in those cell lines in which oxaliplatin and gefitinib were synergistic but down-regulated EGFR phosphorylation in those lines in which oxaliplatin and gefitinib were antagonistic.	Oxaliplatin	95-106	epidermal growth factor receptor	Homo sapiens	157-161
16243822-8	2005	In addition, oxaliplatin treatment increased EGFR phosphorylation in those cell lines in which oxaliplatin and gefitinib were synergistic but down-regulated EGFR phosphorylation in those lines in which oxaliplatin and gefitinib were antagonistic.	Oxaliplatin	13-24	epidermal growth factor receptor	Homo sapiens	157-161
16243822-8	2005	In addition, oxaliplatin treatment increased EGFR phosphorylation in those cell lines in which oxaliplatin and gefitinib were synergistic but down-regulated EGFR phosphorylation in those lines in which oxaliplatin and gefitinib were antagonistic.	Oxaliplatin	95-106	epidermal growth factor receptor	Homo sapiens	45-49
16243822-8	2005	In addition, oxaliplatin treatment increased EGFR phosphorylation in those cell lines in which oxaliplatin and gefitinib were synergistic but down-regulated EGFR phosphorylation in those lines in which oxaliplatin and gefitinib were antagonistic.	Oxaliplatin	95-106	epidermal growth factor receptor	Homo sapiens	157-161
16204068-2	2005	We found that 5-fluorouracil (5-FU) and oxaliplatin only sensitized p53 wild-type (WT) colorectal cancer cell lines to Fas-mediated apoptosis.	Oxaliplatin	40-51	tumor protein p53	Homo sapiens	68-71
16204068-10	2005	We conclude that CPT-11 and tomudex may be more effective than 5-FU and oxaliplatin in the treatment of p53 mutant colorectal cancer tumors by sensitizing them to Fas-mediated apoptosis in a STAT1-dependent manner.	Oxaliplatin	72-83	tumor protein p53	Homo sapiens	104-107
16142353-0	2005	Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10.	Oxaliplatin	49-60	homeobox C10	Homo sapiens	105-108
16227409-0	2005	Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells.	Oxaliplatin	35-46	cyclin dependent kinase inhibitor 1A	Homo sapiens	8-20
16227409-5	2005	Oxaliplatin caused strong p21waf1/cip1 induction and G0-G1 arrest in p53 wild-type cells, whereas cisplatin did not induce G0-G1 arrest.	Oxaliplatin	0-11	cyclin dependent kinase inhibitor 1A	Homo sapiens	34-38
16227409-5	2005	Oxaliplatin caused strong p21waf1/cip1 induction and G0-G1 arrest in p53 wild-type cells, whereas cisplatin did not induce G0-G1 arrest.	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	69-72
16227409-6	2005	Assays using p53 wild but p21waf1/cip1 null HCT116 cells revealed that oxaliplatin did not show G0-G1 arrest and reduced growth-inhibitory effects, suggesting that p21waf1/cip1 may be a key element in oxaliplatin-treated p53 wild-type cells.	Oxaliplatin	71-82	cyclin dependent kinase inhibitor 1A	Homo sapiens	34-38
16227409-8	2005	In p53 mutant cells, on the other hand, oxaliplatin caused an abrupt transition from G1 to S phase and eventually resulted in G2-M arrest.	Oxaliplatin	40-51	tumor protein p53	Homo sapiens	3-6
16227409-10	2005	These findings suggest that p21waf1/cip1 plays a role in oxaliplatin-mediated cell cycle and growth control in p53-dependent and -independent pathways.	Oxaliplatin	57-68	cyclin dependent kinase inhibitor 1A	Homo sapiens	28-40
16227409-10	2005	These findings suggest that p21waf1/cip1 plays a role in oxaliplatin-mediated cell cycle and growth control in p53-dependent and -independent pathways.	Oxaliplatin	57-68	tumor protein p53	Homo sapiens	111-114
16142353-2	2005	To better understand mechanisms involved in this phenomenon, a clonal subline (A2780/C10B) isolated from an oxaliplatin-resistant human ovarian carcinoma cell line (A2780/C10) was developed, as reported previously.	Oxaliplatin	108-119	homeobox C10	Homo sapiens	85-88
16144935-10	2005	In conclusion, low SMAD4 tumor levels identified a subset of patients with poor prognosis following surgery and 5-FU-based adjuvant therapy; therefore, these patients could be good candidates to receive combined treatment with additional chemotherapeutic agents such as CPT-11 and/or oxaliplatin.	Oxaliplatin	284-295	SMAD family member 4	Homo sapiens	19-24
16266509-8	2005	Additionally, there was significant correlation between urinary 1-OHP and serum GST activity (r(s) = 0.31, P &lt; 0.01, n = 78).	Oxaliplatin	64-69	glutathione S-transferase kappa 1	Homo sapiens	80-83
16101140-2	2005	PATIENTS AND METHODS: The impact of gemcitabine, irinotecan and oxaliplatin + 5-FU upon the serum markers vascular endothelial growth factor (VEGF) (pro-angiogenic) and IFN-gamma-inducible protein (IP)-10 (anti-angiogenic) was evaluated by ELISA in locally advanced and/or metastatic cancer versus clinical efficacy and survival.	Oxaliplatin	64-75	vascular endothelial growth factor A	Homo sapiens	106-140
16101140-2	2005	PATIENTS AND METHODS: The impact of gemcitabine, irinotecan and oxaliplatin + 5-FU upon the serum markers vascular endothelial growth factor (VEGF) (pro-angiogenic) and IFN-gamma-inducible protein (IP)-10 (anti-angiogenic) was evaluated by ELISA in locally advanced and/or metastatic cancer versus clinical efficacy and survival.	Oxaliplatin	64-75	vascular endothelial growth factor A	Homo sapiens	142-146
16101140-2	2005	PATIENTS AND METHODS: The impact of gemcitabine, irinotecan and oxaliplatin + 5-FU upon the serum markers vascular endothelial growth factor (VEGF) (pro-angiogenic) and IFN-gamma-inducible protein (IP)-10 (anti-angiogenic) was evaluated by ELISA in locally advanced and/or metastatic cancer versus clinical efficacy and survival.	Oxaliplatin	64-75	C-X-C motif chemokine ligand 10	Homo sapiens	169-204
16144923-0	2005	ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.	Oxaliplatin	78-89	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
15993848-3	2005	We have shown that the Hsp90 inhibitor 17-AAG enhances the cytotoxicity of oxaliplatin in colon cancer cell lines through inhibition of NF-kappaB.	Oxaliplatin	75-86	heat shock protein 90 alpha family class A member 1	Homo sapiens	23-28
16085187-10	2005	We also found that TrxR, but not GR, was efficiently inhibited by both cisplatin, its monohydrated complex, and oxaliplatin.	Oxaliplatin	112-123	peroxiredoxin 5	Homo sapiens	19-23
15993848-3	2005	We have shown that the Hsp90 inhibitor 17-AAG enhances the cytotoxicity of oxaliplatin in colon cancer cell lines through inhibition of NF-kappaB.	Oxaliplatin	75-86	N-methylpurine DNA glycosylase	Homo sapiens	42-45
15887215-0	2005	Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells.	Oxaliplatin	50-61	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	83-87
16062074-2	2005	Gefitinib (Iressa), an inhibitor of the epidermal growth factor receptor tyrosine kinase, is synergistic with oxaliplatin in preclinical colon cancer models.	Oxaliplatin	110-121	epidermal growth factor receptor	Homo sapiens	40-72
15887215-3	2005	In this study, we have compared the mutagenicity of oxaliplatin and cisplatin in the Hprt gene of CHO-K1 cells.	Oxaliplatin	52-63	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	85-89
15887215-6	2005	Sequencing of mutant Hprt genes indicated that the mutation spectra of both oxaliplatin and cisplatin were significantly different from the spontaneous mutation spectrum (P = 0.014 and P = 0.008, respectively).	Oxaliplatin	76-87	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	21-25
16024531-5	2005	Western blot analyses indicated that oxaliplatin decreased mitosis-commencing protein cdc2 and anti-apoptotic proteins, phospho-Bcl(2) and Bcl-xl in the three colon cancer cells tested.	Oxaliplatin	37-48	cyclin dependent kinase 1	Homo sapiens	86-90
16323636-12	2005	There was a significant correlation between the urinary levels of 8-OH-dG and 1-OHP in those with the PON1 Q/Q genotype.	Oxaliplatin	78-83	paraoxonase 1	Homo sapiens	102-106
16024531-5	2005	Western blot analyses indicated that oxaliplatin decreased mitosis-commencing protein cdc2 and anti-apoptotic proteins, phospho-Bcl(2) and Bcl-xl in the three colon cancer cells tested.	Oxaliplatin	37-48	BCL2 like 1	Homo sapiens	139-145
16024531-6	2005	Since cdc2 stabilizes survivin, a putative IAP (inhibitor of apoptosis) family member, through phosphorylation of Thr34, we examined the level of survivin and found a marked decrease due to oxaliplatin.	Oxaliplatin	190-201	cyclin dependent kinase 1	Homo sapiens	6-10
16000573-0	2005	FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.	Oxaliplatin	34-45	Fas ligand	Homo sapiens	4-14
15913612-7	2005	Orthologues of mammalian Ppp4 subunits in Saccharomyces cerevisiae confer resistance to the anticancer, DNA-binding drugs, cisplatin and oxaliplatin.	Oxaliplatin	137-148	protein phosphatase 4 catalytic subunit	Homo sapiens	25-29
16098254-0	2005	Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.	Oxaliplatin	107-118	epidermal growth factor receptor	Homo sapiens	22-54
16098254-0	2005	Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.	Oxaliplatin	107-118	C-X-C motif chemokine ligand 8	Homo sapiens	84-97
16240585-9	2005	The present study demonstrates a correlation between PAH exposure, as assessed by urinary 1-OHP, and the induction of HO-1 expression.	Oxaliplatin	90-95	heme oxygenase 1	Homo sapiens	118-122
15731917-6	2005	Upon 24-h sequential exposure, the sequence of paclitaxel followed by oxaliplatin showed synergistic effects in AZ-521 and HST-1 cells, and greater than additive effects in KSE-1 cells, while the opposite sequence yielded marked antagonistic effects in all three cell lines.	Oxaliplatin	70-81	fibroblast growth factor 4	Homo sapiens	123-128
15763632-2	2005	PAH exposure was estimated by the urinary excretion of 1-hydroxypyrene (1-OHP), whereas the regulatory effects were assessed by the caffeine metabolic ratio (CMR).	Oxaliplatin	72-77	phenylalanine hydroxylase	Homo sapiens	0-3
15890268-8	2005	Other appear determinant for drug response, such as the common SNPs found in glutathione S-transferase P1 or xereoderma pigmentosum group D enzyme for the activity of oxaliplatin.	Oxaliplatin	167-178	glutathione S-transferase pi 1	Homo sapiens	77-105
15629453-5	2005	The suppression of ERCC1 expression in the HeLa S3 cells led to a decrease in the repair activity of cisplatin-induced DNA damage along with a decrease in the cell viability against platinum-based drugs, such as cisplatin, carboplatin, and oxaliplatin.	Oxaliplatin	240-251	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	19-24
15326164-0	2004	Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis.	Oxaliplatin	118-129	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	42-47
15634647-5	2004	Transfection of expression hemagglutinin-tagged hCtr1 cDNA into SCLC and SR2 cells enhanced the uptake of copper, cisplatin, carboplatin, and oxaliplatin, suggesting that hCtr1 transporter can transport these platinum-based drugs.	Oxaliplatin	142-153	solute carrier family 31 member 1	Homo sapiens	48-53
15545975-4	2004	Immunofluorescent staining demonstrated that the apoptotic cascade initiated by oxaliplatin is characterised by translocation of Bax to the mitochondria and cytochrome c release into the cytosol.	Oxaliplatin	80-91	BCL2 associated X, apoptosis regulator	Homo sapiens	129-132
15545975-4	2004	Immunofluorescent staining demonstrated that the apoptotic cascade initiated by oxaliplatin is characterised by translocation of Bax to the mitochondria and cytochrome c release into the cytosol.	Oxaliplatin	80-91	cytochrome c, somatic	Homo sapiens	157-169
15545975-5	2004	Oxaliplatin treatment resulted in caspase 3 activation and oxaliplatin-induced apoptosis was abrogated by inhibition of caspase activity with z-VAD-fmk, but was independent of Fas/FasL association.	Oxaliplatin	0-11	caspase 3	Homo sapiens	34-43
15545975-5	2004	Oxaliplatin treatment resulted in caspase 3 activation and oxaliplatin-induced apoptosis was abrogated by inhibition of caspase activity with z-VAD-fmk, but was independent of Fas/FasL association.	Oxaliplatin	0-11	Fas ligand	Homo sapiens	180-184
15545975-6	2004	Targeted inactivation of Bax or p53 in HCT116 cells resulted in significantly increased resistance to oxaliplatin.	Oxaliplatin	102-113	BCL2 associated X, apoptosis regulator	Homo sapiens	25-28
15545975-6	2004	Targeted inactivation of Bax or p53 in HCT116 cells resulted in significantly increased resistance to oxaliplatin.	Oxaliplatin	102-113	tumor protein p53	Homo sapiens	32-35
15727486-14	2005	The degradation of oxaliplatin is independent of potentially varying enzyme activity, but for this drug, the DNA repair enzyme ERCC1 may influence the survival time after chemotherapy.	Oxaliplatin	19-30	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	127-132
15607931-5	2005	A detailed kinetic analysis of the insertion and extension steps of dNTP incorporation in the vicinity of the adduct shows that both DNA polymerase beta (pol beta) and DNA polymerase eta (pol eta) catalyze translesion synthesis past oxaliplatin-GG adducts with greater efficiency than past cisplatin-GG adducts.	Oxaliplatin	233-244	DNA polymerase beta	Homo sapiens	133-152
15607931-5	2005	A detailed kinetic analysis of the insertion and extension steps of dNTP incorporation in the vicinity of the adduct shows that both DNA polymerase beta (pol beta) and DNA polymerase eta (pol eta) catalyze translesion synthesis past oxaliplatin-GG adducts with greater efficiency than past cisplatin-GG adducts.	Oxaliplatin	233-244	DNA polymerase beta	Homo sapiens	154-162
15607931-5	2005	A detailed kinetic analysis of the insertion and extension steps of dNTP incorporation in the vicinity of the adduct shows that both DNA polymerase beta (pol beta) and DNA polymerase eta (pol eta) catalyze translesion synthesis past oxaliplatin-GG adducts with greater efficiency than past cisplatin-GG adducts.	Oxaliplatin	233-244	DNA polymerase eta	Homo sapiens	168-186
15607932-1	2005	Recent studies have demonstrated that the major Cu influx transporter CTR1 regulates tumor cell uptake of cisplatin (DDP), carboplatin (CBDCA) and oxaliplatin (L-OHP), and that the two Cu efflux transporters ATP7A and ATP7B regulate the efflux of these drugs.	Oxaliplatin	147-158	solute carrier family 31 member 1	Homo sapiens	70-74
15607932-1	2005	Recent studies have demonstrated that the major Cu influx transporter CTR1 regulates tumor cell uptake of cisplatin (DDP), carboplatin (CBDCA) and oxaliplatin (L-OHP), and that the two Cu efflux transporters ATP7A and ATP7B regulate the efflux of these drugs.	Oxaliplatin	160-165	solute carrier family 31 member 1	Homo sapiens	70-74
15607932-1	2005	Recent studies have demonstrated that the major Cu influx transporter CTR1 regulates tumor cell uptake of cisplatin (DDP), carboplatin (CBDCA) and oxaliplatin (L-OHP), and that the two Cu efflux transporters ATP7A and ATP7B regulate the efflux of these drugs.	Oxaliplatin	160-165	ATPase copper transporting alpha	Homo sapiens	208-213
15607932-1	2005	Recent studies have demonstrated that the major Cu influx transporter CTR1 regulates tumor cell uptake of cisplatin (DDP), carboplatin (CBDCA) and oxaliplatin (L-OHP), and that the two Cu efflux transporters ATP7A and ATP7B regulate the efflux of these drugs.	Oxaliplatin	160-165	ATPase copper transporting beta	Homo sapiens	218-223
15514570-7	2004	Elevation of pro-inflammatory cytokines, such as tumor necrosis factor-alpha and interleukin-6, induced by oxaliplatin, may represent the relevant causal links involved in the cascade of events which have led to the immune-mediated demyelination in the peripheral nervous system in this patient.	Oxaliplatin	107-118	tumor necrosis factor	Homo sapiens	49-76
15514570-7	2004	Elevation of pro-inflammatory cytokines, such as tumor necrosis factor-alpha and interleukin-6, induced by oxaliplatin, may represent the relevant causal links involved in the cascade of events which have led to the immune-mediated demyelination in the peripheral nervous system in this patient.	Oxaliplatin	107-118	interleukin 6	Homo sapiens	81-94
15326164-6	2004	Both kinase-defective forms of c-Src co-sensitized cells to apoptosis induced by oxaliplatin and Fas activation but not by SN38.	Oxaliplatin	81-92	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	31-36
15326164-7	2004	Cells harboring kinase-defective forms of c-Src carrying function blocking point mutations in SH3 or SH2 domains were similarly sensitive to oxaliplatin, suggesting that reduction in kinase activity and not a Src SH2-SH3 scaffold function was responsible for the observed altered sensitivity.	Oxaliplatin	141-152	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	42-47
15326164-8	2004	Oxaliplatin-induced apoptosis, potentiated by kinase-defective c-Src mutants, was dependent on activation of caspase 8 and associated with Bid cleavage.	Oxaliplatin	0-11	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	63-68
15326164-8	2004	Oxaliplatin-induced apoptosis, potentiated by kinase-defective c-Src mutants, was dependent on activation of caspase 8 and associated with Bid cleavage.	Oxaliplatin	0-11	caspase 8	Homo sapiens	109-118
15386340-10	2004	Taxol and oxaliplatin significantly increased the levels of expression of COX-2, PGES, GST-mu, and GST-pi in a number of different experimental protocols.	Oxaliplatin	10-21	prostaglandin-endoperoxide synthase 2	Mus musculus	74-79
15386340-10	2004	Taxol and oxaliplatin significantly increased the levels of expression of COX-2, PGES, GST-mu, and GST-pi in a number of different experimental protocols.	Oxaliplatin	10-21	prostaglandin E synthase	Mus musculus	81-85
15458816-7	2004	A detailed kinetic analysis of the insertion and extension steps of dNTP incorporation in the vicinity of the adduct shows that both pol beta and pol eta catalyze translesion synthesis past oxaliplatin-GG adducts with greater efficiency than past cisplatin-GG adducts.	Oxaliplatin	190-201	DNA polymerase beta	Homo sapiens	133-141
15229296-1	2004	Cells selected for resistance to cisplatin are often cross-resistant to copper and vice versa, and the major copper influx transporter copper transport protein 1 (CTR1) has been shown to regulate the uptake of cisplatin, carboplatin, and oxaliplatin in yeast.	Oxaliplatin	238-249	solute carrier family 31 member 1	Homo sapiens	163-167
15252142-4	2004	At equitoxic doses, oxaliplatin is more effective than cisplatin in SSAT induction.	Oxaliplatin	20-31	spermidine/spermine N1-acetyltransferase family member 2	Homo sapiens	68-72
15334700-7	2004	AC-DEVD-CHO, a Caspase-3 specific inhibitor, was used to elucidate the role of activated Caspase-3 in the process of apoptosis induced by oxaliplatin.	Oxaliplatin	138-149	caspase 3	Homo sapiens	15-24
15334700-7	2004	AC-DEVD-CHO, a Caspase-3 specific inhibitor, was used to elucidate the role of activated Caspase-3 in the process of apoptosis induced by oxaliplatin.	Oxaliplatin	138-149	caspase 3	Homo sapiens	89-98
15334700-15	2004	AC-DEVD-CHO, a Caspase-3 specific inhibitor, could significantly inhibit and delay apoptosis induced by oxaliplatin.	Oxaliplatin	104-115	caspase 3	Homo sapiens	15-24
15334700-18	2004	The induction of Caspase-3 m-RNA expression, activation of Caspase-3 and promotion of apoptosis may be some of the therapeutic mechanisms of oxaliplatin on gastric carcinoma.	Oxaliplatin	141-152	caspase 3	Homo sapiens	17-26
15334700-18	2004	The induction of Caspase-3 m-RNA expression, activation of Caspase-3 and promotion of apoptosis may be some of the therapeutic mechanisms of oxaliplatin on gastric carcinoma.	Oxaliplatin	141-152	caspase 3	Homo sapiens	59-68
15273962-3	2004	In this study, we investigated whether polymorphisms of glutathione S-transferase (GSTM1 and GSTT1) can modulate the relationship between urinary 8-OH-dG and 1-OHP concentrations among the COWs.	Oxaliplatin	158-163	glutathione S-transferase Mu 1	Bos taurus	83-88
15273962-3	2004	In this study, we investigated whether polymorphisms of glutathione S-transferase (GSTM1 and GSTT1) can modulate the relationship between urinary 8-OH-dG and 1-OHP concentrations among the COWs.	Oxaliplatin	158-163	glutathione S-transferase theta-1	Bos taurus	93-98
15273962-6	2004	RESULTS: Urinary 1-OHP and 8-OH-dG concentrations (mean +/- SD) in the topside-oven workers with the presence of GSTM1 were 107.2 +/- 107.9 and 15.3 +/- 9.7 ng/ml, respectively, which were not significantly different from those in the absence of GSTM1 (84.1 +/- 104.5 and 12.8 +/- 14.1 ng/ml).	Oxaliplatin	17-22	glutathione S-transferase Mu 1	Bos taurus	113-118
15269138-0	2004	Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.	Oxaliplatin	111-122	ATPase copper transporting alpha	Homo sapiens	54-59
15269138-1	2004	PURPOSE: The goal of this study was to determine the effect of small changes in ATP7A expression on the pharmacodynamics of cisplatin, carboplatin, and oxaliplatin in human ovarian carcinoma cells.	Oxaliplatin	152-163	ATPase copper transporting alpha	Homo sapiens	80-85
15269138-5	2004	In contrast, it was sufficient to render the 2008/MNK cells resistant to cisplatin, carboplatin, and oxaliplatin.	Oxaliplatin	101-112	ATPase copper transporting alpha	Homo sapiens	50-53
15334062-3	2004	We showed that the activity of oxaliplatin is mediated by the induction of Bax/Bak-dependent mitochondrial apoptosis and that oxaliplatin resistance is mediated by a defect in Bax/Bak activation correlating with a reduced loss of the mitochondrial transmembrane potential (DeltaPsim).	Oxaliplatin	31-42	BCL2 associated X, apoptosis regulator	Homo sapiens	75-78
15334062-3	2004	We showed that the activity of oxaliplatin is mediated by the induction of Bax/Bak-dependent mitochondrial apoptosis and that oxaliplatin resistance is mediated by a defect in Bax/Bak activation correlating with a reduced loss of the mitochondrial transmembrane potential (DeltaPsim).	Oxaliplatin	31-42	BCL2 antagonist/killer 1	Homo sapiens	79-82
15334062-3	2004	We showed that the activity of oxaliplatin is mediated by the induction of Bax/Bak-dependent mitochondrial apoptosis and that oxaliplatin resistance is mediated by a defect in Bax/Bak activation correlating with a reduced loss of the mitochondrial transmembrane potential (DeltaPsim).	Oxaliplatin	126-137	BCL2 associated X, apoptosis regulator	Homo sapiens	176-179
15334062-3	2004	We showed that the activity of oxaliplatin is mediated by the induction of Bax/Bak-dependent mitochondrial apoptosis and that oxaliplatin resistance is mediated by a defect in Bax/Bak activation correlating with a reduced loss of the mitochondrial transmembrane potential (DeltaPsim).	Oxaliplatin	126-137	BCL2 antagonist/killer 1	Homo sapiens	180-183
15334062-4	2004	In addition, we observed that p53 only contributed marginally to oxaliplatin-induced cytotoxicity and was not involved in oxaliplatin resistance.	Oxaliplatin	65-76	tumor protein p53	Homo sapiens	30-33
15213713-2	2004	Functional polymorphisms in DNA-repair genes XPD, ERCC1, XRCC1, XPA, and metabolising genes glutathione S-transferase GSTP1, GSTT1, GSTM1, and thymidylate synthase (TS) were assessed retrospectively in 106 patients with refractory stage IV disease who received 5-FU/oxaliplatin combination chemotherapy, using a polymerase chain reaction-based RFLP technique.	Oxaliplatin	266-277	glutathione S-transferase pi 1	Homo sapiens	118-123
15213713-2	2004	Functional polymorphisms in DNA-repair genes XPD, ERCC1, XRCC1, XPA, and metabolising genes glutathione S-transferase GSTP1, GSTT1, GSTM1, and thymidylate synthase (TS) were assessed retrospectively in 106 patients with refractory stage IV disease who received 5-FU/oxaliplatin combination chemotherapy, using a polymerase chain reaction-based RFLP technique.	Oxaliplatin	266-277	glutathione S-transferase theta 1	Homo sapiens	125-130
15213713-2	2004	Functional polymorphisms in DNA-repair genes XPD, ERCC1, XRCC1, XPA, and metabolising genes glutathione S-transferase GSTP1, GSTT1, GSTM1, and thymidylate synthase (TS) were assessed retrospectively in 106 patients with refractory stage IV disease who received 5-FU/oxaliplatin combination chemotherapy, using a polymerase chain reaction-based RFLP technique.	Oxaliplatin	266-277	thymidylate synthetase	Homo sapiens	143-163
15252142-6	2004	When combined with DENSPM to further induce SSAT and to enhance conversion of mRNA to activity, oxaliplatin increased SSAT mRNA 50-fold and activity, 210-fold.	Oxaliplatin	96-107	spermidine/spermine N1-acetyltransferase family member 2	Homo sapiens	44-48
15252142-6	2004	When combined with DENSPM to further induce SSAT and to enhance conversion of mRNA to activity, oxaliplatin increased SSAT mRNA 50-fold and activity, 210-fold.	Oxaliplatin	96-107	spermidine/spermine N1-acetyltransferase family member 2	Homo sapiens	118-122
15057142-0	2004	Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells.	Oxaliplatin	80-91	thymidylate synthetase	Homo sapiens	19-39
15274386-0	2004	5FU and oxaliplatin-containing chemotherapy in two dihydropyrimidine dehydrogenase-deficient patients.	Oxaliplatin	8-19	dihydropyrimidine dehydrogenase	Homo sapiens	51-82
15173006-4	2004	Finally, we identified three novel genes (PSY1-3, "platinum sensitivity") that, when deleted, demonstrate sensitivity to cisplatin and oxaliplatin, but not to mitomycin C.	Oxaliplatin	135-146	Psy2p	Saccharomyces cerevisiae S288C	42-48
15173006-6	2004	Also, the similarity of the sensitivity profiles of the platinum agents with that of the known DNA interstrand cross-linking agent mitomycin C, and the importance of the gene PSO2 known to be involved in DNA interstrand cross-link repair strongly suggests that interstrand cross-links are important toxic lesions for cisplatin and oxaliplatin, at least in yeast.	Oxaliplatin	331-342	DNA cross-link repair protein PSO2	Saccharomyces cerevisiae S288C	175-179
15204521-9	2004	Time-course changes of cell cycle regulatory proteins levels revealed accumulation of cyclins A and B as well as of cdc2 and cdk2 upon exposure of IGROV-1 cells to hyperthermia and oxaliplatin.	Oxaliplatin	181-192	cyclin A2	Homo sapiens	86-101
15204521-9	2004	Time-course changes of cell cycle regulatory proteins levels revealed accumulation of cyclins A and B as well as of cdc2 and cdk2 upon exposure of IGROV-1 cells to hyperthermia and oxaliplatin.	Oxaliplatin	181-192	cyclin dependent kinase 1	Homo sapiens	116-120
15204521-9	2004	Time-course changes of cell cycle regulatory proteins levels revealed accumulation of cyclins A and B as well as of cdc2 and cdk2 upon exposure of IGROV-1 cells to hyperthermia and oxaliplatin.	Oxaliplatin	181-192	cyclin dependent kinase 2	Homo sapiens	125-129
15057142-9	2004	Oxaliplatin treatment results in down-regulation of free thymidylate synthase (TS) protein expression by Western blotting.	Oxaliplatin	0-11	thymidylate synthetase	Homo sapiens	57-77
15057142-9	2004	Oxaliplatin treatment results in down-regulation of free thymidylate synthase (TS) protein expression by Western blotting.	Oxaliplatin	0-11	thymidylate synthetase	Homo sapiens	79-81
15057142-11	2004	Oxaliplatin treatment results in down-regulation of the TS mRNA level up to 40% (mean +/- SD of ratio to reference control = 0.60 +/- 0.21, range 0.42-0.84).	Oxaliplatin	0-11	thymidylate synthetase	Homo sapiens	56-58
15041737-0	2004	Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.	Oxaliplatin	110-121	tumor protein p53	Homo sapiens	20-23
15041737-5	2004	In addition, we found that resistance to 5-FU and oxaliplatin was higher in parental p53(-/-) cells compared with parental p53(+/+) cells, with an approximately 5-fold increase in IC(50 (72 h)) for each drug.	Oxaliplatin	50-61	tumor protein p53	Homo sapiens	85-88
15041737-8	2004	These data suggest that p53 may be an important determinant of sensitivity to 5-FU and oxaliplatin but not CPT-11.	Oxaliplatin	87-98	tumor protein p53	Homo sapiens	24-27
15041737-5	2004	In addition, we found that resistance to 5-FU and oxaliplatin was higher in parental p53(-/-) cells compared with parental p53(+/+) cells, with an approximately 5-fold increase in IC(50 (72 h)) for each drug.	Oxaliplatin	50-61	tumor protein p53	Homo sapiens	123-126
15041737-10	2004	In oxaliplatin-resistant cells, we noted increased mRNA levels of the nucleotide excision repair gene ERCC1 and ATP-binding cassette transporter breast cancer resistance protein.	Oxaliplatin	3-14	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	102-107
15041737-7	2004	Furthermore, apoptosis after treatment with 5-FU and oxaliplatin, but not CPT-11, was significantly reduced in parental p53(-/-) cells compared with parental p53(+/+) cells.	Oxaliplatin	53-64	tumor protein p53	Homo sapiens	120-123
15041737-7	2004	Furthermore, apoptosis after treatment with 5-FU and oxaliplatin, but not CPT-11, was significantly reduced in parental p53(-/-) cells compared with parental p53(+/+) cells.	Oxaliplatin	53-64	tumor protein p53	Homo sapiens	158-161
15015600-5	2004	Treatment of cells with L-OHP resulted in the activation of caspase-8, -9 and -3, in a mitochondrial membrane depolarisation, and in an increase of CD95 receptor and CD95 ligand levels.	Oxaliplatin	24-29	caspase 8	Homo sapiens	60-80
14985457-0	2004	Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.	Oxaliplatin	9-20	BCL2 like 1	Homo sapiens	59-65
14985457-0	2004	Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.	Oxaliplatin	9-20	tumor protein p53	Homo sapiens	85-88
14985457-0	2004	Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.	Oxaliplatin	9-20	BCL2 associated X, apoptosis regulator	Homo sapiens	93-96
14985457-1	2004	INTRODUCTION: Oxaliplatin, licensed for colorectal cancer chemotherapy, damages DNA by generating intrastrand and interstrand cross-links and can induce apoptosis via a Bax-dependent pathway.	Oxaliplatin	14-25	BCL2 associated X, apoptosis regulator	Homo sapiens	169-172
14985457-6	2004	RESULTS: At clinically relevant concentrations, oxaliplatin induced p53 and p53-dependent Bax, Bcl-xl, and p21/WAF1 protein accumulation.	Oxaliplatin	48-59	tumor protein p53	Homo sapiens	68-71
14985457-6	2004	RESULTS: At clinically relevant concentrations, oxaliplatin induced p53 and p53-dependent Bax, Bcl-xl, and p21/WAF1 protein accumulation.	Oxaliplatin	48-59	tumor protein p53	Homo sapiens	76-79
14985457-6	2004	RESULTS: At clinically relevant concentrations, oxaliplatin induced p53 and p53-dependent Bax, Bcl-xl, and p21/WAF1 protein accumulation.	Oxaliplatin	48-59	BCL2 associated X, apoptosis regulator	Homo sapiens	90-93
14985457-6	2004	RESULTS: At clinically relevant concentrations, oxaliplatin induced p53 and p53-dependent Bax, Bcl-xl, and p21/WAF1 protein accumulation.	Oxaliplatin	48-59	BCL2 like 1	Homo sapiens	95-101
14985457-6	2004	RESULTS: At clinically relevant concentrations, oxaliplatin induced p53 and p53-dependent Bax, Bcl-xl, and p21/WAF1 protein accumulation.	Oxaliplatin	48-59	cyclin dependent kinase inhibitor 1A	Homo sapiens	107-110
14985457-6	2004	RESULTS: At clinically relevant concentrations, oxaliplatin induced p53 and p53-dependent Bax, Bcl-xl, and p21/WAF1 protein accumulation.	Oxaliplatin	48-59	cyclin dependent kinase inhibitor 1A	Homo sapiens	111-115
14985457-12	2004	Prior Bcl-xl knockdown enhanced the apoptotic and the global cytotoxic effect of oxaliplatin.	Oxaliplatin	81-92	BCL2 like 1	Homo sapiens	6-12
15360055-0	2004	Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer.	Oxaliplatin	35-46	CEA cell adhesion molecule 3	Homo sapiens	10-13
15360055-4	2004	CEA was measured every second week in 27 patients receiving oxaliplatin, 5-fluororuracil, and folinic acid as first-line therapy against metastatic colorectal cancer.	Oxaliplatin	60-71	CEA cell adhesion molecule 3	Homo sapiens	0-3
15015600-5	2004	Treatment of cells with L-OHP resulted in the activation of caspase-8, -9 and -3, in a mitochondrial membrane depolarisation, and in an increase of CD95 receptor and CD95 ligand levels.	Oxaliplatin	24-29	Fas cell surface death receptor	Homo sapiens	148-152
15015600-5	2004	Treatment of cells with L-OHP resulted in the activation of caspase-8, -9 and -3, in a mitochondrial membrane depolarisation, and in an increase of CD95 receptor and CD95 ligand levels.	Oxaliplatin	24-29	Fas cell surface death receptor	Homo sapiens	166-170
14728946-10	2004	Interestingly, the presence of a K-ras mutation in codon 12 (5/15 xenografts) coincided with a low response rate towards oxaliplatin.	Oxaliplatin	121-132	KRAS proto-oncogene, GTPase	Homo sapiens	33-38
12919719-3	2003	We have evaluated the gene-environment interaction in Santiago of Chile, studying the contribution of CYP1A1 and GSTM1 polymorphisms on 1-OH-P urinary levels used as the PAHs exposure biomarker.	Oxaliplatin	136-142	glutathione S-transferase mu 1	Homo sapiens	113-118
14695170-5	2003	Activation of p38 was shown to be a key proapoptotic mediator of oxaliplatin-induced cell death.	Oxaliplatin	65-76	mitogen-activated protein kinase 14	Homo sapiens	14-17
14695170-9	2003	These data support an interaction between 17-AAG and components of the NF-kappaB pathway in the modulation of oxaliplatin sensitivity in colon cancer cells.	Oxaliplatin	110-121	N-methylpurine DNA glycosylase	Homo sapiens	45-48
12919721-1	2003	The aim of the present study is to evaluate the influence of the genetic polymorphism of two enzymes involved in the biotransformation of xenobiotics, cytochrome P450 1A1 (CYP1A1) and glutathione-S-transferase M1 (GSTM1), on the urinary levels of 1-hydroxypyrene (1-OH-P) in workers exposed to polycyclic aromatic hydrocarbons (PAHs) and in unexposed workers (controls).	Oxaliplatin	264-270	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	151-170
12919721-1	2003	The aim of the present study is to evaluate the influence of the genetic polymorphism of two enzymes involved in the biotransformation of xenobiotics, cytochrome P450 1A1 (CYP1A1) and glutathione-S-transferase M1 (GSTM1), on the urinary levels of 1-hydroxypyrene (1-OH-P) in workers exposed to polycyclic aromatic hydrocarbons (PAHs) and in unexposed workers (controls).	Oxaliplatin	264-270	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	172-178
14640687-0	2003	Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro.	Oxaliplatin	79-90	endothelin receptor type A	Homo sapiens	125-128
14640687-1	2003	DNA polymerases beta and eta are among the few eukaryotic polymerases known to efficiently bypass cisplatin and oxaliplatin adducts in vitro.	Oxaliplatin	112-123	endothelin receptor type A	Homo sapiens	17-20
14640687-4	2003	In this study, we performed a steady-state kinetic analysis of the steps required for fixation of dTTP misinsertion during translesion synthesis past cisplatin- and oxaliplatin-GG adducts by pol beta and pol eta.	Oxaliplatin	165-176	DNA polymerase beta	Homo sapiens	191-199
14640687-4	2003	In this study, we performed a steady-state kinetic analysis of the steps required for fixation of dTTP misinsertion during translesion synthesis past cisplatin- and oxaliplatin-GG adducts by pol beta and pol eta.	Oxaliplatin	165-176	endothelin receptor type A	Homo sapiens	196-199
23573555-10	2003	A phase I/II study is also investigating the combined use of oxaliplatin and ZD1839 ("Iressa"), a small molecule inhibitor of the EGFR specific tyrosine kinase activating the same pathways.	Oxaliplatin	61-72	epidermal growth factor receptor	Homo sapiens	130-134
12919721-1	2003	The aim of the present study is to evaluate the influence of the genetic polymorphism of two enzymes involved in the biotransformation of xenobiotics, cytochrome P450 1A1 (CYP1A1) and glutathione-S-transferase M1 (GSTM1), on the urinary levels of 1-hydroxypyrene (1-OH-P) in workers exposed to polycyclic aromatic hydrocarbons (PAHs) and in unexposed workers (controls).	Oxaliplatin	264-270	glutathione S-transferase mu 1	Homo sapiens	184-212
12919721-1	2003	The aim of the present study is to evaluate the influence of the genetic polymorphism of two enzymes involved in the biotransformation of xenobiotics, cytochrome P450 1A1 (CYP1A1) and glutathione-S-transferase M1 (GSTM1), on the urinary levels of 1-hydroxypyrene (1-OH-P) in workers exposed to polycyclic aromatic hydrocarbons (PAHs) and in unexposed workers (controls).	Oxaliplatin	264-270	glutathione S-transferase mu 1	Homo sapiens	214-219
12919719-7	2003	When 1-OH-P levels were related with genotypes, an association was observed for the CYP1A1*2A genotype, so that the diesel-exposed workers carrying the CYP1A1*2A allele showed significantly higher 1-OH-P levels than the subjects from the rural area with the same genotype (P=0.008).	Oxaliplatin	5-11	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	84-90
12919719-7	2003	When 1-OH-P levels were related with genotypes, an association was observed for the CYP1A1*2A genotype, so that the diesel-exposed workers carrying the CYP1A1*2A allele showed significantly higher 1-OH-P levels than the subjects from the rural area with the same genotype (P=0.008).	Oxaliplatin	5-11	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	152-158
12919719-7	2003	When 1-OH-P levels were related with genotypes, an association was observed for the CYP1A1*2A genotype, so that the diesel-exposed workers carrying the CYP1A1*2A allele showed significantly higher 1-OH-P levels than the subjects from the rural area with the same genotype (P=0.008).	Oxaliplatin	197-203	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	84-90
12919719-7	2003	When 1-OH-P levels were related with genotypes, an association was observed for the CYP1A1*2A genotype, so that the diesel-exposed workers carrying the CYP1A1*2A allele showed significantly higher 1-OH-P levels than the subjects from the rural area with the same genotype (P=0.008).	Oxaliplatin	197-203	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	152-158
12919719-9	2003	These results may suggest an association between levels of the exposure biomarker 1-OH-P and presence of the CYP1A1*2A genotype, a potential genetic susceptibility biomarker which might be useful in identifying individuals at higher risk among people exposed to high PAH levels in diesel exhaust.	Oxaliplatin	82-88	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	109-115
12919719-9	2003	These results may suggest an association between levels of the exposure biomarker 1-OH-P and presence of the CYP1A1*2A genotype, a potential genetic susceptibility biomarker which might be useful in identifying individuals at higher risk among people exposed to high PAH levels in diesel exhaust.	Oxaliplatin	82-88	phenylalanine hydroxylase	Homo sapiens	267-270
12807751-5	2003	After adjusting for these factors, we found that the GSTT1 genotypes affected the urinary 1-OHP levels, i.e. the GSTT1 present subjects had approximately 1.5 times the urinary 1-OHP level than the GSTT1 null subjects (P &lt; 0.05).	Oxaliplatin	90-95	glutathione S-transferase theta 1	Homo sapiens	53-58
14506341-4	2003	The diesel-exposed workers carrying the CYP1A1*2A allele showed significantly higher 1-OH-P levels than the subjects from the rural area with the same genotype.	Oxaliplatin	85-91	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	40-46
14506341-5	2003	The higher levels of 1-OH-P were found in individuals carrying the combined CYP1A1*2A and GSTM1 null genotype.	Oxaliplatin	21-27	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	76-82
14506341-5	2003	The higher levels of 1-OH-P were found in individuals carrying the combined CYP1A1*2A and GSTM1 null genotype.	Oxaliplatin	21-27	glutathione S-transferase mu 1	Homo sapiens	90-95
14979105-7	2003	CC16-S was also negatively correlated with 1-OH-P, but not with naphtol concentrations.	Oxaliplatin	43-49	secretoglobin family 1A member 1	Homo sapiens	0-4
12807751-5	2003	After adjusting for these factors, we found that the GSTT1 genotypes affected the urinary 1-OHP levels, i.e. the GSTT1 present subjects had approximately 1.5 times the urinary 1-OHP level than the GSTT1 null subjects (P &lt; 0.05).	Oxaliplatin	90-95	glutathione S-transferase theta 1	Homo sapiens	113-118
12807751-5	2003	After adjusting for these factors, we found that the GSTT1 genotypes affected the urinary 1-OHP levels, i.e. the GSTT1 present subjects had approximately 1.5 times the urinary 1-OHP level than the GSTT1 null subjects (P &lt; 0.05).	Oxaliplatin	90-95	glutathione S-transferase theta 1	Homo sapiens	113-118
12807751-5	2003	After adjusting for these factors, we found that the GSTT1 genotypes affected the urinary 1-OHP levels, i.e. the GSTT1 present subjects had approximately 1.5 times the urinary 1-OHP level than the GSTT1 null subjects (P &lt; 0.05).	Oxaliplatin	176-181	glutathione S-transferase theta 1	Homo sapiens	53-58
12807751-5	2003	After adjusting for these factors, we found that the GSTT1 genotypes affected the urinary 1-OHP levels, i.e. the GSTT1 present subjects had approximately 1.5 times the urinary 1-OHP level than the GSTT1 null subjects (P &lt; 0.05).	Oxaliplatin	176-181	glutathione S-transferase theta 1	Homo sapiens	113-118
12807751-5	2003	After adjusting for these factors, we found that the GSTT1 genotypes affected the urinary 1-OHP levels, i.e. the GSTT1 present subjects had approximately 1.5 times the urinary 1-OHP level than the GSTT1 null subjects (P &lt; 0.05).	Oxaliplatin	176-181	glutathione S-transferase theta 1	Homo sapiens	113-118
12807751-6	2003	In the case of the subjects who were also GSTM1 null, this trend became stronger, i.e. the GSTT1 present subjects had approximately 2 times the urinary 1-OHP level (P &lt; 0.01).	Oxaliplatin	152-157	glutathione S-transferase mu 1	Homo sapiens	42-47
12807751-6	2003	In the case of the subjects who were also GSTM1 null, this trend became stronger, i.e. the GSTT1 present subjects had approximately 2 times the urinary 1-OHP level (P &lt; 0.01).	Oxaliplatin	152-157	glutathione S-transferase theta 1	Homo sapiens	91-96
12807751-8	2003	Therefore, this study suggests that the GSTT1 genetic polymorphism has the potential to affect the biological monitoring of PAHs with urinary 1-OHP, and might act as a genetic factor in PAH-related toxicity.	Oxaliplatin	142-147	glutathione S-transferase theta 1	Homo sapiens	40-45
12684687-4	2003	We report that Brca1-deficiency in p53-null cells was associated with increased sensitivity to the topoisomerase I poisons camptothecin and topotecan, the topoisomerase II poisons doxorubicin, mitoxantrone and etoposide, and to the platinum compounds carboplatin and oxaliplatin, but not to the antimetabolites 5-fluorouracil and gemcitabine and the taxanes docetaxel and paclitaxel.	Oxaliplatin	267-278	tumor protein p53	Homo sapiens	35-38
12504667-6	2003	The determination of ERCC1 and XPA expression, two enzymes of the NER pathway, by reverse transcriptase-polymerase chain reaction (RT-PCR), demonstrated that ERCC1 expression was predictive of L-OHP sensitivity (r(2)=0.67, P=0.02) and XPA level after oxaliplatin exposure was also correlated to L-OHP IC(50) (r(2)=0.5; P=0.04).	Oxaliplatin	193-198	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	21-26
12578393-2	2003	Because pol beta has been shown to perform translesion DNA synthesis past cisplatin (CP)- and oxaliplatin (OX)-GG adducts, we determined the ability of pol mu to bypass these lesions.	Oxaliplatin	94-105	DNA polymerase beta	Homo sapiens	8-16
14646291-7	2003	Significant positive correlations between 8-OHdG and 1-OHP concentrations were found in subjects with every genotype of the CYP1A1 and CYP2E1 genes, with the GSTM1 null-type, with the NAT2 genotype of a rapid acetylator, and with the UGT1A6 wild-type, respectively.	Oxaliplatin	53-58	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	124-130
14646291-7	2003	Significant positive correlations between 8-OHdG and 1-OHP concentrations were found in subjects with every genotype of the CYP1A1 and CYP2E1 genes, with the GSTM1 null-type, with the NAT2 genotype of a rapid acetylator, and with the UGT1A6 wild-type, respectively.	Oxaliplatin	53-58	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	135-141
14646291-7	2003	Significant positive correlations between 8-OHdG and 1-OHP concentrations were found in subjects with every genotype of the CYP1A1 and CYP2E1 genes, with the GSTM1 null-type, with the NAT2 genotype of a rapid acetylator, and with the UGT1A6 wild-type, respectively.	Oxaliplatin	53-58	glutathione S-transferase mu 1	Homo sapiens	158-163
14646291-7	2003	Significant positive correlations between 8-OHdG and 1-OHP concentrations were found in subjects with every genotype of the CYP1A1 and CYP2E1 genes, with the GSTM1 null-type, with the NAT2 genotype of a rapid acetylator, and with the UGT1A6 wild-type, respectively.	Oxaliplatin	53-58	N-acetyltransferase 2	Homo sapiens	184-188
14646291-7	2003	Significant positive correlations between 8-OHdG and 1-OHP concentrations were found in subjects with every genotype of the CYP1A1 and CYP2E1 genes, with the GSTM1 null-type, with the NAT2 genotype of a rapid acetylator, and with the UGT1A6 wild-type, respectively.	Oxaliplatin	53-58	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	234-240
12570658-7	2003	Indeed, the effect of oxaliplatin could be reduced in tumor cells expressing mutant p53.	Oxaliplatin	22-33	tumor protein p53	Homo sapiens	84-87
12589033-0	2003	p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors.	Oxaliplatin	42-53	transformation related protein 53, pseudogene	Mus musculus	0-3
12589033-6	2003	These findings indicate that even in the context of an activated ras gene that potentially mediates suppression of apoptosis, both cisplatin and oxaliplatin are capable of promoting an efficient p53-independent tumor response.	Oxaliplatin	145-156	transformation related protein 53, pseudogene	Mus musculus	195-198
12504667-6	2003	The determination of ERCC1 and XPA expression, two enzymes of the NER pathway, by reverse transcriptase-polymerase chain reaction (RT-PCR), demonstrated that ERCC1 expression was predictive of L-OHP sensitivity (r(2)=0.67, P=0.02) and XPA level after oxaliplatin exposure was also correlated to L-OHP IC(50) (r(2)=0.5; P=0.04).	Oxaliplatin	193-198	XPA, DNA damage recognition and repair factor	Homo sapiens	31-34
12504667-6	2003	The determination of ERCC1 and XPA expression, two enzymes of the NER pathway, by reverse transcriptase-polymerase chain reaction (RT-PCR), demonstrated that ERCC1 expression was predictive of L-OHP sensitivity (r(2)=0.67, P=0.02) and XPA level after oxaliplatin exposure was also correlated to L-OHP IC(50) (r(2)=0.5; P=0.04).	Oxaliplatin	193-198	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	158-163
12504667-6	2003	The determination of ERCC1 and XPA expression, two enzymes of the NER pathway, by reverse transcriptase-polymerase chain reaction (RT-PCR), demonstrated that ERCC1 expression was predictive of L-OHP sensitivity (r(2)=0.67, P=0.02) and XPA level after oxaliplatin exposure was also correlated to L-OHP IC(50) (r(2)=0.5; P=0.04).	Oxaliplatin	193-198	XPA, DNA damage recognition and repair factor	Homo sapiens	235-238
12504667-6	2003	The determination of ERCC1 and XPA expression, two enzymes of the NER pathway, by reverse transcriptase-polymerase chain reaction (RT-PCR), demonstrated that ERCC1 expression was predictive of L-OHP sensitivity (r(2)=0.67, P=0.02) and XPA level after oxaliplatin exposure was also correlated to L-OHP IC(50) (r(2)=0.5; P=0.04).	Oxaliplatin	251-262	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	158-163
12504667-6	2003	The determination of ERCC1 and XPA expression, two enzymes of the NER pathway, by reverse transcriptase-polymerase chain reaction (RT-PCR), demonstrated that ERCC1 expression was predictive of L-OHP sensitivity (r(2)=0.67, P=0.02) and XPA level after oxaliplatin exposure was also correlated to L-OHP IC(50) (r(2)=0.5; P=0.04).	Oxaliplatin	295-300	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	158-163
12072547-4	2002	In a retrospective study, we investigated associations between common polymorphisms in genes for several GST subclasses (GSTP1, GSTT1, GSTM1) and survival of patients with metastatic colorectal cancer receiving 5-fluorouracil (5-FU)/oxaliplatin chemotherapy.	Oxaliplatin	233-244	glutathione S-transferase kappa 1	Homo sapiens	105-108
12531010-1	2002	DNA polymerases beta (pol beta ) and eta (pol eta ) are the only two eukaryotic polymerases known to efficiently bypass cisplatin and oxaliplatin adducts in vitro.	Oxaliplatin	134-145	DNA polymerase beta	Homo sapiens	22-30
12531010-1	2002	DNA polymerases beta (pol beta ) and eta (pol eta ) are the only two eukaryotic polymerases known to efficiently bypass cisplatin and oxaliplatin adducts in vitro.	Oxaliplatin	134-145	endothelin receptor type A	Homo sapiens	17-20
12531010-1	2002	DNA polymerases beta (pol beta ) and eta (pol eta ) are the only two eukaryotic polymerases known to efficiently bypass cisplatin and oxaliplatin adducts in vitro.	Oxaliplatin	134-145	endothelin receptor type A	Homo sapiens	27-30
12531010-3	2002	We have compared the types of frameshifts that occur during translesion synthesis past cisplatin and oxaliplatin adducts in vitro by pol beta and pol eta on a template containing multiple runs of nucleotides flanking a single platinum-GG adduct.	Oxaliplatin	101-112	DNA polymerase beta	Homo sapiens	133-141
12531010-3	2002	We have compared the types of frameshifts that occur during translesion synthesis past cisplatin and oxaliplatin adducts in vitro by pol beta and pol eta on a template containing multiple runs of nucleotides flanking a single platinum-GG adduct.	Oxaliplatin	101-112	endothelin receptor type A	Homo sapiens	138-141
12531010-6	2002	For pol eta, all of the bypass products for both cisplatin and oxaliplatin adducts contained -1 frameshifts in the upstream TTT sequence and most of the products of replication on oxaliplatin-damaged templates had multiple replication errors, both frameshifts and misinsertions.	Oxaliplatin	63-74	endothelin receptor type A	Homo sapiens	8-11
12531010-6	2002	For pol eta, all of the bypass products for both cisplatin and oxaliplatin adducts contained -1 frameshifts in the upstream TTT sequence and most of the products of replication on oxaliplatin-damaged templates had multiple replication errors, both frameshifts and misinsertions.	Oxaliplatin	180-191	endothelin receptor type A	Homo sapiens	8-11
12391279-10	2002	CTR1-deficient cells also demonstrated impaired accumulation of the DDP analogs carboplatin, oxaliplatin, and ZD0473 [cis-amminedichloro(2-methylpyridine) platinum (II)].	Oxaliplatin	93-104	high-affinity Cu transporter CTR1	Saccharomyces cerevisiae S288C	0-4
12434296-5	2002	We report that lack of the Pms2 gene is associated with an increased sensitivity, ranging from 2-6-fold, to some types of anticancer agents including the topoisomerase II poisons doxorubicin, etoposide and mitoxantrone, the platinum compounds cisplatin and oxaliplatin, the taxanes docetaxel and paclitaxel, and the antimetabolite gemcitabine.	Oxaliplatin	257-268	PMS1 homolog 2, mismatch repair system component	Homo sapiens	27-31
12372606-2	2002	We found that the resistant phenotype was associated with resistance to oxaliplatin-induced apoptosis as demonstrated by FACS analysis and by Western blotting of caspase 3 activation.	Oxaliplatin	72-83	caspase 3	Homo sapiens	162-171
26680890-1	2002	PURPOSE: Oxaliplatin (LOHP), 5-FU, and paclitaxel (PTX) are considered highly active against advanced gastric carcinomas, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, ZD1839 is considered as a good candidate for the treatment of gastric cancers when given alone or in combination with cytotoxic agents.	Oxaliplatin	22-26	epidermal growth factor receptor	Homo sapiens	130-162
12499281-5	2002	Carboplatin and oxaliplatin treatment led also to stabilization of p53, whereas none of the platinums changed p73 levels.	Oxaliplatin	16-27	tumor protein p53	Homo sapiens	67-70
12499281-8	2002	Clonogenic survival was enhanced by expressing a dominant negative p53 or ectopic HPV16 E6 in SiHa and HeLa cells treated with IR, carboplatin, or oxaliplatin or with a combination of IR + carboplatin or oxaliplatin.	Oxaliplatin	147-158	tumor protein p53	Homo sapiens	67-70
12553056-0	2002	Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat.	Oxaliplatin	53-64	nerve growth factor	Rattus norvegicus	12-31
12553056-8	2002	CONCLUSION: This specific association between neurological impairment and NGF modulation indicates that NGF impairment has a role in the neurotoxicity of oxaliplatin.	Oxaliplatin	154-165	nerve growth factor	Rattus norvegicus	74-77
12553056-8	2002	CONCLUSION: This specific association between neurological impairment and NGF modulation indicates that NGF impairment has a role in the neurotoxicity of oxaliplatin.	Oxaliplatin	154-165	nerve growth factor	Rattus norvegicus	104-107
12441268-9	2002	However, in an A2780 subline where loss of hMLH1 and a p53phe172 mutation occurred, 5-fold resistance to cisplatin was observed, but only 1.7-fold resistance to oxaliplatin and no resistance to AMD0473 were observed.	Oxaliplatin	161-172	mutL homolog 1	Homo sapiens	43-48
12072547-13	2002	CONCLUSIONS: The GSTP1 Ile(105)Val polymorphism is associated in a dose-dependent fashion with increased survival of patients with advanced colorectal cancer receiving 5-FU/oxaliplatin chemotherapy.	Oxaliplatin	173-184	glutathione S-transferase pi 1	Homo sapiens	17-22
12008204-7	2002	L-OHP and Dex both induced poly adenosine diphosphate (ADP)-ribose polymerase (PARP) cleavage and this induction was enhanced by the combined treatment.	Oxaliplatin	0-5	poly(ADP-ribose) polymerase 1	Homo sapiens	79-83
12008204-8	2002	L-OHP-induced apoptosis correlated with caspase-3 cleavage, but this correlation could not be demonstrated in Dex-treated cells.	Oxaliplatin	0-5	caspase 3	Homo sapiens	40-49
11919232-11	2002	On the basis of our toxicity experience, we recommend use of capecitabine in combination with oxaliplatin 130 mg/m(2) at an initial dose of 1,250 mg/m(2) bid in nonpretreated patients and at a dose of 1,000 mg/m(2) bid in pretreated patients.	Oxaliplatin	94-105	BH3 interacting domain death agonist	Homo sapiens	154-157
11953866-6	2002	Oxaliplatin was able to reduce thymidylate synthase activity with a marked impact 28 h after the beginning of cell exposure to the drug.	Oxaliplatin	0-11	thymidylate synthetase	Homo sapiens	31-51
12144121-9	2002	DISCUSSION: Our results clearly show that that idiosyncratic reaction observed in colorectal cancer patients after oxaliplatin infusion may be due to a massive release of cytokines such as TNF-alpha and IL-6.	Oxaliplatin	115-126	tumor necrosis factor	Homo sapiens	189-198
12144121-9	2002	DISCUSSION: Our results clearly show that that idiosyncratic reaction observed in colorectal cancer patients after oxaliplatin infusion may be due to a massive release of cytokines such as TNF-alpha and IL-6.	Oxaliplatin	115-126	interleukin 6	Homo sapiens	203-207
11600727-9	2001	The variant homozygotes at exon 7 of the CYP1A1 gene had significantly higher urinary 1-OHP concentrations than other CYP1A1 genotypes among the exposed workers (p=0.03).	Oxaliplatin	86-91	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	41-47
11859435-10	2002	Variation in exon 3 of mEH (His113) was related to a significantly (P=0.01) higher 1-OHP concentration in exposed workers (sampling II).	Oxaliplatin	83-88	epoxide hydrolase 1, microsomal	Mus musculus	23-26
11731512-0	2001	ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.	Oxaliplatin	113-124	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
11731512-0	2001	ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.	Oxaliplatin	113-124	thymidylate synthetase	Homo sapiens	10-30
11731512-10	2001	CONCLUSION: These data suggest that intratumoral ERCC1 mRNA and TS mRNA expression levels are independent predictive markers of survival for 5-FU and oxaliplatin combination chemotherapy in 5-FU-resistant metastatic colorectal cancer.	Oxaliplatin	150-161	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	49-54
11958906-9	2002	In X-ray (10 and 20 Gy) and 1-OHP (6 and 10 mg/kg) combined treatment, the TGDs increased only with X-ray dose.	Oxaliplatin	28-33	TDP-glucose 4,6-dehydratase	Mus musculus	75-79
11824623-0	2002	Application of capillary electrophoresis-mass spectrometry for the investigation of the binding behavior of oxaliplatin to 5"-GMP in the presence of the sulfur-containing amino acid L-methionine.	Oxaliplatin	108-119	5'-nucleotidase, cytosolic II	Homo sapiens	126-129
11824623-1	2002	Capillary electrophoresis-electrospray ionization-mass spectrometry (CE-ESI-MS) has been used for investigating the influence of the sulfur containing amino acid L-methionine (L-Met) on the binding behavior of oxaliplatin (trans-R,R-diaminocyclohexane-(oxalato)platinum(II)) to 5"-GMP.	Oxaliplatin	210-221	5'-nucleotidase, cytosolic II	Homo sapiens	281-284
11824623-2	2002	L-Methionine competes with 5"-GMP for the platinum binding site and forms as well as 5"-GMP adducts with oxaliplatin.	Oxaliplatin	105-116	5'-nucleotidase, cytosolic II	Homo sapiens	88-91
11824623-4	2002	Furthermore, we could now bring forward proofs, that the coordination of 5"-GMP with oxaliplatin is inhibited by L-methionine and could show, that the 5"-GMP ligands of the [Pt(DACH) (5"-GMP)2]2- complex can be replaced slowly by L-methionine whereas methionine can not be replaced by GMP.	Oxaliplatin	85-96	5'-nucleotidase, cytosolic II	Homo sapiens	76-79
11824623-4	2002	Furthermore, we could now bring forward proofs, that the coordination of 5"-GMP with oxaliplatin is inhibited by L-methionine and could show, that the 5"-GMP ligands of the [Pt(DACH) (5"-GMP)2]2- complex can be replaced slowly by L-methionine whereas methionine can not be replaced by GMP.	Oxaliplatin	85-96	5'-nucleotidase, cytosolic II	Homo sapiens	154-157
11824623-4	2002	Furthermore, we could now bring forward proofs, that the coordination of 5"-GMP with oxaliplatin is inhibited by L-methionine and could show, that the 5"-GMP ligands of the [Pt(DACH) (5"-GMP)2]2- complex can be replaced slowly by L-methionine whereas methionine can not be replaced by GMP.	Oxaliplatin	85-96	5'-nucleotidase, cytosolic II	Homo sapiens	154-157
11824623-4	2002	Furthermore, we could now bring forward proofs, that the coordination of 5"-GMP with oxaliplatin is inhibited by L-methionine and could show, that the 5"-GMP ligands of the [Pt(DACH) (5"-GMP)2]2- complex can be replaced slowly by L-methionine whereas methionine can not be replaced by GMP.	Oxaliplatin	85-96	5'-nucleotidase, cytosolic II	Homo sapiens	154-157
11705873-9	2001	Moreover, CPT-11, cisplatin, oxaliplatin, and Taxol remain highly cytotoxic in cells that overexpress TS.	Oxaliplatin	29-40	thymidylate synthetase	Homo sapiens	102-104
11600727-10	2001	There was less association between the concentrations of 1-OHP and the GSTM1, GSTP1, or GSTT1 polymorphism.	Oxaliplatin	57-62	glutathione S-transferase mu 1	Homo sapiens	71-76
11600727-10	2001	There was less association between the concentrations of 1-OHP and the GSTM1, GSTP1, or GSTT1 polymorphism.	Oxaliplatin	57-62	glutathione S-transferase pi 1	Homo sapiens	78-83
11600727-10	2001	There was less association between the concentrations of 1-OHP and the GSTM1, GSTP1, or GSTT1 polymorphism.	Oxaliplatin	57-62	glutathione S-transferase theta 1	Homo sapiens	88-93
11712813-8	2001	The data suggest that the polymorphism in exon 10 of the XRCC1 gene may be associated with resistance to oxaliplatin/5-FU chemotherapy in advanced colorectal cancer.	Oxaliplatin	105-116	X-ray repair cross complementing 1	Homo sapiens	57-62
11593056-8	2001	Pretreatment of these cells with oxaliplatin abolished the increase in PARP cleavage induced by irinotecan (29%).	Oxaliplatin	33-44	poly(ADP-ribose) polymerase 1	Homo sapiens	71-75
11583787-0	2001	Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5"-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry.	Oxaliplatin	38-49	5'-nucleotidase, cytosolic II	Homo sapiens	81-84
11323399-8	2001	Urinary 1-OHP and 2-naphthol concentrations were higher in coke oven workers with the c1/c2 or c2/c2 genotype of CYP2E1 than in those with the c1/c1 genotype.	Oxaliplatin	8-13	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	86-91
11323399-8	2001	Urinary 1-OHP and 2-naphthol concentrations were higher in coke oven workers with the c1/c2 or c2/c2 genotype of CYP2E1 than in those with the c1/c1 genotype.	Oxaliplatin	8-13	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	113-119
11323399-10	2001	In multiple regression analysis CYP2E1 was a significant factor determining urinary 1-OHP concentrations in coke oven workers.	Oxaliplatin	84-89	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	32-38
10753202-9	2000	In the control group as well as in the occupationally exposed group, the highest 1-OHP levels were observed in individuals carrying the CYP1A1 Ile/Val genotype who were also of the GSTM1 null genotype.	Oxaliplatin	81-86	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	136-142
11167991-7	2001	In additional experiments with chemotherapeutic drugs commonly used for the treatment of colorectal cancer, we found that 5-fluorouracil, mitomycin-C and oxaliplatin up-regulated EpCAM and LewisY antigen expression.	Oxaliplatin	154-165	epithelial cell adhesion molecule	Homo sapiens	179-184
11142694-4	2000	Oxaliplatin was found to be active against C32 and G361 cell lines with IC50 values of 49.48 and 9.07 microM (1 h exposure), 9.47 and 1.30 microM (4 h exposure), and 0.98 and 0.14 microM (24 h exposure), respectively.	Oxaliplatin	0-11	chemokine like factor	Homo sapiens	43-46
10777605-0	2000	The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta.	Oxaliplatin	72-83	DNA polymerase beta	Homo sapiens	105-124
10777605-3	2000	The data presented in this paper provide an analysis of translesion synthesis past cisplatin- and oxaliplatin-DNA adducts by pol beta functioning in both distributive and processive modes using primer extension and steady-state kinetic experiments.	Oxaliplatin	98-109	DNA polymerase beta	Homo sapiens	125-133
10777605-5	2000	In the processive mode pol beta did not discriminate between cisplatin and oxaliplatin adducts, while in the distributive mode it displayed about 2-fold increased ability for translesion synthesis past oxaliplatin compared with cisplatin adducts.	Oxaliplatin	202-213	DNA polymerase beta	Homo sapiens	23-31
11053984-0	2000	Oxaliplatin-induced fever and release of IL-6.	Oxaliplatin	0-11	interleukin 6	Homo sapiens	41-45
11053984-10	2000	CONCLUSION: Our data suggest a clear- cut correlation between fever, the release of IL-6 and oxaliplatin administration.	Oxaliplatin	93-104	interleukin 6	Homo sapiens	84-88
11053984-11	2000	Whether IL-6 release is directly triggered by the application of oxaliplatin or is a bystander phenomenon, however, remains unclear at the moment.	Oxaliplatin	65-76	interleukin 6	Homo sapiens	8-12
10769112-0	2000	Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.	Oxaliplatin	39-50	DNA polymerase eta	Homo sapiens	86-104
10769112-4	2000	We have shown that the eukaryotic DNA polymerases yeast pol zeta, human pol beta, and human pol gamma bypass oxaliplatin-GG adducts more efficiently than cisplatin-GG adducts.	Oxaliplatin	109-120	DNA polymerase beta	Homo sapiens	72-80
10753202-9	2000	In the control group as well as in the occupationally exposed group, the highest 1-OHP levels were observed in individuals carrying the CYP1A1 Ile/Val genotype who were also of the GSTM1 null genotype.	Oxaliplatin	81-86	glutathione S-transferase mu 1	Homo sapiens	181-186
10650914-4	1999	Statistically significant (P = 0.03 and P = 0.01) higher percentages of the more susceptible GSTM1- subjects compared to the GSTM1+ subjects and of the more susceptible CYP1A1 Ile/Val individuals compared to the CYP1A1 Ile/Ile individuals were detected for high levels of PAH-DNA adducts in the high exposure group (namely high levels of 1-OHP).	Oxaliplatin	338-343	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	169-175
10606258-4	1999	Due to its excellent safety profile, unique mechanism of action, and lack of cross-resistance with other CRC chemotherapeutic agents, oxaliplatin can be combined with 5-FU, irinotecan (CPT-II), raltitrexed, or other agents.	Oxaliplatin	134-145	carnitine palmitoyltransferase 2	Homo sapiens	185-191
10626357-6	1999	In addition, defects in the mismatch-repair proteins hMSH6 and hMLH1 led to increased replicative bypass of cisplatin adducts, but not of oxaliplatin adducts.	Oxaliplatin	138-149	mutL homolog 1	Homo sapiens	63-68
10626357-7	1999	Finally, primer extension assays performed in the presence of HMG1, which is known to recognize cisplatin-damaged DNA, revealed that inhibition of translesion synthesis by HMG1 also depended on the carrier ligand of the Pt-DNA adduct (cisplatin &gt; oxaliplatin = JM216).	Oxaliplatin	250-261	high mobility group box 1 pseudogene 5	Homo sapiens	172-176
10460158-5	1999	Primer extension assays performed in the presence of high mobility group protein 1 (HMG1), which is known to recognize cisplatin-damaged DNA, revealed that inhibition of translesion synthesis by HMG1 also depended on the carrier ligand of the Pt-DNA adduct (cisplatin &gt; oxaliplatin = JM216 &gt;&gt; dien).	Oxaliplatin	273-284	high mobility group box 1 pseudogene 5	Homo sapiens	53-82
10511262-3	1999	The most widely used urinary PAH metabolites are 1-hydroxypyrene (1-OHP) or 1-hydroxypyrene-O-glucuronide (1-OHP-gluc), the major form of 1-OHP in human urine, because of their relatively high concentration and prevalence in urine and their relative ease of measurement.	Oxaliplatin	66-71	phenylalanine hydroxylase	Homo sapiens	29-32
10511262-3	1999	The most widely used urinary PAH metabolites are 1-hydroxypyrene (1-OHP) or 1-hydroxypyrene-O-glucuronide (1-OHP-gluc), the major form of 1-OHP in human urine, because of their relatively high concentration and prevalence in urine and their relative ease of measurement.	Oxaliplatin	107-112	phenylalanine hydroxylase	Homo sapiens	29-32
10511262-3	1999	The most widely used urinary PAH metabolites are 1-hydroxypyrene (1-OHP) or 1-hydroxypyrene-O-glucuronide (1-OHP-gluc), the major form of 1-OHP in human urine, because of their relatively high concentration and prevalence in urine and their relative ease of measurement.	Oxaliplatin	107-112	phenylalanine hydroxylase	Homo sapiens	29-32
10460158-5	1999	Primer extension assays performed in the presence of high mobility group protein 1 (HMG1), which is known to recognize cisplatin-damaged DNA, revealed that inhibition of translesion synthesis by HMG1 also depended on the carrier ligand of the Pt-DNA adduct (cisplatin &gt; oxaliplatin = JM216 &gt;&gt; dien).	Oxaliplatin	273-284	high mobility group box 1 pseudogene 5	Homo sapiens	195-199
10367745-23	1999	Both oxaliplatin and ormaplatin produced the same types of major plasma biotransformation products including Pt(dach)Cl2, Pt(dach)(Cys)2, Pt(dach)(GSH)2, Pt(dach)(GSH), Pt(dach)(Met), and free dach.	Oxaliplatin	5-16	GS homeobox 2	Rattus norvegicus	147-152
10098743-0	1999	Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.	Oxaliplatin	55-66	mitogen-activated protein kinase 8	Homo sapiens	13-16
10098743-0	1999	Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.	Oxaliplatin	55-66	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	21-26
9804612-7	1998	Oxaliplatin at 200 microM induced approximately 1300, approximately 1500, approximately 800, and approximately 300 lesions/10(6) bp in the human beta-globin, c-myc, and HPRT genes and in mitochondrial DNA, respectively.	Oxaliplatin	0-11	hemoglobin subunit beta	Homo sapiens	145-156
10098901-19	1999	Finally, the biotransformation products of oxaliplatin in the plasma were identified as Pt(dach)Cl2, Pt(dach)(Cys)2, Pt(dach)(GSH), Pt(dach)(Met), Pt(dach)(GSH)2, and free dach.	Oxaliplatin	43-54	GS homeobox 2	Rattus norvegicus	156-161
9804920-5	1998	Urinary 1-hydroxypyrene (1-OHP) excretion was used as a biomarker of occupational exposure to PAH.	Oxaliplatin	25-30	phenylalanine hydroxylase	Homo sapiens	94-97
9804612-7	1998	Oxaliplatin at 200 microM induced approximately 1300, approximately 1500, approximately 800, and approximately 300 lesions/10(6) bp in the human beta-globin, c-myc, and HPRT genes and in mitochondrial DNA, respectively.	Oxaliplatin	0-11	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	158-163
9804612-7	1998	Oxaliplatin at 200 microM induced approximately 1300, approximately 1500, approximately 800, and approximately 300 lesions/10(6) bp in the human beta-globin, c-myc, and HPRT genes and in mitochondrial DNA, respectively.	Oxaliplatin	0-11	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	169-173
9488590-4	1998	The urinary concentration of 1-OH-P was clearly associated with cigarette smoking and, to a lesser extent, with exposure to ETS and particulate PAH pollution.	Oxaliplatin	29-35	phenylalanine hydroxylase	Homo sapiens	144-147
9752993-4	1998	The purpose of this study was to investigate whether CYP1A1 MspI genotypes modulate the relationship of individual occupational exposure to air BSF to urinary 1-OHP concentrations among coke-oven workers.	Oxaliplatin	159-164	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	53-59
9721864-0	1998	The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.	Oxaliplatin	61-72	mutL homolog 1	Homo sapiens	12-17
9721864-0	1998	The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.	Oxaliplatin	61-72	mutS homolog 6	Homo sapiens	30-35
9488590-11	1998	These findings are suggestive of a gene-environment interaction, in which subjects with the CYP1A1 polymorphism, relative to subjects without it, have higher levels of 1-OH-P in their urine at low doses of exposure to PAHs.	Oxaliplatin	168-174	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	92-98
8895738-6	1996	The formation of protein-DNA complexes that contained hMSH2 and hMLH1 was documented by mobility shift assay when nuclear extracts were incubated with DNA platinated with cisplatin but not with oxaliplatin.	Oxaliplatin	194-205	mutS homolog 2	Homo sapiens	54-59
18372523-3	1997	HSP60 mRNA expression was quantitated in three independent model systems by reverse-transcription PCR (A2780 human ovarian carcinoma cell line and sublines selected for cisplatin or oxaliplatin resistance in vitro and also in the UCRU-BL13 human bladder carcinoma cell line and a cisplatin-resistant subline).	Oxaliplatin	182-193	heat shock protein family D (Hsp60) member 1	Homo sapiens	0-5
18372523-4	1997	Increased HSP60 mRNA expression was observed in all resistant sublines (range 2.5-15 fold), correlated with relative resistance to cisplatin and oxaliplatin.	Oxaliplatin	145-156	heat shock protein family D (Hsp60) member 1	Homo sapiens	10-15
9220289-7	1997	Following 24 h or 96 h drug exposure the fold resistance in H12DDP and 1777NRp Cl-A was 1.7-2.2 with oxaliplatin compared to 3.9-6.1 with cisplatin.	Oxaliplatin	101-112	neuropilin 1	Homo sapiens	75-78
8689632-3	1996	We have isolated sublines of the A2780 ovarian carcinoma cell line (C10 and C25) that are 8- and 12-fold resistant to oxaliplatin by repeatedly exposing the cells to increasing concentrations of the platinum agent.	Oxaliplatin	118-129	homeobox C10	Homo sapiens	68-71
33822325-3	2021	In vitro experiments indicated that, the overexpression of LINC00200 facilitated the proliferation of GC cells, constrained their apoptosis, and increased the IC50 of oxaliplatin (Oxa), whereas knockdown of LINC00200 exhibited the opposite effects.	Oxaliplatin	167-178	long intergenic non-protein coding RNA 200	Homo sapiens	59-68
9114434-2	1996	Our previous studies have shown that sublines of human ovarian carcinoma cell line A2780, which exhibited low levels of resistance to oxaliplatin, showed elevated steady state levels of mRNA and activity of gamma-glutamyl transpeptidase (gamma-GT, EC 2.3.2.2), but not of gamma-glutamylcysteine synthetase (gamma-GCS, EC 6.3.2.2) [El-akawi et al., Cancer Lett.	Oxaliplatin	134-145	inactive glutathione hydrolase 2	Homo sapiens	207-236
9114434-2	1996	Our previous studies have shown that sublines of human ovarian carcinoma cell line A2780, which exhibited low levels of resistance to oxaliplatin, showed elevated steady state levels of mRNA and activity of gamma-glutamyl transpeptidase (gamma-GT, EC 2.3.2.2), but not of gamma-glutamylcysteine synthetase (gamma-GCS, EC 6.3.2.2) [El-akawi et al., Cancer Lett.	Oxaliplatin	134-145	inactive glutathione hydrolase 2	Homo sapiens	238-246
9114434-4	1996	To understand this phenomenon better, we have studied the effect of single exposures of oxaliplatin or cisplatin on the mRNA expression of gamma-GT and gamma-GCS in A2780 cells.	Oxaliplatin	88-99	inactive glutathione hydrolase 2	Homo sapiens	139-147
9114434-4	1996	To understand this phenomenon better, we have studied the effect of single exposures of oxaliplatin or cisplatin on the mRNA expression of gamma-GT and gamma-GCS in A2780 cells.	Oxaliplatin	88-99	glutamate-cysteine ligase catalytic subunit	Homo sapiens	152-161
9114434-8	1996	Single exposures of cells to oxaliplatin induced a time- and concentration-dependent increase in the mRNA of gamma-GT, but not of gamma-GCS.	Oxaliplatin	29-40	inactive glutathione hydrolase 2	Homo sapiens	109-117
9114434-8	1996	Single exposures of cells to oxaliplatin induced a time- and concentration-dependent increase in the mRNA of gamma-GT, but not of gamma-GCS.	Oxaliplatin	29-40	glutamate-cysteine ligase catalytic subunit	Homo sapiens	130-139
33761313-3	2021	Here, we found that gut microbial metabolites, especially butyrate, could promote the efficacy of oxaliplatin by modulating CD8+ T cell function in the tumor microenvironment.	Oxaliplatin	98-109	CD8a molecule	Homo sapiens	124-127
33761313-5	2021	In humans, the oxaliplatin responder cancer patients exhibited a higher amount of serum butyrate than did non-responders, which could also increase ID2 expression and function of human CD8+ T cells.	Oxaliplatin	15-26	inhibitor of DNA binding 2	Homo sapiens	148-151
33761313-5	2021	In humans, the oxaliplatin responder cancer patients exhibited a higher amount of serum butyrate than did non-responders, which could also increase ID2 expression and function of human CD8+ T cells.	Oxaliplatin	15-26	CD8a molecule	Homo sapiens	185-188
33772548-0	2021	PBK/TOPK promotes chemoresistance to oxaliplatin in hepatocellular carcinoma cells by regulating PTEN.	Oxaliplatin	37-48	PDZ binding kinase	Homo sapiens	0-3
33772548-0	2021	PBK/TOPK promotes chemoresistance to oxaliplatin in hepatocellular carcinoma cells by regulating PTEN.	Oxaliplatin	37-48	PDZ binding kinase	Homo sapiens	4-8
33772548-0	2021	PBK/TOPK promotes chemoresistance to oxaliplatin in hepatocellular carcinoma cells by regulating PTEN.	Oxaliplatin	37-48	phosphatase and tensin homolog	Homo sapiens	97-101
33772548-4	2021	In this study, we explored whether PBK is involved in the chemoresistance to OXA in HCC.	Oxaliplatin	77-80	PDZ binding kinase	Homo sapiens	35-38
33772548-7	2021	PBK was silenced or overexpressed in OXA-resistant and sensitive cell lines.	Oxaliplatin	37-40	PDZ binding kinase	Homo sapiens	0-3
33772548-10	2021	Results showed that expression of PBK in HCC cells was significantly higher than that in THLE2 cells, and it was further increased in OXA-resistant HCC cells.	Oxaliplatin	134-137	PDZ binding kinase	Homo sapiens	34-37
33772548-11	2021	Silencing of PBK promoted the sensitivity of drug-resistant HCC cells to OXA.	Oxaliplatin	73-76	PDZ binding kinase	Homo sapiens	13-16
33772548-12	2021	Overexpression of PBK relieved the apoptosis induced by OXA and promoted the migration and invasion of OXA-sensitive HCC cells.	Oxaliplatin	56-59	PDZ binding kinase	Homo sapiens	18-21
33772548-12	2021	Overexpression of PBK relieved the apoptosis induced by OXA and promoted the migration and invasion of OXA-sensitive HCC cells.	Oxaliplatin	103-106	PDZ binding kinase	Homo sapiens	18-21
7763011-6	1995	The CDDP analogues were all cross-resistant to CDDP and the order of relative resistance values was CBDCA &gt; 254-S &gt; 1-OHP &gt; OP for PC9/CDDP and 254-S &gt; CBDCA &gt; 1-OHP &gt; OP for PC-14/CDDP.	Oxaliplatin	122-127	proprotein convertase subtilisin/kexin type 9	Homo sapiens	140-143
1316878-7	1992	Formation of NADP+ was 20.3 +/- 1.8 nmol min-1 for pyocyanin (10 microM) at pH 5.5, compared with 0.6 +/- 0.2 nmol min-1 for 1-OHP (10 microM), while at pH 7.5 a value of 2.2 +/- 1.3 nmol min-1 was obtained for pyocyanin, with no detectable activity for 1-OHP.	Oxaliplatin	125-130	CD59 molecule (CD59 blood group)	Homo sapiens	115-120
1316878-7	1992	Formation of NADP+ was 20.3 +/- 1.8 nmol min-1 for pyocyanin (10 microM) at pH 5.5, compared with 0.6 +/- 0.2 nmol min-1 for 1-OHP (10 microM), while at pH 7.5 a value of 2.2 +/- 1.3 nmol min-1 was obtained for pyocyanin, with no detectable activity for 1-OHP.	Oxaliplatin	125-130	CD59 molecule (CD59 blood group)	Homo sapiens	115-120
33772548-13	2021	Thus, this study revealed that high PBK expression is correlated with OXA resistance in HCC cells, which may provide a promising therapeutic target for treating HCC.	Oxaliplatin	70-73	PDZ binding kinase	Homo sapiens	36-39
33822325-3	2021	In vitro experiments indicated that, the overexpression of LINC00200 facilitated the proliferation of GC cells, constrained their apoptosis, and increased the IC50 of oxaliplatin (Oxa), whereas knockdown of LINC00200 exhibited the opposite effects.	Oxaliplatin	180-183	long intergenic non-protein coding RNA 200	Homo sapiens	59-68
33819479-9	2021	Taken together, our results demonstrate that oxaliplatin causes early nucleolar disruption via inhibition of rRNA synthesis accompanied by NPM1 relocalization, and subsequently causes extensive nucleolar reorganization, while cisplatin causes early DNA damage without significant nucleolar disruption.	Oxaliplatin	45-56	nucleophosmin 1	Homo sapiens	139-143
33819186-0	2021	Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin.	Oxaliplatin	130-141	kinesin family member 20A	Homo sapiens	16-22
33819186-0	2021	Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin.	Oxaliplatin	130-141	NUAK family kinase 1	Homo sapiens	23-28
33819186-0	2021	Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin.	Oxaliplatin	130-141	NFE2 like bZIP transcription factor 2	Homo sapiens	29-33
33819186-0	2021	Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin.	Oxaliplatin	130-141	glutathione peroxidase 4	Homo sapiens	34-38
33819186-4	2021	Bioinformatic and cytobiological searches also revealed that KIF20A was highly expressed in the oxaliplatin-resistant cell lines and was strongly correlated with survival among CRC patients.	Oxaliplatin	96-107	kinesin family member 20A	Homo sapiens	61-67
33819186-5	2021	Silencing KIF20A enhanced cellular sensitivity to oxaliplatin both in vivo and in vitro, and silencing KIF20A also suppressed NUAK1 activation, while a NUAK1 agonist (ETC-1002) could reverse the oxaliplatin sensitivity of KIF20A-silenced cells.	Oxaliplatin	50-61	kinesin family member 20A	Homo sapiens	10-16
33819186-7	2021	Applying a Nrf2 agonist (oltipraz) also reversed the oxaliplatin sensitivity of NUAK1-silenced cells.	Oxaliplatin	53-64	NFE2 like bZIP transcription factor 2	Homo sapiens	11-15
33772465-7	2021	We found that oxaliplatin-mediated TREK-TRAAK downregulation, as well as downregulation of other K+ channels of the K2P and Kv families, involves a transcription factor known as the neuron-restrictive silencer factor (NRSF) and its epigenetic co-repressors histone deacetylases (HDACs).	Oxaliplatin	14-25	potassium channel, subfamily K, member 4	Mus musculus	40-45
33819186-7	2021	Applying a Nrf2 agonist (oltipraz) also reversed the oxaliplatin sensitivity of NUAK1-silenced cells.	Oxaliplatin	53-64	NUAK family kinase 1	Homo sapiens	80-85
33819186-8	2021	Therefore, cellular ferroptosis may be inhibited via the KIF20A/NUAK1/PP1beta/GPX4 pathway in CRC cells, which may underly the resistance of CRC to oxaliplatin.	Oxaliplatin	148-159	kinesin family member 20A	Homo sapiens	57-63
33772465-7	2021	We found that oxaliplatin-mediated TREK-TRAAK downregulation, as well as downregulation of other K+ channels of the K2P and Kv families, involves a transcription factor known as the neuron-restrictive silencer factor (NRSF) and its epigenetic co-repressors histone deacetylases (HDACs).	Oxaliplatin	14-25	RE1-silencing transcription factor	Mus musculus	182-216
33819186-8	2021	Therefore, cellular ferroptosis may be inhibited via the KIF20A/NUAK1/PP1beta/GPX4 pathway in CRC cells, which may underly the resistance of CRC to oxaliplatin.	Oxaliplatin	148-159	NUAK family kinase 1	Homo sapiens	64-69
33772465-7	2021	We found that oxaliplatin-mediated TREK-TRAAK downregulation, as well as downregulation of other K+ channels of the K2P and Kv families, involves a transcription factor known as the neuron-restrictive silencer factor (NRSF) and its epigenetic co-repressors histone deacetylases (HDACs).	Oxaliplatin	14-25	RE1-silencing transcription factor	Mus musculus	218-222
33772465-8	2021	NRSF knockdown was able to prevent most of these K+ channel mRNA downregulation in mice dorsal root ganglion neurons as well as oxaliplatin-induced acute cold and mechanical hypersensitivity.	Oxaliplatin	128-139	RE1-silencing transcription factor	Mus musculus	0-4
33819186-8	2021	Therefore, cellular ferroptosis may be inhibited via the KIF20A/NUAK1/PP1beta/GPX4 pathway in CRC cells, which may underly the resistance of CRC to oxaliplatin.	Oxaliplatin	148-159	protein phosphatase 1 catalytic subunit alpha	Homo sapiens	70-77
33765714-0	2021	[The influence of XRCC1 gene polymorphism on the prognosis and safety of stage III patients with colorectal cancer who received oxaliplatin based adjuvant chemotherapy].	Oxaliplatin	128-139	X-ray repair cross complementing 1	Homo sapiens	18-23
33774154-4	2021	OXA increased Reactive Oxygen Species (ROS) production and lipoperoxidation, and augmented the content of pro-inflammatory cytokines (IL-1beta and TNF-alpha) and expression of the astrocytic marker Gfap mRNA in the spinal cord.	Oxaliplatin	0-3	interleukin 1 alpha	Mus musculus	134-142
33774154-4	2021	OXA increased Reactive Oxygen Species (ROS) production and lipoperoxidation, and augmented the content of pro-inflammatory cytokines (IL-1beta and TNF-alpha) and expression of the astrocytic marker Gfap mRNA in the spinal cord.	Oxaliplatin	0-3	tumor necrosis factor	Mus musculus	147-156
33774154-4	2021	OXA increased Reactive Oxygen Species (ROS) production and lipoperoxidation, and augmented the content of pro-inflammatory cytokines (IL-1beta and TNF-alpha) and expression of the astrocytic marker Gfap mRNA in the spinal cord.	Oxaliplatin	0-3	glial fibrillary acidic protein	Mus musculus	198-202
33774154-6	2021	Toll-like receptor 4 (Tlr4) and inflammasome enzyme caspase-1/11 knockout mice treated with OXA showed reduced levels of pro-inflammatory cytokines (but not oxidative stress) in the spinal cord, which were associated with resistance to OXA-induced mechanical allodynia.	Oxaliplatin	92-95	toll-like receptor 4	Mus musculus	0-20
33774154-6	2021	Toll-like receptor 4 (Tlr4) and inflammasome enzyme caspase-1/11 knockout mice treated with OXA showed reduced levels of pro-inflammatory cytokines (but not oxidative stress) in the spinal cord, which were associated with resistance to OXA-induced mechanical allodynia.	Oxaliplatin	92-95	toll-like receptor 4	Mus musculus	22-26
33774154-6	2021	Toll-like receptor 4 (Tlr4) and inflammasome enzyme caspase-1/11 knockout mice treated with OXA showed reduced levels of pro-inflammatory cytokines (but not oxidative stress) in the spinal cord, which were associated with resistance to OXA-induced mechanical allodynia.	Oxaliplatin	92-95	caspase 1	Mus musculus	52-64
33774154-6	2021	Toll-like receptor 4 (Tlr4) and inflammasome enzyme caspase-1/11 knockout mice treated with OXA showed reduced levels of pro-inflammatory cytokines (but not oxidative stress) in the spinal cord, which were associated with resistance to OXA-induced mechanical allodynia.	Oxaliplatin	236-239	caspase 1	Mus musculus	52-64
33765714-1	2021	Objective: To investigate the influence of X-ray repair cross complementing 1 (XRCC1) gene polymorphism on the prognosis and safety of stage III patients with colorectal cancer (CRC) who received oxaliplatin based adjuvant chemotherapy.	Oxaliplatin	196-207	X-ray repair cross complementing 1	Homo sapiens	79-84
33765714-15	2021	Conclusion: The prognosis of patients with CRC who received oxaliplatin based adjuvant chemotherapy may be influenced by XRCC1 rs1799782 through mediating the mRNA expression of XRCC1.	Oxaliplatin	60-71	X-ray repair cross complementing 1	Homo sapiens	121-126
33765714-15	2021	Conclusion: The prognosis of patients with CRC who received oxaliplatin based adjuvant chemotherapy may be influenced by XRCC1 rs1799782 through mediating the mRNA expression of XRCC1.	Oxaliplatin	60-71	X-ray repair cross complementing 1	Homo sapiens	178-183
23307041-10	2013	Moreover, the patients with high FAK only or combined with low JWA had significant benefit from adjuvant fluorouracil-leucovorin-oxaliplatin (FLO) therapy compared with those with surgery alone (P = 0.003); however, the cases with adjuvant fluorouracil-leucovorin-cisplatin (FLP) therapy did not show these effects.	Oxaliplatin	129-140	protein tyrosine kinase 2	Homo sapiens	33-36
32797385-12	2020	In the syngeneic tumor graft model, we found that combination therapy with oxaliplatin and anti-PD-1 antibodies could achieve better outcomes than monotherapy, as indicated by (i) inhibition of tumor growth and TGF-beta secretion and (ii) augmentation of inflammatory cytokine secretion.	Oxaliplatin	75-86	transforming growth factor alpha	Mus musculus	211-219
33235496-10	2020	Consistently, overexpression of GJA1 suppressed the invasive ability of CRC cells while enhancing the sensitivity of CRC cells to oxaliplatin-induced apoptosis.	Oxaliplatin	130-141	gap junction protein alpha 1	Homo sapiens	32-36
23307041-10	2013	Moreover, the patients with high FAK only or combined with low JWA had significant benefit from adjuvant fluorouracil-leucovorin-oxaliplatin (FLO) therapy compared with those with surgery alone (P = 0.003); however, the cases with adjuvant fluorouracil-leucovorin-cisplatin (FLP) therapy did not show these effects.	Oxaliplatin	129-140	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	63-66
34958891-5	2022	Moreover, DUBR facilitated the stemness and oxaliplatin resistance of HCC in vitro and in vivo.	Oxaliplatin	44-55	DPPA2 upstream binding RNA	Homo sapiens	10-14
34820015-6	2022	Inhibiting the tumor necrosis factor receptor-associated protein 1/phosphorylated-extracellular-regulated protein kinases1/2/cell division cycle 25 homolog C/cyclin-dependent kinase-1/cyclin B1 pathway was indispensable to the combined treatment with luteolin and oxaliplatin to induce G2/M cell cycle arrest.	Oxaliplatin	264-275	cyclin B1	Mus musculus	184-193
34463962-4	2022	PGM5-AS1 prevents proliferation, migration, and acquired oxaliplatin tolerance of colon cancer cells.	Oxaliplatin	57-68	phosphoglucomutase 5	Homo sapiens	0-4
34463962-4	2022	PGM5-AS1 prevents proliferation, migration, and acquired oxaliplatin tolerance of colon cancer cells.	Oxaliplatin	57-68	prostaglandin D2 receptor	Homo sapiens	5-8
34784565-0	2022	Oxaliplatin inhibits angiogenin proliferative and cell migration effects in prostate cancer cells.	Oxaliplatin	0-11	angiogenin	Homo sapiens	21-31
34784565-2	2022	Here, by means of an integrated multi-technique approach based on crystallographic, spectrometric and spectroscopic analyses, we demonstrate that the anti-cancer drug oxaliplatin efficiently binds angiogenin.	Oxaliplatin	167-178	angiogenin	Homo sapiens	197-207
34784565-3	2022	Microscopy cellular studies, carried out on the prostate cancer cell (PC-3) line , show that oxaliplatin inhibits the angiogenin prompting effect on cell proliferation and migration, which are typical features of angiogenesis process.	Oxaliplatin	93-104	angiogenin	Homo sapiens	118-128
34784565-4	2022	Overall, our findings point to angiogenin as a possible target of oxaliplatin, thus suggesting a potential novel mechanism for the antineoplastic activity of this platinum drug and opening the avenue to novel approaches in the combined anti-cancer anti-angiogenic therapy.	Oxaliplatin	66-77	angiogenin	Homo sapiens	31-41
34958891-0	2022	SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback.	Oxaliplatin	46-57	DPPA2 upstream binding RNA	Homo sapiens	19-23
34896366-0	2022	Target enzymes in oxaliplatin-induced peripheral neuropathy in Swiss mice: A new acetylcholinesterase inhibitor as therapeutic strategy.	Oxaliplatin	18-29	acetylcholinesterase	Mus musculus	81-101
34896366-1	2022	In the present study it was hypothesized that 5-((4-methoxyphenyl)thio)benzo(c)(1,2,5) thiodiazole (MTDZ), a new acetylcholinesterase inhibitor, exerts antinociceptive action and reduces the oxaliplatin (OXA)-induced peripheral neuropathy and its comorbidities (anxiety and cognitive deficits).	Oxaliplatin	191-202	acetylcholinesterase	Mus musculus	113-133
34896366-1	2022	In the present study it was hypothesized that 5-((4-methoxyphenyl)thio)benzo(c)(1,2,5) thiodiazole (MTDZ), a new acetylcholinesterase inhibitor, exerts antinociceptive action and reduces the oxaliplatin (OXA)-induced peripheral neuropathy and its comorbidities (anxiety and cognitive deficits).	Oxaliplatin	204-207	acetylcholinesterase	Mus musculus	113-133
34896366-7	2022	Here, the negative correlation between the paw withdrawal threshold caused by OXA and acetylcholinesterase (AChE) activity was demonstrated in the cortex, hippocampus, and spinal cord.	Oxaliplatin	78-81	acetylcholinesterase	Mus musculus	86-106
34896366-7	2022	Here, the negative correlation between the paw withdrawal threshold caused by OXA and acetylcholinesterase (AChE) activity was demonstrated in the cortex, hippocampus, and spinal cord.	Oxaliplatin	78-81	acetylcholinesterase	Mus musculus	108-112
34896366-8	2022	OXA inhibited the activity of total ATPase, Na+ K+ - ATPase, Ca2+ - ATPase and altered Mg2+ - ATPase in the cortex, hippocampus, and spinal cord.	Oxaliplatin	0-3	dynein, axonemal, heavy chain 8	Mus musculus	36-42
34779552-6	2022	The pep-AP/TALDO1 pathway attenuates the pentose phosphate pathway (PPP), reducing NADPH/NADP+ and glutathione (GSH) levels and causing ROS accumulation and apoptosis, which sensitizes CRC cells to L-OHP in vitro and in vivo.	Oxaliplatin	198-203	transaldolase 1	Homo sapiens	11-17
34689170-10	2022	CONCLUSIONS: TIMELESS rs2291739 might have different effects on therapeutic efficacy between oxaliplatin- and irinotecan-based chemotherapies.	Oxaliplatin	93-104	timeless circadian regulator	Homo sapiens	13-21
34785775-0	2022	Inhibition of cathepsin K sensitizes oxaliplatin-induced apoptotic cell death by Bax upregulation through OTUB1-mediated p53 stabilization in vitro and in vivo.	Oxaliplatin	37-48	cathepsin K	Homo sapiens	14-25
34785775-0	2022	Inhibition of cathepsin K sensitizes oxaliplatin-induced apoptotic cell death by Bax upregulation through OTUB1-mediated p53 stabilization in vitro and in vivo.	Oxaliplatin	37-48	BCL2 associated X, apoptosis regulator	Homo sapiens	81-84
34785775-0	2022	Inhibition of cathepsin K sensitizes oxaliplatin-induced apoptotic cell death by Bax upregulation through OTUB1-mediated p53 stabilization in vitro and in vivo.	Oxaliplatin	37-48	OTU deubiquitinase, ubiquitin aldehyde binding 1	Homo sapiens	106-111
34785775-0	2022	Inhibition of cathepsin K sensitizes oxaliplatin-induced apoptotic cell death by Bax upregulation through OTUB1-mediated p53 stabilization in vitro and in vivo.	Oxaliplatin	37-48	tumor protein p53	Homo sapiens	121-124
34785775-3	2022	Here, cathepsin K inhibitor (odanacatib; ODN) and knockdown of cathepsin K (siRNA) enhanced oxaliplatin-induced apoptosis in multiple cancer cells through Bax upregulation.	Oxaliplatin	92-103	cathepsin K	Homo sapiens	6-17
34785775-3	2022	Here, cathepsin K inhibitor (odanacatib; ODN) and knockdown of cathepsin K (siRNA) enhanced oxaliplatin-induced apoptosis in multiple cancer cells through Bax upregulation.	Oxaliplatin	92-103	cathepsin K	Homo sapiens	63-74
34785775-3	2022	Here, cathepsin K inhibitor (odanacatib; ODN) and knockdown of cathepsin K (siRNA) enhanced oxaliplatin-induced apoptosis in multiple cancer cells through Bax upregulation.	Oxaliplatin	92-103	BCL2 associated X, apoptosis regulator	Homo sapiens	155-158
34785775-4	2022	Bax knockdown significantly inhibited the combined ODN and oxaliplatin treatment-induced apoptotic cell death.	Oxaliplatin	59-70	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
34881574-4	2021	Accordingly, we develop a biohydrogel scaffold-enabled chemoimmunotherapeutic strategy by targeting myeloid cells with a phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitor (IPI549) to synergize with immunostimulatory chemotherapy (Oxaliplatin, OX) for post-ablative cancer therapy.	Oxaliplatin	234-245	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Mus musculus	121-152
34785775-9	2022	These in vitro results were confirmed by in mouse xenograft model, combined treatment with ODN and oxaliplatin significantly reduced tumor size and induced Bax upregulation.	Oxaliplatin	99-110	BCL2-associated X protein	Mus musculus	156-159
34785775-11	2022	Our results demonstrate that cathepsin K inhibition enhances oxaliplatin-induced apoptosis by increasing OTUB1 phosphorylation via CK2 activation, thereby promoting p53 stabilization, and hence upregulating Bax.	Oxaliplatin	61-72	cathepsin K	Homo sapiens	29-40
34785775-11	2022	Our results demonstrate that cathepsin K inhibition enhances oxaliplatin-induced apoptosis by increasing OTUB1 phosphorylation via CK2 activation, thereby promoting p53 stabilization, and hence upregulating Bax.	Oxaliplatin	61-72	OTU deubiquitinase, ubiquitin aldehyde binding 1	Homo sapiens	105-110
34785775-11	2022	Our results demonstrate that cathepsin K inhibition enhances oxaliplatin-induced apoptosis by increasing OTUB1 phosphorylation via CK2 activation, thereby promoting p53 stabilization, and hence upregulating Bax.	Oxaliplatin	61-72	tumor protein p53	Homo sapiens	165-168
34785775-11	2022	Our results demonstrate that cathepsin K inhibition enhances oxaliplatin-induced apoptosis by increasing OTUB1 phosphorylation via CK2 activation, thereby promoting p53 stabilization, and hence upregulating Bax.	Oxaliplatin	61-72	BCL2 associated X, apoptosis regulator	Homo sapiens	207-210
34881574-4	2021	Accordingly, we develop a biohydrogel scaffold-enabled chemoimmunotherapeutic strategy by targeting myeloid cells with a phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitor (IPI549) to synergize with immunostimulatory chemotherapy (Oxaliplatin, OX) for post-ablative cancer therapy.	Oxaliplatin	234-245	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Mus musculus	154-163
34957631-6	2022	Furthermore, ZNF852 deficiency increased oxaliplatin-induced MGC-803 cell death, implying the role of ZNF852 in drug sensitivity.	Oxaliplatin	41-52	zinc finger protein 852	Homo sapiens	13-19
34954996-3	2021	Cell counting kit (CCK-8) assay was used to detect the effect of USP22 on oxaliplatin resistance in colorectal cancer cells.	Oxaliplatin	74-85	ubiquitin specific peptidase 22	Homo sapiens	65-70
34954996-7	2021	Immunohistochemical methods were used to detect the expressions of USP22 and P-gp in the oxaliplatin chemotherapy-sensitive group and the drug-resistant group and to analyze the correlation between USP22 and MRP1, P-gp.	Oxaliplatin	89-100	ubiquitin specific peptidase 22	Homo sapiens	67-72
34954996-7	2021	Immunohistochemical methods were used to detect the expressions of USP22 and P-gp in the oxaliplatin chemotherapy-sensitive group and the drug-resistant group and to analyze the correlation between USP22 and MRP1, P-gp.	Oxaliplatin	89-100	phosphoglycolate phosphatase	Homo sapiens	77-81
34954996-7	2021	Immunohistochemical methods were used to detect the expressions of USP22 and P-gp in the oxaliplatin chemotherapy-sensitive group and the drug-resistant group and to analyze the correlation between USP22 and MRP1, P-gp.	Oxaliplatin	89-100	ubiquitin specific peptidase 22	Homo sapiens	198-203
34954996-7	2021	Immunohistochemical methods were used to detect the expressions of USP22 and P-gp in the oxaliplatin chemotherapy-sensitive group and the drug-resistant group and to analyze the correlation between USP22 and MRP1, P-gp.	Oxaliplatin	89-100	CD9 molecule	Homo sapiens	208-212
34954996-8	2021	Results: CCK-8 assay showed that the IC50 values of SW480-USP22 (SW480 cells overexpressing USP22) treated with oxaliplatin for 24 h and 48 h was (4.62+-0.05)mumol/L and (2.32+-0.04)mumol/L respectively; which was 2.7 times and 3.0 times higher than that in control cells, respectively.	Oxaliplatin	112-123	ubiquitin specific peptidase 22	Homo sapiens	58-63
34954996-8	2021	Results: CCK-8 assay showed that the IC50 values of SW480-USP22 (SW480 cells overexpressing USP22) treated with oxaliplatin for 24 h and 48 h was (4.62+-0.05)mumol/L and (2.32+-0.04)mumol/L respectively; which was 2.7 times and 3.0 times higher than that in control cells, respectively.	Oxaliplatin	112-123	ubiquitin specific peptidase 22	Homo sapiens	92-97
34954996-9	2021	After treating with 1.25 mumol/L oxaliplatin for 48 h, USP22 overexpression can inhibit SW480 cells apoptosis.	Oxaliplatin	33-44	ubiquitin specific peptidase 22	Homo sapiens	55-60
34954996-12	2021	Immunohistochemistry showed that the positive expression rates of USP22, MRP1, and P-gp in the oxaliplatin chemotherapy-sensitive group were significantly lower than those in the chemotherapy-resistant group, the difference was statistically significant (all P<0.05), and USP22 was positively correlated with the expressions of MRP1 and P-gp in colorectal cancer tissues (r1=0.377, r2=0.423, both P<0.05).	Oxaliplatin	95-106	ubiquitin specific peptidase 22	Homo sapiens	66-71
34954996-12	2021	Immunohistochemistry showed that the positive expression rates of USP22, MRP1, and P-gp in the oxaliplatin chemotherapy-sensitive group were significantly lower than those in the chemotherapy-resistant group, the difference was statistically significant (all P<0.05), and USP22 was positively correlated with the expressions of MRP1 and P-gp in colorectal cancer tissues (r1=0.377, r2=0.423, both P<0.05).	Oxaliplatin	95-106	CD9 molecule	Homo sapiens	73-77
34954996-12	2021	Immunohistochemistry showed that the positive expression rates of USP22, MRP1, and P-gp in the oxaliplatin chemotherapy-sensitive group were significantly lower than those in the chemotherapy-resistant group, the difference was statistically significant (all P<0.05), and USP22 was positively correlated with the expressions of MRP1 and P-gp in colorectal cancer tissues (r1=0.377, r2=0.423, both P<0.05).	Oxaliplatin	95-106	phosphoglycolate phosphatase	Homo sapiens	83-87
34954996-12	2021	Immunohistochemistry showed that the positive expression rates of USP22, MRP1, and P-gp in the oxaliplatin chemotherapy-sensitive group were significantly lower than those in the chemotherapy-resistant group, the difference was statistically significant (all P<0.05), and USP22 was positively correlated with the expressions of MRP1 and P-gp in colorectal cancer tissues (r1=0.377, r2=0.423, both P<0.05).	Oxaliplatin	95-106	ubiquitin specific peptidase 22	Homo sapiens	272-277
34954996-12	2021	Immunohistochemistry showed that the positive expression rates of USP22, MRP1, and P-gp in the oxaliplatin chemotherapy-sensitive group were significantly lower than those in the chemotherapy-resistant group, the difference was statistically significant (all P<0.05), and USP22 was positively correlated with the expressions of MRP1 and P-gp in colorectal cancer tissues (r1=0.377, r2=0.423, both P<0.05).	Oxaliplatin	95-106	CD9 molecule	Homo sapiens	328-332
34954996-12	2021	Immunohistochemistry showed that the positive expression rates of USP22, MRP1, and P-gp in the oxaliplatin chemotherapy-sensitive group were significantly lower than those in the chemotherapy-resistant group, the difference was statistically significant (all P<0.05), and USP22 was positively correlated with the expressions of MRP1 and P-gp in colorectal cancer tissues (r1=0.377, r2=0.423, both P<0.05).	Oxaliplatin	95-106	phosphoglycolate phosphatase	Homo sapiens	337-341
34957631-6	2022	Furthermore, ZNF852 deficiency increased oxaliplatin-induced MGC-803 cell death, implying the role of ZNF852 in drug sensitivity.	Oxaliplatin	41-52	zinc finger protein 852	Homo sapiens	102-108
34954996-13	2021	Conclusions: The up-regulation of USP22 is related to the acquired resistance of colorectal cancer cells to oxaliplatin.	Oxaliplatin	108-119	ubiquitin specific peptidase 22	Homo sapiens	34-39
34952594-5	2021	The tumor cell-specific ligand TRAIL was bioengineered to be stably expressed on HUVECs and the resultant membrane vesicles were wrapped on OXA/HCQ-loaded PLGA nanocores.	Oxaliplatin	140-143	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	31-36
34288822-0	2021	Circular RNA FAT atypical cadherin 1 (circFAT1)/microRNA-525-5p/spindle and kinetochore-associated complex subunit 1 (SKA1) axis regulates oxaliplatin resistance in breast cancer by activating the notch and Wnt signaling pathway.	Oxaliplatin	139-150	spindle and kinetochore associated complex subunit 1	Homo sapiens	118-122
34881526-0	2021	Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer.	Oxaliplatin	76-87	polo like kinase 1	Homo sapiens	18-22
34881526-5	2021	Genetic and pharmacological blockade of PLK1 significantly increases the sensitivity to oxaliplatin in vitro and in vivo.	Oxaliplatin	88-99	polo like kinase 1	Homo sapiens	40-44
34881526-9	2021	Moreover, a CDC7 inhibitor synergistically enhances the anti-tumor effect of oxaliplatin in CRC models, demonstrating the potential utility of targeting the PLK1-MYC-CDC7 axis in the treatment of oxaliplatin-based chemotherapy.	Oxaliplatin	77-88	cell division cycle 7	Homo sapiens	12-16
34881526-9	2021	Moreover, a CDC7 inhibitor synergistically enhances the anti-tumor effect of oxaliplatin in CRC models, demonstrating the potential utility of targeting the PLK1-MYC-CDC7 axis in the treatment of oxaliplatin-based chemotherapy.	Oxaliplatin	77-88	polo like kinase 1	Homo sapiens	157-161
34881526-9	2021	Moreover, a CDC7 inhibitor synergistically enhances the anti-tumor effect of oxaliplatin in CRC models, demonstrating the potential utility of targeting the PLK1-MYC-CDC7 axis in the treatment of oxaliplatin-based chemotherapy.	Oxaliplatin	77-88	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	162-165
34881526-9	2021	Moreover, a CDC7 inhibitor synergistically enhances the anti-tumor effect of oxaliplatin in CRC models, demonstrating the potential utility of targeting the PLK1-MYC-CDC7 axis in the treatment of oxaliplatin-based chemotherapy.	Oxaliplatin	77-88	cell division cycle 7	Homo sapiens	166-170
34881526-9	2021	Moreover, a CDC7 inhibitor synergistically enhances the anti-tumor effect of oxaliplatin in CRC models, demonstrating the potential utility of targeting the PLK1-MYC-CDC7 axis in the treatment of oxaliplatin-based chemotherapy.	Oxaliplatin	196-207	cell division cycle 7	Homo sapiens	12-16
34881526-9	2021	Moreover, a CDC7 inhibitor synergistically enhances the anti-tumor effect of oxaliplatin in CRC models, demonstrating the potential utility of targeting the PLK1-MYC-CDC7 axis in the treatment of oxaliplatin-based chemotherapy.	Oxaliplatin	196-207	polo like kinase 1	Homo sapiens	157-161
34881526-9	2021	Moreover, a CDC7 inhibitor synergistically enhances the anti-tumor effect of oxaliplatin in CRC models, demonstrating the potential utility of targeting the PLK1-MYC-CDC7 axis in the treatment of oxaliplatin-based chemotherapy.	Oxaliplatin	196-207	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	162-165
34881526-9	2021	Moreover, a CDC7 inhibitor synergistically enhances the anti-tumor effect of oxaliplatin in CRC models, demonstrating the potential utility of targeting the PLK1-MYC-CDC7 axis in the treatment of oxaliplatin-based chemotherapy.	Oxaliplatin	196-207	cell division cycle 7	Homo sapiens	166-170
34750753-4	2021	We found that MAPK and PI3K-AKT signaling were increased in oxaliplatin (Ox)-resistant HCT116 (HCT116-OxR) cells compared to Ox-sensitive HCT116 (HCT116-OxS) cells.	Oxaliplatin	60-71	AKT serine/threonine kinase 1	Homo sapiens	28-31
34477047-0	2021	RecQ-like helicase 4 (RECQL4) exacerbates resistance to oxaliplatin in colon adenocarcinoma via activation of the PI3K/AKT signaling pathway.	Oxaliplatin	56-67	RecQ like helicase 4	Homo sapiens	0-20
34477047-0	2021	RecQ-like helicase 4 (RECQL4) exacerbates resistance to oxaliplatin in colon adenocarcinoma via activation of the PI3K/AKT signaling pathway.	Oxaliplatin	56-67	RecQ like helicase 4	Homo sapiens	22-28
34530056-5	2021	We also found that compared with the control group, the 50% inhibitory concentration (IC50) values of oxaliplatin and 5-FU in the SPIB overexpression group were significantly reduced.	Oxaliplatin	102-113	Spi-B transcription factor	Homo sapiens	130-134
34599680-13	2021	CONCLUSION: Exosomal delivery of miR-1915-3p can improve the chemotherapeutic efficacy of oxaliplatin in CRC cells by suppressing the EMT-promoting oncogenes PFKFB3 and USP2.	Oxaliplatin	90-101	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Mus musculus	158-164
34599680-13	2021	CONCLUSION: Exosomal delivery of miR-1915-3p can improve the chemotherapeutic efficacy of oxaliplatin in CRC cells by suppressing the EMT-promoting oncogenes PFKFB3 and USP2.	Oxaliplatin	90-101	ubiquitin specific peptidase 2	Mus musculus	169-173
34477047-2	2021	The promoting role of RecQ-Like Helicase 4 (RECQL4) in chemoresistance to platinum-based drugs has been identified, whereas the effect and specific mechanism of RECQL4 in regulating OXA resistance within COAD have not been explicated yet.	Oxaliplatin	182-185	RecQ like helicase 4	Homo sapiens	161-167
34477047-8	2021	Moreover, RECQL4 promoted OXA resistance in OXA-resistant COAD cells via activating the P13 K/AKT signaling.	Oxaliplatin	26-29	RecQ like helicase 4	Homo sapiens	10-16
34477047-8	2021	Moreover, RECQL4 promoted OXA resistance in OXA-resistant COAD cells via activating the P13 K/AKT signaling.	Oxaliplatin	26-29	AKT serine/threonine kinase 1	Homo sapiens	94-97
34477047-9	2021	To sum up, the results suggest that RECQL4 depletion may be a crucial mechanism to reverse OXA resistance in COAD via inhibition of the P13 K/AKT pathway in vitro, thereby providing a novel target for overcoming OXA resistance in COAD.	Oxaliplatin	91-94	RecQ like helicase 4	Homo sapiens	36-42
34477047-9	2021	To sum up, the results suggest that RECQL4 depletion may be a crucial mechanism to reverse OXA resistance in COAD via inhibition of the P13 K/AKT pathway in vitro, thereby providing a novel target for overcoming OXA resistance in COAD.	Oxaliplatin	212-215	RecQ like helicase 4	Homo sapiens	36-42
34351659-4	2021	Then, we evaluated the impact of erianin on drug resistance, and explored the relationship between erianin- related oxaliplatin resistance and JAK2/STAT3 signaling pathway in vitro.	Oxaliplatin	116-127	Janus kinase 2	Homo sapiens	143-147
34351659-4	2021	Then, we evaluated the impact of erianin on drug resistance, and explored the relationship between erianin- related oxaliplatin resistance and JAK2/STAT3 signaling pathway in vitro.	Oxaliplatin	116-127	signal transducer and activator of transcription 3	Homo sapiens	148-153
34351659-5	2021	Our research showed that erianin could significantly inhibit the proliferation of human colon cancer oxaliplatin-resistant cells, and suppress the cell cycle of oxaliplatin-resistant cells in the G2/M phase, indicating that erianin could regulate the MDR phenotype of oxaliplatin-resistant cells, and its mechanism might be the inhibition of STAT3 signaling pathway and the significant reduction of P-gp expression.	Oxaliplatin	268-279	signal transducer and activator of transcription 3	Homo sapiens	342-347
34351659-5	2021	Our research showed that erianin could significantly inhibit the proliferation of human colon cancer oxaliplatin-resistant cells, and suppress the cell cycle of oxaliplatin-resistant cells in the G2/M phase, indicating that erianin could regulate the MDR phenotype of oxaliplatin-resistant cells, and its mechanism might be the inhibition of STAT3 signaling pathway and the significant reduction of P-gp expression.	Oxaliplatin	268-279	phosphoglycolate phosphatase	Homo sapiens	399-403
34530056-10	2021	In summary, we found that SPIB is a tumor suppressor in colorectal cancer cells and that SPIB sensitizes colorectal cancer cells to oxaliplatin and 5-FU, SPIB exerts its anti-colorectal cancer effect by activating the NFkB and JNK signaling pathways through MAP4K1.	Oxaliplatin	132-143	Spi-B transcription factor	Homo sapiens	26-30
34530056-10	2021	In summary, we found that SPIB is a tumor suppressor in colorectal cancer cells and that SPIB sensitizes colorectal cancer cells to oxaliplatin and 5-FU, SPIB exerts its anti-colorectal cancer effect by activating the NFkB and JNK signaling pathways through MAP4K1.	Oxaliplatin	132-143	Spi-B transcription factor	Homo sapiens	89-93
34530056-10	2021	In summary, we found that SPIB is a tumor suppressor in colorectal cancer cells and that SPIB sensitizes colorectal cancer cells to oxaliplatin and 5-FU, SPIB exerts its anti-colorectal cancer effect by activating the NFkB and JNK signaling pathways through MAP4K1.	Oxaliplatin	132-143	Spi-B transcription factor	Homo sapiens	154-158
34688609-0	2021	CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/beta-catenin-induced glycolytic metabolism.	Oxaliplatin	42-53	carnitine palmitoyltransferase 2	Homo sapiens	0-4
33974471-0	2021	Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer.	Oxaliplatin	66-77	CD44 antigen	Mus musculus	49-53
34688609-4	2021	CPT2 was overexpressed in CRC cell lines (SW480 and RKO), and its effects and molecular mechanism on the proliferation, glycolysis, stemness, and oxaliplatin sensitivity were investigated.	Oxaliplatin	146-157	carnitine palmitoyltransferase 2	Homo sapiens	0-4
34688609-7	2021	Upregulation of CPT2 significantly inhibited the proliferation, glycolytic metabolism, cancer stem cell properties, and oxaliplatin resistance in CRC cells.	Oxaliplatin	120-131	carnitine palmitoyltransferase 2	Homo sapiens	16-20
34688609-8	2021	Also, the increase of CPT2 inhibited tumorigenesis, stemness and glycolysis, while enhanced oxaliplatin sensitivity in mouse models.	Oxaliplatin	92-103	carnitine palmitoyltransferase 2	Mus musculus	22-26
34688609-10	2021	In conclusion, our results demonstrated that CPT2 was decreased in CRC, and CPT2 downregulation could trigger stemness and oxaliplatin resistance in CRC via activating the ROS/Wnt/beta-catenin-induced glycolytic metabolism.	Oxaliplatin	123-134	carnitine palmitoyltransferase 2	Mus musculus	76-80
34688609-10	2021	In conclusion, our results demonstrated that CPT2 was decreased in CRC, and CPT2 downregulation could trigger stemness and oxaliplatin resistance in CRC via activating the ROS/Wnt/beta-catenin-induced glycolytic metabolism.	Oxaliplatin	123-134	catenin beta 1	Homo sapiens	180-192
34649091-0	2021	D-MT prompts the anti-tumor effect of oxaliplatin by inhibiting IDO expression in a mouse model of colon cancer.	Oxaliplatin	38-49	indoleamine 2,3-dioxygenase 1	Mus musculus	64-67
34075792-0	2021	Silencing of E-cadherin expression leads to increased chemosensitivity to irinotecan and oxaliplatin in colorectal cancer cell lines.	Oxaliplatin	89-100	cadherin 1	Homo sapiens	13-23
34322883-0	2021	LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance via SP1-induced p62 Transcription in Hepatocellular Carcinoma.	Oxaliplatin	36-47	lysine demethylase 1A	Homo sapiens	0-4
34322883-0	2021	LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance via SP1-induced p62 Transcription in Hepatocellular Carcinoma.	Oxaliplatin	36-47	long intergenic non-protein coding RNA 1134	Homo sapiens	18-27
34322883-0	2021	LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance via SP1-induced p62 Transcription in Hepatocellular Carcinoma.	Oxaliplatin	36-47	nucleoporin 62	Homo sapiens	75-78
34322883-7	2021	The effects of LINC01134/SP1/p62 axis on OXA resistance were evaluated using cell viability, apoptosis and mitochondrial function and morphology analysis.	Oxaliplatin	41-44	long intergenic non-protein coding RNA 1134	Homo sapiens	15-24
34322883-7	2021	The effects of LINC01134/SP1/p62 axis on OXA resistance were evaluated using cell viability, apoptosis and mitochondrial function and morphology analysis.	Oxaliplatin	41-44	nucleoporin 62	Homo sapiens	29-32
34322883-9	2021	ChIP, cell viability and xenograft assays were used to identify the demethylase for LINC01134 upregulation in OXA resistance.	Oxaliplatin	110-113	methyl-CpG binding domain protein 2	Homo sapiens	68-79
34322883-9	2021	ChIP, cell viability and xenograft assays were used to identify the demethylase for LINC01134 upregulation in OXA resistance.	Oxaliplatin	110-113	long intergenic non-protein coding RNA 1134	Homo sapiens	84-93
34322883-11	2021	Higher LINC01134 expression predicted poorer OXA therapeutic effacacy.	Oxaliplatin	45-48	long intergenic non-protein coding RNA 1134	Homo sapiens	7-16
34322883-13	2021	The LINC01134/SP1/p62 axis regulates OXA resistance by altering cell viability, apoptosis, and mitochondrial homeostasis both in vitro and in vivo.	Oxaliplatin	37-40	long intergenic non-protein coding RNA 1134	Homo sapiens	4-13
34322883-13	2021	The LINC01134/SP1/p62 axis regulates OXA resistance by altering cell viability, apoptosis, and mitochondrial homeostasis both in vitro and in vivo.	Oxaliplatin	37-40	nucleoporin 62	Homo sapiens	18-21
34322883-16	2021	CONCLUSION: LSD1/LINC01134/SP1/p62 axis is critical for OXA resistance in HCC.	Oxaliplatin	56-59	lysine demethylase 1A	Homo sapiens	12-16
34322883-16	2021	CONCLUSION: LSD1/LINC01134/SP1/p62 axis is critical for OXA resistance in HCC.	Oxaliplatin	56-59	long intergenic non-protein coding RNA 1134	Homo sapiens	17-26
34322883-16	2021	CONCLUSION: LSD1/LINC01134/SP1/p62 axis is critical for OXA resistance in HCC.	Oxaliplatin	56-59	nucleoporin 62	Homo sapiens	31-34
34322883-17	2021	Evaluating LINC01134 expression in HCC will be effective in predicting OXA efficacy.	Oxaliplatin	71-74	long intergenic non-protein coding RNA 1134	Homo sapiens	11-20
34322883-18	2021	In treatment-naive patients, targeting the LINC01134/SP1/p62 axis may be a promising strategy to overcome OXA chemoresistance.	Oxaliplatin	106-109	long intergenic non-protein coding RNA 1134	Homo sapiens	43-52
34322883-18	2021	In treatment-naive patients, targeting the LINC01134/SP1/p62 axis may be a promising strategy to overcome OXA chemoresistance.	Oxaliplatin	106-109	nucleoporin 62	Homo sapiens	57-60
34649091-4	2021	Herein, an IDO inhibitor, D-MT (indoximod, 1-Methyl-D-tryptophan), was combined with oxaliplatin to treat colon cancer in mice.	Oxaliplatin	85-96	indoleamine 2,3-dioxygenase 1	Mus musculus	11-14
34213835-0	2021	iRGD-modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation.	Oxaliplatin	88-99	carnitine palmitoyltransferase 1A	Homo sapiens	43-48
34213835-3	2021	Here, we confirmed that CPT1A was heterogeneously expressed in colon cancer cells, with a high expression in oxaliplatin-resistant cells but low expression in oxaliplatin-sensitive cells, and expression could be increased by oxaliplatin stimulation.	Oxaliplatin	109-120	carnitine palmitoyltransferase 1A	Homo sapiens	24-29
34213835-3	2021	Here, we confirmed that CPT1A was heterogeneously expressed in colon cancer cells, with a high expression in oxaliplatin-resistant cells but low expression in oxaliplatin-sensitive cells, and expression could be increased by oxaliplatin stimulation.	Oxaliplatin	159-170	carnitine palmitoyltransferase 1A	Homo sapiens	24-29
34213835-3	2021	Here, we confirmed that CPT1A was heterogeneously expressed in colon cancer cells, with a high expression in oxaliplatin-resistant cells but low expression in oxaliplatin-sensitive cells, and expression could be increased by oxaliplatin stimulation.	Oxaliplatin	225-236	carnitine palmitoyltransferase 1A	Homo sapiens	24-29
34213835-5	2021	Silencing CPT1A by siRNA or etomoxir, a specific small-molecule inhibitor of CPT1A, could reverse the sensitivity of drug-resistant colon cancer cells to oxaliplatin.	Oxaliplatin	154-165	carnitine palmitoyltransferase 1A	Homo sapiens	10-15
34213835-5	2021	Silencing CPT1A by siRNA or etomoxir, a specific small-molecule inhibitor of CPT1A, could reverse the sensitivity of drug-resistant colon cancer cells to oxaliplatin.	Oxaliplatin	154-165	carnitine palmitoyltransferase 1A	Homo sapiens	77-82
34213835-6	2021	Subsequently, the combination of oxaliplatin with CPT1A inhibition promoted apoptosis and inhibited proliferation.	Oxaliplatin	33-44	carnitine palmitoyltransferase 1A	Homo sapiens	50-55
34959286-2	2021	We hypothesized that TKIs may differentially interact with the renal transporter MATE1 (SLC47A1) and influence the elimination and toxicity of the MATE1 substrate oxaliplatin.	Oxaliplatin	163-174	solute carrier family 47, member 1	Mus musculus	147-152
34792764-11	2021	Oxaliplatin increased CB1 in DRG, SC, TG, Sp5C, and ventrolateral PAG, with no interference in CB2 expression.	Oxaliplatin	0-11	cannabinoid receptor 1 (brain)	Mus musculus	22-25
34792764-15	2021	Oxaliplatin also increased Iba-1 in DRG, suggesting immune response modulation which was reduced by cannabidiol and enhanced by AM630.	Oxaliplatin	0-11	induction of brown adipocytes 1	Mus musculus	27-32
34818693-3	2021	Experimental animals were treated with oxaliplatin to induce CINP, and then administered oral CUM for 4 weeks in order to observe the effect of CUM.	Oxaliplatin	39-50	cyclin-dependent kinase 2 interacting protein	Mus musculus	61-65
34959286-5	2021	The urinary excretion of oxaliplatin was reduced by about 2-fold in mice with a deficiency of MATE1 or both OCT2 and MATE1 (p < 0.05), without impacting markers of acute renal injury.	Oxaliplatin	25-36	solute carrier family 47, member 1	Mus musculus	94-99
34959286-5	2021	The urinary excretion of oxaliplatin was reduced by about 2-fold in mice with a deficiency of MATE1 or both OCT2 and MATE1 (p < 0.05), without impacting markers of acute renal injury.	Oxaliplatin	25-36	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	108-112
34959286-5	2021	The urinary excretion of oxaliplatin was reduced by about 2-fold in mice with a deficiency of MATE1 or both OCT2 and MATE1 (p < 0.05), without impacting markers of acute renal injury.	Oxaliplatin	25-36	solute carrier family 47, member 1	Mus musculus	117-122
34808752-10	2021	Moreover, the result of Kyoto Encyclopedia of genes and genomes (KEGG) analyses highlighted that the DEGs induced by oxaliplatin were involved in malaria, African trypanosomiasis, primary immunodeficiency, peroxisome proliferator activated receptor (PPAR) signaling pathway.	Oxaliplatin	117-128	peroxisome proliferator activated receptor alpha	Rattus norvegicus	206-248
34808752-10	2021	Moreover, the result of Kyoto Encyclopedia of genes and genomes (KEGG) analyses highlighted that the DEGs induced by oxaliplatin were involved in malaria, African trypanosomiasis, primary immunodeficiency, peroxisome proliferator activated receptor (PPAR) signaling pathway.	Oxaliplatin	117-128	peroxisome proliferator activated receptor alpha	Rattus norvegicus	250-254
34868951-3	2021	Recently, we showed the add-on effect of autophagy inhibitor UAMC-2526 to prevent HT-29 colorectal tumor growth in CD1-/- Foxn1nu mice treated with oxaliplatin.	Oxaliplatin	148-159	CD1 antigen complex	Mus musculus	115-118
34824551-0	2021	lncRNA MCF2L-AS1/miR-105/ IL-1beta Axis Regulates Colorectal Cancer Cell Oxaliplatin Resistance.	Oxaliplatin	73-84	MCF2L antisense RNA 1	Homo sapiens	7-16
34824551-0	2021	lncRNA MCF2L-AS1/miR-105/ IL-1beta Axis Regulates Colorectal Cancer Cell Oxaliplatin Resistance.	Oxaliplatin	73-84	interleukin 1 alpha	Homo sapiens	26-34
34795209-0	2021	Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin.	Oxaliplatin	91-102	deoxythymidylate kinase	Homo sapiens	14-19
34795209-6	2021	The knockdown of DTYMK was found to significantly inhibit the growth of HCC and increase the sensitivity to oxaliplatin, which is commonly used in HCC treatment.	Oxaliplatin	108-119	deoxythymidylate kinase	Homo sapiens	17-22
34858502-8	2021	Functionally, lncRNA TUG1 increased the characteristics and oxaliplatin resistance of CRC stem cells.	Oxaliplatin	60-71	taurine up-regulated 1	Homo sapiens	21-25
34858502-9	2021	Mechanically, lncRNA TUG1 interacted with GATA6 and positively regulated its protein level and the rescue assays corroborated that lncRNA TUG1 knockdown repressed the characteristics and oxaliplatin resistance of CRC stem cells by decreasing GATA6 and functioned in CRC by targeting the GATA6-BMP signaling pathway.	Oxaliplatin	187-198	taurine up-regulated 1	Homo sapiens	21-25
34858502-9	2021	Mechanically, lncRNA TUG1 interacted with GATA6 and positively regulated its protein level and the rescue assays corroborated that lncRNA TUG1 knockdown repressed the characteristics and oxaliplatin resistance of CRC stem cells by decreasing GATA6 and functioned in CRC by targeting the GATA6-BMP signaling pathway.	Oxaliplatin	187-198	GATA binding protein 6	Homo sapiens	42-47
34858502-9	2021	Mechanically, lncRNA TUG1 interacted with GATA6 and positively regulated its protein level and the rescue assays corroborated that lncRNA TUG1 knockdown repressed the characteristics and oxaliplatin resistance of CRC stem cells by decreasing GATA6 and functioned in CRC by targeting the GATA6-BMP signaling pathway.	Oxaliplatin	187-198	taurine up-regulated 1	Homo sapiens	138-142
34858502-10	2021	Furthermore, the in vivo assay verified the lncRNA TUG1 function in facilitating the characteristics and oxaliplatin resistance of CRC stem cells.	Oxaliplatin	105-116	taurine up-regulated 1	Homo sapiens	51-55
34868951-3	2021	Recently, we showed the add-on effect of autophagy inhibitor UAMC-2526 to prevent HT-29 colorectal tumor growth in CD1-/- Foxn1nu mice treated with oxaliplatin.	Oxaliplatin	148-159	forkhead box N1	Mus musculus	122-127
34761889-0	2021	Twist and Vimentin protein expression in colored cancer tissues and its relationship with oxaliplatin-based reactive reactive chemotherapeutic resistance.	Oxaliplatin	90-101	twist family bHLH transcription factor 1	Homo sapiens	0-5
34785642-5	2021	We conducted in vitro experiments and found that in HCC cells, UBE2S overexpression increases the resistance to 5-FU and oxaliplatin, while UBE2S knockdown achieves an opposite effect.	Oxaliplatin	121-132	ubiquitin conjugating enzyme E2 S	Homo sapiens	63-68
34761889-0	2021	Twist and Vimentin protein expression in colored cancer tissues and its relationship with oxaliplatin-based reactive reactive chemotherapeutic resistance.	Oxaliplatin	90-101	vimentin	Homo sapiens	10-18
34740372-0	2021	Lnc-RP11-536 K7.3/SOX2/HIF-1alpha signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids.	Oxaliplatin	59-70	SRY-box transcription factor 2	Homo sapiens	18-22
34738855-2	2021	Peripheral neuropathy (PN) is a troublesome and dose-dependent adverse effect of oxaliplatin.	Oxaliplatin	81-92	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	23-25
34740372-0	2021	Lnc-RP11-536 K7.3/SOX2/HIF-1alpha signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids.	Oxaliplatin	59-70	hypoxia inducible factor 1 subunit alpha	Homo sapiens	23-33
34740372-10	2021	The accumulative USP7 resulted in deubiquitylation and stabilization of HIF-1alpha, thereby facilitating resistance to oxaliplatin.	Oxaliplatin	119-130	ubiquitin specific peptidase 7	Homo sapiens	17-21
34740372-10	2021	The accumulative USP7 resulted in deubiquitylation and stabilization of HIF-1alpha, thereby facilitating resistance to oxaliplatin.	Oxaliplatin	119-130	hypoxia inducible factor 1 subunit alpha	Homo sapiens	72-82
34390893-3	2021	Flow cytometry and immunostaining assays were performed to evaluate CALR exposure induced by OXA in the murine Lewis lung carcinoma (LLC) cells.	Oxaliplatin	93-96	calreticulin	Mus musculus	68-72
34658162-0	2021	Rational Design of a Modality-Specific Inhibitor of TRPM8 Channel against Oxaliplatin-Induced Cold Allodynia.	Oxaliplatin	74-85	transient receptor potential cation channel subfamily M member 8	Homo sapiens	52-57
34272617-0	2021	Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance.	Oxaliplatin	111-122	myoferlin	Homo sapiens	79-88
34272617-7	2021	The results from cell viability assays and qRT-PCR showed that high expression of MYOF correlated significantly with the IC50 of L-OHP in GCOs.	Oxaliplatin	129-134	myoferlin	Homo sapiens	82-86
34272617-9	2021	The knockdown of MYOF repressed L-OHP resistance, cell growth, stem cell features, migration, invasion, and in vivo tumor growth.	Oxaliplatin	32-37	myoferlin	Homo sapiens	17-21
34272617-10	2021	CONCLUSIONS: Our results suggest that MYOF is highly involved in L-OHP resistance and tumor progression in GC.	Oxaliplatin	65-70	myoferlin	Homo sapiens	38-42
34272617-11	2021	MYOF could be a promising biomarker and therapeutic target for L-OHP-resistant GC cases.	Oxaliplatin	63-68	myoferlin	Homo sapiens	0-4
34474344-0	2021	LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan.	Oxaliplatin	53-64	lymphoid enhancer binding factor 1	Homo sapiens	0-4
34474344-10	2021	In summary, we showed the role of LEF1 in chemo-resistance of colorectal cancer cells to Oxaliplatin, Irinotecan and 5-FU.	Oxaliplatin	89-100	lymphoid enhancer binding factor 1	Homo sapiens	34-38
34390893-6	2021	OXA induced CALR exposure on the surface of LLC cells after low dose and short duration of treatment (20 muM OXA for 24 h).	Oxaliplatin	0-3	calreticulin	Mus musculus	12-16
34390893-6	2021	OXA induced CALR exposure on the surface of LLC cells after low dose and short duration of treatment (20 muM OXA for 24 h).	Oxaliplatin	109-112	calreticulin	Mus musculus	12-16
34333050-6	2021	RESULTS: IGF-1 protein expression decreased significantly in the spinal cord on D3 and D10 (the 3rd and 10th days after beginning oxaliplatin chemotherapy) and was co-localized with astrocytes primarily in the lumbar spinal cord, whereas IGF1R was predominantly expressed on neurons.	Oxaliplatin	130-141	insulin-like growth factor 1	Mus musculus	9-14
34664893-0	2021	Effects of RPA1 gene polymorphisms on the sensitivity to oxaliplatin in the treatment of gastric cancer.	Oxaliplatin	57-68	replication protein A1	Homo sapiens	11-15
34508743-0	2021	KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.	Oxaliplatin	66-77	kinesin family member 18B	Homo sapiens	0-6
34508743-0	2021	KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.	Oxaliplatin	66-77	PARP1 binding protein	Homo sapiens	36-42
34508743-2	2021	In this study, higher expression of PARP-1 binding protein (PARPBP) was detected in oxaliplatin-resistant CRC (OR-CRC) cells than in non-resistant cells.	Oxaliplatin	84-95	PARP1 binding protein	Homo sapiens	36-58
34508743-2	2021	In this study, higher expression of PARP-1 binding protein (PARPBP) was detected in oxaliplatin-resistant CRC (OR-CRC) cells than in non-resistant cells.	Oxaliplatin	84-95	PARP1 binding protein	Homo sapiens	60-66
34508743-3	2021	Further research showed that kinesin family member 18b (KIF18b) induced the overexpression of PARPBP, sustaining oxaliplatin resistance in OR-CRC cells.	Oxaliplatin	113-124	kinesin family member 18B	Homo sapiens	29-54
34508743-3	2021	Further research showed that kinesin family member 18b (KIF18b) induced the overexpression of PARPBP, sustaining oxaliplatin resistance in OR-CRC cells.	Oxaliplatin	113-124	kinesin family member 18B	Homo sapiens	56-62
34508743-3	2021	Further research showed that kinesin family member 18b (KIF18b) induced the overexpression of PARPBP, sustaining oxaliplatin resistance in OR-CRC cells.	Oxaliplatin	113-124	PARP1 binding protein	Homo sapiens	94-100
34649573-9	2021	In the dorsal horn of the spinal cord of animals affected by oxaliplatin-induced neuropathy, VEGF-A expression was increased in astrocytes while VEGFR-1 was mainly detected in neurons, suggesting a VEGF-A/VEGFR-1-mediated astrocyte-neuron cross-talk in neuropathic pain pathophysiology.	Oxaliplatin	61-72	FMS-like tyrosine kinase 1	Mus musculus	205-212
34649573-10	2021	Accordingly, the selective knockdown of astrocytic VEGF-A by intraspinal injection of shRNAmir blocked the development of oxaliplatin-induced neuropathic hyperalgesia and allodynia.	Oxaliplatin	122-133	vascular endothelial growth factor A	Mus musculus	51-57
34649573-11	2021	Interestingly, both intrathecal and systemic administration of the novel anti-VEGFR-1 monoclonal antibody D16F7, endowed with anti-angiogenic and antitumor properties, reverted oxaliplatin-induced neuropathic pain.	Oxaliplatin	177-188	FMS-like tyrosine kinase 1	Mus musculus	78-85
34608940-12	2022	Moreover, positive correlations were observed between the serum levels of IL-1beta, IL-6, and urinary 1-OH-P levels in bitumen fumes-exposed workers, respectively (P < 0.05).	Oxaliplatin	102-108	interleukin 1 alpha	Homo sapiens	74-82
34608940-15	2022	The serum levels of IL-1beta and IL-6 were positive correlated with the urinary 1-OH-P levels in bitumen fumes exposed workers.	Oxaliplatin	80-86	interleukin 1 alpha	Homo sapiens	20-28
34608940-15	2022	The serum levels of IL-1beta and IL-6 were positive correlated with the urinary 1-OH-P levels in bitumen fumes exposed workers.	Oxaliplatin	80-86	interleukin 6	Homo sapiens	33-37
34649573-9	2021	In the dorsal horn of the spinal cord of animals affected by oxaliplatin-induced neuropathy, VEGF-A expression was increased in astrocytes while VEGFR-1 was mainly detected in neurons, suggesting a VEGF-A/VEGFR-1-mediated astrocyte-neuron cross-talk in neuropathic pain pathophysiology.	Oxaliplatin	61-72	vascular endothelial growth factor A	Mus musculus	93-99
34649573-9	2021	In the dorsal horn of the spinal cord of animals affected by oxaliplatin-induced neuropathy, VEGF-A expression was increased in astrocytes while VEGFR-1 was mainly detected in neurons, suggesting a VEGF-A/VEGFR-1-mediated astrocyte-neuron cross-talk in neuropathic pain pathophysiology.	Oxaliplatin	61-72	FMS-like tyrosine kinase 1	Mus musculus	145-152
34649573-9	2021	In the dorsal horn of the spinal cord of animals affected by oxaliplatin-induced neuropathy, VEGF-A expression was increased in astrocytes while VEGFR-1 was mainly detected in neurons, suggesting a VEGF-A/VEGFR-1-mediated astrocyte-neuron cross-talk in neuropathic pain pathophysiology.	Oxaliplatin	61-72	vascular endothelial growth factor A	Mus musculus	198-204
34547581-1	2021	BACKGROUND: In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS) metastatic colorectal cancer (mCRC) to anti-programmed cell death protein-1; the addition of oxaliplatin or bevacizumab (F Hoffmann- la ROCHE AG, Kaiseraugst, Switzerland) enhanced the antitumour effects of FTD/TPI.	Oxaliplatin	73-84	programmed cell death 1	Homo sapiens	209-240
34547581-1	2021	BACKGROUND: In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS) metastatic colorectal cancer (mCRC) to anti-programmed cell death protein-1; the addition of oxaliplatin or bevacizumab (F Hoffmann- la ROCHE AG, Kaiseraugst, Switzerland) enhanced the antitumour effects of FTD/TPI.	Oxaliplatin	73-84	triosephosphate isomerase 1	Homo sapiens	376-379
34547581-1	2021	BACKGROUND: In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS) metastatic colorectal cancer (mCRC) to anti-programmed cell death protein-1; the addition of oxaliplatin or bevacizumab (F Hoffmann- la ROCHE AG, Kaiseraugst, Switzerland) enhanced the antitumour effects of FTD/TPI.	Oxaliplatin	258-269	triosephosphate isomerase 1	Homo sapiens	376-379
34589129-2	2021	Methods: The changes of lncRNA CASC9 in 58 patients with CC were determined using a real-time quantitative PCR (qRT-PCR) assay before and after chemotherapy, and the correlation of serum lncRNA CASC9 with efficacy of FOLFOX4 regimen (oxaliplatin + calcium folinate + fluorouracil) was analyzed.	Oxaliplatin	234-245	cancer susceptibility 9	Homo sapiens	31-36
34461110-7	2021	We also observed that GRIM-19 enhances the effect of oxaliplatin against CRC.	Oxaliplatin	53-64	NADH:ubiquinone oxidoreductase subunit A13	Homo sapiens	22-29
34790400-11	2021	Conclusions: As an oncogene, circ_NOTCH3 can trigger the proliferation, invasion, migration, and oxaliplatin resistance of HCC cells through the miR-875-5p/ZNF146 axis, and may be a promising target for the treatment of HCC.	Oxaliplatin	97-108	microRNA 875	Homo sapiens	145-152
34790400-11	2021	Conclusions: As an oncogene, circ_NOTCH3 can trigger the proliferation, invasion, migration, and oxaliplatin resistance of HCC cells through the miR-875-5p/ZNF146 axis, and may be a promising target for the treatment of HCC.	Oxaliplatin	97-108	zinc finger protein 146	Homo sapiens	156-162
34396431-10	2021	Overall, isolates of the CSC population CD44+ resistant to 5FU and oxaliplatin demonstrated different expression profiles; however, the present study was able to identify overexpression of the KRT-18 gene, in most of the isolates.	Oxaliplatin	67-78	CD44 molecule (Indian blood group)	Homo sapiens	40-44
34396431-10	2021	Overall, isolates of the CSC population CD44+ resistant to 5FU and oxaliplatin demonstrated different expression profiles; however, the present study was able to identify overexpression of the KRT-18 gene, in most of the isolates.	Oxaliplatin	67-78	keratin 18	Homo sapiens	193-199
34396431-11	2021	In conclusion, the results of the present study showed overexpression of KRT-18 in CD44+ cells is associated with chemoresistance to 5FU and oxaliplatin in CRAC.	Oxaliplatin	141-152	keratin 18	Homo sapiens	73-79
34396431-11	2021	In conclusion, the results of the present study showed overexpression of KRT-18 in CD44+ cells is associated with chemoresistance to 5FU and oxaliplatin in CRAC.	Oxaliplatin	141-152	CD44 molecule (Indian blood group)	Homo sapiens	83-87
34611476-5	2021	We observed downregulation of histone genes by 5-FU (that significantly correlates with improved survival in CRC patients) and upregulation of FOS and ATF3 by oxaliplatin (which may contribute to peripheral neuropathy).	Oxaliplatin	159-170	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	143-146
34611476-5	2021	We observed downregulation of histone genes by 5-FU (that significantly correlates with improved survival in CRC patients) and upregulation of FOS and ATF3 by oxaliplatin (which may contribute to peripheral neuropathy).	Oxaliplatin	159-170	activating transcription factor 3	Homo sapiens	151-155
34611476-8	2021	TRAILR2 was down-regulated by oxaliplatin and 5-FU, was not affected by CPT-11, and was increased by cisplatin.	Oxaliplatin	30-41	TNF receptor superfamily member 10b	Homo sapiens	0-7
34611476-9	2021	There was an increase in IL-8 by oxaliplatin and increase in ferritin by cisplatin which may contribute to cancer cell survival.	Oxaliplatin	33-44	C-X-C motif chemokine ligand 8	Homo sapiens	25-29
34562123-7	2022	Knockdown of MIR155HG or ANXA2 suppressed M2 macrophage polarization, and proliferation, migration, invasion and oxaliplatin resistance of CRC cells.	Oxaliplatin	113-124	annexin A2	Homo sapiens	25-30
34562123-10	2022	CONCLUSION: This study highlighted that MIR155HG, by regulating the miR-650/ANXA2 axis, promotes CRC progression and enhances oxaliplatin resistance in CRC cells through M2 macrophage polarization.	Oxaliplatin	126-137	Mir155 host gene (non-protein coding)	Mus musculus	40-48
34589129-2	2021	Methods: The changes of lncRNA CASC9 in 58 patients with CC were determined using a real-time quantitative PCR (qRT-PCR) assay before and after chemotherapy, and the correlation of serum lncRNA CASC9 with efficacy of FOLFOX4 regimen (oxaliplatin + calcium folinate + fluorouracil) was analyzed.	Oxaliplatin	234-245	cancer susceptibility 9	Homo sapiens	194-199
34101295-1	2021	LESSONS LEARNED: Pre-clinical studies have demonstrated that Src inhibition through dasatinib synergistically enhances the anti-tumor effects of oxaliplatin.	Oxaliplatin	145-156	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	61-64
34391932-10	2021	Of note, silencing of GFRalpha1 expression promotes oxaliplatin-mediated HCC cell apoptosis resulting in prolonged survival of HCC-bearing mice, and forced expression of GFRalpha1 markedly increased oxaliplatin resistance of HCC cells.	Oxaliplatin	52-63	glial cell line derived neurotrophic factor family receptor alpha 1	Mus musculus	22-31
34391932-10	2021	Of note, silencing of GFRalpha1 expression promotes oxaliplatin-mediated HCC cell apoptosis resulting in prolonged survival of HCC-bearing mice, and forced expression of GFRalpha1 markedly increased oxaliplatin resistance of HCC cells.	Oxaliplatin	199-210	glial cell line derived neurotrophic factor family receptor alpha 1	Mus musculus	170-179
34551797-10	2021	Pharmacological inhibition of PTK6 using XMU-MP-2 effectively reduces the stemness property of CRC cells and improves its chemosensitivity to 5-FU/L-OHP in both nude mice subcutaneously implanted tumor model and PDX model constructed with NOD-SCID mice.	Oxaliplatin	147-152	PTK6 protein tyrosine kinase 6	Mus musculus	30-34
34229010-0	2021	Raf1 interacts with OIP5 to participate in oxaliplatin-induced neuropathic pain.	Oxaliplatin	43-54	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	0-4
34603016-5	2021	The aim of the study was to investigate the impact of OCT expression on the clinical outcome of patients with esophageal cancer treated with oxaliplatin.	Oxaliplatin	141-152	plexin A2	Homo sapiens	54-57
34603016-9	2021	OCTN2 function in patient-derived cancer cells was evaluated by assessing L-carnitine uptake and sensitivity to oxaliplatin.	Oxaliplatin	112-123	solute carrier family 22 member 5	Homo sapiens	0-5
34603016-12	2021	In patient-derived cancer cells and HEK293 cells, the expression of OCTN2 sensitized to oxaliplatin.	Oxaliplatin	88-99	solute carrier family 22 member 5	Homo sapiens	68-73
34603016-13	2021	Patients treated with oxaliplatin who had high OCTN2 level in the tumor tissue had a reduced risk of recurrence and a longer survival time than those with low expression of OCTN2 in tumor tissue.	Oxaliplatin	22-33	solute carrier family 22 member 5	Homo sapiens	47-52
34603016-14	2021	In conclusion, OCTN2 is expressed in esophageal cancer and it is likely to contribute to the accumulation and cytotoxic activity of oxaliplatin in patients with esophageal carcinoma treated with oxaliplatin.	Oxaliplatin	132-143	solute carrier family 22 member 5	Homo sapiens	15-20
34603016-14	2021	In conclusion, OCTN2 is expressed in esophageal cancer and it is likely to contribute to the accumulation and cytotoxic activity of oxaliplatin in patients with esophageal carcinoma treated with oxaliplatin.	Oxaliplatin	195-206	solute carrier family 22 member 5	Homo sapiens	15-20
34229010-11	2021	SIGNIFICANCE: This study confirmed that Raf1 interacts with OIP5 to participate in oxaliplatin-induced neuropathic pain.	Oxaliplatin	83-94	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	40-44
34229010-11	2021	SIGNIFICANCE: This study confirmed that Raf1 interacts with OIP5 to participate in oxaliplatin-induced neuropathic pain.	Oxaliplatin	83-94	Opa interacting protein 5	Rattus norvegicus	60-64
34229010-12	2021	The restricted expression of OIP5 in normal tissues may make it an ideal drug target for the treatment of oxaliplatin-induced neuropathic pain.	Oxaliplatin	106-117	Opa interacting protein 5	Rattus norvegicus	29-33
34229010-0	2021	Raf1 interacts with OIP5 to participate in oxaliplatin-induced neuropathic pain.	Oxaliplatin	43-54	Opa interacting protein 5	Rattus norvegicus	20-24
34237461-6	2021	In brg1-S1452D cells, we also detected downregulation of various cancer-related proteins (e.g., EGFR and MET) as well as decreased migration, proliferation, and sensitivity to taxanes and oxaliplatin.	Oxaliplatin	188-199	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	3-7
34229010-4	2021	Whether Raf1 and OIP5 can participate in oxaliplatin-induced neuropathic pain has not been reported.	Oxaliplatin	41-52	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	8-12
34229010-8	2021	KEY FINDINGS: The expression levels of p-Raf1 and OIP5 were increased in DRGs of oxaliplatin-induced neuropathic pain rats.	Oxaliplatin	81-92	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	41-45
34229010-8	2021	KEY FINDINGS: The expression levels of p-Raf1 and OIP5 were increased in DRGs of oxaliplatin-induced neuropathic pain rats.	Oxaliplatin	81-92	Opa interacting protein 5	Rattus norvegicus	50-54
34229010-9	2021	Intrathecal administration of siOIP5 to inhibit the expression of OIP5 not only effectively alleviated oxaliplatin-induced mechanical allodynia and cold hyperalgesia, but also decreased the protein expression of Raf1.	Oxaliplatin	103-114	Opa interacting protein 5	Rattus norvegicus	66-70
34229010-9	2021	Intrathecal administration of siOIP5 to inhibit the expression of OIP5 not only effectively alleviated oxaliplatin-induced mechanical allodynia and cold hyperalgesia, but also decreased the protein expression of Raf1.	Oxaliplatin	103-114	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	212-216
34490849-0	2022	Dorsal root ganglion toll-like receptor 4 signaling contributes to oxaliplatin-induced peripheral neuropathy.	Oxaliplatin	67-78	toll-like receptor 4	Rattus norvegicus	21-41
34490849-4	2022	Western blot revealed an increase in TLR4 expression in the DRG of oxaliplatin at days 1 and 7 after oxaliplatin treatment.	Oxaliplatin	67-78	toll-like receptor 4	Rattus norvegicus	37-41
34490849-4	2022	Western blot revealed an increase in TLR4 expression in the DRG of oxaliplatin at days 1 and 7 after oxaliplatin treatment.	Oxaliplatin	101-112	toll-like receptor 4	Rattus norvegicus	37-41
34490849-6	2022	Immunostaining of DRGs revealed an increase in the number of neurons expressing TLR4, its canonical downstream signal molecules myeloid differentiation primary response gene 88 (MyD88) and TIR-domain-containing adapter-inducing interferon-beta, at both day 7 and day 14 after oxaliplatin treatment.	Oxaliplatin	276-287	toll-like receptor 4	Rattus norvegicus	80-84
34490849-6	2022	Immunostaining of DRGs revealed an increase in the number of neurons expressing TLR4, its canonical downstream signal molecules myeloid differentiation primary response gene 88 (MyD88) and TIR-domain-containing adapter-inducing interferon-beta, at both day 7 and day 14 after oxaliplatin treatment.	Oxaliplatin	276-287	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	128-176
34490849-6	2022	Immunostaining of DRGs revealed an increase in the number of neurons expressing TLR4, its canonical downstream signal molecules myeloid differentiation primary response gene 88 (MyD88) and TIR-domain-containing adapter-inducing interferon-beta, at both day 7 and day 14 after oxaliplatin treatment.	Oxaliplatin	276-287	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	178-183
34490849-6	2022	Immunostaining of DRGs revealed an increase in the number of neurons expressing TLR4, its canonical downstream signal molecules myeloid differentiation primary response gene 88 (MyD88) and TIR-domain-containing adapter-inducing interferon-beta, at both day 7 and day 14 after oxaliplatin treatment.	Oxaliplatin	276-287	interferon beta 1	Rattus norvegicus	228-243
34490849-10	2022	Furthermore, upregulation of TLR4 was detected in both sexes when tested 14 days after treatment with oxaliplatin.	Oxaliplatin	102-113	toll-like receptor 4	Rattus norvegicus	29-33
34378321-10	2021	Mechanistically, HK2 interacts with and stabilized Twist1 by preventing its ubiquitin-mediated degradation, which is related to oxaliplatin resistance, in CRC cells.	Oxaliplatin	128-139	twist family bHLH transcription factor 1	Homo sapiens	51-57
34378321-0	2021	Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancer.	Oxaliplatin	52-63	hexokinase 2	Homo sapiens	10-22
34251499-11	2021	Knock-down of lncRNA H19 significantly promoted the anti-viability efficiency of oxaliplatin (the main chemotherapy drug used in TACE) to HCC cells.	Oxaliplatin	81-92	H19 imprinted maternally expressed transcript	Homo sapiens	21-24
34378321-12	2021	Collectively, we discovered that HK2 is a crucial regulator that mediates oxaliplatin resistance through Twist1.	Oxaliplatin	74-85	hexokinase 2	Homo sapiens	33-36
34378321-0	2021	Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancer.	Oxaliplatin	52-63	twist family bHLH transcription factor 1	Homo sapiens	67-73
34378321-12	2021	Collectively, we discovered that HK2 is a crucial regulator that mediates oxaliplatin resistance through Twist1.	Oxaliplatin	74-85	twist family bHLH transcription factor 1	Homo sapiens	105-111
34378321-9	2021	Additionally, transcriptional and enzymatic inhibition of HK2 by 3-bromopyruvate (3-bp) impaired oxaliplatin resistance in vitro and in vivo.	Oxaliplatin	97-108	hexokinase 2	Homo sapiens	58-61
34475782-12	2021	THBS1 overexpression was negatively correlated with some drug sensitivities, such as Oxaliplatin.	Oxaliplatin	85-96	thrombospondin 1	Homo sapiens	0-5
34378321-10	2021	Mechanistically, HK2 interacts with and stabilized Twist1 by preventing its ubiquitin-mediated degradation, which is related to oxaliplatin resistance, in CRC cells.	Oxaliplatin	128-139	hexokinase 2	Homo sapiens	17-20
34862868-10	2021	There was insignificant difference (P>0.05) in Bax expression of tumor tissue of control group, curcumin group and oxaliplatin group while in curcumin plus oxaliplatin group, it was significantly increased.	Oxaliplatin	115-126	BCL2 associated X, apoptosis regulator	Homo sapiens	47-50
34862868-10	2021	There was insignificant difference (P>0.05) in Bax expression of tumor tissue of control group, curcumin group and oxaliplatin group while in curcumin plus oxaliplatin group, it was significantly increased.	Oxaliplatin	156-167	BCL2 associated X, apoptosis regulator	Homo sapiens	47-50
34862868-11	2021	The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously.	Oxaliplatin	27-38	BCL2 apoptosis regulator	Homo sapiens	18-23
34862868-11	2021	The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously.	Oxaliplatin	27-38	BCL2 apoptosis regulator	Homo sapiens	86-91
34862868-11	2021	The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously.	Oxaliplatin	27-38	BCL2 associated X, apoptosis regulator	Homo sapiens	92-95
34862868-11	2021	The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously.	Oxaliplatin	113-124	BCL2 apoptosis regulator	Homo sapiens	18-23
34862868-11	2021	The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously.	Oxaliplatin	113-124	BCL2 apoptosis regulator	Homo sapiens	86-91
34862868-11	2021	The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously.	Oxaliplatin	113-124	BCL2 associated X, apoptosis regulator	Homo sapiens	92-95
34448466-0	2021	5-HT1A receptors mediate the analgesic effect of rosavin in a mouse model of oxaliplatin-induced peripheral neuropathic pain.	Oxaliplatin	77-88	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-6
34278473-10	2021	In addition, the knockdown of MAD2L2 caused by siMAD2L2 or oxaliplatin treatment increased the expression levels of the pro-apoptotic proteins Bax and Bak and decreased the expression levels of the anti-apoptotic protein Bcl-2, compared with the negative control group.	Oxaliplatin	59-70	mitotic arrest deficient 2 like 2	Homo sapiens	30-36
34278473-10	2021	In addition, the knockdown of MAD2L2 caused by siMAD2L2 or oxaliplatin treatment increased the expression levels of the pro-apoptotic proteins Bax and Bak and decreased the expression levels of the anti-apoptotic protein Bcl-2, compared with the negative control group.	Oxaliplatin	59-70	BCL2 associated X, apoptosis regulator	Homo sapiens	143-146
34278473-10	2021	In addition, the knockdown of MAD2L2 caused by siMAD2L2 or oxaliplatin treatment increased the expression levels of the pro-apoptotic proteins Bax and Bak and decreased the expression levels of the anti-apoptotic protein Bcl-2, compared with the negative control group.	Oxaliplatin	59-70	BCL2 antagonist/killer 1	Homo sapiens	151-154
34278473-10	2021	In addition, the knockdown of MAD2L2 caused by siMAD2L2 or oxaliplatin treatment increased the expression levels of the pro-apoptotic proteins Bax and Bak and decreased the expression levels of the anti-apoptotic protein Bcl-2, compared with the negative control group.	Oxaliplatin	59-70	BCL2 apoptosis regulator	Homo sapiens	221-226
34497808-0	2021	PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway.	Oxaliplatin	65-76	poly(ADP-ribose) polymerase 1	Homo sapiens	0-5
34703544-0	2021	Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo.	Oxaliplatin	24-35	albumin	Homo sapiens	0-7
34703544-5	2021	With the aim to exploit the enhanced albumin consumption and accumulation in the malignant tissue, we have recently developed a new albumin-targeted prodrug, which supposed to release oxaliplatin in a highly tumor-specific manner.	Oxaliplatin	184-195	albumin	Homo sapiens	37-44
34703544-5	2021	With the aim to exploit the enhanced albumin consumption and accumulation in the malignant tissue, we have recently developed a new albumin-targeted prodrug, which supposed to release oxaliplatin in a highly tumor-specific manner.	Oxaliplatin	184-195	albumin	Homo sapiens	132-139
34703544-9	2021	The albumin-bound drug is accumulating in the malignant tissue, where it enters the cancer cells via clathrin- and caveolin-dependent endocytosis, and is activated by reduction to release oxaliplatin.	Oxaliplatin	188-199	albumin	Homo sapiens	4-11
34703544-11	2021	Summarizing, albumin-binding of platinum(iv) complexes potently enhances the efficacy of oxaliplatin therapy and should be further developed towards clinical phase I trials.	Oxaliplatin	89-100	albumin	Homo sapiens	13-20
34497808-4	2021	Using sequence analysis of OXA-resistant and non-OXA-resistant organoids, we found that PARP1 is an important gene that mediates OXA resistance.	Oxaliplatin	27-30	poly(ADP-ribose) polymerase 1	Homo sapiens	88-93
34497808-4	2021	Using sequence analysis of OXA-resistant and non-OXA-resistant organoids, we found that PARP1 is an important gene that mediates OXA resistance.	Oxaliplatin	49-52	poly(ADP-ribose) polymerase 1	Homo sapiens	88-93
34539880-0	2021	Inositol hexaphosphate sensitizes hepatocellular carcinoma to oxaliplatin relating inhibition of CCN2-LRP6-beta-catenin-ABCG1 signaling pathway.	Oxaliplatin	62-73	cellular communication network factor 2	Homo sapiens	97-101
34539880-0	2021	Inositol hexaphosphate sensitizes hepatocellular carcinoma to oxaliplatin relating inhibition of CCN2-LRP6-beta-catenin-ABCG1 signaling pathway.	Oxaliplatin	62-73	LDL receptor related protein 6	Homo sapiens	102-106
34539880-0	2021	Inositol hexaphosphate sensitizes hepatocellular carcinoma to oxaliplatin relating inhibition of CCN2-LRP6-beta-catenin-ABCG1 signaling pathway.	Oxaliplatin	62-73	catenin beta 1	Homo sapiens	107-119
34539880-0	2021	Inositol hexaphosphate sensitizes hepatocellular carcinoma to oxaliplatin relating inhibition of CCN2-LRP6-beta-catenin-ABCG1 signaling pathway.	Oxaliplatin	62-73	ATP binding cassette subfamily G member 1	Homo sapiens	120-125
34539880-9	2021	Specifically, up-regulation of ABCG1 and CCN2 were associated with oxaliplatin resistance.	Oxaliplatin	67-78	ATP binding cassette subfamily G member 1	Homo sapiens	31-36
34539880-9	2021	Specifically, up-regulation of ABCG1 and CCN2 were associated with oxaliplatin resistance.	Oxaliplatin	67-78	cellular communication network factor 2	Homo sapiens	41-45
34539880-12	2021	When combined with ABCG1 knocking down in HCC cells, the anti-proliferative effect of oxaliplatin was partly impaired in combination with IP6.	Oxaliplatin	86-97	ATP binding cassette subfamily G member 1	Homo sapiens	19-24
34539880-13	2021	We suggested that IP6 treatment renders HCC sensitive to oxaliplatin and breaking the CCN2-LRP6-beta-catenin-ABCG1 signaling pathway is one of the mechanism after IP6 treatment.	Oxaliplatin	57-68	cellular communication network factor 2	Homo sapiens	86-90
34539880-13	2021	We suggested that IP6 treatment renders HCC sensitive to oxaliplatin and breaking the CCN2-LRP6-beta-catenin-ABCG1 signaling pathway is one of the mechanism after IP6 treatment.	Oxaliplatin	57-68	LDL receptor related protein 6	Homo sapiens	91-95
34539880-13	2021	We suggested that IP6 treatment renders HCC sensitive to oxaliplatin and breaking the CCN2-LRP6-beta-catenin-ABCG1 signaling pathway is one of the mechanism after IP6 treatment.	Oxaliplatin	57-68	catenin beta 1	Homo sapiens	96-108
34539880-13	2021	We suggested that IP6 treatment renders HCC sensitive to oxaliplatin and breaking the CCN2-LRP6-beta-catenin-ABCG1 signaling pathway is one of the mechanism after IP6 treatment.	Oxaliplatin	57-68	ATP binding cassette subfamily G member 1	Homo sapiens	109-114
34497808-4	2021	Using sequence analysis of OXA-resistant and non-OXA-resistant organoids, we found that PARP1 is an important gene that mediates OXA resistance.	Oxaliplatin	129-132	poly(ADP-ribose) polymerase 1	Homo sapiens	88-93
34497808-5	2021	Through the patients" follow-up data, it was observed that the expression level of PARP1 was significantly correlated with OXA resistance.	Oxaliplatin	123-126	poly(ADP-ribose) polymerase 1	Homo sapiens	83-88
34497808-6	2021	This was confirmed by genetic manipulation of PARP1 expression in OXA-resistant organoids used in subcutaneous tumor formation.	Oxaliplatin	66-69	poly(ADP-ribose) polymerase 1	Homo sapiens	46-51
34497808-7	2021	Results further showed that PARP1 mediated OXA resistance by inhibiting the base excision repair pathway.	Oxaliplatin	43-46	poly(ADP-ribose) polymerase 1	Homo sapiens	28-33
34412631-6	2021	RESULTS: We revealed that shBCL10 transfection caused cytoplasmic translocation of BCL10 from the nuclei, inhibited cell viability, and enhanced the cytotoxicities of gemcitabine and oxaliplatin in three PDAC cell lines.	Oxaliplatin	183-194	BCL10 immune signaling adaptor	Homo sapiens	83-88
34497808-8	2021	OXA also inhibited homologous recombination by CDK1 activity and importantly made cancers with normal BRCA1 function sensitive to PARP inhibition.	Oxaliplatin	0-3	cyclin dependent kinase 1	Homo sapiens	47-51
34497808-8	2021	OXA also inhibited homologous recombination by CDK1 activity and importantly made cancers with normal BRCA1 function sensitive to PARP inhibition.	Oxaliplatin	0-3	BRCA1 DNA repair associated	Homo sapiens	102-107
34497808-8	2021	OXA also inhibited homologous recombination by CDK1 activity and importantly made cancers with normal BRCA1 function sensitive to PARP inhibition.	Oxaliplatin	0-3	poly(ADP-ribose) polymerase 1	Homo sapiens	130-134
34497808-9	2021	As a result, combination of OXA and Olaparib (PARP-1/2/3 inhibitor), inhibited in vivo and in vitro OXA resistant organoid growth and viability.	Oxaliplatin	28-31	poly(ADP-ribose) polymerase 1	Homo sapiens	46-56
34497808-9	2021	As a result, combination of OXA and Olaparib (PARP-1/2/3 inhibitor), inhibited in vivo and in vitro OXA resistant organoid growth and viability.	Oxaliplatin	100-103	poly(ADP-ribose) polymerase 1	Homo sapiens	46-56
34445514-6	2021	Real-time polymerase chain reaction (PCR) analysis demonstrated that the upregulation of mRNA of spinal transient receptor potential vanilloid 1 (TRPV1) and astrocytes following oxaliplatin injection was downregulated after JI017 treatment.	Oxaliplatin	178-189	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	104-144
34412665-0	2021	Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.	Oxaliplatin	26-37	thioredoxin reductase 1	Mus musculus	107-112
34412665-11	2021	RESULTS: We found that BBSKE significantly enhanced oxaliplatin-induced growth inhibition in gastric cancer cells by inhibiting TrxR1 activity.	Oxaliplatin	52-63	thioredoxin reductase 1	Homo sapiens	128-133
34412665-12	2021	Because of the inhibition of TrxR1 activity, BBSKE synergized with oxaliplatin to enhance the production of ROS and activate p38 and JNK signaling pathways which eventually induced apoptosis of gastric cancer cells.	Oxaliplatin	67-78	thioredoxin reductase 1	Homo sapiens	29-34
34412665-12	2021	Because of the inhibition of TrxR1 activity, BBSKE synergized with oxaliplatin to enhance the production of ROS and activate p38 and JNK signaling pathways which eventually induced apoptosis of gastric cancer cells.	Oxaliplatin	67-78	mitogen-activated protein kinase 14	Mus musculus	125-128
34412665-12	2021	Because of the inhibition of TrxR1 activity, BBSKE synergized with oxaliplatin to enhance the production of ROS and activate p38 and JNK signaling pathways which eventually induced apoptosis of gastric cancer cells.	Oxaliplatin	67-78	mitogen-activated protein kinase 8	Mus musculus	133-136
34412665-13	2021	In vivo, we also found that BBSKE synergized with oxaliplatin to suppress the gastric cancer tumor growth in xenograft nude mice model, accompanied by the reduced TrxR1 activity.	Oxaliplatin	50-61	thioredoxin reductase 1	Mus musculus	163-168
34412665-15	2021	We also used three cases of GC-PDO and found that the combined treatment of BBSKE and oxaliplatin dramatically inhibited the growth and viability of GC-PDO with increased ROS level, decreased TrxR1 activity and enhanced apoptosis.	Oxaliplatin	86-97	thioredoxin reductase 1	Mus musculus	192-197
34445514-6	2021	Real-time polymerase chain reaction (PCR) analysis demonstrated that the upregulation of mRNA of spinal transient receptor potential vanilloid 1 (TRPV1) and astrocytes following oxaliplatin injection was downregulated after JI017 treatment.	Oxaliplatin	178-189	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	146-151
34445514-7	2021	Moreover, TRPV1 expression and the activation of astrocytes were intensely increased in the superficial area of the spinal dorsal horn after oxaliplatin treatment, whereas JI017 suppressed both.	Oxaliplatin	141-152	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	10-15
34445514-9	2021	), 10 mug) attenuated the activation of astrocytes in the dorsal horn, demonstrating that the functions of spinal TRPV1 and astrocytes are closely related in oxaliplatin-induced neuropathic pain.	Oxaliplatin	158-169	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	114-119
34342264-7	2021	Increased DR4/lipid raft colocalization in CTCs was found to correspond with increased oxaliplatin resistance and increased efficacy of TRAIL liposomes.	Oxaliplatin	87-98	TNF receptor superfamily member 10a	Homo sapiens	10-13
34281797-10	2021	Compared to the Control group, the L-OHP group exhibited significantly lower responses to ACh and eNOS protein levels and significantly higher inflammatory biomarker levels.	Oxaliplatin	35-40	nitric oxide synthase 3	Rattus norvegicus	98-102
34286514-0	2021	LncRNA PCGEM1 mediates oxaliplatin resistance in hepatocellular carcinoma via miR-129-5p/ETV1 axis in vitro.	Oxaliplatin	23-34	PCGEM1 prostate-specific transcript	Homo sapiens	7-13
34286514-0	2021	LncRNA PCGEM1 mediates oxaliplatin resistance in hepatocellular carcinoma via miR-129-5p/ETV1 axis in vitro.	Oxaliplatin	23-34	ETS variant transcription factor 1	Homo sapiens	89-93
34286514-3	2021	OBJECTIVES: Our research aimed to explore the function and molecular mechanism of lncRNA PCGEM1 on oxaliplatin resistance of HCC in vitro.	Oxaliplatin	99-110	PCGEM1 prostate-specific transcript	Homo sapiens	89-95
34286514-4	2021	MATERIAL AND METHODS: Expression of the lncRNA PCGEM1, together with miR-129-5p, and the mRNA level of ETV1 and drug resistance-related genes including LRPA, MDR1 and MDR3 were determined using quantitative real-time polymerase chain reaction (RT-qPCR) in an oxaliplatin-resistant HCC cell line (Hep3B/OXA).	Oxaliplatin	259-270	PCGEM1 prostate-specific transcript	Homo sapiens	47-53
34286514-4	2021	MATERIAL AND METHODS: Expression of the lncRNA PCGEM1, together with miR-129-5p, and the mRNA level of ETV1 and drug resistance-related genes including LRPA, MDR1 and MDR3 were determined using quantitative real-time polymerase chain reaction (RT-qPCR) in an oxaliplatin-resistant HCC cell line (Hep3B/OXA).	Oxaliplatin	259-270	microRNA 1295a	Homo sapiens	69-79
34286514-4	2021	MATERIAL AND METHODS: Expression of the lncRNA PCGEM1, together with miR-129-5p, and the mRNA level of ETV1 and drug resistance-related genes including LRPA, MDR1 and MDR3 were determined using quantitative real-time polymerase chain reaction (RT-qPCR) in an oxaliplatin-resistant HCC cell line (Hep3B/OXA).	Oxaliplatin	259-270	ETS variant transcription factor 1	Homo sapiens	103-107
34286514-4	2021	MATERIAL AND METHODS: Expression of the lncRNA PCGEM1, together with miR-129-5p, and the mRNA level of ETV1 and drug resistance-related genes including LRPA, MDR1 and MDR3 were determined using quantitative real-time polymerase chain reaction (RT-qPCR) in an oxaliplatin-resistant HCC cell line (Hep3B/OXA).	Oxaliplatin	259-270	ATP binding cassette subfamily B member 1	Homo sapiens	158-162
34286514-4	2021	MATERIAL AND METHODS: Expression of the lncRNA PCGEM1, together with miR-129-5p, and the mRNA level of ETV1 and drug resistance-related genes including LRPA, MDR1 and MDR3 were determined using quantitative real-time polymerase chain reaction (RT-qPCR) in an oxaliplatin-resistant HCC cell line (Hep3B/OXA).	Oxaliplatin	259-270	ATP binding cassette subfamily B member 4	Homo sapiens	167-171
34286514-10	2021	CONCLUSIONS: Our findings demonstrated that PCGEM1 modulated oxaliplatin resistance by targeting the miR-129-5p/ETV1 pathway in HCC in vitro, suggesting a potential strategy for the treatment of chemoresistant HCC.	Oxaliplatin	61-72	PCGEM1 prostate-specific transcript	Homo sapiens	44-50
34286514-10	2021	CONCLUSIONS: Our findings demonstrated that PCGEM1 modulated oxaliplatin resistance by targeting the miR-129-5p/ETV1 pathway in HCC in vitro, suggesting a potential strategy for the treatment of chemoresistant HCC.	Oxaliplatin	61-72	microRNA 1295a	Homo sapiens	101-111
34342264-0	2021	Oxaliplatin resistance in colorectal cancer enhances TRAIL sensitivity via death receptor 4 upregulation and lipid raft localization.	Oxaliplatin	0-11	TNF superfamily member 10	Homo sapiens	53-58
34342264-0	2021	Oxaliplatin resistance in colorectal cancer enhances TRAIL sensitivity via death receptor 4 upregulation and lipid raft localization.	Oxaliplatin	0-11	TNF receptor superfamily member 10a	Homo sapiens	75-91
34342264-2	2021	We demonstrate that oxaliplatin-resistant CRC cells are sensitized to TRAIL-mediated apoptosis.	Oxaliplatin	20-31	TNF superfamily member 10	Homo sapiens	70-75
34342264-3	2021	Oxaliplatin-resistant cells exhibited transcriptional downregulation of caspase-10, but this had minimal effects on TRAIL sensitivity following CRISPR-Cas9 deletion of caspase-10 in parental cells.	Oxaliplatin	0-11	caspase 10	Homo sapiens	72-82
34342264-4	2021	Sensitization effects in oxaliplatin-resistant cells were found to be a result of increased DR4, as well as significantly enhanced DR4 palmitoylation and translocation into lipid rafts.	Oxaliplatin	25-36	TNF receptor superfamily member 10a	Homo sapiens	92-95
34342264-4	2021	Sensitization effects in oxaliplatin-resistant cells were found to be a result of increased DR4, as well as significantly enhanced DR4 palmitoylation and translocation into lipid rafts.	Oxaliplatin	25-36	TNF receptor superfamily member 10a	Homo sapiens	131-134
34357103-8	2021	We found that VX-11e, CZC24832, LY2109761, oxaliplatin and erlotinib were effective in inhibiting breast cancer cell lines with high WHSC1L1 expression.	Oxaliplatin	43-54	nuclear receptor binding SET domain protein 3	Homo sapiens	133-140
34314378-0	2021	Correction for: Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin.	Oxaliplatin	146-157	kinesin family member 20A	Homo sapiens	32-38
34314378-0	2021	Correction for: Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin.	Oxaliplatin	146-157	NUAK family kinase 1	Homo sapiens	39-44
34314378-0	2021	Correction for: Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin.	Oxaliplatin	146-157	NFE2 like bZIP transcription factor 2	Homo sapiens	45-49
34314378-0	2021	Correction for: Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin.	Oxaliplatin	146-157	glutathione peroxidase 4	Homo sapiens	50-54
34223709-11	2021	Moreover, miR-383-5p was a direct target of HULC and miR-383-5p reversed the effects of HULC on the progression of HCC cells and chemosensitivity of Oxa.	Oxaliplatin	149-152	microRNA 383	Mus musculus	10-17
34223709-11	2021	Moreover, miR-383-5p was a direct target of HULC and miR-383-5p reversed the effects of HULC on the progression of HCC cells and chemosensitivity of Oxa.	Oxaliplatin	149-152	microRNA 383	Mus musculus	53-60
34224332-0	2021	LncRNA CYTOR drives L-OHP resistance and facilitates the epithelial-mesenchymal transition of colon carcinoma cells via modulating miR-378a-5p/SERPINE1.	Oxaliplatin	20-25	microRNA 378a	Homo sapiens	131-139
34484640-0	2021	The Impact of Nrf2 Silencing on Nrf2-PD-L1 Axis to Overcome Oxaliplatin Resistance and Migration in Colon Cancer Cells.	Oxaliplatin	60-71	NFE2 like bZIP transcription factor 2	Homo sapiens	14-18
34484640-0	2021	The Impact of Nrf2 Silencing on Nrf2-PD-L1 Axis to Overcome Oxaliplatin Resistance and Migration in Colon Cancer Cells.	Oxaliplatin	60-71	NFE2 like bZIP transcription factor 2	Homo sapiens	32-36
34484640-0	2021	The Impact of Nrf2 Silencing on Nrf2-PD-L1 Axis to Overcome Oxaliplatin Resistance and Migration in Colon Cancer Cells.	Oxaliplatin	60-71	CD274 molecule	Homo sapiens	37-42
34484640-4	2021	This study aimed to investigate the potential role of the Nrf2-PD-L1 axis in the promotion of oxaliplatin resistance in colon cancer cells.	Oxaliplatin	94-105	NFE2 like bZIP transcription factor 2	Homo sapiens	58-62
34484640-4	2021	This study aimed to investigate the potential role of the Nrf2-PD-L1 axis in the promotion of oxaliplatin resistance in colon cancer cells.	Oxaliplatin	94-105	CD274 molecule	Homo sapiens	63-68
34484640-6	2021	After that role of the Nrf2-PD-L1 axis in promotion of Oxaliplatin resistance was investigated.	Oxaliplatin	55-66	CD274 molecule	Homo sapiens	28-33
34484640-10	2021	The inhibition of Nrf2 through siRNA treatment in SW480/Res and LS174T/Res cells has decreased the IC50 values of oxaliplatin.	Oxaliplatin	114-125	NFE2 like bZIP transcription factor 2	Homo sapiens	18-22
34484640-11	2021	Inhibition of the Nrf2 has significantly increased the oxaliplatin-induced apoptosis, and reduced the migration in SW480/Res cells.	Oxaliplatin	55-66	NFE2 like bZIP transcription factor 2	Homo sapiens	18-22
34484640-12	2021	Conclusion: It is suggested that effective inhibition of Nrf2-PD-L1 signaling pathways can be considered as a novel approach to improve oxaliplatin efficacy in colon cancer patients.	Oxaliplatin	136-147	NFE2 like bZIP transcription factor 2	Homo sapiens	57-61
34224332-0	2021	LncRNA CYTOR drives L-OHP resistance and facilitates the epithelial-mesenchymal transition of colon carcinoma cells via modulating miR-378a-5p/SERPINE1.	Oxaliplatin	20-25	serpin family E member 1	Homo sapiens	143-151
34484640-12	2021	Conclusion: It is suggested that effective inhibition of Nrf2-PD-L1 signaling pathways can be considered as a novel approach to improve oxaliplatin efficacy in colon cancer patients.	Oxaliplatin	136-147	CD274 molecule	Homo sapiens	62-67
34224332-4	2021	Silencing lncRNA CYTOR in vitro facilitated L-OHP sensitivity of colon carcinoma cells and restrained epithelial-mesenchymal transition (EMT).	Oxaliplatin	44-49	cytoskeleton regulator RNA	Homo sapiens	17-22
34224332-5	2021	Furthermore, lncRNA CYTOR could inhibit miR-378a-5p expression, while suppressing miR-378a-5p could attenuate the inhibition of lncRNA CYTOR silencing on L-OHP resistance and EMT.	Oxaliplatin	154-159	cytoskeleton regulator RNA	Homo sapiens	20-25
34224332-5	2021	Furthermore, lncRNA CYTOR could inhibit miR-378a-5p expression, while suppressing miR-378a-5p could attenuate the inhibition of lncRNA CYTOR silencing on L-OHP resistance and EMT.	Oxaliplatin	154-159	microRNA 378a	Homo sapiens	82-90
34224332-5	2021	Furthermore, lncRNA CYTOR could inhibit miR-378a-5p expression, while suppressing miR-378a-5p could attenuate the inhibition of lncRNA CYTOR silencing on L-OHP resistance and EMT.	Oxaliplatin	154-159	cytoskeleton regulator RNA	Homo sapiens	135-140
34224332-7	2021	Rescue assay indicated that overexpressing miR-378a-5p or silencing SERPINE1 expression counteracted the promotion of lncRNA CYTOR overexpression on L-OHP resistance and EMT of colon carcinoma cells.	Oxaliplatin	149-154	microRNA 378a	Homo sapiens	43-51
34224332-7	2021	Rescue assay indicated that overexpressing miR-378a-5p or silencing SERPINE1 expression counteracted the promotion of lncRNA CYTOR overexpression on L-OHP resistance and EMT of colon carcinoma cells.	Oxaliplatin	149-154	serpin family E member 1	Homo sapiens	68-76
34224332-7	2021	Rescue assay indicated that overexpressing miR-378a-5p or silencing SERPINE1 expression counteracted the promotion of lncRNA CYTOR overexpression on L-OHP resistance and EMT of colon carcinoma cells.	Oxaliplatin	149-154	cytoskeleton regulator RNA	Homo sapiens	125-130
34224332-9	2021	These results testified that lncRNA CYTOR enhanced L-OHP drug resistance and induced EMT in colon carcinoma.	Oxaliplatin	51-56	cytoskeleton regulator RNA	Homo sapiens	36-41
34224332-10	2021	It was also suggested that lncRNA CYTOR/miR-378a-5p/SERPINE1 axis was a regulatory pathway of L-OHP resistance in colon carcinoma.	Oxaliplatin	94-99	cytoskeleton regulator RNA	Homo sapiens	34-39
34224332-10	2021	It was also suggested that lncRNA CYTOR/miR-378a-5p/SERPINE1 axis was a regulatory pathway of L-OHP resistance in colon carcinoma.	Oxaliplatin	94-99	microRNA 378a	Homo sapiens	40-48
34224332-10	2021	It was also suggested that lncRNA CYTOR/miR-378a-5p/SERPINE1 axis was a regulatory pathway of L-OHP resistance in colon carcinoma.	Oxaliplatin	94-99	serpin family E member 1	Homo sapiens	52-60
34140641-0	2021	The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer.	Oxaliplatin	66-77	heat shock transcription factor 1	Homo sapiens	4-8
34145059-6	2021	Additionally, both MYD88- and TRIF-mediated TLR signaling inhibited stress granule assembly in response to endoplasmic reticulum stress in bone marrow-derived macrophages and the chemotherapeutic drug oxaliplatin in murine B16 melanoma cells.	Oxaliplatin	201-212	myeloid differentiation primary response gene 88	Mus musculus	19-24
34145059-6	2021	Additionally, both MYD88- and TRIF-mediated TLR signaling inhibited stress granule assembly in response to endoplasmic reticulum stress in bone marrow-derived macrophages and the chemotherapeutic drug oxaliplatin in murine B16 melanoma cells.	Oxaliplatin	201-212	toll-like receptor adaptor molecule 2	Mus musculus	30-34
34330763-10	2021	Combination therapy using statin and oxaliplatin, an ICD inducer, significantly enhanced the immunogenicity of KRAS mut tumors and promoted tumor-specific immunity in syngeneic and genetically engineered KRAS mut tumor models.	Oxaliplatin	37-48	KRAS proto-oncogene, GTPase	Homo sapiens	111-115
34330763-10	2021	Combination therapy using statin and oxaliplatin, an ICD inducer, significantly enhanced the immunogenicity of KRAS mut tumors and promoted tumor-specific immunity in syngeneic and genetically engineered KRAS mut tumor models.	Oxaliplatin	37-48	KRAS proto-oncogene, GTPase	Homo sapiens	204-208
34140641-0	2021	The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer.	Oxaliplatin	66-77	mitochondrial E3 ubiquitin protein ligase 1	Homo sapiens	101-105
34140641-0	2021	The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer.	Oxaliplatin	66-77	unc-51 like autophagy activating kinase 1	Homo sapiens	106-110
34140641-12	2021	These results indicated that miR-135b-5p upregulation in colorectal cancer could induce protective autophagy through the MUL1/ULK1 signaling pathway and promote oxaliplatin resistance.	Oxaliplatin	161-172	microRNA 135b	Homo sapiens	29-37
34252480-3	2021	Our results revealed that organic cation transporter 2 (OCT2), organic cation/carnitine transporter 1 (OCTN1) and organic cation/carnitine transporter 2 (OCTN2) were involved in the uptake of OXA in dorsal root ganglion (DRG) neurons and mitochondria, respectively.	Oxaliplatin	192-195	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	56-60
34252480-3	2021	Our results revealed that organic cation transporter 2 (OCT2), organic cation/carnitine transporter 1 (OCTN1) and organic cation/carnitine transporter 2 (OCTN2) were involved in the uptake of OXA in dorsal root ganglion (DRG) neurons and mitochondria, respectively.	Oxaliplatin	192-195	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	26-54
34252480-3	2021	Our results revealed that organic cation transporter 2 (OCT2), organic cation/carnitine transporter 1 (OCTN1) and organic cation/carnitine transporter 2 (OCTN2) were involved in the uptake of OXA in dorsal root ganglion (DRG) neurons and mitochondria, respectively.	Oxaliplatin	192-195	solute carrier family 22 (organic cation transporter), member 4	Mus musculus	63-101
34252480-3	2021	Our results revealed that organic cation transporter 2 (OCT2), organic cation/carnitine transporter 1 (OCTN1) and organic cation/carnitine transporter 2 (OCTN2) were involved in the uptake of OXA in dorsal root ganglion (DRG) neurons and mitochondria, respectively.	Oxaliplatin	192-195	solute carrier family 22 (organic cation transporter), member 4	Mus musculus	103-108
34252480-3	2021	Our results revealed that organic cation transporter 2 (OCT2), organic cation/carnitine transporter 1 (OCTN1) and organic cation/carnitine transporter 2 (OCTN2) were involved in the uptake of OXA in dorsal root ganglion (DRG) neurons and mitochondria, respectively.	Oxaliplatin	192-195	solute carrier family 22 (organic cation transporter), member 5	Mus musculus	114-152
34252480-3	2021	Our results revealed that organic cation transporter 2 (OCT2), organic cation/carnitine transporter 1 (OCTN1) and organic cation/carnitine transporter 2 (OCTN2) were involved in the uptake of OXA in dorsal root ganglion (DRG) neurons and mitochondria, respectively.	Oxaliplatin	192-195	solute carrier family 22 (organic cation transporter), member 5	Mus musculus	154-159
34252480-4	2021	L-THP (1-100 muM) reduced OXA (40 muM) induced cytotoxicity in MDCK-hOCT2 (Madin-Darby canine kidney, MDCK), MDCK-hOCTN1, MDCK-hOCTN2, and rat primary DRG cells, and decreased the accumulation of OXA in above cells and rat DRG mitochondria, but did not affect its efflux from MDCK-hMRP2 cells.	Oxaliplatin	26-29	solute carrier family 22 member 2	Homo sapiens	68-73
34252480-7	2021	In conclusion, OCT2, OCTN1 and OCTN2 contribute to OXA uptake in the DRG and mitochondria.	Oxaliplatin	51-54	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	15-19
34252480-7	2021	In conclusion, OCT2, OCTN1 and OCTN2 contribute to OXA uptake in the DRG and mitochondria.	Oxaliplatin	51-54	solute carrier family 22 (organic cation transporter), member 4	Mus musculus	21-26
34252480-7	2021	In conclusion, OCT2, OCTN1 and OCTN2 contribute to OXA uptake in the DRG and mitochondria.	Oxaliplatin	51-54	solute carrier family 22 (organic cation transporter), member 5	Mus musculus	31-36
34193174-0	2021	SRPK1/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-kappaB activation in colon cancer.	Oxaliplatin	24-35	SRSF protein kinase 1	Homo sapiens	0-5
34193174-0	2021	SRPK1/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-kappaB activation in colon cancer.	Oxaliplatin	24-35	AKT serine/threonine kinase 1	Homo sapiens	6-9
34193174-0	2021	SRPK1/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-kappaB activation in colon cancer.	Oxaliplatin	24-35	nuclear factor kappa B subunit 1	Homo sapiens	63-72
34193174-14	2021	SRPK1 overexpression enhanced the anti-apoptosis ability of colon cancer cells, whereas SRPK1 silencing had the opposite effect under oxaliplatin treatment.	Oxaliplatin	134-145	SRSF protein kinase 1	Homo sapiens	88-93
34193174-15	2021	Mechanistically, SRPK1 enhances IKK kinase and IkappaB phosphorylation to promote NF-kappaB nuclear translocation to confer oxaliplatin resistance.	Oxaliplatin	124-135	SRSF protein kinase 1	Homo sapiens	17-22
34193174-15	2021	Mechanistically, SRPK1 enhances IKK kinase and IkappaB phosphorylation to promote NF-kappaB nuclear translocation to confer oxaliplatin resistance.	Oxaliplatin	124-135	nuclear factor kappa B subunit 1	Homo sapiens	82-91
34212047-11	2021	FXYD6 silence inhibited cell apoptosis and enhanced prosurvival autophagy, whereas FXYD6 overexpression produced the opposite effect which alleviated the drug resistance to irinotecan and oxaliplatin of CRC cells.	Oxaliplatin	188-199	FXYD domain containing ion transport regulator 6	Homo sapiens	83-88
34262942-12	2021	In addition, patients with high expression of TRPV4 might be resistant to the treatment of Cisplatin and Oxaliplatin.	Oxaliplatin	105-116	transient receptor potential cation channel subfamily V member 4	Homo sapiens	46-51
34262942-15	2021	Patients with high expression of TRPV4 might be resistant to the treatment of Cisplatin and Oxaliplatin.	Oxaliplatin	92-103	transient receptor potential cation channel subfamily V member 4	Homo sapiens	33-38
34149356-0	2021	Oxaliplatin Depolarizes the IB4- Dorsal Root Ganglion Neurons to Drive the Development of Neuropathic Pain Through TRPM8 in Mice.	Oxaliplatin	0-11	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	115-120
34149356-6	2021	These results suggest that oxaliplatin depolarizes IB4- neurons through TRPM8 channels to drive the development of neuropathic pain and targeting the initial drives of TRPM8 and/or membrane depolarization may prevent oxaliplatin-induce neuropathic pain.	Oxaliplatin	27-38	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	72-77
34149356-6	2021	These results suggest that oxaliplatin depolarizes IB4- neurons through TRPM8 channels to drive the development of neuropathic pain and targeting the initial drives of TRPM8 and/or membrane depolarization may prevent oxaliplatin-induce neuropathic pain.	Oxaliplatin	27-38	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	168-173
35584569-13	2022	BAP1 downregulation by siRNA inhibited apoptosis induced by the combined treatment of ODN and oxaliplatin/etoposide.	Oxaliplatin	94-105	BRCA1 associated protein 1	Homo sapiens	0-4
34075026-0	2021	miR-5000-3p confers oxaliplatin resistance by targeting ubiquitin-specific peptidase 49 in colorectal cancer.	Oxaliplatin	20-31	ubiquitin specific peptidase 49	Homo sapiens	56-87
34066977-5	2021	Here we show that the activity of the transient receptor potential melastatin 8 (TRPM8) channel but not the activity of any other member of the TRP channel family is transiently increased 1 h after oxaliplatin treatment and decreased 24 h after oxaliplatin treatment.	Oxaliplatin	198-209	transient receptor potential cation channel subfamily M member 8	Homo sapiens	38-79
34066977-5	2021	Here we show that the activity of the transient receptor potential melastatin 8 (TRPM8) channel but not the activity of any other member of the TRP channel family is transiently increased 1 h after oxaliplatin treatment and decreased 24 h after oxaliplatin treatment.	Oxaliplatin	198-209	transient receptor potential cation channel subfamily M member 8	Homo sapiens	81-86
34066977-5	2021	Here we show that the activity of the transient receptor potential melastatin 8 (TRPM8) channel but not the activity of any other member of the TRP channel family is transiently increased 1 h after oxaliplatin treatment and decreased 24 h after oxaliplatin treatment.	Oxaliplatin	245-256	transient receptor potential cation channel subfamily M member 8	Homo sapiens	38-79
34066977-5	2021	Here we show that the activity of the transient receptor potential melastatin 8 (TRPM8) channel but not the activity of any other member of the TRP channel family is transiently increased 1 h after oxaliplatin treatment and decreased 24 h after oxaliplatin treatment.	Oxaliplatin	245-256	transient receptor potential cation channel subfamily M member 8	Homo sapiens	81-86
34066977-7	2021	Inhibition of the PLC pathway can reverse the decreased TRPM8 activity as well as the decreased PIP2-concentrations after oxaliplatin treatment.	Oxaliplatin	122-133	transient receptor potential cation channel subfamily M member 8	Homo sapiens	56-61
34066977-8	2021	In summary, these results point out transient changes in TRPM8 activity early after oxaliplatin treatment and a later occurring TRPM8 channel desensitization in primary sensory neurons.	Oxaliplatin	84-95	transient receptor potential cation channel subfamily M member 8	Homo sapiens	57-62
34066977-9	2021	These mechanisms may explain the transient cold allodynia after oxaliplatin treatment and highlight an important role of TRPM8 in oxaliplatin-induced acute and neuropathic pain.	Oxaliplatin	130-141	transient receptor potential cation channel subfamily M member 8	Homo sapiens	121-126
34754473-9	2021	The increased risk of infantile allergic diseases associated with urinary 1-OHP during the early period of pregnancy was limited to the maternal GSTT1 null type (OR: 2.69; 95% CI: 1.17, 6.21, by one log-transformed unit of 1-OHP mug/g creatinine); however, the Relative Excess Risk due to Interaction was not statistically significant.	Oxaliplatin	74-79	glutathione S-transferase theta 1	Homo sapiens	145-150
34754473-9	2021	The increased risk of infantile allergic diseases associated with urinary 1-OHP during the early period of pregnancy was limited to the maternal GSTT1 null type (OR: 2.69; 95% CI: 1.17, 6.21, by one log-transformed unit of 1-OHP mug/g creatinine); however, the Relative Excess Risk due to Interaction was not statistically significant.	Oxaliplatin	223-228	glutathione S-transferase theta 1	Homo sapiens	145-150
34894846-0	2021	Endothelin receptor type A is involved in the development of oxaliplatin-induced mechanical allodynia and cold allodynia acting through spinal and peripheral mechanisms in rats.	Oxaliplatin	61-72	endothelin receptor type A	Rattus norvegicus	0-26
34159294-1	2021	Background: SCOT was an international, randomized phase 3 trial of 3 months vs 6 months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in patients with colorectal cancer.	Oxaliplatin	118-129	3-oxoacid CoA-transferase 1	Homo sapiens	12-16
35623085-0	2022	Duloxetine alleviates oxaliplatin-induced peripheral neuropathy by regulating p53-mediated apoptosis.	Oxaliplatin	22-33	transformation related protein 53, pseudogene	Mus musculus	78-81
35623085-5	2022	Moreover, to explore molecular mechanisms, effects of duloxetine on OXA-induced changes in mRNA and protein expression of components of the p53-related pathways in cultured rat dorsal root ganglion (DRG) neurons were measured.	Oxaliplatin	68-71	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	140-143
35527292-7	2022	Baicalein treatment neutralized the oxaliplatin-induced neuroinflammation, which was evident from the significant loss of inflammatory mediators like TNF-alpha, IL-6 and a shunted NF-kappaB nuclear translocation.	Oxaliplatin	36-47	tumor necrosis factor	Rattus norvegicus	150-159
35527292-7	2022	Baicalein treatment neutralized the oxaliplatin-induced neuroinflammation, which was evident from the significant loss of inflammatory mediators like TNF-alpha, IL-6 and a shunted NF-kappaB nuclear translocation.	Oxaliplatin	36-47	interleukin 6	Rattus norvegicus	161-165
34185411-12	2021	Although reduction of FOLRalpha brought about vulnerability for oxaliplatin by diminishing MDM2 expression, farletuzumab did not suppress the MDM2-mediated chemoresistance and cell proliferation in GC cells.	Oxaliplatin	64-75	MDM2 proto-oncogene	Homo sapiens	91-95
34124145-0	2021	The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer.	Oxaliplatin	30-41	SRY-box transcription factor 9	Homo sapiens	4-8
34124145-0	2021	The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer.	Oxaliplatin	30-41	MMS22 like, DNA repair protein	Homo sapiens	9-15
34124145-11	2021	Overexpression and knockdown of SOX9 were associated with the efficacy of oxaliplatin.	Oxaliplatin	74-85	SRY-box transcription factor 9	Homo sapiens	32-36
34124145-13	2021	SOX9 was upregulated and formed a complex with MMS22L, which promoted the nuclear translocation of MMS22L upon oxaliplatin treatment.	Oxaliplatin	111-122	SRY-box transcription factor 9	Homo sapiens	0-4
34124145-13	2021	SOX9 was upregulated and formed a complex with MMS22L, which promoted the nuclear translocation of MMS22L upon oxaliplatin treatment.	Oxaliplatin	111-122	MMS22 like, DNA repair protein	Homo sapiens	47-53
34124145-13	2021	SOX9 was upregulated and formed a complex with MMS22L, which promoted the nuclear translocation of MMS22L upon oxaliplatin treatment.	Oxaliplatin	111-122	MMS22 like, DNA repair protein	Homo sapiens	99-105
34124145-14	2021	Moreover, the xenograft assay results showed that oxaliplatin abrogated tumor growth from cells with MMS22L downregulation in mice.	Oxaliplatin	50-61	MMS22-like, DNA repair protein	Mus musculus	101-107
34124145-15	2021	Conclusions: In CRC, activation of the SOX9-MMS22L-dependent DNA damage pathway is a core pathway regulating oxaliplatin sensitivity.	Oxaliplatin	109-120	SRY (sex determining region Y)-box 9	Mus musculus	39-43
34124145-15	2021	Conclusions: In CRC, activation of the SOX9-MMS22L-dependent DNA damage pathway is a core pathway regulating oxaliplatin sensitivity.	Oxaliplatin	109-120	MMS22-like, DNA repair protein	Mus musculus	44-50
34066976-8	2021	IL1beta-stimulated-NCF-CM induces migration and differential sensitivity to oxaliplatin in colorectal tumor cells.	Oxaliplatin	76-87	interleukin 1 alpha	Homo sapiens	0-7
34066977-0	2021	Oxaliplatin Causes Transient Changes in TRPM8 Channel Activity.	Oxaliplatin	0-11	transient receptor potential cation channel subfamily M member 8	Homo sapiens	40-45
34667438-10	2021	The miR-224, miR-200a, and beta-catenin expression, when treated with PA alone or with oxaliplatin, was decreased markedly in comparison with the positive control group.	Oxaliplatin	87-98	microRNA 224	Rattus norvegicus	4-11
34667438-10	2021	The miR-224, miR-200a, and beta-catenin expression, when treated with PA alone or with oxaliplatin, was decreased markedly in comparison with the positive control group.	Oxaliplatin	87-98	microRNA 200a	Rattus norvegicus	13-21
34667438-10	2021	The miR-224, miR-200a, and beta-catenin expression, when treated with PA alone or with oxaliplatin, was decreased markedly in comparison with the positive control group.	Oxaliplatin	87-98	catenin beta 1	Rattus norvegicus	27-39
35584569-1	2022	Cathepsin K inhibitor (odanacatib; ODN) and cathepsin K knockdown (siRNA) enhance oxaliplatin-induced apoptosis through p53-dependent Bax upregulation.	Oxaliplatin	82-93	cathepsin K	Homo sapiens	0-11
35584569-1	2022	Cathepsin K inhibitor (odanacatib; ODN) and cathepsin K knockdown (siRNA) enhance oxaliplatin-induced apoptosis through p53-dependent Bax upregulation.	Oxaliplatin	82-93	cathepsin K	Homo sapiens	44-55
35584569-1	2022	Cathepsin K inhibitor (odanacatib; ODN) and cathepsin K knockdown (siRNA) enhance oxaliplatin-induced apoptosis through p53-dependent Bax upregulation.	Oxaliplatin	82-93	tumor protein p53	Homo sapiens	120-123
35584569-1	2022	Cathepsin K inhibitor (odanacatib; ODN) and cathepsin K knockdown (siRNA) enhance oxaliplatin-induced apoptosis through p53-dependent Bax upregulation.	Oxaliplatin	82-93	BCL2 associated X, apoptosis regulator	Homo sapiens	134-137
35367629-3	2022	The treatment of rat primary neurons with increasing dose of the neurotoxic anticancer drug oxaliplatin (0.3-100muM, 48 h) induced the release of IL-1alpha.	Oxaliplatin	92-103	interleukin 1 alpha	Rattus norvegicus	146-155
35367629-6	2022	In a rat model of neuropathy induced by oxaliplatin, the intrathecal treatment with IL-1alpha was able to reduce mechanical and thermal hypersensitivity both after acute injection and continuous infusion.	Oxaliplatin	40-51	interleukin 1 alpha	Rattus norvegicus	84-93
35367629-7	2022	Ex vivo analysis on spinal purified astrocyte processes (gliosomes) and nerve terminals (synaptosomes) revealed the property of IL-1alpha to reduce the endogenous glutamate release induced by oxaliplatin.	Oxaliplatin	192-203	interleukin 1 alpha	Rattus norvegicus	128-137
35367832-6	2022	Overexpression of VPS16 also mediated oxaliplatin (OX) resistance by promoting the maturation of autolysosomes in CRC.	Oxaliplatin	38-49	VPS16 core subunit of CORVET and HOPS complexes	Homo sapiens	18-23
35474580-0	2022	In vitro exosomal transfer of Nrf2 led to the oxaliplatin resistance in human colorectal cancer LS174T cells.	Oxaliplatin	46-57	NFE2 like bZIP transcription factor 2	Homo sapiens	30-34
35194192-9	2022	PMDO cultures were resistant to oxaliplatin and expressed high levels of glutamate-cysteine ligase (GCLC) causing detoxification of oxaliplatin through glutathione synthesis.	Oxaliplatin	132-143	glutamate-cysteine ligase catalytic subunit	Homo sapiens	100-104
35194192-10	2022	Genetic or pharmacological targeting of GCLC sensitised PMDOs to a 1-h exposure to oxaliplatin, through increased platinum-DNA adduct formation.	Oxaliplatin	83-94	glutamate-cysteine ligase catalytic subunit	Homo sapiens	40-44
35358872-0	2022	Improvement of resistance to oxaliplatin by vorinostat in human colorectal cancer cells through inhibition of Nrf2 nuclear translocation.	Oxaliplatin	29-40	NFE2 like bZIP transcription factor 2	Homo sapiens	110-114
35358872-8	2022	In HCT116/OxR cells transfected with Nrf2 siRNA, the improving effects on L-OHP resistance by SAHA were abolished, suggesting that Nrf2-Keap1 pathway was involved in L-OHP-resistance.	Oxaliplatin	74-79	NFE2 like bZIP transcription factor 2	Homo sapiens	37-41
35358872-8	2022	In HCT116/OxR cells transfected with Nrf2 siRNA, the improving effects on L-OHP resistance by SAHA were abolished, suggesting that Nrf2-Keap1 pathway was involved in L-OHP-resistance.	Oxaliplatin	74-79	NFE2 like bZIP transcription factor 2	Homo sapiens	131-135
35358872-8	2022	In HCT116/OxR cells transfected with Nrf2 siRNA, the improving effects on L-OHP resistance by SAHA were abolished, suggesting that Nrf2-Keap1 pathway was involved in L-OHP-resistance.	Oxaliplatin	74-79	kelch like ECH associated protein 1	Homo sapiens	136-141
35358872-8	2022	In HCT116/OxR cells transfected with Nrf2 siRNA, the improving effects on L-OHP resistance by SAHA were abolished, suggesting that Nrf2-Keap1 pathway was involved in L-OHP-resistance.	Oxaliplatin	166-171	NFE2 like bZIP transcription factor 2	Homo sapiens	37-41
35358872-8	2022	In HCT116/OxR cells transfected with Nrf2 siRNA, the improving effects on L-OHP resistance by SAHA were abolished, suggesting that Nrf2-Keap1 pathway was involved in L-OHP-resistance.	Oxaliplatin	166-171	NFE2 like bZIP transcription factor 2	Homo sapiens	131-135
35358872-8	2022	In HCT116/OxR cells transfected with Nrf2 siRNA, the improving effects on L-OHP resistance by SAHA were abolished, suggesting that Nrf2-Keap1 pathway was involved in L-OHP-resistance.	Oxaliplatin	166-171	kelch like ECH associated protein 1	Homo sapiens	136-141
35358872-9	2022	In addition, L-OHP metabolite significantly induced the expression of the nuclear protein Nrf2 and its target gene mRNA expression in HCT116/OxR cells.	Oxaliplatin	13-18	NFE2 like bZIP transcription factor 2	Homo sapiens	90-94
35358872-11	2022	In conclusion, this study demonstrated that SAHA improved L-OHP resistance by inhibiting Nrf2-Keap1 activation via Nrf2 nuclear translocation by L-OHP metabolite.	Oxaliplatin	58-63	NFE2 like bZIP transcription factor 2	Homo sapiens	89-93
35358872-11	2022	In conclusion, this study demonstrated that SAHA improved L-OHP resistance by inhibiting Nrf2-Keap1 activation via Nrf2 nuclear translocation by L-OHP metabolite.	Oxaliplatin	58-63	NFE2 like bZIP transcription factor 2	Homo sapiens	115-119
35358872-11	2022	In conclusion, this study demonstrated that SAHA improved L-OHP resistance by inhibiting Nrf2-Keap1 activation via Nrf2 nuclear translocation by L-OHP metabolite.	Oxaliplatin	145-150	NFE2 like bZIP transcription factor 2	Homo sapiens	89-93
35358872-11	2022	In conclusion, this study demonstrated that SAHA improved L-OHP resistance by inhibiting Nrf2-Keap1 activation via Nrf2 nuclear translocation by L-OHP metabolite.	Oxaliplatin	145-150	kelch like ECH associated protein 1	Homo sapiens	94-99
35358872-11	2022	In conclusion, this study demonstrated that SAHA improved L-OHP resistance by inhibiting Nrf2-Keap1 activation via Nrf2 nuclear translocation by L-OHP metabolite.	Oxaliplatin	145-150	NFE2 like bZIP transcription factor 2	Homo sapiens	115-119
35462329-10	2022	Furthermore, LINC00963 is associated with drug resistance in oral squamous cell carcinoma (cisplatin and 5-fluorouracil) and gastric cancer (oxaliplatin) and predicts neoadjuvant efficacy of taxane-anthracyclines in breast cancer.	Oxaliplatin	141-152	long intergenic non-protein coding RNA 963	Homo sapiens	13-22
35125319-5	2022	RESULTS: Between January 1, 2011 and December 1, 2020, 374 patients who had experienced an oxaliplatin-related HSR were treated via a 3-step graded infusion in the outpatient setting.	Oxaliplatin	91-102	HSR	Homo sapiens	111-114
35125319-15	2022	CONCLUSION: Our data indicate that the simplified 3-step graded infusion protocol is a safe outpatient strategy for patients with a history of HSR to oxaliplatin.	Oxaliplatin	150-161	HSR	Homo sapiens	143-146
35474580-4	2022	Herein, we aimed to evaluate the role of exosomal nuclear factor erythroid 2-related factor 2 (Nrf2) on oxaliplatin (1-OHP) resistance in human colorectal cancer LS174T cells in vitro.	Oxaliplatin	104-115	NFE2 like bZIP transcription factor 2	Homo sapiens	50-93
35474580-4	2022	Herein, we aimed to evaluate the role of exosomal nuclear factor erythroid 2-related factor 2 (Nrf2) on oxaliplatin (1-OHP) resistance in human colorectal cancer LS174T cells in vitro.	Oxaliplatin	104-115	NFE2 like bZIP transcription factor 2	Homo sapiens	95-99
35474580-4	2022	Herein, we aimed to evaluate the role of exosomal nuclear factor erythroid 2-related factor 2 (Nrf2) on oxaliplatin (1-OHP) resistance in human colorectal cancer LS174T cells in vitro.	Oxaliplatin	117-122	NFE2 like bZIP transcription factor 2	Homo sapiens	50-93
35474580-4	2022	Herein, we aimed to evaluate the role of exosomal nuclear factor erythroid 2-related factor 2 (Nrf2) on oxaliplatin (1-OHP) resistance in human colorectal cancer LS174T cells in vitro.	Oxaliplatin	117-122	NFE2 like bZIP transcription factor 2	Homo sapiens	95-99
35474580-5	2022	To this end, exosomal-Nrf2-mediated 1-OHP resistance was examined using different assays.	Oxaliplatin	36-41	NFE2 like bZIP transcription factor 2	Homo sapiens	22-26
35474580-15	2022	Taken together, Exo-mediated transfer of Nrf2 is involved in the development of oxaliplatin resistance in CC cells by upregulating P-gp.	Oxaliplatin	80-91	NFE2 like bZIP transcription factor 2	Homo sapiens	41-45
35474580-15	2022	Taken together, Exo-mediated transfer of Nrf2 is involved in the development of oxaliplatin resistance in CC cells by upregulating P-gp.	Oxaliplatin	80-91	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
35495610-0	2022	Oxaliplatin induces ferroptosis and oxidative stress in HT29 colorectal cancer cells by inhibiting the Nrf2 signaling pathway.	Oxaliplatin	0-11	NFE2 like bZIP transcription factor 2	Homo sapiens	103-107
35495610-10	2022	The results of the present study demonstrated that oxaliplatin inhibited viability and the Nrf2 signaling pathway in CRC cells.	Oxaliplatin	51-62	NFE2 like bZIP transcription factor 2	Homo sapiens	91-95
35495610-11	2022	In addition, oxaliplatin promoted ferroptosis and oxidative stress in CRC cells by inhibiting the Nrf2 signaling pathway.	Oxaliplatin	13-24	NFE2 like bZIP transcription factor 2	Homo sapiens	98-102
35495610-13	2022	In conclusion, oxaliplatin induced ferroptosis and oxidative stress in CRC cells by inhibiting the Nrf2 signaling pathway.	Oxaliplatin	15-26	NFE2 like bZIP transcription factor 2	Homo sapiens	99-103
35495610-5	2022	Western blotting was performed to detect the levels of certain nuclear factor erythroid 2-related factor 2 (Nrf2)-associated proteins in HT29 cells treated with oxaliplatin.	Oxaliplatin	161-172	NFE2 like bZIP transcription factor 2	Homo sapiens	63-106
35495610-5	2022	Western blotting was performed to detect the levels of certain nuclear factor erythroid 2-related factor 2 (Nrf2)-associated proteins in HT29 cells treated with oxaliplatin.	Oxaliplatin	161-172	NFE2 like bZIP transcription factor 2	Homo sapiens	108-112
35490372-9	2022	Moreover, 5-FU and OxaPt treatments significantly modulate protein levels of core-autophagy proteins ATG7 and ATG12.	Oxaliplatin	19-24	autophagy related 7	Homo sapiens	101-105
35490372-9	2022	Moreover, 5-FU and OxaPt treatments significantly modulate protein levels of core-autophagy proteins ATG7 and ATG12.	Oxaliplatin	19-24	autophagy related 12	Homo sapiens	110-115
35478417-10	2022	Lastly, in gastric cancer cells, OE-circ-MTO1 apparently decreased relative cell viabilities at oxaliplatin concentrations of 0.4, 0.8, 1.6, and 3.2 muM (all p < 0.05).	Oxaliplatin	96-107	mitochondrial tRNA translation optimization 1	Homo sapiens	41-45
35626154-0	2022	Blockade LAT1 Mediates Methionine Metabolism to Overcome Oxaliplatin Resistance under Hypoxia in Renal Cell Carcinoma.	Oxaliplatin	57-68	solute carrier family 7 member 5	Homo sapiens	9-13
35611548-3	2022	At the same concentration of OXT, the cytotoxicity of OXT or apoptosis was significantly reduced in SNU-C5/OXTR cells compared with that in SNU-C5 cells.	Oxaliplatin	29-32	oxytocin receptor	Homo sapiens	107-111
35611548-9	2022	These findings suggest that autophagy is significantly reduced in SNU-C5/OXTR cells compared with SNU-C5 cells, which may be related to the production of ROS in OXT-resistant cells.	Oxaliplatin	161-164	oxytocin receptor	Homo sapiens	73-77
35596723-0	2022	The HN1/HMGB1 axis promotes the proliferation and metastasis of hepatocellular carcinoma and attenuates the chemosensitivity to oxaliplatin.	Oxaliplatin	128-139	high mobility group box 1	Homo sapiens	8-13
35596723-8	2022	In the nucleus, downregulation of HMGB1 followed by HN1 knockdown resulted in increased DNA damage and cell death in the oxaliplatin-treated HCC cells.	Oxaliplatin	121-132	high mobility group box 1	Homo sapiens	34-39
35596723-10	2022	Furthermore, HN1 knockdown in combination with HMGB1 overexpression restored the aggressive phenotypes of HCC cells and sensitivity of these cells to oxaliplatin.	Oxaliplatin	150-161	high mobility group box 1	Homo sapiens	47-52
35629045-1	2022	This study aimed to explore the safety and efficacy of neoadjuvant SCRT and tegafur-uracil/leucovorin plus oxaliplatin (TEGAFOX) for LARC in comparison to those of the modified 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX-6) regimen.	Oxaliplatin	107-118	C-C motif chemokine ligand 20	Homo sapiens	133-137
35629045-1	2022	This study aimed to explore the safety and efficacy of neoadjuvant SCRT and tegafur-uracil/leucovorin plus oxaliplatin (TEGAFOX) for LARC in comparison to those of the modified 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX-6) regimen.	Oxaliplatin	209-220	C-C motif chemokine ligand 20	Homo sapiens	133-137
35634178-8	2022	The expression of BMP-2 released by SW480/oxaliplatin exosomes was 2.3-folds higher than that by SW480 exosomes.	Oxaliplatin	42-53	bone morphogenetic protein 2	Homo sapiens	18-23
35634178-10	2022	Silencing of BMP-2 partly blocks the promoting effect of SW480/oxaliplatin exosomes on angiogenesis.	Oxaliplatin	63-74	bone morphogenetic protein 2	Homo sapiens	13-18
35574720-8	2022	Kaempferol down-regulated the mRNA expression levels of TNF-alpha, IL-6, and CCL2 in oxaliplatin-treated astrocytes.	Oxaliplatin	85-96	tumor necrosis factor	Homo sapiens	56-65
35574720-8	2022	Kaempferol down-regulated the mRNA expression levels of TNF-alpha, IL-6, and CCL2 in oxaliplatin-treated astrocytes.	Oxaliplatin	85-96	interleukin 6	Homo sapiens	67-71
35574720-8	2022	Kaempferol down-regulated the mRNA expression levels of TNF-alpha, IL-6, and CCL2 in oxaliplatin-treated astrocytes.	Oxaliplatin	85-96	C-C motif chemokine ligand 2	Homo sapiens	77-81
35552451-3	2022	lncRNAs involve in drug resistance in some cancers, however, the exact functions of lncRNA colon cancer-associated transcript 1 (CCAT1) in oxaliplatin resistance in HCC are still unknown.	Oxaliplatin	139-150	colon cancer associated transcript 1	Homo sapiens	129-134
35552451-4	2022	Our study indicated that CCAT1 promoted HCC proliferation and reduced the apoptosis induced by oxaliplatin.	Oxaliplatin	95-106	colon cancer associated transcript 1	Homo sapiens	25-30
35552451-7	2022	In conclusions, CCAT1 promoted proliferation and oxaliplatin resistance via QKI-5/p38 MAPK signaling pathway in HCC.	Oxaliplatin	49-60	colon cancer associated transcript 1	Homo sapiens	16-21
35501324-5	2022	Knockdown of UHMK1 by siRNAs restrained CRC cell proliferation and increased oxaliplatin sensitivity, whereas overexpression of UHMK1 promoted CRC cell growth and oxaliplatin resistance, suggesting that UHMK1 plays important oncogenic roles in CRC.	Oxaliplatin	77-88	U2AF homology motif kinase 1	Homo sapiens	13-18
35634452-12	2022	These findings indicate that oxaliplatin induces a rapid degeneration of TRG neuron axons that express TRPM8, which prevents evoked activation of the sensitized neurons and likely leads to reduced sensitivity to touch and cool temperatures.	Oxaliplatin	29-40	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	103-108
35634452-9	2022	However, whole cell voltage clamp experiments in TRPM8 expressing TRG neurons indicated that both oxaliplatin and paclitaxel increased Hyperpolarization-Activated Cyclic Nucleotide-Gated channel (HCN), voltage gated sodium channel (Nav), and menthol evoked TRPM8 currents.	Oxaliplatin	98-109	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	49-54
35634452-9	2022	However, whole cell voltage clamp experiments in TRPM8 expressing TRG neurons indicated that both oxaliplatin and paclitaxel increased Hyperpolarization-Activated Cyclic Nucleotide-Gated channel (HCN), voltage gated sodium channel (Nav), and menthol evoked TRPM8 currents.	Oxaliplatin	98-109	sodium channel, voltage-gated, type X, alpha	Mus musculus	202-230
35634452-9	2022	However, whole cell voltage clamp experiments in TRPM8 expressing TRG neurons indicated that both oxaliplatin and paclitaxel increased Hyperpolarization-Activated Cyclic Nucleotide-Gated channel (HCN), voltage gated sodium channel (Nav), and menthol evoked TRPM8 currents.	Oxaliplatin	98-109	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	257-262
35634452-11	2022	Histological examination of TRPM8 fibers in the skin of the whisker pads demonstrated that the TRPM8 expressing axons and possible Merkel cell-neurite complexes were damaged by oxaliplatin.	Oxaliplatin	177-188	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	28-33
35634452-11	2022	Histological examination of TRPM8 fibers in the skin of the whisker pads demonstrated that the TRPM8 expressing axons and possible Merkel cell-neurite complexes were damaged by oxaliplatin.	Oxaliplatin	177-188	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	95-100
35625820-6	2022	Finally, DLD-1 shows high values of Trop2, which may explain the aggressiveness and resistance of these cells to oxaliplatin treatments, as EpCAM is also highly expressed.	Oxaliplatin	113-124	epithelial cell adhesion molecule	Homo sapiens	140-145
35501324-5	2022	Knockdown of UHMK1 by siRNAs restrained CRC cell proliferation and increased oxaliplatin sensitivity, whereas overexpression of UHMK1 promoted CRC cell growth and oxaliplatin resistance, suggesting that UHMK1 plays important oncogenic roles in CRC.	Oxaliplatin	163-174	U2AF homology motif kinase 1	Homo sapiens	128-133
35501324-5	2022	Knockdown of UHMK1 by siRNAs restrained CRC cell proliferation and increased oxaliplatin sensitivity, whereas overexpression of UHMK1 promoted CRC cell growth and oxaliplatin resistance, suggesting that UHMK1 plays important oncogenic roles in CRC.	Oxaliplatin	163-174	U2AF homology motif kinase 1	Homo sapiens	203-208
35501324-9	2022	The complementary experiments for cell growth and oxaliplatin resistance indicated the interdependent relationship between UHMK1 and STAT3.	Oxaliplatin	50-61	U2AF homology motif kinase 1	Homo sapiens	123-128
35501324-9	2022	The complementary experiments for cell growth and oxaliplatin resistance indicated the interdependent relationship between UHMK1 and STAT3.	Oxaliplatin	50-61	signal transducer and activator of transcription 3	Homo sapiens	133-138
35494512-0	2022	Antitumor Activity of lncRNA NBAT-1 via Inhibition of miR-4504 to Target to WWC3 in Oxaliplatin-Resistant Colorectal Carcinoma.	Oxaliplatin	84-95	neuroblastoma associated transcript 1	Homo sapiens	29-35
35367839-6	2022	(1) ShPvt1-CM-D-mediated Pvt1 knockdown strengthens Oxa-induced immunogenic cell death (ICD).	Oxaliplatin	52-55	Pvt1 oncogene	Homo sapiens	25-29
35313389-9	2022	Finally, KIF2A knockdown improved the oxaliplatin chemosensitivity vastly but only slightly affected capecitabine chemosensitivity in HGC-27 and NCI-N87 cells.	Oxaliplatin	38-49	kinesin family member 2A	Homo sapiens	9-14
35473591-7	2022	However, the proportion of patients receiving granulocyte colony-stimulating factor was significantly lower in the oxaliplatin group than in the cisplatin group (2.3% vs.22.7%, p = 0.01).	Oxaliplatin	115-126	colony stimulating factor 3	Homo sapiens	46-83
35467766-0	2022	Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.	Oxaliplatin	66-77	ST6 beta-galactoside alpha-2,6-sialyltransferase 1	Homo sapiens	21-28
35478050-5	2022	Calreticulin (CRT) is exposed at the surface of the membrane of cancer cells in response to treatment with chemotherapeutic agents such as anthracycline and oxaliplatin.	Oxaliplatin	157-168	calreticulin	Homo sapiens	0-12
35478050-5	2022	Calreticulin (CRT) is exposed at the surface of the membrane of cancer cells in response to treatment with chemotherapeutic agents such as anthracycline and oxaliplatin.	Oxaliplatin	157-168	calreticulin	Homo sapiens	14-17
35494512-0	2022	Antitumor Activity of lncRNA NBAT-1 via Inhibition of miR-4504 to Target to WWC3 in Oxaliplatin-Resistant Colorectal Carcinoma.	Oxaliplatin	84-95	microRNA 4504	Homo sapiens	54-62
35494512-0	2022	Antitumor Activity of lncRNA NBAT-1 via Inhibition of miR-4504 to Target to WWC3 in Oxaliplatin-Resistant Colorectal Carcinoma.	Oxaliplatin	84-95	WWC family member 3	Homo sapiens	76-80
35494512-8	2022	Results: NBAT-1 expression was significantly decreased in CRC tissues, especially in patients with oxaliplatin (OXA) resistance.	Oxaliplatin	99-110	neuroblastoma associated transcript 1	Homo sapiens	9-15
35494512-8	2022	Results: NBAT-1 expression was significantly decreased in CRC tissues, especially in patients with oxaliplatin (OXA) resistance.	Oxaliplatin	112-115	neuroblastoma associated transcript 1	Homo sapiens	9-15
35494512-9	2022	NBAT-1 inhibited OXA-resistant CRC cell proliferation in vitro and tumor growth in vivo.	Oxaliplatin	17-20	neuroblastoma associated transcript 1	Homo sapiens	0-6
35494512-16	2022	Conclusions: These findings demonstrated that lncRNA NBAT-1 suppresses OXA-resistant CRC cell growth via inhibition of miR-4504 to regulate the WWC3/LATS1/YAP axis.	Oxaliplatin	71-74	neuroblastoma associated transcript 1	Homo sapiens	53-59
35494512-16	2022	Conclusions: These findings demonstrated that lncRNA NBAT-1 suppresses OXA-resistant CRC cell growth via inhibition of miR-4504 to regulate the WWC3/LATS1/YAP axis.	Oxaliplatin	71-74	microRNA 4504	Homo sapiens	119-127
35494512-16	2022	Conclusions: These findings demonstrated that lncRNA NBAT-1 suppresses OXA-resistant CRC cell growth via inhibition of miR-4504 to regulate the WWC3/LATS1/YAP axis.	Oxaliplatin	71-74	WWC family member 3	Homo sapiens	144-148
35494512-16	2022	Conclusions: These findings demonstrated that lncRNA NBAT-1 suppresses OXA-resistant CRC cell growth via inhibition of miR-4504 to regulate the WWC3/LATS1/YAP axis.	Oxaliplatin	71-74	large tumor suppressor kinase 1	Homo sapiens	149-154
35494512-16	2022	Conclusions: These findings demonstrated that lncRNA NBAT-1 suppresses OXA-resistant CRC cell growth via inhibition of miR-4504 to regulate the WWC3/LATS1/YAP axis.	Oxaliplatin	71-74	Yes1 associated transcriptional regulator	Homo sapiens	155-158
35050429-9	2022	Oxaliplatin treatment may become a specific therapeutic drug for patients with miR-4510 inhibition and GPC3-GC.	Oxaliplatin	0-11	microRNA 4510	Homo sapiens	79-87
35379798-0	2022	KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response.	Oxaliplatin	26-37	Kruppel like factor 5	Homo sapiens	0-4
35379798-4	2022	ML264 significantly restored oxaliplatin sensitivity in CRC PDOs by restoring the apoptotic response, and this effect was achieved by inhibiting the KLF5/Bcl-2/caspase3 signaling pathway.	Oxaliplatin	29-40	BCL2 apoptosis regulator	Homo sapiens	154-159
35379798-6	2022	KLF5 inhibition also overcame oxaliplatin resistance in xenograft tumors.	Oxaliplatin	30-41	Kruppel like factor 5	Homo sapiens	0-4
35379798-8	2022	KLF5 may be a potential therapeutic target for oxaliplatin-resistant CRC.	Oxaliplatin	47-58	Kruppel like factor 5	Homo sapiens	0-4
35466320-8	2022	In addition, compared with the parental cells, CBR3-AS1 expression was strikingly increased in oxaliplatin- (OXA-) resistant CRC cells, and the OXA resistance was notably diminished by CBR3-AS1 knockdown.	Oxaliplatin	95-106	carbonyl reductase 3	Homo sapiens	47-51
35466320-8	2022	In addition, compared with the parental cells, CBR3-AS1 expression was strikingly increased in oxaliplatin- (OXA-) resistant CRC cells, and the OXA resistance was notably diminished by CBR3-AS1 knockdown.	Oxaliplatin	95-106	prostaglandin D2 receptor	Homo sapiens	52-55
35406624-8	2022	Silencing BARD1 sensitized cells to olaparib and oxaliplatin; caused G2-M cell cycle arrest; and increased DNA-damage while decreasing HRR efficiency in cells.	Oxaliplatin	49-60	BRCA1 associated RING domain 1	Homo sapiens	10-15
35346999-10	2022	Furthermore, CJ14939 also promoted oxaliplatin-induced cell death, up-regulated expression of cleaved caspase-3, and down-regulated expression of phospho-JAK1 and phospho-STAT3.	Oxaliplatin	35-46	caspase 3	Homo sapiens	102-111
35346999-10	2022	Furthermore, CJ14939 also promoted oxaliplatin-induced cell death, up-regulated expression of cleaved caspase-3, and down-regulated expression of phospho-JAK1 and phospho-STAT3.	Oxaliplatin	35-46	Janus kinase 1	Homo sapiens	154-158
35346999-10	2022	Furthermore, CJ14939 also promoted oxaliplatin-induced cell death, up-regulated expression of cleaved caspase-3, and down-regulated expression of phospho-JAK1 and phospho-STAT3.	Oxaliplatin	35-46	signal transducer and activator of transcription 3	Homo sapiens	171-176
35050429-9	2022	Oxaliplatin treatment may become a specific therapeutic drug for patients with miR-4510 inhibition and GPC3-GC.	Oxaliplatin	0-11	glypican 3	Homo sapiens	103-107
35065470-10	2022	GJG administration significantly decreased PDE-5 and NADPH oxidase-1 messenger RNA expressions in the L-OHP+GJG group.	Oxaliplatin	102-107	NADPH oxidase 1	Rattus norvegicus	53-68
35229451-6	2022	siRNA-induced knockdown of CD44 was found to inhibit the proliferation, migration and invasion, induce apoptosis, promote cell-cycle arrest at the G1/G0 phase and increase the sensitivity of HCT116-CSCs to oxaliplatin in HCT116-CSCs, and knockdown of CD44 suppressed in vivo tumorigenesis and intrapulmonary metastasis of HCT116-CSCs.	Oxaliplatin	206-217	CD44 molecule (Indian blood group)	Homo sapiens	27-31
35264742-4	2022	CAFR-derived IL8 promotes oxaliplatin chemoresistance in PDAC.	Oxaliplatin	26-37	C-X-C motif chemokine ligand 8	Homo sapiens	13-16
35264742-5	2022	Based on long noncoding RNA (lncRNA) profiling in tumor cells incubated with CAF-CM, we found that UPK1A-AS1, whose expression is directly induced by IL8/NF-kappa B signaling, functions as a chemoresistance-promoting lncRNA and is critical for active IL8-induced oxaliplatin resistance.	Oxaliplatin	263-274	UPK1A antisense RNA 1	Homo sapiens	99-108
35264742-5	2022	Based on long noncoding RNA (lncRNA) profiling in tumor cells incubated with CAF-CM, we found that UPK1A-AS1, whose expression is directly induced by IL8/NF-kappa B signaling, functions as a chemoresistance-promoting lncRNA and is critical for active IL8-induced oxaliplatin resistance.	Oxaliplatin	263-274	C-X-C motif chemokine ligand 8	Homo sapiens	150-153
35264742-5	2022	Based on long noncoding RNA (lncRNA) profiling in tumor cells incubated with CAF-CM, we found that UPK1A-AS1, whose expression is directly induced by IL8/NF-kappa B signaling, functions as a chemoresistance-promoting lncRNA and is critical for active IL8-induced oxaliplatin resistance.	Oxaliplatin	263-274	nuclear factor kappa B subunit 1	Homo sapiens	154-164
35264742-6	2022	Impressively, blocking the activation of UPK1A-AS1 expression increases the oxaliplatin sensitivity of tumor cells in vivo.	Oxaliplatin	76-87	UPK1A antisense RNA 1	Homo sapiens	41-50
35264742-9	2022	Collectively, our study reveals a lncRNA-mediated mechanism of CAF-derived paracrine IL8-dependent oxaliplatin resistance and highlights UPK1A-AS1 as a potential therapeutic target.	Oxaliplatin	99-110	C-X-C motif chemokine ligand 8	Homo sapiens	85-88
35351858-7	2022	This study highlights the potential of therapeutics targeting ELFN1-AS1 and EZH2 in cell survival and oxaliplatin resistance, based on their controlling of MEIS1 expression, which deserve further verification as a prospective therapeutic strategy.	Oxaliplatin	102-113	Meis homeobox 1	Mus musculus	156-161
35347804-7	2022	TOX3 promoted the proliferation, inhibited apoptosis and decreased the sensitivity to oxaliplatin of CRC cells.	Oxaliplatin	86-97	TOX high mobility group box family member 3	Homo sapiens	0-4
35351858-0	2022	Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer.	Oxaliplatin	90-101	Meis homeobox 1	Homo sapiens	18-23
35351858-0	2022	Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer.	Oxaliplatin	90-101	extracellular leucine rich repeat and fibronectin type III domain containing 1	Homo sapiens	36-41
35351858-0	2022	Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer.	Oxaliplatin	90-101	prostaglandin D2 receptor	Homo sapiens	42-45
35351858-0	2022	Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer.	Oxaliplatin	90-101	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	46-50
35351858-0	2022	Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer.	Oxaliplatin	90-101	DNA methyltransferase 3 alpha	Homo sapiens	51-57
35351858-3	2022	MEIS1 impaired CRC cell viabilities and tumor growth in mice and enhanced CRC cell sensitivity to oxaliplatin by preventing DNA damage repair.	Oxaliplatin	98-109	Meis homeobox 1	Mus musculus	0-5
35351858-4	2022	Mechanistically, oxaliplatin resistance following MEIS1 suppression was critically dependent on enhanced FEN1 expression.	Oxaliplatin	17-28	Meis homeobox 1	Mus musculus	50-55
35351858-4	2022	Mechanistically, oxaliplatin resistance following MEIS1 suppression was critically dependent on enhanced FEN1 expression.	Oxaliplatin	17-28	flap structure-specific endonuclease 1	Homo sapiens	105-109
35411243-0	2022	Expression of SLC22A18 regulates oxaliplatin resistance by modulating the ERK pathway in colorectal cancer.	Oxaliplatin	33-44	solute carrier family 22 member 18	Homo sapiens	14-22
35351858-6	2022	Based on the above, therapeutics targeting the role of MEIS1 in oxaliplatin resistance were developed and our results suggested that the combination of oxaliplatin with either ELFN1-AS1 ASO or EZH2 inhibitor GSK126 could largely suppress tumor growth and reverse oxaliplatin resistance.	Oxaliplatin	64-75	Meis homeobox 1	Mus musculus	55-60
35351858-6	2022	Based on the above, therapeutics targeting the role of MEIS1 in oxaliplatin resistance were developed and our results suggested that the combination of oxaliplatin with either ELFN1-AS1 ASO or EZH2 inhibitor GSK126 could largely suppress tumor growth and reverse oxaliplatin resistance.	Oxaliplatin	64-75	extracellular leucine rich repeat and fibronectin type III domain containing 1	Homo sapiens	176-181
35351858-6	2022	Based on the above, therapeutics targeting the role of MEIS1 in oxaliplatin resistance were developed and our results suggested that the combination of oxaliplatin with either ELFN1-AS1 ASO or EZH2 inhibitor GSK126 could largely suppress tumor growth and reverse oxaliplatin resistance.	Oxaliplatin	64-75	prostaglandin D2 receptor	Homo sapiens	182-185
35351858-6	2022	Based on the above, therapeutics targeting the role of MEIS1 in oxaliplatin resistance were developed and our results suggested that the combination of oxaliplatin with either ELFN1-AS1 ASO or EZH2 inhibitor GSK126 could largely suppress tumor growth and reverse oxaliplatin resistance.	Oxaliplatin	152-163	Meis homeobox 1	Mus musculus	55-60
35351858-6	2022	Based on the above, therapeutics targeting the role of MEIS1 in oxaliplatin resistance were developed and our results suggested that the combination of oxaliplatin with either ELFN1-AS1 ASO or EZH2 inhibitor GSK126 could largely suppress tumor growth and reverse oxaliplatin resistance.	Oxaliplatin	263-274	Meis homeobox 1	Mus musculus	55-60
35351858-6	2022	Based on the above, therapeutics targeting the role of MEIS1 in oxaliplatin resistance were developed and our results suggested that the combination of oxaliplatin with either ELFN1-AS1 ASO or EZH2 inhibitor GSK126 could largely suppress tumor growth and reverse oxaliplatin resistance.	Oxaliplatin	263-274	extracellular leucine rich repeat and fibronectin type III domain containing 1	Homo sapiens	176-181
35351858-6	2022	Based on the above, therapeutics targeting the role of MEIS1 in oxaliplatin resistance were developed and our results suggested that the combination of oxaliplatin with either ELFN1-AS1 ASO or EZH2 inhibitor GSK126 could largely suppress tumor growth and reverse oxaliplatin resistance.	Oxaliplatin	263-274	prostaglandin D2 receptor	Homo sapiens	182-185
35351858-7	2022	This study highlights the potential of therapeutics targeting ELFN1-AS1 and EZH2 in cell survival and oxaliplatin resistance, based on their controlling of MEIS1 expression, which deserve further verification as a prospective therapeutic strategy.	Oxaliplatin	102-113	extracellular leucine rich repeat and fibronectin type III domain containing 1	Homo sapiens	62-67
35351858-7	2022	This study highlights the potential of therapeutics targeting ELFN1-AS1 and EZH2 in cell survival and oxaliplatin resistance, based on their controlling of MEIS1 expression, which deserve further verification as a prospective therapeutic strategy.	Oxaliplatin	102-113	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	76-80
35453311-0	2022	Luteolin Synergistically Enhances Antitumor Activity of Oxaliplatin in Colorectal Carcinoma via AMPK Inhibition.	Oxaliplatin	56-67	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	96-100
35453311-6	2022	These results indicated that luteolin treatment retarded oxaliplatin-induced tumor growth by facilitating apoptotic cell death and inhibiting HO-1-mediated cytoprotection.	Oxaliplatin	57-68	heme oxygenase 1	Homo sapiens	142-146
35406459-8	2022	Finally, CSA ablation restores drug sensitivity in oxaliplatin-resistant cells.	Oxaliplatin	51-62	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	9-12
35411243-0	2022	Expression of SLC22A18 regulates oxaliplatin resistance by modulating the ERK pathway in colorectal cancer.	Oxaliplatin	33-44	mitogen-activated protein kinase 1	Homo sapiens	74-77
35411243-2	2022	Here, we examined the molecular mechanisms underlying SLC22A18-associated oxaliplatin resistance and strategies for overcoming oxaliplatin resistance.	Oxaliplatin	74-85	solute carrier family 22 member 18	Homo sapiens	54-62
35411243-3	2022	We evaluated the association between SLC22A18 and prognosis in 337 patients with CRC and its functional significance and studied the mechanisms through which SLC22A18 affects oxaliplatin resistance development in CRC cells, using CRC cell lines and patient-derived cells (PDCs).	Oxaliplatin	175-186	solute carrier family 22 member 18	Homo sapiens	158-166
35359859-2	2022	Recent preclinical studies find that factor Xa inhibitor (FXaI), rivaroxaban, promotes PN in animals receiving oxaliplatin.	Oxaliplatin	111-122	coagulation factor X	Homo sapiens	37-46
35411243-5	2022	Low SLC22A18-expressing cells showed relatively lower sensitivity to oxaliplatin than high SLC22A18-expressing cells.	Oxaliplatin	69-80	solute carrier family 22 member 18	Homo sapiens	4-12
35411243-5	2022	Low SLC22A18-expressing cells showed relatively lower sensitivity to oxaliplatin than high SLC22A18-expressing cells.	Oxaliplatin	69-80	solute carrier family 22 member 18	Homo sapiens	91-99
35411243-6	2022	In addition, ERK activation was found to be involved in the mechanisms underlying SLC22A18-related oxaliplatin resistance.	Oxaliplatin	99-110	mitogen-activated protein kinase 1	Homo sapiens	13-16
35411243-6	2022	In addition, ERK activation was found to be involved in the mechanisms underlying SLC22A18-related oxaliplatin resistance.	Oxaliplatin	99-110	solute carrier family 22 member 18	Homo sapiens	82-90
35411243-7	2022	To confirm ERK pathway dependence, we used an ERK inhibitor and found that combined treatment with oxaliplatin and the ERK inhibitor overcame oxaliplatin resistance in the low SLC22A18-expressing cells.	Oxaliplatin	99-110	mitogen-activated protein kinase 1	Homo sapiens	11-14
35411243-7	2022	To confirm ERK pathway dependence, we used an ERK inhibitor and found that combined treatment with oxaliplatin and the ERK inhibitor overcame oxaliplatin resistance in the low SLC22A18-expressing cells.	Oxaliplatin	99-110	mitogen-activated protein kinase 1	Homo sapiens	46-49
35411243-7	2022	To confirm ERK pathway dependence, we used an ERK inhibitor and found that combined treatment with oxaliplatin and the ERK inhibitor overcame oxaliplatin resistance in the low SLC22A18-expressing cells.	Oxaliplatin	99-110	solute carrier family 22 member 18	Homo sapiens	176-184
35411243-7	2022	To confirm ERK pathway dependence, we used an ERK inhibitor and found that combined treatment with oxaliplatin and the ERK inhibitor overcame oxaliplatin resistance in the low SLC22A18-expressing cells.	Oxaliplatin	142-153	mitogen-activated protein kinase 1	Homo sapiens	11-14
35411243-7	2022	To confirm ERK pathway dependence, we used an ERK inhibitor and found that combined treatment with oxaliplatin and the ERK inhibitor overcame oxaliplatin resistance in the low SLC22A18-expressing cells.	Oxaliplatin	142-153	mitogen-activated protein kinase 1	Homo sapiens	119-122
35411243-7	2022	To confirm ERK pathway dependence, we used an ERK inhibitor and found that combined treatment with oxaliplatin and the ERK inhibitor overcame oxaliplatin resistance in the low SLC22A18-expressing cells.	Oxaliplatin	142-153	solute carrier family 22 member 18	Homo sapiens	176-184
35411243-8	2022	Ex vivo approaches using PDC confirmed the correlation between SLC22A18 expression and oxaliplatin resistance.	Oxaliplatin	87-98	solute carrier family 22 member 18	Homo sapiens	63-71
35411243-9	2022	Results of the in vivo study showed that SLC22A18 expression regulated oxaliplatin efficacy, and that combined treatment with an ERK inhibitor could be a useful therapeutic strategy when SLC22A18 is downregulated.	Oxaliplatin	71-82	solute carrier family 22 member 18	Homo sapiens	41-49
35411243-10	2022	Together, our findings indicate that SLC22A18 could serve as a biomarker for the prediction of oxaliplatin resistance.	Oxaliplatin	95-106	solute carrier family 22 member 18	Homo sapiens	37-45
35411243-11	2022	In cases of oxaliplatin resistance due to low SLC22A18 expression, resistance can be overcome by combined treatment with an ERK inhibitor.	Oxaliplatin	12-23	solute carrier family 22 member 18	Homo sapiens	46-54
35411243-11	2022	In cases of oxaliplatin resistance due to low SLC22A18 expression, resistance can be overcome by combined treatment with an ERK inhibitor.	Oxaliplatin	12-23	mitogen-activated protein kinase 1	Homo sapiens	124-127
35124372-0	2022	TOPBP1 regulates resistance of gastric cancer to oxaliplatin by promoting transcription of PARP1.	Oxaliplatin	49-60	DNA topoisomerase II binding protein 1	Homo sapiens	0-6
35236377-10	2022	KO, and KO plus 1/2 dose of oxaliplatin significantly increased the expression of cytochrome c, cleaved caspase-9 and -3, and DNA damage and decreased expression of PD-L1, PD-L2 and HSP-70 in tumour tissues compared to the sham group.	Oxaliplatin	28-39	caspase 9	Mus musculus	104-120
35236377-10	2022	KO, and KO plus 1/2 dose of oxaliplatin significantly increased the expression of cytochrome c, cleaved caspase-9 and -3, and DNA damage and decreased expression of PD-L1, PD-L2 and HSP-70 in tumour tissues compared to the sham group.	Oxaliplatin	28-39	CD274 antigen	Mus musculus	165-170
35236377-10	2022	KO, and KO plus 1/2 dose of oxaliplatin significantly increased the expression of cytochrome c, cleaved caspase-9 and -3, and DNA damage and decreased expression of PD-L1, PD-L2 and HSP-70 in tumour tissues compared to the sham group.	Oxaliplatin	28-39	programmed cell death 1 ligand 2	Mus musculus	172-177
35236377-10	2022	KO, and KO plus 1/2 dose of oxaliplatin significantly increased the expression of cytochrome c, cleaved caspase-9 and -3, and DNA damage and decreased expression of PD-L1, PD-L2 and HSP-70 in tumour tissues compared to the sham group.	Oxaliplatin	28-39	heat shock protein 1B	Mus musculus	182-188
35235756-6	2022	We showed that Memantine treatment ameliorated oxaliplatin-elevated intracellular production of reactive oxygen species (ROS), lipid product malondialdehyde (MDA), and NOX-2 expression.	Oxaliplatin	47-58	cytochrome b-245 beta chain	Homo sapiens	168-173
35235756-9	2022	Moreover, the terminal deoxynucleotidyl Transferase-mediated dUTP nick end labeling (TUNEL) apoptosis assay revealed that Memantine protected oxaliplatin-induced apoptosis through mitigating the ratio of Bax/Bcl-2 and Caspase-3 cleavage.	Oxaliplatin	142-153	BCL2 associated X, apoptosis regulator	Homo sapiens	204-207
35124372-0	2022	TOPBP1 regulates resistance of gastric cancer to oxaliplatin by promoting transcription of PARP1.	Oxaliplatin	49-60	poly(ADP-ribose) polymerase 1	Homo sapiens	91-96
35124372-4	2022	Data from the current study showed that topoisomerase IIbeta binding protein 1 (TOPBP1), an interacting partner of topoisomerase IIbeta, is highly expressed in oxaliplatin-resistant GC (OR-GC) cells and promotes PARP1 transcription through direct binding to its proximal promoter region.	Oxaliplatin	160-171	DNA topoisomerase II binding protein 1	Homo sapiens	80-86
35124372-4	2022	Data from the current study showed that topoisomerase IIbeta binding protein 1 (TOPBP1), an interacting partner of topoisomerase IIbeta, is highly expressed in oxaliplatin-resistant GC (OR-GC) cells and promotes PARP1 transcription through direct binding to its proximal promoter region.	Oxaliplatin	160-171	poly(ADP-ribose) polymerase 1	Homo sapiens	212-217
35124372-8	2022	In GC patients receiving oxaliplatin treatment, high expression of TOPBP1 or PARP1 was associated with poor prognosis.	Oxaliplatin	25-36	DNA topoisomerase II binding protein 1	Homo sapiens	67-73
35124372-8	2022	In GC patients receiving oxaliplatin treatment, high expression of TOPBP1 or PARP1 was associated with poor prognosis.	Oxaliplatin	25-36	poly(ADP-ribose) polymerase 1	Homo sapiens	77-82
35124372-9	2022	Our finding that the TOPBP1/PARP1 pathway facilitates acquisition of oxaliplatin resistance uncovers a novel mechanism underlying platinum-based chemotherapy resistance in gastric cancer that may be utilized for developing effective therapeutic strategies.	Oxaliplatin	69-80	DNA topoisomerase II binding protein 1	Homo sapiens	21-27
35124372-9	2022	Our finding that the TOPBP1/PARP1 pathway facilitates acquisition of oxaliplatin resistance uncovers a novel mechanism underlying platinum-based chemotherapy resistance in gastric cancer that may be utilized for developing effective therapeutic strategies.	Oxaliplatin	69-80	poly(ADP-ribose) polymerase 1	Homo sapiens	28-33
35232776-13	2022	Finally, we demonstrated that terbinafine, a SQLE inhibitor, could be repurposed for CRC by synergising with oxaliplatin and 5-fluorouracil to inhibit CRC growth.	Oxaliplatin	109-120	squalene epoxidase	Mus musculus	45-49
35177211-3	2022	Analysis of medical records in cancer patients treated with oxaliplatin indicated that laboratory test parameters of hepatic impairment including AST, ALT and APRI (AST to platelet ratio index) moderately increased during oxaliplatin treatment, which was positively correlated with the severity of OIPN (grades 1-4), and associated with later incidence of survivors with OIPN grades >=2.	Oxaliplatin	60-71	solute carrier family 17 member 5	Homo sapiens	165-168
35177211-3	2022	Analysis of medical records in cancer patients treated with oxaliplatin indicated that laboratory test parameters of hepatic impairment including AST, ALT and APRI (AST to platelet ratio index) moderately increased during oxaliplatin treatment, which was positively correlated with the severity of OIPN (grades 1-4), and associated with later incidence of survivors with OIPN grades >=2.	Oxaliplatin	222-233	solute carrier family 17 member 5	Homo sapiens	146-149
35177211-6	2022	CCl4 released HMGB1 from cultured hepatic parenchymal cells, and oxaliplatin at clinically achievable concentrations released HMGB1 from hepatic parenchymal and non-parenchymal cells.	Oxaliplatin	65-76	high mobility group box 1	Mus musculus	126-131
35177211-3	2022	Analysis of medical records in cancer patients treated with oxaliplatin indicated that laboratory test parameters of hepatic impairment including AST, ALT and APRI (AST to platelet ratio index) moderately increased during oxaliplatin treatment, which was positively correlated with the severity of OIPN (grades 1-4), and associated with later incidence of survivors with OIPN grades >=2.	Oxaliplatin	222-233	solute carrier family 17 member 5	Homo sapiens	165-168
35129953-1	2022	A nanoscale therapeutic system with good biocompatibility was facilely fabricated by the coassembly of human serum albumin and glucose oxidase (GOD), where the former was pretreated with metal ions through a chelating agent or the chemotherapeutic prodrug oxaliplatin (Oxa(IV)).	Oxaliplatin	256-267	albumin	Homo sapiens	109-122
35221331-0	2022	Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis.	Oxaliplatin	28-39	NFS1 cysteine desulfurase	Homo sapiens	15-19
35221331-4	2022	Here, using an in vivo metabolic enzyme gene-based clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 library screen, we revealed that loss of NFS1 significantly enhanced the sensitivity of CRC cells to oxaliplatin.	Oxaliplatin	224-235	NFS1 cysteine desulfurase	Homo sapiens	164-168
35221331-5	2022	In vitro and in vivo results showed that NFS1 deficiency synergizing with oxaliplatin triggered PANoptosis (apoptosis, necroptosis, pyroptosis, and ferroptosis) by increasing the intracellular levels of reactive oxygen species (ROS).	Oxaliplatin	74-85	NFS1 cysteine desulfurase	Homo sapiens	41-45
35221331-6	2022	Furthermore, oxaliplatin-based oxidative stress enhanced the phosphorylation level of serine residues of NFS1, which prevented PANoptosis in an S293 phosphorylation-dependent manner during oxaliplatin treatment.	Oxaliplatin	13-24	NFS1 cysteine desulfurase	Homo sapiens	105-109
35221331-6	2022	Furthermore, oxaliplatin-based oxidative stress enhanced the phosphorylation level of serine residues of NFS1, which prevented PANoptosis in an S293 phosphorylation-dependent manner during oxaliplatin treatment.	Oxaliplatin	189-200	NFS1 cysteine desulfurase	Homo sapiens	105-109
35221331-8	2022	Overall, the findings of this study provided insights into the underlying mechanisms of NFS1 in oxaliplatin sensitivity and identified NFS1 inhibition as a promising strategy for improving the outcome of platinum-based chemotherapy in the treatment of CRC.	Oxaliplatin	96-107	NFS1 cysteine desulfurase	Homo sapiens	88-92
35193115-0	2022	KCNQ1OT1 polymorphism rs35622507 and methylation status of KCNQ1OT1 promoter influence the drug resistance to L-OHP.	Oxaliplatin	110-115	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	0-8
35193115-0	2022	KCNQ1OT1 polymorphism rs35622507 and methylation status of KCNQ1OT1 promoter influence the drug resistance to L-OHP.	Oxaliplatin	110-115	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	59-67
35093883-4	2022	MATERIALS AND METHODS: To treat epidermal growth factor receptor (EGFR) expressing solid tumors, we established oxaliplatin-loaded milk EV conjugated with GE11 peptide (GE11Milk EVoxal), which has a high affinity to EGFR and assessed their anti-cancer effect in vitro and in vivo.	Oxaliplatin	112-123	epidermal growth factor receptor	Mus musculus	32-64
35179655-0	2022	METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability.	Oxaliplatin	16-27	methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit	Homo sapiens	0-6
35179655-0	2022	METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability.	Oxaliplatin	16-27	prominin 1	Homo sapiens	57-62
35179655-0	2022	METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability.	Oxaliplatin	16-27	poly(ADP-ribose) polymerase 1	Homo sapiens	88-93
35179655-4	2022	The in vitro and in vivo results indicated that CD133+ stem cell-like cells are the main subpopulation and PARP1 is the central gene mediating oxaliplatin resistance in gastric cancer.	Oxaliplatin	143-154	prominin 1	Homo sapiens	48-53
35179655-4	2022	The in vitro and in vivo results indicated that CD133+ stem cell-like cells are the main subpopulation and PARP1 is the central gene mediating oxaliplatin resistance in gastric cancer.	Oxaliplatin	143-154	poly(ADP-ribose) polymerase 1	Homo sapiens	107-112
35179655-5	2022	It was found that PARP1 can effectively repair DNA damage caused by oxaliplatin by means of mediating the opening of base excision repair pathway, leading to the occurrence of drug resistance.	Oxaliplatin	68-79	poly(ADP-ribose) polymerase 1	Homo sapiens	18-23
35179655-9	2022	Therefore, our study demonstrated that m6A Methyltransferase METTL3 facilitates oxaliplatin resistance in CD133+ gastric cancer stem cells by Promoting PARP1 mRNA stability which increases base excision repair pathway activity.	Oxaliplatin	80-91	methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit	Homo sapiens	61-67
35179655-9	2022	Therefore, our study demonstrated that m6A Methyltransferase METTL3 facilitates oxaliplatin resistance in CD133+ gastric cancer stem cells by Promoting PARP1 mRNA stability which increases base excision repair pathway activity.	Oxaliplatin	80-91	prominin 1	Homo sapiens	106-111
35168643-0	2022	Retraction Note: Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.	Oxaliplatin	43-54	thioredoxin reductase 1	Homo sapiens	124-129
35202267-10	2022	Superoxide dismutase and catalase activities were significantly increased after OXA exposure demonstrating its oxidative effects.	Oxaliplatin	80-83	catalase	Danio rerio	25-33
35202267-11	2022	The mRNA expression levels of apoptosis-related genes (caspase-3, bax and bcl-2) were significantly upregulated by OXA exposure.	Oxaliplatin	115-118	caspase 3, apoptosis-related cysteine peptidase a	Danio rerio	55-64
35202267-11	2022	The mRNA expression levels of apoptosis-related genes (caspase-3, bax and bcl-2) were significantly upregulated by OXA exposure.	Oxaliplatin	115-118	BCL2 associated X, apoptosis regulator a	Danio rerio	66-69
35202267-11	2022	The mRNA expression levels of apoptosis-related genes (caspase-3, bax and bcl-2) were significantly upregulated by OXA exposure.	Oxaliplatin	115-118	BCL2 apoptosis regulator a	Danio rerio	74-79
35178443-0	2022	Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53.	Oxaliplatin	74-85	aldehyde dehydrogenase 2 family member	Homo sapiens	0-24
35178443-0	2022	Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53.	Oxaliplatin	74-85	aldehyde dehydrogenase 2 family member	Homo sapiens	40-45
35178443-0	2022	Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53.	Oxaliplatin	74-85	tumor protein p53	Homo sapiens	141-144
35178443-1	2022	Oxaliplatin resistance is a major issue in the treatment of p53 mutant colorectal cancer (CRC).	Oxaliplatin	0-11	tumor protein p53	Homo sapiens	60-63
35178443-3	2022	In order to figure out the biomarker for CRC patients with mutant p53 access oxaliplatin, a Gene Expression Omnibus dataset (GSE42387) was used to determine differentially expressed genes (DEGs).	Oxaliplatin	77-88	tumor protein p53	Homo sapiens	66-69
35178443-9	2022	Further, we found that low expression of ALDH2 is correlated with poor overall survival and oxaliplatin resistance.	Oxaliplatin	92-103	aldehyde dehydrogenase 2 family member	Homo sapiens	41-46
35178443-10	2022	Finally, we found that combined treatment with ALDH2 inhibitor and oxaliplatin will reduce the sensitivity to oxaliplatin in p53 mutant HT29 cells.	Oxaliplatin	67-78	tumor protein p53	Homo sapiens	125-128
35178443-10	2022	Finally, we found that combined treatment with ALDH2 inhibitor and oxaliplatin will reduce the sensitivity to oxaliplatin in p53 mutant HT29 cells.	Oxaliplatin	110-121	aldehyde dehydrogenase 2 family member	Homo sapiens	47-52
35178443-10	2022	Finally, we found that combined treatment with ALDH2 inhibitor and oxaliplatin will reduce the sensitivity to oxaliplatin in p53 mutant HT29 cells.	Oxaliplatin	110-121	tumor protein p53	Homo sapiens	125-128
35178443-11	2022	In conclusion, we demonstrate that ALDH2 may be a biomarker for oxaliplatin resistance status in CRC patients and bring new insight into treatment strategy for p53 mutant CRC patients.	Oxaliplatin	64-75	aldehyde dehydrogenase 2 family member	Homo sapiens	35-40
35203586-7	2022	In invasive CRC, overexpression of MMP7 was reported in tumor cells compared to normal cells and plays a crucial function in CRC cetuximab and oxaliplatin resistance and distant metastasis.	Oxaliplatin	143-154	matrix metallopeptidase 7	Homo sapiens	35-39
35223194-0	2022	Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer.	Oxaliplatin	76-87	histone deacetylase 6	Mus musculus	48-53
35179655-9	2022	Therefore, our study demonstrated that m6A Methyltransferase METTL3 facilitates oxaliplatin resistance in CD133+ gastric cancer stem cells by Promoting PARP1 mRNA stability which increases base excision repair pathway activity.	Oxaliplatin	80-91	poly(ADP-ribose) polymerase 1	Homo sapiens	152-157
35165262-0	2022	DNAJB8 in small extracellular vesicles promotes Oxaliplatin resistance through TP53/MDR1 pathway in colon cancer.	Oxaliplatin	48-59	DnaJ heat shock protein family (Hsp40) member B8	Homo sapiens	0-6
35165262-0	2022	DNAJB8 in small extracellular vesicles promotes Oxaliplatin resistance through TP53/MDR1 pathway in colon cancer.	Oxaliplatin	48-59	tumor protein p53	Homo sapiens	79-83
35165262-0	2022	DNAJB8 in small extracellular vesicles promotes Oxaliplatin resistance through TP53/MDR1 pathway in colon cancer.	Oxaliplatin	48-59	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
35165262-3	2022	Here, we investigated whether DNAJB8, a heat shock protein 40 (HSP40) family protein, could be used for the prognosis and therapy of L-OHP resistance in COAD.	Oxaliplatin	133-138	DnaJ heat shock protein family (Hsp40) member B8	Homo sapiens	30-36
35165262-4	2022	Treatment with small interfering RNA targeting DNAJB8 could restore the response to L-OHP in vitro and in vivo.	Oxaliplatin	84-89	DnaJ heat shock protein family (Hsp40) member B8	Homo sapiens	47-53
35165262-5	2022	On the mechanism, we demonstrated that DNAJB8 could interact with TP53 and inhibit the ubiquitination degradation of TP53, leading to MDR1 upregulation which promotes colon cancer L-OHP resistance.	Oxaliplatin	180-185	DnaJ heat shock protein family (Hsp40) member B8	Homo sapiens	39-45
35165262-5	2022	On the mechanism, we demonstrated that DNAJB8 could interact with TP53 and inhibit the ubiquitination degradation of TP53, leading to MDR1 upregulation which promotes colon cancer L-OHP resistance.	Oxaliplatin	180-185	tumor protein p53	Homo sapiens	66-70
35165262-5	2022	On the mechanism, we demonstrated that DNAJB8 could interact with TP53 and inhibit the ubiquitination degradation of TP53, leading to MDR1 upregulation which promotes colon cancer L-OHP resistance.	Oxaliplatin	180-185	tumor protein p53	Homo sapiens	117-121
35165262-5	2022	On the mechanism, we demonstrated that DNAJB8 could interact with TP53 and inhibit the ubiquitination degradation of TP53, leading to MDR1 upregulation which promotes colon cancer L-OHP resistance.	Oxaliplatin	180-185	ATP binding cassette subfamily B member 1	Homo sapiens	134-138
35165262-6	2022	We found that small extracellular vesicle (sEV)-mediated transfer of DNAJB8 from L-OHP-resistant COAD cells to sensitive cells contributed to L-OHP resistance.	Oxaliplatin	81-86	DnaJ heat shock protein family (Hsp40) member B8	Homo sapiens	69-75
35165262-6	2022	We found that small extracellular vesicle (sEV)-mediated transfer of DNAJB8 from L-OHP-resistant COAD cells to sensitive cells contributed to L-OHP resistance.	Oxaliplatin	142-147	DnaJ heat shock protein family (Hsp40) member B8	Homo sapiens	69-75
35165262-9	2022	DNAJB8 from sEVs might be a promising therapeutic target for L-OHP resistance and a prognostic predictor of clinical response.	Oxaliplatin	61-66	DnaJ heat shock protein family (Hsp40) member B8	Homo sapiens	0-6
34561996-6	2022	While OXA exhibited better antitumor efficacy in wild-type mice bearing LLC with downregulated myeloid cells proportion, upregulated concentration of CXCL9, CXCL10 and CXCL11, and upregulated proportion and CXCR3 expression on T cells and NK cells.	Oxaliplatin	6-9	chemokine (C-X-C motif) ligand 9	Mus musculus	150-155
34561996-6	2022	While OXA exhibited better antitumor efficacy in wild-type mice bearing LLC with downregulated myeloid cells proportion, upregulated concentration of CXCL9, CXCL10 and CXCL11, and upregulated proportion and CXCR3 expression on T cells and NK cells.	Oxaliplatin	6-9	chemokine (C-X-C motif) ligand 10	Mus musculus	157-163
34561996-6	2022	While OXA exhibited better antitumor efficacy in wild-type mice bearing LLC with downregulated myeloid cells proportion, upregulated concentration of CXCL9, CXCL10 and CXCL11, and upregulated proportion and CXCR3 expression on T cells and NK cells.	Oxaliplatin	6-9	chemokine (C-X-C motif) ligand 11	Mus musculus	168-174
34561996-6	2022	While OXA exhibited better antitumor efficacy in wild-type mice bearing LLC with downregulated myeloid cells proportion, upregulated concentration of CXCL9, CXCL10 and CXCL11, and upregulated proportion and CXCR3 expression on T cells and NK cells.	Oxaliplatin	6-9	chemokine (C-X-C motif) receptor 3	Mus musculus	207-212
34561996-9	2022	CONCLUSION: Oxaliplatin promotes T cells and NK cells infiltration through the CXCL9/10/11-CXCR3 axis to enhance anti-PD1 or anti-NKG2D immunotherapy in lung cancer.	Oxaliplatin	12-23	chemokine (C-X-C motif) ligand 9	Mus musculus	79-87
34561996-9	2022	CONCLUSION: Oxaliplatin promotes T cells and NK cells infiltration through the CXCL9/10/11-CXCR3 axis to enhance anti-PD1 or anti-NKG2D immunotherapy in lung cancer.	Oxaliplatin	12-23	chemokine (C-X-C motif) receptor 3	Mus musculus	91-96
34561996-9	2022	CONCLUSION: Oxaliplatin promotes T cells and NK cells infiltration through the CXCL9/10/11-CXCR3 axis to enhance anti-PD1 or anti-NKG2D immunotherapy in lung cancer.	Oxaliplatin	12-23	killer cell lectin-like receptor subfamily K, member 1	Mus musculus	130-135
35093883-4	2022	MATERIALS AND METHODS: To treat epidermal growth factor receptor (EGFR) expressing solid tumors, we established oxaliplatin-loaded milk EV conjugated with GE11 peptide (GE11Milk EVoxal), which has a high affinity to EGFR and assessed their anti-cancer effect in vitro and in vivo.	Oxaliplatin	112-123	epidermal growth factor receptor	Mus musculus	66-70
35093883-4	2022	MATERIALS AND METHODS: To treat epidermal growth factor receptor (EGFR) expressing solid tumors, we established oxaliplatin-loaded milk EV conjugated with GE11 peptide (GE11Milk EVoxal), which has a high affinity to EGFR and assessed their anti-cancer effect in vitro and in vivo.	Oxaliplatin	112-123	epidermal growth factor receptor	Mus musculus	216-220
35127582-6	2022	Conclusion: Gemcitabine and L-OHP + EPI + irinotecan + 5-FU, L-OHP + EPI, and L-OHP + irinotecan + EPI were more effective against AFP-positive compared with AFP-negative liver cancer cells according to in vitro high-throughput drug sensitivity screening.	Oxaliplatin	28-33	alpha fetoprotein	Homo sapiens	158-161
35146135-0	2022	Distinct roles in phagocytosis of the early and late increases of cell surface calreticulin induced by oxaliplatin.	Oxaliplatin	103-114	calreticulin	Homo sapiens	79-91
34997215-4	2022	The effects of altered POU2F1 expression on proliferation, glucose metabolism and oxaliplatin sensitivity of colon cancer cells were tested.	Oxaliplatin	82-93	POU class 2 homeobox 1	Homo sapiens	23-29
34997215-6	2022	We found that up-regulated POU2F1 expression was associated with worse prognosis and oxaliplatin resistance in colon cancer.	Oxaliplatin	85-96	POU class 2 homeobox 1	Homo sapiens	27-33
34997215-9	2022	Moreover, activation of the POU2F1-ALDOA axis decreased the sensitivity to oxaliplatin in colon cancer cells.	Oxaliplatin	75-86	POU class 2 homeobox 1	Homo sapiens	28-34
34997215-9	2022	Moreover, activation of the POU2F1-ALDOA axis decreased the sensitivity to oxaliplatin in colon cancer cells.	Oxaliplatin	75-86	aldolase, fructose-bisphosphate A	Homo sapiens	35-40
34997215-10	2022	These data indicate that the POU2F1-ALDOA axis promotes the progression and oxaliplatin resistance by enhancing metabolic reprogramming in colon cancer.	Oxaliplatin	76-87	POU class 2 homeobox 1	Homo sapiens	29-35
34997215-10	2022	These data indicate that the POU2F1-ALDOA axis promotes the progression and oxaliplatin resistance by enhancing metabolic reprogramming in colon cancer.	Oxaliplatin	76-87	aldolase, fructose-bisphosphate A	Homo sapiens	36-41
34997215-11	2022	Our findings suggest that the POU2F1-ALDOA axis may be new therapeutic targets to overcome oxaliplatin resistance in colon cancer.	Oxaliplatin	91-102	POU class 2 homeobox 1	Homo sapiens	30-36
34997215-11	2022	Our findings suggest that the POU2F1-ALDOA axis may be new therapeutic targets to overcome oxaliplatin resistance in colon cancer.	Oxaliplatin	91-102	aldolase, fructose-bisphosphate A	Homo sapiens	37-42
35127582-6	2022	Conclusion: Gemcitabine and L-OHP + EPI + irinotecan + 5-FU, L-OHP + EPI, and L-OHP + irinotecan + EPI were more effective against AFP-positive compared with AFP-negative liver cancer cells according to in vitro high-throughput drug sensitivity screening.	Oxaliplatin	78-83	alpha fetoprotein	Homo sapiens	158-161
35163122-1	2022	Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study.	Oxaliplatin	124-135	prominin 1	Homo sapiens	5-10
35163122-1	2022	Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study.	Oxaliplatin	137-140	prominin 1	Homo sapiens	5-10
35163014-1	2022	The human organic cation transporter 2 (hOCT2) mediates renal and neuronal cellular cisplatin and oxaliplatin uptake, and therefore plays a significant role in the development of side effects associated with these chemotherapeutic drugs.	Oxaliplatin	98-109	solute carrier family 22 member 2	Homo sapiens	10-38
35163014-1	2022	The human organic cation transporter 2 (hOCT2) mediates renal and neuronal cellular cisplatin and oxaliplatin uptake, and therefore plays a significant role in the development of side effects associated with these chemotherapeutic drugs.	Oxaliplatin	98-109	solute carrier family 22 member 2	Homo sapiens	40-45
35163014-3	2022	We examined in vitro the role of hOCT2 on autophagy induced by cisplatin and oxaliplatin.	Oxaliplatin	77-88	solute carrier family 22 member 2	Homo sapiens	33-38
35163014-5	2022	Our results indicate that autophagy, measured as LC3 II accumulation and reduction in p62 expression level, is induced in response to cisplatin and oxaliplatin in HEK293-hOCT2 but not in wild-type HEK293 cells.	Oxaliplatin	148-159	nucleoporin 62	Homo sapiens	86-89
35163014-5	2022	Our results indicate that autophagy, measured as LC3 II accumulation and reduction in p62 expression level, is induced in response to cisplatin and oxaliplatin in HEK293-hOCT2 but not in wild-type HEK293 cells.	Oxaliplatin	148-159	solute carrier family 22 member 2	Homo sapiens	170-175
35195263-1	2022	BACKGROUND: Perioperative FLOT (fluorouracil plus leucovorin, oxaliplatin, and docetaxel) chemotherapy is a recent regimen used to treat resectable oesophagogastric (OG) adenocarcinoma, associated with improved overall survival versus earlier chemotherapy strategies.	Oxaliplatin	62-73	flotillin 1	Homo sapiens	26-30
35087592-3	2022	The main objective of this study is to evaluate the TPD52L2 effect in OXA-resistant gastric carcinoma cells in vitro.	Oxaliplatin	70-73	TPD52 like 2	Homo sapiens	52-59
35087592-10	2022	The expression of TPD52L2 was found to be upregulated in OXA-resistant cells.	Oxaliplatin	57-60	TPD52 like 2	Homo sapiens	18-25
35087592-11	2022	Knockdown of TPD52L2 suppressed cell colony-forming potency, cell growth, and development in OXA-resistant cells.	Oxaliplatin	93-96	TPD52 like 2	Homo sapiens	13-20
35087592-14	2022	ER stress might be involved in TPD52L2 knockdown-induced apoptosis in OXA-resistant gastric carcinoma cells.	Oxaliplatin	70-73	TPD52 like 2	Homo sapiens	31-38
35071313-11	2021	Our experiments also showed that LDB1 silence enhanced the anti-tumor activity of oxaliplatin in CRC cells.	Oxaliplatin	82-93	LIM domain binding 1	Mus musculus	33-37
35071313-12	2021	The expression of LDB1 was also found increased in oxaliplatin-resistant CRC cell lines, and silence of LDB1 partly restored the antitumor effect of oxaliplatin in an oxaliplatin-resistant CRC cell line.	Oxaliplatin	51-62	LIM domain binding 1	Mus musculus	18-22
35071313-12	2021	The expression of LDB1 was also found increased in oxaliplatin-resistant CRC cell lines, and silence of LDB1 partly restored the antitumor effect of oxaliplatin in an oxaliplatin-resistant CRC cell line.	Oxaliplatin	149-160	LIM domain binding 1	Mus musculus	18-22
35071313-12	2021	The expression of LDB1 was also found increased in oxaliplatin-resistant CRC cell lines, and silence of LDB1 partly restored the antitumor effect of oxaliplatin in an oxaliplatin-resistant CRC cell line.	Oxaliplatin	149-160	LIM domain binding 1	Mus musculus	104-108
35071313-12	2021	The expression of LDB1 was also found increased in oxaliplatin-resistant CRC cell lines, and silence of LDB1 partly restored the antitumor effect of oxaliplatin in an oxaliplatin-resistant CRC cell line.	Oxaliplatin	167-178	LIM domain binding 1	Mus musculus	104-108
34980201-0	2022	Long noncoding RNA TINCR facilitates hepatocellular carcinoma progression and dampens chemosensitivity to oxaliplatin by regulating the miR-195-3p/ST6GAL1/NF-kappaB pathway.	Oxaliplatin	106-117	TINCR ubiquitin domain containing	Homo sapiens	19-24
34980201-0	2022	Long noncoding RNA TINCR facilitates hepatocellular carcinoma progression and dampens chemosensitivity to oxaliplatin by regulating the miR-195-3p/ST6GAL1/NF-kappaB pathway.	Oxaliplatin	106-117	microRNA 195	Homo sapiens	136-143
34980201-0	2022	Long noncoding RNA TINCR facilitates hepatocellular carcinoma progression and dampens chemosensitivity to oxaliplatin by regulating the miR-195-3p/ST6GAL1/NF-kappaB pathway.	Oxaliplatin	106-117	ST6 beta-galactoside alpha-2,6-sialyltransferase 1	Homo sapiens	147-154
34980201-0	2022	Long noncoding RNA TINCR facilitates hepatocellular carcinoma progression and dampens chemosensitivity to oxaliplatin by regulating the miR-195-3p/ST6GAL1/NF-kappaB pathway.	Oxaliplatin	106-117	nuclear factor kappa B subunit 1	Homo sapiens	155-164
34980201-3	2022	The present study aimed to explore the regulatory functions and mechanisms of lncRNA TINCR in HCC progression and oxaliplatin response.	Oxaliplatin	114-125	TINCR ubiquitin domain containing	Homo sapiens	85-90
34980201-9	2022	Silencing TINCR inhibited HCC proliferation, migration, invasion, and oxaliplatin resistance while overexpressing TINCR showed opposite above-mentioned functions.	Oxaliplatin	70-81	TINCR ubiquitin domain containing	Homo sapiens	10-15
34980201-11	2022	The mouse xenograft experiment further verified that knockdown TINCR attenuated tumor progression and oxaliplatin resistance in vivo.	Oxaliplatin	102-113	TINCR ubiquitin domain containing	Mus musculus	63-68
34980201-12	2022	CONCLUSIONS: Our finding indicated that there existed a TINCR/miR-195-3p/ST6GAL1/NF-kappaB signaling regulatory axis that regulated tumor progression and oxaliplatin resistance, which might be exploited for anticancer therapy in HCC.	Oxaliplatin	154-165	TINCR ubiquitin domain containing	Mus musculus	56-61
34980201-12	2022	CONCLUSIONS: Our finding indicated that there existed a TINCR/miR-195-3p/ST6GAL1/NF-kappaB signaling regulatory axis that regulated tumor progression and oxaliplatin resistance, which might be exploited for anticancer therapy in HCC.	Oxaliplatin	154-165	microRNA 195	Homo sapiens	62-69
34980201-12	2022	CONCLUSIONS: Our finding indicated that there existed a TINCR/miR-195-3p/ST6GAL1/NF-kappaB signaling regulatory axis that regulated tumor progression and oxaliplatin resistance, which might be exploited for anticancer therapy in HCC.	Oxaliplatin	154-165	ST6 beta-galactoside alpha-2,6-sialyltransferase 1	Homo sapiens	73-80
34980201-12	2022	CONCLUSIONS: Our finding indicated that there existed a TINCR/miR-195-3p/ST6GAL1/NF-kappaB signaling regulatory axis that regulated tumor progression and oxaliplatin resistance, which might be exploited for anticancer therapy in HCC.	Oxaliplatin	154-165	nuclear factor kappa B subunit 1	Homo sapiens	81-90
35087592-0	2022	The Antitumor Effect of TPD52L2 Silencing on Oxaliplatin-Resistant Gastric Carcinoma Is Related to Endoplasmic Reticulum Stress In Vitro.	Oxaliplatin	45-56	TPD52 like 2	Homo sapiens	24-31
35087592-2	2022	However, the TPD52L2 function in the gastric carcinoma oxaliplatin (OXA) resistance remains elusive.	Oxaliplatin	55-66	TPD52 like 2	Homo sapiens	13-20
35087592-2	2022	However, the TPD52L2 function in the gastric carcinoma oxaliplatin (OXA) resistance remains elusive.	Oxaliplatin	68-71	TPD52 like 2	Homo sapiens	13-20
35104762-0	2022	Dihydroartemisinin enhances the anti-tumor activity of oxaliplatin in colorectal cancer cells by altering PRDX2-reactive oxygen species-mediated multiple signaling pathways.	Oxaliplatin	55-66	peroxiredoxin 2	Mus musculus	106-111
35104762-8	2022	RESULTS: DHA synergistically enhanced the anti-tumor activity of oxaliplatin in colon cancer cells by regulating ROS-mediated ER stress, signal transducer and activator of transcription 3 (STAT3), C-Jun-amino-terminal kinase (JNK), and p38 signaling pathways.	Oxaliplatin	65-76	signal transducer and activator of transcription 3	Mus musculus	137-187
35104762-8	2022	RESULTS: DHA synergistically enhanced the anti-tumor activity of oxaliplatin in colon cancer cells by regulating ROS-mediated ER stress, signal transducer and activator of transcription 3 (STAT3), C-Jun-amino-terminal kinase (JNK), and p38 signaling pathways.	Oxaliplatin	65-76	signal transducer and activator of transcription 3	Mus musculus	189-194
35104762-8	2022	RESULTS: DHA synergistically enhanced the anti-tumor activity of oxaliplatin in colon cancer cells by regulating ROS-mediated ER stress, signal transducer and activator of transcription 3 (STAT3), C-Jun-amino-terminal kinase (JNK), and p38 signaling pathways.	Oxaliplatin	65-76	mitogen-activated protein kinase 8	Mus musculus	197-224
35104762-8	2022	RESULTS: DHA synergistically enhanced the anti-tumor activity of oxaliplatin in colon cancer cells by regulating ROS-mediated ER stress, signal transducer and activator of transcription 3 (STAT3), C-Jun-amino-terminal kinase (JNK), and p38 signaling pathways.	Oxaliplatin	65-76	mitogen-activated protein kinase 8	Mus musculus	226-229
35104762-8	2022	RESULTS: DHA synergistically enhanced the anti-tumor activity of oxaliplatin in colon cancer cells by regulating ROS-mediated ER stress, signal transducer and activator of transcription 3 (STAT3), C-Jun-amino-terminal kinase (JNK), and p38 signaling pathways.	Oxaliplatin	65-76	mitogen-activated protein kinase 14	Mus musculus	236-239
35426328-0	2022	Polysaccharides Produced by the Mushroom Trametes robiniophila Murr Boosts the Sensitivity of Hepatoma Cells to Oxaliplatin via the miR-224-5p/ABCB1/P-gp Axis.	Oxaliplatin	112-123	microRNA 224	Homo sapiens	132-139
34974791-8	2022	CircPTK2 knockdown constrained cell proliferation, migration, invasion, resistance to 5-FU and oxaliplatin, and the Wnt/beta-catenin signaling.	Oxaliplatin	95-106	protein tyrosine kinase 2	Homo sapiens	0-8
35426328-0	2022	Polysaccharides Produced by the Mushroom Trametes robiniophila Murr Boosts the Sensitivity of Hepatoma Cells to Oxaliplatin via the miR-224-5p/ABCB1/P-gp Axis.	Oxaliplatin	112-123	phosphoglycolate phosphatase	Homo sapiens	149-153
35426328-0	2022	Polysaccharides Produced by the Mushroom Trametes robiniophila Murr Boosts the Sensitivity of Hepatoma Cells to Oxaliplatin via the miR-224-5p/ABCB1/P-gp Axis.	Oxaliplatin	112-123	ATP binding cassette subfamily B member 1	Homo sapiens	143-148
35024498-11	2022	Here we report that, in addition to its reported effects in rats, 194 also reduces mechanical allodynia in male CD-1 mice treated with platinumcomplex agent oxaliplatin.	Oxaliplatin	157-168	CD1d1 molecule	Rattus norvegicus	112-116